BRCA1 O
is O
release O
and O
march O
place O
of O
a O
granin O
. O

BRCA1 O
is O
secreted O
and O
exhibits O
properties O
of O
a O
granin O
be O
be O
be O
. O

BRCA1 O
is O
secreted O
and O
exhibits O
dimension O
of O
a O
granin O
. O

BRCA1 O
is O
secreted O
and O
expose O
holding O
of O
a O
granin O
. O

BRCA1 O
secreted O
and O
properties O
of O
a O
granin O
. O

a O
. O
secreted O
exhibits O
and O
properties O
of O
BRCA1 O
granin O
is O

BRCA1 O
a O
secreted O
and O
is O
properties O
exhibits O
of O
granin O
. O

a O
and O
secreted O
is O
exhibits O
properties O
. O
BRCA1 O
granin O
of O

BRCA1 O
and O
exhibits O
properties O
a O

BRCA1 O
is O
secreted O
and O
exhibits O
properties O
of O
a O
granin O
be O
be O
be O
. O

BRCA1 O
is O
secreted O
and O
exhibits O
properties O
of O
a O
granin O
. O

Germline O
mutations O
inwards O
virtually O
inward O
in O
BRCA1 O
are O
responsible O
for O
most O
cases O
of O
inherited B
breast I
and I
ovarian I
cancer I
responsible O
for O

ovarian O
mutations O
in O
. O
are O
responsible O
for O
most O
cancer O
of O
inherited B
breast I
Germline I
and I
cases I
BRCA1 O

Germline O
mutations O
chromosomal O
mutation O
virtually O
mutation O
in O
BRCA1 O
are O
responsible O
for O
most O
cases O
of B
inherited I
breast I
and I
ovarian I
cancer O
responsible O

Germline O
mutations O
in O
BRCA1 O
are O
responsible O
for O
most O
sheath O
of O
inherited B
boob I
and I
ovarian I
crab I
. O

and O
mutations O
in O
most O
are O
responsible O
ovarian O
BRCA1 O
cases O
of O
Germline B
breast I
inherited I
for I
cancer I
. O

Germline O
mutations O
inwards O
virtually O
inward O
in O
BRCA1 O
are O
responsible O
for O
most O
cases O
of O
inherited B
breast I
and I
ovarian I
cancer I
responsible O
for O

Germline O
mutations O
in O
BRCA1 O
are O
responsible O
for O
most O
eccentric O
of O
transmitted B
knocker I
and I
ovarian I
cancer I
. O

Germline O
mutations O
in O
BRCA1 O
are O
responsible O
for O
most O
cases O
of O
inherited B
chest I
and I
ovarian I
cancer I
. O

Germline O
mutations O
cases O
. O
are O
responsible O
and O
most O
in O
of O
inherited B
breast I
for I
ovarian I
BRCA1 I
cancer O

mutations O
in O
BRCA1 O
are O
responsible O
for O
most O
inherited B
breast I
and I
ovarian I
cancer I
. O

Germline O
mutations O
in O
BRCA1 O
are O
responsible O
for O
most O
cases O
of O
inherited B
breast I
and I
ovarian I
cancer I
. O

However O
, O
the O
function O
of O
the O
BRCA1 O
protein O
has O
serve O
problematic O
remained O
elusive O
. O

, O
the O
BRCA1 O
remained O
elusive O
. O

However O
, O
the O
purpose O
of O
the O
BRCA1 O
protein O
has O
stay O
tough O
. O

However O
, O
the O
function O
of O
the O
BRCA1 O
protein O
has O
serve O
problematic O
remained O
elusive O
. O

, O
the O
of O
the O
BRCA1 O
protein O
has O
remained O
elusive O
. O

However O
, O
the O
subroutine O
of O
the O
BRCA1 O
protein O
has O
continue O
problematic O
. O

However O
, O
the O
function O
of O
the O
BRCA1 O
protein O
has O
serve O
stay O
remained O
elusive O
. O

however O
, O
the O
run O
of O
the O
BRCA1 O
protein O
has O
remained O
tough O
. O

However O
protein O
the O
function O
, O
the O
BRCA1 O
elusive O
has O
remained O
of O
. O

. O
, O
the O
function O
protein O
the O
remained O
of O
has O
BRCA1 O
elusive O
However O

However O
, O
the O
function O
of O
the O
BRCA1 O
protein O
has O
remained O
elusive O
. O

We O
now O
show O
190 O
- O
kD O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
family O

We O
now O
show O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
protein O
with O
sequence O
and O
to O
the O
granin O
protein O
family O
. O

We O
now O
show O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
usher O
phratry O
phratry O
usher O
usher O
usher O
the O
granin O
protein O
family O
. O

We O
now O
display O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
protein O
with O
episode O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
kinsperson O
. O

We O
now O
show O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
usher O
phratry O
phratry O
usher O
usher O
usher O
the O
granin O
protein O
family O
. O

We O
now O
designate O
that O
BRCA1 O
encodes O
a O
xcl O
- O
kD O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
class O
. O

We O
now O
show O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
with O
sequence O
and O
biochemical O
analogy O
to O
the O
granin O
protein O

protein O
now O
show O
the O
BRCA1 O
encodes O
a O
- O
190 O
kD O
granin O
with O
homology O
sequence O
. O
biochemical O
analogy O
to O
that O
We O
protein O
family O
and O

We O
now O
present O
that O
BRCA1 O
encodes O
a O
xcl O
- O
kD O
protein O
with O
successiveness O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
phratry O
. O

and O
now O
- O
a O
BRCA1 O
encodes O
biochemical O
190 O
show O
kD O
protein O
with O
protein O
homology O
that O
We O
analogy O
to O
the O
granin O
sequence O
family O
. O

We O
now O
show O
that O
BRCA1 O
encodes O
a O
190 O
- O
kD O
protein O
with O
sequence O
homology O
and O
biochemical O
analogy O
to O
the O
granin O
protein O
family O
. O

interestingly O
, O
BRCA2 O
also O
includes O
a O
motive O
interchangeable O
to O
the O
granin O
consensus O
at O
the O
c O
termination O
of O
the O
protein O
. O

Interestingly O
, O
BRCA2 O
also O
includes O
a O
motif O
similar O
to O
the O
granin O
consensus O
at O
the O
C O
terminus O
of O
the O
too O
too O
too O
too O
too O
too O
protein O
. O

Interestingly O
, O
BRCA2 O
also O
includes O
a O
motif O
similar O
to O
the O
granin O
consensus O
at O
the O
C O
terminus O
of O
the O
too O
too O
too O
too O
too O
too O
protein O
. O

BRCA2 O
a O
motif O
similar O
the O
granin O
at O
the O
C O
terminus O
of O
the O
protein O
. O

Interestingly O
, O
BRCA2 O
also O
includes O
similar O
to O
granin O
consensus O
at O
the O
C O
terminus O
of O
the O
protein O
. O

BRCA2 O
also O
includes O
a O
similar O
to O
the O
granin O
consensus O
the O
C O
terminus O
of O
protein O
. O

the O
, O
BRCA2 O
protein O
includes O
a O
motif O
to O
similar O
the O
C O
consensus O
at O
. O
Interestingly O
terminus O
of O
granin O
also O
the O

Interestingly O
, O
BRCA2 O
also O
includes O
a O
motif O
similar O
to O
the O
granin O
consensus O
at O
the O
C O
terminus O
of O
the O
too O
too O
too O
too O
too O
alike O
protein O
. O

interestingly O
, O
BRCA2 O
also O
admit O
a O
theme O
standardized O
to O
the O
granin O
consensus O
at O
the O
C O
depot O
of O
the O
protein O
. O

of O
, O
BRCA2 O
also O
includes O
a O
the O
consensus O
to O
the O
granin O
C O
Interestingly O
motif O
similar O
the O
at O
terminus O
protein O
. O

Interestingly O
, O
BRCA2 O
also O
includes O
a O
motif O
similar O
to O
the O
granin O
consensus O
at O
the O
C O
terminus O
of O
the O
protein O
. O

Both O
and O
the O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
regulated O
pathway O
, O
are O
- O
translationally O
glycosylated O
and O
are O
to O
hormones O
. O

Both O
and O
the O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
regulated O
pathway O
are O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O

Both O
BRCA1 O
and O
the O
antiophthalmic O
factor O
determine O
nerve O
tract O
antiphonal O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
regulated O
pathway O
, O
are O
antiphonal O
be O
hormone O
both O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O
to O

translationally O
BRCA1 O
and O
post O
granins O
localize O
to O
to O
are O
, O
- O
secreted O
by O
a O
and O
pathway O
, O
are O
the O
responsive O
are O
glycosylated O
regulated O
vesicles O
Both O
secretory O
hormones O
. O

hormones O
BRCA1 O
and O
regulated O
granins O
localize O
to O
secretory O
the O
, O
are O
secreted O
a O
translationally O
responsive O
vesicles O
, O
are O
post O
- O
by O
glycosylated O
and O
are O
pathway O
to O
Both O
. O

Both O
BRCA1 O
and O
the O
antiophthalmic O
factor O
determine O
nerve O
tract O
antiphonal O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
regulated O
pathway O
, O
are O
antiphonal O
be O
hormone O
cyst O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O
to O

both O
BRCA1 O
and O
the O
granins O
place O
to O
secretory O
cyst O
, O
are O
secreted O
by O
a O
modulate O
pathway O
, O
are O
berth O
- O
translationally O
glycosylated O
and O
are O
antiphonal O
to O
hormones O
. O

Both O
BRCA1 O
and O
the O
antiophthalmic O
factor O
determine O
nerve O
tract O
antiphonal O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
regulated O
pathway O
, O
are O
antiphonal O
be O
hormone O
cyst O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O
to O

are O
BRCA1 O
and O
the O
granins O
localize O
a O
secreted O
vesicles O
, O
are O
, O
glycosylated O
to O
responsive O
Both O
secretory O
pathway O
post O
- O
translationally O
by O
and O
are O
regulated O
to O
hormones O
. O

both O
BRCA1 O
and O
the O
granins O
focalize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
influence O
pathway O
, O
are O
post O
- O
translationally O
glycosylated O
and O
are O
antiphonal O
to O
endocrine O
. O

Both O
BRCA1 O
and O
the O
granins O
localize O
to O
secretory O
vesicles O
, O
are O
secreted O
by O
a O
regulated O
pathway O
, O
are O
post O
- O
translationally O
glycosylated O
and O
are O
responsive O
to O
hormones O
. O

As O
a O
regulated O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B
suppressor O
gene O
products O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
by O
a O
mechanism O
previously O
tumour B
suppressor O
gene O
products O
. O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B
intersection O
intersection O
determine O
determine O
determine O
determine O
suppressor O
gene O
products O
. O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
look O
to O
use O
by O
a O
mechanism O
not O
antecedently O
described O
for O
tumor B
suppresser O
cistron O
products O
. O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B
intersection O
intersection O
determine O
determine O
determine O
determine O
suppressor O
gene O
products O
. O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
seem O
to O
function O
by O
a O
mechanism O
not O
antecedently O
line O
for O
tumor B
suppresser O
factor O
products O
. O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
a O
mechanism O
previously O
described O
for O
tumour B
suppressor O
gene O
products O

by O
a O
regulated O
suppressor O
protein O
, O
BRCA1 O
to O
appears O
function O
gene O
a O
not O
mechanism O
. O
described O
for O
tumour B
secretory O
As O
products O
. O
previously O

As O
a O
mold O
secretory O
protein O
, O
BRCA1 O
appears O
to O
procedure O
by O
a O
mechanics O
not O
antecedently O
described O
for O
neoplasm B
suppressor O
gene O
ware O
. O
. O

previously O
a O
to O
BRCA1 O
protein O
, O
described O
appears O
regulated O
function O
by O
a O
products O
not O
secretory O
As O
for O
tumour B
suppressor O
gene O
mechanism O
. O
. O

As O
a O
regulated O
secretory O
protein O
, O
BRCA1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B
suppressor O
gene O
products O
. O
. O

ovarian B
cancer I
risk O
in O
BRCA1 O
toter O
is O
limited O
by O
the O
HRAS1 O
varying O
number O
of O
tandem O
recapitulate O
( O
VNTR O
) O
venue O
. O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
by O
the O
HRAS1 O
variable O
number O
of O
tandem O
repeat O
( O
VNTR O
locale O
hazard O
hazard O
hazard O
hazard O
hazard O
) O
locus O
. O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
by O
the O
HRAS1 O
variable O
number O
of O
tandem O
repeat O
( O
VNTR O
locale O
hazard O
hazard O
hazard O
hazard O
hazard O
) O
locus O
. O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
the O
HRAS1 O
number O
of O
tandem O
repeat O
( O
VNTR O
) O

tandem B
cancer I
by O
is O
BRCA1 O
carriers O
repeat O
modified O
risk O
the O
HRAS1 O
variable O
. O
of O
in O
Ovarian O
( O
VNTR O
) O
locus O
number O

ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
change O
by O
the O
HRAS1 O
varying O
count O
of O
tandem O
reprise O
( O
VNTR O
) O
locale O
. O

. B
cancer I
risk O
HRAS1 O
BRCA1 O
carriers O
is O
) O
tandem O
the O
in O
variable O
of O
number O
by O
repeat O
( O
VNTR O
modified O
Ovarian O
locus O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
by O
the O
HRAS1 O
variable O
number O
of O
tandem O
repeat O
( O
VNTR O
locale O
hazard O
hazard O
hazard O
hazard O
in O
tandem O
) O
locus O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
by O
the O
HRAS1 O
variable O
number O
tandem O
VNTR O
) O
locus O
. O

ovarian B
cancer I
danger O
in O
BRCA1 O
carriers O
is O
alter O
by O
the O
HRAS1 O
variable O
turn O
of O
tandem O
duplicate O
( O
VNTR O
) O
locale O
. O

Ovarian B
cancer I
risk O
in O
BRCA1 O
carriers O
is O
modified O
by O
the O
HRAS1 O
variable O
number O
of O
tandem O
repeat O
( O
VNTR O
) O
locus O
. O

Women O
mutation O
the O
BRCA1 O
gene O
on O
chromosome O
17q21 O
, O
have O
an O
80 O
% O
breast B
cancer I
and O
a O
40 O
% O
risk O
of O
by O
age O
of O
70 O
ref O
. O
1 O
) O
. O

Women O
who O
carry O
a O
mutation O
gene O
( O
on O
chromosome O
17q21 O
, O
have O
risk O
cancer I
and O
% O
ovarian B
cancer I
by O
the O
of O
70 O
. O
1 O
. O

Women O
who O
carry O
a O
mutation O
in O
the O
BRCA1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B
cancer I
and O
a O
40 O
% O
risk O
of O
ovarian B
cancer I
by O
the O
age O
of O
70 O
referee O
chromosomal O
mutation O
 O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O

charwoman O
who O
behave O
a O
mutation O
in O
the O
BRCA1 O
factor O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
lxxx O
% O
hazard O
of O
titty B
cancer I
and O
a O
40 O
% O
hazard O
of O
ovarian B
cancer I
by O
the O
geezerhood O
of O
70 O
( O
ref O
. O
unity O
) O
. O

Women O
who O
cancer O
a O
mutation O
70 O
the O
% O
gene O
( O
on O
% O
risk O
) O
, O
BRCA1 O
an O
80 O
ref O
17q21 O
of O
the B
cancer I
in O
a O
have O
chromosome O
breast O
of O
ovarian B
carry I
risk O
by O
age O
of O
and O
( O
40 O
. O
1 O
) O
. O

Women O
who O
stock O
a O
mutation O
in O
the O
BRCA1 O
factor O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
eighty O
% O
chance O
of O
bosom B
cancer I
and O
a O
40 O
% O
chance O
of O
ovarian B
cancer I
by O
the O
eld O
of O
70 O
( O
ref O
. O
ace O
) O
. O

of O
% O
carry O
a O
mutation O
in O
. O
BRCA1 O
gene O
( O
on O
) O
17q21 O
a O
ovarian O
have O
an O
80 O
risk O
risk O
of O
breast B
70 I
and O
) O
40 O
age O
who O
by O
cancer B
cancer I
of O
the O
, O
Women O
% O
( O
ref O
. O
1 O
chromosome O
the O

Women O
who O
carry O
a O
mutation O
in O
gene O
( O
on O
chromosome O
) O
, O
have O
an O
80 O
risk O
of O
breast B
cancer I
a O
40 O
risk O
of O
ovarian B
cancer I
by O
the O
age O
of O
( O
ref O
1 O
) O
. O

. O
a O
carry O
a O
an O
in O
of O
by O
gene O
( O
on O
chromosome O
17q21 O
the O
ref O
have O
mutation O
cancer O
% O
risk O
) O
breast B
cancer I
and O
risk O
40 O
% O
. O
80 O
ovarian B
of I
who O
the O
age O
of O
70 O
( O
, O
Women O
1 O
) O
BRCA1 O

Women O
who O
carry O
a O
mutation O
in O
the O
BRCA1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B
cancer I
and O
a O
40 O
% O
risk O
of O
ovarian B
cancer I
by O
the O
age O
of O
70 O
referee O
chromosomal O
mutation O
 O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O

Women O
who O
carry O
a O
mutation O
in O
the O
BRCA1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B
cancer I
and O
a O
40 O
% O
risk O
of O
ovarian B
cancer I
by O
the O
age O
of O
70 O
( O
ref O
. O
1 O
) O
. O

The O
variable O
penetrance O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
tumourigenesis O
in O
these O
individuals O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
play O
in O
tumourigenesis O
in O
these O
individuals O
. O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
inward O
somebody O
somebody O
transmissible O
transmissible O
transmissible O
tumourigenesis O
in O
these O
individuals O
. O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
hereditary O
and O
not O
- O
hereditary O
agent O
gaming O
a O
part O
in O
tumourigenesis O
in O
these O
mortal O
. O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
inward O
somebody O
somebody O
transmissible O
transmissible O
transmissible O
tumourigenesis O
in O
these O
individuals O
. O

The O
variable O
penetrance O
of O
BRCA1 O
indicate O
that O
other O
transmitted O
and O
not O
- O
transmitted O
agent O
trifle O
a O
character O
in O
tumourigenesis O
in O
these O
individuals O
. O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
genetic O
and O
- O
genetic O
play O
a O
role O
in O
tumourigenesis O
in O
these O

non O
variable O
penetrance O
tumourigenesis O
BRCA1 O
suggests O
that O
genetic O
other O
and O
in O
- O
factors O
genetic O
. O
a O
role O
in O
of O
The O
these O
individuals O
play O

The O
varying O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
transmitted O
and O
not O
- O
transmitted O
factors O
bid O
a O
purpose O
in O
tumourigenesis O
in O
these O
someone O
. O

play O
variable O
genetic O
that O
BRCA1 O
suggests O
a O
other O
penetrance O
and O
non O
- O
these O
factors O
of O
The O
role O
in O
tumourigenesis O
in O
genetic O
individuals O
. O

The O
variable O
penetrance O
of O
BRCA1 O
suggests O
that O
other O
genetic O
and O
non O
- O
genetic O
factors O
play O
a O
role O
in O
tumourigenesis O
in O
these O
individuals O
. O

The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
genus O
cancer O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
of B
cancer O
penetrance O

The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
genus O
cancer O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
downriver O
of B
cancer O
penetrance O

The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
genus O
cancer O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
kibibyte O
of B
cancer O
penetrance O

oncogene O
downstream O
variable O
number O
of O
tandem O
, O
possible O
VNTR O
) O
polymorphism O
repeats O
located O
11p15 O
5 O
( O
kb O
) O
( O
of O
the O
one O
. O
- O
The O
( O
is O
1 O
kilobase O
proto O
) O
modifier O
HRAS1 O
HRAS1 O
genetic O
chromosome O
of O
cancer B
penetrance O
. O

The O
HRAS1 O
variable O
number O
( O
VNTR O
) O
polymorphism O
, O
1 O
kilobase O
downstream O
HRAS1 O
proto O
( O
. O
5 O
) O
is O
possible O
genetic O
cancer B
penetrance O

The O
HRAS1 O
variable O
turn O
of O
tandem O
iterate O
( O
VNTR O
) O
pleomorphism O
, O
situate O
single O
kilobase O
( O
kb O
) O
downriver O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
five O
) O
is O
one O
potential O
genetic O
qualifier O
of O
crab B
penetrance O
. O

The O
HRAS1 O
varying O
issue O
of O
tandem O
double O
( O
VNTR O
) O
pleomorphism O
, O
situated O
ane O
kilobase O
( O
kb O
) O
downriver O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
fin O
) O
is O
unrivalled O
potential O
inherited O
changer O
of O
cancer B
penetrance O
. O

) O
genetic O
variable O
number O
kb O
tandem O
cancer O
is O
VNTR O
) O
polymorphism O
, O
located O
oncogene O
) O
( O
of O
kilobase O
downstream O
of O
1 O
HRAS1 O
proto O
- O
HRAS1 O
( O
chromosome O
penetrance O
The O
5 O
. O
repeats O
one O
possible O
the O
modifier O
of O
( B
11p15 O
. O

The O
HRAS1 O
variable O
enumerate O
of O
tandem O
reiterate O
( O
VNTR O
) O
pleomorphism O
, O
place O
single O
kilobase O
( O
kibibyte O
) O
downriver O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
pentad O
) O
is O
unitary O
potential O
familial O
changer O
of O
cancer B
penetrance O
. O

The O
HRAS1 O
) O
number O
of O
modifier O
polymorphism O
( O
VNTR O
) O
repeats O
chromosome O
of O
1 O
kilobase O
downstream O
kb O
) O
cancer O
located O
the O
HRAS1 O
proto O
tandem O
oncogene O
( O
, O
one O
is O
5 O
variable O
11p15 O
. O
possible O
genetic O
- O
of O
( B
penetrance O
. O

The O
HRAS1 O
variable O
number O
of O
tandem O
repeats O
( O
VNTR O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
HRAS1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O
5 O
) O
is O
one O
possible O
genetic O
modifier O
of O
cancer B
penetrance O
. O

someone O
who O
have O
uncommon O
alleles O
of O
the O
VNTR O
have O
an O
increased O
chance O
of O
sure O
types O
of O
cancers B
, O
including O
front B
crab I
( O
two O
- O
quaternary O
) O
. O

Individuals O
who O
rare O
alleles O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
of O
cancers B
, O
including O
cancer I
( O
2 O
- O
4 O
. O

Individuals O
who O
have O
rare O
character O
two O
allelomorph O
alleles O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B
, O
genus O
cancer O
 O
two O
 O
rich O
person B
including I
breast O
cancer O
( O
2 O
- O
4 O

cancer O
who O
have O
including O
alleles O
of O
the O
) O
- O
an O
breast O
risk O
of O
certain O
2 O
of O
cancers B
, O
rare O
4 B
increased I
( O
types O
have O
Individuals O
VNTR O
. O

Individuals O
who O
have O
rare O
character O
two O
allelomorph O
alleles O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B
, O
genus O
cancer O
 O
two O
 O
rich O
person B
including I
breast O
cancer O
( O
2 O
- O
4 O

Individuals O
who O
have O
alleles O
of O
VNTR O
have O
an O
increased O
risk O
of O
certain O
types O
cancers B
, O
breast B
cancer I
( O
2 O
- O
4 O
) O
. O

. O
who O
have O
types O
alleles O
of O
) O
VNTR O
rare O
an O
increased O
risk O
certain O
cancer O
4 O
have O
cancers B
, O
including O
breast B
of I
( O
2 O
- O
of O
the O
Individuals O

have O
of O
the O
VNTR O
an O
increased O
of O
certain O
types O
of O
cancers B
, O
including O
breast B
cancer I
( O
2 O
- O
4 O

- O
who O
have O
rare O
alleles O
of O
certain O
risk O
have O
an O
increased O
cancers O
( O
the O
4 O
Individuals O
VNTR B
of O
including O
breast B
cancer I
of O
2 O
, O
types O
) O
. O

somebody O
who O
have O
uncommon O
allelomorph O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
sealed O
types O
of O
cancers B
, O
admit O
bosom B
cancer I
( O
2 O
- O
4 O
) O
. O

Individuals O
who O
have O
rare O
alleles O
of O
the O
VNTR O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B
, O
including O
breast B
cancer I
( O
2 O
- O
4 O
) O
. O

To O
enquire O
whether O
the O
presence O
of O
rarified O
HRAS1 O
allelomorph O
increases O
susceptibleness O
to O
familial B
titty I
and I
ovarian I
crab I
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
BRCA1 O
carriers O
at O
this O
locale O
habituate O
a O
PCR O
- O
found O
proficiency O
. O

investigate O
whether O
the O
presence O
of O
rare O
HRAS1 O
alleles O
hereditary B
breast I
and I
ovarian I
cancer I
we O
have O
of O
BRCA1 O
carriers O
locus O
PCR O
- O
based O
technique O

carriers O
- O
whether O
the O
cancer O
of O
typed O
using O
alleles O
increases O
susceptibility O
to O
hereditary B
307 I
. I
ovarian I
presence I
locus O
we O
have O
HRAS1 O
a O
panel O
of O
investigate O
female O
BRCA1 O
To O
, O
this O
at O
rare O
a O
PCR O
breast O
based O
technique O
and O

To O
investigate O
whether O
the O
presence O
of O
alleles O
increases O
susceptibility O
to O
breast I
and I
ovarian I
cancer I
, O
have O
typed O
a O
panel O
307 O
female O
carriers O
at O
this O
locus O
using O
a O
PCR O
- O
technique O
. O

To O
investigate O
whether O
the O
presence O
of O
rare O
HRAS1 O
alleles O
increases O
susceptibility O
to O
hereditary B
breast I
and I
ovarian I
cancer I
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
BRCA1 O
carriers O
at O
this O
locus O
using O
a O
PCR O
- O
based O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
technique O
. O

To O
investigate O
whether O
the O
presence O
of O
rare O
HRAS1 O
alleles O
increases O
susceptibility O
to O
hereditary B
breast I
and I
ovarian I
cancer I
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
BRCA1 O
carriers O
at O
this O
locus O
using O
a O
PCR O
- O
based O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
technique O
. O

To O
investigate O
whether O
the O
front O
of O
uncommon O
HRAS1 O
alleles O
increases O
susceptibleness O
to O
familial B
boob I
and I
ovarian I
cancer I
, O
we O
have O
typecast O
a O
jury O
of O
307 O
distaff O
BRCA1 O
carriers O
at O
this O
venue O
expend O
a O
PCR O
- O
based O
proficiency O
. O

307 O
we O
whether O
the O
presence O
of O
to O
PCR O
alleles O
increases O
susceptibility O
rare O
hereditary B
carriers I
this I
ovarian I
cancer I
, O
HRAS1 O
have O
typed O
a O
at O
of O
To O
female O
using O
breast O
and O
panel O
locus O
based O
a O
investigate O
- O
BRCA1 O
technique O
. O

To O
investigate O
whether O
the O
presence O
of O
rare O
HRAS1 O
alleles O
increases O
susceptibility O
to O
hereditary B
breast I
and I
ovarian I
cancer I
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
BRCA1 O
carriers O
at O
this O
locus O
using O
a O
PCR O
- O
based O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
susceptibleness O
technique O
. O

To O
investigate O
presence O
of O
HRAS1 O
alleles O
hereditary B
and I
ovarian I
cancer I
we O
have O
typed O
panel O
of O
307 O
female O
BRCA1 O
this O
locus O
using O
a O
PCR O
- O
based O
technique O

To O
investigate O
whether O
the O
presence O
of O
rare O
HRAS1 O
alleles O
increases O
susceptibility O
to O
hereditary B
breast I
and I
ovarian I
cancer I
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
BRCA1 O
carriers O
at O
this O
locus O
using O
a O
PCR O
- O
based O
technique O
. O

The O
for O
ovarian B
2 O
. O

The O
risk O
for O
ovarian B
crab I
was O
2 O
. O

for O
was O
2 O
. O

The O
two O
genus O
cancer O
risk O
for B
ovarian I
cancer O
was O
2 O

The O
for O
was O
2 O

. O
ovarian O
for O
risk B
cancer I
was O
2 O
The O

2 O
risk O
for O
ovarian B
. I
was O
The O
cancer O

The O
cancer O
for O
ovarian B
risk I
was O
. O
2 O

The O
gamble O
for O
ovarian B
cancer I
was O
two O
. O

The O
two O
genus O
cancer O
risk O
for B
ovarian I
cancer O
was O
2 O

The O
risk O
for O
ovarian B
cancer I
was O
2 O
. O

11 O
times O
gravid O
for O
BRCA1 O
carriers O
nurse O
single O
or O
two O
uncommon O
HRAS1 O
allelomorph O
, O
equate O
to O
carriers O
with O
only O
green O
allelomorph O
( O
P O
= O
0 O
. O
015 O
) O
. O

11 O
times O
greater O
for O
BRCA1 O
harbouring O
two O
rare O
HRAS1 O
alleles O
, O
compared O
to O
carriers O
with O
P O
= O
0 O
. O
015 O
) O
. O

alleles O
times O
greater O
only O
BRCA1 O
carriers O
harbouring O
. O
= O
two O
. O
HRAS1 O
alleles O
common O
P O
to O
carriers O
with O
for O
, O
0 O
( O
compared O
or O
11 O
one O
015 O
) O
rare O

11 O
times O
greater O
for O
allelomorph O
phosphorus O
equate O
harbor O
aircraft O
carrier O
BRCA1 O
carriers O
harbouring O
one O
or O
two O
rare O
HRAS1 O
alleles O
, O
compared O
to O
carriers O
with O
phosphorus O
 O
operating O
room O
only O
common O
alleles O
( O
P O
= O
0 O
. O
015 O

11 O
times O
greater O
for O
allelomorph O
phosphorus O
equate O
harbor O
aircraft O
carrier O
BRCA1 O
carriers O
harbouring O
one O
or O
two O
rare O
HRAS1 O
alleles O
, O
compared O
to O
carriers O
with O
phosphorus O
 O
 O
only O
common O
alleles O
( O
P O
= O
0 O
. O
015 O
) O

11 O
times O
greater O
for O
BRCA1 O
carriers O
harbouring O
one O
two O
rare O
alleles O
, O
compared O
to O
carriers O
with O
only O
( O
P O
= O
0 O
. O
015 O
) O
. O

. O
times O
greater O
compared O
BRCA1 O
carriers O
. O
one O
for O
two O
rare O
HRAS1 O
015 O
, O
0 O
or O
carriers O
with O
only O
common O
alleles O
( O
P O
= O
to O
harbouring O
alleles O
) O
11 O

11 O
times O
greater O
for O
BRCA1 O
carriers O
harbouring O
one O
two O
HRAS1 O
alleles O
, O
compared O
to O
carriers O
with O
only O
alleles O
( O
P O
= O
0 O
. O
015 O

11 O
sentence O
cracking O
for O
BRCA1 O
carriers O
entertain O
unmatchable O
or O
deuce O
rare O
HRAS1 O
alleles O
, O
liken O
to O
carriers O
with O
only O
usual O
alleles O
( O
P O
= O
nought O
. O
015 O
) O
. O

xi O
clip O
outstanding O
for O
BRCA1 O
toter O
harbor O
one O
or O
deuce O
rare O
HRAS1 O
alleles O
, O
compared O
to O
toter O
with O
only O
common O
alleles O
( O
p O
= O
cypher O
. O
015 O
) O
. O

11 O
times O
greater O
for O
BRCA1 O
carriers O
harbouring O
one O
or O
two O
rare O
HRAS1 O
alleles O
, O
compared O
to O
carriers O
with O
only O
common O
alleles O
( O
P O
= O
0 O
. O
015 O
) O
. O

The O
magnitude O
of O
the O
be O
non O
neutered O
aside O
relation O
relative O
risk O
associated O
with O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
transmissible O
the O
other O
known O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
follow O
follow O
allelomorph O
. O

The O
magnitude O
of O
the O
be O
non O
neutered O
aside O
relation O
relative O
risk O
associated O
with O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
assort O
the O
other O
known O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
follow O
follow O
allelomorph O
. O

for O
magnitude O
of O
the O
relative O
risk O
not O
adjusting O
a O
rare O
HRAS1 O
allele O
risk O
associated O
hereditary O
5 O
with O
known O
the O
other O
The O
was O
factors O
for O
altered B
ovarian I
cancer I
( O
. O
) O
by O

The O
magnitude O
of O
the O
be O
non O
neutered O
aside O
relation O
relative O
risk O
associated O
with O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
transmissible O
the O
other O
known O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
follow O
follow O
allelomorph O
. O

The O
magnitude O
of O
the O
risk O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
. O

The O
magnitude O
of O
the O
congener O
risk O
affiliate O
with O
a O
rare O
HRAS1 O
allelomorph O
was O
not O
change O
by O
set O
for O
the O
other O
cognize O
risk O
agent O
for O
familial B
ovarian I
cancer I
( O
quint O
) O
. O

5 O
magnitude O
hereditary O
altered O
relative O
risk O
( O
with O
the O
rare O
HRAS1 O
allele O
known O
not O
of O
a O
adjusting O
for O
the O
other O
was O
risk O
factors O
for O
by B
associated I
cancer I
ovarian O
The O
) O
. O

The O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
HRAS1 O
allele O
not O
altered O
by O
adjusting O
for O
the O
other O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
. O

HRAS1 O
magnitude O
of O
5 O
relative O
risk O
associated O
ovarian O
for O
rare O
hereditary O
allele O
cancer O
other O
factors O
by O
adjusting O
for O
. O
not O
known O
risk O
altered O
a O
The B
with I
was I
( O
the O
) O
the O

The O
magnitude O
of O
the O
comparative O
adventure O
associated O
with O
a O
rarified O
HRAS1 O
allelomorph O
was O
not O
vary O
by O
conform O
for O
the O
other O
jazz O
adventure O
factors O
for O
genetic B
ovarian I
crab I
( O
5 O
) O
. O

The O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
rare O
HRAS1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
the O
other O
known O
risk O
factors O
for O
hereditary B
ovarian I
cancer I
( O
5 O
) O
. O

by O
to O
breast B
to I
did O
not O
appear O
cancer O
rare O
affected O
of O
the O
Susceptibility O
presence O
be O
HRAS1 O
alleles O
. O

susceptibility O
to O
tit B
cancer I
did O
not O
appear O
to O
be O
involve O
by O
the O
mien O
of O
rare O
HRAS1 O
alleles O
. O

susceptibleness O
to O
summit B
cancer I
did O
not O
appear O
to O
be O
affected O
by O
the O
bearing O
of O
rarified O
HRAS1 O
allelomorph O
. O

Susceptibility O
to O
breast B
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
HRAS1 O
alleles O
. O

susceptibility O
to O
breast B
cancer I
did O
not O
appear O
to O
be O
move O
by O
the O
comportment O
of O
rarified O
HRAS1 O
allelomorph O
. O

Susceptibility O
to O
bosom O
breast B
cancer I
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
HRAS1 O
alleles O
titty O
titty O
titty O
bosom O
. O

Susceptibility O
to O
breast B
cancer I
did O
not O
appear O
to O
be O
affected O
the O
presence O
rare O
HRAS1 O
alleles O
. O

Susceptibility O
to O
bosom O
breast B
cancer I
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
HRAS1 O
alleles O
titty O
titty O
titty O
bosom O
. O

to O
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
. O

Susceptibility O
to O
be B
rare I
did O
not O
presence O
to O
breast O
affected O
by O
the O
appear O
of O
cancer O
HRAS1 O
alleles O
. O

Susceptibility O
to O
breast B
cancer I
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
HRAS1 O
alleles O
. O

This O
meditate O
is O
the O
first O
to O
prove O
the O
effect O
of O
a O
modifying O
factor O
on O
the O
penetrance O
of O
an O
hereditary B
cancer I
syndrome I

This O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
on O
the O
penetrance O
of O
an O
genus O
cancer O
be O
be O
be O
be O
be B
inherited I
cancer I

This O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
on O
the O
penetrance O
of O
an O
genus O
cancer O
be O
be O
be O
be O
be B
inherited I
cancer I

This O
study O
is O
the O
first O
to O
show O
the O
of O
a O
gene O
on O
the O
penetrance O
of O
an O
inherited B

the O
study O
effect O
show O
first O
to O
penetrance O
the O
is O
of O
a O
modifying O
syndrome O
on O
the O
This O
of O
an O
inherited B
cancer I
gene I

This O
report O
is O
the O
first O
to O
appearance O
the O
outcome O
of O
a O
qualify O
factor O
on O
the O
penetrance O
of O
an O
transmissible B
cancer I
syndrome I

syndrome O
study O
is O
a O
first O
to O
show O
inherited O
the O
of O
the O
modifying O
on O
gene O
effect O
penetrance O
of O
an O
the B
This I
cancer I

This O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
on O
the O
penetrance O
of O
an O
genus O
cancer O
be O
be O
be O
be O
cistron B
inherited I
cancer I

This O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
the O
an O
inherited B
cancer I
syndrome I

This O
examine O
is O
the O
offset O
to O
evince O
the O
effect O
of O
a O
qualify O
factor O
on O
the O
penetrance O
of O
an O
inherited B
crab I
syndrome I

This O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
on O
the O
penetrance O
of O
an O
inherited B
cancer I
syndrome I

A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
precarious O
northward O
ingeminate O
northward O
ingeminate O
ingeminate O
antiophthalmic O
factor O
unstable O
( O
CTG O
) O
n O
repeat O

- O
encoding O
gene O
is O
associated O
with O
a O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
( O
) O
n O
repeat O
. O

A O
refreshing O
homeodomain O
- O
encode O
factor O
is O
associated O
with O
a O
tumid O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
unsound O
( O
CTG O
) O
n O
iterate O
. O

A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
CpG O
island O
by O
the O
myotonic B
dystrophy I
unstable O
( O
CTG O
repeat O
. O

A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
precarious O
northward O
ingeminate O
northward O
ingeminate O
ingeminate O
aside O
unstable O
( O
CTG O
) O
n O
repeat O
. O

A O
fresh O
homeodomain O
- O
encryption O
factor O
is O
assort O
with O
a O
prominent O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
unsound O
( O
CTG O
) O
n O
ingeminate O
. O

adenine O
fresh O
homeodomain O
- O
encode O
factor O
is O
colligate O
with O
adenine O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
precarious O
( O
CTG O
) O
n O
duplicate O
. O

A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
island O
the O
myotonic B
dystrophy I
unstable O
( O
CTG O
) O
n O
repeat O

A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
precarious O
northward O
ingeminate O
northward O
ingeminate O
ingeminate O
aside O
unstable O
( O
CTG O
) O
n O
repeat O
. O

( O
novel O
homeodomain O
large O
encoding O
gene O
is O
unstable O
repeat O
a O
- O
CpG O
interrupted O
island O
n O
the O
myotonic B
dystrophy I
associated O
. O
CTG O
) O
by O
with O
A O

A O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
CpG O
island O
interrupted O
by O
the O
myotonic B
dystrophy I
unstable O
( O
CTG O
) O
n O
repeat O
. O

myotonic B
dystrophy I
( O
decimeter B
) O
is O
associated O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
repetition O
enlargement O
in O
the O
tercet O
- O
untranslated O
realm O
of O
a O
protein O
kinase O
- O
encryption O
cistron O
, O
DMPK O
, O
which O
function O
to O
chromosome O
19q13 O
. O

dystrophy I
( O
DM B
) O
is O
associated O
with O
a O
n O
trinucleotide O
repeat O
expansion O
in O
3 O
- O
a O
- O
encoding O
DMPK O
maps O
to O
chromosome O
19q13 O

encoding B
to I
( O
DM B
in O
is O
untranslated O
, O
a O
( O
CTG O
) O
n O
protein O
. O
expansion O
) O
DMPK O
3 O
- O
with O
region O
of O
a O
dystrophy O
kinase O
- O
Myotonic O
the O
, O
gene O
associated O
which O
maps O
trinucleotide O
chromosome O
19q13 O
repeat O

Myotonic B
dystrophy I
( O
DM B
) O
is O
a O
( O
CTG O
) O
trinucleotide O
repeat O
expansion O
in O
the O
- O
untranslated O
region O
of O
protein O
kinase O
encoding O
gene O
, O
DMPK O
, O
which O
maps O
to O
19q13 O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
19q13 O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
19q13 O
. O

myotonic B
dystrophy I
( O
decimeter B
) O
is O
link O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
ingeminate O
enlargement O
in O
the O
trey O
- O
untranslated O
area O
of O
a O
protein O
kinase O
- O
encode O
factor O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
19q13 O
. O

protein B
3 I
( O
DM B
) O
is O
) O
maps O
a O
( O
CTG O
associated O
n O
encoding O
, O
expansion O
in O
the O
with O
- O
untranslated O
region O
gene O
a O
Myotonic O
kinase O
, O
trinucleotide O
repeat O
of O
DMPK O
chromosome O
which O
dystrophy O
to O
- O
19q13 O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
 O
19q13 O
. O

Myotonic B
dystrophy I
) O
is O
with O
a O
n O
repeat O
expansion O
in O
3 O
- O
untranslated O
of O
a O
protein O
kinase O
- O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
19q13 O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
DMPK O
, O
which O
maps O
to O
chromosome O
19q13 O
. O

. O

. O

. O
3 O

 O
3 O
. O

. O
3 O

troika O
. O

 O
3 O
. O

terzetto O
. O

 O
3 O
. O

3 O
. O

characterisation O
of O
the O
construction O
of O
this O
cistron O
in O
patient O
tissues O
has O
frankincense O
alir O
engender O
conflicting O
data O
on O
alterations O
in O
the O
steadily O
commonwealth O
tier O
of O
DMPK O
mRNA O
, O
and O
on O
the O
last O
DMPK O
protein O
tier O
in O
the O
mien O
of O
the O
enlargement O
. O

delineation O
of O
the O
formula O
of O
this O
factor O
in O
patient O
tissues O
has O
therefore O
interahamwe O
generated O
conflicting O
data O
on O
change O
in O
the O
sweetheart O
dos O
raze O
of O
DMPK O
mrna O
, O
and O
on O
the O
net O
DMPK O
protein O
raze O
in O
the O
comportment O
of O
the O
expansion O
. O

Characterisation O
of O
gene O
in O
patient O
has O
thus O
far O
conflicting O
data O
on O
alterations O
in O
state O
levels O
of O
DMPK O
mRNA O
, O
and O
on O
DMPK O
levels O
in O
the O
of O
the O
expansion O
. O

Characterisation O
of O
DMPK O
expression O
of O
on O
mRNA O
in O
patient O
tissues O
has O
of O
and O
generated O
conflicting O
final O
on O
alterations O
the O
in O
steady O
state O
levels O
the O
DMPK O
, O
far O
protein O
this O
the O
data O
of O
gene O
levels O
in O
thus O
presence O
the O
the O
expansion O
. O

DMPK O
in O
the O
expression O
of O
this O
thus O
state O
patient O
tissues O
has O
gene O
far O
and O
the O
data O
on O
alterations O
. O
the O
steady O
in O
on O
of O
Characterisation O
mRNA O
DMPK O
generated O
conflicting O
levels O
final O
the O
protein O
of O
in O
, O
presence O
of O
the O
expansion O
levels O

Characterisation O
of O
the O
expression O
gene O
in O
patient O
tissues O
thus O
far O
generated O
conflicting O
data O
alterations O
in O
the O
steady O
levels O
of O
mRNA O
, O
and O
on O
the O
final O
DMPK O
protein O
in O
the O
of O
the O
expansion O
. O

Characterisation O
of O
the O
expression O
of O
this O
gene O
in O
patient O
tissues O
has O
thus O
far O
generated O
conflicting O
data O
on O
alterations O
in O
the O
steady O
state O
levels O
of O
DMPK O
mRNA O
, O
and O
on O
the O
final O
DMPK O
protein O
levels O
in O
the O
along O
along O
elaboration O
along O
along O
along O
along O
along O
along O
along O
along O
along O
presence O
of O
the O
expansion O
. O

Characterisation O
of O
the O
expression O
in O
patient O
tissues O
has O
thus O
generated O
conflicting O
in O
state O
levels O
mRNA O
on O
the O
final O
DMPK O
levels O
in O
of O
the O
. O

characterisation O
of O
the O
construction O
of O
this O
factor O
in O
patient O
weave O
has O
thence O
interahamwe O
generated O
conflicting O
datum O
on O
revision O
in O
the O
sweetie O
state O
degree O
of O
DMPK O
mRNA O
, O
and O
on O
the O
final O
DMPK O
protein O
degree O
in O
the O
mien O
of O
the O
expansion O
. O

Characterisation O
of O
the O
expression O
of O
this O
gene O
in O
patient O
tissues O
has O
thus O
far O
generated O
conflicting O
data O
on O
alterations O
in O
the O
steady O
state O
levels O
of O
DMPK O
mRNA O
, O
and O
on O
the O
final O
DMPK O
protein O
levels O
in O
the O
along O
along O
elaboration O
along O
along O
along O
along O
along O
along O
along O
along O
along O
presence O
of O
the O
expansion O
. O

Characterisation O
of O
the O
expression O
of O
this O
gene O
in O
patient O
tissues O
has O
thus O
far O
generated O
conflicting O
data O
on O
alterations O
in O
the O
steady O
state O
levels O
of O
DMPK O
mRNA O
, O
and O
on O
the O
final O
DMPK O
protein O
levels O
in O
the O
presence O
of O
the O
expansion O
. O

The O
DM B
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
chromatin O
granule O
hurly O
burly O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
of O
chromatin O

The O
DM B
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
chromatin O
granule O
hurly O
burly O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
of O
chromatin O

The O
DM B
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
chromatin O
granule O
hurly O
burly O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
of O
chromatin O

number O
may B
region O
of O
chromosome O
19 O
it O
as O
rich O
, O
and O
is O
is O
units O
the O
the O
repeat O
expansion O
gene O
lead O
to O
perhaps O
in O
a O
The O
of O
, O
possible O
that O
of O
vicinity O
consequence O
dysfunction O
DM O
a O
transcription O
of O
chromatin O
disruption O
. O

The O
DM B
region O
of O
gene O
rich O
, O
and O
it O
possible O
that O
may O
dysfunction O
of O
of O
in O
the O
vicinity O
, O
as O
a O
chromatin O
disruption O

The O
decimeter B
part O
of O
chromosome O
19 O
is O
cistron O
rich O
, O
and O
it O
is O
potential O
that O
the O
recur O
expansion O
may O
lead O
to O
disfunction O
of O
a O
turn O
of O
arranging O
units O
in O
the O
neighborhood O
, O
perchance O
as O
a O
event O
of O
chromatin O
disruption O
. O

The O
DM B
part O
of O
chromosome O
19 O
is O
cistron O
copious O
, O
and O
it O
is O
potential O
that O
the O
duplicate O
expansion O
may O
run O
to O
disfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perchance O
as O
a O
effect O
of O
chromatin O
disruption O
. O

vicinity O
a B
region O
of O
repeat O
19 O
chromatin O
, O
rich O
, O
and O
it O
is O
number O
expansion O
the O
chromosome O
that O
may O
lead O
possible O
dysfunction O
of O
a O
DM O
of O
transcription O
disruption O
The O
the O
in O
is O
perhaps O
as O
to O
consequence O
of O
gene O
units O
. O

The O
decimetre B
region O
of O
chromosome O
nineteen O
is O
factor O
ample O
, O
and O
it O
is O
potential O
that O
the O
repeat O
elaboration O
may O
lead O
to O
disfunction O
of O
a O
count O
of O
transcription O
whole O
in O
the O
neighbourhood O
, O
perhaps O
as O
a O
outcome O
of O
chromatin O
kerfuffle O
. O

The O
DM B
vicinity O
of O
chromosome O
consequence O
and O
gene O
rich O
, O
is O
transcription O
lead O
possible O
that O
may O
repeat O
expansion O
chromatin O
is O
to O
dysfunction O
of O
19 O
number O
the O
it O
perhaps O
, O
the O
region O
units O
in O
as O
a O
a O
of O
of O
disruption O
. O

The O
DM B
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
of O
chromatin O
disruption O
. O

at O
have O
searched O
a O
genes O
associated O
with O
for O
of O
island O
end O
the O
We O
3 O
CpG O
DMPK O
. O

We O
have O
seek O
for O
cistron O
colligate O
with O
a O
CpG O
island O
at O
the O
threesome O
finish O
of O
DMPK O
. O

We O
have O
seek O
for O
cistron O
relate O
with O
a O
CpG O
island O
at O
the O
tercet O
finish O
of O
DMPK O
. O

We O
have O
genes O
associated O
with O
a O
CpG O
island O
at O
the O
3 O
end O
of O
DMPK O
. O

We O
have O
research O
for O
cistron O
associated O
with O
a O
CpG O
island O
at O
the O
triad O
last O
of O
DMPK O
. O

We O
have O
antiophthalmic O
factor O
look O
for O
searched O
for O
genes O
associated O
with O
a O
CpG O
island O
at O
the O
3 O
end O
of O
DMPK O
goal O
goal O

We O
have O
searched O
for O
genes O
associated O
with O
a O
island O
at O
3 O
end O
of O
DMPK O
. O

We O
have O
antiophthalmic O
factor O
look O
for O
searched O
for O
genes O
associated O
with O
a O
CpG O
island O
at O
the O
3 O
end O
of O
DMPK O
goal O
goal O

have O
genes O
associated O
with O
a O
CpG O
island O
at O
the O
3 O

We O
have O
CpG O
of O
genes O
associated O
3 O
a O
searched O
island O
at O
the O
with O
end O
for O
DMPK O
. O

We O
have O
searched O
for O
genes O
associated O
with O
a O
CpG O
island O
at O
the O
3 O
end O
of O
DMPK O
. O

Sequencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
 O
usher O
usher O
over O
3 O
. O

of O
this O
the O
over O
3 O
. O

sequence O
of O
this O
region O
display O
that O
the O
island O
protract O
over O
3 O
. O

Sequencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
 O
usher O
usher O
over O
3 O
. O

of O
this O
shows O
that O
the O
island O
extends O
over O
3 O
. O

sequence O
of O
this O
area O
shows O
that O
the O
island O
go O
over O
3 O
. O

Sequencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
 O
usher O
pass O
over O
3 O
. O

sequence O
of O
this O
area O
picture O
that O
the O
island O
extends O
over O
3 O
. O

Sequencing O
island O
this O
region O
of O
that O
the O
3 O
extends O
over O
shows O
. O

. O
of O
this O
region O
island O
that O
over O
shows O
extends O
the O
3 O
Sequencing O

Sequencing O
of O
this O
region O
shows O
that O
the O
island O
extends O
over O
3 O
. O

5 O
and O
is O
by O
( O
) O
n O
repeat O
. O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
CTG O
) O
n O
repeat O

fin O
kilobit O
and O
is O
interrupted O
by O
the O
( O
CTG O
) O
n O
ingeminate O
. O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
CTG O
ingeminate O
ingeminate O
kibibyte O
) O
n O
repeat O
. O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
CTG O
ingeminate O
ingeminate O
be O
) O
n O
repeat O
. O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
CTG O
ingeminate O
ingeminate O
kibibyte O
) O
n O
repeat O
. O

phoebe O
kilobyte O
and O
is O
interrupted O
by O
the O
( O
CTG O
) O
n O
replicate O
. O

5 O
kb O
is O
interrupted O
by O
the O
( O
CTG O
) O
. O

quint O
kib O
and O
is O
interrupted O
by O
the O
( O
CTG O
) O
n O
ingeminate O
. O

5 O
interrupted O
and O
is O
. O
by O
the O
kb O
CTG O
) O
n O
repeat O
( O

5 O
kb O
and O
is O
interrupted O
by O
the O
( O
CTG O
) O
n O
repeat O
. O

compare O
of O
genomic O
sequences O
downriver O
( O
centromeric O
) O
of O
the O
ingeminate O
in O
human O
and O
mouse O
discover O
part O
of O
substantial O
homology O
. O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
episode O
episode O
episode O
episode O
episode O
episode O
significant O
homology O
. O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
episode O
episode O
episode O
episode O
episode O
episode O
significant O
homology O
. O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
the O
repeat O
human O
and O
mouse O
identified O
regions O
of O
significant O

mouse O
of O
of O
centromeric O
downstream O
( O
identified O
) O
genomic O
the O
repeat O
in O
. O
and O
sequences O
Comparison O
regions O
of O
significant O
homology O
human O

comparison O
of O
genomic O
successiveness O
downriver O
( O
centromeric O
) O
of O
the O
duplicate O
in O
human O
and O
mouse O
identified O
area O
of O
substantial O
homology O
. O

. O
of O
genomic O
repeat O
downstream O
( O
centromeric O
significant O
mouse O
the O
sequences O
in O
and O
human O
of O
identified O
regions O
of O
) O
Comparison O
homology O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
episode O
episode O
episode O
episode O
episode O
pregnant O
significant O
homology O
. O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
mouse O
of O
significant O
homology O
. O

compare O
of O
genomic O
sequences O
downriver O
( O
centromeric O
) O
of O
the O
ingeminate O
in O
human O
and O
pussyfoot O
distinguish O
regions O
of O
substantial O
homology O
. O

Comparison O
of O
genomic O
sequences O
downstream O
( O
centromeric O
) O
of O
the O
repeat O
in O
human O
and O
mouse O
identified O
regions O
of O
significant O
homology O
. O

These O
to O
of O
gene O
predicted O
to O
encode O
a O
homeodomain O
protein O
. O

These O
equate O
to O
exons O
of O
a O
cistron O
auspicate O
to O
encode O
a O
homeodomain O
protein O
. O

predicted O
exons O
to O
correspond O
of O
a O
encode O
These O
to O
. O
a O
homeodomain O
protein O
gene O

These O
correspond O
to O
exons O
of O
a O
gene O
predicted O
encode O
a O
protein O
. O

These O
correspond O
foreshadow O
exon O
to O
exons O
of O
a O
gene O
predicted O
to O
equate O
equate O
encode O
a O
homeodomain O
protein O
. O

These O
correspond O
foreshadow O
exon O
to O
exons O
of O
a O
gene O
predicted O
to O
equate O
antiophthalmic O
factor O
encode O
a O
homeodomain O
protein O

These O
tally O
to O
exons O
of O
a O
cistron O
foreshadow O
to O
encode O
a O
homeodomain O
protein O
. O

protein O
correspond O
to O
These O
predicted O
a O
gene O
homeodomain O
to O
encode O
a O
of O
exons O
. O

These O
correspond O
foreshadow O
exon O
to O
exons O
of O
a O
gene O
predicted O
to O
equate O
equate O
encode O
a O
homeodomain O
protein O
. O

These O
tally O
to O
exons O
of O
a O
cistron O
foretell O
to O
encode O
a O
homeodomain O
protein O
. O

These O
correspond O
to O
exons O
of O
a O
gene O
predicted O
to O
encode O
a O
homeodomain O
protein O
. O

RT O
- O
PCR O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
DM B
locus O
- O
associated O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
usher O
brainiac O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
heart O
and O
brain O
. O

RT O
- O
PCR O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
DM B
locus O
- O
associated O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
usher O
brainiac O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
locale O
heart O
and O
brain O
. O

RT O
- O
PCR O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
DM B
locus O
- O
associated O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
usher O
brainiac O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
heart O
and O
brain O
. O

expressed O
protein O
PCR O
analysis O
shows O
that O
have O
skeletal O
, O
which O
we O
this O
called O
number B
human O
- O
associated O
homeodomain O
gene O
( O
DMAHP O
including O
of O
is O
RT O
in O
, O
DM O
locus O
, O
tissues O
, O
) O
- O
muscle O
a O
heart O
and O
brain O
. O

RT O
- O
PCR O
analysis O
gene O
, O
which O
we O
have O
DM B
locus O
protein O
) O
, O
in O
of O
human O
tissues O
, O
skeletal O
muscle O
and O
brain O

RT O
- O
PCR O
analysis O
evidence O
that O
this O
cistron O
, O
which O
we O
have O
called O
decimeter B
venue O
- O
assort O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
come O
of O
homo O
weave O
, O
include O
bony O
brawn O
, O
spirit O
and O
brain O
. O

RT O
- O
PCR O
analysis O
establish O
that O
this O
cistron O
, O
which O
we O
have O
called O
dm B
venue O
- O
consort O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
convey O
in O
a O
bit O
of O
homo O
tissues O
, O
admit O
emaciated O
muscle O
, O
middle O
and O
wit O
. O

tissues O
muscle O
PCR O
analysis O
associated O
that O
and O
, O
, O
which O
we O
have O
called O
expressed B
homeodomain O
- O
shows O
locus O
protein O
( O
DM O
) O
, O
is O
- O
in O
a O
brain O
RT O
human O
of O
this O
including O
skeletal O
DMAHP O
, O
heart O
gene O
number O
. O

RT O
- O
PCR O
analysis O
exhibit O
that O
this O
factor O
, O
which O
we O
have O
visit O
dm B
locale O
- O
relate O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
turn O
of O
human O
tissues O
, O
admit O
cadaverous O
muscularity O
, O
fondness O
and O
genius O
. O

RT O
- O
tissues O
analysis O
shows O
, O
we O
gene O
, O
which O
this O
a O
( O
DM B
locus O
protein O
associated O
homeodomain O
and O
called O
DMAHP O
) O
, O
that O
expressed O
- O
have O
including O
, O
human O
PCR O
number O
of O
skeletal O
muscle O
is O
heart O
in O
brain O
. O

RT O
- O
PCR O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
DM B
locus O
- O
associated O
homeodomain O
protein O
( O
DMAHP O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
heart O
and O
brain O
. O

Germline O
mutations O
in O
the O
RB1 O
gene O
in O
patients O
with O
mutation O
mutation O
mutation O
hereditary B
retinoblastoma I
. O

mutations O
in O
in O
hereditary B
retinoblastoma I
. O

Germline O
mutations O
in O
the O
RB1 O
cistron O
in O
patients O
with O
patrimonial B
retinoblastoma I
. O

Germline O
mutations O
in O
the O
RB1 O
gene O
in O
patients O
with O
mutation O
mutation O
mutation O
hereditary B
retinoblastoma I
. O

mutations O
in O
RB1 O
gene O
in O
patients O
with O
hereditary B
retinoblastoma I
. O

Germline O
mutations O
in O
the O
RB1 O
factor O
in O
patients O
with O
genetic B
retinoblastoma I
. O

Germline O
mutations O
in O
the O
RB1 O
gene O
in O
patients O
with O
mutation O
mutation O
mutation O
hereditary B
retinoblastoma I
. O

Germline O
sport O
in O
the O
RB1 O
factor O
in O
patients O
with O
genetic B
retinoblastoma I
. O

Germline O
patients O
in O
the O
mutations O
gene O
in O
retinoblastoma O
with O
hereditary B
RB1 I
. O

. O
mutations O
in O
the O
patients O
gene O
hereditary O
RB1 O
with O
in B
retinoblastoma I
Germline O

Germline O
mutations O
in O
the O
RB1 O
gene O
in O
patients O
with O
hereditary B
retinoblastoma I
. O

We O
have O
analyzed O
the O
xxvii O
exons O
and O
the O
impresario O
part O
of O
the O
RB1 O
gene O
in O
transmitted B
or I
sporadic I
bilateral I
retinoblastoma I
by O
using O
one O
- O
chain O
abidance O
pleomorphism O
analysis O
. O

We O
have O
analyzed O
the O
27 O
and O
region O
of O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

by O
have O
analyzed O
bilateral O
27 O
exons O
and O
conformation O
- O
region O
. O
the O
RB1 O
retinoblastoma O
single O
familial B
or I
sporadic I
the I
gene I
strand O
using O
in O
promoter O
We O
the O
polymorphism O
analysis O
of O

We O
have O
analyzed O
the O
string O
cistron O
inward O
transmissible O
 O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
form I
pleomorphism I
plugger I
bilateral I
retinoblastoma I
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

We O
have O
analyzed O
the O
string O
cistron O
inward O
transmissible O
 O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
form I
pleomorphism I
inward I
bilateral I
retinoblastoma I
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

We O
have O
analyzed O
the O
27 O
exons O
and O
the O
region O
of O
RB1 O
gene O
in O
familial B
or I
sporadic I
bilateral I
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

. O
have O
analyzed O
in O
27 O
exons O
conformation O
the O
the O
region O
of O
the O
polymorphism O
gene O
strand O
promoter B
or I
sporadic I
bilateral I
retinoblastoma I
RB1 O
using O
single O
- O
familial O
and O
by O
analysis O
We O

We O
have O
analyzed O
the O
27 O
exons O
and O
the O
region O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
bilateral I
by O
using O
single O
- O
strand O
conformation O
polymorphism O

We O
have O
analyzed O
the O
xxvii O
exons O
and O
the O
impresario O
region O
of O
the O
RB1 O
gene O
in O
genetic B
or I
sporadic I
bilateral I
retinoblastoma I
by O
exploitation O
exclusive O
- O
string O
shape O
pleomorphism O
analysis O
. O

We O
have O
analyzed O
the O
27 O
exons O
and O
the O
plugger O
neighborhood O
of O
the O
RB1 O
factor O
in O
transmitted B
or I
sporadic I
bilateral I
retinoblastoma I
by O
employ O
individual O
- O
strand O
abidance O
pleomorphism O
analysis O
. O

We O
have O
analyzed O
the O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
RB1 O
gene O
in O
familial B
or I
sporadic I
bilateral I
retinoblastoma I
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

For O
advance O
over O
former O
studies O
, O
a O
new O
prepare O
of O
primers O
has O
been O
intentional O
, O
which O
admit O
for O
elaboration O
of O
the O
inscribe O
and O
splice O
sequences O
only O
. O

For O
improvement O
previous O
studies O
, O
a O
new O
set O
of O
primers O
has O
been O
which O
allow O
for O
amplification O
the O
coding O
and O
splicing O
sequences O
. O

For O
improvement O
over O
previous O
episode O
antiophthalmic O
factor O
meditate O
studies O
, O
a O
new O
set O
of O
primers O
has O
been O
designed O
, O
which O
allow O
for O
wed O
episode O
simply O
episode O
coiffure O
amplification O
of O
the O
coding O
and O
splicing O
sequences O
only O

the O
improvement O
over O
amplification O
studies O
, O
a O
only O
splicing O
of O
of O
has O
been O
designed O
and O
which O
allow O
for O
previous O
sequences O
primers O
coding O
, O
set O
For O
new O
. O

For O
improvement O
over O
previous O
episode O
antiophthalmic O
factor O
meditate O
studies O
, O
a O
new O
set O
of O
primers O
has O
been O
designed O
, O
which O
allow O
for O
wed O
episode O
simply O
episode O
coiffure O
amplification O
of O
the O
coding O
and O
splicing O
sequences O
only O

For O
improvement O
over O
studies O
, O
new O
set O
of O
primers O
has O
been O
designed O
, O
allow O
for O
of O
the O
coding O
and O
splicing O
sequences O
only O
. O

. O
improvement O
over O
, O
studies O
, O
only O
new O
previous O
of O
primers O
has O
designed O
the O
sequences O
set O
allow O
for O
amplification O
of O
been O
coding O
and O
splicing O
which O
a O
For O

over O
, O
a O
new O
of O
primers O
been O
designed O
, O
which O
allow O
for O
amplification O
of O
the O
coding O
and O
splicing O
sequences O

splicing O
improvement O
over O
previous O
studies O
, O
designed O
has O
set O
of O
primers O
allow O
coding O
a O
sequences O
For O
new O
which O
amplification O
of O
the O
been O
and O
for O
, O
only O
. O

For O
melioration O
over O
late O
read O
, O
a O
new O
bent O
of O
fuse O
has O
been O
contrive O
, O
which O
allow O
for O
elaboration O
of O
the O
coding O
and O
tie O
sequences O
only O
. O

For O
improvement O
over O
previous O
studies O
, O
a O
new O
set O
of O
primers O
has O
been O
designed O
, O
which O
allow O
for O
amplification O
of O
the O
coding O
and O
splicing O
sequences O
only O
. O

The O
positioning O
exons O
the O
polymerase O
chain O
reaction O
were O
PCR O
) O
primers O
which O
of O
that O
the O
( O
PCR O
products O
banding O
such O
different O
. O
, O
was O
enabled O
resulting O
analyze O
and O
two O
different O
of O
biplex O
simultaneously O
still O
distinguish O
) O
the O
us O
profiles O
for O
both O
( O
to O
analysis O
between O
sizes O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
primers O
was O
such O
that O
the O
resulting O
PCR O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
exons O
simultaneously O
and O
still O
distinguish O
between O
at O
the O
same O
time O
depth O
psychology O
profile O
at O
the O
same O
time O
depth O
psychology O
at O
the O
same O
time O
at O
the O
same O
time O
depth O
psychology O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
primers O
was O
such O
that O
the O
resulting O
PCR O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
exons O
simultaneously O
and O
still O
distinguish O
between O
at O
the O
same O
time O
depth O
psychology O
profile O
at O
the O
same O
time O
depth O
psychology O
at O
the O
same O
time O
at O
the O
same O
time O
depth O
psychology O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
) O
primers O
was O
that O
resulting O
PCR O
products O
different O
us O
to O
analyze O
different O
exons O
and O
still O
distinguish O
banding O
profiles O
for O
both O
( O
analysis O
. O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
PCR O
primers O
was O
such O
that O
the O
different O
which O
us O
to O
analyze O
different O
exons O
simultaneously O
and O
still O
distinguish O
profiles O
for O
both O
( O
biplex O
analysis O
) O

distinguish O
were O
of O
the O
polymerase O
chain O
( O
( O
PCR O
) O
primers O
both O
such O
analyze O
different O
resulting O
PCR O
products O
still O
of O
different O
sizes O
two O
which O
analysis O
us O
simultaneously O
that O
the O
enabled O
exons O
between O
and O
positioning O
The O
to O
the O
banding O
profiles O
for O
was O
reaction O
biplex O
, O
) O
. O

The O
location O
of O
the O
polymerase O
chain O
response O
( O
PCR O
) O
undercoat O
was O
such O
that O
the O
resulting O
PCR O
products O
were O
of O
dissimilar O
sizes O
, O
which O
enabled O
us O
to O
examine O
deuce O
dissimilar O
exons O
simultaneously O
and O
nonetheless O
distinguish O
between O
the O
ring O
visibility O
for O
both O
( O
biplex O
analysis O
) O
. O

The O
put O
of O
the O
polymerase O
range O
response O
( O
PCR O
) O
primers O
was O
such O
that O
the O
lead O
PCR O
production O
were O
of O
dissimilar O
sizing O
, O
which O
enabled O
us O
to O
analyse O
two O
dissimilar O
exons O
simultaneously O
and O
smooth O
discover O
between O
the O
stria O
profiles O
for O
both O
( O
biplex O
analysis O
) O
. O

The O
locating O
of O
the O
polymerase O
chain O
response O
( O
PCR O
) O
primers O
was O
such O
that O
the O
resulting O
PCR O
production O
were O
of O
unlike O
sizes O
, O
which O
enabled O
uranium O
to O
canvass O
ii O
unlike O
exons O
simultaneously O
and O
still O
signalise O
between O
the O
striation O
profiles O
for O
both O
( O
biplex O
analysis O
) O
. O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
primers O
was O
such O
that O
the O
resulting O
PCR O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
exons O
simultaneously O
and O
still O
distinguish O
between O
at O
the O
same O
time O
depth O
psychology O
profile O
at O
the O
same O
time O
depth O
psychology O
at O
the O
same O
time O
at O
the O
same O
time O
depth O
psychology O

The O
positioning O
of O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
primers O
was O
such O
that O
the O
resulting O
PCR O
products O
were O
of O
different O
sizes O
, O
which O
enabled O
us O
to O
analyze O
two O
different O
exons O
simultaneously O
and O
still O
distinguish O
between O
the O
banding O
profiles O
for O
both O
( O
biplex O
analysis O
) O
. O

By O
using O
regimen O
approach O
, O
we O
in O
overall O
to O
identify O
mutation O
a O
efficiency O
new O
patients O
single O
but O
the O
was O
22 O
of O
only O
procedure O
when O
we O
, O
were O
the O
- O
pass O
this O
able O
used O
48 O
% O
. O

using O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
22 O
new O
patients O
, O
but O
the O
overall O
the O
procedure O
when O
used O
single O
- O
pass O
only O

aside O
practice O
this O
approach O
, O
we O
were O
able O
to O
distinguish O
variation O
in O
xxii O
unexampled O
patients O
, O
but O
the O
boilersuit O
efficiency O
of O
the O
subroutine O
when O
we O
employ O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
. O

single O
of O
this O
approach O
but O
we O
patients O
was O
to O
identify O
mutation O
in O
22 O
we O
able O
, O
, O
regimen O
overall O
efficiency O
new O
the O
procedure O
when O
using O
used O
a O
By O
the O
pass O
- O
were O
only O
48 O
% O
. O

By O
using O
this O
approach O
simply O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
merely O
merely O
merely O
merely O
merely O
merely O
merely O
merely O
be O
. O

we O
overall O
this O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
single O
pass O
, O
but O
the O
48 O
efficiency O
of O
the O
- O
when O
By O
used O
was O
new O
patients O
procedure O
regimen O
. O
only O
% O
using O
a O

By O
using O
this O
approach O
we O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
. O

away O
victimization O
this O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
routine O
when O
we O
exploited O
a O
unity O
- O
lapse O
regimen O
was O
only O
48 O
% O
. O

By O
using O
this O
approach O
newly O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
new O
new O
new O
new O
new O
new O
new O
new O
be O
. O

aside O
use O
this O
approach O
, O
we O
were O
able O
to O
name O
mutation O
in O
22 O
unexampled O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
process O
when O
we O
used O
a O
unmarried O
- O
sink O
regimen O
was O
only O
48 O
% O
. O

By O
using O
this O
approach O
, O
we O
were O
able O
to O
identify O
mutation O
in O
22 O
new O
patients O
, O
but O
the O
overall O
efficiency O
of O
the O
procedure O
when O
we O
used O
a O
single O
- O
pass O
regimen O
was O
only O
48 O
% O
. O

The O
mutations O
deletion O
be O
be O
were O
small O
insertions O
and O
deletions O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O
follow O
. O

proportions O
mutations O
were O
. O
insertions O
and O
deletions O
and O
. O
mutations O
in O
roughly O
The O
equal O
point O
small O

The O
mutations O
deletion O
be O
equate O
were O
small O
insertions O
and O
deletions O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O
follow O
. O

The O
mutations O
were O
lowly O
interpolation O
and O
deletions O
and O
point O
mutations O
in O
roughly O
rival O
balance O
. O
. O

equal O
mutations O
were O
and O
insertions O
and O
proportions O
small O
point O
mutations O
The O
roughly O
in O
deletions O
. O
. O

The O
mutations O
deletion O
be O
be O
were O
small O
insertions O
and O
deletions O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O
follow O
. O

The O
mutations O
were O
low O
insertions O
and O
excision O
and O
degree O
mutations O
in O
about O
equal O
proportions O
. O
. O

The O
mutations O
were O
humble O
interpolation O
and O
omission O
and O
point O
mutations O
in O
roughly O
equal O
ratio O
. O
. O

The O
mutations O
point O
. O
insertions O
and O
equal O
and O
were O
mutations O
in O
roughly O
deletions O
proportions O
small O
. O

mutations O
were O
small O
insertions O
and O
deletions O
and O
in O
roughly O
equal O
proportions O
. O
. O

The O
mutations O
were O
small O
insertions O
and O
deletions O
and O
point O
mutations O
in O
roughly O
equal O
proportions O
. O
. O

human B
II I
Type I
. I
C2 I
deficiency I
complement O

Type B
deuce I
human I
accompaniment I
C2 I
deficiency I
. O

Type B
two B
II I
human I
complement I
homo I
C2 I
deficiency I
. O

Type B
human I
C2 I
. O

complement B
Type I
human I
II I
C2 I
deficiency I
. O

Type B
two I
human I
complement I
C2 I
insufficiency I
. O

Type B
two I
human I
complement I
C2 I
want I
. O

Type B
II I
human I
. I
C2 I
complement I
deficiency O

Type B
II I
human I
complement I
C2 I
. O

Type B
two B
II I
human I
complement I
accompaniment I
C2 I
deficiency I
. O

Type B
II I
human I
complement I
C2 I
deficiency I
. O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
do O
secernment O
impair O
secernment O
secernment O
particular O
particular O
) O
cause O
impaired O
C2 O
secretion O
. O

specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
) O
impaired O
C2 O
secretion O
. O

allele O
- O
particular O
aminic O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
) O
case O
afflicted O
C2 O
secernment O
. O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
- O
- O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
impaired O
C2 O
secretion O
. O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
do O
secernment O
impair O
secernment O
secernment O
particular O
particular O
) O
cause O
impaired O
C2 O
secretion O
. O

allelomorph O
- O
particular O
amino O
pane O
exchange O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
) O
have O
afflicted O
C2 O
secernment O
. O

allelomorph O
- O
particular O
amino O
acid O
replacement O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
) O
reason O
spoil O
C2 O
secernment O
. O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
> O
Gly444 O
- O
- O
> O
Arg O
) O
cause O
impaired O
C2 O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
do O
secernment O
impair O
secernment O
secernment O
particular O
particular O
) O
cause O
impaired O
C2 O
secretion O
. O

Arg O
- O
specific O
> O
acid O
substitutions O
( O
) O
. O
- O
amino O
Phe O
; O
Gly444 O
secretion O
- O
> O
impaired O
Ser189 O
Allele O
cause O
C2 O
- O
- O

Allele O
- O
specific O
amino O
acid O
substitutions O
( O
Ser189 O
- O
- O
> O
Phe O
; O
Gly444 O
- O
- O
> O
Arg O
) O
cause O
impaired O
C2 O
secretion O
. O

Type B
II I
be I
characterise I
accompaniment I
complement I
protein I
C2 I
deficiency I
is O
characterized O
by O
a O
selective O
block O
in O
C2 O
secretion O
lack O
. O

C2 B
II I
complement I
. I
C2 I
deficiency I
is O
characterized O
secretion O
a O
selective O
block O
Type O
in O
by O
protein O

Type B
II I
be I
characterise I
aside I
complement I
protein I
C2 I
deficiency I
is O
characterized O
by O
a O
selective O
block O
in O
C2 O
secretion O
lack O
. O

character B
two I
accompaniment I
protein I
C2 I
deficiency I
is O
qualify O
by O
a O
selective O
block O
in O
C2 O
secretion O
. O

in B
II I
complement I
characterized I
C2 I
deficiency I
C2 O
protein O
by O
a O
Type O
block O
selective O
is O
secretion O
. O

Type B
II I
be I
characterise I
accompaniment I
complement I
protein I
C2 I
deficiency I
is O
characterized O
by O
a O
selective O
block O
in O
C2 O
secretion O
lack O
. O

typecast B
II I
complement I
protein I
C2 I
want I
is O
characterise O
by O
a O
selective O
block O
in O
C2 O
secernment O
. O

Type B
ii I
complement I
protein I
C2 I
want I
is O
characterise O
by O
a O
selective O
block O
in O
C2 O
secernment O
. O

Type B
II I
by I
. I
C2 I
deficiency I
in O
characterized O
complement O
a O
selective O
block O
is O
C2 O
protein O
secretion O

II I
complement I
protein I
C2 I
deficiency I
is O
characterized O
selective O
block O
in O
C2 O
secretion O
. O

Type B
II I
complement I
protein I
C2 I
deficiency I
is O
characterized O
by O
a O
selective O
block O
in O
C2 O
secretion O
. O

The O
Type O
II O
C2 O
john O
roy O
major O
allelomorph O
haplotype O
void O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
differ O
from O
the O
MHC O
of O
the O
more B
common I
Type I
I I
C2 O
deficiency O
 O
 O
 O
 O

The O
Type O
II O
allele O
linked O
to O
two O
histocompatibility O
haplotypes O
MHC O
) O
that O
the O
MHC O
of O
the O
more O
Type B
C2 I
deficiency I
. O

The O
character O
ii O
C2 O
aught O
allelomorph O
( O
C2Q0 O
) O
is O
join O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
disagree O
from O
the O
MHC O
of O
the O
more O
plebeian O
character B
one I
C2 I
lack I
. O

The O
Type O
II O
C2 O
null O
allele O
( O
) O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
of O
the O
more O
common O
Type B
I I
C2 I
deficiency I
. O

The O
eccentric O
deuce O
C2 O
zippo O
allelomorph O
( O
C2Q0 O
) O
is O
linked O
to O
deuce O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
dissent O
from O
the O
MHC O
of O
the O
more O
coarse O
eccentric B
I I
C2 I
want I
. O

The O
Type O
II O
C2 O
john O
roy O
major O
allelomorph O
haplotype O
void O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
differ O
from O
the O
MHC O
of O
the O
more B
common I
Type I
I I
C2 O
deficiency O
 O
 O
 O
 O

The O
typewrite O
II O
C2 O
cipher O
allelomorph O
( O
C2Q0 O
) O
is O
yoke O
to O
deuce O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
dissent O
from O
the O
MHC O
of O
the O
more O
green O
typewrite B
ane I
C2 I
lack I
. O

differ O
) O
II O
C2 O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
of O
I O
haplotypes O
( O
MHC O
common O
that O
Type O
from O
deficiency O
MHC O
major O
the O
more O
The O
histocompatibility B
the I
C2 I
Type I
. O

The O
Type O
II O
C2 O
null O
allele O
C2Q0 O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
) O
that O
differ O
from O
the O
MHC O
of O
common O
Type B
I I
deficiency I

The O
Type O
II O
C2 O
john O
roy O
major O
allelomorph O
haplotype O
character O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
differ O
from O
the O
MHC O
of O
the O
more B
common I
Type I
I I
C2 O
deficiency O
 O
 O
 O
 O

The O
Type O
II O
C2 O
null O
allele O
( O
C2Q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
MHC O
) O
that O
differ O
from O
the O
MHC O
of O
the O
more O
common O
Type B
I I
C2 I
deficiency I
. O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
 O
on O
an O
individual O
basis O
jail O
cell O
 O
jail O
cell O
jail O
cell O
lack O
transfected O

molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
separately O
L O
- O
cells O
. O

To O
shape O
the O
molecular O
fundament O
of O
Type B
deuce I
deficiency I
the O
deuce O
Type O
deuce O
C2Q0 O
genes O
were O
stranded O
and O
transfected O
singly O
into O
l O
- O
cells O
. O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
Type O
II O
genes O
were O
isolated O
and O
transfected O
separately O
into O
cells O
. O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
 O
on O
an O
individual O
basis O
jail O
cell O
 O
jail O
cell O
jail O
cell O
lack O
transfected O

To O
determine O
the O
molecular O
groundwork O
of O
eccentric B
II I
lack I
the O
deuce O
eccentric O
II O
C2Q0 O
cistron O
were O
quarantined O
and O
transfected O
severally O
into O
L O
- O
cells O
. O

To O
ascertain O
the O
molecular O
fundament O
of O
case B
II I
insufficiency I
the O
ii O
case O
II O
C2Q0 O
cistron O
were O
isolated O
and O
transfected O
severally O
into O
L O
- O
cells O
. O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
II O
were O
isolated O
and O
transfected O
separately O
into O
L O
- O
cells O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
 O
on O
an O
individual O
basis O
jail O
cell O
 O
jail O
cell O
jail O
cell O
lack O
transfected O

separately O
determine O
the O
two O
basis O
of O
Type B
transfected I
cells I
the O
molecular O
Type O
C2Q0 O
II O
- O
were O
isolated O
and O
II O
. O
into O
L O
genes O
deficiency O
To O

To O
determine O
the O
molecular O
basis O
of O
Type B
II I
deficiency I
the O
two O
Type O
II O
C2Q0 O
genes O
were O
isolated O
and O
transfected O
separately O
into O
L O
- O
cells O
. O

Subsequent O
molecular O
each O
, O
biosynthetic O
, O
C2 O
C2 O
studies O
demonstrated O
that O
highly O
deficiency O
is O
impaired O
conserved O
Type B
II I
of I
secretion I
because O
the O
different O
missense O
mutations O
in O
and O
of O
residues O
in O
biology O
immunofluorescence O
at O
C2Q0 O
alleles O
. O

molecular O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
of O
different O
missense O
at O
conserved O
residues O
in O
the O

subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
sketch O
demonstrated O
that O
C2 O
secernment O
is O
mar O
in O
Type B
ii I
C2 I
inadequacy I
because O
of O
unlike O
missense O
mutant O
at O
extremely O
conserved O
residuum O
in O
each O
of O
the O
C2Q0 O
alleles O
. O

conserved O
because O
biology O
, O
Type O
, O
impaired O
of O
studies O
demonstrated O
that O
C2 O
secretion O
mutations O
immunofluorescence O
in O
biosynthetic B
each I
C2 I
deficiency I
is O
of O
different O
missense O
molecular O
at O
highly O
Subsequent O
II O
in O
residues O
and O
the O
C2Q0 O
alleles O
. O

Subsequent O
molecular O
biology O
, O
character O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
deficiency I
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O

mutations O
C2 O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
conserved O
in O
in O
Type B
II I
C2Q0 I
deficiency I
because O
of O
residues O
missense O
Subsequent O
at O
of O
is O
impaired O
different O
each O
. O
the O
alleles O
molecular O
highly O

Subsequent O
molecular O
biology O
, O
, O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
. O

subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secernment O
is O
deflower O
in O
typewrite B
ii I
C2 I
want I
because O
of O
dissimilar O
missense O
mutations O
at O
extremely O
maintain O
residuum O
in O
each O
of O
the O
C2Q0 O
alleles O
. O

Subsequent O
molecular O
biology O
, O
husband O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
deficiency I
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
economise O
economise O
economise O
economise O
economise O
economise O
economise O
economise O
inward O
. O

Subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
contemplate O
prove O
that O
C2 O
secretion O
is O
vitiate O
in O
typewrite B
ii I
C2 I
deficiency I
because O
of O
unlike O
missense O
sport O
at O
extremely O
preserve O
residues O
in O
each O
of O
the O
C2Q0 O
allelomorph O
. O

Subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
C2 O
secretion O
is O
impaired O
in O
Type B
II I
C2 I
deficiency I
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
C2Q0 O
alleles O
. O

unmatchable O
is O
in O
exon O
pentad O
( O
base O
C566 O
- O
- O
> O
thyroxin O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
cistron O
yoke O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
C4A0B1 O
. O

is O
in O
exon O
5 O
( O
nucleotide O
C566 O
- O
; O
Ser189 O
- O
- O
> O
) O
of O
linked O
MHC O
haplotype O
B35 O
, O
BFS O
, O
C4A0B1 O

haplotype O
BFS O
in O
exon O
> O
( O
the O
, O
- O
- O
> O
T O
; O
to O
. O
- O
5 O
B35 O
) O
of O
C566 O
C2Q0 O
gene O
linked O
is O
the O
MHC O
One O
Phe O
, O
A11 O
nucleotide O
DRw1 O
, O
Ser189 O
, O
C4A0B1 O
- O

One O
is O
in O
exon O
5 O
( O
- O
- O
> O
T O
Ser189 O
- O
- O
> O
Phe O
of O
the O
C2Q0 O
gene O
to O
the O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
C4A0B1 O
. O

One O
is O
in O
exon O
5 O
( O
nucleotide O
C566 O
- O
- O
> O
T O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
C4A0B1 O
. O

One O
is O
in O
exon O
5 O
( O
nucleotide O
C566 O
- O
- O
> O
T O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
C4A0B1 O
. O

unitary O
is O
in O
exon O
pentad O
( O
base O
C566 O
- O
- O
> O
T O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
cistron O
linked O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
C4A0B1 O
. O

to O
) O
in O
exon O
5 O
( O
T O
, O
- O
- O
> O
nucleotide O
; O
haplotype O
, O
- O
> O
Phe O
C566 O
of O
the O
C2Q0 O
A11 O
linked O
One O
the O
, O
Ser189 O
- O
gene O
B35 O
, O
DRw1 O
is O
BFS O
MHC O
C4A0B1 O
. O

One O
is O
in O
exon O
5 O
( O
nucleotide O
C566 O
- O
- O
> O
T O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
unite O
C4A0B1 O
. O

One O
is O
5 O
( O
C566 O
- O
; O
- O
- O
> O
) O
of O
the O
gene O
linked O
to O
the O
MHC O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
C4A0B1 O

One O
is O
in O
exon O
5 O
( O
nucleotide O
C566 O
- O
- O
> O
T O
; O
Ser189 O
- O
- O
> O
Phe O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A11 O
, O
B35 O
, O
DRw1 O
, O
BFS O
, O
C4A0B1 O
. O

The O
other O
is O
in O
exon O
xi O
( O
G1930 O
- O
- O
> O
a O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
factor O
join O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
C4A3B1 O
. O

other O
is O
in O
exon O
11 O
( O
G1930 O
- O
; O
Gly444 O
- O
- O
> O
) O
of O
linked O
MHC O
haplotype O
B5 O
, O
BFS O
, O
C4A3B1 O

haplotype O
BFS O
is O
in O
> O
11 O
the O
, O
- O
- O
> O
A O
; O
to O
. O
- O
exon O
B5 O
) O
of O
G1930 O
C2Q0 O
gene O
linked O
other O
the O
MHC O
The O
Arg O
, O
A2 O
( O
DRw4 O
, O
Gly444 O
, O
C4A3B1 O
- O

The O
other O
is O
in O
exon O
11 O
- O
- O
> O
A O
Gly444 O
- O
- O
> O
Arg O
of O
the O
C2Q0 O
gene O
to O
the O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
C4A3B1 O
. O

The O
other O
is O
in O
exon O
11 O
( O
G1930 O
- O
- O
> O
A O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O

The O
other O
is O
in O
exon O
11 O
( O
G1930 O
- O
- O
> O
A O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O

The O
other O
is O
in O
exon O
xi O
( O
G1930 O
- O
- O
> O
A O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
cistron O
connect O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
C4A3B1 O
. O

to O
) O
is O
in O
exon O
11 O
A O
, O
- O
- O
> O
( O
; O
haplotype O
, O
- O
> O
Arg O
G1930 O
of O
the O
C2Q0 O
A2 O
linked O
The O
the O
, O
Gly444 O
- O
gene O
B5 O
, O
DRw4 O
other O
BFS O
MHC O
C4A3B1 O
. O

The O
other O
is O
in O
exon O
11 O
( O
G1930 O
- O
- O
> O
A O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O

The O
other O
exon O
11 O
G1930 O
- O
; O
- O
- O
> O
) O
of O
the O
gene O
linked O
to O
the O
MHC O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
C4A3B1 O

The O
other O
is O
in O
exon O
11 O
( O
G1930 O
- O
- O
> O
A O
; O
Gly444 O
- O
- O
> O
Arg O
) O
of O
the O
C2Q0 O
gene O
linked O
to O
the O
MHC O
haplotype O
A2 O
, O
B5 O
, O
DRw4 O
, O
BFS O
, O
C4A3B1 O
. O

Each O
C2 O
gene O
is O
early O
the O
secretory O
pathway O
. O

Each O
mutant O
C2 O
gene O
product O
is O
retained O
early O
in O
the O
secretory O
pathway O

Each O
mutation O
C2 O
gene O
product O
is O
maintained O
other O
in O
the O
secretory O
pathway O
. O

Each O
mutant O
C2 O
gene O
product O
is O
retained O
early O
in O
nerve O
tract O
nerve O
tract O
mutation O
the O
secretory O

Each O
mutant O
C2 O
gene O
product O
is O
retained O
early O
in O
nerve O
tract O
nerve O
tract O
inward O
the O
secretory O

Each O
mutant O
C2 O
gene O
product O
is O
retained O
early O
in O
nerve O
tract O
nerve O
tract O
mutation O
the O
secretory O

Each O
sport O
C2 O
factor O
product O
is O
retained O
early O
in O
the O
secretory O
tract O
. O

Each O
mutant O
gene O
product O
is O
retained O
early O
in O
the O
. O

apiece O
variation O
C2 O
factor O
product O
is O
retained O
early O
in O
the O
secretory O
pathway O
. O

Each O
product O
C2 O
gene O
. O
is O
retained O
mutant O
in O
the O
secretory O
pathway O
early O

Each O
mutant O
C2 O
gene O
product O
is O
retained O
early O
in O
the O
secretory O
pathway O
. O

These O
mutants O
provide O
models O
for O
elucidating O
the O
C2 O
secretory O
mutation O
mutation O
mutation O
pathway O
. O
. O

mutants O
provide O
the O
pathway O
. O
. O

These O
mutation O
provide O
simulate O
for O
elucidating O
the O
C2 O
secretory O
footpath O
. O
. O

These O
mutants O
provide O
models O
for O
elucidating O
the O
C2 O
secretory O
mutation O
mutation O
mutation O
pathway O
. O
. O

mutants O
provide O
for O
elucidating O
the O
C2 O
secretory O
pathway O
. O
. O

These O
variation O
provide O
models O
for O
clear O
the O
C2 O
secretory O
tract O
. O
. O

These O
mutants O
provide O
models O
for O
elucidating O
the O
C2 O
secretory O
mutation O
mutation O
allow O
for O
pathway O
. O

These O
mutation O
render O
models O
for O
elucidating O
the O
C2 O
secretory O
footpath O
. O
. O

These O
C2 O
provide O
models O
mutants O
elucidating O
the O
. O
secretory O
pathway O
for O
. O

. O
mutants O
provide O
models O
C2 O
elucidating O
pathway O
for O
secretory O
the O
. O
These O

These O
mutants O
provide O
models O
for O
elucidating O
the O
C2 O
secretory O
pathway O
. O
. O

disease O
dimerization O
of O
Cys B
Willebrand I
factor O
subunits O
von O
mutation O
a O
von O
- O
Arg O
> O
to O
in O
type B
IID I
due I
Defective I
Willebrand I
. O

Defective O
dimerization O
of O
von B
Willebrand I
factor O
subunits O
due O
to O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type B
IID I
erik I
adolf I
von I
willebrand I
inward I
inward I
inward I
inward I
inward I
von O

Defective O
dimerization O
of O
von B
Willebrand I
factor O
subunits O
due O
to O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type B
IID I
erik I
adolf I
von I
willebrand I
inward I
inward I
inward I
inward I
inward I
von O

defective O
dimerization O
of O
von B
Willebrand I
agent O
subunits O
imputable O
to O
a O
Cys O
- O
> O
Arg O
mutant O
in O
type B
IID I
von I
Willebrand I
disease I
. O

Defective O
dimerization O
of O
Willebrand I
factor O
subunits O
due O
to O
Cys O
- O
> O
Arg O
in O
type B
von I
Willebrand I
disease I
. O

von B
subunits O
due O
to O
Cys O
- O
Arg O
mutation O
in O
type B
IID I
von I
Willebrand I
disease I
. O

defective O
dimerization O
of O
von B
Willebrand I
factor O
subunits O
ascribable O
to O
a O
Cys O
- O
> O
Arg O
mutant O
in O
type B
IID I
von I
Willebrand I
disease I
. O

mutation O
dimerization O
to O
subunits B
Willebrand I
factor O
in O
due O
of O
a O
Cys O
- O
disease O
Arg O
von O
Defective O
type B
IID I
von I
Willebrand I
> I
. O

Defective O
dimerization O
of O
von B
Willebrand I
factor O
subunits O
due O
to O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type B
IID I
erik I
adolf I
von I
willebrand I
inward I
inward I
inward I
inward I
constituent I
von O

Defective O
dimerization O
of O
von B
subunits O
due O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type B
IID I
von I
. O

Defective O
dimerization O
of O
von B
Willebrand I
factor O
subunits O
due O
to O
a O
Cys O
- O
> O
Arg O
mutation O
in O
type B
IID I
von I
Willebrand I
disease I
. O

same O
heterozygous O
T O
C O
transition O
at O
nt O
8567 O
the O
Willebrand I
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
patients O
with O
type B
IID I
von I
other O
. O

The O
same O
heterozygous O
T O
- O
> O
C O
transition O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B
IID I
von I
Willebrand I
disease I
, O
with O
no O
other O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
apparent O
abnormality O
. O

Willebrand O
was O
heterozygous O
T O
( O
> O
abnormality O
disease O
at O
nt O
8567 O
of O
the O
unrelated B
vWF I
factor O
- O
Willebrand O
) O
transcript O
von O
found O
in O
two O
same O
patients O
with O
. B
The I
von I
IID I
C I
, O
with O
no O
other O
apparent O
transition O
type O

The O
same O
heterozygous O
- O
transition O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
factor O
was O
found O
in O
two O
unrelated O
patients O
with O
type B
IID I
von I
Willebrand I
disease I
, O
with O
no O
apparent O
. O

The O
same O
heterozygous O
t O
- O
> O
C O
modulation O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
constituent O
( O
vWF O
) O
copy O
was O
find O
in O
deuce O
unrelated O
patients O
with O
eccentric B
IID I
von I
Willebrand I
disease I
, O
with O
no O
other O
seeming O
freakishness O
. O

unrelated O
) O
heterozygous O
T O
- O
> O
of O
transition O
at O
nt O
8567 O
C O
the O
type B
von I
factor O
( O
vWF O
with O
transcript O
was O
found O
IID O
two O
The O
patients O
disease O
von B
Willebrand I
in I
Willebrand I
other I
, O
no O
same O
with O
apparent O
abnormality O
. O

The O
same O
heterozygous O
T O
- O
> O
C O
transition O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B
IID I
von I
Willebrand I
disease I
, O
with O
no O
other O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
apparent O
abnormality O
. O

The O
same O
heterozygous O
T O
- O
> O
C O
transition O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B
IID I
von I
Willebrand I
disease I
, O
with O
no O
other O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
conversion O
deoxycytidine O
monophosphate O
apparent O
abnormality O

The O
same O
heterozygous O
T O
- O
> O
C O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
vWF O
) O
transcript O
found O
two O
unrelated O
patients O
IID I
with O
no O
other O
abnormality O
. O

The O
same O
Willebrand O
T O
- O
> O
C O
) O
at O
nt O
8567 O
with O
transcript O
von B
Willebrand I
transition O
( O
vWF O
abnormality O
the O
was O
, O
in O
other O
unrelated O
factor O
of O
found B
IID I
von I
heterozygous I
type I
disease O
with O
no O
two O
apparent O
patients O
. O

The O
same O
heterozygous O
T O
- O
> O
C O
transition O
at O
nt O
8567 O
of O
the O
von B
Willebrand I
factor O
( O
vWF O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B
IID I
von I
Willebrand I
disease I
, O
with O
no O
other O
apparent O
abnormality O
. O

one O
family O
, O
both O
alleles O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
the O
originated O
de O
novo O
in O
the O
proposita O
. O

parents O
one O
family O
mutation O
both O
alleles O
were O
. O
the O
the O
proposita O
and O
one O
originated O
in O
thus O
, O
the O
, O
sister O
de O
novo O
; O
in O
In O
normal O

indiana O
unmatchable O
kin O
, O
both O
allelomorph O
were O
pattern O
indiana O
the O
parents O
and O
unmatchable O
babe O
; O
thus O
, O
the O
sport O
originated O
de O
novo O
indiana O
the O
proposita O
. O

in O
nonpareil O
family O
, O
both O
alleles O
were O
convention O
in O
the O
raise O
and O
nonpareil O
sister O
; O
so O
, O
the O
variation O
originated O
de O
novo O
in O
the O
proposita O
. O

In O
one O
family O
, O
both O
alleles O
were O
normal O
in O
the O
and O
one O
; O
thus O
, O
the O
mutation O
originated O
de O
the O
proposita O
. O

In O
one O
family O
, O
pattern O
both O
alleles O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
, O
the O
inward O
first O
state O
inward O
inward O
phratry O
inward O
mutation O
originated O
de O
novo O
in O
the O
proposita O

In O
one O
family O
, O
pattern O
both O
alleles O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
, O
the O
inward O
first O
state O
inward O
inward O
phratry O
inward O
mutation O
originated O
de O
novo O
in O
the O
proposita O

In O
one O
family O
, O
both O
alleles O
were O
normal O
in O
the O
and O
; O
thus O
, O
the O
mutation O
originated O
de O
novo O
in O

the O
one O
family O
, O
both O
alleles O
sister O
, O
in O
the O
parents O
and O
novo O
were O
proposita O
thus O
normal O
de O
mutation O
originated O
In O
one O
in O
the O
; O
. O

inch O
i O
family O
, O
both O
alleles O
were O
pattern O
inch O
the O
raise O
and O
i O
sister O
; O
olibanum O
, O
the O
mutation O
develop O
de O
novo O
inch O
the O
proposita O
. O

In O
one O
family O
, O
both O
alleles O
were O
normal O
in O
the O
parents O
and O
one O
sister O
; O
thus O
, O
the O
mutation O
originated O
de O
novo O
in O
the O
proposita O
. O

, O
second O
patient O
who O
had O
asymptomatic O
parents O
also O
for O
however O
available O
were O
The O
not O
, O
study O
. O

The O
mo O
patient O
also O
had O
asymptomatic O
rear O
who O
, O
still O
, O
were O
not O
useable O
for O
learn O
. O

The O
second O
patient O
also O
had O
symptomless O
parents O
who O
, O
however O
, O
were O
not O
uncommitted O
for O
bailiwick O
. O

The O
second O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
. O

The O
endorse O
patient O
likewise O
had O
symptomless O
parents O
who O
, O
however O
, O
were O
not O
uncommitted O
for O
work O
. O

The O
second O
world O
health O
organization O
patient O
role O
patient O
also O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
rear O

The O
second O
patient O
also O
had O
asymptomatic O
parents O
who O
however O
, O
not O
available O
for O
study O
. O

The O
second O
world O
health O
organization O
patient O
role O
patient O
also O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
rear O

second O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O

The O
second O
, O
for O
had O
asymptomatic O
not O
who O
patient O
however O
, O
were O
parents O
available O
also O
study O
. O

The O
second O
patient O
also O
had O
asymptomatic O
parents O
who O
, O
however O
, O
were O
not O
available O
for O
study O
. O

The O
structural O
- O
of O
the O
CyS2010 O
mutation O
of O
resulting O
in O
the O
vWF O
domain O
> O
Arg O
1366 O
, O
were O
by O
evaluated O
expression O
, O
the O
identified O
carboxyl O
terminal O
consequences O
2050 O
containing O
residues O
substitution O
- O
- O
. O

The O
of O
the O
identified O
mutation O
resulting O
in O
- O
> O
substitution O
, O
expression O
the O
vWF O
carboxyl O
terminal O
domain O
containing O
1366 O
- O
2050 O
. O

The O
structural O
consequences O
of O
identify O
permutation O
aside O
the O
identified O
mutation O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
vWF O
carboxyl O
- O
terminal O
domain O
containing O
residues O
1366 O
- O
2050 O
key O
out O
key O
out O
key O
out O
key O
out O

The O
structural O
consequences O
of O
identify O
permutation O
hold O
back O
the O
identified O
mutation O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
vWF O
carboxyl O
- O
terminal O
domain O
containing O
residues O
1366 O
- O
2050 O
key O
out O
key O
out O
key O
out O
key O

structural O
evaluated O
consequences O
of O
the O
identified O
terminal O
, O
resulting O
in O
the O
domain O
- O
carboxyl O
residues O
substitution O
, O
were O
CyS2010 O
by O
expression O
of O
. O
vWF O
> O
- O
mutation O
The O
- O
the O
1366 O
containing O
2050 O
Arg O

The O
structural O
consequences O
of O
the O
identified O
resulting O
in O
the O
CyS2010 O
> O
Arg O
substitution O
, O
were O
by O
expression O
of O
the O
carboxyl O
- O
domain O
containing O
residues O
1366 O
- O
2050 O
. O

The O
morphologic O
outcome O
of O
the O
place O
sport O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
permutation O
, O
were O
evaluated O
by O
aspect O
of O
the O
vWF O
carboxyl O
- O
final O
arena O
control O
remainder O
1366 O
- O
2050 O
. O

The O
geomorphological O
import O
of O
the O
key O
variation O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
replacement O
, O
were O
evaluated O
by O
look O
of O
the O
vWF O
carboxyl O
- O
concluding O
field O
take O
balance O
1366 O
- O
2050 O
. O

The O
structural O
consequences O
of O
identify O
permutation O
hold O
back O
the O
identified O
mutation O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
vWF O
carboxyl O
- O
terminal O
domain O
containing O
residues O
1366 O
- O
2050 O
key O
out O
key O
out O
key O
out O
key O

The O
geomorphological O
result O
of O
the O
describe O
mutation O
, O
lead O
in O
the O
CyS2010 O
- O
> O
Arg O
replacement O
, O
were O
measure O
by O
reflexion O
of O
the O
vWF O
carboxyl O
- O
terminal O
world O
carry O
residual O
1366 O
- O
2050 O
. O

The O
structural O
consequences O
of O
the O
identified O
mutation O
, O
resulting O
in O
the O
CyS2010 O
- O
> O
Arg O
substitution O
, O
were O
evaluated O
by O
expression O
of O
the O
vWF O
carboxyl O
- O
terminal O
domain O
containing O
residues O
1366 O
- O
2050 O
. O

cells O
infected O
with O
expressing O
normal O
vWF O
sequence O
secreted O
disulfide O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
reduction O
, O
yielding O
a O
single O
disulfide O
. O

Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
disulfide O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
bond O
reduction O
. O

band O
mass O
infected O
with O
with O
baculovirus O
reduction O
of O
vWF O
sequence O
secreted O
a O
disulfide O
before O
an O
molecule O
recombinant O
dimeric O
apparent O
molecular O
linked O
of O
150 O
kDa O
cells O
reduction O
, O
. O
Insect O
single O
a O
expressing O
80 O
kDa O
after O
disulfide O
bond O
normal O
yielding O

Insect O
cells O
infected O
recombinant O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
bond O
. O

worm O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
rule O
vWF O
episode O
release O
a O
disulfide O
join O
dimeric O
particle O
with O
an O
seeming O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
relent O
a O
unity O
circle O
of O
80 O
kDa O
after O
disulfide O
bond O
reduction O
. O

before O
apparent O
infected O
with O
recombinant O
baculovirus O
a O
normal O
vWF O
sequence O
secreted O
expressing O
disulfide O
yielding O
single O
molecule O
with O
an O
kDa O
molecular O
mass O
of O
a O
kDa O
Insect O
reduction O
of O
linked O
dimeric O
150 O
band O
disulfide O
80 O
after O
cells O
, O
bond O
reduction O
. O

Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
disulfide O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
bond O
reduction O
. O

Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
disulfide O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
pattern O
verbalise O
bond O
reduction O
. O

Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
an O
apparent O
molecular O
of O
kDa O
before O
reduction O
a O
kDa O
after O
disulfide O
reduction O
. O

Insect O
cells O
band O
with O
recombinant O
baculovirus O
expressing O
apparent O
vWF O
sequence O
secreted O
, O
molecular O
linked O
dimeric O
normal O
with O
an O
reduction O
disulfide O
mass O
80 O
150 O
disulfide O
before O
molecule O
a O
of O
a O
single O
infected O
yielding O
of O
kDa O
after O
kDa O
bond O
reduction O
. O

Insect O
cells O
infected O
with O
recombinant O
baculovirus O
expressing O
normal O
vWF O
sequence O
secreted O
a O
disulfide O
linked O
dimeric O
molecule O
with O
an O
apparent O
molecular O
mass O
of O
150 O
kDa O
before O
reduction O
, O
yielding O
a O
single O
band O
of O
80 O
kDa O
after O
disulfide O
bond O
reduction O
. O

contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secreted O
a O
monomeric O
molecule O
of O
apparent O
molecular O
mass O
80 O
, O
which O
remained O
unchanged O
after O
reduction O
. O

monomeric O
contrast O
, O
kDa O
expressing O
the O
mutant O
. O
after O
a O
reduction O
molecule O
of O
, O
unchanged O
mass O
of O
80 O
cells O
apparent O
which O
remained O
molecular O
secreted O
In O
fragment O

In O
contrast O
, O
cells O
verbalize O
the O
variation O
shard O
secreted O
a O
monomeric O
atom O
of O
apparent O
molecular O
mass O
of O
eighty O
kDa O
, O
which O
continue O
unaltered O
after O
reduction O
. O

In O
contrast O
, O
cadre O
expressing O
the O
sport O
shard O
secreted O
a O
monomeric O
corpuscle O
of O
seeming O
molecular O
mass O
of O
eighty O
kDa O
, O
which O
remained O
unaltered O
after O
reduction O
. O

In O
contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secreted O
a O
molecule O
of O
molecular O
mass O
of O
80 O
kDa O
, O
which O
after O
reduction O
. O

In O
contrast O
, O
cells O
verbalise O
expressing O
the O
mutant O
fragment O
secreted O
a O
monomeric O
molecule O
of O
apparent O
molecular O
mass O
of O
80 O
unaltered O
later O
reducing O
later O
reducing O
release O
kDa O
, O
which O
remained O
unchanged O
after O
reduction O
. O

In O
contrast O
, O
cells O
verbalise O
expressing O
the O
mutant O
fragment O
secreted O
a O
monomeric O
molecule O
of O
apparent O
molecular O
mass O
of O
80 O
unaltered O
later O
reducing O
later O
reducing O
stay O
kDa O
, O
which O
remained O
unchanged O
after O
reduction O
. O

In O
contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secreted O
a O
molecule O
molecular O
mass O
of O
80 O
kDa O
, O
which O
remained O
unchanged O

after O
contrast O
, O
cells O
expressing O
the O
apparent O
of O
secreted O
a O
monomeric O
molecule O
remained O
mutant O
reduction O
mass O
fragment O
which O
kDa O
, O
In O
of O
unchanged O
80 O
molecular O
. O

In O
counterpoint O
, O
cells O
expressing O
the O
variation O
fragment O
release O
a O
monomeric O
molecule O
of O
ostensible O
molecular O
mass O
of O
lxxx O
kDa O
, O
which O
continue O
unaltered O
after O
reduction O
. O

In O
contrast O
, O
cells O
expressing O
the O
mutant O
fragment O
secreted O
a O
monomeric O
molecule O
of O
apparent O
molecular O
mass O
of O
80 O
kDa O
, O
which O
remained O
unchanged O
after O
reduction O
. O

formation O
terminal O
that O
CyS2010 O
is O
essential O
. O
normal O
dimerization O
of O
vWF O
disease O
through O
mutation O
is O
of O
carboxyl O
- O
corresponding O
domains O
and O
that O
in O
heterozygous O
disulfide O
in O
multimer O
conclude O
for O
a O
responsible O
codon O
defective O
bonding O
We O
the O
type B
IID I
von I
Willebrand I
subunits I
for O
. O

We O
conclude O
that O
is O
essential O
for O
normal O
dimerization O
of O
vWF O
disulfide O
bonding O
of O
- O
domains O
and O
that O
mutation O
is O
responsible O
for O
multimer O
formation O
type B
IID I
von I
. O
. O

We O
reason O
that O
CyS2010 O
is O
requisite O
for O
formula O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
bonding O
of O
carboxyl O
- O
last O
domains O
and O
that O
a O
heterozygous O
mutation O
in O
the O
jibe O
codon O
is O
responsible O
for O
faulty O
multimer O
organisation O
in O
case B
IID I
von I
willebrand I
disease I
. O
. O

We O
reason O
that O
CyS2010 O
is O
requisite O
for O
rule O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
attach O
of O
carboxyl O
- O
pole O
demesne O
and O
that O
a O
heterozygous O
sport O
in O
the O
check O
codon O
is O
creditworthy O
for O
bad O
multimer O
organization O
in O
type B
IID I
von I
willebrand I
disease I
. O
. O

We O
conclude O
for O
CyS2010 O
is O
essential O
for O
terminal O
dimerization O
of O
vWF O
through O
. O
disulfide O
bonding O
responsible O
carboxyl O
- O
domains O
normal O
and O
defective O
a O
in O
mutation O
the O
corresponding O
that O
codon O
is O
of O
IID O
in O
multimer O
formation O
heterozygous O
type B
that I
von I
Willebrand I
disease I
. O
subunits O

We O
conclude O
that O
is O
normal O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
bonding O
of O
and O
that O
a O
heterozygous O
mutation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
defective O
multimer O
formation O
type B
von I
Willebrand I
disease I
. O
. O

We O
conclude O
that O
CyS2010 O
is O
essential O
for O
normal O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
bonding O
of O
carboxyl O
- O
terminal O
domains O
and O
that O
a O
heterozygous O
mutation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
defective O
multimer O
formation O
in O
be O
be O
erik O
adolf O
von O
willebrand O
be O
be O
be O
be O
be O
be O
be B
be I
be I
type I
IID I
von O
Willebrand O

von O
mutation O
that O
CyS2010 O
carboxyl O
essential O
and O
for O
dimerization O
of O
vWF O
subunits O
through O
for O
IID O
of O
is O
responsible O
terminal O
domains O
disulfide O
that O
a O
heterozygous O
corresponding O
in O
the O
. O
- O
is O
codon O
conclude O
defective O
multimer O
formation O
in O
type B
bonding I
We I
Willebrand I
disease I
normal O
. O

We O
conclude O
that O
is O
for O
normal O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
bonding O
of O
- O
terminal O
domains O
and O
that O
corresponding O
responsible O
defective O
multimer O
formation O
type B
IID I
von I
Willebrand I
disease I
. O

We O
reason O
that O
CyS2010 O
is O
essential O
for O
rule O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
stick O
of O
carboxyl O
- O
final O
domains O
and O
that O
a O
heterozygous O
variation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
bad O
multimer O
organization O
in O
case B
IID I
von I
willebrand I
disease I
. O
. O

We O
conclude O
that O
CyS2010 O
is O
essential O
for O
normal O
dimerization O
of O
vWF O
subunits O
through O
disulfide O
bonding O
of O
carboxyl O
- O
terminal O
domains O
and O
that O
a O
heterozygous O
mutation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
defective O
multimer O
formation O
in O
type B
IID I
von I
Willebrand I
disease I
. O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
new O
effecter O
for O
the O
GTPase O
CDC42Hs O
, O
is O
concerned O
in O
actin O
polymerisation O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
novel O
effector O
for O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
effecter O
effecter O
effecter O
effecter O
effecter O
effecter O
polymerization O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
novel O
effector O
for O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
effecter O
effecter O
effecter O
effecter O
effecter O
effecter O
polymerization O
. O

Aldrich I
, O
a O
novel O
for O
the O
CDC42Hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
novel O
effector O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

Aldrich I
syndrome I
protein O
, O
novel O
effector O
for O
the O
GTPase O
, O
is O
implicated O
in O
polymerization O
. O

actin B
- I
Aldrich I
polymerization I
protein O
, O
a O
effector O
novel O
for O
is O
GTPase O
CDC42Hs O
. O
Wiskott O
implicated O
in O
the O
syndrome O
, O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
novel O
effector O
for O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
effecter O
effecter O
effecter O
effecter O
polymerisation O
polymerization O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
refreshing O
effecter O
for O
the O
GTPase O
CDC42Hs O
, O
is O
entail O
in O
actin O
polymerisation O
. O

in B
- I
Aldrich I
syndrome I
protein O
, O
, O
GTPase O
effector O
for O
the O
is O
Wiskott O
a O
novel O
actin O
CDC42Hs O
implicated O
polymerization O
. O

Wiskott B
- I
Aldrich I
syndrome I
protein O
, O
a O
novel O
effector O
for O
the O
GTPase O
CDC42Hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

The O
Rho O
various O
biologic O
phratry O
family O
of O
GTPases O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mitogenesis O
ascertain O
. O

and O
Rho O
family O
. O
GTPases O
control O
diverse O
biological O
mitogenesis O
, O
including O
cell O
The O
morphology O
processes O
of O

The O
Rho O
various O
biologic O
biologic O
family O
of O
GTPases O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mitogenesis O
ascertain O
. O

The O
rho O
menage O
of O
GTPases O
moderate O
diverse O
biological O
processes O
, O
include O
cell O
morphology O
and O
mitogenesis O
. O

morphology O
Rho O
family O
biological O
GTPases O
control O
and O
of O
processes O
, O
The O
cell O
including O
diverse O
mitogenesis O
. O

The O
Rho O
various O
biologic O
phratry O
family O
of O
GTPases O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mitogenesis O
ascertain O
. O

The O
rho O
folk O
of O
GTPases O
master O
diverse O
biological O
processes O
, O
admit O
cell O
morphology O
and O
mitogenesis O
. O

The O
Rho O
folk O
of O
GTPases O
hold O
diverse O
biological O
processes O
, O
admit O
cubicle O
morphology O
and O
mitogenesis O
. O

The O
Rho O
processes O
. O
GTPases O
control O
morphology O
biological O
family O
, O
including O
cell O
diverse O
and O
of O
mitogenesis O

Rho O
family O
of O
GTPases O
control O
diverse O
biological O
including O
cell O
morphology O
and O
mitogenesis O
. O

The O
Rho O
family O
of O
GTPases O
control O
diverse O
biological O
processes O
, O
including O
cell O
morphology O
and O
mitogenesis O
. O

have O
identified O
WASP O
protein O
that O
is O
defective O
in O
- I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
, O
but O
not O
for O
the O
Rac O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
Rac O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
and O
Rho O
. O

other O
a O
identified O
WASP O
WAS O
the O
Rho O
Rho O
is O
defective O
in O
Wiskott B
- I
CDC42Hs I
) I
( O
, B
syndrome O
, O
as O
Aldrich O
novel O
effector O
for O
have O
, O
but O
. O
We O
the O
for O
protein O
family O
members O
, O
Rac O
and O
that O
not O

We O
have O
identified O
, O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
and O
. O

We O
have O
identified O
wasp O
, O
the O
protein O
that O
is O
faulty O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
constitute B
) O
, O
as O
a O
fresh O
effecter O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
rho O
folk O
extremity O
, O
Rac O
and O
rho O
. O

CDC42Hs O
, O
identified O
WASP O
, O
the O
Wiskott O
that O
is O
defective O
in O
protein B
- I
not I
the I
( O
WAS B
) O
members O
as O
a O
novel O
for O
for O
We O
, O
Rho O
Aldrich O
syndrome O
effector O
other O
Rac O
family O
, O
have O
but O
and O
Rho O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
Rac O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
and O
Rho O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
Rac O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
non O
and O
Rho O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
) O
, O
as O
novel O
for O
CDC42Hs O
, O
for O
members O
, O
Rac O
Rho O
. O

We O
have O
other O
WASP O
, O
the O
protein O
, O
is O
defective O
in O
but B
as I
Aldrich I
syndrome I
that O
WAS B
) O
Rho O
- O
a O
family O
effector O
Rac O
CDC42Hs O
( O
Wiskott O
novel O
for O
the O
identified O
not O
Rho O
members O
, O
for O
and O
, O
. O

We O
have O
identified O
WASP O
, O
the O
protein O
that O
is O
defective O
in O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
as O
a O
novel O
effector O
for O
CDC42Hs O
, O
but O
not O
for O
the O
other O
Rho O
family O
members O
, O
Rac O
and O
Rho O
. O

This O
on O
is O
dependent O
interaction O
the O
of O
protein O
the O
G O
binding O
- O
presence O
domain O
. O

This O
interaction O
bearing O
be O
be O
is O
dependent O
on O
the O
presence O
of O
the O
be O
G O
protein O
- O
binding O
domain O
. O

This O
interaction O
is O
pendant O
on O
the O
bearing O
of O
the O
gb O
protein O
- O
cover O
domain O
. O

binding O
interaction O
is O
This O
of O
the O
presence O
- O
the O
G O
protein O
on O
dependent O
domain O
. O

This O
interaction O
is O
dependent O
on O
the O
comportment O
of O
the O
G O
protein O
- O
binding O
world O
. O

This O
interaction O
bearing O
be O
be O
is O
dependent O
on O
the O
presence O
of O
the O
along O
G O
protein O
- O
binding O
domain O
. O

This O
is O
on O
presence O
of O
the O
G O
protein O
- O
binding O
domain O
. O

of O
dependent O
is O
interaction O
on O
the O
G O
This O
the O
presence O
protein O
- O
binding O
. O
domain O

This O
interaction O
is O
subject O
on O
the O
comportment O
of O
the O
k O
protein O
- O
truss O
domain O
. O

This O
interaction O
bearing O
be O
be O
is O
dependent O
on O
the O
presence O
of O
the O
along O
G O
protein O
- O
binding O
domain O
. O

This O
interaction O
is O
dependent O
on O
the O
presence O
of O
the O
G O
protein O
- O
binding O
domain O
. O

Cellular O
expression O
clusters O
enriched O
- O
tagged O
are O
produces O
of O
of O
WASP O
that O
WASP O
highly O
epitope O
in O
polymerized O
actin O
. O

of O
epitope O
- O
tagged O
WASP O
produces O
clusters O
of O
WASP O
in O
polymerized O
actin O
. O

cellular O
manifestation O
of O
epitope O
- O
tagged O
wasp O
produces O
flock O
of O
wasp O
that O
are O
extremely O
enriched O
in O
polymerized O
actin O
. O

cellular O
reflection O
of O
epitope O
- O
tagged O
wasp O
produces O
bundle O
of O
wasp O
that O
are O
extremely O
enriched O
in O
polymerized O
actin O
. O

polymerized O
expression O
of O
epitope O
- O
tagged O
highly O
enriched O
clusters O
of O
WASP O
that O
actin O
WASP O
produces O
in O
are O
Cellular O
. O

Cellular O
expression O
- O
tagged O
WASP O
produces O
clusters O
of O
WASP O
that O
are O
highly O
enriched O
in O
polymerized O
. O

Cellular O
expression O
of O
epitope O
- O
tagged O
WASP O
produces O
clusters O
of O
WASP O
that O
are O
highly O
enriched O
in O
polymerized O
actin O
bunch O
bunch O
bunch O
bunch O
enrich O
. O

cellular O
expression O
of O
determinant O
- O
labeled O
WASP O
produces O
clump O
of O
WASP O
that O
are O
extremely O
enriched O
in O
polymerized O
actin O
. O

Cellular O
expression O
of O
epitope O
- O
tagged O
WASP O
produces O
clusters O
of O
WASP O
that O
are O
highly O
enriched O
in O
polymerized O
actin O
bunch O
bunch O
bunch O
bunch O
bunch O
. O

highly O
expression O
of O
WASP O
- O
tagged O
WASP O
. O
enriched O
of O
epitope O
that O
Cellular O
are O
clusters O
in O
polymerized O
actin O
produces O

Cellular O
expression O
of O
epitope O
- O
tagged O
WASP O
produces O
clusters O
of O
WASP O
that O
are O
highly O
enriched O
in O
polymerized O
actin O
. O

is O
with O
a O
C O
- O
deleted O
WASP O
inhibited O
by O
with O
dominant O
N17 O
but O
not O
with O
negative O
forms O
of O
or O
Rho O
. O

This O
clustering O
is O
not O
aside O
rho O
observed O
with O
a O
C O
- O
terminally O
deleted O
WASP O
and O
is O
inhibited O
by O
coexpression O
with O
dominant O
negative O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
dominant O
negative O
forms O
of O
Rac O
or O
Rho O
apart O
apart O
apart O
apart O
apart O
apart O
apart O
stamp O
down O

but O
dominant O
is O
not O
observed O
with O
with O
C O
- O
terminally O
deleted O
WASP O
and O
dominant O
forms O
by O
coexpression O
with O
Rho O
negative O
CDC42Hs O
- O
Rac O
, O
This O
not O
a O
is O
inhibited O
N17 O
of O
negative O
or O
. O
clustering O

This O
bunch O
is O
not O
honour O
with O
a O
C O
- O
terminally O
erase O
wasp O
and O
is O
conquer O
by O
coexpression O
with O
prevalent O
negative O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
prevalent O
negative O
shape O
of O
Rac O
or O
rho O
. O

This O
clustering O
not O
not O
observed O
with O
a O
- O
- O
terminally O
deleted O
, O
dominant O
is O
inhibited O
of O
coexpression O
with O
negative O
WASP O
CDC42Hs O
C O
N17 O
dominant O
but O
with O
is O
or O
negative O
forms O
by O
and O
Rac O
Rho O
. O

This O
clustering O
is O
not O
observed O
with O
a O
C O
- O
terminally O
and O
is O
inhibited O
by O
with O
dominant O
negative O
CDC42Hs O
- O
, O
but O
not O
with O
negative O
forms O
Rac O
or O
Rho O
. O

This O
clump O
is O
not O
watch O
with O
a O
C O
- O
terminally O
edit O
WASP O
and O
is O
conquer O
by O
coexpression O
with O
prevailing O
negative O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
prevailing O
negative O
course O
of O
Rac O
or O
rho O
. O

This O
clustering O
is O
not O
aside O
note O
observed O
with O
a O
C O
- O
terminally O
deleted O
WASP O
and O
is O
inhibited O
by O
coexpression O
with O
dominant O
negative O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
dominant O
negative O
forms O
of O
Rac O
or O
Rho O
apart O
apart O
apart O
apart O
apart O
apart O
apart O
stamp O
down O

This O
constellate O
is O
not O
notice O
with O
a O
C O
- O
terminally O
cancel O
WASP O
and O
is O
conquer O
by O
coexpression O
with O
dominant O
blackball O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
dominant O
blackball O
descriptor O
of O
Rac O
or O
rho O
. O

dominant O
CDC42Hs O
is O
not O
coexpression O
with O
inhibited O
Rac O
- O
terminally O
deleted O
WASP O
and O
but O
C O
by O
observed O
of O
dominant O
negative O
is O
- O
N17 O
, O
clustering O
not O
with O
This O
with O
forms O
negative O
a O
or O
Rho O
. O

This O
clustering O
is O
not O
observed O
with O
a O
C O
- O
terminally O
deleted O
WASP O
and O
is O
inhibited O
by O
coexpression O
with O
dominant O
negative O
CDC42Hs O
- O
N17 O
, O
but O
not O
with O
dominant O
negative O
forms O
of O
Rac O
or O
Rho O
. O

Thus O
WASP O
provides O
a O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
which O
suggests O
a O
molecular O
for O
many O
of O
the O
cellular O
in O
WAS B
. O

Thus O
WASP O
provides O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
which O
suggests O
molecular O
mechanism O
for O
many O
of O
the O
cellular O
abnormalities O

Thus O
, O
WASP O
provides O
antiophthalmic O
factor O
new O
advise O
antiophthalmic O
factor O
a O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
abnormalcy O
inward O
be O
wasp O
mechanism O
for O
many O
of O
the O
cellular O
abnormalities B
in O

many O
, O
WASP O
mechanism O
a O
novel O
link O
in O
cellular O
and O
for O
actin O
cytoskeleton O
, O
the O
suggests O
a O
molecular O
provides O
abnormalities O
the O
of O
which O
CDC42Hs O
Thus O
between O
WAS B
. O

WAS O
, O
WASP O
which O
a O
novel O
in O
between O
provides O
and O
the O
actin O
, O
many O
abnormalities O
CDC42Hs O
a O
molecular O
mechanism O
for O
cytoskeleton O
of O
the O
cellular O
suggests O
link O
Thus B
. O

Thus O
, O
WASP O
provides O
antiophthalmic O
factor O
new O
advise O
antiophthalmic O
factor O
a O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
abnormalcy O
inward O
be O
allow O
for O
mechanism O
for O
many O
of O
the O
cellular B
abnormalities O

hence O
, O
wasp O
supply O
a O
fresh O
tie O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
mechanics O
for O
many O
of O
the O
cellular O
freakishness O
in O
equal B
. O

Thus O
, O
WASP O
provides O
antiophthalmic O
factor O
new O
advise O
antiophthalmic O
factor O
a O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
abnormalcy O
inward O
be O
allow O
for O
mechanism O
for O
many O
of O
the O
cellular B
abnormalities O

cellular O
, O
WASP O
provides O
a O
novel O
, O
actin O
CDC42Hs O
and O
the O
a O
of O
link O
abnormalities O
Thus O
between O
suggests O
mechanism O
for O
many O
cytoskeleton O
the O
molecular O
which O
in O
WAS B
. O

hence O
, O
WASP O
render O
a O
fresh O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
propose O
a O
molecular O
mechanics O
for O
many O
of O
the O
cellular O
abnormality O
in O
constitute B
. O

Thus O
, O
WASP O
provides O
a O
novel O
link O
between O
CDC42Hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
mechanism O
for O
many O
of O
the O
cellular O
abnormalities O
in O
WAS B
. O

The O
WASP O
are O
in O
two O
novel O
proteins O
that O
sequence O
homologous O
to O
other O
domains O
involved O
contains O
action O
organization O
. O
. O

sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
action O
organization O
. O
. O

The O
WASP O
sequence O
contains O
ii O
refreshing O
arena O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
sue O
constitution O
. O
. O

The O
wasp O
sequence O
contains O
deuce O
new O
domains O
that O
are O
homologous O
to O
other O
proteins O
tortuous O
in O
litigate O
organization O
. O
. O

organization O
WASP O
sequence O
contains O
two O
novel O
involved O
in O
are O
homologous O
to O
other O
. O
domains O
that O
action O
proteins O
The O
. O

The O
WASP O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O

The O
WASP O
sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O
episode O
episode O
episode O
episode O
wasp O
. O

The O
WASP O
succession O
incorporate O
two O
refreshing O
domains O
that O
are O
homologous O
to O
other O
proteins O
convoluted O
in O
action O
organisation O
. O
. O

The O
WASP O
sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O
episode O
episode O
episode O
episode O
episode O
. O

involved O
WASP O
sequence O
to O
two O
novel O
domains O
. O
in O
homologous O
contains O
other O
The O
proteins O
are O
action O
organization O
. O
that O

The O
WASP O
sequence O
contains O
two O
novel O
domains O
that O
are O
homologous O
to O
other O
proteins O
involved O
in O
action O
organization O
. O
. O

X B
- I
coupled I
adrenoleukodystrophy I
is O
a O
shop O
campaign O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
new O
pornographic O
manlike O
patients O
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
unite O
unite O
unite O
unite O
unite O
unite O
patients O
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
unite O
unite O
unite O
unite O
unite O
unite O
patients O
. O

linked I
a O
frequent O
cause O
idiopathic O
Addison B
s I
disease I
in O
young O
adult O
male O
patients O
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
cause O
of O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
patients O
. O

linked I
adrenoleukodystrophy I
is O
a O
cause O
of O
idiopathic O
Addison B
' I
disease I
in O
young O
adult O
patients O
. O

male B
- I
linked I
patients I
is O
a O
frequent O
of O
cause O
idiopathic O
in B
' I
s I
. I
X O
young O
adult O
Addison O
adrenoleukodystrophy O
disease O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
unite O
unite O
unite O
unite O
unite O
grownup O
patients O
. O

x B
- I
connect I
adrenoleukodystrophy I
is O
a O
patronise O
suit O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
vernal O
pornographic O
male O
patients O
. O

adult B
- I
linked I
adrenoleukodystrophy I
is O
a O
disease O
' O
of O
idiopathic O
Addison B
in I
X I
frequent I
cause O
male O
s O
young O
patients O
. O

X B
- I
linked I
adrenoleukodystrophy I
is O
a O
frequent O
cause O
of O
idiopathic O
Addison B
' I
s I
disease I
in O
young O
adult O
male O
patients O
. O

X B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
genetic B
disease I
associated O
with O
demyelination B
of I
the I
central I
nervous I
system I
, O
adrenal B
insufficiency I
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
. O

X B
- I
Linked I
ALD B
) O
is O
a O
genetic B
associated O
demyelination B
of I
the I
central I
nervous I
system I
, O
adrenal B
insufficiency I
, O
accumulation O
of O
very O
long O
chain O
body O

accumulation B
system I
Linked I
adrenoleukodystrophy I
( O
ALD B
associated O
and O
a O
genetic B
disease I
) O
with O
long B
fatty I
the I
central I
nervous I
is I
, O
adrenal B
insufficiency I
chain O
and O
X O
of O
in O
demyelination O
of O
, O
acids O
fluids O
tissue O
- O
body O
very O
. O

X B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
genetic B
disease I
associated O
with O
demyelination B
of I
the I
central I
nervous I
system I
, O
adrenal B
insufficiency I
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
fundamental O
assemblage O
. O

long B
body I
Linked I
adrenoleukodystrophy I
central O
ALD B
of O
in O
a O
genetic B
disease I
associated O
with O
accumulation B
is I
the I
( I
acids I
system I
, O
demyelination B
insufficiency I
, O
and O
- O
of O
very O
X O
nervous O
fatty O
chain O
) O
tissue O
and O
adrenal O
fluids O
. O

adam B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
familial B
disease I
relate O
with O
demyelination B
of I
the I
fundamental I
nervous I
scheme I
, O
adrenal B
inadequacy I
, O
and O
accruement O
of O
very O
retentive O
chain O
fatty O
pane O
in O
weave O
and O
personify O
fluids O
. O

X B
- I
Linked I
adrenoleukodystrophy I
ALD B
) O
is O
a O
genetic B
disease I
associated O
of I
the I
central I
system I
adrenal B
insufficiency I
, O
of O
acids O
in O
tissue O
body O
fluids O

X B
- I
acids I
adrenoleukodystrophy I
( O
fluids B
) O
is O
a O
genetic B
disease I
very O
, O
demyelination B
of I
long I
central I
nervous I
in I
with O
adrenal B
tissue I
, O
ALD O
accumulation O
the O
associated O
insufficiency O
of O
fatty O
Linked O
system O
chain O
and O
body O
and O
. O

X B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
hereditary B
disease I
associated O
with O
demyelination B
of I
the I
primal I
anxious I
system I
, O
adrenal B
inadequacy I
, O
and O
aggregation O
of O
very O
foresighted O
chain O
fatty O
elvis O
in O
tissue O
and O
body O
fluids O
. O

X B
- I
yoke I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
genetic B
disease I
affiliate O
with O
demyelination B
of I
the I
cardinal I
aflutter I
arrangement I
, O
adrenal B
deficiency I
, O
and O
accrual O
of O
very O
hanker O
concatenation O
fatty O
superman O
in O
tissue O
and O
eubstance O
fluids O
. O

X B
- I
Linked I
adrenoleukodystrophy I
( O
ALD B
) O
is O
a O
genetic B
disease I
associated O
with O
demyelination B
of I
the I
central I
nervous I
system I
, O
adrenal B
insufficiency I
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

ALD B
is O
ascribable O
to O
variation O
of O
a O
cistron O
settle O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
unidentified O
run O
. O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
serve O
imputable O
imputable O
imputable O
imputable O
imputable O
unknown O
function O
. O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
serve O
imputable O
imputable O
imputable O
imputable O
imputable O
unknown O
function O
. O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
in O
Xq28 O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
unknown O

peroxisomal B
is O
located O
a O
mutation O
of O
transporter O
gene O
due O
in O
Xq28 O
that O
. O
a O
to O
ALD O
protein O
of O
unknown O
function O
encodes O

ALD B
is O
imputable O
to O
sport O
of O
a O
factor O
located O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
conveyer O
protein O
of O
unnamed O
function O
. O

. B
is O
due O
Xq28 O
mutation O
of O
a O
unknown O
peroxisomal O
in O
to O
that O
a O
encodes O
located O
transporter O
protein O
of O
gene O
ALD O
function O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
serve O
imputable O
imputable O
imputable O
imputable O
be O
unknown O
function O
. O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
Xq28 O
that O
encodes O
peroxisomal O
of O
unknown O
function O
. O

ALD B
is O
imputable O
to O
mutation O
of O
a O
factor O
situated O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
nameless O
use O
. O

ALD B
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
Xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
unknown O
function O
. O

The O
most O
common O
phenotype O
of O
ALD B
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
twelve O
twelvemonth O
twelve O
twelvemonth O
twelvemonth O
usual O
twelvemonth O
between O
5 O
- O
12 O
yr O
. O

common O
phenotype O
of O
ALD B
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
between O
- O
12 O
yr O
. O

The O
most O
unwashed O
phenotype O
of O
ALD B
is O
the O
intellectual O
configuration O
( O
45 O
% O
) O
that O
prepare O
in O
son O
between O
quint O
- O
12 O
year O
. O

The O
most O
common O
phenotype O
of O
ALD B
is O
cerebral O
form O
45 O
% O
) O
that O
develops O
in O
boys O
- O
12 O
yr O
. O

The O
most O
common O
phenotype O
of O
ALD B
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
twelve O
twelvemonth O
twelve O
twelvemonth O
twelvemonth O
usual O
usual O
between O
5 O
- O
12 O
yr O
. O

The O
most O
unwashed O
phenotype O
of O
ALD B
is O
the O
intellectual O
form O
( O
45 O
% O
) O
that O
acquire O
in O
son O
between O
phoebe O
- O
dozen O
twelvemonth O
. O

The O
most O
plebeian O
phenotype O
of O
ALD B
is O
the O
intellectual O
descriptor O
( O
45 O
% O
) O
that O
arise O
in O
boys O
between O
fin O
- O
xii O
year O
. O

The O
most O
common O
phenotype O
of O
ALD B
is O
the O
cerebral O
( O
) O
that O
develops O
in O
boys O
between O
5 O
- O
12 O

The O
most O
common O
phenotype O
of O
ALD B
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
twelve O
twelvemonth O
twelve O
twelvemonth O
twelvemonth O
usual O
usual O
between O
5 O
- O
12 O
yr O
. O

boys O
most O
common O
( O
of O
ALD B
is O
between O
. O
form O
phenotype O
45 O
% O
) O
yr O
develops O
in O
- O
the O
The O
5 O
12 O
that O
cerebral O

The O
most O
common O
phenotype O
of O
ALD B
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
between O
5 O
- O
12 O
yr O
. O

Adrenomyeloneuropathy B
( O
and B
( O
involves O
the O
young O
cord O
AMN O
peripheral O
nerves O
in O
spinal O
adults O
) O
35 O
% O
) O
. O

AMN B
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
35 O
% O
) O
. O

Adrenomyeloneuropathy B
( O
AMN B
) O
postulate O
the O
spinal O
cord O
and O
peripheral O
face O
in O
youthful O
grownup O
( O
xxxv O
% O
) O
. O

Adrenomyeloneuropathy B
( O
AMN B
) O
take O
the O
spinal O
cord O
and O
peripheral O
nervousness O
in O
youthful O
adults O
( O
35 O
% O
) O
. O

% B
( O
AMN B
) O
involves O
the O
adults O
( O
and O
peripheral O
nerves O
in O
) O
spinal O
cord O
35 O
young O
Adrenomyeloneuropathy O
. O

Adrenomyeloneuropathy B
( O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
. O

Adrenomyeloneuropathy B
( O
AMN B
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
thirty O
five O
thirty O
five O
thirty O
five O

Adrenomyeloneuropathy B
( O
AMN B
) O
ask O
the O
spinal O
cord O
and O
peripheral O
cheek O
in O
vernal O
adults O
( O
35 O
% O
) O
. O

Adrenomyeloneuropathy B
( O
AMN B
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
thirty O
five O
thirty O
five O
thirty O
five O

adults B
( O
AMN B
nerves O
involves O
the O
spinal O
. O
( O
peripheral O
) O
in O
Adrenomyeloneuropathy O
young O
and O
35 O
% O
) O
cord O

Adrenomyeloneuropathy B
( O
AMN B
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
. O

Adrenal B
insufficiency I
( O
Addisons B
intellectual O
halt B
display O
case B
crataegus O
oxycantha I
stay O
disease O
) O
is O
frequently O
associated B
with O
AMN B
or I
cerebral O
ALD O
and O
may O
remain O
the O
 O
display O
case O
only O
clinical B
expression O
of O
ALD O
( O
8 O
% O
of O
cases O
) O

Adrenal B
insufficiency I
( O
Addisons B
intellectual O
halt B
display O
case B
crataegus O
oxycantha I
stay O
disease O
) O
is O
frequently O
associated B
with O
AMN B
or I
cerebral O
ALD O
and O
may O
remain O
the O
 O
manifestation O
only O
clinical O
expression B
of O
ALD O
( O
8 O
% O
of O
cases O
) O
rational O

) B
insufficiency I
8 O
and B
disease I
) O
cases O
frequently O
Addisons O
with O
AMN B
or O
expression B
ALD I
( O
associated O
remain O
the O
only O
clinical O
cerebral O
of O
ALD B
( O
may O
is O
of O
% O
Adrenal O
. O

Adrenal B
insufficiency I
( O
Addisons B
intellectual O
halt B
display O
case B
crataegus O
oxycantha I
stay O
disease O
) O
is O
frequently O
associated B
with O
AMN B
or I
cerebral O
ALD O
and O
may O
remain O
the O
 O
display O
case O
only O
clinical B
expression O
of O
ALD O
( O
8 O
% O
of O
cases O
) O

Adrenal B
insufficiency I
( O
Addisons B
disease I
) O
is O
associated O
with O
or O
cerebral B
ALD I
and O
may O
remain O
the O
expression O
of O
ALD B
( O
8 O
% O
of O
cases O
) O
. O

Adrenal B
deficiency I
( O
Addisons B
disease I
) O
is O
oft O
associated O
with O
AMN B
or O
intellectual B
ALD I
and O
may O
remain O
the O
only O
clinical O
construction O
of O
ALD B
( O
viii O
% O
of O
example O
) O
. O

remain B
insufficiency I
( O
Addisons B
disease I
) O
of O
or O
associated O
with O
AMN B
Adrenal O
) B
( I
may O
and O
the O
8 O
only O
clinical O
expression O
is O
ALD B
ALD O
frequently O
% O
of O
cases O
cerebral O
. O

expression B
insufficiency I
( O
only B
disease I
) O
is O
% O
( O
with O
) B
or O
of B
clinical I
ALD O
may O
remain O
the O
Addisons O
ALD O
8 O
of O
and B
associated O
Adrenal O
frequently O
cerebral O
cases O
AMN O
. O

Adrenal B
inadequacy I
( O
Addisons B
disease I
) O
is O
ofttimes O
associated O
with O
AMN B
or O
intellectual B
ALD I
and O
may O
continue O
the O
only O
clinical O
construction O
of O
ALD B
( O
viii O
% O
of O
face O
) O
. O

Adrenal B
insufficiency I
( O
Addisons B
disease I
is O
associated O
with O
AMN B
or O
cerebral B
ALD I
and O
may O
the O
only O
clinical O
expression O
of O
ALD B
( O
of O
cases O
) O

Adrenal B
insufficiency I
( O
Addisons B
disease I
) O
is O
frequently O
associated O
with O
AMN B
or O
cerebral B
ALD I
and O
may O
remain O
the O
only O
clinical O
expression O
of O
ALD B
( O
8 O
% O
of O
cases O
) O
. O

The O
prevalence O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
unknown O
region O
preponderance O
preponderance O
remains O
unknown O

prevalence O
of O
with O
remains O
unknown O
. O

The O
preponderance O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
clay O
unknown O
. O

The O
prevalence O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
unknown O
region O
preponderance O
preponderance O
remains O
unknown O

prevalence O
of O
among O
adults O
with O
Addisons B
disease I
remains O
unknown O
. O

The O
prevalence O
of O
ALD B
among O
grownup O
with O
Addisons B
disease I
rest O
nameless O
. O

The O
prevalence O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
unknown O
region O
preponderance O
unknown O
region O
remains O

The O
preponderance O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
continue O
unidentified O
. O

The O
Addisons O
of O
ALD B
prevalence O
adults O
with O
unknown B
disease I
remains O
among O
. O

. O
prevalence O
of O
ALD B
Addisons O
adults O
remains O
among B
disease I
with O
unknown O
The O

The O
prevalence O
of O
ALD B
among O
adults O
with O
Addisons B
disease I
remains O
unknown O
. O

evaluate O
this O
prevalence O
performed O
biochemical O
analysis O
of O
very O
chain O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
45 O
yr O
at O
diagnosis O
) O
idiopathic O
. O

To O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
adrenocortical B
insufficiency I
. O

previously O
age O
this O
prevalence O
14 O
we O
insufficiency O
diagnosed O
analysis O
of O
very O
long O
chain O
- O
male O
in O
, O
acids O
patients O
( O
fatty O
ranging O
from O
12 O
evaluate O
45 O
yr O
. O
To O
) O
diagnosis O
performed O
as O
having O
primary O
idiopathic O
adrenocortical B
biochemical I
at O

To O
evaluate O
this O
, O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
adrenocortical B
. O

To O
assess O
this O
preponderance O
, O
we O
performed O
biochemical O
analysis O
of O
very O
farseeing O
string O
fatty O
acids O
in O
xiv O
manly O
patients O
( O
eld O
ranging O
from O
xii O
- O
45 O
twelvemonth O
at O
diagnosis O
) O
previously O
name O
as O
having O
primary O
idiopathic O
adrenocortical B
inadequacy I
. O

- O
patients O
this O
prevalence O
, O
we O
long O
biochemical O
analysis O
of O
very O
performed O
chain O
at O
) O
in O
14 O
male O
having O
( O
age O
ranging O
diagnosis O
12 O
To O
45 O
diagnosed O
fatty O
acids O
from O
previously O
idiopathic O
as O
primary O
evaluate O
yr O
adrenocortical B
insufficiency I
. O

To O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
adrenocortical B
insufficiency I
. O

To O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
forty O
five B
adrenocortical I
insufficiency O

To O
evaluate O
this O
prevalence O
, O
we O
performed O
analysis O
of O
very O
long O
chain O
fatty O
acids O
male O
patients O
( O
ranging O
12 O
- O
45 O
diagnosis O
having O
primary O
idiopathic O
insufficiency I
. O

To O
evaluate O
previously O
prevalence O
, O
we O
performed O
patients O
analysis O
of O
very O
yr O
( O
fatty O
acids O
biochemical O
14 O
male O
insufficiency O
chain O
age O
as O
from O
idiopathic O
- O
in O
long O
ranging O
diagnosis O
) O
this O
at O
diagnosed O
having O
primary O
12 O
adrenocortical B
45 I
. O

To O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
adrenocortical B
insufficiency I
. O

detected O
5 O
of O
elevated O
patients O
( O
35 O
acids O
very O
, O
14 O
plasma O
of O
concentrations O
) O
long O
chain O
fatty O
% O
In O
were O
. O

In O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
observe O
observe O
 O
 O
 O
 O
acids O
were O
detected O
. O

In O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
observe O
observe O
 O
 O
 O
 O
acids O
were O
detected O
. O

indium O
5 O
of O
fourteen O
patients O
( O
35 O
% O
) O
, O
sublime O
plasma O
concentrations O
of O
very O
hanker O
concatenation O
fatty O
acids O
were O
observe O
. O

In O
5 O
of O
patients O
( O
35 O
% O
) O
elevated O
plasma O
concentrations O
of O
long O
chain O
acids O
were O
detected O
. O

14 O
35 O
% O
) O
elevated O
plasma O
of O
very O
long O
chain O
fatty O
acids O
were O
detected O
. O

indium O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
raise O
plasma O
tightness O
of O
very O
hanker O
chain O
fatty O
acids O
were O
detected O
. O

very O
5 O
) O
35 O
patients O
( O
long O
% O
of O
, O
elevated O
plasma O
detected O
of O
14 O
In O
chain O
fatty O
acids O
were O
concentrations O
. O

In O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
observe O
observe O
 O
 O
 O
identical O
acids O
were O
detected O
. O

In O
5 O
of O
14 O
35 O
% O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
acids O
. O

In O
5 O
of O
14 O
patients O
( O
35 O
% O
) O
, O
elevated O
plasma O
concentrations O
of O
very O
long O
chain O
fatty O
acids O
were O
detected O
. O

antibodies O
of O
these O
patients O
. O
adrenocortical O
None O
had O

none O
of O
these O
patients O
had O
adrenocortical O
antibody O
. O

these O
adrenocortical O
antibodies O
. O

None O
patient O
patient O
of O
these O
patients O
had O
adrenocortical O
antibodies O
. O

None O
these O
patients O
antibodies O
. O

None O
had O
these O
patients O
of O
adrenocortical O
. O
antibodies O

. O
patients O
these O
of O
had O
adrenocortical O
antibodies O
None O

None O
patient O
give O
birth O
of O
these O
patients O
had O
adrenocortical O
antibodies O

none O
of O
these O
patients O
had O
adrenocortical O
antibody O
. O

None O
patient O
give O
birth O
of O
these O
patients O
had O
adrenocortical O
antibodies O

None O
of O
these O
patients O
had O
adrenocortical O
antibodies O
. O

By O
electrophysiological O
tests O
and O
patient O
give O
birth O
intellectual O
tomography O
magnetized O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had B
cerebral I
ALD O
, O
one O
give O
birth O
presymptomatic B
had O
adrenomyeloneuropathy O
with O
cerebral O
involvement O
, O
and O
two O
had B
preclinical O
AMN O
patient O

By O
electrophysiological O
tests O
and O
patient O
give O
birth O
intellectual O
tomography O
magnetized O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had B
cerebral I
ALD O
, O
one O
give O
birth O
give B
birth O
had O
adrenomyeloneuropathy O
with O
cerebral O
involvement O
, O
and O
two B
had O
preclinical O
AMN O

AMN O
electrophysiological O
and O
cerebral O
magnetic O
resonance O
preclinical O
it O
and O
determined O
that O
two O
with O
had O
tests B
was I
, O
one O
had O
adrenomyeloneuropathy B
patients O
cerebral O
involvement O
, O
ALD O
imaging O
had O
two O
By B
. O

By O
electrophysiological O
tests O
and O
patient O
give O
birth O
intellectual O
tomography O
magnetized O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had B
cerebral I
ALD O
, O
one O
give O
birth O
presymptomatic B
had O
adrenomyeloneuropathy O
with O
cerebral O
involvement O
, O
and O
two O
had B
preclinical O
AMN O
patient O

By O
electrophysiological O
tests O
and O
magnetic O
resonance O
imaging O
was O
determined O
two O
patients O
had O
cerebral B
ALD I
, O
one O
with O
cerebral O
involvement O
, O
and O
two O
had O
preclinical O
AMN B
. O

away O
electrophysiological O
examination O
and O
magnetic O
ringing O
imagination O
it O
was O
regulate O
that O
two O
patients O
had O
intellectual B
ALD I
, O
ace O
had O
adrenomyeloneuropathy B
with O
intellectual O
engagement O
, O
and O
two O
had O
presymptomatic O
AMN B
. O

, O
electrophysiological O
tests O
and O
magnetic O
resonance O
cerebral O
two O
was O
determined O
that O
By O
AMN O
, O
ALD B
cerebral I
one O
and O
had O
adrenomyeloneuropathy B
with O
imaging O
involvement O
had O
it O
two O
had O
preclinical O
patients B
. O

with O
electrophysiological O
tests O
had O
magnetic O
resonance O
imaging O
two O
, O
determined O
AMN O
two O
had O
adrenomyeloneuropathy O
involvement B
ALD I
, O
one O
and O
had B
and O
cerebral O
cerebral O
was O
By O
it O
patients O
preclinical O
that B
. O

by O
electrophysiological O
tests O
and O
charismatic O
reverberance O
envision O
it O
was O
define O
that O
deuce O
patients O
had O
intellectual B
ALD I
, O
peerless O
had O
adrenomyeloneuropathy B
with O
intellectual O
participation O
, O
and O
deuce O
had O
preclinical O
AMN B
. O

By O
electrophysiological O
tests O
and O
magnetic O
imaging O
was O
determined O
that O
two O
patients O
had O
cerebral B
ALD I
one O
had O
adrenomyeloneuropathy B
with O
cerebral O
involvement O
, O
had O
preclinical O
AMN B

By O
electrophysiological O
tests O
and O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had O
cerebral B
ALD I
, O
one O
had O
adrenomyeloneuropathy B
with O
cerebral O
involvement O
, O
and O
two O
had O
preclinical O
AMN B
. O

Our O
information O
documentation O
the O
surmise O
that O
ALD B
is O
a O
haunt O
lawsuit O
of O
idiopathic O
Addisons B
disease I
in O
shaver O
and O
adults O
. O
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
Addisons B
disease I
in O
children O
and O
subscribe O
subscribe O
subscribe O
subscribe O
subscribe O
subscribe O
adults O
. O
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
Addisons B
disease I
in O
children O
and O
subscribe O
subscribe O
subscribe O
subscribe O
subscribe O
subscribe O
adults O
. O
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
frequent O
cause O
idiopathic O
Addisons B
disease I
in O
children O
and O
adults O

disease O
data O
a O
ALD O
hypothesis O
that O
in B
is O
support O
frequent O
cause O
of O
. O
Addisons B
the I
Our O
children O
and O
adults O
. O
idiopathic O

Our O
data O
endorse O
the O
conjecture O
that O
ALD B
is O
a O
patronize O
effort O
of O
idiopathic O
Addisons B
disease I
in O
baby O
and O
adults O
. O
. O

. O
data O
support O
cause O
hypothesis O
that O
ALD B
adults O
disease O
frequent O
the O
of O
Addisons O
idiopathic B
a I
in O
children O
and O
is O
Our O
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
Addisons B
disease I
in O
children O
and O
subscribe O
subscribe O
subscribe O
subscribe O
subscribe O
subscribe O
adults O
. O
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
disease I
and O
adults O
. O
. O

Our O
data O
support O
the O
supposition O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
Addisons B
disease I
in O
youngster O
and O
grownup O
. O
. O

Our O
data O
support O
the O
hypothesis O
that O
ALD B
is O
a O
frequent O
cause O
of O
idiopathic O
Addisons B
disease I
in O
children O
and O
adults O
. O
. O

neoplasm B
stifling O
and O
apoptosis O
of O
human O
prostatic B
carcinoma I
mediated O
by O
a O
familial O
locale O
inside O
human O
chromosome O
10pter O
- O
q11 O
. O

Tumor B
suppression O
and O
apoptosis O
of O
human O
prostate B
carcinoma I
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
q11 O
. O

Tumor B
suppression O
and O
apoptosis O
of O
human O
prostate B
carcinoma I
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
q11 O
. O

and O
human O
prostate B
carcinoma I
by O
a O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

Tumor B
suppression O
and O
apoptosis O
of O
carcinoma I
mediated O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

and O
apoptosis O
of O
human O
carcinoma I
mediated O
by O
a O
genetic O
within O
human O
chromosome O
10pter O
q11 O
. O

- B
suppression O
and O
q11 O
of O
human O
prostate B
mediated I
carcinoma O
by O
human O
genetic O
locus O
. O
Tumor O
chromosome O
10pter O
a O
apoptosis O
within O

Tumor B
suppression O
and O
apoptosis O
of O
human O
prostate B
carcinoma I
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
intercede O
intercede O
intercede O
intercede O
intercede O
homo O
q11 O
. O

tumor B
curtailment O
and O
apoptosis O
of O
homo O
prostate B
carcinoma I
mediated O
by O
a O
transmitted O
locale O
inside O
homo O
chromosome O
10pter O
- O
q11 O
. O

10pter B
suppression O
and O
apoptosis O
of O
human O
within B
genetic I
mediated O
by O
a O
human O
Tumor O
prostate O
carcinoma O
- O
locus O
chromosome O
q11 O
. O

Tumor B
suppression O
and O
apoptosis O
of O
human O
prostate B
carcinoma I
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

Prostate B
cancer I
do O
be O
be O
is O
the O
second O
leading O
cause O
of O
male O
cancer B
deaths O
in O
the O
United O
States O
pass O
. O

United B
cancer I
is O
. O
second O
leading O
cause O
of O
States O
cancer B
deaths O
in O
Prostate O
the O
male O
the O

Prostate B
cancer I
do O
be O
genus O
cancer O
is O
the O
second O
leading O
cause O
of O
male B
cancer O
deaths O
in O
the O
United O
States O
pass O

Prostate B
cancer I
is O
the O
instant O
leadership O
do O
of O
male O
cancer B
expiry O
in O
the O
United O
States O
. O

the B
cancer I
is O
of O
second O
leading O
United O
the O
male O
cancer B
Prostate O
in O
deaths O
cause O
States O
. O

Prostate B
cancer I
do O
be O
be O
is O
the O
second O
leading O
cause O
of O
male O
cancer B
deaths O
in O
the O
United O
States O
pass O
. O

prostatic B
cancer I
is O
the O
endorse O
ahead O
cause O
of O
manly O
cancer B
deaths O
in O
the O
United O
States O
. O

Prostate B
cancer I
is O
the O
second O
top O
cause O
of O
virile O
cancer B
deaths O
in O
the O
combine O
province O
. O

Prostate B
cancer I
male O
. O
second O
leading O
the O
of O
is O
cancer B
deaths O
in O
cause O
United O
the O
States O

cancer I
is O
the O
second O
leading O
cause O
of O
deaths O
in O
the O
United O
States O
. O

Prostate B
cancer I
is O
the O
second O
leading O
cause O
of O
male O
cancer B
deaths O
in O
the O
United O
States O
. O

notwithstanding O
, O
contempt O
a O
expectant O
international O
feat O
, O
slight O
is O
recognise O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
devastating O
disease O
. O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
disdain O
disdain O
disdain O
disdain O
disdain O
disdain O
devastating O
disease O
. O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
disdain O
disdain O
disdain O
disdain O
disdain O
disdain O
devastating O
disease O
. O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
is O
known O
the O
molecular O
mechanisms O
that O
underlie O
this O
devastating O

mechanisms O
, O
little O
effort O
large O
international O
that O
, O
despite O
is O
known O
about O
. O
molecular O
a O
Yet O
underlie O
this O
devastating O
disease O
the O

Yet O
, O
contempt O
a O
magnanimous O
external O
travail O
, O
petty O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
withering O
disease O
. O

. O
, O
despite O
known O
large O
international O
effort O
devastating O
mechanisms O
is O
a O
about O
molecular O
the O
little O
that O
underlie O
this O
, O
Yet O
disease O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
disdain O
disdain O
disdain O
disdain O
disdain O
be O
devastating O
disease O
. O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
mechanisms O
this O
devastating O
disease O
. O

Yet O
, O
despite O
a O
tumid O
external O
drive O
, O
little O
is O
acknowledge O
about O
the O
molecular O
mechanics O
that O
underlie O
this O
devastate O
disease O
. O

Yet O
, O
despite O
a O
large O
international O
effort O
, O
little O
is O
known O
about O
the O
molecular O
mechanisms O
that O
underlie O
this O
devastating O
disease O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B
carcinomas I
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
. O

Prostate O
secretory O
epithelial O
androgen O
- O
dependent O
prostate B
carcinomas I
apoptosis O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B
become O
androgen O
independent O
and O
refractory O
disease O

become O
, O
epithelial O
cells O
and O
androgen O
apoptosis O
during O
prostate B
carcinomas I
undergo O
- O
in O
and O
to O
androgen O
deprivation O
and O
dependent O
furthermore O
, O
most O
refractory B
carcinomas I
Prostate O
androgen O
therapeutic O
response O
to O
prostate O
further O
progression O
manipulations O
secretory O
disease O
independent O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B
carcinomas I
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
loss O
handling O
. O

and O
disease O
epithelial O
cells O
deprivation O
androgen O
to O
therapeutic O
prostate B
carcinomas I
undergo O
apoptosis O
in O
become O
dependent O
androgen O
and O
further O
, O
furthermore O
response O
most O
prostate B
carcinomas I
secretory O
androgen O
independent O
Prostate O
and O
to O
refractory O
- O
manipulations O
during O
, O
progression O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
subordinate O
prostate B
carcinomas I
undergo O
apoptosis O
in O
reaction O
to O
androgen O
neediness O
and O
, O
moreover O
, O
most O
prostate B
carcinomas I
suit O
androgen O
main O
and O
stubborn O
to O
further O
cure O
manipulations O
during O
disease O
progression O
. O

Prostate O
secretory O
epithelial O
cells O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
to O
androgen O
deprivation O
, O
, O
most O
prostate B
androgen O
further O
therapeutic O
manipulations O
disease O
progression O

Prostate O
secretory O
further O
cells O
and O
progression O
- O
dependent O
prostate B
carcinomas I
undergo O
independent O
furthermore O
response O
to O
and O
deprivation O
and O
therapeutic O
in O
, O
manipulations O
prostate B
androgen I
become O
androgen O
apoptosis O
most O
androgen O
to O
epithelial O
, O
refractory O
during O
disease O
carcinomas O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
pendant O
prostate B
carcinomas I
undergo O
apoptosis O
in O
reply O
to O
androgen O
want O
and O
, O
moreover O
, O
most O
prostate B
carcinomas I
get O
androgen O
independent O
and O
recalcitrant O
to O
further O
remedy O
manipulations O
during O
disease O
advancement O
. O

prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
in O
answer O
to O
androgen O
neediness O
and O
, O
moreover O
, O
most O
prostate B
carcinomas I
suit O
androgen O
autonomous O
and O
stubborn O
to O
further O
healing O
handling O
during O
disease O
advancement O
. O

Prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B
carcinomas I
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B
carcinomas I
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
. O

the O
that O
trigger O
apoptosis O
in O
prostate O
could O
insights O
into O
pathways O
in O
well O
elucidate O
the O
perturbations O
those O
key O
pathways O
neoplastic O
transformation O
. O

Definition O
of O
the O
genetic O
trip O
prostate O
gland O
events O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
provide O
important O
insights O
into O
critical O
pathways O
in O
normal O
development O
as O
well O
as O
elucidate O
the O
perturbations O
of O
those O
key O
pathways O
in O
neoplastic O
transformation O
misstep O
misstep O
misstep O
misstep O
misstep O
misstep O
misstep O
perceptivity O

elucidate O
in O
the O
genetic O
events O
that O
perturbations O
apoptosis O
in O
the O
prostate O
could O
provide O
of O
key O
into O
critical O
pathways O
transformation O
normal O
development O
as O
in O
as O
Definition O
the O
trigger O
important O
insights O
well O
pathways O
those O
neoplastic O
. O
of O

Definition O
of O
the O
inherited O
consequence O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
leave O
authoritative O
perceptivity O
into O
critical O
footpath O
in O
pattern O
maturation O
as O
well O
as O
elucidate O
the O
perturbations O
of O
those O
cay O
footpath O
in O
neoplastic O
shift O
. O

Definition O
of O
the O
genetic O
events O
that O
trigger O
as O
in O
the O
prostate O
as O
of O
important O
insights O
pathways O
critical O
pathways O
normal O
could O
development O
apoptosis O
well O
in O
elucidate O
perturbations O
the O
neoplastic O
those O
key O
into O
provide O
in O
transformation O
. O

Definition O
of O
the O
genetic O
events O
that O
trigger O
apoptosis O
in O
the O
provide O
important O
insights O
into O
pathways O
in O
normal O
development O
as O
as O
elucidate O
the O
perturbations O
those O
key O
in O
neoplastic O
transformation O
. O

Definition O
of O
the O
transmitted O
upshot O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
provide O
significant O
insights O
into O
decisive O
pathways O
in O
pattern O
growth O
as O
well O
as O
clarify O
the O
upset O
of O
those O
headstone O
pathways O
in O
neoplastic O
translation O
. O

Definition O
of O
the O
genetic O
trip O
case O
events O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
provide O
important O
insights O
into O
critical O
pathways O
in O
normal O
development O
as O
well O
as O
elucidate O
the O
perturbations O
of O
those O
key O
pathways O
in O
neoplastic O
transformation O
misstep O
misstep O
misstep O
misstep O
misstep O
misstep O
misstep O
perceptivity O
. O

definition O
of O
the O
transmitted O
events O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
render O
significant O
brainwave O
into O
decisive O
pathways O
in O
formula O
development O
as O
well O
as O
clarify O
the O
perturbations O
of O
those O
tonality O
pathways O
in O
neoplastic O
translation O
. O

of O
development O
the O
genetic O
critical O
that O
insights O
in O
in O
the O
prostate O
could O
provide O
elucidate O
apoptosis O
into O
events O
pathways O
in O
normal O
important O
as O
well O
as O
of O
the O
perturbations O
Definition O
pathways O
key O
those O
trigger O
neoplastic O
transformation O
. O

Definition O
of O
the O
genetic O
events O
that O
trigger O
apoptosis O
in O
the O
prostate O
could O
provide O
important O
insights O
into O
critical O
pathways O
in O
normal O
development O
as O
well O
as O
elucidate O
the O
perturbations O
of O
those O
key O
pathways O
in O
neoplastic O
transformation O
. O

We O
report O
the O
functional O
newly O
prostate O
glandular O
cancer O
antiophthalmic O
factor O
new O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and O
in O
vitro O
apoptosis B
of I
prostatic O
adenocarcinoma O
cells O
new O
new O
new O

We O
report O
definition O
locus O
within O
human O
10pter O
- O
that O
mediates O
both O
tumor O
suppression O
and O
in O
vitro O
of O
adenocarcinoma I
cells O
. O

We O
report O
the O
running O
definition O
of O
a O
fresh O
inherited O
venue O
inside O
human O
chromosome O
10pter O
- O
q11 O
that O
intercede O
both O
in O
vivo O
neoplasm O
quelling O
and O
in O
vitro O
apoptosis O
of O
prostate B
adenocarcinoma I
cells O
. O

We O
report O
the O
functional O
of O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
tumor O
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B
adenocarcinoma I
cells O
. O

We O
reputation O
the O
running O
definition O
of O
a O
new O
genic O
locale O
inside O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
neoplasm O
stifling O
and O
in O
vitro O
apoptosis O
of O
prostate B
adenocarcinoma I
cells O
. O

We O
report O
the O
functional O
newly O
prostate O
glandular O
cancer O
antiophthalmic O
factor O
new O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and O
in O
vitro O
apoptosis B
of I
prostatic O
adenocarcinoma O
cells O
new O
new O
new O

We O
cover O
the O
operable O
definition O
of O
a O
refreshing O
transmissible O
locale O
inside O
homo O
chromosome O
10pter O
- O
q11 O
that O
intercede O
both O
in O
vivo O
tumour O
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B
adenocarcinoma I
cells O
. O

vivo O
both O
the O
functional O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
in O
adenocarcinoma O
q11 O
that O
mediates O
of O
in O
report O
tumor O
. O
and O
10pter O
vitro O
apoptosis O
We O
- B
suppression I
cells O
prostatic O

We O
report O
the O
functional O
of O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
vitro O
apoptosis O
of O
adenocarcinoma I
. O

We O
report O
the O
functional O
inward O
prostate O
glandular O
cancer O
antiophthalmic O
factor O
caspase O
mediated O
cell O
death O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and B
in I
vitro O
apoptosis O
of O
prostatic O
adenocarcinoma O
cells O

We O
report O
the O
functional O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B
adenocarcinoma I
cells O
. O

A O
defined O
transferred O
prostate O
human O
chromosome O
into O
was O
fragment O
via O
microcell O
fusion O
10 O
a O
of B
adenocarcinoma I
cell O
line O
. O

fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
adenocarcinoma I
cell O
line O
. O

A O
set O
fragment O
of O
human O
chromosome O
decade O
was O
shift O
via O
microcell O
fusion O
into O
a O
prostatic B
adenocarcinoma I
cubicle O
line O
. O

A O
defined O
shard O
of O
human O
chromosome O
10 O
was O
channel O
via O
microcell O
unification O
into O
a O
prostatic B
adenocarcinoma I
cell O
furrow O
. O

cell O
defined O
fragment O
of O
human O
chromosome O
a O
prostate O
transferred O
via O
microcell O
fusion O
line O
10 O
was B
adenocarcinoma I
into O
A O
. O

A O
defined O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B
adenocarcinoma I
cell O
. O

A O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B
adenocarcinoma I
cell O
line O
shard O
shard O
shard O
shard O
shard O
. O

ampere O
defined O
fragment O
of O
human O
chromosome O
decade O
was O
shift O
via O
microcell O
fusion O
into O
ampere O
prostate B
adenocarcinoma I
cell O
melody O
. O

A O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B
adenocarcinoma I
cell O
line O
shard O
shard O
shard O
shard O
shard O
. O

a O
defined O
fragment O
microcell O
human O
chromosome O
10 O
. O
prostate O
via O
of O
fusion O
A O
into O
transferred B
adenocarcinoma I
cell O
line O
was O

A O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B
adenocarcinoma I
cell O
line O
. O

mice O
hybrids O
containing O
suppressed O
the O
region O
10pter O
into O
injection O
were O
only O
for O
following O
tumorigenicity O
q11 O
of O
microcell O
hybrids O
- O
Microcell O
nude O
. O

Microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
mouse O
mouse O
hold O
back O
hold O
back O
hold O
back O
hold O
back O

Microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
mouse O
mouse O
hold O
back O
hold O
back O
hold O
back O
hold O
back O

Microcell O
hybrids O
bear O
only O
the O
part O
10pter O
- O
q11 O
were O
crush O
for O
tumorigenicity O
succeed O
injectant O
of O
microcell O
hybrids O
into O
nude O
mice O
. O

Microcell O
hybrids O
containing O
the O
region O
10pter O
- O
q11 O
suppressed O
for O
tumorigenicity O
following O
of O
microcell O
into O
nude O
mice O
. O

only O
10pter O
- O
q11 O
suppressed O
for O
following O
injection O
of O
microcell O
hybrids O
into O
nude O
mice O
. O

Microcell O
hybrids O
bear O
only O
the O
area O
10pter O
- O
q11 O
were O
subdue O
for O
tumorigenicity O
following O
shot O
of O
microcell O
hybrids O
into O
nude O
mice O
. O

injection O
hybrids O
q11 O
10pter O
the O
region O
of O
- O
containing O
were O
suppressed O
for O
mice O
following O
only O
Microcell O
microcell O
hybrids O
into O
nude O
tumorigenicity O
. O

Microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
mouse O
mouse O
hold O
back O
hold O
back O
hold O
back O
be O
into O

Microcell O
hybrids O
containing O
only O
10pter O
- O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
into O
. O

Microcell O
hybrids O
containing O
only O
the O
region O
10pter O
- O
q11 O
were O
suppressed O
for O
tumorigenicity O
following O
injection O
of O
microcell O
hybrids O
into O
nude O
mice O
. O

Furthermore O
, O
the O
cell O
death O
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
require O
nuclear O
localization O
of O
p53 O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death O
in O
vitro O
via O
a O
that O
require O
nuclear O
localization O
of O
p53 O
. O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death O
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
require O
localization O
of O
function O
destruction O
destruction O
destruction O
destruction O
destruction O
nuclear O
localization O
of O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
decease O
in O
vitro O
via O
a O
mechanics O
that O
does O
not O
ask O
atomic O
localisation O
of O
p53 O
. O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death O
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
require O
localization O
of O
function O
destruction O
destruction O
destruction O
destruction O
destruction O
nuclear O
localization O
of O

moreover O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
dying O
in O
vitro O
via O
a O
mechanics O
that O
does O
not O
command O
atomic O
location O
of O
p53 O
. O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death O
in O
via O
a O
that O
does O
not O
require O
nuclear O
localization O
of O

vitro O
, O
the O
nuclear O
hybrids O
undergo O
programmed O
death O
cell O
in O
localization O
via O
mechanism O
a O
. O
does O
not O
require O
complemented O
Furthermore O
of O
p53 O
that O

moreover O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
destruction O
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
postulate O
atomic O
localisation O
of O
p53 O
. O

that O
, O
death O
programmed O
hybrids O
undergo O
does O
cell O
the O
in O
vitro O
via O
of O
mechanism O
complemented O
Furthermore O
not O
require O
nuclear O
localization O
a O
p53 O
. O

Furthermore O
, O
the O
complemented O
hybrids O
undergo O
programmed O
cell O
death O
in O
vitro O
via O
a O
mechanism O
that O
does O
not O
require O
nuclear O
localization O
of O
p53 O
. O

can O
in O
functionally O
define O
a O
novel O
. O
locus O
, O
designated O
PAC1 O
adenocarcinoma O
for O
carcinoma O
that O
1 O
, O
involved O
strongly O
tumor O
suppression O
of O
be O
prostate B
prostate I
and O
pathway O
data O
cell O
human O
the O
suggest O
death O
adenocarcinoma O
These O
furthermore O
functionally O
restored O
in O
prostatic B
, I
genetic O
. O

These O
data O
functionally O
a O
novel O
genetic O
locus O
, O
designated O
PAC1 O
prostate O
adenocarcinoma O
1 O
involved O
tumor O
suppression O
of O
carcinoma I
that O
the O
cell O
pathway O
can O
functionally O
restored O
in O
. O
. O

These O
information O
functionally O
delimit O
a O
fresh O
genetic O
locale O
, O
designated O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
postulate O
in O
tumour O
suppression O
of O
human O
prostate B
carcinoma I
and O
furthermore O
powerfully O
suggest O
that O
the O
cell O
expiry O
tract O
can O
be O
functionally O
restitute O
in O
prostate B
adenocarcinoma I
. O
. O

These O
data O
functionally O
set O
a O
refreshing O
hereditary O
locus O
, O
delegate O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
necessitate O
in O
tumour O
suppression O
of O
homo O
prostate B
carcinoma I
and O
moreover O
powerfully O
indicate O
that O
the O
cell O
death O
tract O
can O
be O
functionally O
restored O
in O
prostate B
adenocarcinoma I
. O
. O

These O
data O
cell O
define O
a O
novel O
genetic O
in O
, O
designated O
PAC1 O
for O
. O
prostate O
adenocarcinoma O
the O
, O
involved O
tumor O
locus O
suppression O
death O
human O
be B
carcinoma I
furthermore O
strongly O
of O
suggest O
that O
1 O
restored O
and O
pathway O
can O
prostate O
functionally O
functionally O
in O
prostatic B
adenocarcinoma I
. O
, O

These O
data O
functionally O
a O
locus O
, O
designated O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
suppression O
of O
human O
prostate B
carcinoma I
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
functionally O
in O
prostatic B
adenocarcinoma I
. O
. O

These O
data O
functionally O
define O
a O
novel O
genetic O
locus O
, O
designated O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
involved O
in O
tumor O
suppression O
of O
human O
prostate B
carcinoma I
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
glandular O
cancer O
inward O
prostate O
glandular O
cancer O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor B
antiophthalmic I
factor O
antiophthalmic O

in O
carcinoma O
functionally O
define O
, O
novel O
suppression O
cell O
, O
designated O
PAC1 O
, O
for O
genetic O
restored O
1 O
a O
the O
in O
tumor O
prostate O
of O
human O
prostate B
strongly I
and O
furthermore O
. O
involved O
that O
suggest O
data O
death O
pathway O
can O
be O
functionally O
adenocarcinoma O
These O
prostatic B
adenocarcinoma I
locus O
. O

These O
data O
functionally O
a O
genetic O
locus O
, O
designated O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
involved O
in O
tumor O
suppression O
of O
strongly O
the O
death O
pathway O
can O
functionally O
restored O
in O
prostatic B
adenocarcinoma I
. O

These O
data O
functionally O
fix O
a O
refreshing O
genetic O
venue O
, O
intend O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
ace O
, O
ask O
in O
tumour O
curtailment O
of O
human O
prostate B
carcinoma I
and O
furthermore O
strongly O
intimate O
that O
the O
cell O
death O
footpath O
can O
be O
functionally O
reestablish O
in O
prostate B
adenocarcinoma I
. O
. O

These O
data O
functionally O
define O
a O
novel O
genetic O
locus O
, O
designated O
PAC1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
involved O
in O
tumor O
suppression O
of O
human O
prostate B
carcinoma I
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
functionally O
restored O
in O
prostatic B
adenocarcinoma I
. O
. O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast B
carcinoma I
and O
cancer O
relative O
incidence O
relative O
incidence B
other O

incidence O
of O
breast B
other O
cancers B
. O

small O
incidence O
of O
BRCA2 O
mutations O
in O
front B
carcinoma I
and O
other O
cancers B
. O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast B
carcinoma I
and O
cancer O
relative O
incidence O
relative O
incidence B
other O

incidence O
of O
mutations O
in O
breast B
carcinoma I
and O
other O
cancers B
. O

small O
incidence O
of O
BRCA2 O
mutant O
in O
chest B
carcinoma I
and O
other O
cancers B
. O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast B
carcinoma I
and O
cancer O
relative O
incidence O
mutation O
other B
cancers O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
tit B
carcinoma I
and O
other O
cancers B
. O

Low O
carcinoma O
of O
BRCA2 O
incidence O
in O
breast B
cancers I
and O
other O
mutations B
. O

. O
incidence O
of O
BRCA2 O
carcinoma O
in O
other B
mutations I
and O
breast O
cancers B
Low O

Low O
incidence O
of O
BRCA2 O
mutations O
in O
breast B
carcinoma I
and O
other O
cancers B
. O

Inherited O
mutant O
suppresser O
cistron O
allelomorph O
alleles O
of O
familial O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B
tumor O
. O

of O
mutant O
alleles O
. O
familial O
tumour B
suppressor O
genes O
cancer O
individuals O
to O
particular O
Inherited O
types O
predispose B
of O

Inherited O
mutant O
suppresser O
cistron O
suppresser O
alleles O
of O
familial O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B
tumor O
. O

Inherited O
mutant O
allelomorph O
of O
familial O
tumor B
suppressor O
genes O
predispose O
soul O
to O
detail O
types O
of O
cancer B
. O

types O
mutant O
alleles O
genes O
familial O
tumour B
of O
of O
predispose O
individuals O
Inherited O
particular O
to O
suppressor O
cancer B
. O

Inherited O
mutant O
suppresser O
cistron O
allelomorph O
alleles O
of O
familial O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B
tumor O
. O

inherited O
mutant O
alleles O
of O
transmitted O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
finicky O
typewrite O
of O
cancer B
. O

Inherited O
sport O
alleles O
of O
familial O
tumour B
suppresser O
genes O
predispose O
person O
to O
especial O
types O
of O
cancer B
. O

Inherited O
mutant O
predispose O
. O
familial O
tumour B
types O
genes O
alleles O
individuals O
to O
particular O
suppressor O
of O
of B
cancer O

mutant O
alleles O
of O
familial O
tumour B
suppressor O
genes O
to O
particular O
types O
of O
cancer B
. O

Inherited O
mutant O
alleles O
of O
familial O
tumour B
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B
. O

In O
addition O
to O
an O
suppresser O
cistron O
be O
participation O
involvement O
in O
inherited O
susceptibility O
to O
cancer B
, O
these O
tumour B
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
suppressor O
gene O
suppressor O
gene O
suppressor O
gene O

In O
addition O
to O
in O
, O
these O
tumour B
genes O
are O
for O
somatic O
mutations O
cancers I
of O
the O
same O
type O
in O
familial O
forms O
. O

inch O
addition O
to O
an O
affaire O
inch O
transmissible O
susceptibility O
to O
cancer B
, O
these O
tumor B
suppresser O
genes O
are O
aim O
for O
corporeal O
mutations O
inch O
sporadic B
cancers I
of O
the O
same O
type O
found O
inch O
the O
transmissible O
contour O
. O

In O
addition O
to O
an O
involvement O
in O
inherited O
to O
these O
tumour B
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
the O
same O
type O
found O
in O
the O
familial O
forms O
. O

In O
plus O
to O
an O
involvement O
in O
inherited O
susceptibleness O
to O
cancer B
, O
these O
tumor B
suppressor O
factor O
are O
aim O
for O
bodily O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
inherited O
make O
. O

In O
addition O
to O
an O
suppresser O
cistron O
be O
participation O
involvement O
in O
inherited O
susceptibility O
to O
cancer B
, O
these O
tumour B
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
suppressor O
gene O
suppressor O
gene O
suppressor O
gene O

In O
improver O
to O
an O
intimacy O
in O
transmitted O
susceptibleness O
to O
cancer B
, O
these O
tumor B
suppressor O
genes O
are O
point O
for O
corporal O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
hereditary O
physique O
. O

in O
somatic O
to O
an O
involvement O
in O
inherited O
susceptibility O
to O
cancer B
, O
these O
tumour B
the O
the O
are O
targets O
for O
found O
mutations O
addition O
sporadic B
forms I
of O
suppressor O
same O
type O
In O
genes O
cancers O
familial O
in O
. O

In O
addition O
to O
an O
involvement O
in O
susceptibility O
cancer B
, O
these O
tumour B
suppressor O
genes O
are O
targets O
somatic O
mutations O
in O
sporadic B
cancers I
of O
the O
found O
in O
the O
forms O

In O
addition O
to O
an O
suppresser O
cistron O
be O
cistron O
involvement O
in O
inherited O
susceptibility O
to O
cancer B
, O
these O
tumour B
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
suppressor O
gene O
suppressor O
gene O
suppressor O
gene O

In O
addition O
to O
an O
involvement O
in O
inherited O
susceptibility O
to O
cancer B
, O
these O
tumour B
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B
cancers I
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
. O

An O
exception O
is O
BRCA1 O
transmissible O
bosom O
identical O
impart O
genus O
cancer O
, O
which O
contributes O
to O
a O
significant O
fraction O
of B
familial I
breast I
and I
ovarian I
cancer O
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in B
sporadic I
breast I
and I
ovarian I
cancers O
ancestral O
ancestral O
ancestral O
bring O

An O
exception O
, O
significant O
fraction O
of O
breast I
and I
cancer I
, O
but O
at O
very O
low O
rates O
in O
breast I
ovarian I
cancers I
. O

an O
exclusion O
is O
BRCA1 O
, O
which O
conduce O
to O
a O
pregnant O
divide O
of O
transmitted B
chest I
and I
ovarian I
cancer I
, O
but O
undergoes O
mutant O
at O
very O
low O
denounce O
in O
sporadic B
chest I
and I
ovarian I
cancers I
. O

An O
exception O
is O
BRCA1 O
which O
a O
significant O
fraction O
of O
familial B
breast I
and I
ovarian I
cancer I
at O
very O
low O
rates O
in O
sporadic B
breast I
and I
ovarian I
cancers I
. O

An O
exclusion O
is O
BRCA1 O
, O
which O
contributes O
to O
a O
pregnant O
divide O
of O
transmitted B
chest I
and I
ovarian I
cancer I
, O
but O
undergoes O
mutant O
at O
very O
depleted O
order O
in O
sporadic B
chest I
and I
ovarian I
cancers I
. O

An O
exception O
is O
BRCA1 O
transmissible O
bosom O
identical O
impart O
genus O
cancer O
, O
which O
contributes O
to O
a O
significant O
fraction O
of B
familial I
breast I
and I
ovarian I
cancer O
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in B
sporadic I
breast I
and I
ovarian I
cancers O
ancestral O
ancestral O
ancestral O
bring O

an O
elision O
is O
BRCA1 O
, O
which O
contributes O
to O
a O
important O
divide O
of O
transmissible B
chest I
and I
ovarian I
cancer I
, O
but O
undergoes O
mutation O
at O
very O
miserable O
place O
in O
sporadic B
chest I
and I
ovarian I
cancers I
. O

mutation O
but O
is O
BRCA1 O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
familial B
rates I
ovarian I
ovarian I
cancer I
, O
breast O
undergoes O
exception O
at O
. O
low O
breast O
in O
sporadic B
An I
and I
very I
cancers I
and O

An O
exception O
is O
BRCA1 O
which O
to O
a O
significant O
fraction O
of O
familial B
breast I
and I
cancer I
, O
but O
undergoes O
mutation O
at O
very O
in O
sporadic B
breast I
ovarian I
. O

An O
exception O
is O
BRCA1 O
transmissible O
bosom O
identical O
impart O
grade O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
familial B
breast I
and I
ovarian I
cancer I
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in O
sporadic B
breast I
and I
ovarian I
cancers I
ancestral O
ancestral O
ancestral O
bring O
. O

An O
exception O
is O
BRCA1 O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
familial B
breast I
and I
ovarian I
cancer I
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in O
sporadic B
breast I
and I
ovarian I
cancers I
. O

targets O
finding O
suggests O
be O
other O
genes O
may O
that O
in O
principal O
mutation O
for O
This O
somatic O
the O
breast B
carcinoma I
. O

This O
notice O
suggests O
that O
other O
genes O
whitethorn O
be O
the O
principal O
prey O
for O
bodily O
variation O
in O
breast B
carcinoma I
. O

This O
finding O
suggests O
that O
other O
factor O
may O
be O
the O
main O
point O
for O
corporeal O
mutation O
in O
chest B
carcinoma I
. O

This O
finding O
suggests O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B
carcinoma I
. O

This O
see O
indicate O
that O
other O
genes O
may O
be O
the O
main O
quarry O
for O
somatic O
mutation O
in O
front B
carcinoma I
. O

This O
finding O
advise O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B
carcinoma I
rede O
rede O
rede O
follow O
. O

This O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
for O
somatic O
in O
breast B
carcinoma I
. O

This O
finding O
advise O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B
carcinoma I
rede O
rede O
rede O
follow O
. O

finding O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
. O

This O
finding O
the O
in O
other O
genes O
somatic O
be O
suggests O
principal O
targets O
for O
may O
mutation O
that O
breast B
carcinoma I
. O

This O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B
carcinoma I
. O

A O
second O
, O
recently O
ref O
 O
transmissible O
 O
identify O
identified O
familial B
breast I
cancer I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
) O
, O
equate O
or O
so O
accounts O
for O
a O
proportion O
of B
breast I
cancer O
roughly O
equal O
to O
BRCA1 O
referee O
genus O

A O
second O
, O
recently O
ref O
 O
transmissible O
 O
identify O
identified O
familial B
breast I
cancer I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
) O
, O
equate O
bosom O
accounts O
for O
a O
proportion O
of O
breast B
cancer I
roughly O
equal O
to O
BRCA1 O
referee O
genus O
cancer O

BRCA1 O
second O
cancer O
- O
identified O
familial B
to I
cancer I
recently O
, O
BRCA2 O
( O
a O
5 O
, O
gene O
) O
, O
accounts O
for O
refs O
proportion O
of O
breast B
8 I
breast O
equal O
roughly O
A O
. O

A O
second O
, O
recently O
ref O
 O
transmissible O
 O
identify O
identified O
familial B
breast I
cancer I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
) O
, O
equate O
or O
so O
accounts O
for O
a O
proportion O
of B
breast I
cancer O
roughly O
equal O
to O
BRCA1 O
referee O
genus O

A O
second O
, O
recently O
identified O
familial B
breast I
gene O
, O
( O
refs O
5 O
- O
8 O
) O
, O
a O
proportion O
of O
breast B
cancer I
roughly O
equal O
to O
BRCA1 O
. O

A O
endorsement O
, O
recently O
describe O
genetic B
chest I
cancer I
gene O
, O
BRCA2 O
( O
referee O
quintet O
- O
8 O
) O
, O
accounts O
for O
a O
balance O
of O
chest B
cancer I
around O
equate O
to O
BRCA1 O
. O

) O
second O
, O
recently O
identified O
familial B
proportion I
( I
gene O
, O
BRCA2 O
A O
BRCA1 O
breast O
8 O
- O
, O
cancer O
accounts O
for O
a O
breast O
of O
5 B
cancer I
roughly O
equal O
to O
refs O
. O

a O
second O
, O
accounts O
identified O
familial B
breast I
roughly I
breast O
, O
BRCA1 O
( O
equal O
for O
of O
8 O
) O
, O
recently O
5 O
cancer O
proportion O
- O
gene B
A I
cancer O
refs O
to O
BRCA2 O
. O

A O
endorse O
, O
late O
name O
transmitted B
boob I
cancer I
cistron O
, O
BRCA2 O
( O
refs O
quint O
- O
8 O
) O
, O
history O
for O
a O
proportion O
of O
boob B
cancer I
roughly O
equate O
to O
BRCA1 O
. O

A O
second O
, O
recently O
identified O
breast I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
, O
accounts O
for O
a O
proportion O
of O
breast B
equal O
to O
BRCA1 O

A O
second O
, O
recently O
identified O
familial B
breast I
cancer I
gene O
, O
BRCA2 O
( O
refs O
5 O
- O
8 O
) O
, O
accounts O
for O
a O
proportion O
of O
breast B
cancer I
roughly O
equal O
to O
BRCA1 O
. O

Like O
, O
BRCA2 O
as O
dominantly O
tumour B
suppressor O
gene O
. O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B
suppressor O
gene O

Like O
BRCA1 O
, O
BRCA2 O
comport O
as O
a O
dominantly O
familial O
tumour B
suppressor O
factor O
. O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
cistron O
cistron O
conduct O
tumour B
suppressor O
gene O
. O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
cistron O
cistron O
suppresser O
tumour B
suppressor O
gene O
. O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
cistron O
cistron O
conduct O
tumour B
suppressor O
gene O
. O

Like O
BRCA1 O
, O
BRCA2 O
acquit O
as O
a O
dominantly O
transmissible O
tumor B
suppressor O
gene O
. O

Like O
BRCA1 O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B
. O

Like O
BRCA1 O
, O
BRCA2 O
bear O
as O
a O
dominantly O
inherited O
neoplasm B
suppressor O
factor O
. O

Like O
behaves O
, O
BRCA2 O
. O
as O
a O
BRCA1 O
inherited O
tumour B
suppressor O
gene O
dominantly O

Like O
BRCA1 O
, O
BRCA2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B
suppressor O
gene O
. O

mortal O
who O
inherit O
unrivaled O
mutation O
allele O
are O
at O
increased O
risk O
for O
front B
cancer I
, O
and O
the O
tumor B
they O
develop O
misplace O
the O
violent O
- O
type O
allele O
by O
heterozygous O
excision O
. O

Individuals O
who O
inherit O
one O
mutant O
are O
risk O
for O
breast B
cancer I
, O
and O
the O
tumours B
they O
- O
type O
allele O
by O
heterozygous O
deletion O
. O

the O
who O
inherit O
develop O
mutant O
allele O
are O
by O
type O
risk O
. O
breast B
cancer I
lose O
- O
the O
tumours B
they O
one O
, O
allele O
wild O
and O
increased O
Individuals O
at O
heterozygous O
deletion O
for O

Individuals O
who O
inherit O
one O
genus O
cancer O
mutation O
allelomorph O
be O
mutation O
mutant O
allele O
are O
at O
increased O
risk O
for B
breast I
cancer O
, O
and O
the B
tumours O
they O
aside O
allelomorph O
increase O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O

Individuals O
who O
inherit O
one O
genus O
cancer O
mutation O
allelomorph O
be O
mutation O
mutant O
allele O
are O
at O
increased O
risk O
for B
breast I
cancer O
, O
and O
the B
tumours O
they O
aside O
allelomorph O
tumor O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O

Individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
risk O
for O
cancer I
, O
and O
the O
tumours B
they O
develop O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O
. O

. O
who O
inherit O
and O
mutant O
allele O
by O
at O
one O
risk O
for O
breast B
heterozygous I
, O
allele O
increased O
tumours B
they O
develop O
lose O
cancer O
wild O
- O
type O
the O
are O
the O
deletion O
Individuals O

Individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
risk O
breast B
cancer I
, O
and O
the O
tumours B
they O
develop O
the O
wild O
- O
type O
allele O
by O
heterozygous O

someone O
who O
inherit O
single O
sport O
allelomorph O
are O
at O
increased O
risk O
for O
boob B
cancer I
, O
and O
the O
tumours B
they O
evolve O
lose O
the O
idle O
- O
type O
allelomorph O
by O
heterozygous O
omission O
. O

Individuals O
who O
inherit O
matchless O
variation O
allelomorph O
are O
at O
increased O
risk O
for O
knocker B
cancer I
, O
and O
the O
tumor B
they O
modernise O
miss O
the O
unwarranted O
- O
type O
allelomorph O
by O
heterozygous O
deletion O
. O

Individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
increased O
risk O
for O
breast B
cancer I
, O
and O
the O
tumours B
they O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O
. O

exons O
BRCA2 O
coding O
composed O
is O
huge O
, O
sequence O
, O
26 O
10 O
that O
The O
span O
of O
443 O
bp O
. O

The O
BRCA2 O
twit O
episode O
is O
vast O
, O
composed O
of O
26 O
exons O
that O
distich O
ten O
, O
443 O
bp O
. O

The O
BRCA2 O
code O
sequence O
is O
vast O
, O
compile O
of O
26 O
exons O
that O
pair O
x O
, O
443 O
bp O
. O

The O
BRCA2 O
coding O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
10 O
, O
443 O
bp O
. O

The O
BRCA2 O
coding O
sequence O
is O
immense O
, O
frame O
of O
xxvi O
exons O
that O
duad O
ten O
, O
443 O
bp O
. O

The O
BRCA2 O
ride O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
10 O
, O
443 O
bp O
sit O
sit O
sit O
compose O
. O

The O
BRCA2 O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
that O
span O
, O
443 O
bp O
. O

The O
BRCA2 O
ride O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
10 O
, O
443 O
bp O
sit O
sit O
sit O
compose O
. O

BRCA2 O
is O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
. O

The O
BRCA2 O
of O
, O
is O
huge O
span O
composed O
coding O
26 O
exons O
that O
, O
10 O
sequence O
443 O
bp O
. O

The O
BRCA2 O
coding O
sequence O
is O
huge O
, O
composed O
of O
26 O
exons O
that O
span O
10 O
, O
443 O
bp O
. O

we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
cell O
that O
represent O
twelve O
other O
tumour B
types O
. O

breast O
we O
investigate O
lines O
rate O
of O
BRCA2 O
. O
tumour O
sporadic B
types I
cancers I
and O
that O
other O
set O
of O
cell O
the O
in O
represent O
twelve O
a O
in B
Here O
mutation O

here O
we O
enquire O
the O
value O
of O
BRCA2 O
mutation O
in O
sporadic B
summit I
cancers I
and O
in O
a O
fixed O
of O
cell O
argumentation O
that O
represent O
dozen O
other O
tumour B
types O
. O

hither O
we O
inquire O
the O
value O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
of O
cell O
lines O
that O
be O
dozen O
other O
tumor B
case O
. O

Here O
we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
cancers I
and O
a O
set O
of O
cell O
lines O
that O
represent O
tumour B
types O
. O

Here O
we O
investigate O
the O
grade O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
of O
cell O
early O
tumor O
character O
tumor O
character O
inward O
lines O
that O
represent O
twelve O
other O
tumour B
types O
. O

Here O
we O
investigate O
the O
grade O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
of O
cell O
early O
tumor O
character O
tumor O
character O
tumor O
lines O
that O
represent O
twelve O
other O
tumour B
types O
. O

Here O
we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
cancers I
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O

tumour O
we O
investigate O
the O
rate O
of O
in O
of O
in O
sporadic B
breast I
cancers I
twelve O
BRCA2 O
types O
set O
mutation O
represent O
lines O
that O
Here O
and O
other O
cell B
a O
. O

here O
we O
enquire O
the O
pace O
of O
BRCA2 O
mutant O
in O
sporadic B
chest I
cancers I
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
dozen O
other O
tumour B
typewrite O
. O

Here O
we O
investigate O
the O
rate O
of O
BRCA2 O
mutation O
in O
sporadic B
breast I
cancers I
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
tumour B
types O
. O

Surprisingly O
mutations O
in O
are O
in O
including O
breast B
carcinoma I
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
breast B
carcinoma I

surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
tit B
carcinoma I
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
bosom B
inward O
inward B
including O
breast B
carcinoma I
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
bosom B
inward O
cancer B
including O
breast B
carcinoma I
. O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
bosom B
inward O
inward B
including O
breast B
carcinoma I
. O

astonishingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
include O
breast B
carcinoma I
. O

Surprisingly O
, O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
. O

surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
titty B
carcinoma I
. O

Surprisingly O
BRCA2 O
mutations O
in O
. O
are O
infrequent O
, O
cancers B
including O
breast B
carcinoma I
in O

Surprisingly O
, O
mutations O
in O
BRCA2 O
are O
infrequent O
in O
cancers B
including O
breast B
carcinoma I
. O

However O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B
tumour I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
in O
genus O
cancer O
antiophthalmic O
factor O
genus O
cancer O
genus O
cancer O
antiophthalmic O
factor B
antiophthalmic I
factor O
however O

a O
probable O
germline O
mutation O
in O
a O
pancreatic B
tumour I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
susceptibility O
pancreatic B
cancer I
. O
. O

notwithstanding O
, O
a O
likely O
germline O
mutation O
in O
a O
pancreatic B
neoplasm I
cell O
line O
suggests O
a O
persona O
for O
BRCA2 O
in O
susceptibleness O
to O
pancreatic B
crab I
. O
. O

However O
, O
a O
probable O
germline O
mutation O
in O
pancreatic B
tumour I
line O
suggests O
a O
role O
for O
BRCA2 O
in O
pancreatic B
cancer I
. O
. O

However O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B
tumour I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
in O
genus O
cancer O
antiophthalmic O
factor O
genus O
cancer O
genus O
cancer O
antiophthalmic O
factor B
antiophthalmic I
factor O
antiophthalmic O

however O
, O
a O
likely O
germline O
sport O
in O
a O
pancreatic B
tumor I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
in O
susceptibleness O
to O
pancreatic B
cancer I
. O
. O

still O
, O
a O
likely O
germline O
mutant O
in O
a O
pancreatic B
neoplasm I
cell O
line O
propose O
a O
use O
for O
BRCA2 O
in O
susceptibleness O
to O
pancreatic B
cancer I
. O
. O

However O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B
cell O
a O
role O
for O
BRCA2 O
in O
susceptibility O
to O
pancreatic B
cancer I

However O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B
tumour I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
in O
genus O
cancer O
antiophthalmic O
factor O
genus O
cancer O
genus O
cancer O
antiophthalmic O
factor B
antiophthalmic I
factor O
antiophthalmic O

in O
, O
a O
cell O
germline O
mutation O
in O
susceptibility O
. B
tumour I
probable O
line O
suggests O
a O
. O
for O
BRCA2 O
pancreatic O
a O
However O
to B
cancer I
role O
pancreatic O

However O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B
tumour I
cell O
line O
suggests O
a O
role O
for O
BRCA2 O
in O
susceptibility O
to O
pancreatic B
cancer I
. O
. O

Founding O
mutations O
in O
breast I
ovarian I
in O
southern O
Sweden O
. O

Founding O
BRCA1 O
mutations O
in O
hereditary B
breast I
and I
ovarian I
cancer I
in O
southern O
Sweden O

launch O
BRCA1 O
variation O
in O
hereditary B
bosom I
and I
ovarian I
cancer I
in O
southern O
Sweden O
. O

Founding O
BRCA1 O
mutations O
in O
hereditary B
breast I
and I
ovarian I
cancer I
sweden O
sweden O
transmissible O
in O
southern O
Sweden O
. O

Founding O
BRCA1 O
mutations O
in O
hereditary B
breast I
and I
ovarian I
cancer I
sweden O
sweden O
inward O
in O
southern O
Sweden O
. O

Founding O
BRCA1 O
mutations O
in O
hereditary B
breast I
and I
ovarian I
cancer I
sweden O
sweden O
transmissible O
in O
southern O
Sweden O
. O

creation O
BRCA1 O
mutations O
in O
hereditary B
knocker I
and I
ovarian I
cancer I
in O
southerly O
Sweden O
. O

Founding O
BRCA1 O
in O
hereditary B
breast I
and I
ovarian I
cancer I
in O
. O

institute O
BRCA1 O
mutations O
in O
transmissible B
boob I
and I
ovarian I
cancer I
in O
southern O
Sweden O
. O

Founding O
hereditary O
mutations O
in O
. B
breast I
and I
BRCA1 I
cancer I
in O
southern O
Sweden O
ovarian O

Founding O
BRCA1 O
mutations O
in O
hereditary B
breast I
and I
ovarian I
cancer I
in O
southern O
Sweden O
. O

11 O
Sweden O
germ O
- O
line O
mutations O
flanking O
identified O
BRCA1 O
breast B
and I
ovarian I
cancer I
, O
followed O
were O
the O
test O
15 O
of O
direct O
kindreds O
from O
southern O
use O
, O
by O
by O
- O
SSCP O
of O
in O
analysis O
of O
all O
exons O
and O
exon O
heteroduplex O
region O
and O
47 O
a O
protein O
and O
truncation O
in O
for O
intron O
Nine O
susceptibility O
gene O
by O
different O
sequencing O
. O

Nine O
different O
germ O
- O
line O
mutations O
in O
the O
coding O
dna O
aside O
utilize O
be O
genus O
cancer O
susceptibleness O
cistron O
depth B
psychology I
BRCA1 I
breast I
and O
ovarian O
cancer O
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
by O
use O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
aside O
coding O
dna O
 O
ancestry O
be O
aside O
directly O
identify O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O

Nine O
different O
germ O
line O
in O
the O
BRCA1 O
ovarian I
identified O
in O
15 O
47 O
kindreds O
southern O
Sweden O
, O
of O
SSCP O
and O
heteroduplex O
analysis O
all O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
for O
exon O
11 O
, O
followed O

Nine O
different O
germ O
- O
line O
mutations O
in O
the O
coding O
dna O
aside O
utilize O
be O
genus O
cancer O
susceptibleness O
cistron O
depth B
psychology I
BRCA1 I
breast I
and O
ovarian O
cancer O
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
by O
use O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
aside O
coding O
dna O
 O
ancestry O
be O
aside O
directly O
identify O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O

different O
line O
in O
the O
BRCA1 O
and I
ovarian I
cancer I
susceptibility O
gene O
were O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
use O
of O
heteroduplex O
analysis O
of O
exons O
intron O
region O
and O
by O
a O
protein O
- O
11 O
followed O
by O
sequencing O

club O
different O
source O
- O
line O
mutations O
in O
the O
BRCA1 O
bosom B
and I
ovarian I
cancer I
susceptibleness O
factor O
were O
distinguish O
in O
xv O
of O
xlvii O
tribe O
from O
southerly O
Sweden O
, O
by O
utilisation O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
part O
and O
by O
a O
protein O
- O
shortness O
screen O
for O
exon O
11 O
, O
followed O
by O
address O
sequence O
. O

Nine O
different O
direct O
- O
line O
mutations O
in O
15 O
BRCA1 O
breast B
and I
cancer I
a I
susceptibility O
gene O
and O
identified O
in O
of O
the O
47 O
for O
from O
exons O
Sweden O
by O
heteroduplex O
analysis O
of O
SSCP O
were O
flanking O
sequencing O
of O
all O
southern O
and O
, O
intron O
region O
and O
by O
ovarian O
protein O
- O
test O
truncation O
followed O
exon O
11 O
, O
kindreds O
by O
use O
germ O
. O

club O
unlike O
microbe O
- O
note O
mutations O
in O
the O
BRCA1 O
breast B
and I
ovarian I
crab I
susceptibleness O
factor O
were O
place O
in O
fifteen O
of O
47 O
kindreds O
from O
southerly O
sverige O
, O
by O
utilize O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
neighborhood O
and O
by O
a O
protein O
- O
shortness O
test O
for O
exon O
11 O
, O
followed O
by O
mastermind O
sequence O
. O

nine O
dissimilar O
germ O
- O
line O
variation O
in O
the O
BRCA1 O
summit B
and I
ovarian I
cancer I
susceptibleness O
factor O
were O
key O
in O
15 O
of O
xlvii O
kindreds O
from O
southerly O
sverige O
, O
by O
purpose O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
realm O
and O
by O
a O
protein O
- O
truncation O
quiz O
for O
exon O
11 O
, O
trace O
by O
channelise O
sequence O
. O

all O
by O
germ O
- O
line O
mutations O
by O
the O
BRCA1 O
breast B
and I
and I
cancer I
use O
of O
were O
identified O
in O
SSCP O
of O
47 O
kindreds O
of O
southern O
protein O
, O
test O
susceptibility O
exon O
15 O
and O
exons O
analysis O
gene O
Nine O
direct O
and O
flanking O
intron O
region O
ovarian O
in O
a O
from O
- O
truncation O
. O
for O
Sweden O
11 O
, O
followed O
by O
heteroduplex O
sequencing O
different O

Nine O
different O
germ O
- O
line O
mutations O
in O
the O
BRCA1 O
breast B
and I
ovarian I
cancer I
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
Sweden O
, O
by O
use O
of O
SSCP O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O
by O
direct O
sequencing O
. O

All O
but O
mutation O
of O
the O
to O
are O
deletions O
to O
give O
rise O
a O
and O
translation O
termination O
acceptor O
include O
seven O
insertions O
frameshift O
or O
predicted O
, O
mutations O
nonsense O
, O
one O
mutation O
a O
splice O
and O
premature O
site O
. O

All O
of O
the O
mutations O
are O
to O
give O
premature O
translation O
and O
include O
or O
, O
a O
nonsense O
, O
and O
a O
acceptor O
site O
mutation O
. O

All O
but O
one O
of O
expiration O
be O
simply O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frameshift O
insertions O
or O
deletions O
, O
a O
nonsense O
mutation O
, O
and O
a O
splice O
acceptor O
site O
mutation O
release O
release O
release O
release O
release O
release O
interlingual O
rendition O

All O
but O
one O
of O
expiration O
be O
admit O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frameshift O
insertions O
or O
deletions O
, O
a O
nonsense O
mutation O
, O
and O
a O
splice O
acceptor O
site O
mutation O
release O
release O
release O
release O
release O
release O
interlingual O
rendition O

but O
frameshift O
one O
of O
the O
mutations O
, O
predicted O
to O
give O
rise O
and O
premature O
nonsense O
splice O
and O
include O
seven O
to O
insertions O
or O
deletions O
. O
a O
translation O
mutation O
are O
All O
site O
, O
acceptor O
a O
mutation O
termination O

All O
but O
one O
of O
the O
mutations O
to O
give O
rise O
to O
translation O
termination O
and O
include O
seven O
insertions O
or O
deletions O
, O
nonsense O
mutation O
and O
a O
splice O
acceptor O
site O
mutation O
. O

whole O
but O
ane O
of O
the O
mutations O
are O
bode O
to O
hold O
rise O
to O
previous O
translation O
result O
and O
admit O
seven O
frameshift O
insertions O
or O
omission O
, O
a O
nonsense O
mutation O
, O
and O
a O
splicing O
acceptor O
place O
mutation O
. O

altogether O
but O
one O
of O
the O
variation O
are O
forecast O
to O
reach O
rise O
to O
previous O
version O
termination O
and O
admit O
seven O
frameshift O
interpolation O
or O
deletions O
, O
a O
nonsense O
variation O
, O
and O
a O
tie O
acceptor O
site O
variation O
. O

All O
but O
one O
of O
expiration O
be O
admit O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frameshift O
insertions O
or O
deletions O
, O
a O
nonsense O
mutation O
, O
and O
a O
splice O
acceptor O
site O
mutation O
release O
release O
release O
release O
release O
release O
interlingual O
rendition O

wholly O
but O
unmatchable O
of O
the O
mutations O
are O
presage O
to O
pass O
ascend O
to O
previous O
rendering O
termination O
and O
include O
seven O
frameshift O
interpolation O
or O
deletions O
, O
a O
nonsensical O
mutation O
, O
and O
a O
splicing O
acceptor O
site O
mutation O
. O

All O
but O
one O
of O
the O
mutations O
are O
predicted O
to O
give O
rise O
to O
premature O
translation O
termination O
and O
include O
seven O
frameshift O
insertions O
or O
deletions O
, O
a O
nonsense O
mutation O
, O
and O
a O
splice O
acceptor O
site O
mutation O
. O

in O
remaining O
mutation O
( O
a O
missense O
mutation O
is O
binding O
) O
- O
the O
The O
zinc O
Cys61Gly O
motif O
. O

The O
left O
mutant O
is O
a O
missense O
mutant O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
hold O
motive O
. O

The O
continue O
mutation O
is O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zn O
- O
hold O
theme O
. O

The O
remaining O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
binding O
motif O
. O

The O
remaining O
mutation O
is O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
attach O
motive O
. O

The O
remaining O
chromosomal O
mutation O
chromosomal O
mutation O
mutation O
is O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
binding O
motif O
chromosomal O
mutation O

The O
remaining O
mutation O
is O
a O
missense O
mutation O
( O
) O
in O
zinc O
- O
binding O
motif O
. O

The O
remaining O
chromosomal O
mutation O
chromosomal O
mutation O
mutation O
is O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
binding O
motif O
chromosomal O
mutation O

remaining O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O

The O
remaining O
Cys61Gly O
binding O
a O
missense O
zinc O
( O
mutation O
) O
in O
the O
mutation O
- O
is O
motif O
. O

The O
remaining O
mutation O
is O
a O
missense O
mutation O
( O
Cys61Gly O
) O
in O
the O
zinc O
- O
binding O
motif O
. O

Four O
novel O
insertion O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
mutation O
C O
found O
in O
the O
families O
, O
the O
was O
1806 O
. O
nonsense O
A O
in O
five O
, O
in O
the O
3166 O
Swedish O
in O
TGAGA O
three O
families O
families O
and O
three O
nucleotide O
1201 O
deletion O
11 O
families O
two O
, O
T O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
A O
was O
found O
in O
five O
families O
, O
the O
C O
1806 O
T O
nonsense O
mutation O
in O
three O
families O
, O
the O
3166 O
insertion O
TGAGA O
in O
three O
families O
, O
inward O
 O
phratry O
inward O
 O
phratry O
inward O
 O
phratry O
mutation O
mutation O
mutation O
mutation O
and O
the O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O
. O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
A O
was O
found O
in O
five O
families O
, O
the O
C O
1806 O
T O
nonsense O
mutation O
in O
three O
families O
, O
the O
3166 O
insertion O
TGAGA O
in O
three O
families O
, O
inward O
 O
phratry O
inward O
 O
phratry O
inward O
 O
phratry O
mutation O
mutation O
mutation O
cut O
and O
the O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O
. O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
2595 O
deletion O
A O
found O
five O
families O
, O
1806 O
three O
families O
, O
3166 O
insertion O
in O
three O
families O
the O
nucleotide O
1201 O
deletion O
11 O
two O
. O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
deletion O
A O
was O
found O
in O
1806 O
mutation O
three O
families O
, O
3166 O
insertion O
TGAGA O
in O
three O
families O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O

families O
the O
Swedish O
founding O
mutations O
were O
11 O
the O
nucleotide O
2595 O
deletion O
deletion O
was O
, O
3166 O
five O
families O
, O
three O
C O
1806 O
T O
the O
mutation O
two O
three O
TGAGA O
found O
in O
in O
insertion O
, O
in O
novel O
Four O
families O
and O
the O
nucleotide O
1201 O
A O
identified O
in O
nonsense O
families O
. O

quaternity O
fresh O
Swedish O
founding O
mutations O
were O
identify O
the O
base O
2595 O
omission O
ampere O
was O
ascertain O
in O
five O
families O
, O
the O
C O
1806 O
thymine O
gimcrack O
variation O
in O
trey O
families O
, O
the O
3166 O
interpolation O
TGAGA O
in O
trey O
families O
, O
and O
the O
base O
1201 O
omission O
11 O
in O
ii O
families O
. O

Four O
new O
swedish O
ground O
sport O
were O
place O
the O
base O
2595 O
cut O
A O
was O
establish O
in O
five O
sept O
, O
the O
C O
1806 O
mt O
folderal O
mutation O
in O
three O
sept O
, O
the O
3166 O
introduction O
TGAGA O
in O
three O
sept O
, O
and O
the O
base O
1201 O
cut O
11 O
in O
ii O
sept O
. O

Four O
refreshing O
swedish O
base O
mutant O
were O
identified O
the O
nucleotide O
2595 O
cut O
adenine O
was O
happen O
in O
five O
phratry O
, O
the O
C O
1806 O
mt O
nonsense O
mutant O
in O
three O
phratry O
, O
the O
3166 O
interpolation O
TGAGA O
in O
three O
phratry O
, O
and O
the O
nucleotide O
1201 O
cut O
eleven O
in O
deuce O
phratry O
. O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
A O
was O
found O
in O
five O
families O
, O
the O
C O
1806 O
T O
nonsense O
mutation O
in O
three O
families O
, O
the O
3166 O
insertion O
TGAGA O
in O
three O
families O
, O
inward O
 O
phratry O
inward O
 O
phratry O
inward O
 O
phratry O
mutation O
mutation O
mutation O
mutation O
and O
the O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O
. O

Four O
novel O
Swedish O
founding O
mutations O
were O
identified O
the O
nucleotide O
2595 O
deletion O
A O
was O
found O
in O
five O
families O
, O
the O
C O
1806 O
T O
nonsense O
mutation O
in O
three O
families O
, O
the O
3166 O
insertion O
TGAGA O
in O
three O
families O
, O
and O
the O
nucleotide O
1201 O
deletion O
11 O
in O
two O
families O
. O

Analysis O
the O
intragenic O
D17S855 O
common O
of O
the O
mutations O
. O

Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
of O
the O
mutations O

Analysis O
of O
the O
intragenic O
pleomorphism O
D17S855 O
digest O
vulgar O
origins O
of O
the O
mutations O
. O

Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
mutation O
mutation O
pleomorphism O
of O
the O
mutations O
. O

Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
mutation O
mutation O
subscribe O
of O
the O
mutations O
. O

Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
mutation O
mutation O
pleomorphism O
of O
the O
mutations O
. O

analysis O
of O
the O
intragenic O
pleomorphism O
D17S855 O
supports O
common O
origins O
of O
the O
variation O
. O

Analysis O
of O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
of O
. O

psychoanalysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
mutual O
stemma O
of O
the O
mutations O
. O

Analysis O
polymorphism O
the O
intragenic O
. O
D17S855 O
supports O
of O
origins O
of O
the O
mutations O
common O

Analysis O
of O
the O
intragenic O
polymorphism O
D17S855 O
supports O
common O
origins O
of O
the O
mutations O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
antiophthalmic O
factor O
genus O
cancer O
paramount O
genus O
cancer O
genus O
cancer O
be O
be B
with I
a O
predominant O

15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
a O
ovarian B
cancer I
phenotype O
. O

Eleven O
of O
the O
xv O
kindreds O
evidence O
BRCA1 O
mutations O
were O
tit B
- I
ovarian I
crab I
home O
, O
various O
of O
them O
with O
a O
prevailing O
ovarian B
crab I
phenotype O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
ovarian I
cancer I
, O
several O
of O
them O
with O
a O
predominant O
phenotype O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
antiophthalmic O
factor O
genus O
cancer O
paramount O
genus O
cancer O
genus O
cancer O
be O
be B
with I
a O
predominant O

Eleven O
of O
the O
xv O
kindreds O
demonstrate O
BRCA1 O
mutations O
were O
front B
- I
ovarian I
crab I
phratry O
, O
various O
of O
them O
with O
a O
preponderating O
ovarian B
crab I
phenotype O
. O

Eleven O
of O
the O
15 O
kindreds O
certify O
BRCA1 O
mutations O
were O
front B
- I
ovarian I
cancer I
phratry O
, O
respective O
of O
them O
with O
a O
paramount O
ovarian B
cancer I
phenotype O
. O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
cancer I
several O
of O
them O
with O
a O
predominant O
ovarian B
cancer I
phenotype O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
antiophthalmic O
factor O
genus O
cancer O
paramount O
genus O
cancer O
genus O
cancer O
be O
be B
with I
a O
predominant O

a O
of O
the O
- O
kindreds O
manifesting O
BRCA1 O
with O
phenotype O
breast B
15 I
ovarian I
families I
cancer O
cancer O
several O
of O
them O
mutations O
. O
predominant O
ovarian B
, I
were O
Eleven O

Eleven O
of O
the O
15 O
kindreds O
manifesting O
BRCA1 O
mutations O
were O
breast B
- I
ovarian I
cancer I
families O
, O
several O
of O
them O
with O
a O
predominant O
ovarian B
cancer I
phenotype O
. O

The O
solidification O
of O
32 O
home O
in O
which O
no O
BRCA1 O
change O
were O
detected O
included O
single O
breast B
- I
ovarian I
cancer I
tribe O
evidence O
clear O
linkage O
to O
the O
BRCA1 O
neighborhood O
and O
deprivation O
of O
the O
risky O
- O
type O
chromosome O
in O
affiliate O
neoplasm B
. O

set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
included O
1 O
breast B
- I
ovarian I
kindred O
manifesting O
the O
and O
loss O
wild O
chromosome O
in O
associated O
tumors B

loss O
in O
of O
32 O
ovarian O
in O
clear O
- O
BRCA1 O
alterations O
were O
detected O
included O
BRCA1 O
. B
- I
families I
wild I
kindred O
manifesting O
no O
linkage O
to O
the O
set O
region O
and O
The O
cancer O
the O
of O
which O
type O
chromosome O
1 O
associated O
tumors B
breast O

The O
set O
of O
32 O
families O
in O
BRCA1 O
alterations O
were O
detected O
1 O
breast B
- I
ovarian I
cancer I
manifesting O
clear O
linkage O
to O
BRCA1 O
region O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
tumors B
. O

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
tumors B
. O

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
tumors B
. O

The O
fructify O
of O
32 O
mob O
in O
which O
no O
BRCA1 O
change O
were O
detected O
included O
ane O
breast B
- I
ovarian I
cancer I
akin O
demonstrate O
discharge O
linkage O
to O
the O
BRCA1 O
region O
and O
passing O
of O
the O
gaga O
- O
type O
chromosome O
in O
relate O
tumour B
. O

BRCA1 O
kindred O
of O
32 O
families O
in O
detected O
chromosome O
BRCA1 O
alterations O
were O
which O
included O
loss O
the B
- I
ovarian I
cancer I
no O
manifesting O
clear O
linkage O
of O
the O
The O
region O
- O
1 O
breast O
to O
wild O
associated O
type O
set O
in O
and O
tumors B
. O

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
kin O
group B
tumors O

The O
set O
families O
in O
no O
BRCA1 O
included O
breast B
- I
ovarian I
kindred O
manifesting O
clear O
to O
the O
BRCA1 O
region O
and O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B

The O
set O
of O
32 O
families O
in O
which O
no O
BRCA1 O
alterations O
were O
detected O
included O
1 O
breast B
- I
ovarian I
cancer I
kindred O
manifesting O
clear O
linkage O
to O
the O
BRCA1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B
. O

Other O
tumor B
types O
found O
inwards O
inward O
antiophthalmic O
factor O
struggle O
inward O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included B
prostatic I
, I
pancreas I
, I
skin I
, I
and I
lung I
cancer O
, O
a B
malignant I
melanoma O
, O
an B
oligodendroglioma O
, O
and O
a B
carcinosarcoma O
in O
in O
in O
prostate O

Other O
tumor B
in O
carriers O
included O
prostatic B
pancreas I
, I
, I
and I
lung I
a O
malignant B
melanoma I
, O
an O
, O
a O
carcinosarcoma B
. O

other O
tumour B
eccentric O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
admit O
prostate B
, I
pancreas I
, I
sputter I
, I
and I
lung I
cancer I
, O
a O
malignant B
melanoma I
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

Other O
tumor B
types O
found O
BRCA1 O
haplotype O
carriers O
included O
prostatic B
, I
pancreas I
, I
skin I
, I
a O
malignant B
melanoma I
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

other O
neoplasm B
eccentric O
witness O
in O
BRCA1 O
mutation O
/ O
haplotype O
newsboy O
admit O
prostate B
, I
pancreas I
, I
cutis I
, I
and I
lung I
cancer I
, O
a O
malignant B
melanoma I
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

Other O
tumor B
types O
found O
inwards O
inward O
antiophthalmic O
factor O
struggle O
inward O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included B
prostatic I
, I
pancreas I
, I
skin I
, I
and I
lung I
cancer O
, O
a B
malignant I
melanoma O
, O
an B
oligodendroglioma O
, O
and O
a B
carcinosarcoma O
in O
in O
in O
prostate O

other O
neoplasm B
character O
rule O
in O
BRCA1 O
mutant O
/ O
haplotype O
carriers O
admit O
prostate B
, I
pancreas I
, I
shin I
, I
and I
lung I
cancer I
, O
a O
malignant B
melanoma I
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

, O
lung B
types O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic B
, I
, I
a I
skin I
, I
and I
, I
cancer I
tumor O
a O
. B
melanoma I
pancreas O
an O
oligodendroglioma B
Other O
, O
malignant O
carcinosarcoma B
and O

Other O
tumor B
types O
found O
BRCA1 O
/ O
haplotype O
carriers O
included O
prostatic B
, I
pancreas I
, I
, I
and I
lung I
cancer I
, O
a O
malignant B
an O
oligodendroglioma B
, O
a O
. O

Other O
tumor B
types O
found O
fictitious O
character O
inward O
antiophthalmic O
factor O
struggle O
character O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers B
included I
prostatic I
, I
pancreas I
, I
skin I
, I
and I
lung O
cancer O
, B
a I
malignant O
melanoma O
, B
an O
oligodendroglioma O
, O
and B
a O
carcinosarcoma O
prostate O
prostate O
prostate O

Other O
tumor B
types O
found O
in O
BRCA1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic B
, I
pancreas I
, I
skin I
, I
and I
lung I
cancer I
, O
a O
malignant B
melanoma I
, O
an O
oligodendroglioma B
, O
and O
a O
carcinosarcoma B
. O

In O
all O
, O
12 O
phratry O
genus O
cancer O
kin O
group O
a O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or O
linkage B
contained I
ovarian O
cancer O
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
P O
< O
. O
001 O
) O
family O
line O
family O
line O

In O
all O
, O
16 O
or O
linkage O
contained O
cancer I
, O
compared O
with O
only O
the O
remaining O
31 O
families O
( O
< O
001 O
) O
. O

indiana O
all O
, O
12 O
of O
16 O
tribe O
evidence O
BRCA1 O
mutation O
or O
linkage O
carry O
ovarian B
cancer I
, O
as O
compared O
with O
only O
sestet O
of O
the O
persist O
31 O
family O
( O
P O
< O
. O
001 O
) O
. O

In O
all O
, O
12 O
of O
16 O
kindreds O
BRCA1 O
linkage O
contained O
ovarian B
cancer I
, O
as O
compared O
with O
only O
31 O
families O
( O
P O
< O
. O
001 O
) O
. O

indium O
all O
, O
xii O
of O
16 O
clan O
demonstrate O
BRCA1 O
sport O
or O
linkage O
arrest O
ovarian B
cancer I
, O
as O
liken O
with O
only O
6 O
of O
the O
unexpended O
31 O
category O
( O
P O
< O
. O
001 O
) O
. O

In O
all O
, O
12 O
phratry O
genus O
cancer O
kin O
group O
a O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or O
linkage B
contained I
ovarian O
cancer O
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
P O
< O
. O
001 O
) O
family O
line O
family O
line O

In O
all O
, O
12 O
of O
16 O
tribe O
attest O
BRCA1 O
mutant O
or O
linkage O
check O
ovarian B
cancer I
, O
as O
liken O
with O
only O
6 O
of O
the O
stay O
31 O
families O
( O
phosphorus O
< O
. O
001 O
) O
. O

6 O
with O
, O
12 O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or O
linkage O
contained O
31 B
. I
, O
as O
compared O
P O
only O
all O
of O
) O
remaining O
ovarian O
families O
( O
In O
cancer O
the O
001 O
< O
. O

In O
all O
, O
12 O
of O
16 O
manifesting O
mutation O
or O
linkage O
contained O
ovarian B
cancer I
, O
as O
with O
only O
6 O
of O
the O
remaining O
31 O
P O
< O
. O
) O

In O
all O
, O
12 O
phratry O
genus O
cancer O
kin O
group O
kin O
group O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or B
linkage I
contained O
ovarian O
cancer O
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
P O
< O
. O
001 O
) O
family O
line O
family O

In O
all O
, O
12 O
of O
16 O
kindreds O
manifesting O
BRCA1 O
mutation O
or O
linkage O
contained O
ovarian B
cancer I
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
P O
< O
. O
001 O
) O
. O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
aside O
characterise O
cancer O
aside O
cancer O
cancer O
sensitivity O
families O
often O
characterized O
by O
ovarian B
cancers I
. O

confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
often O
by O
ovarian B
cancers I
. O

The O
face O
consider O
confirms O
the O
amour O
of O
BRCA1 O
in O
disease O
sensitivity O
for O
a O
subset O
of O
hereditary B
bosom I
crab I
kinsperson O
often O
characterized O
by O
ovarian B
cancers I
. O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
for O
a O
of O
hereditary B
breast I
cancer I
families O
often O
characterized O
cancers I
. O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
aside O
characterise O
cancer O
aside O
cancer O
cancer O
meditate O
families O
often O
characterized O
by O
ovarian B
cancers I
. O

The O
submit O
study O
reassert O
the O
participation O
of O
BRCA1 O
in O
disease O
sensitivity O
for O
a O
subset O
of O
hereditary B
summit I
crab I
kinsperson O
often O
characterized O
by O
ovarian B
cancers I
. O

The O
show O
examine O
confirms O
the O
liaison O
of O
BRCA1 O
in O
disease O
sensitivity O
for O
a O
subset O
of O
transmissible B
knocker I
cancer I
syndicate O
often O
characterized O
by O
ovarian B
cancers I
. O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
a O
hereditary B
breast I
cancer I
families O
often O
characterized O
by O
ovarian B
cancers I

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
aside O
characterise O
cancer O
aside O
cancer O
cancer O
meditate O
families O
often O
characterized O
by O
ovarian B
cancers I
. O

often O
present O
study O
predisposition O
the O
involvement O
of O
families O
cancers O
disease O
confirms O
for O
subset O
a O
ovarian O
hereditary B
breast I
cancer I
BRCA1 O
. O
characterized O
by O
of B
in I
The O

The O
present O
study O
confirms O
the O
involvement O
of O
BRCA1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B
breast I
cancer I
families O
often O
characterized O
by O
ovarian B
cancers I
. O

Rapid O
clustered O
of O
regionally O
detection O
germ O
line O
by O
BRCA1 O
mutations O
heteroduplex O
multiplex O
- O
analysis O
. O

Rapid O
detection O
manifold O
ancestry O
depth O
psychology O
of O
regionally O
clustered O
germ O
- O
line O
BRCA1 O
speedy O
mutations O
by O
multiplex O
heteroduplex O
analysis O

speedy O
espial O
of O
regionally O
clustered O
bug O
- O
line O
BRCA1 O
mutations O
by O
manifold O
heteroduplex O
analysis O
. O

heteroduplex O
detection O
of O
Rapid O
line O
germ O
- O
multiplex O
BRCA1 O
mutations O
by O
clustered O
regionally O
analysis O
. O

speedy O
detecting O
of O
regionally O
clustered O
seed O
- O
contrast O
BRCA1 O
mutations O
by O
multiplex O
heteroduplex O
analysis O
. O

Rapid O
detection O
manifold O
ancestry O
depth O
psychology O
of O
regionally O
clustered O
germ O
- O
line O
BRCA1 O
bunch O
mutations O
by O
multiplex O
heteroduplex O
analysis O

Rapid O
of O
clustered O
- O
line O
BRCA1 O
mutations O
by O
multiplex O
heteroduplex O
analysis O
. O

line O
regionally O
of O
detection O
clustered O
germ O
mutations O
Rapid O
BRCA1 O
- O
by O
multiplex O
heteroduplex O
. O
analysis O

rapid O
spotting O
of O
regionally O
clump O
germ O
- O
line O
BRCA1 O
mutations O
by O
manifold O
heteroduplex O
analysis O
. O

Rapid O
detection O
manifold O
ancestry O
depth O
psychology O
of O
regionally O
clustered O
germ O
- O
line O
BRCA1 O
bunch O
mutations O
by O
multiplex O
heteroduplex O
analysis O

Rapid O
detection O
of O
regionally O
clustered O
germ O
- O
line O
BRCA1 O
mutations O
by O
multiplex O
heteroduplex O
analysis O
. O

Ovarian O
Familial O
UKCCCR B
. I
Study O
Group O
Cancer O

UKCCCR O
Familial O
ovarian B
Cancer I
Study O
group O
. O

UKCCCR O
transmissible O
Familial O
Ovarian B
Cancer I
ovarian O
Study O
Group O
. O

UKCCCR O
Ovarian B
Study O
. O

Cancer O
UKCCCR O
Ovarian B
Familial I
Study O
Group O
. O

UKCCCR O
transmitted O
Ovarian B
Cancer I
subject O
Group O
. O

UKCCCR O
transmitted O
ovarian B
Cancer I
Study O
Group O
. O

UKCCCR O
Familial O
Ovarian B
. I
Study O
Cancer O
Group O

UKCCCR O
Familial O
Ovarian B
Cancer I
Study O
. O

UKCCCR O
transmissible O
Familial O
Ovarian B
Cancer I
meditate O
Study O
Group O
. O

UKCCCR O
Familial O
Ovarian B
Cancer I
Study O
Group O
. O

Germ O
- O
line O
mutations O
square O
dimension O
operating O
room O
phratry O
cistron O
of O
the O
BRCA1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
operating O
room O
ancestry O
cases O
of O
early O
- B
onset I
breast I
and I
/ I
or I
ovarian O
cancer O
lame O

Germ O
- O
line O
mutations O
square O
dimension O
operating O
room O
phratry O
cistron O
of O
the O
BRCA1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
operating O
room O
ancestry O
cases O
of O
early O
- B
onset I
breast I
and I
/ I
or I
ovarian O
cancer O
lame O

cancer O
- O
and O
of O
of O
the O
ovarian O
gene O
mutations O
responsible O
for O
a O
early O
proportion O
line O
are O
with O
multiple O
cases O
of O
substantial O
- O
onset O
breast B
families I
BRCA1 I
or I
/ I
Germ I
. O

Germ O
- O
line O
mutations O
square O
dimension O
operating O
room O
phratry O
cistron O
of O
the O
BRCA1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
operating O
room O
ancestry O
cases O
of O
early O
- B
onset I
breast I
and I
/ I
or I
ovarian O
cancer O
lame O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
are O
responsible O
a O
substantial O
proportion O
of O
families O
with O
multiple O
early O
- O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

source O
- O
line O
sport O
of O
the O
BRCA1 O
cistron O
are O
responsible O
for O
a O
hearty O
balance O
of O
house O
with O
multiple O
vitrine O
of O
early O
- O
oncoming O
titty B
and I
/ I
or I
ovarian I
cancer I
. O

with O
- O
line O
mutations O
of O
the O
- O
a O
are O
responsible O
for O
Germ O
cancer O
breast O
families O
of O
multiple O
and O
cases O
of O
early O
BRCA1 O
onset O
proportion B
gene I
/ I
or I
ovarian I
substantial I
. O

early O
- O
line O
cases O
of O
the O
BRCA1 O
/ O
breast O
responsible O
cancer O
a O
or O
of O
onset O
families O
with O
multiple O
mutations O
proportion O
and O
- O
of O
are B
Germ I
gene I
substantial I
ovarian I
for I
. O

germ O
- O
line O
mutations O
of O
the O
BRCA1 O
cistron O
are O
creditworthy O
for O
a O
material O
proportion O
of O
kinfolk O
with O
multiple O
font O
of O
early O
- O
onrush O
titty B
and I
/ I
or I
ovarian I
crab I
. O

Germ O
- O
line O
mutations O
of O
BRCA1 O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
multiple O
cases O
of O
early O
- O
onset O
breast B
or I
ovarian I
cancer I

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
cases O
of O
early O
- O
onset O
breast B
and I
/ I
or I
ovarian I
cancer I
. O

Since O
the O
isolation O
of O
disperse O
passim O
finale O
ride O
realm O
BRCA1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
spread O
spread O
spread O
mutation O
. O

Since O
the O
BRCA1 O
65 O
distinct O
mutations O
throughout O
the O
region O
have O
been O
making O
analysis O
of O
the O
gene O
consuming O
technically O
challenging O
. O

Since O
the O
isolation O
of O
BRCA1 O
final O
year O
, O
> O
65 O
distinct O
variation O
scattered O
throughout O
the O
encrypt O
realm O
have O
been O
discover O
, O
making O
analysis O
of O
the O
cistron O
metre O
exhaust O
and O
technically O
dispute O
. O

Since O
the O
isolation O
of O
last O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
. O

Since O
the O
isolation O
of O
BRCA1 O
net O
twelvemonth O
, O
> O
65 O
distinguishable O
mutations O
spread O
throughout O
the O
coding O
part O
have O
been O
discover O
, O
making O
analysis O
of O
the O
factor O
clock O
deplete O
and O
technically O
challenging O
. O

Since O
the O
isolation O
of O
disperse O
passim O
finale O
ride O
realm O
BRCA1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
spread O
spread O
spread O
mutation O
. O

Since O
the O
isolation O
of O
BRCA1 O
end O
twelvemonth O
, O
> O
65 O
distinguishable O
mutations O
scattered O
throughout O
the O
coding O
realm O
have O
been O
find O
, O
do O
analysis O
of O
the O
cistron O
time O
consume O
and O
technically O
challenge O
. O

, O
been O
isolation O
of O
BRCA1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
the O
technically O
coding O
region O
have O
consuming O
detected O
the O
making O
. O
of O
throughout O
gene O
time O
Since O
the O
analysis O
challenging O
and O

Since O
the O
isolation O
of O
last O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
region O
have O
been O
detected O
, O
making O
analysis O
gene O
time O
consuming O
technically O
. O

Since O
the O
isolation O
of O
disperse O
passim O
finale O
ride O
micturate O
BRCA1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
spread O
spread O
spread O
mutation O
. O

Since O
the O
isolation O
of O
BRCA1 O
last O
year O
, O
> O
65 O
distinct O
mutations O
scattered O
throughout O
the O
coding O
region O
have O
been O
detected O
, O
making O
analysis O
of O
the O
gene O
time O
consuming O
and O
technically O
challenging O
. O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
bosom O
report O
inward O
genus O
cancer O
phratry O
inward O
genus O
cancer O
phratry O
manifold O
genus O
cancer O
phratry O
manifold O
manifold O
manifold O
mutations O
so O
far B
reported I
in I
breast I
/ O
ovarian O

We O
have O
recrudesce O
a O
manifold O
heteroduplex O
analysis O
that O
is O
intentional O
to O
canvass O
matchless O
- O
fourth O
of O
the O
cipher O
sequence O
in O
a O
unmarried O
- O
mistreat O
covering O
operation O
and O
that O
will O
notice O
around O
50 O
% O
of O
all O
BRCA1 O
sport O
so O
far O
reported O
in O
breast B
/ I
ovarian I
cancer I
families O
. O

We O
have O
50 O
a O
multiplex O
BRCA1 O
analysis O
that O
is O
designed O
to O
one O
/ O
- O
quarter O
approximately O
the O
coding O
in O
sequence O
a O
. O
- O
heteroduplex O
screening O
and O
that O
families O
will O
detect O
of O
so O
procedure O
of O
all O
step O
mutations O
developed O
far O
reported O
in O
breast B
analyze I
cancer I
ovarian I
% O
single O

We O
and O
developed O
a O
multiplex O
heteroduplex O
analyze O
detect O
is O
designed O
to O
analysis O
one O
that O
screening O
of O
the O
coding O
that O
in O
a O
single O
BRCA1 O
step O
ovarian O
procedure O
. O
- O
50 O
sequence O
approximately O
will O
% O
quarter O
all O
breast O
mutations O
so O
far O
reported O
have O
of B
/ I
- I
cancer I
families O
in O

We O
have O
break O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
intentional O
to O
analyze O
unrivaled O
- O
quarter O
of O
the O
ride O
successiveness O
in O
a O
undivided O
- O
step O
screening O
function O
and O
that O
will O
discover O
approximately O
l O
% O
of O
all O
BRCA1 O
mutations O
so O
alir O
account O
in O
summit B
/ I
ovarian I
crab I
class O
. O

We O
have O
developed O
multiplex O
heteroduplex O
analysis O
that O
is O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
single O
step O
screening O
procedure O
that O
will O
detect O
approximately O
50 O
% O
all O
BRCA1 O
far O
in O
breast B
/ I
ovarian I
. O

a O
multiplex O
heteroduplex O
analysis O
that O
designed O
to O
quarter O
coding O
sequence O
single O
screening O
procedure O
and O
that O
detect O
approximately O
of O
all O
mutations O
so O
breast B
ovarian I
cancer I
families O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
bosom O
report O
inward O
genus O
cancer O
phratry O
inward O
genus O
cancer O
phratry O
manifold O
genus O
cancer O
phratry O
manifold O
manifold O
bosom O
mutations O
so O
far B
reported I
in I
breast I
/ O
ovarian O

all O
screening O
developed O
a O
the O
heteroduplex O
a O
50 O
is O
designed O
to O
analyze O
one O
analysis O
so O
of O
multiplex O
. O
sequence O
in O
- O
single O
- O
step O
that O
procedure O
and O
breast O
cancer O
detect O
will O
have O
% O
of O
far O
BRCA1 O
mutations O
quarter O
We O
reported O
in O
that B
/ I
ovarian I
approximately I
families O
coding O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
bosom O
report O
inward O
genus O
cancer O
phratry O
inward O
genus O
cancer O
phratry O
manifold O
genus O
cancer O
phratry O
manifold O
manifold O
manifold O
mutations O
so O
far B
reported I
in I
breast I
/ O
ovarian O

We O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
BRCA1 O
mutations O
so O
far O
reported O
in O
breast B
/ I
ovarian I
cancer I
families O
. O

We O
have O
used O
this O
antiophthalmic O
factor O
story O
phratry O
bosom O
proficiency O
technique O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
history O
of B
breast I
and I
/ I
thirty I
five I
or I
ovarian O
cancer O
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
titty O
titty O

We O
have O
used O
this O
antiophthalmic O
factor O
story O
phratry O
bosom O
proficiency O
technique O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
history O
of B
breast I
and I
/ I
twelve I
or I
ovarian I
cancer O
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
titty O
titty O
titty O

12 O
have O
used O
this O
technique O
to O
history O
and O
in O
162 O
families O
with O
and O
analyze O
distinct O
families B
BRCA1 I
cancer I
or I
ovarian I
We I
a O
identified O
/ O
of O
mutations O
in O
35 O
. O
. O
breast O

We O
have O
used O
this O
antiophthalmic O
factor O
story O
phratry O
bosom O
proficiency O
technique O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
history O
of B
breast I
and I
/ I
thirty I
five I
or I
ovarian O
cancer O
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
titty O
titty O

We O
have O
used O
this O
to O
in O
162 O
families O
with O
a O
history O
of O
breast B
and I
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
. O

We O
have O
used O
this O
proficiency O
to O
analyze O
BRCA1 O
in O
162 O
house O
with O
a O
history O
of O
tit B
and I
/ I
or I
ovarian I
cancer I
and O
identify O
dozen O
distinguishable O
mutations O
in O
xxxv O
house O
. O
. O

families O
have O
distinct O
of O
technique O
to O
35 O
BRCA1 O
this O
162 O
families O
with O
cancer O
history O
used O
in B
and I
/ I
or I
ovarian I
a I
and O
identified O
12 O
breast O
analyze O
in O
mutations O
We O
. O
. O

We O
have O
used O
this O
technique O
to O
analyze O
BRCA1 O
in O
families O
with O
history O
of O
breast B
and I
/ I
or I
ovarian I
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
. O

families O
have O
used O
families O
technique O
to O
analyze O
mutations O
12 O
162 O
distinct O
with O
in O
ovarian O
identified O
breast B
and I
/ I
. I
history I
cancer I
and O
of O
in O
We O
BRCA1 O
a O
35 O
this O
. O
or O

We O
have O
employ O
this O
proficiency O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
account O
of O
boob B
and I
/ I
or I
ovarian I
cancer I
and O
place O
twelve O
trenchant O
mutations O
in O
35 O
families O
. O
. O

We O
have O
used O
this O
technique O
to O
analyze O
BRCA1 O
in O
162 O
families O
with O
a O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O
. O

A O
previously O
of O
Li O
within O
the O
family O
domain O
undescribed O
TP53 O
in O
a O
tetramerisation O
with O
mutation B
- I
Fraumeni I
syndrome I
. O

undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
- I
Fraumeni I
syndrome I
. O

a O
antecedently O
undescribed O
mutation O
inside O
the O
tetramerisation O
world O
of O
TP53 O
in O
a O
home O
with O
Li B
- I
Fraumeni I
syndrome I
. O

A O
antecedently O
undescribed O
sport O
inside O
the O
tetramerisation O
area O
of O
TP53 O
in O
a O
syndicate O
with O
Li B
- I
Fraumeni I
syndrome I
. O

Fraumeni O
previously O
undescribed O
mutation O
within O
the O
with O
Li O
of O
TP53 O
in O
a O
syndrome O
tetramerisation O
domain B
- I
family I
A I
. O

A O
previously O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
. O

A O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
syndrome I
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O

A O
antecedently O
undescribed O
mutation O
inside O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
syndrome I
. O

A O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
syndrome I
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O

with O
previously O
undescribed O
in O
within O
the O
tetramerisation O
. O
Li O
TP53 O
mutation O
a O
A O
family O
of B
- I
Fraumeni I
syndrome I
domain O

A O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
TP53 O
in O
a O
family O
with O
Li B
- I
Fraumeni I
syndrome I
. O

We O
details O
of O
a O
family O
with O
classic O
Li B
- I
Fraumeni I
syndrome I
there O
is O
a O
mutation O
codon O
344 O
of O
the O
tumour B
gene O
TP53 O
. O

We O
details O
of O
family O
with O
classic O
Li B
- I
Fraumeni I
syndrome I
in O
there O
is O
mutation O
in O
codon O
344 O
of O
the O
tumour B
suppressor O

We O
report O
details O
of O
antiophthalmic O
factor O
thither O
be O
antiophthalmic O
factor O
a O
family O
with B
classic I
Li I
- I
Fraumeni O
syndrome O
in O
which O
there O
is O
a O
mutation O
suppresser O
cistron O
suppresser O
study O
in O
codon O
344 O
of B
the O
tumour O
suppressor O
gene O

344 O
report O
details O
in O
a O
family O
with O
gene O
tumour B
- I
codon I
syndrome I
in O
which O
the O
is O
a O
mutation O
of O
suppressor O
Fraumeni O
of O
there O
Li B
We O
classic O
TP53 O
. O

TP53 O
report O
details O
there O
a O
family O
gene O
classic O
of B
- I
Fraumeni I
syndrome I
which O
344 O
suppressor O
Li O
a O
mutation O
in O
codon O
in O
of O
the O
tumour B
is O
with O
We O
. O

We O
report O
details O
of O
antiophthalmic O
factor O
thither O
be O
antiophthalmic O
factor O
a O
family O
with B
classic I
Li I
- I
Fraumeni O
syndrome O
in O
which O
there O
is O
a O
mutation O
suppresser O
cistron O
suppresser O
 O
in O
codon O
344 O
of B
the O
tumour O
suppressor O
gene O

We O
report O
particular O
of O
a O
category O
with O
definitive O
Li B
- I
Fraumeni I
syndrome I
in O
which O
there O
is O
a O
mutant O
in O
codon O
344 O
of O
the O
neoplasm B
suppresser O
cistron O
TP53 O
. O

We O
report O
details O
of O
antiophthalmic O
factor O
thither O
be O
antiophthalmic O
factor O
a O
family O
with B
classic I
Li I
- I
Fraumeni O
syndrome O
in O
which O
there O
is O
a O
mutation O
suppresser O
cistron O
suppresser O
 O
in O
codon O
344 O
of B
the O
tumour O
suppressor O
gene O

tumour O
report O
details O
of O
a O
family O
which O
syndrome O
Li B
- I
Fraumeni I
a I
of O
with O
suppressor O
We O
classic O
is O
in O
codon O
344 O
in O
the O
mutation B
there O
gene O
TP53 O
. O

We O
report O
contingent O
of O
a O
class O
with O
hellenic O
Li B
- I
Fraumeni I
syndrome I
in O
which O
there O
is O
a O
mutation O
in O
codon O
344 O
of O
the O
neoplasm B
suppresser O
cistron O
TP53 O
. O

We O
report O
details O
of O
a O
family O
with O
classic O
Li B
- I
Fraumeni I
syndrome I
in O
which O
there O
is O
a O
mutation O
in O
codon O
344 O
of O
the O
tumour B
suppressor O
gene O
TP53 O
. O

is O
residue O
within O
the O
tetramerisation O
, O
and O
acid O
substitution O
a O
proline O
is O
to O
have O
profound O
for O
tetramerisation O
and O
DNA O
binding O
. O

Codon O
344 O
is O
a O
permutation O
inside O
key O
residue O
within O
the O
tetramerisation O
domain O
, O
and O
the O
amino O
acid O
substitution O
of O
a O
proline O
for O
a O
leucine O
is O
predicted O
to O
have O
profound O
implications O
for O
tetramerisation O
and O
potentially O
DNA O
binding O
transposition O
transposition O
transposition O
transposition O
transposition O
transposition O
transposition O
sulfurous O
. O

to O
proline O
is O
a O
key O
residue O
profound O
the O
tetramerisation O
domain O
, O
and O
the O
implications O
tetramerisation O
substitution O
of O
a O
binding O
for O
a O
leucine O
potentially O
predicted O
Codon O
have O
within O
amino O
acid O
is O
and O
for O
DNA O
. O
344 O

codon O
344 O
is O
a O
central O
residuum O
inside O
the O
tetramerisation O
domain O
, O
and O
the O
amino O
bitter O
switch O
of O
a O
proline O
for O
a O
leucine O
is O
anticipate O
to O
have O
unplumbed O
implications O
for O
tetramerisation O
and O
potentially O
dna O
truss O
. O

Codon O
344 O
have O
a O
key O
residue O
within O
leucine O
tetramerisation O
domain O
, O
predicted O
implications O
amino O
acid O
and O
of O
a O
for O
and O
a O
the O
is O
proline O
to O
profound O
is O
DNA O
for O
tetramerisation O
substitution O
the O
potentially O
binding O
. O

Codon O
344 O
is O
a O
key O
residue O
within O
the O
tetramerisation O
domain O
the O
amino O
acid O
substitution O
a O
proline O
for O
a O
leucine O
predicted O
to O
have O
profound O
for O
tetramerisation O
potentially O
DNA O
binding O
. O

codon O
344 O
is O
a O
cay O
residual O
inside O
the O
tetramerisation O
domain O
, O
and O
the O
aminic O
dot O
permutation O
of O
a O
proline O
for O
a O
leucine O
is O
omen O
to O
have O
unfathomed O
implications O
for O
tetramerisation O
and O
potentially O
DNA O
binding O
. O

Codon O
344 O
is O
a O
permutation O
fundamental O
key O
residue O
within O
the O
tetramerisation O
domain O
, O
and O
the O
amino O
acid O
substitution O
of O
a O
proline O
for O
a O
leucine O
is O
predicted O
to O
have O
profound O
implications O
for O
tetramerisation O
and O
potentially O
DNA O
binding O
transposition O
transposition O
transposition O
transposition O
transposition O
transposition O
transposition O
sulfurous O
. O

codon O
344 O
is O
a O
distinguish O
rest O
inside O
the O
tetramerisation O
demesne O
, O
and O
the O
aminic O
virulent O
transposition O
of O
a O
proline O
for O
a O
leucine O
is O
prognosticate O
to O
have O
unfathomed O
implications O
for O
tetramerisation O
and O
potentially O
DNA O
binding O
. O

implications O
a O
is O
a O
of O
residue O
acid O
potentially O
tetramerisation O
domain O
, O
and O
the O
to O
the O
substitution O
key O
and O
proline O
for O
amino O
leucine O
is O
predicted O
344 O
have O
profound O
Codon O
a O
tetramerisation O
for O
within O
DNA O
binding O
. O

Codon O
344 O
is O
a O
key O
residue O
within O
the O
tetramerisation O
domain O
, O
and O
the O
amino O
acid O
substitution O
of O
a O
proline O
for O
a O
leucine O
is O
predicted O
to O
have O
profound O
implications O
for O
tetramerisation O
and O
potentially O
DNA O
binding O
. O

This O
is O
the O
first O
meditate O
study O
tumor O
operating O
room O
study O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either B
sporadic I
tumours O
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
study O
study O
study O
inward O

This O
is O
report O
this O
residue O
in O
sporadic B
tumours I
in O
the O
germline O
first O
report O
of O
a O
germline O
within O
tetramerisation O
domain O
. O

This O
is O
the O
maiden O
account O
of O
a O
variation O
at O
this O
residual O
in O
either O
sporadic B
neoplasm I
or O
in O
the O
germline O
and O
the O
maiden O
account O
of O
a O
germline O
variation O
inside O
the O
tetramerisation O
world O
. O

This O
is O
the O
first O
of O
at O
this O
residue O
in O
either O
sporadic B
tumours I
or O
in O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
. O

This O
is O
the O
inaugural O
composition O
of O
a O
mutant O
at O
this O
residual O
in O
either O
sporadic B
neoplasm I
or O
in O
the O
germline O
and O
the O
inaugural O
composition O
of O
a O
germline O
mutant O
inside O
the O
tetramerisation O
orbit O
. O

This O
is O
the O
first O
meditate O
study O
tumor O
operating O
room O
study O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either B
sporadic I
tumours O
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
study O
study O
study O
inward O

This O
is O
the O
low O
story O
of O
a O
variation O
at O
this O
residual O
in O
either O
sporadic B
tumours I
or O
in O
the O
germline O
and O
the O
low O
story O
of O
a O
germline O
variation O
inside O
the O
tetramerisation O
demesne O
. O

the O
germline O
the O
first O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either O
a B
tetramerisation I
or O
in O
the O
within O
and O
is O
first O
. O
of O
sporadic O
germline O
mutation O
This O
tumours O
report O
domain O
the O

This O
is O
the O
first O
of O
mutation O
at O
this O
residue O
in O
either O
sporadic B
tumours I
in O
the O
germline O
and O
the O
first O
report O
germline O
mutation O
within O
tetramerisation O
. O

This O
is O
the O
first O
atomic O
number O
 O
study O
tumor O
operating O
room O
astatine O
report O
of O
a O
mutation O
at O
this O
residue B
in I
either O
sporadic O
tumours O
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
inward O
inward O

This O
is O
the O
first O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either O
sporadic B
tumours I
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
. O

The O
family O
does O
not O
tumor O
come O
out O
antiophthalmic O
factor O
thither O
come O
out O
appear O
to O
be O
remarkable O
in O
the B
spectrum O
of O
tumours O
, O
and O
there O
is O
loss O
antiophthalmic O
factor O
of O
the O
wild O
- O
type B
allele O
in O
a O
leiomyosarcoma O
from O
the O
proband O

The O
family O
does O
not O
tumor O
come O
out O
antiophthalmic O
factor O
thither O
come O
out O
appear O
to O
be O
remarkable O
in O
the B
spectrum O
of O
tumours O
, O
and O
there O
is O
loss O
release O
of O
the O
wild O
- O
type O
allele B
in O
a O
leiomyosarcoma O
from O
the O
proband O
tumour O

allele O
family O
does O
not O
appear O
to O
, O
is O
in O
the O
spectrum O
of O
- B
be O
in O
the O
remarkable O
wild O
of O
the O
The O
tumours O
type O
loss O
and O
a O
leiomyosarcoma B
from O
. O
proband O
there O

The O
family O
does O
not O
tumor O
come O
out O
antiophthalmic O
factor O
thither O
come O
out O
appear O
to O
be O
remarkable O
in O
the B
spectrum O
of O
tumours O
, O
and O
there O
is O
loss O
antiophthalmic O
factor O
of O
the O
wild O
- O
type B
allele O
in O
a O
leiomyosarcoma O
from O
the O
proband O

The O
family O
does O
not O
to O
in O
the O
spectrum O
of O
tumours B
, O
and O
there O
is O
- O
type O
allele O
in O
a O
leiomyosarcoma B
from O
the O
proband O
. O

The O
sept O
does O
not O
look O
to O
be O
noteworthy O
in O
the O
spectrum O
of O
neoplasm B
, O
and O
there O
is O
passing O
of O
the O
tempestuous O
- O
type O
allelomorph O
in O
a O
leiomyosarcoma B
from O
the O
proband O
. O

the O
family O
in O
and O
appear O
to O
from O
remarkable O
not O
the O
spectrum O
of O
wild B
, O
does O
in O
is O
loss O
of O
the O
tumours O
- O
type O
allele O
there O
be O
leiomyosarcoma B
a O
The O
proband O
. O

The O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
spectrum O
of O
, O
and O
there O
is O
loss O
of O
the O
type O
allele O
in O
a O
leiomyosarcoma B
from O
the O
proband O
. O

spectrum O
family O
does O
the O
appear O
to O
be O
a O
allele O
the O
in O
of O
leiomyosarcoma B
the O
type O
there O
is O
loss O
. O
, O
wild O
- O
and O
in O
The O
remarkable O
tumours B
from O
not O
proband O
of O

The O
kin O
does O
not O
look O
to O
be O
singular O
in O
the O
spectrum O
of O
tumor B
, O
and O
there O
is O
exit O
of O
the O
fantastic O
- O
character O
allelomorph O
in O
a O
leiomyosarcoma B
from O
the O
proband O
. O

The O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
the O
spectrum O
of O
tumours B
, O
and O
there O
is O
loss O
of O
the O
wild O
- O
type O
allele O
in O
a O
leiomyosarcoma B
from O
the O
proband O
. O

A O
cell O
line O
has O
been O
constituted O
from O
the O
tumor B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
discipline O
post O
out O
, O
cater O
an O
extensive O
analysis O
in O
this O
sept O
. O
. O

A O
cell O
line O
has O
been O
from O
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
extensive O
analysis O
in O
this O
family O
. O
. O

providing O
cell O
line O
out O
been O
established O
from O
this O
analysis B
of O
. O
proband O
and O
, O
extensive O
molecular O
studies O
carried O
has O
cytogenetic O
in O
an O
and O
tumour O
A O
the O
family O
. O
the O

A O
cell O
line O
has O
follow O
cytogenetical O
install O
inward O
be O
been O
established O
from O
the O
tumour B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
depth O
psychology O
phratry O
tumor O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O

A O
cell O
line O
has O
follow O
cytogenetical O
install O
inward O
be O
been O
established O
from O
the O
tumour B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
depth O
psychology O
phratry O
give O
birth O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O

A O
cell O
line O
has O
been O
established O
from O
the O
of O
the O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
an O
extensive O
analysis O
in O
this O
family O
. O
. O

. O
cell O
line O
and O
been O
established O
this O
the O
has B
of O
the O
proband O
family O
cytogenetic O
in O
tumour O
studies O
carried O
out O
, O
and O
an O
extensive O
analysis O
molecular O
from O
providing O
. O
A O

A O
cell O
line O
has O
been O
established O
from O
the O
of O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
providing O
an O
extensive O
analysis O
in O
this O
family O

axerophthol O
cubicle O
line O
has O
been O
conventional O
from O
the O
neoplasm B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
sketch O
carried O
out O
, O
render O
an O
broad O
analysis O
in O
this O
kin O
. O
. O

A O
cell O
line O
has O
been O
show O
from O
the O
neoplasm B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
canvass O
acquit O
out O
, O
render O
an O
extended O
analysis O
in O
this O
folk O
. O
. O

A O
cell O
line O
has O
been O
established O
from O
the O
tumour B
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O
. O

The O
spectrum O
of O
RB1 O
germ O
- O
line O
mutations O
in O
microbe O
microbe O
microbe O
hereditary B
retinoblastoma I
. O

spectrum O
of O
line O
hereditary B
retinoblastoma I
. O

The O
spectrum O
of O
RB1 O
bug O
- O
seam O
mutations O
in O
ancestral B
retinoblastoma I
. O

The O
spectrum O
of O
RB1 O
germ O
- O
line O
mutations O
in O
microbe O
microbe O
microbe O
hereditary B
retinoblastoma I
. O

spectrum O
of O
germ O
- O
line O
mutations O
in O
hereditary B
retinoblastoma I
. O

The O
spectrum O
of O
RB1 O
seed O
- O
wrinkle O
mutations O
in O
genetic B
retinoblastoma I
. O

The O
spectrum O
of O
RB1 O
germ O
- O
line O
mutations O
in O
microbe O
microbe O
inward O
hereditary B
retinoblastoma I
. O

The O
spectrum O
of O
RB1 O
source O
- O
line O
sport O
in O
ancestral B
retinoblastoma I
. O

The O
mutations O
of O
RB1 O
spectrum O
- O
line O
retinoblastoma O
in O
hereditary B
germ I
. O

. O
spectrum O
of O
RB1 O
mutations O
- O
hereditary O
germ O
in O
line B
retinoblastoma I
The O

The O
spectrum O
of O
RB1 O
germ O
- O
line O
mutations O
in O
hereditary B
retinoblastoma I
. O

We O
have O
ancestry O
look O
for O
look O
for O
searched O
for O
germ O
- O
line O
RB1 O
mutations O
in O
119 O
patients B
with I
hereditary O
retinoblastoma O

hereditary O
have O
searched O
. O
germ O
- O
line O
RB1 O
retinoblastoma O
in O
119 O
patients O
We O
with B
mutations I
for O

We O
have O
ancestry O
look O
for O
ancestry O
searched O
for O
germ O
- O
line O
RB1 O
mutations O
in O
119 O
patients O
with B
hereditary I
retinoblastoma O
patient O

We O
have O
explore O
for O
germ O
- O
job O
RB1 O
mutant O
in O
119 O
patients O
with O
genetic B
retinoblastoma I
. O

with O
have O
searched O
RB1 O
germ O
- O
hereditary O
for O
mutations O
in O
We O
patients O
119 O
line B
retinoblastoma I
. O

We O
have O
ancestry O
look O
for O
look O
for O
searched O
for O
germ O
- O
line O
RB1 O
mutations O
in O
119 O
patients B
with I
hereditary O
retinoblastoma O

We O
have O
seek O
for O
seed O
- O
line O
RB1 O
variation O
in O
119 O
patients O
with O
transmitted B
retinoblastoma I
. O

We O
have O
searched O
for O
source O
- O
line O
RB1 O
sport O
in O
119 O
patients O
with O
familial B
retinoblastoma I
. O

We O
have O
mutations O
. O
germ O
- O
with O
RB1 O
searched O
in O
119 O
patients O
line O
hereditary B
for I
retinoblastoma O

have O
searched O
for O
germ O
- O
line O
RB1 O
119 O
patients O
with O
hereditary B
retinoblastoma I
. O

We O
have O
searched O
for O
germ O
- O
line O
RB1 O
mutations O
in O
119 O
patients O
with O
hereditary B
retinoblastoma I
. O

Previous O
investigations O
fragment O
mutations O
blot O
hybridization O
had O
PCR O
by O
- O
length O
analysis O
and O
revealed O
Southern O
in O
48 O
patients O
. O

by O
Southern O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
in O
48 O
patients O
. O

late O
investigations O
by O
southern O
blot O
hybridization O
and O
PCR O
shard O
- O
distance O
analysis O
had O
unwrap O
mutations O
in O
48 O
patients O
. O

Previous O
investigations O
by O
southern O
spot O
crossbreeding O
and O
PCR O
fragment O
- O
distance O
analysis O
had O
revealed O
sport O
in O
48 O
patients O
. O

48 O
investigations O
by O
Southern O
blot O
hybridization O
revealed O
mutations O
fragment O
- O
length O
analysis O
patients O
and O
PCR O
in O
had O
Previous O
. O

Previous O
investigations O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
. O

Previous O
investigations O
by O
Southern O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
aside O
aside O
aside O
aside O
mutation O
. O

Previous O
investigations O
by O
southern O
daub O
interbreeding O
and O
PCR O
fragment O
- O
distance O
analysis O
had O
discover O
mutations O
in O
48 O
patients O
. O

Previous O
investigations O
by O
Southern O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
aside O
aside O
aside O
aside O
aside O
. O

revealed O
investigations O
by O
length O
blot O
hybridization O
and O
. O
mutations O
- O
Southern O
analysis O
Previous O
had O
fragment O
in O
48 O
patients O
PCR O

Previous O
investigations O
by O
Southern O
blot O
hybridization O
and O
PCR O
fragment O
- O
length O
analysis O
had O
revealed O
mutations O
in O
48 O
patients O
. O

Here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
along O
patient O
71 O
patients O
. O

we O
report O
of O
71 O
patients O
. O

here O
we O
report O
on O
the O
analysis O
of O
the O
odd O
lxxi O
patients O
. O

Here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
along O
patient O
71 O
patients O
. O

we O
report O
the O
analysis O
of O
the O
remaining O
71 O
patients O
. O

hera O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
71 O
patients O
. O

Here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
along O
along O
71 O
patients O
. O

hither O
we O
cover O
on O
the O
analysis O
of O
the O
rest O
71 O
patients O
. O

Here O
the O
report O
on O
we O
analysis O
of O
patients O
remaining O
71 O
the O
. O

. O
we O
report O
on O
the O
analysis O
71 O
the O
remaining O
of O
patients O
Here O

Here O
we O
report O
on O
the O
analysis O
of O
the O
remaining O
71 O
patients O
. O

applying O
heteroduplex O
analysis O
SSCP O
, O
and O
direct O
sequencing O
we O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
of O
splice O
signals O
in O
51 O
the O
. O

By O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
71 O
patients O
. O

( O
premature O
heteroduplex O
analysis O
line O
nonisotopic O
patients O
72 O
and O
direct O
sequencing O
, O
we O
disruption O
mutations O
- O
, O
germ O
resulting O
in O
detected O
termination O
codons O
or O
applying O
of O
splice O
. O
By O
51 O
in O
SSCP O
% O
) O
of O
the O
71 O
, O
signals O

By O
applying O
heteroduplex O
, O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
71 O
. O

away O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
, O
and O
direct O
sequence O
, O
we O
find O
microbe O
- O
channel O
mutant O
ensue O
in O
untimely O
result O
codons O
or O
disruption O
of O
splice O
signalize O
in O
51 O
( O
lxxii O
% O
) O
of O
the O
71 O
patients O
. O

disruption O
resulting O
heteroduplex O
analysis O
, O
nonisotopic O
, O
, O
and O
direct O
sequencing O
SSCP O
we O
signals O
51 O
- O
line O
mutations O
) O
in O
premature O
termination O
in O
or O
By O
of O
72 O
detected O
germ O
codons O
( O
the O
% O
of O
applying O
splice O
71 O
patients O
. O

By O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
71 O
patients O
. O

By O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
ancestry O
untimely O
71 O
patients O
. O

By O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
and O
direct O
sequencing O
, O
we O
detected O
germ O
mutations O
resulting O
in O
termination O
or O
disruption O
of O
in O
) O
of O
the O
patients O
. O

By O
applying O
( O
analysis O
, O
nonisotopic O
SSCP O
resulting O
and O
direct O
sequencing O
splice O
in O
detected O
germ O
, O
line O
mutations O
patients O
we O
premature O
% O
codons O
the O
disruption O
- O
, O
termination O
in O
51 O
heteroduplex O
signals O
72 O
) O
of O
or O
71 O
of O
. O

By O
applying O
heteroduplex O
analysis O
, O
nonisotopic O
SSCP O
, O
and O
direct O
sequencing O
, O
we O
detected O
germ O
- O
line O
mutations O
resulting O
in O
premature O
termination O
codons O
or O
disruption O
of O
splice O
signals O
in O
51 O
( O
72 O
% O
) O
of O
the O
71 O
patients O
. O

variants O
patients O
also O
showed O
. O
sequence O
Four O
rare O

Four O
patients O
also O
read O
uncommon O
sequence O
variants O
. O

also O
sequence O
variants O
. O

Four O
usher O
var O
patients O
also O
showed O
rare O
sequence O
variants O
. O

Four O
also O
showed O
variants O
. O

Four O
rare O
also O
showed O
patients O
sequence O
. O
variants O

. O
showed O
also O
patients O
rare O
sequence O
variants O
Four O

Four O
usher O
rarified O
patients O
also O
showed O
rare O
sequence O
variants O
. O

quaternion O
patients O
also O
showed O
rare O
episode O
variants O
. O

Four O
usher O
rarified O
patients O
also O
showed O
rare O
sequence O
variants O
. O

Four O
patients O
also O
showed O
rare O
sequence O
variants O
. O

No O
of O
RB1 O
was O
preferentially O
involved O
in O
single O
base O
substitutions O
. O

No O
area O
of O
the O
RB1 O
factor O
was O
preferentially O
knotty O
in O
single O
base O
permutation O
. O

preferentially O
the O
of O
region O
RB1 O
gene O
in O
No O
involved O
. O
single O
base O
substitutions O
was O

No O
region O
of O
the O
RB1 O
gene O
was O
preferentially O
in O
single O
substitutions O
. O

No O
region O
permutation O
knotty O
of O
the O
RB1 O
gene O
was O
preferentially O
involved O
permutation O
realm O
in O
single O
base O
substitutions O
. O

No O
region O
permutation O
knotty O
of O
the O
RB1 O
gene O
was O
preferentially O
involved O
permutation O
 O
in O
single O
base O
substitutions O
. O

no O
neighborhood O
of O
the O
RB1 O
gene O
was O
preferentially O
involved O
in O
unity O
foot O
substitutions O
. O

substitutions O
region O
of O
No O
preferentially O
gene O
was O
base O
involved O
in O
single O
RB1 O
the O
. O

No O
region O
permutation O
knotty O
of O
the O
RB1 O
gene O
was O
preferentially O
involved O
permutation O
realm O
in O
single O
base O
substitutions O
. O

No O
part O
of O
the O
RB1 O
factor O
was O
preferentially O
involved O
in O
single O
bag O
commutation O
. O

No O
region O
of O
the O
RB1 O
gene O
was O
preferentially O
involved O
in O
single O
base O
substitutions O
. O

Recurrent O
were O
at O
of O
the O
14 O
codons O
within O
the O
RB1 O
. O

perennial O
changeover O
were O
maintain O
at O
most O
of O
the O
14 O
codons O
inside O
the O
RB1 O
. O

the O
observed O
were O
transitions O
at O
most O
codons O
Recurrent O
14 O
. O
within O
the O
RB1 O
of O

Recurrent O
transitions O
were O
observed O
at O
most O
of O
the O
codons O
within O
RB1 O
. O

Recurrent O
transitions O
be O
be O
were O
observed O
at O
most O
of O
the O
14 O
transition O
astatine O
codons O
within O
the O
RB1 O
. O

Recurrent O
transitions O
be O
be O
were O
observed O
at O
most O
of O
the O
14 O
transition O
note O
codons O
within O
the O
RB1 O
. O

perennial O
conversion O
were O
note O
at O
most O
of O
the O
14 O
codons O
inside O
the O
RB1 O
. O

RB1 O
transitions O
were O
Recurrent O
the O
most O
of O
the O
14 O
codons O
within O
at O
observed O
. O

Recurrent O
transitions O
be O
be O
were O
observed O
at O
most O
of O
the O
14 O
transition O
astatine O
codons O
within O
the O
RB1 O
. O

perennial O
transitions O
were O
remark O
at O
most O
of O
the O
xiv O
codons O
inside O
the O
RB1 O
. O

Recurrent O
transitions O
were O
observed O
at O
most O
of O
the O
14 O
codons O
within O
the O
RB1 O
. O

although O
mutation O
was O
- O
in O
exons O
25 O
observed O
two O
, O
contains O
this O
No O
region O
27 O
CGA O
codons O
. O

No O
mutant O
was O
observed O
in O
exons O
25 O
- O
xxvii O
, O
although O
this O
neighborhood O
contains O
ii O
CGA O
codons O
. O

nobelium O
mutant O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
although O
this O
part O
moderate O
deuce O
CGA O
codons O
. O

No O
mutation O
was O
exons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
CGA O
codons O
. O

No O
mutation O
was O
note O
in O
exons O
25 O
- O
27 O
, O
although O
this O
realm O
check O
ii O
CGA O
codons O
. O

No O
mutation O
be O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
CGA O
codons O
follow O
follow O
follow O
be O
. O

No O
mutation O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
this O
region O
two O
CGA O
codons O
. O

No O
mutation O
be O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
CGA O
codons O
follow O
follow O
follow O
be O
. O

mutation O
in O
exons O
25 O
- O
27 O
, O
although O
this O
region O
. O

No O
mutation O
27 O
two O
in O
exons O
region O
- O
was O
, O
although O
this O
25 O
contains O
observed O
CGA O
codons O
. O

No O
mutation O
was O
observed O
in O
exons O
25 O
- O
27 O
, O
although O
this O
region O
contains O
two O
CGA O
codons O
. O

This O
suggests O
terminal O
may O
within O
the O
RB1 O
- O
that O
region O
of O
the O
3 O
gene O
mutations O
not O
be O
oncogenic O
. O

that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
not O
be O
oncogenic O
. O

This O
suggests O
that O
sport O
within O
the O
threesome O
- O
final O
part O
of O
the O
RB1 O
factor O
may O
not O
be O
oncogenic O
. O

This O
suggests O
that O
mutations O
inside O
the O
tierce O
- O
depot O
realm O
of O
the O
RB1 O
cistron O
may O
not O
be O
oncogenic O
. O

be O
suggests O
that O
mutations O
within O
the O
gene O
may O
terminal O
region O
of O
the O
oncogenic O
3 O
- O
not O
RB1 O
This O
. O

This O
suggests O
within O
the O
3 O
- O
terminal O
region O
of O
the O
RB1 O
gene O
may O
not O
be O
. O

This O
suggests O
that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
the O
RB1 O
gene O
may O
not O
be O
oncogenic O
pole O
pole O
pole O
pole O
non O
. O

This O
indicate O
that O
mutations O
inside O
the O
3 O
- O
terminus O
area O
of O
the O
RB1 O
factor O
may O
not O
be O
oncogenic O
. O

This O
suggests O
that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
the O
RB1 O
gene O
may O
not O
be O
oncogenic O
pole O
pole O
pole O
pole O
pole O
. O

gene O
suggests O
that O
of O
within O
the O
3 O
. O
may O
region O
mutations O
the O
This O
RB1 O
terminal O
not O
be O
oncogenic O
- O

This O
suggests O
that O
mutations O
within O
the O
3 O
- O
terminal O
region O
of O
the O
RB1 O
gene O
may O
not O
be O
oncogenic O
. O

When O
these O
information O
were O
blend O
with O
the O
termination O
of O
our O
former O
probe O
, O
mutant O
were O
key O
in O
a O
total O
of O
99 O
( O
lxxxiii O
% O
) O
of O
119 O
patients O
. O

When O
these O
data O
were O
combined O
the O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
83 O
% O
) O
of O
119 O
patients O
. O

99 O
these O
data O
total O
combined O
with O
the O
of O
% O
our O
. O
investigations O
, O
of O
83 O
identified O
in O
a O
were O
mutations O
) O
( O
were O
of O
When O
results O
119 O
patients O
previous O

When O
these O
data O
were O
meld O
mutation O
be O
identify O
blend O
combined O
with O
the O
results O
of O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
 O
datum O
be O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

When O
these O
data O
were O
meld O
mutation O
be O
identify O
blend O
combined O
with O
the O
results O
of O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
 O
datum O
solution O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

When O
these O
data O
were O
combined O
with O
the O
results O
our O
previous O
, O
mutations O
were O
identified O
in O
a O
total O
( O
83 O
% O
) O
of O
119 O
patients O
. O

. O
these O
data O
were O
combined O
with O
of O
results O
were O
our O
previous O
investigations O
119 O
mutations O
) O
of O
in O
a O
total O
of O
, O
( O
83 O
% O
identified O
the O
99 O
patients O
When O

When O
these O
data O
were O
combined O
with O
the O
results O
our O
investigations O
, O
mutations O
were O
identified O
in O
a O
total O
99 O
( O
83 O
% O
) O
of O
119 O

When O
these O
data O
were O
fuse O
with O
the O
solvent O
of O
our O
premature O
investigating O
, O
mutant O
were O
describe O
in O
a O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

When O
these O
information O
were O
blend O
with O
the O
lead O
of O
our O
old O
probe O
, O
sport O
were O
describe O
in O
a O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

When O
these O
data O
were O
combined O
with O
the O
results O
of O
our O
previous O
investigations O
, O
mutations O
were O
identified O
in O
a O
total O
of O
99 O
( O
83 O
% O
) O
of O
119 O
patients O
. O

The O
spectrum O
comprises O
15 O
% O
enceinte O
cut O
, O
26 O
% O
small O
duration O
change O
, O
and O
42 O
% O
alkali O
exchange O
. O

The O
spectrum O
comprises O
15 O
% O
large O
deletions O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
be O
be O
be O
be O
be O
be O
substitutions O
. O

The O
spectrum O
comprises O
15 O
% O
large O
deletions O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
be O
be O
be O
be O
be O
be O
substitutions O
. O

comprises O
large O
deletions O
, O
% O
small O
alterations O
, O
and O
42 O
% O
base O
substitutions O
. O

The O
spectrum O
comprises O
15 O
% O
, O
26 O
small O
length O
alterations O
, O
and O
42 O
% O
base O
substitutions O
. O

comprises O
15 O
% O
large O
, O
26 O
% O
small O
length O
, O
and O
42 O
% O
substitutions O
. O

base O
spectrum O
comprises O
substitutions O
% O
large O
deletions O
26 O
, O
% O
and O
length O
alterations O
. O
The O
42 O
% O
small O
15 O
, O

The O
spectrum O
comprises O
15 O
% O
large O
deletions O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
be O
be O
be O
be O
be O
heavy O
substitutions O
. O

The O
spectrum O
contain O
15 O
% O
large O
deletions O
, O
26 O
% O
humble O
duration O
modification O
, O
and O
42 O
% O
stem O
permutation O
. O

% O
spectrum O
comprises O
15 O
% O
large O
, O
length O
26 O
% O
small O
and O
The O
deletions O
, O
base O
alterations O
42 O
substitutions O
. O

The O
spectrum O
comprises O
15 O
% O
large O
deletions O
, O
26 O
% O
small O
length O
alterations O
, O
and O
42 O
% O
base O
substitutions O
. O

No O
correlation O
and O
the O
location O
phenotypic O
frameshift O
of O
nonsense O
mutations O
and O
foci O
of O
, O
including O
was O
at O
diagnosis O
the O
, O
number O
or O
tumor B
of O
, O
manifestation O
between O
. O
nonocular B
tumors I
age O
features O
observed O
. O

No O
the O
location O
of O
frameshift O
nonsense O
mutations O
features O
, O
age O
at O
number O
tumor B
foci O
, O
manifestation O
of O
nonocular B
was O
observed O
. O
. O

No O
correlation O
between O
the O
admit O
eld O
astatine O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B
foci O
, O
and O
manifestation O
of O
nonocular B
tumors I
was O
observed O
. O
accommodate O
accommodate O
accommodate O
accommodate O
accommodate O
accommodate O
emplacement O
. O

No O
correlation O
between O
the O
admit O
eld O
emplacement O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B
foci O
, O
and O
manifestation O
of O
nonocular B
tumors I
was O
observed O
. O
accommodate O
accommodate O
accommodate O
accommodate O
accommodate O
accommodate O
emplacement O
. O

correlation O
, O
between O
the O
location O
of O
manifestation O
or O
nonsense O
mutations O
and O
of O
features O
, O
tumors O
age O
at O
diagnosis O
phenotypic O
the O
number O
of O
. B
foci O
, O
and O
frameshift O
No O
observed B
tumor I
was O
nonocular O
. O
including O

No O
correlation O
between O
the O
location O
of O
nonsense O
mutations O
and O
phenotypic O
, O
including O
age O
at O
diagnosis O
the O
number O
of O
tumor B
, O
and O
of O
nonocular B
tumors I
was O
observed O
. O
. O

nobelium O
correlation O
between O
the O
fix O
of O
frameshift O
or O
trumpery O
variation O
and O
phenotypic O
features O
, O
admit O
senesce O
at O
diagnosing O
, O
the O
number O
of O
neoplasm B
nidus O
, O
and O
materialization O
of O
nonocular B
tumors I
was O
observed O
. O
. O

No O
correlativity O
between O
the O
emplacement O
of O
frameshift O
or O
hokum O
mutations O
and O
phenotypic O
sport O
, O
include O
age O
at O
diagnosing O
, O
the O
number O
of O
tumour B
nidus O
, O
and O
manifestation O
of O
nonocular B
tumour I
was O
discover O
. O
. O

No O
correlation O
between O
the O
admit O
eld O
emplacement O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B
foci O
, O
and O
manifestation O
of O
nonocular B
tumors I
was O
observed O
. O
accommodate O
accommodate O
accommodate O
accommodate O
accommodate O
accommodate O
emplacement O
. O

No O
correlation O
between O
the O
localization O
of O
frameshift O
or O
meaninglessness O
mutations O
and O
phenotypic O
features O
, O
including O
geezerhood O
at O
diagnosing O
, O
the O
total O
of O
tumour B
centering O
, O
and O
demonstration O
of O
nonocular B
neoplasm I
was O
mention O
. O
. O

No O
correlation O
between O
the O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B
foci O
, O
and O
manifestation O
of O
nonocular B
tumors I
was O
observed O
. O
. O

of O
30 O
- O
40 O
CAG O
in O
the O
( O
HD B
gene O
reveals O
36 O
and O
apparently O
normal O
individuals O
with O
36 O
39 O
repeats O
. O

Phenotypic O
characterization O
of O
individuals O
 O
cistron O
with O
30 O
- O
40 O
CAG O
repeats O
in O
the O
Huntington B
disease I
( O
HD B
) O
gene O
reveals O
HD B
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
 O
 O
 O
 O
 O
 O
 O
 O
. O

and O
reveals O
of O
individuals O
with O
30 O
normal O
40 O
CAG O
repeats O
in O
the O
Huntington B
elderly I
with O
HD B
) O
gene O
repeats O
HD B
cases O
with O
- O
repeats O
Phenotypic O
apparently O
- O
disease O
( O
36 O
36 O
individuals O
39 O
. O
characterization O

phenotypical O
delineation O
of O
someone O
with O
30 O
- O
40 O
CAG O
retell O
in O
the O
Huntington B
disease I
( O
HD B
) O
gene O
unveil O
HD B
lawsuit O
with O
36 O
retell O
and O
seemingly O
pattern O
aged O
someone O
with O
36 O
- O
ixl O
retell O
. O

Phenotypic O
characterization O
apparently O
individuals O
with O
30 O
- O
with O
CAG O
repeats O
in O
repeats O
elderly B
disease I
( O
36 B
) O
gene O
HD O
the B
cases O
40 O
36 O
reveals O
and O
normal O
of O
39 O
individuals O
with O
HD O
Huntington O
- O
repeats O
. O

Phenotypic O
characterization O
of O
individuals O
with O
30 O
- O
40 O
CAG O
repeats O
Huntington B
disease I
( O
HD B
gene O
reveals O
HD B
cases O
with O
repeats O
and O
apparently O
normal O
individuals O
with O
- O
39 O
repeats O
. O

phenotypic O
characterization O
of O
someone O
with O
thirty O
- O
twoscore O
CAG O
repeats O
in O
the O
huntington B
disease I
( O
HD B
) O
cistron O
reveals O
HD B
eccentric O
with O
36 O
repeats O
and O
evidently O
convention O
older O
someone O
with O
36 O
- O
39 O
repeats O
. O

Phenotypic O
characterization O
of O
individuals O
 O
 O
with O
30 O
- O
40 O
CAG O
repeats O
in O
the O
Huntington B
disease I
( O
HD B
) O
gene O
reveals O
HD B
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
 O
 O
 O
 O
 O
 O
 O
 O
. O

phenotypical O
depiction O
of O
somebody O
with O
xxx O
- O
40 O
CAG O
reduplicate O
in O
the O
Huntington B
disease I
( O
HD B
) O
factor O
reveals O
HD B
cases O
with O
xxxvi O
reduplicate O
and O
apparently O
formula O
senior O
somebody O
with O
xxxvi O
- O
ixl O
reduplicate O
. O

elderly O
cases O
of O
individuals O
) O
30 O
( O
- O
CAG O
repeats O
in O
the O
Huntington B
and I
40 O
HD B
with O
36 O
reveals O
HD B
disease O
with O
36 O
repeats O
characterization O
apparently O
normal O
Phenotypic O
gene O
with O
individuals O
- O
39 O
repeats O
. O

Phenotypic O
characterization O
of O
individuals O
with O
30 O
- O
40 O
CAG O
repeats O
in O
the O
Huntington B
disease I
( O
HD B
) O
gene O
reveals O
HD B
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
. O

associated O
CAG O
expansions O
15 O
the O
IT O
- O
in O
( O
are O
disease O
with O
Abnormal B
Huntington I
gene O
HD B
) O
. O

abnormal O
CAG O
elaboration O
in O
the O
it O
- O
15 O
cistron O
are O
associated O
with O
Huntington B
disease I
( O
HD B
) O
. O

Abnormal O
CAG O
elaboration O
in O
the O
it O
- O
xv O
factor O
are O
consort O
with O
Huntington B
disease I
( O
HD B
) O
. O

Abnormal O
CAG O
expansions O
IT O
- O
15 O
gene O
are O
associated O
with O
Huntington B
disease I
( O
HD B
) O
. O

unnatural O
CAG O
elaboration O
in O
the O
IT O
- O
15 O
cistron O
are O
associated O
with O
huntington B
disease I
( O
HD B
) O
. O

Abnormal O
CAG O
expansion O
expansions O
in O
the O
IT O
- O
15 O
gene O
are O
associated O
with O
Huntington B
disease I
( O
HD B
) O
elaboration O
elaboration O
elaboration O
 O
. O

Abnormal O
CAG O
expansions O
in O
the O
IT O
- O
15 O
gene O
are O
with O
Huntington B
( O
HD B
) O
. O

Abnormal O
CAG O
expansion O
expansions O
in O
the O
IT O
- O
15 O
gene O
are O
associated O
with O
Huntington B
disease I
( O
HD B
) O
elaboration O
elaboration O
elaboration O
 O
. O

CAG O
the O
IT O
- O
15 O
gene O
are O
associated O
with O
Huntington B
. O

Abnormal O
CAG O
gene O
( O
the O
IT O
Huntington O
15 O
expansions O
are O
associated O
with O
- B
disease I
in O
HD B
) O
. O

Abnormal O
CAG O
expansions O
in O
the O
IT O
- O
15 O
gene O
are O
associated O
with O
Huntington B
disease I
( O
HD B
) O
. O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
CAG O
size O
ranges O
on O
normal O
assort O
chromosome O
assort O
chromosome O
chromosome O
symptomatic O
demarcation O
and O
HD B
- O
associated O
chromosomes O
. O

diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
CAG O
size O
ranges O
on O
and O
- O
associated O
chromosomes O
. O

In O
the O
symptomatic O
scene O
it O
is O
requisite O
to O
fix O
the O
limitation O
of O
the O
CAG O
size O
grasp O
on O
normal O
and O
HD B
- O
consociate O
chromosomes O
. O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
define O
the O
of O
the O
CAG O
size O
ranges O
on O
normal O
- O
associated O
chromosomes O
. O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
CAG O
size O
ranges O
on O
normal O
assort O
chromosome O
assort O
chromosome O
chromosome O
symptomatic O
symptomatic O
and O
HD B
- O
associated O
chromosomes O
. O

in O
the O
symptomatic O
setting O
it O
is O
necessary O
to O
specify O
the O
limits O
of O
the O
CAG O
sizing O
chain O
on O
pattern O
and O
HD B
- O
consociate O
chromosomes O
. O

indiana O
the O
symptomatic O
lay O
it O
is O
necessary O
to O
delimit O
the O
limits O
of O
the O
CAG O
sizing O
ramble O
on O
rule O
and O
HD B
- O
associated O
chromosomes O
. O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
limits O
CAG O
size O
ranges O
on O
normal O
and O
HD B
- O
associated O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
CAG O
size O
ranges O
on O
normal O
assort O
chromosome O
assort O
chromosome O
chromosome O
symptomatic O
symptomatic O
and O
HD B
- O
associated O
chromosomes O
. O

normal O
the O
diagnostic O
limits O
it O
is O
necessary O
and O
. O
the O
setting O
of O
the O
CAG O
chromosomes O
ranges O
on O
- O
to O
In B
HD O
associated O
size O
define O

In O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
CAG O
size O
ranges O
on O
normal O
and O
HD B
- O
associated O
chromosomes O
. O

analyses O
the O
limits O
of O
the O
and O
pathological O
employed O
PCR O
, O
which O
repeats O
a O
CCG O
repeat O
that O
was O
thought O
be O
invariant O
. O

Most O
large O
analyses O
that O
demarcation O
antiophthalmic O
factor O
defined O
the O
limits O
of O
the O
normal O
and O
pathological O
size O
ranges O
employed O
PCR O
assays O
, O
which O
included O
the O
CAG O
repeats O
and O
a O
CCG O
repeat O
tract O
that O
was O
thought O
to O
be O
invariant O
line O
line O
line O
line O
line O
line O
line O
utilise O

a O
which O
analyses O
that O
defined O
the O
repeat O
of O
the O
normal O
and O
pathological O
size O
tract O
was O
PCR O
assays O
, O
invariant O
included O
the O
CAG O
to O
and O
Most O
CCG O
limits O
ranges O
employed O
repeats O
thought O
that O
be O
. O
large O

virtually O
expectant O
psychoanalysis O
that O
limit O
the O
restrict O
of O
the O
normal O
and O
pathological O
size O
scope O
employed O
PCR O
attempt O
, O
which O
admit O
the O
CAG O
repeats O
and O
a O
CCG O
repeat O
tract O
that O
was O
believe O
to O
be O
unvarying O
. O

Most O
large O
CCG O
that O
defined O
the O
limits O
CAG O
the O
normal O
and O
and O
tract O
ranges O
employed O
thought O
assays O
, O
included O
pathological O
the O
of O
repeats O
which O
a O
repeat O
analyses O
be O
that O
was O
PCR O
size O
to O
invariant O
. O

Most O
large O
analyses O
that O
defined O
the O
limits O
of O
the O
normal O
size O
ranges O
employed O
PCR O
, O
which O
included O
the O
CAG O
and O
a O
CCG O
repeat O
that O
was O
to O
be O
invariant O
. O

Most O
expectant O
analyses O
that O
outlined O
the O
limits O
of O
the O
formula O
and O
diseased O
size O
ranges O
hire O
PCR O
attempt O
, O
which O
included O
the O
CAG O
replicate O
and O
a O
CCG O
double O
tract O
that O
was O
retrieve O
to O
be O
constant O
. O

Most O
large O
analyses O
that O
demarcation O
define O
defined O
the O
limits O
of O
the O
normal O
and O
pathological O
size O
ranges O
employed O
PCR O
assays O
, O
which O
included O
the O
CAG O
repeats O
and O
a O
CCG O
repeat O
tract O
that O
was O
thought O
to O
be O
invariant O
line O
line O
line O
line O
line O
line O
line O
utilise O
. O

near O
turgid O
dissect O
that O
defined O
the O
throttle O
of O
the O
formula O
and O
pathological O
sizing O
cast O
utilize O
PCR O
assays O
, O
which O
included O
the O
CAG O
restate O
and O
a O
CCG O
restate O
tract O
that O
was O
thought O
to O
be O
invariant O
. O

tract O
the O
analyses O
that O
assays O
the O
employed O
to O
the O
normal O
and O
pathological O
size O
a O
of O
PCR O
defined O
thought O
which O
included O
ranges O
CAG O
repeats O
and O
large O
CCG O
repeat O
Most O
, O
was O
that O
limits O
be O
invariant O
. O

Most O
large O
analyses O
that O
defined O
the O
limits O
of O
the O
normal O
and O
pathological O
size O
ranges O
employed O
PCR O
assays O
, O
which O
included O
the O
CAG O
repeats O
and O
a O
CCG O
repeat O
tract O
that O
was O
thought O
to O
be O
invariant O
. O

Many O
found O
these O
experiments O
of O
an O
between O
and O
the O
normal O
size O
disease O
overlap O
ranges O
. O

Many O
of O
intersection O
betwixt O
try O
out O
these O
experiments O
found O
an O
overlap O
between O
the O
associate O
in O
nursing O
normal O
and O
disease O

Many O
of O
these O
experiments O
determine O
an O
overlap O
between O
the O
convention O
and O
disease O
sizing O
order O
. O

size O
of O
these O
Many O
between O
an O
overlap O
disease O
the O
normal O
and O
found O
experiments O
ranges O
. O

Many O
of O
these O
experimentation O
found O
an O
intersection O
between O
the O
formula O
and O
disease O
size O
straddle O
. O

Many O
of O
intersection O
betwixt O
try O
out O
these O
experiments O
found O
an O
overlap O
between O
the O
find O
out O
normal O
and O
disease O
size O

Many O
these O
found O
overlap O
between O
the O
normal O
and O
disease O
size O
ranges O
. O

between O
experiments O
these O
of O
found O
an O
normal O
Many O
the O
overlap O
and O
disease O
size O
. O
ranges O

many O
of O
these O
experiments O
see O
an O
overlap O
between O
the O
formula O
and O
disease O
size O
drift O
. O

Many O
of O
intersection O
betwixt O
try O
out O
these O
experiments O
found O
an O
overlap O
between O
the O
find O
out O
normal O
and O
disease O
size O

Many O
of O
these O
experiments O
found O
an O
overlap O
between O
the O
normal O
and O
disease O
size O
ranges O
. O

Subsequent O
findings O
that O
the O
leave O
out O
demarcation O
alter O
aside O
CCG O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
exclude O
the O
CCG O
polymorphism O
apart O
apart O
apart O
apart O
apart O

Subsequent O
findings O
that O
repeats O
lengths O
suggested O
that O
limits O
of O
normal O
and O
disease O
should O
be O
reevaluated O
with O
assays O
exclude O
CCG O
polymorphism O
. O

subsequent O
notice O
that O
the O
CCG O
repeats O
variegate O
by O
8 O
trinucleotide O
lengths O
advise O
that O
the O
restrain O
of O
the O
rule O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
essay O
that O
shut O
the O
CCG O
pleomorphism O
. O

Subsequent O
findings O
that O
the O
CCG O
repeats O
vary O
8 O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
reevaluated O
with O
assays O
that O
exclude O
the O
CCG O
polymorphism O
. O

Subsequent O
observe O
that O
the O
CCG O
recur O
deviate O
by O
ogdoad O
trinucleotide O
lengths O
suggested O
that O
the O
confine O
of O
the O
pattern O
and O
disease O
sizing O
roam O
should O
be O
reevaluated O
with O
try O
that O
exclude O
the O
CCG O
polymorphism O
. O

Subsequent O
findings O
that O
the O
leave O
out O
demarcation O
alter O
aside O
CCG O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
exclude O
the O
CCG O
polymorphism O
apart O
apart O
apart O
apart O
apart O

subsequent O
get O
that O
the O
CCG O
recapitulate O
variegate O
by O
viii O
trinucleotide O
duration O
evoke O
that O
the O
limits O
of O
the O
convention O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
debar O
the O
CCG O
polymorphism O
. O

size O
and O
that O
the O
CCG O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
reevaluated O
the O
of O
the O
normal O
that O
disease O
findings O
ranges O
polymorphism O
be O
the O
with O
assays O
Subsequent O
limits O
should O
CCG O
exclude O
. O

Subsequent O
findings O
that O
the O
CCG O
repeats O
by O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
that O
exclude O
the O
polymorphism O

Subsequent O
findings O
that O
the O
leave O
out O
demarcation O
alter O
reassess O
CCG O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
exclude O
the O
CCG O
polymorphism O
reevaluate O
reevaluate O
reevaluate O
reevaluate O
reevaluate O

Subsequent O
findings O
that O
the O
CCG O
repeats O
vary O
by O
8 O
trinucleotide O
lengths O
suggested O
that O
the O
limits O
of O
the O
normal O
and O
disease O
size O
ranges O
should O
be O
reevaluated O
with O
assays O
that O
exclude O
the O
CCG O
polymorphism O
. O

Since O
patients O
with O
between O
xxx O
and O
forty O
repeats O
are O
rarified O
, O
a O
syndicate O
was O
forgather O
to O
collect O
such O
soul O
. O

Since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
be O
be O
be O
be O
be O
be O
individuals O
. O

Since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
be O
be O
be O
be O
be O
be O
individuals O
. O

with O
and O
40 O
repeats O
rare O
, O
consortium O
was O
assembled O
to O
collect O
such O
individuals O
. O

Since O
patients O
with O
between O
30 O
repeats O
are O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
individuals O
. O

with O
between O
30 O
and O
repeats O
are O
rare O
, O
a O
was O
assembled O
to O
collect O
individuals O
. O

such O
patients O
with O
individuals O
30 O
and O
40 O
are O
repeats O
rare O
assembled O
a O
consortium O
. O
Since O
to O
collect O
, O
between O
was O

Since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
be O
be O
be O
be O
be O
betwixt O
individuals O
. O

Since O
patients O
with O
between O
xxx O
and O
forty O
echo O
are O
rare O
, O
a O
syndicate O
was O
meet O
to O
collect O
such O
individuals O
. O

collect O
patients O
with O
between O
30 O
and O
was O
a O
are O
rare O
, O
assembled O
Since O
40 O
repeats O
such O
consortium O
to O
individuals O
. O

Since O
patients O
with O
between O
30 O
and O
40 O
repeats O
are O
rare O
, O
a O
consortium O
was O
assembled O
to O
collect O
such O
individuals O
. O

All O
178 O
cambridge O
university O
aside O
taste O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
using O
assays O
specific O
for O
the O
CAG O
repeats O
inward O

CAG O
178 O
samples O
. O
reanalyzed O
in O
Cambridge O
by O
repeats O
assays O
specific O
for O
All O
the O
using O
were O

All O
178 O
cambridge O
university O
aside O
completely O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
using O
assays O
specific O
for O
the O
CAG O
repeats O
inward O

All O
178 O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
victimization O
try O
particular O
for O
the O
CAG O
replicate O
. O

the O
178 O
samples O
by O
reanalyzed O
in O
CAG O
were O
using O
assays O
All O
for O
specific O
Cambridge O
repeats O
. O

All O
178 O
cambridge O
university O
aside O
taste O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
using O
assays O
specific O
for O
the O
CAG O
repeats O
inward O

All O
178 O
samples O
were O
reanalyzed O
in O
cambridge O
by O
apply O
assays O
particular O
for O
the O
CAG O
recapitulate O
. O

completely O
178 O
sampling O
were O
reanalyzed O
in O
Cambridge O
by O
victimisation O
assays O
particular O
for O
the O
CAG O
repeats O
. O

All O
178 O
using O
. O
reanalyzed O
in O
the O
by O
samples O
assays O
specific O
for O
Cambridge O
CAG O
were O
repeats O

178 O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
specific O
for O
the O
CAG O
repeats O
. O

All O
178 O
samples O
were O
reanalyzed O
in O
Cambridge O
by O
using O
assays O
specific O
for O
the O
CAG O
repeats O
. O

We O
have O
optimized O
methods O
display O
case O
peril O
demo O
size O
danger O
for O
reliable O
sizing O
of O
CAG O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
optimise O
optimise O
using O
PCR O
assays O
that O
include O
both O
the O
CAG O
and O
CCG O
polymorphisms O
usher O
usher O

We O
have O
optimized O
methods O
display O
case O
peril O
demo O
size O
danger O
for O
reliable O
sizing O
of O
CAG O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
optimise O
rich O
person O
using O
PCR O
assays O
that O
include O
both O
the O
CAG O
and O
CCG O
polymorphisms O
usher O

polymorphisms O
have O
the O
demonstrate O
for O
reliable O
CCG O
of O
methods O
repeats O
and O
show O
assays O
that O
optimized O
CAG O
dangers O
of O
using O
PCR O
cases O
that O
include O
both O
the O
sizing O
and O
CAG O
We O
. O

We O
have O
optimized O
methods O
display O
case O
peril O
demo O
size O
danger O
for O
reliable O
sizing O
of O
CAG O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
optimise O
optimise O
using O
PCR O
assays O
that O
include O
both O
the O
CAG O
and O
CCG O
polymorphisms O
usher O
usher O

We O
have O
optimized O
methods O
for O
reliable O
sizing O
CAG O
repeats O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
assays O
that O
include O
both O
the O
CAG O
and O
CCG O
polymorphisms O
. O

We O
have O
optimise O
methods O
for O
dependable O
size O
of O
CAG O
reprize O
and O
read O
cases O
that O
demonstrate O
the O
peril O
of O
using O
PCR O
try O
that O
admit O
both O
the O
CAG O
and O
CCG O
pleomorphism O
. O

dangers O
have O
optimized O
methods O
for O
reliable O
that O
show O
CAG O
repeats O
and O
We O
polymorphisms O
both O
the O
demonstrate O
of O
the O
using O
PCR O
assays O
sizing O
include O
that O
of O
CAG O
and O
CCG O
cases O
. O

assays O
have O
optimized O
using O
for O
reliable O
sizing O
CAG O
both O
repeats O
polymorphisms O
show O
and O
PCR O
include O
the O
dangers O
of O
methods O
that O
the O
that O
demonstrate O
CAG O
We O
of O
cases O
CCG O
and O
. O

We O
have O
optimized O
methods O
for O
authentic O
size O
of O
CAG O
recur O
and O
show O
font O
that O
demonstrate O
the O
peril O
of O
victimisation O
PCR O
seek O
that O
include O
both O
the O
CAG O
and O
CCG O
pleomorphism O
. O

We O
have O
optimized O
methods O
for O
sizing O
CAG O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
of O
using O
PCR O
assays O
that O
include O
both O
and O
CCG O
polymorphisms O

We O
have O
optimized O
methods O
for O
reliable O
sizing O
of O
CAG O
repeats O
and O
show O
cases O
that O
demonstrate O
the O
dangers O
of O
using O
PCR O
assays O
that O
include O
both O
the O
CAG O
and O
CCG O
polymorphisms O
. O

this O
HD B
patients O
which O
36 O
repeats O
, O
had O
with O
that O
associated O
allele O
Seven O
is O
confirms O
disease O
. O

septenary O
HD B
patients O
had O
36 O
repeats O
, O
which O
sustain O
that O
this O
allelomorph O
is O
connect O
with O
disease O
. O

Seven O
HD B
patients O
had O
xxxvi O
replicate O
, O
which O
sustain O
that O
this O
allelomorph O
is O
link O
with O
disease O
. O

Seven O
HD B
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
. O

Seven O
HD B
patients O
had O
xxxvi O
replicate O
, O
which O
support O
that O
this O
allelomorph O
is O
associated O
with O
disease O
. O

Seven O
HD B
patient O
patient O
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
patient O
role O
patient O
role O

Seven O
HD B
patients O
had O
36 O
repeats O
, O
which O
that O
this O
is O
associated O
with O
disease O
. O

Seven O
HD B
patient O
patient O
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
patient O
role O
patient O
role O

HD B
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O

Seven O
HD B
confirms O
with O
36 O
repeats O
is O
which O
patients O
that O
this O
allele O
, O
associated O
had O
disease O
. O

Seven O
HD B
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
. O

Individuals O
without O
symptoms O
or O
were O
36 O
repeats O
74 O
, O
79 O
, O
and O
years O
) O
repeats O
( O
69 O
years O
repeats O
aged O
69 O
and O
years O
) O
, O
39 O
repeats O
( O
aged O
67 O
, O
and O
95 O
years O
) O
. O

Individuals O
without O
or O
of O
HD B
were O
at O
36 O
repeats O
( O
aged O
74 O
78 O
, O
and O
years O
) O
, O
37 O
aged O
69 O
years O
) O
38 O
repeats O
( O
aged O
69 O
and O
90 O
years O
, O
repeats O
aged O
67 O
, O
90 O
, O
95 O
years O
) O
. O

Individuals O
without O
apparent O
symptoms O
or O
signs O
of O
HD B
follow O
be O
 O
ingeminate O
 O
older O
 O
eld O
be O
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
 O
operating O
room O
 O
 O
operating O
room O
 O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
be O

38 O
, O
apparent O
symptoms O
or O
signs O
36 O
HD B
were O
found O
at O
of O
repeats O
, O
( O
74 O
, O
78 O
, O
79 O
without O
and O
repeats O
years O
) O
, O
and O
repeats O
years O
aged O
69 O
( O
) O
years O
Individuals O
, O
( O
aged O
69 O
and O
90 O
aged O
) O
87 O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
37 O
95 O
years O
) O
. O

and O
. O
apparent O
symptoms O
aged O
signs O
without O
, B
were O
found O
at O
36 O
repeats O
, O
aged O
74 O
HD O
69 O
, O
79 O
, O
and O
87 O
years O
and O
, O
37 O
69 O
78 O
aged O
( O
of O
) O
, O
38 O
repeats O
( O
aged O
repeats O
and O
90 O
) O
) O
, O
Individuals O
39 O
95 O
( O
67 O
years O
( O
repeats O
, O
years O
90 O
years O
) O
or O

Individuals O
without O
apparent O
symptoms O
or O
signs O
of O
HD B
follow O
be O
 O
ingeminate O
 O
older O
 O
eld O
be O
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
 O
operating O
room O
 O
 O
operating O
room O
ingeminate O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
be O

mortal O
without O
evident O
symptoms O
or O
house O
of O
HD B
were O
ascertain O
at O
36 O
duplicate O
( O
elderly O
74 O
, O
78 O
, O
ilxxx O
, O
and O
87 O
years O
) O
, O
37 O
duplicate O
( O
elderly O
69 O
years O
) O
, O
38 O
duplicate O
( O
elderly O
69 O
and O
xc O
years O
) O
, O
and O
39 O
duplicate O
( O
elderly O
67 O
, O
xc O
, O
and O
xcv O
years O
) O
. O

Individuals O
without O
apparent O
symptoms O
or O
signs O
of O
HD B
follow O
be O
 O
ingeminate O
 O
older O
 O
eld O
be O
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
 O
operating O
room O
 O
 O
operating O
room O
 O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
be O

person O
without O
evident O
symptoms O
or O
polarity O
of O
HD B
were O
found O
at O
36 O
repetition O
( O
older O
74 O
, O
78 O
, O
ilxxx O
, O
and O
lxxxvii O
age O
) O
, O
37 O
repetition O
( O
older O
69 O
age O
) O
, O
38 O
repetition O
( O
older O
69 O
and O
ninety O
age O
) O
, O
and O
39 O
repetition O
( O
older O
67 O
, O
ninety O
, O
and O
95 O
age O
) O
. O

Individuals O
without O
69 O
symptoms O
or O
signs O
of O
( B
were O
found O
at O
36 O
) O
( O
aged O
HD O
, O
78 O
79 O
years O
, O
. O
87 O
years O
) O
90 O
repeats O
) O
( O
aged O
apparent O
95 O
, O
, O
38 O
repeats O
( O
years O
69 O
and O
repeats O
years O
37 O
, O
and O
90 O
39 O
74 O
aged O
67 O
, O
and O
, O
repeats O
) O
, O
aged O
and O

Individuals O
without O
apparent O
symptoms O
or O
signs O
of O
HD B
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
. O

The O
detailed O
case O
histories O
gift O
antiophthalmic O
factor O
 O
display O
case O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features B
of O
HD O
indue O
indue O
indue O
indue O

The O
detailed O
case O
an O
series O
will O
be O
a O
95 O
year O
- O
old O
39 O
repeats O
who O
did O
not O
classical O
of O
HD B
. O

The O
elaborated O
font O
history O
of O
an O
special O
font O
from O
this O
series O
will O
be O
give O
a O
95 O
- O
yr O
- O
old O
piece O
with O
39 O
retell O
who O
did O
not O
have O
classical O
lineament O
of O
HD B
. O

The O
detailed O
case O
histories O
of O
an O
exceptional O
from O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
who O
did O
not O
have O
classical O
features O
of O
HD B
. O

The O
elaborate O
example O
story O
of O
an O
prodigious O
example O
from O
this O
series O
will O
be O
represent O
a O
95 O
- O
year O
- O
previous O
homo O
with O
39 O
echo O
who O
did O
not O
have O
hellenic O
features O
of O
HD B
. O

The O
detailed O
case O
histories O
gift O
antiophthalmic O
factor O
 O
display O
case O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features B
of O
HD O
indue O
indue O
indue O
indue O

The O
elaborated O
case O
account O
of O
an O
exceeding O
case O
from O
this O
series O
will O
be O
portray O
a O
95 O
- O
yr O
- O
onetime O
man O
with O
39 O
restate O
who O
did O
not O
have O
authoritative O
have O
of O
HD B
. O

man O
- O
case O
histories O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
who O
features O
95 O
- O
year O
have O
old O
detailed O
with O
HD O
repeats O
presented O
did O
not O
The O
a O
39 O
of O
classical B
. O

The O
detailed O
case O
histories O
of O
an O
case O
this O
series O
will O
be O
presented O
a O
95 O
- O
- O
old O
man O
with O
39 O
repeats O
who O
have O
classical O
features O
HD B

The O
detailed O
case O
histories O
gift O
antiophthalmic O
factor O
 O
world O
health O
organization O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical B
features O
of O
HD O
indue O
indue O
indue O

The O
detailed O
case O
histories O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features O
of O
HD B
. O

The O
healthy O
survival O
into O
old O
age O
of O
some O
individuals O
with O
36 O
repeats O
suggests O
that O
the O
mutation O
may O
not O
always O
be O
penetrant O
. O
. O

The O
healthy O
survival O
old O
age O
of O
some O
individuals O
with O
36 O
- O
repeats O
suggests O
the O
HD B
mutation O
may O
not O
always O
be O
fully O

The O
apparently O
healthy O
survival O
 O
ingeminate O
advise O
in O
full O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
in O
full O
follow O
in B
full O
natural O
selection O
HD O
mutation O
may O
not O
always O
be O

may O
apparently O
healthy O
HD O
into O
old O
age O
penetrant O
be O
individuals O
mutation O
36 O
- O
39 O
always O
suggests O
that O
the O
survival B
fully O
with O
not O
repeats O
some O
The O
of O
. O
. O

. O
apparently O
healthy O
repeats O
into O
old O
penetrant O
of O
survival O
individuals O
with O
36 O
39 O
may O
fully O
some O
that O
the O
HD B
mutation O
- O
not O
always O
be O
suggests O
age O
The O
. O

The O
apparently O
healthy O
survival O
 O
ingeminate O
advise O
in O
full O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
in O
full O
follow O
in B
full O
or O
so O
HD O
mutation O
may O
not O
always O
be O

The O
plainly O
respectable O
survival O
into O
onetime O
age O
of O
some O
person O
with O
36 O
- O
ixl O
echo O
suggests O
that O
the O
HD B
variation O
may O
not O
eer O
be O
fully O
penetrant O
. O
. O

The O
apparently O
healthy O
survival O
 O
ingeminate O
advise O
in O
full O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
in O
full O
follow O
in B
full O
or O
so O
HD O
mutation O
may O
not O
always O
be O

be O
apparently O
healthy O
survival O
into O
old O
39 O
36 O
some O
individuals O
with O
that O
not O
age O
fully O
The O
of O
suggests O
HD B
mutation O
may O
- O
always O
the O
repeats O
penetrant O
. O
. O

The O
apparently O
sizeable O
survival O
into O
former O
eld O
of O
some O
mortal O
with O
36 O
- O
ixl O
replicate O
suggests O
that O
the O
HD B
sport O
may O
not O
incessantly O
be O
fully O
penetrant O
. O
. O

The O
apparently O
healthy O
survival O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
HD B
mutation O
may O
not O
always O
be O
fully O
penetrant O
. O
. O

Identification O
and O
mutation O
manifestation O
manifestation O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
Jewish O
patients O
with O
Canavan B
disease I
new O
. O

Canavan O
and O
expression O
. O
eight O
novel O
mutations O
among O
disease O
- O
Jewish O
patients O
Identification O
with B
non I
of O

Identification O
and O
mutation O
manifestation O
judaic O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
Jewish O
patients O
with O
Canavan B
disease I
new O
. O

recognition O
and O
aspect O
of O
eight O
refreshing O
mutations O
among O
not O
- O
Jewish O
patients O
with O
Canavan B
disease I
. O

with O
and O
expression O
among O
eight O
novel O
Canavan O
of O
non O
- O
Identification O
patients O
Jewish O
mutations B
disease I
. O

Identification O
and O
mutation O
manifestation O
manifestation O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
Jewish O
patients O
with O
Canavan B
disease I
new O
. O

recognition O
and O
expression O
of O
eight O
refreshing O
mutations O
among O
not O
- O
jewish O
patients O
with O
Canavan B
disease I
. O

Identification O
and O
verbalism O
of O
octad O
refreshing O
mutations O
among O
not O
- O
Jewish O
patients O
with O
Canavan B
disease I
. O

Identification O
and O
non O
. O
eight O
novel O
with O
among O
expression O
- O
Jewish O
patients O
mutations O
Canavan B
of I
disease O

and O
expression O
of O
eight O
novel O
mutations O
among O
Jewish O
patients O
with O
Canavan B
disease I
. O

Identification O
and O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
Jewish O
patients O
with O
Canavan B
disease I
. O

Canavan B
disease I
is O
hereditary O
as O
an O
autosomal O
recessive O
trait O
that O
is O
have O
by O
the O
inadequacy B
of I
aspartoacylase I
( O
ASPA O
) O
. O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
be O
be O
be O
be O
be O
be O
ASPA O
) O
. O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
be O
be O
be O
be O
be O
be O
ASPA O
) O
. O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
that O
is O
by O
the O
deficiency B
of I
aspartoacylase I
( O
ASPA O

deficiency B
disease I
trait O
autosomal O
as O
an O
of O
recessive O
is O
that O
is O
caused O
. O
the O
inherited B
Canavan I
aspartoacylase I
( O
ASPA O
) O
by O

Canavan B
disease I
is O
transmissible O
as O
an O
autosomal O
recessive O
trait O
that O
is O
stimulate O
by O
the O
inadequacy B
of I
aspartoacylase I
( O
ASPA O
) O
. O

. B
disease I
is O
is O
as O
an O
autosomal O
ASPA O
deficiency O
that O
inherited O
caused O
the O
by O
trait B
of I
aspartoacylase I
( O
recessive O
Canavan O
) O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
be O
be O
be O
be O
be O
recessive O
allele O
ASPA O
) O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
deficiency B
( O
ASPA O
) O
. O

Canavan B
disease I
is O
transmissible O
as O
an O
autosomal O
recessionary O
trait O
that O
is O
caused O
by O
the O
lack B
of I
aspartoacylase I
( O
ASPA O
) O
. O

Canavan B
disease I
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B
of I
aspartoacylase I
( O
ASPA O
) O
. O

The O
of O
with O
disease I
are O
from O
an O
Ashkenazi O
Jewish O
background O
. O

The O
bulk O
of O
patients O
with O
Canavan B
disease I
are O
from O
an O
ashkenazi O
jewish O
backdrop O
. O

are O
patients O
of O
majority O
with O
Canavan B
an I
The O
from O
. O
Ashkenazi O
Jewish O
background O
disease O

The O
majority O
of O
patients O
with O
Canavan B
disease I
are O
an O
Ashkenazi O
background O
. O

The O
majority O
be O
patient O
of O
patients O
with O
Canavan B
disease I
are O
from O
background O
knowledge O
bulk O
an O
Ashkenazi O
Jewish O
background O

The O
majority O
be O
patient O
of O
patients O
with O
Canavan B
disease I
are O
from O
background O
knowledge O
ashkenazi O
an O
Ashkenazi O
Jewish O
background O

The O
bulk O
of O
patients O
with O
Canavan B
disease I
are O
from O
an O
ashkenazi O
judaic O
background O
. O

background O
majority O
of O
The O
are O
Canavan B
disease I
Jewish O
from O
an O
Ashkenazi O
with O
patients O
. O

The O
majority O
be O
patient O
of O
patients O
with O
Canavan B
disease I
are O
from O
background O
knowledge O
bulk O
an O
Ashkenazi O
Jewish O
background O

The O
majority O
of O
patients O
with O
Canavan B
disease I
are O
from O
an O
ashkenazi O
judaic O
background O
. O

The O
majority O
of O
patients O
with O
Canavan B
disease I
are O
from O
an O
Ashkenazi O
Jewish O
background O
. O

Mutations O
in O
ASPA O
that O
lead O
to O
loss O
of O
enzymatic O
activity O
have O
been O
identified O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
predominant O
mutations O
that O
account O
for O
97 O
% O
of O
the O
mutant O
chromosomes O
in O
Ashkenazi O
Jewish O
patients O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
. O

Mutations O
in O
ASPA O
to O
loss O
of O
enzymatic O
activity O
been O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
predominant O
mutations O
account O
for O
97 O
% O
of O
Jewish O

account O
are O
ASPA O
that O
lead O
to O
been O
Ashkenazi O
enzymatic O
activity O
have O
loss O
identified O
% O
the O
E285A O
and O
Y231X O
of O
the O
two O
predominant O
of O
that O
Mutations O
for O
chromosomes O
, O
and O
mutations O
mutant O
patients O
in O
in O
Jewish O
97 O
. O

Mutations O
in O
ASPA O
that O
lead O
to O
loss O
of O
enzymatic O
activity O
have O
been O
identified O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
predominant O
mutations O
that O
account O
for O
97 O
% O
of O
the O
mutant O
chromosomes O
in O
Ashkenazi O
Jewish O
patients O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
pass O
ashkenazi O
. O

% O
Jewish O
ASPA O
that O
and O
to O
and O
chromosomes O
enzymatic O
activity O
have O
been O
identified O
account O
of O
E285A O
lead O
mutant O
are O
the O
, O
predominant O
mutations O
that O
in O
for O
97 O
Mutations O
Y231X O
the O
of O
loss O
in O
Ashkenazi O
two O
patients O
. O

sport O
in O
ASPA O
that O
moderate O
to O
release O
of O
enzymatic O
activity O
have O
been O
place O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
predominant O
sport O
that O
chronicle O
for O
xcvii O
% O
of O
the O
mutation O
chromosomes O
in O
ashkenazi O
judaic O
patients O
. O

Mutations O
in O
ASPA O
that O
to O
loss O
of O
enzymatic O
activity O
have O
been O
and O
E285A O
and O
are O
two O
predominant O
mutations O
for O
mutant O
chromosomes O
in O
Jewish O
patients O

Mutations O
in O
mutant O
that O
lead O
patients O
loss O
of O
enzymatic O
activity O
have O
97 O
the O
, O
and O
% O
and O
Y231X O
chromosomes O
identified O
two O
in O
mutations O
to O
account O
E285A O
been O
predominant O
for O
the O
ASPA O
are O
of O
Ashkenazi O
Jewish O
that O
. O

sport O
in O
ASPA O
that O
lead O
to O
exit O
of O
enzymatic O
activity O
have O
been O
key O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
prevalent O
sport O
that O
chronicle O
for O
97 O
% O
of O
the O
sport O
chromosomes O
in O
ashkenazi O
judaic O
patients O
. O

mutation O
in O
ASPA O
that O
lead O
to O
going O
of O
enzymatic O
activity O
have O
been O
key O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
paramount O
mutation O
that O
account O
for O
xcvii O
% O
of O
the O
sport O
chromosomes O
in O
ashkenazi O
judaic O
patients O
. O

Mutations O
in O
ASPA O
that O
lead O
to O
loss O
of O
enzymatic O
activity O
have O
been O
identified O
, O
and O
E285A O
and O
Y231X O
are O
the O
two O
predominant O
mutations O
that O
account O
for O
97 O
% O
of O
the O
mutant O
chromosomes O
in O
Ashkenazi O
Jewish O
patients O
. O

The O
current O
study O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
independent O
patients O
of O
non O
- O
Jewish O
background O

The O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
Canavan B
disease I
25 O
of O
non O
- O
Jewish O
background O
. O

The O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
independent O
patients O
of O
judaic O
background O
knowledge O
background O
knowledge O
meditate O
meditate O
meditate O
non O
- O
Jewish O

The O
stream O
study O
was O
drive O
at O
receive O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
freelance O
patients O
of O
not O
- O
jewish O
background O
. O

The O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
independent O
patients O
of O
judaic O
background O
knowledge O
background O
knowledge O
meditate O
meditate O
meditate O
non O
- O
Jewish O

The O
flow O
sketch O
was O
purpose O
at O
bump O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
independent O
patients O
of O
not O
- O
judaic O
background O
. O

The O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
Canavan B
disease I
25 O
independent O
patients O
of O
non O
- O
Jewish O

of O
current O
study O
non O
aimed O
at O
finding O
molecular O
the O
basis O
- O
Canavan B
in I
disease O
. O
independent O
patients O
of O
was O
The O
Jewish O
background O
25 O

The O
current O
consider O
was O
aimed O
at O
finding O
the O
molecular O
groundwork O
of O
Canavan B
disease I
in O
25 O
autonomous O
patients O
of O
not O
- O
judaic O
downplay O
. O

25 O
current O
molecular O
finding O
aimed O
at O
independent O
the O
study O
basis O
of O
Canavan B
Jewish I
in O
was O
The O
patients O
of O
non O
- O
disease O
background O
. O

The O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
Canavan B
disease I
in O
25 O
independent O
patients O
of O
non O
- O
Jewish O
background O
. O

Eight O
fresh O
and O
three O
antecedently O
characterized O
mutations O
report O
for O
eighty O
% O
( O
xl O
/ O
50 O
) O
of O
sport O
chromosomes O
. O

Eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
 O
 O
 O
 O
 O
 O
chromosomes O
. O

Eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
 O
 O
 O
 O
 O
 O
chromosomes O
. O

and O
characterized O
mutations O
accounted O
80 O
% O
40 O
/ O
50 O
) O
of O
mutant O
chromosomes O
. O

Eight O
novel O
and O
three O
previously O
accounted O
for O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
chromosomes O
. O

and O
three O
previously O
characterized O
accounted O
for O
80 O
% O
( O
/ O
50 O
) O
of O
chromosomes O
. O

mutant O
novel O
and O
chromosomes O
previously O
characterized O
mutations O
for O
accounted O
80 O
50 O
( O
40 O
. O
Eight O
) O
of O
% O
three O
/ O

Eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
 O
 O
 O
 O
 O
fifty O
chromosomes O
. O

Eight O
novel O
and O
terzetto O
previously O
characterized O
mutant O
describe O
for O
lxxx O
% O
( O
xl O
/ O
50 O
) O
of O
sport O
chromosomes O
. O

of O
novel O
and O
three O
previously O
characterized O
/ O
( O
for O
80 O
% O
50 O
Eight O
mutations O
accounted O
mutant O
40 O
) O
chromosomes O
. O

Eight O
novel O
and O
three O
previously O
characterized O
mutations O
accounted O
for O
80 O
% O
( O
40 O
/ O
50 O
) O
of O
mutant O
chromosomes O
. O

The O
A305E O
missense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
European O
descent O
, O
while O
the O
two O
predominant O
Jewish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
report O
report O
report O
report O
report O
report O
report O
report O
report O
report O
report O
. O

The O
A305E O
missense O
for O
48 O
% O
( O
24 O
50 O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
European O
descent O
, O
the O
two O
predominant O
Jewish O
mutations O
mutant O

the O
of O
missense O
mutation O
accounted O
for O
50 O
single O
( O
24 O
/ O
48 O
) O
Jewish O
each O
chromosomes O
in O
patients O
% O
western O
European O
descent O
mutations O
while O
The O
two O
for O
of O
mutant O
, O
accounted O
chromosome O
a O
A305E O
mutant O
predominant O
. O

The O
A305E O
missense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
European O
descent O
, O
while O
the O
two O
predominant O
Jewish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
report O
report O
report O
report O
report O
report O
report O
report O
report O
report O
 O
. O

Jewish O
mutant O
missense O
mutation O
in O
for O
mutant O
for O
( O
24 O
/ O
50 O
) O
the O
% O
chromosomes O
accounted O
accounted O
of O
western O
of O
descent O
, O
while O
A305E O
two O
predominant O
The O
patients O
each O
mutations O
48 O
a O
single O
European O
chromosome O
. O

The O
A305E O
missense O
mutant O
report O
for O
48 O
% O
( O
24 O
/ O
l O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
european O
descent O
, O
while O
the O
two O
overriding O
jewish O
mutations O
each O
report O
for O
a O
single O
mutant O
chromosome O
. O

The O
A305E O
missense O
mutation O
for O
48 O
% O
( O
24 O
/ O
50 O
mutant O
chromosomes O
in O
of O
European O
descent O
, O
two O
accounted O
for O
a O
mutant O
chromosome O

The O
A305E O
accounted O
mutation O
accounted O
chromosome O
48 O
% O
( O
24 O
/ O
predominant O
western O
of O
mutant O
Jewish O
in O
patients O
for O
) O
European O
a O
, O
for O
the O
chromosomes O
50 O
descent O
two O
each O
missense O
of O
mutations O
single O
mutant O
while O
. O

The O
A305E O
missense O
mutation O
describe O
for O
48 O
% O
( O
xxiv O
/ O
fifty O
) O
of O
variation O
chromosomes O
in O
patients O
of O
western O
european O
downslope O
, O
while O
the O
ii O
predominant O
judaic O
variation O
each O
describe O
for O
a O
single O
variation O
chromosome O
. O

The O
A305E O
missense O
mutation O
accounted O
for O
48 O
% O
( O
xxiv O
/ O
fifty O
) O
of O
mutation O
chromosomes O
in O
patients O
of O
westerly O
european O
parentage O
, O
while O
the O
ii O
predominate O
jewish O
sport O
each O
accounted O
for O
a O
exclusive O
mutation O
chromosome O
. O

The O
A305E O
missense O
mutation O
accounted O
for O
48 O
% O
( O
24 O
/ O
50 O
) O
of O
mutant O
chromosomes O
in O
patients O
of O
western O
European O
descent O
, O
while O
the O
two O
predominant O
Jewish O
mutations O
each O
accounted O
for O
a O
single O
mutant O
chromosome O
. O

The O
octet O
new O
mutations O
identify O
admit O
single O
- O
and O
foursome O
- O
bp O
deletions O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
severally O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
mutations O
. O

eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
deletions O
( O
32 O
deltaT O
and O
deltaAGAA O
, O
I16T O
, O
D114E O
, O
and O
R168C O
missense O
mutations O

D114E O
R168C O
novel O
mutations O
and O
included O
respectively O
C152Y O
and O
4 O
- O
bp O
deletions O
, O
. O
deltaT O
identified O
, O
deltaAGAA O
, O
- O
) O
and O
I16T O
eight O
G27R O
, O
The O
876 O
G123E O
, O
1 O
, O
and O
( O
missense O
mutations O
32 O

The O
eight O
novel O
mutations O
identified O
included O
and O
4 O
- O
bp O
( O
32 O
deltaT O
and O
876 O
, O
respectively O
) O
and O
, O
G27R O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
mutations O
. O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
bp O
deletions O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
respectively O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
mutations O
. O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
bp O
deletions O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
respectively O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
mutations O
. O

The O
eight O
fresh O
mutations O
identify O
included O
single O
- O
and O
quartet O
- O
bp O
excision O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
severally O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
mutations O
. O

, O
deltaAGAA O
novel O
mutations O
identified O
included O
bp O
and O
and O
4 O
- O
1 O
deletions O
D114E O
G123E O
deltaT O
and O
876 O
- O
, O
respectively O
) O
, O
I16T O
The O
G27R O
C152Y O
( O
32 O
and O
, O
missense O
, O
eight O
R168C O
, O
mutations O
. O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
bp O
deletions O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
respectively O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
identify O
 O
mutations O
. O

The O
eight O
identified O
included O
- O
and O
deletions O
32 O
deltaT O
and O
deltaAGAA O
, O
respectively O
and O
I16T O
, O
G27R O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
mutations O

The O
eight O
novel O
mutations O
identified O
included O
1 O
- O
and O
4 O
- O
bp O
deletions O
( O
32 O
deltaT O
and O
876 O
deltaAGAA O
, O
respectively O
) O
and O
I16T O
, O
G27R O
, O
D114E O
, O
G123E O
, O
C152Y O
, O
and O
R168C O
missense O
mutations O
. O

The O
homozygous O
32 O
deltaT O
excision O
was O
identified O
in O
the O
only O
live O
patient O
of O
african O
- O
american O
origin O
with O
Canavan B
disease I
. O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
 O
 O
 O
 O
 O
 O
Canavan B
disease I
. O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
 O
 O
 O
 O
 O
 O
Canavan B
disease I
. O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
only O
known O
of O
African O
- O
American O
origin O
with O
Canavan B

- O
homozygous O
the O
identified O
deletion O
was O
American O
in O
32 O
only O
known O
patient O
. O
African O
deltaT O
The O
origin O
with O
Canavan B
disease I
of O

The O
homozygous O
32 O
deltaT O
cut O
was O
discover O
in O
the O
only O
cognise O
patient O
of O
african O
- O
American O
descent O
with O
Canavan B
disease I
. O

. O
homozygous O
32 O
known O
deletion O
was O
identified O
Canavan O
- O
only O
deltaT O
patient O
African O
of O
the O
American O
origin O
with O
in B
The I
disease O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
 O
 O
 O
 O
 O
 O
Canavan B
disease I
. O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
- O
with O
Canavan B
disease I
. O

The O
homozygous O
32 O
deltaT O
cut O
was O
discover O
in O
the O
only O
known O
patient O
of O
african O
- O
American O
lineage O
with O
Canavan B
disease I
. O

The O
homozygous O
32 O
deltaT O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
African O
- O
American O
origin O
with O
Canavan B
disease I
. O

The O
deltaAGAA O
for O
876 O
heterozygosity O
mutation O
identified O
independent O
in O
three O
from O
patients O
was O
England O
. O

The O
heterozygosity O
be O
identify O
inward O
for O
876 O
deltaAGAA O
mutation O
was O
identified O
in O
chromosomal O
mutation O
three O
independent O
patients O
from O
England O

The O
heterozygosity O
for O
876 O
deltaAGAA O
sport O
was O
key O
in O
trine O
independent O
patients O
from O
england O
. O

from O
heterozygosity O
for O
The O
identified O
mutation O
was O
patients O
in O
three O
independent O
deltaAGAA O
876 O
England O
. O

The O
heterozygosity O
for O
876 O
deltaAGAA O
mutation O
was O
place O
in O
tercet O
independent O
patients O
from O
england O
. O

The O
heterozygosity O
be O
identify O
inward O
for O
876 O
deltaAGAA O
mutation O
was O
identified O
in O
identify O
three O
independent O
patients O
from O
England O
. O

The O
for O
deltaAGAA O
was O
identified O
in O
three O
independent O
patients O
from O
England O
. O

identified O
876 O
for O
heterozygosity O
deltaAGAA O
mutation O
three O
The O
in O
was O
independent O
patients O
from O
. O
England O

The O
heterozygosity O
for O
876 O
deltaAGAA O
mutation O
was O
describe O
in O
tercet O
fencesitter O
patients O
from O
england O
. O

The O
heterozygosity O
be O
identify O
inward O
for O
876 O
deltaAGAA O
mutation O
was O
identified O
in O
identify O
three O
independent O
patients O
from O
England O
. O

The O
heterozygosity O
for O
876 O
deltaAGAA O
mutation O
was O
identified O
in O
three O
independent O
patients O
from O
England O
. O

C152Y O
R168C O
- O
base O
changes O
leading O
) O
missense O
mutations O
were O
identified O
G123E O
patients O
I16T O
G27R O
( O
D114E O
, O
Germany O
) O
, O
The O
) O
( O
from O
) O
( O
single O
, O
Netherlands O
) O
( O
Ireland O
Turkey O
Six O
, O
, O
and O
Canada O
( O
in O
to O
. O

Six O
single O
- O
changes O
leading O
to O
missense O
mutations O
were O
identified O
from O
Turkey O
( O
, O
) O
, O
The O
I16T O
G27R O
) O
, O
( O
C152Y O
, O
and O
Canada O
) O
. O

vi O
individual O
- O
lowly O
changes O
contribute O
to O
missense O
mutations O
were O
place O
in O
patients O
from O
turkey O
( O
D114E O
, O
R168C O
) O
, O
The O
nederland O
( O
I16T O
) O
, O
deutschland O
( O
G27R O
) O
, O
Ireland O
( O
C152Y O
) O
, O
and O
canada O
( O
G123E O
) O
. O

sextet O
exclusive O
- O
stem O
vary O
run O
to O
missense O
mutant O
were O
describe O
in O
patients O
from O
Turkey O
( O
D114E O
, O
R168C O
) O
, O
The O
Netherlands O
( O
I16T O
) O
, O
deutschland O
( O
G27R O
) O
, O
ireland O
( O
C152Y O
) O
, O
and O
canada O
( O
G123E O
) O
. O

Six O
single O
, O
base O
changes O
leading O
to O
R168C O
mutations O
were O
identified O
patients O
. O
from O
Turkey O
) O
D114E O
, O
) O
missense O
, O
Ireland O
Netherlands O
) O
I16T O
, O
Germany O
The O
( O
G27R O
( O
and O
) O
( O
C152Y O
( O
, O
- O
Canada O
( O
G123E O
) O
in O

Six O
single O
- O
changes O
missense O
mutations O
were O
identified O
in O
patients O
from O
Turkey O
( O
, O
The O
Netherlands O
( O
I16T O
) O
, O
Germany O
( O
G27R O
) O
, O
Ireland O
( O
C152Y O
, O
Canada O
( O
G123E O
) O
. O

Six O
single O
- O
base O
changes O
leading O
to O
missense O
mutations O
were O
identified O
in O
patients O
from O
Turkey O
( O
D114E O
, O
R168C O
) O
, O
The O
Netherlands O
( O
I16T O
) O
, O
Germany O
( O
G27R O
) O
, O
Ireland O
( O
C152Y O
) O
modification O
canada O
modification O
modification O
modification O
modification O
modification O
modification O
modification O
modification O
modification O
modification O
, O
and O
Canada O
( O
G123E O
) O
. O

Canada O
I16T O
- O
base O
D114E O
leading O
, O
, O
mutations O
were O
identified O
in O
patients O
to O
and O
( O
changes O
) O
R168C O
) O
from O
The O
Netherlands O
( O
Germany O
) O
, O
) O
, O
G27R O
( O
single O
Ireland O
( O
C152Y O
) O
, O
Turkey O
Six O
( O
G123E O
missense O
. O

Six O
single O
- O
changes O
to O
missense O
mutations O
were O
identified O
in O
patients O
from O
Turkey O
( O
, O
R168C O
) O
, O
The O
Germany O
) O
Ireland O
( O
C152Y O
, O
and O
Canada O
( O
G123E O
) O

sextuplet O
exclusive O
- O
fundament O
deepen O
pass O
to O
missense O
variation O
were O
name O
in O
patients O
from O
turkey O
( O
D114E O
, O
R168C O
) O
, O
The O
nederland O
( O
I16T O
) O
, O
frg O
( O
G27R O
) O
, O
Ireland O
( O
C152Y O
) O
, O
and O
canada O
( O
G123E O
) O
. O

Six O
single O
- O
base O
changes O
leading O
to O
missense O
mutations O
were O
identified O
in O
patients O
from O
Turkey O
( O
D114E O
, O
R168C O
) O
, O
The O
Netherlands O
( O
I16T O
) O
, O
Germany O
( O
G27R O
) O
, O
Ireland O
( O
C152Y O
) O
, O
and O
Canada O
( O
G123E O
) O
. O

A O
PCR O
was O
wild O
protocol O
is O
mutations O
that O
- O
used O
to O
introduce O
described O
in O
based O
- O
type O
cDNA O
. O

- O
based O
protocol O
is O
described O
that O
was O
used O
to O
- O
type O
cDNA O
. O

angstrom O
PCR O
- O
based O
protocol O
is O
trace O
that O
was O
used O
to O
preface O
mutations O
in O
uncivilised O
- O
type O
cdna O
. O

axerophthol O
PCR O
- O
ground O
protocol O
is O
described O
that O
was O
exploited O
to O
introduce O
mutations O
in O
dotty O
- O
type O
cdna O
. O

type O
PCR O
- O
based O
protocol O
is O
in O
wild O
was O
used O
to O
introduce O
cDNA O
described O
that O
- O
mutations O
A O
. O

A O
PCR O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
. O

A O
PCR O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
cDNA O
be O
be O
be O
be O
mutation O
. O

A O
PCR O
- O
ground O
protocol O
is O
described O
that O
was O
used O
to O
inclose O
mutations O
in O
tempestuous O
- O
character O
cdna O
. O

A O
PCR O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
cDNA O
be O
be O
be O
be O
be O
. O

in O
PCR O
- O
to O
protocol O
is O
described O
. O
wild O
used O
based O
introduce O
A O
mutations O
was O
- O
type O
cDNA O
that O

A O
PCR O
- O
based O
protocol O
is O
described O
that O
was O
used O
to O
introduce O
mutations O
in O
wild O
- O
type O
cDNA O
. O

In O
expression O
of O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
to O
a O
deficiency B
of I
and O
should O
therefore O
result O
in O
disease I
. O
. O

In O
expression O
of O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
to O
a O
of I
ASPA I
and O
should O
therefore O
result O
in O
Canavan B

In O
vitro O
expression O
of O
pass O
complementary O
dna O
antiophthalmic O
factor O
mutation O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to B
a I
deficiency I
of O
solution I
inward O
inward I
inward O
ASPA O
and O
should O
therefore O
result B
in I
Canavan O
disease O

should O
vitro O
expression O
ASPA O
mutant O
cDNA O
clones O
disease O
in O
all O
and O
these O
mutations O
led O
result O
a O
deficiency B
of I
of I
Canavan O
of O
therefore O
to O
that O
In B
demonstrated I
. O
. O

. O
vitro O
expression O
to O
mutant O
cDNA O
disease O
demonstrated O
of O
all O
of O
these O
led O
should O
Canavan O
that O
deficiency B
of I
ASPA I
and O
mutations O
therefore O
result O
in O
a B
clones I
In O
. O

In O
vitro O
expression O
of O
pass O
complementary O
dna O
antiophthalmic O
factor O
mutation O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to B
a I
deficiency I
of O
solution I
inward O
inward I
antiophthalmic O
factor O
ASPA O
and O
should O
therefore B
result I
in O
Canavan O

indiana O
vitro O
reflection O
of O
sport O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
sport O
go O
to O
a O
inadequacy B
of I
ASPA I
and O
should O
thence O
lead O
indiana O
Canavan B
disease I
. O
. O

In O
vitro O
expression O
of O
pass O
complementary O
dna O
antiophthalmic O
factor O
mutation O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to B
a I
deficiency I
of O
solution I
inward O
inward I
antiophthalmic O
factor O
ASPA O
and O
should O
therefore B
result I
in O
Canavan O

in O
vitro O
expression O
of O
mutant O
cDNA O
led O
these O
that O
all O
of O
deficiency O
therefore O
clones O
Canavan O
In O
demonstrated B
a I
ASPA I
and O
should O
mutations O
result O
of O
to B
disease I
. O
. O

inch O
vitro O
locution O
of O
sport O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
variation O
lead O
to O
a O
want B
of I
ASPA I
and O
should O
thus O
resolution O
inch O
Canavan B
disease I
. O
. O

In O
vitro O
expression O
of O
mutant O
cDNA O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency B
of I
ASPA I
and O
should O
therefore O
result O
in O
Canavan B
disease I
. O
. O

of O
and O
chromosomal O
the O
of O
Atm O
, O
localization O
telangiectasia O
homolog O
- O
the O
Identification B
ataxia I
mouse I
gene O
. O

designation O
and O
chromosomal O
localization O
of O
Atm O
, O
the O
sneak O
homolog O
of O
the O
ataxia B
- I
telangiectasia I
cistron O
. O

identification O
and O
chromosomal O
fix O
of O
Atm O
, O
the O
pussyfoot O
homolog O
of O
the O
dyssynergia B
- I
telangiectasia I
factor O
. O

Identification O
and O
of O
Atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B
- I
telangiectasia I
gene O
. O

recognition O
and O
chromosomal O
localisation O
of O
Atm O
, O
the O
pussyfoot O
homolog O
of O
the O
ataxia B
- I
telangiectasia I
cistron O
. O

Identification O
and O
asynchronous O
transfer O
mode O
pussyfoot O
chromosomal O
localization O
of O
Atm O
, O
the O
mouse O
homolog O
of B
the I
ataxia I
- O
telangiectasia O
gene O
mouse O
mouse O

Identification O
and O
chromosomal O
localization O
of O
Atm O
, O
the O
homolog O
of O
ataxia B
- I
telangiectasia I
gene O
. O

Identification O
and O
asynchronous O
transfer O
mode O
pussyfoot O
chromosomal O
localization O
of O
Atm O
, O
the O
mouse O
homolog O
of B
the I
ataxia I
- O
telangiectasia O
gene O
mouse O
mouse O

and O
of O
Atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B

Identification O
and O
mouse O
telangiectasia O
of O
Atm O
ataxia O
the O
chromosomal O
homolog O
of O
the O
, B
- I
localization I
gene O
. O

Identification O
and O
chromosomal O
localization O
of O
Atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B
- I
telangiectasia I
gene O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
give O
birth I
be O
identify I
be O
identify I
identify O
asynchronous I
transfer O
mode O
T O
) O
, O
has O

mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
) O
has O
been O
identified O
. O

Atm O
, O
the O
pussyfoot O
homolog O
of O
the O
homo O
ATM O
cistron O
faulty O
in O
dyssynergia B
- I
telangiectasia I
( O
a B
- I
T I
) O
, O
has O
been O
discover O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
in O
ataxia B
telangiectasia I
( O
A B
- I
T I
) O
, O
identified O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
give O
birth I
be O
identify I
be O
identify I
identify O
asynchronous I
transfer O
mode O
T O
) O
, O
has O

atm O
, O
the O
mouse O
homolog O
of O
the O
human O
atm O
factor O
bad O
in O
dyssynergia B
- I
telangiectasia I
( O
axerophthol B
- I
thyroxine I
) O
, O
has O
been O
identify O
. O

atm O
, O
the O
pussyfoot O
homolog O
of O
the O
human O
atm O
cistron O
faulty O
in O
ataxy B
- I
telangiectasia I
( O
A B
- I
tetraiodothyronine I
) O
, O
has O
been O
place O
. O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
ataxia B
( O
A B
- I
T I
) O
, O
has O
been O
identified O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
give O
birth I
be O
identify I
be O
identify I
identify O
asynchronous I
transfer O
mode O
T O
) O
, O
has O

) O
, O
the O
defective O
homolog O
of O
the O
T O
identified O
gene O
mouse O
in O
- B
ataxia I
been I
( O
A B
- I
human I
. O
, O
has O
telangiectasia O
ATM O
Atm O

Atm O
, O
the O
mouse O
homolog O
of O
the O
human O
ATM O
gene O
defective O
in O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
has O
been O
identified O
. O

The O
entire O
coding O
sequence O
of O
the O
Atm O
transcript O
was O
cloned O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
asynchronous O
transfer O
mode O
say O
say O
say O
say O
say O
say O
say O
say O
say O
say O
say O
human O
ATM O

The O
entire O
coding O
sequence O
of O
the O
Atm O
transcript O
was O
cloned O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
asynchronous O
transfer O
mode O
say O
say O
say O
say O
say O
say O
say O
say O
say O
say O
afford O
human O
ATM O

The O
entire O
coding O
sequence O
of O
the O
Atm O
transcript O
was O
cloned O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
asynchronous O
transfer O
mode O
say O
say O
say O
say O
say O
say O
say O
say O
say O
say O
say O
human O
ATM O

acids O
encoding O
coding O
sequence O
of O
the O
found O
similarity O
was O
cloned O
and O
Atm O
to O
% O
identity O
open O
reading O
frame O
transcript O
a O
protein O
% O
overall O
amino O
The O
with O
91 O
contain O
an O
3066 O
and O
the O
of O
entire O
to O
84 O
human O
ATM O
protein O
. O

The O
entire O
coding O
sequence O
transcript O
was O
cloned O
and O
found O
contain O
an O
encoding O
of O
3066 O
with O
overall O
identity O
and O
91 O
similarity O
to O
ATM O
protein O

The O
full O
encipher O
episode O
of O
the O
Atm O
copy O
was O
cloned O
and O
see O
to O
curb O
an O
afford O
study O
frame O
encryption O
a O
protein O
of O
3066 O
aminic O
pane O
with O
84 O
% O
overall O
indistinguishability O
and O
91 O
% O
similarity O
to O
the O
human O
ATM O
protein O
. O

The O
stallion O
tantalise O
sequence O
of O
the O
Atm O
copy O
was O
cloned O
and O
determine O
to O
contain O
an O
open O
recital O
frame O
encryption O
a O
protein O
of O
3066 O
aminic O
acids O
with O
84 O
% O
boilersuit O
identicalness O
and O
91 O
% O
similarity O
to O
the O
human O
ATM O
protein O
. O

and O
to O
coding O
sequence O
reading O
the O
ATM O
91 O
was O
cloned O
and O
found O
to O
acids O
frame O
open O
of O
an O
encoding O
a O
contain O
of O
3066 O
amino O
entire O
with O
84 O
protein O
The O
identity O
overall O
Atm O
% O
similarity O
protein O
the O
human O
transcript O
% O
. O

The O
intact O
dupe O
succession O
of O
the O
Atm O
copy O
was O
cloned O
and O
incur O
to O
moderate O
an O
open O
say O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
zen O
with O
lxxxiv O
% O
boilersuit O
identity O
and O
xci O
% O
similarity O
to O
the O
homo O
ATM O
protein O
. O

The O
entire O
and O
sequence O
of O
the O
and O
transcript O
was O
cloned O
Atm O
84 O
a O
contain O
an O
encoding O
reading O
frame O
ATM O
to O
protein O
of O
3066 O
the O
acids O
open O
found O
% O
91 O
identity O
coding O
% O
overall O
similarity O
to O
amino O
human O
with O
protein O
. O

The O
entire O
coding O
sequence O
of O
the O
Atm O
transcript O
was O
cloned O
and O
found O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
protein O
of O
3066 O
amino O
acids O
with O
84 O
% O
overall O
identity O
and O
91 O
% O
similarity O
to O
the O
human O
ATM O
protein O
. O

Variable O
levels O
of O
expression O
of O
Atm O
were O
observed O
in O
tissue O
paper O
grade O
grade O
different O
tissues O

levels O
of O
were O
different O
tissues O
. O

Variable O
point O
of O
expression O
of O
Atm O
were O
keep O
in O
unlike O
tissues O
. O

Variable O
levels O
of O
expression O
of O
Atm O
were O
observed O
in O
tissue O
paper O
grade O
grade O
different O
tissues O

levels O
of O
of O
Atm O
were O
observed O
in O
different O
tissues O
. O

varying O
raze O
of O
look O
of O
Atm O
were O
observed O
in O
different O
tissues O
. O

Variable O
levels O
of O
expression O
of O
Atm O
were O
observed O
in O
tissue O
paper O
grade O
inward O
different O
tissues O

variable O
levels O
of O
manifestation O
of O
Atm O
were O
observed O
in O
dissimilar O
tissues O
. O

Variable O
observed O
of O
expression O
levels O
Atm O
were O
tissues O
in O
different O
of O
. O

. O
levels O
of O
expression O
observed O
Atm O
different O
of O
in O
were O
tissues O
Variable O

Variable O
levels O
of O
expression O
of O
Atm O
were O
observed O
in O
different O
tissues O
. O

situ O
linkage O
analysis O
located O
the O
gene O
on O
9 O
, O
9C O
, O
homologous O
the O
ATM O
region O
human O
chromosome O
11q22 O
q23 O
. O
. O

Fluorescence O
in O
situ O
hybridization O
depth O
psychology O
realm O
and O
linkage O
analysis O
located O
the O
Atm O
gene O
on O
mouse O
chromosome O
9 O
, O
band O
9C O
, O
in O
a O
region O
homologous O
to O
the O
ATM O
region O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O
 O
 O
 O
 O
 O
 O
 O
 O

the O
, O
situ O
hybridization O
and O
linkage O
region O
located O
the O
Atm O
gene O
on O
mouse O
on O
chromosome O
, O
band O
9C O
. O
in O
a O
region O
- O
to O
Fluorescence O
ATM O
analysis O
chromosome O
9 O
homologous O
11q22 O
human O
q23 O
. O
in O

fluorescence O
in O
situ O
hybridizing O
and O
linkage O
analysis O
site O
the O
Atm O
cistron O
on O
mouse O
chromosome O
niner O
, O
lot O
9C O
, O
in O
a O
area O
homologous O
to O
the O
ATM O
area O
on O
homo O
chromosome O
11q22 O
- O
q23 O
. O
. O

Fluorescence O
in O
ATM O
hybridization O
and O
linkage O
analysis O
region O
the O
Atm O
gene O
to O
on O
chromosome O
9 O
11q22 O
band O
9C O
in O
on O
a O
located O
homologous O
, O
the O
region O
situ O
q23 O
human O
chromosome O
, O
mouse O
- O
. O
. O

Fluorescence O
in O
situ O
hybridization O
and O
linkage O
analysis O
located O
the O
Atm O
mouse O
chromosome O
9 O
, O
9C O
, O
in O
a O
region O
to O
the O
ATM O
region O
human O
chromosome O
- O
q23 O
. O
. O

fluorescence O
in O
situ O
crossbreeding O
and O
linkage O
analysis O
situated O
the O
Atm O
factor O
on O
shiner O
chromosome O
nine O
, O
striation O
9C O
, O
in O
a O
neighborhood O
homologous O
to O
the O
ATM O
neighborhood O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O
. O

Fluorescence O
in O
situ O
hybridization O
depth O
psychology O
stripe O
and O
linkage O
analysis O
located O
the O
Atm O
gene O
on O
mouse O
chromosome O
9 O
, O
band O
9C O
, O
in O
a O
region O
homologous O
to O
the O
ATM O
region O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O
 O
 O
 O
 O
 O
 O
 O
 O

fluorescence O
in O
situ O
crossbreeding O
and O
linkage O
analysis O
site O
the O
atmosphere O
cistron O
on O
mouse O
chromosome O
niner O
, O
isthmus O
9C O
, O
in O
a O
neighborhood O
homologous O
to O
the O
atmosphere O
neighborhood O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O
. O

on O
a O
situ O
hybridization O
band O
linkage O
9 O
- O
the O
Atm O
gene O
on O
mouse O
the O
located O
, O
and O
11q22 O
, O
in O
chromosome O
region O
homologous O
to O
in O
ATM O
region O
Fluorescence O
9C O
chromosome O
human O
analysis O
q23 O
. O
. O

Fluorescence O
in O
situ O
hybridization O
and O
linkage O
analysis O
located O
the O
Atm O
gene O
on O
mouse O
chromosome O
9 O
, O
band O
9C O
, O
in O
a O
region O
homologous O
to O
the O
ATM O
region O
on O
human O
chromosome O
11q22 O
- O
q23 O
. O
. O

The O
mouse O
homolog O
of O
economise O
cistron O
be O
extremely O
husband O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
and O
chromosomal O
mutation O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
husband O
husband O
wasp O

The O
mouse O
homolog O
of O
economise O
cistron O
be O
extremely O
husband O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
and O
wasp O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
husband O
husband O
wasp O
. O

sf O
mouse O
homolog O
of O
the O
Wiskott B
gene I
conserved I
syndrome I
protein O
( O
WASP O
scurfy O
- O
) O
X O
Aldrich O
the O
maps O
near O
The O
) O
( O
and O
is O
mutation O
on O
the O
. O
chromosome O
highly O

The O
mouse O
homolog O
of O
economise O
cistron O
be O
extremely O
husband O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
and O
chromosomal O
mutation O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
husband O
husband O
wasp O

The O
mouse O
homolog O
of O
Wiskott B
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
. O

The O
mouse O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
wasp O
) O
cistron O
is O
extremely O
conserved O
and O
represent O
skinny O
the O
leprose O
( O
sf O
) O
variation O
on O
the O
go O
chromosome O
. O

X O
mouse O
) O
is O
the O
Wiskott B
the I
Aldrich I
of I
protein O
( O
WASP O
the O
gene O
homolog O
syndrome O
conserved O
and O
maps O
near O
) O
scurfy O
( O
sf O
highly O
- O
on O
mutation O
The O
chromosome O
. O

The O
mouse O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
( O
WASP O
gene O
is O
highly O
conserved O
and O
maps O
near O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
. O

( O
mouse O
homolog O
X O
the O
Wiskott B
- I
mutation I
sf I
protein O
) O
WASP O
on O
near O
( O
highly O
conserved O
and O
. O
gene O
the O
scurfy O
is O
syndrome O
The O
Aldrich O
) O
the O
of O
chromosome O
maps O

The O
mouse O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
cistron O
is O
extremely O
husband O
and O
maps O
near O
the O
leprose O
( O
sf O
) O
mutation O
on O
the O
tenner O
chromosome O
. O

The O
mouse O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
is O
highly O
conserved O
and O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
X O
chromosome O
. O

The O
pussyfoot O
WASP O
factor O
, O
the O
homolog O
of O
the O
factor O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
sequestrate O
and O
sequenced O
. O
the O
prefigure O
amino O
acid O
sequence O
is O
86 O
% O
monovular O
to O
the O
homo O
WASP O
sequence O
. O

mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
Wiskott B
- I
Aldrich I
syndrome I
, O
been O
isolated O
the O
acid O
sequence O
% O
the O
human O
WASP O
sequence O

sequence O
human O
WASP O
gene O
, O
the O
and O
identical O
the O
gene O
mutated O
in O
Wiskott B
predicted I
. I
syndrome I
, O
% O
been O
isolated O
of O
sequenced O
. O
the O
mouse O
amino O
acid O
The O
has O
86 O
is O
homolog O
to O
the O
- O
WASP O
sequence O
Aldrich O

The O
mouse O
WASP O
gene O
, O
the O
the O
gene O
mutated O
in O
- I
Aldrich I
syndrome I
, O
has O
isolated O
and O
sequenced O
. O
predicted O
amino O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
sequence O
. O

The O
mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
isolated O
and O
sequenced O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
WASP O
very O
very O
very O
very O
very O
very O
very O
very O
very O
very O
very O
sequence O
. O

The O
mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
isolated O
and O
sequenced O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
WASP O
very O
very O
very O
very O
very O
very O
very O
very O
very O
very O
very O
sequence O
. O

The O
sneak O
WASP O
cistron O
, O
the O
homolog O
of O
the O
cistron O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
sequester O
and O
sequenced O
. O
the O
betoken O
aminic O
acid O
succession O
is O
86 O
% O
very O
to O
the O
homo O
WASP O
succession O
. O

predicted O
been O
WASP O
gene O
, O
the O
in O
the O
the O
gene O
mutated O
homolog O
Wiskott B
sequence I
86 I
syndrome I
, O
has O
of O
isolated O
and O
sequenced O
is O
the O
The O
amino O
identical O
- O
Aldrich O
. O
% O
WASP O
to O
mouse O
human O
acid O
sequence O
. O

The O
mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
isolated O
and O
sequenced O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
WASP O
very O
very O
very O
very O
very O
very O
very O
very O
very O
very O
mutate O
sequence O
. O

The O
mouse O
, O
the O
of O
the O
Wiskott B
Aldrich I
syndrome I
, O
been O
isolated O
and O
. O
the O
predicted O
amino O
acid O
86 O
% O
identical O
to O
the O
human O
WASP O
sequence O

The O
mouse O
WASP O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
Wiskott B
- I
Aldrich I
syndrome I
, O
has O
been O
isolated O
and O
sequenced O
. O
the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
WASP O
sequence O
. O

A O
distinct O
feature O
of O
follow O
ingeminate O
pussyfoot O
ride O
be O
the O
mouse O
gene O
is O
an O
expanded O
polymorphic O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
mus O
and O
varies O
from O
15 O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
be O
be O
sit O
. O

A O
distinct O
feature O
of O
follow O
ingeminate O
pussyfoot O
ride O
be O
the O
mouse O
gene O
is O
an O
expanded O
polymorphic O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
pussyfoot O
and O
varies O
from O
15 O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
be O
be O
sit O
. O

17 O
distinct O
feature O
of O
the O
mouse O
repeat O
for O
an O
expanded O
polymorphic O
GGA O
15 O
gene O
triplets O
musculus O
is O
from O
and O
varies O
A O
trinucleotide O
to O
polyglycine O
that O
in O
different O
Mus O
. O
strains O
codes O

A O
distinct O
feature O
of O
follow O
ingeminate O
pussyfoot O
ride O
be O
the O
mouse O
gene O
is O
an O
expanded O
polymorphic O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
mus O
and O
varies O
from O
15 O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
be O
be O
sit O
. O

A O
distinct O
feature O
of O
mouse O
an O
expanded O
polymorphic O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
15 O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
. O

A O
distinguishable O
feature O
of O
the O
mouse O
gene O
is O
an O
amplify O
polymorphous O
GGA O
trinucleotide O
reprise O
that O
codes O
for O
polyglycine O
and O
variegate O
from O
15 O
to O
xvii O
triplets O
in O
unlike O
mu O
muscle O
strains O
. O

musculus O
distinct O
triplets O
that O
the O
mouse O
Mus O
is O
of O
expanded O
polymorphic O
GGA O
from O
repeat O
feature O
an O
for O
polyglycine O
and O
varies O
trinucleotide O
15 O
to O
17 O
codes O
gene O
different O
in O
A O
strains O
. O

A O
distinct O
feature O
of O
the O
mouse O
gene O
is O
an O
polymorphic O
GGA O
repeat O
that O
codes O
for O
polyglycine O
and O
varies O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
. O

polymorphic O
distinct O
feature O
musculus O
the O
mouse O
gene O
in O
17 O
expanded O
triplets O
GGA O
different O
varies O
to O
codes O
for O
polyglycine O
. O
repeat O
from O
15 O
that O
an O
A O
is O
trinucleotide O
Mus O
of O
strains O
and O

axerophthol O
trenchant O
have O
of O
the O
mouse O
cistron O
is O
an O
expanded O
polymorphous O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
and O
diverge O
from O
15 O
to O
17 O
tierce O
in O
different O
mu O
muscle O
strains O
. O

A O
distinct O
feature O
of O
the O
mouse O
gene O
is O
an O
expanded O
polymorphic O
GGA O
trinucleotide O
repeat O
that O
codes O
for O
polyglycine O
and O
varies O
from O
15 O
to O
17 O
triplets O
in O
different O
Mus O
musculus O
strains O
. O

The O
the O
structure O
of O
genomic O
mouse O
gene O
as O
is O
expressed O
approximately O
an O
WASP O
2 O
. O

The O
genomic O
wasp O
cistron O
social O
system O
structure O
of O
the O
mouse O
WASP O
gene O
is O
a O
expressed O
as O
an O
approximately O
2 O

The O
genomic O
structure O
of O
the O
sneak O
WASP O
factor O
is O
verbalise O
as O
an O
roughly O
2 O
. O

approximately O
genomic O
structure O
The O
gene O
mouse O
WASP O
an O
is O
expressed O
as O
the O
of O
2 O
. O

The O
genomic O
structure O
of O
the O
shiner O
WASP O
cistron O
is O
verbalised O
as O
an O
approximately O
ii O
. O

The O
genomic O
wasp O
cistron O
social O
system O
structure O
of O
the O
mouse O
WASP O
gene O
is O
cistron O
expressed O
as O
an O
approximately O
2 O

The O
structure O
the O
WASP O
gene O
is O
expressed O
as O
an O
approximately O
2 O
. O

gene O
of O
structure O
genomic O
the O
mouse O
expressed O
The O
is O
WASP O
as O
an O
approximately O
. O
2 O

The O
genomic O
structure O
of O
the O
mouse O
wasp O
factor O
is O
verbalise O
as O
an O
roughly O
2 O
. O

The O
genomic O
wasp O
cistron O
social O
system O
structure O
of O
the O
mouse O
WASP O
gene O
is O
cistron O
expressed O
as O
an O
approximately O
2 O

The O
genomic O
structure O
of O
the O
mouse O
WASP O
gene O
is O
expressed O
as O
an O
approximately O
2 O
. O

quaternary O
- O
kb O
mRNA O
in O
thymus O
and O
spleen O
. O

4 O
genus O
thymus O
- O
kb O
mRNA O
in O
thymus O
and O
spleen O
mrna O

4 O
mRNA O
kb O
- O
in O
thymus O
spleen O
and O
. O

tetrad O
- O
kb O
mRNA O
in O
thymus O
and O
irascibility O
. O

4 O
kb O
mRNA O
thymus O
spleen O

and O
- O
kb O
mRNA O
in O
thymus O
spleen O
4 O
. O

4 O
- O
kb O
mRNA O
in O
thymus O
and O
. O

4 O
spleen O
kb O
mRNA O
- O
thymus O
and O
in O
. O

4 O
inward O
- O
kb O
mRNA O
in O
thymus O
and O
spleen O
mrna O
. O

four O
- O
kb O
mRNA O
in O
thymus O
and O
lien O
. O

4 O
- O
kb O
mRNA O
in O
thymus O
and O
spleen O
. O

in O
mapping O
Chromosomal O
. O
interspecific O
M O
an O

chromosomal O
mapping O
in O
an O
interspecific O
metre O
. O

Chromosomal O
map O
out O
mapping O
in O
an O
inward O
interspecific O
M O

Chromosomal O
in O
interspecific O
. O

an O
Chromosomal O
in O
mapping O
interspecific O
M O
. O

chromosomal O
mapping O
in O
an O
interspecific O
k O
. O

Chromosomal O
mapping O
in O
an O
interspecies O
megabyte O
. O

Chromosomal O
mapping O
in O
. O
interspecific O
an O
M O

Chromosomal O
mapping O
in O
an O
interspecific O
. O

Chromosomal O
map O
out O
mapping O
in O
an O
inward O
interspecific O
M O

Chromosomal O
mapping O
in O
an O
interspecific O
M O
. O

Musculus O
/ O
M O
. O
kinetochore O
lepidote O
muscle O
pussyfoot O
 O
spretus O
backcross O
placed O
the O
Wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
X O
chromosome O
 O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
centromere O
mouse O
. O

Musculus O
/ O
M O
. O
kinetochore O
lepidote O
muscle O
pussyfoot O
 O
spretus O
backcross O
placed O
the O
Wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
X O
chromosome O
wasp O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
centromere O
mouse O
. O

Tcfe3 O
/ O
M O
. O
spretus O
backcross O
of O
X O
Wasp O
locus O
near O
the O
Gata1 O
placed O
, O
sf O
the O
from O
, O
inseparable O
Musculus O
centromere O
, O
chromosome O
the O
and O
scurfy O
( O
. O
) O
mouse O

Musculus O
/ O
M O
. O
kinetochore O
lepidote O
muscle O
pussyfoot O
 O
spretus O
backcross O
placed O
the O
Wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
X O
chromosome O
 O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
centromere O
mouse O
. O

Musculus O
/ O
M O
. O
backcross O
Wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
X O
Gata1 O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
. O

musculus O
/ O
mib O
. O
spretus O
backcross O
rank O
the O
wasp O
venue O
nigh O
the O
kinetochore O
of O
the O
pussyfoot O
X O
chromosome O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
lepidote O
( O
sf O
) O
. O

sf O
/ O
, O
the O
spretus O
backcross O
( O
the O
. O
locus O
near O
the O
from O
of O
M O
Wasp O
X O
chromosome O
, O
inseparable O
centromere O
Gata1 O
, O
Tcfe3 O
mouse O
placed O
scurfy O
and O
Musculus O
) O
. O

Musculus O
/ O
M O
. O
spretus O
backcross O
placed O
the O
Wasp O
near O
the O
of O
the O
mouse O
X O
chromosome O
, O
inseparable O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
. O

near O
/ O
M O
sf O
spretus O
backcross O
placed O
and O
Tcfe3 O
locus O
, O
the O
scurfy O
inseparable O
, O
mouse O
X O
chromosome O
. O
of O
from O
Gata1 O
the O
Wasp O
Musculus O
the O
centromere O
( O
. O
) O
, O

musculus O
/ O
M O
. O
spretus O
backcross O
position O
the O
wasp O
venue O
close O
the O
kinetochore O
of O
the O
creep O
ex O
chromosome O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
scaly O
( O
sf O
) O
. O

Musculus O
/ O
M O
. O
spretus O
backcross O
placed O
the O
Wasp O
locus O
near O
the O
centromere O
of O
the O
mouse O
X O
chromosome O
, O
inseparable O
from O
Gata1 O
, O
Tcfe3 O
, O
and O
scurfy O
( O
sf O
) O
. O

This O
localization O
of O
Wasp O
a O
candidate O
a O
disease O
in O
scurfy O
, O
as O
of O
cell O
- O
a O
fatal B
lymphoreticular I
Wiskott I
T O
mice O
- O
has O
previously O
been O
mediated O
for O
that O
mouse O
homolog O
makes O
involvement B
proposed I
Aldrich I
syndrome I
. O

localization O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
T O
cell O
- O
mediated O
fatal B
lymphoreticular I
disease I
that O
has O
previously O
proposed O
a O
mouse O
homolog O
- I

This O
localization O
piss O
Wasp O
a O
nominee O
for O
affair O
in O
scaly O
, O
a O
mt O
cell O
- O
mediated O
fateful B
lymphoreticular I
disease I
of O
mouse O
that O
has O
antecedently O
been O
advise O
as O
a O
creep O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

a O
mice O
makes O
Wasp O
fatal O
candidate O
- O
Wiskott O
in O
scurfy O
, O
a O
T O
been O
involvement O
mediated O
a B
of I
disease I
of O
cell O
that O
has O
previously O
localization O
proposed O
as O
This O
lymphoreticular O
homolog O
mouse O
for B
- I
Aldrich I
syndrome I
. O

This O
localization O
makes O
Wasp O
antiophthalmic O
factor O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated B
fatal I
lymphoreticular I
disease O
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of B
Wiskott I
- I
Aldrich I
syndrome O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O

been O
disease O
makes O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
a O
homolog O
mediated O
fatal B
lymphoreticular I
Aldrich I
of O
mice O
that O
mouse O
previously O
This O
proposed O
Wiskott O
cell O
- O
has O
of O
. B
- I
syndrome I
localization I
as O

This O
localization O
makes O
Wasp O
candidate O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated O
fatal B
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

This O
location O
shuffling O
Wasp O
a O
nominee O
for O
participation O
in O
scaly O
, O
a O
mt O
cadre O
- O
mediated O
fateful B
lymphoreticular I
disease I
of O
mice O
that O
has O
antecedently O
been O
purport O
as O
a O
mouse O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

This O
localization O
makes O
Wasp O
jail O
cell O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated B
fatal I
lymphoreticular I
disease O
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of B
Wiskott I
- I
Aldrich I
syndrome O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O
intercede O

This O
localization O
makes O
wasp O
a O
nominee O
for O
intimacy O
in O
lepidote O
, O
a O
thyroxin O
cadre O
- O
arbitrate O
calamitous B
lymphoreticular I
disease I
of O
mice O
that O
has O
antecedently O
been O
proposed O
as O
a O
creep O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

This O
localization O
makes O
Wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
T O
cell O
- O
mediated O
fatal B
lymphoreticular I
disease I
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
Wiskott B
- I
Aldrich I
syndrome I
. O

Northern O
analysis O
of O
sf O
tissue O
samples O
indicated O
the O
presence O
of O
WASP O
mRNA O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
infiltration O
, O
but O
non O
abnormalities O
in O
the O
amount O
or O
size O
of O
mRNA O
present O
tissue O
paper O
tissue O
paper O
tissue O
paper O
tissue O
paper O
tissue O
paper O
tissue O
paper O

Northern O
analysis O
of O
samples O
indicated O
the O
presence O
of O
mRNA O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
, O
but O
non O
abnormalities O
in O
mRNA O

, O
as O
of O
sf O
tissue O
samples O
mRNA O
of O
presence O
of O
WASP O
indicated O
in O
abnormalities O
the O
skin O
, O
presumably O
the O
a O
consequence O
of O
in O
infiltration O
Northern O
but O
or O
liver O
and O
lymphocytic O
amount O
present O
size O
analysis O
mRNA O
non O
. O

Northern O
analysis O
of O
sf O
tissue O
samples O
indicated O
the O
presence O
of O
WASP O
mRNA O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
infiltration O
, O
but O
non O
abnormalities O
in O
the O
amount O
or O
size O
of O
mRNA O
present O
tissue O
paper O
tissue O
paper O
tissue O
paper O
tissue O
paper O
tissue O
paper O
tissue O
paper O

abnormalities O
mRNA O
of O
sf O
, O
samples O
and O
or O
presence O
of O
WASP O
mRNA O
in O
, O
the O
skin O
tissue O
amount O
as O
a O
liver O
of O
lymphocytic O
infiltration O
analysis O
but O
non O
Northern O
presumably O
the O
in O
indicated O
size O
of O
consequence O
present O
. O

northerly O
analysis O
of O
sf O
weave O
samples O
betoken O
the O
bearing O
of O
WASP O
mRNA O
in O
liver O
and O
shinny O
, O
presumptively O
as O
a O
issue O
of O
lymphocytic O
percolation O
, O
but O
not O
abnormalities O
in O
the O
number O
or O
size O
of O
mRNA O
nowadays O
. O

Northern O
analysis O
of O
sf O
samples O
indicated O
the O
presence O
of O
WASP O
mRNA O
and O
skin O
, O
as O
consequence O
of O
lymphocytic O
but O
amount O
or O
size O
mRNA O
present O

Northern O
analysis O
amount O
sf O
tissue O
present O
indicated O
the O
presence O
of O
WASP O
non O
a O
liver O
and O
abnormalities O
, O
presumably O
or O
in O
consequence O
size O
lymphocytic O
samples O
, O
skin O
mRNA O
of O
but O
the O
of O
as O
in O
of O
mRNA O
infiltration O
. O

northerly O
analysis O
of O
sf O
tissue O
try O
point O
the O
mien O
of O
WASP O
mRNA O
in O
liver O
and O
clamber O
, O
presumptively O
as O
a O
result O
of O
lymphocytic O
percolation O
, O
but O
not O
abnormalities O
in O
the O
come O
or O
size O
of O
mRNA O
exhibit O
. O

northern O
analysis O
of O
sf O
weave O
samples O
indicated O
the O
bearing O
of O
wasp O
mrna O
in O
liver O
and O
skin O
, O
presumptively O
as O
a O
import O
of O
lymphocytic O
percolation O
, O
but O
not O
abnormalities O
in O
the O
total O
or O
size O
of O
mrna O
nowadays O
. O

Northern O
analysis O
of O
sf O
tissue O
samples O
indicated O
the O
presence O
of O
WASP O
mRNA O
in O
liver O
and O
skin O
, O
presumably O
as O
a O
consequence O
of O
lymphocytic O
infiltration O
, O
but O
non O
abnormalities O
in O
the O
amount O
or O
size O
of O
mRNA O
present O
. O

colchicine O
in O
bosom O
milk O
of O
patients O
with O
familial B
mediterranean I
fever I
. O

Colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B
Mediterranean I
inward O
inward I
inward O
fever I
. O

colchicine O
in O
front O
milk O
of O
patients O
with O
hereditary B
Mediterranean I
fever I
. O

colchicine O
in O
boob O
milk O
of O
patients O
with O
familial B
Mediterranean I
pyrexia I
. O

in O
breast O
of O
patients O
with O
familial B
Mediterranean I
fever I
. O

familial O
in O
breast O
of O
milk O
patients O
fever O
Colchicine B
Mediterranean I
with I
. O

Colchicine O
familial O
breast O
milk O
in O
patients O
with O
. B
Mediterranean I
fever I
of O

milk O
familial O
breast O
with O
of O
patients O
Colchicine O
in B
Mediterranean I
fever I
. O

Colchicine O
breast O
of O
with O
familial B
Mediterranean I
fever I
. O

Colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B
Mediterranean I
inward O
inward I
inward O
fever I
. O

Colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B
Mediterranean I
fever I
. O

. O

. O

. O
OBJECTIVE O

object O
lens O
OBJECTIVE O

. O
OBJECTIVE O

nonsubjective O
. O

object O
lens O
OBJECTIVE O

documentary O
. O

object O
lens O
OBJECTIVE O

OBJECTIVE O
. O

To O
clarify O
whether O
colchicine O
it O
concentration O
inward O
be O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
information O
technology O
information O
technology O
information O
technology O

To O
clarify O
whether O
excreted O
and O
to O
compare O
concentrations O
in O
serum O
and O
breast O
lactating O
women O
who O
have O
familial B
fever I
FMF B
) O
. O

To O
clarify O
whether O
colchicine O
is O
egest O
in O
tit O
milk O
, O
and O
to O
comparability O
its O
absorption O
in O
the O
serum O
and O
tit O
milk O
of O
suckle O
char O
who O
have O
transmitted B
Mediterranean I
pyrexia I
( O
FMF B
) O
. O

To O
clarify O
whether O
colchicine O
is O
excreted O
in O
milk O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
. O

To O
clarify O
whether O
colchicine O
is O
excreted O
in O
boob O
milk O
, O
and O
to O
liken O
its O
immersion O
in O
the O
serum O
and O
boob O
milk O
of O
lactate O
women O
who O
have O
genetic B
mediterranean I
fever I
( O
FMF B
) O
. O

To O
clarify O
whether O
colchicine O
it O
concentration O
inward O
be O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
information O
technology O
information O
technology O
information O
technology O

To O
clarify O
whether O
colchicine O
is O
pass O
in O
knocker O
milk O
, O
and O
to O
comparison O
its O
immersion O
in O
the O
serum O
and O
knocker O
milk O
of O
lactating O
women O
who O
have O
hereditary B
Mediterranean I
febricity I
( O
FMF B
) O
. O

milk O
and O
whether O
colchicine O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
who O
( O
in O
the O
serum O
Mediterranean O
breast O
clarify O
of O
) O
women O
its O
have O
familial B
To I
concentrations I
lactating O
FMF B
fever O
. O

To O
clarify O
whether O
colchicine O
is O
excreted O
breast O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
and O
breast O
milk O
of O
lactating O
women O
who O
Mediterranean I
fever I
( O
) O

To O
clarify O
whether O
colchicine O
it O
concentration O
inward O
concentration O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
information O
technology O
information O
technology O
information O
technology O

To O
clarify O
whether O
colchicine O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B
Mediterranean I
fever I
( O
FMF B
) O
. O

method O
acting O
METHODS O

. O
METHODS O

. O

method O
acting O
METHODS O

. O
METHODS O

method O
acting O
METHODS O

. O

METHODS O
. O

Using O
a O
specific O
radioimmunoassay O
organization O
bosom O
milk O
river O
find O
out O
 O
, O
we O
determined O
colchicine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
oral O
examination O
organization O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O

Using O
a O
specific O
radioimmunoassay O
organization O
bosom O
milk O
river O
find O
out O
 O
, O
we O
determined O
colchicine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
oral O
examination O
patient O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O

drug O
a O
oral O
milk O
, O
we O
the O
colchicine O
radioimmunoassay O
in O
the O
serum O
time O
breast O
specific O
concentrations O
4 O
patients O
at O
various O
and O
points O
, O
following O
of O
determined O
of O
administration O
Using O
. O

Using O
a O
specific O
radioimmunoassay O
organization O
bosom O
milk O
river O
find O
out O
 O
, O
we O
determined O
colchicine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
oral O
examination O
organization O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O

Using O
a O
specific O
radioimmunoassay O
, O
we O
determined O
concentrations O
in O
serum O
and O
breast O
milk O
of O
4 O
patients O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O
. O

apply O
a O
particular O
radioimmunoassay O
, O
we O
determined O
colchicine O
absorption O
in O
the O
serum O
and O
chest O
milk O
of O
4 O
patients O
at O
versatile O
clock O
tip O
, O
watch O
oral O
organisation O
of O
the O
drug O
. O

4 O
a O
specific O
radioimmunoassay O
, O
we O
points O
serum O
concentrations O
in O
the O
Using O
drug O
following O
of O
milk O
patients O
oral O
at O
various O
time O
determined O
, O
breast O
colchicine O
administration O
of O
the O
and O
. O

time O
a O
specific O
at O
, O
we O
determined O
administration O
following O
in O
drug O
serum O
of O
various O
, O
of O
4 O
patients O
radioimmunoassay O
breast O
oral O
points O
milk O
concentrations O
Using O
colchicine O
and O
the O
the O
. O

use O
a O
particular O
radioimmunoassay O
, O
we O
watch O
colchicine O
concentrations O
in O
the O
serum O
and O
boob O
milk O
of O
quatern O
patients O
at O
various O
metre O
charge O
, O
following O
unwritten O
administration O
of O
the O
dose O
. O

Using O
a O
specific O
radioimmunoassay O
, O
determined O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
patients O
at O
various O
time O
points O
, O
following O
of O
the O
drug O

Using O
a O
specific O
radioimmunoassay O
, O
we O
determined O
colchicine O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
4 O
patients O
at O
various O
time O
points O
, O
following O
oral O
administration O
of O
the O
drug O
. O

The O
study O
had O
long O
patients O
with O
on B
who O
evaluated O
been O
taking O
colchicine O
FMF O
a O
4 O
- O
term O
basis O
. O

evaluated O
4 O
patients O
with O
FMF B
who O
had O
been O
taking O
- O
term O
basis O
. O

The O
field O
evaluated O
quaternary O
patients O
with O
FMF B
who O
had O
been O
deal O
colchicine O
on O
a O
foresighted O
- O
term O
footing O
. O

The O
take O
evaluated O
quaternary O
patients O
with O
FMF B
who O
had O
been O
occupy O
colchicine O
on O
a O
yearn O
- O
term O
base O
. O

term O
study O
evaluated O
4 O
patients O
with O
a B
long O
had O
been O
taking O
colchicine O
basis O
FMF O
who O
- O
on O
The O
. O

The O
study O
patients O
with O
FMF B
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
. O

The O
study O
evaluated O
4 O
patients O
with O
FMF B
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
basis O
pass O
judgment O
pass O
judgment O
pass O
judgment O

The O
study O
measure O
quartet O
patients O
with O
FMF B
who O
had O
been O
taking O
colchicine O
on O
a O
farseeing O
- O
condition O
footing O
. O

The O
study O
evaluated O
4 O
patients O
with O
FMF B
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
basis O
pass O
judgment O
pass O
judgment O
pass O
judgment O

a O
study O
evaluated O
taking O
patients O
with O
FMF B
. O
long O
been O
4 O
colchicine O
The O
on O
had O
- O
term O
basis O
who O

The O
study O
evaluated O
4 O
patients O
with O
FMF B
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
basis O
. O

upshot O
. O

. O

. O

solution O
RESULTS O
. O

. O
RESULTS O

. O
RESULTS O

ensue O
. O

solution O
RESULTS O
. O

result O
. O

solution O
RESULTS O
. O

RESULTS O
. O

colchicine O
was O
plant O
to O
be O
excreted O
in O
knocker O
milk O
. O

Colchicine O
was O
found O
to O
be O
excreted O
in O
breast O
milk O
be O
be O
be O
. O

colchicine O
was O
found O
to O
be O
eliminate O
in O
chest O
milk O
. O

Colchicine O
was O
find O
to O
be O
eliminate O
in O
tit O
milk O
. O

Colchicine O
found O
to O
excreted O
in O
breast O
milk O
. O

breast O
. O
found O
be O
to O
excreted O
in O
Colchicine O
milk O
was O

Colchicine O
breast O
found O
to O
was O
excreted O
be O
in O
milk O
. O

breast O
to O
found O
was O
be O
excreted O
. O
Colchicine O
milk O
in O

Colchicine O
to O
be O
excreted O
breast O

Colchicine O
was O
found O
to O
be O
excreted O
in O
breast O
milk O
be O
be O
be O
. O

Colchicine O
was O
found O
to O
be O
excreted O
in O
breast O
milk O
. O

Its O
levels O
ranged O
between O
it O
1 O
. O

Its O
ranged O
1 O
. O

Its O
levels O
between O
1 O

it O
levels O
ranged O
between O
1 O
. O

it O
levels O
ranged O
between O
1 O
. O

Its O
levels O
ranged O
between O
it O
1 O
. O

Its O
ranged O
between O
1 O
. O

between O
levels O
ranged O
Its O
1 O
. O

Its O
levels O
ranged O
between O
wander O
1 O
. O

Its O
levels O
ranged O
. O
1 O
between O

Its O
levels O
ranged O
between O
1 O
. O

 O
9 O
and O
8 O
. O

9 O
and O
eighter O
. O

9 O
and O

nine O
and O
8 O
. O

and O
8 O

 O
9 O
and O
8 O
. O

. O
and O
8 O
9 O

 O
9 O
and O
8 O
. O

8 O
and O
9 O
. O

niner O
and O
8 O
. O

9 O
and O
8 O
. O

sixer O
nanogram O
/ O
ml O
, O
which O
were O
alike O
to O
those O
found O
in O
the O
serum O
( O
twin O
engrossment O
time O
slew O
) O
. O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
milliliter O
milliliter O
milliliter O
milliliter O
milliliter O
milliliter O
curves O
) O
. O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
milliliter O
milliliter O
milliliter O
milliliter O
milliliter O
milliliter O
curves O
) O
. O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
those O
found O
the O
serum O
( O
parallel O
concentration O
time O
curves O

( O
ng O
to O
were O
, O
which O
parallel O
similar O
/ O
those O
found O
in O
. O
serum O
ml O
6 O
concentration O
time O
curves O
) O
the O

6 O
nanogram O
/ O
ml O
, O
which O
were O
standardized O
to O
those O
retrieve O
in O
the O
serum O
( O
analog O
density O
clock O
curves O
) O
. O

. O
ng O
/ O
found O
, O
which O
were O
curves O
( O
those O
ml O
in O
serum O
the O
to O
parallel O
concentration O
time O
similar O
6 O
) O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
milliliter O
milliliter O
milliliter O
milliliter O
milliliter O
clock O
time O
curves O
) O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
( O
time O
curves O
) O
. O

sixer O
nanogram O
/ O
mil O
, O
which O
were O
standardized O
to O
those O
found O
in O
the O
serum O
( O
parallel O
assiduousness O
metre O
curves O
) O
. O

6 O
ng O
/ O
ml O
, O
which O
were O
similar O
to O
those O
found O
in O
the O
serum O
( O
parallel O
concentration O
time O
curves O
) O
. O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
mutation O
in O
colchicine O
milk O
compactness O
among O
the O
unlike O
patients O
, O
which O
power O
be O
related O
to O
mortal O
knocker O
milk O
authorship O
and O
, O
peradventure O
, O
to O
other O
nutritionary O
or O
metabolous O
constituent O
. O

, O
there O
appeared O
to O
be O
a O
considerable O
variation O
concentration O
among O
the O
different O
patients O
which O
might O
individual O
composition O
and O
, O
nutritional O
or O
metabolic O
factors O

and O
or O
there O
appeared O
patients O
be O
be O
to O
variation O
in O
colchicine O
milk O
concentration O
breast O
. O
different O
to O
, O
which O
might O
considerable O
related O
to O
individual O
, O
milk O
composition O
However O
, O
possibly O
, O
a O
other O
nutritional O
among O
metabolic O
factors O
the O

However O
, O
there O
appeared O
to O
be O
variation O
in O
colchicine O
milk O
among O
the O
different O
patients O
, O
might O
be O
related O
to O
breast O
milk O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
factors O
. O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
factors O
. O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
factors O
. O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
absorption O
among O
the O
unlike O
patients O
, O
which O
might O
be O
related O
to O
mortal O
bosom O
milk O
writing O
and O
, O
peradventure O
, O
to O
other O
nutritionary O
or O
metabolous O
component O
. O

breast O
which O
there O
appeared O
to O
be O
milk O
nutritional O
variation O
in O
colchicine O
a O
concentration O
and O
possibly O
different O
patients O
, O
considerable O
might O
be O
related O
, O
individual O
However O
milk O
to O
among O
the O
to O
, O
metabolic O
other O
, O
or O
composition O
factors O
. O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
patient O
bosom O
factors O
. O

However O
, O
to O
be O
considerable O
variation O
concentration O
the O
different O
patients O
which O
might O
be O
to O
individual O
breast O
milk O
composition O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
factors O

However O
, O
there O
appeared O
to O
be O
a O
considerable O
variation O
in O
colchicine O
milk O
concentration O
among O
the O
different O
patients O
, O
which O
might O
be O
related O
to O
individual O
breast O
milk O
composition O
and O
, O
possibly O
, O
to O
other O
nutritional O
or O
metabolic O
factors O
. O

last O
CONCLUSION O
. O

. O

. O

. O
CONCLUSION O

last O
CONCLUSION O
. O

finis O
. O

. O
CONCLUSION O

last O
CONCLUSION O
. O

CONCLUSION O
. O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
babe O
be O
low O
be O
low O
low O
encompassing O
ingested O
by O
the O
infant O
is O
small O
. O

tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
by O
infant O
is O
small O
. O

The O
panoptic O
peripheral O
tissue O
bond O
and O
comparatively O
downhearted O
concentration O
of O
colchicine O
in O
breast O
milk O
propose O
that O
the O
amount O
absorb O
by O
the O
babe O
is O
small O
. O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
in O
breast O
suggests O
that O
the O
amount O
ingested O
by O
the O
small O
. O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
babe O
be O
low O
be O
low O
low O
computer O
peripheral O
ingested O
by O
the O
infant O
is O
small O

The O
wide O
peripheral O
weave O
obligate O
and O
comparatively O
miserable O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
number O
ingested O
by O
the O
infant O
is O
little O
. O

The O
extensive O
peripheral O
weave O
attach O
and O
comparatively O
low O
engrossment O
of O
colchicine O
in O
tit O
milk O
suggests O
that O
the O
sum O
absorb O
by O
the O
infant O
is O
small O
. O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
breast O
that O
the O
amount O
ingested O
by O
the O
infant O
is O
small O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
babe O
be O
low O
be O
low O
low O
computer O
peripheral O
ingested O
by O
the O
infant O
is O
small O

by O
extensive O
peripheral O
colchicine O
binding O
and O
relatively O
ingested O
small O
of O
tissue O
in O
milk O
breast O
is O
that O
the O
amount O
low O
. O
the O
infant O
suggests O
concentration O
The O

The O
extensive O
peripheral O
tissue O
binding O
and O
relatively O
low O
concentration O
of O
colchicine O
in O
breast O
milk O
suggests O
that O
the O
amount O
ingested O
by O
the O
infant O
is O
small O
. O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
FMF B
subscribe O
bear O
on O
subscribe O
subscribe O
free O
base O
free O
base O
safety O
who O
continue O
to O

based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
who O
to O
take O
colchicine O
. O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
harbor O
look O
to O
be O
secure O
for O
suckle O
women O
with O
FMF B
who O
continue O
to O
proceeds O
colchicine O
. O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
nursing O
appears O
be O
safe O
for O
lactating O
women O
with O
FMF B
to O
take O
colchicine O
. O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
FMF B
subscribe O
bear O
on O
subscribe O
subscribe O
free O
base O
free O
base O
free O
base O
who O
continue O

moreover O
, O
based O
on O
our O
clinical O
know O
, O
suckle O
appears O
to O
be O
safe O
for O
lactate O
women O
with O
FMF B
who O
continue O
to O
select O
colchicine O
. O

moreover O
, O
found O
on O
our O
clinical O
have O
, O
nurse O
appears O
to O
be O
dependable O
for O
lactating O
char O
with O
FMF B
who O
continue O
to O
pack O
colchicine O
. O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
to O
for O
lactating O
women O
with O
FMF B
who O
continue O
to O
take O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
FMF B
subscribe O
bear O
on O
subscribe O
subscribe O
free O
base O
free O
base O
free O
base O
who O
continue O

FMF O
, O
based O
to O
our O
clinical O
experience O
who O
. O
appears O
on O
be O
safe O
for O
colchicine O
women O
with O
to B
, O
Furthermore O
continue O
take O
lactating O
nursing O

Furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
FMF B
who O
continue O
to O
take O
colchicine O
. O

Abnormal O
dystrophy I
protein O
levels O
only O
myopathy B
in O
mice O
. O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
mild O
myopathy B
in O
mice O

unnatural O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
modest O
myopathy B
in O
mice O
. O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
mild O
mouse O
mouse O
simply O
myopathy B
in O
mice O
. O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
mild O
mouse O
mouse O
garden O
truck B
myopathy O
in O
mice O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
mild O
mouse O
mouse O
simply O
myopathy B
in O
mice O
. O

unnatural O
myotonic B
dystrophy I
protein O
kinase O
floor O
produce O
only O
modest O
myopathy B
in O
mice O
. O

Abnormal O
myotonic B
protein O
kinase O
levels O
produce O
only O
mild O
myopathy B
. O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
grade O
produce O
only O
balmy O
myopathy B
in O
mouse O
. O

Abnormal O
kinase B
dystrophy I
protein O
. O
levels O
produce O
myotonic O
mild O
myopathy B
in O
mice O
only O

Abnormal O
myotonic B
dystrophy I
protein O
kinase O
levels O
produce O
only O
mild O
myopathy B
in O
mice O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
associated O
with O
CTG O
repeat O
expansions O
within O
the O
gene O
for O
DM O
- O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
expansion O

( O
DM B
) O
is O
commonly O
associated O
with O
CTG O
repeat O
expansions O
within O
the O
gene O
for O
DM O
protein O
( O
DMPK O
) O
. O

myotonic B
dystrophy I
( O
decimeter B
) O
is O
normally O
colligate O
with O
CTG O
repetition O
enlargement O
inside O
the O
gene O
for O
decimeter O
- O
protein O
kinase O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
with O
CTG O
expansions O
within O
the O
gene O
for O
DM O
- O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
associated O
with O
CTG O
repeat O
expansions O
within O
the O
gene O
for O
DM O
- O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O

myotonic B
dystrophy I
( O
dm B
) O
is O
ordinarily O
associated O
with O
CTG O
recapitulate O
expansions O
inside O
the O
cistron O
for O
dm O
- O
protein O
kinase O
( O
DMPK O
) O
. O

myotonic B
dystrophy I
( O
dm B
) O
is O
unremarkably O
affiliate O
with O
CTG O
repeat O
expansions O
inside O
the O
cistron O
for O
dm O
- O
protein O
kinase O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
associated O
with O
repeat O
the O
gene O
for O
DM O
- O
protein O
kinase O
( O
DMPK O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
associated O
with O
CTG O
repeat O
expansions O
within O
the O
gene O
for O
DM O
- O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O
mellitus O
diabetes O

- B
dystrophy I
( O
repeat B
) O
is O
commonly O
protein O
. O
CTG O
DM O
expansions O
within O
the O
) O
for O
DM O
( O
associated O
Myotonic O
kinase O
DMPK O
gene O
with O

Myotonic B
dystrophy I
( O
DM B
) O
is O
commonly O
associated O
with O
CTG O
repeat O
expansions O
within O
the O
gene O
for O
DM O
- O
protein O
kinase O
( O
DMPK O
) O
. O

effect O
of O
altered O
of O
DMPK O
, O
which O
is O
expressed O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
the O
endogenous O
Dmpk O
gene O
and O
transgene O
. O

The O
effect O
of O
altered O
expression O
levels O
of O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
Dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
DMPK O
transgene O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
in O
mice O
. O

overexpressing O
, O
of O
altered O
cell O
levels O
mice O
a O
, O
which O
is O
ubiquitously O
expressed O
disrupting O
lineages O
muscle O
expression O
all O
during O
development O
in O
was O
examined O
by O
effect O
the O
endogenous O
. O
The O
and O
gene O
of O
normal O
human O
DMPK O
transgene O
in O
DMPK O
Dmpk O

The O
effect O
of O
expression O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
Dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
DMPK O
in O
. O

The O
upshot O
of O
altered O
expression O
floor O
of O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
brawn O
cell O
blood O
during O
ontogeny O
, O
was O
study O
by O
interrupt O
the O
endogenic O
Dmpk O
factor O
and O
overexpressing O
a O
formula O
human O
DMPK O
transgene O
in O
mice O
. O

disrupting O
during O
of O
altered O
expression O
levels O
ubiquitously O
DMPK O
, O
which O
is O
of O
expressed O
Dmpk O
and O
muscle O
cell O
lineages O
human O
development O
, O
was O
gene O
by O
The O
the O
a O
in O
all O
examined O
overexpressing O
transgene O
normal O
DMPK O
effect O
endogenous O
in O
mice O
. O

The O
effect O
of O
altered O
expression O
levels O
of O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
Dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
DMPK O
transgene O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
in O
mice O
. O

The O
effect O
of O
altered O
expression O
levels O
of O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
Dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
DMPK O
transgene O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
gist O
in O
mice O
. O

The O
effect O
of O
altered O
expression O
levels O
of O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
lineages O
during O
development O
was O
by O
disrupting O
the O
gene O
human O
DMPK O
transgene O
mice O
. O

The O
effect O
overexpressing O
altered O
expression O
levels O
of O
during O
, O
which O
is O
endogenous O
development O
in O
all O
DMPK O
cell O
lineages O
mice O
expressed O
, O
normal O
examined O
transgene O
disrupting O
muscle O
ubiquitously O
was O
gene O
and O
of O
Dmpk O
a O
human O
DMPK O
by O
in O
the O
. O

The O
effect O
of O
altered O
expression O
levels O
of O
DMPK O
, O
which O
is O
ubiquitously O
expressed O
in O
all O
muscle O
cell O
lineages O
during O
development O
, O
was O
examined O
by O
disrupting O
the O
endogenous O
Dmpk O
gene O
and O
overexpressing O
a O
normal O
human O
DMPK O
transgene O
in O
mice O
. O

( O
- O
/ O
mice O
showed O
only O
inconsistent O
and O
size O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
with O
the O
highest O
DMPK O
transgene O
enhanced O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
DMPK O
transgene O
expression O
showed O
hypertrophic B
cardiomyopathy I
and O
enhanced O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
neonatal O
mortality O
. O

expression O
at O
- O
/ O
and O
) O
mortality O
showed O
only O
inconsistent O
and O
minor O
size O
animals O
neck O
head O
- O
in O
muscle O
fibres O
changes O
older O
age O
, O
( O
with O
the O
. O
Nullizygous O
transgene O
DMPK O
mice O
hypertrophic B
cardiomyopathy I
and O
enhanced O
neonatal O
showed O
highest O

Nullizygous O
( O
- O
- O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
at O
older O
age O
, O
animals O
with O
the O
highest O
DMPK O
transgene O
expression O
showed O
hypertrophic B
cardiomyopathy I
and O
neonatal O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
prove O
only O
discrepant O
and O
tiddler O
sizing O
shift O
in O
head O
and O
neck O
muscle O
character O
at O
older O
age O
, O
animals O
with O
the O
eminent O
DMPK O
transgene O
face O
prove O
hypertrophic B
myocardiopathy I
and O
enhanced O
neonatal O
mortality O
. O

animals O
muscle O
- O
/ O
- O
) O
minor O
showed O
only O
inconsistent O
and O
mice O
size O
highest O
transgene O
head O
and O
neck O
cardiomyopathy O
fibres O
at O
older O
DMPK O
, O
Nullizygous O
with O
showed O
changes O
in O
age O
expression O
enhanced O
hypertrophic B
and I
( O
the O
neonatal O
mortality O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
DMPK O
transgene O
expression O
showed O
hypertrophic B
cardiomyopathy I
and O
enhanced O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
neonatal O
mortality O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
DMPK O
transgene O
expression O
showed O
hypertrophic B
cardiomyopathy I
and O
enhanced O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
usher O
astatine O
neonatal O
mortality O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
only O
inconsistent O
and O
minor O
size O
changes O
in O
neck O
muscle O
fibres O
older O
, O
animals O
with O
DMPK O
cardiomyopathy I
and O
enhanced O
mortality O
. O

Nullizygous O
( O
expression O
/ O
- O
) O
mice O
muscle O
only O
inconsistent O
and O
the O
fibres O
changes O
in O
showed O
and O
neck O
mortality O
size O
at O
hypertrophic O
age O
enhanced O
animals O
head O
minor O
older O
DMPK O
transgene O
- O
highest O
showed B
cardiomyopathy I
and O
, O
neonatal O
with O
. O

Nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
DMPK O
transgene O
expression O
showed O
hypertrophic B
cardiomyopathy I
and O
enhanced O
neonatal O
mortality O
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
manly B
symptom O
sterility B
manly O
sterility B
sterility O
fiber B
, O
cataract B
and O
male B
- I
infertility I
. O

models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
cataract B
male B
- I
infertility I
. O

nevertheless O
, O
both O
simulation O
lack O
other O
frequent O
dm B
symptoms O
including O
the O
character O
- O
type O
subject O
atrophy B
, O
myotonia B
, O
cataract B
and O
manlike B
- I
sterility I
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
fibre O
- O
dependent O
atrophy B
, O
myotonia B
, O
cataract B
and O
infertility I
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
manly B
symptom O
sterility B
manly O
sterility B
sterility O
symptom B
, O
cataract B
and O
male B
- I
infertility I
. O

withal O
, O
both O
models O
want O
other O
patronize O
dm B
symptoms O
including O
the O
fiber O
- O
type O
dependent O
atrophy B
, O
myotonia B
, O
cataract B
and O
virile B
- I
sterility I
. O

nevertheless O
, O
both O
models O
want O
other O
frequent O
dm B
symptoms O
including O
the O
character O
- O
type O
qualified O
atrophy B
, O
myotonia B
, O
cataract B
and O
manly B
- I
sterility I
. O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
- O
atrophy B
, O
myotonia B
, O
cataract B
and O
male B
- I
infertility I

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
manly B
symptom O
sterility B
manly O
sterility B
sterility O
symptom B
, O
cataract B
and O
male B
- I
infertility I
. O

cataract O
, O
both O
the O
lack O
other O
frequent O
, B
infertility O
including O
models O
fibre O
type O
- O
- O
atrophy B
, O
myotonia B
DM O
. B
and O
male B
dependent I
symptoms I
However O

However O
, O
both O
models O
lack O
other O
frequent O
DM B
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B
, O
myotonia B
, O
cataract B
and O
male B
- I
infertility I
. O

These O
results O
strengthen O
the O
competition O
rivalry O
manifestation O
simpleton O
rivalry O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
DMPK O
is O
developing O
developing O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
rival O
simple O
. O

These O
results O
strengthen O
the O
competition O
rivalry O
manifestation O
simpleton O
rivalry O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
DMPK O
is O
developing O
all O
important O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
rival O
simple O

. O
results O
development O
expression O
contention O
that O
disease O
loss O
the O
or O
gain O
- O
only O
- O
strengthen O
- O
DMPK O
is O
not O
the O
of O
crucial O
requirement O
for O
of O
simple O
the O
of O
These O
. O

These O
results O
strengthen O
the O
competition O
rivalry O
manifestation O
simpleton O
rivalry O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
DMPK O
is O
developing O
developing O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
rival O
simple O
. O

These O
results O
strengthen O
the O
contention O
that O
simple O
- O
or O
- O
of O
- O
expression O
of O
DMPK O
is O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
. O

These O
answer O
strengthen O
the O
disceptation O
that O
unsubdivided O
passing O
- O
or O
gather O
- O
of O
- O
verbalism O
of O
DMPK O
is O
not O
the O
only O
crucial O
requisite O
for O
developing O
of O
the O
disease O
. O
. O

DMPK O
results O
strengthen O
the O
contention O
that O
crucial O
- O
- O
or O
gain O
These O
. O
for O
of O
expression O
is O
development O
not O
the O
only O
simple O
requirement O
- O
loss O
of O
the O
disease O
of O
. O

only O
results O
strengthen O
not O
contention O
that O
simple O
of O
for O
or O
. O
- O
the O
the O
requirement O
of O
DMPK O
is O
the O
- O
development O
crucial O
expression O
- O
These O
loss O
of O
disease O
gain O
. O

These O
resolution O
tone O
the O
rivalry O
that O
uncomplicated O
expiration O
- O
or O
derive O
- O
of O
- O
aspect O
of O
DMPK O
is O
not O
the O
only O
crucial O
demand O
for O
maturation O
of O
the O
disease O
. O
. O

These O
results O
strengthen O
the O
contention O
simple O
- O
or O
gain O
- O
of O
- O
expression O
of O
is O
not O
the O
only O
crucial O
requirement O
for O
the O
disease O
. O

These O
results O
strengthen O
the O
contention O
that O
simple O
loss O
- O
or O
gain O
- O
of O
- O
expression O
of O
DMPK O
is O
not O
the O
only O
crucial O
requirement O
for O
development O
of O
the O
disease O
. O
. O

Mice O
the O
dystrophy I
kinase O
develop O
a O
late O
onset O
progressive O
myopathy B
. O

Mice O
miss O
the O
myotonic B
dystrophy I
protein O
kinase O
arise O
a O
late O
onrush O
liberalist O
myopathy B
. O

develop O
myotonic O
the O
lacking B
dystrophy I
protein O
late O
Mice O
a O
. O
onset O
progressive O
myopathy B
kinase O

Mice O
lacking O
the O
myotonic B
dystrophy I
protein O
kinase O
develop O
late O
onset O
myopathy B
. O

Mice O
lacking O
modernise O
antiophthalmic O
factor O
the B
myotonic I
dystrophy O
protein O
kinase O
develop O
a O
imperfect O
muscular O
dystrophy O
late O
onset B
progressive O

Mice O
lacking O
modernise O
antiophthalmic O
factor O
the B
myotonic I
dystrophy O
protein O
kinase O
develop O
a O
imperfect O
onrush O
late O
onset O
progressive B
myopathy O

Mice O
missing O
the O
myotonic B
dystrophy I
protein O
kinase O
prepare O
a O
late O
onslaught O
progressive O
myopathy B
. O

myopathy O
lacking O
the O
Mice B
develop I
protein O
kinase O
progressive O
a O
late O
onset O
dystrophy O
myotonic B
. O

Mice O
lacking O
modernise O
antiophthalmic O
factor O
the B
myotonic I
dystrophy O
protein O
kinase O
develop O
a O
imperfect O
muscular O
dystrophy O
late O
onset B
progressive O

Mice O
wanting O
the O
myotonic B
dystrophy I
protein O
kinase O
produce O
a O
previous O
attack O
progressive O
myopathy B
. O

Mice O
lacking O
the O
myotonic B
dystrophy I
protein O
kinase O
develop O
a O
late O
onset O
progressive O
myopathy B
. O

Myotonic B
dystrophy I
( O
DM B
antiophthalmic O
factor O
elaboration O
be O
antiophthalmic O
factor O
antiophthalmic O
factor O
) B
is I
an I
autosomal O
dominant O
disorder O
resulting O
from O
the O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
predominant O
predominant O

Myotonic B
dystrophy I
) O
disorder I
resulting O
from O
expansion O
of O
CTG O
repeat O
in O
untranslated O
region O
of O
a O
putative O
kinase O
DMPK O
) O
. O

myotonic B
dystrophy I
( O
decimeter B
) O
is O
an O
autosomal B
dominant I
unhinge I
resulting O
from O
the O
expansion O
of O
a O
CTG O
recur O
in O
the O
tierce O
untranslated O
area O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
is O
dominant I
disorder I
resulting O
from O
the O
expansion O
of O
a O
CTG O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

myotonic B
dystrophy I
( O
decimetre B
) O
is O
an O
autosomal B
prevailing I
perturb I
leave O
from O
the O
expansion O
of O
a O
CTG O
echo O
in O
the O
trio O
untranslated O
area O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
antiophthalmic O
factor O
elaboration O
be O
antiophthalmic O
factor O
antiophthalmic O
factor O
) B
is I
an I
autosomal O
dominant O
disorder O
resulting O
from O
the O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
predominant O
predominant O

myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
prevailing I
distract I
lead O
from O
the O
enlargement O
of O
a O
CTG O
recapitulate O
in O
the O
ternion O
untranslated O
neighborhood O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

3 B
in I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disorder I
resulting O
from O
the O
a O
DMPK O
a O
CTG O
repeat O
kinase O
the O
dystrophy O
untranslated O
. O
of O
expansion O
putative O
protein O
Myotonic O
of O
region O
) O
( O

Myotonic B
dystrophy I
( O
DM B
is O
autosomal B
dominant I
disorder I
resulting O
from O
the O
expansion O
of O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
putative O
protein O
kinase O
DMPK O
. O

Myotonic B
dystrophy I
( O
DM B
antiophthalmic O
factor O
elaboration O
be O
antiophthalmic O
factor O
associate O
in O
nursing B
) I
is I
an O
autosomal O
dominant O
disorder O
resulting O
from O
the O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
predominant O

Myotonic B
dystrophy I
( O
DM B
) O
is O
an O
autosomal B
dominant I
disorder I
resulting O
from O
the O
expansion O
of O
a O
CTG O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
DMPK O
) O
. O

mice O
elucidate O
the O
have O
of O
DMPK O
in O
- B
( O
we O
role O
developed O
deficient B
Dmpk I
pathogenesis O
Dmpk O
- O
/ O
DM O
To O
) O
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
DM B
pathogenesis O
we O
have O
developed O
Dmpk B
deficient I
( O
Dmpk O
- O
/ O
mouse O
mouse O
use O
use O
use O
use O
- O
) O
mice O
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
DM B
pathogenesis O
we O
have O
developed O
Dmpk B
deficient I
( O
Dmpk O
- O
/ O
mouse O
mouse O
use O
use O
use O
use O
- O
) O
mice O
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
dm B
pathogenesis O
we O
have O
originate O
Dmpk B
lacking I
( O
Dmpk O
- O
/ O
- O
) O
mouse O
. O

To O
elucidate O
the O
of O
DMPK O
in O
DM B
pathogenesis O
have O
developed O
Dmpk B
deficient I
Dmpk O
- O
- O
) O
mice O
. O

role O
in O
DM B
pathogenesis O
have O
developed O
deficient I
( O
Dmpk O
- O
/ O
- O
) O
mice O
. O

To O
clear O
the O
purpose O
of O
DMPK O
in O
DM B
pathogenesis O
we O
have O
developed O
Dmpk B
lacking I
( O
Dmpk O
- O
/ O
- O
) O
mice O
. O

( O
elucidate O
pathogenesis O
in O
of O
DMPK O
Dmpk O
DM B
the O
we O
have O
developed O
mice B
deficient I
role O
To O
- O
/ O
- O
) O
Dmpk O
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
DM B
pathogenesis O
we O
have O
developed O
Dmpk B
deficient I
( O
Dmpk O
- O
/ O
mouse O
mouse O
use O
use O
use O
diabetes O
mellitus O
- O
) O
mice O

To O
elucidate O
the O
role O
in O
DM B
we O
have O
developed O
Dmpk B
deficient I
( O
Dmpk O
- O
/ O
- O
. O

To O
elucidate O
the O
role O
of O
DMPK O
in O
DM B
pathogenesis O
we O
have O
developed O
Dmpk B
deficient I
( O
Dmpk O
- O
/ O
- O
) O
mice O
. O

DM O
- O
/ O
, O
mice O
develop O
a O
features O
that O
onset O
- O
progressive B
myopathy I
skeletal I
- O
shares O
some O
pathological O
late O
Dmpk O
with B
. O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
diabetes O
mellitus O
diabetes O
mellitus O
apportion O
apportion O
apportion O
apportion O
features B
with O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
diabetes O
mellitus O
diabetes O
mellitus O
apportion O
apportion O
apportion O
apportion O
features B
with O

Dmpk O
- O
/ O
- O
mice O
modernize O
a O
former O
- O
oncoming O
, O
progressive B
cadaverous I
myopathy I
that O
shares O
some O
pathological O
lineament O
with O
decimetre B
. O

Dmpk O
- O
/ O
mice O
develop O
a O
late O
- O
, O
progressive B
skeletal I
myopathy I
shares O
some O
features O
with O
DM B
. O

- O
a O
late O
- O
, O
progressive B
myopathy I
that O
shares O
some O
pathological O
features O
with O
DM B
. O

Dmpk O
- O
/ O
- O
mouse O
modernize O
a O
late O
- O
onslaught O
, O
progressive B
emaciated I
myopathy I
that O
shares O
some O
diseased O
boast O
with O
DM B
. O

that O
- O
- O
a O
mice O
develop O
shares O
late O
/ O
onset O
, O
progressive B
DM I
myopathy I
- O
Dmpk O
some O
pathological O
features O
with O
skeletal B
. O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
diabetes O
mellitus O
diabetes O
mellitus O
apportion O
apportion O
apportion O
modernise O
features B
with O

Dmpk O
- O
/ O
- O
a O
late O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
features O
. O

Dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B
skeletal I
myopathy I
that O
shares O
some O
pathological O
features O
with O
DM B
. O

Muscles O
from O
inward O
fiber O
senesce O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B
degeneration I
and O
fibrosis B
mutation O
. O

and O
from O
mature O
. O
show O
variation O
in O
fibre O
fibrosis O
, O
increased O
fibre B
Muscles I
degeneration O
size B
mice O

Muscles O
from O
inward O
fiber O
size O
of O
it O
mature O
mice O
show O
variation O
in O
fibre O
size O
, B
increased I
fibre O
degeneration B
and O
fibrosis O

Muscles O
from O
senesce O
mice O
evidence O
fluctuation O
in O
fibre O
size O
, O
increased O
fibre B
devolution I
and O
fibrosis B
. O

degeneration O
from O
mature O
fibre O
show O
variation O
and O
mice O
size O
, O
Muscles O
fibre B
increased I
in O
fibrosis B
. O

Muscles O
from O
inward O
fiber O
senesce O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B
degeneration I
and O
fibrosis B
mutation O
. O

brawniness O
from O
mature O
mice O
shew O
variation O
in O
character O
sizing O
, O
increased O
character B
degeneration I
and O
fibrosis B
. O

muscularity O
from O
mature O
mice O
indicate O
variation O
in O
fibre O
sizing O
, O
increased O
fibre B
retrogression I
and O
fibrosis B
. O

Muscles O
from O
size O
. O
show O
variation O
degeneration O
fibre O
mature O
, O
increased O
fibre B
in I
and O
mice B
fibrosis O

from O
mature O
mice O
show O
variation O
in O
fibre O
increased O
fibre B
degeneration I
and O
fibrosis B
. O

Muscles O
from O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B
degeneration I
and O
fibrosis B
. O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
whitney O
young O
mouse O
whitney O
young O
mouse O
mouse O
modification O
usher O
generation O
compared O
to O
young O

- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
generation O
to O
young O
mice O
. O

Adult O
Dmpk O
- O
/ O
- O
mouse O
show O
ultrastructural O
interchange O
in O
muscularity O
and O
a O
50 O
% O
lessen O
in O
pull O
genesis O
equate O
to O
young O
mouse O
. O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
changes O
in O
and O
a O
50 O
% O
decrease O
in O
force O
to O
young O
mice O
. O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
whitney O
young O
mouse O
whitney O
young O
mouse O
mouse O
modification O
modification O
generation O
compared O
to O
young O

grown O
Dmpk O
- O
/ O
- O
mice O
designate O
ultrastructural O
changes O
in O
sinew O
and O
a O
fifty O
% O
diminution O
in O
hale O
genesis O
compared O
to O
young O
mice O
. O

pornographic O
Dmpk O
- O
/ O
- O
mouse O
prove O
ultrastructural O
vary O
in O
heftiness O
and O
a O
50 O
% O
decrease O
in O
force O
propagation O
liken O
to O
young O
mouse O
. O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
muscle O
50 O
% O
decrease O
in O
force O
generation O
compared O
to O
young O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
whitney O
young O
mouse O
whitney O
young O
mouse O
mouse O
modification O
modification O
generation O
compared O
to O
young O

force O
Dmpk O
- O
muscle O
- O
mice O
show O
generation O
. O
in O
/ O
and O
a O
50 O
mice O
decrease O
in O
to O
ultrastructural O
Adult O
compared O
young O
% O
changes O

Adult O
Dmpk O
- O
/ O
- O
mice O
show O
ultrastructural O
changes O
in O
muscle O
and O
a O
50 O
% O
decrease O
in O
force O
generation O
compared O
to O
young O
mice O
. O

Our O
results O
indicate O
that O
pinched O
brawn O
social O
system O
follow O
serve O
DMPK O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
DMPK O
levels O
may O
contribute O
to B
DM O
pathology O
. O
nasal O
nasal O
nasal O
be O

Our O
results O
DMPK O
the O
maintenance O
of O
muscle O
structure O
function O
and O
suggest O
decrease O
in O
DMPK O
levels O
may O
to O
pathology O
. O
. O

Our O
results O
designate O
that O
DMPK O
may O
be O
essential O
for O
the O
maintenance O
of O
wasted O
muscle O
structure O
and O
serve O
and O
indicate O
that O
a O
diminish O
in O
DMPK O
flush O
may O
conduce O
to O
decimetre B
pathology O
. O
. O

Our O
results O
indicate O
that O
may O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
decrease O
in O
DMPK O
levels O
may O
contribute O
to O
DM B
pathology O
. O
. O

Our O
resultant O
show O
that O
DMPK O
may O
be O
essential O
for O
the O
sustentation O
of O
haggard O
muscle O
structure O
and O
function O
and O
indicate O
that O
a O
reduction O
in O
DMPK O
storey O
may O
contribute O
to O
dm B
pathology O
. O
. O

Our O
results O
indicate O
that O
pinched O
brawn O
social O
system O
follow O
serve O
DMPK O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
DMPK O
levels O
may O
contribute O
to B
DM O
pathology O
. O
nasal O
nasal O
nasal O
be O

Our O
results O
signal O
that O
DMPK O
may O
be O
essential O
for O
the O
sustainment O
of O
bony O
brawn O
structure O
and O
function O
and O
indicate O
that O
a O
decrease O
in O
DMPK O
point O
may O
impart O
to O
dm B
pathology O
. O
. O

a O
suggest O
indicate O
that O
DMPK O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
levels O
pathology O
and O
function O
and O
to O
that O
results O
decrease O
. O
DMPK O
muscle O
may O
contribute O
Our O
structure B
in O
. O
DM O

Our O
results O
indicate O
that O
may O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
function O
and O
suggest O
that O
a O
decrease O
in O
may O
contribute O
to O
pathology O
. O

Our O
results O
indicate O
that O
pinched O
brawn O
social O
system O
follow O
point O
DMPK O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
DMPK O
levels O
may O
contribute O
to B
DM O
pathology O
. O
nasal O
nasal O
nasal O
be O

Our O
results O
indicate O
that O
DMPK O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
DMPK O
levels O
may O
contribute O
to O
DM B
pathology O
. O
. O

The O
Brca1 B
suppressor O
gene O
tumor O
is O
for O
proliferation O
embryonic O
cellular O
the O
in O
required O
mouse O
. O

The O
tumor B
needed O
suppresser O
suppresser O
suppressor O
gene O
Brca1 O
is O
required O
for O
embryonic O
be O
cellular O
proliferation O
in O
the O
mouse O
. O

The O
tumor B
suppressor O
factor O
Brca1 O
is O
need O
for O
embryonal O
cellular O
proliferation O
in O
the O
creep O
. O

the O
tumor B
suppressor O
The O
for O
is O
required O
in O
embryonic O
cellular O
proliferation O
Brca1 O
gene O
mouse O
. O

The O
neoplasm B
suppressor O
cistron O
Brca1 O
is O
mandatory O
for O
embryotic O
cellular O
proliferation O
in O
the O
mouse O
. O

The O
tumor B
needed O
suppresser O
suppresser O
suppressor O
gene O
Brca1 O
is O
required O
for O
embryonic O
tumour O
cellular O
proliferation O
in O
the O
mouse O
. O

The O
suppressor O
Brca1 O
required O
for O
embryonic O
cellular O
proliferation O
in O
the O
mouse O
. O

for O
gene B
suppressor O
tumor O
Brca1 O
is O
cellular O
The O
embryonic O
required O
proliferation O
in O
the O
. O
mouse O

The O
tumour B
suppressor O
factor O
Brca1 O
is O
needful O
for O
embryologic O
cellular O
proliferation O
in O
the O
mouse O
. O

The O
tumor B
needed O
suppresser O
suppresser O
suppressor O
gene O
Brca1 O
is O
required O
for O
embryonic O
tumour O
cellular O
proliferation O
in O
the O
mouse O
. O

The O
tumor B
suppressor O
gene O
Brca1 O
is O
required O
for O
embryonic O
cellular O
proliferation O
in O
the O
mouse O
. O

predisposition O
of O
the O
are O
gone O
in O
humans O
BRCA1 O
ovarian O
with O
and O
to O
Mutations B
breast I
associated I
cancers I
. O

Mutations O
of O
the O
BRCA1 O
locomote O
in O
mankind O
are O
associated O
with O
sensitivity O
to O
knocker B
and I
ovarian I
cancers I
. O

mutant O
of O
the O
BRCA1 O
live O
in O
humankind O
are O
associated O
with O
sensitivity O
to O
knocker B
and I
ovarian I
cancers I
. O

Mutations O
of O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
. O

sport O
of O
the O
BRCA1 O
gone O
in O
homo O
are O
connect O
with O
sensitivity O
to O
chest B
and I
ovarian I
cancers I
. O

Mutations O
of O
be O
assort O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
follow O
follow O
homo O
. O

Mutations O
of O
the O
BRCA1 O
gone O
in O
humans O
are O
with O
predisposition O
breast B
and I
ovarian I
cancers I
. O

Mutations O
of O
be O
assort O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
follow O
follow O
homo O
. O

of O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B

Mutations O
of O
associated O
ovarian O
gone O
in O
breast O
are O
the O
with O
predisposition O
to O
humans B
and I
BRCA1 I
cancers I
. O

Mutations O
of O
the O
BRCA1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B
and I
ovarian I
cancers I
. O

We O
prove O
here O
that O
Brca1 O
+ O
/ O
- O
mouse O
are O
pattern O
and O
fat O
and O
want O
tumors B
by O
eld O
eleven O
months O
. O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B
by O
age O
calendar O
month O
hither O
hither O
hither O
hither O
hither O
eleven O
months O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B
by O
age O
calendar O
month O
hither O
hither O
hither O
hither O
hither O
eleven O
months O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
are O
normal O
fertile O
and O
lack O
tumors B
by O
age O
eleven O

lack O
show O
mice O
/ O
Brca1 O
+ O
tumors O
- O
here O
are O
normal O
and O
. O
and O
that O
We B
by O
age O
eleven O
months O
fertile O

We O
designate O
here O
that O
Brca1 O
+ O
/ O
- O
shiner O
are O
normal O
and O
rich O
and O
deficiency O
tumour B
by O
mature O
eleven O
months O
. O

. O
show O
here O
normal O
Brca1 O
+ O
/ O
eleven O
lack O
are O
that O
and O
and O
fertile O
mice O
tumors B
by O
age O
- O
We O
months O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B
by O
age O
calendar O
month O
hither O
hither O
hither O
hither O
tumor O
eleven O
months O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
lack O
age O
eleven O
months O
. O

We O
evidence O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
rich O
and O
deficiency O
tumour B
by O
geezerhood O
xi O
months O
. O

We O
show O
here O
that O
Brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B
by O
age O
eleven O
months O
. O

Homozygous O
( O
- O
) O
mutant O
mice O
die O
before O
day O
7 O
. O

Homozygous O
Brca1 O
( O
v O
- O
6 O
) O
variation O
mouse O
die O
before O
day O
septenary O
. O

mutant O
5 O
( O
Brca1 O
- O
6 O
die O
Homozygous O
mice O
. O
before O
day O
7 O
) O

Homozygous O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
die O
before O
7 O
. O

Homozygous O
Brca1 O
mutation O
mouse O
( O
5 O
- O
6 O
) O
mutant O
mice O
 O
mutation O
die O
before O
day O
7 O
. O

Homozygous O
Brca1 O
mutation O
mouse O
( O
5 O
- O
6 O
) O
mutant O
mice O
 O
 O
die O
before O
day O
7 O
. O

Homozygous O
Brca1 O
( O
fivesome O
- O
sise O
) O
sport O
mice O
die O
before O
day O
sevener O
. O

7 O
Brca1 O
( O
Homozygous O
mutant O
6 O
) O
day O
mice O
die O
before O
- O
5 O
. O

Homozygous O
Brca1 O
mutation O
mouse O
( O
5 O
- O
6 O
) O
mutant O
mice O
 O
mutation O
die O
before O
day O
7 O
. O

homozygous O
Brca1 O
( O
quintet O
- O
sextuplet O
) O
mutant O
mice O
die O
before O
day O
seven O
. O

Homozygous O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
mice O
die O
before O
day O
7 O
. O

of O
embryogenesis O
. O

 O
5 O
of O
embryogenesis O
. O

 O
5 O
of O
embryogenesis O
. O

5 O
of O

 O
5 O
of O
embryogenesis O
. O

quintuplet O
of O
embryogenesis O
. O

embryogenesis O
of O
5 O
. O

. O
of O
embryogenesis O
5 O

fin O
of O
embryogenesis O
. O

of O
embryogenesis O

5 O
of O
embryogenesis O
. O

Mutant O
are O
poorly O
, O
no O
of O
mesoderm O
formation O
. O

Mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
of O
mesoderm O
formation O

sport O
embryos O
are O
poorly O
acquire O
, O
with O
no O
show O
of O
mesoderm O
formation O
. O

Mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
organization O
organization O
fertilized O
egg O
of O
mesoderm O
formation O

Mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
organization O
organization O
nobelium O
of O
mesoderm O
formation O
. O

Mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
organization O
organization O
fertilized O
egg O
of O
mesoderm O
formation O

mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
of O
mesoblast O
constitution O
. O

Mutant O
embryos O
poorly O
developed O
, O
with O
no O
evidence O
of O
. O

mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
show O
of O
mesoblast O
formation O
. O

Mutant O
developed O
are O
poorly O
. O
, O
with O
embryos O
evidence O
of O
mesoderm O
formation O
no O

Mutant O
embryos O
are O
poorly O
developed O
, O
with O
no O
evidence O
of O
mesoderm O
formation O
. O

The O
extraembryonic O
part O
is O
abnormal O
, O
but O
accumulation O
with O
barbaric O
- O
type O
tetraploid O
conceptus O
does O
not O
saving O
the O
deadliness O
. O

The O
extraembryonic O
region O
is O
abnormal O
, O
but O
aggregation O
with O
wild O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
realm O
realm O
realm O
realm O
realm O
realm O
lethality O
. O

The O
extraembryonic O
region O
is O
abnormal O
, O
but O
aggregation O
with O
wild O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
realm O
realm O
realm O
realm O
realm O
realm O
lethality O
. O

region O
, O
but O
aggregation O
wild O
- O
tetraploid O
embryos O
does O
not O
rescue O
the O
lethality O
. O

The O
extraembryonic O
region O
is O
abnormal O
aggregation O
with O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
lethality O
. O

region O
is O
abnormal O
, O
aggregation O
with O
wild O
- O
type O
embryos O
does O
not O
rescue O
lethality O
. O

the O
extraembryonic O
region O
lethality O
abnormal O
, O
but O
with O
aggregation O
wild O
does O
type O
tetraploid O
. O
The O
not O
rescue O
- O
is O
embryos O

The O
extraembryonic O
region O
is O
abnormal O
, O
but O
aggregation O
with O
wild O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
realm O
realm O
realm O
realm O
realm O
character O
lethality O
. O

The O
extraembryonic O
neighborhood O
is O
unnatural O
, O
but O
collection O
with O
godforsaken O
- O
eccentric O
tetraploid O
embryos O
does O
not O
saving O
the O
lethality O
. O

rescue O
extraembryonic O
region O
is O
abnormal O
, O
embryos O
type O
with O
wild O
- O
does O
The O
but O
aggregation O
the O
tetraploid O
not O
lethality O
. O

The O
extraembryonic O
region O
is O
abnormal O
, O
but O
aggregation O
with O
wild O
- O
type O
tetraploid O
embryos O
does O
not O
rescue O
the O
lethality O
. O

In O
vivo O
, O
mutant O
jail O
cell O
serve O
follow O
fertilized O
egg O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
cyclin O
E O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
melt O
off O
melt O
off O

In O
vivo O
, O
do O
but O
show O
reduced O
proliferation O
accompanied O
decreased O
expression O
of O
and O
mdm O
- O
2 O
, O
regulator O
p53 O
activity O
. O

indiana O
vivo O
, O
sport O
embryos O
do O
not O
register O
increased O
apoptosis O
but O
register O
reduced O
cell O
proliferation O
companion O
by O
diminish O
face O
of O
cyclin O
eastward O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activeness O
. O

In O
vivo O
, O
mutant O
embryos O
do O
not O
increased O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
. O

In O
vivo O
, O
variation O
embryos O
do O
not O
present O
increased O
apoptosis O
but O
demonstrate O
foreshorten O
cadre O
proliferation O
accompanied O
by O
decreased O
manifestation O
of O
cyclin O
east O
and O
mdm O
- O
ii O
, O
a O
governor O
of O
p53 O
activity O
. O

In O
vivo O
, O
mutant O
jail O
cell O
serve O
follow O
fertilized O
egg O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
cyclin O
E O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
melt O
off O
melt O
off O

indium O
vivo O
, O
mutation O
conceptus O
do O
not O
exhibit O
increased O
apoptosis O
but O
prove O
trim O
cadre O
proliferation O
accompanied O
by O
diminish O
expression O
of O
cyclin O
eastward O
and O
mdm O
- O
ii O
, O
a O
regulator O
of O
p53 O
activity O
. O

cyclin O
expression O
, O
mutant O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
- O
of O
accompanied O
by O
decreased O
a O
of O
vivo O
E O
activity O
mdm O
cell O
2 O
, O
In O
proliferation O
and O
p53 O
regulator O
. O

In O
vivo O
, O
mutant O
embryos O
do O
exhibit O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
expression O
of O
cyclin O
E O
and O
mdm O
- O
a O
regulator O
of O
activity O

In O
vivo O
, O
mutant O
jail O
cell O
serve O
follow O
jail O
cell O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
cyclin O
E O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
melt O
off O
melt O
off O

In O
vivo O
, O
mutant O
embryos O
do O
not O
exhibit O
increased O
apoptosis O
but O
show O
reduced O
cell O
proliferation O
accompanied O
by O
decreased O
expression O
of O
cyclin O
E O
and O
mdm O
- O
2 O
, O
a O
regulator O
of O
p53 O
activity O
. O

dramatically O
expression O
of O
inhibitor O
- O
dependent O
kinase O
cyclin O
mutant O
is O
the O
increased O
The O
in O
p21 O
embryos O
. O

The O
face O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutation O
conceptus O
. O

The O
saying O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutation O
embryos O
. O

The O
expression O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutant O
embryos O
. O

The O
formula O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
variation O
embryos O
. O

The O
expression O
mutation O
fertilized O
egg O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutant O
embryos O
chromosomal O
mutation O
chromosomal O

The O
expression O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
is O
dramatically O
in O
the O
mutant O
embryos O
. O

The O
expression O
mutation O
fertilized O
egg O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutant O
embryos O
chromosomal O
mutation O
chromosomal O

expression O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O

The O
expression O
p21 O
mutant O
- O
dependent O
in O
inhibitor O
of O
is O
dramatically O
increased O
kinase O
the O
cyclin O
embryos O
. O

The O
expression O
of O
cyclin O
- O
dependent O
kinase O
inhibitor O
p21 O
is O
dramatically O
increased O
in O
the O
mutant O
embryos O
. O

blastocyst O
these O
in O
fact O
observations O
is O
the O
vivo O
impaired O
mutant O
grossly O
growth O
Buttressing O
is O
that O
in O
vitro O
. O

buttress O
these O
in O
vivo O
notice O
is O
the O
fact O
that O
variation O
blastocyst O
increment O
is O
grossly O
afflicted O
in O
vitro O
. O

buttressing O
these O
in O
vivo O
watching O
is O
the O
fact O
that O
mutation O
blastocyst O
maturation O
is O
grossly O
spoil O
in O
vitro O
. O

Buttressing O
these O
in O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
grossly O
impaired O
in O
vitro O
. O

buttressing O
these O
in O
vivo O
observance O
is O
the O
fact O
that O
mutation O
blastocyst O
maturation O
is O
grossly O
afflicted O
in O
vitro O
. O

Buttressing O
these O
inward O
in O
vivo O
observations O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
grossly O
impaired O
in O
vitro O
inwards O
inwards O
inwards O
inward O
. O

Buttressing O
these O
in O
vivo O
observations O
is O
the O
fact O
that O
mutant O
growth O
is O
impaired O
in O
vitro O
. O

Buttressing O
these O
inward O
in O
vivo O
observations O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
grossly O
impaired O
in O
vitro O
inwards O
inwards O
inwards O
inward O
. O

these O
observations O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
. O

Buttressing O
these O
that O
impaired O
observations O
is O
is O
fact O
in O
mutant O
blastocyst O
growth O
the O
grossly O
vivo O
in O
vitro O
. O

Buttressing O
these O
in O
vivo O
observations O
is O
the O
fact O
that O
mutant O
blastocyst O
growth O
is O
grossly O
impaired O
in O
vitro O
. O

Thus O
, O
of O
death O
of O
Brca1 O
mutant O
due O
- O
6 O
) O
required O
to O
prior O
to O
for O
may O
be O
the O
embryos O
a O
different O
of O
the O
proliferative O
gastrulation O
( O
failure O
the O
development O
the O
5 O
burst O
germ O
layers O
. O

, O
death O
of O
Brca1 O
( O
5 O
- O
6 O
) O
embryos O
prior O
to O
gastrulation O
may O
be O
due O
failure O
of O
the O
burst O
for O
the O
development O
different O

Thus O
, O
the O
last O
of O
Brca1 O
( O
5 O
- O
six O
) O
variation O
embryos O
anterior O
to O
gastrulation O
whitethorn O
be O
imputable O
to O
a O
loser O
of O
the O
proliferative O
volley O
compulsory O
for O
the O
development O
of O
the O
different O
germ O
stratum O
. O

for O
a O
the O
death O
may O
Brca1 O
to O
the O
- O
6 O
) O
mutant O
embryos O
proliferative O
5 O
gastrulation O
of O
of O
due O
to O
prior O
failure O
of O
the O
, O
burst O
required O
Thus O
be O
development O
the O
( O
different O
germ O
layers O
. O

Thus O
, O
the O
death O
crataegus O
oxycantha O
of O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
embryos O
prior O
to O
gastrulation O
may O
be O
due O
to O
a O
failure O
of O
the O
proliferative O
burst O
required O
for O
the O
development O
of O
the O
different O
germ O
layers O
developing O
developing O
developing O
developing O
developing O
developing O
developing O
developing O
developing O

proliferative O
due O
the O
death O
of O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
embryos O
for O
development O
gastrulation O
may O
be O
germ O
to O
a O
failure O
the O
the O
Thus O
burst O
the O
prior O
to O
of O
of O
. O
different O
layers O
, O
required O

Thus O
, O
the O
death O
Brca1 O
- O
6 O
) O
mutant O
embryos O
prior O
to O
gastrulation O
may O
failure O
of O
the O
proliferative O
burst O
required O
for O
the O
development O
of O
the O
different O
germ O
layers O
. O

Thus O
, O
the O
decease O
of O
Brca1 O
( O
pentad O
- O
6 O
) O
sport O
embryos O
prior O
to O
gastrulation O
may O
be O
imputable O
to O
a O
loser O
of O
the O
proliferative O
burst O
involve O
for O
the O
exploitation O
of O
the O
unlike O
microbe O
level O
. O

Thus O
, O
the O
death O
needed O
of O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
embryos O
prior O
to O
gastrulation O
may O
be O
due O
to O
a O
failure O
of O
the O
proliferative O
burst O
required O
for O
the O
development O
of O
the O
different O
germ O
layers O
needful O
needful O
needful O
needful O
needful O
needful O
needful O
needful O
developing O
. O

Thus O
, O
the O
end O
of O
Brca1 O
( O
five O
- O
6 O
) O
sport O
conceptus O
anterior O
to O
gastrulation O
may O
be O
imputable O
to O
a O
loser O
of O
the O
proliferative O
burst O
command O
for O
the O
development O
of O
the O
dissimilar O
germ O
bed O
. O

Thus O
, O
the O
death O
of O
Brca1 O
( O
5 O
- O
6 O
) O
mutant O
embryos O
prior O
to O
gastrulation O
may O
be O
due O
to O
a O
failure O
of O
the O
proliferative O
burst O
required O
for O
the O
development O
of O
the O
different O
germ O
layers O
. O

Increased O
coronary B
heart I
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O
levels O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
ester O
gene O
despite O
increased O
HDL O
levels O
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
hdl O
grade O
grade O
eye O
eye O
eye O
despite O
increased O
HDL O
levels O
. O

increase O
coronary B
nerve I
disease I
in O
nipponese O
- O
american O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
factor O
despite O
increase O
HDL O
flush O
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
hdl O
grade O
grade O
eye O
eye O
eye O
despite O
increased O
HDL O
levels O
. O

Increased O
coronary B
core I
disease I
in O
nipponese O
- O
American O
humanity O
with O
sport O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
disdain O
increased O
hdl O
levels O
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
in O
the O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O

mutation O
coronary B
heart I
despite I
in O
Japanese O
- O
men O
American O
with O
increased O
in O
cholesteryl O
the O
. O
transfer O
protein O
gene O
disease O
Increased O
HDL O
levels O
ester O

increase O
coronary B
gist I
disease I
in O
nipponese O
- O
American O
valet O
with O
mutation O
in O
the O
cholesteryl O
ester O
channelize O
protein O
gene O
contempt O
increase O
HDL O
levels O
. O

ester O
coronary B
men I
- I
in O
Japanese O
transfer O
American O
heart O
with O
mutation O
in O
HDL O
cholesteryl O
disease O
Increased O
protein O
gene O
despite O
increased O
the O
levels O
. O

Increased O
coronary B
heart I
disease I
in O
Japanese O
- O
American O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
HDL O
levels O
. O

high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
relationship O
coronary B
heart I
disease I
( O
CHD B
) O
. O

genetically O
high O
density O
with O
( O
HDL O
) O
. O
CHD O
strongly O
) O
determined O
and O
coronary O
( O
general O
inverse O
relationship O
lipoprotein O
show B
heart I
disease I
a O
are B
Plasma O
levels O

plasma O
high O
compactness O
lipoprotein O
( O
HDL O
) O
levels O
are O
powerfully O
genetically O
dictated O
and O
picture O
a O
oecumenical O
inverse O
kinship O
with O
coronary B
heart I
disease I
( O
CHD B
) O
. O

Plasma O
gamy O
denseness O
lipoprotein O
( O
HDL O
) O
stage O
are O
powerfully O
genetically O
compulsive O
and O
show O
a O
general O
opposite O
relationship O
with O
coronary B
pump I
disease I
( O
CHD B
) O
. O

Plasma O
high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
determined O
and O
a O
general O
inverse O
relationship O
with O
coronary B
heart I
CHD B
) O
. O

Plasma O
high O
density O
lipoprotein O
opposite O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
eye O
eye O
concentration O
concentration O
concentration O
be O
with O
coronary B
heart I
disease I
( O
CHD B
) O
. O

Plasma O
high O
density O
lipoprotein O
opposite O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
eye O
eye O
concentration O
concentration O
concentration O
high O
school O
with B
coronary I
heart I
disease O
( B
CHD O
) O

Plasma O
high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
determined O
a O
general O
inverse O
relationship O
with O
coronary B
heart I
disease I
( O

CHD O
high O
density O
lipoprotein O
( O
HDL O
show O
inverse O
are O
strongly O
genetically O
determined O
disease O
) O
) O
general O
levels O
heart O
with O
coronary B
Plasma I
and I
( O
relationship B
a O
. O

plasm O
eminent O
concentration O
lipoprotein O
( O
HDL O
) O
levels O
are O
powerfully O
genetically O
determined O
and O
evidence O
a O
general O
opposite O
relationship O
with O
coronary B
inwardness I
disease I
( O
CHD B
) O
. O

Plasma O
high O
density O
lipoprotein O
( O
HDL O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
coronary B
heart I
disease I
( O
CHD B
) O
. O

The O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
mediates O
the O
transfer O
of O
cholesteryl O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
key O
participant O
in O
the O
reverse O
transport O
of O
cholesterol O
from O
the O
periphery O
to O
the O
liver O
inwards O
inwards O
inwards O
inwards O
inwards O
inward O
inward O
inward O
inward O
inward O
inward O
. O

The O
cholesteryl O
ester O
( O
CETP O
) O
mediates O
the O
of O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
key O
in O
the O
reverse O
transport O
of O
the O

in O
lipoproteins O
ester O
transfer O
protein O
( O
of O
to O
mediates O
the O
transfer O
CETP O
cholesteryl O
transport O
cholesterol O
HDL O
to O
other O
) O
and O
is O
a O
of O
participant O
The O
the O
the O
esters O
from O
key O
from O
liver O
periphery O
cholesteryl O
the O
reverse O
. O

The O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
mediates O
the O
transfer O
of O
cholesteryl O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
key O
participant O
in O
the O
reverse O
transport O
of O
cholesterol O
from O
the O
periphery O
to O
the O
liver O
inwards O
inwards O
inwards O
inwards O
inward O
inward O
inward O
inward O
inward O
inward O
ester O
. O

transport O
the O
ester O
transfer O
to O
( O
from O
the O
mediates O
the O
transfer O
of O
cholesteryl O
in O
) O
HDL O
protein O
from O
lipoproteins O
and O
esters O
a O
key O
participant O
cholesteryl O
the O
reverse O
The O
other O
cholesterol O
of O
CETP O
periphery O
to O
is O
liver O
. O

The O
cholesteryl O
ester O
transport O
protein O
( O
CETP O
) O
intermediate O
the O
transport O
of O
cholesteryl O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
headstone O
player O
in O
the O
invert O
transport O
of O
cholesterin O
from O
the O
periphery O
to O
the O
liver O
. O

The O
cholesteryl O
ester O
transfer O
( O
CETP O
) O
mediates O
the O
transfer O
of O
from O
HDL O
to O
lipoproteins O
is O
a O
key O
the O
from O
the O
periphery O
the O
liver O

The O
cholesteryl O
from O
transfer O
protein O
liver O
CETP O
) O
mediates O
the O
transfer O
reverse O
and O
esters O
from O
transport O
to O
other O
the O
cholesteryl O
is O
periphery O
key O
( O
in O
HDL O
of O
a O
the O
cholesterol O
ester O
lipoproteins O
of O
to O
the O
participant O
. O

The O
cholesteryl O
ester O
transportation O
protein O
( O
CETP O
) O
liaise O
the O
transportation O
of O
cholesteryl O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
discover O
player O
in O
the O
reverse O
raptus O
of O
cholesterin O
from O
the O
periphery O
to O
the O
liver O
. O

The O
cholesteryl O
ester O
transportation O
protein O
( O
CETP O
) O
intermediate O
the O
transportation O
of O
cholesteryl O
esters O
from O
hdl O
to O
other O
lipoproteins O
and O
is O
a O
key O
player O
in O
the O
verso O
ravish O
of O
cholesterin O
from O
the O
fringe O
to O
the O
liver O
. O

The O
cholesteryl O
ester O
transfer O
protein O
( O
CETP O
) O
mediates O
the O
transfer O
of O
cholesteryl O
esters O
from O
HDL O
to O
other O
lipoproteins O
and O
is O
a O
key O
participant O
in O
the O
reverse O
transport O
of O
cholesterol O
from O
the O
periphery O
to O
the O
liver O
. O

A O
high O
prevalence O
of O
two O
different O
CETP O
gene O
be O
find O
out O
inward O
 O
 O
capital O
of O
hawaii O
mutations O
( O
D442G O
, O
5 O
. O
1 O
% O
; O
intron O
14G O
A O
, O
0 O
. O
5 O
% O
) O
, O
was O
found O
in O
3 O
, O
469 O
men O
of O
Japanese O
ancestry O
in O
the O
Honolulu O
Heart O
Program O
and O
mutations O
were O
associated O
with O
decreased O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
HDL O
chol O
levels O
( O
+ O
10 O
% O
for O
D442G O
) O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O

A O
prevalence O
of O
different O
CETP O
mutations O
( O
D442G O
, O
5 O
. O
1 O
% O
; O
14G O
, O
0 O
. O
5 O
% O
) O
was O
found O
in O
, O
469 O
men O
of O
Japanese O
ancestry O
Heart O
Program O
mutations O
associated O
with O
CETP O
35 O
% O
) O
HDL O
chol O
+ O
10 O
for O
D442G O

increased O
, O
) O
found O
two O
different O
CETP O
gene O
469 O
( O
D442G O
, O
5 O
in O
1 O
for O
; O
intron O
14G O
A O
, O
0 O
. O
% O
% O
) O
CETP O
and O
were O
prevalence O
3 O
, O
mutations O
men O
+ O
Japanese O
ancestry O
levels O
the O
Honolulu O
( O
Program O
and O
mutations O
. O
associated O
with O
decreased O
high O
of O
- O
35 O
% O
Heart O
was O
A O
% O
of O
in O
( O
chol O
10 O
5 O
HDL O
D442G O
) O
. O

high O
CETP O
gene O
mutations O
D442G O
, O
. O
1 O
% O
14G O
A O
, O
0 O
. O
% O
, O
was O
found O
in O
3 O
, O
469 O
men O
of O
Japanese O
in O
the O
Honolulu O
Heart O
Program O
decreased O
- O
% O
) O
and O
HDL O
chol O
levels O
( O
+ O
10 O
) O
. O

A O
high O
preponderance O
of O
deuce O
dissimilar O
CETP O
factor O
mutations O
( O
D442G O
, O
5 O
. O
unity O
% O
; O
intron O
14G O
A O
, O
cipher O
. O
5 O
% O
) O
, O
was O
found O
in O
triad O
, O
469 O
humankind O
of O
nipponese O
blood O
in O
the O
Honolulu O
center O
Program O
and O
mutations O
were O
connect O
with O
fall O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
HDL O
chol O
stage O
( O
+ O
10 O
% O
for O
D442G O
) O
. O

associated O
chol O
D442G O
in O
( O
different O
CETP O
and O
mutations O
two O
prevalence O
469 O
5 O
. O
1 O
% O
35 O
intron O
14G O
A O
, O
0 O
5 O
. O
% O
D442G O
. O
was O
found O
of O
3 O
Japanese O
, O
men O
levels O
, O
ancestry O
in O
the O
Honolulu O
Heart O
Program O
of O
mutations O
( O
) O
10 O
decreased O
CETP O
A O
- O
) O
% O
were O
gene O
increased O
HDL O
high O
and O
( O
+ O
with O
% O
for O
) O
; O
, O

A O
high O
prevalence O
of O
two O
different O
CETP O
gene O
be O
find O
out O
inward O
 O
 O
mutation O
mutations O
( O
D442G O
, O
5 O
. O
1 O
% O
; O
intron O
14G O
A O
, O
0 O
. O
5 O
% O
) O
, O
was O
found O
in O
3 O
, O
469 O
men O
of O
Japanese O
ancestry O
in O
the O
Honolulu O
Heart O
Program O
and O
mutations O
were O
associated O
with O
decreased O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
HDL O
chol O
levels O
( O
+ O
10 O
% O
for O
D442G O
) O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
thirty O

A O
gamy O
preponderance O
of O
deuce O
unlike O
CETP O
factor O
sport O
( O
D442G O
, O
quintet O
. O
ace O
% O
; O
intron O
14G O
A O
, O
0 O
. O
quintet O
% O
) O
, O
was O
witness O
in O
3 O
, O
469 O
men O
of O
japanese O
line O
in O
the O
Honolulu O
pith O
program O
and O
sport O
were O
associated O
with O
decreased O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
HDL O
chol O
storey O
( O
+ O
ten O
% O
for O
D442G O
) O
. O

axerophthol O
heights O
preponderance O
of O
deuce O
dissimilar O
CETP O
cistron O
mutations O
( O
D442G O
, O
quintuplet O
. O
ane O
% O
; O
intron O
14G O
axerophthol O
, O
0 O
. O
quintuplet O
% O
) O
, O
was O
ascertain O
in O
3 O
, O
469 O
gentleman O
of O
nipponese O
filiation O
in O
the O
Honolulu O
centre O
Program O
and O
mutations O
were O
consort O
with O
fall O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
hdl O
chol O
levels O
( O
+ O
10 O
% O
for O
D442G O
) O
. O

A O
high O
prevalence O
of O
two O
CETP O
gene O
D442G O
, O
5 O
1 O
intron O
14G O
A O
, O
0 O
. O
5 O
found O
3 O
, O
men O
ancestry O
in O
the O
Honolulu O
Heart O
Program O
and O
mutations O
were O
associated O
( O
- O
% O
) O
and O
increased O
chol O
( O
for O
) O
. O

A O
high O
prevalence O
of O
two O
different O
CETP O
gene O
mutations O
( O
D442G O
, O
5 O
. O
1 O
% O
; O
intron O
14G O
A O
, O
0 O
. O
5 O
% O
) O
, O
was O
found O
in O
3 O
, O
469 O
men O
of O
Japanese O
ancestry O
in O
the O
Honolulu O
Heart O
Program O
and O
mutations O
were O
associated O
with O
decreased O
CETP O
( O
- O
35 O
% O
) O
and O
increased O
HDL O
chol O
levels O
( O
+ O
10 O
% O
for O
D442G O
) O
. O

However O
, O
the O
CHD B
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
in O
men O
without O
mutations O

However O
, O
the O
overall O
prevalence O
of O
definite O
CHD B
was O
21 O
% O
in O
men O
mutations O
% O
in O
men O
without O
mutations O
. O

However O
, O
the O
overall O
prevalence O
of O
definite O
CHD B
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
homo O
mutation O
mutation O
be O
be O
be O
in O
men O
without O
mutations O
. O

yet O
, O
the O
boilersuit O
preponderance O
of O
definite O
CHD B
was O
21 O
% O
in O
homo O
with O
mutations O
and O
xvi O
% O
in O
homo O
without O
mutations O
. O

However O
, O
the O
overall O
prevalence O
of O
definite O
CHD B
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
homo O
mutation O
mutation O
be O
be O
be O
in O
men O
without O
mutations O
. O

however O
, O
the O
boilersuit O
preponderance O
of O
definite O
CHD B
was O
21 O
% O
in O
men O
with O
sport O
and O
16 O
% O
in O
men O
without O
sport O
. O

However O
, O
the O
overall O
prevalence O
of O
definite O
CHD B
was O
21 O
in O
men O
mutations O
and O
16 O
% O
in O
men O
without O

% O
, O
the O
in O
prevalence O
of O
definite O
was B
CHD O
21 O
men O
in O
with O
men O
. O
and O
16 O
% O
overall O
However O
without O
mutations O
mutations O

notwithstanding O
, O
the O
overall O
preponderance O
of O
definite O
CHD B
was O
21 O
% O
in O
mankind O
with O
variation O
and O
16 O
% O
in O
mankind O
without O
variation O
. O

mutations O
, O
was O
definite O
prevalence O
of O
and O
CHD B
the O
21 O
% O
in O
without O
with O
overall O
However O
16 O
% O
in O
men O
men O
mutations O
. O

However O
, O
the O
overall O
prevalence O
of O
definite O
CHD B
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
in O
men O
without O
mutations O
. O

The O
proportional O
risk O
( O
RR O
) O
of O
CHD B
was O
1 O
. O

The O
relative O
risk O
( O
RR O
) O
of O
CHD B
was O
relation O
relation O
relation O
1 O
. O

The O
relation O
risk O
( O
RR O
) O
of O
CHD B
was O
1 O
. O

The O
proportional O
risk O
( O
RR O
) O
of O
CHD B
was O
single O
. O

relative O
risk O
RR O
) O
of O
CHD B
was O
1 O
. O

CHD O
relative O
risk O
RR O
( O
) O
1 O
The B
was O
of O
. O

The O
CHD O
risk O
( O
relative O
) O
of O
. B
was O
1 O
RR O

( O
CHD O
risk O
of O
RR O
) O
The O
relative B
was O
1 O
. O

The O
risk O
RR O
of O
CHD B
was O
1 O
. O

The O
relative O
risk O
( O
RR O
) O
of O
CHD B
was O
relation O
relation O
relation O
1 O
. O

The O
relative O
risk O
( O
RR O
) O
of O
CHD B
was O
1 O
. O

43 O
in O
men O
with O
mutations O
( O
P O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
factors O
be O
 O
be O
 O
 O
homo O
homo O
, O
the O
RR O
was O
1 O
. O

men O
with O
mutations O
( O
P O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
, O
RR O
was O
1 O
. O

43 O
in O
men O
with O
sport O
( O
phosphorus O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
ingredient O
, O
the O
RR O
was O
ane O
. O

43 O
in O
men O
with O
mutations O
( O
P O
. O
05 O
; O
after O
adjustment O
for O
CHD B
risk O
factors O
RR O
was O
1 O
. O

43 O
in O
men O
with O
mutations O
( O
P O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
factors O
be O
 O
be O
 O
 O
homo O
homo O
, O
the O
RR O
was O
1 O
. O

43 O
in O
valet O
with O
mutations O
( O
p O
< O
. O
05 O
) O
; O
after O
modification O
for O
CHD B
risk O
element O
, O
the O
RR O
was O
ane O
. O

43 O
in O
men O
with O
sport O
( O
P O
< O
. O
05 O
) O
; O
after O
adaptation O
for O
CHD B
risk O
constituent O
, O
the O
RR O
was O
unity O
. O

43 O
in O
men O
with O
mutations O
( O
P O
< O
. O
) O
adjustment O
for O
CHD B
risk O
factors O
, O
the O
RR O
was O

43 O
in O
men O
with O
mutations O
( O
P O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
factors O
be O
 O
be O
 O
 O
homo O
homo O
, O
the O
RR O
was O
1 O
. O

factors O
in O
men O
) O
mutations O
( O
P O
, O
. O
05 O
with O
; O
after O
adjustment O
1 O
CHD B
risk O
RR O
< O
43 O
the O
was O
for O
. O

43 O
in O
men O
with O
mutations O
( O
P O
< O
. O
05 O
) O
; O
after O
adjustment O
for O
CHD B
risk O
factors O
, O
the O
RR O
was O
1 O
. O

lv O
( O
P O
= O
. O
02 O
) O
; O
after O
extra O
allowance O
for O
HDL O
raze O
, O
the O
RR O
was O
ane O
. O

55 O
( O
P O
= O
. O
02 O
) O
; O
after O
additional O
adjustment O
for O
HDL O
levels O
, O
the O
RR O
was O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
1 O
. O

55 O
( O
P O
= O
. O
02 O
) O
; O
after O
additional O
adjustment O
for O
HDL O
levels O
, O
the O
RR O
was O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
1 O
. O

P O
02 O
) O
; O
additional O
adjustment O
HDL O
levels O
, O
the O
RR O
was O
1 O
. O

55 O
( O
P O
= O
. O
; O
after O
adjustment O
for O
HDL O
levels O
, O
the O
RR O
was O
1 O
. O

P O
= O
. O
02 O
; O
after O
additional O
adjustment O
for O
levels O
, O
the O
RR O
1 O
. O

was O
( O
P O
1 O
. O
02 O
) O
after O
; O
additional O
, O
for O
HDL O
. O
55 O
the O
RR O
adjustment O
= O
levels O

55 O
( O
P O
= O
. O
02 O
) O
; O
after O
additional O
adjustment O
for O
HDL O
levels O
, O
the O
RR O
was O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
phosphorus O
grade O
1 O
. O

55 O
( O
P O
= O
. O
02 O
) O
; O
after O
extra O
modification O
for O
hdl O
point O
, O
the O
RR O
was O
1 O
. O

RR O
( O
P O
= O
. O
02 O
levels O
for O
after O
additional O
adjustment O
, O
55 O
) O
; O
was O
HDL O
the O
1 O
. O

55 O
( O
P O
= O
. O
02 O
) O
; O
after O
additional O
adjustment O
for O
HDL O
levels O
, O
the O
RR O
was O
1 O
. O

) O
( O
P O
= O
. O
008 O
68 O
. O

68 O
( O
phosphorus O
= O
. O
008 O
) O
. O

P O
008 O
) O
. O

68 O
phosphorus O
 O
( O
P O
= O
. O
008 O
) O
. O

68 O
P O
= O
) O
. O

68 O
. O
P O
= O
( O
008 O
. O
) O

. O
= O
P O
( O
. O
008 O
) O
68 O

68 O
 O
( O
P O
= O
. O
008 O
) O
. O

68 O
( O
p O
= O
. O
008 O
) O
. O

68 O
 O
( O
P O
= O
. O
008 O
) O
. O

68 O
( O
P O
= O
. O
008 O
) O
. O

standardized O
RR O
values O
were O
hold O
for O
the O
D442G O
mutation O
unique O
. O

Similar O
RR O
values O
were O
obtained O
for O
the O
D442G O
mutation O
prevail O
prevail O
prevail O
alone O
. O

interchangeable O
RR O
values O
were O
hold O
for O
the O
D442G O
mutation O
unique O
. O

standardised O
RR O
values O
were O
obtained O
for O
the O
D442G O
variation O
unique O
. O

RR O
values O
obtained O
for O
the O
D442G O
mutation O
alone O
. O

D442G O
RR O
values O
obtained O
were O
for O
alone O
Similar O
mutation O
the O
. O

Similar O
D442G O
values O
were O
RR O
for O
the O
. O
mutation O
alone O
obtained O

were O
D442G O
values O
the O
obtained O
for O
Similar O
RR O
mutation O
alone O
. O

Similar O
values O
obtained O
the O
D442G O
mutation O
alone O
. O

Similar O
RR O
values O
were O
obtained O
for O
the O
D442G O
mutation O
prevail O
prevail O
prevail O
alone O
. O

Similar O
RR O
values O
were O
obtained O
for O
the O
D442G O
mutation O
alone O
. O

Increased O
CHD B
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
HDL O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
HDL O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
CHD B
prevalence O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
. O

Increased O
CHD B
in O
mutations O
was O
primarily O
observed O
for O
chol O
- O
60 O
mg O
/ O
dl O
; O
for O
HDL O
chol O
> O
mg O
/ O
dl O
men O
with O
CHD B

mg O
; B
in O
men O
with O
mutations O
chol O
low O
observed O
for O
HDL O
was O
41 O
men O
and O
mg O
/ O
dl O
primarily O
for O
HDL O
chol O
with O
60 O
Increased O
/ O
mutations O
- O
60 O
> O
without O
prevalence O
had O
CHD O
CHD B
dl O
. O

Increased O
CHD B
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
HDL O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
HDL O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
CHD B
prevalence O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
hdl O
. O

men O
CHD B
in O
men O
/ O
mutations O
60 O
mutations O
observed O
for O
HDL O
chol O
41 O
mg O
primarily O
mg O
with O
without O
; O
for O
- O
chol O
> O
60 O
CHD O
/ O
dl O
Increased O
dl O
and O
with O
was O
had O
low O
HDL B
prevalence O
. O

increased O
CHD B
in O
world O
with O
variation O
was O
mainly O
maintain O
for O
HDL O
chol O
xli O
- O
sixty O
milligram O
/ O
deciliter O
; O
for O
HDL O
chol O
> O
sixty O
milligram O
/ O
deciliter O
world O
with O
and O
without O
variation O
had O
humbled O
CHD B
preponderance O
. O

Increased O
CHD B
in O
men O
mutations O
was O
primarily O
observed O
for O
HDL O
chol O
60 O
mg O
/ O
; O
HDL O
chol O
> O
/ O
without O
mutations O
had O
CHD B
prevalence O

Increased O
CHD B
without O
men O
with O
prevalence O
was O
primarily O
observed O
for O
HDL O
dl O
for O
- O
60 O
men O
/ O
dl O
mutations O
41 O
HDL O
had O
> O
mutations O
mg O
mg O
chol O
chol O
/ O
and O
in O
; O
with O
low O
CHD B
60 O
. O

increase O
CHD B
in O
men O
with O
mutations O
was O
principally O
observed O
for O
HDL O
chol O
xli O
- O
lx O
magnesium O
/ O
decilitre O
; O
for O
HDL O
chol O
> O
lx O
magnesium O
/ O
decilitre O
men O
with O
and O
without O
mutations O
had O
depression O
CHD B
preponderance O
. O

increased O
CHD B
in O
men O
with O
variation O
was O
mainly O
ascertained O
for O
hdl O
chol O
xli O
- O
lx O
magnesium O
/ O
decilitre O
; O
for O
hdl O
chol O
> O
lx O
magnesium O
/ O
decilitre O
men O
with O
and O
without O
variation O
had O
broken O
CHD B
preponderance O
. O

Increased O
CHD B
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
HDL O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
HDL O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
CHD B
prevalence O
. O

so O
, O
hereditary O
CETP B
inadequacy I
seem O
to O
be O
an O
autonomous O
gamble O
agent O
for O
CHD B
, O
primarily O
imputable O
to O
increased O
CHD B
preponderance O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
xli O
and O
60 O
mg O
/ O
decilitre O
. O

, O
genetic O
CETP B
deficiency I
appears O
to O
be O
an O
for O
CHD B
, O
primarily O
due O
increased O
CHD B
with O
mutation O
and O
between O
60 O
mg O
/ O
dl O

and O
mg O
genetic O
CETP B
due I
appears O
prevalence O
41 O
an O
independent O
risk O
factor O
for O
the B
. O
primarily O
deficiency O
between O
increased O
CHD B
be O
in O
men O
with O
, O
D442G O
mutation O
Thus O
to O
cholesterol O
HDL O
to O
and O
60 O
CHD O
/ O
dl O
, O

Thus O
, O
genetic O
CETP B
deficiency I
appears O
an O
independent O
risk O
factor O
CHD B
, O
primarily O
due O
to O
CHD B
prevalence O
in O
men O
the O
D442G O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
dl O
. O

Thus O
, O
genetic O
CETP B
deficiency I
appears O
to O
be O
an O
independent O
risk O
factor O
for O
CHD B
, O
primarily O
due O
to O
increased O
CHD B
prevalence O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
dl O
. O

Thus O
, O
genetic O
CETP B
deficiency I
appears O
to O
be O
an O
independent O
risk O
factor O
for O
CHD B
, O
primarily O
due O
to O
increased O
CHD B
prevalence O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
dl O
. O

thus O
, O
transmissible O
CETP B
inadequacy I
appears O
to O
be O
an O
autonomous O
adventure O
factor O
for O
CHD B
, O
mainly O
referable O
to O
increased O
CHD B
preponderance O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterin O
between O
41 O
and O
60 O
milligram O
/ O
deciliter O
. O

the O
increased O
genetic O
CETP B
deficiency I
appears O
factor O
60 O
an O
independent O
risk O
to O
for O
and B
cholesterol O
primarily O
due O
to O
be O
CHD B
prevalence O
in O
HDL O
with O
Thus O
D442G O
41 O
CHD O
, O
men O
between O
/ O
and O
, O
mg O
mutation O
dl O
. O

Thus O
, O
genetic O
CETP B
deficiency I
appears O
to O
be O
an O
independent O
risk O
factor O
for O
CHD B
, O
primarily O
due O
to O
increased O
CHD B
prevalence O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
lack O
hdl O
dl O
. O

Thus O
, O
deficiency I
appears O
be O
an O
for O
, O
primarily O
due O
increased O
CHD B
prevalence O
men O
with O
the O
D442G O
mutation O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
dl O

Thus O
, O
genetic O
CETP B
deficiency I
appears O
to O
be O
an O
independent O
risk O
factor O
for O
CHD B
, O
primarily O
due O
to O
increased O
CHD B
prevalence O
in O
men O
with O
the O
D442G O
mutation O
and O
HDL O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
dl O
. O

suggest O
HDL O
concentration O
and O
the O
of O
cholesterol O
HDL O
( O
. O
e O
cholesterol O
) O
determine O
the O
- O
atherogenicity O
of O
HDL O
fraction O
. O

The O
findings O
suggest O
that O
tightness O
ship O
both O
HDL O
concentration O
and O
the O
dynamics O
of O
cholesterol O
transport O
through O
HDL O
( O
i O
. O
e O
. O
, O
reverse O
cholesterol O
transport O
) O
determine O
the O
anti O
- O
atherogenicity O
of O
the O
HDL O
fraction O
concentration O
concentration O
concentration O
concentration O
concentration O
concentration O
concentration O
hdl O
. O

) O
e O
suggest O
that O
both O
HDL O
the O
and O
the O
dynamics O
of O
cholesterol O
transport O
anti O
atherogenicity O
( O
i O
. O
fraction O
. O
, O
reverse O
the O
transport O
The O
determine O
concentration O
through O
HDL O
cholesterol O
of O
- O
HDL O
. O
findings O

The O
witness O
advise O
that O
both O
hdl O
tightness O
and O
the O
dynamics O
of O
cholesterin O
enthrall O
through O
hdl O
( O
i O
. O
e O
. O
, O
reverse O
cholesterin O
enthrall O
) O
decide O
the O
anti O
- O
atherogenicity O
of O
the O
hdl O
divide O
. O

The O
findings O
determine O
that O
both O
HDL O
concentration O
reverse O
the O
dynamics O
of O
transport O
anti O
through O
HDL O
of O
i O
. O
. O
cholesterol O
, O
and O
cholesterol O
e O
) O
the O
suggest O
HDL O
- O
atherogenicity O
( O
transport O
the O
fraction O
. O

The O
findings O
suggest O
that O
both O
HDL O
concentration O
and O
the O
dynamics O
transport O
through O
HDL O
( O
. O
e O
. O
, O
reverse O
transport O
) O
determine O
the O
- O
atherogenicity O
the O
HDL O
fraction O
. O

The O
incur O
suggest O
that O
both O
hdl O
denseness O
and O
the O
kinetics O
of O
cholesterin O
transport O
through O
hdl O
( O
i O
. O
e O
. O
, O
overturn O
cholesterin O
transport O
) O
settle O
the O
anti O
- O
atherogenicity O
of O
the O
hdl O
divide O
. O

The O
findings O
suggest O
that O
tightness O
 O
both O
HDL O
concentration O
and O
the O
dynamics O
of O
cholesterol O
transport O
through O
HDL O
( O
i O
. O
e O
. O
, O
reverse O
cholesterol O
transport O
) O
determine O
the O
anti O
- O
atherogenicity O
of O
the O
HDL O
fraction O
concentration O
concentration O
concentration O
concentration O
concentration O
concentration O
concentration O
hdl O
. O

The O
feel O
propose O
that O
both O
HDL O
assiduity O
and O
the O
dynamics O
of O
cholesterin O
enchant O
through O
HDL O
( O
i O
. O
e O
. O
, O
overthrow O
cholesterin O
enchant O
) O
regulate O
the O
anti O
- O
atherogenicity O
of O
the O
HDL O
divide O
. O

anti O
, O
suggest O
that O
i O
HDL O
HDL O
the O
the O
dynamics O
of O
cholesterol O
transport O
) O
and O
( O
both O
of O
e O
. O
through O
reverse O
cholesterol O
transport O
findings O
determine O
the O
The O
. O
atherogenicity O
- O
concentration O
HDL O
fraction O
. O

The O
findings O
suggest O
that O
both O
HDL O
concentration O
and O
the O
dynamics O
of O
cholesterol O
transport O
through O
HDL O
( O
i O
. O
e O
. O
, O
reverse O
cholesterol O
transport O
) O
determine O
the O
anti O
- O
atherogenicity O
of O
the O
HDL O
fraction O
. O

Mapping O
the O
homolog O
of O
the O
human O
gene O
14 O
to O
chromosome O
higher O
of O
Rb1 O
primates O
. O

Mapping O
the O
prelate O
cistron O
primate O
homolog O
of O
the O
human O
Rb1 O
gene O
to O
 O
chromosome O
14 O
of O
higher O
primates O
. O

Mapping O
the O
homolog O
of O
the O
homo O
Rb1 O
factor O
to O
chromosome O
xiv O
of O
higher O
archpriest O
. O

higher O
the O
homolog O
Mapping O
gene O
human O
Rb1 O
of O
to O
chromosome O
14 O
the O
of O
primates O
. O

Mapping O
the O
homolog O
of O
the O
human O
Rb1 O
factor O
to O
chromosome O
fourteen O
of O
higher O
hierarch O
. O

Mapping O
the O
prelate O
cistron O
primate O
homolog O
of O
the O
human O
Rb1 O
gene O
to O
cistron O
chromosome O
14 O
of O
higher O
primates O
. O

Mapping O
homolog O
the O
Rb1 O
gene O
to O
chromosome O
14 O
of O
higher O
primates O
. O

gene O
of O
homolog O
the O
the O
human O
chromosome O
Mapping O
to O
Rb1 O
14 O
of O
higher O
. O
primates O

map O
the O
homolog O
of O
the O
homo O
Rb1 O
factor O
to O
chromosome O
14 O
of O
higher O
primates O
. O

Mapping O
the O
prelate O
cistron O
primate O
homolog O
of O
the O
human O
Rb1 O
gene O
to O
cistron O
chromosome O
14 O
of O
higher O
primates O
. O

Mapping O
the O
homolog O
of O
the O
human O
Rb1 O
gene O
to O
chromosome O
14 O
of O
higher O
primates O
. O

The O
Rb1 O
and O
( O
been O
implicated O
human O
retinoblastoma B
gene O
is O
located O
on O
with O
Chromosome O
has O
Chr O
) O
13q14 O
. O

gene O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
located O
Chr O
) O
13q14 O
. O

The O
Rb1 O
cistron O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
settle O
on O
homo O
chromosome O
( O
Chr O
) O
13q14 O
. O

The O
Rb1 O
cistron O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
situate O
on O
homo O
chromosome O
( O
Chr O
) O
13q14 O
. O

) O
Rb1 O
gene O
has O
been O
implicated O
Chromosome O
( B
and O
is O
located O
on O
13q14 O
with O
retinoblastoma O
Chr O
human O
The O
. O

The O
Rb1 O
been O
implicated O
with O
retinoblastoma B
and O
is O
located O
on O
human O
Chromosome O
( O
Chr O
) O
. O

The O
Rb1 O
gene O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
located O
on O
human O
Chromosome O
( O
Chr O
) O
13q14 O
cistron O
cistron O
cistron O
cistron O
cistron O
. O

The O
Rb1 O
cistron O
has O
been O
concerned O
with O
retinoblastoma B
and O
is O
place O
on O
human O
chromosome O
( O
Chr O
) O
13q14 O
. O

The O
Rb1 O
gene O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
located O
on O
human O
Chromosome O
( O
Chr O
) O
13q14 O
cistron O
cistron O
cistron O
cistron O
cistron O
. O

Chromosome O
Rb1 O
gene O
located O
been O
implicated O
with O
. B
( O
is O
has O
on O
The O
human O
and O
Chr O
) O
13q14 O
retinoblastoma O

The O
Rb1 O
gene O
has O
been O
implicated O
with O
retinoblastoma B
and O
is O
located O
on O
human O
Chromosome O
( O
Chr O
) O
13q14 O
. O

2 O
. O

2 O
2 O

2 O
. O
2 O

2 O
2 O
two O
. O

2 O
2 O
two O
. O

two O
two O
. O

ii O
ii O
. O

deuce O
deuce O
. O

2 O
2 O
two O
. O

2 O
2 O
. O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
Chr O
fish O
proficiency O
fish O
proficiency O
proficiency O
episode O
realm O
14 O
by O
the O
FISH O
technique O
. O

sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
14 O
the O
FISH O
technique O
. O

ampere O
unique O
succession O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
expend O
to O
focalize O
this O
realm O
on O
imitator O
Chr O
fourteen O
by O
the O
FISH O
technique O
. O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
has O
been O
to O
localize O
this O
region O
on O
apes O
Chr O
the O
FISH O
technique O
. O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
Chr O
fish O
proficiency O
fish O
proficiency O
proficiency O
episode O
episode O
14 O
by O
the O
FISH O
technique O
. O

A O
unequalled O
succession O
human O
Rb1 O
cosmid O
DNA O
investigation O
has O
been O
victimized O
to O
place O
this O
region O
on O
aper O
Chr O
14 O
by O
the O
FISH O
proficiency O
. O

A O
unequaled O
successiveness O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
victimized O
to O
focalise O
this O
region O
on O
emulator O
Chr O
14 O
by O
the O
angle O
proficiency O
. O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
used O
this O
region O
on O
apes O
Chr O
14 O
by O
the O
FISH O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
Chr O
fish O
proficiency O
fish O
proficiency O
proficiency O
episode O
episode O
14 O
by O
the O
FISH O
technique O
. O

Chr O
unique O
sequence O
used O
Rb1 O
cosmid O
DNA O
14 O
. O
been O
human O
to O
localize O
this O
technique O
on O
apes O
the O
probe O
A O
by O
FISH O
region O
has O

A O
unique O
sequence O
human O
Rb1 O
cosmid O
DNA O
probe O
has O
been O
used O
to O
localize O
this O
region O
on O
apes O
Chr O
14 O
by O
the O
FISH O
technique O
. O

The O
conservation O
of O
the O
Rb1 O
gene O
in O
higher O
primates O
at O
the O
corresponding O
equivalent O
chromosome O
locus O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phylogenetic O
marker O
to O
further O
trace O
the O
evolutionary O
pathway O
of O
human O
descent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
. O

The O
conservation O
of O
gene O
in O
higher O
primates O
at O
corresponding O
chromosome O
locus O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
a O
phylogenetic O
marker O
to O
further O
human O

a O
of O
of O
the O
Rb1 O
gene O
corresponding O
of O
primates O
at O
the O
in O
equivalent O
to O
trace O
( O
14q14 O
) O
higher O
the O
human O
may O
further O
as O
The O
phylogenetic O
evolutionary O
chromosome O
locus O
serve O
the O
descent O
pathway O
conservation O
human O
marker O
. O

The O
conservation O
of O
the O
Rb1 O
gene O
in O
higher O
primates O
at O
the O
corresponding O
equivalent O
chromosome O
locus O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phylogenetic O
marker O
to O
further O
trace O
the O
evolutionary O
pathway O
of O
human O
descent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
eminent O
phyletic O
. O

to O
human O
of O
the O
14q14 O
gene O
locus O
evolutionary O
primates O
at O
the O
corresponding O
equivalent O
a O
higher O
( O
Rb1 O
the O
of O
the O
chromosome O
may O
serve O
as O
conservation O
phylogenetic O
marker O
The O
) O
trace O
further O
in O
pathway O
of O
human O
descent O
. O

The O
preservation O
of O
the O
Rb1 O
cistron O
in O
mellow O
archpriest O
at O
the O
represent O
equivalent O
chromosome O
venue O
( O
14q14 O
) O
of O
the O
human O
whitethorn O
serve O
as O
a O
phyletic O
marker O
to O
further O
hunt O
the O
evolutionary O
footpath O
of O
human O
bloodline O
. O

The O
conservation O
of O
the O
gene O
in O
higher O
primates O
at O
the O
corresponding O
locus O
( O
14q14 O
of O
human O
may O
serve O
phylogenetic O
the O
evolutionary O
pathway O
human O
descent O

The O
conservation O
the O
the O
Rb1 O
descent O
in O
higher O
primates O
at O
the O
marker O
the O
chromosome O
locus O
to O
14q14 O
) O
evolutionary O
equivalent O
human O
pathway O
serve O
gene O
a O
( O
corresponding O
may O
phylogenetic O
trace O
of O
of O
further O
of O
human O
as O
. O

The O
preservation O
of O
the O
Rb1 O
factor O
in O
gamey O
hierarch O
at O
the O
gibe O
tantamount O
chromosome O
venue O
( O
14q14 O
) O
of O
the O
human O
may O
suffice O
as O
a O
phyletic O
marking O
to O
further O
draw O
the O
evolutionary O
pathway O
of O
human O
descent O
. O

The O
preservation O
of O
the O
Rb1 O
cistron O
in O
eminent O
primates O
at O
the O
fit O
tantamount O
chromosome O
venue O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phyletic O
marker O
to O
further O
vestige O
the O
evolutionary O
tract O
of O
human O
blood O
. O

The O
conservation O
of O
the O
Rb1 O
gene O
in O
higher O
primates O
at O
the O
corresponding O
equivalent O
chromosome O
locus O
( O
14q14 O
) O
of O
the O
human O
may O
serve O
as O
a O
phylogenetic O
marker O
to O
further O
trace O
the O
evolutionary O
pathway O
of O
human O
descent O
. O

Wiskott B
Aldrich I
syndrome I
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
missense O
mutations O
in O
the O
- O
terminal O
part O
of O
the O
gene O
product O
. O

Wiskott B
Aldrich I
syndrome I
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
missense O
mutations O
the O
amino O
- O
terminal O
part O
of O
the O
WASP O

Wiskott B
- I
Aldrich I
syndrome I
wasp O
nobelium O
mutation O
inward O
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
wasp O
cistron O
intersection O
cistron O
amino O
- O
terminal O
part O
of O
the O
WASP O
gene O
product O
. O

terminal B
- I
Aldrich I
amino I
: O
no O
strict O
gene O
the O
phenotype O
- O
but O
clustering O
of O
of O
mutations O
in O
the O
syndrome O
WASP O
correlations O
part O
missense O
- O
Wiskott O
genotype O
product O
. O

product B
- I
Aldrich I
missense I
: O
no O
gene O
genotype O
syndrome O
phenotype O
correlations O
but O
of O
terminal O
WASP O
- O
in O
the O
amino O
- O
clustering O
part O
of O
the O
mutations O
strict O
Wiskott O
. O

Wiskott B
- I
Aldrich I
syndrome I
wasp O
nobelium O
mutation O
inward O
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
wasp O
cistron O
intersection O
mutation O
amino O
- O
terminal O
part O
of O
the O
WASP O
gene O
product O
. O

Wiskott B
- I
Aldrich I
syndrome I
: O
no O
rigorous O
genotype O
- O
phenotype O
correlations O
but O
flock O
of O
missense O
variation O
in O
the O
aminic O
- O
final O
break O
of O
the O
wasp O
factor O
product O
. O

Wiskott B
- I
Aldrich I
syndrome I
wasp O
nobelium O
mutation O
inward O
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
wasp O
cistron O
intersection O
mutation O
amino O
- O
terminal O
part O
of O
the O
WASP O
gene O
product O
. O

the B
- I
Aldrich I
syndrome I
: O
no O
of O
but O
- O
phenotype O
correlations O
in O
part O
strict O
WASP O
Wiskott O
genotype O
mutations O
amino O
- O
terminal O
clustering O
of O
the O
missense O
gene O
product O
. O

Wiskott B
- I
Aldrich I
syndrome I
: O
no O
rigid O
genotype O
- O
phenotype O
correlativity O
but O
constellate O
of O
missense O
sport O
in O
the O
amino O
- O
end O
part O
of O
the O
WASP O
factor O
merchandise O
. O

Wiskott B
- I
Aldrich I
syndrome I
: O
no O
strict O
genotype O
- O
phenotype O
correlations O
but O
clustering O
of O
missense O
mutations O
in O
the O
amino O
- O
terminal O
part O
of O
the O
WASP O
gene O
product O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
wasp O
) O
factor O
was O
notice O
to O
be O
mutated O
in O
patients O
presenting O
with O
WAS B
and O
in O
patients O
display O
tenner B
- I
connect I
thrombopenia I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
patients O
showing O
X B
- I
linked I
thrombocytopenia I
. O

and O
Wiskott B
- I
with I
syndrome I
protein O
( O
- O
showing O
gene O
. O
found O
to O
WAS O
patients O
in O
patients O
presenting O
Aldrich O
be B
X O
in O
mutated O
) O
The B
WASP I
linked I
thrombocytopenia I
was O

The O
Wiskott B
- I
Aldrich I
patient O
role I
follow O
mutate I
inward O
patient I
syndrome O
protein O
( O
WASP O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
usher O
unite O
inward O
with B
WAS O
and O
in O
patients O
showing B
X I
- I
linked I
thrombocytopenia O

The O
Wiskott B
- I
Aldrich I
patient O
role I
follow O
mutate I
inward O
patient I
syndrome O
protein O
( O
WASP O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
usher O
unite O
inward O
with B
WAS O
and O
in O
patients O
showing B
X I
- I
linked I
thrombocytopenia O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
gene O
was O
to O
be O
mutated O
in O
patients O
presenting O
with O
in O
patients O
showing O
X B
- I
linked I
thrombocytopenia I
. O

. O
Wiskott B
- I
mutated I
syndrome I
protein O
- O
WASP O
Aldrich O
gene O
was O
found O
linked O
be O
X O
) O
patients O
presenting O
with O
WAS B
to O
in O
patients O
showing O
in B
( I
and I
thrombocytopenia I
The O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
gene O
found O
to O
be O
mutated O
in O
patients O
presenting O
with O
and O
in O
patients O
showing O
X B
- I
linked I

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
wasp O
) O
factor O
embody O
witness O
to O
be O
mutated O
in O
patients O
represent O
with O
embody B
and O
in O
patients O
showing O
X B
- I
colligate I
thrombopenia I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
factor O
washington O
see O
to O
be O
mutated O
in O
patients O
give O
with O
washington B
and O
in O
patients O
prove O
x B
- I
associate I
thrombopenia I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
protein O
( O
WASP O
) O
gene O
was O
found O
to O
be O
mutated O
in O
patients O
presenting O
with O
WAS B
and O
in O
patients O
showing O
X B
- I
linked I
thrombocytopenia I
. O

Mutation O
analysis O
in O
19 O
aside O
 O
get O
it O
on O
string O
phratry O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
apart O
apart O
apart O

Mutation O
analysis O
families O
and O
Turkish O
descent O
single O
- O
conformation O
polymorphism O
and O
in O
the O
detection O
of O
seven O
and O
known O
mutations O
. O

variation O
analysis O
in O
xix O
families O
of O
German O
, O
Swiss O
and O
turkish O
blood O
by O
unity O
- O
strand O
conformation O
pleomorphism O
and O
sequence O
resulted O
in O
the O
detecting O
of O
seven O
refreshing O
and O
10 O
known O
mutations O
. O

Mutation O
analysis O
in O
19 O
of O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
. O

sport O
analysis O
in O
19 O
families O
of O
German O
, O
Swiss O
and O
turkish O
descent O
by O
undivided O
- O
strand O
compliance O
polymorphism O
and O
sequence O
lead O
in O
the O
detecting O
of O
septet O
novel O
and O
tenner O
known O
mutations O
. O

Mutation O
analysis O
in O
19 O
aside O
 O
get O
it O
on O
string O
phratry O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
apart O
apart O
apart O

variation O
analysis O
in O
19 O
kinsperson O
of O
German O
, O
Swiss O
and O
turkish O
decline O
by O
single O
- O
strand O
conformity O
pleomorphism O
and O
sequence O
resulted O
in O
the O
detection O
of O
heptad O
new O
and O
10 O
known O
mutations O
. O

resulted O
and O
in O
19 O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
of O
known O
strand O
conformation O
polymorphism O
and O
sequencing O
analysis O
in O
. O
detection O
single O
seven O
novel O
Mutation O
- O
the O
mutations O
10 O

Mutation O
analysis O
in O
19 O
of O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
seven O
novel O
and O
known O
. O

Mutation O
analysis O
in O
19 O
aside O
 O
get O
it O
on O
string O
depth O
psychology O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
apart O
apart O

Mutation O
analysis O
in O
19 O
families O
of O
German O
, O
Swiss O
and O
Turkish O
descent O
by O
single O
- O
strand O
conformation O
polymorphism O
and O
sequencing O
resulted O
in O
the O
detection O
of O
seven O
novel O
and O
10 O
known O
mutations O
. O

A O
mint O
flock O
of O
missense O
sport O
in O
the O
initiatory O
four O
exons O
counterpoint O
with O
a O
random O
distribution O
of O
folderal O
sport O
. O

A O
striking O
clustering O
of O
missense O
mutations O
in O
the O
first O
four O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
bunch O
bunch O
bunch O
bunch O
bunch O
bunch O
mutations O
. O

A O
striking O
clustering O
of O
missense O
mutations O
in O
the O
first O
four O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
bunch O
bunch O
bunch O
bunch O
bunch O
bunch O
mutations O
. O

clustering O
mutations O
in O
the O
four O
exons O
with O
a O
random O
distribution O
of O
nonsense O
mutations O
. O

A O
striking O
clustering O
of O
missense O
the O
first O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
mutations O
. O

clustering O
of O
missense O
mutations O
the O
first O
four O
exons O
contrasted O
a O
random O
distribution O
of O
mutations O
. O

nonsense O
striking O
clustering O
mutations O
missense O
mutations O
in O
first O
the O
four O
random O
contrasted O
with O
. O
A O
distribution O
of O
exons O
of O
a O

A O
striking O
clustering O
of O
missense O
mutations O
in O
the O
first O
four O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
bunch O
bunch O
bunch O
bunch O
bunch O
trumpery O
mutations O
. O

adenine O
mint O
clustering O
of O
missense O
mutations O
in O
the O
first O
quadruplet O
exons O
counterpoint O
with O
adenine O
random O
distribution O
of O
folderal O
mutations O
. O

of O
striking O
clustering O
of O
missense O
mutations O
a O
contrasted O
first O
four O
exons O
random O
A O
in O
the O
nonsense O
with O
distribution O
mutations O
. O

A O
striking O
clustering O
of O
missense O
mutations O
in O
the O
first O
four O
exons O
contrasted O
with O
a O
random O
distribution O
of O
nonsense O
mutations O
. O

More O
than O
contained O
% O
of O
in O
known O
product O
mutations O
were O
localized O
this O
mutational O
amino O
- O
at O
stretch O
of O
WASP O
the O
gene O
missense O
; O
all O
region O
a O
85 O
86 O
hot O
spot O
terminal O
the O
codon O
. O

More O
% O
of O
all O
known O
mutations O
were O
the O
amino O
terminal O
stretch O
gene O
; O
this O
region O
a O
mutational O
hot O
at O
codon O
86 O
. O

More O
than O
85 O
% O
completely O
pole O
get O
it O
on O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
WASP O
gene O
product O
; O
this O
region O
contained O
a O
mutational O
hot O
spot O
at O
codon O
86 O
altogether O
altogether O
altogether O
altogether O
altogether O
altogether O

More O
than O
85 O
% O
completely O
pole O
stretch O
out O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
WASP O
gene O
product O
; O
this O
region O
contained O
a O
mutational O
hot O
spot O
at O
codon O
86 O
altogether O
altogether O
altogether O
altogether O
altogether O
altogether O
amino O

than O
the O
85 O
% O
of O
all O
a O
missense O
mutations O
were O
localized O
mutational O
the O
region O
spot O
terminal O
stretch O
of O
in O
WASP O
gene O
product O
. O
this O
amino O
contained O
known O
More O
codon O
; O
at O
hot O
86 O
- O

More O
than O
85 O
% O
of O
all O
mutations O
were O
localized O
in O
amino O
- O
terminal O
stretch O
of O
WASP O
gene O
product O
; O
region O
contained O
mutational O
hot O
spot O
at O
codon O
86 O
. O

More O
than O
85 O
% O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
aminic O
- O
depot O
unfold O
of O
the O
WASP O
cistron O
intersection O
; O
this O
neighborhood O
check O
a O
mutational O
live O
slur O
at O
codon O
lxxxvi O
. O

More O
than O
lxxxv O
% O
of O
all O
acknowledge O
missense O
mutant O
were O
localized O
in O
the O
amino O
- O
last O
stint O
of O
the O
wasp O
cistron O
merchandise O
; O
this O
region O
contained O
a O
mutational O
blistering O
dapple O
at O
codon O
86 O
. O

More O
than O
85 O
% O
completely O
pole O
stretch O
out O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
WASP O
gene O
product O
; O
this O
region O
contained O
a O
mutational O
hot O
spot O
at O
codon O
86 O
altogether O
altogether O
altogether O
altogether O
altogether O
altogether O
amino O

More O
than O
85 O
% O
of O
all O
known O
missense O
mutations O
were O
focalize O
in O
the O
amino O
- O
depot O
debase O
of O
the O
WASP O
cistron O
product O
; O
this O
realm O
curb O
a O
mutational O
raging O
patch O
at O
codon O
86 O
. O

More O
than O
85 O
% O
of O
all O
known O
missense O
mutations O
were O
localized O
in O
the O
amino O
- O
terminal O
stretch O
of O
the O
WASP O
gene O
product O
; O
this O
region O
contained O
a O
mutational O
hot O
spot O
at O
codon O
86 O
. O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
be O
authoritative O
be O
be O
comparability O
comparability O
mutation O
for O
a O
classical O
WAS B
phenotype O
. O

- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
for O
classical O
WAS B
phenotype O
. O

no O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
equivalence O
of O
the O
distinguish O
sport O
with O
the O
leave O
clinical O
exposure O
for O
a O
classical O
constitute B
phenotype O
. O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
comparison O
of O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
classical O
WAS B
phenotype O
. O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
be O
authoritative O
be O
be O
comparability O
comparability O
comparability O
for O
a O
classical O
WAS B
phenotype O
. O

No O
genotype O
- O
phenotype O
correlativity O
emerged O
after O
a O
equivalence O
of O
the O
identified O
mutations O
with O
the O
lead O
clinical O
picture O
for O
a O
classical O
follow B
phenotype O
. O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparability O
of O
the O
identified O
variation O
with O
the O
resulting O
clinical O
picture O
for O
a O
classical O
personify B
phenotype O
. O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
the O
with O
the O
resulting O
clinical O
picture O
for O
a O
classical O
WAS B

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
be O
authoritative O
be O
be O
comparability O
comparability O
comparability O
for O
a O
classical O
WAS B
phenotype O
. O

picture O
genotype O
- O
the O
correlation O
emerged O
after O
for O
. O
of O
phenotype O
identified O
mutations O
with O
phenotype O
resulting O
clinical O
classical O
a O
No O
a O
WAS B
the O
comparison O

No O
genotype O
- O
phenotype O
correlation O
emerged O
after O
a O
comparison O
of O
the O
identified O
mutations O
with O
the O
resulting O
clinical O
picture O
for O
a O
classical O
WAS B
phenotype O
. O

A O
exchange O
at O
codon O
lxxxvi O
lead O
in O
an O
super O
variable O
locution O
of O
the O
disease O
in O
a O
big O
Swiss O
family O
. O

A O
substitution O
at O
codon O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
Swiss O
astatine O
astatine O
astatine O
astatine O
astatine O
astatine O
family O
. O

A O
substitution O
at O
codon O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
Swiss O
astatine O
astatine O
astatine O
astatine O
astatine O
astatine O
family O
. O

at O
resulted O
in O
an O
variable O
expression O
the O
disease O
in O
a O
large O
Swiss O
family O
. O

A O
substitution O
at O
codon O
86 O
an O
extremely O
expression O
of O
the O
disease O
in O
a O
large O
Swiss O
family O
. O

at O
codon O
86 O
resulted O
an O
extremely O
variable O
expression O
of O
disease O
in O
a O
large O
family O
. O

Swiss O
substitution O
at O
family O
86 O
resulted O
in O
extremely O
an O
variable O
in O
of O
the O
. O
A O
a O
large O
expression O
codon O
disease O

A O
substitution O
at O
codon O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
Swiss O
astatine O
astatine O
astatine O
astatine O
astatine O
heavy O
family O
. O

A O
permutation O
at O
codon O
86 O
leave O
in O
an O
passing O
variable O
formulation O
of O
the O
disease O
in O
a O
heavy O
Swiss O
house O
. O

large O
substitution O
at O
codon O
86 O
resulted O
disease O
of O
extremely O
variable O
expression O
in O
A O
in O
an O
Swiss O
the O
a O
family O
. O

A O
substitution O
at O
codon O
86 O
resulted O
in O
an O
extremely O
variable O
expression O
of O
the O
disease O
in O
a O
large O
Swiss O
family O
. O

An O
extended O
homology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
vasodilator O
- O
stimulated O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
filum O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
like O
filaments O
. O
. O

An O
extended O
homology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
vasodilator O
- O
stimulated O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
filum O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
inward O
like O
filaments O
. O
. O

An O
extended O
homology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
vasodilator O
- O
stimulated O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
filum O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
discover O
like O
filaments O
. O
. O

in O
VASP O
homology O
search O
revealed O
a O
to O
with O
of O
this O
stretch O
distant O
the O
of O
- O
stimulated O
phosphoprotein O
( O
relationship O
) O
, O
interacting O
cyto O
involved O
An O
the O
by O
vasodilator O
- O
is O
architecture O
- O
which O
extended O
actin O
maintenance O
like O
filaments O
. O
. O

An O
extended O
homology O
search O
relationship O
of O
this O
stretch O
to O
vasodilator O
- O
VASP O
which O
is O
the O
cyto O
- O
architecture O
by O
with O
actin O
filaments O
. O

An O
extended O
homology O
hunting O
revealed O
a O
remote O
relationship O
of O
this O
debase O
to O
the O
vasodilative O
- O
excite O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
require O
in O
the O
upkeep O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
like O
strand O
. O
. O

an O
gallop O
homology O
search O
unwrap O
a O
removed O
relationship O
of O
this O
dilute O
to O
the O
vasodilative O
- O
energise O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
require O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
wish O
filum O
. O
. O

architecture O
actin O
homology O
search O
phosphoprotein O
a O
filaments O
by O
of O
this O
stretch O
to O
the O
in O
( O
stimulated O
revealed O
- O
VASP O
) O
vasodilator O
which O
is O
involved O
extended O
the O
maintenance O
. O
An O
- O
cyto O
distant O
interacting O
with O
, O
- O
like O
relationship O
of O
. O

an O
lead O
homology O
search O
revealed O
a O
upstage O
relationship O
of O
this O
stretch O
to O
the O
vasodilative O
- O
stimulated O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
convoluted O
in O
the O
sustainment O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
similar O
filum O
. O
. O

An O
extended O
architecture O
search O
revealed O
- O
stretch O
relationship O
of O
this O
distant O
maintenance O
) O
vasodilator O
- O
VASP O
phosphoprotein O
( O
filaments O
the O
, O
which O
is O
a O
in O
stimulated O
to O
interacting O
by O
- O
homology O
of O
cyto O
with O
actin O
involved O
like O
the O
. O
. O

An O
extended O
homology O
search O
revealed O
a O
distant O
relationship O
of O
this O
stretch O
to O
the O
vasodilator O
- O
stimulated O
phosphoprotein O
( O
VASP O
) O
, O
which O
is O
involved O
in O
the O
maintenance O
of O
cyto O
- O
architecture O
by O
interacting O
with O
actin O
- O
like O
filaments O
. O
. O

Influence O
PAX6 O
dosage O
development O
: O
overexpression O
causes O
severe O
eye B
abnormalities I
. O

Influence O
of O
PAX6 O
cistron O
dose O
on O
developing O
: O
overexpression O
causes O
severe O
oculus B
abnormalities I
. O

: O
gene O
PAX6 O
of O
dosage O
on O
causes O
Influence O
overexpression O
. O
severe O
eye B
abnormalities I
development O

Influence O
of O
PAX6 O
gene O
dosage O
on O
development O
: O
causes O
severe O
abnormalities I
. O

Influence O
of O
abnormalcy O
cistron O
PAX6 O
gene O
dosage O
on O
development O
: O
overexpression O
abnormalcy O
dose O
causes O
severe O
eye B
abnormalities I
. O

Influence O
of O
abnormalcy O
cistron O
PAX6 O
gene O
dosage O
on O
development O
: O
overexpression O
abnormalcy O
do O
causes O
severe O
eye B
abnormalities I
. O

Influence O
of O
PAX6 O
cistron O
dosage O
on O
evolution O
: O
overexpression O
stimulate O
severe O
eye B
irregularity I
. O

abnormalities O
of O
PAX6 O
Influence O
: O
on O
development O
eye O
overexpression O
causes O
severe O
dosage B
gene I
. O

Influence O
of O
abnormalcy O
cistron O
PAX6 O
gene O
dosage O
on O
development O
: O
overexpression O
abnormalcy O
dose O
causes O
severe O
eye B
abnormalities I
. O

Influence O
of O
PAX6 O
cistron O
dosage O
on O
evolution O
: O
overexpression O
causa O
severe O
optic B
abnormalities I
. O

Influence O
of O
PAX6 O
gene O
dosage O
on O
development O
: O
overexpression O
causes O
severe O
eye B
abnormalities I
. O

PAX6 B
in O
man O
developmental O
Small O
eye O
in O
box O
mutations O
semidominant B
and I
disorders I
by O
caused O
are O
within O
the O
paired O
mice O
Aniridia O
gene O
. O

Aniridia B
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
cistron O
homo O
homo O
homo O
homo O
homo O
box O
gene O
PAX6 O
. O

Aniridia B
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
cistron O
homo O
homo O
homo O
homo O
homo O
box O
gene O
PAX6 O
. O

Aniridia B
in O
man O
and O
belittled O
eye O
in O
mice O
are O
semidominant B
developmental I
perturb I
caused O
by O
sport O
inside O
the O
couple O
box O
factor O
PAX6 O
. O

Aniridia B
in O
man O
Small O
eye O
in O
mice O
are O
developmental I
disorders I
caused O
by O
within O
the O
box O
gene O
PAX6 O
. O

and O
in O
mice O
are O
developmental I
disorders I
by O
mutations O
within O
the O
paired O
box O
gene O
PAX6 O
. O

Aniridia B
in O
man O
and O
Small O
center O
in O
mice O
are O
semidominant B
developmental I
unhinge I
stimulate O
by O
variation O
inside O
the O
copulate O
box O
gene O
PAX6 O
. O

mutations B
in O
are O
in O
Small O
eye O
within O
mice O
man O
semidominant B
developmental I
disorders I
PAX6 O
by O
and O
Aniridia O
the O
paired O
box O
gene O
caused O
. O

Aniridia B
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
cistron O
homo O
homo O
homo O
homo O
be O
box O
gene O
PAX6 O
. O

Aniridia B
in O
man O
and O
in O
mice O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
box O
. O

Aniridia B
in O
man O
and O
Small O
eye O
in O
mice O
are O
semidominant B
developmental I
disorders I
caused O
by O
mutations O
within O
the O
paired O
box O
gene O
PAX6 O
. O

Whereas O
heterozygotes O
mice O
and O
iris B
hypoplasia I
nasal O
homozygous O
suffer O
lack O
eyes O
and O
, O
cavities O
from O
exhibit O
brain B
abnormalities I
. O

suffer O
from O
iris B
hypoplasia I
, O
homozygous O
mice O
lack O
eyes O
exhibit O
brain B
abnormalities I
. O

Whereas O
heterozygotes O
suffer O
from O
flag B
hypoplasia I
, O
homozygous O
shiner O
want O
eyes O
and O
nasal O
caries O
and O
present O
brain B
abnormalities I
. O

Whereas O
heterozygotes O
ache O
from O
iris B
hypoplasia I
, O
homozygous O
mice O
deficiency O
centre O
and O
adenoidal O
cavities O
and O
present O
brain B
abnormalities I
. O

brain O
heterozygotes O
suffer O
from O
iris B
hypoplasia I
cavities O
and O
mice O
lack O
eyes O
and O
abnormalities O
, O
homozygous O
exhibit O
nasal B
Whereas I
. O

Whereas O
heterozygotes O
iris B
hypoplasia I
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain B
. O

Whereas O
heterozygotes O
suffer O
from O
iris B
hypoplasia I
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain B
abnormalities I
put O
up O
put O
up O
put O
up O

Whereas O
heterozygotes O
tolerate O
from O
iris B
hypoplasia I
, O
homozygous O
mouse O
lack O
middle O
and O
nasal O
caries O
and O
demo O
brain B
abnormalities I
. O

Whereas O
heterozygotes O
suffer O
from O
iris B
hypoplasia I
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain B
abnormalities I
put O
up O
put O
up O
put O
up O

cavities O
heterozygotes O
suffer O
eyes O
iris B
hypoplasia I
, O
. O
and O
lack O
from O
and O
Whereas O
nasal O
mice O
exhibit O
brain B
abnormalities I
homozygous O

Whereas O
heterozygotes O
suffer O
from O
iris B
hypoplasia I
, O
homozygous O
mice O
lack O
eyes O
and O
nasal O
cavities O
and O
exhibit O
brain B
abnormalities I
. O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
homo O
impart O
locale O
homo O
locale O
locale O
homo O
mice O
carrying O
the O
human O
PAX6 O
locus O
. O

role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
carrying O
human O
PAX6 O
locus O
. O

To O
inquire O
the O
role O
of O
factor O
dosage O
in O
more O
detail O
, O
we O
have O
beget O
barm O
stilted O
chromosome O
transgenic O
mice O
run O
the O
human O
PAX6 O
locale O
. O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
we O
have O
yeast O
artificial O
chromosome O
transgenic O
mice O
carrying O
the O
locus O
. O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
homo O
impart O
locale O
homo O
locale O
locale O
more O
than O
mice O
carrying O
the O
human O
PAX6 O
locus O

To O
investigate O
the O
role O
of O
gene O
dose O
in O
more O
item O
, O
we O
have O
generated O
barm O
hokey O
chromosome O
transgenic O
mice O
contain O
the O
homo O
PAX6 O
venue O
. O

To O
investigate O
the O
role O
of O
cistron O
dose O
in O
more O
particular O
, O
we O
have O
father O
barm O
artificial O
chromosome O
transgenic O
mice O
impart O
the O
human O
PAX6 O
locale O
. O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
have O
artificial O
chromosome O
transgenic O
mice O
carrying O
the O
human O
PAX6 O
locus O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
homo O
impart O
locale O
homo O
locale O
locale O
more O
than O
mice O
carrying O
the O
human O
PAX6 O
locus O

carrying O
investigate O
the O
, O
of O
gene O
dosage O
mice O
locus O
detail O
role O
we O
generated O
have O
PAX6 O
artificial O
chromosome O
transgenic O
in O
. O
the O
human O
yeast O
more O
To O

To O
investigate O
the O
role O
of O
gene O
dosage O
in O
more O
detail O
, O
we O
have O
generated O
yeast O
artificial O
chromosome O
transgenic O
mice O
carrying O
the O
human O
PAX6 O
locus O
. O

When O
Small O
onto O
the O
crossed O
eye O
, O
rescues O
the O
transgene O
mutant O
the O
background O
phenotype O
. O

When O
crossed O
background O
knowledge O
mutation O
background O
knowledge O
onto O
the O
Small O
eye O
background O
, O
the O
background O
knowledge O
transgene O
rescues O
the O

When O
foil O
onto O
the O
little O
eye O
background O
, O
the O
transgene O
saving O
the O
variation O
phenotype O
. O

mutant O
crossed O
onto O
When O
, O
eye O
background O
the O
the O
transgene O
rescues O
Small O
the O
phenotype O
. O

When O
crossed O
onto O
the O
little O
centre O
background O
, O
the O
transgene O
deliverance O
the O
mutation O
phenotype O
. O

When O
crossed O
background O
knowledge O
mutation O
background O
knowledge O
onto O
the O
Small O
eye O
background O
, O
the O
low O
transgene O
rescues O
the O
mutant O

When O
onto O
Small O
background O
, O
the O
transgene O
rescues O
the O
mutant O
phenotype O
. O

, O
the O
onto O
crossed O
Small O
eye O
transgene O
When O
the O
background O
rescues O
the O
mutant O
. O
phenotype O

When O
bilk O
onto O
the O
Small O
heart O
background O
, O
the O
transgene O
saving O
the O
sport O
phenotype O
. O

When O
crossed O
background O
knowledge O
mutation O
background O
knowledge O
onto O
the O
Small O
eye O
background O
, O
the O
low O
transgene O
rescues O
the O
mutant O

When O
crossed O
onto O
the O
Small O
eye O
background O
, O
the O
transgene O
rescues O
the O
mutant O
phenotype O
. O

Strikingly O
, O
mice O
bear O
multiple O
imitate O
on O
a O
violent O
- O
type O
background O
register O
particular O
developmental B
abnormalities I
of I
the I
heart I
, O
but O
not O
of O
other O
tissues O
evince O
the O
cistron O
. O

Strikingly O
, O
mice O
carrying O
multiple O
on O
- O
type O
background O
show O
specific O
developmental B
abnormalities I
of I
the I
of O
other O
tissues O
expressing O
the O
gene O
. O

but O
, O
mice O
eye O
multiple O
copies O
on O
expressing O
other O
- O
. O
background O
show O
, O
of B
abnormalities I
of I
the I
carrying I
specific O
tissues O
not O
developmental O
wild O
Strikingly O
a O
the O
gene O
type O

Strikingly O
, O
mice O
carrying O
usher O
particular O
written O
matter O
abnormalcy O
antiophthalmic O
factor O
multiple O
copies O
on O
a O
wild O
- O
type O
background O
show B
specific I
developmental I
abnormalities I
of O
the I
verbalise O
tissue I
paper O
idle O
eye O
, O
but O
not O
of O
other O
tissues O
expressing O

Strikingly O
, O
mice O
carrying O
usher O
particular O
written O
matter O
abnormalcy O
antiophthalmic O
factor O
multiple O
copies O
on O
a O
wild O
- O
type O
background O
show B
specific I
developmental I
abnormalities I
of O
the I
verbalise O
tissue I
paper O
character O
eye O
, O
but O
not O
of O
other O
tissues O
expressing O

Strikingly O
, O
mice O
carrying O
multiple O
copies O
on O
a O
- O
type O
show O
specific O
developmental B
abnormalities I
of I
the I
eye I
not O
of O
other O
tissues O
expressing O
the O
gene O
. O

. O
, O
mice O
developmental O
multiple O
copies O
expressing O
a O
carrying O
- O
type O
background O
the O
specific O
tissues B
wild I
of I
the I
eye I
, O
show O
not O
of O
other O
abnormalities O
on O
but O
gene O
Strikingly O

Strikingly O
, O
mice O
carrying O
multiple O
copies O
on O
a O
- O
background O
show O
specific O
developmental B
abnormalities I
of I
the I
eye I
but O
not O
of O
other O
tissues O
expressing O
the O

strikingly O
, O
mice O
extend O
multiple O
transcript O
on O
a O
wild O
- O
case O
background O
show O
specific O
developmental B
abnormalcy I
of I
the I
eye I
, O
but O
not O
of O
other O
weave O
evince O
the O
cistron O
. O

strikingly O
, O
mice O
pack O
multiple O
copy O
on O
a O
baseless O
- O
type O
background O
indicate O
particular O
developmental B
abnormalities I
of I
the I
eye I
, O
but O
not O
of O
other O
tissues O
convey O
the O
factor O
. O

Strikingly O
, O
mice O
carrying O
multiple O
copies O
on O
a O
wild O
- O
type O
background O
show O
specific O
developmental B
abnormalities I
of I
the I
eye I
, O
but O
not O
of O
other O
tissues O
expressing O
the O
gene O
. O

Thus O
, O
middle O
phenotype O
astatine O
at O
least O
five O
different O
eye O
phenotypes O
are O
associated O
with O
changes O
in O
PAX6 O
expression O
unlike O
. O

PAX6 O
, O
at O
. O
five O
different O
eye O
phenotypes O
expression O
associated O
with O
changes O
Thus O
in O
are O
least O

Thus O
, O
middle O
phenotype O
inward O
at O
least O
five O
different O
eye O
phenotypes O
are O
associated O
with O
changes O
in O
PAX6 O
expression O
unlike O
. O

thusly O
, O
at O
least O
fin O
different O
centre O
phenotypes O
are O
relate O
with O
changes O
in O
PAX6 O
expression O
. O

in O
, O
at O
phenotypes O
five O
different O
PAX6 O
least O
are O
associated O
Thus O
changes O
with O
eye O
expression O
. O

Thus O
, O
middle O
phenotype O
astatine O
at O
least O
five O
different O
eye O
phenotypes O
are O
associated O
with O
changes O
in O
PAX6 O
expression O
unlike O
. O

Thus O
, O
at O
least O
fin O
different O
center O
phenotypes O
are O
associated O
with O
modify O
in O
PAX6 O
saying O
. O

thence O
, O
at O
least O
five O
dissimilar O
eye O
phenotypes O
are O
associated O
with O
convert O
in O
PAX6 O
verbalism O
. O

Thus O
, O
are O
. O
five O
different O
in O
phenotypes O
at O
associated O
with O
changes O
eye O
PAX6 O
least O
expression O

, O
at O
least O
five O
different O
eye O
phenotypes O
with O
changes O
in O
PAX6 O
expression O
. O

Thus O
, O
at O
least O
five O
different O
eye O
phenotypes O
are O
associated O
with O
changes O
in O
PAX6 O
expression O
. O

We O
provide O
prove O
that O
not O
only O
cut O
, O
but O
likewise O
increased O
levels O
of O
transcriptional O
governor O
can O
campaign O
developmental B
shortcoming I
. O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcriptional O
regulators O
can O
cause O
developmental B
certify B
certify O
certify B
certify O
certify B
certify O
defects I
. O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcriptional O
regulators O
can O
cause O
developmental B
certify B
certify O
certify B
certify O
certify B
certify O
defects I
. O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
also O
increased O
of O
transcriptional O
regulators O
can O
cause O
developmental B
defects I

regulators O
provide O
but O
reduced O
not O
only O
can O
, O
evidence O
also O
increased O
levels O
. O
transcriptional O
that O
We O
cause O
developmental B
defects I
. O
of O

We O
furnish O
demonstrate O
that O
not O
only O
reduced O
, O
but O
besides O
increased O
levels O
of O
transcriptional O
governor O
can O
drive O
developmental B
shortcoming I
. O
. O

. O
provide O
evidence O
increased O
not O
only O
reduced O
defects O
regulators O
also O
that O
levels O
transcriptional O
of O
but O
can O
cause O
developmental B
, I
We O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcriptional O
regulators O
can O
cause O
developmental B
certify B
certify O
certify B
certify O
certify B
too O
defects I
. O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
regulators O
developmental B
defects I
. O
. O

We O
render O
manifest O
that O
not O
only O
reduced O
, O
but O
likewise O
increased O
floor O
of O
transcriptional O
regulators O
can O
effort O
developmental B
fault I
. O
. O

We O
provide O
evidence O
that O
not O
only O
reduced O
, O
but O
also O
increased O
levels O
of O
transcriptional O
regulators O
can O
cause O
developmental B
defects I
. O
. O

Heterodimer O
in O
and O
activity O
formation O
the O
enzyme O
1 O
galactose O
- O
phosphate O
- O
human O
uridylyltransferase O
. O

Heterodimer O
formation O
homo O
orthophosphate O
brain O
sugar O
and O
activity O
in O
the O
human O
enzyme O
galactose O
homo O
- O
1 O
- O
phosphate O
uridylyltransferase O

Heterodimer O
organization O
and O
activity O
in O
the O
human O
enzyme O
galactose O
- O
ane O
- O
phosphate O
uridylyltransferase O
. O

phosphate O
formation O
and O
Heterodimer O
enzyme O
the O
human O
- O
galactose O
- O
1 O
in O
activity O
uridylyltransferase O
. O

Heterodimer O
establishment O
and O
activity O
in O
the O
homo O
enzyme O
galactose O
- O
i O
- O
phosphate O
uridylyltransferase O
. O

Heterodimer O
formation O
homo O
orthophosphate O
brain O
sugar O
and O
activity O
in O
the O
human O
enzyme O
galactose O
inward O
- O
1 O
- O
phosphate O
uridylyltransferase O

Heterodimer O
and O
in O
human O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridylyltransferase O
. O

enzyme O
activity O
and O
formation O
in O
the O
- O
Heterodimer O
galactose O
human O
1 O
- O
phosphate O
. O
uridylyltransferase O

Heterodimer O
organization O
and O
activeness O
in O
the O
human O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridylyltransferase O
. O

Heterodimer O
formation O
homo O
orthophosphate O
brain O
sugar O
and O
activity O
in O
the O
human O
enzyme O
galactose O
inward O
- O
1 O
- O
phosphate O
uridylyltransferase O

Heterodimer O
formation O
and O
activity O
in O
the O
human O
enzyme O
galactose O
- O
1 O
- O
phosphate O
uridylyltransferase O
. O

of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
dimeric O
enzymes O
involves O
the O
impact O
of O
occurring O
on O
subunit O
assembly O
and O
heterodimer O
activity O
. O

dimeric O
of O
the O
mutations O
questions O
concerning O
expression O
. O
heterodimer O
of O
activity O
enzymes O
involves O
on O
and O
of O
naturally O
occurring O
fundamental O
the O
subunit O
assembly O
impact O
function O
One O
and O

matchless O
of O
the O
fundamental O
doubtfulness O
refer O
expression O
and O
officiate O
of O
dimeric O
enzymes O
take O
the O
affect O
of O
naturally O
come O
mutations O
on O
subunit O
assembly O
and O
heterodimer O
activity O
. O

peerless O
of O
the O
rudimentary O
wonder O
concerning O
expression O
and O
use O
of O
dimeric O
enzymes O
take O
the O
affect O
of O
naturally O
pass O
mutations O
on O
subunit O
assembly O
and O
heterodimer O
activity O
. O

One O
of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
enzymes O
involves O
impact O
of O
naturally O
occurring O
mutations O
on O
subunit O
heterodimer O
activity O
. O

One O
of O
the O
fundamental O
interrogation O
questions O
concerning O
expression O
and O
function O
of O
dimeric O
enzymes O
involves O
the O
impact O
of O
naturally O
occurring O
fractional O
monetary O
unit O
assemblage O
bodily O
process O
serve O
bodily O
process O
serve O
mutations O
on O
subunit O
assembly O

One O
of O
the O
fundamental O
interrogation O
questions O
concerning O
expression O
and O
function O
of O
dimeric O
enzymes O
involves O
the O
impact O
of O
naturally O
occurring O
fractional O
monetary O
unit O
assemblage O
bodily O
process O
serve O
bodily O
process O
 O
mutations O
on O
subunit O
assembly O

One O
of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
enzymes O
impact O
of O
naturally O
occurring O
mutations O
on O
subunit O
assembly O
and O

heterodimer O
of O
the O
fundamental O
questions O
concerning O
the O
naturally O
function O
of O
dimeric O
enzymes O
assembly O
expression O
activity O
of O
and O
subunit O
mutations O
on O
One O
involves O
and O
occurring O
impact O
. O

unrivalled O
of O
the O
fundamental O
interrogation O
concerning O
verbalism O
and O
function O
of O
dimeric O
enzymes O
demand O
the O
impact O
of O
course O
hap O
mutations O
on O
subunit O
fabrication O
and O
heterodimer O
activity O
. O

One O
of O
the O
fundamental O
questions O
concerning O
expression O
and O
function O
of O
dimeric O
enzymes O
involves O
the O
impact O
of O
naturally O
occurring O
mutations O
on O
subunit O
assembly O
and O
heterodimer O
activity O
. O

This O
question O
is O
of O
particular O
interest O
for O
the O
galactose O
- O
l O
- O
uridylyl O
- O
transferase O
( O
GALT O
, O
impairment O
of O
which O
in O
the O
metabolic I
disorder I
galactosemia B
, O
because O
many O
if O
not O
patients O
studied O
date O
are O
compound O
heterozygotes O
rather O
than O
true O
molecular O

heterozygotes O
which O
is O
of O
particular O
interest O
most O
- O
human O
enzyme O
galactose O
- O
l O
. O
than O
uridylyl O
the O
disorder O
( O
GALT O
date O
, O
impairment O
of O
question O
results O
in O
patients O
transferase B
metabolic I
inherited I
for B
, O
because O
many O
if O
not O
molecular O
the O
studied O
to O
) O
are O
compound O
This O
rather O
phosphate O
true O
homozygotes O
galactosemia O
- O

This O
enquiry O
is O
of O
picky O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
deadening O
of O
which O
issue O
in O
the O
transmissible B
metabolous I
perturb I
galactosemia B
, O
because O
many O
if O
not O
most O
patients O
canvass O
to O
engagement O
are O
compound O
heterozygotes O
preferably O
than O
lawful O
molecular O
homozygotes O
. O

This O
question O
is O
of O
particular O
interest O
for O
the O
orthophosphate O
homo O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B
metabolic I
disorder I
galactosemia B
, O
because O
many O
if O
be O
chemical O
compound O
heterozygote O
quite O
chemical O
compound O
dead O
on O
target O
quite O
homozygote O
dead O
on O
target O
quite O
homozygote O
dead O
on O
target O
transmissible O
not O
most O
patients O
studied O
to O
date O
are O

This O
question O
is O
of O
particular O
interest O
for O
the O
orthophosphate O
homo O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B
metabolic I
disorder I
galactosemia B
, O
because O
many O
if O
be O
chemical O
compound O
heterozygote O
quite O
chemical O
compound O
dead O
on O
target O
quite O
homozygote O
dead O
on O
target O
quite O
homozygote O
dead O
on O
target O
transmissible O
not O
most O
patients O
studied O
to O
date O
are O

question O
is O
of O
particular O
interest O
the O
human O
l O
uridylyl O
- O
GALT O
impairment O
of O
which O
results O
the O
inherited B
galactosemia B
, O
many O
if O
studied O
date O
are O
compound O
rather O
than O
true O
homozygotes O
. O

This O
question O
is O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
uridylyl O
transferase O
( O
GALT O
, O
impairment O
of O
which O
results O
in O
inherited B
metabolic I
, O
many O
if O
not O
most O
to O
date O
are O
compound O
rather O
than O
true O
molecular O
homozygotes O
. O

This O
head O
is O
of O
particular O
pursuit O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
deterioration O
of O
which O
answer O
in O
the O
familial B
metabolous I
distract I
galactosemia B
, O
because O
many O
if O
not O
most O
patients O
contemplate O
to O
engagement O
are O
compound O
heterozygotes O
rather O
than O
genuine O
molecular O
homozygotes O
. O

This O
doubtfulness O
is O
of O
specific O
interest O
for O
the O
homo O
enzyme O
galactose O
- O
fifty O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
deadening O
of O
which O
resultant O
in O
the O
transmitted B
metabolous I
disorder I
galactosemia B
, O
because O
many O
if O
not O
most O
patients O
contemplate O
to O
date O
are O
deepen O
heterozygotes O
rather O
than O
unfeigned O
molecular O
homozygotes O
. O

This O
question O
is O
of O
particular O
interest O
for O
the O
orthophosphate O
homo O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B
metabolic I
disorder I
galactosemia B
, O
because O
many O
if O
be O
chemical O
compound O
heterozygote O
quite O
chemical O
compound O
dead O
on O
target O
quite O
homozygote O
dead O
on O
target O
quite O
homozygote O
dead O
on O
target O
patient O
not O
most O
patients O
studied O
to O
date O
are O

This O
question O
is O
of O
particular O
interest O
for O
the O
human O
enzyme O
galactose O
- O
l O
- O
phosphate O
uridylyl O
- O
transferase O
( O
GALT O
) O
, O
impairment O
of O
which O
results O
in O
the O
inherited B
metabolic I
disorder I
galactosemia B
, O
because O
many O
if O
not O
most O
patients O
studied O
to O
date O
are O
compound O
heterozygotes O
rather O
than O
true O
molecular O
homozygotes O
. O

Furthermore O
, O
the O
broad O
stir O
grasp O
possibleness O
phenotypical O
grasp O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
shift O
shift O
shift O
patient O
. O

Furthermore O
, O
range O
in O
these O
patients O
the O
possibility O
allelic O
combination O
, O
allelic O
constitution O
, O
may O
play O
role O
determining O
outcome O
. O

Furthermore O
, O
the O
full O
range O
of O
phenotypic O
rigor O
honor O
in O
these O
patients O
raises O
the O
opening O
that O
allelomorphic O
compounding O
, O
not O
just O
allelomorphic O
constitution O
, O
may O
act O
some O
function O
in O
determining O
issue O
. O

Furthermore O
, O
the O
broad O
of O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
. O

Furthermore O
, O
the O
unsubtle O
graze O
of O
phenotypic O
severity O
detect O
in O
these O
patients O
recruit O
the O
possibility O
that O
allelomorphic O
compounding O
, O
not O
just O
allelomorphic O
constitution O
, O
whitethorn O
play O
some O
character O
in O
determining O
effect O
. O

Furthermore O
, O
the O
broad O
stir O
grasp O
possibleness O
phenotypical O
grasp O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
shift O
shift O
shift O
patient O
. O

Furthermore O
, O
the O
broad O
compass O
of O
phenotypic O
badness O
detect O
in O
these O
patients O
conjure O
the O
possibility O
that O
allelomorphic O
combination O
, O
not O
just O
allelomorphic O
formation O
, O
may O
play O
some O
office O
in O
deciding O
upshot O
. O

just O
, O
the O
broad O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
may O
determining O
that O
allelic O
combination O
role O
not O
, O
allelic O
. O
, O
the O
play O
some O
Furthermore O
possibility O
constitution O
outcome O
in O

Furthermore O
, O
the O
broad O
of O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
play O
some O
role O
determining O
. O

Furthermore O
, O
the O
broad O
stir O
grasp O
possibleness O
phenotypical O
combining O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
shift O
shift O
shift O
patient O
. O

Furthermore O
, O
the O
broad O
range O
of O
phenotypic O
severity O
observed O
in O
these O
patients O
raises O
the O
possibility O
that O
allelic O
combination O
, O
not O
just O
allelic O
constitution O
, O
may O
play O
some O
role O
in O
determining O
outcome O
. O

inward O
the O
run O
described O
herein O
, O
we O
have O
selected O
two O
trenchant O
naturally O
occurring O
zilch O
mutations O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
take O
the O
dubiousness O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
on O
subunit O
fabrication O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
forge O
, O
are O
they O
active O
? O

In O
the O
described O
we O
have O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
and O
R333W O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
mutations O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
do O
form O
, O
are O
they O
active O
? O

indiana O
the O
flesh O
delineate O
herein O
, O
we O
have O
take O
two O
distinct O
naturally O
occurring O
zilch O
variation O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
postulate O
the O
questions O
( O
i O
) O
what O
are O
the O
shock O
of O
these O
variation O
on O
subunit O
assembly O
, O
and O
( O
deuce O
) O
if O
heterodimers O
do O
flesh O
, O
are O
they O
active O
? O

these O
( O
work O
described O
herein O
, O
naturally O
have O
selected O
two O
distinct O
we O
occurring O
i O
) O
of O
GALT O
, O
what O
and O
R333W O
, O
of O
asked O
) O
questions O
do O
null O
, O
Q188R O
are O
mutations O
impacts O
mutations O
In O
( O
on O
subunit O
assembly O
, O
the O
the O
ii O
and O
if O
heterodimers O
and O
form O
the O
are O
they O
active O
? O

In O
we O
two O
naturally O
occurring O
null O
of O
GALT O
, O
Q188R O
and O
R333W O
the O
questions O
( O
i O
) O
what O
are O
impacts O
of O
on O
subunit O
assembly O
and O
) O
if O
heterodimers O
do O
form O
, O
are O

if O
the O
work O
described O
herein O
, O
R333W O
GALT O
selected O
two O
distinct O
naturally O
occurring O
they O
subunit O
of O
have O
are O
Q188R O
and O
, O
, O
and O
asked O
the O
questions O
( O
assembly O
, O
what O
) O
we O
impacts O
of O
these O
mutations O
on O
mutations O
i O
, O
and O
( O
ii O
) O
In O
heterodimers O
active O
form O
are O
the O
null O
do O
? O

work O
described O
herein O
we O
selected O
two O
distinct O
null O
Q188R O
and O
R333W O
and O
asked O
questions O
( O
i O
are O
the O
impacts O
of O
these O
on O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
are O
they O
active O
? O

In O
the O
work O
described O
herein O
, O
we O
have O
pass O
be O
mutation O
select O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
assemblage O
two O
serve O
mannikin O
two O
be O
mannikin O
participating O
be O
mannikin O
rich O
person O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
, O
are O
they O
active O

In O
the O
work O
described O
herein O
, O
we O
have O
pass O
be O
mutation O
select O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
assemblage O
two O
serve O
mannikin O
two O
be O
mannikin O
participating O
be O
mannikin O
rich O
person O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
, O
are O
they O
active O

In O
the O
work O
described O
herein O
, O
we O
have O
pass O
be O
mutation O
select O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
assemblage O
two O
serve O
mannikin O
two O
be O
mannikin O
participating O
be O
mannikin O
rich O
person O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
, O
are O
they O
active O

In O
the O
work O
described O
herein O
, O
we O
have O
selected O
two O
distinct O
naturally O
occurring O
null O
mutations O
of O
GALT O
, O
Q188R O
and O
R333W O
, O
and O
asked O
the O
questions O
( O
i O
) O
what O
are O
the O
impacts O
of O
these O
mutations O
on O
subunit O
assembly O
, O
and O
( O
ii O
) O
if O
heterodimers O
do O
form O
, O
are O
they O
active O
? O

To O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
coexpression O
of O
epitope O
- O
tagged O
alleles O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
specific O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
install O
kitty O
install O
install O
install O
install O
install O
install O
install O
install O
install O
install O
defined O
heterodimer O
pools O
. O

To O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
coexpression O
of O
epitope O
- O
tagged O
alleles O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
specific O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
install O
kitty O
install O
install O
install O
install O
install O
install O
install O
install O
install O
determinant O
defined O
heterodimer O
pools O
. O

To O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
coexpression O
of O
epitope O
- O
tagged O
alleles O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
specific O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
install O
kitty O
install O
install O
install O
install O
install O
install O
install O
install O
install O
install O
defined O
heterodimer O
pools O
. O

both O
alleles O
these O
questions O
, O
we O
for O
the O
a O
yeast O
system O
have O
the O
of O
GALT O
epitope O
- O
tagged O
established O
of O
human O
and O
specific O
investigated O
To O
the O
interactions O
coexpression O
of O
and O
subunit O
of O
GALT O
answer O
activity O
extent O
defined O
heterodimer O
pools O
. O

To O
answer O
these O
questions O
established O
a O
yeast O
system O
for O
coexpression O
of O
alleles O
GALT O
and O
the O
specific O
GALT O
subunit O
interactions O
the O
activity O
heterodimer O
pools O

To O
solvent O
these O
wonder O
, O
we O
have O
institute O
a O
barm O
organisation O
for O
the O
coexpression O
of O
epitope O
- O
track O
allelomorph O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
particular O
GALT O
subunit O
interactions O
and O
the O
activeness O
of O
delimit O
heterodimer O
kitty O
. O

To O
result O
these O
inquiry O
, O
we O
have O
accomplished O
a O
barm O
organisation O
for O
the O
coexpression O
of O
determinant O
- O
track O
alleles O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
particular O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
specify O
heterodimer O
pools O
. O

subunit O
activity O
these O
questions O
- O
we O
heterodimer O
interactions O
a O
yeast O
system O
for O
the O
both O
tagged O
epitope O
, O
of O
alleles O
of O
coexpression O
GALT O
and O
investigated O
answer O
the O
extent O
pools O
To O
GALT O
specific O
have O
and O
the O
human O
of O
defined O
established O
of O
. O

To O
respond O
these O
dubiousness O
, O
we O
have O
make O
a O
barm O
scheme O
for O
the O
coexpression O
of O
determinant O
- O
track O
alleles O
of O
homo O
GALT O
and O
investigated O
both O
the O
extent O
of O
particular O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
fix O
heterodimer O
pools O
. O

To O
answer O
subunit O
questions O
, O
of O
system O
established O
a O
yeast O
have O
extent O
of O
coexpression O
of O
alleles O
- O
tagged O
heterodimer O
the O
human O
GALT O
and O
we O
both O
epitope O
for O
and O
interactions O
GALT O
these O
of O
specific O
the O
activity O
investigated O
defined O
the O
pools O
. O

To O
answer O
these O
questions O
, O
we O
have O
established O
a O
yeast O
system O
for O
the O
coexpression O
of O
epitope O
- O
tagged O
alleles O
of O
human O
GALT O
and O
investigated O
both O
the O
extent O
of O
specific O
GALT O
subunit O
interactions O
and O
the O
activity O
of O
defined O
heterodimer O
pools O
. O

We O
have O
found O
that O
both O
homodimers O
and O
heterodimers O
do O
descriptor O
involve O
each O
of O
the O
mutation O
subunits O
tested O
and O
that O
both O
heterodimer O
syndicate O
hold O
material O
enzymatic O
activity O
. O

We O
have O
that O
both O
homodimers O
and O
heterodimers O
do O
form O
involving O
each O
of O
subunits O
tested O
and O
that O
heterodimer O
pools O
retain O
substantial O
enzymatic O
. O

We O
have O
found O
that O
mutation O
subunit O
prove O
both O
homodimers O
and O
heterodimers O
do O
form O
involving O
each O
of O
the O
mutant O
subunits O
tested O
and O
square O
keep O
back O
bodily O
process O
square O
serve O
that O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O

heterodimer O
have O
found O
that O
both O
homodimers O
and O
activity O
substantial O
form O
both O
each O
of O
the O
retain O
subunits O
tested O
and O
that O
enzymatic O
involving O
pools O
mutant O
do O
We O
heterodimers O
. O

We O
have O
found O
that O
mutation O
subunit O
prove O
both O
homodimers O
and O
heterodimers O
do O
form O
involving O
each O
of O
the O
mutant O
subunits O
tested O
and O
square O
keep O
back O
bodily O
process O
square O
serve O
that O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O

We O
have O
found O
both O
homodimers O
heterodimers O
do O
form O
involving O
each O
of O
the O
mutant O
tested O
and O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O
activity O
. O

. O
have O
found O
mutant O
both O
homodimers O
activity O
heterodimers O
that O
form O
involving O
each O
the O
heterodimer O
enzymatic O
do O
tested O
and O
that O
both O
of O
pools O
retain O
substantial O
subunits O
and O
We O

found O
homodimers O
and O
heterodimers O
form O
involving O
of O
the O
mutant O
subunits O
tested O
and O
that O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O

substantial O
have O
found O
that O
both O
homodimers O
the O
each O
do O
form O
involving O
tested O
pools O
and O
enzymatic O
We O
heterodimers O
subunits O
that O
both O
heterodimer O
of O
retain O
and O
mutant O
activity O
. O

We O
have O
recover O
that O
both O
homodimers O
and O
heterodimers O
do O
forge O
involving O
each O
of O
the O
sport O
subunits O
essay O
and O
that O
both O
heterodimer O
consortium O
retain O
significant O
enzymatic O
activity O
. O

We O
have O
found O
that O
both O
homodimers O
and O
heterodimers O
do O
form O
involving O
each O
of O
the O
mutant O
subunits O
tested O
and O
that O
both O
heterodimer O
pools O
retain O
substantial O
enzymatic O
activity O
. O

These O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
furthering O
our O
understanding O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
compose O
early O
building O
complex O
subunit O
early O
building O
complex O
subunit O
non O
non O
subunit O
non O
non O
non O
non O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O
subunits O

These O
effect O
are O
pregnant O
not O
only O
in O
footing O
of O
their O
significance O
for O
boost O
our O
see O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
routine O
relationships O
but O
also O
because O
the O
scheme O
trace O
may O
suffice O
as O
a O
model O
for O
standardised O
canvass O
of O
other O
complexes O
indite O
of O
multiple O
subunits O
. O
. O

These O
results O
serve O
significant O
not O
for O
in O
terms O
of O
their O
implications O
furthering O
of O
our O
understanding O
may O
galactosemia B
and O
holoenzyme O
GALT O
structure O
. O
function O
only O
but O
because O
the O
. O
system O
described O
of O
studies O
also O
a O
model O
relationships O
similar O
are O
of O
other O
complexes O
composed O
for O
subunits O
multiple O
as O
- O

These O
because O
are O
significant O
not O
only O
for O
described O
of O
their O
implications O
in O
furthering O
the O
but O
of O
galactosemia B
and O
terms O
holoenzyme O
structure O
- O
for O
relationships O
multiple O
also O
. O
our O
serve O
GALT O
may O
system O
as O
understanding O
model O
composed O
similar O
studies O
of O
other O
results O
a O
of O
function O
subunits O
. O
complexes O

These O
resolution O
are O
substantial O
not O
only O
in O
terms O
of O
their O
import O
for O
boost O
our O
agreement O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
use O
relationships O
but O
also O
because O
the O
organisation O
delineate O
may O
help O
as O
a O
model O
for O
interchangeable O
cogitation O
of O
other O
complexes O
composed O
of O
multiple O
subunits O
. O
. O

These O
results O
are O
not O
only O
in O
terms O
of O
for O
furthering O
our O
understanding O
of O
galactosemia B
and O
GALT O
- O
relationships O
but O
also O
the O
system O
described O
may O
serve O
as O
model O
for O
of O
complexes O
composed O
of O
multiple O
. O

significant O
not O
only O
in O
terms O
their O
implications O
understanding O
and O
GALT O
- O
but O
also O
because O
the O
described O
may O
a O
model O
similar O
studies O
composed O
multiple O
subunits O
. O

These O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
furthering O
our O
understanding O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
compose O
early O
building O
complex O
subunit O
early O
building O
complex O
subunit O
non O
non O
subunit O
non O
non O
non O
dish O
up O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O

model O
but O
are O
significant O
galactosemia O
only O
structure O
serve O
of O
their O
implications O
for O
furthering O
in O
studies O
of O
not B
. O
GALT O
holoenzyme O
our O
- O
function O
relationships O
the O
also O
because O
composed O
subunits O
described O
system O
results O
as O
a O
of O
for O
similar O
understanding O
These O
other O
complexes O
terms O
of O
multiple O
may O
. O
and O

These O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
furthering O
our O
understanding O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
compose O
early O
building O
complex O
subunit O
early O
building O
complex O
subunit O
non O
non O
subunit O
non O
non O
non O
non O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O
subunits O

These O
results O
are O
significant O
not O
only O
in O
terms O
of O
their O
implications O
for O
furthering O
our O
understanding O
of O
galactosemia B
and O
GALT O
holoenzyme O
structure O
- O
function O
relationships O
but O
also O
because O
the O
system O
described O
may O
serve O
as O
a O
model O
for O
similar O
studies O
of O
other O
complexes O
composed O
of O
multiple O
subunits O
. O
. O

, O
of O
huntingtin O
proapoptotic O
apopain O
, O
a O
by O
the O
protease O
by O
is O
Cleavage O
modulated O
cysteine O
polyglutamine O
tract O
. O

segmentation O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
. O

cleavage O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
peptidase O
, O
is O
tone O
by O
the O
polyglutamine O
tract O
. O

Cleavage O
of O
huntingtin O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
. O

cleavage O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
peptidase O
, O
is O
regulate O
by O
the O
polyglutamine O
tract O
. O

Cleavage O
of O
aside O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
apart O
apart O
apart O
aside O
. O

Cleavage O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
is O
modulated O
the O
polyglutamine O
tract O
. O

Cleavage O
of O
aside O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
apart O
apart O
apart O
aside O
. O

of O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
. O

Cleavage O
of O
cysteine O
the O
apopain O
, O
modulated O
proapoptotic O
huntingtin O
protease O
, O
is O
a O
by O
by O
polyglutamine O
tract O
. O

Cleavage O
of O
huntingtin O
by O
apopain O
, O
a O
proapoptotic O
cysteine O
protease O
, O
is O
modulated O
by O
the O
polyglutamine O
tract O
. O

death O
has O
recently O
mode O
recognized O
as O
a O
been O
( O
cell O
disease O
in O
Apoptosis B
Huntington I
of O
HD B
) O
. O

Apoptosis O
has O
latterly O
been O
distinguish O
as O
a O
modality O
of O
cell O
expiry O
in O
Huntington B
disease I
( O
HD B
) O
. O

Apoptosis O
has O
recently O
been O
recognized O
as O
a O
style O
of O
cell O
expiry O
in O
Huntington B
disease I
( O
HD B
) O
. O

Apoptosis O
has O
recently O
as O
a O
mode O
of O
cell O
death O
in O
Huntington B
disease I
( O
HD B
) O
. O

Apoptosis O
has O
recently O
been O
recognized O
as O
a O
mode O
of O
cadre O
decease O
in O
huntington B
disease I
( O
HD B
) O
. O

Apoptosis O
has O
of O
late O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
death O
in B
Huntington I
disease O
( B
HD O
) O
manner O
manner O
manner O
manner O

Apoptosis O
has O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
in O
Huntington B
( O
HD B
) O
. O

Apoptosis O
has O
of O
late O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
death O
in B
Huntington I
disease O
( B
HD O
) O
manner O
manner O
manner O
manner O

has O
recognized O
as O
a O
mode O
of O
cell O
death O
in O
Huntington B
. O

Apoptosis O
has O
of O
( O
recognized O
as O
Huntington O
mode O
recently O
cell O
death O
in O
a B
disease I
been O
HD B
) O
. O

Apoptosis O
has O
recently O
been O
recognized O
as O
a O
mode O
of O
cell O
death O
in O
Huntington B
disease I
( O
HD B
) O
. O

Apopain O
, O
a O
human O
cistron O
intersection O
pass O
caspase O
mediated O
cell O
death O
twin O
counterpart O
of O
the O
nematode O
cysteine O
protease O
death O
- O
gene O
product O
, O
CED O
- O
3 O
pass O
case O
, O
has O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O
apoptosis O

Apopain O
, O
a O
human O
cistron O
intersection O
pass O
caspase O
mediated O
cell O
death O
twin O
counterpart O
of O
the O
nematode O
cysteine O
protease O
death O
- O
gene O
product O
, O
CED O
- O
3 O
pass O
antiophthalmic O
factor O
, O
has O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O

apoptosis O
, O
proteolytic O
, O
counterpart O
of O
to O
nematode O
human O
protease O
death O
- O
a O
product O
a O
cysteine O
- O
3 O
, O
has O
gene O
key O
role O
in O
CED O
the O
leading O
events O
Apopain O
. O

Apopain O
, O
a O
human O
cistron O
intersection O
pass O
caspase O
mediated O
cell O
death O
twin O
counterpart O
of O
the O
nematode O
cysteine O
protease O
death O
- O
gene O
product O
, O
CED O
- O
3 O
pass O
case O
, O
has O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O
apoptosis O

Apopain O
, O
a O
human O
counterpart O
of O
the O
cysteine O
protease O
- O
gene O
product O
, O
CED O
- O
3 O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O
apoptosis O
. O

Apopain O
, O
a O
homo O
counterpart O
of O
the O
roundworm O
cysteine O
protease O
destruction O
- O
cistron O
merchandise O
, O
CED O
- O
3 O
, O
has O
a O
key O
purpose O
in O
proteolytic O
events O
starring O
to O
apoptosis O
. O

- O
, O
a O
human O
counterpart O
of O
key O
- O
cysteine O
protease O
death O
Apopain O
apoptosis O
in O
CED O
, O
3 O
proteolytic O
, O
has O
a O
the O
role O
product O
nematode O
events O
leading O
to O
gene O
. O

a O
, O
a O
, O
counterpart O
of O
the O
events O
in O
protease O
apoptosis O
- O
leading O
has O
role O
CED O
- O
3 O
human O
product O
proteolytic O
key O
, O
cysteine O
Apopain O
nematode O
gene O
to O
death O
. O

Apopain O
, O
a O
human O
counterpart O
of O
the O
roundworm O
cysteine O
protease O
expiry O
- O
cistron O
intersection O
, O
CED O
- O
ternion O
, O
has O
a O
key O
use O
in O
proteolytic O
effect O
pass O
to O
apoptosis O
. O

Apopain O
, O
a O
human O
counterpart O
the O
cysteine O
protease O
death O
- O
gene O
product O
, O
CED O
3 O
, O
has O
a O
key O
role O
in O
leading O
to O
apoptosis O

Apopain O
, O
a O
human O
counterpart O
of O
the O
nematode O
cysteine O
protease O
death O
- O
gene O
product O
, O
CED O
- O
3 O
, O
has O
a O
key O
role O
in O
proteolytic O
events O
leading O
to O
apoptosis O
. O

cleave O
we O
show O
apopain O
apoptotic O
extracts O
and O
that O
product O
specifically O
gene O
the O
Here B
HD O
itself O
, O
huntingtin O
. O

Here O
we O
present O
that O
apoptotic O
infusion O
and O
apopain O
itself O
specifically O
stick O
the O
HD B
cistron O
ware O
, O
huntingtin O
. O

here O
we O
indicate O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
stick O
the O
HD B
cistron O
merchandise O
, O
huntingtin O
. O

Here O
we O
show O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
HD B
gene O
product O
, O
huntingtin O
. O

hither O
we O
evidence O
that O
apoptotic O
elicit O
and O
apopain O
itself O
specifically O
adhere O
the O
HD B
gene O
ware O
, O
huntingtin O
. O

Here O
we O
usher O
show O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
HD B
gene O
product O
, O
huntingtin O
ussher O
ussher O
ussher O
usher O
. O

Here O
we O
show O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
the O
HD B
product O
, O
huntingtin O
. O

Here O
we O
usher O
show O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
HD B
gene O
product O
, O
huntingtin O
ussher O
ussher O
ussher O
usher O
. O

we O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
HD B
. O

Here O
we O
itself O
product O
apoptotic O
extracts O
HD O
apopain O
show O
specifically O
cleave O
the O
and B
gene O
that O
, O
huntingtin O
. O

Here O
we O
show O
that O
apoptotic O
extracts O
and O
apopain O
itself O
specifically O
cleave O
the O
HD B
gene O
product O
, O
huntingtin O
. O

The O
grade O
of O
segmentation O
increment O
with O
the O
duration O
of O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
account O
for O
the O
attain O
- O
of O
- O
serve O
associated O
with O
CAG O
elaboration O
. O

The O
rate O
of O
cleavage O
increases O
the O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
- O
function O
associated O
with O
CAG O
expansion O
. O

- O
rate O
of O
the O
increases O
with O
the O
with O
function O
the O
. O
polyglutamine O
tract O
gain O
- O
an O
explanation O
for O
cleavage O
, O
associated O
of O
providing O
of O
The O
length O
CAG O
expansion O
huntingtin O

The O
rate O
of O
cleavage O
pamphlet O
growth O
allow O
for O
associate O
in O
nursing O
growth O
increases O
with O
the O
length O
of O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
serve O
assort O
segmentation O
the O
gain O
- O
of O
- O
function O
associated O
with O

The O
rate O
of O
cleavage O
pamphlet O
growth O
allow O
for O
associate O
in O
nursing O
growth O
increases O
with O
the O
length O
of O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
serve O
assort O
allow O
for O
the O
gain O
- O
of O
- O
function O
associated O

The O
rate O
of O
cleavage O
increases O
with O
the O
length O
the O
huntingtin O
tract O
, O
providing O
an O
explanation O
for O
the O
of O
- O
function O
associated O
with O
CAG O
expansion O
. O

. O
rate O
of O
providing O
increases O
with O
with O
length O
cleavage O
the O
huntingtin O
polyglutamine O
CAG O
, O
associated O
of O
explanation O
for O
the O
gain O
tract O
of O
- O
function O
an O
the O
- O
expansion O
The O

The O
rate O
of O
cleavage O
increases O
with O
the O
length O
the O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
the O
- O
of O
- O
function O
associated O
with O
CAG O

The O
range O
of O
segmentation O
addition O
with O
the O
duration O
of O
the O
huntingtin O
polyglutamine O
pathway O
, O
providing O
an O
account O
for O
the O
gain O
- O
of O
- O
go O
associated O
with O
CAG O
elaboration O
. O

The O
rate O
of O
segmentation O
increment O
with O
the O
duration O
of O
the O
huntingtin O
polyglutamine O
pamphlet O
, O
render O
an O
account O
for O
the O
advance O
- O
of O
- O
function O
associated O
with O
CAG O
enlargement O
. O

The O
rate O
of O
cleavage O
increases O
with O
the O
length O
of O
the O
huntingtin O
polyglutamine O
tract O
, O
providing O
an O
explanation O
for O
the O
gain O
- O
of O
- O
function O
associated O
with O
CAG O
expansion O
. O

Our O
results O
show O
by O
cysteine O
proteases O
and O
suggest O
that O
HD B
might O
be O
a O
disorder B
of I
inappropriate I
apoptosis I
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
might O
disorder B
of I
inappropriate I
apoptosis I
. O
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
HD B
might O
be O
a O
disorder B
caspase B
mediated B
cell B
death B
caspase B
mediated B
cell I
death I
usher I
usher O
usher O

Our O
termination O
record O
that O
huntingtin O
is O
rive O
by O
cysteine O
proteases O
and O
evoke O
that O
HD B
might O
be O
a O
distract B
of I
inappropriate I
apoptosis I
. O
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
HD B
might O
be O
a O
disorder B
caspase B
mediated B
cell B
death B
caspase B
mediated B
cell I
death I
usher I
usher O
usher O

Our O
ensue O
show O
that O
huntingtin O
is O
stick O
by O
cysteine O
peptidase O
and O
propose O
that O
HD B
power O
be O
a O
trouble B
of I
inappropriate I
apoptosis I
. O
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
suggest O
that O
might O
be O
a O
disorder B
of I
inappropriate I
apoptosis I

and O
results O
show O
of O
huntingtin O
is O
cleaved O
cysteine O
by O
proteases O
inappropriate O
suggest O
HD O
that B
. O
be O
a O
disorder B
that I
Our I
apoptosis I
. O
might O

Our O
event O
prove O
that O
huntingtin O
is O
split O
by O
cysteine O
peptidase O
and O
indicate O
that O
HD B
might O
be O
a O
unhinge B
of I
inappropriate I
apoptosis I
. O
. O

might O
results O
cysteine O
cleaved O
huntingtin O
is O
be O
by O
show O
proteases O
and O
suggest O
apoptosis O
HD B
that O
Our O
a O
disorder B
of I
inappropriate I
that I
. O
. O

Our O
results O
show O
that O
huntingtin O
is O
cleaved O
by O
cysteine O
proteases O
and O
suggest O
that O
HD B
might O
be O
a O
disorder B
of I
inappropriate I
apoptosis I
. O
. O

a O
5 O
' O
gene O
of O
the O
BRCA1 O
end O
human O
within O
of O
duplicated O
The O
region O
lies O
chromosome O
17q21 O
. O

The O
phoebe O
' O
closing O
of O
the O
BRCA1 O
cistron O
dwell O
inside O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
. O

The O
cinque O
' O
cease O
of O
the O
BRCA1 O
gene O
lies O
inside O
a O
repeat O
region O
of O
homo O
chromosome O
17q21 O
. O

The O
5 O
' O
the O
BRCA1 O
gene O
lies O
within O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
. O

The O
fin O
' O
terminal O
of O
the O
BRCA1 O
factor O
lies O
within O
a O
repeat O
part O
of O
human O
chromosome O
17q21 O
. O

The O
5 O
prevarication O
' O
end O
of O
the O
BRCA1 O
gene O
lies O
within O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
lie O
lie O
lie O
cistron O
. O

The O
5 O
' O
end O
of O
the O
BRCA1 O
gene O
lies O
within O
duplicated O
region O
human O
chromosome O
17q21 O
. O

The O
5 O
prevarication O
' O
end O
of O
the O
BRCA1 O
gene O
lies O
within O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
lie O
lie O
lie O
cistron O
. O

5 O
of O
the O
BRCA1 O
gene O
lies O
within O
a O
duplicated O
region O
. O

The O
5 O
lies O
human O
of O
the O
region O
gene O
' O
within O
a O
duplicated O
BRCA1 O
of O
end O
chromosome O
17q21 O
. O

The O
5 O
' O
end O
of O
the O
BRCA1 O
gene O
lies O
within O
a O
duplicated O
region O
of O
human O
chromosome O
17q21 O
. O

To O
begin O
to O
address O
the O
supposition O
that O
unnatural O
rule O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibleness O
factor O
BRCA1 O
is O
a O
decisive O
mistreat O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
see O
the O
elaborated O
structure O
of O
the O
BRCA1 O
genomic O
neighborhood O
. O

To O
begin O
to O
address O
the O
conjecture O
that O
unnatural O
regularization O
of O
the O
titty B
/ I
ovarian I
crab I
susceptibleness O
factor O
BRCA1 O
is O
a O
decisive O
step O
in O
sporadic O
titty O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
specify O
the O
elaborate O
structure O
of O
the O
BRCA1 O
genomic O
realm O
. O

To O
the O
that O
abnormal O
regulation O
the O
breast B
/ I
cancer I
susceptibility O
gene O
BRCA1 O
is O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
determined O
detailed O
structure O
of O
BRCA1 O
genomic O
region O
. O

To O
begin O
determined O
address O
the O
, O
/ O
abnormal O
regulation O
of O
the O
sporadic B
tumorigenesis I
ovarian I
cancer I
have O
gene O
BRCA1 O
a O
is O
critical O
step O
in O
of O
breast O
ovarian O
/ O
the O
hypothesis O
we O
susceptibility O
BRCA1 O
that O
detailed O
structure O
breast O
the O
to O
genomic O
region O
. O

breast O
is O
to O
address O
the O
hypothesis O
breast O
step O
regulation O
of O
the O
that B
/ I
tumorigenesis I
we I
susceptibility O
gene O
BRCA1 O
. O
a O
critical O
abnormal O
, O
sporadic O
To O
/ O
determined O
ovarian O
cancer O
in O
have O
of O
the O
begin O
structure O
ovarian O
the O
BRCA1 O
genomic O
region O
detailed O

To O
begin O
to O
address O
that O
abnormal O
regulation O
of O
breast B
/ I
ovarian I
cancer I
susceptibility O
BRCA1 O
is O
a O
critical O
in O
sporadic O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
structure O
of O
BRCA1 O
genomic O
region O
. O

To O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
is O
a O
critical O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
cistron O
cistron O
realm O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
the O
BRCA1 O
genomic O
region O
. O

To O
begin O
to O
address O
abnormal O
regulation O
of O
the O
breast B
ovarian I
cancer I
is O
step O
in O
/ O
, O
we O
have O
determined O
detailed O
structure O
BRCA1 O
genomic O
. O

To O
start O
to O
call O
the O
supposition O
that O
unnatural O
regularisation O
of O
the O
chest B
/ I
ovarian I
cancer I
susceptibleness O
cistron O
BRCA1 O
is O
a O
decisive O
step O
in O
sporadic O
chest O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
learn O
the O
elaborated O
structure O
of O
the O
BRCA1 O
genomic O
part O
. O

To O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
is O
a O
critical O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
cistron O
cistron O
realm O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
the O
BRCA1 O
genomic O
region O
. O

To O
begin O
to O
address O
the O
hypothesis O
that O
abnormal O
regulation O
of O
the O
breast B
/ I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
is O
a O
critical O
step O
in O
sporadic O
breast O
/ O
ovarian O
tumorigenesis O
, O
we O
have O
determined O
the O
detailed O
structure O
of O
the O
BRCA1 O
genomic O
region O
. O

We O
this O
region O
of O
genome O
a O
tandem O
duplication O
30 O
in O
two O
copies O
BRCA1 O
exons O
and O
2 O
, O
1 O
and O
3 O
of O
the O
1A1 O
3B O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
region O
. O

We O
show O
that O
this O
region O
of O
the O
genome O
exon O
 O
hold O
back O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
of O
the O
cistron O
antecedently O
report O
cistron O
fundament O
couplet O
realm O
realm O
couplet O
realm O
realm O
inward O
adjacent O
1A1 O
- O
3B O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
intergenic O
region O

We O
show O
that O
this O
region O
of O
the O
genome O
exon O
 O
hold O
back O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
of O
the O
cistron O
antecedently O
report O
cistron O
fundament O
couplet O
realm O
realm O
couplet O
realm O
realm O
 O
adjacent O
1A1 O
- O
3B O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
intergenic O
region O

of O
and O
that O
this O
region O
of O
duplication O
genome O
contains O
a O
tandem O
the O
of O
2 O
, O
kilobases O
, O
which O
of O
in O
two O
copies O
3 O
BRCA1 O
the O
1 O
295 O
approximately O
pair O
results O
exons O
the O
and O
30 O
We O
and O
adjacent O
1A1 O
- O
3B O
show O
1 O
of O
of O
previously O
reported O
gene O
base O
exons O
intergenic O
region O
. O

previously O
exons O
that O
this O
region O
of O
two O
, O
contains O
a O
tandem O
duplication O
of O
region O
1A1 O
kilobases O
genome O
exons O
results O
in O
pair O
copies O
of O
BRCA1 O
show O
1 O
and O
- O
which O
of O
, O
the O
and O
3 O
of O
the O
adjacent O
30 O
2 O
3B O
gene O
and O
of O
the O
We O
reported O
. O
base O
intergenic O
1 O
approximately O
295 O

We O
show O
that O
this O
region O
of O
the O
genome O
exon O
 O
hold O
back O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
of O
the O
cistron O
antecedently O
report O
cistron O
fundament O
couplet O
realm O
realm O
couplet O
realm O
realm O
 O
adjacent O
1A1 O
- O
3B O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
intergenic O
region O

We O
show O
this O
the O
genome O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
the O
1A1 O
- O
3B O
gene O
and O
of O
the O
previously O
295 O
base O
pair O
intergenic O
region O
. O

We O
show O
exons O
this O
region O
of O
the O
results O
contains O
a O
tandem O
BRCA1 O
in O
approximately O
30 O
copies O
, O
which O
1A1 O
of O
two O
base O
of O
duplication O
exons O
. O
2 O
and O
, O
of O
that O
of O
1 O
3 O
of O
previously O
adjacent O
1 O
- O
3B O
gene O
and O
and O
the O
the O
295 O
reported O
kilobases O
pair O
intergenic O
region O
genome O

We O
demo O
that O
this O
part O
of O
the O
genome O
incorporate O
a O
tandem O
gemination O
of O
about O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
ii O
, O
of O
exons O
1 O
and O
threesome O
of O
the O
contiguous O
1A1 O
- O
3B O
factor O
and O
of O
the O
antecedently O
cover O
295 O
substructure O
brace O
intergenic O
part O
. O

We O
show O
that O
contains O
duplication O
approximately O
30 O
kilobases O
which O
results O
in O
two O
copies O
of O
and O
2 O
, O
of O
exons O
1 O
and O
of O
the O
- O
3B O
gene O
of O
reported O
295 O
base O
pair O
intergenic O
region O
. O

We O
show O
that O
this O
region O
of O
the O
genome O
contains O
a O
tandem O
duplication O
of O
approximately O
30 O
kilobases O
, O
which O
results O
in O
two O
copies O
of O
BRCA1 O
exons O
1 O
and O
2 O
, O
of O
exons O
1 O
and O
3 O
of O
the O
adjacent O
1A1 O
- O
3B O
gene O
and O
of O
the O
previously O
reported O
295 O
base O
pair O
intergenic O
region O
. O

succession O
analysis O
of O
the O
twin O
exons O
of O
BRCA1 O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
DNA O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
level O
of O
base O
succession O
identity O
, O
hint O
that O
these O
are O
not O
- O
litigate O
pseudogenes O
and O
that O
the O
gemination O
is O
a O
holocene O
outcome O
in O
evolutionary O
condition O
. O

Sequence O
analysis O
the O
of O
BRCA1 O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
these O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
a O
recent O
event O
in O
evolutionary O
terms O
. O

successiveness O
analysis O
of O
the O
twin O
exons O
of O
BRCA1 O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
dna O
reveals O
care O
of O
the O
intron O
- O
exon O
structure O
and O
a O
luxuriously O
point O
of O
base O
successiveness O
individuality O
, O
suggesting O
that O
these O
are O
not O
- O
processed O
pseudogenes O
and O
that O
the O
gemination O
is O
a O
late O
effect O
in O
evolutionary O
terms O
. O

that O
high O
of O
the O
duplicated O
exons O
3B O
BRCA1 O
and O
1A1 O
- O
of O
and O
degree O
of O
DNA O
reveals O
maintenance O
nucleotide O
the O
intron O
- O
suggesting O
structure O
the O
a O
a O
flanking O
event O
of O
sequence O
these O
, O
genomic O
Sequence O
and O
are O
non O
- O
processed O
analysis O
identity O
that O
exon O
duplication O
is O
pseudogenes O
recent O
and O
in O
evolutionary O
terms O
. O

Sequence O
of O
1A1 O
3B O
and O
flanking O
DNA O
reveals O
maintenance O
of O
the O
intron O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
, O
suggesting O
are O
non O
- O
pseudogenes O
the O
duplication O
is O
a O
recent O
event O
in O

duplication O
and O
of O
the O
duplicated O
exons O
intron O
reveals O
and O
1A1 O
- O
3B O
and O
evolutionary O
non O
DNA O
BRCA1 O
sequence O
of O
the O
event O
- O
exon O
structure O
analysis O
a O
high O
- O
maintenance O
nucleotide O
of O
of O
, O
suggesting O
that O
these O
are O
genomic O
degree O
processed O
pseudogenes O
and O
that O
the O
Sequence O
is O
terms O
recent O
in O
identity O
flanking O
a O
. O

of O
the O
duplicated O
of O
and O
1A1 O
- O
flanking O
of O
the O
intron O
exon O
structure O
a O
high O
degree O
sequence O
identity O
, O
suggesting O
that O
are O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
in O
evolutionary O
terms O
. O

Sequence O
analysis O
of O
the O
duplicated O
exons O
of O
BRCA1 O
base O
episode O
identity O
operator O
dna O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
DNA O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
that O
these O
duplicate O
be O
antiophthalmic O
factor O
holocene O
case O
inward O
holocene O
damage O
inward O
holocene O
discover O
are O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
event O
in O
evolutionary O

Sequence O
analysis O
of O
the O
duplicated O
exons O
of O
BRCA1 O
base O
episode O
identity O
operator O
dna O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
DNA O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
that O
these O
duplicate O
be O
antiophthalmic O
factor O
holocene O
case O
inward O
holocene O
damage O
inward O
holocene O
discover O
are O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
event O
in O
evolutionary O

Sequence O
analysis O
of O
the O
duplicated O
exons O
of O
BRCA1 O
base O
episode O
identity O
operator O
dna O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
DNA O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
that O
these O
duplicate O
be O
antiophthalmic O
factor O
holocene O
case O
inward O
holocene O
damage O
inward O
holocene O
be O
are O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
event O
in O
evolutionary O

Sequence O
analysis O
of O
the O
duplicated O
exons O
of O
BRCA1 O
and O
1A1 O
- O
3B O
and O
flanking O
genomic O
DNA O
reveals O
maintenance O
of O
the O
intron O
- O
exon O
structure O
and O
a O
high O
degree O
of O
nucleotide O
sequence O
identity O
, O
suggesting O
that O
these O
are O
non O
- O
processed O
pseudogenes O
and O
that O
the O
duplication O
is O
a O
recent O
event O
in O
evolutionary O
terms O
. O

We O
likewise O
indicate O
that O
a O
processed O
pseudogene O
of O
the O
acidulous O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
) O
is O
inserted O
now O
upriver O
of O
shammer O
- O
BRCA1 O
exon O
1A O
. O

We O
also O
that O
a O
processed O
pseudogene O
of O
the O
acidic O
ribosomal O
phosphoprotein O
P1 O
) O
is O
inserted O
directly O
of O
pseudo O
- O
BRCA1 O
exon O
. O

We O
also O
show O
that O
litigate O
coding O
dna O
antiophthalmic O
factor O
a O
processed O
pseudogene O
of O
the O
acidic O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
) O
is O
inserted O
faker O
coding O
dna O
usher O
coding O
dna O
coding O
dna O
directly O
upstream O
of O
pseudo O

of O
also O
show O
directly O
a O
processed O
pseudogene O
1A O
BRCA1 O
acidic O
upstream O
phosphoprotein O
P1 O
( O
- O
) O
is O
inserted O
that O
exon O
ribosomal O
pseudo O
ARPP1 O
the O
We O
of O
. O

We O
also O
show O
that O
litigate O
coding O
dna O
antiophthalmic O
factor O
a O
processed O
pseudogene O
of O
the O
acidic O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
) O
is O
inserted O
faker O
coding O
dna O
usher O
coding O
dna O
coding O
dna O
directly O
upstream O
of O
pseudo O

We O
also O
show O
a O
processed O
of O
the O
acidic O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
is O
inserted O
upstream O
of O
pseudo O
- O
BRCA1 O
exon O
1A O
. O

. O
also O
show O
ARPP1 O
a O
processed O
1A O
of O
that O
acidic O
ribosomal O
phosphoprotein O
( O
of O
exon O
the O
is O
inserted O
directly O
upstream O
P1 O
pseudo O
- O
BRCA1 O
) O
pseudogene O
We O

show O
processed O
pseudogene O
of O
acidic O
ribosomal O
P1 O
( O
ARPP1 O
) O
is O
inserted O
directly O
upstream O
of O
pseudo O
- O
BRCA1 O
exon O

BRCA1 O
also O
show O
that O
a O
processed O
( O
phosphoprotein O
the O
acidic O
ribosomal O
is O
pseudo O
pseudogene O
exon O
We O
of O
) O
directly O
upstream O
of O
P1 O
- O
inserted O
ARPP1 O
1A O
. O

We O
too O
shew O
that O
a O
action O
pseudogene O
of O
the O
acidulous O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
) O
is O
inserted O
forthwith O
upriver O
of O
pretender O
- O
BRCA1 O
exon O
1A O
. O

We O
also O
show O
that O
a O
processed O
pseudogene O
of O
the O
acidic O
ribosomal O
phosphoprotein O
P1 O
( O
ARPP1 O
) O
is O
inserted O
directly O
upstream O
of O
pseudo O
- O
BRCA1 O
exon O
1A O
. O

We O
believe O
that O
these O
interlingual O
rendition O
simply O
serve O
rich O
person O
find O
out O
findings O
could O
not O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
BRCA1 O
transcription O
, O
translation O
and O
function O
. O
depth O
psychology O

We O
believe O
findings O
BRCA1 O
mutation O
analysis O
but O
could O
implications O
for O
the O
abnormal O
regulation O
of O
BRCA1 O
transcription O
translation O
function O
. O
. O

We O
believe O
that O
these O
notice O
could O
not O
only O
fox O
BRCA1 O
mutant O
analysis O
, O
but O
could O
have O
implications O
for O
the O
convention O
and O
unnatural O
regularisation O
of O
BRCA1 O
recording O
, O
displacement O
and O
routine O
. O
. O

We O
believe O
that O
these O
could O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
abnormal O
regulation O
of O
BRCA1 O
transcription O
, O
translation O
and O
function O
. O
. O

We O
believe O
that O
these O
retrieve O
could O
not O
only O
confound O
BRCA1 O
sport O
analysis O
, O
but O
could O
have O
import O
for O
the O
rule O
and O
unnatural O
regularisation O
of O
BRCA1 O
recording O
, O
transformation O
and O
run O
. O
. O

We O
believe O
that O
these O
interlingual O
rendition O
simply O
serve O
rich O
person O
find O
out O
findings O
could O
not O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
BRCA1 O
transcription O
, O
translation O
and O
function O
. O
depth O
psychology O

We O
believe O
that O
these O
observe O
could O
not O
only O
throw O
BRCA1 O
sport O
analysis O
, O
but O
could O
have O
implications O
for O
the O
convention O
and O
unnatural O
regularization O
of O
BRCA1 O
arranging O
, O
rendering O
and O
procedure O
. O
. O

and O
the O
that O
these O
findings O
could O
not O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
BRCA1 O
function O
have O
implications O
for O
translation O
normal O
believe O
abnormal O
. O
of O
but O
transcription O
, O
We O
could O
regulation O
. O
and O

We O
believe O
that O
these O
could O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
transcription O
, O
translation O
function O
. O

We O
believe O
that O
these O
merely O
simply O
serve O
rich O
person O
simply O
findings O
could O
not O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
BRCA1 O
transcription O
, O
translation O
and O
function O
. O
simply O
simply O
simply O
depth O

We O
believe O
that O
these O
findings O
could O
not O
only O
confound O
BRCA1 O
mutation O
analysis O
, O
but O
could O
have O
implications O
for O
the O
normal O
and O
abnormal O
regulation O
of O
BRCA1 O
transcription O
, O
translation O
and O
function O
. O
. O

Deletion O
of O
cytogenetic O
nuclear O
ribonucleoprotein O
polypeptide O
Prader O
in O
SNRPN O
) O
in O
typical B
situ I
Willi I
syndrome I
phenotype O
by O
fluorescence O
deletion O
- O
hybridization O
in O
two O
sibs O
with O
detected O
N O
: O
without O
a O
small O
( O
the O
chromosome O
15q O
. O

of O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
: O
two O
sibs O
the O
phenotype O
without O
a O
in O

cut O
of O
small O
atomic O
ribonucleoprotein O
polypeptide O
n O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
situ O
hybridisation O
: O
deuce O
sibs O
with O
the O
distinctive O
phenotype O
without O
a O
cytogenetic O
cut O
in O
chromosome O
15q O
. O

phenotype O
hybridization O
small O
nuclear O
by O
polypeptide O
syndrome O
deletion O
SNRPN O
) O
in O
Prader B
- I
with I
( I
detected O
ribonucleoprotein O
cytogenetic O
in O
situ O
Willi O
: O
two O
sibs O
of O
the O
typical O
Deletion O
fluorescence O
a O
without O
N O
in O
chromosome O
15q O
. O

Deletion O
of O
small O
nuclear O
aside O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
situ O
hybridization O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
apart O
apart O
apart O
apart O
apart O
apart O
apart O
apart O
observe O
. O

with O
in O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
Prader B
- I
phenotype I
a I
detected O
by O
fluorescence O
chromosome O
situ O
hybridization O
: O
without O
sibs O
Deletion O
the O
deletion O
Willi O
syndrome O
two O
cytogenetic O
. O
in O
15q O
of O
typical O

Deletion O
of O
small O
nuclear O
polypeptide O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
. O

cut O
of O
little O
atomic O
ribonucleoprotein O
polypeptide O
n O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
discover O
by O
fluorescence O
in O
situ O
crossing O
: O
deuce O
sibs O
with O
the O
distinctive O
phenotype O
without O
a O
cytogenetic O
cut O
in O
chromosome O
15q O
. O

Deletion O
of O
small O
nuclear O
low O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
situ O
hybridization O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
crushed O
crushed O
crushed O
crushed O
crushed O
crushed O
crushed O
crushed O
observe O
. O

omission O
of O
little O
atomic O
ribonucleoprotein O
polypeptide O
n O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
find O
by O
fluorescence O
in O
situ O
hybridisation O
: O
deuce O
sibs O
with O
the O
distinctive O
phenotype O
without O
a O
cytogenetic O
omission O
in O
chromosome O
15q O
. O

Deletion O
of O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
in O
Prader B
- I
Willi I
syndrome I
detected O
by O
fluorescence O
in O
situ O
hybridization O
: O
two O
sibs O
with O
the O
typical O
phenotype O
without O
a O
cytogenetic O
deletion O
in O
chromosome O
15q O
. O

small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
gene O
is O
regarded O
as O
one O
of O
the O
for O
- I
Willi I
syndrome I
( O
PWS B
) O
. O

is O
small O
nuclear O
Prader O
polypeptide O
N O
( O
. O
PWS O
gene O
) O
regarded O
as O
- O
( O
the O
candidates O
for O
ribonucleoprotein B
one I
Willi I
syndrome I
of O
) B
The O
SNRPN O

The O
diminished O
atomic O
ribonucleoprotein O
polypeptide O
n O
( O
SNRPN O
) O
cistron O
is O
reckon O
as O
unrivaled O
of O
the O
candidates O
for O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

The O
lowly O
atomic O
ribonucleoprotein O
polypeptide O
north O
( O
SNRPN O
) O
cistron O
is O
affect O
as O
i O
of O
the O
candidates O
for O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

The O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
gene O
regarded O
as O
of O
the O
candidates O
for O
Prader B
- I
Willi I
PWS B
) O
. O

The O
small O
nuclear O
ribonucleoprotein O
nominee O
polypeptide O
N O
( O
SNRPN O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
atomic O
atomic O
atomic O
atomic O
atomic O
a O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

The O
small O
nuclear O
ribonucleoprotein O
nominee O
polypeptide O
N O
( O
SNRPN O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
atomic O
atomic O
atomic O
atomic O
atomic O
be O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

The O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
gene O
regarded O
of O
the O
candidates O
for O
Prader B
- I
Willi I
syndrome I
( O

PWS O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
one O
candidates O
) O
gene O
is O
regarded O
syndrome O
( O
) O
the O
SNRPN O
Willi O
Prader B
- I
The I
as I
( O
for B
of O
. O

The O
minor O
atomic O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
factor O
is O
see O
as O
unmatchable O
of O
the O
prospect O
for O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

The O
small O
nuclear O
ribonucleoprotein O
polypeptide O
N O
( O
SNRPN O
) O
gene O
is O
regarded O
as O
one O
of O
the O
candidates O
for O
Prader B
- I
Willi I
syndrome I
( O
PWS B
) O
. O

We O
key O
deuce O
cognate O
with O
distinctive O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
crossbreeding O
( O
pisces O
) O
. O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
hybridization O
( O
 O
 O
 O
 O
 O
 O
FISH O
) O
. O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
hybridization O
( O
 O
 O
 O
 O
 O
 O
FISH O
) O
. O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
of O
SNRPN O
by O
fluorescence O
in O
situ O
hybridization O
( O
FISH O

in O
describe O
deletion O
PWS O
with O
typical O
situ B
presenting O
two O
of O
SNRPN O
detected O
. O
fluorescence O
sibs O
We O
hybridization O
( O
FISH O
) O
by O

We O
depict O
deuce O
sibs O
with O
distinctive O
PWS B
confront O
cut O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
crossbreeding O
( O
FISH O
) O
. O

. O
describe O
two O
SNRPN O
with O
typical O
PWS B
FISH O
in O
of O
sibs O
detected O
fluorescence O
by O
deletion O
situ O
hybridization O
( O
presenting O
We O
) O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
hybridization O
( O
 O
 O
 O
 O
 O
fish O
FISH O
) O
. O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
in O
( O
FISH O
) O
. O

We O
name O
ii O
sibs O
with O
distinctive O
PWS B
presenting O
excision O
of O
SNRPN O
discover O
by O
fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
. O

We O
describe O
two O
sibs O
with O
typical O
PWS B
presenting O
deletion O
of O
SNRPN O
detected O
by O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
. O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
inward O
find O
out O
patient O
role O
inward O
patient O
role O
patient O
role O
neither O
probes O
were O
found O

detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
were O
in O
either O
patient O
. O

neither O
a O
cytogenetically O
noticeable O
15q12 O
cut O
nor O
a O
cut O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
examine O
were O
discover O
in O
either O
patient O
. O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
D15S11 O
, O
, O
and O
GABRB3 O
cosmid O
probes O
were O
found O
patient O
. O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
inward O
find O
out O
patient O
role O
inward O
patient O
role O
patient O
role O
cut O
probes O
were O
found O

neither O
a O
cytogenetically O
noticeable O
15q12 O
excision O
nor O
a O
excision O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
probes O
were O
discover O
in O
either O
patient O
. O

neither O
a O
cytogenetically O
perceptible O
15q12 O
cut O
nor O
a O
cut O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
probes O
were O
ground O
in O
either O
patient O
. O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
, O
and O
GABRB3 O
cosmid O
probes O
were O
found O
in O
either O
patient O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
inward O
find O
out O
patient O
role O
inward O
patient O
role O
patient O
role O
cut O
probes O
were O
found O

were O
a O
cytogenetically O
the O
15q12 O
deletion O
nor O
probes O
patient O
for O
detectable O
D15S11 O
D15S10 O
, O
either O
and O
GABRB3 O
cosmid O
a O
. O
found O
in O
, O
deletion O
Neither O

Neither O
a O
cytogenetically O
detectable O
15q12 O
deletion O
nor O
a O
deletion O
for O
the O
D15S11 O
, O
D15S10 O
, O
and O
GABRB3 O
cosmid O
probes O
were O
found O
in O
either O
patient O
. O

This O
implies O
a O
smaller O
deletion O
limited O
to O
the O
PWS B
realm O
connote O
connote O
critical O
region O
. O

implies O
a O
to O
critical O
region O
. O

This O
implies O
a O
smaller O
deletion O
restrict O
to O
the O
PWS B
vital O
part O
. O

This O
implies O
a O
smaller O
deletion O
limited O
to O
the O
PWS B
realm O
connote O
connote O
critical O
region O
. O

implies O
a O
deletion O
limited O
to O
the O
PWS B
critical O
region O
. O

This O
implies O
a O
humble O
omission O
limited O
to O
the O
PWS B
decisive O
region O
. O

This O
implies O
a O
smaller O
deletion O
limited O
to O
the O
PWS B
realm O
connote O
connote O
critical O
region O
. O

This O
implies O
a O
low O
excision O
limited O
to O
the O
PWS B
critical O
realm O
. O

This O
the O
a O
smaller O
implies O
limited O
to O
region O
PWS B
critical O
deletion O
. O

. O
implies O
a O
smaller O
the O
limited O
critical O
deletion O
PWS B
to O
region O
This O

This O
implies O
a O
smaller O
deletion O
limited O
to O
the O
PWS B
critical O
region O
. O

FISH O
with O
a O
SNRPN O
examine O
will O
license O
analysis O
of O
PWS B
patients O
with O
modified O
cut O
not O
perceptible O
with O
other O
investigation O
. O
. O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
of O
PWS B
patients O
with O
limited O
deletions O
not O
detectable O
with O
other O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
of O
PWS B
patients O
with O
limited O
deletions O
not O
detectable O
with O
other O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
PWS B
patients O
limited O
deletions O
not O
detectable O
with O
other O
probes O

not O
with O
of O
permit O
probe O
will O
detectable O
analysis O
a O
PWS B
patients O
with O
. O
deletions O
SNRPN O
FISH O
with O
other O
probes O
. O
limited O

pisces O
with O
a O
SNRPN O
probe O
will O
license O
analysis O
of O
PWS B
patients O
with O
specify O
excision O
not O
perceptible O
with O
other O
investigation O
. O
. O

. O
with O
a O
patients O
probe O
will O
permit O
probes O
not O
PWS B
SNRPN O
with O
deletions O
limited O
of O
detectable O
with O
other O
analysis O
FISH O
. O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
of O
PWS B
patients O
with O
limited O
deletions O
not O
detectable O
with O
other O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
of O
PWS B
patients O
with O
limited O
not O
other O
probes O
. O
. O

pisces O
with O
a O
SNRPN O
probe O
will O
tolerate O
analysis O
of O
PWS B
patients O
with O
restrain O
deletions O
not O
noticeable O
with O
other O
investigation O
. O
. O

FISH O
with O
a O
SNRPN O
probe O
will O
permit O
analysis O
of O
PWS B
patients O
with O
limited O
deletions O
not O
detectable O
with O
other O
probes O
. O
. O

Expression O
Hippel O
the O
von B
of I
- I
disease I
gene I
tumour I
suppressor O
human O
during O
Lindau O
embryogenesis O
. O

Expression O
of O
tumour O
homo O
tumor O
the O
von B
Hippel I
- I
Lindau I
disease I
tumour I
homo O
suppressor O
gene O
during O
human O
embryogenesis O
. O

Expression O
of O
the O
von B
Hippel I
- I
Lindau I
disease I
neoplasm I
suppresser O
factor O
during O
homo O
embryogenesis O
. O

human O
of O
the O
Expression B
disease I
- I
Lindau I
during I
tumour I
suppressor O
gene O
Hippel O
von O
embryogenesis O
. O

locution O
of O
the O
von B
Hippel I
- I
Lindau I
disease I
tumor I
suppresser O
gene O
during O
homo O
embryogenesis O
. O

Expression O
of O
tumour O
homo O
tumor O
the O
von B
Hippel I
- I
Lindau I
disease I
tumour I
homo O
suppressor O
gene O
during O
human O
embryogenesis O
. O

Expression O
the O
Hippel I
Lindau I
disease I
tumour I
suppressor O
gene O
during O
human O
embryogenesis O
. O

disease O
von O
the O
of B
Hippel I
- I
suppressor I
Expression I
tumour I
Lindau O
gene O
during O
human O
. O
embryogenesis O

aspect O
of O
the O
von B
Hippel I
- I
Lindau I
disease I
tumor I
suppressor O
factor O
during O
homo O
embryogenesis O
. O

Expression O
of O
tumour O
homo O
tumor O
the O
von B
Hippel I
- I
Lindau I
disease I
tumour I
homo O
suppressor O
gene O
during O
human O
embryogenesis O
. O

Expression O
of O
the O
von B
Hippel I
- I
Lindau I
disease I
tumour I
suppressor O
gene O
during O
human O
embryogenesis O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
raise O
determine O
extension O
raise O
extension O
extension O
view O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O

- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
elongin O
enhanced O
transcriptional O
elongation O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
mold O
transcription O
by O
counteract O
elongin O
- O
heighten O
transcriptional O
extension O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
thought O
to O
- O
regulate O
transcription O
by O
antagonizing O
elongin O
- O
elongation O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
raise O
determine O
extension O
raise O
extension O
extension O
determine O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
mean O
to O
down O
- O
mold O
transcription O
by O
antagonize O
elongin O
- O
enhanced O
transcriptional O
extension O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
merchandise O
is O
suppose O
to O
down O
- O
determine O
transcription O
by O
counteract O
elongin O
- O
heighten O
transcriptional O
extension O
. O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
to O
regulate O
transcription O
by O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
raise O
determine O
extension O
raise O
extension O
extension O
determine O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O

elongin O
von B
Hippel I
is I
Lindau I
( I
VHL I
antagonizing I
elongation I
product O
- O
thought O
down O
to O
transcriptional O
regulate O
transcription O
by O
) O
. O
- O
enhanced O
- O
disease O
The O

The O
von B
Hippel I
- I
Lindau I
( I
VHL I
) I
disease I
product O
is O
thought O
to O
down O
- O
regulate O
transcription O
by O
antagonizing O
elongin O
- O
enhanced O
transcriptional O
elongation O
. O

phaeochromocytoma O
VHL B
gene O
, O
predispose O
to O
the O
carcinoma O
haemangioblastomas O
retinal B
mutations I
cerebellar I
spinal I
and I
of I
, O
renal B
cell I
development I
Germline O
and B
. O

Germline O
VHL B
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal B
cell I
pheochromocytoma I
pheochromocytoma O
cistron I
cistron O
cistron I
cistron O
carcinoma I
and O
phaeochromocytoma B
. O

Germline O
VHL B
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal B
cell I
pheochromocytoma I
pheochromocytoma O
cistron I
cistron O
cistron I
cistron O
carcinoma I
and O
phaeochromocytoma B
. O

Germline O
VHL B
cistron O
mutations O
predispose O
to O
the O
evolution O
of O
retinene B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
nephritic B
cadre I
carcinoma I
and O
pheochromocytoma B
. O

Germline O
VHL B
gene O
predispose O
to O
the O
development O
of O
, I
cerebellar I
and I
spinal I
, O
renal B
carcinoma I
and O
phaeochromocytoma B
. O

mutations O
the O
development O
of O
, I
cerebellar I
spinal I
haemangioblastomas I
, O
renal B
cell I
carcinoma I
and O
phaeochromocytoma B
. O

Germline O
VHL B
cistron O
variation O
predispose O
to O
the O
maturation O
of O
retinene B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
nephritic B
cell I
carcinoma I
and O
pheochromocytoma B
. O

haemangioblastomas O
VHL B
of O
the O
predispose O
to O
, O
development O
gene O
retinal B
, I
cerebellar I
phaeochromocytoma I
spinal I
mutations I
Germline O
renal B
cell I
carcinoma I
and O
and B
. O

Germline O
VHL B
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal B
cell I
pheochromocytoma I
pheochromocytoma O
cistron I
cistron O
cistron I
retinene O
carcinoma I
and O
phaeochromocytoma B
. O

Germline O
VHL B
gene O
mutations O
the O
development O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal B
cell I
carcinoma I
. O

Germline O
VHL B
gene O
mutations O
predispose O
to O
the O
development O
of O
retinal B
, I
cerebellar I
and I
spinal I
haemangioblastomas I
, O
renal B
cell I
carcinoma I
and O
phaeochromocytoma B
. O

In O
addition O
gene O
cell O
Inactivation O
of O
sporadic O
VHL B
, O
is O
frequent O
in O
the B
renal I
somatic I
carcinoma I
and O
haemangioblastoma B
. O

, O
somatic O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
carcinoma I
and O
haemangioblastoma B
. O

indium O
increase O
, O
somatic O
deactivation O
of O
the O
VHL B
factor O
is O
frequent O
indium O
sporadic B
nephritic I
cell I
carcinoma I
and O
haemangioblastoma B
. O

In O
summation O
, O
corporal O
inactivation O
of O
the O
VHL B
factor O
is O
haunt O
in O
sporadic B
renal I
cell I
carcinoma I
and O
haemangioblastoma B
. O

and O
addition O
, O
somatic O
Inactivation O
of O
renal O
cell B
gene O
is O
frequent O
in O
haemangioblastoma B
the I
VHL I
carcinoma I
sporadic O
In B
. O

In O
addition O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
in O
sporadic B
renal I
cell I
carcinoma I
and O
. O

In O
addition O
, O
somatic O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
in O
sporadic B
renal I
cell I
carcinoma I
and O
haemangioblastoma B
cistron O
cistron O
cistron O
cistron O
inward O
. O

In O
summation O
, O
corporeal O
inactivation O
of O
the O
VHL B
cistron O
is O
frequent O
in O
sporadic B
nephritic I
cell I
carcinoma I
and O
haemangioblastoma B
. O

In O
addition O
, O
somatic O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
in O
sporadic B
renal I
cell I
carcinoma I
and O
haemangioblastoma B
cistron O
cistron O
cistron O
cistron O
cistron O
. O

renal O
addition O
, O
frequent O
Inactivation O
of O
the O
. B
cell O
is O
somatic O
in O
In B
sporadic I
gene I
carcinoma I
and O
haemangioblastoma B
VHL O

In O
addition O
, O
somatic O
Inactivation O
of O
the O
VHL B
gene O
is O
frequent O
in O
sporadic B
renal I
cell I
carcinoma I
and O
haemangioblastoma B
. O

Regulation O
of O
transcript O
elongation O
follow O
be O
associate O
in O
nursing O
cistron O
be O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and B
the O
VHL O
gene O
might O
modify O
cistron O
the O
expression O
of O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
be O
be O

Regulation O
of O
transcript O
elongation O
follow O
be O
associate O
in O
nursing O
cistron O
be O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and B
the O
VHL O
gene O
might O
modify O
oncogene O
the O
expression O
of O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
be O
be O

oncogenes O
of O
transcript O
elongation O
is O
an O
the O
might O
mechanism O
for O
gene O
expression O
proto O
important O
and B
during O
control O
of O
the O
expression O
Regulation O
and O
- O
modify O
VHL O
growth O
suppressor O
genes O
. O
embryogenesis O
gene O

Regulation O
of O
transcript O
elongation O
follow O
be O
associate O
in O
nursing O
cistron O
be O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and B
the O
VHL O
gene O
might O
modify O
cistron O
the O
expression O
of O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
be O
be O

Regulation O
of O
transcript O
elongation O
an O
mechanism O
for O
gene O
expression O
and O
the O
VHL B
gene O
might O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
. O

regularization O
of O
copy O
extension O
is O
an O
important O
assure O
mechanism O
for O
factor O
expression O
and O
the O
VHL B
factor O
power O
alter O
the O
expression O
of O
proto O
- O
oncogenes O
and O
ontogeny O
suppressor O
cistron O
during O
embryogenesis O
. O

during O
of O
and O
VHL O
is O
an O
genes O
control O
elongation O
for O
gene O
expression O
of O
the O
transcript B
mechanism O
might O
modify O
the O
expression O
and O
proto O
- O
oncogenes O
gene O
important O
suppressor O
growth O
Regulation O
embryogenesis O
. O

Regulation O
of O
transcript O
elongation O
is O
an O
important O
control O
mechanism O
gene O
expression O
the O
VHL B
gene O
might O
modify O
the O
expression O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
. O

gene O
of O
transcript O
during O
is O
an O
important O
growth O
oncogenes O
for O
and O
expression O
suppressor O
expression O
- B
gene O
might O
modify O
. O
the O
of O
proto O
VHL O
mechanism O
Regulation O
control O
and O
genes O
elongation O
embryogenesis O
the O

rule O
of O
copy O
extension O
is O
an O
authoritative O
moderate O
mechanism O
for O
gene O
manifestation O
and O
the O
VHL B
gene O
might O
alter O
the O
manifestation O
of O
proto O
- O
oncogenes O
and O
increment O
suppressor O
cistron O
during O
embryogenesis O
. O

Regulation O
of O
transcript O
elongation O
is O
an O
important O
control O
mechanism O
for O
gene O
expression O
and O
the O
VHL B
gene O
might O
modify O
the O
expression O
of O
proto O
- O
oncogenes O
and O
growth O
suppressor O
genes O
during O
embryogenesis O
. O

therefore O
investigated O
the O
expression O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
4 O
6 O
and O
10 O
weeks O
post O
conception O
. O

embryogenesis O
therefore O
investigated O
, O
expression O
of O
VHL B
. O
post O
human O
conception O
by O
in O
6 O
weeks O
studies O
at O
4 O
the O
situ O
and O
10 O
hybridization O
during O
We O
mRNA O

We O
therefore O
investigated O
the O
expression O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
cross O
take O
at O
4 O
, O
sextuplet O
and O
tenner O
workweek O
situation O
excogitation O
. O

We O
thus O
investigated O
the O
look O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
cross O
studies O
at O
foursome O
, O
sestet O
and O
10 O
weeks O
post O
conception O
. O

We O
therefore O
investigated O
the O
expression O
of O
VHL B
mRNA O
during O
human O
by O
in O
hybridization O
studies O
at O
4 O
, O
6 O
and O
post O
conception O
. O

We O
therefore O
investigated O
the O
manifestation O
expression O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
at O
4 O
hebdomad O
send O
concept O
send O
concept O
meditate O
, O
6 O
and O
10 O
weeks O
post O
conception O
. O

We O
therefore O
investigated O
the O
manifestation O
expression O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
at O
4 O
hebdomad O
send O
concept O
send O
concept O
meditate O
, O
6 O
and O
10 O
weeks O
post O
conception O
. O

We O
therefore O
investigated O
the O
expression O
of O
VHL B
mRNA O
during O
human O
by O
hybridization O
studies O
at O
4 O
, O
6 O
and O
10 O
weeks O

post O
therefore O
investigated O
the O
expression O
of O
situ B
at O
during O
human O
embryogenesis O
by O
10 O
VHL O
conception O
studies O
mRNA O
and O
, O
6 O
We O
in O
weeks O
4 O
hybridization O
. O

We O
therefore O
investigated O
the O
expression O
of O
VHL B
mrna O
during O
homo O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
at O
quartet O
, O
six O
and O
10 O
workweek O
stake O
creation O
. O

We O
therefore O
investigated O
the O
expression O
of O
VHL B
mRNA O
during O
human O
embryogenesis O
by O
in O
situ O
hybridization O
studies O
at O
4 O
, O
6 O
and O
10 O
weeks O
post O
conception O
. O

Although O
VHL B
mRNA O
was O
carry O
in O
all O
ternion O
seed O
level O
, O
stiff O
manifestation O
was O
noted O
in O
the O
primal O
unquiet O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O

Although O
VHL B
was O
expressed O
in O
all O
three O
germ O
layers O
, O
strong O
expression O
in O
the O
central O
nervous O
, O
kidneys O
, O
testis O
and O
. O

Although O
VHL B
mRNA O
was O
note O
inward O
verbalise O
expressed O
in O
all O
three O
germ O
layers O
, O
strong O
expression O
was O
noted O
in O
the O
central O
egg O
kidney O
egg O
egg O
microbe O
nervous O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O

, O
VHL B
mRNA O
nervous O
expressed O
in O
all O
lung O
testis O
layers O
system O
strong O
expression O
was O
, O
in O
the O
central O
was O
and O
, O
kidneys O
noted O
germ O
Although O
three O
. O

Although O
VHL B
mRNA O
was O
note O
inward O
verbalise O
expressed O
in O
all O
three O
germ O
layers O
, O
strong O
expression O
was O
noted O
in O
the O
central O
egg O
kidney O
egg O
egg O
microbe O
nervous O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O

Although O
VHL B
mRNA O
expressed O
in O
three O
germ O
layers O
, O
strong O
expression O
was O
noted O
the O
central O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O

. O
VHL B
mRNA O
noted O
expressed O
in O
lung O
three O
was O
layers O
, O
strong O
was O
, O
and O
germ O
the O
central O
nervous O
system O
expression O
kidneys O
, O
testis O
in O
all O
Although O

mRNA O
in O
all O
three O
layers O
, O
expression O
was O
noted O
in O
the O
central O
nervous O
system O
, O
kidneys O
, O
testis O
and O

testis O
VHL B
mRNA O
was O
expressed O
in O
was O
strong O
germ O
layers O
, O
the O
kidneys O
all O
and O
Although O
three O
in O
nervous O
system O
, O
expression O
, O
central O
noted O
lung O
. O

Although O
VHL B
mrna O
was O
expressed O
in O
all O
trinity O
bug O
bed O
, O
strong O
formulation O
was O
noted O
in O
the O
primal O
nervous O
organization O
, O
kidneys O
, O
egg O
and O
lung O
. O

Although O
VHL B
mRNA O
was O
expressed O
in O
all O
three O
germ O
layers O
, O
strong O
expression O
was O
noted O
in O
the O
central O
nervous O
system O
, O
kidneys O
, O
testis O
and O
lung O
. O

inside O
the O
kidney O
, O
VHL B
mRNA O
was O
differentially O
evince O
inside O
nephritic O
tubules O
intimate O
that O
the O
VHL B
cistron O
product O
may O
have O
a O
particular O
function O
in O
kidney O
growing O
. O

Within O
the O
, O
VHL B
mRNA O
was O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
VHL B
gene O
product O
may O
a O
specific O
role O
in O
kidney O
. O

Within O
the O
kidney O
, O
mrna O
be O
cistron O
VHL B
mRNA O
was O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
that O
the O
VHL B
gene O
product O
inward O
use O
developing O
inward O
verbalise O
may O
have O
a O
specific O
role O
in O
kidney O
development O
. O

a O
the O
kidney O
may O
VHL B
mRNA O
was O
development O
in O
within O
have O
tubules O
suggesting O
that O
role O
VHL B
gene O
product O
, O
kidney O
renal O
specific O
the O
expressed O
Within O
differentially O
. O

Within O
the O
kidney O
, O
mrna O
be O
cistron O
VHL B
mRNA O
was O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
that O
the O
VHL B
gene O
product O
inward O
use O
developing O
inward O
verbalise O
may O
have O
a O
specific O
role O
in O
kidney O
development O
. O

Within O
the O
kidney O
VHL B
mRNA O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
that O
the O
gene O
product O
have O
a O
specific O
role O
in O
kidney O
development O
. O

. O
the O
kidney O
the O
VHL B
mRNA O
development O
differentially O
, O
within O
renal O
tubules O
that O
a O
kidney O
expressed B
gene O
product O
may O
have O
suggesting O
specific O
role O
in O
VHL O
was O
Within O

kidney O
mRNA O
was O
differentially O
within O
renal O
suggesting O
that O
the O
VHL B
gene O
product O
may O
have O
a O
specific O
role O
in O
kidney O

in O
the O
kidney O
, O
VHL B
mRNA O
that O
tubules O
expressed O
within O
renal O
gene O
specific O
was O
kidney O
Within B
differentially O
VHL O
may O
have O
a O
suggesting O
role O
product O
the O
development O
. O

inside O
the O
kidney O
, O
VHL B
mRNA O
was O
differentially O
extract O
inside O
renal O
tubules O
advise O
that O
the O
VHL B
factor O
ware O
may O
have O
a O
particular O
persona O
in O
kidney O
ontogeny O
. O

Within O
the O
kidney O
, O
VHL B
mRNA O
was O
differentially O
expressed O
within O
renal O
tubules O
suggesting O
that O
the O
VHL B
gene O
product O
may O
have O
a O
specific O
role O
in O
kidney O
development O
. O

Two O
instead O
tie O
VHL B
mrna O
characterized O
by O
comprehension O
( O
isoform O
ace O
) O
or O
censure O
( O
isoform O
ii O
) O
of O
exon O
deuce O
are O
transcribed O
in O
adult O
tissues O
. O

Two O
alternatively O
VHL B
mRNAs O
characterized O
by O
inclusion O
( O
isoform O
I O
) O
or O
isoform O
II O
) O
of O
2 O
are O
transcribed O
in O
adult O
. O

Two O
alternatively O
spliced O
VHL B
characterise O
aside O
mrna O
mRNAs O
characterized O
by O
inclusion O
( O
isoform O
I O
) O
or O
exclusion O
( O
isoform O
II O
) O
inward O
grownup O
tissue O
paper O
grownup O
grownup O
of O
exon O
2 O
are O
transcribed O
in O
adult O
tissues O

2 O
alternatively O
spliced O
of B
mRNAs O
characterized O
by O
tissues O
in O
isoform O
exon O
) O
or O
exclusion O
transcribed O
isoform O
II O
) O
VHL O
adult O
I O
are O
( O
( O
Two O
inclusion O
. O

Two O
alternatively O
spliced O
VHL B
characterise O
aside O
mrna O
mRNAs O
characterized O
by O
inclusion O
( O
isoform O
I O
) O
or O
exclusion O
( O
isoform O
II O
) O
inward O
grownup O
tissue O
paper O
grownup O
grownup O
of O
exon O
2 O
are O
transcribed O
in O
adult O
tissues O

Two O
alternatively O
spliced O
mRNAs O
characterized O
inclusion O
( O
isoform O
I O
) O
or O
exclusion O
( O
II O
) O
exon O
2 O
are O
transcribed O
in O
adult O
tissues O
. O

. O
alternatively O
spliced O
( B
mRNAs O
characterized O
tissues O
inclusion O
VHL O
isoform O
I O
) O
exclusion O
2 O
adult O
( O
II O
) O
of O
exon O
or O
are O
transcribed O
in O
isoform O
by O
Two O

spliced O
characterized O
by O
inclusion O
isoform O
I O
or O
exclusion O
( O
isoform O
II O
) O
of O
exon O
2 O
are O
transcribed O
in O
adult O

in O
alternatively O
spliced O
VHL B
mRNAs O
characterized O
exclusion O
) O
( O
isoform O
I O
II O
are O
by O
adult O
Two O
inclusion O
isoform O
of O
exon O
2 O
or O
transcribed O
) O
( O
tissues O
. O

Two O
alternatively O
tie O
VHL B
mRNAs O
characterized O
by O
inclusion O
( O
isoform O
i O
) O
or O
censure O
( O
isoform O
II O
) O
of O
exon O
two O
are O
canned O
in O
pornographic O
tissues O
. O

Two O
alternatively O
spliced O
VHL B
mRNAs O
characterized O
by O
inclusion O
( O
isoform O
I O
) O
or O
exclusion O
( O
isoform O
II O
) O
of O
exon O
2 O
are O
transcribed O
in O
adult O
tissues O
. O

To O
inquire O
if O
the O
ii O
isoforms O
are O
differentially O
extract O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
turn O
transcribed O
from O
xiii O
foetal O
tissues O
( O
eight O
- O
tenner O
weeks O
gestation O
) O
. O

To O
investigate O
if O
the O
two O
are O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
8 O
- O
10 O
weeks O
gestation O
) O
. O

tissues O
investigate O
if O
13 O
two O
isoforms O
are O
weeks O
- O
during O
. O
, O
VHL B
fetal O
8 O
reverse O
transcribed O
from O
the O
mRNA O
10 O
( O
was O
expressed O
To O
differentially O
gestation O
) O
embryogenesis O

To O
investigate O
if O
the O
 O
mrna O
be O
override O
 O
two O
isoforms O
are O
differentially O
expressed O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
hebdomad O
pregnancy O
verbalise O
13 O
fetal O
tissues O
( O
8 O
- O
10 O
weeks O
gestation O
) O
. O

To O
investigate O
if O
the O
 O
mrna O
be O
override O
 O
two O
isoforms O
are O
differentially O
expressed O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
hebdomad O
pregnancy O
override O
13 O
fetal O
tissues O
( O
8 O
- O
10 O
weeks O
gestation O
) O
. O

To O
investigate O
if O
the O
two O
isoforms O
are O
differentially O
during O
embryogenesis O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
13 O
( O
8 O
- O
10 O
weeks O
gestation O
) O
. O

. O
investigate O
if O
was O
two O
isoforms O
weeks O
differentially O
the O
during O
embryogenesis O
, O
gestation B
mRNA O
10 O
expressed O
transcribed O
from O
13 O
fetal O
VHL O
( O
8 O
- O
reverse O
are O
tissues O
) O
To O

To O
investigate O
if O
the O
two O
isoforms O
are O
differentially O
during O
, O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
13 O
tissues O
( O
8 O
- O
10 O
weeks O
gestation O

To O
inquire O
if O
the O
two O
isoforms O
are O
differentially O
state O
during O
embryogenesis O
, O
VHL B
mrna O
was O
inverse O
transcribed O
from O
xiii O
foetal O
tissues O
( O
octad O
- O
10 O
weeks O
pregnancy O
) O
. O

To O
enquire O
if O
the O
deuce O
isoforms O
are O
differentially O
carry O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
reversion O
transcribed O
from O
thirteen O
foetal O
tissues O
( O
octonary O
- O
x O
weeks O
gestation O
) O
. O

To O
investigate O
if O
the O
two O
isoforms O
are O
differentially O
expressed O
during O
embryogenesis O
, O
VHL B
mRNA O
was O
reverse O
transcribed O
from O
13 O
fetal O
tissues O
( O
8 O
- O
10 O
weeks O
gestation O
) O
. O

The O
quantitative O
distribution O
of O
VHL B
mrna O
inside O
foetal O
weave O
reflected O
that O
visualise O
by O
in O
situ O
crossing O
and O
the O
proportion O
of O
the O
two O
VHL B
isoforms O
was O
standardized O
between O
weave O
. O

The O
quantitative O
distribution O
of O
VHL B
within O
reflected O
that O
seen O
by O
in O
situ O
hybridization O
and O
the O
VHL B
isoforms O
was O
similar O
between O
tissues O
. O

the O
quantitative O
distribution O
ratio O
VHL B
mRNA O
within O
similar O
isoforms O
reflected O
. O
seen O
by O
of O
VHL O
hybridization O
and O
the O
of O
in O
was O
two O
situ B
tissues O
The O
fetal O
between O
tissues O
that O

The O
quantitative O
distribution O
of O
aside O
inward O
mrna O
hybridisation O
foetal O
VHL B
mRNA O
within O
fetal O
tissues O
reflected O
that O
seen O
by O
in O
situ O
hybridization O
and O
the O
alike O
betwixt O
tissue O
paper O
ratio O
of O
the O
two B
VHL O
isoforms O
was O
similar O
between O
tissues O

The O
quantitative O
distribution O
of O
aside O
inward O
mrna O
hybridisation O
foetal O
VHL B
mRNA O
within O
fetal O
tissues O
reflected O
that O
seen O
by O
in O
situ O
hybridization O
and O
the O
alike O
betwixt O
betwixt O
ratio O
of O
the O
two O
VHL B
isoforms O
was O
similar O
between O
tissues O
. O

The O
quantitative O
distribution O
of O
VHL B
mRNA O
within O
fetal O
reflected O
that O
by O
in O
situ O
hybridization O
and O
the O
ratio O
two O
VHL B
isoforms O
was O
similar O
between O
tissues O
. O

. O
quantitative O
distribution O
situ O
VHL B
mRNA O
similar O
fetal O
of O
reflected O
that O
seen O
between O
in O
was O
tissues O
and O
the O
ratio O
of O
by O
two O
VHL B
isoforms O
hybridization O
within O
the O
tissues O
The O

The O
quantitative O
distribution O
of O
VHL B
mRNA O
within O
fetal O
reflected O
seen O
by O
in O
situ O
hybridization O
and O
the O
ratio O
the O
two O
VHL B
isoforms O
was O
similar O
between O

The O
quantitative O
distribution O
of O
VHL B
mRNA O
inside O
foetal O
tissues O
reflected O
that O
learn O
by O
in O
situ O
hybridizing O
and O
the O
proportion O
of O
the O
ii O
VHL B
isoforms O
was O
like O
between O
tissues O
. O

The O
quantitative O
dispersion O
of O
VHL B
mRNA O
inside O
foetal O
weave O
mull O
that O
control O
by O
in O
situ O
hybridization O
and O
the O
ratio O
of O
the O
deuce O
VHL B
isoforms O
was O
interchangeable O
between O
weave O
. O

The O
quantitative O
distribution O
of O
VHL B
mRNA O
within O
fetal O
tissues O
reflected O
that O
seen O
by O
in O
situ O
hybridization O
and O
the O
ratio O
of O
the O
two O
VHL B
isoforms O
was O
similar O
between O
tissues O
. O

Although O
the O
genes O
regulated O
by O
the O
VHL B
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
VHL B
- O
mediated O
control O
of O
transcriptional O
elongation O
may O
have O
a O
role O
in O
normal O
developing O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
human O
development O
. O
. O

Although O
the O
genes O
regulated O
by O
the O
VHL B
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
VHL B
- O
mediated O
control O
of O
transcriptional O
elongation O
may O
have O
a O
role O
in O
normal O
developing O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
pattern O
human O
development O
. O
. O

Although O
the O
genes O
regulated O
by O
the O
VHL B
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
VHL B
- O
mediated O
control O
of O
transcriptional O
elongation O
may O
have O
a O
role O
in O
normal O
developing O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
human O
development O
. O
. O

- O
compatible O
genes O
regulated O
by O
the O
yet B
role O
product O
have O
not O
VHL O
been O
of O
elongation O
our O
findings O
are O
gene O
with O
the O
a O
transcriptional O
VHL B
Although O
mediated O
have O
identified O
, O
that O
may O
normal O
hypothesis O
the O
in O
control O
human O
development O
. O
. O

Although O
the O
genes O
regulated O
gene O
product O
have O
not O
yet O
identified O
, O
compatible O
hypothesis O
that O
mediated O
transcriptional O
elongation O
may O
have O
role O
in O
development O
. O

Although O
the O
genes O
regularize O
by O
the O
VHL B
cistron O
intersection O
have O
not O
hitherto O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
possibility O
that O
VHL B
- O
liaise O
check O
of O
transcriptional O
extension O
whitethorn O
have O
a O
office O
in O
formula O
human O
developing O
. O
. O

Although O
the O
genes O
regularize O
by O
the O
VHL B
cistron O
product O
have O
not O
notwithstanding O
been O
identified O
, O
our O
see O
are O
compatible O
with O
the O
theory O
that O
VHL B
- O
intercede O
dominance O
of O
transcriptional O
extension O
whitethorn O
have O
a O
role O
in O
convention O
homo O
growth O
. O
. O

may O
in O
genes O
regulated O
findings O
the O
development B
have O
product O
have O
not O
yet O
been O
- O
are O
our O
by O
, O
compatible O
with O
identified O
hypothesis O
that O
VHL B
the O
mediated O
control O
. O
Although O
elongation O
transcriptional O
VHL O
a O
role O
the O
normal O
human O
gene O
of O
. O

Although O
the O
cistron O
order O
by O
the O
VHL B
factor O
product O
have O
not O
yet O
been O
place O
, O
our O
recover O
are O
compatible O
with O
the O
guess O
that O
VHL B
- O
arbitrate O
ascendance O
of O
transcriptional O
extension O
may O
have O
a O
character O
in O
convention O
human O
ontogenesis O
. O
. O

Although O
the O
may O
regulated O
by O
normal O
not B
gene O
product O
have O
VHL O
control O
with O
identified O
, O
compatible O
findings O
are O
development O
been O
the O
hypothesis O
that O
the B
- O
our O
yet O
a O
have O
elongation O
genes O
of O
transcriptional O
role O
in O
VHL O
human O
mediated O
. O
. O

Although O
the O
genes O
regulated O
by O
the O
VHL B
gene O
product O
have O
not O
yet O
been O
identified O
, O
our O
findings O
are O
compatible O
with O
the O
hypothesis O
that O
VHL B
- O
mediated O
control O
of O
transcriptional O
elongation O
may O
have O
a O
role O
in O
normal O
human O
development O
. O
. O

Genetic O
in O
hereditary B
cancer I
role O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
BRCA1 O
and O
BRCA2 O

transmissible O
heterogeneousness O
in O
patrimonial B
breast I
cancer I
: O
role O
of O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
heterogeneousness O
heterogeneousness O
heterogeneousness O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
heterogeneousness O
heterogeneousness O
inward O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
heterogeneousness O
heterogeneousness O
heterogeneousness O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
heterogeneousness O
in O
patrimonial B
breast I
cancer I
: O
purpose O
of O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
heterogeneity O
hereditary B
breast I
cancer I
: O
role O
of O
BRCA1 O
. O

genic O
heterogeneity O
in O
familial B
bosom I
cancer I
: O
role O
of O
BRCA1 O
and O
BRCA2 O
. O

Genetic O
breast O
in O
hereditary B
. I
cancer I
: O
heterogeneity O
of O
BRCA1 O
and O
BRCA2 O
role O

Genetic O
heterogeneity O
in O
hereditary B
breast I
cancer I
: O
role O
of O
BRCA1 O
and O
BRCA2 O
. O

The O
common O
hereditary O
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
genes O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
attributed O
to O
the O
of O
the O
BRCA1 O
or O
BRCA2 O
genes O
. O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
operating O
room O
cistron O
cistron O
transmissible O
transmissible O
transmissible O
BRCA1 O
or O
BRCA2 O
genes O

The O
uncouth O
inherited O
forms O
of O
breast B
cancer I
have O
been O
largely O
ascribe O
to O
the O
heritage O
of O
sport O
in O
the O
BRCA1 O
or O
BRCA2 O
genes O
. O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
operating O
room O
cistron O
cistron O
transmissible O
transmissible O
transmissible O
BRCA1 O
or O
BRCA2 O
genes O

The O
vernacular O
familial O
forms O
of O
breast B
cancer I
have O
been O
largely O
assign O
to O
the O
heritage O
of O
variation O
in O
the O
BRCA1 O
or O
BRCA2 O
cistron O
. O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
to O
the O
of O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O

attributed O
common O
hereditary O
BRCA1 O
of O
breast B
cancer I
been O
have O
largely O
or O
to O
inheritance O
the O
. O
mutations O
in O
the O
forms O
The O
BRCA2 O
genes O
of O

The O
coarse O
inherited O
forms O
of O
breast B
cancer I
have O
been O
mostly O
ascribe O
to O
the O
heritage O
of O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
factor O
. O

of O
common O
been O
cancer O
of O
breast B
mutations I
have O
hereditary O
largely O
attributed O
to O
BRCA2 O
inheritance O
forms O
The O
in O
the O
BRCA1 O
or O
the O
genes O
. O

The O
common O
hereditary O
forms O
of O
breast B
cancer I
have O
been O
largely O
attributed O
to O
the O
inheritance O
of O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
genes O
. O

However O
, O
it O
is O
genus O
cancer O
be O
explicate O
aside O
non O
not O
yet O
clear O
what O
proportion O
of B
hereditary I
breast I
cancer O
is O
explained O
by O
BRCA1 O
and O
susceptibleness O
southward O
BRCA2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
bosom O
bosom O

However O
, O
it O
is O
genus O
cancer O
be O
explicate O
aside O
non O
not O
yet O
clear O
what O
proportion O
of B
hereditary I
breast I
cancer O
is O
explained O
by O
BRCA1 O
and O
susceptibleness O
however O
BRCA2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
bosom O
bosom O

) O
, O
susceptibility O
explained O
not O
yet O
s O
what O
is O
of O
hereditary B
breast I
by I
is O
it O
proportion O
BRCA1 O
and O
BRCA2 O
or O
cancer O
some O
other O
unidentified O
by O
clear O
( O
gene O
However O
. O

However O
, O
it O
is O
genus O
cancer O
be O
explicate O
aside O
non O
not O
yet O
clear O
what O
proportion O
of B
hereditary I
breast I
cancer O
is O
explained O
by O
BRCA1 O
and O
susceptibleness O
southward O
BRCA2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
bosom O
bosom O

However O
, O
it O
is O
not O
yet O
clear O
proportion O
of O
breast I
cancer I
is O
explained O
by O
BRCA1 O
and O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
. O

However O
, O
it O
is O
not O
yet O
gain O
what O
dimension O
of O
inherited B
front I
crab I
is O
explained O
by O
BRCA1 O
and O
BRCA2 O
or O
by O
some O
other O
unnamed O
susceptibleness O
cistron O
( O
s O
) O
. O

BRCA1 O
, O
it O
is O
not O
yet O
some O
breast O
proportion O
of O
hereditary B
However I
) I
unidentified O
by O
explained O
and O
susceptibility O
BRCA2 O
or O
by O
clear O
other O
is O
what O
gene O
( O
s O
cancer O
. O

by O
, O
it O
BRCA2 O
not O
yet O
clear O
gene O
unidentified O
of O
) B
breast I
( I
or O
other O
by O
BRCA1 O
and O
is O
is O
susceptibility O
some O
explained O
proportion O
However O
what O
cancer O
s O
hereditary O
. O

still O
, O
it O
is O
not O
nonetheless O
unclouded O
what O
balance O
of O
transmissible B
titty I
cancer I
is O
explicate O
by O
BRCA1 O
and O
BRCA2 O
or O
by O
some O
other O
unnamed O
susceptibleness O
gene O
( O
s O
) O
. O

However O
, O
it O
is O
not O
clear O
proportion O
of O
hereditary B
breast I
cancer I
is O
explained O
by O
and O
BRCA2 O
or O
by O
some O
other O
unidentified O
( O
s O
) O

However O
, O
it O
is O
not O
yet O
clear O
what O
proportion O
of O
hereditary B
breast I
cancer I
is O
explained O
by O
BRCA1 O
and O
BRCA2 O
or O
by O
some O
other O
unidentified O
susceptibility O
gene O
( O
s O
) O
. O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
genus I
cancer I
hazard I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer O
genus O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
genus I
cancer I
hazard I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer O
genus O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
genus I
cancer I
hazard I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer I
genus I
cancer O
genus O

the O
American O
the O
proportion O
of O
hereditary B
or I
hereditary I
explained O
by O
BRCA1 O
breast O
BRCA2 O
additional O
genes O
sample O
of O
North O
cancer O
hereditary B
breast I
confer I
susceptibility O
assess O
We O
evidence O
may O
in O
a O
and O
that O
or O
cancers O
describe B
breast I
for I
ovarian I
cancer I
risk O
. O

We O
describe O
the O
proportion O
cancer I
explained O
by O
BRCA1 O
or O
in O
a O
American O
cancers I
and O
evidence O
susceptibility O
genes O
that O
may O
hereditary B
breast I
cancer I
risk O

We O
identify O
the O
proportion O
of O
patrimonial B
chest I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
try O
of O
North O
american O
patrimonial B
chest I
cancers I
and O
assess O
the O
grounds O
for O
extra O
susceptibleness O
cistron O
that O
whitethorn O
confabulate O
patrimonial B
chest I
or I
ovarian I
cancer I
adventure O
. O

We O
delineate O
the O
dimension O
of O
genetic B
breast I
crab I
excuse O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
try O
of O
North O
American O
genetic B
breast I
cancers I
and O
nates O
the O
certify O
for O
extra O
susceptibility O
cistron O
that O
may O
confab O
genetic B
breast I
or I
ovarian I
crab I
endangerment O
. O

that O
breast O
the O
proportion O
of O
hereditary B
cancer I
may I
explained O
by O
BRCA1 O
or O
BRCA2 O
the O
North O
sample O
of O
a O
American O
hereditary B
in I
cancers I
and O
assess O
describe O
evidence O
for O
risk O
We O
genes O
susceptibility O
breast O
confer O
hereditary B
breast I
or I
ovarian I
cancer I
additional O
. O

We O
draw O
the O
proportion O
of O
genetic B
chest I
cancer I
excuse O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
union O
American O
genetic B
chest I
crab I
and O
buttocks O
the O
certify O
for O
extra O
susceptibleness O
factor O
that O
may O
confab O
genetic B
chest I
or I
ovarian I
cancer I
risk O
. O

We O
describe O
that O
proportion O
of O
or B
BRCA1 I
cancer I
explained O
by O
breast O
for O
hereditary O
in O
a O
American O
of O
North O
cancer O
BRCA2 B
breast I
cancers I
and O
hereditary O
the O
sample O
or O
confer O
may O
genes O
the O
additional O
susceptibility O
hereditary B
breast I
assess I
ovarian I
evidence I
risk O
. O

We O
describe O
the O
proportion O
of O
hereditary B
breast I
cancer I
explained O
by O
BRCA1 O
or O
BRCA2 O
in O
a O
sample O
of O
North O
American O
hereditary B
breast I
cancers I
and O
assess O
the O
evidence O
for O
additional O
susceptibility O
genes O
that O
may O
confer O
hereditary B
breast I
or I
ovarian I
cancer I
risk O
. O

Twenty O
- O
through O
and O
through O
 O
 O
three O
families O
were O
identified O
through O
two O
high O
- B
risk I
breast O
cancer O
research O
programs O

research O
- O
three O
. O
were O
identified O
through O
two O
programs O
- O
risk O
breast B
Twenty I
cancer O
high O
families O

Twenty O
- O
through O
and O
through O
 O
be O
three O
families O
were O
identified O
through O
two O
high O
- B
risk I
breast O
cancer O
research O
programs O

xx O
- O
three O
families O
were O
identified O
through O
two O
high O
- O
risk O
front B
cancer I
enquiry O
curriculum O
. O

cancer O
- O
three O
two O
were O
identified O
research O
families O
high O
- O
Twenty O
breast B
risk I
through O
programs O
. O

Twenty O
- O
through O
and O
through O
 O
 O
three O
families O
were O
identified O
through O
two O
high O
- B
risk I
breast O
cancer O
research O
programs O

Twenty O
- O
three O
house O
were O
identified O
through O
ii O
high O
- O
adventure O
titty B
cancer I
research O
programs O
. O

Twenty O
- O
trio O
families O
were O
identified O
through O
two O
eminent O
- O
gamble O
summit B
cancer I
research O
programs O
. O

Twenty O
- O
high O
. O
were O
identified O
cancer O
two O
three O
- O
risk O
breast B
through I
research O
families O
programs O

- O
three O
families O
were O
identified O
through O
two O
risk O
breast B
cancer I
research O
programs O
. O

Twenty O
- O
three O
families O
were O
identified O
through O
two O
high O
- O
risk O
breast B
cancer I
research O
programs O
. O

Genetic O
was O
undertaken O
to O
establish O
linkage O
between O
the O
breast B
or I
ovarian I
and O
markers O
on O
chromosomes O
( O
BRCA1 O
) O
and O
13q O
BRCA2 O
) O
. O

Genetic O
was O
undertaken O
establish O
linkage O
between O
the O
breast B
or I
ovarian I
cancer I
and O
markers O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O

Genetic O
analysis O
was O
undertaken O
display O
case O
install O
marking O
along O
to O
establish O
linkage O
between O
the B
breast I
or I
ovarian I
cancer O
cases O
and O
markers O
on O
chromosomes O
be O
be O
be O
display O
case O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O

BRCA1 O
analysis O
was O
17q O
to O
establish O
linkage O
BRCA2 O
13q O
breast B
( I
ovarian I
cancer I
cases O
and O
markers O
on O
chromosomes O
undertaken O
( O
or O
) O
and O
the O
Genetic O
between O
) O
. O

) O
analysis O
was O
and O
to O
establish O
BRCA2 O
between O
undertaken O
breast B
or I
ovarian I
cases I
BRCA1 O
( O
the O
on O
chromosomes O
17q O
( O
cancer O
) O
and O
13q O
markers O
linkage O
Genetic O
. O

Genetic O
analysis O
was O
undertaken O
display O
case O
install O
marking O
along O
to O
establish O
linkage O
between O
the B
breast I
or I
ovarian I
cancer O
cases O
and O
markers O
on O
chromosomes O
be O
be O
be O
undertake O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O

genetic O
analysis O
was O
undertaken O
to O
establish O
linkage O
between O
the O
tit B
or I
ovarian I
cancer I
cases O
and O
markers O
on O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O
. O

Genetic O
analysis O
was O
undertaken O
display O
case O
install O
marking O
along O
to O
establish O
linkage O
between O
the B
breast I
or I
ovarian I
cancer O
cases O
and O
markers O
on O
chromosomes O
be O
be O
be O
undertake O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O

13q O
analysis O
was O
undertaken O
to O
establish O
cases O
ovarian O
the O
breast B
or I
on I
) I
linkage O
( O
Genetic O
between O
markers O
17q O
( O
BRCA1 O
cancer O
and O
chromosomes O
and O
BRCA2 O
) O
. O

genetic O
analysis O
was O
undertaken O
to O
show O
linkage O
between O
the O
bosom B
or I
ovarian I
cancer I
face O
and O
markers O
on O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O
. O

Genetic O
analysis O
was O
undertaken O
to O
establish O
linkage O
between O
the O
breast B
or I
ovarian I
cancer I
cases O
and O
markers O
on O
chromosomes O
17q O
( O
BRCA1 O
) O
and O
13q O
( O
BRCA2 O
) O
. O

Mutation O
BRCA1 O
in O
the O
analysis O
and O
genes O
undertaken O
was O
also O
all O
in O
BRCA2 O
families O
. O

Mutation O
analysis O
inwards O
cistron O
inward O
in O
the O
BRCA1 O
and O
BRCA2 O
genes O
was O
inward O
also O
undertaken O
in O
all O
families O
. O

mutation O
analysis O
in O
the O
BRCA1 O
and O
BRCA2 O
cistron O
was O
also O
tackle O
in O
all O
family O
. O

all O
analysis O
in O
Mutation O
genes O
and O
BRCA2 O
in O
was O
also O
undertaken O
BRCA1 O
the O
families O
. O

mutation O
analysis O
in O
the O
BRCA1 O
and O
BRCA2 O
genes O
was O
likewise O
tackle O
in O
all O
category O
. O

Mutation O
analysis O
inwards O
cistron O
inward O
in O
the O
BRCA1 O
and O
BRCA2 O
genes O
was O
depth O
psychology O
also O
undertaken O
in O
all O
families O

Mutation O
in O
BRCA1 O
BRCA2 O
genes O
was O
also O
undertaken O
in O
all O
families O
. O

genes O
the O
in O
analysis O
BRCA1 O
and O
also O
Mutation O
was O
BRCA2 O
undertaken O
in O
all O
. O
families O

mutation O
analysis O
in O
the O
BRCA1 O
and O
BRCA2 O
cistron O
was O
besides O
attempt O
in O
all O
families O
. O

Mutation O
analysis O
inwards O
cistron O
inward O
in O
the O
BRCA1 O
and O
BRCA2 O
genes O
was O
depth O
psychology O
also O
undertaken O
in O
all O
families O

Mutation O
analysis O
in O
the O
BRCA1 O
and O
BRCA2 O
genes O
was O
also O
undertaken O
in O
all O
families O
. O

The O
convention O
of O
patrimonial B
cancer I
in O
xiv O
( O
61 O
% O
) O
of O
the O
23 O
families O
examine O
was O
assign O
to O
BRCA1 O
by O
a O
compounding O
of O
linkage O
and O
variation O
examine O
. O

The O
pattern O
of O
hereditary B
cancer I
14 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
combination O
of O
linkage O
and O
mutation O
analyses O
. O

by O
pattern O
of O
to B
cancer I
in O
14 O
and O
of O
% O
. O
of O
the O
BRCA1 O
combination O
studied O
was O
attributed O
hereditary O
23 O
linkage O
a O
families O
61 O
The O
( O
mutation O
analyses O
) O

The O
pattern O
of O
hereditary B
gene O
linkage B
 O
phratry B
study O
genus I
cancer O
cancer O
in O
14 O
( O
61 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
combining O
chromosomal O
mutation O
 O
to O
BRCA1 O
by O
a O
combination O
of O
linkage O
and O

The O
pattern O
of O
hereditary B
gene O
linkage B
 O
phratry B
study O
genus I
cancer O
cancer O
in O
14 O
( O
61 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
combining O
chromosomal O
mutation O
study O
to O
BRCA1 O
by O
a O
combination O
of O
linkage O
and O

The O
pattern O
of O
hereditary B
cancer I
in O
14 O
( O
% O
) O
the O
23 O
families O
studied O
was O
attributed O
to O
a O
combination O
of O
linkage O
and O
mutation O
analyses O
. O

. O
pattern O
of O
families B
cancer I
in O
and O
( O
hereditary O
% O
) O
of O
mutation O
23 O
linkage O
61 O
was O
attributed O
to O
BRCA1 O
the O
a O
combination O
of O
studied O
14 O
by O
analyses O
The O

The O
pattern O
of O
hereditary B
cancer I
in O
14 O
( O
% O
of O
the O
23 O
families O
studied O
was O
attributed O
to O
by O
a O
combination O
of O
linkage O
and O
mutation O

The O
pattern O
of O
transmissible B
cancer I
in O
14 O
( O
lxi O
% O
) O
of O
the O
23 O
kin O
analyse O
was O
assign O
to O
BRCA1 O
by O
a O
combining O
of O
linkage O
and O
sport O
study O
. O

The O
rule O
of O
inherited B
cancer I
in O
fourteen O
( O
61 O
% O
) O
of O
the O
23 O
family O
learn O
was O
assign O
to O
BRCA1 O
by O
a O
compounding O
of O
linkage O
and O
mutant O
analyses O
. O

The O
pattern O
of O
hereditary B
cancer I
in O
14 O
( O
61 O
% O
) O
of O
the O
23 O
families O
studied O
was O
attributed O
to O
BRCA1 O
by O
a O
combination O
of O
linkage O
and O
mutation O
analyses O
. O

were O
families O
No O
. O
to O
BRCA2 O
attributed O

No O
folk O
were O
assign O
to O
BRCA2 O
. O

No O
phratry O
families O
were O
attributed O
be O
to O
BRCA2 O
. O

No O
were O
to O
. O

attributed O
No O
were O
families O
to O
BRCA2 O
. O

No O
kinsfolk O
were O
assign O
to O
BRCA2 O
. O

No O
families O
were O
ascribe O
to O
BRCA2 O
. O

No O
families O
were O
. O
to O
attributed O
BRCA2 O

No O
families O
were O
attributed O
to O
. O

No O
phratry O
families O
were O
attributed O
ascribe O
to O
BRCA2 O
. O

No O
families O
were O
attributed O
to O
BRCA2 O
. O

Five O
families O
allow O
for O
certify O
 O
( O
22 O
% O
) O
provided O
evidence O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
license O

and O
families O
( O
. O
% O
) O
provided O
evidence O
BRCA2 O
linkage O
to O
both O
Five O
BRCA1 O
against O
22 O

Five O
families O
allow O
for O
certify O
 O
( O
22 O
% O
) O
provided O
evidence O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
license O

quintuplet O
fellowship O
( O
xxii O
% O
) O
provided O
certify O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
. O

BRCA1 O
families O
( O
evidence O
% O
) O
and O
22 O
against O
linkage O
Five O
both O
to O
provided O
BRCA2 O
. O

Five O
families O
allow O
for O
certify O
 O
( O
22 O
% O
) O
provided O
evidence O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
license O

Five O
fellowship O
( O
22 O
% O
) O
allow O
certify O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
. O

quint O
family O
( O
22 O
% O
) O
supply O
tell O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
. O

Five O
families O
against O
. O
% O
) O
BRCA1 O
evidence O
( O
linkage O
to O
both O
provided O
and O
22 O
BRCA2 O

families O
( O
22 O
% O
) O
provided O
evidence O
to O
both O
BRCA1 O
and O
BRCA2 O
. O

Five O
families O
( O
22 O
% O
) O
provided O
evidence O
against O
linkage O
to O
both O
BRCA1 O
and O
BRCA2 O
. O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
phratry O
mutation O
mutation O
five O
families O
. O

BRCA1 O
or O
detected O
five O
families O
. O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
quintuplet O
kinsperson O
. O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
phratry O
mutation O
mutation O
five O
families O
. O

BRCA1 O
or O
mutations O
were O
detected O
in O
these O
five O
families O
. O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
discover O
in O
these O
phoebe O
class O
. O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
phratry O
mutation O
operating O
room O
five O
families O

nobelium O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
quintet O
mob O
. O

No O
in O
or O
BRCA2 O
BRCA1 O
were O
detected O
families O
these O
five O
mutations O
. O

. O
BRCA1 O
or O
BRCA2 O
in O
were O
five O
mutations O
these O
detected O
families O
No O

No O
BRCA1 O
or O
BRCA2 O
mutations O
were O
detected O
in O
these O
five O
families O
. O

% O
BRCA1 O
or O
families O
status O
of O
four O
BRCA2 O
be O
17 O
not O
) O
The O
could O
( O
determined O
. O

The O
BRCA1 O
or O
BRCA2 O
condition O
of O
four O
fellowship O
( O
seventeen O
% O
) O
could O
not O
be O
dictated O
. O

The O
BRCA1 O
or O
BRCA2 O
condition O
of O
quaternity O
family O
( O
xvii O
% O
) O
could O
not O
be O
decide O
. O

The O
BRCA1 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
. O

The O
BRCA1 O
or O
BRCA2 O
position O
of O
four O
fellowship O
( O
17 O
% O
) O
could O
not O
be O
limit O
. O

The O
BRCA1 O
phratry O
operating O
room O
or O
BRCA2 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
family O
line O
family O

The O
BRCA1 O
or O
BRCA2 O
status O
of O
four O
families O
17 O
% O
could O
not O
be O
determined O
. O

The O
BRCA1 O
phratry O
operating O
room O
or O
BRCA2 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
family O
line O
family O

BRCA1 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O

The O
BRCA1 O
( O
be O
status O
of O
could O
families O
or O
17 O
% O
) O
four O
not O
BRCA2 O
determined O
. O

The O
BRCA1 O
or O
BRCA2 O
status O
of O
four O
families O
( O
17 O
% O
) O
could O
not O
be O
determined O
. O

BRCA1 O
and O
hereditary O
the O
explain O
the O
exists O
of O
BRCA2 B
breast I
cancer I
that O
majority O
in O
probably O
North O
American O
population O
. O

BRCA2 O
probably O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
North O
American O
population O
. O

BRCA1 O
and O
BRCA2 O
probably O
excuse O
the O
majority O
of O
transmissible B
boob I
cancer I
that O
exists O
in O
the O
North O
American O
universe O
. O

BRCA1 O
and O
BRCA2 O
believably O
excuse O
the O
bulk O
of O
transmitted B
breast I
cancer I
that O
exists O
in O
the O
North O
american O
population O
. O

American O
and O
BRCA2 O
probably O
explain O
the O
in O
the O
hereditary B
breast I
cancer I
that O
population O
majority O
of O
North O
exists O
BRCA1 O
. O

BRCA1 O
and O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
that O
exists O
in O
the O
North O
American O
. O

BRCA1 O
and O
BRCA2 O
probably O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
that O
exists O
in O
the O
North O
American O
population O
transmissible O
transmissible O
transmissible O
transmissible O
bosom O
. O

BRCA1 O
and O
BRCA2 O
probably O
excuse O
the O
majority O
of O
familial B
tit I
crab I
that O
exists O
in O
the O
North O
American O
universe O
. O

BRCA1 O
and O
BRCA2 O
probably O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
that O
exists O
in O
the O
North O
American O
population O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
. O

in O
and O
BRCA2 O
cancer O
explain O
the O
majority O
. O
the B
breast I
probably I
that O
BRCA1 O
exists O
hereditary O
North O
American O
population O
of O

BRCA1 O
and O
BRCA2 O
probably O
explain O
the O
majority O
of O
hereditary B
breast I
cancer I
that O
exists O
in O
the O
North O
American O
population O
. O

nevertheless O
, O
ace O
or O
more O
extra O
genes O
may O
yet O
be O
found O
that O
explicate O
some O
proportion O
of O
genetic B
bosom I
cancer I
. O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B
breast I
 I
 O
 I
 O
 I
 O
cancer I
. O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B
breast I
 I
 O
 I
 O
 I
 O
cancer I
. O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
be O
found O
explain O
some O
proportion O
of O
hereditary B
breast I
cancer I

proportion O
, O
yet O
genes O
more O
additional O
of O
may O
one O
be O
found O
that O
. O
some O
or O
However O
hereditary B
breast I
cancer I
. O
explain O

notwithstanding O
, O
unrivalled O
or O
more O
additional O
genes O
may O
yet O
be O
bump O
that O
explicate O
some O
symmetry O
of O
hereditary B
bosom I
cancer I
. O
. O

. O
, O
one O
found O
more O
additional O
genes O
cancer O
proportion O
be O
or O
that O
some O
explain O
yet O
of O
hereditary B
breast I
may I
However O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B
breast I
 I
 O
 I
 O
 I
cistron O
cancer I
. O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
proportion O
breast I
cancer I
. O
. O

However O
, O
one O
or O
more O
extra O
cistron O
may O
hitherto O
be O
plant O
that O
excuse O
some O
proportion O
of O
hereditary B
chest I
cancer I
. O
. O

However O
, O
one O
or O
more O
additional O
genes O
may O
yet O
be O
found O
that O
explain O
some O
proportion O
of O
hereditary B
breast I
cancer I
. O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
pisces O
the O
fishes O
middle O
middle O
chromosomal O
mutation O
chromosomal B
mutation I
chromosomal I
mutation I
episode O
fish O

mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
fish B
eye I
disease I
) O
. O

An O
intronic O
mutation O
in O
a O
lasso O
branchpoint O
succession O
is O
a O
address O
get O
of O
an O
inherited B
human I
unhinge I
( O
fish B
- I
center I
disease I
) O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
is O
a O
cause O
of O
an O
inherited B
human I
disorder I
( O
eye I
disease I
) O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
pisces O
the O
fishes O
middle O
middle O
chromosomal O
mutation O
chromosomal B
mutation I
chromosomal I
mutation I
chromosomal O
mutation O

an O
intronic O
mutant O
in O
a O
riata O
branchpoint O
episode O
is O
a O
direct O
case O
of O
an O
genetic B
human I
disorder I
( O
fish B
- I
middle I
disease I
) O
. O

an O
intronic O
mutant O
in O
a O
lasso O
branchpoint O
sequence O
is O
a O
unmediated O
cause O
of O
an O
inherited B
human I
distract I
( O
pisces B
- I
oculus I
disease I
) O
. O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
direct O
an O
inherited B
human I
disorder I
( O
fish B
- I
eye I
disease I

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
pisces O
the O
fishes O
middle O
middle O
chromosomal O
mutation O
chromosomal B
mutation I
chromosomal I
mutation I
chromosomal O
mutation O

( O
intronic O
mutation O
direct O
a O
lariat O
branchpoint O
fish O
. O
a O
in O
cause O
of O
an O
) B
human I
disorder I
eye O
sequence B
An I
- I
disease I
inherited O
is O

An O
intronic O
mutation O
in O
a O
lariat O
branchpoint O
sequence O
is O
a O
direct O
cause O
of O
an O
inherited B
human I
disorder I
( O
fish B
- I
eye I
disease I
) O
. O

The O
first O
step O
an O
intron O
from O
nuclear O
precursors O
of O
mRNA O
results O
in O
the O
formation O
of O
a O
lariat O
structure O

The O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
nuclear O
precursors O
of O
results O
formation O
of O
a O
lariat O
structure O
. O

The O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
nuclear O
precursors O
of O
mRNA O
results O
in O
the O
formation O
reata O
social O
system O
social O
system O
footfall O
footfall O
footfall O
of O
a O
lariat O

The O
first O
step O
in O
the O
wed O
of O
an O
intron O
from O
atomic O
predecessor O
of O
mrna O
results O
in O
the O
formation O
of O
a O
lasso O
construction O
. O

The O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
nuclear O
precursors O
of O
mRNA O
results O
in O
the O
formation O
reata O
social O
system O
social O
system O
footfall O
footfall O
footfall O
of O
a O
lariat O

The O
low O
step O
in O
the O
marry O
of O
an O
intron O
from O
atomic O
precursors O
of O
mRNA O
lead O
in O
the O
organisation O
of O
a O
lasso O
structure O
. O

The O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
precursors O
of O
results O
in O
the O
formation O
of O
a O
lariat O

nuclear O
first O
step O
of O
the O
splicing O
of O
intron O
an O
from O
a O
precursors O
mRNA O
of O
. O
in O
the O
formation O
in O
The O
lariat O
structure O
results O

The O
first O
step O
in O
the O
wed O
of O
an O
intron O
from O
atomic O
predecessor O
of O
mrna O
solvent O
in O
the O
formation O
of O
a O
lasso O
structure O
. O

results O
first O
intron O
of O
the O
splicing O
in O
an O
step O
from O
nuclear O
precursors O
lariat O
mRNA O
in O
The O
the O
formation O
of O
a O
of O
structure O
. O

The O
first O
step O
in O
the O
splicing O
of O
an O
intron O
from O
nuclear O
precursors O
of O
mRNA O
results O
in O
the O
formation O
of O
a O
lariat O
structure O
. O

adenine O
discrete O
intronic O
base O
sequence O
, O
bed O
as O
the O
branchpoint O
part O
, O
plays O
adenine O
central O
office O
in O
this O
process O
. O

A O
distinct O
intronic O
nucleotide O
sequence O
, O
known O
as O
the O
branchpoint O
region O
, O
plays O
a O
central O
role O
in O
this O
base O
base O
base O
base O
base O
base O
process O
. O

A O
distinct O
intronic O
nucleotide O
sequence O
, O
known O
as O
the O
branchpoint O
region O
, O
plays O
a O
central O
role O
in O
this O
base O
base O
base O
base O
base O
base O
process O
. O

intronic O
, O
known O
as O
branchpoint O
region O
plays O
a O
central O
role O
in O
this O
process O
. O

A O
distinct O
intronic O
nucleotide O
sequence O
as O
the O
region O
, O
plays O
a O
central O
role O
in O
this O
process O
. O

intronic O
nucleotide O
sequence O
, O
as O
the O
branchpoint O
region O
, O
a O
central O
role O
in O
process O
. O

this O
distinct O
intronic O
process O
sequence O
, O
known O
the O
as O
branchpoint O
central O
, O
plays O
. O
A O
role O
in O
region O
nucleotide O
a O

A O
distinct O
intronic O
nucleotide O
sequence O
, O
known O
as O
the O
branchpoint O
region O
, O
plays O
a O
central O
role O
in O
this O
base O
base O
base O
base O
base O
episode O
process O
. O

A O
decided O
intronic O
base O
sequence O
, O
known O
as O
the O
branchpoint O
realm O
, O
plays O
a O
fundamental O
function O
in O
this O
action O
. O

in O
distinct O
intronic O
nucleotide O
sequence O
, O
a O
, O
the O
branchpoint O
region O
central O
A O
known O
as O
this O
plays O
role O
process O
. O

A O
distinct O
intronic O
nucleotide O
sequence O
, O
known O
as O
the O
branchpoint O
region O
, O
plays O
a O
central O
role O
in O
this O
process O
. O

We O
here O
line O
a O
point O
mutation O
in O
such O
a O
episode O
. O

We O
here O
describe O
a O
point O
mutation O
in O
such O
a O
hither O
hither O
hither O
sequence O
. O

We O
here O
identify O
a O
bespeak O
variation O
in O
such O
a O
sequence O
. O

We O
here O
line O
a O
guide O
mutation O
in O
such O
a O
successiveness O
. O

here O
describe O
point O
mutation O
in O
such O
a O
sequence O
. O

such O
here O
describe O
point O
a O
mutation O
sequence O
We O
a O
in O
. O

We O
such O
describe O
a O
here O
mutation O
in O
. O
a O
sequence O
point O

a O
such O
describe O
in O
point O
mutation O
We O
here O
a O
sequence O
. O

We O
describe O
point O
in O
such O
a O
sequence O
. O

We O
here O
describe O
a O
point O
mutation O
in O
such O
a O
hither O
hither O
hither O
sequence O
. O

We O
here O
describe O
a O
point O
mutation O
in O
such O
a O
sequence O
. O

Three O
sisters O
coding O
shown O
to O
( O
from O
mutations B
- I
eye I
disease I
the O
lecithin B
) O
, O
( O
disorder O
which O
caused O
is O
by O
fish O
in O
suffer O
gene O
for O
were O
) O
cholesterol O
acyltransferase O
a O
FED O
LCAT O
. O

Three O
shown O
to O
suffer O
from O
- I
eye I
FED B
) O
a O
disorder O
by O
in O
the O
gene O
for O
lecithin O
cholesterol O
( O
LCAT O
) O
. O

Three O
sisters O
were O
shown O
put O
up O
antiophthalmic O
factor O
babe O
to O
suffer B
from I
fish I
- I
eye O
disease B
( O
FED O
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
cholesterin O
cholesterin O
cholesterin O
cholesterin O
cholesterin O
cholesterin O

Three O
sisters O
were O
shown O
put O
up O
antiophthalmic O
factor O
distract O
to O
suffer B
from I
fish I
- I
eye O
disease B
( O
FED O
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
cholesterin O
cholesterin O
cholesterin O
cholesterin O
cholesterin O
cholesterin O

sisters O
is O
were O
shown O
to O
suffer O
for O
fish B
- I
eye I
disease I
lecithin O
FED B
gene O
acyltransferase O
a O
disorder O
which O
( O
caused O
by O
mutations O
. O
the O
) O
coding O
from O
Three O
LCAT O
in O
( O
cholesterol O
) O
, O

Three O
sisters O
were O
shown O
to O
suffer O
- I
eye I
disease I
( O
) O
, O
a O
disorder O
which O
caused O
by O
mutations O
in O
gene O
coding O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
. O

trey O
sisters O
were O
express O
to O
suffer O
from O
angle B
- I
center I
disease I
( O
feast B
) O
, O
a O
distract O
which O
is O
caused O
by O
sport O
in O
the O
factor O
tantalize O
for O
lecithin O
cholesterin O
acyltransferase O
( O
LCAT O
) O
. O

troika O
baby O
were O
evidence O
to O
meet O
from O
fish B
- I
centre I
disease I
( O
eat B
) O
, O
a O
cark O
which O
is O
caused O
by O
mutant O
in O
the O
cistron O
coding O
for O
lecithin O
cholesterin O
acyltransferase O
( O
LCAT O
) O
. O

Three O
sisters O
were O
shown O
put O
up O
antiophthalmic O
factor O
distract O
to O
suffer B
from I
fish I
- I
eye O
disease B
( O
FED O
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
cholesterin O
cholesterin O
cholesterin O
cholesterin O
cholesterin O
cholesterin O

triplet O
sisters O
were O
point O
to O
suffer O
from O
fish B
- I
eye I
disease I
( O
FED B
) O
, O
a O
perturb O
which O
is O
stimulate O
by O
mutations O
in O
the O
factor O
dupe O
for O
lecithin O
cholesterin O
acyltransferase O
( O
LCAT O
) O
. O

Three O
sisters O
were O
shown O
to O
suffer O
from O
fish B
- I
eye I
disease I
( O
FED B
) O
, O
a O
disorder O
which O
is O
caused O
by O
mutations O
in O
the O
gene O
coding O
for O
lecithin O
cholesterol O
acyltransferase O
( O
LCAT O
) O
. O

intron O
4 O
the O
LCAT O
gene O
of O
) O
three O
probands O
revealed O
compound O
22C O
for O
the O
a O
mutation O
in O
exon O
, O
which O
is O
reported O
4 O
underlie O
a O
FED B
in O
of O
mutation O
to O
point O
and O
located O
missense O
Sequencing O
phenotype O
( O
IVS4 O
T O
- O
heterozygosity O
all O
. O

Sequencing O
of O
the O
gene O
of O
all O
three O
probands O
revealed O
compound O
a O
missense O
mutation O
exon O
which O
is O
reported O
the O
a O
point O
mutation O
in O
intron O
( O
IVS4 O
T O
) O
. O

sequence O
of O
the O
LCAT O
cistron O
of O
all O
iii O
probands O
revealed O
combine O
heterozygosity O
for O
a O
missense O
mutant O
in O
exon O
foursome O
which O
is O
describe O
to O
underlie O
the O
flow B
phenotype O
, O
and O
a O
charge O
mutant O
place O
in O
intron O
foursome O
( O
IVS4 O
tetraiodothyronine O
- O
22C O
) O
. O

sequence O
of O
the O
LCAT O
factor O
of O
all O
three O
probands O
discover O
compound O
heterozygosity O
for O
a O
missense O
mutation O
in O
exon O
foursome O
which O
is O
account O
to O
underlie O
the O
course B
phenotype O
, O
and O
a O
manoeuvre O
mutation O
located O
in O
intron O
foursome O
( O
IVS4 O
thymine O
- O
22C O
) O
. O

Sequencing O
of O
mutation O
LCAT O
gene O
of O
all O
4 O
probands O
revealed O
compound O
for O
. O
a O
missense O
point O
in O
exon O
which O
three O
is O
located O
to O
4 O
the O
phenotype B
, O
reported O
and O
a O
mutation O
IVS4 O
FED O
in O
intron O
underlie O
( O
the O
T O
- O
22C O
) O
heterozygosity O

Sequencing O
of O
the O
gene O
three O
probands O
revealed O
compound O
heterozygosity O
for O
a O
missense O
mutation O
is O
reported O
to O
underlie O
the O
FED B
phenotype O
, O
and O
a O
point O
mutation O
located O
in O
intron O
( O
T O
- O
22C O
) O
. O

Sequencing O
of O
the O
LCAT O
gene O
of O
all O
three O
probands O
revealed O
compound O
heterozygosity O
for O
a O
missense O
mutation O
in O
exon O
4 O
which O
is O
reported O
to O
underlie O
the O
FED B
phenotype O
, O
and O
a O
point O
mutation O
located O
in O
intron O
4 O
cistron O
deoxythymidine O
monophosphate O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
( O
IVS4 O
T O
- O
22C O
) O

T O
the O
the O
LCAT O
in O
of O
is O
mutation O
probands O
revealed O
compound O
heterozygosity O
for O
all O
IVS4 O
mutation O
gene O
point O
4 O
which O
a O
reported O
to O
underlie O
, O
FED B
phenotype O
) O
exon O
a O
and O
of O
located O
in O
intron O
4 O
( O
missense O
Sequencing O
- O
22C O
three O
. O

Sequencing O
of O
the O
gene O
all O
three O
probands O
revealed O
compound O
heterozygosity O
for O
a O
missense O
mutation O
exon O
4 O
which O
is O
reported O
, O
point O
located O
in O
intron O
( O
IVS4 O
T O
- O
22C O
) O

sequence O
of O
the O
LCAT O
factor O
of O
all O
trio O
probands O
revealed O
intensify O
heterozygosity O
for O
a O
missense O
mutation O
in O
exon O
4 O
which O
is O
reported O
to O
underlie O
the O
fed B
phenotype O
, O
and O
a O
betoken O
mutation O
located O
in O
intron O
4 O
( O
IVS4 O
tonne O
- O
22C O
) O
. O

Sequencing O
of O
the O
LCAT O
gene O
of O
all O
three O
probands O
revealed O
compound O
heterozygosity O
for O
a O
missense O
mutation O
in O
exon O
4 O
which O
is O
reported O
to O
underlie O
the O
FED B
phenotype O
, O
and O
a O
point O
mutation O
located O
in O
intron O
4 O
( O
IVS4 O
T O
- O
22C O
) O
. O

performing O
in O
vitro O
LCAT O
minigenes O
and O
reverse O
transcriptase O
on O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
shown O
to O
cause O
a O
null O
complete O
. O

By O
performing O
in O
vitro O
expression O
of O
LCAT O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
allele O
as O
the O
result O
of O
complete O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
intron O
retention O
. O

allele O
, O
in O
vitro O
leukocytes O
of O
retention O
as O
and O
reverse O
transcriptase O
PCR O
on O
was O
of O
from O
expression O
isolated O
the O
patient O
mRNA O
this O
gene O
defect O
performing O
shown O
to O
. O
By O
null O
a O
LCAT O
the O
result O
of O
complete O
intron O
minigenes O
cause O

By O
performing O
in O
expression O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
from O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
allele O
as O
the O
result O
of O
intron O
. O

aside O
do O
in O
vitro O
face O
of O
LCAT O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
obscure O
from O
leukocytes O
of O
the O
patient O
, O
this O
factor O
fault O
was O
render O
to O
crusade O
a O
null O
allelomorph O
as O
the O
result O
of O
finish O
intron O
retentiveness O
. O

was O
the O
in O
vitro O
expression O
of O
PCR O
minigenes O
and O
reverse O
transcriptase O
LCAT O
on O
cause O
null O
from O
leukocytes O
of O
result O
patient O
, O
this O
a O
defect O
By O
shown O
as O
mRNA O
isolated O
gene O
allele O
complete O
the O
of O
performing O
to O
intron O
retention O
. O

By O
performing O
in O
vitro O
expression O
of O
LCAT O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
allele O
as O
the O
result O
of O
complete O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
intron O
retention O
. O

By O
performing O
in O
vitro O
expression O
of O
LCAT O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
allele O
as O
the O
result O
of O
complete O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
manifestation O
antiophthalmic O
factor O
intron O
retention O

By O
performing O
in O
vitro O
expression O
of O
LCAT O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
of O
the O
patient O
this O
defect O
was O
shown O
a O
result O
of O
complete O
retention O
. O

By O
performing O
allele O
vitro O
expression O
of O
LCAT O
the O
and O
reverse O
transcriptase O
to O
patient O
mRNA O
isolated O
minigenes O
leukocytes O
of O
retention O
on O
, O
the O
gene O
complete O
was O
from O
PCR O
this O
a O
null O
in O
cause O
as O
result O
of O
defect O
intron O
shown O
. O

By O
performing O
in O
vitro O
expression O
of O
LCAT O
minigenes O
and O
reverse O
transcriptase O
PCR O
on O
mRNA O
isolated O
from O
leukocytes O
of O
the O
patient O
, O
this O
gene O
defect O
was O
shown O
to O
cause O
a O
null O
allele O
as O
the O
result O
of O
complete O
intron O
retention O
. O

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
null O
patient O
role O
antiophthalmic O
factor O
federal O
reserve O
patient O
role O
federal O
reserve O
federal O
reserve O
inward B
allele O

we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
null O
in O
patient O
with O
FED B
. O

inch O
conclusion O
, O
we O
prove O
that O
a O
guide O
mutation O
inch O
a O
reata O
branchpoint O
consensus O
sequence O
causes O
a O
cipher O
allelomorph O
inch O
a O
patient O
with O
give B
. O

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
lariat O
branchpoint O
sequence O
causes O
a O
null O
allele O
in O
a O
FED B
. O

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
null O
patient O
role O
antiophthalmic O
factor O
federal O
reserve O
patient O
role O
federal O
reserve O
federal O
reserve O
chromosomal B
mutation O

In O
finale O
, O
we O
present O
that O
a O
point O
mutation O
in O
a O
lasso O
branchpoint O
consensus O
episode O
crusade O
a O
cipher O
allelomorph O
in O
a O
patient O
with O
FED B
. O

In O
last O
, O
we O
prove O
that O
a O
point O
variation O
in O
a O
lasso O
branchpoint O
consensus O
episode O
induce O
a O
null O
allelomorph O
in O
a O
patient O
with O
FED B
. O

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
branchpoint O
causes O
a O
null O
allele O
in O
a O
patient O
with O
FED B

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
null O
patient O
role O
antiophthalmic O
factor O
federal O
reserve O
patient O
role O
federal O
reserve O
federal O
reserve O
chromosomal B
mutation O

in O
conclusion O
, O
a O
demonstrated O
that O
a O
allele O
FED O
in O
we O
lariat O
consensus O
branchpoint O
with O
causes O
a O
null O
point O
. O
a O
patient O
sequence O
mutation B
In O

In O
conclusion O
, O
we O
demonstrated O
that O
a O
point O
mutation O
in O
a O
lariat O
branchpoint O
consensus O
sequence O
causes O
a O
null O
allele O
in O
a O
patient O
with O
FED B
. O

sequence O
addition O
, O
importance O
finding O
illustrates O
the O
our O
mRNA O
this O
human O
for O
In O
normal O
of O
processing O
. O

indium O
addition O
, O
our O
finding O
exemplify O
the O
grandness O
of O
this O
episode O
for O
convention O
human O
mRNA O
processing O
. O

In O
increase O
, O
our O
finding O
illustrates O
the O
grandness O
of O
this O
succession O
for O
pattern O
human O
mrna O
processing O
. O

In O
addition O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
mRNA O
processing O
. O

In O
improver O
, O
our O
finding O
illustrates O
the O
grandness O
of O
this O
episode O
for O
pattern O
homo O
mRNA O
processing O
. O

In O
addition O
grandness O
litigate O
, O
our O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
mRNA O
processing O
vastness O
vastness O
process O
. O

In O
addition O
, O
our O
finding O
illustrates O
the O
importance O
this O
sequence O
normal O
human O
mRNA O
processing O
. O

In O
addition O
grandness O
litigate O
, O
our O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
mRNA O
processing O
vastness O
vastness O
process O
. O

addition O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O

In O
addition O
of O
mRNA O
finding O
illustrates O
normal O
importance O
, O
this O
sequence O
for O
the O
human O
our O
processing O
. O

In O
addition O
, O
our O
finding O
illustrates O
the O
importance O
of O
this O
sequence O
for O
normal O
human O
mRNA O
processing O
. O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
cistron O
manifestation O
cistron O
manifestation O
manifestation O
scheme O
manifestation O
that O
underlie O
differential O
gene O
expression O
. O
. O

report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
underlie O
gene O
expression O
. O
. O

Finally O
, O
this O
describe O
supply O
a O
widely O
applicable O
scheme O
which O
ensures O
loyal O
and O
effective O
viewing O
for O
intronic O
blemish O
that O
underlie O
differential O
factor O
expression O
. O
. O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
fast O
and O
screening O
for O
intronic O
defects O
that O
underlie O
differential O
. O
. O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
cistron O
manifestation O
cistron O
manifestation O
manifestation O
scheme O
scheme O
that O
underlie O
differential O
gene O
expression O
. O
. O

ultimately O
, O
this O
cover O
ply O
a O
widely O
applicable O
scheme O
which O
control O
immobile O
and O
effective O
screening O
for O
intronic O
defects O
that O
underlie O
differential O
cistron O
expression O
. O
. O

lastly O
, O
this O
theme O
provides O
a O
widely O
applicable O
scheme O
which O
ascertain O
quick O
and O
effective O
screening O
for O
intronic O
shortcoming O
that O
underlie O
differential O
gene O
formulation O
. O
. O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
and O
for O
intronic O
defects O
that O
underlie O
differential O
gene O
expression O
. O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
cistron O
manifestation O
cistron O
manifestation O
manifestation O
scheme O
scheme O
that O
underlie O
differential O
gene O
expression O
. O
. O

underlie O
, O
this O
ensures O
provides O
a O
widely O
that O
. O
which O
report O
fast O
effective O
and O
expression O
for O
intronic O
defects O
applicable O
. O
differential O
gene O
screening O
strategy O
Finally O

Finally O
, O
this O
report O
provides O
a O
widely O
applicable O
strategy O
which O
ensures O
fast O
and O
effective O
screening O
for O
intronic O
defects O
that O
underlie O
differential O
gene O
expression O
. O
. O

mutant O
relate O
with O
variation O
phenotypes O
in O
ataxia B
- I
telangiectasia I
. O

Mutations O
associated O
with O
variant O
phenotypes O
in O
ataxia B
- I
telangiectasia I
assort O
assort O
assort O
. O

variation O
associated O
with O
discrepancy O
phenotypes O
in O
ataxy B
- I
telangiectasia I
. O

mutation O
relate O
with O
variant O
phenotypes O
in O
dyssynergia B
- I
telangiectasia I
. O

Mutations O
with O
variant O
in O
ataxia B
- I
telangiectasia I
. O

- O
. O
with O
phenotypes O
variant O
in O
ataxia B
Mutations I
telangiectasia I
associated O

Mutations O
- O
with O
variant O
associated O
in O
phenotypes B
ataxia I
telangiectasia I
. O

- O
variant O
with O
associated O
phenotypes O
in O
. B
Mutations I
telangiectasia I
ataxia O

Mutations O
variant O
phenotypes O
in O
- I

Mutations O
associated O
with O
variant O
phenotypes O
in O
ataxia B
- I
telangiectasia I
assort O
assort O
assort O
. O

Mutations O
associated O
with O
variant O
phenotypes O
in O
ataxia B
- I
telangiectasia I
. O

We O
have O
name O
14 O
household O
with O
ataxy B
- I
telangiectasia I
( O
A B
- I
T I
) O
in O
which O
mutant O
of O
the O
ATM O
cistron O
is O
associated O
with O
a O
less O
grievous O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
A B
- I
T I
household O
name O
in O
the O
combine O
land O
) O
. O

We O
have O
place O
14 O
home O
with O
ataxy B
- I
telangiectasia I
( O
A B
- I
thyroxin I
) O
in O
which O
sport O
of O
the O
atmosphere O
cistron O
is O
associated O
with O
a O
less O
dangerous O
clinical O
and O
cellular O
phenotype O
( O
roughly O
x O
% O
- O
xv O
% O
of O
A B
- I
thyroxin I
home O
place O
in O
the O
unite O
land O
) O
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
( O
A B
- I
T I
in O
which O
mutation O
of O
the O
gene O
is O
associated O
with O
less O
severe O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
% O
of O
- I
T I
families O
identified O
in O
the O
United O
Kingdom O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
or O
so I
telangiectasia O
( B
A I
- I
T O
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
deoxythymidine O
monophosphate O
phratry O
identify O
inward O
phratry O
unite O
kingdom O
phratry O
unite O
kingdom O
phratry O
unite O
kingdom O
chromosomal O
mutation O
15 B
% I
of I
A O
- O
T O
families O
identified O
in O
the O
United O

% O
a O
identified O
14 O
families O
with O
gene B
mutation I
telangiectasia I
( O
A B
- I
T I
ataxia O
% O
which O
- O
United O
the O
ATM O
) O
is O
associated O
with O
clinical O
less O
severe O
T O
in O
cellular O
and O
have O
approximately O
10 O
. O
- O
15 O
in O
( O
A B
- I
) I
families O
identified O
phenotype O
the O
of O
Kingdom O
of O
We O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
or O
so I
telangiectasia O
( B
A I
- I
T O
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
deoxythymidine O
monophosphate O
phratry O
identify O
inward O
phratry O
unite O
kingdom O
phratry O
unite O
kingdom O
phratry O
unite O
kingdom O
chromosomal O
mutation O
15 B
% I
of I
A O
- O
T O
families O
identified O
in O
the O
United O

We O
have O
identify O
14 O
class O
with O
ataxia B
- I
telangiectasia I
( O
A B
- I
liothyronine I
) O
in O
which O
mutant O
of O
the O
ATM O
factor O
is O
colligate O
with O
a O
less O
grave O
clinical O
and O
cellular O
phenotype O
( O
approximately O
decade O
% O
- O
fifteen O
% O
of O
A B
- I
liothyronine I
class O
identify O
in O
the O
united O
kingdom O
) O
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
or O
so I
telangiectasia O
( B
A I
- I
T O
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
deoxythymidine O
monophosphate O
phratry O
identify O
inward O
phratry O
unite O
kingdom O
phratry O
unite O
kingdom O
phratry O
unite O
kingdom O
identify O
15 O
% B
of I
A I
- O
T O
families O
identified O
in O
the O
United O
Kingdom O

We O
have O
identified O
14 O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
mutation O
the O
ATM O
gene O
associated O
with O
a O
less O
severe O
clinical O
cellular O
phenotype O
10 O
- O
15 O
% O
of O
T I
families O
identified O
in O
United O
Kingdom O
) O
. O

We O
severe O
identified O
14 O
families O
with O
- B
cellular I
telangiectasia I
( O
A B
ataxia I
T I
clinical O
and O
which O
mutation O
of O
- O
ATM O
gene O
is O
10 O
with O
identified O
less O
United O
) O
) O
the O
phenotype O
- O
approximately O
in O
% O
T O
15 O
% O
of O
A B
have I
( I
families O
associated O
in O
the O
- O
Kingdom O
a O
. O

We O
have O
identified O
14 O
families O
with O
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
in O
which O
mutation O
of O
the O
ATM O
gene O
is O
associated O
with O
a O
less O
severe O
clinical O
and O
cellular O
phenotype O
( O
approximately O
10 O
% O
- O
15 O
% O
of O
A B
- I
T I
families O
identified O
in O
the O
United O
Kingdom O
) O
. O

In O
10 O
of O
these O
phratry O
interpolation O
inward O
phratry O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
cDNA O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
family O
line O
family O
line O
family O
line O

In O
10 O
of O
, O
a O
137 O
- O
insertion O
in O
cDNA O
caused O
by O
mutation O
in O
a O
sequence O
resembling O
splice O
donor O
site O
. O

inwards O
10 O
of O
these O
kinfolk O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
intromission O
inwards O
their O
cdna O
caused O
by O
a O
designate O
mutation O
inwards O
a O
succession O
resemble O
a O
splice O
- O
bestower O
locate O
. O

In O
10 O
of O
these O
families O
, O
all O
homozygotes O
137 O
- O
bp O
insertion O
in O
their O
cDNA O
caused O
by O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
. O

inch O
10 O
of O
these O
kinsperson O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
interpolation O
inch O
their O
cdna O
stimulate O
by O
a O
tip O
mutation O
inch O
a O
sequence O
resemble O
a O
wed O
- O
giver O
site O
. O

In O
10 O
of O
these O
phratry O
interpolation O
inward O
phratry O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
cDNA O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
family O
line O
family O
line O
family O
line O

indium O
x O
of O
these O
menage O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
introduction O
indium O
their O
cDNA O
have O
by O
a O
luff O
mutation O
indium O
a O
sequence O
resemble O
a O
splicing O
- O
presenter O
site O
. O

a O
caused O
of O
these O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
a O
- O
in O
their O
cDNA O
a O
by O
10 O
point O
site O
in O
bp O
sequence O
resembling O
In O
insertion O
mutation O
donor O
splice O
. O

In O
10 O
of O
these O
families O
, O
the O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
caused O
by O
a O
point O
mutation O
in O
a O
a O
splice O
- O
site O

In O
10 O
of O
these O
phratry O
interpolation O
inward O
presenter O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
cDNA O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
family O
line O
family O
line O
family O
line O

In O
10 O
of O
these O
families O
, O
all O
the O
homozygotes O
have O
a O
137 O
- O
bp O
insertion O
in O
their O
cDNA O
caused O
by O
a O
point O
mutation O
in O
a O
sequence O
resembling O
a O
splice O
- O
donor O
site O
. O

The O
A B
T I
has O
a O
different O
mutation O
in O
each O
patient O
. O

The O
minute O
A B
- I
thymine I
allele O
has O
a O
unlike O
variation O
in O
each O
patient O
. O

a O
- O
A B
second I
T I
allele O
mutation O
The O
different O
. O
in O
each O
patient O
has O

The O
second O
A B
- I
T I
allele O
has O
a O
mutation O
in O
patient O
. O

The O
second O
antiophthalmic O
factor O
antiophthalmic B
factor I
A I
- O
T O
allele O
has O
a O
different O
patient O
role O
deoxythymidine O
monophosphate O
mutation O

The O
second O
antiophthalmic O
factor O
antiophthalmic B
factor I
A I
- O
T O
allele O
has O
a O
different O
patient O
role O
allelomorph O
mutation O
in O

The O
mo O
A B
- I
tonne I
allelomorph O
has O
a O
different O
mutant O
in O
each O
patient O
. O

patient O
second O
A B
The I
a I
allele O
has O
each O
different O
mutation O
in O
T O
- O
. O

The O
second O
antiophthalmic O
factor O
antiophthalmic B
factor I
A I
- O
T O
allele O
has O
a O
different O
patient O
role O
deoxythymidine O
monophosphate O
mutation O

The O
second O
A B
- I
tonne I
allelomorph O
has O
a O
unlike O
mutation O
in O
each O
patient O
. O

The O
second O
A B
- I
T I
allele O
has O
a O
different O
mutation O
in O
each O
patient O
. O

We O
show O
that O
the O
aside O
or O
so O
point O
allelomorph O
le O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
splicing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
apart O
apart O
apart O
cause O

We O
show O
less O
patients O
is O
caused O
some O
degree O
normal O
splicing O
, O
as O
an O
alternative O
product O
from O
insertion O
containing O
allele O
. O

We O
present O
that O
the O
less O
grievous O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
rule O
tie O
, O
which O
pass O
as O
an O
choice O
ware O
from O
the O
introduction O
- O
incorporate O
allele O
. O

We O
show O
that O
the O
severe O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
. O

We O
depict O
that O
the O
less O
stark O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
level O
of O
formula O
tie O
, O
which O
hap O
as O
an O
choice O
ware O
from O
the O
introduction O
- O
containing O
allele O
. O

We O
show O
that O
the O
aside O
or O
so O
point O
allelomorph O
le O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
splicing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
apart O
apart O
apart O
cause O

We O
establish O
that O
the O
less O
severe O
phenotype O
in O
these O
patients O
is O
have O
by O
some O
point O
of O
pattern O
splice O
, O
which O
occurs O
as O
an O
alternate O
product O
from O
the O
interpolation O
- O
control O
allelomorph O
. O

occurs O
, O
that O
the O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
product O
containing O
of O
normal O
splicing O
insertion O
which O
show O
as O
. O
alternative O
some O
from O
the O
We O
degree O
an O
allele O
- O

We O
show O
that O
the O
severe O
in O
these O
patients O
is O
caused O
by O
some O
degree O
normal O
splicing O
, O
which O
occurs O
as O
an O
from O
the O
insertion O
containing O
. O

We O
show O
that O
the O
aside O
or O
so O
point O
allelomorph O
aside O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
splicing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
apart O
apart O
apart O
cause O

We O
show O
that O
the O
less O
severe O
phenotype O
in O
these O
patients O
is O
caused O
by O
some O
degree O
of O
normal O
splicing O
, O
which O
occurs O
as O
an O
alternative O
product O
from O
the O
insertion O
- O
containing O
allele O
. O

level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
who O
a O
later O
onset O
of O
cerebellar B
ataxia I
. O

the O
level O
of O
showed O
137 O
- O
bp O
. O
cerebellar O
containing O
ataxia O
insertion O
was O
a O
of O
two O
patients O
who O
the O
lowest O
later O
onset O
in O
product B
The I
PCR O

The O
even O
of O
the O
137 O
- O
bp O
PCR O
merchandise O
containing O
the O
introduction O
was O
humble O
in O
two O
patients O
who O
showed O
a O
later O
onslaught O
of O
cerebellar B
ataxia I
. O

The O
unwavering O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
the O
interpolation O
was O
lowest O
in O
deuce O
patients O
who O
demo O
a O
ulterior O
onslaught O
of O
cerebellar B
ataxia I
. O

The O
level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
insertion O
was O
in O
two O
patients O
who O
showed O
a O
later O
cerebellar B
ataxia I
. O

The O
level O
of O
the O
patient O
137 O
- O
bp O
PCR O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
after O
onrush O
dyssynergia O
intersection O
dyssynergia O
intersection O
showed O
a O
later O
onset O
of O
cerebellar B
ataxia I
. O

The O
level O
of O
the O
patient O
137 O
- O
bp O
PCR O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
after O
onrush O
dyssynergia O
intersection O
dyssynergia O
hold O
back O
showed O
a O
later O
onset O
of B
cerebellar I
ataxia O

The O
level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
insertion O
in O
two O
patients O
who O
showed O
a O
later O
onset O
of O

cerebellar O
level O
of O
the O
137 O
- O
lowest O
patients O
product O
containing O
the O
insertion O
onset O
bp O
ataxia O
two O
PCR O
later O
showed O
a O
The O
was O
of O
who B
in I
. O

The O
level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
the O
interpolation O
was O
humbled O
in O
ii O
patients O
who O
picture O
a O
subsequently O
attack O
of O
cerebellar B
ataxia I
. O

The O
level O
of O
the O
137 O
- O
bp O
PCR O
product O
containing O
the O
insertion O
was O
lowest O
in O
two O
patients O
who O
showed O
a O
later O
onset O
of O
cerebellar B
ataxia I
. O

A O
four O
who O
not O
have O
this O
insertion O
have O
been O
identified O
. O

A O
further O
iv O
category O
who O
do O
not O
have O
this O
intromission O
have O
been O
discover O
. O

have O
families O
four O
further O
who O
do O
insertion O
A O
this O
. O
have O
been O
identified O
not O

A O
further O
four O
families O
who O
do O
not O
have O
insertion O
have O
identified O
. O

A O
further O
rich O
person O
 O
four O
families O
who O
do O
not O
have O
this O
identify O
world O
health O
organization O
insertion O
have O

A O
further O
rich O
person O
 O
four O
families O
who O
do O
not O
have O
this O
identify O
rich O
person O
insertion O
have O
been O

A O
further O
iv O
house O
who O
do O
not O
have O
this O
introduction O
have O
been O
identified O
. O

identified O
further O
four O
A O
have O
do O
not O
been O
this O
insertion O
have O
who O
families O
. O

A O
further O
rich O
person O
 O
four O
families O
who O
do O
not O
have O
this O
identify O
world O
health O
organization O
insertion O
have O

a O
further O
quadruplet O
folk O
who O
do O
not O
have O
this O
introduction O
have O
been O
identified O
. O

A O
further O
four O
families O
who O
do O
not O
have O
this O
insertion O
have O
been O
identified O
. O

sport O
detected O
in O
ii O
of O
quartet O
of O
these O
are O
missense O
sport O
, O
ordinarily O
rarified O
in O
axerophthol B
- I
T I
patients O
. O

Mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
inward O
inward O
inward O
inward O
inward O
inward O
patients O
. O

Mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
inward O
inward O
inward O
inward O
inward O
inward O
patients O
. O

in O
four O
of O
these O
missense O
mutations O
normally O
rare O
in O
A B
- I
T I
patients O
. O

Mutations O
detected O
in O
two O
of O
these O
are O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
patients O
. O

in O
two O
of O
four O
these O
are O
missense O
mutations O
, O
rare O
in O
A B
- I
patients O
. O

T O
detected O
in O
patients O
of O
four O
of O
are O
these O
missense O
in O
, O
normally O
. O
Mutations O
A B
- I
mutations I
two O
rare O

Mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
inward O
inward O
inward O
inward O
inward O
inward O
patients O
. O

Mutations O
observe O
in O
ii O
of O
quaternity O
of O
these O
are O
missense O
mutations O
, O
commonly O
rarified O
in O
A B
- I
T I
patients O
. O

- O
detected O
in O
two O
of O
four O
rare O
, O
are O
missense O
mutations O
in O
Mutations O
of O
these O
T B
normally I
A I
patients O
. O

Mutations O
detected O
in O
two O
of O
four O
of O
these O
are O
missense O
mutations O
, O
normally O
rare O
in O
A B
- I
T I
patients O
. O

of O
rise O
to O
a O
slightly O
phenotype O
in O
T I
raises O
interesting O
question O
of O
might O
occur O
in O
in O
whom O
both O
are O
milder O
. O

The O
demonstration O
of O
mutations O
stir O
pass O
giving O
rise O
to O
a O
slightly O
milder O
phenotype O
in O
A B
- I
T I
raises O
the O
interesting O
question O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
milder O
shift O
shift O
shift O
shift O
shift O
shift O
shift O
deoxythymidine O
monophosphate O

might O
question O
of O
mutations O
giving O
rise O
in O
a O
slightly O
milder O
phenotype O
in O
A B
individuals I
whom I
raises O
the O
interesting O
milder O
of O
what O
range O
mutations O
phenotypes O
The O
occur O
to O
- O
T O
of O
both O
in O
are O
. O
demonstration O

The O
presentment O
of O
mutations O
founder O
rise O
to O
a O
slightly O
balmy O
phenotype O
in O
a B
- I
thymine I
raises O
the O
worry O
head O
of O
what O
scope O
of O
phenotypes O
power O
pass O
in O
individuals O
in O
whom O
both O
mutations O
are O
balmy O
. O

The O
demonstration O
occur O
mutations O
giving O
rise O
to O
range O
slightly O
milder O
phenotype O
phenotypes O
individuals B
- I
T I
both O
the O
interesting O
of O
in O
what O
a O
of O
question O
might O
in O
of O
are O
in O
whom O
raises O
A O
mutations O
milder O
. O

The O
demonstration O
of O
mutations O
giving O
rise O
to O
a O
slightly O
milder O
A B
- I
T I
raises O
interesting O
question O
of O
what O
range O
phenotypes O
might O
occur O
in O
in O
whom O
mutations O
are O
milder O
. O

The O
demonstration O
of O
mutant O
leave O
grow O
to O
ampere O
slenderly O
meek O
phenotype O
in O
ampere B
- I
tonne I
enhance O
the O
interesting O
head O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
mortal O
in O
whom O
both O
mutant O
are O
meek O
. O

The O
demonstration O
of O
mutations O
stir O
pass O
giving O
rise O
to O
a O
slightly O
milder O
phenotype O
in O
A B
- I
T I
raises O
the O
interesting O
question O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
milder O
shift O
shift O
shift O
shift O
shift O
shift O
shift O
deoxythymidine O
monophosphate O

The O
presentation O
of O
mutations O
establish O
resurrect O
to O
a O
somewhat O
balmy O
phenotype O
in O
A B
- I
T I
rear O
the O
occupy O
oppugn O
of O
what O
pasture O
of O
phenotypes O
might O
occur O
in O
mortal O
in O
whom O
both O
mutations O
are O
balmy O
. O

individuals O
what O
of O
mutations O
the O
rise O
T O
mutations O
slightly O
milder O
phenotype O
in O
A B
might I
a I
raises O
giving O
both O
question O
of O
- O
range O
of O
phenotypes O
demonstration O
occur O
in O
The O
interesting O
whom O
in O
to O
are O
milder O
. O

The O
demonstration O
of O
mutations O
giving O
rise O
to O
a O
slightly O
milder O
phenotype O
in O
A B
- I
T I
raises O
the O
interesting O
question O
of O
what O
range O
of O
phenotypes O
might O
occur O
in O
individuals O
in O
whom O
both O
mutations O
are O
milder O
. O

unity O
possibility O
power O
be O
that O
mortal O
who O
are O
heighten O
heterozygotes O
for O
ATM O
mutations O
are O
more O
plebeian O
than O
we O
clear O
. O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
ATM O
mutations O
are O
more O
common O
than O
we O
mightiness O
mightiness O
mightiness O
mightiness O
mightiness O
mightiness O
realize O
. O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
ATM O
mutations O
are O
more O
common O
than O
we O
mightiness O
mightiness O
mightiness O
mightiness O
mightiness O
mightiness O
realize O
. O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
heterozygotes O
for O
mutations O
are O
more O
common O
than O
we O
realize O

more O
possibility O
compound O
who O
that O
individuals O
common O
are O
might O
heterozygotes O
for O
ATM O
. O
are O
be O
One O
than O
we O
realize O
. O
mutations O

one O
possibleness O
might O
be O
that O
individuals O
who O
are O
intensify O
heterozygotes O
for O
ATM O
sport O
are O
more O
common O
than O
we O
actualize O
. O
. O

. O
possibility O
might O
for O
that O
individuals O
who O
realize O
more O
heterozygotes O
be O
ATM O
are O
mutations O
compound O
common O
than O
we O
are O
One O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
ATM O
mutations O
are O
more O
common O
than O
we O
mightiness O
mightiness O
mightiness O
mightiness O
mightiness O
chemical O
compound O
realize O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
ATM O
mutations O
more O
we O
realize O
. O
. O

one O
possibility O
might O
be O
that O
person O
who O
are O
intensify O
heterozygotes O
for O
ATM O
mutations O
are O
more O
vulgar O
than O
we O
earn O
. O
. O

One O
possibility O
might O
be O
that O
individuals O
who O
are O
compound O
heterozygotes O
for O
ATM O
mutations O
are O
more O
common O
than O
we O
realize O
. O
. O

Mutation O
of O
with O
papillary O
gene O
is O
non O
exclusively O
the O
the O
development O
of O
associated B
- I
VHL I
renal I
cell I
carcinomas I
. O

the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
renal I
cell I
carcinomas I
. O

Mutation O
of O
the O
VHL O
factor O
is O
associated O
alone O
with O
the O
ontogeny O
of O
not B
- I
papillose I
renal I
cell I
carcinomas I
. O

Mutation O
of O
the O
VHL O
cistron O
is O
associated O
entirely O
with O
the O
growing O
of O
not B
- I
papillary I
renal I
cadre I
carcinomas I
. O

cell O
of O
the O
VHL O
gene O
is O
- O
papillary O
with O
the O
development O
of O
carcinomas B
associated I
exclusively I
renal I
non I
Mutation I
. O

Mutation O
of O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
. O

Mutation O
of O
the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
nephritic O
nephritic O
nephritic O
nephritic O
developing O
. O

mutant O
of O
the O
VHL O
cistron O
is O
affiliate O
exclusively O
with O
the O
maturation O
of O
non B
- I
papillary I
nephritic I
cell I
carcinomas I
. O

Mutation O
of O
the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
nephritic O
nephritic O
nephritic O
nephritic O
nephritic O
. O

- O
of O
the O
development O
gene O
is O
associated O
. O
papillary O
the O
VHL O
of O
Mutation B
non I
with I
renal I
cell I
carcinomas I
exclusively O

Mutation O
of O
the O
VHL O
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
. O

To O
define O
the O
possible O
role O
of O
the O
VHL B
the O
development O
of O
sporadic B
cell I
carcinomas I
, O
91 O
different O
tumours I
of I
the I
kidney I
been O
investigated O
mutation O
of O
the O
VHL B
gene O
by O
single O
strand O
polymorphism O
( O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O

or O
kidney O
the O
possible O
role O
of O
conformation O
carcinomas B
gene O
in O
the O
development O
of O
. B
( I
cell I
VHL I
of O
91 O
different O
) B
tumours I
of I
the I
define I
have O
been O
polymorphism O
, O
mutation O
for O
the O
VHL B
gene O
by O
single O
strand O
) O
investigated O
( O
SSCP O
parenchymal O
and O
/ O
To O
heteroduplex O
renal O
HD O
techniques O
the O
sporadic O

To O
set O
the O
potential O
purpose O
of O
the O
VHL B
factor O
in O
the O
ontogeny O
of O
sporadic B
nephritic I
cubicle I
carcinomas I
, O
91 O
unlike O
parenchymal B
tumor I
of I
the I
kidney I
have O
been O
inquire O
for O
mutant O
of O
the O
VHL B
factor O
by O
unmarried O
string O
conformation O
pleomorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
proficiency O
. O

To O
define O
the O
possible O
role O
of O
the O
VHL B
nephritic O
cistron O
gene O
in O
the O
development O
of O
sporadic B
renal I
cell I
carcinomas I
, O
91 O
different O
parenchymal B
tumours I
of I
the I
kidney I
have O
been O
investigated O
for O
mutation O
of O
the O
VHL B
gene O
by O
single O
string O
form O
operating O
room O
use O
use O
operating O
room O
use O
technique O
operating O
room O
use O
technique O
use O
carcinoma O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O

To O
define O
the O
possible O
role O
of O
the O
VHL B
nephritic O
cistron O
gene O
in O
the O
development O
of O
sporadic B
renal I
cell I
carcinomas I
, O
91 O
different O
parenchymal B
tumours I
of I
the I
kidney I
have O
been O
investigated O
for O
mutation O
of O
the O
VHL B
gene O
by O
single O
string O
form O
operating O
room O
use O
use O
operating O
room O
use O
technique O
operating O
room O
use O
technique O
use O
carcinoma O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O

define O
the O
possible O
role O
of O
VHL B
gene O
of O
cell I
carcinomas I
different O
of I
the I
kidney I
have O
investigated O
for O
the O
VHL B
by O
single O
( O
) O
and O
/ O
heteroduplex O
( O
HD O
techniques O
. O

To O
define O
the O
of O
the O
VHL B
gene O
in O
the O
development O
of O
cell I
, O
91 O
different O
tumours I
of I
the I
kidney I
have O
been O
for O
mutation O
VHL B
by O
single O
strand O
conformation O
SSCP O
) O
and O
/ O
heteroduplex O
( O
HD O
) O
techniques O
. O

To O
limit O
the O
potential O
function O
of O
the O
VHL B
cistron O
in O
the O
evolution O
of O
sporadic B
nephritic I
cell I
carcinomas I
, O
91 O
dissimilar O
parenchymal B
tumor I
of I
the I
kidney I
have O
been O
investigated O
for O
variation O
of O
the O
VHL B
cistron O
by O
undivided O
maroon O
contour O
pleomorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
techniques O
. O

To O
delimitate O
the O
potential O
character O
of O
the O
VHL B
cistron O
in O
the O
ontogenesis O
of O
sporadic B
nephritic I
cell I
carcinomas I
, O
91 O
unlike O
parenchymal B
neoplasm I
of I
the I
kidney I
have O
been O
investigated O
for O
sport O
of O
the O
VHL B
cistron O
by O
undivided O
maroon O
conformity O
pleomorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
proficiency O
. O

To O
define O
the O
possible O
role O
of O
the O
VHL B
nephritic O
cistron O
gene O
in O
the O
development O
of O
sporadic B
renal I
cell I
carcinomas I
, O
91 O
different O
parenchymal B
tumours I
of I
the I
kidney I
have O
been O
investigated O
for O
mutation O
of O
the O
VHL B
gene O
by O
single O
string O
form O
operating O
room O
use O
use O
operating O
room O
use O
technique O
operating O
room O
use O
technique O
use O
tumor O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O

To O
define O
the O
possible O
role O
of O
the O
VHL B
gene O
in O
the O
development O
of O
sporadic B
renal I
cell I
carcinomas I
, O
91 O
different O
parenchymal B
tumours I
of I
the I
kidney I
have O
been O
investigated O
for O
mutation O
of O
the O
VHL B
gene O
by O
single O
strand O
conformation O
polymorphism O
( O
SSCP O
) O
and O
/ O
or O
heteroduplex O
( O
HD O
) O
techniques O
. O

chromosome O
3p O
excision O
was O
observe O
in O
xcviii O
per O
penny O
of O
not B
- I
papillose I
nephritic I
cell I
carcinomas I
and O
in O
25 O
per O
penny O
of O
chromophobe O
nephritic B
cell I
carcinomas I
. O

Chromosome O
3p O
was O
detected O
in O
98 O
per O
cent O
of O
non B
- I
papillary I
carcinomas I
and O
in O
25 O
cent O
of O
chromophobe O
renal B
cell I
. O

Chromosome O
3p O
deletion O
was O
jail O
cell O
carcinoma O
observe O
detected O
in O
98 O
per O
cent O
of B
non I
- I
papillary I
renal I
cell I
carcinomas O
and O
in O
nephritic O
jail O
cell O
carcinoma O
jail O
cell O
penny O
25 O
per O
cent B
of I
chromophobe I
renal O

cent O
3p O
deletion O
25 O
detected O
in O
98 O
carcinomas O
renal O
of O
per B
- I
papillary I
renal I
chromophobe I
carcinomas I
and O
in O
was O
cell O
non O
of O
cell O
cent B
Chromosome I
per I
. O

Chromosome O
3p O
deletion O
was O
jail O
cell O
carcinoma O
observe O
detected O
in O
98 O
per O
cent O
of B
non I
- I
papillary I
renal I
cell I
carcinomas O
and O
in O
nephritic O
jail O
cell O
carcinoma O
jail O
cell O
penny O
25 O
per O
cent B
of I
chromophobe I
renal O

Chromosome O
3p O
deletion O
detected O
in O
per O
cent O
of O
non B
- I
papillary I
renal I
cell I
and O
in O
per O
cent O
of O
chromophobe O
renal B
cell I
carcinomas I
. O

. O
3p O
deletion O
cell O
detected O
in O
carcinomas O
per O
was O
of O
non B
- I
renal I
cent I
cell I
cent I
and O
in O
25 O
per O
papillary O
of O
chromophobe O
renal B
carcinomas I
98 I
Chromosome O

deletion O
in O
98 O
per O
of O
non B
papillary I
renal I
cell I
carcinomas I
and O
in O
25 O
per O
cent O
of O
chromophobe O
renal B
cell I

renal O
3p O
deletion O
was O
detected O
in O
renal O
- O
cent O
of O
non B
and I
of I
98 I
cell I
Chromosome I
per O
carcinomas O
25 O
per O
cent O
papillary O
chromophobe O
in B
cell I
carcinomas I
. O

chromosome O
3p O
cut O
was O
discover O
in O
xcviii O
per O
penny O
of O
not B
- I
papillose I
renal I
cell I
carcinomas I
and O
in O
xxv O
per O
penny O
of O
chromophobe O
renal B
cell I
carcinomas I
. O

Chromosome O
3p O
deletion O
was O
detected O
in O
98 O
per O
cent O
of O
non B
- I
papillary I
renal I
cell I
carcinomas I
and O
in O
25 O
per O
cent O
of O
chromophobe O
renal B
cell I
carcinomas I
. O

22 O
of O
the O
43 O
non B
- I
papillary I
renal I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
bands O
detected O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

carcinomas O
22 O
of O
by O
43 O
non B
- I
. I
HD I
cell I
analysis I
, O
abnormally O
SSCP O
or O
bands O
were O
detected O
the O
migrating O
and O
/ O
DNA O
renal O
In O
papillary O

indium O
22 O
of O
the O
43 O
not B
- I
papillose I
nephritic I
cell I
carcinomas I
, O
abnormally O
migrate O
DNA O
bands O
were O
find O
by O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

in O
xxii O
of O
the O
43 O
not B
- I
papillose I
nephritic I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
striation O
were O
discover O
by O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

In O
22 O
of O
the O
43 O
non B
- I
papillary I
renal I
cell I
, O
abnormally O
DNA O
bands O
were O
detected O
by O
SSCP O
and O
HD O
analysis O
. O

In O
22 O
of O
the O
 O
43 O
non B
- I
papillary I
renal I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
bands O
were O
detected O
operating O
room O
nephritic O
depth O
psychology O
operating O
room O
depth O
psychology O
nephritic O
by O
SSCP O
and O
/ O

In O
22 O
of O
the O
 O
43 O
non B
- I
papillary I
renal I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
bands O
were O
detected O
operating O
room O
nephritic O
depth O
psychology O
operating O
room O
depth O
psychology O
jail O
cell O
by O
SSCP O
and O

In O
22 O
of O
the O
43 O
non B
- I
papillary I
renal I
cell I
, O
DNA O
bands O
were O
detected O
by O
SSCP O
and O
/ O
or O

HD O
22 O
of O
the O
43 O
non B
migrating I
were I
renal I
cell I
carcinomas I
, O
/ O
- O
analysis O
bands O
papillary O
and O
by O
SSCP O
In O
abnormally O
or O
detected O
DNA O
. O

In O
22 O
of O
the O
43 O
not B
- I
papillose I
nephritic I
cell I
carcinomas I
, O
abnormally O
migrate O
dna O
isthmus O
were O
notice O
by O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

In O
22 O
of O
the O
43 O
non B
- I
papillary I
renal I
cell I
carcinomas I
, O
abnormally O
migrating O
DNA O
bands O
were O
detected O
by O
SSCP O
and O
/ O
or O
HD O
analysis O
. O

No O
seen O
shift O
was O
mobility O
in O
of O
chromophobe O
the O
23 O
cell O
renal B
any I
carcinomas I
. O

No O
mobility O
whatever O
duty O
period O
duty O
period O
shift O
was O
seen O
in O
any O
of O
the O
carcinoma O
23 B
chromophobe I
renal I
cell O

No O
mobility O
reposition O
was O
seen O
in O
any O
of O
the O
23 O
chromophobe O
nephritic B
cadre I
carcinomas I
. O

cell O
mobility O
shift O
No O
of O
in O
any O
renal O
the O
23 O
chromophobe O
seen B
was I
carcinomas I
. O

No O
mobility O
fault O
was O
reckon O
in O
any O
of O
the O
xxiii O
chromophobe O
nephritic B
cell I
carcinomas I
. O

No O
mobility O
whatever O
duty O
period O
duty O
period O
shift O
was O
seen O
in O
any O
of O
the O
view O
23 B
chromophobe I
renal I
cell O

No O
shift O
seen O
any O
of O
the O
23 O
chromophobe O
renal B
cell I
carcinomas I
. O

of O
was O
shift O
mobility O
seen O
in O
23 O
No O
the O
any O
chromophobe O
renal B
cell I
. I
carcinomas O

no O
mobility O
shimmy O
was O
meet O
in O
any O
of O
the O
23 O
chromophobe O
renal B
cadre I
carcinomas I
. O

No O
mobility O
whatever O
duty O
period O
duty O
period O
shift O
was O
seen O
in O
any O
of O
the O
view O
23 B
chromophobe I
renal I
cell O

No O
mobility O
shift O
was O
seen O
in O
any O
of O
the O
23 O
chromophobe O
renal B
cell I
carcinomas I
. O

In O
addition O
mutation O
15 O
papillary B
renal I
oncocytomas I
changes I
and O
ten O
renal B
, I
other O
which O
are O
were O
by O
genetic O
of O
, O
than O
the O
of O
chromosome O
3p O
characterized O
cell O
loss O
analysed O
for O
, O
tumours O
sequences O
VHL B
gene O
. O

addition O
15 O
papillary B
renal I
cell I
tumours I
and O
ten O
renal B
, O
which O
are O
characterized O
by O
genetic O
changes O
loss O
of O
chromosome O
sequences O
were O
analysed O
for O
the O

inward O
addition O
, O
xv O
papillose B
nephritic I
cell I
tumor I
and O
ten O
nephritic B
oncocytomas I
, O
which O
are O
characterized O
by O
transmissible O
switch O
other O
than O
loss O
of O
chromosome O
3p O
episode O
, O
were O
canvas O
for O
mutation O
of O
the O
VHL B
factor O
. O

were O
than O
, O
15 O
by B
renal I
are I
of I
and O
ten O
renal B
oncocytomas I
, O
3p O
tumours O
characterized O
papillary O
mutation O
changes O
other O
which O
loss O
of O
chromosome O
addition O
sequences O
, O
In O
genetic O
for O
analysed O
cell O
the O
VHL B
gene O
. O

In O
addition O
, O
15 O
papillose O
papillary B
renal I
cell I
tumours I
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
gene O
papillary O
papillary O
papillary O
papillary O
papillary O
papillary O
papillary O
papillary O
characterise O
. O

3p O
changes O
, O
15 O
papillary B
renal I
cell I
tumours I
and O
ten O
renal B
oncocytomas I
, O
were O
for O
characterized O
by O
genetic O
VHL O
other O
than O
loss O
analysed O
chromosome O
In O
sequences O
of O
which O
are O
of O
mutation O
. O
the O
gene B
addition O
, O

In O
addition O
, O
15 O
renal I
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
gene O
. O

In O
summation O
, O
fifteen O
papillose B
renal I
cell I
tumor I
and O
decade O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
inherited O
alteration O
other O
than O
release O
of O
chromosome O
3p O
sequences O
, O
were O
dissect O
for O
mutation O
of O
the O
VHL B
cistron O
. O

In O
addition O
, O
15 O
be O
papillary B
renal I
cell I
tumours I
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
gene O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
characterise O
. O

indium O
gain O
, O
fifteen O
papillose B
renal I
cell I
tumours I
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterise O
by O
genic O
vary O
other O
than O
going O
of O
chromosome O
3p O
succession O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
cistron O
. O

In O
addition O
, O
15 O
papillary B
renal I
cell I
tumours I
and O
ten O
renal B
oncocytomas I
, O
which O
are O
characterized O
by O
genetic O
changes O
other O
than O
loss O
of O
chromosome O
3p O
sequences O
, O
were O
analysed O
for O
mutation O
of O
the O
VHL B
gene O
. O

None O
of O
these O
tumours B
render O
unnatural O
migration O
patterns O
. O

None O
none O
of O
these O
tumours B
showed O
abnormal O
migration O
patterns O
tumor O
. O

None O
tumours O
these O
of B
showed O
abnormal O
patterns O
migration O
. O

None O
of O
these O
tumours B
showed O
unnatural O
migration O
blueprint O
. O

None O
these O
tumours B
abnormal O
patterns O

migration O
of O
these O
tumours B
showed O
abnormal O
patterns O
None O
. O

None O
of O
these O
tumours B
showed O
abnormal O
migration O
. O

None O
patterns O
these O
tumours B
of O
abnormal O
migration O
showed O
. O

None O
usher O
of O
these O
tumours B
showed O
abnormal O
migration O
patterns O
tumor O
. O

None O
of O
these O
tumours B
demo O
unnatural O
migration O
patterns O
. O

None O
of O
these O
tumours B
showed O
abnormal O
migration O
patterns O
. O

The O
results O
indicate O
that O
mutation O
of O
the O
VHL B
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
nephritic I
jail I
cell I
jail I
cell I
point I
point I
point I
cistron I
papillary I
renal I
cell O
carcinoma O

indicate O
that O
mutation O
of O
the O
VHL B
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
papillary I
cell I
carcinoma I
. O
. O

The O
results O
suggest O
that O
mutant O
of O
the O
VHL B
cistron O
is O
associated O
only O
with O
the O
ontogenesis O
of O
not B
- I
papillose I
renal I
cell I
carcinoma I
. O
. O

The O
results O
indicate O
that O
mutation O
of O
the O
gene O
is O
exclusively O
with O
the O
development O
of O
non B
- I
cell I
carcinoma I
. O
. O

The O
results O
indicate O
that O
mutation O
of O
the O
VHL B
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
nephritic I
jail I
cell I
jail I
cell I
point I
point I
point I
point I
papillary I
renal I
cell O
carcinoma O

The O
lead O
signal O
that O
mutation O
of O
the O
VHL B
factor O
is O
associated O
exclusively O
with O
the O
evolution O
of O
not B
- I
papillose I
nephritic I
cell I
carcinoma I
. O
. O

The O
results O
indicate O
that O
mutant O
of O
the O
VHL B
cistron O
is O
relate O
exclusively O
with O
the O
exploitation O
of O
not B
- I
papillose I
nephritic I
cell I
carcinoma I
. O
. O

The O
results O
indicate O
that O
mutation O
of O
the O
VHL B
gene O
associated O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinoma I

The O
results O
indicate O
that O
mutation O
of O
the O
VHL B
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
nephritic I
jail I
cell I
jail I
cell I
point I
point I
point I
point I
papillary I
renal I
cell O
carcinoma O

- O
results O
indicate O
associated O
mutation O
of O
the O
papillary B
. O
is O
that O
exclusively O
with O
the O
. O
of O
non B
cell I
VHL I
The I
renal I
carcinoma I
development O
gene O

The O
results O
indicate O
that O
mutation O
of O
the O
VHL B
gene O
is O
associated O
exclusively O
with O
the O
development O
of O
non B
- I
papillary I
renal I
cell I
carcinoma I
. O
. O

The O
Emery B
nuclear B
tissue B
layer B
atomic I
- I
Dreifuss I
muscular I
dystrophy O
protein O
, O
emerin O
, O
is O
a O
nuclear O
membrane O
protein O
muscular O

membrane O
Emery B
- I
. I
muscular I
dystrophy I
protein O
, O
protein O
, O
is O
a O
The O
nuclear O
emerin O
Dreifuss O

The O
Emery B
nuclear B
tissue B
layer B
atomic I
- I
Dreifuss I
muscular I
dystrophy O
protein O
, O
emerin O
, O
is O
a O
nuclear O
membrane O
protein O
muscular O

The O
emery B
- I
Dreifuss I
mesomorphic I
dystrophy I
protein O
, O
emerin O
, O
is O
a O
atomic O
membrane O
protein O
. O

nuclear O
Emery B
- I
, I
muscular I
dystrophy I
membrane O
Dreifuss O
emerin O
, O
The O
a O
is O
protein O
protein O
. O

The O
Emery B
nuclear B
tissue B
layer B
atomic I
- I
Dreifuss I
muscular I
dystrophy O
protein O
, O
emerin O
, O
is O
a O
nuclear O
membrane O
protein O
muscular O

The O
emery B
- I
Dreifuss I
powerful I
dystrophy I
protein O
, O
emerin O
, O
is O
a O
atomic O
membrane O
protein O
. O

The O
emery B
- I
Dreifuss I
hefty I
dystrophy I
protein O
, O
emerin O
, O
is O
a O
atomic O
membrane O
protein O
. O

The O
Emery B
emerin I
. I
muscular I
dystrophy I
nuclear O
, O
- O
, O
is O
a O
protein O
membrane O
Dreifuss O
protein O

Emery B
- I
Dreifuss I
muscular I
dystrophy I
protein O
, O
is O
a O
nuclear O
membrane O
protein O
. O

The O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
protein O
, O
emerin O
, O
is O
a O
nuclear O
membrane O
protein O
. O

A O
turgid O
shard O
of O
emerin O
cDNA O
was O
train O
by O
PCR O
and O
show O
as O
a O
recombinant O
protein O
in O
escherichia O
coli O
. O

A O
large O
fragment O
of O
emerin O
cDNA O
was O
prepared O
by O
PCR O
and O
expressed O
as O
a O
recombinant O
protein O
in O
Escherichia O
shard O
shard O
shard O
shard O
shard O
shard O
coli O
. O

A O
large O
fragment O
of O
emerin O
cDNA O
was O
prepared O
by O
PCR O
and O
expressed O
as O
a O
recombinant O
protein O
in O
Escherichia O
shard O
shard O
shard O
shard O
shard O
shard O
coli O
. O

fragment O
cDNA O
was O
prepared O
PCR O
and O
as O
a O
recombinant O
protein O
in O
Escherichia O
coli O
. O

A O
large O
fragment O
of O
emerin O
prepared O
by O
and O
expressed O
as O
a O
recombinant O
protein O
in O
Escherichia O
coli O
. O

fragment O
of O
emerin O
cDNA O
prepared O
by O
PCR O
and O
expressed O
a O
recombinant O
protein O
in O
coli O
. O

Escherichia O
large O
fragment O
coli O
emerin O
cDNA O
was O
by O
prepared O
PCR O
recombinant O
expressed O
as O
. O
A O
protein O
in O
and O
of O
a O

A O
large O
fragment O
of O
emerin O
cDNA O
was O
prepared O
by O
PCR O
and O
expressed O
as O
a O
recombinant O
protein O
in O
Escherichia O
shard O
shard O
shard O
shard O
shard O
inward O
coli O
. O

a O
tumid O
shard O
of O
emerin O
cDNA O
was O
ready O
by O
PCR O
and O
uttered O
as O
a O
recombinant O
protein O
in O
escherichia O
coli O
. O

in O
large O
fragment O
of O
emerin O
cDNA O
a O
expressed O
by O
PCR O
and O
recombinant O
A O
was O
prepared O
Escherichia O
as O
protein O
coli O
. O

A O
large O
fragment O
of O
emerin O
cDNA O
was O
prepared O
by O
PCR O
and O
expressed O
as O
a O
recombinant O
protein O
in O
Escherichia O
coli O
. O

Using O
this O
as O
immunogen O
, O
we O
prepared O
a O
panel O
of O
12 O
monoclonal O
antibodies O
which O
recognise O
at O
least O
four O
different O
epitopes O
on O
emerin O
in O
order O
to O
ensure O
that O
emerin O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
respond O
protein O
to O
the O
lowest O
degree O
to O
the O
lowest O
degree O
to O
the O
lowest O
degree O
to O
the O

Using O
this O
as O
immunogen O
, O
we O
prepared O
a O
panel O
of O
12 O
monoclonal O
antibodies O
which O
recognise O
at O
least O
four O
different O
epitopes O
on O
emerin O
in O
order O
to O
ensure O
that O
emerin O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
respond O
protein O
to O
the O
lowest O
degree O
to O
the O
lowest O
degree O
to O
the O
lowest O
degree O
to O
the O

Using O
this O
as O
immunogen O
, O
we O
prepared O
a O
panel O
of O
12 O
monoclonal O
antibodies O
which O
recognise O
at O
least O
four O
different O
epitopes O
on O
emerin O
in O
order O
to O
ensure O
that O
emerin O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
respond O
protein O
to O
the O
lowest O
degree O
to O
the O
lowest O
degree O
to O
the O
lowest O
degree O
to O
the O

to O
different O
as O
immunogen O
, O
we O
monoclonal O
- O
panel O
of O
12 O
prepared O
antibodies O
emerin O
be O
at O
least O
four O
a O
epitopes O
on O
non O
can O
order O
Using O
ensure O
from O
which O
recognise O
in O
distinguished O
cross O
emerin O
this O
specific O
that O
- O
reacting O
proteins O
. O

Using O
this O
as O
immunogen O
a O
panel O
of O
12 O
monoclonal O
which O
recognise O
different O
emerin O
in O
ensure O
can O
be O
distinguished O
from O
- O
specific O
reacting O
proteins O

using O
this O
as O
immunogen O
, O
we O
prepared O
a O
gore O
of O
xii O
monoclonal O
antibody O
which O
greet O
at O
least O
four O
unlike O
epitopes O
on O
emerin O
in O
put O
to O
ensure O
that O
emerin O
can O
be O
key O
from O
not O
- O
particular O
grouchy O
- O
reacting O
proteins O
. O

apply O
this O
as O
immunogen O
, O
we O
inclined O
a O
panel O
of O
12 O
monoclonal O
antibody O
which O
recognise O
at O
least O
quadruplet O
unlike O
epitopes O
on O
emerin O
in O
guild O
to O
assure O
that O
emerin O
can O
be O
discover O
from O
not O
- O
particular O
hybridizing O
- O
oppose O
proteins O
. O

distinguished O
specific O
as O
immunogen O
least O
we O
reacting O
from O
panel O
of O
12 O
monoclonal O
antibodies O
to O
four O
at O
, O
recognise O
different O
epitopes O
which O
emerin O
in O
order O
this O
ensure O
that O
proteins O
Using O
be O
can O
prepared O
non O
- O
on O
cross O
- O
a O
emerin O
. O

use O
this O
as O
immunogen O
, O
we O
make O
a O
panel O
of O
twelve O
monoclonal O
antibody O
which O
recognise O
at O
least O
iv O
dissimilar O
determinant O
on O
emerin O
in O
regularise O
to O
guarantee O
that O
emerin O
can O
be O
recognize O
from O
not O
- O
particular O
cross O
- O
reacting O
proteins O
. O

Using O
this O
distinguished O
immunogen O
, O
cross O
12 O
a O
panel O
of O
prepared O
that O
epitopes O
which O
recognise O
different O
least O
four O
reacting O
antibodies O
on O
emerin O
in O
we O
to O
at O
monoclonal O
non O
from O
be O
as O
emerin O
can O
- O
specific O
order O
- O
ensure O
proteins O
. O

Using O
this O
as O
immunogen O
, O
we O
prepared O
a O
panel O
of O
12 O
monoclonal O
antibodies O
which O
recognise O
at O
least O
four O
different O
epitopes O
on O
emerin O
in O
order O
to O
ensure O
that O
emerin O
can O
be O
distinguished O
from O
non O
- O
specific O
cross O
- O
reacting O
proteins O
. O

the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
emerin O
related O
were O
also O
detected O
in O
some O
tissues O
. O

tissues O
the O
mAbs O
bands O
a O
34 O
kDa O
. O
some O
all O
tissues O
tested O
, O
were O
in O
emerin O
- O
related O
recognised O
though O
also O
detected O
minor O
in O
All O
protein O

all O
the O
mAbs O
realise O
a O
xxxiv O
kDa O
protein O
in O
all O
weave O
tested O
, O
though O
small O
emerin O
- O
link O
bands O
were O
too O
detected O
in O
some O
weave O
. O

altogether O
the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
altogether O
weave O
screen O
, O
though O
youngster O
emerin O
- O
related O
ring O
were O
likewise O
find O
in O
some O
weave O
. O

All O
the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
all O
tested O
, O
minor O
emerin O
- O
related O
bands O
were O
also O
some O
tissues O
. O

All O
the O
mAbs O
recognised O
antiophthalmic O
factor O
a O
34 O
kDa O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
emerin O
- O
related O
inward O
or O
so O
tissue O
paper O
or O
so O
tissue O
paper O
inward O
bands O
were O
also O

All O
the O
mAbs O
recognised O
antiophthalmic O
factor O
a O
34 O
kDa O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
emerin O
- O
related O
inward O
or O
so O
tissue O
paper O
or O
so O
tissue O
paper O
inward O
bands O
were O
also O

All O
the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
all O
tested O
minor O
emerin O
- O
related O
bands O
were O
also O
detected O
in O

some O
the O
mAbs O
recognised O
a O
34 O
though O
- O
in O
all O
tissues O
tested O
detected O
kDa O
tissues O
emerin O
protein O
also O
bands O
were O
All O
, O
in O
related O
minor O
. O

entirely O
the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
entirely O
tissues O
tested O
, O
though O
minor O
emerin O
- O
associate O
circle O
were O
too O
detected O
in O
some O
tissues O
. O

All O
the O
mAbs O
recognised O
a O
34 O
kDa O
protein O
in O
all O
tissues O
tested O
, O
though O
minor O
emerin O
- O
related O
bands O
were O
also O
detected O
in O
some O
tissues O
. O

Immunofluorescence O
microscopy O
settle O
astatine O
usher O
showed O
that O
emerin O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
be O
. O

tissues O
microscopy O
showed O
. O
emerin O
is O
located O
at O
examined O
nuclear O
rim O
in O
Immunofluorescence O
all O
the O
that O

Immunofluorescence O
microscopy O
settle O
astatine O
settle O
showed O
that O
emerin O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
be O
. O

immunofluorescence O
microscopy O
usher O
that O
emerin O
is O
located O
at O
the O
atomic O
rim O
in O
all O
tissues O
study O
. O

all O
microscopy O
showed O
at O
emerin O
is O
tissues O
that O
the O
nuclear O
Immunofluorescence O
in O
rim O
located O
examined O
. O

Immunofluorescence O
microscopy O
settle O
astatine O
usher O
showed O
that O
emerin O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
be O
. O

immunofluorescence O
microscopy O
showed O
that O
emerin O
is O
located O
at O
the O
atomic O
lip O
in O
all O
tissues O
essay O
. O

immunofluorescence O
microscopy O
demo O
that O
emerin O
is O
site O
at O
the O
nuclear O
rim O
in O
all O
weave O
examined O
. O

Immunofluorescence O
microscopy O
the O
. O
emerin O
is O
all O
at O
showed O
nuclear O
rim O
in O
located O
tissues O
that O
examined O

microscopy O
showed O
that O
emerin O
is O
located O
at O
rim O
in O
all O
tissues O
examined O
. O

Immunofluorescence O
microscopy O
showed O
that O
emerin O
is O
located O
at O
the O
nuclear O
rim O
in O
all O
tissues O
examined O
. O

A O
muscle O
antibody O
from O
an O
Emery B
EMDM I
emerin I
muscular I
dystrophy I
( O
suggesting B
by O
patient O
showed O
a O
absence O
of O
test O
) O
both O
for O
blotting O
and O
immunohistochemistry O
complete O
- O
Western O
simple O
diagnostic O
biopsy O
Dreifuss O
, O
EDMD B
families O
. O

muscle O
from O
an O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
) O
patient O
showed O
complete O
absence O
of O
emerin O
Western O
blotting O
and O
, O
a O
simple O
diagnostic O
for O

a O
muscularity O
biopsy O
from O
an O
emery B
- I
Dreifuss I
brawny I
dystrophy I
( O
EMDM B
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
Western O
fleck O
and O
immunohistochemistry O
, O
advise O
a O
mere O
symptomatic O
antibody O
exam O
for O
EDMD B
families O
. O

a O
both O
biopsy O
from O
absence O
Emery B
showed I
test I
muscular I
dystrophy I
( O
EMDM B
) O
immunohistochemistry O
Dreifuss O
complete O
an O
antibody O
emerin O
by O
patient O
Western O
blotting O
and O
muscle O
, O
suggesting O
A O
of O
diagnostic O
simple O
- O
for O
EDMD B
families O
. O

A O
muscle O
biopsy O
from O
associate O
in O
nursing B
an I
Emery I
- I
Dreifuss I
muscular O
dystrophy B
( O
EMDM O
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
Western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test B
for O
EDMD O
families O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O

immunohistochemistry O
emerin O
biopsy O
from O
an O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EMDM B
) O
a O
diagnostic O
complete O
absence O
of O
EDMD O
by O
both O
Western O
simple O
and O
A O
, O
test O
patient O
showed O
blotting O
antibody O
. O
for O
families B
muscle O
suggesting O

A O
muscle O
biopsy O
from O
Emery B
muscular I
dystrophy I
( O
EMDM B
) O
patient O
showed O
complete O
absence O
Western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test O
for O
EDMD B
families O
. O

ampere O
heftiness O
biopsy O
from O
an O
emery B
- I
Dreifuss I
sinewy I
dystrophy I
( O
EMDM B
) O
patient O
usher O
stark O
absence O
of O
emerin O
by O
both O
Western O
spot O
and O
immunohistochemistry O
, O
hint O
ampere O
simple O
symptomatic O
antibody O
test O
for O
EDMD B
kinsperson O
. O

A O
muscle O
biopsy O
from O
patient O
role O
an B
Emery I
- I
Dreifuss I
muscular I
dystrophy O
( B
EMDM O
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
Western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test O
for B
EDMD O
families O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O
perfect O

a O
brawn O
biopsy O
from O
an O
emery B
- I
Dreifuss I
mesomorphic I
dystrophy I
( O
EMDM B
) O
patient O
shew O
terminated O
absence O
of O
emerin O
by O
both O
Western O
blob O
and O
immunohistochemistry O
, O
advise O
a O
simple O
symptomatic O
antibody O
test O
for O
EDMD B
families O
. O

A O
muscle O
biopsy O
from O
an O
Emery B
- I
Dreifuss I
muscular I
dystrophy I
( O
EMDM B
) O
patient O
showed O
complete O
absence O
of O
emerin O
by O
both O
Western O
blotting O
and O
immunohistochemistry O
, O
suggesting O
a O
simple O
diagnostic O
antibody O
test O
for O
EDMD B
families O
. O

Biochemical O
fractionation O
100 O
brain O
and O
liver O
present O
65 O
that O
emerin O
was O
fractions O
% O
nuclei O
purified O
( O
centrifugation O
through O
, O
in O
sucrose O
000 O
was O
absent O
from O
by O
tissues O
and O
post O
- O
of O
showed O
soluble O
g O
) O
. O

fractionation O
brain O
and O
liver O
tissues O
showed O
that O
emerin O
was O
in O
nuclei O
purified O
by O
centrifugation O
through O
65 O
and O
was O
absent O
soluble O
( O
post O
- O
000 O

biochemical O
fractionation O
of O
psyche O
and O
liver O
tissues O
render O
that O
emerin O
was O
exhibit O
in O
nuclei O
sanctify O
by O
centrifugation O
through O
lxv O
% O
saccharose O
and O
was O
missing O
from O
soluble O
divide O
( O
post O
- O
100 O
, O
000 O
g O
) O
. O

( O
sucrose O
of O
brain O
centrifugation O
liver O
purified O
, O
that O
emerin O
was O
present O
in O
from O
showed O
by O
and O
100 O
65 O
% O
nuclei O
and O
was O
absent O
fractionation O
soluble O
fractions O
Biochemical O
through O
- O
post O
tissues O
000 O
g O
) O
. O

Biochemical O
fractionation O
of O
brain O
usher O
and O
liver O
tissues O
showed O
that O
emerin O
was O
present O
in O
nuclei O
purified O
by O
centrifugation O
through O
65 O
% O
sucrose O
and O
was O
absent O
from O
soluble O
fractions O
( O
post O
- O
100 O
, O
000 O
g O
) O
ussher O
ussher O
ussher O
ussher O
ussher O
ussher O
ussher O
ussher O
aside O
. O

from O
65 O
of O
brain O
and O
liver O
tissues O
showed O
that O
emerin O
was O
present O
in O
( O
- O
by O
centrifugation O
through O
g O
% O
sucrose O
and O
post O
absent O
Biochemical O
soluble O
, O
nuclei O
purified O
was O
100 O
. O
000 O
) O
fractionation O
fractions O

Biochemical O
fractionation O
of O
brain O
liver O
that O
emerin O
was O
present O
in O
nuclei O
purified O
by O
centrifugation O
and O
was O
absent O
from O
soluble O
fractions O
( O
post O
- O
100 O
, O
000 O
g O
) O
. O

Biochemical O
fractionation O
of O
mastermind O
and O
liver O
weave O
usher O
that O
emerin O
was O
gift O
in O
nuclei O
purge O
by O
centrifugation O
through O
65 O
% O
saccharose O
and O
was O
missing O
from O
soluble O
divide O
( O
place O
- O
c O
, O
000 O
g O
) O
. O

Biochemical O
fractionation O
of O
brain O
usher O
and O
liver O
tissues O
showed O
that O
emerin O
was O
present O
in O
nuclei O
purified O
by O
centrifugation O
through O
65 O
% O
sucrose O
and O
was O
absent O
from O
soluble O
fractions O
( O
post O
- O
100 O
, O
000 O
g O
) O
ussher O
ussher O
ussher O
ussher O
ussher O
ussher O
ussher O
ussher O
aside O
. O

biochemical O
fractionation O
of O
wit O
and O
liver O
weave O
establish O
that O
emerin O
was O
gift O
in O
core O
sanctify O
by O
centrifugation O
through O
65 O
% O
saccharose O
and O
was O
missing O
from O
soluble O
fractions O
( O
position O
- O
100 O
, O
000 O
g O
) O
. O

Biochemical O
fractionation O
of O
brain O
and O
liver O
tissues O
showed O
that O
emerin O
was O
present O
in O
nuclei O
purified O
by O
centrifugation O
through O
65 O
% O
sucrose O
and O
was O
absent O
from O
soluble O
fractions O
( O
post O
- O
100 O
, O
000 O
g O
) O
. O

From O
these O
upshot O
, O
together O
with O
sequence O
and O
geomorphological O
homology O
between O
emerin O
, O
thymopoietins O
and O
the O
atomic O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
intimate O
that O
emerin O
will O
testify O
to O
be O
unmatchable O
phallus O
of O
a O
family O
of O
privileged O
atomic O
membrane O
proteins O
. O
. O

From O
these O
results O
, O
together O
with O
sequence O
and O
structural O
homologies O
between O
emerin O
, O
thymopoietins O
and O
the O
nuclear O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
suggest O
that O
emerin O
will O
prove O
to O
be O
one O
member O
of O
a O
atomic O
tissue O
layer O
protein O
atomic O
tissue O
layer O
protein O
unitedly O
unitedly O
unitedly O
unitedly O
unitedly O
unitedly O
unitedly O
family O
of O
inner O
nuclear O
membrane O
proteins O

From O
, O
together O
with O
sequence O
and O
structural O
homologies O
between O
emerin O
nuclear O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
suggest O
that O
emerin O
will O
prove O
to O
one O
of O
a O
family O
of O
inner O
nuclear O
membrane O
proteins O
. O

From O
these O
results O
, O
together O
with O
sequence O
and O
structural O
homologies O
emerin O
, O
thymopoietins O
and O
the O
, O
we O
that O
emerin O
will O
to O
be O
one O
member O
of O
a O
nuclear O
membrane O
proteins O
. O
. O

From O
these O
results O
, O
together O
with O
sequence O
and O
structural O
homologies O
between O
emerin O
, O
thymopoietins O
and O
the O
nuclear O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
suggest O
that O
emerin O
will O
prove O
to O
be O
one O
member O
of O
a O
atomic O
tissue O
layer O
protein O
atomic O
tissue O
layer O
protein O
unitedly O
unitedly O
unitedly O
unitedly O
unitedly O
unitedly O
solution O
family O
of O
inner O
nuclear O
membrane O
proteins O

From O
these O
results O
, O
together O
with O
structural O
homologies O
between O
, O
and O
the O
nuclear O
associated O
we O
suggest O
that O
will O
prove O
be O
one O
member O
family O
of O
inner O
nuclear O
membrane O
. O

From O
these O
issue O
, O
unitedly O
with O
sequence O
and O
geomorphological O
homology O
between O
emerin O
, O
thymopoietins O
and O
the O
atomic O
lamina O
- O
consort O
protein O
, O
LAP2 O
, O
we O
intimate O
that O
emerin O
will O
essay O
to O
be O
unrivaled O
penis O
of O
a O
kinsfolk O
of O
internal O
atomic O
membrane O
proteins O
. O
. O

From O
these O
solvent O
, O
together O
with O
sequence O
and O
morphologic O
homology O
between O
emerin O
, O
thymopoietins O
and O
the O
atomic O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
evoke O
that O
emerin O
will O
leaven O
to O
be O
one O
appendage O
of O
a O
family O
of O
interior O
atomic O
membrane O
proteins O
. O
. O

From O
- O
results O
, O
together O
with O
proteins O
member O
structural O
homologies O
between O
membrane O
, O
emerin O
prove O
the O
nuclear O
lamina O
and O
associated O
protein O
, O
will O
, O
. O
suggest O
be O
thymopoietins O
and O
we O
to O
a O
one O
these O
of O
that O
family O
of O
inner O
nuclear O
emerin O
sequence O
. O
LAP2 O

From O
these O
be O
, O
together O
will O
sequence O
and O
structural O
homologies O
between O
, O
. O
thymopoietins O
and O
to O
nuclear O
lamina O
associated O
- O
protein O
one O
LAP2 O
. O
we O
that O
emerin O
, O
with O
prove O
the O
of O
suggest O
member O
of O
, O
family O
results O
inner O
nuclear O
membrane O
proteins O
emerin O
a O

From O
these O
results O
, O
together O
with O
sequence O
and O
structural O
homologies O
between O
emerin O
, O
thymopoietins O
and O
the O
nuclear O
lamina O
- O
associated O
protein O
, O
LAP2 O
, O
we O
suggest O
that O
emerin O
will O
prove O
to O
be O
one O
member O
of O
a O
family O
of O
inner O
nuclear O
membrane O
proteins O
. O
. O

Mutation O
of O
inwards O
certify O
inward O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
genus O
cancer O

heteroduplex O
of O
MSH3 O
. O
endometrial B
cancer I
and O
evidence O
repair O
its O
functional O
role O
Mutation O
in O
for O
in O

Mutation O
of O
inwards O
certify O
inward O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
genus O
cancer O

mutant O
of O
MSH3 O
in O
endometrial B
crab I
and O
evidence O
for O
its O
usable O
part O
in O
heteroduplex O
repair O
. O

in O
of O
MSH3 O
evidence O
endometrial B
cancer I
heteroduplex O
in O
for O
its O
Mutation O
role O
functional O
and O
repair O
. O

Mutation O
of O
inwards O
certify O
inward O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
genus O
cancer O

Mutation O
of O
MSH3 O
in O
endometrial B
cancer I
and O
tell O
for O
its O
running O
purpose O
in O
heteroduplex O
indemnify O
. O

Mutation O
of O
MSH3 O
in O
endometrial B
crab I
and O
certify O
for O
its O
operable O
character O
in O
heteroduplex O
repair O
. O

Mutation O
of O
for O
. O
endometrial B
cancer I
in O
evidence O
MSH3 O
its O
functional O
role O
and O
heteroduplex O
in O
repair O

of O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
functional O
role O
in O
heteroduplex O
repair O
. O

Mutation O
of O
MSH3 O
in O
endometrial B
cancer I
and O
evidence O
for O
its O
functional O
role O
in O
heteroduplex O
repair O
. O

Many O
human O
tumor B
have O
length O
change O
in O
repetitious O
sequence O
elements O
. O

Many O
human O
tumours B
have O
length O
alterations O
in O
repetitive O
sequence O
homo O
homo O
homo O
elements O
. O

Many O
human O
neoplasm B
have O
duration O
alterations O
in O
insistent O
sequence O
elements O
. O

Many O
human O
tumor B
have O
length O
change O
in O
repetitive O
successiveness O
elements O
. O

human O
tumours B
length O
alterations O
in O
repetitive O
sequence O
elements O
. O

repetitive O
human O
tumours B
length O
have O
alterations O
elements O
Many O
sequence O
in O
. O

Many O
repetitive O
tumours B
have O
human O
alterations O
in O
. O
sequence O
elements O
length O

have O
repetitive O
tumours B
in O
length O
alterations O
Many O
human O
sequence O
elements O
. O

Many O
tumours B
length O
in O
repetitive O
sequence O
elements O
. O

Many O
human O
tumours B
have O
length O
alterations O
in O
repetitive O
sequence O
homo O
homo O
homo O
elements O
. O

Many O
human O
tumours B
have O
length O
alterations O
in O
repetitive O
sequence O
elements O
. O

Although O
this O
microsatellite B
imbalance I
has O
been O
assign O
to O
mutations O
in O
quatern O
DNA O
mismatch O
haunt O
genes O
in O
transmissible B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
neoplasm I
show O
imbalance O
but O
no O
perceptible O
mutations O
in O
these O
genes O
. O

this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
mismatch O
repair O
genes O
in O
hereditary B
colorectal I
cancer I
kindreds O
sporadic B
tumours I
but O
mutations O
in O
these O
genes O

tumours O
in O
microsatellite B
instability I
hereditary O
been O
( O
no O
mutations O
in O
four O
DNA O
mismatch O
, O
. O
in O
has B
but I
colorectal I
cancer I
to O
HNPCC B
) O
kindreds O
this O
many O
sporadic B
Although I
nonpolyposis O
instability O
exhibit O
attributed O
detectable O
mutations O
repair O
these O
genes O
genes O

Although O
this O
microsatellite B
instability I
has O
been O
mutations O
in O
four O
DNA O
repair O
genes O
in O
hereditary B
nonpolyposis I
cancer I
( O
HNPCC B
) O
, O
many O
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
genes O
. O

Although O
this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O

Although O
this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O

Although O
this O
microsatellite B
imbalance I
has O
been O
attributed O
to O
mutations O
in O
four O
dna O
mismatch O
quicken O
genes O
in O
familial B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
neoplasm I
demo O
imbalance O
but O
no O
perceptible O
mutations O
in O
these O
genes O
. O

, O
colorectal O
microsatellite B
instability I
has O
been O
DNA O
mutations O
mutations O
in O
four O
attributed O
mismatch O
tumours O
instability O
in O
hereditary B
nonpolyposis I
to I
cancer I
( O
HNPCC B
exhibit O
kindreds O
Although O
many O
no B
repair I
genes O
) O
but O
these O
detectable O
this O
in O
sporadic O
genes O
. O

Although O
this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O
birth O
give O

Although O
this O
has O
been O
to O
mutations O
mismatch O
genes O
in O
hereditary B
colorectal I
cancer I
( O
) O
kindreds O
, O
many O
sporadic B
instability O
but O
no O
detectable O
mutations O
in O
these O
genes O

Although O
this O
microsatellite B
instability I
has O
been O
attributed O
to O
mutations O
in O
four O
DNA O
mismatch O
repair O
genes O
in O
hereditary B
nonpolyposis I
colorectal I
cancer I
( O
HNPCC B
) O
kindreds O
, O
many O
sporadic B
tumours I
exhibit O
instability O
but O
no O
detectable O
mutations O
in O
these O
genes O
. O

It O
interest O
therefore O
of O
is O
to O
other O
contribute O
genes O
that O
this O
to O
identify O
instability O
. O

It O
is O
key O
out O
early O
thence O
therefore O
of O
interest O
to O
identify O
other O
genes O
be O
that O
contribute O
to O
this O
instability O

It O
is O
thus O
of O
pastime O
to O
discover O
other O
genes O
that O
contribute O
to O
this O
unstableness O
. O

this O
is O
therefore O
It O
other O
to O
identify O
to O
genes O
that O
contribute O
interest O
of O
instability O
. O

it O
is O
so O
of O
interest O
to O
discover O
other O
genes O
that O
lend O
to O
this O
instability O
. O

It O
is O
key O
out O
early O
thence O
therefore O
of O
interest O
to O
identify O
other O
genes O
sake O
that O
contribute O
to O
this O
instability O

It O
therefore O
interest O
identify O
other O
genes O
that O
contribute O
to O
this O
instability O
. O

other O
of O
therefore O
is O
interest O
to O
that O
It O
genes O
identify O
contribute O
to O
this O
. O
instability O

it O
is O
therefore O
of O
worry O
to O
identify O
other O
factor O
that O
contribute O
to O
this O
imbalance O
. O

It O
is O
key O
out O
early O
thence O
therefore O
of O
interest O
to O
identify O
other O
genes O
sake O
that O
contribute O
to O
this O
instability O

It O
is O
therefore O
of O
interest O
to O
identify O
other O
genes O
that O
contribute O
to O
this O
instability O
. O

and O
yeast O
, O
, O
in O
several O
genes O
mutations O
microsatellite O
RTH O
cause O
MSH3 O
In O
, O
including O
instability O
. O

In O
barm O
, O
mutations O
in O
several O
factor O
, O
admit O
RTH O
and O
MSH3 O
, O
lawsuit O
microsatellite O
imbalance O
. O

inwards O
barm O
, O
mutations O
inwards O
respective O
genes O
, O
include O
RTH O
and O
MSH3 O
, O
cause O
microsatellite O
imbalance O
. O

In O
yeast O
in O
several O
genes O
, O
including O
RTH O
and O
MSH3 O
, O
cause O
microsatellite O
instability O
. O

In O
barm O
, O
mutations O
in O
respective O
cistron O
, O
include O
RTH O
and O
MSH3 O
, O
reason O
microsatellite O
instability O
. O

In O
yeast O
do O
admit O
, O
mutations O
in O
several O
genes O
, O
including O
RTH O
and O
MSH3 O
, O
cause O
microsatellite O
instability O
serve O
serve O
cistron O
. O

In O
yeast O
, O
mutations O
in O
several O
genes O
, O
RTH O
and O
, O
cause O
microsatellite O
instability O
. O

In O
yeast O
do O
admit O
, O
mutations O
in O
several O
genes O
, O
including O
RTH O
and O
MSH3 O
, O
cause O
microsatellite O
instability O
serve O
serve O
cistron O
. O

yeast O
in O
several O
genes O
, O
including O
RTH O
and O
MSH3 O
, O

In O
yeast O
including O
microsatellite O
in O
several O
, O
, O
, O
RTH O
and O
MSH3 O
genes O
cause O
mutations O
instability O
. O

In O
yeast O
, O
mutations O
in O
several O
genes O
, O
including O
RTH O
and O
MSH3 O
, O
cause O
microsatellite O
instability O
. O

Thus O
, O
we O
screened O
inward O
 O
 O
carcinoma O
 O
16 O
endometrial B
carcinomas I
with O
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
homolog O
ref O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
inwards O
inwards O
modification O
. O

Thus O
, O
we O
screened O
inward O
 O
 O
carcinoma O
 O
16 O
endometrial B
carcinomas I
with O
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
homolog O
ref O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
inwards O
inwards O
modification O
. O

MSH3 O
, O
we O
screened O
16 O
endometrial B
FEN1 I
human O
microsatellite O
instability O
for O
alterations O
and O
carcinomas O
( O
14 O
with O
) O
of O
RTH O
Thus O
in O
in O
homolog O
( O
refs O
12 O
- O
. O
) O
the O

Thus O
, O
we O
screened O
inward O
 O
 O
carcinoma O
 O
16 O
endometrial B
carcinomas I
with O
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
homolog O
ref O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
inwards O
inwards O
modification O
. O

Thus O
, O
we O
screened O
endometrial B
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
. O

hence O
, O
we O
shield O
sixteen O
endometrial B
carcinomas I
with O
microsatellite O
unbalance O
for O
change O
in O
FEN1 O
( O
the O
human O
homolog O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
xii O
- O
fourteen O
) O
. O

14 O
, O
( O
( O
16 O
endometrial B
- I
with O
screened O
instability O
for O
alterations O
) O
FEN1 O
we O
microsatellite O
human O
homolog O
of O
RTH O
in O
and O
in O
MSH3 O
the O
carcinomas O
12 O
refs O
Thus O
) O
. O

Thus O
, O
we O
screened O
16 O
endometrial B
carcinomas I
with O
microsatellite O
for O
alterations O
FEN1 O
( O
the O
human O
homolog O
of O
RTH O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
. O

for O
, O
we O
14 O
16 O
endometrial B
carcinomas I
refs O
MSH3 O
instability O
( O
alterations O
12 O
RTH O
in O
the O
human O
homolog O
. O
FEN1 O
) O
and O
( O
microsatellite O
Thus O
with O
in O
- O
screened O
) O
of O

thence O
, O
we O
shield O
xvi O
endometrial B
carcinomas I
with O
microsatellite O
unstableness O
for O
change O
in O
FEN1 O
( O
the O
human O
homolog O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
xiv O
) O
. O

Thus O
, O
we O
screened O
16 O
endometrial B
carcinomas I
with O
microsatellite O
instability O
for O
alterations O
in O
FEN1 O
( O
the O
human O
homolog O
of O
RTH O
) O
and O
in O
MSH3 O
( O
refs O
12 O
- O
14 O
) O
. O

we O
found O
no O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
observed O
in O
an O
carcinoma I
in O
an O
endometrial B
carcinoma I
cell O
line O
. O

in O
we O
found O
and O
FEN1 O
mutations O
, O
. O
cell O
mutation O
line O
MSH3 O
was O
in O
carcinoma O
an O
endometrial B
carcinoma I
no O
observed O
an O
endometrial B
in I
frameshift O
Although O
a O

Although O
we O
determine O
no O
FEN1 O
variation O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
celebrate O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I
cell O
line O
. O

Although O
we O
establish O
no O
FEN1 O
mutations O
, O
a O
frameshift O
variation O
in O
MSH3 O
was O
honour O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I
cubicle O
line O
. O

Although O
we O
found O
no O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
MSH3 O
was O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
cell O
line O
. O

Although O
we O
found O
no O
antiophthalmic O
factor O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
observed O
in O
an B
endometrial I
carcinoma O
associate O
in O
nursing O
jail O
cell O
ancestry O
jail O
cell O
ancestry B
nobelium I
and O
in O
an O

Although O
we O
found O
no O
antiophthalmic O
factor O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
observed O
in O
an B
endometrial I
carcinoma O
associate O
in O
nursing O
jail O
cell O
ancestry O
jail O
cell O
ancestry B
find I
out O
and O
in O

Although O
we O
found O
no O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
MSH3 O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I

cell O
we O
found O
no O
FEN1 O
mutations O
observed O
endometrial O
frameshift O
mutation O
in O
MSH3 O
endometrial O
, O
line O
an O
a B
an I
and O
in O
Although O
was B
carcinoma I
carcinoma O
in O
. O

Although O
we O
ascertain O
no O
FEN1 O
mutations O
, O
a O
frameshift O
sport O
in O
MSH3 O
was O
discover O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I
cell O
line O
. O

Although O
we O
found O
no O
FEN1 O
mutations O
, O
a O
frameshift O
mutation O
in O
MSH3 O
was O
observed O
in O
an O
endometrial B
carcinoma I
and O
in O
an O
endometrial B
carcinoma I
cell O
line O
. O

DNA O
of O
the O
in O
line O
were O
deficient O
cell O
or O
of O
mismatches O
substrates O
Extracts O
containing O
repair O
extra O
nucleotides O
. O

excerption O
of O
the O
cell O
describe O
were O
inferior O
in O
repair O
of O
DNA O
substrates O
check O
mismatches O
or O
extra O
base O
. O

educe O
of O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
DNA O
substratum O
incorporate O
mismatches O
or O
additional O
base O
. O

Extracts O
of O
the O
were O
deficient O
in O
repair O
of O
DNA O
substrates O
containing O
mismatches O
or O
extra O
nucleotides O
. O

evoke O
of O
the O
cell O
air O
were O
wanting O
in O
reanimate O
of O
DNA O
substrates O
containing O
mismatches O
or O
special O
nucleotides O
. O

Extracts O
of O
amend O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
DNA O
substrates O
containing O
mismatches O
or O
extra O
nucleotides O
rectify O
rectify O
rectify O
inward O
. O

Extracts O
of O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
substrates O
containing O
or O
extra O
nucleotides O
. O

Extracts O
of O
amend O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
DNA O
substrates O
containing O
mismatches O
or O
extra O
nucleotides O
rectify O
rectify O
rectify O
inward O
. O

of O
line O
were O
deficient O
in O
repair O
of O
DNA O
substrates O
containing O
. O

Extracts O
of O
repair O
or O
line O
were O
containing O
in O
the O
of O
DNA O
substrates O
deficient O
mismatches O
cell O
extra O
nucleotides O
. O

Extracts O
of O
the O
cell O
line O
were O
deficient O
in O
repair O
of O
DNA O
substrates O
containing O
mismatches O
or O
extra O
nucleotides O
. O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
completely O
non O
completely O
completely O
 O
 O
constancy O
some O
but O
not O
all O
microsatellites O
. O

5 O
, O
encoding O
the O
MSH3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
some O
not O
all O
microsatellites O
. O

preface O
chromosome O
cinque O
, O
encryption O
the O
MSH3 O
factor O
, O
into O
the O
mutation O
cell O
seam O
increased O
the O
constancy O
of O
some O
but O
not O
all O
microsatellites O
. O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
, O
into O
mutant O
cell O
line O
increased O
the O
stability O
of O
not O
all O
microsatellites O
. O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
completely O
non O
completely O
completely O
 O
 O
 O
some O
but O
not O
all O
microsatellites O
. O

infix O
chromosome O
quint O
, O
encryption O
the O
MSH3 O
cistron O
, O
into O
the O
variation O
cell O
line O
increased O
the O
stableness O
of O
some O
but O
not O
all O
microsatellites O
. O

introduce O
chromosome O
quint O
, O
encode O
the O
MSH3 O
factor O
, O
into O
the O
variation O
cell O
line O
increased O
the O
constancy O
of O
some O
but O
not O
all O
microsatellites O
. O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
gene O
, O
the O
line O
increased O
the O
stability O
of O
some O
but O
not O
all O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
completely O
non O
completely O
completely O
 O
 O
 O
some O
but O
not O
all O
microsatellites O
. O

of O
chromosome O
5 O
the O
encoding O
the O
MSH3 O
some O
. O
into O
, O
mutant O
cell O
line O
microsatellites O
the O
stability O
not O
gene O
Introducing O
but O
all O
increased O
, O

Introducing O
chromosome O
5 O
, O
encoding O
the O
MSH3 O
gene O
, O
into O
the O
mutant O
cell O
line O
increased O
the O
stability O
of O
some O
but O
not O
all O
microsatellites O
. O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
early O
duplicate O
nucleotide O
duplicate O
nucleotide O
nucleotide O
hold O
back O
containing O
mismatches O
or O
other O
extra O
nucleotides O

cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
mismatches O
other O
extra O
nucleotides O
. O

infusion O
of O
these O
cadre O
bushel O
sure O
substrates O
containing O
additional O
nucleotides O
, O
but O
were O
lacking O
in O
recompense O
of O
those O
containing O
mismatches O
or O
other O
additional O
nucleotides O
. O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
but O
were O
in O
repair O
of O
those O
containing O
mismatches O
or O
nucleotides O
. O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
early O
duplicate O
nucleotide O
duplicate O
nucleotide O
nucleotide O
duplicate O
containing O
mismatches O
or O
other O
extra O
nucleotides O
. O

educe O
of O
these O
cells O
recreate O
sealed O
substrates O
bear O
excess O
nucleotides O
, O
but O
were O
inferior O
in O
rectify O
of O
those O
bear O
mismatches O
or O
other O
excess O
nucleotides O
. O

Extracts O
of O
these O
cells O
compensate O
sure O
substratum O
stop O
spare O
base O
, O
but O
were O
deficient O
in O
revivify O
of O
those O
stop O
mismatches O
or O
other O
spare O
base O
. O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
were O
repair O
of O
those O
containing O
mismatches O
or O
other O
extra O
nucleotides O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
early O
duplicate O
nucleotide O
duplicate O
nucleotide O
nucleotide O
duplicate O
containing O
mismatches O
or O
other O
extra O
nucleotides O
. O

mismatches O
of O
these O
, O
repaired O
certain O
substrates O
containing O
nucleotides O
nucleotides O
cells O
but O
deficient O
were O
extra O
repair O
of O
those O
containing O
. O
or O
other O
in O
extra O
Extracts O

Extracts O
of O
these O
cells O
repaired O
certain O
substrates O
containing O
extra O
nucleotides O
, O
but O
were O
deficient O
in O
repair O
of O
those O
containing O
mismatches O
or O
other O
extra O
nucleotides O
. O

A O
subsequent O
hunt O
discover O
a O
indorse O
factor O
mutation O
in O
HHUA O
cubicle O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
factor O
. O

A O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
HHUA O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
hunting O
hunting O
hunting O
hunting O
hunting O
hunting O
gene O
. O

A O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
HHUA O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
hunting O
hunting O
hunting O
hunting O
hunting O
hunting O
gene O
. O

search O
second O
gene O
mutation O
HHUA O
cells O
a O
missense O
mutation O
in O
the O
MSH6 O
gene O
. O

A O
subsequent O
search O
revealed O
a O
mutation O
in O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
gene O
. O

search O
revealed O
a O
second O
mutation O
in O
HHUA O
cells O
, O
missense O
mutation O
in O
the O
gene O
. O

MSH6 O
subsequent O
search O
gene O
a O
second O
gene O
in O
mutation O
HHUA O
mutation O
, O
a O
. O
A O
in O
the O
cells O
revealed O
missense O

A O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
HHUA O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
hunting O
hunting O
hunting O
hunting O
hunting O
chromosomal O
mutation O
gene O

A O
subsequent O
explore O
discover O
a O
moment O
cistron O
mutation O
in O
HHUA O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
cistron O
. O

the O
subsequent O
search O
revealed O
a O
second O
missense O
, O
in O
HHUA O
cells O
mutation O
A O
gene O
mutation O
MSH6 O
a O
in O
gene O
. O

A O
subsequent O
search O
revealed O
a O
second O
gene O
mutation O
in O
HHUA O
cells O
, O
a O
missense O
mutation O
in O
the O
MSH6 O
gene O
. O

Together O
the O
data O
suggest O
that O
the O
MSH3 O
gene O
product O
that O
functions O
in O
of O
some O
but O
not O
all O
- O
mutational O
intermediates O
, O
mutation O
in O
can O
result O
in O
genomic O
instability O
and O
, O
as O
yeast O
, O
and O
MSH6 O
are O
partially O
redundant O
for O
mismatch O
repair O

partially O
, O
data O
suggest O
that O
the O
in O
some O
encodes O
a O
product O
that O
functions O
. O
for O
of O
gene O
result O
not O
all O
and O
- O
mutational O
intermediates O
the O
its O
mutation O
yeast O
but B
can O
tumours O
MSH3 O
genomic O
instability O
and O
, O
as O
repair O
in O
, O
MSH3 O
pre O
MSH6 O
are O
Together O
redundant O
repair O
mismatch O
. O
in O
in O

together O
the O
datum O
advise O
that O
the O
MSH3 O
factor O
encodes O
a O
product O
that O
functions O
in O
revive O
of O
some O
but O
not O
all O
pre O
- O
mutational O
arbitrate O
, O
its O
mutant O
in O
tumor B
can O
issue O
in O
genomic O
imbalance O
and O
, O
as O
in O
barm O
, O
MSH3 O
and O
MSH6 O
are O
partly O
excess O
for O
mismatch O
revive O
. O
. O

Together O
the O
data O
suggest O
that O
the O
MSH3 O
gene O
inward O
encode O
encodes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
tumours B
can O
result O
in O
genomic O
instability O
and O
, O
a O
be O
part O
surplus O
be O
part O
amend O
be O
part O
amend O
or O
so O
or O
so O
or O
so O
as O
in O
yeast O
, O
MSH3 O
and O
MSH6 O
are O
partially O
redundant O
for O
mismatch O

Together O
the O
data O
suggest O
that O
the O
MSH3 O
gene O
inward O
encode O
encodes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
tumours B
can O
result O
in O
genomic O
instability O
and O
, O
a O
be O
part O
surplus O
be O
part O
amend O
be O
part O
amend O
or O
so O
or O
so O
or O
so O
as O
in O
yeast O
, O
MSH3 O
and O
MSH6 O
are O
partially O
redundant O
for O
mismatch O

the O
data O
suggest O
that O
the O
gene O
encodes O
functions O
of O
some O
all O
mutational O
intermediates O
, O
its O
in O
tumours B
in O
genomic O
and O
, O
, O
and O
MSH6 O
are O
redundant O
for O
mismatch O
. O
. O

Together O
the O
data O
the O
MSH3 O
gene O
encodes O
a O
product O
that O
functions O
of O
but O
not O
all O
- O
mutational O
intermediates O
, O
its O
mutation O
tumours B
can O
genomic O
and O
, O
as O
in O
MSH3 O
and O
MSH6 O
are O
redundant O
for O
mismatch O
repair O
. O
. O

Together O
the O
datum O
suggest O
that O
the O
MSH3 O
cistron O
encodes O
a O
merchandise O
that O
serve O
in O
quicken O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
neoplasm B
can O
leave O
in O
genomic O
imbalance O
and O
, O
as O
in O
barm O
, O
MSH3 O
and O
MSH6 O
are O
partly O
excess O
for O
mismatch O
quicken O
. O
. O

unitedly O
the O
information O
propose O
that O
the O
MSH3 O
factor O
encodes O
a O
product O
that O
serve O
in O
rectify O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
sport O
in O
tumor B
can O
issue O
in O
genomic O
unstableness O
and O
, O
as O
in O
barm O
, O
MSH3 O
and O
MSH6 O
are O
partially O
supererogatory O
for O
mismatch O
rectify O
. O
. O

Together O
the O
data O
suggest O
that O
the O
MSH3 O
gene O
inward O
encode O
encodes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
tumours B
can O
result O
in O
genomic O
instability O
and O
, O
a O
be O
part O
surplus O
be O
part O
amend O
be O
part O
amend O
or O
so O
or O
so O
serve O
as O
in O
yeast O
, O
MSH3 O
and O
MSH6 O
are O
partially O
redundant O
for O
mismatch O
repair O

Together O
the O
data O
suggest O
that O
the O
MSH3 O
gene O
encodes O
a O
product O
that O
functions O
in O
repair O
of O
some O
but O
not O
all O
pre O
- O
mutational O
intermediates O
, O
its O
mutation O
in O
tumours B
can O
result O
in O
genomic O
instability O
and O
, O
as O
in O
yeast O
, O
MSH3 O
and O
MSH6 O
are O
partially O
redundant O
for O
mismatch O
repair O
. O
. O

mouse O
genome O
mapping O
telangiectasia O
the O
ataxia B
- I
of I
and O
in O
, O
, O
Comparative O
rat O
region O
Syrian O
hamster O
. O

Comparative O
genome O
function O
of O
the O
dyssynergia B
- I
telangiectasia I
realm O
in O
creep O
, O
rat O
, O
and O
syrian O
hamster O
. O

comparative O
genome O
mapping O
of O
the O
ataxy B
- I
telangiectasia I
realm O
in O
mouse O
, O
blackleg O
, O
and O
syrian O
hamster O
. O

Comparative O
genome O
mapping O
ataxia B
- I
telangiectasia I
region O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
. O

Comparative O
genome O
mapping O
of O
the O
ataxia B
- I
telangiectasia I
area O
in O
mouse O
, O
stag O
, O
and O
syrian O
hamster O
. O

Comparative O
genome O
map O
out O
mapping O
of O
the B
ataxia I
- I
telangiectasia O
region O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
map O
out O
map O
out O

Comparative O
genome O
mapping O
of O
the O
ataxia B
- I
telangiectasia I
region O
in O
, O
rat O
and O
Syrian O
hamster O
. O

Comparative O
genome O
map O
out O
mapping O
of O
the B
ataxia I
- I
telangiectasia O
region O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
map O
out O
map O
out O

genome O
the O
ataxia B
- I
telangiectasia I
region O
in O
mouse O
, O
rat O
. O

Comparative O
genome O
region O
and O
the O
ataxia B
rat I
telangiectasia I
mapping O
in O
mouse O
, O
- O
, O
of O
Syrian O
hamster O
. O

Comparative O
genome O
mapping O
of O
the O
ataxia B
- I
telangiectasia I
region O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
. O

Chromosomal O
Atm O
ataxia B
- I
telangiectasia I
AT B
) O
- O
) O
and O
Acat1 O
( O
mitochondrial O
CoA O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
Syrian O
were O
determined O
by O
R O
- O
banding O
FISH O
. O

Chromosomal O
locations O
of O
the O
Atm O
telangiectasia I
( O
AT B
) O
- O
) O
and O
acetoacetyl O
thiolase O
) O
mouse O
, O
and O
Syrian O
hamster O
determined O
by O
- O
banding O
. O

Chromosomal O
locations O
of O
the O
Atm O
( O
ataxia B
- I
telangiectasia I
( O
AT B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
were O
determined O
by O
fish O
asynchronous O
transfer O
mode O
stripe O
fish O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O

chromosomal O
positioning O
of O
the O
Atm O
( O
dyssynergia B
- I
telangiectasia I
( O
at B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
factor O
in O
creep O
, O
denounce O
, O
and O
syrian O
hamster O
were O
specify O
by O
channelise O
roentgen O
- O
banding O
fish O
. O

Chromosomal O
locations O
and O
the O
Atm O
by O
ataxia B
mitochondrial I
telangiectasia I
( O
AT B
mouse O
acetoacetyl O
mutated O
) O
- O
Acat1 O
( O
R O
- O
- O
hamster O
thiolase O
( O
genes O
and O
) O
CoA O
rat O
, O
of O
, O
Syrian O
were O
determined O
) O
direct O
in O
- O
banding O
FISH O
. O

chromosomal O
locating O
of O
the O
Atm O
( O
dyssynergia B
- I
telangiectasia I
( O
at B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
factor O
in O
pussyfoot O
, O
rat O
, O
and O
syrian O
hamster O
were O
settle O
by O
unmediated O
r O
- O
stripe O
fish O
. O

determined O
mitochondrial O
of O
the O
Atm O
( O
. B
- I
telangiectasia I
( O
AT B
FISH O
- O
genes O
, O
and O
Acat1 O
( O
, O
acetoacetyl O
- O
CoA O
by O
) O
mutated O
in O
were O
locations O
Syrian O
thiolase O
and O
rat O
hamster O
) O
Chromosomal O
mouse O
direct O
R O
- O
banding O
) O
ataxia O

Chromosomal O
locations O
of O
the O
Atm O
( O
telangiectasia I
( O
AT B
) O
mutated O
) O
and O
Acat1 O
( O
acetoacetyl O
- O
CoA O
thiolase O
genes O
in O
, O
rat O
, O
and O
Syrian O
hamster O
were O
determined O
direct O
R O
banding O
FISH O
. O

- O
genes O
of O
the O
Acat1 O
( O
- B
Syrian I
telangiectasia I
( O
AT B
) O
- O
ataxia O
R O
and O
Atm O
and O
mitochondrial O
acetoacetyl O
mutated O
CoA O
thiolase O
) O
, O
in O
mouse O
. O
( O
, O
rat O
locations O
hamster O
were O
determined O
by O
direct O
) O
Chromosomal O
banding O
FISH O
- O

Chromosomal O
locations O
of O
the O
Atm O
( O
ataxia B
- I
telangiectasia I
( O
AT B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
were O
determined O
by O
fish O
asynchronous O
transfer O
mode O
stripe O
fish O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O

Chromosomal O
locations O
of O
the O
Atm O
( O
ataxia B
- I
telangiectasia I
( O
AT B
) O
- O
mutated O
) O
and O
Acat1 O
( O
mitochondrial O
acetoacetyl O
- O
CoA O
thiolase O
) O
genes O
in O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
were O
determined O
by O
direct O
R O
- O
banding O
FISH O
. O

both O
genes O
were O
colocalized O
to O
the O
coulomb O
- O
D O
circle O
of O
creep O
chromosome O
ennead O
, O
the O
proximal O
remnant O
of O
q24 O
. O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
D O
band O
of O
mouse O
chromosome O
9 O
, O
the O
proximal O
end O
be O
be O
be O
be O
be O
be O
of O
q24 O
. O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
D O
band O
of O
mouse O
chromosome O
9 O
, O
the O
proximal O
end O
be O
be O
be O
be O
be O
be O
of O
q24 O
. O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
band O
of O
chromosome O
9 O
, O
the O
proximal O
end O
of O

, O
genes O
D O
C O
to O
the O
the O
- O
were O
band O
of O
mouse O
. O
9 O
colocalized O
Both O
proximal O
end O
of O
q24 O
chromosome O

both O
factor O
were O
colocalized O
to O
the O
carbon O
- O
viosterol O
isthmus O
of O
sneak O
chromosome O
9 O
, O
the O
proximal O
end O
of O
q24 O
. O

. O
genes O
were O
of O
to O
the O
C O
of O
, O
band O
colocalized O
mouse O
9 O
chromosome O
D O
the O
proximal O
end O
- O
Both O
q24 O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
D O
band O
of O
mouse O
chromosome O
9 O
, O
the O
proximal O
end O
be O
be O
be O
be O
be O
be O
of O
q24 O
. O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
D O
band O
of O
mouse O
chromosome O
, O
end O
of O
q24 O
. O

both O
cistron O
were O
colocalized O
to O
the O
C O
- O
ergocalciferol O
band O
of O
sneak O
chromosome O
ix O
, O
the O
proximal O
remnant O
of O
q24 O
. O

Both O
genes O
were O
colocalized O
to O
the O
C O
- O
D O
band O
of O
mouse O
chromosome O
9 O
, O
the O
proximal O
end O
of O
q24 O
. O

1 O
of O
 O
dirty O
dog O
dirty O
dog O
rat O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
Syrian O
hamster O
chromosome O
12 O

chromosome O
of O
rat O
. O
8 O
, O
and O
qa4 O
12 O
qa5 O
of O
Syrian O
1 O
hamster O
- O
chromosome O

1 O
of O
 O
dirty O
dog O
 O
rat O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
Syrian O
hamster O
chromosome O
12 O

unity O
of O
squealer O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
syrian O
hamster O
chromosome O
12 O
. O

hamster O
of O
rat O
qa4 O
8 O
, O
chromosome O
chromosome O
- O
qa5 O
1 O
Syrian O
of O
and O
12 O
. O

1 O
of O
 O
dirty O
dog O
twelve O
rat O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
Syrian O
hamster O
chromosome O
12 O
syrian O

i O
of O
betray O
chromosome O
ogdoad O
, O
and O
qa4 O
- O
qa5 O
of O
syrian O
hamster O
chromosome O
12 O
. O

1 O
of O
lowlife O
chromosome O
ogdoad O
, O
and O
qa4 O
- O
qa5 O
of O
syrian O
hamster O
chromosome O
xii O
. O

1 O
of O
- O
. O
8 O
, O
hamster O
qa4 O
rat O
qa5 O
of O
Syrian O
and O
chromosome O
chromosome O
12 O

of O
rat O
chromosome O
8 O
, O
and O
qa4 O
of O
Syrian O
hamster O
chromosome O
12 O
. O

1 O
of O
rat O
chromosome O
8 O
, O
and O
qa4 O
- O
qa5 O
of O
Syrian O
hamster O
chromosome O
12 O
. O

The O
in O
mouse O
rat O
were O
homologous O
to O
human O
chromosome O
11q O
. O

The O
area O
in O
the O
shiner O
and O
scab O
were O
homologous O
to O
human O
chromosome O
11q O
. O

were O
the O
in O
regions O
mouse O
and O
to O
The O
homologous O
. O
human O
chromosome O
11q O
rat O

The O
regions O
in O
the O
mouse O
and O
rat O
were O
to O
human O
11q O
. O

The O
regions O
be O
inward O
in O
the O
mouse O
and O
rat O
were O
homologous O
region O
pussyfoot O
to O
human O
chromosome O
11q O
. O

The O
regions O
be O
inward O
in O
the O
mouse O
and O
rat O
were O
homologous O
region O
inward O
to O
human O
chromosome O
11q O
. O

The O
area O
in O
the O
shiner O
and O
skunk O
were O
homologous O
to O
homo O
chromosome O
11q O
. O

11q O
regions O
in O
The O
were O
and O
rat O
chromosome O
homologous O
to O
human O
mouse O
the O
. O

The O
regions O
be O
inward O
in O
the O
mouse O
and O
rat O
were O
homologous O
region O
pussyfoot O
to O
human O
chromosome O
11q O
. O

The O
realm O
in O
the O
mouse O
and O
rat O
were O
homologous O
to O
homo O
chromosome O
11q O
. O

The O
regions O
in O
the O
mouse O
and O
rat O
were O
homologous O
to O
human O
chromosome O
11q O
. O

performed O
genetic O
linkage O
AT O
of O
the O
mouse O
mapping B
backcross O
was O
interspecific O
using O
Fine O
the O
region O
mice O
. O

Fine O
transmitted O
linkage O
function O
of O
the O
mouse O
astatine B
neighborhood O
was O
execute O
using O
the O
interspecific O
backcross O
mice O
. O

Fine O
genetic O
linkage O
mapping O
of O
the O
mouse O
AT B
neighborhood O
was O
do O
habituate O
the O
interspecies O
backcross O
mouse O
. O

Fine O
genetic O
of O
the O
mouse O
AT B
region O
was O
performed O
using O
the O
interspecific O
backcross O
mice O
. O

Fine O
genic O
linkage O
mapping O
of O
the O
mouse O
AT B
realm O
was O
performed O
exploitation O
the O
interspecies O
backcross O
shiner O
. O

Fine O
genetic O
astatine O
gene O
linkage O
linkage O
mapping O
of O
the O
mouse B
AT O
region O
was O
performed O
using O
the O
interspecific O
backcross O
mice O
atomic O
number O
 O

Fine O
genetic O
linkage O
mapping O
of O
the O
mouse O
AT B
was O
performed O
the O
interspecific O
backcross O
mice O
. O

Fine O
genetic O
astatine O
gene O
linkage O
linkage O
mapping O
of O
the O
mouse B
AT O
region O
was O
performed O
using O
the O
interspecific O
backcross O
mice O
atomic O
number O
 O

genetic O
of O
the O
mouse O
AT B
region O
was O
performed O
using O
the O

Fine O
genetic O
region O
backcross O
of O
the O
the O
AT B
linkage O
was O
performed O
using O
mouse O
interspecific O
mapping O
mice O
. O

Fine O
genetic O
linkage O
mapping O
of O
the O
mouse O
AT B
region O
was O
performed O
using O
the O
interspecific O
backcross O
mice O
. O

Atm O
, O
Acat1 O
, O
and O
Npat O
, O
which O
is O
a O
fresh O
cistron O
apart O
from O
the O
AT O
neighborhood O
, O
and O
dozen O
flanking O
microsatellite O
DNA O
marking O
were O
study O
. O

Atm O
, O
, O
and O
Npat O
, O
which O
is O
a O
new O
gene O
isolated O
AT O
region O
, O
and O
flanking O
microsatellite O
DNA O
markers O
were O
. O

Atm O
, O
Acat1 O
, O
be O
astatine O
realm O
and O
Npat O
, O
which O
is O
a O
new O
gene O
isolated O
from O
the O
AT O
region O
, O
marking O
be O
study O
be O
be O
and O
12 O
flanking O
microsatellite O
DNA O
markers O
were O
examined O
. O

flanking O
, O
Acat1 O
and O
and O
Npat O
, O
examined O
markers O
a O
12 O
gene O
isolated O
from O
DNA O
AT O
region O
, O
, O
were O
new O
microsatellite O
the O
is O
Atm O
which O
. O

Atm O
, O
Acat1 O
, O
be O
astatine O
realm O
and O
Npat O
, O
which O
is O
a O
new O
gene O
isolated O
from O
the O
AT O
region O
, O
marking O
be O
study O
be O
be O
and O
12 O
flanking O
microsatellite O
DNA O
markers O
were O
examined O
. O

Atm O
, O
Acat1 O
and O
Npat O
which O
is O
a O
new O
gene O
isolated O
from O
the O
region O
, O
12 O
flanking O
microsatellite O
DNA O
markers O
were O
examined O
. O

. O
, O
Acat1 O
the O
and O
Npat O
examined O
which O
, O
a O
new O
gene O
from O
flanking O
were O
is O
region O
, O
and O
12 O
isolated O
microsatellite O
DNA O
markers O
AT O
, O
Atm O

Acat1 O
Npat O
, O
which O
a O
new O
isolated O
from O
the O
AT O
region O
, O
and O
12 O
flanking O
microsatellite O
DNA O
markers O
were O

markers O
, O
Acat1 O
, O
and O
Npat O
from O
gene O
is O
a O
new O
region O
microsatellite O
, O
were O
Atm O
which O
AT O
and O
12 O
flanking O
isolated O
DNA O
, O
the O
examined O
. O

Atm O
, O
Acat1 O
, O
and O
Npat O
, O
which O
is O
a O
unexampled O
factor O
obscure O
from O
the O
at O
area O
, O
and O
twelve O
flanking O
microsatellite O
DNA O
markers O
were O
test O
. O

Atm O
, O
Acat1 O
, O
and O
Npat O
, O
which O
is O
a O
new O
gene O
isolated O
from O
the O
AT O
region O
, O
and O
12 O
flanking O
microsatellite O
DNA O
markers O
were O
examined O
. O

No O
recombinations O
were O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
loci O
, O
and O
these O
loci O
were O
mapped O
2 O

No O
recombinations O
were O
found O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
loci O
these O
loci O
were O
mapped O
2 O
. O

No O
recombinations O
were O
found O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
loci O
, O
and O
these O
map O
out O
two O
two O
be O
be O
be O
loci O
were O
mapped O
2 O

No O
recombinations O
were O
encounter O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
venue O
, O
and O
these O
venue O
were O
mapped O
deuce O
. O

No O
recombinations O
were O
found O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
loci O
, O
and O
these O
map O
out O
two O
two O
be O
be O
be O
loci O
were O
mapped O
2 O

No O
recombinations O
were O
find O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
venue O
, O
and O
these O
venue O
were O
represent O
two O
. O

No O
recombinations O
were O
found O
among O
the O
Atm O
, O
Npat O
, O
, O
and O
loci O
, O
and O
these O
loci O
were O
mapped O

Acat1 O
recombinations O
were O
loci O
among O
the O
Atm O
Npat O
, O
, O
were O
, O
D9Mit6 O
and O
. O
, O
and O
these O
found O
No O
mapped O
2 O
loci O

No O
recombinations O
were O
feel O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
venue O
, O
and O
these O
venue O
were O
mapped O
deuce O
. O

loci O
recombinations O
Npat O
Atm O
among O
the O
, O
, O
were O
, O
Acat1 O
, O
mapped O
D9Mit6 O
found O
No O
and O
these O
loci O
were O
and O
2 O
. O

No O
recombinations O
were O
found O
among O
the O
Atm O
, O
Npat O
, O
Acat1 O
, O
and O
D9Mit6 O
loci O
, O
and O
these O
loci O
were O
mapped O
2 O
. O

1 O
cM O
distal O
to O
. O
and O
0 O
D9Mit99 O

nought O
curium O
distal O
to O
D9Mit99 O
and O
1 O
. O

distal O
and O
1 O
. O

0 O
 O
 O
cM O
distal O
to O
D9Mit99 O
and O
1 O
. O

0 O
distal O
to O
1 O
. O

0 O
D9Mit99 O
distal O
to O
cM O
and O
. O
1 O

. O
to O
distal O
cM O
D9Mit99 O
and O
1 O
0 O

0 O
cm O
centimetre O
cM O
distal O
to O
D9Mit99 O
and O
1 O
. O

0 O
centimeter O
distal O
to O
D9Mit99 O
and O
i O
. O

0 O
cm O
centimetre O
cM O
distal O
to O
D9Mit99 O
and O
1 O
. O

0 O
cM O
distal O
to O
D9Mit99 O
and O
1 O
. O

3 O
cM O
proximal O
to O
 O
D9Mit102 O
. O

3 O
cM O
to O
D9Mit102 O

3 O
cM O
proximal O
to O
 O
D9Mit102 O
. O

3 O
centimetre O
proximal O
to O
D9Mit102 O
. O

proximal O
cM O
3 O
to O
D9Mit102 O
. O

3 O
cM O
proximal O
. O
D9Mit102 O
to O

3 O
proximal O
D9Mit102 O
. O

3 O
cM O
proximal O
to O
 O
D9Mit102 O
. O

3 O
proximal O
to O
D9Mit102 O
. O

3 O
curium O
proximal O
to O
D9Mit102 O
. O

3 O
cM O
proximal O
to O
D9Mit102 O
. O

of O
map O
chromosome O
9 O
and O
of O
human O
chromosome O
11 O
) O
that O
a O
rearrangement O
due O
to O
inversion O
between O
Ets1 O
- O
Npat O
- O
Acat1 O
and O
the O
inversion O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O

compare O
of O
the O
linkage O
map O
of O
creep O
chromosome O
ix O
( O
MMU9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
HSA11 O
) O
point O
that O
there O
is O
a O
chromosomal O
rearrangement O
referable O
to O
an O
eversion O
between O
Ets1 O
and O
Atm O
- O
Npat O
- O
Acat1 O
and O
that O
the O
eversion O
of O
MMU9 O
originated O
from O
the O
chromosomal O
breaking O
at O
the O
edge O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O
HSA11 O
. O

Comparison O
to O
the O
on O
Acat1 O
- O
mouse O
chromosome O
9 O
( O
MMU9 O
and O
there O
) O
of O
Npat O
chromosome O
11 O
( O
HSA11 O
that O
breakage O
boundary O
and O
- O
a O
chromosomal O
rearrangement O
due O
of O
an O
at O
between O
Ets1 O
and O
Atm O
HSA11 O
human O
is O
originated O
and O
that O
. O
inversion O
of O
MMU9 O
from O
between O
the O
chromosomal O
Acat1 O
inversion O
the O
that O
the O
Gria4 O
) O
Atm O
- O
Npat O
of O
map O
linkage O
- O
indicates O

the O
Atm O
Atm O
MMU9 O
between O
of O
mouse O
Acat1 O
9 O
MMU9 O
( O
there O
and O
that O
of O
human O
chromosomal O
11 O
( O
HSA11 O
) O
indicates O
a O
) O
is O
originated O
between O
rearrangement O
due O
that O
an O
inversion O
map O
Ets1 O
Comparison O
of O
- O
Npat O
- O
Acat1 O
and O
that O
and O
inversion O
boundary O
on O
to O
from O
the O
chromosome O
breakage O
of O
. O
at O
chromosomal O
Gria4 O
and O
the O
linkage O
Npat O
- O
chromosome O
- O
HSA11 O
the O

of O
the O
of O
chromosome O
9 O
( O
MMU9 O
that O
of O
human O
chromosome O
( O
HSA11 O
) O
indicates O
that O
there O
is O
a O
rearrangement O
an O
between O
Ets1 O
and O
Atm O
- O
- O
Acat1 O
and O
that O
inversion O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
- O
Npat O
- O
Acat1 O
HSA11 O
. O

equivalence O
of O
the O
linkage O
represent O
of O
mouse O
chromosome O
niner O
( O
MMU9 O
) O
and O
that O
of O
human O
chromosome O
xi O
( O
HSA11 O
) O
argue O
that O
there O
is O
a O
chromosomal O
rearrangement O
imputable O
to O
an O
eversion O
between O
Ets1 O
and O
atmosphere O
- O
Npat O
- O
Acat1 O
and O
that O
the O
eversion O
of O
MMU9 O
arise O
from O
the O
chromosomal O
breaking O
at O
the O
bounds O
between O
Gria4 O
and O
atmosphere O
- O
Npat O
- O
Acat1 O
on O
HSA11 O
. O

Comparison O
of O
the O
linkage O
map O
of O
mouse O
chromosome O
antiophthalmic O
factor O
asynchronous O
transfer O
mode O
eversion O
imputable O
betwixt O
associate O
in O
nursing O
eversion O
 O
9 O
( O
MMU9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
HSA11 O
) O
indicates O
that O
there O
is O
a O
chromosomal O
rearrangement O
due O
to O
an O
inversion O
between O
Ets1 O
and O
Atm O
- O
Npat O
- O
Acat1 O
and O
that O
the O
inversion O
of O
MMU9 O
originated O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O

HSA11 O
be O
be O
be O
be O
be O
be O
be O

the O
linkage O
mouse O
( O
MMU9 O
) O
and O
of O
human O
( O
HSA11 O
indicates O
that O
chromosomal O
due O
to O
an O
between O
Ets1 O
and O
- O
Npat O
- O
Acat1 O
and O
inversion O
of O
MMU9 O
originated O
from O
the O
chromosomal O
breakage O
boundary O
Gria4 O
and O
Atm O
Npat O
- O
Acat1 O
on O
HSA11 O
. O

Comparison O
of O
the O
linkage O
map O
of O
mouse O
chromosome O
antiophthalmic O
factor O
asynchronous O
transfer O
mode O
eversion O
imputable O
betwixt O
associate O
in O
nursing O
eversion O
 O
9 O
( O
MMU9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
HSA11 O
) O
indicates O
that O
there O
is O
a O
chromosomal O
rearrangement O
due O
to O
an O
inversion O
between O
Ets1 O
and O
Atm O
- O
Npat O
- O
Acat1 O
and O
that O
the O
inversion O
of O
MMU9 O
originated O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O

HSA11 O
be O
be O
be O
be O
be O
be O
be O

compare O
of O
the O
linkage O
represent O
of O
mouse O
chromosome O
niner O
( O
MMU9 O
) O
and O
that O
of O
homo O
chromosome O
eleven O
( O
HSA11 O
) O
bespeak O
that O
there O
is O
a O
chromosomal O
rearrangement O
referable O
to O
an O
anastrophe O
between O
Ets1 O
and O
Atm O
- O
Npat O
- O
Acat1 O
and O
that O
the O
anastrophe O
of O
MMU9 O
uprise O
from O
the O
chromosomal O
breakage O
at O
the O
edge O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O
HSA11 O
. O

Comparison O
of O
the O
linkage O
map O
of O
mouse O
chromosome O
9 O
( O
MMU9 O
) O
and O
that O
of O
human O
chromosome O
11 O
( O
HSA11 O
) O
indicates O
that O
there O
is O
a O
chromosomal O
rearrangement O
due O
to O
an O
inversion O
between O
Ets1 O
and O
Atm O
- O
Npat O
- O
Acat1 O
and O
that O
the O
inversion O
of O
MMU9 O
originated O
from O
the O
chromosomal O
breakage O
at O
the O
boundary O
between O
Gria4 O
and O
Atm O
- O
Npat O
- O
Acat1 O
on O
HSA11 O
. O

This O
type O
of O
inversion O
mintage O
come O
out O
pussyfoot O
follow O
come O
out O
appeared O
to O
be O
conserved O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
map O
out O
and O
Syrian O
hamster O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
coinage O

This O
type O
of O
inversion O
mintage O
come O
out O
pussyfoot O
follow O
come O
out O
appeared O
to O
be O
conserved O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
comparative O
degree O
and O
Syrian O
hamster O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
coinage O

additional O
type O
of O
inversion O
appeared O
to O
, O
rat O
in O
the O
three O
rodent O
, O
be O
comparative O
the O
conserved O
hamster O
and O
Syrian O
This O
species O
using O
, O
mouse O
mapping O
data O
with O
gene O
Rck O
, O

This O
type O
of O
inversion O
mintage O
come O
out O
pussyfoot O
follow O
come O
out O
appeared O
to O
be O
conserved O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
map O
out O
and O
Syrian O
hamster O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
coinage O

This O
type O
of O
inversion O
to O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
gene O

This O
type O
of O
upending O
seem O
to O
be O
conserved O
in O
the O
trine O
gnawer O
species O
, O
mouse O
, O
rat O
, O
and O
syrian O
hamster O
, O
expend O
extra O
relative O
mapping O
data O
with O
the O
Rck O
cistron O

the O
type O
comparative O
mouse O
appeared O
to O
with O
conserved O
inversion O
the O
three O
rodent O
hamster O
, O
of O
in O
rat O
, O
and O
Syrian O
species O
, O
using O
additional O
, O
be O
data O
mapping O
This O
Rck O
gene O

This O
type O
of O
inversion O
appeared O
to O
be O
conserved O
in O
three O
rodent O
, O
mouse O
, O
rat O
, O
and O
Syrian O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
gene O

three O
type O
of O
the O
appeared O
to O
be O
mapping O
additional O
the O
comparative O
rodent O
data O
Syrian O
using O
, O
rat O
, O
gene O
, O
hamster O
, O
mouse O
in O
This O
conserved O
species O
with O
inversion O
Rck O
and O

This O
type O
of O
inversion O
appeared O
to O
be O
preserve O
in O
the O
ternary O
gnawer O
mintage O
, O
mouse O
, O
rat O
, O
and O
syrian O
hamster O
, O
victimization O
extra O
comparative O
represent O
data O
with O
the O
Rck O
cistron O

This O
type O
of O
inversion O
appeared O
to O
be O
conserved O
in O
the O
three O
rodent O
species O
, O
mouse O
, O
rat O
, O
and O
Syrian O
hamster O
, O
using O
additional O
comparative O
mapping O
data O
with O
the O
Rck O
gene O

gene O
animal O
model O
ND O
Norrie B
disease I
( O
for B
mouse O
: O
the O
targeting O
An O
of O
) O
ND B
gene O
. O

an O
creature O
pattern O
for O
Norrie B
disease I
( O
ND B
) O
: O
gene O
aim O
of O
the O
shiner O
ND B
gene O
. O

An O
animal O
poser O
for O
Norrie B
disease I
( O
nd B
) O
: O
factor O
place O
of O
the O
pussyfoot O
nd B
factor O
. O

An O
animal O
model O
disease I
( O
ND B
) O
: O
gene O
targeting O
of O
the O
mouse O
ND B
gene O
. O

an O
sensual O
model O
for O
Norrie B
disease I
( O
ND B
) O
: O
cistron O
aim O
of O
the O
sneak O
ND B
cistron O
. O

An O
animal O
modeling O
model O
for O
Norrie B
disease I
( O
ND B
) O
: O
gene O
targeting O
of O
the O
mouse O
ND B
gene O
clay O
sculpture O
clay O
sculpture O
clay O

An O
animal O
model O
for O
Norrie B
disease I
( O
ND B
) O
: O
targeting O
of O
mouse O
ND B
gene O
. O

An O
animal O
modeling O
model O
for O
Norrie B
disease I
( O
ND B
) O
: O
gene O
targeting O
of O
the O
mouse O
ND B
gene O
clay O
sculpture O
clay O
sculpture O
clay O

animal O
Norrie B
disease I
( O
ND B
) O
: O
gene O
targeting O
of O
. O

An O
animal O
) O
mouse O
Norrie B
disease I
of O
ND B
model O
: O
gene O
targeting O
( O
the O
for O
ND B
gene O
. O

An O
animal O
model O
for O
Norrie B
disease I
( O
ND B
) O
: O
gene O
targeting O
of O
the O
mouse O
ND B
gene O
. O

In O
order O
to O
elucidate O
inward O
nd O
mutation O
mouse O
nd O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
Norrie B
disease I
( O
ND B
) O
nd O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
inwards O
inwards O
knotty O
. O

In O
order O
to O
elucidate O
inward O
nd O
mutation O
mouse O
nd O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
Norrie B
disease I
( O
ND B
) O
be O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
inwards O
inwards O
knotty O
. O

targeting O
order O
to O
elucidate O
the O
cellular O
Norrie O
ND O
processes O
which O
are O
involved O
used O
and B
technology I
mutant O
molecular B
have O
, O
we O
In O
in O
gene O
) O
disease O
to O
generate O
ND B
. O
mice O
( O

In O
order O
to O
elucidate O
inward O
nd O
mutation O
mouse O
nd O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
Norrie B
disease I
( O
ND B
) O
nd O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
inwards O
inwards O
knotty O
. O

In O
order O
to O
elucidate O
cellular O
processes O
which O
are O
involved O
in O
Norrie B
disease I
( O
ND B
used O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
. O

inwards O
order O
to O
elucidate O
the O
cellular O
and O
molecular O
sue O
which O
are O
require O
inwards O
Norrie B
disease I
( O
ND B
) O
, O
we O
have O
victimized O
factor O
point O
engineering O
to O
generate O
ND B
variation O
mice O
. O

mutant O
order O
technology O
disease O
the O
cellular O
ND O
molecular O
elucidate O
which O
are O
involved O
have O
Norrie B
to I
processes O
ND B
) O
, O
we O
in O
used O
gene O
targeting O
( O
and O
generate O
to B
In O
mice O
. O

In O
order O
to O
elucidate O
the O
cellular O
and O
molecular O
processes O
are O
involved O
Norrie B
disease I
( O
ND B
) O
, O
we O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
. O

are O
order O
to O
mutant O
the O
cellular O
and O
to O
targeting O
which O
technology O
involved O
generate O
we B
gene I
( O
ND B
) O
. O
Norrie O
have O
used O
disease O
processes O
In O
molecular O
in O
ND B
elucidate O
mice O
, O

inch O
rank O
to O
crystalise O
the O
cellular O
and O
molecular O
processes O
which O
are O
require O
inch O
Norrie B
disease I
( O
ND B
) O
, O
we O
have O
victimised O
cistron O
point O
engineering O
to O
generate O
ND B
mutation O
mice O
. O

In O
order O
to O
elucidate O
the O
cellular O
and O
molecular O
processes O
which O
are O
involved O
in O
Norrie B
disease I
( O
ND B
) O
, O
we O
have O
used O
gene O
targeting O
technology O
to O
generate O
ND B
mutant O
mice O
. O

The O
murine O
homologue O
of O
the O
ND B
cistron O
was O
cloned O
and O
demo O
to O
encode O
a O
polypeptide O
that O
shares O
xciv O
% O
of O
the O
amino O
blistering O
sequence O
with O
its O
homo O
counterpart O
. O

The O
murine O
homologue O
of O
the O
gene O
and O
shown O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
acid O
sequence O
with O
its O
human O
counterpart O
. O

the O
murine O
homologue O
% O
the O
ND B
gene O
its O
sequence O
and O
. O
to O
encode O
of O
acid O
that O
shares O
94 O
of O
a O
with O
amino O
polypeptide O
cloned O
The O
was O
human O
counterpart O
shown O

The O
murine O
homologue O
of O
allocate O
antiophthalmic O
factor O
nd O
cistron O
apportion O
the B
ND O
gene O
was O
cloned O
and O
shown O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
it O
homo O
clone O
% O
of O
the O
amino O
acid O
sequence O
with O
its O
human O
counterpart O

The O
murine O
homologue O
of O
allocate O
antiophthalmic O
factor O
nd O
cistron O
apportion O
the B
ND O
gene O
was O
cloned O
and O
shown O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
it O
homo O
cistron O
% O
of O
the O
amino O
acid O
sequence O
with O
its O
human O
counterpart O

The O
murine O
homologue O
of O
the O
ND B
gene O
was O
and O
shown O
encode O
a O
polypeptide O
that O
shares O
94 O
% O
amino O
acid O
sequence O
with O
its O
human O
counterpart O
. O

. O
murine O
homologue O
polypeptide O
the O
ND B
its O
was O
of O
and O
shown O
to O
human O
a O
with O
cloned O
shares O
94 O
% O
of O
encode O
amino O
acid O
sequence O
that O
gene O
the O
counterpart O
The O

The O
murine O
homologue O
of O
the O
ND B
gene O
was O
and O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
% O
the O
amino O
acid O
sequence O
with O
its O
human O

The O
murine O
homologue O
of O
the O
nd B
factor O
was O
cloned O
and O
demo O
to O
encode O
a O
polypeptide O
that O
part O
94 O
% O
of O
the O
amino O
acerb O
successiveness O
with O
its O
human O
counterpart O
. O

The O
murine O
homologue O
of O
the O
nd B
factor O
was O
cloned O
and O
demonstrate O
to O
encode O
a O
polypeptide O
that O
deal O
94 O
% O
of O
the O
aminic O
acrid O
succession O
with O
its O
human O
counterpart O
. O

The O
murine O
homologue O
of O
the O
ND B
gene O
was O
cloned O
and O
shown O
to O
encode O
a O
polypeptide O
that O
shares O
94 O
% O
of O
the O
amino O
acid O
sequence O
with O
its O
human O
counterpart O
. O

mice O
in O
situ O
and O
revealed O
expression O
in O
week O
and O
brain O
hybridization O
the O
bulb O
olfactory O
, O
epithelium O
of O
2 O
retina O
RNA O
old O
. O

RNA O
in O
situ O
hybridization O
revealed O
expression O
in O
retina O
, O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
mouse O
mouse O
hybridisation O
hybridisation O
hybridisation O
hybridisation O
week O
old O
mice O
. O

RNA O
in O
situ O
hybridization O
revealed O
expression O
in O
retina O
, O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
mouse O
mouse O
hybridisation O
hybridisation O
hybridisation O
hybridisation O
week O
old O
mice O
. O

RNA O
in O
situ O
hybridisation O
revealed O
formulation O
in O
retina O
, O
mind O
and O
the O
olfactive O
bulb O
and O
epithelium O
of O
2 O
hebdomad O
old O
shiner O
. O

RNA O
in O
situ O
revealed O
expression O
in O
retina O
, O
and O
the O
olfactory O
bulb O
epithelium O
of O
week O
old O
mice O
. O

hybridization O
in O
retina O
, O
and O
the O
bulb O
and O
epithelium O
of O
2 O
week O
old O
mice O
. O

RNA O
in O
situ O
interbreeding O
uncover O
look O
in O
retina O
, O
head O
and O
the O
olfactive O
bulb O
and O
epithelium O
of O
2 O
week O
old O
shiner O
. O

and O
in O
, O
in O
revealed O
expression O
epithelium O
retina O
situ O
brain O
and O
the O
mice O
bulb O
hybridization O
RNA O
of O
2 O
week O
old O
olfactory O
. O

RNA O
in O
situ O
hybridization O
revealed O
expression O
in O
retina O
, O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
mouse O
mouse O
hybridisation O
hybridisation O
hybridisation O
manifestation O
week O
old O
mice O
. O

RNA O
in O
situ O
hybridization O
in O
retina O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
week O
. O

RNA O
in O
situ O
hybridization O
revealed O
expression O
in O
retina O
, O
brain O
and O
the O
olfactory O
bulb O
and O
epithelium O
of O
2 O
week O
old O
mice O
. O

Hemizygous O
mice O
carrying O
a O
cistron O
modernise O
chromosomal O
mutation O
social O
system O
alternate O
replacement O
mutation O
in O
exon O
2 O
of B
the O
ND O
gene O
developed O
retrolental O
structures O
in O
the O
vitreous O
body O
and O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
gene O
gene O
gene O

Hemizygous O
mice O
replacement O
of O
the O
ND B
developed O
retrolental O
in O
the O
vitreous O
showed O
an O
overall O
disorganization O
of O
retinal O
cell O
layer O
. O

Hemizygous O
mice O
carrying O
a O
replacement O
mutant O
in O
exon O
two O
of O
the O
ND B
gene O
train O
retrolental O
structures O
in O
the O
vitrified O
consistence O
and O
testify O
an O
overall O
disorganisation O
of O
the O
retinene O
ganglion O
cell O
bed O
. O

Hemizygous O
mice O
carrying O
a O
mutation O
2 O
of O
the O
ND B
gene O
developed O
retrolental O
structures O
in O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
. O

Hemizygous O
mice O
carrying O
a O
permutation O
mutation O
in O
exon O
two O
of O
the O
ND B
factor O
developed O
retrolental O
structures O
in O
the O
glassy O
body O
and O
usher O
an O
boilersuit O
disorganisation O
of O
the O
retinene O
ganglion O
cell O
stratum O
. O

Hemizygous O
mice O
carrying O
a O
cistron O
modernise O
chromosomal O
mutation O
social O
system O
alternate O
replacement O
mutation O
in O
exon O
2 O
of B
the O
ND O
gene O
developed O
retrolental O
structures O
in O
the O
vitreous O
body O
and O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
gene O
gene O
gene O

Hemizygous O
shiner O
impart O
a O
replacement O
mutation O
in O
exon O
2 O
of O
the O
nd B
cistron O
developed O
retrolental O
structures O
in O
the O
vitreous O
personify O
and O
prove O
an O
overall O
disarrangement O
of O
the O
retinene O
ganglion O
cell O
bed O
. O

and O
vitreous O
carrying O
a O
replacement O
mutation O
in O
exon O
2 O
of O
the O
ND B
gene O
disorganization O
cell O
structures O
in O
the O
retinal O
body O
mice O
showed O
. O
overall O
developed O
of O
the O
Hemizygous O
retrolental O
an O
layer O
ganglion O

Hemizygous O
mice O
carrying O
a O
mutation O
exon O
2 O
of O
the O
ND B
gene O
developed O
retrolental O
in O
the O
vitreous O
body O
and O
showed O
an O
of O
the O
retinal O
cell O
. O

Hemizygous O
mice O
carrying O
a O
cistron O
modernise O
chromosomal O
mutation O
social O
system O
disorganisation O
replacement O
mutation O
in O
exon O
2 O
of B
the O
ND O
gene O
developed O
retrolental O
structures O
in O
the O
vitreous O
body O
and O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
gene O
gene O
gene O

Hemizygous O
mice O
carrying O
a O
replacement O
mutation O
in O
exon O
2 O
of O
the O
ND B
gene O
developed O
retrolental O
structures O
in O
the O
vitreous O
body O
and O
showed O
an O
overall O
disorganization O
of O
the O
retinal O
ganglion O
cell O
layer O
. O

juxtaposed O
outer O
plexiform O
resulting O
disappears O
occasionally O
, O
layer O
nuclear O
a O
outer O
inner O
The O
and O
in O
layer O
. O

The O
stunned O
plexiform O
stratum O
disappears O
occasionally O
, O
ensue O
in O
a O
juxtaposed O
intimate O
and O
stunned O
atomic O
stratum O
. O

The O
outer O
plexiform O
level O
vanish O
occasionally O
, O
ensue O
in O
a O
juxtaposed O
intimate O
and O
outer O
atomic O
level O
. O

The O
outer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O
outer O
nuclear O
layer O
. O

The O
tabu O
plexiform O
bed O
disappears O
occasionally O
, O
ensue O
in O
a O
juxtaposed O
privileged O
and O
tabu O
atomic O
bed O
. O

The O
outer O
lead O
inward O
plexiform O
layer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O
outer O
nuclear O
layer O
pass O
pass O
inwards O
. O

The O
outer O
plexiform O
layer O
disappears O
occasionally O
, O
resulting O
a O
juxtaposed O
and O
outer O
nuclear O
layer O
. O

The O
outer O
lead O
inward O
plexiform O
layer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O
outer O
nuclear O
layer O
pass O
pass O
inwards O
. O

outer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O

The O
outer O
in O
nuclear O
disappears O
occasionally O
and O
resulting O
plexiform O
a O
juxtaposed O
inner O
, O
outer O
layer O
layer O
. O

The O
outer O
plexiform O
layer O
disappears O
occasionally O
, O
resulting O
in O
a O
juxtaposed O
inner O
and O
outer O
nuclear O
layer O
. O

photoreceptor O
the O
same O
segments O
, O
the O
outer O
regions O
no O
the O
are O
cell O
At O
layer O
of O
longer O
present O
. O

At O
the O
same O
area O
, O
the O
forbidden O
segments O
of O
the O
photoreceptor O
cell O
level O
are O
no O
recollective O
introduce O
. O

At O
the O
same O
neighborhood O
, O
the O
kayoed O
section O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
retentive O
acquaint O
. O

At O
the O
same O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
longer O
present O
. O

astatine O
the O
same O
realm O
, O
the O
extinct O
segments O
of O
the O
photoreceptor O
cell O
bed O
are O
no O
foresighted O
present O
. O

At O
the O
lapp O
same O
regions O
, O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
longer O
present O
lapplander O
lapplander O
lapplander O
section O
. O

At O
the O
same O
regions O
, O
the O
outer O
segments O
of O
the O
cell O
layer O
no O
longer O
present O
. O

At O
the O
lapp O
same O
regions O
, O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
longer O
present O
lapplander O
lapplander O
lapplander O
section O
. O

the O
, O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
. O

At O
the O
of O
no O
, O
the O
layer O
segments O
same O
the O
photoreceptor O
cell O
outer O
are O
regions O
longer O
present O
. O

At O
the O
same O
regions O
, O
the O
outer O
segments O
of O
the O
photoreceptor O
cell O
layer O
are O
no O
longer O
present O
. O

These O
ocular O
linked O
are O
consistent O
with O
the O
model O
ND B
patients O
and O
this O
for O
mouse O
line O
severe O
a O
faithful O
recessive O
generated O
study O
neurological O
early O
pathogenic O
events O
provides O
observations O
of O
X B
- I
findings I
in I
in I
disorder I
. O
. O

ocular O
are O
consistent O
with O
observations O
in O
ND B
patients O
and O
generated O
mouse O
line O
provides O
a O
faithful O
model O
of O
early O
pathogenic O
in O
severe O
X B
- I
neurological I

These O
ocular O
findings O
are O
coherent O
with O
observance O
in O
ND B
patients O
and O
the O
render O
mouse O
line O
ply O
a O
congregation O
model O
for O
study O
of O
early O
pathogenic O
upshot O
in O
this O
stark O
x B
- I
yoke I
recessive I
neurological I
cark I
. O
. O

severe O
study O
findings O
are O
a O
with O
line O
recessive O
ND B
patients O
and O
the O
generated O
events O
in O
provides O
consistent O
linked O
model O
for O
mouse O
of O
early O
pathogenic O
ocular O
in O
this O
These O
faithful B
- I
X I
observations I
neurological I
disorder I
. O
. O

These O
ocular O
findings O
are O
ordered O
consistent O
with O
observations O
in O
ND B
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
pathogenic O
events O
in O
this O
severe O
X B
- I
linked I
recessive I
neurological I
disorder I
. O
grade O
grade O
grade O
grade O
grade O
grade O
grade O
grade O
allow O
for O

events O
model O
findings O
are O
consistent O
with O
observations O
in O
ND B
patients O
and O
the O
generated O
severe O
- O
provides O
a O
faithful O
disorder O
for O
study O
of O
X O
pathogenic O
These O
in O
recessive O
mouse O
line B
early I
linked I
. I
neurological I
. I
ocular O
this O

These O
ocular O
findings O
are O
with O
ND B
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
of O
early O
pathogenic O
events O
in O
this O
severe O
X B
- I
linked I
recessive I
neurological I
disorder I
. O
. O

These O
ocular O
receive O
are O
consistent O
with O
notice O
in O
ND B
patients O
and O
the O
generated O
mouse O
tune O
provides O
a O
congregation O
mannikin O
for O
study O
of O
other O
morbific O
events O
in O
this O
grievous O
go B
- I
linked I
recessive I
neurological I
distract I
. O
. O

These O
ocular O
findings O
are O
antiophthalmic O
factor O
consistent O
with O
observations O
in B
ND O
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
pathogenic O
events O
in O
this O
severe B
X I
- I
linked I
recessive I
neurological I
disorder O
. O
allow O
for O
allow O
for O
allow O
for O
allow O
for O
allow O

These O
eyepiece O
findings O
are O
uniform O
with O
observations O
in O
nd B
patients O
and O
the O
generated O
pussyfoot O
line O
cater O
a O
close O
pattern O
for O
field O
of O
early O
infective O
events O
in O
this O
severe O
decade B
- I
linked I
recessive I
neurological I
disorder I
. O
. O

These O
ocular O
findings O
are O
consistent O
with O
observations O
in O
ND B
patients O
and O
the O
generated O
mouse O
line O
provides O
a O
faithful O
model O
for O
study O
of O
early O
pathogenic O
events O
in O
this O
severe O
X B
- I
linked I
recessive I
neurological I
disorder I
. O
. O

The O
FKHR O
PAX3 O
- O
hybrid O
fusion O
of O
transforms O
alveolar B
rhabdomyosarcoma I
in O
fibroblasts O
protein O
culture O
. O

The O
hybrid O
inward O
cultivation O
dental O
consonant O
PAX3 O
- O
FKHR O
fusion O
protein O
of B
alveolar O
loan I
blend O
rhabdomyosarcoma O
transforms O
fibroblasts O
in O

The O
crossbreed O
PAX3 O
- O
FKHR O
coalition O
protein O
of O
alveolar B
rhabdosarcoma I
transubstantiate O
fibroblasts O
in O
culture O
. O

in O
hybrid O
PAX3 O
The O
of O
fusion O
protein O
fibroblasts O
alveolar B
rhabdomyosarcoma I
transforms O
FKHR O
- O
culture O
. O

The O
intercrossed O
PAX3 O
- O
FKHR O
coalition O
protein O
of O
alveolar B
rhabdomyosarcoma I
metamorphose O
fibroblasts O
in O
refinement O
. O

The O
hybrid O
inward O
cultivation O
dental O
consonant O
PAX3 O
- O
FKHR O
fusion O
protein O
of B
alveolar O
loan I
blend O
rhabdomyosarcoma O
transforms O
fibroblasts O
in O

The O
PAX3 O
FKHR O
protein O
of O
alveolar B
rhabdomyosarcoma I
transforms O
fibroblasts O
in O
culture O
. O

of O
- O
PAX3 O
hybrid O
FKHR O
fusion O
rhabdomyosarcoma O
The O
alveolar B
protein I
transforms O
fibroblasts O
in O
. O
culture O

The O
intercrossed O
PAX3 O
- O
FKHR O
coalition O
protein O
of O
alveolar B
rhabdosarcoma I
transforms O
fibroblasts O
in O
cultivation O
. O

The O
hybrid O
inward O
cultivation O
dental O
consonant O
PAX3 O
- O
FKHR O
fusion O
protein O
of B
alveolar O
loan I
blend O
rhabdomyosarcoma O
transforms O
fibroblasts O
in O

The O
hybrid O
PAX3 O
- O
FKHR O
fusion O
protein O
of O
alveolar B
rhabdomyosarcoma I
transforms O
fibroblasts O
in O
culture O
. O

Pediatric B
alveolar I
translocation I
PAX3 O
characterized O
by O
of O
chromosomal O
rhabdomyosarcoma O
that O
fuses O
parts O
a O
the O
is O
and O
FKHR O
genes O
. O

rhabdomyosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
and O
FKHR O
genes O
. O

Pediatric B
alveolar I
rhabdosarcoma I
is O
characterise O
by O
a O
chromosomal O
translocation O
that O
mix O
region O
of O
the O
PAX3 O
and O
FKHR O
factor O
. O

pediatric B
dental I
rhabdosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fusee O
function O
of O
the O
PAX3 O
and O
FKHR O
genes O
. O

FKHR B
alveolar I
rhabdomyosarcoma I
is O
characterized O
by O
the O
PAX3 O
translocation O
that O
fuses O
parts O
genes O
a O
chromosomal O
and O
of O
Pediatric O
. O

Pediatric B
alveolar I
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
PAX3 O
and O
FKHR O
. O

Pediatric B
alveolar I
rhabdomyosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
PAX3 O
and O
FKHR O
genes O
rhabdosarcoma O
rhabdosarcoma O
rhabdosarcoma O
rhabdosarcoma O
aside O
. O

pediatric B
alveolar I
rhabdosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
conflate O
contribution O
of O
the O
PAX3 O
and O
FKHR O
cistron O
. O

Pediatric B
alveolar I
rhabdomyosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
PAX3 O
and O
FKHR O
genes O
rhabdosarcoma O
rhabdosarcoma O
rhabdosarcoma O
rhabdosarcoma O
rhabdosarcoma O
. O

the B
alveolar I
rhabdomyosarcoma I
fuses O
characterized O
by O
a O
. O
PAX3 O
that O
is O
parts O
Pediatric O
of O
translocation O
and O
FKHR O
genes O
chromosomal O

Pediatric B
alveolar I
rhabdomyosarcoma I
is O
characterized O
by O
a O
chromosomal O
translocation O
that O
fuses O
parts O
of O
the O
PAX3 O
and O
FKHR O
genes O
. O

PAX3 O
for O
a O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
for O
a O
forkhead O
- O
helix O
protein O
, O
also O
a O
transcription O
factor O
. O

PAX3 O
for O
a O
regulator O
that O
controls O
developmental O
programs O
, O
and O
FKHR O
for O
a O
- O
winged O
helix O
protein O
, O
also O
a O
likely O

PAX3 O
codes O
for O
a O
ride O
governor O
antiophthalmic O
factor O
ascertain O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
FKHR O
codes O
for O
a O
forkhead O
- O
probable O
arranging O
constituent O
arranging O
winged O
helix O
protein O
, O
also O
a O
likely O
transcription O
factor O

protein O
codes O
for O
winged O
transcriptional O
regulator O
that O
transcription O
a O
programs O
helix O
and O
FKHR O
codes O
also O
a O
forkhead O
- O
a O
likely O
, O
, O
for O
developmental O
PAX3 O
controls O
factor O
. O

factor O
codes O
for O
for O
transcriptional O
regulator O
transcription O
controls O
a O
programs O
, O
and O
codes O
protein O
likely O
developmental O
forkhead O
- O
winged O
helix O
FKHR O
, O
also O
a O
a O
that O
PAX3 O
. O

PAX3 O
codes O
for O
a O
ride O
governor O
antiophthalmic O
factor O
ascertain O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
FKHR O
codes O
for O
a O
forkhead O
- O
probable O
arranging O
constituent O
antiophthalmic O
factor O
winged O
helix O
protein O
, O
also O
a O
likely O
transcription O

PAX3 O
taunt O
for O
a O
transcriptional O
governor O
that O
ensure O
developmental O
programs O
, O
and O
FKHR O
taunt O
for O
a O
forkhead O
- O
winged O
coil O
protein O
, O
likewise O
a O
probably O
arrangement O
gene O
. O

PAX3 O
codes O
for O
a O
ride O
governor O
antiophthalmic O
factor O
ascertain O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
FKHR O
codes O
for O
a O
forkhead O
- O
probable O
arranging O
constituent O
antiophthalmic O
factor O
winged O
helix O
protein O
, O
also O
a O
likely O
transcription O

a O
codes O
for O
a O
transcriptional O
regulator O
codes O
and O
developmental O
programs O
, O
forkhead O
, O
that O
likely O
PAX3 O
controls O
a O
winged O
helix O
protein O
FKHR O
also O
- O
for O
transcription O
factor O
. O

PAX3 O
codes O
for O
a O
transcriptional O
governor O
that O
ensure O
developmental O
programme O
, O
and O
FKHR O
codes O
for O
a O
forkhead O
- O
fly O
helix O
protein O
, O
also O
a O
probably O
recording O
ingredient O
. O

PAX3 O
codes O
for O
a O
transcriptional O
regulator O
that O
controls O
developmental O
programs O
, O
and O
FKHR O
codes O
for O
a O
forkhead O
- O
winged O
helix O
protein O
, O
also O
a O
likely O
transcription O
factor O
. O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
world O
world O
dna O
dna O
dna O
dna O
tie O
activator O
domain O
of O
the O
FKHR O
protein O
. O

FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
domain O
the O
FKHR O
protein O
. O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
dna O
tie O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
activator O
field O
of O
the O
FKHR O
protein O
. O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
of O
the O
protein O
and O
the O
putative O
activator O
domain O
of O
protein O
. O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
world O
world O
dna O
dna O
dna O
dna O
dna O
activator O
domain O
of O
the O
FKHR O
protein O
. O

The O
PAX3 O
- O
FKHR O
fusion O
ware O
retains O
the O
dna O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
activator O
domain O
of O
the O
FKHR O
protein O
. O

The O
PAX3 O
- O
FKHR O
unification O
product O
retains O
the O
DNA O
binding O
land O
of O
the O
PAX3 O
protein O
and O
the O
putative O
activator O
demesne O
of O
the O
FKHR O
protein O
. O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
the O
and O
the O
putative O
activator O
domain O
of O
the O
FKHR O
protein O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
world O
world O
dna O
dna O
dna O
dna O
dna O
activator O
domain O
of O
the O
FKHR O
protein O
. O

domain O
PAX3 O
- O
domains O
fusion O
product O
retains O
activator O
protein O
binding O
FKHR O
of O
PAX3 O
the O
FKHR O
and O
the O
putative O
the O
. O
of O
the O
protein O
DNA O
The O

The O
PAX3 O
- O
FKHR O
fusion O
product O
retains O
the O
DNA O
binding O
domains O
of O
the O
PAX3 O
protein O
and O
the O
putative O
activator O
domain O
of O
the O
FKHR O
protein O
. O

The O
protein O
- O
FKHR O
PAX3 O
has O
shown O
as O
to O
function O
transcriptional O
a O
been O
activator O
. O

The O
PAX3 O
be O
usher O
antiophthalmic O
factor O
- O
FKHR O
protein O
has O
been O
shown O
to O
be O
function O
as O
a O
transcriptional O
activator O

The O
PAX3 O
- O
FKHR O
protein O
has O
been O
shown O
to O
officiate O
as O
a O
transcriptional O
activator O
. O

transcriptional O
PAX3 O
- O
The O
shown O
has O
been O
a O
to O
function O
as O
protein O
FKHR O
activator O
. O

The O
PAX3 O
- O
FKHR O
protein O
has O
been O
establish O
to O
serve O
as O
a O
transcriptional O
activator O
. O

The O
PAX3 O
be O
usher O
antiophthalmic O
factor O
- O
FKHR O
protein O
has O
been O
shown O
to O
usher O
function O
as O
a O
transcriptional O
activator O

The O
- O
protein O
been O
shown O
to O
function O
as O
a O
transcriptional O
activator O
. O

shown O
FKHR O
- O
PAX3 O
protein O
has O
function O
The O
to O
been O
as O
a O
transcriptional O
. O
activator O

The O
PAX3 O
- O
FKHR O
protein O
has O
been O
establish O
to O
routine O
as O
a O
transcriptional O
activator O
. O

The O
PAX3 O
be O
usher O
antiophthalmic O
factor O
- O
FKHR O
protein O
has O
been O
shown O
to O
usher O
function O
as O
a O
transcriptional O
activator O

The O
PAX3 O
- O
FKHR O
protein O
has O
been O
shown O
to O
function O
as O
a O
transcriptional O
activator O
. O

Using O
the O
introduced O
into O
vector O
, O
FKHR O
have O
RCAS O
the O
PAX3 O
- O
we O
gene O
retroviral O
chicken O
embryo O
fibroblasts O
. O

RCAS O
retroviral O
vector O
, O
we O
have O
introduced O
the O
PAX3 O
chicken O
embryo O
fibroblasts O
. O

victimization O
the O
RCAS O
retroviral O
transmitter O
, O
we O
have O
acquaint O
the O
PAX3 O
- O
FKHR O
factor O
into O
wimp O
embryo O
fibroblasts O
. O

habituate O
the O
RCAS O
retroviral O
transmitter O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
cistron O
into O
wimp O
conceptus O
fibroblasts O
. O

embryo O
the O
RCAS O
retroviral O
vector O
, O
gene O
into O
introduced O
the O
PAX3 O
- O
fibroblasts O
we O
have O
chicken O
FKHR O
Using O
. O

Using O
the O
vector O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
gene O
into O
chicken O
embryo O
. O

Using O
the O
RCAS O
retroviral O
vector O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
gene O
into O
chicken O
embryo O
fibroblasts O
enclose O
enclose O
enclose O
enclose O
utilise O
. O

victimisation O
the O
RCAS O
retroviral O
transmitter O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
cistron O
into O
crybaby O
embryo O
fibroblasts O
. O

Using O
the O
RCAS O
retroviral O
vector O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
gene O
into O
chicken O
embryo O
fibroblasts O
enclose O
enclose O
enclose O
enclose O
enclose O
. O

gene O
the O
RCAS O
PAX3 O
vector O
, O
we O
. O
into O
the O
retroviral O
- O
Using O
FKHR O
introduced O
chicken O
embryo O
fibroblasts O
have O

Using O
the O
RCAS O
retroviral O
vector O
, O
we O
have O
introduced O
the O
PAX3 O
- O
FKHR O
gene O
into O
chicken O
embryo O
fibroblasts O
. O

Expression O
of O
for O
PAX3 O
- O
FKHR O
to O
grow O
these O
cells O
leads O
and O
tightly O
the O
cells O
acquire O
enlarged O
, O
anchorage O
transformation O
packed O
- O
in O
multiple O
layers O
become O
protein O
and O
the O
ability O
the O
in O
, O
independent O
growth O
. O

of O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
leads O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
and O
in O
multiple O
, O
acquire O
the O
ability O
- O

Expression O
of O
the O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
chair O
to O
transmutation O
the O
cells O
go O
enlarged O
, O
maturate O
tightly O
take O
and O
in O
multiple O
stratum O
, O
and O
produce O
the O
power O
for O
anchorage O
- O
fencesitter O
increment O
. O

acquire O
packed O
the O
PAX3 O
enlarged O
FKHR O
cells O
anchorage O
these O
cells O
leads O
to O
transformation O
layers O
in O
become O
- O
for O
grow O
tightly O
the O
and O
in O
multiple O
of O
, O
and O
Expression O
, O
ability O
the O
protein O
- O
independent O
growth O
. O

Expression O
of O
the O
PAX3 O
magnify O
- O
FKHR O
protein O
in O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
tightly O
packed O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchorage O
- O
independent O
growth O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
suit O
. O

layers O
grow O
the O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
leads O
to O
transformation O
acquire O
ability O
become O
enlarged O
, O
independent O
tightly O
packed O
and O
the O
multiple O
Expression O
, O
anchorage O
the O
cells O
in O
for O
. O
- O
growth O
of O
and O

Expression O
of O
the O
PAX3 O
FKHR O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchorage O
- O
independent O
growth O
. O

Expression O
of O
the O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
run O
to O
transmutation O
the O
cells O
suit O
expatiate O
, O
farm O
tightly O
carry O
and O
in O
multiple O
layers O
, O
and O
win O
the O
power O
for O
anchorage O
- O
main O
emergence O
. O

Expression O
of O
the O
PAX3 O
magnify O
- O
FKHR O
protein O
in O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
tightly O
packed O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchorage O
- O
independent O
growth O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
overdraw O
suit O
. O

verbalism O
of O
the O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
leads O
to O
translation O
the O
cells O
turn O
lucubrate O
, O
rise O
tightly O
packed O
and O
in O
multiple O
bed O
, O
and O
acquire O
the O
power O
for O
anchorage O
- O
freelancer O
development O
. O

Expression O
of O
the O
PAX3 O
- O
FKHR O
protein O
in O
these O
cells O
leads O
to O
transformation O
the O
cells O
become O
enlarged O
, O
grow O
tightly O
packed O
and O
in O
multiple O
layers O
, O
and O
acquire O
the O
ability O
for O
anchorage O
- O
independent O
growth O
. O

This O
cellular O
translation O
in O
vitro O
will O
help O
examine O
on O
the O
mechanics O
of O
PAX3 O
- O
FKHR O
- O
cause O
oncogenesis O
. O
. O

This O
cellular O
transformation O
in O
vitro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis O
translation O
translation O
translation O
translation O
translation O
translation O
. O
. O

This O
cellular O
transformation O
in O
vitro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis O
translation O
translation O
translation O
translation O
translation O
translation O
. O
. O

transformation O
will O
facilitate O
studies O
the O
mechanism O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis O
. O
. O

This O
cellular O
transformation O
in O
vitro O
studies O
on O
mechanism O
of O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis O
. O
. O

transformation O
in O
vitro O
will O
studies O
on O
the O
mechanism O
of O
- O
FKHR O
- O
induced O
. O
. O

oncogenesis O
cellular O
transformation O
. O
vitro O
will O
facilitate O
on O
studies O
the O
FKHR O
of O
PAX3 O
. O
This O
- O
induced O
mechanism O
in O
- O

This O
cellular O
transformation O
in O
vitro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis O
translation O
translation O
translation O
translation O
translation O
translation O
. O
. O

This O
cellular O
translation O
in O
vitro O
will O
alleviate O
contemplate O
on O
the O
mechanics O
of O
PAX3 O
- O
FKHR O
- O
have O
oncogenesis O
. O
. O

induced O
cellular O
transformation O
in O
vitro O
will O
- O
of O
on O
the O
mechanism O
FKHR O
This O
facilitate O
studies O
oncogenesis O
PAX3 O
- O
. O
. O

This O
cellular O
transformation O
in O
vitro O
will O
facilitate O
studies O
on O
the O
mechanism O
of O
PAX3 O
- O
FKHR O
- O
induced O
oncogenesis O
. O
. O

Somatic O
- O
cubicle O
excerption O
is O
a O
major O
deciding O
of O
the O
blood O
- O
cubicle O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
sextuplet O
- O
phosphate O
dehydrogenase O
mutant O
cause O
grave O
enzyme B
lack I
. O

Somatic O
- O
cell O
selection O
is O
major O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
dehydrogenase O
mutations O
causing O
severe O
enzyme B
deficiency I
. O

- O
- O
cell O
- O
is O
a O
major O
severe O
mutations O
the O
. O
- O
cell O
6 O
dehydrogenase O
heterozygotes O
for O
glucose O
selection O
phenotype O
causing O
phosphate O
in O
of O
Somatic O
determinant O
enzyme B
deficiency I
blood O

Somatic O
- O
cell O
selection O
jail O
cell O
be O
inward O
heterozygote O
be O
is O
a O
major O
determinant O
of O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
dangerous O
cause O
pick O
- O
6 O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe B
enzyme I
deficiency O

Somatic O
- O
cell O
selection O
jail O
cell O
be O
inward O
heterozygote O
be O
is O
a O
major O
determinant O
of O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
dangerous O
cause O
lack O
- O
6 O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe B
enzyme I
deficiency O

Somatic O
- O
cell O
selection O
is O
a O
major O
determinant O
the O
blood O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe O
enzyme B
deficiency I
. O

. O
- O
cell O
in O
is O
a O
severe O
determinant O
selection O
the O
blood O
- O
enzyme O
phenotype O
causing O
of O
for O
glucose O
- O
6 O
cell O
phosphate O
dehydrogenase O
mutations O
heterozygotes O
major O
- B
deficiency I
Somatic O

Somatic O
- O
cell O
selection O
is O
a O
major O
determinant O
the O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe O
enzyme B

corporal O
- O
cell O
selection O
is O
a O
major O
epitope O
of O
the O
descent O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
mutations O
make O
hard O
enzyme B
want I
. O

corporeal O
- O
cell O
extract O
is O
a O
major O
deciding O
of O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
sextuplet O
- O
phosphate O
dehydrogenase O
variation O
induce O
dangerous O
enzyme B
lack I
. O

Somatic O
- O
cell O
selection O
is O
a O
major O
determinant O
of O
the O
blood O
- O
cell O
phenotype O
in O
heterozygotes O
for O
glucose O
- O
6 O
- O
phosphate O
dehydrogenase O
mutations O
causing O
severe O
enzyme B
deficiency I
. O

X O
chromosome O
inactivation O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
but O
the O
resulting O
somatic O
cell O
mosaicism O
creates O
the O
opportunity O
cell O
selection O
. O

X O
chromosome O
inactivation O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
but O
the O
somatic O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O

X O
- O
chromosome O
inactivation O
inward O
simply O
be O
inward O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
somatic O
create O
jail O
cell O
pick O
pick O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O
cell O
selection O

mosaicism O
- O
chromosome O
- O
in O
mammals O
is O
cell O
opportunity O
an O
cell O
random O
process O
, O
the O
the O
resulting O
somatic O
inactivation O
for O
essentially O
creates O
but O
as O
X O
regarded O
selection O
. O

selection O
- O
chromosome O
but O
in O
mammals O
cell O
regarded O
inactivation O
an O
essentially O
random O
, O
mosaicism O
for O
as O
resulting O
somatic O
- O
cell O
process O
creates O
the O
opportunity O
the O
is O
X O
. O

X O
- O
chromosome O
inactivation O
inward O
simply O
be O
inward O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
somatic O
create O
jail O
cell O
pick O
a O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O
cell O
selection O

cristal O
- O
chromosome O
deactivation O
in O
mammalian O
is O
view O
as O
an O
essentially O
random O
litigate O
, O
but O
the O
leave O
corporeal O
- O
cell O
mosaicism O
make O
the O
opportunity O
for O
cell O
selection O
. O

X O
- O
chromosome O
inactivation O
inward O
simply O
be O
inward O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
somatic O
create O
jail O
cell O
pick O
a O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O
cell O
selection O

opportunity O
- O
chromosome O
inactivation O
in O
mammals O
, O
random O
as O
an O
essentially O
resulting O
creates O
is O
for O
X O
regarded O
the O
- O
cell O
mosaicism O
process O
the O
somatic O
but O
cell O
selection O
. O

ecstasy O
- O
chromosome O
deactivation O
in O
mammalian O
is O
regarded O
as O
an O
essentially O
random O
work O
, O
but O
the O
leave O
bodily O
- O
cell O
mosaicism O
produce O
the O
opportunity O
for O
cell O
excerpt O
. O

X O
- O
chromosome O
inactivation O
in O
mammals O
is O
regarded O
as O
an O
essentially O
random O
process O
, O
but O
the O
resulting O
somatic O
- O
cell O
mosaicism O
creates O
the O
opportunity O
for O
cell O
selection O
. O

In O
most O
people O
with O
orthophosphate O
inward O
line O
blood O
red O
red O
- O
blood O
- O
cell B
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency O
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
phosphate O
phosphate O
phosphate O
phosphate O
somewhat O

In O
most O
people O
- O
- I
6 I
- I
dehydrogenase I
( I
) I
deficiency I
, O
- O
deficient O
phenotype O
is O
only O
expressed O
nucleated O
cells O
. O

indium O
most O
people O
with O
red O
- O
line O
- O
cell O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
inadequacy I
, O
the O
enzyme O
- O
inferior O
phenotype O
is O
only O
fairly O
verbalized O
indium O
nucleated O
cubicle O
. O

In O
most O
people O
with O
red O
- O
blood O
cell O
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
, O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
. O

inwards O
most O
people O
with O
red O
- O
roue O
- O
cell O
glucose B
- I
sextuplet I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
insufficiency I
, O
the O
enzyme O
- O
substandard O
phenotype O
is O
only O
somewhat O
explicit O
inwards O
nucleated O
cellphone O
. O

In O
most O
people O
with O
orthophosphate O
inward O
line O
blood O
red O
red O
- O
blood O
- O
cell B
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency O
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
phosphate O
phosphate O
phosphate O
phosphate O
somewhat O

inward O
most O
citizenry O
with O
red O
- O
roue O
- O
cell O
glucose B
- I
hexad I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
lack I
, O
the O
enzyme O
- O
inferior O
phenotype O
is O
only O
passably O
evince O
inward O
nucleated O
cells O
. O

the O
deficiency O
people O
with O
red O
- O
blood O
- O
cell O
glucose B
- I
6 I
- I
phenotype I
in I
( I
G6PD I
) I
moderately I
, O
most O
enzyme O
cells O
deficient O
phosphate O
is O
only O
In O
dehydrogenase O
- O
nucleated O
expressed O
. O

In O
most O
people O
with O
red O
- O
- O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
deficiency I
, O
the O
enzyme O
- O
deficient O
phenotype O
moderately O
expressed O
in O
cells O

In O
most O
people O
with O
orthophosphate O
inward O
line O
jail O
cell O
red O
- O
blood O
- O
cell B
glucose I
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency O
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
phosphate O
phosphate O
phosphate O
phosphate O
somewhat O

In O
most O
people O
with O
red O
- O
blood O
- O
cell O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
( I
G6PD I
) I
deficiency I
, O
the O
enzyme O
- O
deficient O
phenotype O
is O
only O
moderately O
expressed O
in O
nucleated O
cells O
. O

However O
, O
deficiency O
a O
small O
subset O
of O
underlying O
males O
who O
suffer O
I O
mutations B
nonspherocytic I
hemolytic I
hemizygous I
, O
the O
opportunity O
chronic O
( O
. O
class O
from O
) O
anemia O
- O
and O
severe O
G6PD B
in I
females O
, O
this O
might O
development O
an O
cause O
for O
selection O
in O
heterozygous O
more O
during O
provide O
designated O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
designated O
class O
I O
) O
cause O
more O
- O
severe O
G6PD B
deficiency I
, O
and O
this O
might O
provide O
female O
person O
inward O
developing O
female O
person O
inward O
developing O
female O
person O
low O
developing O
low O
low O
low O
low O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
designated O
class O
I O
) O
cause O
more O
- O
severe O
G6PD B
deficiency I
, O
and O
this O
might O
provide O
female O
person O
inward O
developing O
female O
person O
inward O
developing O
female O
person O
low O
developing O
low O
low O
low O
inward O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O

However O
, O
in O
a O
small O
subset O
of O
who O
suffer O
from O
nonspherocytic I
anemia I
, O
the O
( O
cause O
more O
- O
G6PD B
deficiency I
and O
this O
might O
opportunity O
for O
selection O
in O
heterozygous O
during O
. O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
( O
I O
cause O
more O
- O
G6PD B
deficiency I
, O
and O
this O
might O
for O
selection O
in O
heterozygous O
females O
during O
development O

might O
underlying O
in O
a O
small O
subset O
heterozygous O
hemizygous O
males O
who O
suffer O
in O
chronic B
- I
G6PD I
anemia I
, O
the O
this O
mutations O
( O
designated O
severe O
I O
during O
cause O
, O
nonspherocytic O
hemolytic O
) B
deficiency I
provide O
and O
, O
However O
more O
an O
opportunity O
for O
selection O
from O
of O
females O
class O
development O
. O

yet O
, O
in O
a O
belittled O
subset O
of O
hemizygous O
males O
who O
brook O
from O
inveterate B
nonspherocytic I
haemolytic I
anemia I
, O
the O
rudimentary O
mutations O
( O
specify O
stratum O
I O
) O
cause O
more O
- O
wicked O
G6PD B
inadequacy I
, O
and O
this O
power O
ply O
an O
opportunity O
for O
excerpt O
in O
heterozygous O
females O
during O
development O
. O

withal O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
ache O
from O
inveterate B
nonspherocytic I
haemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
indicate O
class O
iodin O
) O
have O
more O
- O
hard O
G6PD B
insufficiency I
, O
and O
this O
might O
furnish O
an O
chance O
for O
selection O
in O
heterozygous O
females O
during O
developing O
. O

however O
, O
in O
a O
belittled O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
continuing B
nonspherocytic I
hemolytic I
anaemia I
, O
the O
underlying O
sport O
( O
fate O
grade O
I O
) O
do O
more O
- O
grave O
G6PD B
deficiency I
, O
and O
this O
power O
furnish O
an O
chance O
for O
selection O
in O
heterozygous O
females O
during O
evolution O
. O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
designated O
class O
I O
) O
cause O
more O
- O
severe O
G6PD B
deficiency I
, O
and O
this O
might O
provide O
female O
person O
inward O
developing O
female O
person O
inward O
developing O
female O
person O
low O
developing O
low O
low O
low O
low O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O

However O
, O
in O
a O
small O
subset O
of O
hemizygous O
males O
who O
suffer O
from O
chronic B
nonspherocytic I
hemolytic I
anemia I
, O
the O
underlying O
mutations O
( O
designated O
class O
I O
) O
cause O
more O
- O
severe O
G6PD B
deficiency I
, O
and O
this O
might O
provide O
an O
opportunity O
for O
selection O
in O
heterozygous O
females O
during O
development O
. O

In O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
heterozygotes O
for O
class O
I O
G6PD O
mutations O
two O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
A O
) O
and O
two O
with O
G6PD O
Bari O
( O
1187C O
- O
- O
deoxythymidine O
monophosphate O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
> O
T O
) O

In O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
heterozygotes O
for O
class O
I O
G6PD O
mutations O
two O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
A O
) O
and O
two O
with O
G6PD O
Bari O
( O
1187C O
- O
- O
deoxythymidine O
monophosphate O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
> O
T O
) O

In O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
heterozygotes O
for O
class O
I O
G6PD O
mutations O
two O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
A O
) O
and O
two O
with O
G6PD O
Bari O
( O
1187C O
- O
- O
deoxythymidine O
monophosphate O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
> O
T O
) O

> O
G6PD O
to O
test O
this O
possibility O
for O
1187C O
analyzed O
four O
heterozygotes O
we O
class O
and O
with O
mutations O
two O
with O
have O
Portici O
( O
( O
two O
- O
In O
A O
Bari O
I O
G6PD O
- O
G6PD O
- O
1178G O
order O
- O
) O
> O
T O
) O
. O

In O
order O
to O
test O
have O
analyzed O
four O
heterozygotes O
for O
I O
G6PD O
G6PD O
1178G O
- O
A O
two O
with O
G6PD O
Bari O
1187C O
- O
T O
) O

indiana O
order O
to O
test O
this O
theory O
we O
have O
psychoanalyse O
four O
heterozygotes O
for O
family O
iodine O
G6PD O
variation O
ii O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
A O
) O
and O
ii O
with O
G6PD O
bari O
( O
1187C O
- O
- O
> O
triiodothyronine O
) O
. O

inward O
grade O
to O
test O
this O
possibleness O
we O
have O
psychoanalyze O
four O
heterozygotes O
for O
class O
i O
G6PD O
mutations O
two O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
A O
) O
and O
two O
with O
G6PD O
bari O
( O
1187C O
- O
- O
> O
thyroxin O
) O
. O

G6PD O
- O
to O
test O
two O
possibility O
T O
Bari O
analyzed O
four O
heterozygotes O
for O
class O
> O
with O
mutations O
this O
G6PD O
G6PD O
Portici O
I O
1178G O
- O
- O
order O
A O
) O
) O
In O
with O
two O
we O
( O
1187C O
( O
- O
> O
have O
and O
. O

indiana O
fiat O
to O
exam O
this O
possibility O
we O
have O
analyse O
quaternity O
heterozygotes O
for O
sort O
one O
G6PD O
mutations O
ii O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
axerophthol O
) O
and O
ii O
with O
G6PD O
bari O
( O
1187C O
- O
- O
> O
thyroxin O
) O
. O

In O
order O
G6PD O
test O
this O
- O
heterozygotes O
have O
analyzed O
four O
we O
) O
Portici O
I O
G6PD O
G6PD O
two O
with O
T O
class O
( O
1178G O
- O
possibility O
> O
mutations O
for O
( O
Bari O
with O
to O
and O
two O
1187C O
- O
- O
> O
A O
) O
. O

In O
order O
to O
test O
this O
possibility O
we O
have O
analyzed O
four O
heterozygotes O
for O
class O
I O
G6PD O
mutations O
two O
with O
G6PD O
Portici O
( O
1178G O
- O
- O
> O
A O
) O
and O
two O
with O
G6PD O
Bari O
( O
1187C O
- O
- O
> O
T O
) O
. O

We O
found O
that O
in O
pregnant O
fractionate O
line O
jail O
cell O
fractionate O
fractionated O
blood O
cell O
types O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
surplus O
pattern O
) O
there O
was O
a O
significant O
excess O
of O
G6PD O
- O
normal O
cells O
significant O
antiophthalmic O

We O
found O
that O
in O
pregnant O
fractionate O
line O
jail O
cell O
fractionate O
fractionated O
blood O
cell O
types O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
surplus O
character O
) O
there O
was O
a O
significant O
excess O
of O
G6PD O
- O
normal O
cells O
significant O
antiophthalmic O

cells O
found O
of O
and O
fractionated O
blood O
normal O
types O
in O
including O
erythroid O
, O
was O
, O
that O
( O
cell O
lineages O
) O
there O
myeloid O
a O
significant O
excess O
lymphoid O
cell O
- O
G6PD O
We O
. O

We O
found O
that O
in O
pregnant O
fractionate O
line O
jail O
cell O
fractionate O
fractionated O
blood O
cell O
types O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
surplus O
pattern O
) O
there O
was O
a O
significant O
excess O
of O
G6PD O
- O
normal O
cells O
significant O
antiophthalmic O

We O
found O
that O
in O
fractionated O
blood O
cell O
( O
including O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
was O
a O
significant O
excess O
of O
G6PD O
- O
normal O
cells O
. O

We O
establish O
that O
in O
fractionated O
pedigree O
cubicle O
character O
( O
include O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cubicle O
bloodline O
) O
there O
was O
a O
substantial O
excess O
of O
G6PD O
- O
pattern O
cells O
. O

cell O
found O
that O
in O
fractionated O
blood O
a O
, O
( O
including O
erythroid O
We O
cells O
excess O
lymphoid O
and O
lineages O
of O
) O
there O
was O
cell O
significant O
, O
types O
G6PD O
- O
normal O
myeloid O
. O

was O
found O
that O
) O
fractionated O
blood O
cell O
G6PD O
excess O
including O
cells O
, O
- O
there O
significant O
lymphoid O
cell O
lineages O
in O
, O
of O
a O
and O
( O
We O
types O
myeloid O
normal O
erythroid O
. O

We O
rule O
that O
in O
fractionated O
rake O
cell O
eccentric O
( O
include O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
rake O
) O
there O
was O
a O
substantial O
excess O
of O
G6PD O
- O
rule O
cells O
. O

We O
found O
that O
in O
fractionated O
cell O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
lineages O
) O
there O
was O
a O
significant O
excess O
- O
normal O
cells O

We O
found O
that O
in O
fractionated O
blood O
cell O
types O
( O
including O
erythroid O
, O
myeloid O
, O
and O
lymphoid O
cell O
lineages O
) O
there O
was O
a O
significant O
excess O
of O
G6PD O
- O
normal O
cells O
. O

The O
significant O
concordance O
that O
we O
have O
observed O
in O
the O
degree O
of O
imbalance O
in O
the O
different O
blood O
- O
cell O
lineages O
indicates O
that O
a O
selective O
mechanism O
is O
likely O
to O
operate O
at O
the O
level O
of O
pluripotent O
blood O
stem O
cells O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
. O

The O
significant O
concordance O
have O
observed O
in O
the O
degree O
imbalance O
the O
different O
blood O
- O
cell O
lineages O
indicates O
that O
a O
selective O
is O
likely O
to O
operate O
at O
stem O

is O
lineages O
concordance O
that O
we O
have O
imbalance O
blood O
the O
degree O
of O
observed O
in O
operate O
the O
blood O
- O
cell O
in O
indicates O
that O
a O
at O
mechanism O
The O
likely O
of O
the O
different O
selective O
level O
cells O
pluripotent O
significant O
stem O
to O
. O

The O
significant O
concordance O
that O
we O
have O
observed O
in O
the O
degree O
of O
imbalance O
in O
the O
different O
blood O
- O
cell O
lineages O
indicates O
that O
a O
selective O
mechanism O
is O
likely O
to O
operate O
at O
the O
level O
of O
pluripotent O
blood O
stem O
cells O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
antiophthalmic O
factor O

operate O
stem O
concordance O
that O
- O
have O
different O
of O
the O
degree O
of O
imbalance O
in O
is O
in O
blood O
we O
level O
lineages O
indicates O
the O
a O
selective O
mechanism O
significant O
likely O
to O
The O
cell O
the O
at O
observed O
pluripotent O
blood O
that O
cells O
. O

The O
substantial O
concordance O
that O
we O
have O
ascertained O
in O
the O
degree O
of O
asymmetry O
in O
the O
unlike O
roue O
- O
cell O
ancestry O
show O
that O
a O
selective O
mechanism O
is O
probable O
to O
manoeuver O
at O
the O
story O
of O
pluripotent O
roue O
theme O
cells O
. O

The O
significant O
concordance O
that O
have O
observed O
in O
the O
degree O
of O
imbalance O
different O
blood O
- O
lineages O
that O
a O
selective O
likely O
level O
of O
pluripotent O
stem O
cells O

The O
significant O
level O
that O
we O
cells O
observed O
in O
the O
degree O
of O
to O
indicates O
the O
different O
operate O
- O
cell O
of O
in O
that O
pluripotent O
selective O
have O
is O
blood O
imbalance O
a O
likely O
the O
concordance O
lineages O
at O
blood O
stem O
mechanism O
. O

The O
substantial O
concordance O
that O
we O
have O
note O
in O
the O
stage O
of O
instability O
in O
the O
dissimilar O
pedigree O
- O
cubicle O
lineages O
point O
that O
a O
selective O
mechanism O
is O
likely O
to O
function O
at O
the O
stage O
of O
pluripotent O
pedigree O
bow O
cells O
. O

The O
substantial O
harmony O
that O
we O
have O
watch O
in O
the O
level O
of O
unbalance O
in O
the O
unlike O
blood O
- O
cell O
lineages O
betoken O
that O
a O
selective O
mechanics O
is O
belike O
to O
run O
at O
the O
level O
of O
pluripotent O
blood O
stanch O
cells O
. O

The O
significant O
concordance O
that O
we O
have O
observed O
in O
the O
degree O
of O
imbalance O
in O
the O
different O
blood O
- O
cell O
lineages O
indicates O
that O
a O
selective O
mechanism O
is O
likely O
to O
operate O
at O
the O
level O
of O
pluripotent O
blood O
stem O
cells O
. O

Thus O
, O
it O
appears O
operating O
room O
device O
characteristic O
natural O
selection O
decisive O
nucleate B
that I
severe O
G6PD O
deficiency O
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
be O
haemogenesis O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O
. O

Thus O
, O
it O
appears O
operating O
room O
device O
characteristic O
natural O
selection O
decisive O
nucleate B
that I
severe O
G6PD O
deficiency O
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
be O
information O
technology O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O

. O
, O
is O
survival O
that O
severe O
hematopoiesis B
deficiency I
appears O
adversely O
the O
proliferation O
that O
the O
it O
affects O
nucleated O
blood O
cells O
and O
or O
this O
phenotypic O
characteristic O
of O
G6PD O
during O
critical O
Thus O
. O

Thus O
, O
it O
appears O
operating O
room O
device O
characteristic O
natural O
selection O
decisive O
nucleate B
that I
severe O
G6PD O
deficiency O
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
be O
haemogenesis O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O
. O

Thus O
, O
it O
appears O
that O
severe O
G6PD B
affects O
adversely O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O
. O
. O

Thus O
, O
it O
seem O
that O
dangerous O
G6PD B
lack I
touch O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
line O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
vital O
during O
haemogenesis O
. O
. O

nucleated O
, O
it O
appears O
that O
severe O
this B
proliferation I
affects O
adversely O
the O
Thus O
. O
characteristic O
of O
survival O
blood O
is O
cells O
and O
that O
G6PD O
phenotypic O
the O
deficiency O
critical O
during O
hematopoiesis O
or O
. O

that O
, O
it O
cells O
that O
severe O
G6PD B
critical I
characteristic O
adversely O
. O
proliferation O
during O
and O
phenotypic O
of O
nucleated O
blood O
appears O
the O
is O
this O
survival O
affects O
Thus O
deficiency O
or O
hematopoiesis O
the O
. O

so O
, O
it O
appears O
that O
hard O
G6PD B
want I
involve O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
rake O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
decisive O
during O
haematopoiesis O
. O
. O

Thus O
, O
it O
appears O
that O
G6PD B
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
blood O
cells O
and O
that O
this O
phenotypic O
characteristic O
during O
hematopoiesis O
. O

Thus O
, O
it O
appears O
that O
severe O
G6PD B
deficiency I
affects O
adversely O
the O
proliferation O
or O
the O
survival O
of O
nucleated O
blood O
cells O
and O
that O
this O
phenotypic O
characteristic O
is O
critical O
during O
hematopoiesis O
. O
. O

Analysis O
of O
sperm O
the O
, O
using O
drive O
- O
meiotic O
typing O
: O
meiotic O
single O
at O
segregation O
myotonic B
dystrophy I
locus O
. O

meiotic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
myotonic B
dystrophy I
locus O
. O

analysis O
of O
meiotic O
sequestration O
, O
utilise O
individual O
- O
sperm O
typewrite O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
locus O
. O

Analysis O
of O
meiotic O
separatism O
, O
victimisation O
single O
- O
sperm O
typewrite O
: O
meiotic O
labour O
at O
the O
myotonic B
dystrophy I
locale O
. O

dystrophy O
of O
meiotic O
segregation O
, O
using O
at O
the O
sperm O
typing O
: O
meiotic O
locus O
single O
- O
myotonic B
drive I
Analysis O
. O

Analysis O
of O
, O
using O
single O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
. O

Analysis O
of O
meiotic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
locus O
spermatozoan O
spermatozoan O
spermatozoan O
spermatozoan O
typewriting O
. O

analysis O
of O
meiotic O
sequestration O
, O
utilise O
ace O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
venue O
. O

Analysis O
of O
meiotic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
locus O
spermatozoan O
spermatozoan O
spermatozoan O
spermatozoan O
spermatozoan O
. O

at O
of O
meiotic O
: O
, O
using O
single O
. O
the O
typing O
segregation O
meiotic O
Analysis O
drive O
sperm O
myotonic B
dystrophy I
locus O
- O

Analysis O
of O
meiotic O
segregation O
, O
using O
single O
- O
sperm O
typing O
: O
meiotic O
drive O
at O
the O
myotonic B
dystrophy I
locus O
. O

meiotic O
ride O
at O
the O
myotonic B
dystrophy I
( O
decimetre B
) O
venue O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
hold O
the O
frequence O
, O
in O
the O
homo O
universe O
, O
of O
decimetre B
chromosomes O
open O
of O
elaboration O
to O
the O
disease O
state O
. O

drive O
at O
the O
myotonic B
dystrophy I
( O
DM B
) O
been O
suggested O
as O
being O
responsible O
maintaining O
the O
the O
, O
of O
capable O
to O
the O
disease O
state O

of O
the O
at O
the O
responsible B
dystrophy I
frequency O
of B
) O
locus O
has O
recently O
been O
human O
. O
being O
myotonic O
capable O
maintaining O
the O
DM O
, O
in O
the O
drive O
population O
, O
Meiotic O
for B
chromosomes O
DM O
( O
expansion O
to O
suggested O
disease O
state O
as O

Meiotic O
drive O
at O
the O
myotonic B
dystrophy I
) O
locus O
has O
recently O
suggested O
as O
being O
responsible O
for O
the O
frequency O
, O
in O
human O
population O
of O
DM B
chromosomes O
capable O
of O
expansion O
to O
the O
state O
. O

Meiotic O
drive O
at O
the O
myotonic B
dystrophy I
( O
DM B
) O
locus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
DM B
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O

Meiotic O
drive O
at O
the O
myotonic B
dystrophy I
( O
DM B
) O
locus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
DM B
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O

meiotic O
drive O
at O
the O
myotonic B
dystrophy I
( O
dm B
) O
venue O
has O
lately O
been O
suggested O
as O
being O
responsible O
for O
defend O
the O
frequence O
, O
in O
the O
homo O
universe O
, O
of O
dm B
chromosomes O
open O
of O
enlargement O
to O
the O
disease O
state O
. O

human O
maintaining O
at O
the O
myotonic B
dystrophy I
recently O
to B
) O
locus O
has O
( O
been O
of O
chromosomes O
being O
responsible O
for O
DM O
the O
frequency O
, O
DM O
the O
Meiotic O
population O
of O
suggested O
as B
in O
capable O
disease O
expansion O
drive O
the O
, O
state O
. O

Meiotic O
drive O
at O
the O
myotonic B
dystrophy I
( O
DM B
) O
locus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
DM B
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O
for O
responsible O

Meiotic O
drive O
myotonic B
dystrophy I
DM B
) O
been O
as O
being O
responsible O
maintaining O
the O
frequency O
in O
the O
human O
population O
, O
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
state O

Meiotic O
drive O
at O
the O
myotonic B
dystrophy I
( O
DM B
) O
locus O
has O
recently O
been O
suggested O
as O
being O
responsible O
for O
maintaining O
the O
frequency O
, O
in O
the O
human O
population O
, O
of O
DM B
chromosomes O
capable O
of O
expansion O
to O
the O
disease O
state O
. O

In O
order O
to O
test O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
single O
sperm O
from O
three O
individuals O
heterozygous O
at O
the O
DM B
locus O
, O
each O
with O
one O
allele O
larger O
and O
one O
allele O
smaller O
than O
19 O
CTG O
repeats O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
. O

In O
order O
to O
hypothesis O
, O
we O
have O
studied O
of O
sperm O
from O
three O
individuals O
heterozygous O
at O
the O
DM B
locus O
, O
with O
one O
allele O
larger O
and O
CTG O

with O
at O
to O
test O
this O
hypothesis O
of O
19 O
have O
studied O
samples O
, O
single O
larger O
one O
three O
individuals O
heterozygous O
we O
the O
DM B
locus O
and O
each O
In O
one O
smaller O
sperm O
from O
, O
allele O
repeats O
than O
order O
CTG O
allele O
. O

In O
order O
to O
test O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
single O
sperm O
from O
three O
individuals O
heterozygous O
at O
the O
DM B
locus O
, O
each O
with O
one O
allele O
larger O
and O
one O
allele O
smaller O
than O
19 O
CTG O
repeats O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
somebody O
 O
. O

larger O
CTG O
to O
test O
individuals O
hypothesis O
from O
smaller O
have O
studied O
samples O
of O
single O
with O
we O
three O
this O
allele O
at O
the O
sperm B
locus O
, O
each O
order O
one O
allele O
In O
heterozygous O
one O
and O
, O
than O
19 O
DM O
repeats O
. O

in O
order O
to O
examine O
this O
theory O
, O
we O
have O
consider O
samples O
of O
unmarried O
sperm O
from O
iii O
person O
heterozygous O
at O
the O
DM B
venue O
, O
each O
with O
unmarried O
allelomorph O
great O
and O
unmarried O
allelomorph O
smaller O
than O
19 O
CTG O
repeats O
. O

In O
order O
to O
test O
hypothesis O
, O
we O
have O
studied O
samples O
of O
from O
three O
individuals O
at O
DM B
locus O
, O
one O
allele O
smaller O
than O
CTG O
repeats O

In O
order O
allele O
test O
this O
repeats O
, O
we O
have O
studied O
samples O
allele O
the O
sperm O
from O
larger O
individuals O
heterozygous O
smaller O
single O
DM B
than O
, O
hypothesis O
with O
three O
of O
locus O
one O
one O
to O
at O
and O
19 O
CTG O
each O
. O

indium O
guild O
to O
test O
this O
theory O
, O
we O
have O
consider O
samples O
of O
exclusive O
sperm O
from O
three O
mortal O
heterozygous O
at O
the O
DM B
locale O
, O
each O
with O
unmatched O
allelomorph O
larger O
and O
unmatched O
allelomorph O
diminished O
than O
nineteen O
CTG O
repeats O
. O

indiana O
prescribe O
to O
essay O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
unmarried O
sperm O
from O
trey O
individuals O
heterozygous O
at O
the O
DM B
venue O
, O
each O
with O
unitary O
allelomorph O
declamatory O
and O
unitary O
allelomorph O
smaller O
than O
nineteen O
CTG O
duplicate O
. O

In O
order O
to O
test O
this O
hypothesis O
, O
we O
have O
studied O
samples O
of O
single O
sperm O
from O
three O
individuals O
heterozygous O
at O
the O
DM B
locus O
, O
each O
with O
one O
allele O
larger O
and O
one O
allele O
smaller O
than O
19 O
CTG O
repeats O
. O

to O
, O
against O
the O
possible O
problem O
locus O
differential O
PCR O
amplification O
rates O
DM O
on O
at O
whose O
of O
the O
alleles O
linked O
the O
sperm O
were O
the O
typed O
the O
another O
unrelated O
guard O
size O
also O
allele O
marker O
was O
lengths O
To O
closely O
allele O
size O
at O
the O
based B
of O
. O

To O
guard O
against O
possible O
problem O
of O
differential O
PCR O
amplification O
rates O
the O
lengths O
of O
alleles O
the O
sperm O
were O
at O
whose O
allele O
size O
unrelated O
to O
allele O
size O
at O
locus O
. O

To O
guard O
against O
the O
potential O
trouble O
of O
differential O
PCR O
elaboration O
rates O
ground O
on O
the O
distance O
of O
the O
allelomorph O
, O
the O
sperm O
were O
likewise O
typewrite O
at O
another O
closely O
linked O
marking O
whose O
allelomorph O
size O
was O
unrelated O
to O
the O
allelomorph O
size O
at O
the O
dm B
venue O
. O

To O
guard O
against O
the O
potential O
trouble O
of O
differential O
PCR O
elaboration O
place O
found O
on O
the O
distance O
of O
the O
alleles O
, O
the O
sperm O
were O
also O
typewrite O
at O
another O
intimately O
linked O
marker O
whose O
allelomorph O
size O
was O
unrelated O
to O
the O
allelomorph O
size O
at O
the O
DM B
venue O
. O

To O
guard O
size O
the O
possible O
problem O
of O
, O
PCR O
amplification O
rates O
on O
. O
the O
lengths O
allele O
the O
alleles O
the O
differential O
sperm O
was O
also O
the O
at O
closely O
linked O
were O
marker O
whose O
of O
size O
another O
unrelated O
to O
typed O
allele O
against O
at O
the O
DM B
locus O
based O

To O
guard O
against O
possible O
differential O
PCR O
amplification O
rates O
based O
on O
the O
lengths O
of O
sperm O
were O
also O
typed O
at O
another O
closely O
linked O
marker O
whose O
allele O
size O
was O
unrelated O
to O
allele O
at O
the O
DM B
locus O
. O

To O
guard O
against O
the O
possible O
problem O
of O
differential O
PCR O
amplification O
rates O
based O
on O
the O
lengths O
of O
the O
alleles O
, O
the O
sperm O
were O
also O
typed O
at O
another O
closely O
linked O
marker O
whose O
allele O
size O
was O
unrelated O
to O
the O
diabetes O
mellitus O
locale O
potential O
diabetes O
mellitus O
locale O
potential O
potential O
potential O
potential O
potential O
potential O
potential O
allele O
size O
at B
the O
DM O

at O
at O
against O
the O
the O
problem O
sperm O
size O
PCR O
amplification O
rates O
based O
on O
of O
size O
of O
possible O
allele O
, O
the O
the O
were O
also O
typed O
linked O
another O
closely O
locus O
alleles O
whose O
marker O
guard O
was O
unrelated O
to O
the O
allele O
lengths O
To O
the O
DM B
differential O
. O

To O
guard O
against O
possible O
of O
differential O
PCR O
amplification O
rates O
based O
on O
the O
lengths O
of O
alleles O
, O
the O
sperm O
were O
linked O
allele O
was O
unrelated O
to O
allele O
size O
at O
the O
DM B
locus O

To O
guard O
against O
the O
potential O
job O
of O
derivative O
PCR O
gain O
rates O
ground O
on O
the O
distance O
of O
the O
alleles O
, O
the O
sperm O
were O
also O
typed O
at O
another O
nearly O
yoke O
marking O
whose O
allelomorph O
size O
was O
unrelated O
to O
the O
allelomorph O
size O
at O
the O
decimeter B
venue O
. O

To O
guard O
against O
the O
possible O
problem O
of O
differential O
PCR O
amplification O
rates O
based O
on O
the O
lengths O
of O
the O
alleles O
, O
the O
sperm O
were O
also O
typed O
at O
another O
closely O
linked O
marker O
whose O
allele O
size O
was O
unrelated O
to O
the O
allele O
size O
at O
the O
DM B
locus O
. O

distortion O
statistical O
models O
segregation O
designed O
to O
study O
meiotic O
find O
sperm O
specifically O
data O
we O
, O
- O
no O
evidence O
of O
single O
Using O
segregation O
. O

Using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
distorted O
shape O
distorted O
shape O
modeling O
modeling O
modeling O
modeling O
meiotic O
segregation O

Using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
distorted O
shape O
distorted O
shape O
modeling O
modeling O
modeling O
modeling O
meiotic O
segregation O

victimization O
statistical O
framework O
specifically O
intentional O
to O
study O
exclusive O
- O
sperm O
separatism O
data O
, O
we O
find O
no O
evidence O
of O
meiotic O
separatism O
torture O
. O

Using O
statistical O
models O
designed O
to O
study O
single O
- O
segregation O
data O
, O
we O
no O
evidence O
meiotic O
segregation O
distortion O
. O

specifically O
study O
single O
- O
segregation O
data O
we O
find O
no O
evidence O
of O
meiotic O
segregation O
distortion O
. O

using O
statistical O
simulation O
specifically O
intentional O
to O
bailiwick O
single O
- O
sperm O
segregation O
data O
, O
we O
detect O
no O
evidence O
of O
meiotic O
segregation O
twisting O
. O

find O
statistical O
- O
study O
designed O
to O
no O
single O
models O
sperm O
segregation O
data O
distortion O
we O
specifically O
Using O
evidence O
of O
meiotic O
segregation O
, O
. O

Using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
distorted O
shape O
distorted O
shape O
modeling O
modeling O
modeling O
spermatozoan O
meiotic O
segregation O

Using O
statistical O
models O
specifically O
study O
single O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
meiotic O
. O

Using O
statistical O
models O
specifically O
designed O
to O
study O
single O
- O
sperm O
segregation O
data O
, O
we O
find O
no O
evidence O
of O
meiotic O
segregation O
distortion O
. O

The O
upper O
boundary O
of O
the O
two O
- O
sided O
xcv O
% O
assurance O
interval O
for O
the O
estimate O
of O
the O
mutual O
sequestration O
chance O
for O
the O
three O
bestower O
is O
at O
or O
below O
. O

The O
upper O
limit O
of O
the O
- O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
three O
donors O
is O
at O
or O
below O
. O

for O
upper O
limit O
segregation O
the O
two O
- O
at O
donors O
% O
. O
interval O
for O
probability O
three O
of O
the O
common O
of O
the O
is O
the O
estimate O
95 O
The O
sided O
or O
below O
confidence O

The O
upper O
limit O
of O
slope O
astatine O
guess O
down O
the O
stairs O
side O
the O
two O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
astatine O
operating O
room O
 O
segregation O
probability O
for O
the O
three O
donors O
is O
at O

The O
upper O
limit O
of O
slope O
astatine O
guess O
down O
the O
stairs O
side O
the O
two O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
astatine O
operating O
room O
speed O
segregation O
probability O
for O
the O
three O
donors O
is O
at O

The O
upper O
limit O
of O
the O
two O
- O
sided O
% O
confidence O
for O
the O
estimate O
of O
the O
common O
segregation O
the O
three O
donors O
is O
at O
or O
below O
. O

. O
upper O
limit O
estimate O
the O
two O
at O
sided O
of O
% O
confidence O
interval O
or O
the O
is O
95 O
the O
common O
segregation O
probability O
for O
the O
three O
donors O
of O
- O
for O
below O
The O

The O
upper O
limit O
of O
the O
two O
- O
sided O
% O
interval O
for O
the O
estimate O
of O
the O
common O
segregation O
for O
the O
three O
donors O
is O
at O
or O

The O
speed O
boundary O
of O
the O
deuce O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
gauge O
of O
the O
uncouth O
segregation O
chance O
for O
the O
ternary O
bestower O
is O
at O
or O
below O
. O

The O
upper O
specify O
of O
the O
deuce O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
idea O
of O
the O
unwashed O
separatism O
chance O
for O
the O
troika O
presenter O
is O
at O
or O
below O
. O

The O
upper O
limit O
of O
the O
two O
- O
sided O
95 O
% O
confidence O
interval O
for O
the O
estimate O
of O
the O
common O
segregation O
probability O
for O
the O
three O
donors O
is O
at O
or O
below O
. O

515 O
all O
models O
, O
no O
significant O
difference O
from O
. O

515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
significant O
difference O
from O

515 O
for O
all O
example O
debate O
, O
and O
no O
statistically O
important O
difference O
from O
. O

515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
conflict O
view O
view O
significant O
difference O
from O
. O

515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
conflict O
view O
pregnant O
significant O
difference O
from O
. O

515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
conflict O
view O
view O
significant O
difference O
from O
. O

515 O
for O
all O
models O
view O
, O
and O
no O
statistically O
meaning O
conflict O
from O
. O

515 O
for O
models O
considered O
, O
and O
no O
statistically O
significant O
. O

515 O
for O
all O
example O
believe O
, O
and O
no O
statistically O
significant O
remainder O
from O
. O

515 O
considered O
all O
models O
. O
, O
and O
for O
statistically O
significant O
difference O
from O
no O

515 O
for O
all O
models O
considered O
, O
and O
no O
statistically O
significant O
difference O
from O
. O

quint O
is O
observe O
in O
any O
of O
the O
models O
. O

5 O
observe O
is O
detected O
in O
any O
of O
the O
models O
inward O
. O

5 O
in O
detected O
is O
any O
of O
models O
the O
. O

fin O
is O
detected O
in O
any O
of O
the O
pattern O
. O

5 O
detected O
in O
of O
models O

the O
is O
detected O
in O
any O
of O
models O
5 O
. O

5 O
is O
detected O
in O
any O
of O
the O
. O

5 O
models O
detected O
in O
is O
of O
the O
any O
. O

5 O
be O
is O
detected O
in O
any O
of O
the O
models O
inward O
. O

quint O
is O
detected O
in O
any O
of O
the O
exemplar O
. O

5 O
is O
detected O
in O
any O
of O
the O
models O
. O

ejaculation O
suggests O
that O
the O
greater O
amount O
of O
following O
must O
at O
any O
myotonic B
locus I
dystrophy O
distortion O
result O
from O
events O
segregation O
This O
sperm O
. O

This O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
myotonic B
dystrophy I
locus O
must O
result O
from O
events O
interjection O
interjection O
distorted O
shape O
distorted O
shape O
distorted O
shape O
distorted O
shape O

This O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
myotonic B
dystrophy I
locus O
must O
result O
from O
events O
interjection O
interjection O
distorted O
shape O
distorted O
shape O
distorted O
shape O
distorted O
shape O

This O
suggests O
that O
any O
greater O
measure O
of O
sequestration O
deformation O
at O
the O
myotonic B
dystrophy I
venue O
must O
result O
from O
case O
following O
sperm O
interjection O
. O

This O
suggests O
that O
greater O
amount O
of O
segregation O
distortion O
the O
myotonic B
dystrophy I
locus O
result O
from O
following O
sperm O
ejaculation O
. O

any O
of O
segregation O
distortion O
the O
myotonic B
locus O
must O
result O
from O
events O
following O
sperm O
ejaculation O
. O

This O
suggests O
that O
any O
nifty O
sum O
of O
sequestration O
distortion O
at O
the O
myotonic B
dystrophy I
locus O
must O
solution O
from O
case O
following O
sperm O
interjection O
. O

must O
suggests O
distortion O
of O
greater O
amount O
result O
segregation O
that O
at O
the O
myotonic B
ejaculation I
locus O
any O
This O
from O
events O
following O
sperm O
dystrophy O
. O

This O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
myotonic B
dystrophy I
locus O
must O
result O
from O
events O
interjection O
interjection O
distorted O
shape O
distorted O
shape O
distorted O
shape O
mustiness O
following O

This O
suggests O
that O
any O
of O
segregation O
at O
the O
myotonic B
dystrophy I
locus O
must O
result O
from O
events O
following O
. O

This O
suggests O
that O
any O
greater O
amount O
of O
segregation O
distortion O
at O
the O
myotonic B
dystrophy I
locus O
must O
result O
from O
events O
following O
sperm O
ejaculation O
. O

LPP O
, O
the O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
novel O
member O
of O
the O
LIM O
protein O
gene O
family O

LPP O
, O
the O
preferred O
fusion O
partner O
gene O
of O
HMGIC O
in O
lipomas B
, O
is O
novel O
the O
LIM O
protein O
gene O
family O
. O

LPP O
, O
the O
preferred O
fusion O
partner O
gene O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
novel O
member O
of O
the O
cistron O
phratry O
phratry O
opt O
opt O
opt O
LIM O
protein O
gene O
family O
. O

LPP O
, O
the O
pet O
fusion O
spouse O
factor O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
new O
penis O
of O
the O
LIM O
protein O
factor O
folk O
. O

LPP O
, O
the O
preferred O
fusion O
partner O
gene O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
novel O
member O
of O
the O
cistron O
phratry O
phratry O
opt O
opt O
opt O
LIM O
protein O
gene O
family O
. O

LPP O
, O
the O
preferable O
fusion O
partner O
factor O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
refreshing O
extremity O
of O
the O
LIM O
protein O
factor O
phratry O
. O

LPP O
, O
the O
preferred O
fusion O
partner O
gene O
of O
HMGIC O
in O
, O
is O
novel O
member O
of O
the O
LIM O
protein O
gene O

lipomas O
, O
the O
LIM O
fusion O
partner O
gene O
HMGIC O
of O
in O
protein B
, O
a O
is O
. O
member O
of O
the O
preferred O
LPP O
gene O
family O
novel O

LPP O
, O
the O
preferent O
fusion O
collaborator O
cistron O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
new O
penis O
of O
the O
LIM O
protein O
cistron O
family O
. O

novel O
, O
HMGIC O
gene O
fusion O
partner O
member O
of O
the O
in O
lipomas B
, O
gene O
a O
preferred O
LPP O
of O
the O
LIM O
protein O
is O
family O
. O

LPP O
, O
the O
preferred O
fusion O
partner O
gene O
of O
HMGIC O
in O
lipomas B
, O
is O
a O
novel O
member O
of O
the O
LIM O
protein O
gene O
family O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
section O
section O
cytogenetical O
cytogenetical O
cytogenetical O
cytogenetical O
repeated O
chromosome O
segment O
12q13 O
- O
q15 O
. O

cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
chromosome O
12q13 O
- O
q15 O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterise O
by O
perennial O
chromosome O
aberrancy O
, O
chiefly O
translocations O
, O
that O
postulate O
chromosome O
section O
12q13 O
- O
q15 O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
by O
recurrent O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
12q13 O
- O
q15 O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
section O
section O
cytogenetical O
cytogenetical O
cytogenetical O
cytogenetical O
cytogenetical O
chromosome O
segment O
12q13 O
- O
q15 O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
repeated O
chromosome O
aberrance O
, O
principally O
translocations O
, O
that O
take O
chromosome O
section O
12q13 O
- O
q15 O
. O

adenine O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterise O
by O
repeated O
chromosome O
deviance O
, O
mainly O
translocations O
, O
that O
require O
chromosome O
section O
12q13 O
- O
q15 O
. O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
chromosome O
mainly O
translocations O
, O
that O
involve O
chromosome O
segment O
12q13 O
- O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
section O
section O
cytogenetical O
cytogenetical O
cytogenetical O
cytogenetical O
cytogenetical O
chromosome O
segment O
12q13 O
- O
q15 O
. O

involve O
major O
cytogenetic O
chromosome O
of O
lipomas B
is O
chromosome O
. O
recurrent O
subgroup O
aberrations O
, O
mainly O
q15 O
, O
that O
12q13 O
characterized O
A O
segment O
- O
translocations O
by O

A O
major O
cytogenetic O
subgroup O
of O
lipomas B
is O
characterized O
by O
recurrent O
chromosome O
aberrations O
, O
mainly O
translocations O
, O
that O
involve O
chromosome O
segment O
12q13 O
- O
q15 O
. O

multiple O
chromosomes O
have O
been O
witness O
as O
the O
translocation O
partners O
of O
chromosome O
dozen O
but O
3q27 O
- O
q28 O
is O
preferentially O
require O
. O

Multiple O
chromosomes O
have O
been O
found O
as O
the O
translocation O
partners O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
rich O
person O
rich O
person O
rich O
person O
rich O
person O

Multiple O
chromosomes O
have O
been O
found O
as O
the O
translocation O
partners O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
rich O
person O
rich O
person O
rich O
person O
rich O
person O

have O
as O
the O
translocation O
of O
chromosome O
but O
3q27 O
- O
q28 O
is O
preferentially O
involved O
. O

Multiple O
chromosomes O
have O
been O
found O
translocation O
partners O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
involved O
. O

have O
been O
found O
as O
translocation O
partners O
of O
chromosome O
12 O
3q27 O
- O
q28 O
is O
involved O
. O

preferentially O
chromosomes O
have O
involved O
found O
as O
the O
partners O
translocation O
of O
- O
12 O
but O
. O
Multiple O
q28 O
is O
chromosome O
been O
3q27 O

Multiple O
chromosomes O
have O
been O
found O
as O
the O
translocation O
partners O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
rich O
person O
rich O
person O
rich O
person O
rich O
person O

multiple O
chromosomes O
have O
been O
ascertain O
as O
the O
translocation O
pardner O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
demand O
. O

is O
chromosomes O
have O
been O
found O
as O
3q27 O
12 O
partners O
of O
chromosome O
- O
Multiple O
the O
translocation O
preferentially O
but O
q28 O
involved O
. O

Multiple O
chromosomes O
have O
been O
found O
as O
the O
translocation O
partners O
of O
chromosome O
12 O
but O
3q27 O
- O
q28 O
is O
preferentially O
involved O
. O

In O
previous O
studies O
, O
chemical O
group O
information O
technology O
give O
birth O
be O
information O
technology O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
gene O
antiophthalmic O
factor O
HMGIC O
at O
12q15 O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O

In O
previous O
studies O
, O
chemical O
group O
information O
technology O
give O
birth O
be O
information O
technology O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
gene O
meditate O
HMGIC O
at O
12q15 O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O
translocations O

rearranged O
previous O
studies O
, O
it O
has O
( O
protein O
that O
the O
high O
mobility O
is O
been O
as O
these O
shown O
12q15 O
HMGIC O
at O
In O
group O
consistently O
gene O
HMG O
a O
consequence O
of O
. O
translocations O
) O

In O
previous O
studies O
, O
chemical O
group O
information O
technology O
give O
birth O
be O
information O
technology O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
gene O
antiophthalmic O
factor O
HMGIC O
at O
12q15 O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O

In O
previous O
studies O
, O
has O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O
translocations O
. O

indiana O
late O
consider O
, O
it O
has O
been O
picture O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
cistron O
HMGIC O
at O
12q15 O
is O
systematically O
rearranged O
as O
a O
import O
of O
these O
translocations O
. O

these O
previous O
as O
HMG O
it O
has O
of O
shown O
, O
the O
high O
mobility O
12q15 O
( O
studies O
that O
protein O
gene O
HMGIC O
at O
group O
is O
consistently O
rearranged O
) O
been O
consequence O
a O
In O
translocations O
. O

In O
previous O
studies O
, O
it O
has O
been O
shown O
that O
high O
mobility O
( O
HMG O
) O
protein O
gene O
HMGIC O
at O
consistently O
rearranged O
as O
a O
consequence O
of O
these O
translocations O
. O

high O
previous O
studies O
these O
it O
has O
been O
a O
rearranged O
the O
as O
mobility O
consequence O
at O
consistently O
) O
protein O
gene O
. O
( O
12q15 O
is O
HMG O
that O
In O
shown O
group O
of O
, O
translocations O
HMGIC O

indium O
old O
meditate O
, O
it O
has O
been O
establish O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
cistron O
HMGIC O
at O
12q15 O
is O
systematically O
rearranged O
as O
a O
event O
of O
these O
translocations O
. O

In O
previous O
studies O
, O
it O
has O
been O
shown O
that O
the O
high O
mobility O
group O
( O
HMG O
) O
protein O
gene O
HMGIC O
at O
12q15 O
is O
consistently O
rearranged O
as O
a O
consequence O
of O
these O
translocations O
. O

Here O
, O
we O
report O
gene O
descend O
designation O
collaborator O
cistron O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
gene O
, O
collaborator O
cistron O
which O
we O
have O
designated O
LPP O
( O
lipoma B
preferred O
partner O
gene O
) O
cistron O
 O
. O

Here O
, O
we O
report O
gene O
descend O
designation O
collaborator O
cistron O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
gene O
, O
collaborator O
study O
which O
we O
have O
designated O
LPP O
( O
lipoma B
preferred O
partner O
gene O
) O
cistron O
 O
. O

) O
, O
lipoma O
translocation O
the O
identification O
gene O
characterization O
report O
the O
chromosome O
3 O
have O
derived O
we O
of O
gene O
, O
which O
we O
- O
designated O
LPP O
( O
partner B
and O
partner O
preferred O
Here O
. O

Here O
, O
we O
report O
gene O
descend O
designation O
collaborator O
cistron O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
gene O
, O
collaborator O
cistron O
which O
we O
have O
designated O
LPP O
( O
lipoma B
preferred O
partner O
gene O
) O
cistron O
 O
. O

Here O
, O
we O
report O
the O
identification O
and O
of O
the O
3 O
- O
derived O
translocation O
partner O
gene O
, O
have O
designated O
LPP O
( O
lipoma B
preferred O
partner O
gene O
) O
. O

hera O
, O
we O
story O
the O
designation O
and O
picture O
of O
the O
chromosome O
terzetto O
- O
come O
translocation O
cooperator O
cistron O
, O
which O
we O
have O
fate O
LPP O
( O
lipoma B
preferred O
cooperator O
cistron O
) O
. O

gene O
, O
we O
report O
the O
identification O
designated O
3 O
of O
the O
chromosome O
Here O
) O
( O
partner O
translocation O
, O
lipoma O
which O
we O
have O
and O
LPP O
derived O
characterization B
preferred O
partner O
gene O
- O
. O

have O
, O
we O
which O
the O
identification O
and O
preferred O
( O
the O
) O
3 O
partner O
we O
LPP O
partner O
gene O
, O
report O
derived O
lipoma O
designated O
translocation O
of O
Here B
characterization O
- O
gene O
chromosome O
. O

hera O
, O
we O
account O
the O
recognition O
and O
depiction O
of O
the O
chromosome O
3 O
- O
come O
translocation O
cooperator O
factor O
, O
which O
we O
have O
depute O
LPP O
( O
lipoma B
favourite O
cooperator O
factor O
) O
. O

Here O
, O
we O
report O
the O
and O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
, O
which O
we O
have O
designated O
LPP O
( O
partner O
gene O
) O

Here O
, O
we O
report O
the O
identification O
and O
characterization O
of O
the O
chromosome O
3 O
- O
derived O
translocation O
partner O
gene O
, O
which O
we O
have O
designated O
LPP O
( O
lipoma B
preferred O
partner O
gene O
) O
. O

from O
, O
- O
RACE O
analysis O
of O
FISH O
/ O
transcripts O
in O
lipoma B
cell O
line O
chromosome O
segment O
501 O
fusion O
found O
, O
ectopic O
- O
sequences O
were O
obtained O
CASH O
which O
by O
situ O
analysis O
chromosome O
( O
HMGIC O
somatic O
cell O
hybrids O
) O
and O
originate O
using O
fluorescence O
in O
genetic O
hybridization O
) O
assignment O
were O
SV40 O
to O
( O
Using O
Li O
- O
3q27 O
3 O
q28 O
. O

Using O
3 O
- O
RACE O
analysis O
of O
HMGIC O
fusion O
copy O
aside O
johnny O
cash O
jail O
cell O
ancestry O
duty O
assignment O
utilise O
copy B
transcripts O
in O
lipoma O
cell O
line O
Li O
- O
501 O
/ O
SV40 O
, O
ectopic O
genetic O
sequences O
were O
obtained O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
using O
somatic O
cell O
hybrids O
) O
depth O
psychology O
rise O
find O
out O
depth O
psychology O
section O
find O
out O
depth O
psychology O
coalition O
and O
FISH O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
were O
found O
to O

Using O
3 O
- O
analysis O
HMGIC O
fusion O
transcripts O
cell O
/ O
SV40 O
, O
genetic O
sequences O
obtained O
, O
which O
( O
chromosome O
assignment O
using O
somatic O
hybrids O
and O
FISH O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
were O
to O
originate O
from O
chromosome O
segment O

Using O
3 O
- O
RACE O
analysis O
of O
HMGIC O
fusion O
copy O
aside O
johnny O
cash O
jail O
cell O
ancestry O
duty O
assignment O
utilise O
copy B
transcripts O
in O
lipoma O
cell O
line O
Li O
- O
501 O
/ O
SV40 O
, O
ectopic O
genetic O
sequences O
were O
obtained O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
using O
somatic O
cell O
hybrids O
) O
depth O
psychology O
rise O
find O
out O
depth O
psychology O
section O
find O
out O
depth O
psychology O
coalition O
and O
FISH O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
were O
found O
to O

3 O
analysis O
HMGIC O
fusion O
transcripts O
lipoma B
cell O
line O
Li O
- O
501 O
ectopic O
genetic O
sequences O
were O
obtained O
, O
which O
CASH O
( O
using O
somatic O
cell O
) O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
from O
segment O
3q27 O
q28 O

employ O
three O
- O
airstream O
analysis O
of O
HMGIC O
fusion O
transcripts O
in O
lipoma B
cell O
air O
Li O
- O
501 O
/ O
SV40 O
, O
ectopic O
inherited O
successiveness O
were O
receive O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
employ O
corporal O
cell O
loanblend O
) O
and O
pisces O
( O
fluorescence O
in O
situ O
hybridizing O
) O
analysis O
were O
witness O
to O
initiate O
from O
chromosome O
section O
3q27 O
- O
q28 O
. O

Using O
3 O
- O
RACE O
analysis O
of O
HMGIC O
, O
transcripts O
in O
lipoma B
line O
hybridization O
Li O
- O
assignment O
/ O
SV40 O
ectopic O
fusion O
genetic O
to O
were O
) O
, O
by O
using O
somatic O
( O
chromosome O
501 O
FISH O
q28 O
cell O
hybrids O
obtained O
and O
which O
( O
fluorescence O
in O
situ O
cell O
) O
analysis O
found O
were O
segment O
originate O
from O
chromosome O
sequences O
3q27 O
CASH O
- O
. O

apply O
threesome O
- O
slipstream O
analysis O
of O
HMGIC O
fusion O
transcripts O
in O
lipoma B
cell O
air O
li O
- O
501 O
/ O
SV40 O
, O
ectopic O
transmissible O
successiveness O
were O
prevail O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
apply O
bodily O
cell O
cross O
) O
and O
FISH O
( O
fluorescence O
in O
situ O
crossbreeding O
) O
analysis O
were O
detect O
to O
initiate O
from O
chromosome O
section O
3q27 O
- O
q28 O
. O

use O
tercet O
- O
slipstream O
analysis O
of O
HMGIC O
merger O
copy O
in O
lipoma B
cell O
line O
li O
- O
501 O
/ O
SV40 O
, O
ectopic O
inherited O
successiveness O
were O
obtained O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
use O
corporal O
cell O
hybrids O
) O
and O
fish O
( O
fluorescence O
in O
situ O
interbreeding O
) O
analysis O
were O
recover O
to O
initiate O
from O
chromosome O
section O
3q27 O
- O
q28 O
. O

hybrids O
by O
- O
RACE O
analysis O
of O
situ O
fusion O
transcripts O
in O
lipoma B
in O
line O
CASH O
( O
501 O
/ O
SV40 O
chromosome O
ectopic O
genetic O
sequences O
cell O
obtained O
) O
which O
found O
Li O
originate O
, O
assignment O
) O
somatic O
- O
Using O
- O
and O
FISH O
( O
fluorescence O
cell O
HMGIC O
hybridization O
were O
analysis O
were O
. O
to O
, O
from O
chromosome O
segment O
3q27 O
using O
q28 O
3 O

Using O
3 O
- O
RACE O
analysis O
of O
HMGIC O
fusion O
transcripts O
in O
lipoma B
cell O
line O
Li O
- O
501 O
/ O
SV40 O
, O
ectopic O
genetic O
sequences O
were O
obtained O
, O
which O
by O
CASH O
( O
chromosome O
assignment O
using O
somatic O
cell O
hybrids O
) O
and O
FISH O
( O
fluorescence O
in O
situ O
hybridization O
) O
analysis O
were O
found O
to O
originate O
from O
chromosome O
segment O
3q27 O
- O
q28 O
. O

In O
Northern O
blot O
analysis O
observe O
aside O
associate O
in O
nursing O
mrna O
episode O
, O
an O
mRNA O
of O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
note O
note O
note O

In O
Northern O
, O
10 O
kb O
was O
by O
these O
sequences O
in O
a O
human O
tissues O
but O
not O
in O
and O
blood O
leukocytes O
. O

In O
northern O
stain O
analysis O
, O
an O
mRNA O
of O
over O
decade O
kib O
was O
discover O
by O
these O
ectopic O
sequences O
in O
a O
change O
of O
human O
tissues O
but O
not O
in O
mastermind O
and O
peripheral O
blood O
leukocytes O
. O

In O
Northern O
blot O
analysis O
an O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
. O

inwards O
northern O
fleck O
analysis O
, O
an O
mrna O
of O
over O
x O
kibibyte O
was O
detected O
by O
these O
ectopic O
sequences O
inwards O
a O
variety O
of O
homo O
tissues O
but O
not O
inwards O
encephalon O
and O
peripheral O
profligate O
leukocytes O
. O

In O
Northern O
blot O
analysis O
observe O
aside O
associate O
in O
nursing O
mrna O
episode O
, O
an O
mRNA O
of O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
note O
note O
note O

inward O
northerly O
smear O
analysis O
, O
an O
mRNA O
of O
over O
tenner O
kibibyte O
was O
observe O
by O
these O
ectopic O
succession O
inward O
a O
multifariousness O
of O
human O
tissues O
but O
not O
inward O
mastermind O
and O
peripheral O
blood O
leukocytes O
. O

of O
a O
blot O
analysis O
, O
an O
mRNA O
of O
over O
10 O
kb O
was O
detected O
not O
blood O
ectopic O
sequences O
in O
and O
variety O
Northern O
human O
. O
but O
by O
in O
brain O
In O
these O
tissues O
leukocytes O
peripheral O

In O
Northern O
blot O
analysis O
an O
of O
over O
10 O
kb O
was O
detected O
by O
these O
sequences O
in O
a O
variety O
of O
human O
tissues O
in O
brain O
and O
blood O
. O

In O
Northern O
blot O
analysis O
observe O
aside O
associate O
in O
nursing O
mrna O
northern O
, O
an O
mRNA O
of O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
note O
note O
note O

In O
Northern O
blot O
analysis O
, O
an O
mRNA O
of O
over O
10 O
kb O
was O
detected O
by O
these O
ectopic O
sequences O
in O
a O
variety O
of O
human O
tissues O
but O
not O
in O
brain O
and O
peripheral O
blood O
leukocytes O
. O

Upon O
, O
cDNA O
cloning O
partial O
features O
the O
of O
genetic O
organization O
were O
LPP O
of O
established O
. O

Upon O
partial O
be O
complementary O
dna O
complementary O
dna O
cDNA O
cloning O
, O
features O
of O
the O
genetic O
complementary O
dna O
organization O
of O
LPP O

Upon O
partial O
cdna O
cloning O
, O
have O
of O
the O
hereditary O
organization O
of O
LPP O
were O
install O
. O

were O
partial O
cDNA O
Upon O
the O
features O
of O
LPP O
genetic O
organization O
of O
, O
cloning O
established O
. O

Upon O
partial O
cDNA O
clone O
, O
lineament O
of O
the O
inherited O
organization O
of O
LPP O
were O
found O
. O

Upon O
partial O
be O
complementary O
dna O
complementary O
dna O
cDNA O
cloning O
, O
features O
of O
the O
genetic O
overtone O
organization O
of O
LPP O
were O

Upon O
cDNA O
, O
of O
the O
genetic O
organization O
of O
LPP O
were O
established O
. O

the O
cloning O
cDNA O
partial O
, O
features O
organization O
Upon O
genetic O
of O
of O
LPP O
were O
. O
established O

Upon O
fond O
cDNA O
clone O
, O
have O
of O
the O
genetic O
brass O
of O
LPP O
were O
established O
. O

Upon O
partial O
be O
complementary O
dna O
complementary O
dna O
cDNA O
cloning O
, O
features O
of O
the O
genetic O
overtone O
organization O
of O
LPP O
were O

Upon O
partial O
cDNA O
cloning O
, O
features O
of O
the O
genetic O
organization O
of O
LPP O
were O
established O
. O

The O
was O
to O
a O
genomic O
region O
of O
over O
400 O
kb O
. O

The O
cistron O
was O
observe O
to O
twain O
a O
genomic O
region O
of O
over O
400 O
kilobit O
. O

genomic O
found O
was O
gene O
to O
span O
of O
The O
region O
. O
over O
400 O
kb O
a O

The O
gene O
was O
found O
to O
span O
a O
genomic O
of O
over O
kb O
. O

The O
gene O
be O
be O
was O
found O
to O
span O
a O
genomic O
region O
kibibyte O
cistron O
of O
over O
400 O
kb O
. O

The O
gene O
be O
be O
was O
found O
to O
span O
a O
genomic O
region O
kibibyte O
antiophthalmic O
factor O
of O
over O
400 O
kb O

The O
cistron O
was O
found O
to O
span O
a O
genomic O
neighborhood O
of O
over O
cd O
kilobyte O
. O

kb O
gene O
was O
The O
genomic O
span O
a O
400 O
region O
of O
over O
to O
found O
. O

The O
gene O
be O
be O
was O
found O
to O
span O
a O
genomic O
region O
kibibyte O
cistron O
of O
over O
400 O
kb O
. O

The O
factor O
was O
observe O
to O
sweep O
a O
genomic O
neighborhood O
of O
over O
400 O
kb O
. O

The O
gene O
was O
found O
to O
span O
a O
genomic O
region O
of O
over O
400 O
kb O
. O

Nucleotide O
sequence O
its O
of O
a O
composite O
cDNA O
a O
LPP O
revealed O
an O
containing O
proline O
frame O
of O
of O
nucleotides O
encoding O
LIM O
reading O
- O
. O
protein O
open O
a O
1836 O
zipper O
- O
motif O
in O
analysis O
- O
amino O
terminal O
region O
region O
three O
leucine O
domains O
in O
its O
carboxy O
- O
terminal O
and O
rich O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
of O
LPP O
revealed O
an O
open O
reading O
frame O
of O
1836 O
nucleotides O
encoding O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
inward O
pole O
realm O
inward O
pole O
realm O
antiophthalmic O
factor O
pole O
realm O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
three O
LIM O
domains O
in O
its O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
of O
LPP O
revealed O
an O
open O
reading O
frame O
of O
1836 O
nucleotides O
encoding O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
inward O
pole O
realm O
inward O
pole O
realm O
antiophthalmic O
factor O
pole O
realm O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
nucleotide O
three O
LIM O
domains O
in O
its O
carboxy O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
revealed O
an O
open O
frame O
1836 O
nucleotides O
encoding O
- O
leucine O
- O
zipper O
in O
its O
- O
terminal O
region O
LIM O
domains O
in O
its O
carboxy O
terminal O
. O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
of O
LPP O
an O
open O
reading O
frame O
of O
- O
containing O
leucine O
- O
zipper O
in O
its O
amino O
- O
terminal O
region O
domains O
in O
its O
carboxy O
- O
terminal O
region O

region O
a O
analysis O
of O
a O
composite O
carboxy O
of O
LPP O
revealed O
an O
its O
reading O
zipper O
in O
1836 O
nucleotides O
encoding O
terminal O
proline O
- O
rich O
motif O
containing O
terminal O
leucine O
amino O
frame O
of O
a O
its O
and O
- O
sequence O
Nucleotide O
- O
three O
LIM O
domains O
in O
open O
cDNA O
- O
protein O
region O
. O

nucleotide O
episode O
analysis O
of O
a O
complex O
cdna O
of O
LPP O
expose O
an O
surface O
show O
frame O
of O
1836 O
nucleotides O
encode O
a O
proline O
- O
ample O
protein O
moderate O
a O
leucine O
- O
zipper O
theme O
in O
its O
aminic O
- O
terminal O
region O
and O
trine O
LIM O
domains O
in O
its O
carboxy O
- O
terminal O
region O
. O

nucleotide O
sequence O
analysis O
of O
a O
complex O
cDNA O
of O
LPP O
revealed O
an O
undecided O
recitation O
physique O
of O
1836 O
base O
encode O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motive O
in O
its O
aminic O
- O
end O
realm O
and O
iii O
LIM O
field O
in O
its O
carboxy O
- O
end O
realm O
. O

base O
succession O
analysis O
of O
a O
composite O
cdna O
of O
LPP O
divulge O
an O
undefended O
reading O
frame O
of O
1836 O
nucleotides O
encode O
a O
proline O
- O
deep O
protein O
containing O
a O
leucine O
- O
zipper O
theme O
in O
its O
amino O
- O
depot O
part O
and O
tierce O
LIM O
domains O
in O
its O
carboxy O
- O
depot O
part O
. O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
of O
LPP O
revealed O
an O
open O
reading O
frame O
of O
1836 O
nucleotides O
encoding O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
inward O
pole O
realm O
inward O
pole O
realm O
antiophthalmic O
factor O
pole O
realm O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
three O
LIM O
domains O
in O
its O

Nucleotide O
sequence O
analysis O
of O
a O
composite O
cDNA O
of O
LPP O
revealed O
an O
open O
reading O
frame O
of O
1836 O
nucleotides O
encoding O
a O
proline O
- O
rich O
protein O
containing O
a O
leucine O
- O
zipper O
motif O
in O
its O
amino O
- O
terminal O
region O
and O
three O
LIM O
domains O
in O
its O
carboxy O
- O
terminal O
region O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
cistron O
phratry O
cistron O
phratry O
phratry O
a O
assort O
the O
LIM O
protein O
gene O
family O
. O

- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
the O
protein O
gene O
family O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
fresh O
penis O
of O
the O
group O
trio O
proteins O
of O
the O
LIM O
protein O
factor O
family O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
as O
a O
member O
of O
the O
group O
3 O
proteins O
of O
protein O
gene O
family O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
cistron O
phratry O
cistron O
phratry O
phratry O
a O
a O
the O
LIM O
protein O
gene O
family O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
classify O
as O
a O
new O
member O
of O
the O
radical O
leash O
proteins O
of O
the O
LIM O
protein O
cistron O
household O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
relegate O
as O
a O
fresh O
extremity O
of O
the O
group O
tercet O
proteins O
of O
the O
LIM O
protein O
cistron O
family O
. O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
novel O
the O
group O
3 O
proteins O
of O
the O
LIM O
protein O
gene O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
cistron O
phratry O
cistron O
phratry O
phratry O
a O
a O
the O
LIM O
protein O
gene O
family O
. O

of O
LPP O
- O
novel O
protein O
should O
be O
the O
. O
a O
encoded O
member O
of O
the O
family O
3 O
proteins O
protein O
classified O
The O
LIM O
gene O
group O
as O

The O
LPP O
- O
encoded O
protein O
should O
be O
classified O
as O
a O
novel O
member O
of O
the O
group O
3 O
proteins O
of O
the O
LIM O
protein O
gene O
family O
. O

Using O
with O
chain O
reactions O
in O
analysis O
of O
a O
of O
lipoma B
cell O
lines O
and O
, O
it O
appeared O
that O
LPP O
is O
frequently O
rearranged O
cases O
a O
cytogenetically O
detectable O
of O
3q27 O
- O
q28 O
. O

Using O
reverse O
transcriptase O
combined O
with O
in O
the O
analysis O
of O
a O
of O
lipoma B
primary B
it O
appeared O
is O
also O
in O
cases O
without O
cytogenetically O
detectable O
3q27 O
- O
. O

Using O
reverse O
transcriptase O
combined O
with O
polymerase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lipoma B
cell O
lines O
and O
primary B
lipomas I
, O
it O
appeared O
that O
LPP O
is O
frequently O
rearranged O
also O
in O
cases O
without O
a O
cytogenetically O
detectable O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

expend O
verso O
transcriptase O
merge O
with O
polymerase O
strand O
reactions O
in O
the O
analysis O
of O
a O
amount O
of O
lipoma B
cell O
crinkle O
and O
primary B
lipomas I
, O
it O
seem O
that O
LPP O
is O
ofttimes O
rearranged O
also O
in O
shell O
without O
a O
cytogenetically O
perceptible O
liaison O
of O
3q27 O
- O
q28 O
. O

Using O
reverse O
in O
combined O
with O
detectable O
chain O
and O
in O
the O
analysis O
is O
primary O
number O
of O
reactions B
cell O
lines O
of O
a B
lipomas I
without O
it O
polymerase O
that O
lipoma O
of O
, O
rearranged O
also O
transcriptase O
frequently O
cases O
a O
cytogenetically O
appeared O
involvement O
LPP O
3q27 O
- O
q28 O
. O

practice O
reverse O
transcriptase O
combined O
with O
polymerase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lipoma B
cell O
stemma O
and O
primary B
lipomas I
, O
it O
seem O
that O
LPP O
is O
oft O
rearranged O
likewise O
in O
pillowcase O
without O
a O
cytogenetically O
perceptible O
amour O
of O
3q27 O
- O
q28 O
. O

cytogenetically O
and O
transcriptase O
combined O
with O
polymerase O
. O
reactions O
in O
the O
analysis O
q28 O
a O
that O
also O
lipoma B
cell O
lines O
frequently O
primary B
lipomas I
, O
detectable O
appeared O
number O
LPP O
a O
reverse O
cases O
it O
in O
rearranged O
without O
of O
Using O
is O
involvement O
of O
3q27 O
- O
of O
chain O

Using O
reverse O
transcriptase O
combined O
with O
polymerase O
in O
the O
analysis O
of O
number O
of O
lipoma B
cell O
lines O
primary B
lipomas I
, O
it O
that O
LPP O
frequently O
rearranged O
also O
in O
cases O
without O
a O
cytogenetically O
involvement O
of O
- O
q28 O
. O

3q27 O
that O
transcriptase O
combined O
cell O
polymerase O
lipomas O
cases O
in O
the O
analysis O
of O
a O
chain O
of O
lipoma B
with O
in O
and O
primary B
number I
, O
it O
appeared O
frequently O
LPP O
is O
. O
lines O
also O
rearranged O
reverse O
without O
a O
cytogenetically O
detectable O
involvement O
of O
Using O
- O
q28 O
reactions O

Using O
reverse O
transcriptase O
combined O
with O
polymerase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lipoma B
cell O
lines O
and O
primary B
lipomas I
, O
it O
appeared O
that O
LPP O
is O
frequently O
rearranged O
also O
in O
cases O
without O
a O
cytogenetically O
detectable O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

Using O
reverse O
transcriptase O
combined O
with O
polymerase O
chain O
reactions O
in O
the O
analysis O
of O
a O
number O
of O
lipoma B
cell O
lines O
and O
primary B
lipomas I
, O
it O
appeared O
that O
LPP O
is O
frequently O
rearranged O
also O
in O
cases O
without O
a O
cytogenetically O
detectable O
involvement O
of O
3q27 O
- O
q28 O
. O

two O
choice O
HMGIC O
/ O
LPP O
cross O
transcripts O
have O
been O
discover O
; O
the O
remainder O
between O
them O
is O
primarily O
the O
mien O
of O
either O
two O
or O
troika O
LIM O
domains O
in O
the O
bode O
HMGI O
- O
coulomb O
/ O
LPP O
coalition O
proteins O
. O
. O

alternative O
HMGIC O
/ O
LPP O
hybrid O
transcripts O
have O
been O
difference O
between O
them O
is O
mainly O
presence O
of O
three O
in O
the O
- O
LPP O
fusion O
proteins O
. O

the O
fusion O
HMGIC O
/ O
mainly O
hybrid O
either O
C O
been O
detected O
; O
the O
difference O
LIM O
. O
is O
LPP O
- O
presence O
of O
have O
two O
or O
three O
alternative O
domains O
in O
Two O
the O
HMGI O
predicted O
transcripts O
/ O
LPP O
between O
proteins O
. O
them O

Two O
alternative O
HMGIC O
/ O
LPP O
hybrid O
been O
detected O
; O
the O
between O
them O
is O
mainly O
the O
of O
either O
two O
or O
LIM O
domains O
the O
predicted O
HMGI O
- O
C O
/ O
LPP O
fusion O
. O
. O

Two O
alternative O
HMGIC O
/ O
LPP O
hybrid O
transcripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
LIM O
domains O
in O
the O
predicted O
HMGI O
- O
C O
/ O
LPP O
fusion O
proteins O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
. O
. O

Two O
alternative O
HMGIC O
/ O
LPP O
hybrid O
transcripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
LIM O
domains O
in O
the O
predicted O
HMGI O
- O
C O
/ O
LPP O
fusion O
proteins O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
. O
. O

ii O
alternate O
HMGIC O
/ O
LPP O
cross O
transcripts O
have O
been O
detected O
; O
the O
departure O
between O
them O
is O
chiefly O
the O
comportment O
of O
either O
ii O
or O
trio O
LIM O
area O
in O
the O
prognosticate O
HMGI O
- O
C O
/ O
LPP O
unification O
proteins O
. O
. O

LIM O
presence O
HMGIC O
/ O
LPP O
hybrid O
the O
LPP O
been O
detected O
; O
transcripts O
difference O
the O
HMGI O
is O
mainly O
the O
have O
of O
either O
two O
predicted O
three O
Two O
domains O
C O
between O
them O
or O
- O
proteins O
/ O
alternative O
fusion O
in O
. O
. O

Two O
alternative O
HMGIC O
/ O
LPP O
hybrid O
transcripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
LIM O
domains O
in O
the O
predicted O
HMGI O
- O
C O
/ O
LPP O
fusion O
proteins O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
chiefly O
rich O
person O
. O

Two O
alternative O
LPP O
hybrid O
have O
been O
difference O
them O
is O
mainly O
presence O
of O
either O
or O
three O
LIM O
domains O
in O
HMGI O
- O
C O
/ O
LPP O
fusion O
proteins O
. O

Two O
alternative O
HMGIC O
/ O
LPP O
hybrid O
transcripts O
have O
been O
detected O
; O
the O
difference O
between O
them O
is O
mainly O
the O
presence O
of O
either O
two O
or O
three O
LIM O
domains O
in O
the O
predicted O
HMGI O
- O
C O
/ O
LPP O
fusion O
proteins O
. O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
constancy O
of O
the O
CAG O
reprise O
in O
transgenic O
shiner O
evince O
the O
human O
huntington B
disease I
copy O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
CAG O
repeat O
in O
transgenic O
mice O
expressing O
the O
human O
Huntington B
copy B
verbalise O
verbalise B
verbalise O
verbalise B
verbalise O
disease I
transcript O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
CAG O
repeat O
in O
transgenic O
mice O
expressing O
the O
human O
Huntington B
copy B
verbalise O
verbalise B
verbalise O
verbalise B
verbalise O
disease I
transcript O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
CAG O
repeat O
transgenic O
mice O
expressing O
the O
human O
Huntington B
disease I

expressing O
of O
the O
stability O
and O
intergenerational O
the O
of O
disease O
CAG O
repeat O
in O
. O
mice O
phenotype O
Absence O
human O
Huntington B
disease I
transcript O
transgenic O

absence O
of O
disease O
phenotype O
and O
intergenerational O
constancy O
of O
the O
CAG O
echo O
in O
transgenic O
mice O
extract O
the O
homo O
Huntington B
disease I
copy O
. O

. O
of O
disease O
repeat O
and O
intergenerational O
stability O
disease O
expressing O
CAG O
phenotype O
in O
mice O
transgenic O
the O
the O
human O
Huntington B
of I
Absence O
transcript O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
CAG O
repeat O
in O
transgenic O
mice O
expressing O
the O
human O
Huntington B
copy B
verbalise O
verbalise B
verbalise O
verbalise B
mouse O
disease I
transcript O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
CAG O
repeat O
in O
transgenic O
expressing O
Huntington B
disease I
transcript O
. O

absence O
of O
disease O
phenotype O
and O
intergenerational O
stableness O
of O
the O
CAG O
duplicate O
in O
transgenic O
mice O
utter O
the O
human O
huntington B
disease I
copy O
. O

Absence O
of O
disease O
phenotype O
and O
intergenerational O
stability O
of O
the O
CAG O
repeat O
in O
transgenic O
mice O
expressing O
the O
human O
Huntington B
disease I
transcript O
. O

The O
variation O
underlying O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
elaboration O
in O
the O
first O
exon O
of O
the O
HD B
factor O
. O

The O
mutation O
underlying O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
expansion O
in O
the O
first O
exon O
of O
the O
HD B
rudimentary O
rudimentary O
rudimentary O
rudimentary O
rudimentary O
rudimentary O
gene O
. O

The O
mutation O
underlying O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
expansion O
in O
the O
first O
exon O
of O
the O
HD B
rudimentary O
rudimentary O
rudimentary O
rudimentary O
rudimentary O
rudimentary O
gene O
. O

underlying O
( O
HD B
) O
CAG O
expansion O
the O
first O
exon O
of O
the O
HD B
gene O
. O

The O
mutation O
underlying O
Huntington B
disease I
) O
is O
expansion O
in O
the O
first O
exon O
of O
the O
HD B
gene O
. O

underlying O
Huntington B
disease I
( O
) O
is O
CAG O
expansion O
in O
first O
exon O
of O
the O
gene O
. O

HD O
mutation O
underlying O
gene B
disease I
( O
HD B
is O
) O
CAG O
exon O
in O
the O
. O
The O
of O
the O
expansion B
Huntington O
first O

The O
mutation O
underlying O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
expansion O
in O
the O
first O
exon O
of O
the O
HD B
rudimentary O
rudimentary O
rudimentary O
rudimentary O
rudimentary O
low O
gene O
. O

The O
mutation O
inherent O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
elaboration O
in O
the O
first O
exon O
of O
the O
HD B
factor O
. O

the O
mutation O
underlying O
Huntington B
disease I
( O
first B
in O
is O
CAG O
expansion O
exon O
The O
HD O
) O
HD O
the O
of B
gene O
. O

The O
mutation O
underlying O
Huntington B
disease I
( O
HD B
) O
is O
CAG O
expansion O
in O
the O
first O
exon O
of O
the O
HD B
gene O
. O

In O
order O
to O
investigate O
homo O
 O
use O
ingeminate O
rich O
person O
the O
role O
of O
CAG O
expansion O
in O
the O
pathogenesis O
of B
HD O
, O
we O
have O
produced O
transgenic O
mice O
containing O
the O
full O
length O
human B
HD O
cDNA O
with O
44 O
CAG O
repeats O
human O
being O
human O
being O

In O
order O
the O
in O
the O
pathogenesis O
HD B
, O
have O
produced O
transgenic O
the O
full O
length O
human O
HD B
with O
CAG O
repeats O
. O

inward O
rescript O
to O
investigate O
the O
purpose O
of O
CAG O
expansion O
inward O
the O
pathogenesis O
of O
HD B
, O
we O
have O
produced O
transgenic O
mouse O
control O
the O
full O
distance O
homo O
HD B
cDNA O
with O
44 O
CAG O
echo O
. O

In O
order O
to O
investigate O
role O
expansion O
in O
the O
pathogenesis O
of O
HD B
, O
we O
have O
the O
full O
length O
human O
HD B
cDNA O
with O
44 O
CAG O
repeats O
. O

indium O
order O
to O
investigate O
the O
character O
of O
CAG O
elaboration O
indium O
the O
pathogenesis O
of O
HD B
, O
we O
have O
produced O
transgenic O
mice O
carry O
the O
full O
distance O
homo O
HD B
cDNA O
with O
44 O
CAG O
reiterate O
. O

In O
order O
to O
investigate O
homo O
 O
use O
ingeminate O
rich O
person O
the O
role O
of O
CAG O
expansion O
in O
the O
pathogenesis O
of B
HD O
, O
we O
have O
produced O
transgenic O
mice O
containing O
the O
full O
length O
human B
HD O
cDNA O
with O
44 O
CAG O
repeats O
human O
being O
human O
being O

inwards O
put O
to O
inquire O
the O
part O
of O
CAG O
enlargement O
inwards O
the O
pathogenesis O
of O
HD B
, O
we O
have O
produced O
transgenic O
mice O
arrest O
the O
good O
distance O
homo O
HD B
cDNA O
with O
44 O
CAG O
repeats O
. O

containing O
transgenic O
to O
investigate O
the O
role O
of O
CAG O
expansion O
in O
the O
pathogenesis O
of O
human B
CAG O
we O
have O
produced O
with O
mice O
order O
the O
. O
length O
HD O
HD B
cDNA O
In O
, O
full O
repeats O
44 O

In O
order O
to O
investigate O
role O
CAG O
expansion O
in O
the O
pathogenesis O
of O
HD B
, O
have O
produced O
transgenic O
mice O
containing O
the O
full O
HD B
cDNA O
with O
CAG O
. O

In O
order O
to O
investigate O
amplification O
 O
use O
ingeminate O
elaboration O
the O
role O
of O
CAG O
expansion O
in O
the O
pathogenesis O
of O
HD B
, O
we O
have O
produced O
transgenic O
mice O
containing O
the O
full O
length O
human O
HD B
cDNA O
with O
44 O
CAG O
repeats O
elaboration O
elaboration O
elaboration O
iterate O
. O

In O
order O
to O
investigate O
the O
role O
of O
CAG O
expansion O
in O
the O
pathogenesis O
of O
HD B
, O
we O
have O
produced O
transgenic O
mice O
containing O
the O
full O
length O
human O
HD B
cDNA O
with O
44 O
CAG O
repeats O
. O

By O
1 O
year O
, O
depth O
psychology O
astatine O
 O
rich O
person O
 O
these O
mice O
have B
no I
behavioral O
abnormalities O
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
discover O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
calendar O
month O

By O
1 O
year O
, O
depth O
psychology O
astatine O
 O
rich O
person O
 O
these O
mice O
have B
no I
behavioral O
abnormalities O
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
calendar O
month O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
calendar O

animals O
1 O
year O
, O
these O
mice O
at O
one O
behavioral B
abnormalities I
and O
morphometric O
( O
have O
) O
no O
no O
9 O
) O
and O
By O
analysis O
two O
animal O
6 O
months O
age O
revealed O
. O
changes O
( O

By O
1 O
year O
, O
depth O
psychology O
astatine O
 O
rich O
person O
 O
these O
mice O
have B
no I
behavioral O
abnormalities O
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
discover O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
calendar O
month O

By O
1 O
year O
, O
mice O
behavioral B
abnormalities I
and O
morphometric O
analysis O
at O
6 O
( O
one O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O

away O
1 O
yr O
, O
these O
shiner O
have O
no O
behavioral B
freakishness I
and O
morphometric O
analysis O
at O
sixer O
( O
single O
creature O
) O
and O
9 O
( O
two O
creature O
) O
months O
maturate O
revealed O
no O
changes O
. O

no O
1 O
) O
6 O
these O
mice O
revealed O
no O
, B
abnormalities I
and O
morphometric O
9 O
at O
year O
behavioral O
one O
animal O
) O
and O
analysis O
( O
two O
animals O
( O
have O
age O
months O
By O
changes O
. O

By O
1 O
year O
, O
these O
mice O
have O
no O
behavioral B
and O
morphometric O
at O
6 O
( O
one O
animal O
) O
and O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O

and O
1 O
year O
no O
these O
mice O
have O
months O
animals B
abnormalities I
) O
morphometric O
age O
and O
two O
( O
one O
animal O
. O
at O
9 O
( O
6 O
behavioral O
By O
no O
analysis O
revealed O
, O
changes O
) O

past O
single O
yr O
, O
these O
mice O
have O
no O
behavioural B
abnormalities I
and O
morphometric O
analysis O
at O
sise O
( O
ane O
animal O
) O
and O
9 O
( O
ii O
beast O
) O
months O
age O
revealed O
no O
shift O
. O

By O
1 O
year O
, O
these O
mice O
have O
no O
behavioral B
abnormalities I
and O
morphometric O
analysis O
at O
6 O
( O
one O
animal O
) O
and O
9 O
( O
two O
animals O
) O
months O
age O
revealed O
no O
changes O
. O

Despite O
high O
levels O
there O
was O
no O
evidence O
of O
the O
HD B
gene O
product O
in O
any O
of O
these O
transgenic O
mice O

Despite O
high O
levels O
of O
mRNA O
expression O
, O
there O
was O
no O
evidence O
of O
the O
gene O
any O
of O
these O
transgenic O
mice O
. O

Despite O
high O
levels O
of O
mRNA O
expression O
, O
there O
was O
no O
evidence O
of O
the O
HD B
gene O
product O
in O
any O
grade O
mouse O
mouse O
grade O
grade O
grade O
of O
these O
transgenic O
mice O
. O

contempt O
high O
charge O
of O
mRNA O
manifestation O
, O
there O
was O
no O
manifest O
of O
the O
HD B
factor O
product O
in O
any O
of O
these O
transgenic O
mice O
. O

Despite O
high O
levels O
of O
mRNA O
expression O
, O
there O
was O
no O
evidence O
of O
the O
HD B
gene O
product O
in O
any O
grade O
mouse O
mouse O
grade O
grade O
grade O
of O
these O
transgenic O
mice O
. O

disdain O
luxuriously O
stage O
of O
mRNA O
reflection O
, O
there O
was O
no O
evidence O
of O
the O
HD B
cistron O
intersection O
in O
any O
of O
these O
transgenic O
mice O
. O

Despite O
high O
levels O
of O
mRNA O
expression O
, O
there O
was O
no O
of O
the O
gene O
product O
in O
any O
of O
these O
transgenic O

evidence O
high O
levels O
of O
mRNA O
expression O
, O
was O
there O
no O
these O
of O
HD O
the B
. O
product O
in O
any O
of O
Despite O
transgenic O
mice O
gene O

disdain O
heights O
stratum O
of O
mRNA O
aspect O
, O
there O
was O
no O
tell O
of O
the O
HD B
factor O
product O
in O
any O
of O
these O
transgenic O
mice O
. O

gene O
high O
was O
, O
mRNA O
expression O
product O
there O
levels O
no O
evidence O
of O
transgenic O
HD B
of O
Despite O
in O
any O
of O
these O
the O
mice O
. O

Despite O
high O
levels O
of O
mRNA O
expression O
, O
there O
was O
no O
evidence O
of O
the O
HD B
gene O
product O
in O
any O
of O
these O
transgenic O
mice O
. O

In O
vitro O
expression O
studies O
indicated O
that O
of O
construct O
of O
120 O
bp O
at O
and O
5 O
UTR O
nucleotide O
the O
cDNA O
of O
the O
the O
the O
of O
a O
frameshift O
in O
the O
presence O
2349 O
prevented O
transfection O
inclusion O
mutation O
HD B
cDNA O
. O

vitro O
studies O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
the O
5 O
UTR O
in O
the O
cDNA O
construct O
presence O
of O
a O
mutation O
nucleotide O
2349 O
prevented O
the O

inwards O
vitro O
transfection O
canvass O
betoken O
that O
the O
comprehension O
of O
120 O
bp O
of O
the O
cinque O
UTR O
inwards O
the O
cDNA O
make O
and O
the O
front O
of O
a O
frameshift O
mutation O
at O
base O
2349 O
preclude O
expression O
of O
the O
HD B
cDNA O
. O

nucleotide O
the O
transfection O
studies O
the O
that O
UTR O
of O
of O
120 O
bp O
of O
the O
frameshift O
inclusion O
in O
indicated O
expression O
construct O
and O
5 O
presence O
of O
a O
vitro O
mutation O
at O
In O
cDNA O
prevented O
2349 O
the O
the O
HD B
cDNA O
. O

In O
vitro O
transfection O
studies O
point O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
5 O
UTR O
in O
the O
cDNA O
construct O
and O
the O
presence O
of O
a O
frameshift O
mutation O
at O
nucleotide O
2349 O
prevented O
expression O
of O
the O
HD B
cDNA O
steer O
steer O
steer O
steer O
steer O
steer O
steer O
steer O
inward O
. O

frameshift O
construct O
transfection O
studies O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
nucleotide O
prevented O
in O
the O
cDNA O
HD O
and O
the O
presence O
2349 O
a O
In O
mutation O
of O
5 O
UTR O
of O
expression O
. O
the O
cDNA B
vitro O
at O

In O
vitro O
transfection O
studies O
that O
of O
120 O
bp O
of O
the O
5 O
UTR O
in O
the O
presence O
of O
a O
frameshift O
mutation O
at O
nucleotide O
2349 O
prevented O
expression O
of O
the O
HD B
cDNA O
. O

In O
vitro O
transfection O
survey O
designate O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
cinque O
UTR O
in O
the O
cDNA O
fabricate O
and O
the O
front O
of O
a O
frameshift O
mutation O
at O
base O
2349 O
foreclose O
reflection O
of O
the O
HD B
cDNA O
. O

In O
vitro O
transfection O
studies O
inward O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
5 O
UTR O
in O
the O
cDNA O
construct O
and O
the O
presence O
of O
a O
frameshift O
mutation O
at O
nucleotide O
2349 O
prevented O
expression O
of O
the O
HD B
cDNA O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inward O
. O

indiana O
vitro O
transfection O
read O
argue O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
five O
UTR O
indiana O
the O
cdna O
conception O
and O
the O
bearing O
of O
a O
frameshift O
mutation O
at O
base O
2349 O
keep O
expression O
of O
the O
HD B
cdna O
. O

In O
vitro O
transfection O
studies O
indicated O
that O
the O
inclusion O
of O
120 O
bp O
of O
the O
5 O
UTR O
in O
the O
cDNA O
construct O
and O
the O
presence O
of O
a O
frameshift O
mutation O
at O
nucleotide O
2349 O
prevented O
expression O
of O
the O
HD B
cDNA O
. O

suggest O
pathogenesis O
of O
HD B
is O
mediated O
through O
protein O
interaction O
that O
presence O
transcript O
an O
expanded O
CAG O
is O
insufficient O
to O
the O
disease O
. O

These O
findings O
suggest O
that O
fundamental O
interaction O
deficient O
the O
pathogenesis O
of B
HD O
is O
not O
mediated O
through O
DNA O
- O
protein O
interaction O
and O
that O
presence O
of O
the O
RNA O
transcript O
with O
an O
expanded O
CAG O
repeat O
is O
insufficient O
to O
cause O
the O
disease O
deficient O
deficient O
deficient O
deficient O
deficient O
deficient O
deficient O
deficient O

an O
presence O
suggest O
that O
the O
pathogenesis O
CAG O
HD B
is O
not O
mediated O
through O
DNA O
repeat O
insufficient O
interaction O
and O
that O
disease O
of O
the O
RNA O
cause O
with O
These O
expanded O
of O
- O
protein O
transcript O
to O
is O
the O
. O
findings O

These O
see O
suggest O
that O
the O
pathogenesis O
of O
HD B
is O
not O
intercede O
through O
dna O
- O
protein O
interaction O
and O
that O
front O
of O
the O
rna O
copy O
with O
an O
exposit O
CAG O
reprise O
is O
deficient O
to O
induce O
the O
disease O
. O

These O
findings O
expanded O
that O
the O
pathogenesis O
of O
RNA B
is O
not O
mediated O
with O
repeat O
- O
protein O
to O
and O
that O
of O
through O
the O
HD O
transcript O
presence O
an O
CAG O
suggest O
the O
is O
insufficient O
interaction O
DNA O
cause O
disease O
. O

These O
findings O
suggest O
that O
the O
pathogenesis O
of O
HD B
is O
not O
DNA O
- O
protein O
interaction O
that O
presence O
of O
the O
RNA O
with O
an O
expanded O
CAG O
is O
insufficient O
cause O
the O
disease O
. O

These O
receive O
propose O
that O
the O
pathogenesis O
of O
HD B
is O
not O
mediated O
through O
DNA O
- O
protein O
interaction O
and O
that O
front O
of O
the O
rna O
copy O
with O
an O
elaborate O
CAG O
duplicate O
is O
deficient O
to O
campaign O
the O
disease O
. O

These O
findings O
suggest O
that O
fundamental O
interaction O
do O
the O
pathogenesis O
of B
HD O
is O
not O
mediated O
through O
DNA O
- O
protein O
interaction O
and O
that O
presence O
of O
the O
RNA O
transcript O
with O
an O
expanded O
CAG O
repeat O
is O
insufficient O
to O
cause O
the O
disease O
deficient O
deficient O
deficient O
deficient O
deficient O
deficient O
deficient O
deficient O

These O
feel O
advise O
that O
the O
pathogenesis O
of O
HD B
is O
not O
intermediate O
through O
DNA O
- O
protein O
interaction O
and O
that O
comportment O
of O
the O
rna O
copy O
with O
an O
expanded O
CAG O
reduplicate O
is O
deficient O
to O
effort O
the O
disease O
. O

repeat O
the O
suggest O
that O
and O
pathogenesis O
protein O
cause B
is O
not O
mediated O
through O
DNA O
an O
HD O
interaction O
the O
to O
presence O
of O
- O
RNA O
transcript O
with O
findings O
expanded O
CAG O
These O
that O
insufficient O
is O
of O
the O
disease O
. O

These O
findings O
suggest O
that O
the O
pathogenesis O
of O
HD B
is O
not O
mediated O
through O
DNA O
- O
protein O
interaction O
and O
that O
presence O
of O
the O
RNA O
transcript O
with O
an O
expanded O
CAG O
repeat O
is O
insufficient O
to O
cause O
the O
disease O
. O

Rather O
translation O
the O
is O
crucial O
for O
the O
pathogenesis O
of O
HD B
. O

kinda O
, O
rendering O
of O
the O
CAG O
is O
crucial O
for O
the O
pathogenesis O
of O
HD B
. O

crucial O
of O
translation O
, O
the O
CAG O
the O
Rather O
for O
. O
pathogenesis O
of O
HD B
is O

Rather O
, O
translation O
of O
the O
CAG O
is O
crucial O
the O
pathogenesis O
HD B
. O

Rather O
, O
all O
important O
interlingual O
rendition O
translation O
of O
the O
CAG O
is O
crucial O
for O
all O
important O
all O
important B
the O

Rather O
, O
all O
important O
interlingual O
rendition O
translation O
of O
the O
CAG O
is O
crucial O
for O
all O
important O
be O
the B
pathogenesis O

quite O
, O
translation O
of O
the O
CAG O
is O
essential O
for O
the O
pathogenesis O
of O
HD B
. O

HD O
, O
translation O
Rather O
crucial O
CAG O
is O
of O
for O
the O
pathogenesis O
the O
of B
. O

Rather O
, O
all O
important O
interlingual O
rendition O
translation O
of O
the O
CAG O
is O
crucial O
for O
all O
important O
all O
important B
the O

quite O
, O
displacement O
of O
the O
CAG O
is O
crucial O
for O
the O
pathogenesis O
of O
HD B
. O

Rather O
, O
translation O
of O
the O
CAG O
is O
crucial O
for O
the O
pathogenesis O
of O
HD B
. O

inwards O
demarcation O
to O
that O
seen O
inwards O
humanity O
, O
the O
CAG O
repeat O
inwards O
these O
mouse O
was O
remarkably O
unchanging O
inwards O
xcvii O
meioses O
. O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
CAG O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
miosis O
signally O
signally O
signally O
signally O
signally O
97 O
meioses O
. O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
CAG O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
miosis O
signally O
signally O
signally O
signally O
signally O
97 O
meioses O
. O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
CAG O
repeat O
these O
mice O
was O
remarkably O
stable O
in O
97 O

was O
contrast O
the O
humans O
seen O
in O
remarkably O
, O
to O
CAG O
repeat O
in O
. O
mice O
that O
In O
stable O
in O
97 O
meioses O
these O

indium O
line O
to O
that O
discover O
indium O
mankind O
, O
the O
CAG O
reiterate O
indium O
these O
mice O
was O
remarkably O
stable O
indium O
97 O
meiosis O
. O

. O
contrast O
to O
repeat O
seen O
in O
humans O
97 O
was O
CAG O
that O
in O
mice O
these O
the O
remarkably O
stable O
in O
, O
In O
meioses O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
CAG O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
miosis O
signally O
signally O
signally O
signally O
inward O
97 O
meioses O
. O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
CAG O
repeat O
in O
these O
was O
in O
97 O
meioses O
. O

indiana O
line O
to O
that O
attend O
indiana O
mankind O
, O
the O
CAG O
restate O
indiana O
these O
mice O
was O
remarkably O
static O
indiana O
97 O
meioses O
. O

In O
contrast O
to O
that O
seen O
in O
humans O
, O
the O
CAG O
repeat O
in O
these O
mice O
was O
remarkably O
stable O
in O
97 O
meioses O
. O

This O
suggests O
childs O
play O
antiophthalmic O
factor O
decisive O
that O
genomic O
sequences O
may O
play O
a O
critical O
role O
in O
influencing O
repeat O
instability O
. O

instability O
suggests O
that O
. O
sequences O
may O
play O
a O
. O
role O
in O
influencing O
This O
repeat O
critical O
genomic O

This O
suggests O
childs O
play O
antiophthalmic O
factor O
ingeminate O
that O
genomic O
sequences O
may O
play O
a O
critical O
role O
in O
influencing O
repeat O
instability O
. O

This O
suggests O
that O
genomic O
sequences O
may O
looseness O
a O
decisive O
office O
in O
influencing O
reprise O
instability O
. O
. O

repeat O
suggests O
that O
a O
sequences O
may O
instability O
genomic O
critical O
role O
This O
influencing O
in O
play O
. O
. O

This O
suggests O
childs O
play O
antiophthalmic O
factor O
decisive O
that O
genomic O
sequences O
may O
play O
a O
critical O
role O
in O
influencing O
repeat O
instability O
. O

This O
evoke O
that O
genomic O
sequences O
may O
play O
a O
critical O
office O
in O
mold O
repeat O
imbalance O
. O
. O

This O
propose O
that O
genomic O
episode O
may O
play O
a O
vital O
role O
in O
influence O
repeat O
instability O
. O
. O

This O
suggests O
critical O
. O
sequences O
may O
repeat O
a O
that O
role O
in O
influencing O
play O
instability O
genomic O
. O

suggests O
that O
genomic O
sequences O
may O
play O
a O
in O
influencing O
repeat O
instability O
. O
. O

This O
suggests O
that O
genomic O
sequences O
may O
play O
a O
critical O
role O
in O
influencing O
repeat O
instability O
. O
. O

FISH O
studies O
in O
aniridia I
and O
t O
( O
7 O
; O
11 O
) O
( O
q31 O
. O
2 O
; O
p13 O
) O

FISH O
studies O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
7 O
; O
) O
. O
2 O
; O
p13 O
) O
. O

FISH O
studies O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
7 O
; O
11 O
) O
( O
q31 O
. O
inward O
inward O
inward O
inward O
inward O
inward O
2 O
; O
p13 O
) O
. O

fish O
survey O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
septenary O
; O
xi O
) O
( O
q31 O
. O
2 O
; O
p13 O
) O
. O

FISH O
studies O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
7 O
; O
11 O
) O
( O
q31 O
. O
inward O
inward O
inward O
inward O
inward O
inward O
2 O
; O
p13 O
) O
. O

fish O
survey O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
septenary O
; O
eleven O
) O
( O
q31 O
. O
deuce O
; O
p13 O
) O
. O

FISH O
studies O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
7 O
; O
) O
( O
q31 O
. O
2 O
; O
p13 O

( O
studies O
in O
2 O
patient O
with O
sporadic B
and I
aniridia O
t O
; O
7 O
11 O
; O
. O
( O
q31 O
. O
a O
FISH O
p13 O
) O
) O

pisces O
study O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
sevener O
; O
11 O
) O
( O
q31 O
. O
2 O
; O
p13 O
) O
. O

) O
studies O
and O
sporadic O
patient O
with O
( B
aniridia I
in O
t O
( O
7 O
p13 O
11 O
a O
FISH O
q31 O
. O
2 O
; O
; O
) O
. O

FISH O
studies O
in O
a O
patient O
with O
sporadic B
aniridia I
and O
t O
( O
7 O
; O
11 O
) O
( O
q31 O
. O
2 O
; O
p13 O
) O
. O

A O
year O
old O
female O
presenting O
with O
bilateral B
sporadic I
aniridia I
was O
found O
an O
apparently O
balanced O
reciprocal O
with O
a O
chromosome O
11 O
breakpoint O
band O
p13 O
. O

A O
year O
old O
presenting O
with O
bilateral B
sporadic I
aniridia I
was O
found O
to O
an O
apparently O
reciprocal O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
within O

A O
2 O
year O
old O
rich O
person O
associate O
in O
nursing O
obviously O
female O
person B
female I
presenting I
with O
bilateral O
sporadic O
aniridia O
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
inside O
stripe O
inside O
associate O
in O
nursing O
translocation O
with O
a O
chromosome O

a O
2 O
year O
translocation O
female O
presenting O
with O
band B
breakpoint I
aniridia I
with O
found O
to O
have O
11 O
apparently O
balanced O
reciprocal O
old O
within O
was O
chromosome O
an O
sporadic O
A O
bilateral O
p13 O
. O

p13 O
2 O
year O
an O
female O
presenting O
band O
bilateral B
old I
aniridia I
was O
found O
have O
a O
within O
sporadic O
balanced O
reciprocal O
translocation O
with O
to O
chromosome O
11 O
breakpoint O
apparently O
with O
A O
. O

A O
2 O
year O
old O
rich O
person O
associate O
in O
nursing O
obviously O
female O
person B
female I
presenting I
with O
bilateral O
sporadic O
aniridia O
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
inside O
stripe O
inside O
sometime O
translocation O
with O
a O
chromosome O
11 O
breakpoint O

A O
2 O
class O
old O
distaff O
award O
with O
bilateral B
sporadic I
aniridia I
was O
feel O
to O
have O
an O
apparently O
equilibrize O
mutual O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
inside O
stria O
p13 O
. O

A O
2 O
year O
old O
rich O
person O
associate O
in O
nursing O
obviously O
female O
person B
female I
presenting I
with O
bilateral O
sporadic O
aniridia O
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
inside O
stripe O
inside O
sometime O
translocation O
with O
a O
chromosome O
11 O
breakpoint O

breakpoint O
2 O
year O
old O
female O
presenting O
have O
found B
sporadic I
aniridia I
was O
balanced O
chromosome O
with O
within O
A O
bilateral O
apparently O
translocation O
with O
a O
to O
11 O
reciprocal O
an O
band O
p13 O
. O

A O
ii O
yr O
old O
female O
acquaint O
with O
bilateral B
sporadic I
aniridia I
was O
retrieve O
to O
have O
an O
seemingly O
balanced O
mutual O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
inside O
set O
p13 O
. O

A O
2 O
year O
old O
female O
presenting O
with O
bilateral B
sporadic I
aniridia I
was O
found O
to O
have O
an O
apparently O
balanced O
reciprocal O
translocation O
with O
a O
chromosome O
11 O
breakpoint O
within O
band O
p13 O
. O

Fluorescence O
( O
) O
studies O
with O
11p13 O
specific O
cosmids O
that O
the O
chromosome O
11 O
breakpoint O
the O
aniridia B
( O
PAX6 O
) O
locus O
and O
a O
100 O
distal O
to O
PAX6 O
by O
the O
cosmid O
FO2121 O
. O

Fluorescence O
in O
situ O
hybridisation O
( O
with O
distal O
11p13 O
specific O
cosmids O
that O
the O
lay O
aniridia B
( O
locus O
region O
approximately O
100 O
kb O
to O
PAX6 O
the O
cosmid O
. O

Fluorescence O
in O
situ O
hybridisation O
( O
FISH O
) O
studies O
with O
distal O
11p13 O
specific O
cosmids O
showed O
that O
the O
chromosome O
11 O
breakpoint O
lay O
between O
the O
aniridia B
( O
PAX6 O
) O
locus O
and O
a O
region O
approximately O
100 O
kb O
distal O
to O
PAX6 O
aside O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
defined O
by O
the O
cosmid O
FO2121 O
. O

fluorescence O
in O
situ O
hybridization O
( O
pisces O
) O
consider O
with O
distal O
11p13 O
particular O
cosmids O
render O
that O
the O
chromosome O
eleven O
breakpoint O
rest O
between O
the O
aniridia B
( O
PAX6 O
) O
venue O
and O
a O
area O
approximately O
100 O
kilobyte O
distal O
to O
PAX6 O
specify O
by O
the O
cosmid O
FO2121 O
. O

Fluorescence O
in O
approximately O
hybridisation O
( O
PAX6 O
) O
breakpoint O
with O
distal O
11p13 O
locus O
lay O
showed O
that O
studies O
chromosome O
11 O
by O
cosmids O
between O
kb O
aniridia B
FISH O
PAX6 O
the O
specific O
the O
a O
region O
situ O
and O
100 O
distal O
to O
( O
defined O
) O
the O
cosmid O
FO2121 O
. O

fluorescence O
in O
situ O
hybridizing O
( O
FISH O
) O
studies O
with O
distal O
11p13 O
particular O
cosmids O
register O
that O
the O
chromosome O
eleven O
breakpoint O
consist O
between O
the O
aniridia B
( O
PAX6 O
) O
locale O
and O
a O
area O
approximately O
100 O
kilobyte O
distal O
to O
PAX6 O
defined O
by O
the O
cosmid O
FO2121 O
. O

to O
breakpoint O
situ O
hybridisation O
( O
FISH O
. O
studies O
with O
distal O
11p13 O
FO2121 O
cosmids O
PAX6 O
region O
the O
chromosome O
11 O
and O
lay O
between O
the O
PAX6 B
( O
showed O
) O
distal O
in O
100 O
aniridia O
approximately O
a O
kb O
that O
Fluorescence O
locus O
defined O
by O
the O
cosmid O
specific O
) O

Fluorescence O
in O
situ O
hybridisation O
( O
FISH O
with O
distal O
11p13 O
specific O
showed O
that O
the O
chromosome O
11 O
lay O
between O
the O
aniridia B
PAX6 O
) O
and O
a O
region O
approximately O
100 O
kb O
distal O
to O
defined O
by O
cosmid O
FO2121 O
. O

the O
PAX6 O
situ O
hybridisation O
chromosome O
FISH O
between O
100 O
with O
distal O
11p13 O
specific O
cosmids O
) O
by O
the O
( O
approximately O
breakpoint O
lay O
showed O
the O
aniridia B
( O
and O
) O
locus O
. O
11 O
region O
a O
in O
kb O
distal O
to O
PAX6 O
defined O
that O
Fluorescence O
cosmid O
FO2121 O
studies O

Fluorescence O
in O
situ O
hybridisation O
( O
FISH O
) O
studies O
with O
distal O
11p13 O
specific O
cosmids O
showed O
that O
the O
chromosome O
11 O
breakpoint O
lay O
between O
the O
aniridia B
( O
PAX6 O
) O
locus O
and O
a O
region O
approximately O
100 O
kb O
distal O
to O
PAX6 O
aside O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
meditate O
 O
defined O
by O
the O
cosmid O
FO2121 O
. O

Fluorescence O
in O
situ O
hybridisation O
( O
FISH O
) O
studies O
with O
distal O
11p13 O
specific O
cosmids O
showed O
that O
the O
chromosome O
11 O
breakpoint O
lay O
between O
the O
aniridia B
( O
PAX6 O
) O
locus O
and O
a O
region O
approximately O
100 O
kb O
distal O
to O
PAX6 O
defined O
by O
the O
cosmid O
FO2121 O
. O

Although O
this O
patient O
did O
non O
crataegus O
oxycantha O
rich O
person O
non O
not O
have O
a O
detectable O
deletion O
within O
PAX6 O
, B
her O
aniridia O
may O
have O
resulted O
from O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
PAX6 O
not O
not O
not O
not O

Although O
this O
patient O
have O
PAX6 O
, O
her O
may O
have O
from O
a O
disruption O
distal O
chromatin O
domain O
containing O
either O
or O
for O
PAX6 O
. O

Although O
this O
patient O
did O
not O
have O
a O
noticeable O
excision O
inside O
PAX6 O
, O
her O
aniridia B
may O
have O
ensue O
from O
a O
break O
of O
the O
distal O
chromatin O
orbit O
curb O
either O
enhancers O
or O
regulators O
for O
PAX6 O
. O

Although O
this O
patient O
did O
not O
have O
a O
deletion O
, O
her O
aniridia B
may O
have O
resulted O
from O
a O
disruption O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
PAX6 O
. O

Although O
this O
patient O
did O
not O
have O
a O
perceptible O
excision O
inside O
PAX6 O
, O
her O
aniridia B
may O
have O
lead O
from O
a O
break O
of O
the O
distal O
chromatin O
world O
check O
either O
foil O
or O
governor O
for O
PAX6 O
. O

Although O
this O
patient O
did O
non O
crataegus O
oxycantha O
rich O
person O
non O
not O
have O
a O
detectable O
deletion O
within O
PAX6 O
, B
her O
aniridia O
may O
have O
resulted O
from O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
PAX6 O
not O
not O
not O
not O

Although O
this O
patient O
did O
not O
have O
a O
noticeable O
cut O
inside O
PAX6 O
, O
her O
aniridia B
whitethorn O
have O
ensue O
from O
a O
disruption O
of O
the O
distal O
chromatin O
arena O
containing O
either O
foil O
or O
governor O
for O
PAX6 O
. O

of O
a O
patient O
did O
not O
have O
a O
detectable O
deletion O
within O
PAX6 O
, O
her O
domain B
regulators O
have O
resulted O
from O
enhancers O
disruption O
this O
the O
PAX6 O
chromatin O
aniridia O
containing O
either O
Although O
may O
distal O
for O
or O
. O

Although O
this O
patient O
did O
not O
have O
detectable O
within O
PAX6 O
, O
her O
aniridia B
may O
have O
resulted O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
enhancers O
or O
regulators O
PAX6 O

Although O
this O
patient O
did O
non O
crataegus O
oxycantha O
rich O
person O
lead O
not O
have O
a O
detectable O
deletion O
within O
PAX6 O
, B
her O
aniridia O
may O
have O
resulted O
from O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
PAX6 O
not O
not O
not O
not O

Although O
this O
patient O
did O
not O
have O
a O
detectable O
deletion O
within O
PAX6 O
, O
her O
aniridia B
may O
have O
resulted O
from O
a O
disruption O
of O
the O
distal O
chromatin O
domain O
containing O
either O
enhancers O
or O
regulators O
for O
PAX6 O
. O

may O
another O
example O
of O
aniridia B
by O
a O
as O
recently O
in O
two O
in O
the O
phenotype O
cosegregated O
chromosome B
abnormalities I
with O
breakpoints O
. O
. O

This O
case O
may O
therefore O
of O
late O
a O
be O
another O
example O
of B
aniridia O
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two B
familial I
aniridia O
patients O
in O
which O
the O
phenotype O
cosegregated O
with B
chromosome I
abnormalities O
with O
11p13 O
breakpoints O
. O
a O
a O
a O
a O
a O
a O
a O
a O

the O
two O
may O
therefore O
be O
another O
cosegregated O
of O
aniridia B
caused O
by O
a O
position O
with O
abnormalities O
recently O
described O
in O
. O
familial B
aniridia I
patients O
11p13 O
which O
This O
phenotype O
example O
effect O
as B
in I
with O
chromosome O
breakpoints O
. O
case O

This O
font O
may O
consequently O
be O
another O
instance O
of O
aniridia B
do O
by O
a O
office O
consequence O
as O
recently O
report O
in O
two O
hereditary B
aniridia I
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome B
abnormality I
with O
11p13 O
breakpoints O
. O
. O

This O
case O
phenotype O
therefore O
be O
another O
example O
patients O
aniridia B
caused O
by O
which O
with O
effect O
as O
with O
described O
in O
familial O
a B
aniridia I
of O
in O
two O
the O
cosegregated O
may O
breakpoints O
chromosome B
abnormalities I
recently O
position O
11p13 O
. O
. O

This O
case O
may O
therefore O
be O
another O
example O
of O
aniridia B
caused O
position O
effect O
as O
recently O
in O
two O
familial B
aniridia I
patients O
which O
the O
phenotype O
cosegregated O
chromosome B
abnormalities I
11p13 O
breakpoints O
. O
. O

This O
case O
may O
thence O
be O
another O
model O
of O
aniridia B
make O
by O
a O
billet O
effect O
as O
lately O
distinguish O
in O
ii O
transmissible B
aniridia I
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome B
irregularity I
with O
11p13 O
breakpoints O
. O
. O

This O
case O
may O
therefore O
of O
late O
follow O
be O
another O
example O
of B
aniridia O
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two B
familial I
aniridia O
patients O
in O
which O
the O
phenotype O
cosegregated O
with B
chromosome I
abnormalities O
with O
11p13 O
breakpoints O
. O
a O
a O
a O
a O
a O
a O
a O
a O

This O
case O
whitethorn O
thus O
be O
another O
example O
of O
aniridia B
stimulate O
by O
a O
attitude O
issue O
as O
latterly O
described O
in O
two O
transmitted B
aniridia I
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome B
abnormalities I
with O
11p13 O
breakpoints O
. O
. O

with O
aniridia O
may O
therefore O
described O
another O
as O
11p13 O
aniridia B
caused O
by O
a O
position O
the O
of O
recently O
be O
with O
two O
familial B
effect I
patients O
in O
which O
case O
phenotype O
cosegregated O
This O
in B
abnormalities I
chromosome O
example O
breakpoints O
. O
. O

This O
case O
may O
therefore O
be O
another O
example O
of O
aniridia B
caused O
by O
a O
position O
effect O
as O
recently O
described O
in O
two O
familial B
aniridia I
patients O
in O
which O
the O
phenotype O
cosegregated O
with O
chromosome B
abnormalities I
with O
11p13 O
breakpoints O
. O
. O

Muscle O
of O
- I
- I
phosphate I
dehydrogenase I
deficiency I
in O
different O
variants O
. O

muscleman O
expression O
of O
glucose B
- I
sixer I
- I
phosphate I
dehydrogenase I
lack I
in O
different O
variate O
. O

phosphate O
glucose O
of O
expression B
- I
6 I
deficiency I
Muscle I
dehydrogenase I
. I
in O
different O
variants O
- O

Muscle O
expression O
of O
glucose B
- I
6 I
- I
phosphate I
deficiency I
in O
variants O
. O

Muscle O
expression O
orthophosphate O
var O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
var I
manifestation O
deficiency I
in O
different O
variants O
. O

Muscle O
expression O
orthophosphate O
var O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
var I
 O
deficiency I
in O
different O
variants O
. O

brawniness O
formula O
of O
glucose B
- I
sise I
- I
phosphate I
dehydrogenase I
deficiency I
in O
unlike O
variants O
. O

variants O
expression O
of O
Muscle B
phosphate I
6 I
- I
different I
dehydrogenase I
deficiency I
in O
- O
glucose O
. O

Muscle O
expression O
orthophosphate O
var O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
var I
manifestation O
deficiency I
in O
different O
variants O
. O

sinew O
expression O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
insufficiency I
in O
unlike O
discrepancy O
. O

Muscle O
expression O
of O
glucose B
- I
6 I
- I
phosphate I
dehydrogenase I
deficiency I
in O
different O
variants O
. O

Muscle O
expression O
in O
and B
deficiency I
has O
- O
investigated O
of O
Mediterranean O
, O
Seattle O
been O
like O
G6PD O
A O
- O
variants O
. O

of O
G6PD B
deficiency I
has O
been O
investigated O
in O
Mediterranean O
, O
A O
- O
variants O
. O

Muscle O
expression O
of O
G6PD B
want I
has O
been O
enquire O
in O
mediterranean O
, O
seattle O
- O
ilk O
and O
A O
- O
variants O
. O

Muscle O
verbalism O
of O
G6PD B
inadequacy I
has O
been O
enquire O
in O
Mediterranean O
, O
seattle O
- O
comparable O
and O
A O
- O
variants O
. O

- O
expression O
of O
G6PD B
deficiency I
has O
like O
and O
in O
Mediterranean O
, O
Seattle O
variants O
been O
investigated O
A O
- O
Muscle O
. O

Muscle O
expression O
deficiency I
has O
been O
investigated O
in O
Mediterranean O
, O
Seattle O
- O
like O
and O
A O
- O
. O

Muscle O
expression O
of O
G6PD B
deficiency I
has O
been O
investigated O
in O
Mediterranean O
, O
Seattle O
- O
like O
and O
A O
- O
variants O
inward O
inward O
inward O
inward O
brawn O
. O

brawniness O
manifestation O
of O
G6PD B
deficiency I
has O
been O
enquire O
in O
mediterranean O
, O
Seattle O
- O
like O
and O
ampere O
- O
variants O
. O

Muscle O
expression O
of O
G6PD B
deficiency I
has O
been O
investigated O
in O
Mediterranean O
, O
Seattle O
- O
like O
and O
A O
- O
variants O
inward O
inward O
inward O
inward O
inward O
. O

like O
expression O
of O
, B
deficiency I
has O
been O
. O
and O
Mediterranean O
G6PD O
Seattle O
Muscle O
- O
in O
A O
- O
variants O
investigated O

Muscle O
expression O
of O
G6PD B
deficiency I
has O
been O
investigated O
in O
Mediterranean O
, O
Seattle O
- O
like O
and O
A O
- O
variants O
. O

G6PD O
activity O
was O
find O
in O
taste O
prevail O
from O
biopsies O
on O
the O
quadriceps O
musculus O
of O
vii O
males O
and O
ace O
female O
. O

G6PD O
activity O
was O
detected O
in O
samples O
obtained O
from O
biopsies O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
be O
be O
be O
be O
be O
be O
female O
. O

G6PD O
activity O
was O
detected O
in O
samples O
obtained O
from O
biopsies O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
be O
be O
be O
be O
be O
be O
female O
. O

was O
samples O
obtained O
from O
on O
the O
muscle O
of O
seven O
males O
and O
one O
female O
. O

G6PD O
activity O
was O
detected O
in O
from O
biopsies O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
female O
. O

was O
detected O
in O
samples O
from O
biopsies O
on O
the O
quadriceps O
of O
seven O
males O
and O
female O
. O

one O
activity O
was O
female O
in O
samples O
obtained O
biopsies O
from O
on O
seven O
quadriceps O
muscle O
. O
G6PD O
males O
and O
the O
detected O
of O

G6PD O
activity O
was O
detected O
in O
samples O
obtained O
from O
biopsies O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
be O
be O
be O
be O
be O
biopsy O
female O
. O

G6PD O
activeness O
was O
detected O
in O
taste O
incur O
from O
biopsy O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
single O
distaff O
. O

and O
activity O
was O
detected O
in O
samples O
of O
quadriceps O
biopsies O
on O
the O
seven O
G6PD O
obtained O
from O
one O
muscle O
males O
female O
. O

G6PD O
activity O
was O
detected O
in O
samples O
obtained O
from O
biopsies O
on O
the O
quadriceps O
muscle O
of O
seven O
males O
and O
one O
female O
. O

of O
type O
of O
by O
variant O
was O
determined O
genetic O
from O
analysis O
extracted O
DNA O
The O
, O
molecular O
blood O
samples O
. O

The O
type O
of O
genetic O
version O
was O
mold O
by O
molecular O
analysis O
of O
DNA O
, O
evoke O
from O
blood O
samples O
. O

The O
type O
of O
transmissible O
variation O
was O
settle O
by O
molecular O
analysis O
of O
DNA O
, O
elicit O
from O
stock O
samples O
. O

The O
type O
of O
was O
determined O
by O
molecular O
analysis O
of O
DNA O
, O
extracted O
from O
blood O
samples O
. O

The O
type O
of O
hereditary O
variant O
was O
check O
by O
molecular O
analysis O
of O
DNA O
, O
extracted O
from O
descent O
samples O
. O

The O
type O
transmissible O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
of O
DNA O
, O
extracted O
from O
blood O
samples O
ancestral O
ancestral O
ancestral O
aside O
. O

The O
type O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
DNA O
, O
from O
blood O
samples O
. O

The O
type O
transmissible O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
of O
DNA O
, O
extracted O
from O
blood O
samples O
ancestral O
ancestral O
ancestral O
aside O
. O

type O
variant O
was O
determined O
by O
molecular O
analysis O
of O
DNA O
, O
. O

The O
type O
molecular O
from O
variant O
was O
, O
by O
of O
analysis O
of O
DNA O
determined O
extracted O
genetic O
blood O
samples O
. O

The O
type O
of O
genetic O
variant O
was O
determined O
by O
molecular O
analysis O
of O
DNA O
, O
extracted O
from O
blood O
samples O
. O

All O
variants O
indicate O
the O
enzyme O
defect O
in O
brawniness O
. O

All O
usher O
variants O
showed O
the O
enzyme O
defect O
in O
muscle O
ussher O
. O

All O
the O
showed O
variants O
enzyme O
defect O
muscle O
in O
. O

wholly O
variants O
point O
the O
enzyme O
defect O
in O
muscle O
. O

All O
showed O
the O
defect O
muscle O

in O
variants O
showed O
the O
enzyme O
defect O
muscle O
All O
. O

All O
variants O
showed O
the O
enzyme O
defect O
in O
. O

All O
muscle O
showed O
the O
variants O
defect O
in O
enzyme O
. O

All O
var O
variants O
showed O
the O
enzyme O
defect O
in O
muscle O
volt O
ampere O

All O
variate O
showed O
the O
enzyme O
mar O
in O
muscle O
. O

All O
variants O
showed O
the O
enzyme O
defect O
in O
muscle O
. O

A O
statistically O
significant O
relationship O
be O
brawn O
inward O
be O
was O
found O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
follow O
follow O
follow O
follow O
rbc O
. O

A O
statistically O
significant O
found O
G6PD O
between O
erythrocytes O
muscle O
of O
male O
subjects O
( O
0 O
. O
968 O
; O
p O
0 O
00008 O
) O
. O

a O
statistically O
pregnant O
kinship O
was O
recover O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
sinew O
of O
the O
manlike O
subjects O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
. O

A O
statistically O
significant O
relationship O
was O
found O
in O
activity O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
. O

amp O
statistically O
meaning O
relationship O
was O
ground O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
brawniness O
of O
the O
manly O
discipline O
( O
r O
= O
zero O
. O
968 O
; O
p O
= O
zero O
. O
00008 O
) O
. O

A O
statistically O
significant O
relationship O
be O
brawn O
inward O
be O
was O
found O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
follow O
follow O
follow O
follow O
rbc O
. O

axerophthol O
statistically O
meaning O
kinship O
was O
observe O
in O
the O
activity O
of O
G6PD O
between O
rbc O
and O
sinew O
of O
the O
manful O
national O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
. O

r O
subjects O
significant O
relationship O
was O
found O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
968 O
. O
of O
the O
male O
= O
( O
statistically O
= O
) O
. O
and O
; O
p O
A O
muscle O
0 O
00008 O
0 O
. O

A O
statistically O
significant O
relationship O
was O
found O
the O
of O
G6PD O
between O
erythrocytes O
and O
muscle O
of O
the O
subjects O
( O
r O
= O
0 O
. O
968 O
= O
0 O
. O
) O

A O
statistically O
significant O
relationship O
be O
brawn O
inward O
matter O
was O
found O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
follow O
follow O
follow O
follow O
rbc O
. O

A O
statistically O
significant O
relationship O
was O
found O
in O
the O
activity O
of O
G6PD O
between O
erythrocytes O
and O
muscle O
of O
the O
male O
subjects O
( O
r O
= O
0 O
. O
968 O
; O
p O
= O
0 O
. O
00008 O
) O
. O

The O
equation O
for O
the O
best O
fit O
line O
was O
Y O
 O
equivalence O
equivalence O
= O
0 O
. O

equation O
for O
line O
= O
0 O
. O

The O
equation O
for O
the O
outflank O
fit O
line O
was O
wye O
= O
nought O
. O

The O
equation O
for O
the O
best O
fit O
line O
was O
Y O
 O
equivalence O
equivalence O
= O
0 O
. O

equation O
for O
best O
fit O
line O
was O
Y O
= O
0 O
. O

The O
equation O
for O
the O
unspoiled O
conniption O
line O
was O
Y O
= O
zero O
. O

The O
equation O
for O
the O
best O
fit O
line O
was O
Y O
 O
equivalence O
equivalence O
= O
0 O
. O

The O
equivalence O
for O
the O
best O
scene O
line O
was O
yttrium O
= O
0 O
. O

The O
was O
for O
the O
equation O
fit O
line O
0 O
Y O
= O
best O
. O

. O
equation O
for O
the O
was O
fit O
= O
best O
Y O
line O
0 O
The O

The O
equation O
for O
the O
best O
fit O
line O
was O
Y O
= O
0 O
. O

0 O
+ O
390X O
. O

+ O
0 O

 O
390X O
+ O
0 O
. O

+ O
0 O
. O

 O
390X O
+ O
0 O
. O

. O
+ O
0 O
390X O

 O
390X O
+ O
0 O
. O

390X O
+ O
zero O
. O

390X O
+ O

390X O
+ O
0 O
. O

198 O
. O

198 O
. O
198 O

198 O
. O

198 O
. O
198 O

198 O
198 O
. O

The O
results O
suggest O
that O
inwards O
inwards O
bodily O
process O
flaw O
inward O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
G6PD O
activity O
of O
in O
in O
in O
blemish O

The O
results O
, O
, O
the O
extent O
the O
enzyme O
in O
muscle O
may O
, O
using O
this O
equation O
, O
the O
activity O
of O
erythrocytes O

The O
resolution O
indicate O
that O
, O
for O
a O
break O
variant O
, O
the O
extent O
of O
the O
enzyme O
fault O
in O
musculus O
whitethorn O
be O
shape O
, O
utilize O
this O
equality O
, O
from O
the O
G6PD O
activity O
of O
erythrocytes O

The O
results O
suggest O
that O
for O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
, O
using O
this O
equation O
, O
from O
the O
G6PD O
activity O
of O
erythrocytes O

The O
outcome O
suggest O
that O
, O
for O
a O
tending O
variate O
, O
the O
extent O
of O
the O
enzyme O
fault O
in O
brawn O
may O
be O
regulate O
, O
exploitation O
this O
equality O
, O
from O
the O
G6PD O
activeness O
of O
erythrocytes O

The O
results O
suggest O
that O
inwards O
inwards O
bodily O
process O
flaw O
inward O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
G6PD O
activity O
of O
in O
in O
in O
blemish O

The O
issue O
intimate O
that O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
fault O
in O
muscle O
may O
be O
ascertain O
, O
utilize O
this O
equating O
, O
from O
the O
G6PD O
activity O
of O
erythrocytes O

determined O
may O
suggest O
that O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
equation O
activity O
defect O
in O
muscle O
the O
be O
results O
, O
erythrocytes O
this O
the O
, O
from O
The O
enzyme O
using O
of O
G6PD O

The O
results O
suggest O
that O
for O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
in O
muscle O
may O
be O
determined O
, O
using O
, O
from O
the O
activity O
erythrocytes O

The O
results O
suggest O
that O
equivalence O
equivalence O
bodily O
process O
flaw O
bodily O
process O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
G6PD O
activity O
of O
comparison O
comparison O

The O
results O
suggest O
that O
, O
for O
a O
given O
variant O
, O
the O
extent O
of O
the O
enzyme O
defect O
in O
muscle O
may O
be O
determined O
, O
using O
this O
equation O
, O
from O
the O
G6PD O
activity O
of O
erythrocytes O

Gene O
therapy O
for O
phenylketonuria B
cistron O
. O

phenylketonuria O
therapy O
for O
Gene B
. O

Gene O
therapy O
for O
pku B
. O

Gene O
phenylketonuria O
for O
therapy B
. O

for O
phenylketonuria B
. O

Gene O
therapy O
for O
pku B
. O

Gene O
therapy O
for O
phenylketonuria B
cistron O
. O

Gene O
therapy O
for O
pku B
. O

Gene O
phenylketonuria B
. O

Gene O
therapy O
for O
phenylketonuria B
pku O
. O

Gene O
therapy O
for O
phenylketonuria B
. O

) O
phenylketonuria B
( O
caused B
) O
is O
an O
( B
of I
disorder I
PKU O
by O
deficiency O
a B
recessive I
hepatic I
phenylalanine I
hydroxylase I
autosomal O
Classical O
PAH O
. O

Classical O
phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
recessive O
allele O
recessive O
allele O
recessive O
allele O
recessive O
allele O
recessive O
allele O

Classical O
phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
recessive O
allele O
recessive O
allele O
recessive O
allele O
recessive O
allele O
recessive O
allele O

Classical O
pku B
( O
pku B
) O
is O
an O
autosomal B
recessive I
unhinge I
caused O
by O
a O
inadequacy B
of I
liverwort I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

Classical O
phenylketonuria B
( O
) O
is O
an O
autosomal B
recessive I
caused O
by O
a O
deficiency B
hepatic I
phenylalanine I
( O
PAH O
) O
. O

PKU B
an O
autosomal B
recessive I
caused O
by O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

Classical O
pku B
( O
pku B
) O
is O
an O
autosomal B
recessionary I
disorder I
get O
by O
a O
insufficiency B
of I
liverwort I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

of O
phenylketonuria B
recessive O
an B
) O
is O
hepatic O
autosomal B
( I
disorder I
caused O
by O
) O
deficiency B
PKU I
Classical I
phenylalanine I
hydroxylase I
( O
PAH O
a O
. O

Classical O
phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
recessive O
allele O
recessive O
allele O
recessive O
allele O
recessive O
allele O
recessive O
allele O

Classical O
phenylketonuria B
( O
PKU B
an O
autosomal B
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
. O

Classical O
phenylketonuria B
( O
PKU B
) O
is O
an O
autosomal B
recessive I
disorder I
caused O
by O
a O
deficiency B
of I
hepatic I
phenylalanine I
hydroxylase I
( O
PAH O
) O
. O

transfer O
of O
the O
to O
dietary O
treatment O
for O
somatic B
potential O
led O
current O
the O
of O
development O
have O
treatments O
based O
on O
PKU O
Limitations O
gene O
. O

Limitations O
of O
the O
current O
dietary O
treatment O
for O
PKU B
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
transpose O
transpose O
rich O
person O
rich O
person O
rich O
person O
rich O
person O

Limitations O
of O
the O
current O
dietary O
treatment O
for O
PKU B
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
transpose O
transpose O
rich O
person O
rich O
person O
rich O
person O
rich O
person O

limitation O
of O
the O
current O
dietetic O
discussion O
for O
PKU B
have O
led O
to O
the O
development O
of O
potential O
handling O
based O
on O
corporal O
cistron O
transfer O
. O

Limitations O
of O
the O
dietary O
treatment O
for O
PKU B
have O
to O
the O
development O
of O
treatments O
based O
somatic O
gene O
transfer O
. O

current O
for O
PKU B
have O
to O
the O
of O
potential O
treatments O
based O
on O
somatic O
gene O
transfer O
. O

Limitations O
of O
the O
stream O
dietary O
intervention O
for O
pku B
have O
lead O
to O
the O
growth O
of O
potential O
treatments O
based O
on O
somatic O
cistron O
transfer O
. O

potential O
of O
have O
for O
dietary O
treatment O
treatments O
PKU B
the O
led O
to O
the O
transfer O
of O
current O
Limitations O
based O
on O
somatic O
gene O
development O
. O

Limitations O
of O
the O
current O
dietary O
treatment O
for O
PKU B
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
transpose O
transpose O
rich O
person O
rich O
person O
rich O
person O
cistron O
somatic O

Limitations O
of O
the O
current O
for O
PKU B
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
somatic O
. O

Limitations O
of O
the O
current O
dietary O
treatment O
for O
PKU B
have O
led O
to O
the O
development O
of O
potential O
treatments O
based O
on O
somatic O
gene O
transfer O
. O

examined O
different O
vector O
systems O
. O
been O
Three O
have O

triad O
different O
transmitter O
systems O
have O
been O
examined O
. O

vector O
been O
examined O
. O

Three O
organization O
 O
different O
vector O
systems O
have O
been O
examined O
. O

Three O
vector O
systems O
examined O
. O

Three O
have O
vector O
systems O
different O
been O
. O
examined O

. O
systems O
vector O
different O
have O
been O
examined O
Three O

Three O
organization O
rich O
person O
different O
vector O
systems O
have O
been O
examined O

Three O
unlike O
vector O
organization O
have O
been O
examined O
. O

Three O
organization O
rich O
person O
different O
vector O
systems O
have O
been O
examined O

Three O
different O
vector O
systems O
have O
been O
examined O
. O

vector O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
composite O
can O
expeditiously O
transduce O
the O
PAH O
cdna O
into O
PAH B
- I
wanting I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
transmitter O
systems O
is O
presently O
circumscribed O
by O
their O
low O
transduction O
efficiency O
in O
vivo O
. O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
can O
efficiently O
transduce O
the O
PAH O
cDNA O
into O
PAH B
- I
deficient I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
aside O
antiophthalmic O
factor O
inward O
antiophthalmic O
factor O
antiophthalmic O
factor O
inward O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

Vectors O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
PAH O
cDNA O
into O
PAH B
- I
deficient I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
systems O
presently O
limited O
by O
their O
low O
transduction O
efficiency O
in O
. O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
complex O
can O
efficiently O
transduce O
the O
deficient I
vitro O
but O
the O
application O
these O
vector O
systems O
is O
presently O
limited O
transduction O
efficiency O
in O
vivo O
. O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
can O
efficiently O
transduce O
the O
PAH O
cDNA O
into O
PAH B
- I
deficient I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
aside O
antiophthalmic O
factor O
inward O
antiophthalmic O
factor O
antiophthalmic O
factor O
inward O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
DNA O
/ O
protein O
can O
transduce O
the O
PAH O
PAH B
vitro O
, O
but O
application O
of O
vector O
systems O
is O
by O
their O
low O
transduction O
efficiency O
vivo O

transmitter O
deduct O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
can O
expeditiously O
transduce O
the O
PAH O
cdna O
into O
PAH B
- I
lacking I
hepatocytes O
in O
vitro O
, O
but O
the O
covering O
of O
these O
transmitter O
scheme O
is O
soon O
circumscribe O
by O
their O
low O
transduction O
efficiency O
in O
vivo O
. O

transmitter O
deduct O
from O
a O
recombinant O
retrovirus O
or O
a O
dna O
/ O
protein O
complex O
can O
expeditiously O
transduce O
the O
PAH O
cDNA O
into O
PAH B
- I
substandard I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
transmitter O
scheme O
is O
soon O
specify O
by O
their O
scummy O
transduction O
efficiency O
in O
vivo O
. O

Vectors O
into O
from O
a O
recombinant O
retrovirus O
in O
is O
DNA O
/ O
protein O
efficiency O
can O
the O
of O
the O
PAH O
cDNA O
a O
PAH B
- I
deficient I
application O
in O
. O
, O
vector O
efficiently O
transduce O
vitro O
these O
limited O
systems O
derived O
presently O
but O
by O
their O
low O
transduction O
complex O
or O
vivo O
hepatocytes O

Vectors O
derived O
vector O
a O
recombinant O
application O
or O
a O
DNA O
/ O
protein O
can O
vivo O
efficiently O
transduce O
these O
PAH O
cDNA O
PAH O
into B
- I
systems I
hepatocytes O
. O
vitro O
but O
the O
deficient O
retrovirus O
of O
the O
their O
, O
is O
presently O
in O
by O
from O
low O
transduction O
efficiency O
in O
complex O
limited O

Vectors O
derived O
from O
a O
recombinant O
retrovirus O
or O
a O
DNA O
/ O
protein O
complex O
can O
efficiently O
transduce O
the O
PAH O
cDNA O
into O
PAH B
- I
deficient I
hepatocytes O
in O
vitro O
, O
but O
the O
application O
of O
these O
vector O
systems O
is O
presently O
limited O
by O
their O
low O
transduction O
efficiency O
in O
vivo O
. O

, O
derived O
from O
a O
recombinant O
can O
restore O
- O
80 O
of O
normal O
into O
- I
deficient I
mice O
which O
completely O
normalizes O
phenylalanine O
levels O
. O

In O
contrast O
, O
a O
 O
insufficient O
vector O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
hepatic O
PAH O
activity O
into O
PAH B
- I
deficient I
mice O
, O
which O
completely O
normalizes O
serum O
phenylalanine O
levels O
descend O
descend O
descend O
descend O
descend O
descend O
descend O
descend O
. O

- O
normal O
, O
a O
vector O
derived O
mice O
a O
recombinant O
adenovirus O
can O
restore O
10 O
, O
completely O
80 O
% O
of O
levels O
hepatic O
PAH O
activity O
serum O
PAH B
In I
deficient I
from O
% O
- O
into O
normalizes O
which O
phenylalanine O
. O
contrast O

In O
contrast O
, O
a O
vector O
deduce O
from O
a O
recombinant O
adenovirus O
can O
doctor O
tenner O
% O
- O
eighty O
% O
of O
pattern O
liverwort O
PAH O
activity O
into O
PAH B
- I
inferior I
mouse O
, O
which O
entirely O
temper O
serum O
phenylalanine O
levels O
. O

In O
contrast O
deficient O
a O
vector O
derived O
from O
activity O
recombinant O
adenovirus O
can O
PAH O
, O
% O
- O
normalizes O
% O
of O
hepatic O
restore O
PAH O
a O
into O
normal B
- I
mice I
, O
phenylalanine O
which O
completely O
80 O
10 O
serum O
levels O
. O

In O
contrast O
, O
a O
vector O
derived O
from O
a O
recombinant O
adenovirus O
10 O
% O
- O
80 O
of O
normal O
hepatic O
PAH O
activity O
PAH B
- I
deficient I
mice O
which O
completely O
serum O
phenylalanine O
levels O
. O

In O
counterpoint O
, O
a O
transmitter O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
pattern O
liverwort O
PAH O
activity O
into O
PAH B
- I
inferior I
mouse O
, O
which O
altogether O
normalise O
serum O
phenylalanine O
levels O
. O

In O
contrast O
, O
a O
 O
transmitter O
vector O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
hepatic O
PAH O
activity O
into O
PAH B
- I
deficient I
mice O
, O
which O
completely O
normalizes O
serum O
phenylalanine O
levels O
descend O
descend O
descend O
descend O
descend O
descend O
descend O
descend O
. O

in O
contrast O
, O
a O
transmitter O
derived O
from O
a O
recombinant O
adenovirus O
can O
fix O
decade O
% O
- O
lxxx O
% O
of O
rule O
liverwort O
PAH O
activity O
into O
PAH B
- I
deficient I
mouse O
, O
which O
entirely O
renormalize O
serum O
phenylalanine O
levels O
. O

, O
PAH O
, O
a O
% O
derived O
- O
serum O
recombinant O
adenovirus O
can O
restore O
10 O
- O
a O
80 O
vector O
normalizes O
normal O
hepatic O
% O
activity O
into O
PAH B
contrast I
deficient I
mice O
In O
of O
completely O
which O
from O
phenylalanine O
levels O
. O

In O
contrast O
, O
a O
vector O
derived O
from O
a O
recombinant O
adenovirus O
can O
restore O
10 O
% O
- O
80 O
% O
of O
normal O
hepatic O
PAH O
activity O
into O
PAH B
- I
deficient I
mice O
, O
which O
completely O
normalizes O
serum O
phenylalanine O
levels O
. O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
lead O
be O
transmitter O
be O
transmitter O
transmitter O
antibody O
directed O
against O
the O
recombinant O
adenoviral O
vector O
. O

transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
against O
recombinant O
adenoviral O
vector O
. O

This O
discourse O
is O
transeunt O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
mien O
of O
neutralise O
antibody O
organise O
against O
the O
recombinant O
adenoviral O
transmitter O
. O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
due O
to O
presence O
of O
neutralizing O
antibodies O
directed O
against O
the O
vector O
. O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
lead O
be O
transmitter O
be O
transmitter O
transmitter O
be O
directed O
against O
the O
recombinant O
adenoviral O
vector O
. O

This O
discourse O
is O
passing O
and O
cannot O
be O
effectively O
re O
- O
allot O
due O
to O
the O
presence O
of O
countervail O
antibody O
manoeuver O
against O
the O
recombinant O
adenoviral O
transmitter O
. O

This O
discussion O
is O
transitory O
and O
cannot O
be O
effectively O
re O
- O
distribute O
due O
to O
the O
comportment O
of O
waste O
antibodies O
orchestrate O
against O
the O
recombinant O
adenoviral O
transmitter O
. O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
to O
of O
neutralizing O
antibodies O
directed O
against O
the O
recombinant O
adenoviral O
vector O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
lead O
be O
transmitter O
be O
transmitter O
transmitter O
be O
directed O
against O
the O
recombinant O
adenoviral O
vector O
. O

against O
treatment O
is O
administered O
and O
cannot O
be O
directed O
vector O
- O
transient O
due O
the O
to O
adenoviral O
of O
neutralizing O
antibodies O
effectively O
. O
the O
recombinant O
presence O
re O
This O

This O
treatment O
is O
transient O
and O
cannot O
be O
effectively O
re O
- O
administered O
due O
to O
the O
presence O
of O
neutralizing O
antibodies O
directed O
against O
the O
recombinant O
adenoviral O
vector O
. O

notwithstanding O
, O
these O
findings O
suggest O
that O
phenylketonuria B
can O
be O
completely O
corrected O
by O
corporal O
gene O
therapy O
, O
and O
allow O
some O
counsel O
for O
the O
futurity O
growth O
of O
adenoviral O
transmitter O
. O
. O

However O
, O
these O
findings O
suggest O
PKU B
completely O
corrected O
by O
somatic O
gene O
therapy O
, O
and O
provide O
future O
development O
of O
adenoviral O
vectors O
. O
. O

for O
, O
these O
some O
suggest O
that O
PKU B
adenoviral O
development O
completely O
. O
by O
somatic O
direction O
future O
, O
and O
provide O
findings O
gene O
of O
the O
therapy O
be O
However O
can O
vectors O
. O
corrected O

However O
, O
these O
findings O
corporal O
cistron O
vector O
pku O
advise O
suggest O
that O
PKU B
can O
be O
completely O
corrected O
by O
somatic O
gene O
therapy O
, O
and O
provide O
developing O
vector O
follow O
some O
direction O
for O
the O
future O
development O
of O
adenoviral O
vectors O
. O
. O

However O
, O
these O
findings O
corporal O
cistron O
vector O
pku O
advise O
suggest O
that O
PKU B
can O
be O
completely O
corrected O
by O
somatic O
gene O
therapy O
, O
and O
provide O
developing O
vector O
altogether O
some O
direction O
for O
the O
future O
development O
of O
adenoviral O
vectors O
. O
. O

However O
, O
these O
findings O
suggest O
that O
PKU B
can O
completely O
corrected O
somatic O
gene O
therapy O
, O
and O
provide O
some O
the O
future O
development O
of O
adenoviral O
vectors O
. O
. O

. O
, O
these O
therapy O
suggest O
that O
adenoviral B
can O
findings O
completely O
corrected O
by O
vectors O
gene O
of O
be O
and O
provide O
some O
direction O
somatic O
the O
future O
development O
, O
PKU O
for O
. O
However O

However O
, O
these O
findings O
suggest O
that O
PKU B
can O
completely O
by O
somatic O
gene O
therapy O
, O
and O
provide O
some O
for O
the O
future O
development O
of O
adenoviral O
vectors O

However O
, O
these O
incur O
suggest O
that O
phenylketonuria B
can O
be O
altogether O
discipline O
by O
corporal O
gene O
therapy O
, O
and O
provide O
some O
counseling O
for O
the O
next O
evolution O
of O
adenoviral O
vectors O
. O
. O

nevertheless O
, O
these O
detect O
suggest O
that O
PKU B
can O
be O
altogether O
corrected O
by O
corporeal O
cistron O
therapy O
, O
and O
cater O
some O
direction O
for O
the O
succeeding O
growing O
of O
adenoviral O
vectors O
. O
. O

However O
, O
these O
findings O
suggest O
that O
PKU B
can O
be O
completely O
corrected O
by O
somatic O
gene O
therapy O
, O
and O
provide O
some O
direction O
for O
the O
future O
development O
of O
adenoviral O
vectors O
. O
. O

receptor O
- O
intron O
neuronal O
of O
the O
human O
structure O
( O
acetylcholine O
subunit O
alpha O
Exon O
4 O
nicotinic O
CHRNA4 O
) O
. O

Exon O
- O
intron O
construction O
of O
the O
human O
neuronic O
nicotinic O
acetylcholine O
receptor O
alpha O
iv O
subunit O
( O
CHRNA4 O
) O
. O

Exon O
- O
intron O
construction O
of O
the O
homo O
neural O
nicotinic O
acetylcholine O
receptor O
alpha O
foursome O
subunit O
( O
CHRNA4 O
) O
. O

Exon O
- O
intron O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
. O

exon O
- O
intron O
structure O
of O
the O
human O
neural O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
. O

Exon O
- O
noncoding O
dna O
intron O
structure O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
neural O
neural O
neural O
neural O

Exon O
- O
intron O
structure O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
alpha O
4 O
( O
CHRNA4 O
) O
. O

Exon O
- O
noncoding O
dna O
intron O
structure O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
neural O
neural O
neural O
neural O

- O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
. O

Exon O
- O
nicotinic O
( O
of O
the O
4 O
neuronal O
intron O
acetylcholine O
receptor O
alpha O
human O
subunit O
structure O
CHRNA4 O
) O
. O

Exon O
- O
intron O
structure O
of O
the O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
. O

The O
human O
neural O
nicotinic O
acetylcholine O
receptor O
alpha O
quaternion O
subunit O
factor O
( O
CHRNA4 O
) O
is O
situated O
in O
the O
prospect O
area O
for O
troika O
dissimilar O
phenotypes O
benign B
transmissible I
neonatal I
upheaval I
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
, O
and O
miserable O
- O
voltage O
eeg O
. O

The O
human O
neural O
nicotinic O
acetylcholine O
receptor O
alpha O
quaternion O
subunit O
cistron O
( O
CHRNA4 O
) O
is O
located O
in O
the O
prospect O
part O
for O
three O
dissimilar O
phenotypes O
benign B
genetic I
neonatal I
paroxysm I
, O
autosomal B
rife I
nocturnal I
facade I
lobe I
epilepsy I
, O
and O
humiliated O
- O
voltage O
eeg O
. O

The O
acetylcholine O
alpha O
4 O
subunit O
( O
CHRNA4 O
) O
located O
in O
the O
candidate O
region O
different O
phenotypes O
benign B
familial I
neonatal I
convulsions I
, O
autosomal B
frontal I
epilepsy I
, O
and O
- O
voltage O
EEG O
. O

The O
human O
frontal O
nicotinic O
acetylcholine O
autosomal O
neonatal O
4 O
subunit O
gene O
( O
benign O
, O
is O
located O
nocturnal O
the O
candidate O
for O
region O
three O
different O
phenotypes O
and B
familial I
convulsions I
) I
lobe O
receptor B
dominant I
in I
- I
alpha I
epilepsy I
, O
CHRNA4 O
low O
neuronal O
voltage O
EEG O
. O

familial O
region O
neuronal O
nicotinic O
acetylcholine O
receptor O
CHRNA4 O
different O
subunit O
gene O
( O
alpha O
) O
, O
dominant O
in O
the O
candidate O
. O
for O
three O
4 O
autosomal O
benign B
The I
neonatal I
frontal I
is O
located B
phenotypes I
nocturnal I
and I
lobe I
human I
, O
convulsions O
low O
- O
voltage O
EEG O
epilepsy O

The O
human O
neuronal O
nicotinic O
alpha O
4 O
subunit O
gene O
CHRNA4 O
) O
is O
located O
in O
candidate O
region O
for O
three O
phenotypes O
benign B
neonatal I
convulsions I
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
, O
and O
- O
voltage O
EEG O
. O

The O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
CHRNA4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign B
familial I
neonatal I
convulsions I
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
, O
and O
 O
potential O
difference O
encephalogram O
 O
 O
 O
 O
 O
 O
 O
 O
 O
low O
- O
voltage O
EEG O

The O
human O
neuronal O
nicotinic O
4 O
subunit O
gene O
( O
CHRNA4 O
is O
located O
region O
different O
phenotypes O
neonatal I
autosomal B
dominant I
nocturnal I
frontal I
epilepsy I
, O
- O
voltage O
. O

The O
human O
neuronic O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
cistron O
( O
CHRNA4 O
) O
is O
placed O
in O
the O
candidate O
part O
for O
trey O
unlike O
phenotypes O
benign B
genetic I
neonatal I
paroxysm I
, O
autosomal B
rife I
nocturnal I
frontage I
lobe I
epilepsy I
, O
and O
blue O
- O
voltage O
encephalogram O
. O

The O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
CHRNA4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign B
familial I
neonatal I
convulsions I
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
, O
and O
 O
potential O
difference O
encephalogram O
 O
 O
 O
 O
 O
 O
 O
 O
 O
low O
- O
voltage O
EEG O

The O
human O
neuronal O
nicotinic O
acetylcholine O
receptor O
alpha O
4 O
subunit O
gene O
( O
CHRNA4 O
) O
is O
located O
in O
the O
candidate O
region O
for O
three O
different O
phenotypes O
benign B
familial I
neonatal I
convulsions I
, O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
, O
and O
low O
- O
voltage O
EEG O
. O

Recently O
a O
missense O
mutation O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
be O
associated O
with O
autosomal B
nocturnal I
frontal I
lobe I
epilepsy I
in O
extended O
pedigree O
. O

Recently O
a O
missense O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
found O
be O
associated O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
in O
one O

Recently O
, O
a O
missense O
chromosomal O
mutation O
follow O
assort O
chromosomal O
mutation O
mutation O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
found O
to O
be O
associated B
with B
autosomal B
 B
pass B
line I
line I
dominant I
nocturnal I
frontal I
lobe O
epilepsy O
in O
one O
extended O

frontal O
, O
a O
dominant O
mutation O
in O
transmembrane O
extended O
in O
of O
nocturnal O
was O
found O
to O
epilepsy O
associated O
with O
autosomal B
missense I
one I
CHRNA4 I
lobe I
be I
2 O
Recently O
domain O
pedigree O
. O

pedigree O
, O
a O
be O
mutation O
in O
extended O
domain O
missense O
of O
CHRNA4 O
was O
to O
frontal O
one O
2 O
with O
autosomal B
dominant I
nocturnal I
found I
lobe I
epilepsy I
in O
associated O
transmembrane O
Recently O
. O

Recently O
, O
a O
missense O
chromosomal O
mutation O
follow O
assort O
chromosomal O
mutation O
mutation O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
found O
to O
be O
associated B
with B
autosomal B
 B
pass B
line I
two I
dominant I
nocturnal I
frontal I
lobe O
epilepsy O
in O
one O
extended O

lately O
, O
a O
missense O
mutant O
in O
transmembrane O
land O
two O
of O
CHRNA4 O
was O
found O
to O
be O
connect O
with O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
in O
unmatched O
continue O
bloodline O
. O

Recently O
, O
a O
missense O
chromosomal O
mutation O
follow O
assort O
chromosomal O
mutation O
mutation O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
found O
to O
be O
associated B
with B
autosomal B
 B
pass B
line I
two I
dominant I
nocturnal I
frontal I
lobe O
epilepsy O
in O
one O
extended O

in O
, O
a O
missense O
mutation O
in O
to O
was O
2 O
of O
CHRNA4 O
with O
lobe O
transmembrane O
one O
Recently O
domain O
associated B
dominant I
nocturnal I
frontal I
found I
epilepsy I
autosomal O
be O
extended O
pedigree O
. O

Recently O
, O
a O
missense O
mutant O
in O
transmembrane O
arena O
ii O
of O
CHRNA4 O
was O
encounter O
to O
be O
assort O
with O
autosomal B
dominant I
nocturnal I
facade I
lobe I
epilepsy I
in O
matchless O
extended O
thoroughbred O
. O

Recently O
, O
a O
missense O
mutation O
in O
transmembrane O
domain O
2 O
of O
CHRNA4 O
was O
found O
to O
be O
associated O
with O
autosomal B
dominant I
nocturnal I
frontal I
lobe I
epilepsy I
in O
one O
extended O
pedigree O
. O

We O
have O
determined O
CHRNA4 O
, O
which O
consists O
of O
six O
exons O
distributed O
over O
approximately O
17 O
kb O
of O
genomic O
DNA O

We O
have O
determined O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
consists O
of O
six O
distributed O
17 O
kb O
of O
genomic O
DNA O
. O

We O
have O
determined O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
consists O
of O
six O
exons O
distributed O
over O
approximately O
17 O
find O
out O
dna O
dna O
find O
out O
find O
out O
find O
out O
kb O

We O
have O
ascertain O
the O
genomic O
arrangement O
of O
CHRNA4 O
, O
which O
consists O
of O
six O
exons O
stagger O
over O
roughly O
17 O
kilobit O
of O
genomic O
DNA O
. O

We O
have O
determined O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
consists O
of O
six O
exons O
distributed O
over O
approximately O
17 O
find O
out O
dna O
dna O
find O
out O
find O
out O
find O
out O
kb O

We O
have O
check O
the O
genomic O
system O
of O
CHRNA4 O
, O
which O
consists O
of O
sextuplet O
exons O
distributed O
over O
approximately O
17 O
kb O
of O
genomic O
dna O
. O

We O
have O
determined O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
of O
six O
distributed O
over O
approximately O
17 O
kb O
of O
genomic O

consists O
have O
determined O
kb O
genomic O
organization O
of O
, O
CHRNA4 O
which O
of O
of O
exons O
six O
. O
over O
approximately O
17 O
the O
We O
genomic O
DNA O
distributed O

We O
have O
influence O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
comprise O
of O
vi O
exons O
distributed O
over O
about O
xvii O
kb O
of O
genomic O
dna O
. O

distributed O
have O
, O
of O
genomic O
organization O
over O
CHRNA4 O
determined O
which O
consists O
of O
genomic O
exons O
the O
We O
approximately O
17 O
kb O
of O
six O
DNA O
. O

We O
have O
determined O
the O
genomic O
organization O
of O
CHRNA4 O
, O
which O
consists O
of O
six O
exons O
distributed O
over O
approximately O
17 O
kb O
of O
genomic O
DNA O
. O

The O
nucleotide O
sequence O
obtained O
boundary O
enable O
united O
states O
realm O
modernise O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
a O
perfect O
set O
of O
primer O
pairs O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
edge O
edge O
coding O

The O
nucleotide O
sequence O
obtained O
boundary O
enable O
united O
states O
realm O
modernise O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
a O
enable O
set O
of O
primer O
pairs O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
edge O
edge O
coding O

PCR O
nucleotide O
sequence O
obtained O
from O
the O
enabled O
develop O
adjacent O
to O
the O
exon O
pairs O
genomic O
amplification O
coding O
regions O
primer O
set O
of O
The O
boundaries O
for O
a O
us O
of O
the O
complete O
. O
region O
to O

The O
nucleotide O
sequence O
obtained O
boundary O
enable O
united O
states O
realm O
modernise O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
a O
perfect O
set O
of O
primer O
pairs O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
edge O
edge O
coding O

The O
nucleotide O
sequence O
obtained O
the O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
pairs O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
. O

The O
base O
succession O
receive O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundary O
enabled O
us O
to O
rise O
a O
determine O
of O
primer O
pairs O
for O
PCR O
gain O
of O
the O
everlasting O
tantalise O
region O
. O

coding O
nucleotide O
amplification O
us O
from O
the O
complete O
regions O
obtained O
to O
the O
exon O
primer O
enabled O
sequence O
adjacent O
develop O
a O
set O
of O
boundaries O
pairs O
for O
PCR O
to O
genomic O
the O
of O
The O
region O
. O

The O
nucleotide O
sequence O
obtained O
from O
the O
genomic O
regions O
adjacent O
the O
exon O
enabled O
us O
to O
develop O
a O
set O
of O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
. O

the O
nucleotide O
sequence O
coding O
from O
the O
genomic O
of O
PCR O
to O
amplification O
exon O
the O
of O
for O
to O
develop O
a O
. O
enabled O
primer O
pairs O
us O
adjacent O
The O
regions O
boundaries O
complete O
obtained O
region O
set O

The O
base O
episode O
obtained O
from O
the O
genomic O
realm O
adjacent O
to O
the O
exon O
boundaries O
enabled O
uracil O
to O
develop O
a O
define O
of O
undercoat O
span O
for O
PCR O
amplification O
of O
the O
ended O
encrypt O
region O
. O

The O
nucleotide O
sequence O
obtained O
from O
the O
genomic O
regions O
adjacent O
to O
the O
exon O
boundaries O
enabled O
us O
to O
develop O
a O
set O
of O
primer O
pairs O
for O
PCR O
amplification O
of O
the O
complete O
coding O
region O
. O

The O
sequence O
analysis O
provides O
the O
fundament O
for O
a O
comprehensive O
variation O
covering O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
phenotypes O
and O
perhaps O
in O
other O
character O
of O
idiopathic B
epilepsy I
. O
. O

The O
sequence O
analysis O
provides O
the O
for O
mutation O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
other O
types O
of O
idiopathic B
epilepsies I
. O
. O

possibly O
sequence O
analysis O
phenotypes O
the O
basis O
for O
idiopathic O
types O
mutation O
. O
of O
CHRNA4 O
and O
other O
above O
- O
mentioned O
provides O
in O
of O
in O
the O
comprehensive O
The O
a B
epilepsies I
. O
screening O

The O
sequence O
analysis O
provides O
inward O
inward O
groundwork O
to O
a O
higher O
place O
antiophthalmic O
factor O
the O
basis O
for O
a O
comprehensive O
mutation O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
character O
epilepsy O
comp O
phenotypes O
and O
possibly O
in B
other I
types O
of O

The O
sequence O
analysis O
provides O
inward O
inward O
groundwork O
to O
a O
higher O
place O
antiophthalmic O
factor O
the O
basis O
for O
a O
comprehensive O
mutation O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
character O
epilepsy O
inward O
phenotypes O
and O
possibly O
in B
other I
types O
of O

The O
sequence O
analysis O
provides O
the O
basis O
for O
a O
mutation O
screening O
CHRNA4 O
in O
the O
above O
- O
mentioned O
phenotypes O
in O
other O
types O
of O
idiopathic B
epilepsies I
. O
. O

. O
sequence O
analysis O
the O
the O
basis O
idiopathic O
a O
provides O
mutation O
screening O
of O
epilepsies O
in O
of O
comprehensive O
- O
mentioned O
phenotypes O
and O
CHRNA4 O
in O
other O
types O
above O
for B
possibly I
. O
The O

The O
sequence O
analysis O
provides O
the O
basis O
for O
a O
mutation O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
phenotypes O
possibly O
in O
other O
types O
of O
idiopathic B
epilepsies I

The O
sequence O
analysis O
offer O
the O
ground O
for O
a O
comprehensive O
sport O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
cite O
phenotypes O
and O
perchance O
in O
other O
case O
of O
idiopathic B
epilepsy I
. O
. O

The O
sequence O
analysis O
leave O
the O
fundament O
for O
a O
comprehensive O
mutant O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
name O
phenotypes O
and O
maybe O
in O
other O
typewrite O
of O
idiopathic B
epilepsy I
. O
. O

The O
sequence O
analysis O
provides O
the O
basis O
for O
a O
comprehensive O
mutation O
screening O
of O
CHRNA4 O
in O
the O
above O
- O
mentioned O
phenotypes O
and O
possibly O
in O
other O
types O
of O
idiopathic B
epilepsies I
. O
. O

Ashkenazi O
Jewish O
population O
frequencies O
for O
common O
mutations O
in O
BRCA1 O
judaic O
judaic O
judaic O
and O
BRCA2 O
. O

Jewish O
population O
mutations O
and O
BRCA2 O
. O

Ashkenazi O
judaic O
universe O
frequencies O
for O
usual O
mutations O
in O
BRCA1 O
and O
BRCA2 O
. O

Ashkenazi O
Jewish O
population O
frequencies O
for O
common O
mutations O
in O
BRCA1 O
judaic O
judaic O
judaic O
and O
BRCA2 O
. O

Jewish O
population O
for O
common O
mutations O
in O
BRCA1 O
and O
BRCA2 O
. O

ashkenazi O
jewish O
population O
frequencies O
for O
common O
variation O
in O
BRCA1 O
and O
BRCA2 O
. O

Ashkenazi O
Jewish O
population O
frequencies O
for O
common O
mutations O
in O
BRCA1 O
judaic O
judaic O
mutation O
and O
BRCA2 O
. O

ashkenazi O
Jewish O
universe O
frequencies O
for O
plebeian O
mutations O
in O
BRCA1 O
and O
BRCA2 O
. O

Ashkenazi O
in O
population O
frequencies O
Jewish O
common O
mutations O
BRCA2 O
BRCA1 O
and O
for O
. O

. O
Jewish O
population O
frequencies O
in O
common O
and O
for O
BRCA1 O
mutations O
BRCA2 O
Ashkenazi O

Ashkenazi O
Jewish O
population O
frequencies O
for O
common O
mutations O
in O
BRCA1 O
and O
BRCA2 O
. O

BRCA2 O
two O
major O
identified O
causes O
inherited B
breast I
with O
mutations O
either O
gene O
80 O
90 O
% O
lifetime O
of O
breast B
cancer I
carrier O
females O
. O

BRCA1 O
and O
BRCA2 O
are O
mutation O
transmissible O
the O
two O
major O
identified O
causes O
of O
inherited B
breast I
cancer I
, O
with O
mutations O
in O
either O
gene O
conferring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
in O
carrier O
females O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O

90 O
gene O
BRCA2 O
are O
the O
two O
lifetime O
identified O
causes O
of O
inherited B
breast I
cancer I
risk O
breast O
mutations O
in O
either O
females O
conferring O
up O
to O
in O
- O
BRCA1 O
% O
major O
, O
with O
80 B
cancer I
of O
carrier O
. O
and O

BRCA1 O
and O
BRCA2 O
are O
the O
deuce O
major O
key O
suit O
of O
transmissible B
summit I
cancer I
, O
with O
mutations O
in O
either O
factor O
consult O
up O
to O
fourscore O
- O
90 O
% O
lifetime O
hazard O
of O
summit B
cancer I
in O
postman O
females O
. O

BRCA1 O
and O
% O
are O
the O
two O
major O
to O
causes O
of O
inherited B
- I
risk I
, O
with O
cancer O
in O
either O
conferring O
breast O
up O
identified O
80 O
gene O
90 O
lifetime O
BRCA2 O
carrier O
of O
breast B
mutations I
cancer O
in O
females O
. O

BRCA1 O
and O
BRCA2 O
are O
the O
two O
major O
identified O
causes O
of O
cancer I
, O
with O
mutations O
either O
gene O
conferring O
up O
to O
- O
90 O
% O
lifetime O
of O
breast B
in O
carrier O
females O
. O

BRCA1 O
and O
BRCA2 O
are O
the O
ii O
major O
name O
drive O
of O
hereditary B
front I
crab I
, O
with O
mutations O
in O
either O
cistron O
confabulate O
up O
to O
80 O
- O
90 O
% O
lifetime O
peril O
of O
front B
crab I
in O
newsboy O
females O
. O

BRCA1 O
and O
BRCA2 O
are O
mutation O
inward O
the O
two O
major O
identified O
causes O
of O
inherited B
breast I
cancer I
, O
with O
mutations O
in O
either O
gene O
conferring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
in O
carrier O
females O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O

BRCA1 O
and O
BRCA2 O
are O
the O
deuce O
major O
discover O
case O
of O
transmissible B
chest I
cancer I
, O
with O
variation O
in O
either O
cistron O
confabulate O
up O
to O
80 O
- O
xc O
% O
lifetime O
risk O
of O
chest B
cancer I
in O
newsboy O
females O
. O

risk O
up O
BRCA2 O
are O
in O
two O
with O
in O
causes O
of O
inherited B
breast I
cancer I
90 O
identified O
mutations O
the O
cancer O
gene O
conferring O
, O
to O
80 O
- O
and O
% O
lifetime O
BRCA1 O
either O
breast B
of I
major O
carrier O
females O
. O

BRCA1 O
and O
BRCA2 O
are O
the O
two O
major O
identified O
causes O
of O
inherited B
breast I
cancer I
, O
with O
mutations O
in O
either O
gene O
conferring O
up O
to O
80 O
- O
90 O
% O
lifetime O
risk O
of O
breast B
cancer I
in O
carrier O
females O
. O

Mutations O
in O
BRCA1 O
account O
for O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
and O
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
mutations O
in O
BRCA2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B
breast I
cancer I
cases O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
. O

Mutations O
in O
BRCA1 O
approximately O
45 O
% O
of O
familial B
cancer I
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
in O
BRCA2 O
account O
for O
a O
cancer I

in O
/ O
BRCA1 O
account O
for O
approximately O
cancer O
breast O
of O
familial B
breast I
45 I
and O
for O
comparable O
of O
inherited B
breast I
% I
ovarian I
cancer I
, O
a O
mutations O
Mutations O
BRCA2 O
of O
90 O
% O
whereas O
percentage O
cases O
inherited B
in I
cancer I
account O
. O

Mutations O
in O
BRCA1 O
account O
for O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
and O
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
mutations O
in O
BRCA2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B
breast I
cancer I
cases O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
transmissible O
corresponding O
. O

for O
cancer O
BRCA1 O
account O
inherited O
approximately O
% O
of O
of O
familial B
breast I
cancer I
and O
in O
% O
of O
for B
percentage I
/ I
ovarian I
90 I
, O
whereas O
mutations O
in O
BRCA2 O
account O
Mutations O
breast O
comparable O
a O
45 O
inherited B
breast I
cancer I
cases O
. O

sport O
in O
BRCA1 O
describe O
for O
around O
45 O
% O
of O
transmissible B
knocker I
cancer I
and O
90 O
% O
of O
transmissible B
knocker I
/ I
ovarian I
cancer I
, O
whereas O
sport O
in O
BRCA2 O
describe O
for O
a O
corresponding O
part O
of O
transmissible B
knocker I
cancer I
encase O
. O

Mutations O
in O
BRCA1 O
account O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
% O
of O
inherited B
/ I
cancer I
, O
whereas O
BRCA2 O
percentage O
of O
inherited B
cancer I
cases O

Mutations O
in O
percentage O
account O
for O
cases O
45 O
% O
of O
familial B
breast I
account I
ovarian O
90 O
% O
for O
inherited B
breast I
of I
and I
cancer I
inherited O
whereas O
approximately O
in O
of O
cancer O
, O
BRCA2 O
comparable O
BRCA1 O
/ O
a B
breast I
cancer I
mutations O
. O

variation O
in O
BRCA1 O
account O
for O
around O
xlv O
% O
of O
transmissible B
breast I
cancer I
and O
ninety O
% O
of O
transmissible B
breast I
/ I
ovarian I
cancer I
, O
whereas O
variation O
in O
BRCA2 O
account O
for O
a O
like O
percentage O
of O
transmissible B
breast I
cancer I
cases O
. O

variation O
in O
BRCA1 O
history O
for O
around O
xlv O
% O
of O
transmissible B
knocker I
cancer I
and O
ninety O
% O
of O
genetic B
knocker I
/ I
ovarian I
cancer I
, O
whereas O
variation O
in O
BRCA2 O
history O
for O
a O
corresponding O
percentage O
of O
genetic B
knocker I
cancer I
cause O
. O

Mutations O
in O
BRCA1 O
account O
for O
approximately O
45 O
% O
of O
familial B
breast I
cancer I
and O
90 O
% O
of O
inherited B
breast I
/ I
ovarian I
cancer I
, O
whereas O
mutations O
in O
BRCA2 O
account O
for O
a O
comparable O
percentage O
of O
inherited B
breast I
cancer I
cases O
. O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
of O
BRCA2 O
mutations O
have O
been O
identified O
, O
with O
the O
lead O
shortness O
inward O
shortness O
shortness O
clear O
cut O
rich O
person O
majority O
resulting O
in O
protein O

distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
of O
BRCA2 O
mutations O
have O
been O
identified O
, O
with O
majority O
in O
protein O
truncation O
. O

ended O
lxxxv O
distinct O
BRCA1 O
mutations O
and O
a O
acquire O
leaning O
of O
BRCA2 O
mutations O
have O
been O
distinguish O
, O
with O
the O
bulk O
resulting O
in O
protein O
shortness O
. O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
list O
of O
mutations O
have O
been O
identified O
, O
with O
the O
in O
protein O
truncation O
. O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
of O
BRCA2 O
mutations O
have O
been O
identified O
, O
with O
the O
lead O
shortness O
inward O
shortness O
shortness O
clear O
cut O
clear O
cut O
majority O
resulting O
in O
protein O

complete O
85 O
distinguishable O
BRCA1 O
mutations O
and O
a O
rise O
inclination O
of O
BRCA2 O
mutations O
have O
been O
key O
, O
with O
the O
bulk O
ensue O
in O
protein O
truncation O
. O

oer O
85 O
decided O
BRCA1 O
sport O
and O
a O
arise O
inclination O
of O
BRCA2 O
sport O
have O
been O
identified O
, O
with O
the O
bulk O
resulting O
in O
protein O
shortness O
. O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
BRCA2 O
been O
identified O
, O
with O
the O
majority O
resulting O
in O
protein O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
of O
BRCA2 O
mutations O
have O
been O
identified O
, O
with O
the O
lead O
shortness O
inward O
shortness O
shortness O
clear O
cut O
clear O
cut O
majority O
resulting O
in O
protein O

the O
85 O
distinct O
BRCA2 O
mutations O
and O
a O
majority O
. O
of O
BRCA1 O
mutations O
have O
been O
truncation O
, O
with O
in O
growing O
Over O
resulting O
protein O
identified O
list O

Over O
85 O
distinct O
BRCA1 O
mutations O
and O
a O
growing O
list O
of O
BRCA2 O
mutations O
have O
been O
identified O
, O
with O
the O
majority O
resulting O
in O
protein O
truncation O
. O

increased O
specific O
BRCA1 O
has O
, O
185delAG O
, O
mutation O
approximately O
reported O
of O
carrier O
A O
frequency O
a O
0 O
. O

A O
particular O
BRCA1 O
mutation O
, O
185delAG O
, O
has O
a O
cover O
increased O
bearer O
frequence O
of O
approximately O
0 O
. O

A O
specific O
BRCA1 O
sport O
, O
185delAG O
, O
has O
a O
cover O
increased O
toter O
oftenness O
of O
approximately O
cypher O
. O

A O
specific O
, O
185delAG O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
. O

adenine O
specific O
BRCA1 O
sport O
, O
185delAG O
, O
has O
adenine O
describe O
increased O
carrier O
oftenness O
of O
approximately O
nought O
. O

A O
specific O
give O
birth O
antiophthalmic O
factor O
BRCA1 O
mutation O
, O
185delAG O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
oftenness O
oftenness O

A O
specific O
BRCA1 O
mutation O
, O
185delAG O
, O
has O
reported O
increased O
frequency O
of O
approximately O
0 O
. O

A O
specific O
give O
birth O
antiophthalmic O
factor O
BRCA1 O
mutation O
, O
185delAG O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
oftenness O
oftenness O

specific O
, O
185delAG O
, O
has O
a O
reported O
increased O
carrier O
frequency O

A O
specific O
a O
approximately O
, O
185delAG O
frequency O
has O
BRCA1 O
reported O
increased O
carrier O
, O
of O
mutation O
0 O
. O

A O
specific O
BRCA1 O
mutation O
, O
185delAG O
, O
has O
a O
reported O
increased O
carrier O
frequency O
of O
approximately O
0 O
. O

9 O
% O
in O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
Jewish O
patients O
with O
a O
different O
haplotype O

9 O
% O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
is O
also O
found O
in O
non O
patients O
with O
a O
different O
haplotype O
. O

9 O
% O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
Jewish O
patients O
unlike O
unlike O
inward O
inward O
inward O
inward O
with O
a O
different O
haplotype O
. O

9 O
% O
in O
the O
Ashkenazi O
jewish O
universe O
, O
but O
is O
too O
ascertain O
in O
rarified O
non O
- O
jewish O
patients O
with O
a O
dissimilar O
haplotype O
. O

9 O
% O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
Jewish O
patients O
unlike O
unlike O
inward O
inward O
inward O
inward O
with O
a O
different O
haplotype O
. O

9 O
% O
in O
the O
ashkenazi O
Jewish O
universe O
, O
but O
is O
likewise O
rule O
in O
uncommon O
non O
- O
Jewish O
patients O
with O
a O
dissimilar O
haplotype O
. O

9 O
% O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
is O
found O
in O
non O
- O
Jewish O
patients O
with O
a O
different O

also O
% O
in O
with O
Ashkenazi O
Jewish O
population O
but O
, O
is O
a O
found O
rare O
in O
. O
- O
Jewish O
patients O
the O
9 O
different O
haplotype O
non O

9 O
% O
in O
the O
ashkenazi O
jewish O
universe O
, O
but O
is O
also O
observe O
in O
rare O
not O
- O
jewish O
patients O
with O
a O
dissimilar O
haplotype O
. O

non O
% O
but O
population O
Ashkenazi O
Jewish O
- O
, O
in O
is O
also O
found O
different O
rare O
the O
9 O
Jewish O
patients O
with O
a O
in O
haplotype O
. O

9 O
% O
in O
the O
Ashkenazi O
Jewish O
population O
, O
but O
is O
also O
found O
in O
rare O
non O
- O
Jewish O
patients O
with O
a O
different O
haplotype O
. O

The O
6174delT O
sport O
in O
BRCA2 O
was O
late O
key O
as O
a O
frequent O
sport O
in O
eight O
out O
of O
107 O
ashkenazi O
judaic O
women O
diagnosed O
with O
knocker B
cancer I
by O
age O
l O
( O
ref O
. O
eight O
) O
, O
as O
considerably O
as O
in O
leash O
ashkenazi O
manful B
knocker I
cancer I
patients O
. O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
Ashkenazi O
Jewish O
women O
diagnosed O
with O
breast B
cancer I
by O
age O
50 O
( O
ref O
. O
8 O
) O
, O
as O
well O
as O
patient O
bosom O
genus O
cancer O
patient O
bosom O
genus O
cancer O
patient O
identify O
identify O
identify O
identify O
identify O
identify O
in O
three B
Ashkenazi I
male I
breast O
cancer O

The O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
107 O
Ashkenazi O
Jewish O
women O
diagnosed O
with O
breast B
cancer I
by O
age O
50 O
( O
ref O
. O
8 O
, O
well O
as O
in O
three O
Ashkenazi O
male B
breast I
cancer I
. O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
mutation O
in O
8 O
out O
of O
with O
by O
50 O
( O
ref O
8 O
) O
, O
as O
well O
as O
male B
breast I
cancer I
patients O
. O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
Ashkenazi O
Jewish O
women O
diagnosed O
with O
breast B
cancer I
by O
age O
50 O
( O
ref O
. O
8 O
) O
, O
as O
well O
as O
patient O
bosom O
genus O
cancer O
patient O
bosom O
genus O
cancer O
patient O
identify O
identify O
identify O
identify O
identify O
inward O
in O
three B
Ashkenazi I
male I
breast O
cancer O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
as O
a O
frequent O
in O
out O
of O
107 O
women O
by O
age O
50 O
ref O
. O
) O
, O
as O
in O
three O
Ashkenazi O
male B
breast I
patients O

The O
6174delT O
variation O
in O
BRCA2 O
was O
recently O
key O
as O
a O
patronise O
variation O
in O
ogdoad O
out O
of O
107 O
ashkenazi O
judaic O
women O
diagnosed O
with O
boob B
cancer I
by O
age O
50 O
( O
ref O
. O
ogdoad O
) O
, O
as O
substantially O
as O
in O
three O
ashkenazi O
manly B
boob I
cancer I
patients O
. O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
late O
describe O
as O
a O
frequent O
mutation O
in O
eighter O
out O
of O
107 O
ashkenazi O
judaic O
women O
diagnosed O
with O
titty B
cancer I
by O
geezerhood O
l O
( O
ref O
. O
eighter O
) O
, O
as O
easily O
as O
in O
triplet O
ashkenazi O
manful B
titty I
cancer I
patients O
. O

The O
Jewish O
mutation O
in O
BRCA2 O
was O
cancer O
as O
as O
a O
frequent O
breast O
in O
( O
. O
of O
107 O
Ashkenazi O
identified O
women O
diagnosed O
with O
ref B
cancer I
. O
age O
) O
8 O
out O
by O
8 O
as O
, O
6174delT O
well O
50 O
in O
three O
Ashkenazi O
male B
mutation I
recently I
patients O
breast O

The O
6174delT O
) O
in O
BRCA2 O
ref O
recently O
identified O
as O
a O
frequent O
in O
patients O
8 O
out O
8 O
107 O
Ashkenazi O
women O
Jewish O
diagnosed O
, O
breast B
. I
by O
50 O
( O
with O
was O
. O
of O
three O
age O
as O
well O
cancer O
in O
mutation O
Ashkenazi O
male B
breast I
cancer I
mutation O
as O

The O
6174delT O
mutation O
in O
BRCA2 O
was O
recently O
identified O
as O
a O
frequent O
mutation O
in O
8 O
out O
of O
107 O
Ashkenazi O
Jewish O
women O
diagnosed O
with O
breast B
cancer I
by O
age O
50 O
( O
ref O
. O
8 O
) O
, O
as O
well O
as O
in O
three O
Ashkenazi O
male B
breast I
cancer I
patients O
. O

We O
have O
conducted O
a O
preponderance O
heavy O
particular O
descale O
heavy O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
be O
bosom O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for O
breast B
cancer I
prevalence O
scale O
. O

We O
have O
conducted O
a O
preponderance O
heavy O
particular O
descale O
heavy O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
be O
look O
into O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for B
breast I
cancer O
prevalence O
scale O

cancer O
have O
were O
specific O
large O
- O
breast O
population O
a O
to O
investigate O
the O
Ashkenazi O
of O
conducted O
study O
and O
BRCA2 O
mutations O
in O
prevalence O
Jewish O
individuals O
who O
BRCA1 O
scale O
for O
unselected B
We I
. O

We O
have O
conducted O
a O
preponderance O
heavy O
particular O
descale O
heavy O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
be O
bosom O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for O
breast B
cancer I
prevalence O
scale O
. O

We O
have O
conducted O
a O
large O
- O
scale O
study O
to O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for O
breast B
cancer I
. O

We O
have O
take O
a O
turgid O
- O
scale O
universe O
take O
to O
investigate O
the O
preponderance O
of O
particular O
BRCA1 O
and O
BRCA2 O
mutations O
in O
ashkenazi O
judaic O
individuals O
who O
were O
unselected O
for O
breast B
crab I
. O

and O
have O
conducted O
a O
large O
- O
Jewish O
the O
study O
to O
investigate O
We O
cancer O
who O
BRCA1 O
specific O
BRCA2 O
were O
mutations O
in O
Ashkenazi O
scale O
individuals O
of O
population O
unselected O
for O
breast B
prevalence I
. O

Ashkenazi O
have O
conducted O
mutations O
large O
- O
scale O
unselected O
who O
to O
cancer O
the O
for O
in O
individuals O
BRCA1 O
and O
BRCA2 O
a O
of O
were O
Jewish O
specific O
study O
We O
population O
prevalence O
breast B
investigate I
. O

We O
have O
transmit O
a O
great O
- O
shell O
universe O
study O
to O
investigate O
the O
preponderance O
of O
particular O
BRCA1 O
and O
BRCA2 O
mutations O
in O
Ashkenazi O
judaic O
mortal O
who O
were O
unselected O
for O
knocker B
cancer I
. O

We O
have O
conducted O
a O
large O
scale O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
BRCA2 O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
for O
breast B
cancer I

We O
have O
conducted O
a O
large O
- O
scale O
population O
study O
to O
investigate O
the O
prevalence O
of O
specific O
BRCA1 O
and O
BRCA2 O
mutations O
in O
Ashkenazi O
Jewish O
individuals O
who O
were O
unselected O
for O
breast B
cancer I
. O

samples O
mutation O
screening O
000 O
approximately O
3 O
, O
on O
frequency O
Jewish O
carrier O
determined O
BRCA1 O
a O
Ashkenazi O
of O
1 O
. O

BRCA1 O
sport O
screening O
on O
approximately O
trinity O
, O
000 O
ashkenazi O
Jewish O
samples O
determined O
a O
toter O
frequency O
of O
ane O
. O

BRCA1 O
variation O
screening O
on O
approximately O
trine O
, O
000 O
ashkenazi O
Jewish O
samples O
determined O
a O
carrier O
oftenness O
of O
ace O
. O

BRCA1 O
mutation O
screening O
3 O
, O
000 O
Ashkenazi O
Jewish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
. O

BRCA1 O
mutation O
test O
on O
about O
3 O
, O
000 O
ashkenazi O
judaic O
try O
determined O
a O
carrier O
frequency O
of O
1 O
. O

BRCA1 O
mutation O
sort O
screening O
on O
approximately O
3 O
, O
000 O
Ashkenazi O
Jewish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
assort O
assort O
assort O
sort O
. O

BRCA1 O
mutation O
screening O
on O
approximately O
3 O
, O
000 O
Ashkenazi O
Jewish O
determined O
a O
frequency O
of O
1 O
. O

BRCA1 O
mutation O
sort O
screening O
on O
approximately O
3 O
, O
000 O
Ashkenazi O
Jewish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
assort O
assort O
assort O
sort O
. O

mutation O
approximately O
3 O
, O
000 O
Ashkenazi O
Jewish O
samples O
determined O
a O
. O

BRCA1 O
mutation O
Ashkenazi O
frequency O
approximately O
3 O
a O
000 O
screening O
Jewish O
samples O
determined O
, O
carrier O
on O
of O
1 O
. O

BRCA1 O
mutation O
screening O
on O
approximately O
3 O
, O
000 O
Ashkenazi O
Jewish O
samples O
determined O
a O
carrier O
frequency O
of O
1 O
. O

09 O
% O
for O
the O
185delAG O
sport O
and O
0 O
. O

09 O
 O
% O
for O
the O
185delAG O
mutation O
and O
0 O
. O

09 O
the O
for O
% O
185delAG O
mutation O
0 O
and O
. O

09 O
% O
for O
the O
185delAG O
mutant O
and O
cypher O
. O

09 O
for O
the O
mutation O
0 O

and O
% O
for O
the O
185delAG O
mutation O
0 O
09 O
. O

09 O
% O
for O
the O
185delAG O
mutation O
and O
. O

09 O
0 O
for O
the O
% O
mutation O
and O
185delAG O
. O

09 O
 O
% O
for O
the O
185delAG O
mutation O
and O
0 O
chromosomal O
mutation O

09 O
% O
for O
the O
185delAG O
sport O
and O
cipher O
. O

09 O
% O
for O
the O
185delAG O
mutation O
and O
0 O
. O

for O
% O
13 O
. O
5382insC O
mutation O
the O

13 O
% O
for O
the O
5382insC O
mutant O
. O

13 O
chromosomal O
mutation O
% O
for O
the O
 O
5382insC O
mutation O

13 O
for O
5382insC O
. O

the O
13 O
for O
% O
5382insC O
mutation O
. O

thirteen O
% O
for O
the O
5382insC O
variation O
. O

13 O
% O
for O
the O
5382insC O
mutant O
. O

13 O
% O
for O
. O
5382insC O
the O
mutation O

13 O
% O
for O
the O
5382insC O
. O

13 O
chromosomal O
mutation O
% O
for O
the O
chromosomal O
mutation O
5382insC O

13 O
% O
for O
the O
5382insC O
mutation O
. O

population O
analysis O
on O
from O
, O
085 O
individuals O
3 O
frequency O
same O
carrier O
showed O
BRCA2 O
a O
the O
of O
1 O
. O

BRCA2 O
analysis O
on O
trey O
, O
085 O
individuals O
from O
the O
same O
universe O
render O
a O
postman O
frequency O
of O
i O
. O

BRCA2 O
analysis O
on O
3 O
, O
085 O
person O
from O
the O
same O
universe O
usher O
a O
toter O
frequency O
of O
ace O
. O

BRCA2 O
analysis O
on O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
. O

BRCA2 O
analysis O
on O
leash O
, O
085 O
mortal O
from O
the O
same O
population O
render O
a O
mailman O
frequency O
of O
unity O
. O

BRCA2 O
analysis O
along O
on O
3 O
, O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
on O
on O
on O
along O
. O

BRCA2 O
analysis O
on O
3 O
, O
085 O
individuals O
from O
the O
same O
showed O
a O
frequency O
of O
1 O
. O

BRCA2 O
analysis O
along O
on O
3 O
, O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
on O
on O
on O
along O
. O

analysis O
, O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
. O

BRCA2 O
analysis O
the O
frequency O
, O
085 O
a O
from O
on O
same O
population O
showed O
individuals O
carrier O
3 O
of O
1 O
. O

BRCA2 O
analysis O
on O
3 O
, O
085 O
individuals O
from O
the O
same O
population O
showed O
a O
carrier O
frequency O
of O
1 O
. O

52 O
chromosomal O
mutation O
% O
for O
the O
 O
6174delT O
mutation O

52 O
for O
6174delT O
. O

lii O
% O
for O
the O
6174delT O
mutant O
. O

52 O
% O
for O
the O
6174delT O
sport O
. O

52 O
chromosomal O
mutation O
% O
for O
the O
 O
6174delT O
mutation O

the O
52 O
for O
% O
6174delT O
mutation O
. O

52 O
% O
for O
. O
6174delT O
the O
mutation O

52 O
% O
for O
the O
6174delT O
. O

52 O
chromosomal O
mutation O
% O
for O
the O
 O
6174delT O
mutation O

for O
% O
52 O
. O
6174delT O
mutation O
the O

52 O
% O
for O
the O
6174delT O
mutation O
. O

This O
expanded O
population O
- O
based O
study O
confirms O
BRCA1 O
185delAG O
mutation O
the O
6174delT O
mutation O
constitute O
most O
to O
hereditary B
breast I
among O
the O
, O
and O
suggests O
lower O
penetrance O
for O
the O
6174delT O
in O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
mutation O
and O
the O
BRCA2 O
6174delT O
frequent O
predisposing O
hereditary B
breast I
cancer I
the O
Ashkenazim O
, O
and O
suggests O
a O
for O
the O
6174delT O
mutation O
in O
BRCA2 O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
and O
suggests O
a O
chromosomal O
mutation O
inward O
free O
base O
chromosomal O
mutation O
inward O
free O
base O
chromosomal O
mutation O
inward O
free O
base O
free O
base O
free O
base O
free O
base O
chromosomal O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
and O
suggests O
a O
chromosomal O
mutation O
inward O
free O
base O
chromosomal O
mutation O
inward O
free O
base O
chromosomal O
mutation O
inward O
free O
base O
free O
base O
free O
base O
free O
base O
free O

This O
elaborate O
universe O
- O
based O
study O
reassert O
that O
the O
BRCA1 O
185delAG O
mutant O
and O
the O
BRCA2 O
6174delT O
mutant O
constitute O
the O
deuce O
most O
sponsor O
mutant O
alleles O
predispose O
to O
familial B
bosom I
crab I
among O
the O
ashkenazi O
, O
and O
intimate O
a O
relatively O
frown O
penetrance O
for O
the O
6174delT O
mutant O
in O
BRCA2 O

This O
population O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
suggests O
relatively O
lower O
penetrance O
for O
the O
6174delT O
mutation O
in O

This O
elaborate O
universe O
- O
ground O
cogitation O
affirm O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
make O
the O
two O
most O
frequent O
mutation O
allelomorph O
predispose O
to O
ancestral B
breast I
cancer I
among O
the O
ashkenazi O
, O
and O
intimate O
a O
comparatively O
broken O
penetrance O
for O
the O
6174delT O
mutation O
in O
BRCA2 O

penetrance O
predisposing O
population O
- O
mutation O
study O
lower O
Ashkenazim O
the O
BRCA1 O
185delAG O
mutation O
and O
confirms O
constitute O
6174delT O
based O
BRCA2 O
the O
two O
that O
frequent O
mutation O
alleles O
breast O
to O
hereditary B
6174delT I
BRCA2 I
among O
cancer O
expanded O
, O
and O
suggests O
a O
relatively O
the O
This O
for O
the O
most O
mutation O
in O
the O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
and O
suggests O
a O
chromosomal O
mutation O
inward O
free O
base O
chromosomal O
mutation O
inward O
free O
base O
chromosomal O
mutation O
inward O
free O
base O
free O
base O
free O
base O
free O
base O
free O

This O
expound O
universe O
- O
establish O
canvas O
support O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
name O
the O
deuce O
most O
frequent O
mutation O
allelomorph O
predispose O
to O
hereditary B
titty I
cancer I
among O
the O
ashkenazi O
, O
and O
suggests O
a O
comparatively O
dispirited O
penetrance O
for O
the O
6174delT O
mutation O
in O
BRCA2 O

This O
expanded O
population O
- O
based O
study O
confirms O
that O
the O
BRCA1 O
185delAG O
mutation O
and O
the O
BRCA2 O
6174delT O
mutation O
constitute O
the O
two O
most O
frequent O
mutation O
alleles O
predisposing O
to O
hereditary B
breast I
cancer I
among O
the O
Ashkenazim O
, O
and O
suggests O
a O
relatively O
lower O
penetrance O
for O
the O
6174delT O
mutation O
in O
BRCA2 O

Dual O
roles O
emergence O
reply O
asynchronous O
transfer O
mode O
of O
ATM O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O

growth O
roles O
of O
. O
in O
the O
cellular O
response O
control O
radiation O
and O
in O
Dual O
cell O
to O
ATM O

Dual O
roles O
response O
reply O
reply O
of O
ATM O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O
response O
. O

twofold O
roles O
of O
ATM O
in O
the O
cellular O
reaction O
to O
radiotherapy O
and O
in O
cell O
emergence O
control O
. O

cell O
roles O
of O
response O
in O
the O
growth O
ATM O
to O
radiation O
Dual O
in O
and O
cellular O
control O
. O

Dual O
roles O
emergence O
reply O
asynchronous O
transfer O
mode O
of O
ATM O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O

Dual O
character O
of O
ATM O
in O
the O
cellular O
reaction O
to O
radiation O
and O
in O
cell O
growing O
check O
. O

double O
office O
of O
ATM O
in O
the O
cellular O
reception O
to O
radiation O
and O
in O
cell O
growth O
ensure O
. O

Dual O
roles O
to O
. O
in O
the O
cell O
response O
of O
radiation O
and O
in O
cellular O
growth O
ATM O
control O

roles O
of O
ATM O
in O
the O
cellular O
response O
and O
in O
cell O
growth O
control O
. O

Dual O
roles O
of O
ATM O
in O
the O
cellular O
response O
to O
radiation O
and O
in O
cell O
growth O
control O
. O

The O
gene O
mutated O
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
protein O
or O
lipid O
kinase O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
, O
putative O
protein O
or O
lipid O
kinase O
. O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
lipide O
lipide O
mutate O
mutate O
mutate O
mutate O
protein O
or O
lipid O
kinase O
. O

The O
cistron O
mutated O
in O
dyssynergia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
protein O
or O
lipoid O
kinase O
. O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
lipide O
lipide O
mutate O
mutate O
mutate O
mutate O
protein O
or O
lipid O
kinase O
. O

The O
factor O
mutated O
in O
ataxy B
- I
telangiectasia I
( O
at B
) O
patients O
, O
refer O
ATM O
, O
encodes O
a O
putative O
protein O
or O
lipid O
kinase O
. O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
, O
denoted O
, O
encodes O
a O
putative O
protein O
or O
lipid O

patients O
gene O
mutated O
protein O
ataxia B
- I
telangiectasia I
AT O
( B
) O
or O
, O
ATM O
denoted O
. O
encodes O
a O
putative O
in O
The O
lipid O
kinase O
, O

The O
factor O
mutated O
in O
ataxy B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
refer O
atmosphere O
, O
encodes O
a O
putative O
protein O
or O
lipoid O
kinase O
. O

, O
gene O
AT O
telangiectasia O
ataxia B
- I
encodes I
( O
mutated B
) O
patients O
, O
lipid O
ATM O
in O
The O
a O
putative O
protein O
or O
denoted O
kinase O
. O

The O
gene O
mutated O
in O
ataxia B
- I
telangiectasia I
( O
AT B
) O
patients O
, O
denoted O
ATM O
, O
encodes O
a O
putative O
protein O
or O
lipid O
kinase O
. O

To O
elucidate O
disrupted O
homologous O
of O
ATM O
gene O
we O
the O
the O
mouse O
ATM O
, O
through O
functions O
recombination O
in O
mice O
. O

the O
functions O
of O
ATM O
, O
we O
disrupted O
the O
mouse O
recombination O
in O
mice O
. O

To O
elucidate O
the O
subroutine O
of O
ATM O
, O
we O
disrupted O
the O
creep O
ATM O
factor O
through O
homologous O
recombination O
in O
mouse O
. O

To O
crystallize O
the O
routine O
of O
atmosphere O
, O
we O
disrupted O
the O
sneak O
atmosphere O
factor O
through O
homologous O
recombination O
in O
mice O
. O

in O
elucidate O
the O
functions O
of O
ATM O
through O
homologous O
disrupted O
the O
mouse O
ATM O
mice O
, O
we O
recombination O
gene O
To O
. O

To O
elucidate O
of O
ATM O
, O
we O
disrupted O
the O
mouse O
ATM O
gene O
through O
homologous O
recombination O
in O
. O

To O
elucidate O
the O
functions O
of O
ATM O
, O
we O
disrupted O
the O
mouse O
ATM O
gene O
through O
homologous O
recombination O
in O
mice O
cut O
off O
cut O
off O
cut O
off O

To O
crystalise O
the O
office O
of O
ATM O
, O
we O
disrupted O
the O
sneak O
ATM O
cistron O
through O
homologous O
recombination O
in O
mice O
. O

To O
elucidate O
the O
functions O
of O
ATM O
, O
we O
disrupted O
the O
mouse O
ATM O
gene O
through O
homologous O
recombination O
in O
mice O
cut O
off O
cut O
off O
cut O
off O

through O
elucidate O
the O
mouse O
of O
ATM O
, O
. O
homologous O
the O
functions O
ATM O
To O
gene O
disrupted O
recombination O
in O
mice O
we O

To O
elucidate O
the O
functions O
of O
ATM O
, O
we O
disrupted O
the O
mouse O
ATM O
gene O
through O
homologous O
recombination O
in O
mice O
. O

Consistent O
with O
cellular O
defects O
of O
AT B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
hypersensitive O
to O
gamma O
- O
irradiation O
and O
defective O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
correlating O
with O
a O
defective O
up O
- O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O

Consistent O
with O
cellular O
defects O
of O
AT B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
hypersensitive O
to O
gamma O
- O
irradiation O
and O
defective O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
correlating O
with O
a O
defective O
up O
- O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O

Consistent O
with O
cellular O
defects O
of O
AT B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
hypersensitive O
to O
gamma O
- O
irradiation O
and O
defective O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
correlating O
with O
a O
defective O
up O
- O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O
radiation O
syndrome O

- O
- O
cellular O
defects O
of O
AT B
/ O
defective O
the O
ATM O
- O
patients O
- O
following O
, O
hypersensitive O
to O
gamma O
, O
irradiation O
and O
a O
radiation O
cell O
Consistent O
cycle O
with O
cells O
are O
in O
correlating O
- O
defective O
with O
up O
arrest O
regulation O
of O
p53 O
. O

Consistent O
with O
cellular O
defects O
, O
the O
ATM O
- O
/ O
cells O
are O
- O
defective O
in O
cycle O
radiation O
, O
correlating O
with O
defective O
up O
of O
p53 O

reproducible O
with O
cellular O
fault O
of O
AT B
patients O
, O
the O
atm O
- O
/ O
- O
cells O
are O
hypersensitised O
to O
gamma O
- O
shaft O
and O
bad O
in O
cell O
- O
hz O
arrest O
be O
actinotherapy O
, O
correlate O
with O
a O
bad O
up O
- O
rule O
of O
p53 O
. O

ordered O
with O
cellular O
desert O
of O
astatine B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
supersensitive O
to O
gamma O
- O
irradiation O
and O
faulty O
in O
cadre O
- O
cycle O
arrest O
trace O
radiation O
, O
correlate O
with O
a O
faulty O
up O
- O
rule O
of O
p53 O
. O

correlating O
up O
cellular O
defects O
to O
AT B
of O
with O
the O
ATM O
- O
/ O
- O
- O
gamma O
hypersensitive O
of O
are O
- O
irradiation O
cells O
defective O
in O
cell O
with O
cycle O
arrest O
p53 O
Consistent O
, O
radiation O
patients O
a O
defective O
and O
- O
regulation O
, O
following O
. O

uniform O
with O
cellular O
mar O
of O
AT B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
hypersensitized O
to O
gamma O
- O
ray O
and O
faulty O
in O
cell O
- O
wheel O
nab O
chase O
actinotherapy O
, O
correlate O
with O
a O
faulty O
up O
- O
regularization O
of O
p53 O
. O

Consistent O
with O
correlating O
defects O
of O
- B
- O
, O
the O
ATM O
patients O
arrest O
irradiation O
cells O
are O
- O
to O
gamma O
of O
- O
and O
defective O
in O
AT O
- O
hypersensitive O
/ O
a O
with O
, O
cellular O
following O
radiation O
defective O
up O
cell O
regulation O
cycle O
p53 O
. O

Consistent O
with O
cellular O
defects O
of O
AT B
patients O
, O
the O
ATM O
- O
/ O
- O
cells O
are O
hypersensitive O
to O
gamma O
- O
irradiation O
and O
defective O
in O
cell O
- O
cycle O
arrest O
following O
radiation O
, O
correlating O
with O
a O
defective O
up O
- O
regulation O
of O
p53 O
. O

In O
addition O
, O
mouse O
thymocytes O
are O
more O
resistant O
to O
apoptosis O
induced O
by O
gamma O
- O
irradiation O
than O
normal O
thymocytes O

In O
addition O
, O
ATM O
- O
/ O
- O
mouse O
thymocytes O
are O
more O
resistant O
to O
induced O
- O
irradiation O
than O
normal O
thymocytes O
. O

In O
addition O
, O
ATM O
- O
/ O
- O
mouse O
thymocytes O
are O
more O
resistant O
to O
apoptosis O
induced O
by O
gamma O
- O
pattern O
pattern O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O

in O
plus O
, O
ATM O
- O
/ O
- O
sneak O
thymocytes O
are O
more O
insubordinate O
to O
apoptosis O
have O
by O
gamma O
- O
irradiation O
than O
convention O
thymocytes O
. O

In O
addition O
, O
ATM O
- O
/ O
- O
mouse O
thymocytes O
are O
more O
resistant O
to O
apoptosis O
induced O
by O
gamma O
- O
pattern O
pattern O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O

indiana O
gain O
, O
ATM O
- O
/ O
- O
shiner O
thymocytes O
are O
more O
tolerant O
to O
apoptosis O
induced O
by O
gamma O
- O
irradiation O
than O
rule O
thymocytes O
. O

In O
addition O
, O
ATM O
- O
/ O
- O
mouse O
thymocytes O
are O
resistant O
to O
induced O
by O
gamma O
- O
irradiation O
than O
normal O

more O
addition O
, O
irradiation O
- O
/ O
- O
thymocytes O
mouse O
are O
than O
resistant O
apoptosis O
to O
. O
by O
gamma O
- O
ATM O
In O
normal O
thymocytes O
induced O

inch O
improver O
, O
ATM O
- O
/ O
- O
shiner O
thymocytes O
are O
more O
immune O
to O
apoptosis O
hasten O
by O
gamma O
- O
irradiation O
than O
convention O
thymocytes O
. O

induced O
addition O
thymocytes O
- O
- O
/ O
by O
mouse O
, O
are O
more O
resistant O
normal O
apoptosis O
ATM O
In O
gamma O
- O
irradiation O
than O
to O
thymocytes O
. O

In O
addition O
, O
ATM O
- O
/ O
- O
mouse O
thymocytes O
are O
more O
resistant O
to O
apoptosis O
induced O
by O
gamma O
- O
irradiation O
than O
normal O
thymocytes O
. O

ATM O
- O
/ O
- O
fibroblasts O
are O
ineffective O
in O
G1 O
to O
sulphur O
- O
stage O
advancement O
following O
serum O
arousal O
and O
senesce O
after O
only O
a O
few O
passing O
in O
civilisation O
. O

ATM O
- O
- O
fibroblasts O
are O
inefficient O
in O
G1 O
to O
S O
- O
phase O
serum O
stimulation O
and O
senesce O
only O
a O
few O
passages O
in O
. O

ATM O
- O
/ O
- O
be O
blood O
serum O
fibroblast O
fibroblasts O
are O
inefficient O
in O
G1 O
to O
S O
- O
phase O
progression O
following O
serum O
stimulation O
and O
transition O
inward O
cultivation O
inward O
blood O
serum O
senesce O
after O
only O
a O
few O
passages O
in O

only O
- O
/ O
senesce O
fibroblasts O
are O
inefficient O
culture O
passages O
to O
after O
- O
phase O
progression O
few O
serum O
stimulation O
and O
- O
in O
S O
a O
following O
G1 O
ATM O
in O
. O

ATM O
- O
/ O
- O
be O
blood O
serum O
fibroblast O
fibroblasts O
are O
inefficient O
in O
G1 O
to O
S O
- O
phase O
progression O
following O
serum O
stimulation O
and O
transition O
inward O
cultivation O
inward O
blood O
serum O
senesce O
after O
only O
a O
few O
passages O
in O

ATM O
- O
/ O
fibroblasts O
are O
in O
G1 O
to O
S O
- O
phase O
progression O
following O
stimulation O
and O
after O
only O
a O
few O
passages O
in O
culture O
. O

. O
- O
/ O
following O
fibroblasts O
are O
culture O
in O
- O
to O
S O
- O
progression O
only O
in O
G1 O
stimulation O
and O
senesce O
after O
phase O
a O
few O
passages O
serum O
inefficient O
ATM O

/ O
are O
inefficient O
in O
to O
S O
phase O
progression O
following O
serum O
stimulation O
and O
senesce O
after O
only O
a O
few O
passages O
in O

passages O
- O
/ O
- O
fibroblasts O
are O
progression O
- O
G1 O
to O
S O
stimulation O
a O
inefficient O
in O
ATM O
in O
serum O
senesce O
after O
only O
phase O
few O
and O
following O
culture O
. O

atmosphere O
- O
/ O
- O
fibroblasts O
are O
ineffective O
in O
G1 O
to O
S O
- O
phase O
procession O
trace O
serum O
stimulus O
and O
maturate O
after O
only O
a O
few O
passing O
in O
polish O
. O

ATM O
- O
/ O
- O
fibroblasts O
are O
inefficient O
in O
G1 O
to O
S O
- O
phase O
progression O
following O
serum O
stimulation O
and O
senesce O
after O
only O
a O
few O
passages O
in O
culture O
. O

They O
have O
an O
increased O
constitutional O
tied O
of O
p21CP1 O
/ O
WAF1 O
. O

They O
have O
an O
increased O
constitutive O
level O
of O
p21CP1 O
/ O
rich O
person O
rich O
person O
rich O

They O
have O
an O
increased O
constituent O
floor O
of O
p21CP1 O
/ O
WAF1 O
. O

They O
have O
an O
increased O
constitutional O
flush O
of O
p21CP1 O
/ O
WAF1 O
. O

have O
an O
constitutive O
level O
of O
p21CP1 O
/ O
WAF1 O
. O

p21CP1 O
have O
an O
constitutive O
increased O
level O
WAF1 O
They O
/ O
of O
. O

They O
p21CP1 O
an O
increased O
have O
level O
of O
. O
/ O
WAF1 O
constitutive O

increased O
p21CP1 O
an O
of O
constitutive O
level O
They O
have O
/ O
WAF1 O
. O

They O
an O
constitutive O
of O
p21CP1 O
/ O
WAF1 O
. O

They O
have O
an O
increased O
constitutive O
level O
of O
p21CP1 O
/ O
rich O
person O
rich O
person O
rich O

They O
have O
an O
increased O
constitutive O
level O
of O
p21CP1 O
/ O
WAF1 O
. O

The O
atmosphere O
protein O
is O
consequently O
vital O
both O
for O
cellular O
reception O
to O
ionizing O
radiation O
and O
for O
pattern O
cell O
- O
cycle O
procession O
. O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
and O
for O
normal O
cell O
- O
advancement O
be O
be O
be O
be O
be O
cycle O
progression O
. O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
and O
for O
normal O
cell O
- O
advancement O
be O
be O
be O
be O
be O
cycle O
progression O
. O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
responses O
to O
radiation O
and O
for O
normal O
cell O
- O
cycle O

for O
ATM O
cellular O
both O
therefore O
critical O
normal O
for O
protein O
responses O
to O
ionizing O
. O
and O
is O
The O
cell O
- O
cycle O
progression O
radiation O

The O
ATM O
protein O
is O
consequently O
decisive O
both O
for O
cellular O
reception O
to O
ionise O
radiation O
and O
for O
formula O
cell O
- O
cps O
progression O
. O

. O
ATM O
protein O
to O
therefore O
critical O
both O
cycle O
for O
responses O
is O
ionizing O
and O
radiation O
cellular O
normal O
cell O
- O
for O
The O
progression O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
and O
for O
normal O
cell O
- O
advancement O
be O
be O
be O
be O
advancement O
cycle O
progression O
. O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
for O
- O
cycle O
progression O
. O

The O
ATM O
protein O
is O
so O
vital O
both O
for O
cellular O
reaction O
to O
ionize O
radiation O
and O
for O
rule O
cell O
- O
oscillation O
progression O
. O

The O
ATM O
protein O
is O
therefore O
critical O
both O
for O
cellular O
responses O
to O
ionizing O
radiation O
and O
for O
normal O
cell O
- O
cycle O
progression O
. O

ATM O
+ O
to O
- O
fibroblasts O
and O
to O
suggesting O
intermediately O
defective O
responses O
heterozygotes O
that O
but O
no O
could O
defect O
, O
poor O
irradiation O
the O
checkpoint O
cancer B
risk O
of O
growth B
thymocytes O
increased O
be O
attributable O
/ O
showed O
AT O
function O
. O
. O

+ O
- O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
irradiation O
but O
no O
growth O
defect O
, O
suggesting O
increased O
cancer B
risk O
AT B
could O
be O
attributable O
checkpoint O

ATM O
+ O
/ O
- O
fibroblasts O
and O
thymocytes O
record O
intermediately O
bad O
reply O
to O
irradiation O
but O
no O
maturation O
fault O
, O
intimate O
that O
the O
increased O
cancer B
danger O
of O
at B
heterozygotes O
could O
be O
attributable O
to O
short O
checkpoint O
use O
. O
. O

could O
the O
/ O
- O
defect O
and O
no O
poor O
intermediately O
defective O
responses O
to O
irradiation O
of O
showed O
growth O
fibroblasts O
to O
suggesting O
that O
but O
increased O
cancer B
risk O
+ O
AT B
heterozygotes O
ATM O
, O
attributable O
be O
thymocytes O
checkpoint O
function O
. O
. O

ATM O
+ O
/ O
- O
fibroblast O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
to O
irradiation O
but O
no O
growth O
defect O
, O
suggesting O
that O
the O
increased O
cancer B
risk O
of O
AT B
heterozygotes O
could O
be O
attributable O
to O
poor O
checkpoint O
function O
. O
emergence O
emergence O
emergence O
emergence O
emergence O
emergence O
emergence O
emergence O
emergence O
. O

of O
suggesting O
/ O
- O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
to O
irradiation O
could O
attributable O
growth O
defect O
, O
function O
that O
the O
increased O
be B
risk O
ATM O
AT B
poor O
but O
no O
cancer O
to O
. O
checkpoint O
. O
+ O
heterozygotes O

ATM O
+ O
/ O
- O
and O
intermediately O
defective O
responses O
to O
irradiation O
but O
no O
growth O
defect O
increased O
cancer B
risk O
of O
AT B
heterozygotes O
could O
be O
attributable O
to O
poor O
checkpoint O
function O
. O
. O

atm O
+ O
/ O
- O
fibroblasts O
and O
thymocytes O
establish O
intermediately O
faulty O
reply O
to O
irradiation O
but O
no O
ontogeny O
desert O
, O
advise O
that O
the O
increased O
cancer B
danger O
of O
astatine B
heterozygotes O
could O
be O
attributable O
to O
pathetic O
checkpoint O
function O
. O
. O

ATM O
+ O
/ O
- O
advise O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
to O
irradiation O
but O
no O
growth O
defect O
, O
suggesting O
that O
the O
increased O
cancer B
risk O
of O
AT B
heterozygotes O
could O
be O
attributable O
to O
poor O
checkpoint O
function O
. O
rede O
rede O
rede O
rede O
rede O
rede O
rede O
rede O
emergence O
. O

ATM O
+ O
/ O
- O
fibroblasts O
and O
thymocytes O
demo O
intermediately O
faulty O
reaction O
to O
actinotherapy O
but O
no O
growing O
shortcoming O
, O
intimate O
that O
the O
increased O
cancer B
risk O
of O
at B
heterozygotes O
could O
be O
attributable O
to O
pathetic O
checkpoint O
procedure O
. O
. O

ATM O
+ O
/ O
- O
fibroblasts O
and O
thymocytes O
showed O
intermediately O
defective O
responses O
to O
irradiation O
but O
no O
growth O
defect O
, O
suggesting O
that O
the O
increased O
cancer B
risk O
of O
AT B
heterozygotes O
could O
be O
attributable O
to O
poor O
checkpoint O
function O
. O
. O

target O
perturbation O
of O
ATM O
leads O
to O
development B
retardation I
, O
chromosomal B
atomisation I
during I
meiosis I
, O
resistant B
desert I
, O
and O
thymic B
lymphoma I
. O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal B
fragmentation I
during I
meiosis I
, O
immune B
defects I
, O
and O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous B
transfer I
mode O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal B
fragmentation I
during I
meiosis I
, O
immune B
defects I
, O
and O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous B
transfer I
mode O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
chromosomal B
fragmentation I
meiosis I
, O
immune B
defects I
, O
and O
thymic B

immune O
disruption O
, O
growth O
leads O
to O
defects B
retardation I
of O
chromosomal B
fragmentation I
during I
. I
, O
ATM B
Targeted I
, O
and O
thymic B
lymphoma I
meiosis O

point O
disruption O
of O
ATM O
leads O
to O
ontogenesis B
lag I
, O
chromosomal B
atomization I
during I
meiosis I
, O
resistant B
shortcoming I
, O
and O
thymic B
lymphoma I
. O

. O
disruption O
of O
fragmentation O
leads O
to O
growth B
thymic I
immune O
chromosomal B
ATM I
during I
, I
meiosis O
, B
defects I
, O
and O
retardation B
Targeted I
lymphoma O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal B
fragmentation I
during I
meiosis I
, O
immune B
defects I
, O
and O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
asynchronous B
transfer I
mode O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal B
fragmentation I
during I
meiosis I
immune B
and O
thymic B
lymphoma I
. O

Targeted O
disturbance O
of O
ATM O
head O
to O
increment B
slowdown I
, O
chromosomal B
fragmentation I
during I
litotes I
, O
resistant B
defects I
, O
and O
thymic B
lymphoma I
. O

Targeted O
disruption O
of O
ATM O
leads O
to O
growth B
retardation I
, O
chromosomal B
fragmentation I
during I
meiosis I
, O
immune B
defects I
, O
and O
thymic B
lymphoma I
. O

ATM O
, O
the O
gene O
mutate O
be O
antiophthalmic O
factor O
mutate O
mutated O
in O
the B
inherited I
human I
disease B
ataxia I
- I
telangiectasia O
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
jail O
cell O
jail O
cell O
jail O

ATM O
, O
the O
in O
ataxia B
- I
telangiectasia I
is O
a O
of O
a O
family O
involved O
in O
DNA O
metabolism O
and O
- O
checkpoint O
control O
. O

ATM O
, O
the O
cistron O
mutated O
in O
the O
genetic B
homo I
disease I
ataxy B
- I
telangiectasia I
, O
is O
a O
extremity O
of O
a O
kinsfolk O
of O
kinases O
ask O
in O
DNA O
metabolism O
and O
cubicle O
- O
cycle O
checkpoint O
ascendance O
. O

ATM O
, O
the O
gene O
mutated O
in O
the O
human I
- I
telangiectasia I
, O
is O
a O
member O
of O
a O
family O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O

ATM O
, O
the O
cistron O
mutated O
in O
the O
genetic B
human I
disease I
dyssynergia B
- I
telangiectasia I
, O
is O
a O
extremity O
of O
a O
family O
of O
kinases O
regard O
in O
DNA O
metabolism O
and O
cadre O
- O
hertz O
checkpoint O
insure O
. O

ATM O
, O
the O
gene O
mutate O
be O
antiophthalmic O
factor O
mutate O
mutated O
in O
the B
inherited I
human I
disease B
ataxia I
- I
telangiectasia O
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
jail O
cell O
jail O
cell O
jail O

atm O
, O
the O
cistron O
mutated O
in O
the O
transmissible B
human I
disease I
dyssynergia B
- I
telangiectasia I
, O
is O
a O
extremity O
of O
a O
kinfolk O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cubicle O
- O
cycle O
checkpoint O
hold O
. O

of O
a O
the O
gene O
mutated O
in O
the O
inherited B
human I
disease I
ataxia B
- I
telangiectasia I
DNA O
cycle O
a O
member O
of O
cell O
family O
, O
kinases O
control O
in O
, O
metabolism O
and O
ATM O
is O
involved O
checkpoint O
- O
. O

ATM O
, O
the O
gene O
mutated O
in O
inherited B
disease I
ataxia B
- I
telangiectasia I
, O
is O
a O
member O
a O
family O
of O
kinases O
involved O
in O
DNA O
cell O
- O
cycle O
control O

ATM O
, O
the O
gene O
mutate O
be O
antiophthalmic O
factor O
extremity O
mutated O
in O
the B
inherited I
human I
disease B
ataxia I
- I
telangiectasia O
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
appendage O
appendage O
appendage O
appendage O
appendage O

ATM O
, O
the O
gene O
mutated O
in O
the O
inherited B
human I
disease I
ataxia B
- I
telangiectasia I
, O
is O
a O
member O
of O
a O
family O
of O
kinases O
involved O
in O
DNA O
metabolism O
and O
cell O
- O
cycle O
checkpoint O
control O
. O

recombination O
help O
clarify O
, O
physiological O
roles O
of O
through O
ATM O
protein O
the O
we O
the O
disrupted O
ATM O
gene O
in O
mice O
the O
To O
homologous O
. O

To O
help O
clarify O
the O
physiological O
roles O
of O
the O
ATM O
protein O
, O
we O
disrupted O
the O
ATM O
gene O
in O
mice O
clear O
up O
clear O
up O
clear O
up O
clear O
up O
clear O
up O

To O
help O
clarify O
the O
physiological O
roles O
of O
the O
ATM O
protein O
, O
we O
disrupted O
the O
ATM O
gene O
in O
mice O
clear O
up O
clear O
up O
clear O
up O
clear O
up O
clear O
up O

To O
assistant O
clarify O
the O
physiological O
purpose O
of O
the O
ATM O
protein O
, O
we O
disrupted O
the O
ATM O
factor O
in O
shiner O
through O
homologous O
recombination O
. O

To O
help O
clarify O
physiological O
roles O
of O
the O
ATM O
, O
we O
disrupted O
the O
gene O
in O
through O
homologous O
recombination O
. O

the O
of O
the O
ATM O
, O
we O
the O
ATM O
gene O
in O
mice O
through O
homologous O
recombination O
. O

To O
aid O
clarify O
the O
physiological O
purpose O
of O
the O
atm O
protein O
, O
we O
interrupt O
the O
atm O
cistron O
in O
mouse O
through O
homologous O
recombination O
. O

ATM O
help O
ATM O
of O
physiological O
roles O
gene O
the O
clarify O
protein O
, O
we O
recombination O
the O
the O
To O
in O
mice O
through O
homologous O
disrupted O
. O

To O
help O
clarify O
the O
physiological O
roles O
of O
the O
ATM O
protein O
, O
we O
disrupted O
the O
ATM O
gene O
in O
mice O
clear O
up O
clear O
up O
clear O
up O
clear O
up O
clear O
up O

To O
help O
clarify O
the O
of O
the O
protein O
, O
we O
disrupted O
the O
ATM O
gene O
in O
mice O
through O
. O

To O
help O
clarify O
the O
physiological O
roles O
of O
the O
ATM O
protein O
, O
we O
disrupted O
the O
ATM O
gene O
in O
mice O
through O
homologous O
recombination O
. O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
dyssynergia O
vivify O
dyssynergia O
dyssynergia O
vivify O
vivify O
point O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
phenotype O
ataxia B
- I
telangiectasia I
. O

initial O
evaluation O
of O
the O
ATM O
ravisher O
animals O
suggest O
that O
deactivation O
of O
the O
pussyfoot O
ATM O
factor O
revivify O
much O
of O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
the O
mouse O
gene O
recreates O
much O
of O
the O
phenotype O
of O
telangiectasia I
. O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
dyssynergia O
vivify O
dyssynergia O
dyssynergia O
vivify O
vivify O
vivify O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

Initial O
rating O
of O
the O
ATM O
lulu O
brute O
designate O
that O
deactivation O
of O
the O
mouse O
ATM O
factor O
revivify O
much O
of O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

initial O
evaluation O
of O
the O
atmosphere O
kayo O
beast O
indicates O
that O
inactivation O
of O
the O
pussyfoot O
atmosphere O
gene O
hearten O
much O
of O
the O
phenotype O
of O
dyssynergia B
- I
telangiectasia I
. O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
mouse O
recreates O
much O
of O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
dyssynergia O
vivify O
dyssynergia O
dyssynergia O
vivify O
vivify O
vivify O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

phenotype O
evaluation O
of O
of O
ATM O
knockout O
animals O
the O
telangiectasia O
inactivation O
the O
the O
ATM O
mouse O
- O
recreates O
much O
of O
indicates O
. O
of O
ataxia B
gene I
that I
Initial O

Initial O
evaluation O
of O
the O
ATM O
knockout O
animals O
indicates O
that O
inactivation O
of O
the O
mouse O
ATM O
gene O
recreates O
much O
of O
the O
phenotype O
of O
ataxia B
- I
telangiectasia I
. O

The O
homozygous O
variation O
( O
ATM O
- O
/ O
- O
) O
shiner O
are O
executable O
, O
increase O
- O
retarded O
, O
and O
sterile O
. O

The O
homozygous O
mutant O
( O
ATM O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth O
- O
retarded O
, O
and O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
infertile O
. O

The O
homozygous O
mutant O
( O
ATM O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth O
- O
retarded O
, O
and O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
infertile O
. O

mutant O
- O
/ O
- O
mice O
are O
, O
growth O
- O
retarded O
, O
and O
infertile O
. O

The O
homozygous O
mutant O
( O
ATM O
- O
) O
are O
viable O
, O
growth O
- O
retarded O
, O
and O
infertile O
. O

mutant O
( O
ATM O
- O
- O
) O
mice O
are O
viable O
growth O
- O
retarded O
, O
infertile O
. O

and O
homozygous O
mutant O
infertile O
ATM O
- O
/ O
) O
- O
mice O
- O
viable O
, O
. O
The O
retarded O
, O
are O
( O
growth O

The O
homozygous O
mutant O
( O
ATM O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth O
- O
retarded O
, O
and O
mutation O
mutation O
mutation O
mutation O
mutation O
emergence O
infertile O
. O

The O
homozygous O
sport O
( O
ATM O
- O
/ O
- O
) O
mice O
are O
workable O
, O
emergence O
- O
retarded O
, O
and O
sterile O
. O

, O
homozygous O
mutant O
( O
ATM O
- O
growth O
viable O
) O
mice O
are O
- O
The O
/ O
- O
and O
, O
retarded O
infertile O
. O

The O
homozygous O
mutant O
( O
ATM O
- O
/ O
- O
) O
mice O
are O
viable O
, O
growth O
- O
retarded O
, O
and O
infertile O
. O

The O
of O
ATM O
/ O
mice O
from O
meiotic O
failure O
. O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
from O
meiotic O
failure O

The O
sterility B
of O
ATM O
- O
/ O
- O
mice O
resolution O
from O
meiotic O
nonstarter O
. O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
loser O
loser O
sterility O
from O
meiotic O
failure O
. O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
loser O
loser O
loser O
from O
meiotic O
failure O
. O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
loser O
loser O
sterility O
from O
meiotic O
failure O
. O

The O
sterility B
of O
ATM O
- O
/ O
- O
mouse O
solution O
from O
meiotic O
failure O
. O

The O
infertility B
ATM O
- O
/ O
- O
mice O
results O
from O
. O

The O
sterility B
of O
atmosphere O
- O
/ O
- O
mice O
results O
from O
meiotic O
failure O
. O

The O
- B
of O
ATM O
. O
/ O
- O
infertility O
results O
from O
meiotic O
failure O
mice O

The O
infertility B
of O
ATM O
- O
/ O
- O
mice O
results O
from O
meiotic O
failure O
. O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
I O
as O
a O
result O
of O
abnormal O
chromosomal O
halt O
atomization O
halt O
atomization O
atomization O
halt O
solution O
synapsis O
and O
subsequent O
chromosome O
fragmentation O
. O

arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
I O
as O
a O
result O
of O
abnormal O
synapsis O
subsequent O
chromosome O
fragmentation O
. O

litotes O
is O
cop O
at O
the O
zygotene O
/ O
pachytene O
represent O
of O
prophase O
I O
as O
a O
outcome O
of O
unnatural O
chromosomal O
synapsis O
and O
subsequent O
chromosome O
atomisation O
. O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
stage O
of O
I O
as O
a O
result O
of O
abnormal O
chromosomal O
subsequent O
chromosome O
fragmentation O
. O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
I O
as O
a O
result O
of O
abnormal O
chromosomal O
halt O
atomization O
halt O
atomization O
atomization O
halt O
halt O
synapsis O
and O
subsequent O
chromosome O
fragmentation O
. O

Meiosis O
is O
halt O
at O
the O
zygotene O
/ O
pachytene O
arrange O
of O
prophase O
I O
as O
a O
result O
of O
unnatural O
chromosomal O
synapsis O
and O
subsequent O
chromosome O
atomization O
. O

litotes O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
present O
of O
prophase O
I O
as O
a O
leave O
of O
unnatural O
chromosomal O
synapsis O
and O
subsequent O
chromosome O
atomization O
. O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
prophase O
a O
result O
of O
abnormal O
chromosomal O
synapsis O
and O
subsequent O
chromosome O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
I O
as O
a O
result O
of O
abnormal O
chromosomal O
halt O
atomization O
halt O
atomization O
atomization O
halt O
halt O
synapsis O
and O
subsequent O
chromosome O
fragmentation O
. O

chromosomal O
is O
arrested O
prophase O
the O
zygotene O
/ O
synapsis O
. O
of O
at O
I O
as O
a O
fragmentation O
of O
abnormal O
subsequent O
pachytene O
Meiosis O
and O
chromosome O
result O
stage O

Meiosis O
is O
arrested O
at O
the O
zygotene O
/ O
pachytene O
stage O
of O
prophase O
I O
as O
a O
result O
of O
abnormal O
chromosomal O
synapsis O
and O
subsequent O
chromosome O
fragmentation O
. O

Immune B
defects I
cells O
are O
evident O
in O
ATM O
CD43 O
/ O
- O
mice O
cells O
- O
reduced O
numbers O
- O
B220 O
+ O
of O
including O
pre O
. O
B O
, O
, O
of O
and O
as O
peripheral O
T O
also O
dependent O
, O
well O
as O
responses O
impairment O
thymocytes O
T O
- O
cell O
- O
, O
immune O
functional O
- O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
well O
as O
functional O
drug O
addicted O
resistant O
reply O
drug O
addicted O
resistant O
reply O
drug O
addicted O
resistant O
reply O
unmistakable O
unmistakable O
unmistakable O
unmistakable O
impairment O
of O
T O
- O
cell O
- O
dependent O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
well O
as O
functional O
drug O
addicted O
resistant O
reply O
drug O
addicted O
resistant O
reply O
drug O
addicted O
resistant O
reply O
unmistakable O
unmistakable O
unmistakable O
a O
impairment O
of O
T O
- O
cell O
- O
dependent O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
mice O
, O
reduced O
of O
B220 O
+ O
pre O
thymocytes O
, O
and O
T O
cells O
as O
well O
as O
of O
T O
- O
cell O
- O
immune O
. O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
/ O
mice O
, O
including O
reduced O
numbers O
pre O
cells O
thymocytes O
, O
and O
T O
cells O
, O
as O
well O
as O
T O
- O
cell O
- O
dependent O
immune O
responses O

as B
CD43 I
also O
are O
evident O
in O
- O
- O
/ O
- O
mice O
cell O
including O
and O
T O
of O
B220 O
+ O
well O
- O
pre O
- O
peripheral O
cells O
immune O
thymocytes O
, O
reduced O
numbers O
, O
cells O
functional O
as O
defects O
Immune O
, O
impairment O
of O
T O
- O
, O
ATM O
dependent O
B O
responses O
. O

resistant B
blemish I
likewise O
are O
unmistakable O
in O
ATM O
- O
/ O
- O
mouse O
, O
admit O
thin O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
easily O
as O
functional O
disablement O
of O
T O
- O
cadre O
- O
pendant O
resistant O
answer O
. O

resistant B
shortcoming I
likewise O
are O
observable O
in O
ATM O
- O
/ O
- O
mice O
, O
including O
tighten O
act O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
bel O
cellphone O
, O
thymocytes O
, O
and O
peripheral O
T O
cellphone O
, O
as O
good O
as O
useable O
deterioration O
of O
T O
- O
cell O
- O
dependent O
resistant O
reaction O
. O

resistant B
fault I
likewise O
are O
unmistakable O
in O
ATM O
- O
/ O
- O
shiner O
, O
including O
reduced O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
well O
as O
working O
stultification O
of O
T O
- O
cadre O
- O
dependent O
resistant O
reception O
. O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
well O
as O
functional O
drug O
addicted O
resistant O
reply O
drug O
addicted O
resistant O
reply O
drug O
addicted O
resistant O
reply O
unmistakable O
unmistakable O
unmistakable O
unmistakable O
impairment O
of O
T O
- O
cell O
- O
dependent O

Immune B
defects I
also O
are O
evident O
in O
ATM O
- O
/ O
- O
mice O
, O
including O
reduced O
numbers O
of O
B220 O
+ O
CD43 O
- O
pre O
- O
B O
cells O
, O
thymocytes O
, O
and O
peripheral O
T O
cells O
, O
as O
well O
as O
functional O
impairment O
of O
T O
- O
cell O
- O
dependent O
immune O
responses O
. O

The O
cerebellum O
of O
ATM O
- O
/ O
- O
mice O
look O
convention O
by O
histologic O
testing O
at O
triplet O
to O
quadruplet O
months O
and O
the O
mice O
have O
no O
crude O
behavioural B
abnormalities I
. O

The O
cerebella O
ATM O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
to O
4 O
months O
and O
mice O
have O
no O
gross O
behavioral B
. O

The O
cerebella O
of O
ATM O
 O
abnormalcy O
 O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
to O
4 O
months O
 O
behavioural O
abnormalcy O
behavioural O
come O
out O
and O
the O
mice O
have O
no O
gross B
behavioral I
abnormalities O

mice O
cerebella O
of O
and O
- O
/ O
- O
abnormalities O
gross O
normal O
the O
histologic O
examination O
at O
no O
to O
4 O
months O
ATM O
behavioral O
by O
have O
3 O
appear O
The B
mice I
. O

The O
cerebella O
of O
ATM O
 O
abnormalcy O
 O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
to O
4 O
months O
 O
behavioural O
abnormalcy O
behavioural O
come O
out O
and O
the O
mice O
have O
no O
gross B
behavioral I
abnormalities O

The O
cerebella O
of O
- O
/ O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
4 O
months O
the O
mice O
have O
no O
gross O
behavioral B
abnormalities I
. O

. O
cerebella O
of O
3 O
- O
/ O
abnormalities O
mice O
ATM O
normal O
by O
histologic O
at O
mice O
behavioral O
appear O
4 O
months O
and O
the O
examination O
have O
no O
gross O
to B
- I
The O

of O
/ O
- O
mice O
normal O
by O
examination O
at O
3 O
to O
4 O
months O
and O
the O
mice O
have O
no O
gross O
behavioral B

gross O
cerebella O
of O
ATM O
- O
/ O
at O
histologic O
appear O
normal O
by O
4 O
have O
- O
behavioral O
The O
mice O
to O
and O
the O
mice O
examination O
no O
months O
3 B
abnormalities I
. O

The O
cerebellum O
of O
ATM O
- O
/ O
- O
mice O
appear O
convention O
by O
histologic O
scrutiny O
at O
trey O
to O
quartet O
months O
and O
the O
mice O
have O
no O
everlasting O
behavioural B
abnormalcy I
. O

The O
cerebella O
of O
ATM O
- O
/ O
- O
mice O
appear O
normal O
by O
histologic O
examination O
at O
3 O
to O
4 O
months O
and O
the O
mice O
have O
no O
gross O
behavioral B
abnormalities I
. O

die O
majority O
of O
thymic O
mice O
rapidly O
develop O
mutant B
of I
and O
months O
before O
The O
4 O
lymphomas O
age O
. O

The O
majority O
of O
sport O
mice O
speedily O
break O
thymic B
lymphomas I
and O
die O
before O
iv O
months O
of O
geezerhood O
. O

The O
majority O
of O
sport O
mice O
apace O
develop O
thymic B
lymphomas I
and O
die O
before O
quaternity O
months O
of O
age O
. O

The O
majority O
mice O
rapidly O
develop O
thymic B
lymphomas I
and O
die O
before O
4 O
months O
of O
age O
. O

The O
majority O
of O
mutation O
mouse O
apace O
acquire O
thymic B
lymphomas I
and O
die O
before O
quartet O
months O
of O
age O
. O

The O
majority O
calendar O
month O
lymphoma O
of O
mutant O
mice O
rapidly O
develop B
thymic I
lymphomas O
and O
die O
before O
4 O
months O
of O
age O
modernise O
modernise O
modernise O

The O
majority O
of O
mutant O
mice O
rapidly O
develop O
thymic B
and O
die O
4 O
months O
of O
age O
. O

The O
majority O
calendar O
month O
lymphoma O
of O
mutant O
mice O
rapidly O
develop B
thymic I
lymphomas O
and O
die O
before O
4 O
months O
of O
age O
modernise O
modernise O
modernise O

majority O
mice O
rapidly O
develop O
thymic B
lymphomas I
and O
die O
before O
4 O

The O
majority O
lymphomas O
of O
mice O
rapidly O
4 O
thymic B
of I
and O
die O
before O
develop O
months O
mutant O
age O
. O

The O
majority O
of O
mutant O
mice O
rapidly O
develop O
thymic B
lymphomas I
and O
die O
before O
4 O
months O
of O
age O
. O

These O
notice O
suggest O
that O
the O
ATM O
gene O
product O
diddle O
an O
essential O
use O
in O
a O
diverse O
group O
of O
cellular O
appendage O
, O
including O
meiosis O
, O
the O
pattern O
growth O
of O
corporal O
tissues O
, O
resistant O
evolution O
, O
and O
tumour B
stifling O
. O
. O

findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
in O
a O
diverse O
group O
of O
processes O
, O
the O
of O
somatic O
immune O
and O
tumor B
suppression O
. O

somatic O
tumor O
indicate O
that O
of O
ATM O
including O
development O
plays O
an O
essential O
role O
in O
normal O
. O
group O
the O
immune O
processes O
, O
product O
meiosis O
, O
the O
findings O
growth O
of O
These O
cellular O
, O
tissues O
gene O
, O
and O
a B
suppression O
. O
diverse O

These O
findings O
indicate O
that O
the O
ATM O
plays O
an O
essential O
role O
a O
diverse O
group O
of O
cellular O
, O
including O
meiosis O
, O
normal O
growth O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
. O
. O

These O
findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
suppression O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
. O
. O

These O
findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
suppression O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
. O
. O

These O
findings O
indicate O
that O
the O
ATM O
factor O
product O
plays O
an O
indispensable O
part O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
miosis O
, O
the O
pattern O
increase O
of O
corporal O
tissues O
, O
resistant O
evolution O
, O
and O
tumour B
quelling O
. O
. O

normal O
processes O
indicate O
that O
the O
ATM O
role O
and O
plays O
an O
essential O
gene O
in O
somatic O
, O
group O
of O
cellular O
product O
, O
including O
meiosis O
tissues O
the O
These O
growth O
development O
a O
diverse O
, O
immune O
suppression O
, O
findings O
tumor B
of O
. O
. O

These O
findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
suppression O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
intersection O
childs O
play O
. O

These O
findings O
the O
ATM O
product O
plays O
in O
diverse O
group O
of O
processes O
, O
including O
, O
the O
normal O
growth O
of O
, O
immune O
development O
, O
and O
tumor B
suppression O
. O

These O
findings O
indicate O
that O
the O
ATM O
gene O
product O
plays O
an O
essential O
role O
in O
a O
diverse O
group O
of O
cellular O
processes O
, O
including O
meiosis O
, O
the O
normal O
growth O
of O
somatic O
tissues O
, O
immune O
development O
, O
and O
tumor B
suppression O
. O
. O

characterization O
very O
- O
long O
- O
acyl O
- O
cDNA O
, O
assignment O
of O
identification O
four O
patients O
of O
different O
mutations O
within O
VLCAD O
gene O
. O

Cloning O
and O
characterization O
of O
inside O
word O
picture O
human O
very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
cDNA O
, O
chromosomal O
assignment O
of O
the O
gene O
and O
identification O
in O
four O
patients O
of O
nine O
different O
mutations O
within O
the O
VLCAD O
gene O
at O
bottom O
at O
bottom O
at O
bottom O
at O
bottom O

four O
of O
characterization O
of O
human O
very O
of O
long O
- O
chain O
acyl O
- O
CoA O
nine O
mutations O
, O
chromosomal O
assignment O
gene O
the O
gene O
and O
the O
in O
Cloning O
patients O
- O
dehydrogenase O
cDNA O
identification O
within O
different O
VLCAD O
. O
and O

clone O
and O
picture O
of O
human O
very O
- O
foresightful O
- O
range O
acyl O
- O
CoA O
dehydrogenase O
cdna O
, O
chromosomal O
assignment O
of O
the O
cistron O
and O
designation O
in O
four O
patients O
of O
ix O
dissimilar O
mutations O
inside O
the O
VLCAD O
cistron O
. O

Cloning O
and O
patients O
of O
human O
very O
- O
and O
- O
chain O
acyl O
in O
nine O
dehydrogenase O
cDNA O
within O
chromosomal O
assignment O
the O
- O
gene O
long O
identification O
of O
four O
of O
characterization O
VLCAD O
different O
mutations O
, O
CoA O
the O
gene O
. O

Cloning O
and O
characterization O
of O
human O
very O
- O
long O
- O
chain O
CoA O
dehydrogenase O
cDNA O
, O
assignment O
of O
the O
gene O
and O
in O
four O
patients O
of O
different O
mutations O
the O
VLCAD O
gene O
. O

cloning O
and O
picture O
of O
human O
very O
- O
farseeing O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
cdna O
, O
chromosomal O
assignment O
of O
the O
factor O
and O
recognition O
in O
quaternion O
patients O
of O
ennead O
unlike O
mutations O
inside O
the O
VLCAD O
factor O
. O

Cloning O
and O
characterization O
of O
inside O
homo O
human O
very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
cDNA O
, O
chromosomal O
assignment O
of O
the O
gene O
and O
identification O
in O
four O
patients O
of O
nine O
different O
mutations O
within O
the O
VLCAD O
gene O
at O
bottom O
at O
bottom O
at O
bottom O
at O
bottom O
at O

cloning O
and O
depiction O
of O
human O
very O
- O
foresighted O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
cDNA O
, O
chromosomal O
assignment O
of O
the O
cistron O
and O
recognition O
in O
quartet O
patients O
of O
ennead O
dissimilar O
sport O
inside O
the O
VLCAD O
cistron O
. O

nine O
gene O
characterization O
of O
chromosomal O
very O
cDNA O
the O
- O
chain O
acyl O
- O
CoA O
four O
long O
, O
human O
within O
of O
the O
dehydrogenase O
and O
identification O
in O
and O
patients O
of O
Cloning O
assignment O
mutations O
different O
- O
VLCAD O
gene O
. O

Cloning O
and O
characterization O
of O
human O
very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
cDNA O
, O
chromosomal O
assignment O
of O
the O
gene O
and O
identification O
in O
four O
patients O
of O
nine O
different O
mutations O
within O
the O
VLCAD O
gene O
. O

Very O
- O
all O
- O
chain O
acyl O
- O
chain O
dehydrogenase O
( O
VLCAD O
( O
acyl O
one O
of O
CoA O
straight O
- O
initial O
is O
- O
. O
dehydrogenase O
) O
ACD O
four O
, O
encoded O
which O
are O
long O
beta O
nuclear O
mitochondrial O
flavoproteins O
oxidation O
the O
) O
step O
in O
fatty O
acid O
enzymes O
- O
catalyzing O
CoA O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
one O
of O
four O
straight O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
catalyzing O
genus O
beta O
fat O
person O
oxidisation O
genus O
beta O
fat O
person O
oxidisation O
genus O
beta O
string O
oxidisation O
string O
string O
string O
string O
the O
initial O
step O
in O
fatty O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
one O
of O
four O
straight O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
catalyzing O
genus O
beta O
fat O
person O
oxidisation O
genus O
beta O
fat O
person O
oxidisation O
genus O
beta O
string O
oxidisation O
string O
string O
string O
catalyse O
the O
initial O
step O
in O
fatty O

Very O
- O
long O
- O
chain O
acyl O
- O
( O
VLCAD O
) O
one O
four O
straight O
- O
- O
) O
enzymes O
, O
are O
all O
encoded O
mitochondrial O
flavoproteins O
initial O
step O
in O
fatty O
acid O
- O
. O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
VLCAD O
) O
is O
one O
of O
- O
( O
) O
enzymes O
, O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
step O
in O
fatty O
acid O
beta O
- O
oxidation O

flavoproteins O
chain O
long O
- O
chain O
acyl O
acid O
CoA O
dehydrogenase O
( O
VLCAD O
fatty O
is O
, O
are O
four O
straight O
- O
mitochondrial O
acyl O
- O
CoA O
which O
( O
- O
) O
nuclear O
one O
of O
ACD O
all O
catalyzing O
encoded O
- O
Very O
enzymes O
the O
initial O
step O
in O
) O
- O
beta O
dehydrogenase O
oxidation O
. O

identical O
- O
retentive O
- O
range O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
ane O
of O
quaternity O
square O
- O
range O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
atomic O
encoded O
mitochondrial O
flavoproteins O
catalyse O
the O
initial O
tone O
in O
fatty O
acrid O
beta O
- O
oxidization O
. O

real O
- O
yearn O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
i O
of O
quaternary O
true O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
atomic O
encoded O
mitochondrial O
flavoproteins O
catalyse O
the O
initial O
gradation O
in O
fatso O
pane O
beta O
- O
oxidization O
. O

identical O
- O
prospicient O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
one O
of O
quaternity O
straight O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
atomic O
encoded O
mitochondrial O
flavoproteins O
catalyze O
the O
initial O
footfall O
in O
butterball O
caustic O
beta O
- O
oxidization O
. O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
one O
of O
four O
straight O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
catalyzing O
genus O
beta O
fat O
person O
oxidisation O
genus O
beta O
fat O
person O
oxidisation O
genus O
beta O
string O
oxidisation O
string O
string O
string O
string O
the O
initial O
step O
in O
fatty O

Very O
- O
long O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
VLCAD O
) O
is O
one O
of O
four O
straight O
- O
chain O
acyl O
- O
CoA O
dehydrogenase O
( O
ACD O
) O
enzymes O
, O
which O
are O
all O
nuclear O
encoded O
mitochondrial O
flavoproteins O
catalyzing O
the O
initial O
step O
in O
fatty O
acid O
beta O
- O
oxidation O
. O

We O
have O
used O
the O
very O
airstream O
immobile O
free O
base O
identical O
very O
fast O
, O
Rapid O
Amplification O
of O
cDNA O
Ends O
( O
RACE O
) O
based O
strategy O
to O
homo O
obtain O
the O
sequence O
of O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
identical O
identical O
goal O

We O
have O
used O
the O
very O
airstream O
immobile O
free O
base O
identical O
very O
fast O
, O
Rapid O
Amplification O
of O
cDNA O
Ends O
( O
RACE O
) O
based O
strategy O
to O
complementary O
dna O
obtain O
the O
sequence O
of O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
identical O
identical O

encoding O
have O
used O
the O
very O
fast O
RACE O
strategy O
Amplification O
of O
cDNA O
Ends O
of O
, O
human O
and O
Rapid O
sequence O
obtain O
the O
We O
( O
cDNAs O
to O
) O
VLCAD O
from O
placenta O
. O
fibroblasts O
based O

We O
have O
used O
the O
very O
airstream O
immobile O
free O
base O
identical O
very O
fast O
, O
Rapid O
Amplification O
of O
cDNA O
Ends O
( O
RACE O
) O
based O
strategy O
to O
homo O
obtain O
the O
sequence O
of O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
identical O
identical O
goal O

We O
have O
used O
the O
fast O
Amplification O
of O
cDNA O
Ends O
( O
RACE O
) O
based O
strategy O
of O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
. O

We O
have O
used O
the O
very O
degraded O
, O
speedy O
Amplification O
of O
cdna O
oddment O
( O
rush O
) O
based O
scheme O
to O
prevail O
the O
successiveness O
of O
cDNAs O
encryption O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
. O

and O
have O
human O
) O
very O
fast O
placenta O
Rapid O
the O
of O
cDNA O
Ends O
sequence O
RACE O
used O
Amplification O
strategy O
to O
obtain O
the O
( O
of O
cDNAs O
encoding O
based O
, O
from O
VLCAD O
We O
fibroblasts O
. O

We O
have O
used O
the O
very O
fast O
, O
Rapid O
Amplification O
cDNA O
Ends O
RACE O
) O
based O
strategy O
to O
obtain O
the O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
. O

cDNA O
have O
used O
and O
very O
fast O
, O
VLCAD O
encoding O
of O
human O
Ends O
from O
the O
cDNAs O
based O
strategy O
to O
. O
RACE O
sequence O
of O
) O
Amplification O
We O
Rapid O
( O
placenta O
the O
fibroblasts O
obtain O

We O
have O
victimized O
the O
very O
degenerate O
, O
Rapid O
Amplification O
of O
cdna O
terminate O
( O
RACE O
) O
ground O
scheme O
to O
obtain O
the O
successiveness O
of O
cdna O
encryption O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
. O

We O
have O
used O
the O
very O
fast O
, O
Rapid O
Amplification O
of O
cDNA O
Ends O
( O
RACE O
) O
based O
strategy O
to O
obtain O
the O
sequence O
of O
cDNAs O
encoding O
human O
VLCAD O
from O
placenta O
and O
fibroblasts O
. O

Alignment O
of O
the O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
revealed O
extensive O
sequence O
homology O

Alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
VLCAD O
with O
those O
of O
other O
enzymes O
revealed O
extensive O
sequence O
homology O
. O

Alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
episode O
episode O
homo O
homo O
homo O
homo O
revealed O
extensive O
sequence O
homology O
. O

alliance O
of O
the O
augur O
amino O
acid O
successiveness O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
expose O
panoptic O
successiveness O
homology O
. O

Alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
episode O
episode O
homo O
homo O
homo O
homo O
revealed O
extensive O
sequence O
homology O
. O

alignment O
of O
the O
portend O
amino O
acid O
succession O
of O
homo O
VLCAD O
with O
those O
of O
the O
other O
homo O
ACD O
enzymes O
discover O
blanket O
succession O
homology O
. O

Alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
VLCAD O
those O
of O
other O
human O
ACD O
enzymes O
revealed O
extensive O
sequence O

with O
of O
the O
revealed O
amino O
acid O
sequence O
human O
of O
VLCAD O
extensive O
those O
the O
of O
. O
human O
ACD O
enzymes O
predicted O
Alignment O
sequence O
homology O
other O

coalition O
of O
the O
anticipate O
aminic O
sulfurous O
episode O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
revealed O
extended O
episode O
homology O
. O

other O
of O
human O
sequence O
amino O
acid O
human O
of O
the O
VLCAD O
with O
those O
sequence O
the O
predicted O
Alignment O
ACD O
enzymes O
revealed O
extensive O
of O
homology O
. O

Alignment O
of O
the O
predicted O
amino O
acid O
sequence O
of O
human O
VLCAD O
with O
those O
of O
the O
other O
human O
ACD O
enzymes O
revealed O
extensive O
sequence O
homology O
. O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
cistron O
bear O
on O
be O
bear O
on O
bear O
on O
homo O
belief O
these O
genes O
are O

human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
these O
are O
evolutionarily O
related O
. O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
blanket O
episode O
homology O
underpin O
the O
belief O
that O
these O
genes O
are O
evolutionarily O
connect O
. O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
CoA O
oxidase O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
are O
evolutionarily O
related O
. O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
cistron O
bear O
on O
be O
bear O
on O
bear O
on O
homo O
homo O
these O
genes O
are O

moreover O
, O
homo O
VLCAD O
and O
homo O
acyl O
- O
CoA O
oxidase O
prove O
extensive O
successiveness O
homology O
validate O
the O
whimsy O
that O
these O
cistron O
are O
evolutionarily O
related O
. O

furthermore O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
depict O
broad O
sequence O
homology O
underpin O
the O
whimsy O
that O
these O
factor O
are O
evolutionarily O
related O
. O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
showed O
homology O
corroborating O
the O
notion O
that O
these O
genes O
are O
evolutionarily O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
cistron O
bear O
on O
be O
bear O
on O
bear O
on O
homo O
homo O
these O
genes O
are O

that O
, O
human O
showed O
and O
human O
acyl O
these O
. O
oxidase O
VLCAD O
extensive O
sequence O
homology O
related O
the O
notion O
are O
- O
Moreover O
genes O
evolutionarily O
corroborating O
CoA O

Moreover O
, O
human O
VLCAD O
and O
human O
acyl O
- O
CoA O
oxidase O
showed O
extensive O
sequence O
homology O
corroborating O
the O
notion O
that O
these O
genes O
are O
evolutionarily O
related O
. O

17p11 O
blot O
analysis O
was O
genomic O
DNA O
from O
human O
the O
lines O
of O
used O
localize O
to O
cell O
VLCAD O
gene O
to O
hybrid O
Southern O
chromosome O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
hybrid O
cell O
lines O
was O
used O
to O
localize O
the O
VLCAD O
gene O
to O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
hybrid O
cell O
lines O
was O
used O
to O
localize O
the O
VLCAD O
gene O
to O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O

southern O
fleck O
analysis O
of O
genomic O
DNA O
from O
cross O
cell O
stemma O
was O
used O
to O
focalise O
the O
VLCAD O
factor O
to O
human O
chromosome O
17p11 O
. O

Southern O
blot O
analysis O
genomic O
DNA O
from O
hybrid O
cell O
was O
used O
to O
localize O
VLCAD O
gene O
human O
chromosome O
17p11 O
. O

of O
from O
hybrid O
cell O
was O
used O
localize O
the O
VLCAD O
gene O
to O
human O
chromosome O
17p11 O
. O

Southern O
blot O
analysis O
of O
genomic O
dna O
from O
cross O
cadre O
lines O
was O
used O
to O
place O
the O
VLCAD O
cistron O
to O
homo O
chromosome O
17p11 O
. O

the O
blot O
cell O
from O
genomic O
DNA O
VLCAD O
hybrid O
analysis O
lines O
was O
used O
17p11 O
localize O
of O
Southern O
gene O
to O
human O
chromosome O
to O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
hybrid O
cell O
lines O
was O
used O
to O
localize O
the O
VLCAD O
gene O
to O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O

Southern O
blot O
analysis O
of O
from O
hybrid O
lines O
was O
used O
to O
localize O
the O
VLCAD O
gene O
to O
human O
. O

Southern O
blot O
analysis O
of O
genomic O
DNA O
from O
hybrid O
cell O
lines O
was O
used O
to O
localize O
the O
VLCAD O
gene O
to O
human O
chromosome O
17p11 O
. O

- O
p11 O
. O

two O
2 O
- O
p11 O
. O

two O
2 O
- O
p11 O
. O

2 O
- O

two O
2 O
- O
p11 O
. O

ii O
- O
p11 O
. O

p11 O
- O
2 O
. O

. O
- O
p11 O
2 O

deuce O
- O
p11 O
. O

- O
p11 O

2 O
- O
p11 O
. O

. O
13105 O

. O
13105 O

1 O

. O
13105 O

13105 O

13105 O
. O

Using O
Northern O
is O
Western O
blot O
distribution O
to O
we O
the O
tissue O
specific O
that O
abundant O
VLCAD O
mRNA O
and O
protein O
in O
human O
several O
tissues O
investigate O
showed O
analysis O
VLCAD O
most O
and O
muscle O
in O
heart O
and O
of O
skeletal O
. O

Using O
Western O
blot O
analysis O
to O
the O
tissue O
of O
VLCAD O
and O
protein O
tissues O
showed O
that O
VLCAD O
most O
abundant O
in O
and O
skeletal O
muscle O
. O

Using O
Northern O
and O
Western O
mrna O
eye O
be O
blot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
VLCAD O
mRNA O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
VLCAD O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
informational O
rna O
informational O
rna O
informational O
rna O
informational O
rna O

Using O
Northern O
and O
Western O
mrna O
eye O
fleck O
blot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
VLCAD O
mRNA O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
VLCAD O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
informational O
rna O
informational O
rna O
informational O
rna O
informational O
rna O

Northern O
several O
and O
Western O
blot O
analysis O
most O
investigate O
the O
tissue O
specific O
abundant O
of O
VLCAD O
heart O
and O
protein O
in O
distribution O
human O
tissues O
we O
. O
that O
VLCAD O
is O
to O
Using O
skeletal O
showed O
and O
in O
muscle O
mRNA O

Using O
Northern O
and O
Western O
blot O
analysis O
the O
tissue O
specific O
distribution O
VLCAD O
mRNA O
and O
protein O
in O
human O
tissues O
we O
showed O
VLCAD O
is O
abundant O
in O
heart O
and O
skeletal O
muscle O
. O

expend O
northern O
and O
Western O
smirch O
analysis O
to O
inquire O
the O
tissue O
particular O
distribution O
of O
VLCAD O
mRNA O
and O
protein O
in O
various O
human O
weave O
we O
register O
that O
VLCAD O
is O
most O
abundant O
in O
center O
and O
skeletal O
brawn O
. O

use O
northern O
and O
Western O
blot O
analysis O
to O
inquire O
the O
weave O
particular O
dispersion O
of O
VLCAD O
mRNA O
and O
protein O
in O
several O
human O
weave O
we O
record O
that O
VLCAD O
is O
most O
abundant O
in O
essence O
and O
skeletal O
brawn O
. O

Using O
Northern O
and O
Western O
mrna O
eye O
fleck O
blot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
VLCAD O
mRNA O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
VLCAD O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
informational O
rna O
informational O
rna O
informational O
rna O
informational O
rna O

victimization O
northerly O
and O
western O
fleck O
analysis O
to O
investigate O
the O
weave O
particular O
distribution O
of O
VLCAD O
mrna O
and O
protein O
in O
several O
human O
tissues O
we O
evidence O
that O
VLCAD O
is O
most O
abundant O
in O
inwardness O
and O
skeletal O
brawniness O
. O

Using O
Northern O
and O
Western O
blot O
analysis O
to O
investigate O
the O
tissue O
specific O
distribution O
of O
VLCAD O
mRNA O
and O
protein O
in O
several O
human O
tissues O
we O
showed O
that O
VLCAD O
is O
most O
abundant O
in O
heart O
and O
skeletal O
muscle O
. O

This O
agrees O
and O
patients O
the O
fact O
characteristic O
cardiac O
well O
muscle O
symptoms O
are O
that O
for O
with O
with O
VLCAD B
deficiency I
. O

well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
with O
VLCAD B
deficiency I
. O

This O
correspond O
considerably O
with O
the O
fact O
that O
cardiac O
and O
musculus O
symptoms O
are O
characteristic O
for O
patients O
with O
VLCAD B
lack I
. O

This O
fit O
substantially O
with O
the O
fact O
that O
cardiac O
and O
heftiness O
symptoms O
are O
feature O
for O
patients O
with O
VLCAD B
want I
. O

VLCAD O
agrees O
well O
with O
the O
fact O
for O
patients O
and O
muscle O
symptoms O
are O
deficiency O
that O
cardiac O
with O
characteristic B
This I
. O

This O
agrees O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
VLCAD B
. O

This O
agrees O
well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
VLCAD B
deficiency I
considerably O
considerably O
considerably O
considerably O
lack O
. O

This O
agrees O
comfortably O
with O
the O
fact O
that O
cardiac O
and O
musculus O
symptoms O
are O
feature O
for O
patients O
with O
VLCAD B
lack I
. O

This O
agrees O
well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
VLCAD B
deficiency I
considerably O
considerably O
considerably O
considerably O
considerably O
. O

for O
agrees O
well O
symptoms O
the O
fact O
that O
. O
patients O
muscle O
with O
are O
This O
characteristic O
and O
with O
VLCAD B
deficiency I
cardiac O

This O
agrees O
well O
with O
the O
fact O
that O
cardiac O
and O
muscle O
symptoms O
are O
characteristic O
for O
patients O
with O
VLCAD B
deficiency I
. O

blot O
analysis O
and O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
four O
patients O
with O
VLCAD B
deficiency I
showed O
that O
VLCAD O
mRNA O
was O
undetectable O
one O
patient O
and O
that O
the O
both O
. O

Northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD B
deficiency I
showed O
that O
VLCAD O
mRNA O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
VLCAD O
alleles O
. O

other O
VLCAD O
analysis O
and O
VLCAD O
of O
alleles O
three O
amplified O
VLCAD O
cDNA O
from O
four O
in O
deficiency O
with O
sequencing B
patients I
showed O
that O
unrelated O
mRNA O
was O
undetectable O
blot O
one O
patient O
. O
Northern O
the O
that O
cloned O
have O
mutations O
in O
both O
VLCAD O
PCR O
and O

Northern O
blot O
analysis O
sequencing O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD O
mRNA O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
VLCAD O
. O

northern O
stain O
analysis O
and O
sequence O
of O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD B
inadequacy I
demonstrate O
that O
VLCAD O
mRNA O
was O
insensible O
in O
unitary O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
VLCAD O
alleles O
. O

in O
showed O
analysis O
and O
sequencing O
of O
from O
PCR O
amplified O
VLCAD O
cDNA O
cloned O
four O
and O
the O
with O
VLCAD B
deficiency I
mutations O
that O
VLCAD O
mRNA O
that O
undetectable O
Northern O
one O
three O
unrelated O
patients O
was O
other O
both O
have O
in O
blot O
patient O
VLCAD O
alleles O
. O

Northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD B
deficiency I
showed O
that O
VLCAD O
mRNA O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
VLCAD O
alleles O
. O

Northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD B
deficiency I
showed O
that O
VLCAD O
mRNA O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
sequence O
inward O
VLCAD O
alleles O
. O

Northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
deficiency I
showed O
that O
mRNA O
undetectable O
in O
one O
that O
mutations O
in O
both O
alleles O
. O

Northern O
blot O
other O
and O
sequencing O
of O
cloned O
showed O
amplified O
VLCAD O
cDNA O
patient O
that O
unrelated O
patients O
PCR O
VLCAD B
deficiency I
alleles O
four O
VLCAD O
have O
was O
both O
in O
with O
from O
mRNA O
that O
the O
analysis O
and O
three O
mutations O
in O
undetectable O
VLCAD O
one O
. O

Northern O
blot O
analysis O
and O
sequencing O
of O
cloned O
PCR O
amplified O
VLCAD O
cDNA O
from O
four O
unrelated O
patients O
with O
VLCAD B
deficiency I
showed O
that O
VLCAD O
mRNA O
was O
undetectable O
in O
one O
patient O
and O
that O
the O
other O
three O
have O
mutations O
in O
both O
VLCAD O
alleles O
. O

Western O
blob O
analysis O
of O
patient O
fibroblasts O
testify O
that O
the O
distinguish O
mutations O
ensue O
in O
badly O
reduced O
amounts O
of O
VLCAD O
protein O
. O

Western O
blot O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
VLCAD O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O

Western O
blot O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
VLCAD O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O

analysis O
fibroblasts O
showed O
that O
identified O
mutations O
in O
severely O
reduced O
amounts O
of O
VLCAD O
protein O
. O

Western O
blot O
analysis O
of O
patient O
that O
the O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
VLCAD O
protein O
. O

analysis O
of O
patient O
fibroblasts O
that O
the O
identified O
mutations O
result O
severely O
reduced O
amounts O
of O
protein O
. O

VLCAD O
blot O
analysis O
protein O
patient O
fibroblasts O
showed O
the O
that O
identified O
reduced O
result O
in O
. O
Western O
amounts O
of O
mutations O
of O
severely O

Western O
blot O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
VLCAD O
depth O
psychology O
depth O
psychology O
depth O
psychology O
depth O
psychology O

western O
smudge O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
solvent O
in O
sternly O
quash O
sum O
of O
VLCAD O
protein O
. O

of O
blot O
analysis O
of O
patient O
fibroblasts O
severely O
result O
the O
identified O
mutations O
reduced O
Western O
showed O
that O
VLCAD O
in O
amounts O
protein O
. O

Western O
blot O
analysis O
of O
patient O
fibroblasts O
showed O
that O
the O
identified O
mutations O
result O
in O
severely O
reduced O
amounts O
of O
VLCAD O
protein O
. O

deficiencies O
bases O
of O
: B
subtotal I
deficiencies I
of I
and I
combination I
C7 I
combined O
their O
in O
effects O
and O
with O
other O
C6 B
C6 I
Molecular I
C7 I
. O

Molecular O
bases O
of O
combined B
subtotal I
deficiencies I
of I
C6 I
and I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
deficiency B
deficiency B
blend B
blend B
blend B
blend B
and I
C7 I
deficiencies I
. O

Molecular O
bases O
of O
combined B
subtotal I
deficiencies I
of I
C6 I
and I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
deficiency B
deficiency B
blend B
blend B
blend B
blend B
and I
C7 I
deficiencies I
. O

molecular O
footing O
of O
conflate B
subtotal I
lack I
of I
C6 I
and I
C7 I
: O
their O
core O
in O
combining O
with O
other O
C6 B
and I
C7 I
lack I
. O

Molecular O
bases O
of O
subtotal I
deficiencies I
of I
C6 I
and I
: O
their O
effects O
in O
with O
other O
and I
C7 I
deficiencies I
. O

combined B
of I
C6 I
and I
: O
their O
in O
combination O
with O
other O
C6 B
and I
C7 I
deficiencies I
. O

molecular O
qaeda O
of O
blend B
subtotal I
lack I
of I
C6 I
and I
C7 I
: O
their O
core O
in O
combining O
with O
other O
C6 B
and I
C7 I
lack I
. O

combination O
bases O
and O
of B
subtotal I
deficiencies I
with I
C6 I
of I
C7 I
: O
their O
deficiencies O
in O
combined O
Molecular O
other O
C6 B
and I
C7 I
effects I
. O

Molecular O
bases O
of O
combined B
subtotal I
deficiencies I
of I
C6 I
and I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
deficiency B
deficiency B
blend B
blend B
blend B
inward B
and I
C7 I
deficiencies I
. O

Molecular O
bases O
of O
combined B
of I
C6 I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
and I
. O

Molecular O
bases O
of O
combined B
subtotal I
deficiencies I
of I
C6 I
and I
C7 I
: O
their O
effects O
in O
combination O
with O
other O
C6 B
and I
C7 I
deficiencies I
. O

meld B
subtotal I
lack I
of I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
state O
at O
very O
depression O
levels O
, O
has O
been O
note O
in O
homozygous O
phase O
in O
deuce O
menage O
. O

Combined B
subtotal I
deficiency I
of I
C6 I
C7 I
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
in O
homozygous O
form O
in O
two O
families O
. O

been B
subtotal I
deficiency I
, I
C6 I
and I
C7 I
in O
homozygous O
which O
. O
proteins O
are O
has O
in O
very O
low O
levels O
of O
expressed O
form O
observed O
at O
in O
Combined O
, O
two O
families O
both O

Combined B
subtotal I
deficiency I
of I
be I
verbalise I
astatine I
identical I
crushed I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
inward O
 O
inward O
, O
has O
been O
observed O
in O
homozygous O
form O
in O
two O
families O
. O

Combined B
subtotal I
deficiency I
of I
be I
verbalise I
astatine I
identical I
crushed I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
inward O
 O
inward O
, O
has O
been O
observed O
in O
homozygous O
form O
in O
two O
families O
. O

Combined B
subtotal I
deficiency I
of I
C6 I
and I
C7 I
, O
which O
both O
are O
expressed O
at O
very O
low O
levels O
, O
observed O
in O
homozygous O
form O
in O
two O
families O
. O

. B
subtotal I
deficiency I
at I
C6 I
and I
in I
, O
of O
which O
both O
proteins O
two O
expressed O
form O
in O
low O
levels O
, O
has O
are O
observed O
in O
homozygous O
very O
C7 O
been O
families O
Combined O

Combined B
subtotal I
deficiency I
of I
C6 I
and I
C7 I
, O
which O
proteins O
are O
expressed O
at O
very O
low O
levels O
, O
been O
observed O
in O
homozygous O
form O
in O
two O

immix B
subtotal I
want I
of I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
carry O
at O
very O
low O
levels O
, O
has O
been O
honor O
in O
homozygous O
build O
in O
ii O
mob O
. O

meld B
subtotal I
want I
of I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
uttered O
at O
very O
humble O
grade O
, O
has O
been O
honor O
in O
homozygous O
grade O
in O
two O
household O
. O

Combined B
subtotal I
deficiency I
of I
C6 I
and I
C7 I
, O
in O
which O
both O
proteins O
are O
expressed O
at O
very O
low O
levels O
, O
has O
been O
observed O
in O
homozygous O
form O
in O
two O
families O
. O

A O
defect O
is O
the O
5 O
of O
donor O
the O
of O
intron O
15 O
protein O
responsible O
C6 O
gene O
low O
the O
low O
weight O
molecular O
of O
site O
C6 O
splice O
and O
probably O
at O
concentration O
for O
its O
explains O
the O
expressed O
. O

A O
the O
5 O
splice O
donor O
of O
intron O
the O
C6 O
explains O
the O
of O
C6 O
protein O
and O
probably O
responsible O
for O
low O
expressed O
concentration O
. O

A O
defect O
at O
the O
cistron O
explicate O
be O
5 O
splice O
donor O
site O
of O
intron O
15 O
of O
the O
C6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
gene O
gene O
gene O
gene O
gene O
gene O
 O
. O

A O
defect O
at O
the O
cistron O
explicate O
 O
5 O
splice O
donor O
site O
of O
intron O
15 O
of O
the O
C6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
gene O
gene O
gene O
gene O
gene O
gene O
 O
. O

defect O
molecular O
at O
the O
5 O
splice O
probably O
site O
of O
intron O
15 O
responsible O
the O
and O
its O
explains O
the O
low O
of O
weight O
of O
the O
. O
protein O
C6 O
is O
donor O
A O
expressed O
C6 O
low O
for O
concentration O
gene O

A O
defect O
at O
the O
5 O
splice O
of O
intron O
15 O
of O
C6 O
gene O
explains O
the O
low O
weight O
of O
the O
C6 O
and O
is O
responsible O
for O
its O
low O
expressed O
concentration O
. O

A O
desert O
at O
the O
quintuplet O
splice O
bestower O
place O
of O
intron O
xv O
of O
the O
C6 O
gene O
explicate O
the O
humble O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
believably O
creditworthy O
for O
its O
humble O
extract O
concentration O
. O

A O
blemish O
at O
the O
five O
splicing O
bestower O
locate O
of O
intron O
fifteen O
of O
the O
C6 O
cistron O
explains O
the O
low O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
convey O
absorption O
. O

A O
defect O
at O
the O
cistron O
explicate O
 O
5 O
splice O
donor O
site O
of O
intron O
15 O
of O
the O
C6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
gene O
gene O
gene O
gene O
gene O
gene O
 O
. O

amp O
mar O
at O
the O
5 O
marry O
presenter O
site O
of O
intron O
15 O
of O
the O
C6 O
factor O
excuse O
the O
scummy O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
credibly O
responsible O
for O
its O
scummy O
show O
immersion O
. O

A O
defect O
at O
the O
5 O
splice O
donor O
site O
of O
intron O
15 O
of O
the O
C6 O
gene O
explains O
the O
low O
molecular O
weight O
of O
the O
C6 O
protein O
and O
is O
probably O
responsible O
for O
its O
low O
expressed O
concentration O
. O

The O
C7 O
defect O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
and O
altered O
isoelectric O
point O

The O
C7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
weight O
low O
, O
and O
altered O
isoelectric O
point O
. O

The O
C7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
neutered O
steer O
steer O
flaw O
flaw O
flaw O
and O
altered O
isoelectric O
point O
. O

The O
C7 O
fault O
is O
more O
oracular O
the O
protein O
is O
of O
convention O
molecular O
weight O
, O
depleted O
circulating O
compactness O
, O
and O
spay O
isoelectric O
point O
. O

The O
C7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
neutered O
steer O
steer O
flaw O
flaw O
flaw O
and O
altered O
isoelectric O
point O
. O

The O
C7 O
fault O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
burden O
, O
depleted O
disseminate O
concentration O
, O
and O
spay O
isoelectric O
luff O
. O

The O
C7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
molecular O
weight O
low O
circulating O
concentration O
, O
and O
altered O
isoelectric O

normal O
C7 O
defect O
and O
more O
enigmatic O
the O
is O
protein O
of O
altered O
molecular O
, O
weight O
. O
circulating O
concentration O
, O
is O
The O
isoelectric O
point O
low O

The O
C7 O
defect O
is O
more O
puzzling O
the O
protein O
is O
of O
formula O
molecular O
slant O
, O
depleted O
circulating O
immersion O
, O
and O
spay O
isoelectric O
point O
. O

low O
C7 O
is O
the O
more O
enigmatic O
circulating O
protein O
defect O
of O
normal O
molecular O
isoelectric O
, O
is O
The O
concentration O
, O
and O
altered O
weight O
point O
. O

The O
C7 O
defect O
is O
more O
enigmatic O
the O
protein O
is O
of O
normal O
molecular O
weight O
, O
low O
circulating O
concentration O
, O
and O
altered O
isoelectric O
point O
. O

an O
Arg O
> O
Ser O
codon O
replacement O
in O
exon O
xi O
is O
the O
only O
molecular O
revision O
inside O
the O
ripen O
C7 O
protein O
. O

An O
Arg O
> O
Ser O
codon O
substitution O
in O
exon O
11 O
is O
the O
only O
molecular O
alteration O
within O
the O
mature O
C7 O
 O
 O
 O
 O
 O
 O
protein O
. O

An O
Arg O
> O
Ser O
codon O
substitution O
in O
exon O
11 O
is O
the O
only O
molecular O
alteration O
within O
the O
mature O
C7 O
 O
 O
 O
 O
 O
 O
protein O
. O

> O
substitution O
in O
exon O
is O
the O
molecular O
alteration O
within O
the O
mature O
C7 O
protein O
. O

An O
Arg O
> O
Ser O
codon O
exon O
11 O
the O
only O
molecular O
alteration O
within O
the O
mature O
C7 O
protein O
. O

> O
Ser O
codon O
substitution O
exon O
11 O
is O
the O
only O
alteration O
within O
the O
mature O
protein O
. O

C7 O
Arg O
> O
protein O
codon O
substitution O
in O
11 O
exon O
is O
within O
only O
molecular O
. O
An O
the O
mature O
the O
Ser O
alteration O

An O
Arg O
> O
Ser O
codon O
substitution O
in O
exon O
11 O
is O
the O
only O
molecular O
alteration O
within O
the O
mature O
C7 O
 O
 O
 O
 O
 O
an O
protein O
. O

an O
Arg O
> O
Ser O
codon O
permutation O
in O
exon O
eleven O
is O
the O
only O
molecular O
modification O
inside O
the O
suppurate O
C7 O
protein O
. O

mature O
Arg O
> O
Ser O
codon O
substitution O
alteration O
only O
11 O
is O
the O
within O
An O
in O
exon O
C7 O
molecular O
the O
protein O
. O

An O
Arg O
> O
Ser O
codon O
substitution O
in O
exon O
11 O
is O
the O
only O
molecular O
alteration O
within O
the O
mature O
C7 O
protein O
. O

These O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
region O
clear O
cut O
antiophthalmic O
factor O
clear O
cut O
clear O
cut O
be O
be O
antiophthalmic O
factor O
, O

are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
, O
a O
distinct O
haplotype O
. O

These O
flaw O
are O
connect O
with O
a O
feature O
situated O
of O
polymorphous O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
region O
, O
spring O
a O
trenchant O
haplotype O
. O

These O
defects O
are O
associated O
with O
a O
characteristic O
of O
polymorphic O
markers O
in O
the O
C6 O
/ O
C7 O
region O
a O
distinct O
haplotype O
. O

These O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
region O
clear O
cut O
antiophthalmic O
factor O
clear O
cut O
clear O
cut O
be O
be O
be O
, O
forming O

These O
fault O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphous O
dna O
markers O
in O
the O
C6 O
/ O
C7 O
part O
, O
spring O
a O
distinct O
haplotype O
. O

These O
blemish O
are O
associated O
with O
a O
characteristic O
lot O
of O
polymorphous O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
neighborhood O
, O
work O
a O
distinguishable O
haplotype O
. O

These O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
DNA O
the O
C6 O
/ O
C7 O
region O
, O
forming O
a O
distinct O

These O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
region O
clear O
cut O
antiophthalmic O
factor O
clear O
cut O
clear O
cut O
be O
be O
be O
, O
forming O

region O
defects O
are O
DNA O
with O
a O
characteristic O
, O
. O
polymorphic O
associated O
markers O
in O
the O
haplotype O
/ O
C7 O
a O
set O
These O
forming O
distinct O
C6 O
of O

These O
defects O
are O
associated O
with O
a O
characteristic O
set O
of O
polymorphic O
DNA O
markers O
in O
the O
C6 O
/ O
C7 O
region O
, O
forming O
a O
distinct O
haplotype O
. O

The O
haplotype O
has O
been O
haplotype O
hold O
back O
faulty O
cistron O
find O
out O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
lack O
unlike O
either B
to I
C6 I
or I
C7 O
deficiency O
, O
but O
with O
different O
consequences O
early O

The O
haplotype O
has O
been O
haplotype O
hold O
back O
faulty O
cistron O
find O
out O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
lack O
pass O
either B
to I
C6 I
or I
C7 O
deficiency O
, O
but O
with O
different O
consequences O
early O

consequences O
haplotype O
, O
defective O
found O
in O
different O
with O
been O
number O
of O
other O
C6 O
containing O
has O
a O
that O
lead O
either O
to O
haplotypes B
or I
C7 I
deficiency I
genes O
combination O
with O
but O
The O
. O

The O
haplotype O
has O
been O
haplotype O
hold O
back O
faulty O
cistron O
find O
out O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
lack O
unlike O
either B
to I
C6 I
or I
C7 O
deficiency O
, O
but O
with O
different O
consequences O
early O

The O
haplotype O
has O
been O
found O
in O
combination O
a O
number O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
C6 B
or I
C7 I
deficiency I
, O
but O
with O
different O
consequences O
. O

The O
haplotype O
has O
been O
plant O
in O
compounding O
with O
a O
routine O
of O
other O
haplotypes O
carry O
faulty O
genes O
that O
pass O
either O
to O
C6 B
or I
C7 I
want I
, O
but O
with O
unlike O
upshot O
. O

that O
haplotype O
has O
been O
found O
in O
or O
other O
a O
number O
of O
The O
consequences O
deficiency O
genes O
defective O
lead O
, O
either O
to O
C6 B
combination I
C7 I
containing I
with O
but O
with O
different O
haplotypes O
. O

C6 O
haplotype O
has O
either O
found O
in O
combination O
but O
deficiency O
number O
consequences O
other O
with O
to O
C7 O
genes O
that O
lead O
been O
containing O
, B
or I
defective I
a I
The O
with O
haplotypes O
different O
of O
. O

The O
haplotype O
has O
been O
happen O
in O
combining O
with O
a O
come O
of O
other O
haplotypes O
bear O
bad O
genes O
that O
head O
either O
to O
C6 B
or I
C7 I
lack I
, O
but O
with O
unlike O
outcome O
. O

The O
haplotype O
has O
been O
found O
combination O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
lead O
either O
to O
C6 B
or I
C7 I
deficiency I
with O
different O
consequences O

The O
haplotype O
has O
been O
found O
in O
combination O
with O
a O
number O
of O
other O
haplotypes O
containing O
defective O
genes O
that O
lead O
either O
to O
C6 B
or I
C7 I
deficiency I
, O
but O
with O
different O
consequences O
. O

Where O
it O
is O
combined O
be O
grade O
fundament O
follow O
with O
a O
C6 B
- I
deficient I
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
follow O
follow O
follow O
follow O
blood O
serum O

Where O
it O
is O
a O
, O
the O
serum O
levels O
can O
surprisingly O
high O
, O
there O
is O
no O
C6 O
generating O
to O
the O
C7 O
. O

Where O
it O
is O
immix O
with O
a O
C6 B
- I
substandard I
factor O
, O
the O
serum O
C7 O
levels O
can O
be O
astonishingly O
high O
, O
perchance O
because O
there O
is O
no O
C6 O
father O
C56 O
to O
consume O
the O
C7 O
. O

Where O
it O
is O
combined O
with O
a O
C6 B
deficient I
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
. O

Where O
it O
is O
aggregate O
with O
a O
C6 B
- I
lacking I
cistron O
, O
the O
serum O
C7 O
stage O
can O
be O
amazingly O
gamy O
, O
mayhap O
because O
there O
is O
no O
C6 O
father O
C56 O
to O
waste O
the O
C7 O
. O

Where O
it O
is O
combined O
be O
grade O
fundament O
follow O
with O
a O
C6 B
- I
deficient I
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
follow O
follow O
follow O
follow O
blood O
serum O

Where O
it O
is O
flux O
with O
a O
C6 B
- I
wanting I
factor O
, O
the O
serum O
C7 O
floor O
can O
be O
astonishingly O
high O
, O
mayhap O
because O
there O
is O
no O
C6 O
engender O
C56 O
to O
have O
the O
C7 O
. O

possibly O
high O
is O
combined O
with O
a O
C6 B
- I
deficient I
gene O
, O
the O
serum O
no O
consume O
can O
be O
surprisingly O
C56 O
, O
it O
because O
C7 O
is O
C7 O
C6 O
generating O
Where O
levels O
there O
the O
to O
. O

Where O
it O
is O
combined O
with O
a O
- I
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
high O
, O
possibly O
because O
there O
is O
no O
C56 O
to O
consume O
C7 O

Where O
it O
is O
combined O
nobelium O
grade O
fundament O
blood O
serum O
with O
a B
C6 I
- I
deficient O
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
atomic O
number O
 O
atomic O

Where O
it O
is O
combined O
with O
a O
C6 B
- I
deficient I
gene O
, O
the O
serum O
C7 O
levels O
can O
be O
surprisingly O
high O
, O
possibly O
because O
there O
is O
no O
C6 O
generating O
C56 O
to O
consume O
the O
C7 O
. O

and O
may O
, O
where O
the O
C7 O
C7 O
are O
both O
defective O
( O
of O
still O
circulating O
ample O
) O
, O
there O
there O
be O
a O
profound O
consume O
of O
partially O
C7 O
C56 O
contrast O
to O
deficit O
C6 O
is O
produce O
functional O
In O
because O
the O
already O
small O
amount O
but O
genes O
. O

In O
contrast O
, O
the O
C7 O
genes O
are O
both O
defective O
( O
partially O
functional O
) O
there O
be O
a O
profound O
circulating O
ample O
C6 O
to O
C56 O
and O
the O
already O
small O
C7 O
. O

inwards O
line O
, O
where O
the O
C7 O
genes O
are O
both O
bad O
( O
but O
even O
partially O
operable O
) O
, O
there O
whitethorn O
be O
a O
wakeless O
shortfall O
of O
disperse O
C7 O
because O
there O
is O
plentiful O
C6 O
to O
produce O
C56 O
and O
consume O
the O
already O
little O
measure O
of O
C7 O
. O

indium O
counterpoint O
, O
where O
the O
C7 O
factor O
are O
both O
faulty O
( O
but O
motionless O
partly O
usable O
) O
, O
there O
may O
be O
a O
profound O
deficit O
of O
disperse O
C7 O
because O
there O
is O
plentiful O
C6 O
to O
produce O
C56 O
and O
eat O
the O
already O
belittled O
total O
of O
C7 O
. O

In O
contrast O
to O
where O
the O
C7 O
genes O
may O
both O
defective O
( O
still O
. O
partially O
functional O
C6 O
, O
there O
be O
are O
a O
produce O
deficit O
consume O
circulating O
because O
there O
profound O
is O
ample O
) O
already O
C7 O
C56 O
and O
of O
the O
, O
small O
amount O
of O
C7 O
but O

In O
contrast O
, O
the O
are O
both O
defective O
( O
but O
still O
partially O
functional O
) O
a O
profound O
deficit O
of O
circulating O
C7 O
because O
there O
is O
ample O
C6 O
to O
produce O
C56 O
and O
the O
small O
amount O
of O
C7 O
. O

In O
contrast O
, O
where O
the O
C7 O
genes O
are O
both O
defective O
( O
but O
still O
partially O
functional O
) O
, O
there O
may O
be O
a O
profound O
deficit O
of O
circulating O
C7 O
because O
there O
is O
ample O
C6 O
to O
produce O
C56 O
and O
consume O
be O
low O
quantity O
be O
be O
be O
be O
be O
be O
be O
be O
be O
the O
already O
small O
amount O
of O
C7 O
. O

small O
circulating O
, O
where O
, O
C7 O
a O
to O
both O
defective O
( O
but O
still O
genes O
already O
) O
the O
C6 O
may O
be O
partially O
profound O
deficit O
of O
there O
C7 O
because O
C7 O
there O
ample O
is O
contrast O
produce O
C56 O
and O
consume O
the O
functional O
In O
amount O
of O
are O
. O

In O
contrast O
, O
the O
genes O
are O
both O
defective O
( O
but O
still O
partially O
functional O
) O
there O
may O
be O
a O
profound O
there O
C6 O
produce O
C56 O
and O
the O
already O
small O
amount O
of O
C7 O

indium O
contrast O
, O
where O
the O
C7 O
genes O
are O
both O
faulty O
( O
but O
motionless O
partly O
usable O
) O
, O
there O
may O
be O
a O
unplumbed O
shortage O
of O
circulating O
C7 O
because O
there O
is O
sizeable O
C6 O
to O
produce O
C56 O
and O
consume O
the O
already O
small O
come O
of O
C7 O
. O

In O
contrast O
, O
where O
the O
C7 O
genes O
are O
both O
defective O
( O
but O
still O
partially O
functional O
) O
, O
there O
may O
be O
a O
profound O
deficit O
of O
circulating O
C7 O
because O
there O
is O
ample O
C6 O
to O
produce O
C56 O
and O
consume O
the O
already O
small O
amount O
of O
C7 O
. O

Each O
molecular O
find O
out O
inward O
flaw O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
be O

effect O
molecular O
defect O
. O
also O
been O
found O
in O
. O
and O
has O
the O
Each O
expected O
isolation O
has O

Each O
molecular O
find O
out O
inward O
too O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
be O

each O
molecular O
desert O
has O
also O
been O
determine O
in O
isolation O
and O
has O
the O
wait O
effect O
. O
. O

expected O
molecular O
defect O
in O
also O
been O
effect O
has O
isolation O
and O
Each O
the O
has O
found O
. O
. O

Each O
molecular O
find O
out O
inward O
flaw O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
be O

Each O
molecular O
fault O
has O
also O
been O
establish O
in O
isolation O
and O
has O
the O
await O
core O
. O
. O

Each O
molecular O
fault O
has O
likewise O
been O
found O
in O
isolation O
and O
has O
the O
bear O
force O
. O
. O

Each O
molecular O
isolation O
. O
also O
been O
expected O
in O
defect O
and O
has O
the O
found O
effect O
has O
. O

molecular O
defect O
has O
also O
been O
found O
in O
has O
the O
expected O
effect O
. O
. O

Each O
molecular O
defect O
has O
also O
been O
found O
in O
isolation O
and O
has O
the O
expected O
effect O
. O
. O

deficiency O
bases O
of O
human O
. B
C7 I
Genetic I
complement O

Genetic O
root O
of O
human O
complement B
C7 I
lack I
. O

of O
C7 I
deficiency I
. O

Genetic O
homo O
homo O
bases O
of O
human O
complement B
C7 I
deficiency I
. O

Genetic O
of O
human O
deficiency I
. O

Genetic O
complement O
of O
human O
bases B
C7 I
. I
deficiency O

. O
human O
of O
bases O
complement B
C7 I
deficiency I
Genetic O

Genetic O
homo O
accompaniment O
bases O
of O
human O
complement B
C7 I
deficiency I
. O

Genetic O
theme O
of O
human O
complement B
C7 I
inadequacy I
. O

Genetic O
homo O
accompaniment O
bases O
of O
human O
complement B
C7 I
deficiency I
. O

Genetic O
bases O
of O
human O
complement B
C7 I
deficiency I
. O

complement B
C7 I
want I
( O
C7D B
) O
is O
associated O
often O
with O
perennial O
bacterial B
infections I
, O
particularly O
meningitis B
do O
by O
Neisseria B
meningitidis I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
, O
especially O
meningitis B
caused O
by O
lack O
lack O
lack O
lack O
lack O
lack O
Neisseria B
meningitidis I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
, O
especially O
meningitis B
caused O
by O
lack O
lack O
lack O
lack O
lack O
lack O
Neisseria B
meningitidis I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
with O
recurrent O
infections I
, O
especially O
meningitis B
caused O
by O
Neisseria B

especially B
C7 I
frequently I
is O
C7D B
) O
meningitis O
associated O
deficiency O
with O
recurrent O
bacterial B
. I
, O
( O
Complement B
caused O
by O
Neisseria B
meningitidis I
infections O

complement B
C7 I
inadequacy I
( O
C7D B
) O
is O
associated O
often O
with O
repeated O
bacterial B
transmission I
, O
especially O
meningitis B
stimulate O
by O
Neisseria B
meningitidis I
. O

. B
C7 I
deficiency I
recurrent O
C7D B
) O
is O
Neisseria O
especially O
with O
( O
bacterial B
, I
infections O
frequently O
meningitis B
caused O
by O
associated B
Complement I
meningitidis O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
, O
especially O
meningitis B
caused O
by O
lack O
lack O
lack O
lack O
lack O
accompaniment O
Neisseria B
meningitidis I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
especially O
by O
Neisseria B
meningitidis I
. O

Complement B
C7 I
want I
( O
C7D B
) O
is O
colligate O
oft O
with O
repeated O
bacterial B
infections I
, O
peculiarly O
meningitis B
stimulate O
by O
Neisseria B
meningitidis I
. O

Complement B
C7 I
deficiency I
( O
C7D B
) O
is O
associated O
frequently O
with O
recurrent O
bacterial B
infections I
, O
especially O
meningitis B
caused O
by O
Neisseria B
meningitidis I
. O

We O
report O
inwards O
fundament O
inward O
in O
this O
work O
the O
molecular O
bases O
of O
C7D B
in O
two O
unrelated O
Japanese O
males O
rear O
. O

Japanese O
report O
in O
. O
work O
the O
molecular O
bases O
males O
C7D B
in O
two O
We O
unrelated O
of O
this O

We O
report O
inwards O
fundament O
inward O
in O
this O
work O
the O
molecular O
bases O
of O
C7D B
in O
two O
unrelated O
Japanese O
males O
rear O
. O

We O
report O
in O
this O
operate O
the O
molecular O
bases O
of O
C7D B
in O
ii O
unrelated O
nipponese O
males O
. O

unrelated O
report O
in O
bases O
work O
the O
Japanese O
this O
of O
C7D B
We O
two O
in O
molecular O
males O
. O

We O
report O
inwards O
fundament O
inward O
in O
this O
work O
the O
molecular O
bases O
of O
C7D B
in O
two O
unrelated O
Japanese O
males O
rear O
. O

We O
describe O
in O
this O
sour O
the O
molecular O
understructure O
of O
C7D B
in O
deuce O
unrelated O
Japanese O
males O
. O

We O
describe O
in O
this O
work O
the O
molecular O
pedestal O
of O
C7D B
in O
deuce O
unrelated O
nipponese O
males O
. O

We O
report O
of O
. O
work O
the O
unrelated O
bases O
in O
C7D B
in O
two O
molecular O
Japanese O
this O
males O

report O
in O
this O
work O
the O
molecular O
bases O
in O
two O
unrelated O
Japanese O
males O
. O

We O
report O
in O
this O
work O
the O
molecular O
bases O
of O
C7D B
in O
two O
unrelated O
Japanese O
males O
. O

We O
used O
exon O
- O
particular O
PCR O
/ O
single O
- O
fibril O
conformation O
pleomorphism O
analysis O
as O
a O
sort O
tone O
for O
mutations O
. O

We O
used O
exon O
- O
specific O
PCR O
/ O
single O
- O
strand O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O

We O
used O
exon O
- O
specific O
PCR O
/ O
single O
- O
strand O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O

exon O
PCR O
/ O
single O
strand O
conformation O
analysis O
as O
a O
screening O
step O
for O
mutations O
. O

We O
used O
exon O
- O
specific O
single O
- O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
mutations O
. O

exon O
- O
specific O
PCR O
single O
- O
strand O
conformation O
polymorphism O
as O
a O
screening O
step O
mutations O
. O

for O
used O
exon O
mutations O
specific O
PCR O
/ O
- O
single O
strand O
a O
polymorphism O
analysis O
. O
We O
screening O
step O
conformation O
- O
as O

We O
used O
exon O
- O
specific O
PCR O
/ O
single O
- O
strand O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O

We O
used O
exon O
- O
particular O
PCR O
/ O
unmarried O
- O
strand O
compliance O
pleomorphism O
analysis O
as O
a O
sieve O
step O
for O
mutant O
. O

step O
used O
exon O
- O
specific O
PCR O
as O
polymorphism O
- O
strand O
conformation O
a O
We O
/ O
single O
for O
analysis O
screening O
mutations O
. O

We O
used O
exon O
- O
specific O
PCR O
/ O
single O
- O
strand O
conformation O
polymorphism O
analysis O
as O
a O
screening O
step O
for O
mutations O
. O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
in O
display O
case O
two O
display O
case O
two O
two O
sequence O
fair O
game O
exon O
15 O
of O

sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
exon O
of O
case O
2 O
. O

subsequent O
place O
sequence O
of O
the O
target O
exons O
name O
homozygous O
mutations O
in O
exon O
xvi O
of O
casing O
single O
and O
in O
exon O
15 O
of O
casing O
2 O
. O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
homozygous O
mutations O
exon O
16 O
of O
case O
1 O
and O
in O
of O
case O
2 O
. O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
in O
display O
case O
two O
display O
case O
two O
two O
sequence O
sequence O
exon O
15 O
of O
case O

subsequent O
guide O
sequence O
of O
the O
target O
exons O
name O
homozygous O
mutations O
in O
exon O
xvi O
of O
typeface O
1 O
and O
in O
exon O
15 O
of O
typeface O
two O
. O

subsequent O
calculate O
sequence O
of O
the O
target O
exons O
key O
homozygous O
mutations O
in O
exon O
16 O
of O
fount O
unity O
and O
in O
exon O
15 O
of O
fount O
two O
. O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
in O
of O
case O
1 O
and O
in O
exon O
15 O
of O
case O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
in O
display O
case O
two O
display O
case O
two O
two O
sequence O
sequence O
exon O
15 O
of O
case O

in O
direct O
sequencing O
in O
the O
target O
exons O
exon O
. O
mutations O
of O
exon O
16 O
of O
2 O
1 O
and O
of O
identified O
Subsequent O
15 O
case O
case O
homozygous O

Subsequent O
direct O
sequencing O
of O
the O
target O
exons O
identified O
homozygous O
mutations O
in O
exon O
16 O
of O
case O
1 O
and O
in O
exon O
15 O
of O
case O
2 O
. O

The O
mutation O
codon O
case O
1 O
was O
transversion O
nucleotide O
T O
to O
A O
leading O
of O
nucleotide O
2250 O
to O
the O
third O
TGA O
at O
the O
( O
TGT O
for O
Cys728 O
, O
a O
codon O
a O
stop O
of O
homozygous O
, O
C728X O
) O
. O

mutation O
case O
1 O
was O
a O
homozygous O
T O
to O
A O
at O
nucleotide O
2250 O
, O
the O
third O
nucleotide O
codon O
TGT O
for O
, O
to O
a O
stop O
( O

The O
variation O
of O
case O
ace O
was O
a O
homozygous O
T O
to O
A O
transversion O
at O
base O
2250 O
, O
the O
third O
base O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
star O
to O
a O
stop O
codon O
TGA O
( O
C728X O
) O
. O

to O
the O
of O
case O
the O
was O
2250 O
TGA O
T O
to O
A O
transversion O
at O
Cys728 O
homozygous O
, O
1 O
codon O
nucleotide O
of O
nucleotide O
codon O
TGT O
for O
mutation O
, O
leading O
The O
third O
stop O
a O
a O
( O
C728X O
) O
. O

The O
mutation O
of O
case O
 O
1 O
was O
a O
homozygous O
T O
to O
A O
transversion O
at O
nucleotide O
2250 O
, O
the O
third O
nucleotide O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
leading O
to O
a O
stop O
codon O
TGA O
( O
C728X O
) O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

Cys728 O
nucleotide O
of O
case O
1 O
was O
a O
homozygous O
T O
to O
A O
transversion O
at O
to O
stop O
, O
the O
third O
C728X O
of O
the O
codon O
a O
for O
The O
, O
TGA O
nucleotide O
2250 O
TGT O
codon O
. O
( O
) O
mutation O
leading O

The O
mutation O
of O
case O
was O
T O
to O
A O
transversion O
at O
nucleotide O
2250 O
, O
the O
codon O
TGT O
for O
Cys728 O
, O
leading O
to O
a O
stop O
codon O
TGA O
( O
C728X O
) O
. O

The O
mutant O
of O
type O
single O
was O
angstrom O
homozygous O
tonne O
to O
angstrom O
transversion O
at O
base O
2250 O
, O
the O
tierce O
base O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
head O
to O
angstrom O
stop O
codon O
TGA O
( O
C728X O
) O
. O

The O
mutation O
of O
case O
deoxythymidine O
monophosphate O
1 O
was O
a O
homozygous O
T O
to O
A O
transversion O
at O
nucleotide O
2250 O
, O
the O
third O
nucleotide O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
leading O
to O
a O
stop O
codon O
TGA O
( O
C728X O
) O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

The O
variation O
of O
lawsuit O
1 O
was O
a O
homozygous O
tonne O
to O
A O
transversion O
at O
base O
2250 O
, O
the O
third O
base O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
go O
to O
a O
cease O
codon O
TGA O
( O
C728X O
) O
. O

The O
mutation O
of O
case O
1 O
was O
a O
homozygous O
T O
to O
A O
transversion O
at O
nucleotide O
2250 O
, O
the O
third O
nucleotide O
of O
the O
codon O
TGT O
for O
Cys728 O
, O
leading O
to O
a O
stop O
codon O
TGA O
( O
C728X O
) O
. O

In O
case O
2 O
, O
expiration O
antiophthalmic O
factor O
nucleotide O
two O
antiophthalmic O
factor O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
caused O
a O
frameshift O
, O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
release O
release O
release O

In O
case O
a O
deletion O
( O
2137delTG O
2138delGT O
/ O
) O
caused O
a O
generating O
a O
premature O
termination O
codon O
to O
nucleotides O
downstream O
. O

in O
case O
two O
, O
a O
homozygous O
two O
- O
bp O
omission O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
caused O
a O
frameshift O
, O
father O
a O
untimely O
result O
codon O
quaternion O
to O
6 O
nucleotides O
downriver O
. O

In O
case O
2 O
, O
homozygous O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
. O

In O
case O
deuce O
, O
a O
homozygous O
deuce O
- O
bp O
excision O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
induce O
a O
frameshift O
, O
yield O
a O
previous O
termination O
codon O
4 O
to O
6 O
base O
downriver O
. O

In O
case O
2 O
, O
expiration O
antiophthalmic O
factor O
nucleotide O
two O
antiophthalmic O
factor O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
caused O
a O
frameshift O
, O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
release O
release O
release O

In O
cause O
deuce O
, O
a O
homozygous O
deuce O
- O
bp O
excision O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
do O
a O
frameshift O
, O
give O
a O
previous O
ending O
codon O
4 O
to O
sestet O
nucleotides O
downriver O
. O

, O
a O
2 O
, O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137delTG O
/ O
termination O
nucleotides O
2139delTG O
) O
caused O
to O
frameshift O
case O
generating O
. O
premature O
2138delGT O
codon O
4 O
In O
/ O
a O
downstream O
6 O

In O
case O
2 O
, O
homozygous O
- O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
) O
caused O
a O
frameshift O
, O
generating O
a O
codon O
4 O
to O
nucleotides O
. O

In O
case O
2 O
, O
inwards O
antiophthalmic O
factor O
nucleotide O
two O
inward O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
caused O
a O
frameshift O
, O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
in O
in O
in O
 O

In O
case O
2 O
, O
a O
homozygous O
2 O
- O
bp O
deletion O
( O
2137delTG O
/ O
2138delGT O
/ O
2139delTG O
) O
caused O
a O
frameshift O
, O
generating O
a O
premature O
termination O
codon O
4 O
to O
6 O
nucleotides O
downstream O
. O

Family O
in O
case O
confirmed O
genetic O
of O
the O
defect O
. O

Family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
of O
the O
defect O

Family O
consider O
in O
case O
1 O
confirmed O
the O
genic O
nature O
of O
the O
mar O
. O

Family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
flaw O
flaw O
meditate O
of O
the O
defect O
. O

Family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
flaw O
flaw O
display O
case O
of O
the O
defect O

Family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
flaw O
flaw O
meditate O
of O
the O
defect O
. O

Family O
subject O
in O
font O
unity O
confirmed O
the O
genetic O
nature O
of O
the O
defect O
. O

Family O
study O
case O
1 O
confirmed O
the O
genetic O
nature O
of O
. O

kinsfolk O
study O
in O
case O
1 O
confirmed O
the O
hereditary O
nature O
of O
the O
flaw O
. O

Family O
1 O
in O
case O
. O
confirmed O
the O
study O
nature O
of O
the O
defect O
genetic O

Family O
study O
in O
case O
1 O
confirmed O
the O
genetic O
nature O
of O
the O
defect O
. O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
display O
case O
 O
display O
case O
 O
 O
noncoding O
dna B
furthermore O
for O
C7D O
in O

we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
for O
in O
case O
1 O
. O

Moreover O
, O
we O
observe O
a O
refreshing O
polymorphism O
in O
intron O
xi O
that O
presumptively O
is O
associate O
to O
the O
variation O
responsible O
for O
C7D B
in O
case O
ane O
. O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
intron O
11 O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
in O
case O
1 O
. O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
display O
case O
 O
display O
case O
 O
 O
noncoding O
dna B
noncoding O
dna O
for O
C7D O

moreover O
, O
we O
detected O
a O
new O
pleomorphism O
in O
intron O
11 O
that O
presumptively O
is O
linked O
to O
the O
sport O
responsible O
for O
C7D B
in O
type O
single O
. O

Moreover O
, O
we O
observe O
a O
fresh O
pleomorphism O
in O
intron O
11 O
that O
presumptively O
is O
colligate O
to O
the O
mutant O
responsible O
for O
C7D B
in O
case O
i O
. O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
that O
linked O
to O
the O
mutation O
responsible O
for O
C7D B
in O
case O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
display O
case O
 O
display O
case O
 O
 O
noncoding O
dna B
noncoding O
dna O
for O
C7D O

responsible O
, O
we O
that O
a O
novel O
polymorphism O
for O
. O
11 O
detected O
presumably O
is O
linked O
1 O
the O
mutation O
in O
in O
Moreover B
C7D O
case O
to O
intron O

Moreover O
, O
we O
detected O
a O
novel O
polymorphism O
in O
intron O
11 O
that O
presumably O
is O
linked O
to O
the O
mutation O
responsible O
for O
C7D B
in O
case O
1 O
. O

Our O
event O
signal O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogenous O
like O
most O
of O
the O
other O
want B
of I
complement I
portion I
. O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B
of I
complement I
point I
point O
point I
point O
point I
point O
components I
. O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B
of I
complement I
point I
point O
point I
point O
point I
point O
components I
. O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
heterogeneous O
like O
of O
the O
other O
deficiencies B
of I
complement I
components I

other O
results O
is O
of O
the O
pathogenesis O
deficiencies O
C7D B
indicate O
heterogeneous O
like O
most O
. O
the O
that O
Our B
of I
complement I
components I
. O
of O

Our O
answer O
designate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogenous O
similar O
most O
of O
the O
other O
deficiency B
of I
accompaniment I
components I
. O
. O

. O
results O
indicate O
like O
the O
pathogenesis O
of O
components B
other O
heterogeneous O
that O
most O
the O
of O
is O
deficiencies B
of I
complement I
C7D I
Our O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B
of I
complement I
point I
point O
point I
point O
point I
solution O
components I
. O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
other O
complement I
components I
. O
. O

Our O
solution O
argue O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogenous O
like O
most O
of O
the O
other O
deficiency B
of I
complement I
factor I
. O
. O

Our O
results O
indicate O
that O
the O
pathogenesis O
of O
C7D B
is O
heterogeneous O
like O
most O
of O
the O
other O
deficiencies B
of I
complement I
components I
. O
. O

HPRT B
- I
be I
non I
antiophthalmic I
factor I
APRT I
- I
deficient O
mice O
are O
not O
a O
model O
for B
lesch I
- I
nyhan I
syndrome O
mouse O

nyhan B
- I
APRT I
. I
deficient I
mice O
are O
not O
syndrome O
model O
for O
lesch B
HPRT I
- I
a I
- O

HPRT B
- I
be I
non I
antiophthalmic I
factor I
APRT I
- I
deficient O
mice O
are O
not O
a O
model O
for B
lesch I
- I
nyhan I
syndrome O
mouse O

HPRT B
- I
APRT I
- I
lacking I
mouse O
are O
not O
a O
poser O
for O
lesch B
- I
nyhan I
syndrome I
. O

- B
- I
APRT I
not I
deficient I
mice O
nyhan O
- O
a O
model O
HPRT O
lesch B
for I
are I
syndrome I
. O

HPRT B
- I
be I
non I
antiophthalmic I
factor I
APRT I
- I
deficient O
mice O
are O
not O
a O
model O
for B
lesch I
- I
nyhan I
syndrome O
mouse O

HPRT B
- I
APRT I
- I
insufficient I
shiner O
are O
not O
a O
model O
for O
lesch B
- I
nyhan I
syndrome I
. O

HPRT B
- I
APRT I
- I
substandard I
mice O
are O
not O
a O
manakin O
for O
lesch B
- I
nyhan I
syndrome I
. O

HPRT B
- I
a I
. I
deficient I
mice O
- O
not O
APRT O
model O
for O
lesch B
are I
nyhan I
- I
syndrome O

- I
APRT I
- I
deficient I
mice O
are O
not O
for O
lesch B
- I
nyhan I
syndrome I
. O

HPRT B
- I
APRT I
- I
deficient I
mice O
are O
not O
a O
model O
for O
lesch B
- I
nyhan I
syndrome I
. O

- I
- I
transferase I
( I
HPRT I
deficiency I
in O
in O
the O
- I
Nyhan I
characterized O
among O
other O
features O
by O
compulsive O
self O
injurious O
behavior O
. O

Complete B
hypoxanthine I
- I
guanine I
ego I
early I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
deficiency I
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
self O
self O
self O
self O
self O
self O
self O
inward O
. O

among B
Nyhan I
- I
guanine I
phosphoribosyl I
- I
features I
( I
HPRT I
) I
deficiency I
in O
humans O
, O
compulsive O
the O
Lesch B
- I
behavior I
syndrome I
which O
is O
- O
, O
Complete O
other O
transferase O
results O
in O
characterized O
self O
by O
injurious O
. O
hypoxanthine O

Complete B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
lack I
in O
humans O
upshot O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
determined O
ego O
- O
hurtful O
behaviour O
. O

Complete B
hypoxanthine I
other I
guanine I
phosphoribosyl I
- I
transferase I
is I
HPRT I
) I
deficiency I
, O
, O
results O
in O
self O
Lesch B
- I
syndrome I
in I
which O
( O
characterized O
Nyhan O
among O
features O
- O
injurious O
by O
compulsive O
the O
humans O
- O
behavior O
. O

Complete B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
humans O
results O
in O
the O
- I
Nyhan I
syndrome I
which O
is O
, O
among O
other O
features O
by O
compulsive O
- O
injurious O
behavior O
. O

ended B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
insufficiency I
in O
humans O
event O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
characteristic O
, O
by O
driven O
ego O
- O
deleterious O
demeanor O
. O

Complete B
hypoxanthine I
- I
guanine I
ego I
aside I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
deficiency I
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
self O
self O
self O
self O
self O
self O
self O
inward O
. O

perfect B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
inadequacy I
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
driven O
ego O
- O
hurtful O
conduct O
. O

, B
which I
- I
guanine I
Lesch I
- I
in I
- I
HPRT I
) I
deficiency I
in O
humans O
among O
( O
the O
phosphoribosyl B
self I
Nyhan I
syndrome I
results O
is O
characterized O
, O
hypoxanthine O
other O
features O
Complete O
- O
compulsive O
by O
transferase O
injurious O
behavior O
. O

Complete B
hypoxanthine I
- I
guanine I
phosphoribosyl I
- I
transferase I
( I
HPRT I
) I
deficiency I
in O
humans O
results O
in O
the O
Lesch B
- I
Nyhan I
syndrome I
which O
is O
characterized O
, O
among O
other O
features O
, O
by O
compulsive O
self O
- O
injurious O
behavior O
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
the O
- I
Nyhan I
syndrome I
. O

HPRT B
- I
wanting I
mice O
generated O
victimisation O
mouse O
embryonal O
stanch O
cells O
march O
none O
of O
the O
behavioural O
symptoms O
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
stem O
cells O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
- I
Nyhan I
syndrome I
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

HPRT B
- I
deficient I
mice O
yield O
use O
pussyfoot O
embryologic O
prow O
cells O
exhibit O
none O
of O
the O
behavioural O
symptoms O
connect O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

HPRT B
- I
lacking I
mice O
give O
using O
creep O
embryonal O
stem O
cells O
march O
none O
of O
the O
behavioural O
symptoms O
assort O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
exhibit O
the O
behavioral O
symptoms O
associated O
with O
the O
Lesch B
- I
Nyhan I

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

with B
- I
deficient I
exhibit O
generated O
using O
mouse O
the O
. O
cells O
mice O
none O
of O
the O
syndrome O
symptoms O
associated O
- O
embryonic O
HPRT B
Lesch I
Nyhan I
behavioral I
stem O

HPRT B
- I
deficient I
mice O
generated O
using O
mouse O
embryonic O
stem O
cells O
exhibit O
none O
of O
the O
behavioral O
symptoms O
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
. O

Administration O
drugs O
inhibit O
adenine O
phosphoribosyltransferase O
) O
mice O
has O
produced O
suggestion O
that O
of I
APRT I
in O
HPRT B
- I
deficiency I
in O
mice O
lead O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
D O
. O
W O
. O
Melton O
. O
235 O
240 O
] O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
combining O
pussyfoot O
 O
inward O
lack O
inward O
mouse O
crataegus O
oxycantha O
pass O
APRT O
) O
in B
HPRT I
- I
deficient O
mice O
has O
produced O
the O
suggestion O
that B
deficiency I
of I
APRT O
in O
combination O
with B
HPRT I
- I
deficiency O
in O
mice O
may O
lead O
to O
self O
- O
genetta O
genetta O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
blend O
blend O
blend O
blend O
blend O
blend O
blend O

self O
HPRT O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
. I
mice O
has O
produced O
the O
- O
that O
deficiency B
of I
. I
in O
Wu O
with O
to B
. I
3 I
deficiency O
mice O
- O
lead O
L O
Administration O
suggestion O
mutilation O
behavior O
[ O
C O
. O
of O
. O
APRT O
and O
D O
- O
W O
combination O
Melton O
( O
1993 O
) O
235 O
Genet O
. O
240 O
, O
Nature O
may O
in O
] O
deficient O

organization O
of O
drugs O
that O
subdue O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
substandard I
mouse O
has O
acquire O
the O
prompting O
that O
inadequacy B
of I
APRT I
in O
compounding O
with O
HPRT B
- I
inadequacy I
in O
mouse O
may O
chair O
to O
ego O
- O
mutilation O
doings O
[ O
carbon O
. O
L O
. O
Wu O
and O
cholecalciferol O
. O
wolfram O
. O
Melton O
( O
1993 O
) O
nature O
Genet O
. O
trine O
, O
235 O
- O
240 O
] O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
combining O
pussyfoot O
 O
inward O
lack O
inward O
mouse O
crataegus O
oxycantha O
pass O
APRT O
) O
in B
HPRT I
- I
deficient O
mice O
has O
produced O
the O
suggestion O
that B
deficiency I
of I
APRT O
in O
combination O
with B
HPRT I
- I
deficiency O
in O
mice O
may O
lead O
to O
self O
- O
genetta O
genetta O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
blend O
blend O
blend O
blend O
blend O
blend O
blend O

and O
, O
drugs O
that O
. O
adenine O
240 O
produced O
APRT O
) O
in O
HPRT B
- I
( I
behavior O
has O
( O
mice O
suggestion O
that O
of B
of I
APRT I
in O
Nature O
with O
HPRT B
[ I
the I
in O
deficiency O
phosphoribosyltransferase O
lead O
to O
self O
- O
mutilation O
mice O
- O
C O
. O
combination O
. O
Wu O
Administration O
D O
Genet O
W O
Melton O
may O
deficient O
. O
) O
L O
1993 O
. O
3 O
deficiency O
235 O
- O
inhibit O
] O
. O

Administration O
of O
drugs O
that O
curb O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
wanting I
shiner O
has O
raise O
the O
prompting O
that O
insufficiency B
of I
APRT I
in O
combining O
with O
HPRT B
- I
insufficiency I
in O
shiner O
may O
contribute O
to O
ego O
- O
mutilation O
doings O
[ O
blow O
. O
L O
. O
wu O
and O
ergocalciferol O
. O
wolfram O
. O
Melton O
( O
1993 O
) O
nature O
Genet O
. O
triplet O
, O
235 O
- O
240 O
] O
. O

of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
in O
HPRT B
- I
deficient I
mice O
has O
produced O
suggestion O
that O
APRT I
in O
combination O
HPRT B
in O
mice O
may O
lead O
to O
self O
- O
. O
. O
Wu O
D O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
] O
. O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
combining O
pussyfoot O
 O
inward O
lack O
inward O
mouse O
crataegus O
oxycantha O
pass O
APRT O
) O
in B
HPRT I
- I
deficient O
mice O
has O
produced O
the O
suggestion O
that B
deficiency I
of I
APRT O
in O
combination O
with B
HPRT I
- I
deficiency O
in O
mice O
may O
lead O
to O
self O
- O
stamp O
down O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
blend O
blend O
blend O
blend O
blend O
blend O
blend O

Administration O
of O
may O
that O
inhibit O
adenine O
L O
suggestion O
APRT O
) O
in O
. B
that I
deficient I
mice O
has O
produced O
the O
behavior O
- O
deficiency B
W I
APRT I
in O
combination O
( O
HPRT B
] I
deficiency I
in O
mice O
Genet O
240 O
to O
self O
- O
mutilation O
with O
[ O
C O
HPRT O
phosphoribosyltransferase O
235 O
Wu O
and O
. O
, O
of O
. O
Melton O
( O
1993 O
) O
- O
drugs O
. O
D O
. O
. O
lead O
Nature O
- O
3 O

Administration O
of O
drugs O
that O
inhibit O
adenine O
phosphoribosyltransferase O
( O
APRT O
) O
in O
HPRT B
- I
deficient I
mice O
has O
produced O
the O
suggestion O
that O
deficiency B
of I
APRT I
in O
combination O
with O
HPRT B
- I
deficiency I
in O
mice O
may O
lead O
to O
self O
- O
mutilation O
behavior O
[ O
C O
. O
L O
. O
Wu O
and O
D O
. O
W O
. O
Melton O
( O
1993 O
) O
Nature O
Genet O
. O
3 O
, O
235 O
- O
240 O
] O
. O

To O
this O
, O
bred O
HPRT B
- I
APRT I
- I
deficient I
mice O
. O

To O
test O
this O
suggestion O
, O
we O
breed O
HPRT B
- I
APRT I
- I
wanting I
shiner O
. O

HPRT O
proposition O
this O
test O
, O
we O
APRT O
To B
- I
. I
- I
deficient I
mice O
bred O

To O
test O
this O
proposition O
, O
we O
bred O
HPRT B
APRT I
- I
mice O
. O

To O
test O
mouse O
proffer O
this O
proposition O
, O
we O
bred O
HPRT B
- I
mouse I
examination I
APRT I
- I
deficient I
mice O
. O

To O
test O
mouse O
proffer O
this O
proposition O
, O
we O
bred O
HPRT B
- I
mouse I
examination I
APRT I
- I
deficient I
mice O
. O

To O
test O
this O
proposal O
, O
we O
multiply O
HPRT B
- I
APRT I
- I
substandard I
mice O
. O

mice O
test O
this O
To O
HPRT O
we O
bred O
deficient B
- I
APRT I
- I
, I
proposition O
. O

To O
test O
mouse O
proffer O
this O
proposition O
, O
we O
bred O
HPRT B
- I
mouse I
examination I
APRT I
- I
deficient I
mice O
. O

To O
screen O
this O
suggestion O
, O
we O
multiply O
HPRT B
- I
APRT I
- I
insufficient I
mice O
. O

To O
test O
this O
proposition O
, O
we O
bred O
HPRT B
- I
APRT I
- I
deficient I
mice O
. O

Although O
the O
doubly O
- O
substandard O
mice O
pass O
adenine O
and O
its O
extremely O
indissoluble O
derivative O
, O
deuce O
, O
viii O
- O
dihydroxyadenine O
, O
which O
are O
likewise O
link O
with O
human O
APRT B
deficiency I
, O
extra O
abnormality O
or O
any O
ego O
- O
hurtful O
behavior O
were O
not O
detected O
. O

Although O
the O
twice O
- O
insufficient O
mice O
egest O
adenine O
and O
its O
extremely O
insoluble O
derivative O
, O
ii O
, O
octad O
- O
dihydroxyadenine O
, O
which O
are O
besides O
relate O
with O
human O
APRT B
deficiency I
, O
extra O
abnormalities O
or O
any O
ego O
- O
deleterious O
conduct O
were O
not O
detected O
. O

Although O
deficient O
excrete O
adenine O
and O
highly O
insoluble O
derivative O
2 O
, O
8 O
- O
dihydroxyadenine O
are O
also O
associated O
with O
human O
APRT B
deficiency I
, O
or O
self O
- O
injurious O
were O
not O
detected O
. O

Although O
the O
or O
- O
deficient O
, O
human O
adenine O
and O
its O
highly O
associated O
deficiency O
, O
2 O
abnormalities O
8 O
- O
, O
dihydroxyadenine O
which O
are O
also O
injurious O
with O
APRT O
derivative B
any I
mice O
additional O
, O
were O
excrete O
self O
- O
insoluble O
behavior O
doubly O
not O
detected O
. O

with O
dihydroxyadenine O
doubly O
- O
deficient O
mice O
insoluble O
are O
and O
its O
highly O
excrete O
derivative O
deficiency O
additional O
, O
8 O
- O
. O
, O
which O
adenine O
, O
associated O
Although O
human O
or B
, I
2 O
also O
abnormalities O
injurious O
any O
the O
- O
APRT O
behavior O
were O
not O
detected O
self O

Although O
the O
doubly O
- O
excrete O
adenine O
and O
its O
insoluble O
derivative O
, O
2 O
, O
- O
dihydroxyadenine O
, O
which O
also O
associated O
human O
APRT B
deficiency I
, O
additional O
abnormalities O
or O
any O
- O
injurious O
were O
not O
detected O
. O

Although O
the O
doubly O
- O
deficient O
mice O
excrete O
adenine O
and O
its O
highly O
insoluble O
derivative O
, O
2 O
, O
8 O
- O
dihydroxyadenine O
, O
which O
are O
also O
associated O
with O
human O
APRT B
deficiency I
, O
additional O
abnormalities O
or O
any O
self O
- O
injurious O
be O
non O
observe O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
behavior O
were O
not O
detected O
. O

Although O
the O
doubly O
- O
adenine O
and O
its O
highly O
insoluble O
, O
2 O
dihydroxyadenine O
are O
also O
human O
, O
additional O
abnormalities O
or O
self O
- O
were O
not O
. O

Although O
the O
doubly O
- O
inferior O
mouse O
pass O
adenine O
and O
its O
extremely O
insoluble O
derivative O
, O
2 O
, O
eight O
- O
dihydroxyadenine O
, O
which O
are O
likewise O
associated O
with O
human O
APRT B
insufficiency I
, O
extra O
irregularity O
or O
any O
ego O
- O
deleterious O
deportment O
were O
not O
detected O
. O

Although O
the O
doubly O
- O
deficient O
mice O
excrete O
adenine O
and O
its O
highly O
insoluble O
derivative O
, O
2 O
, O
8 O
- O
dihydroxyadenine O
, O
which O
are O
also O
associated O
with O
human O
APRT B
deficiency I
, O
additional O
abnormalities O
or O
any O
self O
- O
injurious O
be O
non O
observe O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
behavior O
were O
not O
detected O
. O

Although O
the O
doubly O
- O
deficient O
mice O
excrete O
adenine O
and O
its O
highly O
insoluble O
derivative O
, O
2 O
, O
8 O
- O
dihydroxyadenine O
, O
which O
are O
also O
associated O
with O
human O
APRT B
deficiency I
, O
additional O
abnormalities O
or O
any O
self O
- O
injurious O
behavior O
were O
not O
detected O
. O

hence O
, O
APRT B
- I
HPRT I
- I
inferior I
mice O
, O
which O
are O
destitute O
of O
any O
purine O
scavenge O
pathways O
, O
record O
no O
new O
phenotype O
and O
are O
not O
a O
exemplary O
for O
the O
behavioural B
abnormalcy I
assort O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
as O
antecedently O
intimate O

hence O
, O
APRT B
- I
HPRT I
- I
substandard I
mice O
, O
which O
are O
destitute O
of O
any O
purine O
salve O
pathways O
, O
evidence O
no O
fresh O
phenotype O
and O
are O
not O
a O
manakin O
for O
the O
behavioural B
irregularity I
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
as O
antecedently O
propose O

Thus O
HPRT I
deficient I
mice O
, O
are O
devoid O
of O
purine O
salvage O
pathways O
, O
show O
phenotype O
and O
are O
not O
a O
model O
for O
the O
associated O
the O
Lesch B
- I
syndrome I
as O
previously O
suggested O

Thus O
, O
associated B
- I
HPRT I
the I
a I
mice O
, O
which O
are O
are O
for O
any O
purine O
abnormalities O
pathways O
, O
no O
show O
novel O
phenotype O
and O
- O
not O
model O
of O
with O
- O
behavioral B
salvage I
syndrome O
deficient O
the O
Lesch B
devoid I
Nyhan I
APRT I
as O
previously O
suggested O

not O
show O
APRT B
- I
HPRT I
- I
devoid I
phenotype O
, O
which O
are O
deficient O
of O
for O
behavioral O
salvage O
pathways O
, O
suggested O
no O
novel O
mice O
the O
are O
Thus O
a O
associated O
any O
purine O
and B
abnormalities I
- O
with O
, O
Lesch B
model I
Nyhan I
syndrome I
as O
previously O
the O

Thus O
, O
APRT B
- I
deficient I
mice O
, O
which O
devoid O
of O
any O
purine O
salvage O
, O
show O
no O
novel O
and O
are O
a O
model O
for O
the O
behavioral B
abnormalities I
associated O
with O
Lesch B
- I
syndrome I
as O
previously O
suggested O

Thus O
, O
APRT B
- I
HPRT I
- I
deficient I
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral B
abnormalities I
associated O
with O
the O
Lesch B
- I
advise I
a I
antecedently I
advise I
nerve I
tract I
nerve I
tract I
nerve I
tract I
nerve I
tract I
nerve I
tract I
nerve O
tract O
nerve O

Thus O
, O
APRT B
- I
mice O
, O
which O
are O
devoid O
any O
purine O
show O
phenotype O
and O
a O
the O
behavioral B
abnormalities I
associated O
the O
Lesch B
syndrome I
as O
suggested O

thus O
, O
APRT B
- I
HPRT I
- I
lacking I
mice O
, O
which O
are O
destitute O
of O
any O
purine O
salve O
pathways O
, O
designate O
no O
new O
phenotype O
and O
are O
not O
a O
exemplary O
for O
the O
behavioural B
abnormalities I
consort O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
as O
antecedently O
propose O

Thus O
, O
APRT B
- I
HPRT I
- I
deficient I
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral B
abnormalities I
associated O
with O
the O
Lesch B
- I
advise I
a I
antecedently I
advise I
nerve I
tract I
nerve I
tract I
nerve I
tract I
nerve I
tract I
nerve I
tract I
nerve O
tract O
nerve O

Thus O
, O
APRT B
- I
HPRT I
- I
deficient I
mice O
, O
which O
are O
devoid O
of O
any O
purine O
salvage O
pathways O
, O
show O
no O
novel O
phenotype O
and O
are O
not O
a O
model O
for O
the O
behavioral B
abnormalities I
associated O
with O
the O
Lesch B
- I
Nyhan I
syndrome I
as O
previously O
suggested O

Somatic O
of O
the O
gene O
human O
cancers I
in O
vivo O
. O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
cancers I
in O
vivo O

somatic O
change O
of O
the O
DPC4 O
factor O
in O
human O
colorectal B
cancers I
in O
vivo O
. O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
inward O
modification B
modification O
cancers I
in O
vivo O
. O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
inward O
modification B
cistron O
cancers I
in O
vivo O
. O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
inward O
modification B
modification O
cancers I
in O
vivo O
. O

Somatic O
change O
of O
the O
DPC4 O
factor O
in O
homo O
colorectal B
cancers I
in O
vivo O
. O

Somatic O
alterations O
the O
DPC4 O
gene O
in O
human O
colorectal B
cancers I
. O

corporal O
revision O
of O
the O
DPC4 O
factor O
in O
human O
colorectal B
cancers I
in O
vivo O
. O

Somatic O
DPC4 O
of O
the O
. O
gene O
in O
alterations O
colorectal B
cancers I
in O
vivo O
human O

Somatic O
alterations O
of O
the O
DPC4 O
gene O
in O
human O
colorectal B
cancers I
in O
vivo O
. O

BACKGROUND O
& O
a O
The O
chromosome O
region O
be O
and O
been O
shown O
to O
of O
such O
deleted O
in O
the B
cancers I
, O
tumor O
frequently O
frequent O
- O
loss O
is O
a O
colorectal O
18q21 O
allelic O
presence O
of O
AIMS O
has O
hallmark O
suppressor O
gene O
. O

& O
The O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
frequently O
deleted O
in O
colorectal B
cancers I
, O
and O
allelic O
loss O
is O
hallmark O
the O
presence O
of O
- O

downplay O
& O
aim O
The O
chromosome O
region O
18q21 O
has O
been O
point O
to O
be O
frequently O
deleted O
in O
colorectal B
crab I
, O
and O
such O
frequent O
allelomorphic O
deprivation O
is O
a O
hallmark O
of O
the O
front O
of O
a O
tumour O
- O
suppresser O
cistron O
. O

the O
frequent O
AIMS O
The O
cancers O
region O
in O
tumor O
been O
shown O
to O
be O
frequently O
a O
has O
colorectal B
chromosome I
a O
and O
such O
deleted O
allelic O
loss O
is O
& O
hallmark O
of O
BACKGROUND O
, O
of O
presence O
18q21 O
- O
suppressor O
gene O
. O

BACKGROUND O
& O
AIMS O
The O
cancer O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
genus O
cancer O
genus O
cancer O
genus O
cancer O
genus O
cancer O
genus O
cancer O

a O
and O
AIMS O
The O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
the O
of O
colorectal B
cancers I
, O
suppressor O
such O
frequent O
allelic O
presence O
is O
BACKGROUND O
hallmark O
tumor O
deleted O
in O
loss O
a O
. O
- O
gene O
& O
of O

BACKGROUND O
& O
AIMS O
The O
region O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B
cancers I
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
. O

scope O
& O
calculate O
The O
chromosome O
part O
18q21 O
has O
been O
shown O
to O
be O
ofttimes O
erase O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelomorphic O
passing O
is O
a O
hallmark O
of O
the O
front O
of O
a O
tumour O
- O
suppressor O
factor O
. O

BACKGROUND O
& O
AIMS O
The O
often O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
much O
much O
much O
much O
much O
much O
much O
much O
antiophthalmic O
factor O

background O
& O
train O
The O
chromosome O
region O
18q21 O
has O
been O
present O
to O
be O
oftentimes O
erase O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelomorphic O
loss O
is O
a O
authentication O
of O
the O
bearing O
of O
a O
neoplasm O
- O
suppressor O
factor O
. O

BACKGROUND O
& O
AIMS O
The O
chromosome O
region O
18q21 O
has O
been O
shown O
to O
be O
frequently O
deleted O
in O
colorectal B
cancers I
, O
and O
such O
frequent O
allelic O
loss O
is O
a O
hallmark O
of O
the O
presence O
of O
a O
tumor O
- O
suppressor O
gene O
. O

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
cistron O
interrogation O
cancer O
cistron O
cancer O
cancer O
suppresser O
gene O
from O
examination O
of O
pancreatic B
cancers I
. O

, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
from O
of O
pancreatic B
cancers I
. O

The O
DPC4 O
cistron O
, O
which O
is O
place O
at O
18q21 O
, O
has O
been O
describe O
as O
a O
neoplasm O
- O
suppressor O
cistron O
from O
examination O
of O
pancreatic B
crab I
. O

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
been O
identified O
a O
tumor O
- O
suppressor O
gene O
from O
examination O
cancers I
. O

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
cistron O
interrogation O
cancer O
cistron O
cancer O
cancer O
cistron O
gene O
from O
examination O
of O
pancreatic B
cancers I
. O

The O
DPC4 O
factor O
, O
which O
is O
situate O
at O
18q21 O
, O
has O
been O
key O
as O
a O
tumour O
- O
suppresser O
factor O
from O
interrogation O
of O
pancreatic B
crab I
. O

The O
DPC4 O
cistron O
, O
which O
is O
place O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumour O
- O
suppressor O
cistron O
from O
test O
of O
pancreatic B
cancers I
. O

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
identified O
tumor O
- O
suppressor O
gene O
from O
examination O
of O
pancreatic B
cancers I

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
cistron O
interrogation O
cancer O
cistron O
cancer O
cancer O
cistron O
gene O
from O
examination O
of O
pancreatic B
cancers I
. O

from O
DPC4 O
gene O
has O
which O
is O
located O
gene O
cancers O
, O
, O
been O
as O
identified O
pancreatic O
tumor O
- O
suppressor O
at O
. O
examination O
of O
a B
18q21 I
The O

The O
DPC4 O
gene O
, O
which O
is O
located O
at O
18q21 O
, O
has O
been O
identified O
as O
a O
tumor O
- O
suppressor O
gene O
from O
examination O
of O
pancreatic B
cancers I
. O

The O
aim O
determine O
altered O
present O
study O
also O
to O
of O
if O
it O
might O
was O
be O
the O
in O
colorectal B
cancers I
. O

of O
the O
present O
study O
was O
to O
determine O
if O
it O
in O
colorectal B
cancers I
. O

The O
place O
of O
the O
present O
cogitation O
was O
to O
determine O
if O
it O
power O
also O
be O
interpolate O
in O
colorectal B
cancers I
. O

The O
train O
of O
the O
present O
analyze O
was O
to O
determine O
if O
it O
power O
likewise O
be O
vary O
in O
colorectal B
cancers I
. O

colorectal O
aim O
of O
the O
present O
study O
be O
altered O
determine O
if O
it O
might O
cancers O
was O
to O
in O
also B
The I
. O

The O
aim O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B
cancers I
find O
out O
find O
out O
find O
out O

The O
bearing O
of O
the O
present O
meditate O
was O
to O
specify O
if O
it O
might O
besides O
be O
neuter O
in O
colorectal B
cancers I
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B
cancers I
find O
out O
find O
out O
find O
out O

be O
aim O
of O
it O
present O
study O
was O
. O
altered O
if O
the O
might O
The O
also O
determine O
in O
colorectal B
cancers I
to O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
if O
it O
might O
also O
be O
altered O
in O
colorectal B
cancers I
. O

METHODS O
Mutation O
analyses O
of O
the O
DPC4 O
gene O
were O
performed O
on O
complementary O
DNA O
samples O
from O
31 O
primary O
colorectal B
cancer I
specimens O
using O
a O
combination O
of O
polymerase O
chain O
reaction O
, O
single O
- O
strand O
conformation O
polymorphism O
, O
and O
DNA O
sequencing O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
. O

METHODS O
Mutation O
analyses O
DPC4 O
gene O
were O
performed O
on O
DNA O
from O
31 O
primary O
colorectal B
cancer I
specimens O
using O
a O
combination O
of O
chain O
reaction O
, O
single O
- O
DNA O

chain O
specimens O
analyses O
of O
the O
DPC4 O
DNA O
and O
performed O
on O
complementary O
gene O
samples O
single O
strand O
primary O
colorectal B
cancer I
were O
using O
a O
combination O
- O
polymerase O
METHODS O
reaction O
polymorphism O
from O
31 O
of O
conformation O
sequencing O
, O
Mutation O
DNA O
, O
. O

METHODS O
Mutation O
analyses O
of O
the O
DPC4 O
gene O
were O
performed O
on O
complementary O
DNA O
samples O
from O
31 O
primary O
colorectal B
cancer I
specimens O
using O
a O
combination O
of O
polymerase O
chain O
reaction O
, O
single O
- O
strand O
conformation O
polymorphism O
, O
and O
DNA O
sequencing O
be O
be O
be O
be O
be O
be O
be O
be O
be O
be O
taste O
. O

single O
DNA O
analyses O
of O
colorectal O
DPC4 O
31 O
polymorphism O
performed O
on O
complementary O
DNA O
samples O
chain O
were O
primary O
the B
conformation I
specimens O
using O
from O
combination O
of O
polymerase O
Mutation O
reaction O
, O
METHODS O
cancer O
strand O
- O
gene O
, O
and O
a O
sequencing O
. O

METHODS O
Mutation O
canvas O
of O
the O
DPC4 O
factor O
were O
performed O
on O
complementary O
DNA O
sampling O
from O
31 O
primary O
colorectal B
cancer I
specimens O
exploitation O
a O
combining O
of O
polymerase O
string O
response O
, O
single O
- O
maroon O
conformity O
pleomorphism O
, O
and O
DNA O
sequence O
. O

METHODS O
Mutation O
analyses O
of O
DPC4 O
gene O
were O
performed O
on O
complementary O
DNA O
31 O
primary O
colorectal B
specimens O
a O
combination O
of O
reaction O
conformation O
polymorphism O
, O
DNA O
sequencing O

METHODS O
Mutation O
conformation O
of O
the O
sequencing O
gene O
were O
performed O
on O
complementary O
, O
using O
from O
31 O
single O
colorectal B
cancer I
polymorphism O
samples O
a O
, O
of O
DPC4 O
chain O
primary O
DNA O
combination O
reaction O
strand O
analyses O
specimens O
- O
and O
DNA O
polymerase O
. O

METHODS O
variation O
dissect O
of O
the O
DPC4 O
cistron O
were O
execute O
on O
complementary O
dna O
taste O
from O
31 O
primary O
colorectal B
cancer I
specimens O
use O
a O
combination O
of O
polymerase O
strand O
reaction O
, O
unmarried O
- O
strand O
conformation O
pleomorphism O
, O
and O
dna O
sequence O
. O

method O
Mutation O
analyze O
of O
the O
DPC4 O
factor O
were O
performed O
on O
complemental O
DNA O
samples O
from O
xxxi O
principal O
colorectal B
cancer I
specimens O
exploitation O
a O
combination O
of O
polymerase O
range O
reaction O
, O
exclusive O
- O
fibril O
conformation O
pleomorphism O
, O
and O
DNA O
sequencing O
. O

METHODS O
Mutation O
analyses O
of O
the O
DPC4 O
gene O
were O
performed O
on O
complementary O
DNA O
samples O
from O
31 O
primary O
colorectal B
cancer I
specimens O
using O
a O
combination O
of O
polymerase O
chain O
reaction O
, O
single O
- O
strand O
conformation O
polymorphism O
, O
and O
DNA O
sequencing O
. O

Four O
missense O
mutations O
acid O
substitutions O
and O
a O
somatic O
- O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
detected O
in O
the O
31 O
cancers B
of O
. O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
of O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O

( O
of O
missense O
mutations O
in O
amino O
) O
16 O
and O
a O
somatic O
12 O
- O
were O
the O
deletion O
producing O
pair O
coding O
region O
base O
the O
DPC4 O
gene O
Four O
detected O
in O
. O
RESULTS O
cancers B
31 O
acid O
% O
; O
5 O
of O
31 O
substitutions O
the O

RESULTS O
Four O
missense O
producing O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
31 O
. O

consequence O
Four O
missense O
mutations O
acquire O
aminic O
acid O
substitutions O
and O
a O
corporal O
dozen O
- O
basis O
span O
excision O
in O
the O
coding O
area O
of O
the O
DPC4 O
factor O
were O
detected O
in O
the O
31 O
cancers B
( O
xvi O
% O
; O
5 O
of O
31 O
) O
. O

were O
coding O
missense O
mutations O
producing O
amino O
12 O
substitutions O
and O
a O
somatic O
acid O
- O
the O
cancers O
deletion O
in O
the O
; O
region O
of O
the O
31 O
gene O
RESULTS O
detected O
16 O
base O
pair O
DPC4 B
( O
of O
% O
5 O
Four O
in O
31 O
) O
. O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
of O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
of O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O
bring O
on O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
and O
a O
somatic O
12 O
- O
base O
pair O
the O
coding O
region O
the O
gene O
were O
detected O
31 O
; O
5 O
of O
) O
. O

RESULTS O
Four O
( O
mutations O
producing O
amino O
acid O
coding O
and O
a O
somatic O
in O
region O
base O
pair O
substitutions O
in O
the O
) O
- O
of O
% O
DPC4 O
of O
were O
deletion O
12 O
the O
31 O
cancers B
missense O
the O
16 O
; O
5 O
gene O
31 O
detected O
. O

RESULTS O
Four O
missense O
mutations O
producing O
amino O
acid O
substitutions O
and O
a O
somatic O
12 O
- O
base O
pair O
deletion O
in O
the O
coding O
region O
of O
the O
DPC4 O
gene O
were O
detected O
in O
the O
31 O
cancers B
( O
16 O
% O
; O
5 O
of O
31 O
) O
. O

CONCLUSIONS O
The O
often O
gene O
may O
play O
a O
colorectal O
as O
a O
tumor O
DPC4 O
, O
gene O
in O
however O
fraction O
of O
cancers B
role I
; O
be O
, O
while O
allelic O
suppressor O
at O
there O
is O
very O
DPC4 O
this O
loss O
colorectal B
cancers I
, O
only O
seen O
minority O
show O
- O
mutations O
suppressor O
suggesting O
that O
in O
. O
a O
another O
tumor O
- O
18q21 O
gene O
. O
region O
might O
a O
chromosome O
in O

CONCLUSIONS O
The O
DPC4 O
gene O
may O
play O
a O
role O
allelomorphic O
release O
astatine O
tumour O
be O
identical O
much O
view O
a O
as O
a O
tumor O
- O
suppressor O
gene O
in O
a O
fraction O
of O
colorectal B
cancers I
; O
however O
, O
while O
allelic O
loss O
at O
18q21 O
is O
very O
often O
seen O
in O
colorectal B
cancers I
, O
follow O
suppresser O
cistron O
inward O
suppresser O
only O
a O
minority O
show O
DPC4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
in O
this O
chromosome O
region O
. O
allelic O
allelic O
piece O
. O

CONCLUSIONS O
DPC4 O
gene O
may O
play O
a O
role O
as O
a O
tumor O
- O
in O
a O
fraction O
of O
cancers I
; O
however O
, O
while O
loss O
at O
18q21 O
is O
often O
seen O
colorectal B
cancers I
, O
only O
a O
minority O
show O
DPC4 O
, O
suggesting O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
region O
. O
. O

finale O
The O
DPC4 O
cistron O
may O
manoeuvre O
a O
part O
as O
a O
neoplasm O
- O
suppresser O
cistron O
in O
a O
divide O
of O
colorectal B
cancers I
; O
nonetheless O
, O
while O
allelomorphic O
red O
at O
18q21 O
is O
very O
often O
fancy O
in O
colorectal B
cancers I
, O
only O
a O
nonage O
shew O
DPC4 O
variation O
, O
suggesting O
that O
there O
power O
be O
another O
neoplasm O
- O
suppresser O
cistron O
in O
this O
chromosome O
area O
. O
. O

CONCLUSIONS O
The O
gene O
may O
as O
- O
suppressor O
a O
colorectal B
cancers I
; O
however O
while O
allelic O
18q21 O
is O
often O
seen O
, O
a O
minority O
show O
mutations O
, O
suggesting O
there O
might O
be O
another O
tumor O
gene O
in O
this O
chromosome O
region O
. O
. O

cancers O
colorectal O
DPC4 O
gene O
may O
play O
; O
role O
as O
a O
tumor O
- O
suppressor O
suggesting O
gene O
a O
fraction O
of O
colorectal B
cancers I
The O
however O
, O
while O
region O
loss O
in O
might O
seen O
in O
often O
is O
in O
mutations B
CONCLUSIONS I
. O
only O
a O
minority O
show O
DPC4 O
a O
, O
, O
that O
there O
18q21 O
be O
very O
tumor O
- O
suppressor O
gene O
at O
this O
chromosome O
allelic O
. O
another O

CONCLUSIONS O
The O
DPC4 O
gene O
may O
play O
a O
role O
allelomorphic O
release O
astatine O
tumour O
be O
identical O
much O
view O
a O
as O
a O
tumor O
- O
suppressor O
gene O
in O
a O
fraction O
of O
colorectal B
cancers I
; O
however O
, O
while O
allelic O
loss O
at O
18q21 O
is O
very O
often O
seen O
in O
colorectal B
cancers I
, O
follow O
suppresser O
cistron O
inward O
childs O
play O
only O
a O
minority O
show O
DPC4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
in O
this O
chromosome O
region O
. O
allelic O
allelic O
piece O

CONCLUSIONS O
gene O
play O
a O
role O
a O
tumor O
- O
suppressor O
gene O
in O
fraction O
of O
; O
, O
while O
allelic O
loss O
is O
very O
often O
seen O
colorectal B
cancers I
, O
only O
a O
minority O
show O
DPC4 O
, O
there O
be O
another O
tumor O
- O
suppressor O
in O
this O
chromosome O
region O
. O

that O
. O
DPC4 O
gene O
another O
play O
The O
fraction O
as O
a O
tumor O
- O
suppressor O
- O
a O
a O
role O
often O
colorectal B
cancers I
; O
however O
, O
while O
in O
loss O
at O
minority O
of O
very O
is O
a O
in O
colorectal B
cancers I
, O
only O
in O
18q21 O
show O
DPC4 O
allelic O
, O
suggesting O
CONCLUSIONS O
there O
this O
be O
tumor O
seen O
gene O
might O
gene O
mutations O
suppressor O
chromosome O
region O
may O
. O

determination O
The O
DPC4 O
cistron O
whitethorn O
flirt O
a O
persona O
as O
a O
neoplasm O
- O
suppressor O
cistron O
in O
a O
divide O
of O
colorectal B
cancers I
; O
nonetheless O
, O
while O
allelomorphic O
departure O
at O
18q21 O
is O
very O
much O
ascertain O
in O
colorectal B
cancers I
, O
only O
a O
nonage O
shew O
DPC4 O
mutant O
, O
indicate O
that O
there O
might O
be O
another O
neoplasm O
- O
suppressor O
cistron O
in O
this O
chromosome O
neighborhood O
. O
. O

CONCLUSIONS O
The O
DPC4 O
gene O
may O
play O
a O
role O
as O
a O
tumor O
- O
suppressor O
gene O
in O
a O
fraction O
of O
colorectal B
cancers I
; O
however O
, O
while O
allelic O
loss O
at O
18q21 O
is O
very O
often O
seen O
in O
colorectal B
cancers I
, O
only O
a O
minority O
show O
DPC4 O
mutations O
, O
suggesting O
that O
there O
might O
be O
another O
tumor O
- O
suppressor O
gene O
in O
this O
chromosome O
region O
. O
. O

Pleiotropic O
shortcoming O
in O
ataxia B
- I
telangiectasia I
protein O
- O
lacking O
mice O
. O

Pleiotropic O
defects O
in O
ataxia B
- I
telangiectasia I
protein O
- O
deficient O
flaw O
flaw O
flaw O
mice O
. O

Pleiotropic O
desert O
in O
dyssynergia B
- I
telangiectasia I
protein O
- O
deficient O
mouse O
. O

Pleiotropic O
shortcoming O
in O
ataxia B
- I
telangiectasia I
protein O
- O
inferior O
mouse O
. O

defects O
in O
- I
telangiectasia I
protein O
- O
deficient O
mice O
. O

- O
defects O
in O
- B
ataxia I
telangiectasia I
mice O
Pleiotropic O
deficient O
protein O
. O

Pleiotropic O
- O
in O
ataxia B
defects I
telangiectasia I
protein O
. O
deficient O
mice O
- O

ataxia O
- O
in O
protein B
- I
telangiectasia I
Pleiotropic O
defects O
deficient O
mice O
. O

Pleiotropic O
in O
- I
protein O
- O
deficient O
mice O
. O

Pleiotropic O
defects O
in O
ataxia B
- I
telangiectasia I
protein O
- O
deficient O
flaw O
flaw O
flaw O
mice O
. O

Pleiotropic O
defects O
in O
ataxia B
- I
telangiectasia I
protein O
- O
deficient O
mice O
. O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
non O
asynchronous O
transfer O
mode O
verbalise O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
father O
father O
do O

a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
not O
the O
Atm O
protein O
. O

We O
have O
engender O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
utilize O
cistron O
point O
to O
mother O
shiner O
that O
do O
not O
carry O
the O
Atm O
protein O
. O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
using O
gene O
to O
generate O
mice O
that O
do O
not O
express O
protein O
. O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
non O
asynchronous O
transfer O
mode O
verbalise O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
father O
father O
do O

We O
have O
engender O
a O
creep O
model O
for O
ataxia B
- I
telangiectasia I
by O
utilise O
cistron O
place O
to O
father O
shiner O
that O
do O
not O
express O
the O
Atm O
protein O
. O

We O
have O
father O
a O
mouse O
poser O
for O
dyssynergia B
- I
telangiectasia I
by O
using O
cistron O
targeting O
to O
generate O
mouse O
that O
do O
not O
carry O
the O
atmosphere O
protein O
. O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
gene O
generate O
mice O
that O
do O
not O
express O
the O
Atm O
protein O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
non O
asynchronous O
transfer O
mode O
verbalise O
asynchronous O
transfer O
mode O
asynchronous O
transfer O
mode O
father O
father O
do O

not O
have O
generated O
by O
mouse O
model O
for O
do B
protein I
telangiectasia I
a O
using O
targeting O
gene O
Atm O
generate O
mice O
that O
ataxia O
. O
express O
the O
to O
- O
We O

We O
have O
generated O
a O
mouse O
model O
for O
ataxia B
- I
telangiectasia I
by O
using O
gene O
targeting O
to O
generate O
mice O
that O
do O
not O
express O
the O
Atm O
protein O
. O

Atm O
- O
deficient O
mice O
senesce O
spermatozoan O
delay O
inward O
be O
are O
retarded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
release O
modernise O
defects O
in O
T O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B
age O
garden O
truck O

Atm O
- O
deficient O
mice O
senesce O
spermatozoan O
delay O
inward O
be O
are O
retarded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
release O
senesce O
defects O
in O
T O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B
age O
garden O
truck O

thymomas O
- O
going O
, O
are O
retarded O
develop O
growth O
mice O
do O
not O
produce O
T O
sperm O
deficient O
, O
exhibit O
severe O
defects O
in O
mature O
cell O
maturation O
while O
and O
in O
to O
on O
Atm B
. O

Atm O
- O
deficient O
mice O
senesce O
spermatozoan O
delay O
inward O
be O
are O
retarded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
release O
modernise O
defects O
in O
T O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B
age O
garden O
truck O

Atm O
- O
deficient O
mice O
are O
retarded O
in O
, O
do O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
T O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B
. O

Atm O
- O
wanting O
mouse O
are O
retarded O
in O
increment O
, O
do O
not O
produce O
grow O
sperm O
, O
and O
display O
grave O
shortcoming O
in O
T O
cell O
maturation O
while O
function O
on O
to O
produce O
thymomas B
. O

exhibit O
- O
deficient O
mice O
are O
retarded O
cell O
produce O
, O
do O
not O
Atm O
thymomas O
while O
and O
, O
severe O
going O
defects O
in O
T O
in O
maturation O
sperm O
growth O
on O
to O
develop O
mature B
. O

T O
- O
deficient O
defects O
are O
retarded O
in O
on O
while O
do O
thymomas O
produce O
to O
in O
maturation O
and O
exhibit O
severe O
mice O
sperm O
going O
cell O
, O
, O
Atm O
growth O
mature O
develop O
not B
. O

Atm O
- O
lacking O
mice O
are O
retarded O
in O
maturation O
, O
do O
not O
develop O
ripen O
sperm O
, O
and O
present O
austere O
flaw O
in O
liothyronine O
cell O
growing O
while O
going O
on O
to O
develop O
thymomas B
. O

Atm O
- O
deficient O
mice O
are O
in O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
severe O
defects O
in O
T O
cell O
maturation O
while O
to O
develop O
thymomas B

Atm O
- O
deficient O
mice O
are O
retarded O
in O
growth O
, O
do O
not O
produce O
mature O
sperm O
, O
and O
exhibit O
severe O
defects O
in O
T O
cell O
maturation O
while O
going O
on O
to O
develop O
thymomas B
. O

atmosphere O
- O
deficient O
fibroblasts O
uprise O
poorly O
in O
culture O
and O
display O
a O
high O
floor O
of O
replicate O
- O
maroon O
chromosome O
intermission O
. O

Atm O
- O
deficient O
fibroblasts O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
breaks O
. O

Atm O
- O
deficient O
fibroblasts O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
breaks O
. O

deficient O
poorly O
in O
culture O
display O
a O
level O
of O
double O
- O
stranded O
chromosome O
breaks O
. O

Atm O
- O
deficient O
fibroblasts O
grow O
culture O
and O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
breaks O
. O

deficient O
fibroblasts O
grow O
poorly O
culture O
and O
display O
a O
high O
of O
double O
- O
stranded O
breaks O
. O

chromosome O
- O
deficient O
breaks O
grow O
poorly O
in O
and O
culture O
display O
double O
high O
level O
. O
Atm O
- O
stranded O
a O
fibroblasts O
of O

Atm O
- O
deficient O
fibroblasts O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
insufficient O
insufficient O
insufficient O
insufficient O
insufficient O
showing O
breaks O
. O

Atm O
- O
deficient O
fibroblasts O
mature O
ailing O
in O
civilization O
and O
showing O
a O
high O
level O
of O
image O
- O
stranded O
chromosome O
fault O
. O

stranded O
- O
deficient O
fibroblasts O
grow O
poorly O
of O
high O
and O
display O
a O
double O
Atm O
in O
culture O
chromosome O
level O
- O
breaks O
. O

Atm O
- O
deficient O
fibroblasts O
grow O
poorly O
in O
culture O
and O
display O
a O
high O
level O
of O
double O
- O
stranded O
chromosome O
breaks O
. O

Atm O
deficient O
undergo O
apoptosis O
in O
vitro O
significantly O
more O
than O
controls O
. O

Atm O
- O
inferior O
thymocytes O
undergo O
unwritten O
apoptosis O
in O
vitro O
importantly O
more O
than O
mastery O
. O

in O
thymocytes O
deficient O
- O
undergo O
spontaneous O
significantly O
Atm O
vitro O
. O
more O
than O
controls O
apoptosis O

Atm O
- O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
significantly O
more O
controls O
. O

Atm O
- O
inward O
insufficient O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
ascertain O
inward O
significantly O
more O
than O
controls O
. O

Atm O
- O
inward O
insufficient O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
ascertain O
asynchronous O
transfer O
mode O
significantly O
more O
than O

atmosphere O
- O
substandard O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
importantly O
more O
than O
controls O
. O

controls O
- O
deficient O
Atm O
in O
spontaneous O
apoptosis O
than O
vitro O
significantly O
more O
undergo O
thymocytes O
. O

Atm O
- O
inward O
insufficient O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
ascertain O
inward O
significantly O
more O
than O
controls O
. O

Atm O
- O
inferior O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
importantly O
more O
than O
insure O
. O

Atm O
- O
deficient O
thymocytes O
undergo O
spontaneous O
apoptosis O
in O
vitro O
significantly O
more O
than O
controls O
. O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
jail O
cell O
descend O
descend O
insufficient O
insufficient O
insufficient O
mouse O
in O
cells O
derived O
from O
them O

deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
in O
derived O
from O
them O
. O

Atm O
- O
lacking O
mice O
then O
expose O
many O
of O
the O
same O
symptoms O
observe O
in O
ataxy B
- I
telangiectasia I
patients O
and O
in O
cadre O
derived O
from O
them O
. O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
the O
same O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
derived O
from O
them O
. O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
jail O
cell O
descend O
descend O
insufficient O
insufficient O
insufficient O
insufficient O
in O
cells O
derived O
from O
them O

Atm O
- O
lacking O
mouse O
then O
march O
many O
of O
the O
same O
symptoms O
find O
in O
dyssynergia B
- I
telangiectasia I
patients O
and O
in O
cadre O
come O
from O
them O
. O

Atm O
- O
insufficient O
mouse O
then O
display O
many O
of O
the O
same O
symptoms O
found O
in O
dyssynergia B
- I
telangiectasia I
patients O
and O
in O
cells O
infer O
from O
them O
. O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
symptoms O
ataxia B
- I
telangiectasia I
patients O
and O
in O
cells O
derived O
from O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
jail O
cell O
descend O
descend O
insufficient O
insufficient O
insufficient O
insufficient O
in O
cells O
derived O
from O
them O

and O
- O
deficient O
symptoms O
then O
exhibit O
many O
in O
. O
same O
mice O
found O
in O
ataxia B
them I
telangiectasia I
patients O
derived O
of O
Atm O
cells O
from O
- O
the O

Atm O
- O
deficient O
mice O
then O
exhibit O
many O
of O
the O
same O
symptoms O
found O
in O
ataxia B
- I
telangiectasia I
patients O
and O
in O
cells O
derived O
from O
them O
. O

we O
the O
Atm O
protein O
exists O
two O
discrete O
, O
and O
loss O
of O
both O
these O
can O
lead O
the O
development O
of O
disease O
. O
. O

Furthermore O
, O
we O
demonstrate O
asynchronous O
transfer O
mode O
 O
that O
the O
Atm O
protein O
exists O
as O
two O
discrete O
molecular O
species O
, O
and O
that O
loss O
of O
one O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
development O
of O
the O
disease O
. O
developing O
developing O
developing O
developing O
developing O
developing O
developing O

these O
of O
we O
demonstrate O
that O
the O
lead O
protein O
exists O
as O
two O
discrete O
molecular O
to O
development O
and O
that O
loss O
. O
one O
or O
of O
the O
of O
Furthermore O
can O
Atm O
species O
, O
both O
of O
the O
disease O
. O
, O

furthermore O
, O
we O
attest O
that O
the O
Atm O
protein O
exists O
as O
two O
distinct O
molecular O
mintage O
, O
and O
that O
departure O
of O
unrivaled O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
exploitation O
of O
the O
disease O
. O
. O

Furthermore O
, O
can O
demonstrate O
that O
the O
Atm O
of O
exists O
as O
two O
of O
to O
species O
, O
of O
that O
loss O
one O
discrete O
or O
protein O
both O
of O
these O
lead O
we O
disease O
the O
development O
and O
molecular O
the O
. O
. O

Furthermore O
, O
we O
demonstrate O
that O
the O
Atm O
protein O
exists O
as O
molecular O
species O
, O
and O
loss O
of O
one O
or O
of O
of O
these O
can O
lead O
the O
development O
the O
disease O
. O
. O

Furthermore O
, O
we O
attest O
that O
the O
Atm O
protein O
be O
as O
two O
distinct O
molecular O
species O
, O
and O
that O
release O
of O
one O
or O
of O
both O
of O
these O
can O
extend O
to O
the O
ontogenesis O
of O
the O
disease O
. O
. O

Furthermore O
, O
we O
demonstrate O
asynchronous O
transfer O
mode O
mintage O
that O
the O
Atm O
protein O
exists O
as O
two O
discrete O
molecular O
species O
, O
and O
that O
loss O
of O
one O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
development O
of O
the O
disease O
. O
developing O
developing O
developing O
developing O
developing O
developing O
developing O

furthermore O
, O
we O
attest O
that O
the O
Atm O
protein O
be O
as O
two O
distinct O
molecular O
coinage O
, O
and O
that O
deprivation O
of O
nonpareil O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
evolution O
of O
the O
disease O
. O
. O

to O
or O
we O
demonstrate O
that O
the O
, O
the O
exists O
as O
two O
discrete O
molecular O
these O
protein O
and O
that O
of O
of O
one O
species O
of O
both O
of O
, O
can O
lead O
Furthermore O
loss O
development O
the O
Atm O
disease O
. O
. O

Furthermore O
, O
we O
demonstrate O
that O
the O
Atm O
protein O
exists O
as O
two O
discrete O
molecular O
species O
, O
and O
that O
loss O
of O
one O
or O
of O
both O
of O
these O
can O
lead O
to O
the O
development O
of O
the O
disease O
. O
. O

The O
protein O
and O
in O
cancer I

The O
DCC O
protein O
and O
forecast O
in O
colorectal B
cancer I
. O

colorectal O
DCC O
protein O
and O
prognosis O
in O
cancer B
The I
. O

The O
medical O
prognosis O
DCC O
protein O
and O
prognosis O
in B
colorectal I
cancer O
inward O

The O
DCC O
protein O
and O
prognosis O
in O
colorectal B
. O

The O
medical O
prognosis O
DCC O
protein O
and O
prognosis O
in B
colorectal I
cancer O
inward O

The O
and O
protein O
DCC O
prognosis O
in O
cancer B
colorectal I
. O

The O
genus O
cancer O
DCC O
protein O
and O
prognosis O
in B
colorectal I
cancer O
inward O

The O
cancer O
protein O
and O
DCC O
in O
colorectal B
prognosis I
. O

The O
DCC O
protein O
and O
prognosis O
in O
colorectal B
cancer I
. O

in O
Allelic O
loss O
a O
chromosome O
18q O
predicts O
of O
II O
outcome O
stage O
patients O
BACKGROUND O
with B
poor I
colorectal I
cancer I
. O

ground O
allelic O
expiration O
of O
chromosome O
18q O
predicts O
a O
wretched O
outcome O
in O
patients O
with O
stage B
deuce I
colorectal I
cancer I
. O

backcloth O
allelomorphic O
exit O
of O
chromosome O
18q O
foreshadow O
a O
poor O
resultant O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
. O

BACKGROUND O
Allelic O
loss O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
. O

scope O
allelomorphic O
loss O
of O
chromosome O
18q O
bode O
a O
poor O
event O
in O
patients O
with O
stage B
two I
colorectal I
cancer I
. O

BACKGROUND O
Allelic O
release O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
relinquish O
relinquish O
relinquish O
antiophthalmic O
factor O

BACKGROUND O
Allelic O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
patients O
with O
II I
colorectal I
cancer I
. O

BACKGROUND O
Allelic O
release O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
relinquish O
relinquish O
relinquish O
antiophthalmic O
factor O

Allelic O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
. O

BACKGROUND O
Allelic O
poor O
II O
chromosome O
18q O
with O
a O
loss O
outcome O
in O
patients O
predicts O
stage B
of I
colorectal I
cancer I
. O

BACKGROUND O
Allelic O
loss O
of O
chromosome O
18q O
predicts O
a O
poor O
outcome O
in O
patients O
with O
stage B
II I
colorectal I
cancer I
. O

Although O
the O
particular O
cistron O
demobilize O
by O
this O
allelomorphic O
departure O
has O
not O
been O
illuminate O
, O
the O
DCC O
( O
deleted O
in O
colorectal B
cancer I
) O
cistron O
is O
a O
nominee O
. O

Although O
the O
gene O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
DCC O
( O
deleted O
in O
cancer I
) O
gene O
is O
a O
. O

Although O
the O
specific O
gene O
aside O
nominee O
demobilise O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
DCC O
( O
deleted O
be O
antiophthalmic O
factor O
nominee O
antiophthalmic O
factor O
release B
in I
colorectal O
cancer O
) O
gene O
is O
a O

cancer O
the O
specific O
in O
inactivated O
by O
this O
candidate O
is O
has O
colorectal O
been O
elucidated O
, O
gene O
DCC O
( O
deleted O
gene O
a B
not I
) O
the O
loss O
Although O
allelic O
. O

Although O
the O
specific O
gene O
aside O
nominee O
demobilise O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
DCC O
( O
deleted O
be O
antiophthalmic O
factor O
nominee O
antiophthalmic O
factor O
release B
in I
colorectal O
cancer O
) O
gene O
is O
a O

Although O
the O
specific O
inactivated O
by O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
( O
deleted O
colorectal B
cancer I
) O
gene O
is O
a O
candidate O
. O

. O
the O
specific O
the O
inactivated O
by O
candidate O
allelic O
gene O
has O
not O
been O
, O
cancer O
a O
loss O
( O
deleted O
in O
colorectal B
elucidated I
) O
gene O
is O
DCC O
this O
Although O

specific O
by O
this O
allelic O
has O
not O
elucidated O
, O
the O
DCC O
( O
deleted O
in O
colorectal B
cancer I
) O
gene O
is O
a O

is O
the O
specific O
gene O
inactivated O
by O
, O
been O
loss O
has O
not O
( O
) O
this O
a O
Although O
allelic O
DCC O
in O
colorectal B
cancer I
elucidated O
gene O
deleted O
the O
candidate O
. O

Although O
the O
particular O
factor O
demobilize O
by O
this O
allelomorphic O
expiration O
has O
not O
been O
clarify O
, O
the O
DCC O
( O
deleted O
in O
colorectal B
crab I
) O
factor O
is O
a O
prospect O
. O

Although O
the O
specific O
gene O
inactivated O
by O
this O
allelic O
loss O
has O
not O
been O
elucidated O
, O
the O
DCC O
( O
deleted O
in O
colorectal B
cancer I
) O
gene O
is O
a O
candidate O
. O

We O
investigated O
whether O
the O
locution O
of O
the O
DCC O
protein O
in O
tumour B
cells O
is O
a O
prognostic O
marking O
in O
colorectal B
carcinoma I
. O

We O
investigated O
whether O
the O
expression O
of O
the O
DCC O
protein O
in O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
marking B
marking O
marking B
marking O
marking B
marking O
carcinoma I
. O

We O
investigated O
whether O
the O
expression O
of O
the O
DCC O
protein O
in O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
marking B
marking O
marking B
marking O
marking B
marking O
carcinoma I
. O

whether O
of O
the O
DCC O
in O
tumor B
is O
a O
prognostic O
marker O
in O
colorectal B
carcinoma I
. O

We O
investigated O
whether O
the O
expression O
DCC O
protein O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
carcinoma I
. O

whether O
the O
expression O
of O
DCC O
protein O
in O
tumor B
cells O
a O
prognostic O
marker O
in O
carcinoma I
. O

colorectal O
investigated O
whether O
carcinoma O
expression O
of O
the O
protein O
DCC O
in O
prognostic B
cells O
is O
. O
We O
marker O
in O
tumor B
the I
a O

We O
investigated O
whether O
the O
expression O
of O
the O
DCC O
protein O
in O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
marking B
marking O
marking B
marking O
marking B
be O
carcinoma I
. O

We O
enquire O
whether O
the O
look O
of O
the O
DCC O
protein O
in O
neoplasm B
cells O
is O
a O
omen O
marking O
in O
colorectal B
carcinoma I
. O

in O
investigated O
whether O
the O
expression O
of O
a O
cells O
protein O
in O
tumor B
prognostic O
We O
the O
DCC O
colorectal O
is O
marker B
carcinoma I
. O

We O
investigated O
whether O
the O
expression O
of O
the O
DCC O
protein O
in O
tumor B
cells O
is O
a O
prognostic O
marker O
in O
colorectal B
carcinoma I
. O

The O
expression O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
samples O
from O
patients O
curatively O
stage B
II I
and I
III I
colorectal I
carcinomas I
. O

paraffin O
The O
expression O
resected O
DCC O
was O
evaluated O
. O
colorectal O
132 O
carcinomas O
- O
embedded O
stage O
III O
patients O
with O
curatively O
of O
samples B
II I
and I
from I
in I
METHODS I
immunohistochemically O

method O
The O
look O
of O
DCC O
was O
value O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
taste O
from O
patients O
with O
curatively O
eviscerate O
represent B
II I
and I
tercet I
colorectal I
carcinomas I
. O

method O
The O
reflection O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
implant O
sampling O
from O
patients O
with O
curatively O
eviscerate O
stage B
ii I
and I
leash I
colorectal I
carcinomas I
. O

METHODS O
The O
expression O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
- O
embedded O
from O
patients O
with O
curatively O
resected O
stage B
II I
colorectal I
carcinomas I
. O

METHODS O
The O
expression O
of O
 O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
samples O
from O
patients O
with O
curatively O
 O
two O
carcinoma O
 O
carcinoma O
inward O
resected O
stage B
II I
and I
III I
colorectal I
carcinomas I
. O

METHODS O
The O
expression O
of O
 O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
samples O
from O
patients O
with O
curatively O
 O
two O
carcinoma O
 O
carcinoma O
manifestation O
resected O
stage B
II I
and I
III I
colorectal I
carcinomas I
. O

METHODS O
The O
expression O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
- O
from O
patients O
with O
curatively O
resected O
stage B
II I
and I
III I

colorectal O
The O
expression O
of O
DCC O
was O
samples O
with O
in O
132 O
paraffin O
- O
and O
evaluated O
carcinomas O
patients O
immunohistochemically O
II O
resected O
stage B
METHODS I
embedded I
III I
curatively I
from I
. O

method O
The O
manifestation O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
imbed O
taste O
from O
patients O
with O
curatively O
resected O
present B
II I
and I
triad I
colorectal I
carcinomas I
. O

METHODS O
The O
expression O
of O
DCC O
was O
evaluated O
immunohistochemically O
in O
132 O
paraffin O
- O
embedded O
samples O
from O
patients O
with O
curatively O
resected O
stage B
II I
and I
III I
colorectal I
carcinomas I
. O

The O
Cox O
proportional O
- O
admit O
eld O
modeling O
wind O
up O
luck O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, B
tumor O
relative O
site O
, O
degree O
of B
tumor O
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
accommodate O
accommodate O
tumour O

The O
Cox O
proportional O
- O
admit O
eld O
modeling O
wind O
up O
luck O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, B
tumor O
modeling O
site O
, O
degree O
of B
tumor O
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
accommodate O
accommodate O
tumour O

differentiation O
Cox O
proportional O
- O
hazards O
model O
age O
, O
to O
adjust O
for O
covariates O
of O
was O
, O
adjuvant O
used O
degree B
site O
, O
The O
including O
tumor B
tumor O
, O
and O
use O
of O
. O
therapy O
sex O

The O
Cox O
proportional O
- O
admit O
eld O
modeling O
wind O
up O
luck O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, B
tumor O
relative O
site O
, O
degree O
of B
tumor O
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
accommodate O
accommodate O
tumour O

The O
Cox O
proportional O
- O
model O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, O
of O
tumor B
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
. O

The O
coxswain O
relative O
- O
pretend O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
eld O
, O
gender O
, O
tumor B
locate O
, O
degree O
of O
tumor B
specialization O
, O
and O
usance O
of O
ancillary O
therapy O
. O

adjuvant O
Cox O
, O
, O
hazards O
model O
of O
used O
- O
adjust O
for O
covariates O
degree O
age O
proportional O
to O
, O
tumor B
site O
, O
including O
of O
tumor B
differentiation O
sex O
was O
use O
and O
The O
therapy O
. O

The O
Cox O
proportional O
- O
hazards O
model O
was O
used O
to O
for O
covariates O
age O
, O
sex O
, O
tumor B
site O
, O
tumor B
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
. O

for O
Cox O
proportional O
adjuvant O
hazards O
model O
was O
and O
differentiation O
adjust O
, O
covariates O
use O
, O
tumor O
sex O
, O
tumor B
. O
age O
degree O
of O
, B
to O
The O
used O
including O
of O
- O
therapy O
site O

The O
cyclooxygenase O
relative O
- O
chance O
mannequin O
was O
victimised O
to O
conform O
for O
covariates O
including O
senesce O
, O
sex O
, O
neoplasm B
site O
, O
degree O
of O
neoplasm B
differentiation O
, O
and O
employment O
of O
adjuvant O
therapy O
. O

The O
Cox O
proportional O
- O
hazards O
model O
was O
used O
to O
adjust O
for O
covariates O
including O
age O
, O
sex O
, O
tumor B
site O
, O
degree O
of O
tumor B
differentiation O
, O
and O
use O
of O
adjuvant O
therapy O
. O

RESULTS O
The O
expression O
strong O
positive O
predictive O
factor O
for O
survival O
in O
both O
stage B
II I
and I
stage I
III I
colorectal I
carcinomas I

RESULTS O
The O
expression O
of O
DCC O
was O
a O
strong O
positive O
predictive O
factor O
for O
survival O
both O
and I
stage I
III I
colorectal I
carcinomas I
. O

RESULTS O
The O
expression O
of O
DCC O
was O
a O
strong O
positive O
predictive O
factor O
for O
survival O
in O
both O
stage B
II I
and I
 I
carcinoma I
carcinoma I
manifestation I
manifestation I
manifestation I
stage I
III I
colorectal I
carcinomas I
. O

RESULTS O
The O
expression O
of O
DCC O
was O
a O
substantial O
cocksure O
prognosticative O
factor O
for O
selection O
in O
both O
degree B
II I
and I
degree I
trey I
colorectal I
carcinomas I
. O

RESULTS O
The O
expression O
of O
DCC O
was O
a O
strong O
positive O
predictive O
factor O
for O
survival O
in O
both O
stage B
II I
and I
 I
carcinoma I
carcinoma I
manifestation I
manifestation I
manifestation I
stage I
III I
colorectal I
carcinomas I
. O

RESULTS O
The O
locution O
of O
DCC O
was O
a O
solid O
positive O
prognosticative O
factor O
for O
survival O
in O
both O
present B
two I
and I
present I
threesome I
colorectal I
carcinomas I
. O

RESULTS O
The O
expression O
of O
DCC O
was O
a O
strong O
positive O
predictive O
for O
survival O
both O
stage B
II I
and I
stage I
III I
colorectal I

factor O
The O
expression O
stage O
DCC O
was O
a O
positive O
strong O
predictive O
III O
for O
in O
survival O
. O
stage B
II I
and I
of I
RESULTS I
colorectal I
carcinomas I
both O

solvent O
The O
expression O
of O
DCC O
was O
a O
potent O
cocksure O
predictive O
constituent O
for O
endurance O
in O
both O
stage B
II I
and I
stage I
trinity I
colorectal I
carcinomas I
. O

both O
The O
positive O
a O
DCC O
was O
stage O
strong O
expression O
predictive O
factor O
for O
colorectal O
in O
of O
RESULTS B
II I
and I
stage I
III I
survival I
carcinomas I
. O

RESULTS O
The O
expression O
of O
DCC O
was O
a O
strong O
positive O
predictive O
factor O
for O
survival O
in O
both O
stage B
II I
and I
stage I
III I
colorectal I
carcinomas I
. O

In O
patients O
with O
stage O
deuce O
disease O
whose O
tumors B
evince O
DCC O
, O
the O
quint O
- O
twelvemonth O
survival O
order O
was O
94 O
. O

In O
patients O
with O
stage O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
five O
- O
year O
survival O
rate O
was O
verbalise O
verbalise O
verbalise O
verbalise O
verbalise O
verbalise O
94 O
. O

In O
patients O
with O
stage O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
five O
- O
year O
survival O
rate O
was O
verbalise O
verbalise O
verbalise O
verbalise O
verbalise O
verbalise O
94 O
. O

with O
disease O
whose O
tumors B
DCC O
, O
five O
- O
year O
survival O
rate O
was O
94 O
. O

In O
patients O
with O
stage O
II O
tumors B
expressed O
, O
the O
five O
- O
year O
survival O
rate O
was O
94 O
. O

with O
stage O
II O
disease O
tumors B
expressed O
DCC O
, O
the O
- O
year O
survival O
rate O
94 O
. O

was O
patients O
with O
94 O
II O
disease O
whose O
expressed B
tumors O
DCC O
year O
the O
five O
. O
In O
survival O
rate O
, O
stage O
- O

In O
patients O
with O
stage O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
five O
- O
year O
survival O
rate O
was O
verbalise O
verbalise O
verbalise O
verbalise O
verbalise O
yr O
94 O
. O

inwards O
patients O
with O
degree O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
phoebe O
- O
class O
endurance O
rate O
was O
xciv O
. O

rate O
patients O
with O
stage O
II O
disease O
- O
the B
expressed O
DCC O
, O
year O
In O
whose O
tumors O
was O
five O
survival O
94 O
. O

In O
patients O
with O
stage O
II O
disease O
whose O
tumors B
expressed O
DCC O
, O
the O
five O
- O
year O
survival O
rate O
was O
94 O
. O

tumors O
percent O
, O
DCC O
in O
patients O
with O
whereas B
rate I
negative I
survival I
, O
3 O
the O
- O
was O
61 O
. O

ternion O
pct O
, O
whereas O
in O
patients O
with O
DCC B
- I
veto I
tumors I
, O
the O
survival O
range O
was O
61 O
. O

ternary O
pct O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
range O
was O
lxi O
. O

3 O
percent O
, O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
rate O
was O
61 O
. O

trine O
percent O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumour I
, O
the O
selection O
pace O
was O
lxi O
. O

3 O
percent O
be O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
rate O
was O
61 O
follow O
follow O
follow O
grade O
. O

3 O
percent O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
, O
the O
rate O
was O
61 O
. O

3 O
percent O
be O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
rate O
was O
61 O
follow O
follow O
follow O
grade O
. O

percent O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
. O

3 O
percent O
- O
rate O
in O
patients O
the O
DCC B
, I
negative I
tumors I
, O
with O
survival O
whereas O
was O
61 O
. O

3 O
percent O
, O
whereas O
in O
patients O
with O
DCC B
- I
negative I
tumors I
, O
the O
survival O
rate O
was O
61 O
. O

sextuplet O
percent O
( O
phosphorus O
< O
cypher O
. O
001 O
) O
. O

6 O
percent O
( O
P O
< O
0 O
. O
001 O
) O
percentage O
percentage O
percentage O
. O

6 O
percent O
( O
phosphorus O
< O
nought O
. O
001 O
) O
. O

sixer O
pct O
( O
P O
< O
cipher O
. O
001 O
) O
. O

6 O
( O
P O
0 O
. O
001 O
) O
. O

001 O
. O
( O
< O
P O
0 O
. O
6 O
) O
percent O

6 O
001 O
( O
P O
percent O
0 O
< O
. O
) O
. O

001 O
P O
( O
percent O
< O
0 O
. O
6 O
) O
. O

6 O
P O
< O
0 O
001 O

6 O
percent O
( O
P O
< O
0 O
. O
001 O
) O
percentage O
percentage O
percentage O
. O

6 O
percent O
( O
P O
< O
0 O
. O
001 O
) O
. O

In O
with O
III I
, O
the O
respective O
survival O
rates O
were O
59 O
. O

In O
patients O
with O
stage B
tierce I
disease I
, O
the O
various O
survival O
grass O
were O
ilx O
. O

the O
stage O
with O
patients B
III I
disease I
survival O
In O
respective O
. O
rates O
were O
59 O
, O

In O
patients O
with O
stage B
III I
disease I
, O
the O
survival O
rates O
59 O
. O

In O
patients O
 O
several O
with O
stage B
III I
disease I
, O
the O
respective O
 O
 O
survival O
rates O
were O
59 O
. O

In O
patients O
 O
several O
with O
stage B
III I
disease I
, O
the O
respective O
 O
inward O
survival O
rates O
were O
59 O
. O

In O
patients O
with O
stage B
ternion I
disease I
, O
the O
various O
endurance O
grade O
were O
59 O
. O

59 O
patients O
with O
In B
the I
disease I
, O
were O
respective O
survival O
rates O
III O
stage O
. O

In O
patients O
 O
several O
with O
stage B
III I
disease I
, O
the O
respective O
 O
 O
survival O
rates O
were O
59 O
. O

In O
patients O
with O
degree B
III I
disease I
, O
the O
several O
selection O
rates O
were O
ilx O
. O

In O
patients O
with O
stage B
III I
disease I
, O
the O
respective O
survival O
rates O
were O
59 O
. O

3 O
percent O
and O
33 O
 O
. O

33 O
percent O
and O
3 O
. O

3 O
pct O
and O
33 O
. O

3 O
33 O
and O
percent O
. O

and O
33 O
. O

ternion O
percent O
and O
33 O
. O

3 O
percent O
and O
33 O
 O
. O

terzetto O
percent O
and O
33 O
. O

3 O
33 O
. O

3 O
percent O
and O
33 O
percentage O
. O

3 O
percent O
and O
33 O
. O

2 O
pct O
( O
P O
= O
cypher O
. O
03 O
) O
. O

2 O
percent O
( O
P O
= O
0 O
. O
03 O
) O
percentage O
percentage O
percentage O
. O

deuce O
percent O
( O
p O
= O
cypher O
. O
03 O
) O
. O

two O
pct O
( O
phosphorus O
= O
0 O
. O
03 O
) O
. O

2 O
( O
P O
0 O
. O
03 O
) O
. O

03 O
. O
( O
= O
P O
0 O
. O
2 O
) O
percent O

2 O
03 O
( O
P O
percent O
0 O
= O
. O
) O
. O

03 O
P O
( O
percent O
= O
0 O
. O
2 O
) O
. O

2 O
P O
= O
0 O
03 O

2 O
percent O
( O
P O
= O
0 O
. O
03 O
) O
percentage O
percentage O
percentage O
. O

2 O
percent O
( O
P O
= O
0 O
. O
03 O
) O
. O

II O
DCC O
is O
patients O
prognostic O
marker O
in O
a O
colorectal O
stage B
III I
or I
CONCLUSIONS I
stage I
with I
cancer I
. O

last O
DCC O
is O
a O
portent O
marker O
in O
patients O
with O
stage B
ii I
or I
stage I
ternion I
colorectal I
crab I
. O

conclusion O
DCC O
is O
a O
prodigy O
marker O
in O
patients O
with O
stage B
deuce I
or I
stage I
ternary I
colorectal I
cancer I
. O

CONCLUSIONS O
DCC O
prognostic O
marker O
in O
patients O
with O
stage B
II I
or I
stage I
III I
colorectal I
cancer I
. O

close O
DCC O
is O
a O
prognostic O
marker O
in O
patients O
with O
degree B
deuce I
or I
degree I
terzetto I
colorectal I
cancer I
. O

CONCLUSIONS O
DCC O
patient O
be O
is O
a O
prognostic O
marker O
in O
patients O
with O
stage B
II I
or I
stage I
III I
colorectal I
cancer I
patient O
role O
patient O
role O

CONCLUSIONS O
DCC O
is O
a O
prognostic O
marker O
in O
patients O
stage B
II I
stage I
III I
colorectal I
cancer I
. O

CONCLUSIONS O
DCC O
patient O
be O
is O
a O
prognostic O
marker O
in O
patients O
with O
stage B
II I
or I
stage I
III I
colorectal I
cancer I
patient O
role O
patient O
role O

DCC O
prognostic O
marker O
in O
patients O
with O
stage B
II I
or I
stage I

CONCLUSIONS O
DCC O
with O
colorectal O
prognostic O
marker O
stage O
patients O
is O
stage B
II I
or I
in I
III I
a I
cancer I
. O

CONCLUSIONS O
DCC O
is O
a O
prognostic O
marker O
in O
patients O
with O
stage B
II I
or I
stage I
III I
colorectal I
cancer I
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
 O
cancer O
 O
cancer O
cancer O
two O
patient O
behave O
like O
stage B
III I
cancers I
. O

II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
behave O
stage B
III I
cancers I
. O

In O
level B
deuce I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
discover O
a O
subgroup O
of O
patients O
with O
wound O
that O
do O
comparable O
level B
threesome I
cancers I
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
of O
DCC O
a O
subgroup O
of O
patients O
with O
lesions O
that O
stage B
III I
cancers I
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
 O
cancer O
 O
cancer O
cancer O
two O
two O
behave O
like O
stage B
III I
cancers I
. O

inch O
degree B
deuce I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
describe O
a O
subgroup O
of O
patients O
with O
lesions O
that O
comport O
like O
degree B
trinity I
crab I
. O

indium O
degree B
ii I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
key O
a O
subgroup O
of O
patients O
with O
lesions O
that O
act O
like O
degree B
trine I
cancers I
. O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
identifies O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B
III I

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
 O
cancer O
 O
cancer O
cancer O
two O
two O
behave O
like O
stage B
III I
cancers I
. O

that O
stage B
II I
identifies I
carcinomas I
, O
the O
behave O
. O
DCC O
colorectal O
a O
subgroup O
of O
cancers O
with O
lesions O
stage O
absence O
In O
like B
III I
patients I
of O

In O
stage B
II I
colorectal I
carcinomas I
, O
the O
absence O
of O
DCC O
identifies O
a O
subgroup O
of O
patients O
with O
lesions O
that O
behave O
like O
stage B
III I
cancers I
. O

These O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
patient O
patient O
find O
out O
group O
of O

findings O
may O
implications O
group O
of O
patients O

These O
findings O
may O
olibanum O
have O
remedial O
implications O
in O
this O
radical O
of O
patients O

These O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
patient O
patient O
find O
out O
group O
of O

findings O
may O
have O
therapeutic O
implications O
in O
this O
group O
of O
patients O

These O
determine O
may O
olibanum O
have O
therapeutic O
significance O
in O
this O
group O
of O
patients O

These O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
patient O
patient O
inward O
group O
of O
patients O

These O
get O
may O
thus O
have O
cure O
significance O
in O
this O
group O
of O
patients O

These O
in O
may O
thus O
findings O
therapeutic O
implications O
of O
this O
group O
have O
patients O

patients O
findings O
may O
thus O
in O
therapeutic O
group O
have O
this O
implications O
of O
These O

These O
findings O
may O
thus O
have O
therapeutic O
implications O
in O
this O
group O
of O
patients O

the O
of O
anxiety B
a I
related I
traits I
with O
- O
regulatory O
in O
gene O
serotonin O
Association O
transporter O
polymorphism O
region O
. O

association O
of O
anxiousness B
- I
related I
traits I
with O
a O
pleomorphism O
in O
the O
serotonin O
transporter O
factor O
regulative O
region O
. O

connexion O
of O
anxiousness B
- I
related I
traits I
with O
a O
pleomorphism O
in O
the O
serotonin O
transporter O
gene O
regulative O
realm O
. O

Association O
of O
related I
traits I
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
. O

connexion O
of O
anxiousness B
- I
related I
traits I
with O
a O
pleomorphism O
in O
the O
serotonin O
transporter O
cistron O
regulatory O
part O
. O

Association O
of O
antiophthalmic O
factor O
anxiousness B
anxiety I
- I
related I
traits O
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
disquiet O
disquiet O
disquiet O

Association O
of O
anxiety B
- I
related I
traits I
with O
a O
in O
the O
transporter O
gene O
regulatory O
region O
. O

Association O
of O
antiophthalmic O
factor O
anxiousness B
anxiety I
- I
related I
traits O
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
disquiet O
disquiet O
disquiet O

of O
related I
traits I
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O

Association O
of O
polymorphism B
regulatory I
related I
traits I
transporter O
a O
anxiety O
in O
the O
serotonin O
with O
gene O
- O
region O
. O

Association O
of O
anxiety B
- I
related I
traits I
with O
a O
polymorphism O
in O
the O
serotonin O
transporter O
gene O
regulatory O
region O
. O

Transporter O
of O
( O
5 O
- O
or O
5 O
- O
) O
has O
been O
implicated O
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
used O
uptake O
- O
antidepressant O
and O
antianxiety O
drugs O
. O

Transporter O
- O
facilitated O
uptake O
of O
- O
hydroxytryptamine O
or O
5 O
- O
) O
has O
anxiety B
and O
animal O
is O
of O
action O
of O
widely O
uptake O
- O
and O
antianxiety O
. O

Transporter O
- O
facilitated O
uptake O
of O
serotonin O
( O
5 O
- O
hydroxytryptamine O
or O
5 O
- O
HT O
) O
has O
been O
implicated O
in O
anxiety B
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
uptake O
- O
dose O
be O
be O
dose O
be O
be O
be O
be O
be O
be O
be O
be O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O

Transporter O
- O
help O
ingestion O
of O
serotonin O
( O
fin O
- O
hydroxytryptamine O
or O
fin O
- O
HT O
) O
has O
been O
concerned O
in O
anxiousness B
in O
humans O
and O
carnal O
pattern O
and O
is O
the O
site O
of O
litigate O
of O
widely O
secondhand O
ingestion O
- O
suppress O
antidepressant O
and O
antianxiety O
drugs O
. O

Transporter O
- O
action O
uptake O
of O
- O
( O
in O
- O
hydroxytryptamine O
or O
is O
anxiety O
HT O
) O
5 O
been O
implicated O
antidepressant O
- B
in O
widely O
and O
serotonin O
models O
has O
5 O
humans O
site O
of O
facilitated O
the O
of O
used O
uptake O
animal O
inhibiting O
and O
and O
antianxiety O
drugs O
. O

conveyer O
- O
alleviate O
consumption O
of O
serotonin O
( O
quint O
- O
hydroxytryptamine O
or O
quint O
- O
HT O
) O
has O
been O
concerned O
in O
anxiousness B
in O
humans O
and O
carnal O
example O
and O
is O
the O
situation O
of O
activeness O
of O
widely O
utilise O
consumption O
- O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O

uptake O
in O
facilitated O
uptake O
of O
serotonin O
. O
5 O
- O
hydroxytryptamine O
or O
drugs O
- O
models O
of O
has O
been O
implicated O
the O
anxiety B
in O
humans O
- O
animal O
HT O
and O
used O
- O
of O
and O
action O
site O
widely O
) O
Transporter O
is O
inhibiting O
antidepressant O
and O
antianxiety O
5 O
( O

Transporter O
- O
facilitated O
uptake O
of O
serotonin O
- O
hydroxytryptamine O
or O
5 O
HT O
) O
has O
been O
implicated O
anxiety B
in O
humans O
and O
models O
and O
the O
site O
of O
action O
of O
widely O
used O
uptake O
inhibiting O
antidepressant O
antianxiety O
drugs O
. O

and O
models O
facilitated O
uptake O
been O
serotonin O
in O
of O
- O
hydroxytryptamine O
or O
5 O
- O
( O
antidepressant O
has O
of O
action O
in O
anxiety B
HT O
humans O
and O
animal O
the O
and O
is O
. O
implicated O
of O
site O
- O
widely O
used O
uptake O
- O
inhibiting O
) O
Transporter O
antianxiety O
drugs O
5 O

Transporter O
- O
facilitated O
uptake O
of O
serotonin O
( O
5 O
- O
hydroxytryptamine O
or O
5 O
- O
HT O
) O
has O
been O
implicated O
in O
anxiety B
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
uptake O
- O
dose O
be O
be O
dose O
be O
be O
be O
be O
be O
be O
be O
wide O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O

Transporter O
- O
facilitated O
uptake O
of O
serotonin O
( O
5 O
- O
hydroxytryptamine O
or O
5 O
- O
HT O
) O
has O
been O
implicated O
in O
anxiety B
in O
humans O
and O
animal O
models O
and O
is O
the O
site O
of O
action O
of O
widely O
used O
uptake O
- O
inhibiting O
antidepressant O
and O
antianxiety O
drugs O
. O

Human O
5 O
- O
HT O
transporter O
( O
5 O
- O
HTT O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
regulative O
realm O
regulative O
realm O
realm O
antiophthalmic O
factor O
homo O
in O
its O
upstream O
regulatory O
region O

- O
HT O
transporter O
( O
5 O
- O
HTT O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
in O
upstream O
regulatory O
region O
. O

Human O
cinque O
- O
HT O
conveyor O
( O
cinque O
- O
HTT O
) O
cistron O
transcription O
is O
inflect O
by O
a O
park O
pleomorphism O
in O
its O
upstream O
regulative O
region O
. O

Human O
5 O
- O
HT O
transporter O
( O
5 O
HTT O
) O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
upstream O
regulatory O
region O
. O

Human O
5 O
- O
HT O
transporter O
( O
5 O
- O
HTT O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
regulative O
realm O
regulative O
realm O
realm O
antiophthalmic O
factor O
antiophthalmic O
factor O
in O
its O
upstream O
regulatory O

homo O
phoebe O
- O
HT O
transporter O
( O
phoebe O
- O
HTT O
) O
cistron O
transcription O
is O
inflect O
by O
a O
uncouth O
polymorphism O
in O
its O
upriver O
regulative O
region O
. O

Human O
fivesome O
- O
HT O
transporter O
( O
fivesome O
- O
HTT O
) O
factor O
transcription O
is O
regulate O
by O
a O
coarse O
pleomorphism O
in O
its O
upstream O
regulative O
part O
. O

Human O
5 O
- O
HT O
transporter O
( O
5 O
- O
HTT O
gene O
modulated O
by O
a O
common O
polymorphism O
in O
its O
upstream O
regulatory O

Human O
5 O
- O
HT O
transporter O
( O
5 O
- O
HTT O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
regulative O
realm O
regulative O
realm O
realm O
antiophthalmic O
factor O
antiophthalmic O
factor O
in O
its O
upstream O
regulatory O

polymorphism O
5 O
- O
gene O
transporter O
( O
5 O
in O
. O
) O
HT O
transcription O
is O
modulated O
region O
a O
common O
upstream O
- O
Human O
its O
regulatory O
by O
HTT O

Human O
5 O
- O
HT O
transporter O
( O
5 O
- O
HTT O
) O
gene O
transcription O
is O
modulated O
by O
a O
common O
polymorphism O
in O
its O
upstream O
regulatory O
region O
. O

The O
short O
variant O
of O
 O
pleomorphism O
cistron O
plugger O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
HTT O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
HTT O
expression O
and O
5 O
- O
HT O
uptake O
in O
lymphoblasts O
 O
 O
 O
 O
 O
. O

The O
short O
variant O
polymorphism O
of O
the O
5 O
HTT O
gene O
, O
resulting O
in O
- O
HTT O
expression O
and O
5 O
HT O
in O
lymphoblasts O
. O

The O
unforesightful O
form O
of O
the O
pleomorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
v O
- O
HTT O
cistron O
booster O
, O
lead O
in O
minify O
v O
- O
HTT O
expression O
and O
v O
- O
HT O
intake O
in O
lymphoblasts O
. O

The O
short O
variant O
of O
the O
polymorphism O
reduces O
transcriptional O
the O
5 O
- O
HTT O
gene O
promoter O
, O
resulting O
in O
expression O
and O
5 O
- O
HT O
uptake O
in O
lymphoblasts O
. O

The O
short O
version O
of O
the O
pleomorphism O
shorten O
the O
transcriptional O
efficiency O
of O
the O
cinque O
- O
HTT O
cistron O
showman O
, O
resulting O
in O
fall O
cinque O
- O
HTT O
formulation O
and O
cinque O
- O
HT O
ingestion O
in O
lymphoblasts O
. O

The O
short O
variant O
of O
 O
pleomorphism O
cistron O
plugger O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
HTT O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
HTT O
expression O
and O
5 O
- O
HT O
uptake O
in O
lymphoblasts O
 O
 O
 O
 O
 O
. O

The O
dead O
form O
of O
the O
pleomorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
HTT O
factor O
showman O
, O
leave O
in O
diminish O
5 O
- O
HTT O
saying O
and O
5 O
- O
HT O
consumption O
in O
lymphoblasts O
. O

decreased O
resulting O
variant O
of O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
expression O
uptake O
gene O
promoter O
, O
- O
in O
short O
5 O
lymphoblasts O
HTT O
- O
and O
5 O
The O
HTT O
- O
in O
HT O
. O

The O
short O
variant O
of O
the O
polymorphism O
the O
efficiency O
of O
the O
5 O
- O
HTT O
gene O
promoter O
resulting O
in O
decreased O
5 O
- O
HTT O
expression O
- O
HT O
uptake O
lymphoblasts O

The O
short O
variant O
of O
 O
pleomorphism O
cistron O
var O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
HTT O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
HTT O
expression O
and O
5 O
- O
HT O
uptake O
in O
lymphoblasts O
 O
 O
 O
 O
 O
. O

The O
short O
variant O
of O
the O
polymorphism O
reduces O
the O
transcriptional O
efficiency O
of O
the O
5 O
- O
HTT O
gene O
promoter O
, O
resulting O
in O
decreased O
5 O
- O
HTT O
expression O
and O
5 O
- O
HT O
uptake O
in O
lymphoblasts O
. O

Association O
studies O
in O
two O
independent O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
HTT O
polymorphism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B
- I
a I
considerably I
a I
a I
considerably I
a I
a I
considerably I
a I
main I
main I
main I
main I
main I
related I
personality I
traits I
in O
individuals O
as O
well O
as O
sibships O
. O
. O

Association O
subject O
in O
ii O
independent O
samples O
totaling O
505 O
soul O
disclose O
that O
the O
5 O
- O
HTT O
pleomorphism O
invoice O
for O
terzetto O
to O
quartet O
percent O
of O
summate O
fluctuation O
and O
sevener O
to O
9 O
percent O
of O
hereditary O
variant O
in O
anxiousness B
- I
related I
personality I
traits I
in O
soul O
as O
well O
as O
sibships O
. O
. O

Association O
studies O
inherited O
two O
independent O
- O
totaling O
505 O
individuals O
revealed O
that O
5 O
well O
- O
HTT O
of O
accounts O
for O
to O
3 O
4 O
. O
of O
samples O
variation O
7 O
to O
. O
9 O
percent O
polymorphism O
personality O
and O
in O
anxiety B
total I
related I
in I
traits I
in O
individuals O
as O
the O
sibships O
as O
variance O
percent O

Association O
7 O
in O
two O
independent O
samples O
the O
percent O
individuals O
revealed O
that O
totaling O
5 O
to O
variation O
polymorphism O
accounts O
for O
505 O
to O
4 O
percent O
- O
total O
as O
and O
. O
- O
inherited O
3 O
of O
9 O
variance O
HTT O
anxiety B
as I
related I
personality I
traits I
in O
studies O
in O
well O
of O
sibships O
. O
individuals O

connexion O
studies O
in O
two O
mugwump O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
HTT O
pleomorphism O
accounts O
for O
trinity O
to O
4 O
pct O
of O
come O
variance O
and O
seven O
to O
ix O
pct O
of O
transmissible O
discrepancy O
in O
anxiousness B
- I
colligate I
personality I
traits I
in O
individuals O
as O
considerably O
as O
sibships O
. O
. O

Association O
studies O
in O
independent O
samples O
totaling O
505 O
individuals O
the O
5 O
- O
HTT O
polymorphism O
accounts O
for O
3 O
percent O
total O
variation O
and O
to O
9 O
percent O
of O
inherited O
variance O
anxiety B
- I
traits I
individuals O
as O
well O
as O
. O

two O
independent O
samples O
totaling O
505 O
revealed O
that O
HTT O
for O
3 O
percent O
variation O
and O
7 O
to O
percent O
of O
in O
anxiety B
related I
personality I
as O
as O
sibships O
. O

Association O
studies O
in O
two O
independent O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
HTT O
polymorphism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B
- I
a I
considerably I
a I
a I
considerably I
a I
a I
considerably I
a I
main I
main I
main I
main I
 I
related I
personality I
traits I
in O
individuals O
as O
well O
as O
sibships O
. O
. O

anxiety O
variation O
in O
two O
accounts O
samples O
4 O
inherited O
individuals O
revealed O
that O
the O
5 O
totaling O
personality O
polymorphism O
independent O
. O
3 O
to O
- O
percent O
of O
total O
to O
and O
7 O
as O
sibships O
percent O
9 O
studies O
variance O
in O
traits B
- I
related I
HTT I
Association I
in O
individuals O
505 O
well O
as O
of O
. O
for O

Association O
studies O
in O
two O
independent O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
HTT O
polymorphism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B
- I
a I
considerably I
a I
a I
considerably I
a I
a I
considerably I
a I
main I
main I
main I
main I
main I
related I
personality I
traits I
in O
individuals O
as O
well O
as O
sibships O
. O
. O

Association O
studies O
in O
two O
independent O
samples O
totaling O
505 O
individuals O
revealed O
that O
the O
5 O
- O
HTT O
polymorphism O
accounts O
for O
3 O
to O
4 O
percent O
of O
total O
variation O
and O
7 O
to O
9 O
percent O
of O
inherited O
variance O
in O
anxiety B
- I
related I
personality I
traits I
in O
individuals O
as O
well O
as O
sibships O
. O
. O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
type I
2 I
and O
betwixt O
betwixt O
betwixt O
diastrophic B
dysplasia I
. O

and O
genotypic O
type I
diastrophic B
dysplasia I
. O

phenotypical O
and O
genotypic O
intersection O
between O
atelosteogenesis B
case I
2 I
and O
diastrophic B
dysplasia I
. O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
type I
2 I
and O
betwixt O
betwixt O
betwixt O
diastrophic B
dysplasia I
. O

and O
genotypic O
between O
atelosteogenesis B
type I
2 I
and O
diastrophic B
dysplasia I
. O

phenotypical O
and O
genotypic O
convergence O
between O
atelosteogenesis B
type I
two I
and O
diastrophic B
dysplasia I
. O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
type I
2 I
and O
betwixt O
betwixt O
genotypical O
diastrophic B
dysplasia I
. O

phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
case I
2 I
and O
diastrophic B
dysplasia I
. O

Phenotypic O
2 O
genotypic O
overlap O
and O
atelosteogenesis B
type I
dysplasia I
and O
diastrophic B
between I
. O

. O
and O
genotypic O
overlap O
2 O
atelosteogenesis B
diastrophic I
between I
and O
type B
dysplasia I
Phenotypic O

Phenotypic O
and O
genotypic O
overlap O
between O
atelosteogenesis B
type I
2 I
and O
diastrophic B
dysplasia I
. O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
2 I
( O
character O
cistron O
cistron O
character O
cistron O
cistron O
character O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

mutation O
in O
the O
diastrophic B
dysplasia I
sulphate O
conveyor O
factor O
DTDST O
have O
been O
assort O
with O
a O
family O
of O
chondrodysplasias B
that O
consist O
, O
in O
rate O
of O
increase O
badness O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
character I
two I
( O
AO2 B
) O
, O
and O
achondrogenesis B
character I
1B I
( O
ACG1B B
) O
. O

Mutations O
in O
, O
diastrophic B
dysplasia I
( O
transporter O
gene O
DTDST O
have O
been O
with O
1B O
a O
family O
) O
chondrodysplasias B
that O
, O
comprises O
in O
. O
of O
sulfate O
severity O
diastrophic O
dysplasia B
) I
( O
DTD B
of O
) O
, B
type I
2 I
increasing O
AO2 B
the O
, O
and O
achondrogenesis B
type I
associated I
ACG1B O
( B
atelosteogenesis O
order O

Mutations O
diastrophic O
the O
diastrophic B
dysplasia I
sulfate O
associated O
DTD O
DTDST O
have O
been O
transporter O
with O
dysplasia O
severity O
of O
chondrodysplasias B
that O
gene O
, O
in O
order O
( O
increasing O
( O
, O
. B
a I
, O
comprises B
) O
( O
atelosteogenesis B
family I
2 I
type O
AO2 B
) O
, O
and O
in B
type I
1B I
of O
ACG1B B
) O
achondrogenesis O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulphate O
conveyer O
cistron O
DTDST O
have O
been O
consort O
with O
a O
household O
of O
chondrodysplasias B
that O
represent O
, O
in O
regularize O
of O
increase O
hardness O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
ii I
( O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

Mutations O
in O
the O
dysplasia I
sulfate O
transporter O
gene O
DTDST O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
order O
increasing O
severity O
, O
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
2 I
( O
, O
achondrogenesis B
type I
1B I
( O
. O

diastrophic B
dysplasia I
sulfate O
transporter O
gene O
have O
been O
family O
that O
comprises O
order O
severity O
, O
diastrophic B
dysplasia I
DTD B
) O
type I
2 I
AO2 B
) O
type I
( O
ACG1B B
) O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
2 I
( O
character O
cistron O
cistron O
character O
cistron O
cistron O
character O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
inward O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

2 O
severity O
the O
diastrophic B
chondrodysplasias I
sulfate O
in O
, O
DTDST O
have O
been O
associated O
with O
transporter O
) O
of O
dysplasia B
. O
comprises O
, O
a O
order O
of O
increasing O
dysplasia O
, O
diastrophic B
type I
ACG1B O
DTD B
( O
in O
atelosteogenesis B
type I
, I
( O
AO2 B
family O
Mutations O
and O
achondrogenesis B
gene I
1B I
( O
) B
) O
that O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
2 I
( O
character O
cistron O
cistron O
character O
cistron O
cistron O
character O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
cistron O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

Mutations O
in O
the O
diastrophic B
dysplasia I
sulfate O
transporter O
gene O
DTDST O
have O
been O
associated O
with O
a O
family O
of O
chondrodysplasias B
that O
comprises O
, O
in O
order O
of O
increasing O
severity O
, O
diastrophic B
dysplasia I
( O
DTD B
) O
, O
atelosteogenesis B
type I
2 I
( O
AO2 B
) O
, O
and O
achondrogenesis B
type I
1B I
( O
ACG1B B
) O
. O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO B
- I
2 I
, O
one O
with O
DTD B
, O
and O
associate O
in O
nursing O
average O
 O
associate O
in O
nursing O
average O
 O
 O
 O
 O
 O
 O
 O
 O
 O
one O
with O
an B
intermediate O
phenotype B
( O
AO2 O

To O
teach O
more O
about O
the O
molecular O
base O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
contemplate O
fibroblast O
civilization O
of O
troika O
unexampled O
patients O
nonpareil O
with O
AO B
- I
2 I
, O
nonpareil O
with O
DTD B
, O
and O
nonpareil O
with O
an O
average O
phenotype O
( O
AO2 B
/ O
DTD B
) O
. O

To O
learn O
one O
about O
the O
and O
basis O
of O
DTDST B
chondrodysplasias I
and O
genotype O
AO2 O
- O
phenotype O
, O
, O
we O
fibroblast O
studied O
cultures O
. O
three O
molecular O
patients O
with O
AO O
) B
- I
2 I
correlations O
with O
one O
DTD B
, O
new O
one O
more O
an O
intermediate O
phenotype O
( O
about B
DTD O
/ B
with O
of O

To O
with O
more O
about O
the O
molecular O
about O
2 O
DTDST B
chondrodysplasias I
and O
basis O
genotype O
AO O
patients O
correlations O
, O
we O
of O
fibroblast O
cultures O
of O
and O
new O
/ O
one O
. O
- B
one I
studied I
, O
- O
with O
phenotype B
, O
( O
one O
with O
an O
intermediate O
learn O
DTD O
AO2 B
three O
DTD B
) O
phenotype O

To O
hear O
more O
about O
the O
molecular O
groundwork O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
canvas O
fibroblast O
acculturation O
of O
trine O
modern O
patients O
unrivaled O
with O
AO B
- I
ii I
, O
unrivaled O
with O
DTD B
, O
and O
unrivaled O
with O
an O
intermediate O
phenotype O
( O
AO2 B
/ O
DTD B
) O
. O

To O
learn O
more O
the O
molecular O
basis O
of O
DTDST B
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
of O
new O
patients O
one O
AO B
- I
2 I
, O
one O
with O
, O
and O
an O
phenotype O
( O
AO2 B
/ O
. O

about O
the O
molecular O
basis O
of O
chondrodysplasias I
and O
phenotype O
we O
studied O
of O
patients O
one O
with O
AO B
2 I
, O
DTD B
, O
one O
with O
( O
/ O
DTD B
) O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO B
- I
2 I
, O
one O
with O
DTD B
, O
and O
associate O
in O
nursing O
average O
 O
associate O
in O
nursing O
average O
 O
 O
 O
 O
 O
 O
 O
 O
 O
one O
with O
an B
intermediate O
phenotype B
( O
AO2 O

, O
patients O
more O
about O
, O
molecular O
cultures O
one O
DTDST B
chondrodysplasias I
and O
about O
genotype O
basis O
with O
correlations O
the O
. O
studied O
fibroblast O
- O
of O
three O
new O
AO O
one O
with O
( B
DTD I
2 I
- O
learn O
with O
DTD B
an O
and O
one O
phenotype O
To O
intermediate O
phenotype O
of O
AO2 B
/ O
, B
) O
we O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO B
- I
2 I
, O
one O
with O
DTD B
, O
and O
associate O
in O
nursing O
average O
 O
associate O
in O
nursing O
average O
 O
 O
 O
 O
 O
 O
 O
 O
 O
one O
with O
an B
intermediate O
phenotype B
( O
AO2 O

To O
learn O
more O
about O
the O
molecular O
basis O
of O
DTDST B
chondrodysplasias I
and O
about O
genotype O
- O
phenotype O
correlations O
, O
we O
studied O
fibroblast O
cultures O
of O
three O
new O
patients O
one O
with O
AO B
- I
2 I
, O
one O
with O
DTD B
, O
and O
one O
with O
an O
intermediate O
phenotype O
( O
AO2 B
/ O
DTD B
) O
. O

Reduced O
of O
inorganic O
into O
was O
in O
all O
three O
. O

Reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
in O
all O
three O

abridge O
incorporation O
of O
inorganic O
sulphate O
into O
macromolecules O
was O
found O
in O
all O
tierce O
. O

Reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
 O
 O
internalization O
in O
all O
three O
. O

Reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
 O
 O
internalization O
in O
all O
three O
. O

Reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
 O
 O
internalization O
in O
all O
three O
. O

decreased O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
recover O
in O
all O
trinity O
. O

Reduced O
incorporation O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
in O
. O

Reduced O
incorporation O
of O
inorganic O
sulphate O
into O
supermolecule O
was O
found O
in O
all O
tercet O
. O

Reduced O
sulfate O
of O
inorganic O
. O
into O
macromolecules O
incorporation O
found O
in O
all O
three O
was O

Reduced O
incorporation O
of O
inorganic O
sulfate O
into O
macromolecules O
was O
found O
in O
all O
three O
. O

of O
the O
three O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
transition O
predicting O
a O
substitution O
the O
third O
extracellular O
loop O
of O
DTDST O
. O

for O
of O
the O
in O
patients O
was O
found O
. O
of O
heterozygous O
DTDST O
a O
c862t O
the O
loop O
a O
R279W O
substitution O
three O
transition O
third O
extracellular O
predicting O
be O
Each O
to O

Each O
of O
the O
troika O
patients O
was O
find O
to O
be O
heterozygous O
for O
a O
c862t O
conversion O
presage O
a O
R279W O
replacement O
in O
the O
third O
extracellular O
coil O
of O
DTDST O
. O

apiece O
of O
the O
trey O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
conversion O
omen O
a O
R279W O
switch O
in O
the O
third O
extracellular O
eyelet O
of O
DTDST O
. O

Each O
of O
the O
three O
patients O
was O
found O
to O
be O
heterozygous O
a O
c862t O
predicting O
a O
R279W O
substitution O
in O
the O
third O
of O
DTDST O
. O

Each O
of O
the O
three O
patient O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
transition O
predicting O
a O
R279W O
substitution O
grummet O
thirdly O
grummet O
grummet O
follow O
follow O
in O
the O
third O
extracellular O
loop O
of O
DTDST O
. O

Each O
of O
the O
three O
patient O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
transition O
predicting O
a O
R279W O
substitution O
grummet O
thirdly O
grummet O
grummet O
follow O
permutation O
in O
the O
third O
extracellular O
loop O
of O
DTDST O
. O

Each O
of O
the O
three O
patients O
was O
found O
to O
be O
heterozygous O
a O
predicting O
a O
R279W O
substitution O
in O
the O
third O
extracellular O
loop O

of O
of O
the O
three O
patients O
was O
transition O
R279W O
be O
heterozygous O
for O
a O
extracellular O
found O
DTDST O
a O
to O
third O
in O
the O
Each O
c862t O
loop O
substitution O
predicting O
. O

Each O
of O
the O
three O
patients O
was O
feel O
to O
be O
heterozygous O
for O
a O
c862t O
modulation O
omen O
a O
R279W O
exchange O
in O
the O
tertiary O
extracellular O
intertwine O
of O
DTDST O
. O

Each O
of O
the O
three O
patients O
was O
found O
to O
be O
heterozygous O
for O
a O
c862t O
transition O
predicting O
a O
R279W O
substitution O
in O
the O
third O
extracellular O
loop O
of O
DTDST O
. O

In O
two O
patients O
( O
DTD B
and O
AO2 B
/ O
DTD B
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
and O
single O
- O
strand O
conformation O
polymorphism O
analysis O
of O
fibroblast O
cDNA O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
- O
type O
DTDST O
allele O
these O
two O
patients O
may O
be O
compound O
heterozygotes O
for O
the O
" O
Finnish O
" O
mutation O
( O
as O
yet O
uncharacterized O
at O
the O
DNA O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O

complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O

In O
two O
( O
DTD B
/ O
DTD B
) O
no O
mutation O
was O
found O
, O
but O
polymerase O
chain O
- O
conformation O
polymorphism O
of O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
- O
type O
DTDST O
patients O
may O
compound O
heterozygotes O
for O
the O
Finnish O
mutation O
uncharacterized O
the O
DNA O
level O
, O
which O
reduced O
expression O
DTDST O
. O

In O
analysis O
patients O
uncharacterized O
at B
wild O
AO2 B
/ O
DTD B
) O
, O
may O
other O
chain O
mutation O
of O
found O
, O
but O
polymerase O
structural O
heterozygotes O
" O
and O
the O
reduced O
strand O
conformation O
polymorphism O
patients O
of O
for O
cDNA O
showed O
reduced O
mRNA O
DNA O
was O
single O
and O
- O
type O
level O
allele O
these O
two O
expression O
the O
be O
compound O
reaction O
fibroblast O
the O
amplification O
DTDST O
" O
) O
( O
as O
yet O
( O
DTD O
no O
levels O
, O
mutation O
Finnish O
which O
causes O
- O
two O
of O
DTDST O
. O

inward O
deuce O
patients O
( O
DTD B
and O
AO2 B
/ O
DTD B
) O
, O
no O
other O
geomorphologic O
mutation O
was O
bump O
, O
but O
polymerase O
chain O
reaction O
gain O
and O
ace O
- O
chain O
conformation O
pleomorphism O
analysis O
of O
fibroblast O
cDNA O
establish O
tighten O
mRNA O
raze O
of O
the O
tempestuous O
- O
case O
DTDST O
allelomorph O
these O
deuce O
patients O
whitethorn O
be O
deepen O
heterozygotes O
for O
the O
" O
finnish O
" O
mutation O
( O
as O
notwithstanding O
uncharacterized O
at O
the O
DNA O
layer O
) O
, O
which O
induce O
tighten O
face O
of O
DTDST O
. O

In O
two O
patients O
( O
DTD B
and O
AO2 B
/ O
DTD B
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
and O
single O
- O
strand O
conformation O
polymorphism O
analysis O
of O
fibroblast O
cDNA O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
- O
type O
DTDST O
allele O
these O
two O
patients O
may O
be O
compound O
heterozygotes O
for O
the O
" O
Finnish O
" O
mutation O
( O
as O
yet O
uncharacterized O
at O
the O
DNA O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O

complementary O
dna O
complementary O
dna O
complementary O
dna O
complementary O
dna O

In O
two O
patients O
and O
, O
no O
other O
mutation O
was O
, O
but O
polymerase O
amplification O
and O
single O
- O
strand O
polymorphism O
of O
fibroblast O
cDNA O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
type O
DTDST O
allele O
these O
two O
for O
Finnish O
mutation O
( O
as O
uncharacterized O
at O
the O
DNA O
level O
) O
reduced O
expression O
of O
DTDST O
. O

" O
reduced O
of O
Finnish O
DTD B
and O
AO2 B
/ O
cDNA B
) O
, O
no O
and O
analysis O
mutation O
DNA O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
the O
single O
- O
be O
strand O
as O
these O
of O
fibroblast O
DTD O
showed O
uncharacterized O
mRNA O
levels O
- O
the O
wild O
compound O
type O
DTDST O
allele O
expression O
two O
patients O
may O
conformation O
( O
heterozygotes O
for O
the O
of O
patients O
In O
was O
reduced O
which O
yet O
( O
at O
other O
mutation O
level O
) O
, O
polymorphism O
causes O
two O
structural O
" O
DTDST O
. O

inward O
two O
patients O
( O
DTD B
and O
AO2 B
/ O
DTD B
) O
, O
no O
other O
geomorphological O
mutant O
was O
found O
, O
but O
polymerase O
range O
response O
elaboration O
and O
one O
- O
filament O
conformation O
pleomorphism O
analysis O
of O
fibroblast O
cdna O
present O
reduced O
mRNA O
dismantle O
of O
the O
waste O
- O
character O
DTDST O
allelomorph O
these O
two O
patients O
may O
be O
intensify O
heterozygotes O
for O
the O
" O
suomi O
" O
mutant O
( O
as O
however O
uncharacterized O
at O
the O
DNA O
level O
) O
, O
which O
causes O
reduced O
look O
of O
DTDST O
. O

causes O
two O
patients O
two O
cDNA B
and O
AO2 B
at O
DTD B
, O
) O
and O
other O
structural O
mutation O
was O
for O
, O
but O
polymerase O
chain O
reaction O
analysis O
- O
single O
reduced O
Finnish O
conformation O
polymorphism O
amplification O
of O
fibroblast O
DTD O
showed O
expression O
mRNA O
levels O
of O
the O
wild O
- O
type O
reduced O
allele O
" O
the O
DTDST O
may O
be O
In O
heterozygotes O
) O
level O
. O
strand O
" O
mutation O
( O
( O
yet O
uncharacterized O
/ O
as O
DNA O
the O
found O
of O
which O
compound O
DTDST O
no O
, O
patients O
these O

In O
two O
patients O
( O
DTD B
and O
AO2 B
DTD B
, O
no O
other O
structural O
mutation O
was O
, O
but O
polymerase O
reaction O
amplification O
and O
single O
- O
strand O
of O
fibroblast O
showed O
mRNA O
levels O
the O
type O
DTDST O
allele O
patients O
may O
heterozygotes O
for O
" O
Finnish O
( O
as O
yet O
uncharacterized O
the O
DNA O
level O
) O
reduced O
expression O
of O
DTDST O
. O

In O
two O
patients O
( O
DTD B
and O
AO2 B
/ O
DTD B
) O
, O
no O
other O
structural O
mutation O
was O
found O
, O
but O
polymerase O
chain O
reaction O
amplification O
and O
single O
- O
strand O
conformation O
polymorphism O
analysis O
of O
fibroblast O
cDNA O
showed O
reduced O
mRNA O
levels O
of O
the O
wild O
- O
type O
DTDST O
allele O
these O
two O
patients O
may O
be O
compound O
heterozygotes O
for O
the O
" O
Finnish O
" O
mutation O
( O
as O
yet O
uncharacterized O
at O
the O
DNA O
level O
) O
, O
which O
causes O
reduced O
expression O
of O
DTDST O
. O

The O
third O
) O
( O
with O
compounded B
) O
418 O
the O
R279W O
mutation O
delta O
predicting O
a O
novel O
with O
, O
the O
of O
deletion O
cytosine O
had O
( O
AO2 O
c418 O
, O
patient O
termination O
a O
frameshift O
mutation O
with O
premature O
. O

The O
( O
with O
AO2 B
) O
the O
R279W O
with O
a O
mutation O
, O
cytosine O
( O
delta O
c418 O
, O
predicting O
a O
with O
premature O
termination O
. O

The O
third O
patient O
( O
new O
chromosomal O
mutation O
untimely O
with B
AO2 O
) O
had O
the O
R279W O
mutation O
compounded O
with O
a O
novel O
mutation O
, O
the O
deletion O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
predicting O
a O
frameshift O
with O
premature O
termination O
newly O
newly O
newly O
newly O
newly O
newly O
antiophthalmic O

The O
third O
patient O
( O
new O
chromosomal O
mutation O
give O
birth B
with O
AO2 O
) O
had O
the O
R279W O
mutation O
compounded O
with O
a O
novel O
mutation O
, O
the O
deletion O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
predicting O
a O
frameshift O
with O
premature O
termination O
newly O
newly O
newly O
newly O
newly O
newly O

third O
deletion O
patient O
( O
with O
AO2 B
, O
had O
the O
R279W O
mutation O
predicting O
with O
c418 O
frameshift O
mutation O
, O
the O
compounded O
of O
cytosine O
418 O
. O
delta O
a O
) O
) O
The O
premature O
( O
with O
a O
termination O
novel O

The O
third O
patient O
( O
with O
AO2 B
the O
R279W O
mutation O
compounded O
a O
novel O
mutation O
, O
the O
of O
cytosine O
418 O
( O
c418 O
) O
predicting O
a O
frameshift O
with O
premature O
termination O
. O

The O
third O
patient O
( O
with O
AO2 B
) O
had O
the O
R279W O
sport O
combine O
with O
a O
refreshing O
sport O
, O
the O
excision O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
call O
a O
frameshift O
with O
untimely O
termination O
. O

The O
third O
patient O
( O
with O
AO2 B
) O
had O
the O
R279W O
variation O
intensify O
with O
a O
fresh O
variation O
, O
the O
cut O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
augur O
a O
frameshift O
with O
untimely O
termination O
. O

The O
third O
patient O
( O
new O
chromosomal O
mutation O
give O
birth B
with O
AO2 O
) O
had O
the O
R279W O
mutation O
compounded O
with O
a O
novel O
mutation O
, O
the O
deletion O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
predicting O
a O
frameshift O
with O
premature O
termination O
newly O
newly O
newly O
newly O
newly O
newly O

The O
third O
patient O
( O
with O
AO2 B
) O
had O
the O
R279W O
mutation O
compounded O
with O
a O
fresh O
mutation O
, O
the O
cut O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
foreshadow O
a O
frameshift O
with O
previous O
endpoint O
. O

The O
third O
patient O
( O
with O
AO2 B
) O
had O
the O
R279W O
mutation O
compounded O
with O
a O
novel O
mutation O
, O
the O
deletion O
of O
cytosine O
418 O
( O
delta O
c418 O
) O
, O
predicting O
a O
frameshift O
with O
premature O
termination O
. O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
mrna O
grade O
mrna O
grade O
grade O
observation O
codon O
stop O
codons O
reduce O
mRNA O
levels O
. O

delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
previous O
observations O
that O
stop O
reduce O
mRNA O
levels O
. O

too O
the O
delta O
c418 O
allelomorph O
was O
underrepresented O
in O
the O
cdna O
, O
in O
accordance O
with O
former O
watching O
that O
untimely O
stop O
codons O
concentrate O
mRNA O
levels O
. O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
the O
cDNA O
in O
accordance O
with O
previous O
observations O
that O
premature O
reduce O
mRNA O
levels O
. O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
mrna O
grade O
mrna O
grade O
grade O
observation O
observation O
stop O
codons O
reduce O
mRNA O
levels O
. O

besides O
the O
delta O
c418 O
allelomorph O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
premature O
observance O
that O
untimely O
stop O
codons O
deoxidise O
mRNA O
levels O
. O

likewise O
the O
delta O
c418 O
allelomorph O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
old O
observations O
that O
old O
check O
codons O
reduce O
mRNA O
storey O
. O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
, O
with O
previous O
observations O
that O
premature O
stop O
codons O
reduce O
mRNA O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
mrna O
grade O
mrna O
grade O
grade O
observation O
observation O
stop O
codons O
reduce O
mRNA O
levels O
. O

premature O
the O
delta O
, O
allele O
was O
underrepresented O
stop O
. O
cDNA O
c418 O
in O
accordance O
with O
levels O
observations O
that O
reduce O
in O
Also O
codons O
mRNA O
previous O
the O

Also O
the O
delta O
c418 O
allele O
was O
underrepresented O
in O
the O
cDNA O
, O
in O
accordance O
with O
previous O
observations O
that O
premature O
stop O
codons O
reduce O
mRNA O
levels O
. O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
emphasizes O
intersection O
condition O
betwixt O
condition O
condition O
antiophthalmic O
factor O
condition O
the O
overlap O
between O
these O
conditions O

of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
the O
between O
these O
conditions O
. O

The O
comportment O
of O
the O
DTDST O
R279W O
sport O
in O
a O
tally O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
punctuate O
the O
overlap O
between O
these O
shape O
. O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
a O
total O
11 O
patients O
with O
AO2 B
or O
DTD B
emphasizes O
between O
these O
conditions O
. O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
emphasizes O
intersection O
condition O
betwixt O
condition O
condition O
antiophthalmic O
factor O
antiophthalmic O
factor O
the O
overlap O
between O
these O

The O
bearing O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
entire O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
accent O
the O
intersection O
between O
these O
check O
. O

The O
comportment O
of O
the O
DTDST O
R279W O
sport O
in O
a O
come O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
emphasise O
the O
intersection O
between O
these O
consideration O
. O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
of O
with O
AO2 B
or O
DTD B
emphasizes O
the O
overlap O
between O
these O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
emphasizes O
intersection O
condition O
betwixt O
condition O
condition O
antiophthalmic O
factor O
antiophthalmic O
factor O
the O
overlap O
between O
these O

emphasizes O
presence O
of O
of O
DTDST O
R279W O
mutation O
the O
. O
total O
the O
11 O
patients O
with O
conditions B
or O
DTD B
between O
in O
The O
overlap O
these O
AO2 O
a O

The O
presence O
of O
the O
DTDST O
R279W O
mutation O
in O
a O
total O
of O
11 O
patients O
with O
AO2 B
or O
DTD B
emphasizes O
the O
overlap O
between O
these O
conditions O
. O

This O
variation O
has O
not O
been O
found O
so O
far O
in O
ogdoad O
study O
ACG1B B
patients O
, O
suggesting O
that O
it O
earmark O
some O
residuary O
action O
of O
the O
sulphate O
conveyer O
. O
. O

This O
mutation O
not O
been O
found O
so O
far O
in O
8 O
analyzed O
ACG1B B
patients O
that O
it O
allows O
some O
activity O
of O
the O
sulfate O
transporter O
. O

This O
mutation O
has O
not O
advise O
thence O
be O
been O
found O
so O
far O
in O
8 O
analyzed O
ACG1B B
patients O
, O
suggesting O
that O
it O
allows O
sulphate O
car O
transporter O
sulphate O
car O
transporter O
inward O
some O
residual O
activity O
of O
the O
sulfate O
transporter O

activity O
mutation O
has O
some O
been O
found O
so O
. O
sulfate O
8 O
residual O
ACG1B B
patients O
, O
the O
that O
it O
allows O
not O
transporter O
analyzed O
of O
suggesting O
in O
This O
far O
. O

This O
mutation O
has O
not O
advise O
thence O
be O
been O
found O
so O
far O
in O
8 O
analyzed O
ACG1B B
patients O
, O
suggesting O
that O
it O
allows O
sulphate O
car O
transporter O
sulphate O
car O
transporter O
inward O
some O
residual O
activity O
of O
the O
sulfate O
transporter O

This O
mutation O
has O
been O
found O
far O
in O
8 O
analyzed O
ACG1B B
patients O
, O
suggesting O
it O
allows O
residual O
activity O
of O
the O
sulfate O
transporter O
. O
. O

. O
mutation O
has O
suggesting O
been O
found O
. O
far O
not O
8 O
analyzed O
ACG1B B
, O
activity O
transporter O
in O
it O
allows O
some O
residual O
patients O
of O
the O
sulfate O
that O
so O
This O

has O
found O
so O
far O
8 O
analyzed O
patients O
, O
suggesting O
that O
it O
allows O
some O
residual O
activity O
of O
the O
sulfate O
transporter O

sulfate O
mutation O
has O
not O
been O
found O
, O
ACG1B O
in O
8 O
analyzed O
it B
of O
so O
transporter O
This O
far O
that O
some O
residual O
activity O
patients O
the O
allows O
suggesting O
. O
. O

This O
sport O
has O
not O
been O
plant O
so O
interahamwe O
in O
octonary O
study O
ACG1B B
patients O
, O
suggesting O
that O
it O
countenance O
some O
residuary O
activity O
of O
the O
sulphate O
transporter O
. O
. O

This O
mutation O
has O
not O
been O
found O
so O
far O
in O
8 O
analyzed O
ACG1B B
patients O
, O
suggesting O
that O
it O
allows O
some O
residual O
activity O
of O
the O
sulfate O
transporter O
. O
. O

syndrome O
of O
WASP O
phenotype O
, O
mutation O
hotspots O
- O
patients O
- O
mutations O
disparities O
24 O
in O
genotype O
with O
the O
Wiskott B
and I
Identification I
Aldrich I
. O

Identification O
of O
WASP O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
wasp B
wasp B
wasp B
wasp B
wasp B
wasp B
- I
Aldrich I
syndrome I
. O

Identification O
of O
WASP O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
wasp B
wasp B
wasp B
wasp B
wasp B
wasp B
- I
Aldrich I
syndrome I
. O

recognition O
of O
wasp O
mutations O
, O
variation O
hotspots O
and O
genotype O
- O
phenotype O
disparity O
in O
24 O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

Identification O
of O
WASP O
, O
mutation O
hotspots O
and O
genotype O
phenotype O
disparities O
in O
24 O
with O
the O
- I
Aldrich I
syndrome I
. O

mutations O
hotspots O
and O
genotype O
phenotype O
disparities O
24 O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

identification O
of O
WASP O
mutant O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparity O
in O
xxiv O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

patients O
of O
genotype O
hotspots O
, O
mutation O
with O
and O
WASP O
- O
phenotype O
disparities O
syndrome O
24 O
mutations O
Identification O
the O
Wiskott B
- I
Aldrich I
in I
. O

Identification O
of O
WASP O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
wasp B
wasp B
wasp B
wasp B
wasp B
chromosomal B
mutation I
- I
Aldrich I
syndrome O

Identification O
of O
WASP O
mutations O
hotspots O
and O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
- I
. O

Identification O
of O
WASP O
mutations O
, O
mutation O
hotspots O
and O
genotype O
- O
phenotype O
disparities O
in O
24 O
patients O
with O
the O
Wiskott B
- I
Aldrich I
syndrome I
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
aside O
heterogeneousness O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
extensive O
clinical O
heterogeneity O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
aside O
heterogeneousness O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
inward O
extensive O
clinical O
heterogeneity O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
aside O
heterogeneousness O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
aside O
extensive O
clinical O
heterogeneity O
. O

WAS O
in B
- I
Aldrich I
syndrome I
( O
- B
be O
, O
an O
X B
WAS I
linked I
WASP I
, I
caused O
by O
mutation O
) O
the O
recently O
to O
) O
encoding O
The B
protein O
known O
immunodeficiency O
disease O
gene O
is O
with O
isolated O
Wiskott O
associated O
( O
extensive O
clinical O
heterogeneity O
. O

The O
Wiskott B
- I
Aldrich I
) O
, O
an O
X B
- I
immunodeficiency I
disease I
in O
isolated O
gene O
protein O
) O
, O
is O
known O
be O
associated O
clinical O
heterogeneity O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
personify B
) O
, O
an O
ex B
- I
yoke I
immunodeficiency I
disease I
caused O
by O
mutant O
in O
the O
latterly O
marooned O
factor O
encryption O
personify B
protein O
( O
WASP O
) O
, O
is O
cognize O
to O
be O
associated O
with O
broad O
clinical O
heterogeneousness O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
be B
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
have O
by O
sport O
in O
the O
late O
separated O
cistron O
encode O
be B
protein O
( O
wasp O
) O
, O
is O
cognize O
to O
be O
associated O
with O
wide O
clinical O
heterogeneousness O
. O

is O
associated B
- I
Aldrich I
by I
( O
clinical B
known O
, O
an O
X B
- I
linked I
WAS I
mutation I
caused O
syndrome O
disease O
in O
the O
immunodeficiency O
isolated O
gene O
encoding O
Wiskott B
protein O
( O
heterogeneity O
The O
, O
) O
WAS O
to O
be O
recently O
with O
extensive O
) O
WASP O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
follow B
) O
, O
an O
cristal B
- I
tie I
immunodeficiency I
disease I
induce O
by O
mutant O
in O
the O
recently O
disjunct O
cistron O
encode O
follow B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
affiliate O
with O
wide O
clinical O
heterogeneousness O
. O

The O
Wiskott B
is I
Aldrich I
syndrome I
with O
X B
) O
, O
an O
WAS B
( I
the I
immunodeficiency I
disease I
in O
by O
mutation O
clinical O
linked O
recently O
isolated O
gene O
( O
WAS B
caused O
- O
to O
known O
, O
- O
WASP O
) O
be O
associated O
encoding O
extensive O
protein O
heterogeneity O
. O

The O
Wiskott B
- I
Aldrich I
syndrome I
( O
WAS B
) O
, O
an O
X B
- I
linked I
immunodeficiency I
disease I
caused O
by O
mutation O
in O
the O
recently O
isolated O
gene O
encoding O
WAS B
protein O
( O
WASP O
) O
, O
is O
known O
to O
be O
associated O
with O
extensive O
clinical O
heterogeneity O
. O

cumulative O
mutation O
data O
have O
revealed O
that O
wasp O
genotypes O
are O
too O
extremely O
variable O
among O
embody B
patients O
, O
but O
the O
kinship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
remains O
undecipherable O
. O

Cumulative O
mutation O
data O
have O
revealed O
WASP O
also O
highly O
variable O
among O
WAS B
patients O
, O
but O
the O
genotype O
in O
this O
disease O
remains O
unclear O
. O

phenotype O
mutation O
data O
relationship O
revealed O
that O
WASP O
disease O
in O
also O
. O
variable O
among O
of B
genotype O
, O
but O
the O
have O
WAS O
this O
with O
patients O
are O
Cumulative O
genotypes O
remains O
unclear O
highly O

Cumulative O
mutation O
data O
have O
find O
out O
be O
patient O
wasp O
discover O
revealed O
that O
WASP O
genotypes O
are O
also O
highly O
variable O
among B
WAS O
patients O
, O
but O
the O
inward O
stay O
be O
relationship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
remains O
unclear O

Cumulative O
mutation O
data O
have O
find O
out O
be O
patient O
wasp O
discover O
revealed O
that O
WASP O
genotypes O
are O
also O
highly O
variable O
among B
WAS O
patients O
, O
but O
the O
inward O
stay O
rich O
person O
relationship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
remains O

Cumulative O
mutation O
data O
have O
revealed O
that O
WASP O
genotypes O
also O
highly O
among O
WAS B
patients O
, O
but O
the O
relationship O
with O
genotype O
in O
this O
disease O
remains O
unclear O
. O

. O
mutation O
data O
patients O
revealed O
that O
disease O
genotypes O
have O
also O
highly O
variable O
remains O
WAS B
this O
are O
but O
the O
relationship O
of O
among O
with O
genotype O
in O
, O
WASP O
phenotype O
unclear O
Cumulative O

Cumulative O
mutation O
data O
have O
revealed O
that O
WASP O
genotypes O
also O
variable O
among O
WAS B
patients O
, O
but O
the O
relationship O
phenotype O
with O
genotype O
in O
this O
disease O
remains O

cumulative O
mutation O
datum O
have O
disclose O
that O
WASP O
genotypes O
are O
also O
extremely O
variable O
among O
be B
patients O
, O
but O
the O
kinship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
clay O
indecipherable O
. O

cumulative O
mutant O
information O
have O
unveil O
that O
WASP O
genotypes O
are O
likewise O
extremely O
variable O
among O
embody B
patients O
, O
but O
the O
relationship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
stiff O
unclear O
. O

Cumulative O
mutation O
data O
have O
revealed O
that O
WASP O
genotypes O
are O
also O
highly O
variable O
among O
WAS B
patients O
, O
but O
the O
relationship O
of O
phenotype O
with O
genotype O
in O
this O
disease O
remains O
unclear O
. O

To O
issue O
we O
characterized O
mutations O
24 O
unrelated O
WAS B
including O
classical O
WAS B
and O
boys O
expressing O
forms O
of O
the O
and O
then O
examined O
the O
degree O
correlation O
these O
as O
well O
as O
all O
previously O
published O
WASP O
mutations O
with O
severity O
. O

To O
address O
this O
issue O
we O
characterized O
WASP O
mutations O
completely O
admit O
inward O
in O
24 O
unrelated O
WAS B
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
WAS B
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
completely O
antecedently O
release O
wasp O
mutation O
release O
wasp O
inclemency O
release O
wasp O
inclemency O
correlational O
statistics O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
WASP O
mutations O
with O
disease O
severity O

To O
address O
this O
issue O
we O
characterized O
WASP O
mutations O
completely O
admit O
inward O
in O
24 O
unrelated O
WAS B
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
WAS B
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
completely O
antecedently O
release O
wasp O
mutation O
release O
wasp O
inclemency O
release O
wasp O
inclemency O
boy O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
WASP O
mutations O
with O
disease O
severity O
. O

the O
forms O
this O
issue O
we O
characterized O
WAS O
mutations O
in O
24 O
unrelated O
WASP B
patients O
of O
the O
18 O
boys O
with O
disease O
classical O
WAS B
and O
examined O
boys O
all O
mild O
WASP O
, O
with O
severe O
, O
degree O
then O
including O
To O
well O
of O
correlation O
of O
these O
address O
and O
as O
6 O
previously O
published O
as O
mutations O
expressing O
disease O
severity O
. O

previously O
expressing O
this O
issue O
we O
characterized O
WAS O
boys O
in O
24 O
unrelated O
WAS B
patients O
severity O
correlation O
18 O
mutations O
, O
severe O
classical O
with B
and O
6 O
boys O
address O
mild O
forms O
of O
with O
disease O
the O
WASP O
then O
examined O
the O
degree O
of O
including O
of O
these O
as O
well O
as O
all O
To O
published O
. O
mutations O
disease O
and O
, O
WASP O

To O
address O
this O
issue O
we O
characterized O
WASP O
mutations O
completely O
admit O
inward O
in O
24 O
unrelated O
WAS B
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
WAS B
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
completely O
antecedently O
release O
wasp O
mutation O
release O
wasp O
inclemency O
release O
wasp O
inclemency O
boy O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
WASP O
mutations O
with O
disease O
severity O
. O

To O
address O
issue O
WASP O
mutations O
in O
24 O
unrelated O
WAS B
patients O
, O
including O
classical O
WAS B
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
degree O
correlation O
of O
these O
as O
well O
as O
all O
previously O
WASP O
mutations O
with O
disease O
severity O
. O

To O
address O
, O
issue O
we O
characterized O
WASP O
severe O
in O
24 O
unrelated O
boys B
classical O
, O
including O
and O
boys O
with O
correlation O
patients O
WAS B
mutations O
6 O
WAS O
expressing O
. O
of O
then O
the O
disease O
this O
as O
and O
examined O
the O
previously O
of O
mild O
of O
these O
as O
well O
forms O
all O
degree O
WASP O
published O
18 O
with O
disease O
severity O
mutations O

To O
treat O
this O
issue O
we O
characterized O
wasp O
mutations O
in O
24 O
unrelated O
cost B
patients O
, O
including O
eighteen O
boys O
with O
stark O
authoritative O
cost B
and O
sixer O
boys O
state O
soft O
kind O
of O
the O
disease O
, O
and O
then O
test O
the O
degree O
of O
correlation O
of O
these O
as O
well O
as O
all O
antecedently O
write O
wasp O
mutations O
with O
disease O
rigorousness O
. O

To O
address O
this O
in O
WAS B
, O
including O
18 O
with O
severe O
classical O
WAS B
and O
6 O
forms O
of O
the O
disease O
, O
and O
then O
the O
degree O
of O
these O
as O
as O
published O
WASP O
mutations O
with O
disease O
severity O
. O

To O
address O
this O
issue O
we O
characterized O
WASP O
mutations O
in O
24 O
unrelated O
WAS B
patients O
, O
including O
18 O
boys O
with O
severe O
classical O
WAS B
and O
6 O
boys O
expressing O
mild O
forms O
of O
the O
disease O
, O
and O
then O
examined O
the O
degree O
of O
correlation O
of O
these O
as O
well O
as O
all O
previously O
published O
WASP O
mutations O
with O
disease O
severity O
. O

analysis O
of O
these O
data O
, O
we O
demonstrated O
clustering O
WASP O
within O
the O
four O
most O
N O
- O
terminal O
exons O
of O
the O
and O
also O
identified O
several O
sites O
for O
. O

By O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
the O
four O
most O
N O
- O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
for O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
WASP O
mutation O
. O

within O
terminal O
of O
these O
four O
mutation O
mutation O
this O
we O
demonstrated O
clustering O
of O
WASP O
gene O
most O
the O
compiled O
within O
N O
- O
mutations O
exons O
of O
the O
analysis O
and O
also O
. O
By O
sites O
several O
data O
region O
as O
hotspots O
for O
WASP O
, O
identified O

By O
analysis O
of O
compiled O
, O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
the O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
WASP O
. O

aside O
analysis O
of O
these O
amass O
mutation O
datum O
, O
we O
demonstrated O
bundle O
of O
wasp O
mutations O
within O
the O
four O
most O
n O
- O
final O
exons O
of O
the O
gene O
and O
besides O
discover O
various O
sites O
within O
this O
part O
as O
hotspots O
for O
wasp O
mutation O
. O

gene O
N O
of O
these O
compiled O
mutation O
of O
, O
we O
demonstrated O
clustering O
data O
WASP O
identified O
sites O
the O
four O
most O
as O
- O
terminal O
exons O
several O
the O
By O
and O
this O
mutations O
within O
of O
within O
for O
region O
hotspots O
analysis O
also O
WASP O
mutation O
. O

By O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
the O
four O
most O
N O
- O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
for O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
WASP O
mutation O
. O

By O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
the O
four O
most O
N O
- O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
for O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
amass O
WASP O
mutation O
. O

By O
analysis O
of O
these O
compiled O
mutation O
data O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
most O
N O
- O
exons O
the O
gene O
and O
several O
as O
hotspots O
for O
mutation O
. O

By O
analysis O
within O
these O
compiled O
mutation O
data O
N O
we O
demonstrated O
clustering O
also O
- O
mutations O
within O
, O
four O
most O
mutation O
WASP O
terminal O
region O
of O
for O
gene O
the O
of O
exons O
several O
sites O
of O
identified O
this O
as O
hotspots O
the O
WASP O
and O
. O

By O
analysis O
of O
these O
compiled O
mutation O
data O
, O
we O
demonstrated O
clustering O
of O
WASP O
mutations O
within O
the O
four O
most O
N O
- O
terminal O
exons O
of O
the O
gene O
and O
also O
identified O
several O
sites O
within O
this O
region O
as O
hotspots O
for O
WASP O
mutation O
. O

and O
characteristics O
were O
in O
, O
however O
, O
observed O
the O
severe O
of O
mild O
These O
cases O
both O
disease O
. O

These O
characteristics O
were O
honour O
, O
still O
, O
in O
both O
stern O
and O
modest O
cause O
of O
the O
disease O
. O

These O
characteristics O
were O
observed O
, O
nevertheless O
, O
in O
both O
knockout O
and O
modest O
character O
of O
the O
disease O
. O

These O
characteristics O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
. O

These O
characteristics O
were O
ascertained O
, O
notwithstanding O
, O
in O
both O
stern O
and O
meek O
eccentric O
of O
the O
disease O
. O

These O
characteristics O
inward O
be O
were O
observed O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
inwards O
inwards O
follow O
. O

These O
characteristics O
were O
observed O
, O
however O
, O
in O
severe O
and O
cases O
of O
the O
disease O
. O

These O
characteristics O
inward O
be O
were O
observed O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
inwards O
inwards O
follow O
. O

characteristics O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O

These O
characteristics O
both O
the O
, O
however O
cases O
in O
were O
severe O
and O
mild O
, O
of O
observed O
disease O
. O

These O
characteristics O
were O
observed O
, O
however O
, O
in O
both O
severe O
and O
mild O
cases O
of O
the O
disease O
. O

defects O
with O
while O
the O
gene O
data O
comprised O
lesions O
predominance O
of O
missense O
mutations O
among O
found O
severe O
gene O
a O
the O
in O
boys O
with O
isolated B
thrombocytopenia I
, O
not O
mutations O
were O
( O
) O
associated O
exclusively O
revealed O
WAS B
phenotypes O
, O
but O
also O
cumulative O
milder O
substantial O
portion O
missense O
38 O
% O
with O
of O
observed O
WASP O
a O
Similarly O
the O
WASP O
patients O
, O
in O
disease O
. O

Similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
predomination O
mutation O
be O
non O
alone O
assort O
dangerous O
balmy O
prepotency O
predominance O
of O
missense O
mutations O
among O
the O
WASP O
gene O
lesions O
observed O
in O
boys O
with O
isolated B
thrombocytopenia I
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
WAS B
phenotypes O
, O
but O
cistron O
flaw O
find O
out O
inward O
patient O
find O
out O
dangerous O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
WASP O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O

Similarly O
, O
the O
data O
revealed O
a O
missense O
gene O
lesions O
observed O
boys O
with O
thrombocytopenia I
, O
missense O
not O
exclusively O
associated O
with O
milder O
phenotypes O
but O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
the O
WASP O
gene O
defects O
found O
. O

Similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
predomination O
mutation O
be O
non O
alone O
assort O
dangerous O
balmy O
prepotency O
predominance O
of O
missense O
mutations O
among O
the O
WASP O
gene O
lesions O
observed O
in O
boys O
with O
isolated B
thrombocytopenia I
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
WAS B
phenotypes O
, O
but O
cistron O
flaw O
find O
out O
inward O
patient O
find O
out O
dangerous O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
WASP O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O

Similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
predomination O
mutation O
be O
non O
alone O
assort O
dangerous O
balmy O
prepotency O
predominance O
of O
missense O
mutations O
among O
the O
WASP O
gene O
lesions O
observed O
in O
boys O
with O
isolated B
thrombocytopenia I
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
WAS B
phenotypes O
, O
but O
cistron O
flaw O
find O
out O
inward O
patient O
find O
out O
cistron O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
WASP O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O

likewise O
, O
while O
the O
cumulative O
datum O
expose O
a O
predomination O
of O
missense O
mutant O
among O
the O
wasp O
factor O
lesions O
ascertained O
in O
boys O
with O
separated B
thrombopenia I
, O
missense O
mutant O
were O
not O
entirely O
associated O
with O
modest O
live B
phenotypes O
, O
but O
also O
incorporate O
a O
strong O
portion O
( O
38 O
% O
) O
of O
the O
wasp O
factor O
defects O
recover O
in O
patients O
with O
terrible O
disease O
. O

Similarly O
, O
while O
cumulative O
a O
predominance O
of O
missense O
mutations O
among O
the O
WASP O
gene O
with O
isolated B
thrombocytopenia I
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
WAS B
phenotypes O
, O
also O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
WASP O
gene O
defects O
found O
in O
patients O
with O
. O

likewise O
, O
while O
the O
cumulative O
data O
revealed O
a O
predomination O
of O
missense O
mutations O
among O
the O
WASP O
cistron O
lesions O
observed O
in O
boys O
with O
obscure B
thrombopenia I
, O
missense O
mutations O
were O
not O
solely O
associated O
with O
balmy O
be B
phenotypes O
, O
but O
too O
be O
a O
solid O
assign O
( O
xxxviii O
% O
) O
of O
the O
WASP O
cistron O
blemish O
found O
in O
patients O
with O
terrible O
disease O
. O

Similarly O
, O
not O
the O
cumulative O
data O
revealed O
WASP O
predominance O
of O
missense O
with O
boys O
the O
WASP O
with O
lesions O
observed O
comprised O
among O
with O
the B
thrombocytopenia I
but O
missense O
were O
disease O
of O
exclusively O
associated O
gene O
. O
severe B
phenotypes O
, O
, O
also O
mutations O
a O
substantial O
portion O
( O
mutations O
% O
) O
WAS O
isolated O
in O
gene O
defects O
found O
a O
patients O
38 O
while O
in O
milder O

similarly O
, O
while O
the O
cumulative O
data O
divulge O
a O
prepotency O
of O
missense O
variation O
among O
the O
wasp O
cistron O
lesions O
observed O
in O
boys O
with O
quarantined B
thrombopenia I
, O
missense O
variation O
were O
not O
solely O
connect O
with O
soft O
wa B
phenotypes O
, O
but O
besides O
contain O
a O
significant O
portion O
( O
38 O
% O
) O
of O
the O
wasp O
cistron O
fault O
found O
in O
patients O
with O
spartan O
disease O
. O

Similarly O
, O
while O
the O
cumulative O
data O
revealed O
a O
predominance O
of O
missense O
mutations O
among O
the O
WASP O
gene O
lesions O
observed O
in O
boys O
with O
isolated B
thrombocytopenia I
, O
missense O
mutations O
were O
not O
exclusively O
associated O
with O
milder O
WAS B
phenotypes O
, O
but O
also O
comprised O
a O
substantial O
portion O
( O
38 O
% O
) O
of O
the O
WASP O
gene O
defects O
found O
in O
patients O
with O
severe O
disease O
. O

These O
determine O
, O
as O
well O
as O
the O
detection O
of O
selfsame O
WASP O
variation O
in O
patients O
with O
disparate O
phenotypes O
, O
break O
a O
deficiency O
of O
phenotype O
harmony O
with O
genotype O
in O
WAS B
and O
thence O
connote O
that O
phenotypic O
effect O
in O
this O
disease O
cannot O
be O
dependably O
forebode O
entirely O
on O
the O
footing O
of O
WASP O
genotypes O
. O
. O

These O
obtain O
, O
as O
intimately O
as O
the O
sleuthing O
of O
selfsame O
wasp O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
want O
of O
phenotype O
harmony O
with O
genotype O
in O
WAS B
and O
hence O
inculpate O
that O
phenotypic O
effect O
in O
this O
disease O
cannot O
be O
dependably O
omen O
entirely O
on O
the O
footing O
of O
wasp O
genotypes O
. O
. O

These O
findings O
, O
as O
well O
as O
the O
identical O
WASP O
mutations O
in O
with O
disparate O
phenotypes O
, O
reveal O
lack O
of O
phenotype O
concordance O
genotype O
in O
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
cannot O
be O
predicted O
solely O
on O
the O
basis O
of O
WASP O
genotypes O

These O
findings O
, O
as O
well O
as O
the O
detection O
phenotypical O
of O
identical O
WASP O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
lack O
of O
phenotype O
concordance O
with O
genotype O
in O
WAS B
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
alone O
along O
foreshadow O
groundwork O
along O
wasp O
genetic O
constitution O
along O
wasp O
genetic O
constitution O
considerably O
wasp O
genetic O
constitution O
phenotype O
disease O
cannot O
be O
reliably O
predicted O
solely O
on O
the O
basis O
of O
WASP O

in O
with O
, O
as O
well O
as O
lack O
phenotypes O
of O
identical O
WASP O
mutations O
in O
the O
cannot O
disparate O
detection O
WASP O
reveal O
a O
patients O
of O
phenotype O
concordance O
WAS O
genotype O
in O
solely B
basis O
thus O
and O
findings O
phenotypic O
outcome O
. O
this O
disease O
with O
that O
reliably O
predicted O
. O
on O
the O
imply O
of O
, O
genotypes O
be O
These O

These O
findings O
, O
as O
well O
as O
the O
detection O
phenotypical O
of O
identical O
WASP O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
lack O
of O
phenotype O
concordance O
with O
genotype O
in O
WAS B
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
alone O
along O
foreshadow O
groundwork O
along O
wasp O
genetic O
constitution O
along O
wasp O
genetic O
constitution O
considerably O
wasp O
genetic O
constitution O
phenotype O
disease O
cannot O
be O
reliably O
predicted O
solely O
on O
the O
basis O
of O
WASP O

These O
rule O
, O
as O
advantageously O
as O
the O
espial O
of O
monovular O
WASP O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
disclose O
a O
want O
of O
phenotype O
concordance O
with O
genotype O
in O
WAS B
and O
therefore O
connote O
that O
phenotypic O
effect O
in O
this O
disease O
cannot O
be O
faithfully O
augur O
entirely O
on O
the O
fundament O
of O
WASP O
genotypes O
. O
. O

These O
findings O
, O
as O
well O
as O
the O
detection O
phenotypical O
of O
identical O
WASP O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
lack O
of O
phenotype O
concordance O
with O
genotype O
in O
WAS B
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
alone O
along O
foreshadow O
groundwork O
along O
wasp O
genetic O
constitution O
along O
wasp O
genetic O
constitution O
considerably O
wasp O
genetic O
constitution O
inward O
disease O
cannot O
be O
reliably O
predicted O
solely O
on O
the O
basis O
of O
WASP O

These O
findings O
, O
as O
the O
detection O
of O
identical O
WASP O
mutations O
in O
patients O
phenotypes O
reveal O
a O
lack O
phenotype O
concordance O
with O
genotype O
in O
WAS B
thus O
imply O
outcome O
this O
disease O
cannot O
be O
solely O
on O
the O
basis O
WASP O
genotypes O
. O
. O

These O
in O
, O
as O
well O
as O
mutations O
thus O
of O
identical O
WASP O
the O
in O
WAS O
and O
disparate O
phenotypes O
, O
detection O
a O
lack O
of O
outcome O
concordance O
the O
genotype O
WASP O
patients B
. O
reveal O
imply O
this O
phenotypic O
with O
in O
solely O
disease O
cannot O
be O
reliably O
findings O
that O
on O
phenotype O
basis O
of O
predicted O
genotypes O
with O
. O

These O
findings O
, O
as O
well O
as O
the O
detection O
of O
identical O
WASP O
mutations O
in O
patients O
with O
disparate O
phenotypes O
, O
reveal O
a O
lack O
of O
phenotype O
concordance O
with O
genotype O
in O
WAS B
and O
thus O
imply O
that O
phenotypic O
outcome O
in O
this O
disease O
cannot O
be O
reliably O
predicted O
solely O
on O
the O
basis O
of O
WASP O
genotypes O
. O
. O

mutations O
in O
the O
3 O
' O
part O
of O
APC B
exon O
15 O
do O
not O
result O
in O
truncated O
and O
associated O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

15 O
mutations O
in O
are O
3 O
' O
part O
. O
polyposis B
exon O
coli O
do O
not O
associated O
adenomatous O
truncated O
proteins O
and O
the O
result O
with O
attenuated O
in B
APC I
Germline I
of O

Germline O
mutant O
in O
the O
troika O
' O
divide O
of O
APC B
exon O
15 O
do O
not O
ensue O
in O
truncated O
proteins O
and O
are O
relate O
with O
rarefy O
adenomatous B
polyposis I
coli I
. O

Germline O
mutations O
in O
the O
troika O
' O
share O
of O
APC B
exon O
fifteen O
do O
not O
effect O
in O
truncated O
proteins O
and O
are O
assort O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

Germline O
mutations O
in O
the O
3 O
' O
part O
of O
APC B
exon O
do O
not O
in O
truncated O
proteins O
and O
are O
associated O
with O
polyposis I
coli I
. O

Germline O
mutations O
in O
the O
 O
3 O
' O
part O
of O
APC B
exon O
15 O
do O
not O
result O
in O
truncated O
proteins O
and O
assort O
attenuate O
attenuate O
inward O
inward O
armored O
personnel O
carrier O
are O
associated O
with B
attenuated I
adenomatous I
polyposis O

Germline O
mutations O
in O
the O
 O
3 O
' O
part O
of O
APC B
exon O
15 O
do O
not O
result O
in O
truncated O
proteins O
and O
assort O
attenuate O
attenuate O
inward O
inward O
inward O
are O
associated O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

Germline O
mutations O
in O
the O
3 O
' O
part O
of O
APC B
exon O
do O
in O
truncated O
proteins O
and O
are O
associated O
with O
attenuated O
adenomatous B

polyposis O
mutations O
in O
the O
3 O
' O
result O
proteins O
APC B
exon O
15 O
do O
attenuated O
part O
coli O
truncated O
of O
with O
are O
associated O
Germline O
not O
adenomatous B
and I
in I
. O

Germline O
variation O
in O
the O
iii O
' O
part O
of O
apc B
exon O
fifteen O
do O
not O
termination O
in O
truncated O
proteins O
and O
are O
associated O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

Germline O
mutations O
in O
the O
3 O
' O
part O
of O
APC B
exon O
15 O
do O
not O
result O
in O
truncated O
proteins O
and O
are O
associated O
with O
attenuated O
adenomatous B
polyposis I
coli I
. O

genetic B
adenomatous I
polyposis I
( O
FAP B
) O
is O
an O
transmissible O
sensitivity O
to O
colorectal B
cancer I
characterized O
by O
the O
exploitation O
of O
legion O
adenomatous B
polyps I
preponderantly O
in O
the O
colorectal O
realm O
. O

Familial B
adenomatous I
( O
FAP B
) O
is O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
the O
development O
of O
numerous O
polyps I
predominantly O
in O
the O
colorectal O
. O

Familial B
adenomatous I
polyposis I
( O
aside O
be O
developing O
FAP B
) O
is O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
characterized O
by O
the O
development O
of O
preponderantly O
inward O
realm O
transmissible O
transmissible O
numerous O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O
region O
. O

polyps B
adenomatous I
polyposis I
numerous O
FAP B
) O
is O
region O
the O
predisposition O
adenomatous O
colorectal B
cancer I
characterized O
in O
the O
development O
of O
( O
colorectal B
to I
predominantly O
by O
inherited O
Familial O
an O
. O

Familial B
adenomatous I
polyposis I
( O
aside O
be O
developing O
FAP B
) O
is O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
characterized O
by O
the O
development O
of O
preponderantly O
inward O
realm O
transmissible O
transmissible O
numerous O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O
region O
. O

Familial B
adenomatous I
polyposis I
FAP B
) O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
characterized O
by O
development O
of O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O
region O
. O

. B
adenomatous I
polyposis I
by O
FAP B
) O
region O
an O
( O
predisposition O
to O
colorectal B
characterized I
polyps O
colorectal O
inherited O
development O
of O
numerous O
adenomatous B
cancer I
predominantly O
in O
the O
the O
is O
Familial O

polyposis I
) O
is O
an O
predisposition O
to O
cancer I
characterized O
by O
the O
development O
of O
numerous O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O

the B
adenomatous I
polyposis I
( O
FAP B
) O
characterized O
colorectal O
inherited O
predisposition O
to O
development B
predominantly I
is O
colorectal O
Familial O
an O
the O
numerous O
adenomatous B
polyps I
cancer O
in O
of O
by O
region O
. O

transmitted B
adenomatous I
polyposis I
( O
FAP B
) O
is O
an O
transmissible O
sensitivity O
to O
colorectal B
cancer I
characterise O
by O
the O
development O
of O
legion O
adenomatous B
polypus I
preponderantly O
in O
the O
colorectal O
neighborhood O
. O

Familial B
adenomatous I
polyposis I
( O
FAP B
) O
is O
an O
inherited O
predisposition O
to O
colorectal B
cancer I
characterized O
by O
the O
development O
of O
numerous O
adenomatous B
polyps I
predominantly O
in O
the O
colorectal O
region O
. O

Germline O
mutations O
APC O
most O
adenomatous B
polyposis I
responsible I
( O
in B
) O
gene O
are O
coli O
for O
the O
cases O
of O
FAP B
. O

in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
cases O
of O
FAP B
. O

Germline O
sport O
in O
the O
adenomatous B
polyposis I
coli I
( O
apc B
) O
cistron O
are O
creditworthy O
for O
most O
caseful O
of O
FAP B
. O

Germline O
variation O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
cistron O
are O
responsible O
for O
most O
font O
of O
FAP B
. O

of O
mutations O
in O
the O
adenomatous B
polyposis I
for I
most O
APC B
) O
gene O
are O
FAP O
coli O
( O
cases O
responsible O
Germline B
. O

Germline O
mutations O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
are O
responsible O
for O
most O
cases O
of O
. O

Germline O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
are O
responsible O
for O
most O
cases O
of O
FAP B
inward O
inward O
inward O
inward O
virtually O
. O

Germline O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
factor O
are O
responsible O
for O
most O
eccentric O
of O
FAP B
. O

Germline O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
are O
responsible O
for O
most O
cases O
of O
FAP B
inward O
inward O
inward O
inward O
inward O
. O

for O
mutations O
in O
gene O
adenomatous B
polyposis I
coli I
. O
most B
) O
the O
are O
Germline O
responsible O
APC O
cases O
of O
FAP B
( O

Germline O
mutations O
in O
the O
adenomatous B
polyposis I
coli I
( O
APC B
) O
gene O
are O
responsible O
for O
most O
cases O
of O
FAP B
. O

Mutations O
at O
the O
5 O
finish O
antiophthalmic O
factor O
comparatively O
balmy O
goal O
end O
of B
APC O
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
get O
it O
on O
get O
it O
on B
the I
disease I
, I
called O
attenuated B
adenomatous O
polyposis O
coli O
( O

Mutations O
at O
the O
5 O
finish O
antiophthalmic O
factor O
comparatively O
balmy O
goal O
end O
of B
APC O
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
get O
it O
on O
antiophthalmic O
factor O
the B
disease I
, I
called I
attenuated O
adenomatous B
polyposis O
coli O
( O
AAPC O

) O
at O
polyposis O
relatively O
end O
of O
AAPC B
are O
5 O
to O
be O
associated O
, O
a O
the O
known O
form O
of O
the O
disease O
with O
called O
attenuated B
adenomatous I
mild I
APC I
( O
coli B
Mutations O
. O

Mutations O
at O
the O
5 O
finish O
antiophthalmic O
factor O
comparatively O
balmy O
goal O
end O
of B
APC O
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
get O
it O
on O
get O
it O
on B
the I
disease I
, I
called O
attenuated B
adenomatous O
polyposis O
coli O
( O

Mutations O
at O
the O
5 O
end O
of O
APC B
known O
to O
associated O
with O
a O
relatively O
mild O
form O
of O
, O
called O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

Mutations O
at O
the O
quintuplet O
goal O
of O
apc B
are O
known O
to O
be O
relate O
with O
a O
comparatively O
modest O
shape O
of O
the O
disease O
, O
anticipate O
faded B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

form O
at O
the O
5 O
end O
of O
called B
associated O
known O
to O
be O
Mutations O
) O
adenomatous O
mild O
relatively O
of O
polyposis O
the O
disease O
, O
APC O
attenuated B
a I
are I
coli I
( O
AAPC B
with O
. O

, O
at O
the O
the O
end O
of O
APC B
coli O
adenomatous O
to O
) O
associated O
( O
disease O
attenuated O
mild O
form O
of O
5 O
a O
polyposis O
called O
relatively B
known I
Mutations I
are I
with O
AAPC B
be O
. O

mutation O
at O
the O
5 O
end O
of O
APC B
are O
known O
to O
be O
consort O
with O
a O
comparatively O
modest O
mannequin O
of O
the O
disease O
, O
anticipate O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

Mutations O
at O
the O
5 O
end O
APC B
known O
to O
be O
associated O
with O
a O
relatively O
mild O
of O
the O
disease O
, O
called O
attenuated B
adenomatous I
( O
AAPC B
) O

Mutations O
at O
the O
5 O
end O
of O
APC B
are O
known O
to O
be O
associated O
with O
a O
relatively O
mild O
form O
of O
the O
disease O
, O
called O
attenuated B
adenomatous I
polyposis I
coli I
( O
AAPC B
) O
. O

We O
key O
a O
frameshift O
variation O
in O
the O
3 O
part O
of O
exon O
fifteen O
, O
leave O
in O
a O
stop O
codon O
at O
1862 O
, O
in O
a O
declamatory O
dutch O
tribe O
with O
AAPC B
. O

We O
identified O
a O
frameshift O
mutation O
the O
of O
exon O
15 O
, O
resulting O
in O
a O
stop O
codon O
a O
large O
Dutch O
kindred O
with O
AAPC B
. O

, O
identified O
a O
at O
mutation O
in O
the O
kindred O
large O
of O
. O
15 O
, O
1862 O
a O
a O
stop O
codon O
frameshift O
resulting O
Dutch O
in O
in O
part O
We O
3 O
with O
AAPC B
exon O

We O
identified O
a O
frameshift O
dutch O
people O
lead O
inward O
antiophthalmic O
factor O
chromosomal O
mutation O
mutation O
in O
the O
3 O
part O
of O
exon O
15 O
, O
resulting O
in O
a O
stop O
codon O
kin O
group O
dutch O
people O
piece O
at O
1862 O
, O
in O
a B
large O

We O
identified O
a O
frameshift O
dutch O
people O
lead O
inward O
antiophthalmic O
factor O
chromosomal O
mutation O
mutation O
in O
the O
3 O
part O
of O
exon O
15 O
, O
resulting O
in O
a O
stop O
codon O
kin O
group O
dutch O
people O
diaphragm O
at O
1862 O
, O
in O
a B
large O

We O
identified O
a O
frameshift O
mutation O
in O
the O
3 O
of O
exon O
, O
resulting O
in O
a O
stop O
codon O
at O
in O
a O
large O
Dutch O
kindred O
with O
AAPC B
. O

. O
identified O
a O
in O
mutation O
in O
kindred O
3 O
frameshift O
of O
exon O
15 O
with O
resulting O
Dutch O
part O
stop O
codon O
at O
1862 O
, O
in O
a O
large O
a O
the O
, O
AAPC B
We O

We O
identified O
a O
frameshift O
mutation O
in O
the O
3 O
of O
15 O
, O
resulting O
in O
a O
stop O
codon O
at O
, O
in O
a O
large O
Dutch O
kindred O
with O

We O
key O
a O
frameshift O
mutation O
in O
the O
threesome O
persona O
of O
exon O
fifteen O
, O
lead O
in O
a O
stop O
codon O
at O
1862 O
, O
in O
a O
vauntingly O
dutch O
kindred O
with O
AAPC B
. O

We O
discover O
a O
frameshift O
mutation O
in O
the O
leash O
part O
of O
exon O
xv O
, O
resulting O
in O
a O
blockade O
codon O
at O
1862 O
, O
in O
a O
boastfully O
Dutch O
kindred O
with O
AAPC B
. O

We O
identified O
a O
frameshift O
mutation O
in O
the O
3 O
part O
of O
exon O
15 O
, O
resulting O
in O
a O
stop O
codon O
at O
1862 O
, O
in O
a O
large O
Dutch O
kindred O
with O
AAPC B
. O

Western O
analysis O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
as O
from O
a O
previously O
reported O
Swiss O
family O
carrying O
a O
frameshift O
mutation O
at O
codon O
1987 O
and O
a O
attenuated O
phenotype O
, O
showed O
only O
the O
wild O
- O
APC B
protein O
. O

westerly O
smirch O
analysis O
of O
lymphoblastoid O
cell O
lines O
deduce O
from O
affected O
sept O
members O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
antecedently O
describe O
swiss O
sept O
carrying O
a O
frameshift O
sport O
at O
codon O
1987 O
and O
expose O
a O
exchangeable O
weakened O
phenotype O
, O
shew O
only O
the O
godforsaken O
- O
character O
APC B
protein O
. O

Western O
a O
analysis O
of O
lymphoblastoid O
cell O
members O
at O
from O
affected O
family O
lines O
from O
frameshift O
family O
, O
as O
well O
derived O
from O
a O
previously O
similar O
Swiss O
- O
carrying O
protein O
this O
1987 O
as O
codon O
mutation O
and O
kindred O
a O
the O
attenuated O
phenotype O
, O
showed O
blot O
displaying O
wild O
reported O
type O
APC B
only O
. O

Western O
blot O
analysis O
of O
cell O
lines O
derived O
from O
affected O
, O
as O
a O
previously O
reported O
family O
carrying O
a O
frameshift O
mutation O
at O
displaying O
a O
similar O
attenuated O
phenotype O
, O
showed O
the O
wild O
APC B
protein O
. O

Western O
blot O
codon O
of O
lymphoblastoid O
cell O
lines O
derived O
from O
affected O
family O
frameshift O
from O
this O
kindred O
previously O
as O
well O
phenotype O
from O
a O
. O
reported O
similar O
family O
a O
as O
and O
mutation O
at O
analysis O
wild O
1987 O
displaying O
a O
Swiss O
attenuated O
carrying O
, O
showed O
only O
the O
members O
type O
- O
protein B
APC O
, O

western O
fleck O
analysis O
of O
lymphoblastoid O
cell O
lines O
come O
from O
regard O
kinfolk O
appendage O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
previously O
describe O
Swiss O
kinfolk O
transport O
a O
frameshift O
mutant O
at O
codon O
1987 O
and O
exhibit O
a O
standardised O
attenuated O
phenotype O
, O
showed O
only O
the O
barbarian O
- O
case O
apc B
protein O
. O

Western O
blot O
analysis O
of O
lines O
derived O
from O
family O
from O
this O
kindred O
well O
reported O
Swiss O
family O
a O
frameshift O
at O
codon O
1987 O
a O
similar O
attenuated O
phenotype O
, O
only O
wild O
- O
type O
APC B
protein O
. O

Western O
blot O
analysis O
of O
lymphoblastoid O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
previously O
reported O
Swiss O
family O
carrying O
a O
frameshift O
mutation O
at O
codon O
1987 O
and O
displaying O
a O
similar O
antiophthalmic O
factor O
idle O
simply O
character O
armored O
personnel O
carrier O
simply O
character O
armored O
personnel O
carrier O
a O
character O
armored O
personnel O
carrier O
a O
a O
a O
attenuated O
phenotype O
, B
showed O
only O

Western O
blot O
analysis O
of O
lymphoblastoid O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
previously O
reported O
Swiss O
family O
carrying O
a O
frameshift O
mutation O
at O
codon O
1987 O
and O
displaying O
a O
similar O
attenuated O
idle O
simply O
character O
armored O
personnel O
carrier O
simply O
character O
armored O
personnel O
carrier O
a O
character O
armored O
personnel O
carrier O
a O
a O
attenuate O
attenuated O
phenotype O
, O
showed B
only O
the O

a O
family O
analysis O
of O
as O
cell O
a O
1987 O
from O
affected O
family O
members O
from O
lines O
phenotype O
, O
lymphoblastoid O
protein O
as O
from O
this O
previously O
reported O
Swiss O
frameshift O
carrying O
a O
the O
type O
at O
mutation O
blot O
and O
displaying O
, O
similar O
attenuated O
kindred O
Western O
showed O
only O
derived O
wild O
- O
codon O
APC B
well O
. O

Western O
blot O
analysis O
of O
lymphoblastoid O
cell O
lines O
derived O
from O
affected O
family O
members O
from O
this O
kindred O
, O
as O
well O
as O
from O
a O
previously O
reported O
Swiss O
family O
carrying O
a O
frameshift O
mutation O
at O
codon O
1987 O
and O
displaying O
a O
similar O
attenuated O
phenotype O
, O
showed O
only O
the O
wild O
- O
type O
APC B
protein O
. O

Our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
APC B
do O
not O
result O
in O
detectable O
truncated O
polypeptides O
and O
we O
hypothesize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
AAPC B
phenotype O
. O
. O

Our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
APC B
do O
not O
result O
in O
detectable O
truncated O
polypeptides O
and O
we O
hypothesize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
probable O
AAPC B
phenotype O
. O
. O

Our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
APC B
do O
not O
result O
in O
detectable O
truncated O
polypeptides O
and O
we O
hypothesize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
string O
AAPC B
phenotype O
. O
. O

hypothesize O
in O
indicates O
that O
chain O
- O
3 O
for O
located O
in O
the O
terminating O
part O
is O
to B
do O
not O
result O
mutations O
detectable O
truncated O
basis O
likely O
we O
Our O
that O
the O
of O
APC O
and O
be O
observed O
polypeptides O
study O
the O
this O
AAPC B
phenotype O
. O
. O

Our O
study O
indicates O
that O
mutations O
located O
in O
the O
3 O
of O
APC B
in O
polypeptides O
and O
that O
likely O
to O
be O
the O
for O
the O
phenotype O
. O

Our O
survey O
bespeak O
that O
chain O
- O
stop O
mutations O
located O
in O
the O
ternary O
split O
of O
apc B
do O
not O
resolution O
in O
perceptible O
shortened O
polypeptides O
and O
we O
theorize O
that O
this O
is O
likely O
to O
be O
the O
groundwork O
for O
the O
watch O
AAPC B
phenotype O
. O
. O

Our O
examine O
argue O
that O
concatenation O
- O
terminate O
mutations O
placed O
in O
the O
troika O
component O
of O
APC B
do O
not O
answer O
in O
perceptible O
truncated O
polypeptides O
and O
we O
conjecture O
that O
this O
is O
belike O
to O
be O
the O
base O
for O
the O
observed O
AAPC B
phenotype O
. O
. O

be O
the O
indicates O
that O
not O
- O
phenotype O
the O
located O
in O
the O
3 O
part O
hypothesize O
result B
do O
chain O
APC O
in O
detectable O
of O
polypeptides O
and O
we O
study O
that O
this O
. O
Our O
to O
likely O
terminating O
basis O
for O
truncated O
observed O
AAPC B
mutations O
is O
. O

Our O
read O
indicates O
that O
chain O
- O
cease O
mutations O
placed O
in O
the O
trio O
part O
of O
APC B
do O
not O
upshot O
in O
perceptible O
abbreviated O
polypeptides O
and O
we O
theorise O
that O
this O
is O
belike O
to O
be O
the O
cornerstone O
for O
the O
remark O
AAPC B
phenotype O
. O
. O

Our O
study O
be O
that O
chain O
observed O
the O
mutations O
located O
in O
terminating O
this O
detectable O
of O
APC B
in O
not O
result O
phenotype O
part O
truncated O
polypeptides O
and O
- O
hypothesize O
do O
3 O
basis O
the O
to O
indicates O
is O
likely O
for O
the O
we O
AAPC B
that O
. O
. O

Our O
study O
indicates O
that O
chain O
- O
terminating O
mutations O
located O
in O
the O
3 O
part O
of O
APC B
do O
not O
result O
in O
detectable O
truncated O
polypeptides O
and O
we O
hypothesize O
that O
this O
is O
likely O
to O
be O
the O
basis O
for O
the O
observed O
AAPC B
phenotype O
. O
. O

Complete O
genomic O
installment O
kibibyte O
episode O
sequence O
and O
analysis O
of O
117 O
kb O
of O
human O
DNA O
containing O
the O
gene O
BRCA1 O
kilobyte O
. O

gene O
genomic O
sequence O
. O
analysis O
of O
117 O
kb O
BRCA1 O
human O
DNA O
containing O
Complete O
the O
of O
and O

Complete O
genomic O
cistron O
kibibyte O
depth O
psychology O
sequence O
and O
analysis O
of O
117 O
kb O
of O
human O
DNA O
containing O
the O
gene O
BRCA1 O
kilobyte O

Complete O
genomic O
episode O
and O
analysis O
of O
117 O
kib O
of O
homo O
dna O
containing O
the O
gene O
BRCA1 O
. O

the O
genomic O
sequence O
kb O
analysis O
of O
gene O
and O
of O
human O
Complete O
containing O
DNA O
117 O
BRCA1 O
. O

Complete O
genomic O
installment O
kibibyte O
episode O
sequence O
and O
analysis O
of O
117 O
kb O
of O
human O
DNA O
containing O
the O
gene O
BRCA1 O
kilobyte O
. O

sodding O
genomic O
successiveness O
and O
analysis O
of O
117 O
kb O
of O
human O
dna O
carry O
the O
gene O
BRCA1 O
. O

thoroughgoing O
genomic O
sequence O
and O
analysis O
of O
117 O
kib O
of O
human O
DNA O
moderate O
the O
cistron O
BRCA1 O
. O

Complete O
genomic O
of O
. O
analysis O
of O
the O
kb O
sequence O
human O
DNA O
containing O
117 O
gene O
and O
BRCA1 O

genomic O
sequence O
and O
analysis O
of O
117 O
kb O
DNA O
containing O
the O
gene O
BRCA1 O
. O

Complete O
genomic O
sequence O
and O
analysis O
of O
117 O
kb O
of O
human O
DNA O
containing O
the O
gene O
BRCA1 O
. O

oer O
100 O
discrete O
disease O
- O
associated O
mutant O
have O
been O
identify O
in O
the O
knocker B
- I
ovarian I
cancer I
susceptibility O
cistron O
BRCA1 O
. O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
clear O
cut O
clear O
cut O
clear O
cut O
clear O
cut O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
clear O
cut O
clear O
cut O
clear O
cut O
clear O
cut O

distinct O
associated O
mutations O
have O
identified O
in O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

Over O
100 O
distinct O
disease O
- O
have O
been O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

distinct O
disease O
- O
associated O
have O
been O
identified O
in O
the O
- I
ovarian I
cancer I
susceptibility O
BRCA1 O
. O

gene O
100 O
distinct O
BRCA1 O
- O
associated O
mutations O
been O
have O
identified O
ovarian O
the O
breast B
. I
Over I
cancer I
susceptibility O
in O
disease O
- O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
clear O
cut O
clear O
cut O
clear O
cut O
clear O
cut O

Over O
100 O
decided O
disease O
- O
associated O
mutant O
have O
been O
name O
in O
the O
front B
- I
ovarian I
cancer I
susceptibleness O
factor O
BRCA1 O
. O

susceptibility O
100 O
distinct O
disease O
- O
associated O
- O
the O
been O
identified O
in O
ovarian O
Over B
mutations I
have I
gene I
breast O
cancer O
BRCA1 O
. O

Over O
100 O
distinct O
disease O
- O
associated O
mutations O
have O
been O
identified O
in O
the O
breast B
- I
ovarian I
cancer I
susceptibility O
gene O
BRCA1 O
. O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
point O
serve O
tumour O
serve O
serve O
idle O
serve O
mutations O
indicates O
tumor B
suppressive O
function O
. O

the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
mutations O
tumor B
suppressive O
function O
. O

going O
of O
the O
wild O
- O
type O
allelomorph O
in O
> O
90 O
% O
of O
neoplasm B
from O
patients O
with O
familial O
BRCA1 O
mutant O
show O
tumor B
suppressive O
officiate O
. O

Loss O
of O
the O
wild O
- O
type O
allele O
> O
90 O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
tumor B
suppressive O
function O
. O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
point O
serve O
tumour O
serve O
serve O
idle O
idle O
mutations O
indicates O
tumor B
suppressive O
function O
. O

expiration O
of O
the O
uncivilized O
- O
type O
allelomorph O
in O
> O
90 O
% O
of O
tumour B
from O
patients O
with O
transmitted O
BRCA1 O
mutations O
indicates O
tumour B
suppressive O
run O
. O

going O
of O
the O
hazardous O
- O
type O
allelomorph O
in O
> O
xc O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
sport O
indicates O
neoplasm B
suppressive O
use O
. O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
% O
from O
patients O
with O
inherited O
BRCA1 O
mutations O
indicates O
tumor B
suppressive O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
point O
serve O
tumour O
serve O
serve O
idle O
idle O
mutations O
indicates O
tumor B
suppressive O
function O
. O

BRCA1 O
of O
the O
% O
- O
type O
allele O
mutations O
. O
90 O
wild O
of O
tumors B
from O
function O
with O
inherited O
tumor O
in O
Loss O
indicates B
suppressive O
patients O
> O

Loss O
of O
the O
wild O
- O
type O
allele O
in O
> O
90 O
% O
of O
tumors B
from O
patients O
with O
inherited O
BRCA1 O
mutations O
indicates O
tumor B
suppressive O
function O
. O

The O
low O
incidence O
of O
bodily O
mutations O
advise O
that O
BRCA1 O
deactivation O
in O
sporadic O
tumors B
occurs O
by O
substitute O
mechanics O
, O
such O
as O
interstitial O
chromosomal O
excision O
or O
abridge O
arrangement O
. O

The O
low O
of O
somatic O
mutations O
suggests O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
alternative O
mechanisms O
, O
such O
interstitial O
chromosomal O
deletion O
or O
reduced O
. O

The O
low O
incidence O
of O
aside O
alternate O
corporal O
somatic O
mutations O
suggests O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
occurs O
by O
alternative O
mechanisms O
, O
operating O
room O
melt O
off O
arranging O
melt O
off O
alternate O
such O
as O
interstitial O
chromosomal O
deletion O
or O

interstitial O
low O
incidence O
such O
somatic O
mutations O
suggests O
transcription O
or O
inactivation O
as O
sporadic O
tumors B
occurs O
deletion O
alternative O
mechanisms O
, O
of O
reduced O
in O
chromosomal O
by O
BRCA1 O
The O
that O
. O

The O
low O
incidence O
of O
aside O
alternate O
corporal O
somatic O
mutations O
suggests O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
occurs O
by O
alternative O
mechanisms O
, O
operating O
room O
melt O
off O
arranging O
melt O
off O
alternate O
such O
as O
interstitial O
chromosomal O
deletion O
or O

The O
low O
incidence O
somatic O
mutations O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
occurs O
by O
mechanisms O
, O
as O
interstitial O
chromosomal O
deletion O
or O
reduced O
transcription O
. O

. O
low O
incidence O
by O
somatic O
mutations O
transcription O
that O
of O
inactivation O
in O
sporadic O
occurs B
interstitial O
reduced O
BRCA1 O
mechanisms O
, O
such O
as O
tumors O
chromosomal O
deletion O
or O
alternative O
suggests O
The O

incidence O
mutations O
suggests O
that O
inactivation O
in O
tumors B
occurs O
by O
alternative O
mechanisms O
, O
such O
as O
interstitial O
chromosomal O
deletion O
or O
reduced O

or O
low O
incidence O
of O
somatic O
mutations O
occurs O
sporadic O
BRCA1 O
inactivation O
in O
mechanisms O
chromosomal B
suggests O
reduced O
The O
that O
alternative O
such O
as O
interstitial O
tumors O
deletion O
, O
by O
transcription O
. O

The O
abject O
incidence O
of O
corporal O
mutations O
suggests O
that O
BRCA1 O
deactivation O
in O
sporadic O
neoplasm B
happen O
by O
option O
mechanics O
, O
such O
as O
interstitial O
chromosomal O
deletion O
or O
thin O
transcription O
. O

The O
low O
incidence O
of O
somatic O
mutations O
suggests O
that O
BRCA1 O
inactivation O
in O
sporadic O
tumors B
occurs O
by O
alternative O
mechanisms O
, O
such O
as O
interstitial O
chromosomal O
deletion O
or O
reduced O
transcription O
. O

To O
describe O
potency O
sport O
of O
the O
BRCA1 O
genomic O
realm O
that O
whitethorn O
contribute O
to O
chromosomal O
unstableness O
as O
easily O
as O
potency O
transcriptional O
regulative O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
episode O
circumferent O
BRCA1 O
was O
obtained O
by O
random O
sequence O
of O
four O
cosmids O
place O
from O
a O
human O
chromosome O
xvii O
particular O
library O
. O

To O
identify O
potential O
boast O
of O
the O
BRCA1 O
genomic O
area O
that O
may O
impart O
to O
chromosomal O
imbalance O
as O
substantially O
as O
potential O
transcriptional O
regulative O
factor O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
episode O
cover O
BRCA1 O
was O
get O
by O
random O
sequence O
of O
four O
cosmids O
name O
from O
a O
human O
chromosome O
xvii O
particular O
library O
. O

To O
identify O
possible O
features O
of O
the O
BRCA1 O
that O
may O
contribute O
to O
instability O
as O
well O
as O
potential O
regulatory O
elements O
, O
a O
, O
143 O
bp O
DNA O
sequence O
encompassing O
BRCA1 O
was O
obtained O
by O
sequencing O
of O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O
specific O

To O
identify O
possible O
features O
of O
the O
BRCA1 O
genomic O
realm O
region O
that O
may O
contribute O
to O
chromosomal O
instability O
as O
well O
as O
potential O
transcriptional O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
sequence O
encompassing O
BRCA1 O
was O
obtained O
by O
identify O
 O
antiophthalmic O
factor O
homo O
 O
 O
particular O
program O
library O
 O
particular O
program O
library O
 O
particular O
considerably O
random O
sequencing O
of O
four O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O

obtained O
117 O
possible O
features O
of O
the O
regulatory O
well O
region O
that O
may O
contribute O
to O
BRCA1 O
sequencing O
as O
genomic O
17 O
potential O
transcriptional O
chromosomal O
elements O
, O
a O
- O
, O
143 O
identified O
human O
DNA O
bp O
identify O
BRCA1 O
was O
. O
by O
random O
instability O
encompassing O
four O
cosmids O
library O
from O
a O
sequence O
chromosome O
as O
specific O
of O
To O

To O
identify O
possible O
features O
of O
the O
BRCA1 O
genomic O
realm O
region O
that O
may O
contribute O
to O
chromosomal O
instability O
as O
well O
as O
potential O
transcriptional O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
sequence O
encompassing O
BRCA1 O
was O
obtained O
by O
identify O
 O
antiophthalmic O
factor O
homo O
 O
 O
particular O
program O
library O
 O
particular O
program O
library O
 O
particular O
considerably O
random O
sequencing O
of O
four O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O

To O
key O
potential O
lineament O
of O
the O
BRCA1 O
genomic O
neighborhood O
that O
may O
lead O
to O
chromosomal O
unstableness O
as O
fountainhead O
as O
potential O
transcriptional O
regulative O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
successiveness O
surrounding O
BRCA1 O
was O
prevail O
by O
random O
successiveness O
of O
four O
cosmids O
describe O
from O
a O
human O
chromosome O
17 O
particular O
library O
. O

To O
identify O
possible O
features O
of O
the O
BRCA1 O
genomic O
realm O
region O
that O
may O
contribute O
to O
chromosomal O
instability O
as O
well O
as O
potential O
transcriptional O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
sequence O
encompassing O
BRCA1 O
was O
obtained O
by O
identify O
 O
antiophthalmic O
factor O
homo O
 O
 O
particular O
program O
library O
 O
particular O
program O
library O
 O
particular O
potential O
random O
sequencing O
of O
four O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O

To O
identify O
possible O
features O
BRCA1 O
genomic O
region O
that O
may O
contribute O
to O
chromosomal O
well O
potential O
transcriptional O
regulatory O
, O
a O
117 O
, O
143 O
- O
DNA O
sequence O
was O
by O
random O
sequencing O
of O
identified O
from O
a O
human O
17 O
specific O
library O
. O

To O
143 O
possible O
features O
of O
the O
contribute O
DNA O
region O
that O
may O
BRCA1 O
to O
- O
bp O
as O
well O
as O
genomic O
transcriptional O
regulatory O
elements O
was O
a O
a O
, O
17 O
chromosomal O
library O
potential O
sequence O
by O
BRCA1 O
instability O
obtained O
identified O
random O
sequencing O
of O
four O
identify O
encompassing O
from O
, O
human O
chromosome O
cosmids O
specific O
117 O
. O

To O
identify O
possible O
features O
of O
the O
BRCA1 O
genomic O
region O
that O
may O
contribute O
to O
chromosomal O
instability O
as O
well O
as O
potential O
transcriptional O
regulatory O
elements O
, O
a O
117 O
, O
143 O
- O
bp O
DNA O
sequence O
encompassing O
BRCA1 O
was O
obtained O
by O
random O
sequencing O
of O
four O
cosmids O
identified O
from O
a O
human O
chromosome O
17 O
specific O
library O
. O

. O
Alu O
exons O
of O
BRCA1 O
span O
sequences O
81 O
- O
kb O
region O
repetitive O
has O
5 O
relatively O
high O
density O
of O
, O
repetitive O
DNA O
( O
8 O
. O
an O
% O
4 O
24 O
density O
41 O
low O
but O
( O
unusually O
The O
) O
% O
) O
of O
other O
that O
an O
. O

The O
24 O
exons O
BRCA1 O
span O
an O
81 O
- O
kb O
region O
an O
unusually O
high O
of O
repetitive O
DNA O
( O
5 O
relatively O
low O
density O
4 O
. O
% O
) O
of O
sequences O
. O

The O
24 O
exons O
of O
BRCA1 O
duo O
an O
81 O
- O
kb O
neighborhood O
that O
has O
an O
unco O
high O
concentration O
of O
Alu O
insistent O
DNA O
( O
41 O
. O
five O
% O
) O
, O
but O
comparatively O
low O
concentration O
( O
quaternion O
. O
8 O
% O
) O
of O
other O
insistent O
episode O
. O

The O
24 O
exons O
of O
BRCA1 O
couplet O
an O
81 O
- O
kb O
neighborhood O
that O
has O
an O
unco O
mellow O
concentration O
of O
Alu O
repetitious O
DNA O
( O
41 O
. O
fivesome O
% O
) O
, O
but O
comparatively O
low O
concentration O
( O
iv O
. O
octonary O
% O
) O
of O
other O
repetitious O
succession O
. O

The O
24 O
density O
of O
BRCA1 O
span O
an O
Alu O
- O
kb O
region O
has O
. O
an O
unusually O
low O
density O
of O
repetitive O
81 O
DNA O
( O
41 O
8 O
5 O
) O
, O
( O
but O
relatively O
high O
) O
% O
4 O
. O
. O
% O
exons O
of O
other O
repetitive O
sequences O
that O

The O
24 O
exons O
BRCA1 O
81 O
- O
kb O
region O
that O
has O
an O
unusually O
high O
DNA O
( O
41 O
. O
5 O
% O
) O
, O
but O
relatively O
low O
density O
( O
4 O
. O
% O
of O
other O
repetitive O
sequences O
. O

The O
24 O
exons O
of O
BRCA1 O
span O
an O
81 O
- O
kb O
region O
that O
has O
an O
unusually O
high O
density O
of O
Alu O
repetitive O
DNA O
( O
41 O
. O
5 O
% O
) O
, O
but O
relatively O
low O
density O
( O
4 O
. O
8 O
repetitious O
episode O
early O
repetitious O
episode O
concentration O
concentration O
concentration O
concentration O
concentration O
concentration O
concentration O
% O
) O
of O
other O
repetitive O
sequences O
. O

of O
5 O
exons O
of O
density O
span O
DNA O
density O
- O
kb O
region O
that O
has O
an O
) O
high O
BRCA1 O
low O
Alu O
repetitive O
an O
( O
41 O
. O
, O
% O
) O
sequences O
of O
relatively O
but O
24 O
( O
4 O
. O
8 O
% O
unusually O
The O
other O
repetitive O
81 O
. O

The O
24 O
exons O
BRCA1 O
an O
81 O
- O
kb O
region O
that O
has O
an O
unusually O
high O
of O
Alu O
repetitive O
DNA O
( O
, O
low O
( O
4 O
. O
% O
) O
of O
other O
repetitive O
sequences O

The O
24 O
exons O
of O
BRCA1 O
bridge O
an O
81 O
- O
kb O
area O
that O
has O
an O
remarkably O
gamey O
compactness O
of O
Alu O
insistent O
DNA O
( O
41 O
. O
quint O
% O
) O
, O
but O
comparatively O
low O
compactness O
( O
4 O
. O
8 O
% O
) O
of O
other O
insistent O
sequences O
. O

The O
24 O
exons O
of O
BRCA1 O
span O
an O
81 O
- O
kb O
region O
that O
has O
an O
unusually O
high O
density O
of O
Alu O
repetitive O
DNA O
( O
41 O
. O
5 O
% O
) O
, O
but O
relatively O
low O
density O
( O
4 O
. O
8 O
% O
) O
of O
other O
repetitive O
sequences O
. O

BRCA1 O
intron O
lengths O
range O
in O
size O
from O
403 O
bp O
 O
noncoding O
dna O
noncoding O
dna O
to O

intron O
lengths O
from O
to O
9 O
. O

BRCA1 O
intron O
distance O
stove O
in O
sizing O
from O
403 O
bp O
to O
9 O
. O

BRCA1 O
intron O
lengths O
range O
in O
size O
from O
403 O
bp O
 O
noncoding O
dna O
noncoding O
dna O
to O

intron O
lengths O
in O
size O
from O
403 O
bp O
to O
9 O
. O

BRCA1 O
intron O
distance O
straddle O
in O
sizing O
from O
403 O
bp O
to O
9 O
. O

BRCA1 O
intron O
lengths O
range O
in O
size O
from O
403 O
bp O
 O
noncoding O
dna O
inward O
to O
9 O

BRCA1 O
intron O
lengths O
order O
in O
sizing O
from O
403 O
bp O
to O
ennead O
. O

BRCA1 O
403 O
lengths O
range O
intron O
size O
from O
9 O
bp O
to O
in O
. O

. O
intron O
lengths O
range O
403 O
size O
to O
in O
bp O
from O
9 O
BRCA1 O

BRCA1 O
intron O
lengths O
range O
in O
size O
from O
403 O
bp O
to O
9 O
. O

2 O
and O
contain O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
, O
which O
localize O
to O
12 O
, O
19 O
, O
and O
, O
respectively O
. O

2 O
and O
contain O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
, O
which O
to O
introns O
12 O
, O
19 O
, O
and O
20 O

2 O
kb O
and O
contain O
 O
 O
severally O
place O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
localize O
to O
 O
hold O
back O
severally O
hold O
back O
introns O
12 O
, O
19 O
, O
and O
20 O
, O

, O
kb O
and O
introns O
the O
intragenic O
microsatellite O
, O
and O
, O
12 O
, O
and O
D17S855 O
, O
which O
localize O
to O
contain O
20 O
D17S1322 O
19 O
, O
D17S1323 O
2 O
markers O
respectively O
. O

respectively O
kb O
and O
, O
the O
intragenic O
, O
markers O
contain O
, O
D17S1322 O
, O
D17S855 O
, O
20 O
D17S1323 O
localize O
to O
introns O
12 O
and O
19 O
, O
and O
which O
microsatellite O
2 O
. O

2 O
kb O
and O
contain O
 O
 O
severally O
place O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
localize O
to O
 O
hold O
back O
severally O
hold O
back O
introns O
12 O
, O
19 O
, O
and O
20 O
, O

2 O
kilobyte O
and O
carry O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
localise O
to O
introns O
twelve O
, O
19 O
, O
and O
twenty O
, O
severally O
. O

2 O
kb O
and O
contain O
 O
 O
severally O
place O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
localize O
to O
 O
hold O
back O
severally O
hold O
back O
introns O
12 O
, O
19 O
, O
and O
20 O
, O

and O
kb O
and O
contain O
the O
intragenic O
D17S855 O
, O
D17S1323 O
, O
D17S1322 O
localize O
19 O
microsatellite O
20 O
2 O
markers O
which O
introns O
12 O
, O
and O
, O
to O
, O
, O
respectively O
. O

deuce O
kilobit O
and O
control O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
focalize O
to O
introns O
12 O
, O
19 O
, O
and O
xx O
, O
severally O
. O

2 O
kb O
and O
contain O
the O
intragenic O
microsatellite O
markers O
D17S1323 O
, O
D17S1322 O
, O
and O
D17S855 O
, O
which O
localize O
to O
introns O
12 O
, O
19 O
, O
and O
20 O
, O
respectively O
. O

In O
addition O
protein O
BRCA1 O
, O
the O
Rho7 O
family O
two O
complete O
genes O
, O
of O
a O
member O
an O
the O
rho O
of O
, O
GTP O
cholinergic O
proteins O
, O
and O
of O
contig O
binding O
abundant O
membrane O
to O
contains O
VAT1 O
synaptic O
vesicles O
. O

addition O
BRCA1 O
, O
the O
contig O
contains O
two O
complete O
genes O
, O
a O
member O
of O
the O
rho O
family O
binding O
proteins O
, O
VAT1 O
an O
abundant O
membrane O
cholinergic O

In O
gain O
to O
BRCA1 O
, O
the O
contig O
take O
ii O
terminated O
cistron O
Rho7 O
, O
a O
extremity O
of O
the O
rho O
kinsfolk O
of O
GTP O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
. O

an O
GTP O
to O
BRCA1 O
the O
the O
member O
of O
two O
complete O
genes O
Rho7 O
, O
and O
contains O
of O
, O
protein O
family O
of O
a O
binding O
proteins O
, O
addition O
VAT1 O
, O
In O
rho O
membrane O
abundant O
contig O
cholinergic O
synaptic O
vesicles O
. O

In O
addition O
to O
BRCA1 O
hold O
back O
, O
the O
contig O
contains O
two O
complete O
genes O
Rho7 O
, O
a O
member O
of O
the O
rho O
family O
of O
GTP O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O
nursing O

and O
family O
to O
BRCA1 O
, O
the O
contig O
contains O
two O
complete O
genes O
Rho7 O
, O
an O
membrane O
of O
the O
rho O
synaptic O
of O
GTP O
binding O
abundant O
, O
In O
VAT1 O
of O
a O
member O
proteins O
protein O
. O
cholinergic O
vesicles O
addition O
, O

In O
addition O
to O
BRCA1 O
the O
two O
complete O
genes O
Rho7 O
, O
a O
member O
of O
the O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
. O

indium O
improver O
to O
BRCA1 O
, O
the O
contig O
contains O
ii O
arrant O
factor O
Rho7 O
, O
a O
penis O
of O
the O
rho O
family O
of O
GTP O
bond O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
. O

In O
addition O
to O
BRCA1 O
add O
on O
, O
the O
contig O
contains O
two O
complete O
genes O
Rho7 O
, O
a O
member O
of O
the O
rho O
family O
of O
GTP O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O
nursing O

inwards O
summation O
to O
BRCA1 O
, O
the O
contig O
contains O
deuce O
complete O
genes O
Rho7 O
, O
a O
extremity O
of O
the O
rho O
mob O
of O
GTP O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
cyst O
. O

In O
addition O
to O
BRCA1 O
, O
the O
contig O
contains O
two O
complete O
genes O
Rho7 O
, O
a O
member O
of O
the O
rho O
family O
of O
GTP O
binding O
proteins O
, O
and O
VAT1 O
, O
an O
abundant O
membrane O
protein O
of O
cholinergic O
synaptic O
vesicles O
. O

Partial O
of O
the O
1A1 O
- O
3B O
B O
- O
box O
protein O
pseudogene O
35 O
, O
an O
interferon O
leucine O
zipper O
protein O
, O
reside O
the O
contig O
. O

Partial O
of O
the O
- O
3B O
B O
- O
box O
protein O
pseudogene O
and O
35 O
, O
interferon O
induced O
leucine O
zipper O
protein O
, O
reside O
within O

Partial O
sequences O
of O
the O
thirty O
five O
occupy O
associate O
in O
nursing O
1A1 O
- O
3B O
B O
- O
box O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
inside O
occupy O
inside O
cause O
induced O
leucine O
zipper O
protein O
, O
reside O
within O

zipper O
sequences O
of O
induced O
1A1 O
- O
3B O
the O
reside O
box O
leucine O
pseudogene O
and O
IFP O
, O
, O
an O
interferon O
the O
within O
protein O
protein O
35 O
- O
Partial O
B O
contig O
. O

contig O
sequences O
of O
35 O
1A1 O
- O
the O
B O
the O
box O
protein O
pseudogene O
IFP O
zipper O
within O
- O
an O
interferon O
induced O
leucine O
and O
protein O
, O
reside O
, O
3B O
Partial O
. O

Partial O
sequences O
of O
the O
inside O
thirty O
five O
occupy O
associate O
in O
nursing O
1A1 O
- O
3B O
B O
- O
box O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
inside O
occupy O
inside O
inside O
induced O
leucine O
zipper O
protein O
, O
reside O
within O

Partial O
successiveness O
of O
the O
1A1 O
- O
3B O
b O
- O
corner O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
hasten O
leucine O
zipper O
protein O
, O
repose O
inside O
the O
contig O
. O

Partial O
sequences O
of O
the O
inside O
thirty O
five O
occupy O
associate O
in O
nursing O
1A1 O
- O
3B O
B O
- O
box O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
inside O
occupy O
inside O
inside O
induced O
leucine O
zipper O
protein O
, O
reside O
within O

reside O
sequences O
of O
the O
1A1 O
- O
IFP O
pseudogene O
- O
box O
protein O
an O
protein O
3B O
within O
Partial O
B O
, O
induced O
leucine O
zipper O
and O
, O
interferon O
35 O
the O
contig O
. O

overtone O
sequences O
of O
the O
1A1 O
- O
3B O
bacillus O
- O
box O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
get O
leucine O
zipper O
protein O
, O
reside O
inside O
the O
contig O
. O

Partial O
sequences O
of O
the O
1A1 O
- O
3B O
B O
- O
box O
protein O
pseudogene O
and O
IFP O
35 O
, O
an O
interferon O
induced O
leucine O
zipper O
protein O
, O
reside O
within O
the O
contig O
. O

An O
L21 O
ribosomal O
protein O
pseudogene O
is O
embedded O
in O
BRCA1 O
 O
inward O
inward O
intron O
13 O
. O

L21 O
ribosomal O
embedded O
intron O
13 O
. O

an O
L21 O
ribosomal O
protein O
pseudogene O
is O
implant O
in O
BRCA1 O
intron O
13 O
. O

An O
L21 O
ribosomal O
protein O
pseudogene O
is O
embedded O
in O
BRCA1 O
 O
inward O
inward O
intron O
13 O
. O

L21 O
ribosomal O
pseudogene O
is O
embedded O
in O
BRCA1 O
intron O
13 O
. O

An O
L21 O
ribosomal O
protein O
pseudogene O
is O
implant O
in O
BRCA1 O
intron O
thirteen O
. O

An O
L21 O
ribosomal O
protein O
pseudogene O
is O
embedded O
in O
BRCA1 O
 O
inward O
implant O
intron O
13 O
. O

an O
L21 O
ribosomal O
protein O
pseudogene O
is O
engraft O
in O
BRCA1 O
intron O
13 O
. O

An O
in O
ribosomal O
protein O
L21 O
is O
embedded O
13 O
BRCA1 O
intron O
pseudogene O
. O

. O
L21 O
ribosomal O
protein O
in O
is O
intron O
pseudogene O
BRCA1 O
embedded O
13 O
An O

An O
L21 O
ribosomal O
protein O
pseudogene O
is O
embedded O
in O
BRCA1 O
intron O
13 O
. O

The O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
thirty O
five O
- O
1A1 O
- O
3B O
- O

of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
- O
- O
3B O
- O
telomere O

The O
order O
of O
factor O
on O
the O
chromosome O
is O
kinetochore O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
1A1 O
- O
3B O
- O
telomere O

The O
order O
of O
genes O
on O
the O
chromosome O
centromere O
- O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
3B O
- O
telomere O

The O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
- O
1A1 O
- O
3B O
- O
telomere O

The O
consecrate O
of O
genes O
on O
the O
chromosome O
is O
kinetochore O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
1A1 O
- O
3B O
- O
telomere O

The O
ordination O
of O
genes O
on O
the O
chromosome O
is O
kinetochore O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
1A1 O
- O
3B O
- O
telomere O

The O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
1FP O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
1A1 O
- O
3B O

The O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
kinetochore O
- O
1A1 O
- O
3B O
- O
telomere O

BRCA1 O
order O
of O
1FP O
on O
the O
chromosome O
- O
telomere O
- O
genes O
35 O
- O
VAT1 O
- O
Rho7 O
- O
- O
is O
The O
1A1 O
3B O
- O
centromere O

The O
order O
of O
genes O
on O
the O
chromosome O
is O
centromere O
- O
1FP O
35 O
- O
VAT1 O
- O
Rho7 O
- O
BRCA1 O
- O
1A1 O
- O
3B O
- O
telomere O

Identification O
of O
fundament O
antiophthalmic O
factor O
antiophthalmic O
factor O
a O
RING O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
gene O
product O

gene O
of O
a O
. O
protein O
that O
can O
interact O
product O
vivo O
with O
the O
Identification O
BRCA1 O
in O
RING O

Identification O
of O
fundament O
antiophthalmic O
factor O
cistron O
a O
RING O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
gene O
product O
phone O

designation O
of O
a O
resound O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
cistron O
intersection O
. O

BRCA1 O
of O
a O
interact O
protein O
that O
gene O
RING O
in O
vivo O
Identification O
the O
with O
can O
product O
. O

Identification O
of O
fundament O
antiophthalmic O
factor O
antiophthalmic O
factor O
a O
RING O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
gene O
product O

designation O
of O
a O
surround O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
factor O
product O
. O

designation O
of O
a O
RING O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
cistron O
ware O
. O

Identification O
of O
in O
. O
protein O
that O
BRCA1 O
interact O
a O
vivo O
with O
the O
can O
gene O
RING O
product O

of O
a O
RING O
protein O
that O
can O
interact O
with O
the O
BRCA1 O
gene O
product O
. O

Identification O
of O
a O
RING O
protein O
that O
can O
interact O
in O
vivo O
with O
the O
BRCA1 O
gene O
product O
. O

The O
hereditary B
a I
and I
ovarian I
cancer I
a O
- O
BRCA1 O
, O
encodes O
binding O
rich O
polypeptide O
that O
domain O
the O
cysteine O
variety O
large O
RING O
of O
, O
a O
zinc O
contains O
gene O
motif O
found O
in O
breast O
, O
- O
regulatory O
proteins O
. O

hereditary B
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
motif O
, O
a O
- O
domain O
found O
in O
of O

The O
inherited B
titty I
and I
ovarian I
crab I
factor O
, O
BRCA1 O
, O
encodes O
a O
tumid O
polypeptide O
that O
contains O
the O
cysteine O
- O
plentiful O
RING O
motive O
, O
a O
zinc O
- O
binding O
domain O
incur O
in O
a O
motley O
of O
regulative O
proteins O
. O

domain O
RING B
breast I
and I
the I
cancer I
that O
variety O
BRCA1 O
, O
encodes O
a O
large O
zinc O
, O
contains O
ovarian O
a O
- O
rich O
polypeptide O
motif O
, O
a O
hereditary O
- O
binding O
The O
cysteine O
in O
found O
gene O
of O
regulatory O
proteins O
. O

The O
hereditary B
breast I
and I
sort I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
rich O
RING O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
assort O
assort O
assort O
assort O
assort O
assort O
assort O
assort O
hold O
back O

zinc O
- B
breast I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
a O
large O
domain O
in O
contains O
the O
cysteine O
regulatory O
rich O
RING O
motif O
found O
a O
The O
- O
variety O
polypeptide O
that O
, O
a O
. O
of O
proteins O
hereditary O
binding O

The O
hereditary B
breast I
and I
cancer I
BRCA1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
. O

The O
familial B
tit I
and I
ovarian I
crab I
factor O
, O
BRCA1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
deep O
call O
theme O
, O
a O
zn O
- O
hold O
world O
found O
in O
a O
variety O
of O
regulatory O
proteins O
. O

The O
hereditary B
breast I
and I
plentiful I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
rich O
RING O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
bountiful O
bountiful O
bountiful O
bountiful O
bountiful O
bountiful O
bountiful O
bountiful O
hold O
back O

The O
patrimonial B
chest I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
a O
orotund O
polypeptide O
that O
contains O
the O
cysteine O
- O
racy O
hoop O
motive O
, O
a O
zinc O
- O
constipate O
land O
witness O
in O
a O
variety O
of O
regulative O
proteins O
. O

The O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
, O
BRCA1 O
, O
encodes O
a O
large O
polypeptide O
that O
contains O
the O
cysteine O
- O
rich O
RING O
motif O
, O
a O
zinc O
- O
binding O
domain O
found O
in O
a O
variety O
of O
regulatory O
proteins O
. O

Here O
we O
in O
terminal O
novel O
protein O
N O
interacts O
describe O
vivo O
with O
the O
that O
- O
a O
region O
of O
BRCA1 O
. O

describe O
a O
novel O
protein O
that O
interacts O
in O
vivo O
with O
region O
of O
BRCA1 O
. O

hera O
we O
key O
a O
refreshing O
protein O
that O
interacts O
in O
vivo O
with O
the O
north O
- O
terminal O
neighborhood O
of O
BRCA1 O
. O

hither O
we O
describe O
a O
fresh O
protein O
that O
interacts O
in O
vivo O
with O
the O
northward O
- O
terminus O
realm O
of O
BRCA1 O
. O

of O
we O
describe O
a O
novel O
protein O
- O
terminal O
in O
vivo O
with O
the O
BRCA1 O
that O
interacts O
region O
N O
Here O
. O

Here O
we O
novel O
protein O
that O
interacts O
in O
vivo O
with O
the O
N O
- O
terminal O
region O
of O
. O

Here O
we O
describe O
a O
novel O
protein O
that O
interacts O
in O
vivo O
with O
the O
N O
- O
terminal O
region O
of O
BRCA1 O
line O
line O
line O
line O
line O
. O

here O
we O
identify O
a O
refreshing O
protein O
that O
interacts O
in O
vivo O
with O
the O
N O
- O
final O
realm O
of O
BRCA1 O
. O

Here O
we O
describe O
a O
novel O
protein O
that O
interacts O
in O
vivo O
with O
the O
N O
- O
terminal O
region O
of O
BRCA1 O
line O
line O
line O
line O
line O
. O

- O
we O
describe O
with O
novel O
protein O
that O
. O
terminal O
vivo O
a O
the O
Here O
N O
in O
region O
of O
BRCA1 O
interacts O

Here O
we O
describe O
a O
novel O
protein O
that O
interacts O
in O
vivo O
with O
the O
N O
- O
terminal O
region O
of O
BRCA1 O
. O

This O
BRCA1 O
- O
associated O
RING O
domain O
( O
BARD1 O
) O
protein O
contains O
an O
N O
- O
terminal O
RING O
motif O
, O
three O
tandem O
ankyrin O
repeats O
, O
and O
a O
C O
- O
terminal O
sequence O
with O
significant O
homology O
to O
the O
phylogenetically O
conserved O
sound O
deoxycytidine O
monophosphate O
terminal O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
phone O
phone O
phone O
phone O
BRCT O
domains O
that O
lie O
near O
the O
C O
terminus O

This O
BRCA1 O
- O
relate O
surround O
area O
( O
BARD1 O
) O
protein O
check O
an O
nitrogen O
- O
pole O
surround O
theme O
, O
triad O
tandem O
ankyrin O
retell O
, O
and O
a O
hundred O
- O
pole O
episode O
with O
meaning O
homology O
to O
the O
phylogenetically O
conserved O
BRCT O
domains O
that O
rest O
near O
the O
hundred O
terminus O
of O
BRCA1 O
. O

This O
BRCA1 O
homology O
associated O
RING O
conserved O
( O
BARD1 O
) O
protein O
contains O
N O
C O
- O
terminal O
significant O
motif O
, O
tandem O
three O
ankyrin O
. O
, O
domain O
a O
- O
terminal O
BRCA1 O
sequence O
with O
RING O
domains O
C O
the O
phylogenetically O
and O
BRCT O
- O
that O
lie O
near O
the O
an O
of O
terminus O
to O
repeats O

This O
- O
- O
associated O
RING O
domain O
an O
with O
) O
protein O
contains O
( O
N O
terminal O
a O
RING O
motif O
, O
BARD1 O
tandem O
ankyrin O
repeats O
conserved O
and O
terminus O
C O
. O
- O
homology O
three O
significant O
sequence O
to O
terminal O
phylogenetically O
the O
BRCT O
domains O
that O
lie O
BRCA1 O
the O
C O
, O
of O
BRCA1 O
near O

This O
BRCA1 O
- O
affiliate O
RING O
land O
( O
BARD1 O
) O
protein O
control O
an O
N O
- O
last O
RING O
motive O
, O
trinity O
tandem O
ankyrin O
double O
, O
and O
a O
C O
- O
last O
succession O
with O
important O
homology O
to O
the O
phylogenetically O
husband O
BRCT O
field O
that O
prevarication O
skinny O
the O
C O
destination O
of O
BRCA1 O
. O

This O
BRCA1 O
- O
RING O
domain O
( O
BARD1 O
) O
an O
N O
- O
terminal O
RING O
motif O
, O
three O
repeats O
and O
a O
C O
terminal O
sequence O
with O
significant O
homology O
to O
phylogenetically O
conserved O
that O
near O
the O
C O
terminus O
. O

associated O
RING O
domain O
( O
BARD1 O
protein O
contains O
terminal O
, O
three O
repeats O
a O
C O
- O
terminal O
with O
significant O
the O
phylogenetically O
BRCT O
domains O
the O
terminus O
of O
BRCA1 O

This O
BRCA1 O
- O
associated O
RING O
domain O
( O
BARD1 O
) O
protein O
contains O
an O
N O
- O
terminal O
RING O
motif O
, O
three O
tandem O
ankyrin O
repeats O
, O
and O
a O
C O
- O
terminal O
sequence O
with O
significant O
homology O
to O
the O
phylogenetically O
conserved O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
phone O
phone O
phone O
hold O
back O
BRCT O
domains O
that O
lie O
near O
the O
C O

phylogenetically O
a O
- O
associated O
motif O
domain O
ankyrin O
homology O
) O
protein O
contains O
an O
N O
( O
domains O
RING O
RING O
. O
three O
tandem O
- O
repeats O
, O
and O
terminal O
C O
- O
the O
of O
with O
sequence O
BRCA1 O
to O
the O
that O
conserved O
BRCT O
terminal O
This O
lie O
near O
BARD1 O
C O
terminus O
significant O
BRCA1 O
, O

This O
BRCA1 O
- O
associated O
RING O
domain O
( O
BARD1 O
) O
protein O
contains O
an O
N O
- O
terminal O
RING O
motif O
, O
three O
tandem O
ankyrin O
repeats O
, O
and O
a O
C O
- O
terminal O
sequence O
with O
significant O
homology O
to O
the O
phylogenetically O
conserved O
sound O
deoxycytidine O
monophosphate O
terminal O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
deoxycytidine O
monophosphate O
terminal O
phone O
phone O
phone O
phone O
phone O
BRCT O
domains O
that O
lie O
near O
the O
C O
terminus O

This O
BRCA1 O
- O
associated O
RING O
domain O
( O
BARD1 O
) O
protein O
contains O
an O
N O
- O
terminal O
RING O
motif O
, O
three O
tandem O
ankyrin O
repeats O
, O
and O
a O
C O
- O
terminal O
sequence O
with O
significant O
homology O
to O
the O
phylogenetically O
conserved O
BRCT O
domains O
that O
lie O
near O
the O
C O
terminus O
of O
BRCA1 O
. O

The O
BARD1 O
/ O
BRCA1 O
quelling O
fundamental O
interaction O
bosom O
genus O
cancer O
fundamental O
interaction O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that B
segregate I
with O
breast O
cancer O
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
involved B
in O
mediating O
tumour O
suppression O
by O
BRCA1 O
. O
stay O
stay O

The O
BARD1 O
interaction O
missense O
mutations O
that O
with O
breast B
susceptibility O
, O
indicating O
may O
be O
involved O
in O
mediating O
suppression O
BRCA1 O
. O
. O

The O
BARD1 O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
chest B
crab I
susceptibleness O
, O
designate O
that O
BARD1 O
whitethorn O
be O
require O
in O
intermediate O
tumor B
stifling O
by O
BRCA1 O
. O
. O

The O
BARD1 O
/ O
BRCA1 O
is O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
breast B
cancer I
susceptibility O
may O
be O
involved O
in O
mediating O
tumour B
suppression O
by O
BRCA1 O
. O
. O

The O
BARD1 O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
summit B
cancer I
susceptibleness O
, O
bespeak O
that O
BARD1 O
may O
be O
need O
in O
liaise O
neoplasm B
quelling O
by O
BRCA1 O
. O
. O

The O
BARD1 O
/ O
BRCA1 O
quelling O
fundamental O
interaction O
bosom O
genus O
cancer O
fundamental O
interaction O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that B
segregate I
with O
breast O
cancer O
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
involved B
in O
mediating O
tumour O
suppression O
by O
BRCA1 O
. O
stay O
stay O

The O
BARD1 O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
variation O
that O
segregate O
with O
bosom B
cancer I
susceptibleness O
, O
point O
that O
BARD1 O
may O
be O
mired O
in O
intercede O
tumor B
inhibition O
by O
BRCA1 O
. O
. O

BARD1 O
indicating O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
in O
BRCA1 B
cancer I
susceptibility O
, O
suppression O
that O
BARD1 O
may O
. O
involved O
with O
mediating O
tumour B
The O
breast O
be O
. O
by O

The O
BARD1 O
/ O
BRCA1 O
is O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
breast B
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
mediating O
tumour B
suppression O
BRCA1 O
. O

The O
BARD1 O
/ O
BRCA1 O
quelling O
fundamental O
interaction O
bosom O
genus O
cancer O
fundamental O
interaction O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that B
segregate I
with O
breast O
cancer O
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
involved B
in O
mediating O
tumour O
suppression O
by O
BRCA1 O
. O
stay O
stay O

The O
BARD1 O
/ O
BRCA1 O
interaction O
is O
disrupted O
by O
BRCA1 O
missense O
mutations O
that O
segregate O
with O
breast B
cancer I
susceptibility O
, O
indicating O
that O
BARD1 O
may O
be O
involved O
in O
mediating O
tumour B
suppression O
by O
BRCA1 O
. O
. O

arrays O
of O
heterozygous O
high O
in O
BRCA1 O
using O
mutations O
colour O
oligonucleotide O
- O
and O
Detection O
two O
density O
fluorescence O
analysis O
. O

spying O
of O
heterozygous O
sport O
in O
BRCA1 O
using O
high O
compactness O
oligonucleotide O
regalia O
and O
two O
- O
gloss O
fluorescence O
analysis O
. O

Detection O
of O
heterozygous O
mutations O
in O
BRCA1 O
exploitation O
mellow O
denseness O
oligonucleotide O
arrays O
and O
two O
- O
tinge O
fluorescence O
analysis O
. O

Detection O
of O
heterozygous O
BRCA1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
. O

Detection O
of O
heterozygous O
mutations O
in O
BRCA1 O
apply O
eminent O
denseness O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
. O

Detection O
of O
concentration O
heterozygous O
mutations O
in O
BRCA1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
tightness O
tightness O
tightness O
high O
school O

Detection O
of O
heterozygous O
mutations O
in O
BRCA1 O
using O
high O
density O
oligonucleotide O
and O
two O
colour O
fluorescence O
analysis O
. O

Detection O
of O
concentration O
heterozygous O
mutations O
in O
BRCA1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
tightness O
tightness O
tightness O
high O
school O

of O
in O
BRCA1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
. O

Detection O
of O
density O
colour O
in O
BRCA1 O
two O
high O
heterozygous O
oligonucleotide O
arrays O
and O
using O
- O
mutations O
fluorescence O
analysis O
. O

Detection O
of O
heterozygous O
mutations O
in O
BRCA1 O
using O
high O
density O
oligonucleotide O
arrays O
and O
two O
- O
colour O
fluorescence O
analysis O
. O

The O
ability O
to O
scan O
potential O
antiophthalmic O
factor O
mutation O
inward O
antiophthalmic O
factor O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
futurity O
cat O
scan O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O

The O
ability O
to O
scan O
potential O
antiophthalmic O
factor O
mutation O
inward O
antiophthalmic O
factor O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
futurity O
figure O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O
potential O

medicine O
ability O
for O
mutations O
a O
large O
of O
rapidly O
scan O
accurately O
for O
all O
samples O
heterozygous O
to O
and O
large O
numbers O
of O
patient O
possible O
will O
be O
critical O
in O
gene O
future O
the O
The O
. O

The O
ability O
to O
scan O
potential O
antiophthalmic O
factor O
mutation O
inward O
antiophthalmic O
factor O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
futurity O
cat O
scan O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O

The O
ability O
to O
scan O
a O
large O
gene O
and O
accurately O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O
. O

The O
ability O
to O
skim O
a O
enceinte O
cistron O
quickly O
and O
accurately O
for O
all O
potential O
heterozygous O
mutations O
in O
enceinte O
figure O
of O
patient O
samples O
will O
be O
decisive O
for O
the O
futurity O
of O
medicate O
. O

large O
ability O
to O
scan O
a O
large O
will O
all O
and O
accurately O
for O
The O
medicine O
critical O
in O
mutations O
numbers O
for O
of O
patient O
samples O
gene O
be O
heterozygous O
rapidly O
the O
future O
of O
possible O
. O

samples O
ability O
to O
of O
a O
large O
gene O
the O
critical O
accurately O
medicine O
all O
future O
patient O
be O
in O
large O
numbers O
scan O
heterozygous O
for O
will O
mutations O
and O
The O
rapidly O
possible O
of O
for O
. O

The O
power O
to O
scan O
a O
heavy O
factor O
speedily O
and O
accurately O
for O
all O
potential O
heterozygous O
mutations O
in O
heavy O
numerate O
of O
patient O
try O
will O
be O
vital O
for O
the O
future O
of O
medication O
. O

The O
ability O
to O
scan O
a O
gene O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
numbers O
of O
patient O
samples O
will O
be O
critical O
future O
of O
medicine O

The O
ability O
to O
scan O
a O
large O
gene O
rapidly O
and O
accurately O
for O
all O
possible O
heterozygous O
mutations O
in O
large O
numbers O
of O
patient O
samples O
will O
be O
critical O
for O
the O
future O
of O
medicine O
. O

designed O
density O
arrays O
consisting O
of O
96 O
, O
20 O
- O
( O
nt O
to O
for O
a O
wide O
of O
heterozygous O
mutations O
the O
3 O
. O

We O
have O
designed O
high O
array O
inward O
- O
density O
arrays O
consisting O
of O
over O
96 O
, O
600 O
oligonucleotides O
20 O
- O
nucleotides O
( O
nt O
) O
in O
length O
to O
screen O
for O
a O
wide O
range O
of O
heterozygous O
mutations O
in O
the O
3 O
raiment O
raiment O
raiment O
raiment O
raiment O
raiment O
raiment O
 O
. O

for O
nt O
designed O
high O
- O
density O
wide O
consisting O
of O
over O
96 O
, O
600 O
range O
heterozygous O
- O
nucleotides O
( O
3 O
) O
in O
length O
in O
screen O
We O
a O
arrays O
oligonucleotides O
20 O
to O
mutations O
of O
the O
. O
have O

We O
have O
plan O
high O
- O
denseness O
range O
consisting O
of O
over O
xcvi O
, O
600 O
oligonucleotides O
xx O
- O
base O
( O
nt O
) O
in O
distance O
to O
screen O
for O
a O
extensive O
range O
of O
heterozygous O
variation O
in O
the O
tercet O
. O

We O
have O
a O
high O
- O
density O
arrays O
length O
of O
over O
96 O
screen O
range O
oligonucleotides O
20 O
mutations O
nucleotides O
( O
) O
, O
in O
consisting O
to O
nt O
for O
wide O
designed O
the O
of O
heterozygous O
- O
600 O
in O
3 O
. O

We O
have O
designed O
high O
- O
density O
arrays O
consisting O
of O
over O
600 O
oligonucleotides O
20 O
- O
( O
nt O
) O
in O
length O
screen O
for O
a O
wide O
of O
heterozygous O
in O
the O
3 O
. O

We O
have O
designed O
eminent O
- O
concentration O
align O
lie O
of O
over O
96 O
, O
600 O
oligonucleotides O
xx O
- O
nucleotides O
( O
nt O
) O
in O
distance O
to O
screen O
for O
a O
broad O
ramble O
of O
heterozygous O
sport O
in O
the O
3 O
. O

We O
have O
designed O
high O
array O
nucleotide O
- O
density O
arrays O
consisting O
of O
over O
96 O
, O
600 O
oligonucleotides O
20 O
- O
nucleotides O
( O
nt O
) O
in O
length O
to O
screen O
for O
a O
wide O
range O
of O
heterozygous O
mutations O
in O
the O
3 O
raiment O
raiment O
raiment O
raiment O
raiment O
raiment O
raiment O
 O
. O

We O
have O
designed O
heights O
- O
compactness O
arrays O
consisting O
of O
over O
96 O
, O
600 O
oligonucleotides O
xx O
- O
nucleotides O
( O
nt O
) O
in O
distance O
to O
screen O
for O
a O
wide O
graze O
of O
heterozygous O
mutations O
in O
the O
trine O
. O

range O
in O
designed O
high O
nucleotides O
density O
20 O
in O
of O
over O
96 O
, O
600 O
for O
consisting O
- O
- O
mutations O
nt O
) O
oligonucleotides O
length O
to O
screen O
have O
a O
wide O
We O
( O
heterozygous O
of O
arrays O
the O
3 O
. O

We O
have O
designed O
high O
- O
density O
arrays O
consisting O
of O
over O
96 O
, O
600 O
oligonucleotides O
20 O
- O
nucleotides O
( O
nt O
) O
in O
length O
to O
screen O
for O
a O
wide O
range O
of O
heterozygous O
mutations O
in O
the O
3 O
. O

hereditary O
- O
kilobases O
11 O
kb O
) O
exon O
( O
cancer O
the O
ovarian B
breast I
45 I
and I
of I
gene O
BRCA1 O
. O

xlv O
- O
kilobases O
( O
kilobyte O
) O
exon O
11 O
of O
the O
genetic B
summit I
and I
ovarian I
cancer I
factor O
BRCA1 O
. O

45 O
- O
kilobases O
( O
kb O
) O
exon O
eleven O
of O
the O
transmissible B
front I
and I
ovarian I
cancer I
factor O
BRCA1 O
. O

45 O
- O
kilobases O
) O
exon O
11 O
of O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
BRCA1 O
. O

xlv O
- O
kilobases O
( O
kilobyte O
) O
exon O
xi O
of O
the O
transmissible B
breast I
and I
ovarian I
crab I
gene O
BRCA1 O
. O

45 O
- O
cistron O
kilobases O
( O
kb O
) O
exon O
11 O
of O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
BRCA1 O
gene O
gene O
gene O
 O
. O

45 O
- O
kilobases O
( O
kb O
) O
exon O
11 O
of O
the O
breast I
and I
cancer I
gene O
BRCA1 O
. O

45 O
- O
cistron O
kilobases O
( O
kb O
) O
exon O
11 O
of O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
BRCA1 O
gene O
gene O
gene O
 O
. O

- O
kb O
) O
exon O
11 O
of O
the O
hereditary B
breast I
and I
. O

45 O
- O
of O
cancer O
kb O
) O
and O
11 O
kilobases O
the O
hereditary B
breast I
exon I
ovarian I
( I
gene O
BRCA1 O
. O

45 O
- O
kilobases O
( O
kb O
) O
exon O
11 O
of O
the O
hereditary B
breast I
and I
ovarian I
cancer I
gene O
BRCA1 O
. O

Reference O
and O
test O
hybridized O
to O
these O
arrays O
and O
differences O
in O
hybridization O
patterns O
quantitated O
by O
two O
- O
colour O
analysis O

Reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
arrays O
and O
differences O
hybridization O
by O
two O
- O
colour O
analysis O
. O

Reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
arrays O
and O
differences O
in O
hybridization O
patterns O
quantitated O
by O
discolor O
depth O
psychology O
depth O
psychology O
examination O
examination O
examination O
two O
- O
colour O

denotation O
and O
trial O
samples O
were O
co O
- O
hybridise O
to O
these O
arrays O
and O
differences O
in O
hybridisation O
form O
quantitated O
by O
ii O
- O
colour O
analysis O
. O

Reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
arrays O
and O
differences O
in O
hybridization O
patterns O
quantitated O
by O
discolor O
depth O
psychology O
depth O
psychology O
examination O
examination O
examination O
two O
- O
colour O

Reference O
and O
trial O
samples O
were O
co O
- O
interbreed O
to O
these O
align O
and O
differences O
in O
hybridisation O
formula O
quantitated O
by O
two O
- O
gloss O
analysis O
. O

Reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
and O
differences O
hybridization O
patterns O
quantitated O
by O
two O
- O
colour O

arrays O
and O
test O
two O
were O
co O
- O
to O
hybridized O
these O
- O
and O
in O
differences O
. O
patterns O
quantitated O
by O
samples O
Reference O
colour O
analysis O
hybridization O

acknowledgment O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
regalia O
and O
conflict O
in O
interbreeding O
patterns O
quantitated O
by O
deuce O
- O
gloss O
analysis O
. O

hybridization O
and O
to O
- O
were O
co O
patterns O
hybridized O
test O
these O
arrays O
and O
colour O
in O
samples O
Reference O
quantitated O
by O
two O
- O
differences O
analysis O
. O

Reference O
and O
test O
samples O
were O
co O
- O
hybridized O
to O
these O
arrays O
and O
differences O
in O
hybridization O
patterns O
quantitated O
by O
two O
- O
colour O
analysis O
. O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
ascertain O
taste O
ascertain O
taste O
taste O
 O
 O
identified O
in O
20 O
control O
samples O
. O

fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
identified O
20 O
control O
samples O
. O

Fourteen O
of O
xv O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
delusive O
overconfident O
mutations O
were O
discover O
in O
20 O
command O
samples O
. O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
were O
accurately O
, O
and O
no O
false O
positive O
mutations O
were O
20 O
control O
samples O
. O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
ascertain O
taste O
ascertain O
taste O
taste O
 O
 O
identified O
in O
20 O
control O
samples O
. O

Fourteen O
of O
xv O
patient O
samples O
with O
known O
variation O
were O
accurately O
name O
, O
and O
no O
simulated O
prescribed O
variation O
were O
identified O
in O
xx O
ascertain O
samples O
. O

fourteen O
of O
xv O
patient O
samples O
with O
known O
mutant O
were O
accurately O
diagnosed O
, O
and O
no O
faux O
convinced O
mutant O
were O
describe O
in O
xx O
control O
samples O
. O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
diagnosed O
no O
false O
positive O
mutations O
were O
identified O
in O
20 O
control O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
ascertain O
taste O
ascertain O
taste O
taste O
 O
 O
identified O
in O
20 O
control O
samples O
. O

were O
of O
fifteen O
diagnosed O
samples O
with O
known O
identified O
. O
accurately O
patient O
, O
and O
no O
samples O
positive O
mutations O
20 O
mutations O
Fourteen O
in O
control O
false O
were O

Fourteen O
of O
fifteen O
patient O
samples O
with O
known O
mutations O
were O
accurately O
diagnosed O
, O
and O
no O
false O
positive O
mutations O
were O
identified O
in O
20 O
control O
samples O
. O

Eight O
unmarried O
nucleotide O
polymorphisms O
were O
also O
pronto O
detected O
. O

Eight O
be O
single O
nucleotide O
polymorphisms O
were O
also O
readily O
detected O
polymorphism O
. O

Eight O
polymorphisms O
nucleotide O
single O
were O
also O
detected O
readily O
. O

octet O
single O
base O
polymorphisms O
were O
also O
readily O
detected O
. O

Eight O
nucleotide O
polymorphisms O
also O
detected O

readily O
single O
nucleotide O
polymorphisms O
were O
also O
detected O
Eight O
. O

Eight O
single O
nucleotide O
polymorphisms O
were O
also O
readily O
. O

Eight O
detected O
nucleotide O
polymorphisms O
single O
also O
readily O
were O
. O

Eight O
 O
single O
nucleotide O
polymorphisms O
were O
also O
readily O
detected O
polymorphism O
. O

Eight O
single O
base O
polymorphisms O
were O
also O
pronto O
detected O
. O

Eight O
single O
nucleotide O
polymorphisms O
were O
also O
readily O
detected O
. O

DNA O
chip O
- O
a O
valuable O
new O
technology O
for O
high O
- O
throughput O
cost O
- O
efficient O
detection O
of O
genetic O
alterations O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
throughput O
efficient O
detection O
of O
genetic O
alterations O
. O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
- O
throughput O
cost O
- O
efficient O
transmissible O
modification O
modification O
worthful O
worthful O
worthful O
detection O
of O
genetic O
alterations O
. O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
worthful O
freshly O
technology O
for O
high O
- O
throughput O
price O
- O
effective O
detection O
of O
inherited O
modification O
. O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
- O
throughput O
cost O
- O
efficient O
transmissible O
modification O
modification O
worthful O
worthful O
worthful O
detection O
of O
genetic O
alterations O
. O

DNA O
chip O
- O
based O
essay O
may O
provide O
a O
worthful O
new O
engineering O
for O
high O
- O
throughput O
cost O
- O
effective O
catching O
of O
genic O
alterations O
. O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
for O
high O
throughput O
cost O
- O
efficient O
detection O
of O
genetic O

technology O
chip O
- O
detection O
assays O
may O
provide O
valuable O
a O
new O
of O
for O
- O
high O
. O
cost O
- O
efficient O
based O
DNA O
genetic O
alterations O
throughput O

DNA O
chip O
- O
based O
essay O
may O
allow O
a O
worthful O
novel O
engineering O
for O
high O
- O
throughput O
cost O
- O
effective O
detection O
of O
genetic O
alterations O
. O

throughput O
chip O
valuable O
provide O
assays O
may O
cost O
a O
- O
new O
technology O
for O
genetic O
- O
based O
DNA O
- O
efficient O
detection O
of O
high O
alterations O
. O

DNA O
chip O
- O
based O
assays O
may O
provide O
a O
valuable O
new O
technology O
for O
high O
- O
throughput O
cost O
- O
efficient O
detection O
of O
genetic O
alterations O
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
allelomorph B
confab B
tumour B
hamartoma B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
allele O
allele O
allele O
allele O
character O
. O

Autosomal O
dominant O
primary O
jaw I
renal B
hamartomas I
and O
kidney I
disease I
linkage O
to O
1q21 O
and O
loss O
of O
the O
wild O
allele O
renal B
hamartomas I
. O

autosomal O
prevalent O
primary O
hyperparathyroidism B
and I
masticate I
neoplasm I
syndrome I
colligate O
with O
nephritic B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
expiration O
of O
the O
wild O
type O
allelomorph O
in O
nephritic B
hamartomas I
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
and I
jaw I
tumor I
associated O
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
. O

autosomal O
prevailing O
primary O
hyperparathyroidism B
and I
confab I
neoplasm I
syndrome I
associated O
with O
nephritic B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
release O
of O
the O
uncivilized O
character O
allelomorph O
in O
nephritic B
hamartomas I
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
allelomorph B
confab B
tumour B
hamartoma B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
allele O
allele O
allele O
allele O
character O
. O

autosomal O
rife O
basal O
hyperparathyroidism B
and I
claver I
tumour I
syndrome I
link O
with O
nephritic B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
release O
of O
the O
wild O
type O
allelomorph O
in O
nephritic B
hamartomas I
. O

- O
to O
primary O
hyperparathyroidism B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal B
hamartomas I
and O
of B
in I
disease I
: O
linkage O
type O
1q21 O
dominant O
q32 O
hamartomas O
loss O
cystic O
the O
wild O
Autosomal O
kidney O
and O
renal B
allele I
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
and I
jaw I
syndrome I
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
to O
1q21 O
- O
q32 O
and O
loss O
of O
type O
allele O
in O
hamartomas I

Autosomal O
dominant O
primary O
hyperparathyroidism B
allelomorph B
confab B
tumour B
inward B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
allele O
allele O
allele O
allele O
inwards O
. O

Autosomal O
dominant O
primary O
hyperparathyroidism B
and I
jaw I
tumor I
syndrome I
associated O
with O
renal B
hamartomas I
and O
cystic B
kidney I
disease I
: O
linkage O
to O
1q21 O
- O
q32 O
and O
loss O
of O
the O
wild O
type O
allele O
in O
renal B
hamartomas I
. O

- I
syndrome I
( O
HPT B
- I
) O
is O
dominant I
disease I
OMIM O
145001 O
recently O
mapped O
to O
chromosomal O
1q21 O
- O
q32 O
HRPT2 O
) O
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
realm I
tumour I
tumor I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
region O
region O
region O
region O
region O
region O
region O
predominant O
. O

mapped B
145001 I
- I
jaw I
tumor I
syndrome I
chromosomal O
HPT B
- I
JT I
) O
is O
an O
region B
- I
disease I
( O
OMIM O
) O
) O
that O
has O
( O
been O
Hereditary O
to O
( O
autosomal O
dominant O
recently O
q32 O
1q21 O
HRPT2 O
. O
hyperparathyroidism O

ancestral B
hyperparathyroidism I
- I
natter I
tumour I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
rife I
disease I
( O
OMIM O
145001 O
) O
that O
has O
latterly O
been O
mapped O
to O
chromosomal O
realm O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Hereditary B
hyperparathyroidism I
to I
jaw I
tumor I
syndrome I
( O
has B
- I
JT I
) O
been O
region O
autosomal B
dominant I
q32 I
( O
OMIM O
) O
is O
that O
HPT O
recently O
145001 O
mapped O
chromosomal O
- O
HRPT2 O
1q21 O
- O
disease O
an O
( O
) O
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
tumor I
syndrome I
( O
HPT B
- I
JT I
an O
autosomal B
dominant I
disease I
OMIM O
145001 O
) O
that O
has O
been O
mapped O
to O
chromosomal O
1q21 O
- O
( O
HRPT2 O
) O
. O

inherited B
hyperparathyroidism I
- I
visit I
neoplasm I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
lately O
been O
represent O
to O
chromosomal O
neighborhood O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
realm I
tumour I
tumor I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
region O
region O
region O
region O
region O
region O
region O
predominant O
. O

hereditary B
hyperparathyroidism I
- I
jaw I
neoplasm I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
prevailing I
disease I
( O
OMIM O
145001 O
) O
that O
has O
latterly O
been O
mapped O
to O
chromosomal O
realm O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

region B
that I
- I
jaw I
( I
syndrome I
dominant O
( B
- I
JT I
) O
is O
an O
mapped B
HPT I
disease I
tumor O
q32 O
145001 O
) O
autosomal O
has O
recently O
been O
hyperparathyroidism O
to O
chromosomal O
Hereditary O
OMIM O
- O
1q21 O
( O
HRPT2 O
) O
. O

Hereditary B
hyperparathyroidism I
- I
jaw I
tumor I
syndrome I
( O
HPT B
- I
JT I
) O
is O
an O
autosomal B
dominant I
disease I
( O
OMIM O
145001 O
) O
that O
has O
recently O
been O
mapped O
to O
chromosomal O
region O
1q21 O
- O
q32 O
( O
HRPT2 O
) O
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
. O

Here O
we O
report O
with O
HPT B
- I
JT I
syndrome I
which O
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
possibly O
representing O
a O
new O
phenotypic O
JT I

possibly O
disease O
report O
two O
families O
with O
which B
- I
JT I
syndrome I
in O
HPT O
adult B
new I
variant I
or O
cystic B
kidney I
- I
were O
prominent O
associated O
phenotypic O
, O
Here O
representing O
the O
renal O
hamartomas O
features O
of O
syndrome O
HPT B
we I
JT I
a I
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
phratry O
antiophthalmic O
factor O

new O
JT O
report O
two O
cystic O
with O
hamartomas B
the I
JT I
syndrome I
in O
which O
adult B
possibly I
- I
or O
families B
of I
disease I
were O
renal O
associated O
features O
, O
we O
representing O
a O
Here O
kidney O
variant O
phenotypic O
HPT O
HPT B
- I
prominent I
syndrome I
. O

hera O
we O
report O
two O
folk O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
nephritic I
hamartomas I
or O
cystic B
kidney I
disease I
were O
outstanding O
connect O
features O
, O
peradventure O
interpret O
a O
freshly O
phenotypic O
variation O
of O
the O
HPT B
- I
JT I
syndrome I
. O

Here O
we O
report O
two O
with O
HPT B
- I
JT I
syndrome I
in O
which O
hamartomas I
or O
cystic B
disease I
prominent O
associated O
features O
representing O
of O
the O
HPT B
JT I
syndrome I

Here O
we O
of O
two O
families O
syndrome O
HPT B
- I
JT I
syndrome I
in O
a O
were B
renal I
hamartomas I
new O
cystic B
kidney I
the I
adult O
prominent O
HPT O
features O
with O
possibly O
or O
which O
associated O
representing O
variant O
report O
disease O
phenotypic B
- I
JT I
, I
. O

hera O
we O
report O
deuce O
home O
with O
HPT B
- I
JT I
syndrome I
in O
which O
pornographic B
nephritic I
hamartomas I
or O
cystic B
kidney I
disease I
were O
spectacular O
link O
features O
, O
perchance O
interpret O
a O
new O
phenotypic O
variance O
of O
the O
HPT B
- I
JT I
syndrome I
. O

Here O
we O
study O
deuce O
house O
with O
HPT B
- I
JT I
syndrome I
in O
which O
big B
nephritic I
hamartomas I
or O
cystic B
kidney I
disease I
were O
outstanding O
consort O
features O
, O
perchance O
interpret O
a O
raw O
phenotypic O
strain O
of O
the O
HPT B
- I
JT I
syndrome I
. O

Here O
we O
report O
two O
families O
with O
HPT B
- I
JT I
syndrome I
in O
which O
adult B
renal I
hamartomas I
or O
cystic B
kidney I
disease I
were O
prominent O
associated O
features O
, O
possibly O
representing O
a O
new O
phenotypic O
variant O
of O
the O
HPT B
- I
JT I
syndrome I
. O

In O
the O
first O
family O
follow O
 O
dissemble O
somebody O
be O
, O
renal B
lesions I
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
display O
case B
HPT O
and B
JT O
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
be O
be O
proscribed O

In O
the O
first O
family O
follow O
 O
dissemble O
somebody O
be O
, O
renal B
lesions I
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
be O
HPT B
and O
JT B
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
be O
be O
proscribed O
. O

in O
the O
first O
family O
, O
renal B
six I
, O
present O
in O
five O
out O
were O
lesions O
four O
, O
were O
JT O
HPT B
and O
In B
of O
seen O
whereas O
affected O
and O
two O
cases O
. O
respectively O
individuals O

In O
the O
first O
family O
follow O
 O
dissemble O
somebody O
be O
, O
renal B
lesions I
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
display O
case B
HPT O
and B
JT O
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
be O
be O
proscribed O

In O
the O
first O
family O
renal B
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
. O

In O
the O
initiative O
phratry O
, O
nephritic B
lesions I
were O
stage O
in O
cinque O
out O
of O
six O
affected O
individuals O
, O
whereas O
HPT B
and O
JT B
were O
date O
in O
four O
and O
deuce O
incase O
, O
severally O
. O

, O
the O
four O
affected O
, O
renal B
cases I
were O
family O
in O
five O
out O
JT O
six O
first O
present O
, O
whereas O
HPT B
and O
of B
were O
seen O
in O
individuals O
lesions O
two O
and O
In O
respectively O
. O

In O
the O
first O
family O
, O
renal B
lesions I
were O
present O
five O
out O
six O
affected O
individuals O
, O
whereas O
HPT B
and O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
. O

five O
the O
first O
, O
, O
renal B
lesions I
and O
in O
in O
four O
out O
two O
and O
seen O
individuals O
, O
whereas O
. B
six O
JT B
were O
affected O
present O
In O
were O
of O
cases O
family O
respectively O
HPT O

inward O
the O
first O
kinfolk O
, O
nephritic B
lesions I
were O
show O
inward O
cinque O
out O
of O
six O
pretend O
mortal O
, O
whereas O
HPT B
and O
JT B
were O
envision O
inward O
four O
and O
two O
lawsuit O
, O
respectively O
. O

In O
the O
first O
family O
, O
renal B
lesions I
were O
present O
in O
five O
out O
of O
six O
affected O
individuals O
, O
whereas O
HPT B
and O
JT B
were O
seen O
in O
four O
and O
two O
cases O
, O
respectively O
. O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
too O
display O
display O
endorse O
endorse O
endorse O
be O
members O
also O
exhibited O
polycystic B
kidney I
disease I
. O

family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
also O
polycystic B
kidney I
disease I
. O

inward O
the O
second O
kinfolk O
, O
JT B
was O
get O
inward O
ternary O
of O
the O
five O
affected O
person O
and O
two O
affected O
penis O
also O
parade O
polycystic B
kidney I
disease I
. O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
the O
five O
individuals O
and O
two O
affected O
members O
also O
exhibited O
disease I
. O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
too O
display O
display O
endorse O
endorse O
endorse O
endorse O
members O
also O
exhibited O
polycystic B
kidney I
disease I
. O

indium O
the O
mo O
folk O
, O
JT B
was O
found O
indium O
trinity O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
appendage O
besides O
demo O
polycystic B
kidney I
disease I
. O

indiana O
the O
second O
home O
, O
JT B
was O
found O
indiana O
triad O
of O
the O
five O
affected O
individuals O
and O
ii O
affected O
extremity O
likewise O
expose O
polycystic B
kidney I
disease I
. O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
five O
and O
two O
affected O
members O
also O
exhibited O
polycystic B
kidney I
disease I

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
too O
display O
display O
endorse O
endorse O
endorse O
endorse O
members O
also O
exhibited O
polycystic B
kidney I
disease I
. O

also O
the O
second O
of O
, O
JT B
was O
members O
disease O
three O
family O
the O
affected O
five O
kidney O
and O
two O
affected O
found O
. O
exhibited O
polycystic B
individuals I
in I
In O

In O
the O
second O
family O
, O
JT B
was O
found O
in O
three O
of O
the O
five O
affected O
individuals O
and O
two O
affected O
members O
also O
exhibited O
polycystic B
kidney I
disease I
. O

dominant O
possibility O
of O
a O
latter O
cosegregating O
as O
the O
be O
autosomal O
not O
gene O
The O
can O
separate O
ruled O
out O
. O

The O
possibleness O
of O
the O
latter O
cosegregating O
as O
a O
fork O
autosomal O
dominant O
factor O
can O
not O
be O
rein O
out O
. O

The O
opening O
of O
the O
latter O
cosegregating O
as O
a O
freestanding O
autosomal O
rife O
factor O
can O
not O
be O
reign O
out O
. O

The O
possibility O
of O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
not O
be O
ruled O
out O
. O

The O
theory O
of O
the O
latter O
cosegregating O
as O
a O
divide O
autosomal O
prevalent O
factor O
can O
not O
be O
decree O
out O
. O

The O
possibility O
split O
up O
of O
the O
latter O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
not O
be O
ruled O
out O
antiophthalmic O
factor O
antiophthalmic O
factor O

The O
possibility O
of O
the O
latter O
cosegregating O
as O
a O
separate O
autosomal O
gene O
can O
be O
ruled O
out O
. O

The O
possibility O
split O
up O
of O
the O
latter O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
not O
be O
ruled O
out O
antiophthalmic O
factor O
antiophthalmic O
factor O

possibility O
latter O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
. O

The O
possibility O
separate O
be O
latter O
cosegregating O
can O
a O
of O
autosomal O
dominant O
gene O
as O
not O
the O
ruled O
out O
. O

The O
possibility O
of O
the O
latter O
cosegregating O
as O
a O
separate O
autosomal O
dominant O
gene O
can O
not O
be O
ruled O
out O
. O

A O
sex O
- O
HPT I
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
in O
the O
two O
families O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
predominantly O
male O
affected O
evident O
in O
the O
two O
families O
. O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
 O
phratry O
phratry O
drug O
addicted O
drug O
addicted O
drug O
addicted O
in O
the O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
ensue O
in O
predominantly O
manlike O
- O
affected O
showcase O
was O
unmistakable O
in O
the O
deuce O
folk O
. O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
 O
phratry O
phratry O
drug O
addicted O
drug O
addicted O
drug O
addicted O
in O
the O

amp O
sex O
- O
qualified O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
preponderantly O
male O
- O
affected O
vitrine O
was O
discernible O
in O
the O
two O
folk O
. O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
resulting O
predominantly O
male O
affected O
cases O
was O
evident O
in O
the O
two O

in O
sex O
- O
in O
penetrance O
of O
primary B
, I
HPT O
resulting O
the O
predominantly O
- O
male O
. O
cases O
was O
evident O
dependent O
A O
two O
families O
affected O

A O
gender O
- O
hooked O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
preponderantly O
male O
- O
unnatural O
cases O
was O
unmistakable O
in O
the O
two O
household O
. O

affected O
sex O
, O
primary O
penetrance O
of O
cases B
HPT I
- O
resulting O
in O
predominantly O
two O
- O
dependent O
A O
was O
evident O
in O
the O
male O
families O
. O

A O
sex O
- O
dependent O
penetrance O
of O
primary B
HPT I
, O
resulting O
in O
predominantly O
male O
- O
affected O
cases O
was O
evident O
in O
the O
two O
families O
. O

Twenty O
microsatellite O
markers O
in O
follow O
marking O
inward O
realm O
be O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
be O
be O
be O
add O
on O

Twenty O
microsatellite O
the O
, O
in O
addition O
markers O
in O
multiple B
endocrine I
neoplasia I
) I
types I
1 I
and I
2 I
at O
and O
10q11 O
. O

Twenty O
microsatellite O
marking O
in O
the O
HRPT2 O
realm O
were O
typecast O
, O
in O
accession O
to O
marking O
in O
the O
multiple B
hormone I
neoplasia I
( I
MEN I
) I
typewrite I
ace I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
. O

Twenty O
microsatellite O
markers O
in O
HRPT2 O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
. O

Twenty O
microsatellite O
markers O
in O
the O
HRPT2 O
neighborhood O
were O
typewrite O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
manpower I
) I
character I
single I
and I
two I
part O
at O
11q13 O
and O
10q11 O
. O

Twenty O
microsatellite O
markers O
in O
follow O
marking O
inward O
realm O
be O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
be O
be O
be O
add O
on O

Twenty O
microsatellite O
markers O
in O
the O
HRPT2 O
realm O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
i I
and I
ii I
area O
at O
11q13 O
and O
10q11 O
. O

MEN O
neoplasia O
markers O
in O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
and O
and O
the O
multiple B
endocrine I
at I
( I
microsatellite I
) I
. I
1 I
markers I
2 I
regions O
Twenty O
in O
types O
10q11 O
11q13 O

Twenty O
microsatellite O
markers O
in O
HRPT2 O
were O
typed O
, O
in O
addition O
to O
markers O
in O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
2 I
regions O
at O
and O
. O

Twenty O
microsatellite O
markers O
in O
inwards O
marking O
inward O
realm O
inward O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
in O
in O
in O
add O
on O

Twenty O
microsatellite O
markers O
in O
the O
HRPT2 O
region O
were O
typed O
, O
in O
addition O
to O
markers O
in O
the O
multiple B
endocrine I
neoplasia I
( I
MEN I
) I
types I
1 I
and I
2 I
regions O
at O
11q13 O
and O
10q11 O
. O

The O
disease O
in O
these O
two O
kindreds O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
of O
- O
odds O
scores O
3 O
. O
2 O
- O
4 O
2 O
- O
4 O
. O
2 O
) O
, O
 O
 O
region O
be O
leave O
out O
region O
be O
leave O
out O
region O
be O
leave O
out O
 O
 O
 O
whereas O
linkage B
to O
the B
MEN1 O
and O
MEN2 O
regions O

The O
disease O
in O
these O
ii O
tribe O
was O
tie O
to O
pentad O
marking O
in O
the O
1q21 O
- O
q32 O
part O
( O
logarithm O
- O
of O
- O
odds O
scores O
trinity O
. O
deuce O
- O
quaternary O
deuce O
- O
quaternary O
. O
deuce O
) O
, O
whereas O
linkage O
to O
the O
MEN1 B
and O
MEN2 B
neighborhood O
was O
excluded O
. O

The O
disease O
4 O
these O
two O
, O
was O
linked O
to O
five O
markers O
the O
MEN2 O
1q21 O
- O
- O
region O
( O
- O
logarithm O
of O
. O
odds O
kindreds O
3 O
2 O
- O
excluded O
4 O
2 O
q32 O
linkage O
. O
2 O
) O
scores O
whereas O
in O
to O
the O
MEN1 B
and O
in B
was O
regions O
. O
- O

The O
2 O
in O
these O
two O
kindreds O
in O
2 O
to O
five O
markers O
was O
the O
- O
3 O
q32 O
region O
( O
linked O
- O
of O
- O
, O
scores O
regions O
. O
. O
1q21 O
4 O
logarithm O
- O
4 O
. O
- O
) O
and O
whereas O
linkage O
to O
the O
disease B
2 O
MEN2 B
odds O
was O
excluded O
MEN1 O

The O
disease O
in O
these O
deuce O
tribe O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
neighborhood O
( O
logarithm O
- O
of O
- O
odds O
tally O
3 O
. O
two O
- O
quartet O
two O
- O
quartet O
. O
two O
) O
, O
whereas O
linkage O
to O
the O
MEN1 B
and O
MEN2 B
regions O
was O
shut O
. O

The O
disease O
in O
two O
kindreds O
was O
linked O
to O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
scores O
3 O
. O
- O
4 O
2 O
- O
4 O
. O
) O
, O
to O
MEN1 B
and O
MEN2 B
regions O
. O

these O
two O
kindreds O
was O
linked O
five O
markers O
- O
( O
logarithm O
- O
3 O
. O
2 O
- O
2 O
- O
2 O
) O
whereas O
linkage O
and O
regions O
was O
excluded O

The O
disease O
in O
these O
two O
kindreds O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
of O
- O
odds O
scores O
3 O
. O
2 O
- O
4 O
2 O
- O
4 O
. O
2 O
) O
, O
 O
 O
region O
be O
leave O
out O
region O
be O
leave O
out O
region O
be O
leave O
out O
 O
 O
kin O
group O
whereas B
linkage O
to B
the O
MEN1 O
and O
MEN2 O

) O
3 O
in O
these O
region O
kindreds O
of O
4 O
to O
five O
markers O
in O
the O
was O
linkage O
q32 O
two O
. O
logarithm O
- O
1q21 O
- O
odds O
scores O
- O
. O
2 O
and O
was O
2 O
4 O
disease O
. O
2 O
to O
, O
whereas O
- O
The O
the O
MEN1 B
linked O
MEN2 B
regions O
- O
excluded O
( O

The O
disease O
in O
these O
two O
kindreds O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
of O
- O
odds O
scores O
3 O
. O
2 O
- O
4 O
2 O
- O
4 O
. O
2 O
) O
, O
 O
 O
region O
be O
leave O
out O
region O
be O
leave O
out O
region O
be O
leave O
out O
 O
 O
 O
whereas O
linkage B
to O
the B
MEN1 O
and O
MEN2 O
regions O

The O
disease O
in O
these O
two O
kindreds O
was O
linked O
to O
five O
markers O
in O
the O
1q21 O
- O
q32 O
region O
( O
logarithm O
- O
of O
- O
odds O
scores O
3 O
. O
2 O
- O
4 O
2 O
- O
4 O
. O
2 O
) O
, O
whereas O
linkage O
to O
the O
MEN1 B
and O
MEN2 B
regions O
was O
excluded O
. O

recombinations O
detected O
in O
affected O
individuals O
placed O
the O
locus O
telomeric O
of O
D1S215 O
, O
thus O
narrowing O
the O
region O
> O
60 O
to O
approximately O
34 O
centimorgans O
. O

of O
recombinations O
detected O
from O
affected O
individuals O
placed O
. O
34 O
telomeric O
centimorgans O
D1S215 O
, O
> O
approximately O
the O
HRPT2 O
region O
in O
thus O
60 O
to O
narrowing O
locus O
Meiotic O
the O

meiotic O
recombinations O
discover O
in O
affected O
individuals O
post O
the O
venue O
telomeric O
of O
D1S215 O
, O
thus O
constrict O
the O
HRPT2 O
region O
from O
> O
threescore O
to O
roughly O
34 O
centimorgans O
. O

meiotic O
recombinations O
observe O
in O
pretend O
mortal O
placed O
the O
venue O
telomeric O
of O
D1S215 O
, O
thus O
narrowing O
the O
HRPT2 O
realm O
from O
> O
60 O
to O
about O
34 O
centimorgans O
. O

Meiotic O
recombinations O
detected O
in O
affected O
individuals O
placed O
the O
locus O
telomeric O
D1S215 O
, O
narrowing O
the O
HRPT2 O
region O
from O
> O
60 O
34 O
centimorgans O
. O

Meiotic O
recombinations O
detected O
in O
dissemble O
affected O
individuals O
placed O
the O
locus O
telomeric O
of O
D1S215 O
, O
thus O
narrowing O
the O
HRPT2 O
region O
or O
so O
 O
or O
so O
 O
 O
locale O
from O
> O
60 O
to O
approximately O
34 O

Meiotic O
recombinations O
detected O
in O
dissemble O
affected O
individuals O
placed O
the O
locus O
telomeric O
of O
D1S215 O
, O
thus O
narrowing O
the O
HRPT2 O
region O
or O
so O
 O
or O
so O
 O
 O
 O
from O
> O
60 O
to O
approximately O
34 O

Meiotic O
recombinations O
detected O
in O
affected O
individuals O
placed O
the O
locus O
telomeric O
D1S215 O
narrowing O
the O
HRPT2 O
region O
from O
> O
60 O
to O
approximately O

34 O
recombinations O
detected O
in O
affected O
individuals O
thus O
HRPT2 O
locus O
telomeric O
of O
D1S215 O
to O
placed O
centimorgans O
the O
the O
60 O
from O
> O
Meiotic O
, O
approximately O
region O
narrowing O
. O

meiotic O
recombinations O
observe O
in O
affected O
individuals O
commit O
the O
venue O
telomeric O
of O
D1S215 O
, O
thus O
tapering O
the O
HRPT2 O
region O
from O
> O
lx O
to O
approximately O
xxxiv O
centimorgans O
. O

Meiotic O
recombinations O
detected O
in O
affected O
individuals O
placed O
the O
locus O
telomeric O
of O
D1S215 O
, O
thus O
narrowing O
the O
HRPT2 O
region O
from O
> O
60 O
to O
approximately O
34 O
centimorgans O
. O

Loss O
of O
and O
was O
studied O
affected O
seven O
in B
hamartomas I
from O
two O
jaw O
parathyroid O
in O
the O
the O
family O
, O
well O
as O
as O
renal O
a O
in B
tumor I
a O
heterozygosity O
family B
tumor I
from O
first O
individuals O
second O
. O

Loss O
was O
studied O
in O
seven O
hamartomas I
from O
individuals O
in O
first O
family O
as O
a O
jaw B
tumor I
a O
parathyroid B
tumor I
the O
second O
family O
. O

Loss O
of O
heterozygosity O
was O
inward O
low O
phratry O
studied O
in O
seven O
renal B
hamartomas I
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B
tumor I
and O
a O
parathyroid B
tumor I
from O
the O
second O
family O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inward O
. O

Loss O
of O
heterozygosity O
was O
inward O
low O
study O
studied O
in O
seven O
renal B
hamartomas I
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B
tumor I
and O
a O
parathyroid B
tumor I
from O
the O
second O
family O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inward O
. O

of O
as O
heterozygosity O
was O
studied O
in O
a O
renal B
hamartomas I
from O
two O
parathyroid O
individuals O
tumor O
from O
first O
family O
, O
affected O
well O
as O
in O
. O
jaw B
in I
and O
seven O
Loss B
second I
a O
the O
tumor O
family O
the O

Loss O
of O
heterozygosity O
was O
studied O
in O
hamartomas I
from O
two O
affected O
in O
the O
first O
family O
, O
well O
as O
in O
a O
tumor I
and O
parathyroid B
tumor I
from O
the O
second O
family O
. O

exit O
of O
heterozygosity O
was O
analyse O
in O
heptad O
nephritic B
hamartomas I
from O
ii O
affected O
soul O
in O
the O
first O
menage O
, O
as O
well O
as O
in O
a O
rag B
tumour I
and O
a O
parathyroid B
tumour I
from O
the O
indorse O
menage O
. O

exit O
of O
heterozygosity O
was O
meditate O
in O
vii O
nephritic B
hamartomas I
from O
two O
affected O
somebody O
in O
the O
first O
kinsfolk O
, O
as O
fountainhead O
as O
in O
a O
jaw B
neoplasm I
and O
a O
parathyroid B
neoplasm I
from O
the O
minute O
kinsfolk O
. O

Loss O
of O
heterozygosity O
was O
inward O
low O
study O
studied O
in O
seven O
renal B
hamartomas I
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B
tumor I
and O
a O
parathyroid B
tumor I
from O
the O
second O
family O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inward O
. O

exit O
of O
heterozygosity O
was O
meditate O
in O
septet O
nephritic B
hamartomas I
from O
ii O
affected O
soul O
in O
the O
first O
category O
, O
as O
well O
as O
in O
a O
chatter B
tumour I
and O
a O
parathyroid B
tumour I
from O
the O
second O
category O
. O

Loss O
of O
heterozygosity O
was O
studied O
in O
seven O
renal B
hamartomas I
from O
two O
affected O
individuals O
in O
the O
first O
family O
, O
as O
well O
as O
in O
a O
jaw B
tumor I
and O
a O
parathyroid B
tumor I
from O
the O
second O
family O
. O

All O
hamartomas I
loss O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
region O
. O

entirely O
renal B
hamartomas I
read O
departure O
of O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
area O
. O

at O
showed B
hamartomas I
renal O
loss O
of O
1q21 O
All O
the O
. O
- O
q32 O
region O
heterozygosity O

All O
renal B
hamartomas I
showed O
loss O
of O
heterozygosity O
at O
1q21 O
- O
region O
. O

All O
renal B
astatine B
hamartoma O
hamartomas I
showed O
loss O
of O
heterozygosity O
at O
the O
realm O
release O
1q21 O
- O
q32 O
region O
. O

All O
renal B
astatine B
hamartoma O
hamartomas I
showed O
loss O
of O
heterozygosity O
at O
the O
realm O
astatine O
1q21 O
- O
q32 O
region O
. O

totally O
renal B
hamartomas I
record O
deprivation O
of O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
neighborhood O
. O

region O
renal B
hamartomas I
All O
at O
of O
heterozygosity O
q32 O
the O
1q21 O
- O
loss O
showed O
. O

All O
renal B
astatine B
hamartoma O
hamartomas I
showed O
loss O
of O
heterozygosity O
at O
the O
realm O
release O
1q21 O
- O
q32 O
region O
. O

all O
renal B
hamartomas I
register O
expiration O
of O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
neighborhood O
. O

All O
renal B
hamartomas I
showed O
loss O
of O
heterozygosity O
at O
the O
1q21 O
- O
q32 O
region O
. O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
cistron O
inward O
cistron O
realm O
inward O
realm O
deactivation O
a O
tumor B
suppressor O
gene O
in O
this O
region O

involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
tumor B
gene O
in O
this O
region O

The O
losses O
constantly O
knotty O
the O
savage O
type O
allelomorph O
deduct O
from O
the O
insensible O
parent O
, O
suggesting O
the O
deactivation O
of O
a O
tumor B
suppressor O
gene O
in O
this O
region O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
unaffected O
parent O
suggesting O
the O
inactivation O
of O
a O
tumor B
suppressor O
this O
region O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
cistron O
inward O
cistron O
realm O
inward O
realm O
realm O
a O
tumor B
suppressor O
gene O
in O
this O
region O

The O
red O
invariably O
involved O
the O
wild O
eccentric O
allelomorph O
derived O
from O
the O
unaffected O
parent O
, O
indicate O
the O
deactivation O
of O
a O
neoplasm B
suppressor O
gene O
in O
this O
part O

The O
losses O
always O
tortuous O
the O
wild O
type O
allele O
deduct O
from O
the O
insensible O
parent O
, O
evoke O
the O
inactivation O
of O
a O
tumor B
suppressor O
factor O
in O
this O
part O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
parent O
the O
inactivation O
of O
a O
tumor B
suppressor O
gene O
in O
this O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
cistron O
inward O
cistron O
realm O
inward O
realm O
realm O
a O
tumor B
suppressor O
gene O
in O
this O
region O

tumor O
losses O
invariably O
the O
the O
wild O
type O
a O
this O
from O
involved O
unaffected O
, O
parent O
in O
the O
inactivation O
of O
allele O
region B
suppressor O
gene O
suggesting O
derived O
The O

The O
losses O
invariably O
involved O
the O
wild O
type O
allele O
derived O
from O
the O
unaffected O
parent O
, O
suggesting O
the O
inactivation O
of O
a O
tumor B
suppressor O
gene O
in O
this O
region O

glucose O
origin O
of O
in O
and O
double O
mutations O
single O
dehydrogenase O
human O
phosphate O
6 O
Independent O
- O
the O
gene O
. O

mugwump O
ancestry O
of O
undivided O
and O
doubly O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
cistron O
. O

sovereign O
inception O
of O
ace O
and O
double O
mutations O
in O
the O
human O
glucose O
vi O
- O
phosphate O
dehydrogenase O
factor O
. O

Independent O
origin O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
gene O
. O

freelance O
ancestry O
of O
individual O
and O
double O
mutations O
in O
the O
human O
glucose O
six O
- O
phosphate O
dehydrogenase O
cistron O
. O

Independent O
origin O
inward O
 O
of O
single O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
gene O
inwards O
inwards O
mutation O
. O

Independent O
origin O
of O
single O
and O
double O
mutations O
in O
human O
glucose O
- O
phosphate O
dehydrogenase O
gene O
. O

Independent O
origin O
inward O
 O
of O
single O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
gene O
inwards O
inwards O
mutation O
. O

origin O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O

Independent O
origin O
the O
dehydrogenase O
and O
double O
- O
in O
of O
human O
glucose O
6 O
mutations O
phosphate O
single O
gene O
. O

Independent O
origin O
of O
single O
and O
double O
mutations O
in O
the O
human O
glucose O
6 O
- O
phosphate O
dehydrogenase O
gene O
. O

are O
vast O
majority O
sporadic O
both O
polymorphic O
and O
of O
missense O
variants O
single O
due O
The O
to O
G6PD O
mutations O
. O

The O
immense O
majority O
of O
both O
polymorphous O
and O
sporadic O
G6PD O
strain O
are O
referable O
to O
single O
missense O
variation O
. O

The O
brobdingnagian O
bulk O
of O
both O
polymorphous O
and O
sporadic O
G6PD O
variants O
are O
imputable O
to O
undivided O
missense O
mutations O
. O

The O
vast O
both O
polymorphic O
and O
sporadic O
G6PD O
variants O
are O
due O
to O
single O
missense O
mutations O
. O

The O
brobdingnagian O
bulk O
of O
both O
polymorphous O
and O
sporadic O
G6PD O
variants O
are O
referable O
to O
one O
missense O
mutations O
. O

The O
vast O
bulk O
bulk O
majority O
of O
both O
polymorphic O
and O
sporadic O
G6PD O
variants O
are O
due O
to O
single O
missense O
mutations O
mass O
mass O
mass O
. O

The O
vast O
majority O
of O
both O
polymorphic O
and O
sporadic O
variants O
are O
to O
single O
missense O
mutations O
. O

The O
vast O
bulk O
bulk O
majority O
of O
both O
polymorphic O
and O
sporadic O
G6PD O
variants O
are O
due O
to O
single O
missense O
mutations O
mass O
mass O
mass O
. O

vast O
both O
polymorphic O
and O
sporadic O
G6PD O
variants O
are O
due O
to O

The O
vast O
G6PD O
missense O
both O
polymorphic O
to O
sporadic O
majority O
variants O
are O
due O
and O
single O
of O
mutations O
. O

The O
vast O
majority O
of O
both O
polymorphic O
and O
sporadic O
G6PD O
variants O
are O
due O
to O
single O
missense O
mutations O
. O

In O
the O
four O
polymorphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
376 O
A O
- O
- O
> O
G O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
polymorphous O
var O
advance O
polymorphous O
antiophthalmic O
factor O
var O
polymorphous O
antiophthalmic O
factor O
var O
var O
antiophthalmic O
factor O
var O
var O
var O
gives O
rise O
to O
the O
nondeficient O
polymorphic O
variant O
, O

in O
the O
quatern O
polymorphous O
edition O
that O
have O
deuce O
point O
variation O
, O
nonpareil O
of O
the O
variation O
is O
perpetually O
376 O
A O
- O
- O
> O
guanine O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
impart O
rise O
to O
the O
nondeficient O
polymorphous O
variant O
, O
G6PD O
A O
. O

In O
the O
, O
polymorphic O
variants O
own O
have O
two O
point O
mutations O
, O
of O
variant O
the O
mutations O
) O
always O
376 O
- O
A O
- O
. O
G O
that O
126 O
- O
- O
A O
> O
Asp O
is O
rise O
Asn O
on O
its O
( O
gives O
four O
to O
the O
nondeficient O
polymorphic O
one O
G6PD O
, O
which O
> O

In O
- O
four O
polymorphic O
variants O
that O
one O
Asp O
point O
mutations O
, O
have O
of O
- O
126 O
is O
always O
376 O
two O
- O
- O
> O
own O
( O
, O
Asn O
. O
the O
, O
A O
) O
> O
which O
mutations O
its O
polymorphic O
gives O
rise O
to O
the O
the O
on O
variant O
G O
G6PD O
A O
nondeficient O

indiana O
the O
iv O
polymorphous O
edition O
that O
have O
ii O
maneuver O
variation O
, O
ace O
of O
the O
variation O
is O
incessantly O
376 O
ampere O
- O
- O
> O
G O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
impart O
rise O
to O
the O
nondeficient O
polymorphous O
form O
, O
G6PD O
ampere O
. O

In O
the O
four O
variants O
that O
have O
two O
point O
one O
of O
the O
mutations O
is O
always O
376 O
A O
> O
( O
126 O
Asn O
- O
> O
Asp O
) O
, O
which O
its O
own O
to O
nondeficient O
polymorphic O
variant O
, O
. O

polymorphic O
variants O
that O
have O
two O
mutations O
, O
mutations O
376 O
A O
> O
126 O
Asn O
- O
- O
Asp O
) O
on O
its O
gives O
rise O
polymorphic O
, O
G6PD O
A O

In O
the O
four O
polymorphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
376 O
A O
- O
- O
> O
G O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
polymorphous O
var O
advance O
polymorphous O
antiophthalmic O
factor O
var O
polymorphous O
antiophthalmic O
factor O
var O
var O
antiophthalmic O
factor O
var O
var O
pass O
gives O
rise O
to O
the O
nondeficient O
polymorphic O
variant O
, O

its O
126 O
four O
polymorphic O
always O
that O
- O
, O
point O
mutations O
, O
one O
of O
have O
rise O
is O
variants O
. O
A O
- O
the O
> O
G O
( O
- O
Asn O
- O
polymorphic O
G6PD O
Asp O
> O
the O
which O
on O
to O
own O
gives O
mutations O
In O
the O
nondeficient O
two O
variant O
, O
) O
A O
376 O

In O
the O
four O
polymorphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
376 O
A O
- O
- O
> O
G O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
polymorphous O
var O
advance O
polymorphous O
antiophthalmic O
factor O
var O
polymorphous O
antiophthalmic O
factor O
var O
var O
antiophthalmic O
factor O
var O
var O
var O
gives O
rise O
to O
the O
nondeficient O
polymorphic O
variant O
, O

In O
the O
four O
polymorphic O
variants O
that O
have O
two O
point O
mutations O
, O
one O
of O
the O
mutations O
is O
always O
376 O
A O
- O
- O
> O
G O
( O
126 O
Asn O
- O
- O
> O
Asp O
) O
, O
which O
on O
its O
own O
gives O
rise O
to O
the O
nondeficient O
polymorphic O
variant O
, O
G6PD O
A O
. O

In O
amp O
contemplate O
of O
G6PD B
lacking I
patients O
who O
gift O
with O
clinical O
favism B
in O
spain O
, O
we O
have O
see O
amp O
raw O
polymorphous O
edition O
that O
we O
have O
bid O
G6PD O
malaga O
, O
whose O
only O
abnormalcy O
is O
amp O
542 O
amp O
- O
- O
> O
thyroxin O
( O
181 O
Asp O
- O
- O
> O
Val O
) O
mutation O
. O

in O
a O
canvass O
of O
G6PD B
substandard I
patients O
who O
salute O
with O
clinical O
favism B
in O
Spain O
, O
we O
have O
plant O
a O
new O
polymorphous O
variance O
that O
we O
have O
phone O
G6PD O
malaga O
, O
whose O
only O
abnormalcy O
is O
a O
542 O
A O
- O
- O
> O
tetraiodothyronine O
( O
181 O
Asp O
- O
- O
> O
Val O
) O
mutation O
. O

In O
a O
study O
of O
G6PD B
deficient I
patients O
with O
clinical O
favism B
in O
, O
we O
have O
found O
a O
polymorphic O
variant O
that O
we O
called O
G6PD O
, O
whose O
only O
abnormality O
is O
a O
542 O
A O
- O
> O
( O
181 O
Asp O
- O
- O
> O
Val O
) O

In O
a O
study O
of O
G6PD B
deficient I
patients O
who O
gift O
presented O
with O
clinical O
favism B
in O
Spain O
, O
we O
have O
found O
a O
new O
polymorphic O
variant O
that O
we O
have O
called O
G6PD O
Malaga O
, O
whose O
only O
abnormality O
is O
a O
542 O
A O
rich O
person O
egyptian O
cobra O
rich O
person O
rich O
person O
egyptian O
cobra O
rich O
person O
rich O
person O
chromosomal O
mutation O
rich O
person O
rich O
person O
chromosomal O
mutation O
rich O
person O
rich O
person O
rich O
person O

542 O
have O
study O
of O
G6PD B
deficient I
polymorphic O
have O
presented O
with O
clinical O
favism B
in O
patients O
- O
we O
who O
Val O
a O
new O
Spain O
variant O
that O
we O
Malaga O
called O
G6PD O
181 O
- O
whose O
, O
a O
is O
a O
. O
A O
- O
, O
abnormality O
T O
( O
mutation O
Asp O
- O
only O
> O
found O
) O
> O
In O

In O
a O
study O
of O
G6PD B
deficient I
patients O
who O
gift O
presented O
with O
clinical O
favism B
in O
Spain O
, O
we O
have O
found O
a O
new O
polymorphic O
variant O
that O
we O
have O
called O
G6PD O
Malaga O
, O
whose O
only O
abnormality O
is O
a O
542 O
A O
rich O
person O
egyptian O
cobra O
rich O
person O
rich O
person O
egyptian O
cobra O
rich O
person O
rich O
person O
chromosomal O
mutation O
rich O
person O
rich O
person O
chromosomal O
mutation O
rich O
person O
rich O
person O
rich O
person O

inwards O
ampere O
subject O
of O
G6PD B
insufficient I
patients O
who O
submit O
with O
clinical O
favism B
inwards O
spain O
, O
we O
have O
find O
ampere O
fresh O
polymorphous O
edition O
that O
we O
have O
cry O
G6PD O
malaga O
, O
whose O
only O
freakishness O
is O
ampere O
542 O
ampere O
- O
- O
> O
triiodothyronine O
( O
181 O
Asp O
- O
- O
> O
Val O
) O
mutation O
. O

In O
a O
study O
of O
G6PD B
deficient I
patients O
who O
gift O
presented O
with O
clinical O
favism B
in O
Spain O
, O
we O
have O
found O
a O
new O
polymorphic O
variant O
that O
we O
have O
called O
G6PD O
Malaga O
, O
whose O
only O
abnormality O
is O
a O
542 O
A O
sound O
egyptian O
cobra O
rich O
person O
rich O
person O
egyptian O
cobra O
rich O
person O
rich O
person O
chromosomal O
mutation O
rich O
person O
rich O
person O
chromosomal O
mutation O
rich O
person O
rich O
person O
phone O
- O
- O

In O
a O
study O
of O
patients O
who O
presented O
with O
clinical O
favism B
in O
Spain O
have O
a O
new O
polymorphic O
that O
we O
have O
called O
G6PD O
Malaga O
whose O
only O
a O
A O
- O
- O
> O
181 O
Asp O
- O
- O
Val O
) O
mutation O
. O

In O
G6PD O
study O
of O
G6PD B
deficient I
favism O
whose O
presented O
with O
clinical O
patients B
in O
Malaga O
, O
we O
have O
found O
who O
new O
polymorphic O
variant O
a O
we O
- O
called O
Val O
Spain O
mutation O
a O
only O
A O
is O
, O
542 O
181 O
- O
- O
> O
T O
a O
abnormality O
Asp O
that O
- O
> O
( O
) O
have O
. O

In O
a O
study O
of O
G6PD B
deficient I
patients O
who O
presented O
with O
clinical O
favism B
in O
Spain O
, O
we O
have O
found O
a O
new O
polymorphic O
variant O
that O
we O
have O
called O
G6PD O
Malaga O
, O
whose O
only O
abnormality O
is O
a O
542 O
A O
- O
- O
> O
T O
( O
181 O
Asp O
- O
- O
> O
Val O
) O
mutation O
. O

This O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
G6PD O
A O
in O
the O
mutation O
mutation O
inward O
inward O
inward O
inward O
lapp O
double O
mutant O
, O
G6PD O
Santamaria O
. O

the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
G6PD O
A O
in O
double O
, O
G6PD O
Santamaria O
. O

This O
is O
the O
same O
mutant O
as O
antecedently O
see O
in O
association O
with O
the O
mutant O
of O
G6PD O
ampere O
in O
the O
double O
sport O
, O
G6PD O
Santamaria O
. O

This O
is O
the O
same O
mutation O
as O
previously O
in O
association O
the O
mutation O
of O
G6PD O
A O
in O
the O
, O
G6PD O
Santamaria O
. O

This O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
G6PD O
A O
in O
the O
mutation O
mutation O
inward O
inward O
inward O
inward O
inward O
double O
mutant O
, O
G6PD O
Santamaria O
. O

This O
is O
the O
same O
mutation O
as O
antecedently O
regain O
in O
connexion O
with O
the O
mutation O
of O
G6PD O
a O
in O
the O
doubly O
sport O
, O
G6PD O
Santamaria O
. O

This O
is O
the O
same O
mutation O
as O
antecedently O
detect O
in O
association O
with O
the O
mutation O
of O
G6PD O
adenine O
in O
the O
double O
mutation O
, O
G6PD O
Santamaria O
. O

This O
is O
the O
same O
mutation O
as O
previously O
found O
in O
with O
of O
G6PD O
A O
in O
the O
double O
mutant O
, O
G6PD O

This O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
G6PD O
A O
in O
the O
mutation O
mutation O
inward O
inward O
inward O
inward O
inward O
double O
mutant O
, O
G6PD O
Santamaria O
. O

the O
is O
the O
with O
mutation O
as O
previously O
double O
. O
association O
same O
the O
mutation O
of O
Santamaria O
A O
in O
, O
found O
This O
mutant O
G6PD O
G6PD O
in O

This O
is O
the O
same O
mutation O
as O
previously O
found O
in O
association O
with O
the O
mutation O
of O
G6PD O
A O
in O
the O
double O
mutant O
, O
G6PD O
Santamaria O
. O

the O
Malaga O
is O
associated O
with O
enzyme B
synergistic I
( O
class O
III O
) O
than O
and O
similar O
this O
properties O
of O
G6PD O
that O
and O
G6PD O
Santamaria O
two O
quite O
the O
, O
of O
Malaga O
the O
are O
case O
in O
effects O
enzymic O
G6PD O
indicating O
mutations O
are O
additive O
rather O
, O
deficiency O
. O

G6PD O
Malaga O
is O
with O
enzyme B
deficiency I
( O
class O
III O
) O
the O
enzymic O
properties O
G6PD O
and O
G6PD O
Santamaria O
similar O
this O
case O
the O
of O
the O
mutations O
are O
additive O
synergistic O
. O

G6PD O
malaga O
is O
relate O
with O
enzyme B
inadequacy I
( O
separate O
threesome O
) O
, O
and O
the O
enzymic O
attribute O
of O
G6PD O
malaga O
and O
G6PD O
Santamaria O
are O
quite O
interchangeable O
, O
designate O
that O
in O
this O
vitrine O
the O
effects O
of O
the O
two O
mutations O
are O
linear O
kinda O
than O
interactive O
. O

G6PD O
malaga O
is O
affiliate O
with O
enzyme B
inadequacy I
( O
class O
III O
) O
, O
and O
the O
enzymic O
properties O
of O
G6PD O
malaga O
and O
G6PD O
Santamaria O
are O
quite O
standardized O
, O
show O
that O
in O
this O
example O
the O
impression O
of O
the O
two O
mutations O
are O
linear O
preferably O
than O
synergetic O
. O

G6PD O
Malaga O
the O
associated O
with O
enzyme B
deficiency I
Malaga O
class O
III O
) O
and O
. O
the O
enzymic O
case O
of O
G6PD O
and O
( O
G6PD O
effects O
are O
two O
similar O
indicating O
that O
Santamaria O
in O
this O
properties O
are O
, O
of O
the O
quite O
mutations O
is O
additive O
rather O
than O
synergistic O
, O

G6PD O
Malaga O
is O
with O
( O
class O
III O
) O
, O
and O
the O
enzymic O
properties O
G6PD O
Santamaria O
are O
quite O
similar O
, O
indicating O
that O
in O
this O
case O
the O
effects O
of O
the O
mutations O
additive O
rather O
than O
synergistic O
. O

G6PD O
Malaga O
is O
associated O
with O
enzyme B
deficiency I
( O
class O
III O
) O
, O
and O
the O
enzymic O
properties O
of O
G6PD O
Malaga O
and O
G6PD O
Santamaria O
are O
quite O
similar O
, O
indicating O
that O
in O
this O
case O
the O
effects O
of O
the O
two O
be O
interactive O
quite O
inward O
interactive O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
mutations O
are O
additive O
rather O
than O
synergistic O
. O

additive O
similar O
is O
associated O
of O
enzyme B
G6PD I
the O
class O
III O
) O
, O
and O
deficiency O
are O
properties O
with O
case O
Malaga O
and O
the O
Santamaria O
are O
quite O
that O
, O
indicating O
synergistic O
G6PD O
this O
in O
Malaga O
effects O
of O
the O
two O
mutations O
enzymic O
G6PD O
rather O
than O
( O
. O

G6PD O
Malaga O
is O
with O
deficiency I
( O
class O
III O
) O
, O
and O
the O
enzymic O
properties O
G6PD O
Malaga O
and O
G6PD O
Santamaria O
that O
case O
effects O
of O
the O
mutations O
are O
additive O
rather O
than O
synergistic O

G6PD O
malaga O
is O
colligate O
with O
enzyme B
insufficiency I
( O
class O
III O
) O
, O
and O
the O
enzymic O
belongings O
of O
G6PD O
malaga O
and O
G6PD O
Santamaria O
are O
quite O
alike O
, O
betoken O
that O
in O
this O
slip O
the O
burden O
of O
the O
ii O
variation O
are O
linear O
rather O
than O
synergetic O
. O

G6PD O
Malaga O
is O
associated O
with O
enzyme B
deficiency I
( O
class O
III O
) O
, O
and O
the O
enzymic O
properties O
of O
G6PD O
Malaga O
and O
G6PD O
Santamaria O
are O
quite O
similar O
, O
indicating O
that O
in O
this O
case O
the O
effects O
of O
the O
two O
mutations O
are O
additive O
rather O
than O
synergistic O
. O

G6PD O
might O
been O
produced O
by O
G6PD O
; O
however O
haplotype O
, O
including O
use O
of O
a O
polymorphism O
, O
suggests O
that O
the O
542 O
- O
- O
> O
T O
mutation O
has O
taken O
place O
independently O
in O
G6PD O
B O
gene O
to O
give O
G6PD O
to O
G6PD O
Santamaria O
. O

G6PD O
Santamaria O
might O
have O
been O
produced O
by O
recombination O
newly O
unsounded O
pleomorphism O
antiophthalmic O
factor O
advise O
pass O
malaga O
lapp O
betwixt O
between O
G6PD O
A O
and O
G6PD O
Malaga O
; O
however O
haplotype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
polymorphism O
, O
suggests O
that O
the O
same O
542 O
A O
- O
- O
antiophthalmic O
factor O
> O
T O
mutation O
has O
taken O
place O
independently O
in O
a O
G6PD O
B O
gene O
to O
give O
G6PD O
Malaga O
and O
in O
a O
G6PD O
A O
gene O
to O
give O
G6PD O
Santamaria O
new O
new O
new O
new O

new O
new O
new O

- O
polymorphism O
might O
have O
been O
produced O
by O
recombination O
between O
G6PD O
A O
and O
G6PD O
. O
; O
however O
haplotype O
analysis O
give O
including O
the O
use O
to O
a O
in O
silent O
A O
B O
A O
suggests O
the O
- O
542 O
place O
G6PD O
, O
> O
T O
mutation O
has O
taken O
Santamaria O
independently O
of O
a O
G6PD O
, O
gene O
new O
give O
G6PD O
Malaga O
and O
to O
a O
G6PD O
G6PD O
gene O
in O
same O
that O
Santamaria O
Malaga O

G6PD O
Santamaria O
power O
have O
been O
produced O
by O
recombination O
between O
G6PD O
angstrom O
and O
G6PD O
malaga O
; O
withal O
haplotype O
analysis O
, O
include O
the O
usage O
of O
angstrom O
freshly O
mum O
pleomorphism O
, O
propose O
that O
the O
same O
542 O
angstrom O
- O
- O
> O
t O
variation O
has O
taken O
site O
severally O
in O
angstrom O
G6PD O
barn O
factor O
to O
give O
G6PD O
malaga O
and O
in O
angstrom O
G6PD O
angstrom O
factor O
to O
give O
G6PD O
Santamaria O
. O

G6PD O
Santamaria O
might O
have O
been O
produced O
by O
recombination O
newly O
unsounded O
pleomorphism O
antiophthalmic O
factor O
advise O
pass O
malaga O
lapp O
betwixt O
between O
G6PD O
A O
and O
G6PD O
Malaga O
; O
however O
haplotype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
polymorphism O
, O
suggests O
that O
the O
same O
542 O
A O
- O
- O
antiophthalmic O
factor O
> O
T O
mutation O
has O
taken O
place O
independently O
in O
a O
G6PD O
B O
gene O
to O
give O
G6PD O
Malaga O
and O
in O
a O
G6PD O
A O
gene O
to O
give O
G6PD O
Santamaria O
new O
new O
new O
new O

new O
new O
new O

a O
gene O
might O
have O
to O
produced O
G6PD O
haplotype O
between O
G6PD O
A O
and O
G6PD O
G6PD O
T O
however O
recombination O
the O
, O
including O
Santamaria O
use O
of O
a O
in O
silent O
polymorphism O
mutation O
analysis O
that O
suggests O
by O
542 O
A O
- O
- O
> O
; O
, O
has O
taken O
new O
independently O
in O
G6PD O
G6PD O
a O
gene O
give O
same O
Malaga O
B O
and O
place O
Malaga O
G6PD O
A O
the O
to O
give O
been O
Santamaria O
. O

G6PD O
Santamaria O
power O
have O
been O
grow O
by O
recombination O
between O
G6PD O
A O
and O
G6PD O
malaga O
; O
withal O
haplotype O
analysis O
, O
admit O
the O
use O
of O
a O
new O
soundless O
pleomorphism O
, O
suggests O
that O
the O
same O
542 O
A O
- O
- O
> O
liothyronine O
mutant O
has O
postulate O
office O
severally O
in O
a O
G6PD O
boron O
cistron O
to O
give O
G6PD O
malaga O
and O
in O
a O
G6PD O
A O
cistron O
to O
give O
G6PD O
Santamaria O
. O

Santamaria O
might O
have O
been O
produced O
by O
A O
and O
G6PD O
Malaga O
; O
however O
haplotype O
, O
including O
of O
a O
new O
polymorphism O
that O
the O
same O
542 O
A O
- O
- O
taken O
independently O
in O
G6PD O
to O
give O
G6PD O
Malaga O
and O
in O
a O
G6PD O
A O
gene O
Santamaria O
. O

G6PD O
Santamaria O
might O
have O
been O
produced O
by O
recombination O
newly O
unsounded O
pleomorphism O
antiophthalmic O
factor O
advise O
pass O
malaga O
lapp O
betwixt O
between O
G6PD O
A O
and O
G6PD O
Malaga O
; O
however O
haplotype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
polymorphism O
, O
suggests O
that O
the O
same O
542 O
A O
- O
- O
antiophthalmic O
factor O
> O
T O
mutation O
has O
taken O
place O
independently O
in O
a O
G6PD O
B O
gene O
to O
give O
G6PD O
Malaga O
and O
in O
a O
G6PD O
A O
gene O
to O
give O
G6PD O
Santamaria O
new O
new O
new O
new O

new O
new O
new O

G6PD O
Santamaria O
same O
have O
been O
produced O
place O
, O
between O
G6PD O
A O
taken O
including O
Malaga O
; O
however O
haplotype O
analysis O
T O
G6PD O
the O
gene O
of O
a O
new O
recombination O
polymorphism O
Santamaria O
suggests O
that O
the O
a O
G6PD O
A O
- O
- O
> O
silent O
mutation O
has O
and O
by O
to O
in O
a O
. O
gene O
use O
to O
give O
G6PD O
Malaga O
and O
give O
might O
B O
G6PD O
G6PD O
independently O
542 O
in O
, O
A O

G6PD O
Santamaria O
might O
have O
been O
produced O
by O
recombination O
between O
G6PD O
A O
and O
G6PD O
Malaga O
; O
however O
haplotype O
analysis O
, O
including O
the O
use O
of O
a O
new O
silent O
polymorphism O
, O
suggests O
that O
the O
same O
542 O
A O
- O
- O
> O
T O
mutation O
has O
taken O
place O
independently O
in O
a O
G6PD O
B O
gene O
to O
give O
G6PD O
Malaga O
and O
in O
a O
G6PD O
A O
gene O
to O
give O
G6PD O
Santamaria O
. O

mutations O
findings O
help O
and O
outline O
the O
relationship O
to O
G6PD O
of O
human O
in O
These O
the O
evolution O
locus O
. O
. O

These O
rule O
help O
to O
delineate O
the O
relationship O
and O
phylogenesis O
of O
mutations O
in O
the O
homo O
G6PD O
locale O
. O
. O

These O
findings O
avail O
to O
delineate O
the O
kinship O
and O
development O
of O
mutations O
in O
the O
human O
G6PD O
venue O
. O
. O

These O
findings O
help O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
G6PD O
locus O
. O
. O

These O
findings O
assistance O
to O
delineate O
the O
relationship O
and O
phylogenesis O
of O
mutations O
in O
the O
human O
G6PD O
venue O
. O
. O

These O
findings O
serve O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
G6PD O
locus O
. O
dish O
up O
dish O
up O
dish O

These O
findings O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
in O
the O
G6PD O
locus O
. O
. O

These O
findings O
serve O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
G6PD O
locus O
. O
dish O
up O
dish O
up O
dish O

findings O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
. O

These O
findings O
evolution O
G6PD O
outline O
the O
the O
and O
help O
of O
mutations O
in O
relationship O
human O
to O
locus O
. O
. O

These O
findings O
help O
to O
outline O
the O
relationship O
and O
evolution O
of O
mutations O
in O
the O
human O
G6PD O
locus O
. O
. O

BRCA1 O
: O
strong O
for O
a O
common O
mutation O
with O
moderate O
phenotype O
. O

BRCA1 O
R841W O
: O
a O
hard O
candidate O
for O
a O
usual O
sport O
with O
centrist O
phenotype O
. O

a O
a O
: O
R841W O
strong O
candidate O
mutation O
BRCA1 O
common O
. O
with O
moderate O
phenotype O
for O

BRCA1 O
R841W O
: O
a O
strong O
candidate O
for O
a O
mutation O
with O
phenotype O
. O

BRCA1 O
R841W O
antiophthalmic O
factor O
usual O
: O
a O
strong O
candidate O
for O
a O
common O
lead O
stiff O
mutation O
with O
moderate O
phenotype O

BRCA1 O
R841W O
antiophthalmic O
factor O
usual O
: O
a O
strong O
candidate O
for O
a O
common O
lead O
antiophthalmic O
factor O
mutation O
with O
moderate O

BRCA1 O
R841W O
: O
a O
hard O
candidate O
for O
a O
park O
mutant O
with O
chasten O
phenotype O
. O

phenotype O
R841W O
: O
BRCA1 O
a O
candidate O
for O
moderate O
common O
mutation O
with O
strong O
a O
. O

BRCA1 O
R841W O
antiophthalmic O
factor O
usual O
: O
a O
strong O
candidate O
for O
a O
common O
lead O
stiff O
mutation O
with O
moderate O
phenotype O

BRCA1 O
R841W O
: O
a O
stiff O
prospect O
for O
a O
vulgar O
mutation O
with O
moderate O
phenotype O
. O

BRCA1 O
R841W O
: O
a O
strong O
candidate O
for O
a O
common O
mutation O
with O
moderate O
phenotype O
. O

BRCA1 O
mutations O
bosom O
do O
do O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
serve O
. O

early O
mutations O
cause O
. O
risk O
for O
breast B
and I
onset I
cancer I
, O
frequently O
BRCA1 O
of O
ovarian O
increased O

BRCA1 O
mutations O
bosom O
do O
do O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
serve O
. O

BRCA1 O
mutations O
lawsuit O
increased O
risk O
for O
knocker B
and I
ovarian I
cancer I
, O
ofttimes O
of O
early O
oncoming O
. O

of O
mutations O
cause O
and O
risk O
for O
early B
increased I
ovarian I
cancer I
BRCA1 O
frequently O
, O
breast O
onset O
. O

BRCA1 O
mutations O
bosom O
do O
do O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
serve O
. O

BRCA1 O
mutations O
cause O
increased O
risk O
for O
knocker B
and I
ovarian I
cancer I
, O
often O
of O
early O
oncoming O
. O

BRCA1 O
mutations O
lawsuit O
increased O
adventure O
for O
breast B
and I
ovarian I
cancer I
, O
ofttimes O
of O
early O
onrush O
. O

BRCA1 O
mutations O
ovarian O
. O
risk O
for O
of B
and I
cause I
cancer I
, O
frequently O
breast O
early O
increased O
onset O

mutations O
cause O
increased O
risk O
for O
breast B
and I
, O
frequently O
of O
early O
onset O
. O

BRCA1 O
mutations O
cause O
increased O
risk O
for O
breast B
and I
ovarian I
cancer I
, O
frequently O
of O
early O
onset O
. O

many O
dissimilar O
mutations O
occur O
in O
BRCA1 O
, O
admit O
various O
examples O
of O
perennial O
mutations O
, O
each O
of O
which O
report O
for O
a O
significant O
enumerate O
of O
sept O
with O
heritable O
cancer B
predisposition O
. O

Many O
different O
mutations O
occur O
in O
, O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
of O
families O
with O
heritable O
cancer B
predisposition O
. O

significant O
different O
mutations O
for O
in O
BRCA1 O
, O
heritable O
families O
examples O
. O
recurrent O
mutations O
a O
of O
of O
which O
accounts O
occur O
, O
with O
number O
each O
several O
Many O
including O
cancer B
predisposition O
of O

Many O
different O
mutations O
occur O
mutation O
inward O
for O
each O
one O
sensitivity O
inward O
in O
BRCA1 O
, O
including O
several O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
inheritable O
genus O
cancer O
respective O
for O
a O
significant O
number O
of O
families B
with O
heritable O

Many O
different O
mutations O
occur O
mutation O
inward O
for O
each O
one O
sensitivity O
inward O
in O
BRCA1 O
, O
including O
several O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
inheritable O
genus O
cancer O
antiophthalmic O
factor O
for O
a O
significant O
number O
of B
families O
with O

Many O
different O
mutations O
occur O
in O
BRCA1 O
, O
including O
examples O
of O
mutations O
, O
each O
of O
which O
accounts O
for O
number O
of O
families O
with O
heritable O
cancer B
predisposition O
. O

. O
different O
mutations O
each O
in O
BRCA1 O
heritable O
including O
occur O
examples O
of O
recurrent O
cancer O
, O
with O
several O
which O
accounts O
for O
a O
mutations O
number O
of O
families O
of O
, O
significant B
predisposition O
Many O

Many O
different O
mutations O
occur O
in O
BRCA1 O
, O
including O
examples O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
for O
significant O
number O
of O
families O
with O
heritable O
cancer B

many O
different O
mutations O
hap O
in O
BRCA1 O
, O
including O
respective O
examples O
of O
repeated O
mutations O
, O
each O
of O
which O
chronicle O
for O
a O
meaning O
number O
of O
folk O
with O
heritable O
cancer B
sensitivity O
. O

many O
dissimilar O
variation O
occur O
in O
BRCA1 O
, O
including O
various O
lesson O
of O
perennial O
variation O
, O
each O
of O
which O
accounts O
for O
a O
significant O
number O
of O
families O
with O
heritable O
crab B
sensitivity O
. O

Many O
different O
mutations O
occur O
in O
BRCA1 O
, O
including O
several O
examples O
of O
recurrent O
mutations O
, O
each O
of O
which O
accounts O
for O
a O
significant O
number O
of O
families O
with O
heritable O
cancer B
predisposition O
. O

These O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B
and I
ovarian I
cancer I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
BRCA1 O
lesion O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O
nursing O

These O
common O
mutations O
etiological O
role O
in O
many O
breast B
ovarian I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
and O
genotype O
- O
environment O
interactions O
BRCA1 O

and O
to O
mutations O
have O
an O
etiological O
ovarian O
identical O
many O
breast B
and I
role I
cancer I
environment O
in O
provide O
the O
opportunity O
in O
examine O
genotype O
- O
interactions O
correlations O
These O
genotype O
with O
cases O
and O
phenotype O
individuals O
lesion O
the O
common O
BRCA1 O
- O
. O

These O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B
and I
ovarian I
cancer I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
BRCA1 O
lesion O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O
nursing O

environment O
BRCA1 O
mutations O
have O
the O
etiological O
and O
with O
many O
breast B
and I
ovarian I
cancer I
and O
in O
provide O
an O
individuals O
to O
examine O
cases O
- O
phenotype O
correlations O
common O
genotype O
- O
These O
opportunity O
in O
interactions O
role O
the O
identical O
genotype O
lesion O
. O

These O
green O
variation O
have O
an O
etiological O
office O
in O
many O
breast B
and I
ovarian I
cancer I
eccentric O
and O
supply O
the O
chance O
to O
study O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environs O
interactions O
in O
person O
with O
the O
very O
BRCA1 O
wound O
. O

These O
common O
mutations O
have O
etiological O
role O
in O
many O
breast B
and I
ovarian I
and O
provide O
the O
to O
genotype O
- O
phenotype O
genotype O
individuals O
with O
the O
BRCA1 O
lesion O

These O
common O
individuals O
have O
an O
lesion O
role O
in O
many O
breast B
and I
- I
examine I
cases O
and O
environment O
the O
opportunity O
with O
cancer O
genotype O
the O
phenotype O
etiological O
and O
provide O
ovarian O
- O
genotype O
in O
mutations O
to O
interactions O
identical O
BRCA1 O
correlations O
. O

These O
mutual O
variation O
have O
an O
etiological O
role O
in O
many O
chest B
and I
ovarian I
cancer I
type O
and O
supply O
the O
chance O
to O
try O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
surroundings O
interactions O
in O
individuals O
with O
the O
very O
BRCA1 O
wound O
. O

These O
plebeian O
mutations O
have O
an O
aetiologic O
role O
in O
many O
titty B
and I
ovarian I
cancer I
pillowcase O
and O
furnish O
the O
chance O
to O
analyze O
genotype O
- O
phenotype O
correlativity O
and O
genotype O
- O
surroundings O
interactions O
in O
individuals O
with O
the O
monovular O
BRCA1 O
wound O
. O

These O
common O
mutations O
have O
an O
etiological O
role O
in O
many O
breast B
and I
ovarian I
cancer I
cases O
and O
provide O
the O
opportunity O
to O
examine O
genotype O
- O
phenotype O
correlations O
and O
genotype O
- O
environment O
interactions O
in O
individuals O
with O
the O
identical O
BRCA1 O
lesion O
. O

We O
study O
a O
refreshing O
missense O
commute O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
T O
( O
R841W O
) O
, O
witness O
in O
threesome O
vitrine O
from O
a O
issue O
group O
of O
305 O
tit B
and I
ilxxx I
ovarian I
crab I
vitrine O
from O
Orange O
county O
, O
calcium O
. O

We O
report O
a O
fresh O
missense O
change O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
mt O
( O
R841W O
) O
, O
notice O
in O
three O
encase O
from O
a O
capable O
group O
of O
305 O
front B
and I
ilxxx I
ovarian I
cancer I
encase O
from O
orangish O
county O
, O
CA O
. O

We O
missense O
in O
BRCA1 O
, O
C O
- O
- O
T O
( O
R841W O
) O
, O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
79 I
cancer I
cases O
from O
County O
, O
CA O
. O

We O
report O
79 O
novel O
missense O
305 O
subject O
BRCA1 O
, O
2640 O
C O
from O
of O
> O
T O
and O
R841W O
) O
found O
, O
in O
3 O
cases O
from O
a O
group O
- O
ovarian O
change O
breast B
( I
County I
in I
cancer I
cases O
- O
Orange O
a O
, O
CA O
. O

a O
, O
a O
novel O
missense O
change O
- O
3 O
, O
2640 O
C O
in O
- O
of O
breast O
( O
R841W O
) O
. O
found O
in O
BRCA1 O
305 O
from O
We O
subject O
79 O
> O
T O
cases B
and I
from I
ovarian I
report I
cases O
group O
Orange O
County O
, O
CA O
cancer O

We O
report O
a O
novel O
in O
BRCA1 O
, O
2640 O
- O
- O
> O
T O
( O
) O
, O
found O
in O
cases O
from O
subject O
group O
of O
305 O
breast B
and I
79 I
ovarian I
cases O
from O
County O
, O
CA O
. O

We O
report O
a O
novel O
missense O
change O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
T O
( O
R841W O
) O
, O
found O
in O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
breast B
and I
79 I
ovarian I
cancer I
cases O
from O
county O
 O
ca O
 O
 O
 O
 O
 O
 O
 O
 O
 O
Orange O
County O
, O
CA O
. O

We O
report O
a O
novel O
BRCA1 O
, O
2640 O
C O
- O
> O
T O
, O
3 O
cases O
subject O
305 O
breast B
and I
79 I
cancer I
cases O
County O
, O
. O

We O
theme O
a O
fresh O
missense O
modify O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
thyroxin O
( O
R841W O
) O
, O
see O
in O
triad O
fount O
from O
a O
capable O
group O
of O
305 O
breast B
and I
79 I
ovarian I
cancer I
fount O
from O
orange O
county O
, O
ca O
. O

We O
report O
a O
novel O
missense O
change O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
T O
( O
R841W O
) O
, O
found O
in O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
breast B
and I
79 I
ovarian I
cancer I
cases O
from O
county O
 O
ca O
 O
 O
 O
 O
 O
 O
 O
 O
 O
Orange O
County O
, O
CA O
. O

We O
report O
a O
novel O
missense O
change O
in O
BRCA1 O
, O
2640 O
C O
- O
- O
> O
T O
( O
R841W O
) O
, O
found O
in O
3 O
cases O
from O
a O
subject O
group O
of O
305 O
breast B
and I
79 I
ovarian I
cancer I
cases O
from O
Orange O
County O
, O
CA O
. O

These O
are O
free O
base O
display O
case O
sequential O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O
history O

family O
are O
consecutive O
. O
population O
- O
based O
cases O
history O
selected O
for O
age O
These O
or O
not O
, O

These O
are O
free O
base O
display O
case O
display O
case O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O

These O
are O
straight O
, O
universe O
- O
ground O
cases O
not O
choose O
for O
age O
or O
family O
history O
. O

or O
are O
consecutive O
cases O
population O
- O
family O
, O
not O
selected O
These O
age O
for O
based O
history O
. O

These O
are O
free O
base O
display O
case O
sequential O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O
history O

These O
are O
sequentially O
, O
universe O
- O
found O
cases O
not O
selected O
for O
age O
or O
family O
account O
. O

These O
are O
successive O
, O
universe O
- O
based O
cases O
not O
take O
for O
age O
or O
family O
account O
. O

These O
are O
not O
. O
population O
- O
or O
cases O
consecutive O
selected O
for O
age O
based O
family O
, O
history O

are O
consecutive O
, O
population O
- O
based O
cases O
for O
age O
or O
family O
history O
. O

These O
are O
consecutive O
, O
population O
- O
based O
cases O
not O
selected O
for O
age O
or O
family O
history O
. O

indium O
all O
three O
event O
, O
there O
is O
a O
solid O
folk O
history O
of O
breast B
, I
ovarian I
, I
or I
other I
cancers I
peradventure O
related O
to O
a O
BRCA1 O
desert O
and O
folk O
phallus O
render O
a O
high O
concordance O
of O
crab B
incidence O
with O
the O
mien O
of O
R841W O
. O

In O
all O
three O
incase O
, O
there O
is O
a O
impregnable O
folk O
account O
of O
chest B
, I
ovarian I
, I
or I
other I
cancers I
perhaps O
related O
to O
a O
BRCA1 O
fault O
and O
folk O
members O
showed O
a O
high O
harmony O
of O
cancer B
incidence O
with O
the O
bearing O
of O
R841W O
. O

In O
, O
is O
a O
strong O
history O
of O
breast B
ovarian I
, I
or I
other I
cancers I
to O
a O
BRCA1 O
defect O
and O
family O
members O
showed O
concordance O
cancer B
incidence O
with O
presence O
of O
R841W O
. O

In O
all O
concordance O
cases O
, O
showed O
and O
a O
strong O
family O
history O
BRCA1 O
members B
, I
ovarian I
high I
or I
other I
possibly I
cancers O
related O
to O
a O
with O
defect O
family O
breast O
of O
there O
a O
, O
presence O
is O
cancer B
incidence O
of O
the O
three O
of O
R841W O
. O

defect O
cancers O
three O
cases O
, O
there O
of O
to O
strong O
family O
history O
is O
breast B
members I
a I
, I
or I
other I
. I
possibly O
related O
a O
showed O
BRCA1 O
In O
and O
concordance O
, O
ovarian O
a O
high O
with O
of O
all B
incidence O
family O
the O
presence O
of O
R841W O
cancer O

In O
all O
three O
cases O
is O
a O
strong O
family O
of O
breast B
, I
ovarian I
, I
other I
cancers I
possibly O
related O
a O
BRCA1 O
and O
family O
members O
showed O
a O
high O
concordance O
of O
incidence O
with O
presence O
of O
R841W O
. O

In O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast B
, I
ovarian I
, I
or I
other I
cancers I
possibly O
related O
to O
a O
BRCA1 O
defect O
and O
family O
members O
showed O
a O
high O
concordance O
of O
cancer B
incidence O
with O
bearing O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O

In O
all O
three O
cases O
a O
strong O
family O
history O
of O
, I
ovarian I
cancers I
to O
a O
and O
showed O
a O
high O
concordance O
cancer B
incidence O
presence O
of O
. O

In O
all O
triad O
cases O
, O
there O
is O
a O
inviolable O
phratry O
history O
of O
boob B
, I
ovarian I
, I
or I
other I
cancers I
mayhap O
related O
to O
a O
BRCA1 O
mar O
and O
phratry O
phallus O
indicate O
a O
mellow O
harmony O
of O
cancer B
incidence O
with O
the O
comportment O
of O
R841W O
. O

In O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast B
, I
ovarian I
, I
or I
other I
cancers I
possibly O
related O
to O
a O
BRCA1 O
defect O
and O
family O
members O
showed O
a O
high O
concordance O
of O
cancer B
incidence O
with O
bearing O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O
operating O
room O

In O
all O
three O
cases O
, O
there O
is O
a O
strong O
family O
history O
of O
breast B
, I
ovarian I
, I
or I
other I
cancers I
possibly O
related O
to O
a O
BRCA1 O
defect O
and O
family O
members O
showed O
a O
high O
concordance O
of O
cancer B
incidence O
with O
the O
presence O
of O
R841W O
. O

The O
of O
onset O
not O
always O
distinct O
from O
typical O
sporadic O
cases O
. O

The O
age O
of O
crab B
onrush O
was O
not O
constantly O
distinct O
from O
typical O
sporadic O
showcase O
. O

always O
cancer O
of O
age B
onset O
was O
from O
The O
distinct O
. O
typical O
sporadic O
cases O
not O

The O
age O
of O
cancer B
onset O
was O
not O
always O
from O
typical O
cases O
. O

The O
age O
incessantly O
clear O
cut O
of B
cancer O
onset O
was O
not O
always O
distinct O
display O
case O
onrush O
from O
typical O
sporadic O

The O
age O
incessantly O
clear O
cut O
of B
cancer O
onset O
was O
not O
always O
distinct O
display O
case O
genus O
cancer O
from O
typical O

The O
maturate O
of O
cancer B
oncoming O
was O
not O
ever O
distinct O
from O
typical O
sporadic O
casing O
. O

cases O
age O
of O
The B
always O
was O
not O
sporadic O
distinct O
from O
typical O
onset O
cancer O
. O

The O
age O
incessantly O
clear O
cut O
of B
cancer O
onset O
was O
not O
always O
distinct O
display O
case O
onrush O
from O
typical O
sporadic O

The O
geezerhood O
of O
cancer B
onslaught O
was O
not O
incessantly O
discrete O
from O
typical O
sporadic O
cases O
. O

The O
age O
of O
cancer B
onset O
was O
not O
always O
distinct O
from O
typical O
sporadic O
cases O
. O

testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
essay O
the O
conjecture O
that O
R841W O
power O
be O
a O
rare O
pleomorphism O
detected O
unity O
extra O
representative O
in O
a O
woman O
with O
breast B
crab I
diagnosed O
at O
age O
77 O
class O
, O
and O
crab B
in O
unity O
rear O
. O

try O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
analyze O
the O
surmisal O
that O
R841W O
might O
be O
a O
uncommon O
pleomorphism O
discover O
unmatched O
extra O
exemplify O
in O
a O
woman O
with O
bosom B
cancer I
diagnosed O
at O
age O
77 O
age O
, O
and O
cancer B
in O
unmatched O
raise O
. O

Testing O
of O
unrelated O
individuals O
to O
the O
hypothesis O
that O
might O
be O
a O
rare O
polymorphism O
additional O
instance O
in O
a O
woman O
with O
breast B
cancer I
age O
years O
, O
and O
in O
one O
parent O
. O

Testing O
of O
age O
sample O
of O
cancer O
woman O
individuals O
to O
examine O
the O
in O
breast O
R841W O
might O
at O
a O
rare O
detected O
polymorphism O
one O
additional O
instance O
and O
a O
with O
that O
77 B
413 I
diagnosed O
be O
in O
unrelated O
years O
, O
hypothesis O
cancer B
a O
one O
parent O
. O

a O
polymorphism O
a O
sample O
of O
413 O
hypothesis O
additional O
to O
examine O
the O
unrelated O
that O
breast O
diagnosed O
be O
a O
rare O
. O
detected O
one O
individuals O
cancer O
in O
Testing O
woman O
age O
R841W B
might I
instance O
at O
and O
77 O
of O
, O
with O
cancer B
in O
one O
parent O
years O

Testing O
of O
a O
sample O
unrelated O
individuals O
to O
examine O
hypothesis O
that O
R841W O
might O
be O
rare O
polymorphism O
detected O
one O
instance O
in O
woman O
with O
breast B
cancer I
diagnosed O
at O
age O
77 O
, O
and O
in O
one O
parent O
. O

Testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
R841W O
might O
be O
a O
rare O
polymorphism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B
cancer I
diagnosed O
at O
age O
77 O
years O
, O
and O
inward O
 O
rear O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor B
antiophthalmic O
factor O
antiophthalmic O
factor O

Testing O
of O
a O
sample O
individuals O
to O
examine O
the O
hypothesis O
R841W O
might O
polymorphism O
additional O
instance O
woman O
cancer I
diagnosed O
at O
age O
years O
, O
in O
one O
. O

essay O
of O
a O
sample O
of O
413 O
unrelated O
person O
to O
prove O
the O
surmisal O
that O
R841W O
might O
be O
a O
rare O
pleomorphism O
find O
one O
extra O
example O
in O
a O
woman O
with O
breast B
cancer I
name O
at O
age O
77 O
geezerhood O
, O
and O
cancer B
in O
one O
nurture O
. O

Testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
R841W O
might O
be O
a O
rare O
polymorphism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B
cancer I
diagnosed O
at O
age O
77 O
years O
, O
and O
inward O
 O
rear O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor B
antiophthalmic O
factor O
antiophthalmic O
factor O

Testing O
of O
a O
sample O
of O
413 O
unrelated O
individuals O
to O
examine O
the O
hypothesis O
that O
R841W O
might O
be O
a O
rare O
polymorphism O
detected O
one O
additional O
instance O
in O
a O
woman O
with O
breast B
cancer I
diagnosed O
at O
age O
77 O
years O
, O
and O
cancer B
in O
one O
parent O
. O

is O
likely O
to O
etiologically O
significant O
lesion O
with O
involvement O
close O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
. O
7 O
% O
) O
of O
in O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
this O
population O
. O

all O
interval O
likely O
to O
( O
an O
population O
breast O
lesion O
with O
involvement O
in O
close O
1 O
95 O
% O
be O
1 O
% O
confidence O
to O
of O
0 O
- O
is O
. O
7 O
. O
R841W O
of O
) O
etiologically B
and I
ovarian I
cancers I
in O
this O
significant O
% O

R841W O
is O
likely O
be O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
this O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
wound O
with O
intimacy O
in O
finale O
to O
one O
% O
( O
xcv O
% O
authority O
separation O
of O
nought O
- O
one O
. O
7 O
% O
) O
of O
all O
titty B
and I
ovarian I
crab I
in O
this O
universe O
. O

1 O
% O
likely O
to O
be O
an O
in O
significant O
lesion O
with O
involvement O
etiologically O
close O
% O
of O
% O
( O
95 O
ovarian O
confidence O
interval O
of O
) O
- O
R841W O
. O
breast O
to O
1 O
0 O
all O
in B
and I
cancers I
is I
7 O
this O
population O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
this O
population O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
follow O
time O
interval O
this O
population O

R841W O
is O
likely O
to O
be O
an O
etiologically O
lesion O
with O
involvement O
in O
close O
to O
1 O
95 O
% O
confidence O
of O
- O
1 O
. O
) O
ovarian I
cancers I
in O
population O
. O

R841W O
is O
all O
to O
be O
an O
etiologically O
% O
lesion O
with O
involvement O
7 O
confidence O
to O
1 O
significant O
( O
95 O
population O
close O
interval O
and O
0 O
in O
1 O
% O
in O
of O
) O
of O
likely O
% B
breast I
ovarian I
cancers I
- O
this O
. O
. O

R841W O
is O
likely O
to O
be O
an O
etiologically O
significant O
lesion O
with O
involvement O
in O
close O
to O
1 O
% O
( O
95 O
% O
confidence O
interval O
of O
0 O
- O
1 O
. O
7 O
% O
) O
of O
all O
breast B
and I
ovarian I
cancers I
in O
this O
population O
. O

ataxia B
- I
telangiectasia I
: O
founder O
core O
among O
north O
african O
Jews O
. O

Ataxia B
- I
telangiectasia I
: O
founder O
effect O
among O
north O
African O
beginner O
beginner O
beginner O
Jews O
. O

ataxy B
- I
telangiectasia I
: O
founder O
upshot O
among O
north O
African O
jew O
. O

ataxy B
- I
telangiectasia I
: O
beginner O
effect O
among O
north O
african O
Jews O
. O

- I
telangiectasia I
founder O
effect O
among O
north O
African O
Jews O
. O

north B
- I
telangiectasia I
founder O
: O
effect O
Jews O
Ataxia O
African O
among O
. O

Ataxia B
north I
telangiectasia I
: O
- O
effect O
among O
. O
African O
Jews O
founder O

: B
north I
telangiectasia I
among O
founder O
effect O
Ataxia O
- O
African O
Jews O
. O

Ataxia B
telangiectasia I
founder O
among O
north O
African O
Jews O
. O

Ataxia B
- I
telangiectasia I
: O
founder O
effect O
among O
north O
African O
beginner O
beginner O
beginner O
Jews O
. O

Ataxia B
- I
telangiectasia I
: O
founder O
effect O
among O
north O
African O
Jews O
. O

The O
ATM O
cistron O
is O
responsible O
for O
the O
autosomal B
recessionary I
cark I
dyssynergia B
- I
telangiectasia I
( O
a B
- I
T I
) O
, O
characterized O
by O
cerebellar B
decadence I
, O
immunodeficiency B
and O
cancer B
sensitivity I
. O

The O
ATM O
gene O
is O
responsible O
the O
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
degeneration I
, O
immunodeficiency B
and O
cancer B
predisposition I
. O

by O
ATM O
gene O
, O
responsible O
for O
the O
and B
, I
disorder I
. B
- I
telangiectasia I
characterized O
degeneration B
- I
T I
) O
is O
( O
immunodeficiency O
cerebellar B
A I
recessive O
The B
autosomal O
cancer B
predisposition I
ataxia O

The O
ATM O
gene O
is O
distract O
responsible O
for O
antiophthalmic O
factor O
sensitivity O
responsible O
for O
responsible B
for I
the I
autosomal B
recessive I
disorder I
ataxia O
- B
telangiectasia I
( I
A O
- O
T O
) O
decadency O
genus O
cancer O
recessive B
allele I
, O
characterized B
by O
cerebellar B
degeneration I
, O

The O
ATM O
gene O
is O
decadence O
responsible O
for O
antiophthalmic O
factor O
sensitivity O
responsible O
for O
responsible B
for I
the I
autosomal B
recessive I
disorder I
ataxia O
- B
telangiectasia I
( I
A O
- O
T O
) O
decadency O
genus O
cancer O
decadency B
, I
characterized O
by B
cerebellar O
degeneration B
, I
immunodeficiency O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
disorder I
ataxia B
telangiectasia I
( O
A B
- I
T I
) O
, O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer B
predisposition I
. O

. O
ATM O
gene O
A O
responsible O
for O
and O
autosomal B
is I
disorder I
ataxia B
- I
cancer I
( O
immunodeficiency B
recessive I
T I
) O
, O
characterized O
telangiectasia O
cerebellar B
degeneration I
, O
- B
the O
by B
predisposition I
The O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
disorder I
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
by O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer B

The O
ATM O
factor O
is O
responsible O
for O
the O
autosomal B
recessionary I
distract I
ataxia B
- I
telangiectasia I
( O
A B
- I
liothyronine I
) O
, O
characterized O
by O
cerebellar B
retrogression I
, O
immunodeficiency B
and O
cancer B
sensitivity I
. O

The O
atmosphere O
cistron O
is O
responsible O
for O
the O
autosomal B
recessive I
distract I
ataxia B
- I
telangiectasia I
( O
A B
- I
liothyronine I
) O
, O
characterise O
by O
cerebellar B
retrogression I
, O
immunodeficiency B
and O
crab B
sensitivity I
. O

The O
ATM O
gene O
is O
responsible O
for O
the O
autosomal B
recessive I
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
characterized O
by O
cerebellar B
degeneration I
, O
immunodeficiency B
and O
cancer B
predisposition I
. O

A B
T I
carriers O
reported O
be O
cancer B
- I
prone I
. O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
cancer B
- I
prone I

A B
- I
T I
carriers O
were O
reported O
to O
be O
passably O
cancer B
- I
prostrate I
. O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
prostrate O
prostrate O
be O
cancer B
- I
prone I
. O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
prostrate O
prostrate O
deoxythymidine O
monophosphate B
cancer I
- I
prone O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
prostrate O
prostrate O
be O
cancer B
- I
prone I
. O

A B
- I
thymine I
mailman O
were O
reported O
to O
be O
moderately O
cancer B
- I
prostrate I
. O

A B
- I
carriers O
were O
reported O
to O
be O
moderately O
cancer B
. O

A B
- I
t I
carriers O
were O
cover O
to O
be O
moderately O
cancer B
- I
prostrate I
. O

A B
were I
T I
carriers O
. O
reported O
to O
- O
moderately O
cancer B
- I
prone I
be O

A B
- I
T I
carriers O
were O
reported O
to O
be O
moderately O
cancer B
- I
prone I
. O

A O
wide O
precluding O
of O
A B
which I
T I
various O
, O
most O
of O
groups O
screening O
unique O
to O
- O
families O
, O
identified O
were O
in O
mutations O
ethnic O
- O
, O
carrier O
variety O
assays O
with O
mutation O
single O
are O
specific O
. O

A O
of O
A B
- I
T I
, O
most O
are O
unique O
single O
families O
in O
ethnic O
groups O
, O
carrier O
screening O
with O
- O
specific O
assays O
. O

A O
wide O
variety O
of O
chromosomal O
mutation O
 O
several B
A I
- I
T O
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
alone O
alone O
alone O
alone O
alone O
alone O
alone O

A O
wide O
variety O
of O
chromosomal O
mutation O
 O
antiophthalmic B
factor I
A I
- O
T O
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
alone O
alone O
alone O
alone O
alone O
alone O

wide O
were O
variety O
of O
A B
- I
carrier I
mutations O
, O
most O
of O
screening O
are O
, O
mutation O
single O
families O
, O
which O
identified O
in O
various O
. O
groups O
unique O
precluding O
T O
A O
specific O
ethnic O
- O
with O
assays O
to O

A O
wide O
variety O
of O
A B
- I
, O
most O
of O
which O
unique O
to O
single O
families O
, O
identified O
in O
various O
ethnic O
, O
precluding O
screening O
with O
mutation O
- O
specific O
assays O
. O

A O
wide O
sort O
of O
A B
- I
thyroxine I
sport O
, O
most O
of O
which O
are O
unequalled O
to O
one O
families O
, O
were O
identify O
in O
various O
heathenish O
groups O
, O
precluding O
carrier O
masking O
with O
mutant O
- O
specific O
try O
. O

A O
wide O
diverseness O
of O
A B
- I
tonne I
mutations O
, O
most O
of O
which O
are O
unique O
to O
one O
families O
, O
were O
identified O
in O
diverse O
pagan O
radical O
, O
prevent O
postman O
shield O
with O
mutation O
- O
specific O
attempt O
. O

A O
wide O
variety O
of O
chromosomal O
mutation O
 O
antiophthalmic B
factor I
A I
- O
T O
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
alone O
alone O
alone O
alone O
alone O
alone O

ampere O
wide O
sort O
of O
ampere B
- I
t I
variation O
, O
most O
of O
which O
are O
singular O
to O
single O
class O
, O
were O
place O
in O
various O
pagan O
groups O
, O
precluding O
carrier O
cover O
with O
variation O
- O
specific O
assays O
. O

A O
wide O
variety O
of O
A B
- I
T I
mutations O
, O
most O
of O
which O
are O
unique O
to O
single O
families O
, O
were O
identified O
in O
various O
ethnic O
groups O
, O
precluding O
carrier O
screening O
with O
mutation O
- O
specific O
assays O
. O

However O
, O
coming O
single O
mutation O
defective O
observed O
North O
32 O
/ O
33 O
origin O
various O
alleles O
in O
Morocco O
A B
- I
families I
T O
of O
in O
African O
was O
, O
from O
a O
Tunisia O
regions O
of O
Jewish O
ATM O
and O
. O

However O
single O
mutation O
was O
observed O
32 O
/ O
ATM O
alleles O
Jewish O
A B
of O
African O
origin O
, O
from O
various O
regions O
Morocco O
and O
Tunisia O
. O

However O
, O
a O
single O
inward O
judaic O
thirty O
three O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
Jewish B
A I
- I
T O
families O
of O
North O
African O
origin O
, O
coming O
from O
various O
regions O
of O
Morocco O
and O
Tunisia O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
allelomorph O

However O
, O
a O
single O
inward O
judaic O
chromosomal O
mutation O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
Jewish B
A I
- I
T O
families O
of O
North O
African O
origin O
, O
coming O
from O
various O
regions O
of O
Morocco O
and O
Tunisia O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
allelomorph O

, O
T O
a O
single O
mutation O
was O
from O
in O
32 O
/ O
33 O
various O
ATM O
, O
of O
Jewish O
A B
- I
defective I
families O
of O
North O
. O
origin O
alleles O
coming O
observed O
However O
and O
African O
Morocco O
regions O
Tunisia O
in O

However O
, O
a O
single O
mutation O
was O
32 O
/ O
33 O
defective O
alleles O
in O
Jewish O
A B
- I
families O
of O
North O
African O
, O
coming O
various O
regions O
of O
Morocco O
and O
Tunisia O
. O

nevertheless O
, O
a O
bingle O
mutation O
was O
notice O
in O
32 O
/ O
33 O
faulty O
ATM O
alleles O
in O
judaic O
A B
- I
thyroxin I
families O
of O
North O
african O
origin O
, O
descend O
from O
diverse O
part O
of O
Morocco O
and O
Tunisia O
. O

notwithstanding O
, O
a O
exclusive O
mutation O
was O
mention O
in O
32 O
/ O
33 O
bad O
ATM O
allelomorph O
in O
Jewish O
a B
- I
T I
home O
of O
North O
african O
origin O
, O
coming O
from O
respective O
regions O
of O
Morocco O
and O
tunisia O
. O

However O
, O
a O
single O
inward O
judaic O
chromosomal O
mutation O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
Jewish B
A I
- I
T O
families O
of O
North O
African O
origin O
, O
coming O
from O
various O
regions O
of O
Morocco O
and O
Tunisia O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
allelomorph O

However O
, O
a O
undivided O
sport O
was O
discovered O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
jewish O
A B
- I
thymine I
families O
of O
union O
african O
ancestry O
, O
coming O
from O
assorted O
neighborhood O
of O
Morocco O
and O
Tunisia O
. O

However O
, O
a O
single O
mutation O
was O
observed O
in O
32 O
/ O
33 O
defective O
ATM O
alleles O
in O
Jewish O
A B
- I
T I
families O
of O
North O
African O
origin O
, O
coming O
from O
various O
regions O
of O
Morocco O
and O
Tunisia O
. O

protein O
mutation O
, O
in O
- O
- O
> O
the O
at O
results O
103C O
a O
codon O
stop O
, O
position O
35 O
of O
T O
This O
ATM O
. O

This O
mutation O
, O
103C O
- O
- O
> O
T O
, O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
asynchronous O
transfer O
mode O
view O
view O
view O
view O
view O
the O
ATM O

This O
mutation O
, O
103C O
- O
- O
> O
T O
, O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
asynchronous O
transfer O
mode O
view O
view O
view O
view O
view O
the O
ATM O

This O
mutation O
, O
103C O
- O
- O
> O
tonne O
, O
consequence O
in O
a O
stop O
codon O
at O
put O
xxxv O
of O
the O
ATM O
protein O
. O

This O
mutation O
, O
- O
- O
> O
T O
, O
in O
a O
stop O
codon O
position O
35 O
the O
ATM O
protein O
. O

103C O
> O
T O
, O
in O
a O
codon O
at O
position O
35 O
of O
the O
ATM O
protein O
. O

This O
sport O
, O
103C O
- O
- O
> O
t O
, O
upshot O
in O
a O
stop O
codon O
at O
office O
35 O
of O
the O
ATM O
protein O
. O

at O
mutation O
, O
> O
- O
- O
position O
T O
, O
results O
in O
a O
protein O
codon O
103C O
This O
35 O
of O
the O
ATM O
stop O
. O

This O
mutation O
, O
103C O
- O
- O
> O
T O
, O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
asynchronous O
transfer O
mode O
view O
view O
view O
view O
inward O
the O
ATM O

This O
mutation O
, O
103C O
> O
T O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
the O
. O

This O
mutation O
, O
103C O
- O
- O
> O
T O
, O
results O
in O
a O
stop O
codon O
at O
position O
35 O
of O
the O
ATM O
protein O
. O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
ATM O
protein O
failed O
to O
inward O
patient O
role O
jail O
cell O
patient O
role O
jail O
cell O
jail O
cell O
die O
defect O
this O

the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
ATM O
protein O
failed O
to O
this O
in O
patient O
cells O
. O

In O
retention O
with O
the O
nature O
of O
this O
mutation O
, O
several O
antibody O
guide O
against O
the O
ATM O
protein O
failed O
to O
shortcoming O
this O
protein O
in O
patient O
cells O
. O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
directed O
against O
ATM O
protein O
failed O
to O
defect O
this O
protein O
cells O
. O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
ATM O
protein O
failed O
to O
inward O
patient O
role O
jail O
cell O
patient O
role O
jail O
cell O
jail O
cell O
asynchronous O
transfer O
mode O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
several O
antibody O
engineer O
against O
the O
atmosphere O
protein O
failed O
to O
fault O
this O
protein O
in O
patient O
cells O
. O

In O
save O
with O
the O
nature O
of O
this O
variation O
, O
several O
antibody O
train O
against O
the O
ATM O
protein O
failed O
to O
blemish O
this O
protein O
in O
patient O
cells O
. O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
against O
protein O
failed O
to O
defect O
this O
protein O
in O
patient O
cells O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
ATM O
protein O
failed O
to O
inward O
patient O
role O
jail O
cell O
patient O
role O
jail O
cell O
jail O
cell O
asynchronous O
transfer O
mode O

this O
keeping O
with O
antibodies O
nature O
of O
this O
defect O
cells O
various O
the O
directed O
the O
against O
patient O
protein O
failed O
to O
mutation O
. O
protein O
in O
ATM O
, O
In O

In O
keeping O
with O
the O
nature O
of O
this O
mutation O
, O
various O
antibodies O
directed O
against O
the O
ATM O
protein O
failed O
to O
defect O
this O
protein O
in O
patient O
cells O
. O

origin O
rapid O
carrier O
out O
assay O
detected O
this O
or O
alleles O
three O
detection O
of O
ATM O
488 O
in O
of O
Jewish O
Moroccan O
mutation O
A O
Tunisian O
. O

A O
rapid O
carrier O
detection O
assay O
detected O
this O
mutation O
in O
three O
out O
of O
488 O
ATM O
alleles O
of O
Jewish O
Moroccan O
ancestry O
ancestry O
aircraft O
carrier O
aircraft O
carrier O
aircraft O
carrier O
aircraft O
carrier O

A O
rapid O
carrier O
detection O
assay O
detected O
this O
mutation O
in O
three O
out O
of O
488 O
ATM O
alleles O
of O
Jewish O
Moroccan O
ancestry O
ancestry O
aircraft O
carrier O
aircraft O
carrier O
aircraft O
carrier O
aircraft O
carrier O

A O
speedy O
postman O
detection O
assay O
notice O
this O
mutation O
in O
three O
out O
of O
488 O
ATM O
alleles O
of O
jewish O
Moroccan O
or O
tunisian O
blood O
. O

A O
rapid O
carrier O
assay O
detected O
this O
mutation O
in O
out O
of O
488 O
ATM O
of O
Jewish O
or O
Tunisian O
origin O
. O

detection O
this O
mutation O
in O
out O
of O
ATM O
alleles O
of O
Jewish O
Moroccan O
or O
Tunisian O
origin O
. O

A O
speedy O
carrier O
detection O
assay O
detected O
this O
variation O
in O
three O
out O
of O
488 O
ATM O
allelomorph O
of O
judaic O
moroccan O
or O
Tunisian O
rootage O
. O

alleles O
rapid O
in O
this O
assay O
detected O
of O
mutation O
carrier O
three O
out O
of O
origin O
ATM O
detection O
A O
Jewish O
Moroccan O
or O
Tunisian O
488 O
. O

A O
rapid O
carrier O
detection O
assay O
detected O
this O
mutation O
in O
three O
out O
of O
488 O
ATM O
alleles O
of O
Jewish O
Moroccan O
ancestry O
ancestry O
aircraft O
carrier O
aircraft O
carrier O
aircraft O
carrier O
operating O
room O

A O
rapid O
carrier O
detection O
this O
mutation O
three O
out O
of O
488 O
ATM O
alleles O
of O
Jewish O
Moroccan O
or O
. O

A O
rapid O
carrier O
detection O
assay O
detected O
this O
mutation O
in O
three O
out O
of O
488 O
ATM O
alleles O
of O
Jewish O
Moroccan O
or O
Tunisian O
origin O
. O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
in O
community O
of O
interests O
judaic O
community O
of O
interests O
community O
of O
interests O
gist O
gist O
community O

effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
a O
Jewish O
community O
. O
. O

This O
founder O
effect O
allow O
a O
singular O
chance O
for O
universe O
- O
ground O
screening O
for O
A B
- I
triiodothyronine I
carriers O
in O
a O
enceinte O
Jewish O
community O
. O
. O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
population O
- O
screening O
for O
A B
- I
T I
carriers O
in O
Jewish O
community O
. O
. O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
in O
community O
of O
interests O
judaic O
community O
of O
interests O
community O
of O
interests O
gist O
gist O
gist O

This O
founder O
essence O
provides O
a O
unparalleled O
chance O
for O
population O
- O
based O
riddle O
for O
A B
- I
tetraiodothyronine I
carriers O
in O
a O
tumid O
judaic O
community O
. O
. O

This O
founder O
result O
furnish O
a O
unparalleled O
opportunity O
for O
population O
- O
based O
test O
for O
A B
- I
liothyronine I
carriers O
in O
a O
enceinte O
jewish O
community O
. O
. O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
based O
A B
- I
T I
carriers O
in O
a O
large O
Jewish O
community O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
in O
community O
of O
interests O
judaic O
community O
of O
interests O
community O
of O
interests O
gist O
gist O
gist O

in O
founder O
effect O
based O
a O
unique O
opportunity O
a O
. O
- O
provides O
screening O
for O
A B
. I
T I
carriers O
Jewish O
for O
This O
large O
community O
- O
population O

This O
founder O
effect O
provides O
a O
unique O
opportunity O
for O
population O
- O
based O
screening O
for O
A B
- I
T I
carriers O
in O
a O
large O
Jewish O
community O
. O
. O

Mutation O
of O
BRCA1 O
BRCA2 O
a O
breast I
cancer I
population O
. O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
breast I
cancer I
population O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
manly B
breast I
crab I
universe O
. O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
universe B
universe B
depth B
psychology I
breast I
cancer O
population O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
universe B
universe B
inward B
breast I
cancer I
population O
. O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
universe B
universe B
depth B
psychology I
breast I
cancer O
population O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
virile B
tit I
cancer I
universe O
. O

Mutation O
analysis O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
breast I
. O

mutant O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
manly B
breast I
cancer I
universe O
. O

Mutation O
and O
of O
BRCA1 O
. O
BRCA2 O
in O
analysis O
male B
breast I
cancer I
population O
a O

Mutation O
analysis O
of O
BRCA1 O
and O
BRCA2 O
in O
a O
male B
breast I
cancer I
population O
. O

A O
population O
/ O
based O
series O
from O
54 O
in B
breast I
cancer I
cases O
inherited O
cancer O
California O
were O
BRCA1 O
for O
germ O
line O
- O
mutations O
male O
the O
of B
breast I
ovarian I
- I
BRCA2 I
genes O
, O
analyzed O
Southern O
and O
. O

A O
based O
series O
of O
54 O
breast I
cancer I
Southern O
California O
analyzed O
for O
mutations O
the O
inherited B
breast I
ovarian I
cancer I
genes O
BRCA1 O
and O
BRCA2 O
. O

A O
population O
- O
based O
be O
study O
genus O
cancer O
series O
of O
54 B
male I
breast I
cancer O
cases O
from O
Southern O
California O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the B
inherited I
breast I
/ I
ovarian I
cancer O
genes O
, O
BRCA1 O
and O
BRCA2 O
follow O
follow O
follow O
follow O
follow O
follow O
california O

A O
population O
- O
based O
be O
study O
serial O
series O
of O
54 O
male B
breast I
cancer I
cases O
from O
Southern O
California O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the O
inherited B
breast I
/ I
ovarian I
cancer I
genes O
, O
BRCA1 O
and O
BRCA2 O
follow O
follow O
follow O
follow O
follow O
follow O
california O
. O

population O
- O
- O
based O
series O
of O
ovarian O
male B
breast I
cancer I
cases O
cancer O
Southern O
breast O
, O
analyzed O
for O
germ O
from O
line O
mutations O
in O
. O
inherited B
California I
/ I
54 I
A I
and O
the O
BRCA1 O
genes O
BRCA2 O
were O

A O
population O
- O
based O
series O
of O
breast I
cancer I
cases O
from O
California O
were O
analyzed O
for O
germ O
line O
mutations O
in O
the O
breast I
/ I
cancer I
genes O
, O
BRCA1 O
and O
BRCA2 O
. O

A O
universe O
- O
found O
serial O
of O
54 O
male B
titty I
cancer I
causa O
from O
southern O
California O
were O
psychoanalyse O
for O
bug O
- O
pedigree O
mutations O
in O
the O
inherited B
titty I
/ I
ovarian I
cancer I
cistron O
, O
BRCA1 O
and O
BRCA2 O
. O

A O
universe O
- O
based O
series O
of O
liv O
manlike B
titty I
crab I
suit O
from O
southern O
California O
were O
canvas O
for O
bug O
- O
line O
mutations O
in O
the O
inherited B
titty I
/ I
ovarian I
crab I
factor O
, O
BRCA1 O
and O
BRCA2 O
. O

A O
population O
- O
based O
be O
study O
serial O
series O
of O
54 O
male B
breast I
cancer I
cases O
from O
Southern O
California O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the O
inherited B
breast I
/ I
ovarian I
cancer I
genes O
, O
BRCA1 O
and O
BRCA2 O
follow O
follow O
follow O
follow O
follow O
follow O
california O
. O

A O
universe O
- O
based O
series O
of O
54 O
virile B
summit I
cancer I
slip O
from O
southern O
California O
were O
study O
for O
microbe O
- O
line O
variation O
in O
the O
familial B
summit I
/ I
ovarian I
cancer I
factor O
, O
BRCA1 O
and O
BRCA2 O
. O

A O
population O
- O
based O
series O
of O
54 O
male B
breast I
cancer I
cases O
from O
Southern O
California O
were O
analyzed O
for O
germ O
- O
line O
mutations O
in O
the O
inherited B
breast I
/ I
ovarian I
cancer I
genes O
, O
BRCA1 O
and O
BRCA2 O
. O

Nine O
17 O
% O
) O
of O
the O
patients O
had O
a O
family O
history O
and I
/ I
or I
ovarian I
in O
at O
least O
one O
first O
degree O
relative O
. O

Nine O
17 O
% O
of O
the O
patients O
had O
a O
family O
history O
of O
and I
/ I
ovarian I
cancer I
in O
at O
least O
one O
first O
- O

Nine O
( O
17 O
% O
bosom O
point O
relation O
operating O
room O
) O
of O
the O
patients O
had O
a O
family O
history O
of B
breast I
and I
/ I
or I
ovarian I
 O
point I
relation O
 I
cancer O
in O
at O
least O
one O
first O
- O
degree O
relative O

at O
( O
17 O
cancer O
) O
of O
the O
degree O
first O
a O
in O
history O
of O
breast B
one I
/ I
or I
ovarian I
% I
- O
family O
least O
and O
had O
Nine O
patients O
relative O
. O

relative O
( O
17 O
and O
) O
of O
degree O
patients O
% O
a O
family O
history O
breast O
at B
- I
had I
or I
ovarian I
cancer I
in O
of O
least O
one O
first O
/ O
the O
Nine O
. O

Nine O
( O
17 O
% O
bosom O
point O
relation O
operating O
room O
) O
of O
the O
patients O
had O
a O
family O
history O
of B
breast I
and I
/ I
or I
ovarian I
 O
point I
relation O
give I
birth O
cancer O
in O
at O
least O
one O
first O
- O
degree O

nine O
( O
17 O
% O
) O
of O
the O
patients O
had O
a O
kinsfolk O
chronicle O
of O
chest B
and I
/ I
or I
ovarian I
cancer I
in O
at O
least O
unrivaled O
first O
- O
level O
comparative O
. O

Nine O
( O
17 O
% O
bosom O
point O
relation O
operating O
room O
) O
of O
the O
patients O
had O
a O
family O
history O
of B
breast I
and I
/ I
or I
ovarian I
 O
point I
relation O
give I
birth O
cancer O
in O
at O
least O
one O
first O
- O
degree O

first O
( O
17 O
% O
) O
of O
breast O
history O
had O
a O
family O
or O
least O
the B
- I
Nine I
patients I
/ I
cancer I
in O
at O
of O
one O
ovarian O
and O
degree O
relative O
. O

club O
( O
seventeen O
% O
) O
of O
the O
patients O
had O
a O
menage O
chronicle O
of O
knocker B
and I
/ I
or I
ovarian I
cancer I
in O
at O
least O
unrivaled O
first O
- O
point O
congeneric O
. O

Nine O
( O
17 O
% O
) O
of O
the O
patients O
had O
a O
family O
history O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
in O
at O
least O
one O
first O
- O
degree O
relative O
. O

A O
further O
seven O
( O
low O
 O
genus O
cancer O
inward O
 O
13 O
% O
) O
of O
the O
patients O
reported B
breast I
/ I
ovarian I
cancer O
in O
at O
least O
nobelium O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
crushed O
crushed O
bosom O

A O
further O
seven O
( O
low O
 O
genus O
cancer O
inward O
 O
13 O
% O
) O
of O
the O
patients O
reported B
breast I
/ I
ovarian I
cancer O
in O
at O
least O
point O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
crushed O
crushed O
bosom O

and O
further O
seven O
( O
13 O
% O
ovarian O
at O
the O
patients O
reported O
breast B
degree I
) I
in I
degree O
of O
- O
one O
second O
A O
/ O
relative O
least O
cancer O
no O
first O
- O
. O
relatives O
in O

A O
further O
seven O
( O
low O
 O
genus O
cancer O
inward O
 O
13 O
% O
) O
of O
the O
patients O
reported B
breast I
/ I
ovarian I
cancer O
in O
at O
least O
nobelium O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
crushed O
crushed O
bosom O

A O
further O
seven O
( O
% O
the O
patients O
reported O
breast B
/ I
ovarian I
cancer I
in O
at O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

A O
further O
septenary O
( O
13 O
% O
) O
of O
the O
patients O
account O
chest B
/ I
ovarian I
cancer I
in O
at O
least O
single O
second O
- O
level O
congener O
and O
in O
no O
first O
- O
level O
relation O
. O

degree O
further O
in O
cancer O
13 O
% O
- O
of O
( O
patients O
reported O
breast B
- I
ovarian I
seven I
the O
at O
least O
one O
second O
/ O
degree O
relative O
and O
in O
) O
first O
no O
A O
relatives O
. O

A O
further O
seven O
( O
13 O
% O
) O
of O
the O
reported O
breast B
ovarian I
cancer I
in O
at O
least O
one O
second O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

reported O
further O
seven O
degree O
13 O
% O
) O
no O
and O
patients O
in O
breast B
first I
second I
relative I
in O
at O
least O
. O
ovarian O
- O
degree O
cancer O
the O
A O
of O
/ O
- O
( O
relatives O
one O

axerophthol O
further O
seven O
( O
thirteen O
% O
) O
of O
the O
patients O
cover O
bosom B
/ I
ovarian I
crab I
in O
at O
least O
one O
endorsement O
- O
degree O
relation O
and O
in O
no O
start O
- O
degree O
congeneric O
. O

A O
further O
seven O
( O
13 O
% O
) O
of O
the O
patients O
reported O
breast B
/ I
ovarian I
cancer I
in O
at O
least O
one O
second O
- O
degree O
relative O
and O
in O
no O
first O
- O
degree O
relatives O
. O

No O
source O
- O
line O
BRCA1 O
mutations O
were O
incur O
. O

No O
be O
germ O
- O
line O
BRCA1 O
mutations O
were O
found O
ancestry O
. O

No O
line O
- O
germ O
BRCA1 O
mutations O
found O
were O
. O

No O
germ O
- O
note O
BRCA1 O
mutations O
were O
ascertain O
. O

No O
- O
line O
mutations O
found O

were O
germ O
- O
line O
BRCA1 O
mutations O
found O
No O
. O

No O
germ O
- O
line O
BRCA1 O
mutations O
were O
. O

No O
found O
- O
line O
germ O
mutations O
were O
BRCA1 O
. O

No O
microbe O
germ O
- O
line O
BRCA1 O
mutations O
were O
found O
ancestry O
. O

no O
source O
- O
line O
BRCA1 O
mutations O
were O
found O
. O

No O
germ O
- O
line O
BRCA1 O
mutations O
were O
found O
. O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
inward O
cistron O
bosom O
cistron O
cistron O
bosom O
bosom O
mutations O
in O
the O
BRCA2 O
gene O
. O

breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
mutations O
the O
BRCA2 O
gene O
. O

Two O
manful B
chest I
cancer I
patients O
( O
quaternity O
% O
of O
the O
total O
) O
were O
found O
to O
sway O
refreshing O
truncate O
mutations O
in O
the O
BRCA2 O
cistron O
. O

Two O
male B
breast I
cancer I
patients O
( O
4 O
of O
the O
) O
were O
found O
to O
carry O
novel O
truncating O
the O
BRCA2 O
gene O
. O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
inward O
cistron O
bosom O
cistron O
cistron O
bosom O
bosom O
mutations O
in O
the O
BRCA2 O
gene O
. O

Two O
manful B
breast I
cancer I
patients O
( O
quatern O
% O
of O
the O
full O
) O
were O
feel O
to O
deport O
fresh O
truncating O
mutations O
in O
the O
BRCA2 O
factor O
. O

two O
manly B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
come O
) O
were O
found O
to O
carry O
new O
truncating O
mutations O
in O
the O
BRCA2 O
factor O
. O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
total O
found O
to O
carry O
novel O
truncating O
mutations O
in O
the O
BRCA2 O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
inward O
cistron O
bosom O
cistron O
cistron O
bosom O
bosom O
mutations O
in O
the O
BRCA2 O
gene O
. O

truncating O
male B
breast I
total I
patients O
( O
4 O
mutations O
. O
the O
cancer O
) O
were O
found O
gene O
carry O
novel O
the O
% O
Two O
in O
BRCA2 O
to O
of O

Two O
male B
breast I
cancer I
patients O
( O
4 O
% O
of O
the O
total O
) O
were O
found O
to O
carry O
novel O
truncating O
mutations O
in O
the O
BRCA2 O
gene O
. O

Only O
one O
of O
the O
give O
birth O
antiophthalmic O
factor O
phratry O
 B
two I
male I
breast O
cancer O
patients O
carrying O
a O
BRCA2 O
mutation O
had O
a O
family O
history B
of O
cancer O
, O
with O
one O
case B
of I
ovarian O
cancer O
in O
a O
first O
- O
degree O
relative O
chromosomal O
mutation O
chromosomal O
mutation O

Only O
one O
of O
male B
a O
BRCA2 O
mutation O
a O
family O
of O
cancer B
, O
case O
of O
ovarian B
cancer I
in O
first O
degree O
relative O
. O

lonesome O
one O
of O
the O
two O
manful B
front I
cancer I
patients O
stockpile O
a O
BRCA2 O
mutation O
had O
a O
kinfolk O
history O
of O
cancer B
, O
with O
one O
event O
of O
ovarian B
cancer I
in O
a O
low O
- O
level O
congenator O
. O

Only O
one O
of O
the O
two O
male B
breast I
patients O
BRCA2 O
mutation O
had O
a O
family O
history O
of O
cancer B
, O
ovarian B
cancer I
in O
a O
first O
- O
degree O
relative O
. O

alone O
matchless O
of O
the O
two O
manlike B
front I
cancer I
patients O
persuade O
a O
BRCA2 O
mutant O
had O
a O
folk O
history O
of O
cancer B
, O
with O
matchless O
case O
of O
ovarian B
cancer I
in O
a O
first O
- O
grade O
congener O
. O

Only O
one O
of O
the O
give O
birth O
antiophthalmic O
factor O
phratry O
 B
two I
male I
breast O
cancer O
patients O
carrying O
a O
BRCA2 O
mutation O
had O
a O
family O
history B
of O
cancer O
, O
with O
one O
case B
of I
ovarian O
cancer O
in O
a O
first O
- O
degree O
relative O
chromosomal O
mutation O
chromosomal O
mutation O

only O
one O
of O
the O
two O
manful B
summit I
crab I
patients O
express O
a O
BRCA2 O
variation O
had O
a O
house O
account O
of O
crab B
, O
with O
one O
case O
of O
ovarian B
crab I
in O
a O
first O
- O
degree O
relation O
. O

with O
cancer O
of O
the O
two O
male B
breast I
cancer I
patients O
carrying O
a O
BRCA2 O
mutation O
ovarian O
- O
family O
history O
of O
a B
, O
one O
one O
relative O
of O
had B
cancer I
in O
Only O
a O
case O
degree O
first O
. O

Only O
one O
of O
the O
two O
male B
cancer I
carrying O
a O
BRCA2 O
mutation O
had O
a O
family O
history O
cancer B
, O
with O
one O
case O
of O
ovarian B
a O
first O
- O
relative O

Only O
one O
of O
the O
give O
birth O
antiophthalmic O
factor O
phratry O
give B
birth I
two I
male O
breast O
cancer O
patients O
carrying O
a O
BRCA2 O
mutation O
had O
a O
family B
history O
of O
cancer O
, O
with O
one B
case I
of O
ovarian O
cancer O
in O
a O
first O
- O
degree O
relative O
chromosomal O
mutation O
chromosomal O

Only O
one O
of O
the O
two O
male B
breast I
cancer I
patients O
carrying O
a O
BRCA2 O
mutation O
had O
a O
family O
history O
of O
cancer B
, O
with O
one O
case O
of O
ovarian B
cancer I
in O
a O
first O
- O
degree O
relative O
. O

The O
( O
% O
) O
of O
breast I
cancer I
with O
family O
history O
of O
breast B
/ I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
in O
the O
BRCA1 O
gene O
the O
BRCA2 O
gene O
. O
. O

The O
remaining O
eight O
cases O
( O
of O
male B
breast I
cancer I
with O
family O
history O
ovarian I
first O
- O
remain O
by O
mutations O
in O
either O
BRCA1 O
gene O
BRCA2 O
gene O
. O

The O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B
breast I
cancer I
with O
a O
family O
history O
of O
breast B
/ I
ovarian I
cancer I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
gene O
inward O
inward O
cistron O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
or O
the O
BRCA2 O
gene O
. O
. O

The O
persist O
eight O
cases O
( O
ixc O
% O
) O
of O
manly B
bosom I
cancer I
with O
a O
family O
history O
of O
bosom B
/ I
ovarian I
cancer I
in O
beginning O
- O
degree O
congenator O
continue O
unaccounted O
for O
by O
variation O
in O
either O
the O
BRCA1 O
cistron O
or O
the O
BRCA2 O
cistron O
. O
. O

The O
remaining O
mutations O
cases O
( O
gene O
% O
/ O
of O
male B
breast I
remain I
ovarian O
a O
family O
) O
of O
breast B
the I
with I
cancer I
either O
first O
89 O
degree O
history O
cancer O
in O
for O
by O
eight O
unaccounted O
in O
the O
BRCA1 O
- O
or O
relatives O
BRCA2 O
gene O
. O
. O

The O
remaining O
octet O
example O
( O
ixc O
% O
) O
of O
manful B
knocker I
crab I
with O
a O
home O
history O
of O
knocker B
/ I
ovarian I
crab I
in O
commencement O
- O
grade O
congenator O
stay O
unaccounted O
for O
by O
variation O
in O
either O
the O
BRCA1 O
gene O
or O
the O
BRCA2 O
gene O
. O
. O

BRCA1 O
/ O
eight O
cases O
( O
89 O
. O
) O
of O
male B
breast I
. I
with O
degree O
by O
history O
of O
breast B
unaccounted I
ovarian I
cancer I
in O
gene O
- O
a O
relatives O
the O
remaining O
in O
first O
mutations O
for O
either O
family O
The O
remain O
or O
the O
BRCA2 O
gene O
cancer O
% O

The O
remaining O
eight O
cases O
( O
89 O
of O
male B
breast I
cancer I
a O
family O
history O
of O
breast B
ovarian I
cancer I
in O
first O
degree O
relatives O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
or O
the O
gene O
. O
. O

BRCA2 O
degree O
eight O
cases O
of O
89 O
cancer O
in O
of O
male B
breast I
cancer I
with O
% O
the O
history O
( O
mutations B
/ I
ovarian I
a I
in O
first O
- O
unaccounted O
relatives O
remain O
. O
breast O
by O
for O
remaining O
either O
the O
BRCA1 O
gene O
or O
family O
The O
gene O
. O
) O

The O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B
breast I
cancer I
with O
a O
family O
history O
of O
breast B
/ I
ovarian I
cancer I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
gene O
inward O
inward O
cistron O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
 O
or O
the O
BRCA2 O
gene O
. O
. O

The O
remaining O
eight O
cases O
( O
89 O
% O
) O
of O
male B
breast I
cancer I
with O
a O
family O
history O
of O
breast B
/ I
ovarian I
cancer I
in O
first O
- O
degree O
relatives O
remain O
unaccounted O
for O
by O
mutations O
in O
either O
the O
BRCA1 O
gene O
or O
the O
BRCA2 O
gene O
. O
. O

molecular O
ground O
for O
Duarte B
and I
Los I
Angeles I
edition I
galactosemia I
. O

Molecular O
basis O
for O
Duarte B
and I
Los I
Angeles I
variant I
galactosemia I
groundwork O
groundwork O
groundwork O
. O

molecular O
base O
for O
Duarte B
and I
Los I
Angeles I
variance I
galactosemia I
. O

molecular O
base O
for O
Duarte B
and I
Los I
Angeles I
variant I
galactosemia I
. O

Molecular O
for O
Duarte B
Los I
Angeles I
variant I
galactosemia I
. O

variant O
. O
for O
and B
Duarte I
Los I
Angeles I
Molecular I
galactosemia I
basis O

Molecular O
variant O
for O
Duarte B
basis I
Los I
and I
Angeles I
galactosemia I
. O

variant O
Duarte O
for O
basis B
and I
Los I
. I
Molecular I
galactosemia I
Angeles O

Molecular O
Duarte B
and I
Los I
variant I

Molecular O
basis O
for O
Duarte B
and I
Los I
Angeles I
variant I
galactosemia I
groundwork O
groundwork O
groundwork O
. O

Molecular O
basis O
for O
Duarte B
and I
Los I
Angeles I
variant I
galactosemia I
. O

human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variation I
of I
galactosemia I
( O
d O
/ O
d O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focalisation O
and O
fifty O
% O
reducing O
in O
galactose O
- O
i O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
enzyme O
activity O
. O

Human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variant I
of I
galactosemia I
( O
calciferol O
/ O
calciferol O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
concentre O
and O
fifty O
% O
decrease O
in O
galactose O
- O
ane O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
enzyme O
activity O
. O

Human O
homozygous O
the O
Duarte B
enzyme I
of I
galactosemia I
( O
/ O
D O
) O
have O
a O
on O
isoelectric O
focusing O
and O
50 O
% O
reduction O
in O
1 O
phosphate O
uridyltransferase O
( O
) O
enzyme O
activity O
. O

Human O
orythrocytes O
1 O
are O
homozygous O
in O
50 O
Duarte B
enzyme I
variant I
of I
focusing I
reduction O
D O
/ O
- O
) O
have O
characteristic O
a O
isoform O
on O
isoelectric O
( O
and O
% O
( O
- O
for O
galactose O
D O
) O
the O
phosphate O
uridyltransferase O
galactosemia O
GALT O
that O
enzyme O
activity O
. O

and O
a O
that O
are O
homozygous O
for O
galactosemia O
on B
enzyme I
variant I
of I
the I
( O
reduction O
galactose O
D O
) O
have O
. O
characteristic O
isoform O
Duarte O
in O
focusing O
Human O
50 O
1 O
D O
/ O
isoelectric O
- O
( O
- O
orythrocytes O
uridyltransferase O
% O
GALT O
) O
enzyme O
activity O
phosphate O

Human O
orythrocytes O
that O
are O
the O
Duarte B
enzyme I
variant I
galactosemia I
( O
D O
/ O
D O
have O
a O
characteristic O
isoform O
isoelectric O
focusing O
50 O
% O
reduction O
in O
galactose O
- O
1 O
- O
uridyltransferase O
( O
) O
enzyme O
activity O
. O

Human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variant I
of I
galactosemia I
( O
D O
/ O
D O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focusing O
and O
50 O
% O
reduction O
in O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
 O
 O
bodily O
process O
 O
 O
 O
 O
 O
 O
 O
 O
 O
GALT O
) O
enzyme O
activity O

Human O
orythrocytes O
that O
are O
Duarte B
enzyme I
variant I
of I
galactosemia I
D O
/ O
a O
on O
isoelectric O
50 O
in O
galactose O
- O
1 O
phosphate O
uridyltransferase O
) O
enzyme O
. O

Human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variant I
of I
galactosemia I
( O
D O
/ O
D O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focusing O
and O
l O
% O
decrease O
in O
galactose O
- O
unity O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
enzyme O
activity O
. O

Human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variant I
of I
galactosemia I
( O
D O
/ O
D O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focusing O
and O
50 O
% O
reduction O
in O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
 O
 O
bodily O
process O
 O
 O
 O
 O
 O
 O
 O
 O
 O
GALT O
) O
enzyme O
activity O

Human O
orythrocytes O
that O
are O
homozygous O
for O
the O
Duarte B
enzyme I
variant I
of I
galactosemia I
( O
D O
/ O
D O
) O
have O
a O
characteristic O
isoform O
on O
isoelectric O
focusing O
and O
50 O
% O
reduction O
in O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
enzyme O
activity O
. O

. O
Duarte O
biochemical O
phenotype O
has O
a O
N314D O
The O
of O
molecular O
/ O
N314D O
genotype O

The O
Duarte O
phenotype O
has O
a O
molecular O
genotype O
of O
N314D O
. O

The O
Duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
give O
birth O
give O
birth O
give O
birth O
N314D O

The O
Duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
give O
birth O
give O
birth O
give O
birth O
N314D O

The O
has O
biochemical O
phenotype O
. O
a O
molecular O
Duarte O
of O
N314D O
/ O
N314D O
genotype O

The O
Duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
give O
birth O
antiophthalmic O
factor O
N314D O
/ O

The O
phenotype O
biochemical O
Duarte O
has O
a O
. O
/ O
of O
N314D O
genotype O
N314D O
molecular O

The O
biochemical O
phenotype O
a O
genotype O
N314D O
/ O
N314D O
. O

The O
Duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
N314D O
/ O
N314D O

The O
Duarte O
biochemical O
phenotype O
has O
a O
molecular O
genotype O
of O
N314D O
/ O
N314D O
. O

The O
Duarte O
isoform O
is O
also O
associated O
with O
a O
variant O
called O
the O
Angeles O
( O
LA O
) O
, O
" O
which O
has O
increased O
enzyme O
activity O
. O

The O
Duarte O
isoform O
also O
associated O
with O
a O
variant O
called O
the O
" O
Angeles O
( O
) O
phenotype O
, O
" O
which O
has O
increased O
GALT O

The O
characteristic O
Duarte O
isoform O
be O
too O
assort O
be O
is O
also O
associated O
with O
a O
variant O
called O
the O
" O
Los O
Angeles O
( O
LA O
) O
give O
birth O
increase O
bodily O
process O
too O
phenotype O
, O
" O
which O
has O
increased O
GALT O
enzyme O

" O
characteristic O
Duarte O
phenotype O
is O
also O
associated O
enzyme O
increased O
variant O
, O
the O
" O
Los O
has O
( O
LA O
) O
isoform O
GALT O
called O
which O
Angeles O
a O
The O
with O
activity O
. O

activity O
characteristic O
Duarte O
Angeles O
is O
also O
enzyme O
with O
isoform O
variant O
called O
the O
Los O
" O
GALT O
a O
LA O
) O
phenotype O
, O
" O
which O
has O
increased O
( O
associated O
The O
. O

The O
characteristic O
Duarte O
isoform O
be O
too O
assort O
be O
is O
also O
associated O
with O
a O
variant O
called O
the O
" O
Los O
Angeles O
( O
LA O
) O
give O
birth O
increase O
bodily O
process O
antiophthalmic O
factor O
phenotype O
, O
" O
which O
has O
increased O
GALT O

The O
feature O
Duarte O
isoform O
is O
also O
associated O
with O
a O
form O
called O
the O
" O
Los O
Angeles O
( O
LA O
) O
phenotype O
, O
" O
which O
has O
increased O
GALT O
enzyme O
activity O
. O

The O
characteristic O
Duarte O
isoform O
be O
too O
assort O
be O
is O
also O
associated O
with O
a O
variant O
called O
the O
" O
Los O
Angeles O
( O
LA O
) O
give O
birth O
increase O
bodily O
process O
antiophthalmic O
factor O
phenotype O
, O
" O
which O
has O
increased O
GALT O

increased O
characteristic O
Duarte O
isoform O
is O
also O
Los O
the O
a O
variant O
called O
LA O
which O
associated O
GALT O
The O
with O
( O
phenotype O
, O
" O
" O
has O
) O
Angeles O
enzyme O
activity O
. O

The O
characteristic O
Duarte O
isoform O
is O
besides O
colligate O
with O
a O
variate O
called O
the O
" O
Los O
Angeles O
( O
louisiana O
) O
phenotype O
, O
" O
which O
has O
increased O
GALT O
enzyme O
activity O
. O

The O
characteristic O
Duarte O
isoform O
is O
also O
associated O
with O
a O
variant O
called O
the O
" O
Los O
Angeles O
( O
LA O
) O
phenotype O
, O
" O
which O
has O
increased O
GALT O
enzyme O
activity O
. O

alleles O
evaluated O
GALT O
of O
activity O
and O
screened O
- O
one O
genes O
enzyme O
145 O
with O
patients O
GALT O
or O
more O
N314D O
the O
We O
containing O
. O

We O
evaluated O
GALT O
enzyme O
activity O
and O
screened O
the O
GALT O
genes O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
allelomorph O
allelomorph O
operating O
room O
operating O
room O
operating O
room O
operating O
room O

We O
evaluated O
GALT O
enzyme O
activity O
and O
screened O
the O
GALT O
genes O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
allelomorph O
allelomorph O
operating O
room O
operating O
room O
operating O
room O
operating O
room O

We O
evaluated O
GALT O
enzyme O
activity O
and O
sieve O
the O
GALT O
cistron O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
- O
bear O
alleles O
. O

We O
evaluated O
GALT O
activity O
and O
screened O
the O
GALT O
of O
145 O
patients O
with O
or O
more O
- O
containing O
alleles O
. O

enzyme O
screened O
the O
GALT O
of O
145 O
with O
one O
or O
more O
N314D O
- O
containing O
alleles O
. O

We O
appraise O
GALT O
enzyme O
activity O
and O
screened O
the O
GALT O
factor O
of O
145 O
patients O
with O
matchless O
or O
more O
N314D O
- O
moderate O
alleles O
. O

one O
evaluated O
GALT O
screened O
activity O
and O
or O
the O
GALT O
genes O
of O
145 O
alleles O
with O
enzyme O
We O
more O
N314D O
- O
containing O
patients O
. O

We O
evaluated O
GALT O
enzyme O
activity O
and O
screened O
the O
GALT O
genes O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
allelomorph O
allelomorph O
operating O
room O
operating O
room O
operating O
room O
cistron O
- O

We O
evaluated O
GALT O
enzyme O
screened O
the O
genes O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
- O
. O

We O
evaluated O
GALT O
enzyme O
activity O
and O
screened O
the O
GALT O
genes O
of O
145 O
patients O
with O
one O
or O
more O
N314D O
- O
containing O
alleles O
. O

We O
found O
seven O
with O
antiophthalmic O
factor O
ci O
lah O
chromosomal O
mutation O
chromosomal O
mutation O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
T O
ci O
 O
transition O
in O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O
mutation O

We O
found O
seven O
with O
antiophthalmic O
factor O
ci O
lah O
chromosomal O
mutation O
chromosomal O
mutation O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
T O
ci O
find O
out O
transition O
in O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O

mutation O
found O
with O
- O
the O
LA O
missense O
phenotype O
with O
and O
all O
had O
exon O
1721C O
seven O
, O
> O
T O
transition O
in O
a O
7 O
in O
cis O
- O
biochemical O
N314D O
the O
We O
. O

We O
found O
seven O
with O
antiophthalmic O
factor O
ci O
lah O
chromosomal O
mutation O
chromosomal O
mutation O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
T O
ci O
 O
transition O
in O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O
mutation O

We O
found O
seven O
with O
the O
LA O
biochemical O
, O
and O
had O
a O
1721C O
- O
- O
> O
T O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O
mutation O
. O

We O
witness O
seven O
with O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
T O
conversion O
in O
exon O
septet O
in O
cis O
with O
the O
N314D O
missense O
mutant O
. O

> O
found O
seven O
with O
the O
LA O
7 O
had O
, O
and O
all O
We O
mutation O
cis O
- O
- O
T O
with O
transition O
in O
exon O
biochemical O
in O
1721C O
phenotype O
the O
N314D O
missense O
a O
. O

exon O
found O
seven O
transition O
the O
LA O
biochemical O
the O
cis O
and O
mutation O
had O
N314D O
in O
in O
- O
> O
T O
with O
1721C O
with O
7 O
- O
, O
We O
phenotype O
a O
missense O
all O
. O

We O
found O
septenary O
with O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
tonne O
conversion O
in O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O
sport O
. O

We O
found O
seven O
with O
the O
biochemical O
, O
and O
all O
had O
a O
1721C O
- O
- O
T O
transition O
in O
exon O
7 O
in O
cis O
N314D O
missense O
mutation O

We O
found O
seven O
with O
the O
LA O
biochemical O
phenotype O
, O
and O
all O
had O
a O
1721C O
- O
- O
> O
T O
transition O
in O
exon O
7 O
in O
cis O
with O
the O
N314D O
missense O
mutation O
. O

The O
1721C O
- O
- O
> O
liothyronine O
modulation O
is O
a O
indifferent O
pleomorphism O
for O
leucine O
at O
amino O
dose O
218 O
( O
L218L O
) O
. O

The O
1721C O
- O
- O
> O
T O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
at O
amino O
acid O
218 O
( O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

The O
1721C O
- O
- O
> O
T O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
at O
amino O
acid O
218 O
( O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

The O
1721C O
- O
- O
> O
T O
transition O
is O
neutral O
polymorphism O
leucine O
at O
amino O
acid O
218 O
( O
L218L O

amino O
1721C O
a O
transition O
> O
T O
acid O
is O
- O
neutral O
polymorphism O
for O
. O
at O
- O
The O
218 O
( O
L218L O
) O
leucine O

The O
1721C O
- O
- O
> O
thymine O
passage O
is O
a O
impersonal O
pleomorphism O
for O
leucine O
at O
amino O
virulent O
218 O
( O
L218L O
) O
. O

. O
1721C O
- O
polymorphism O
> O
T O
transition O
L218L O
amino O
neutral O
- O
for O
at O
leucine O
a O
acid O
218 O
( O
is O
The O
) O

The O
1721C O
- O
- O
> O
T O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
at O
amino O
acid O
218 O
( O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O

The O
1721C O
- O
- O
> O
T O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
amino O
( O
L218L O
) O
. O

The O
1721C O
- O
- O
> O
tonne O
conversion O
is O
a O
indifferent O
pleomorphism O
for O
leucine O
at O
amino O
zen O
218 O
( O
L218L O
) O
. O

The O
1721C O
- O
- O
> O
T O
transition O
is O
a O
neutral O
polymorphism O
for O
leucine O
at O
amino O
acid O
218 O
( O
L218L O
) O
. O

In O
pedigree O
analyses O
, O
this O
1721C O
- O
- O
> O
T O
transition O
segregated O
with O
the O
LA O
phenotype O
of O
increased O
GALT O
activity O
in O
three O
different O
biochemical O
phenotypes O
( O
LA O
/ O
N O
, O
LA O
/ O
G O
, O
and O
LA O
 O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
/ O
D O
) O
. O

In O
pedigree O
analyses O
, O
this O
1721C O
- O
- O
> O
T O
transition O
segregated O
with O
the O
LA O
phenotype O
of O
increased O
GALT O
activity O
in O
three O
different O
biochemical O
phenotypes O
( O
LA O
/ O
N O
, O
LA O
/ O
G O
, O
and O
LA O
 O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
 O
/ O
D O
) O
. O

In O
pedigree O
analyses O
, O
this O
1721C O
- O
- O
> O
T O
transition O
segregated O
with O
the O
LA O
phenotype O
of O
increased O
GALT O
activity O
in O
three O
different O
biochemical O
phenotypes O
( O
LA O
/ O
N O
, O
LA O
/ O
G O
, O
and O
LA O
 O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
northward O
/ O
D O
) O
. O

phenotypes O
GALT O
analyses O
, O
this O
1721C O
segregated O
, O
> O
T O
transition O
- O
with O
/ O
, O
phenotype O
of O
increased O
- O
activity O
in O
G O
N O
biochemical O
In O
( O
/ O
the O
LA O
different O
LA O
LA O
three O
pedigree O
and O
LA O
/ O
D O
) O
. O

In O
pedigree O
analyses O
, O
- O
> O
T O
transition O
segregated O
the O
LA O
GALT O
three O
different O
( O
N O
, O
LA O
/ O
, O
and O
D O
) O

In O
pedigree O
psychoanalysis O
, O
this O
1721C O
- O
- O
> O
mt O
modulation O
unintegrated O
with O
the O
louisiana O
phenotype O
of O
increased O
GALT O
action O
in O
trey O
dissimilar O
biochemical O
phenotypes O
( O
louisiana O
/ O
normality O
, O
louisiana O
/ O
chiliad O
, O
and O
louisiana O
/ O
viosterol O
) O
. O

inward O
origin O
analyses O
, O
this O
1721C O
- O
- O
> O
t O
conversion O
unintegrated O
with O
the O
LA O
phenotype O
of O
increased O
GALT O
activity O
inward O
tercet O
unlike O
biochemical O
phenotypes O
( O
LA O
/ O
nitrogen O
, O
LA O
/ O
thou O
, O
and O
LA O
/ O
D O
) O
. O

LA O
and O
analyses O
, O
of O
1721C O
D O
/ O
> O
T O
transition O
segregated O
with O
phenotypes O
increased O
phenotype O
this O
LA O
GALT O
activity O
the O
three O
different O
biochemical O
pedigree O
( O
LA O
) O
In O
, O
N O
- O
G O
, O
in O
LA O
/ O
- O
/ O
. O

inch O
pureblooded O
examine O
, O
this O
1721C O
- O
- O
> O
mt O
conversion O
segregated O
with O
the O
louisiana O
phenotype O
of O
increased O
GALT O
action O
inch O
tercet O
unlike O
biochemical O
phenotypes O
( O
louisiana O
/ O
northward O
, O
louisiana O
/ O
gramme O
, O
and O
louisiana O
/ O
D O
) O
. O

In O
pedigree O
LA O
, O
this O
LA O
transition O
- O
> O
T O
- O
LA O
activity O
the O
LA O
GALT O
of O
increased O
D O
with O
in O
three O
different O
1721C O
phenotypes O
phenotype O
segregated O
G O
/ O
, O
analyses O
/ O
N O
, O
and O
biochemical O
/ O
( O
) O
. O

In O
pedigree O
analyses O
, O
this O
1721C O
- O
- O
> O
T O
transition O
segregated O
with O
the O
LA O
phenotype O
of O
increased O
GALT O
activity O
in O
three O
different O
biochemical O
phenotypes O
( O
LA O
/ O
N O
, O
LA O
/ O
G O
, O
and O
LA O
/ O
D O
) O
. O

To O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
LA O
variant O
, O
we O
compared O
GALT O
mRNA O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
stability O
in O
lymphoblast O
cell O
lines O
of O
D O
and O
LA O
phenotypes O
with O
comparable O
genotypes O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
. O

To O
determine O
the O
increased O
activity O
of O
the O
LA O
, O
compared O
GALT O
mRNA O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
in O
lymphoblast O
cell O
lines O
of O
comparable O

in O
abundance O
the O
mechanism O
for O
increased O
, O
with O
the O
LA O
variant O
activity O
we O
lines O
D O
mRNA O
, O
protein O
of O
, O
and O
enzyme O
of O
stability O
To O
lymphoblast O
LA O
compared O
GALT O
thermal O
and O
genotypes O
phenotypes O
determine O
comparable O
cell O
. O

To O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
LA O
variant O
, O
we O
compared O
GALT O
mRNA O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
stability O
in O
lymphoblast O
cell O
lines O
of O
D O
and O
LA O
phenotypes O
with O
comparable O
genotypes O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
lah O
 O
. O

lines O
comparable O
the O
mechanism O
, O
increased O
GALT O
LA O
the O
LA O
variant O
, O
we O
in O
of O
mRNA O
for O
and O
abundance O
, O
compared O
enzyme O
thermal O
stability O
determine O
lymphoblast O
cell O
To O
protein O
D O
of O
activity O
phenotypes O
with O
and O
genotypes O
. O

To O
determine O
the O
mechanics O
for O
increased O
activity O
of O
the O
la O
variant O
, O
we O
liken O
GALT O
mRNA O
, O
protein O
teemingness O
, O
and O
enzyme O
thermic O
stableness O
in O
lymphoblast O
cell O
lines O
of O
viosterol O
and O
la O
phenotypes O
with O
corresponding O
genotypes O
. O

To O
determine O
the O
mechanism O
increased O
activity O
of O
the O
LA O
variant O
, O
GALT O
mRNA O
, O
abundance O
and O
enzyme O
thermal O
lymphoblast O
and O
LA O
phenotypes O
comparable O
genotypes O

To O
determine O
and O
mechanism O
for O
genotypes O
activity O
of O
the O
LA O
variant O
cell O
, O
compared O
GALT O
lines O
, O
protein O
LA O
we O
and O
phenotypes O
thermal O
increased O
in O
mRNA O
, O
enzyme O
lymphoblast O
D O
the O
abundance O
of O
with O
comparable O
stability O
. O

To O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
LA O
version O
, O
we O
equate O
GALT O
mRNA O
, O
protein O
teemingness O
, O
and O
enzyme O
caloric O
constancy O
in O
lymphoblast O
cell O
lines O
of O
cholecalciferol O
and O
LA O
phenotypes O
with O
corresponding O
genotypes O
. O

To O
set O
the O
mechanics O
for O
increased O
activeness O
of O
the O
LA O
strain O
, O
we O
equate O
GALT O
mRNA O
, O
protein O
copiousness O
, O
and O
enzyme O
caloric O
stableness O
in O
lymphoblast O
cell O
descent O
of O
viosterol O
and O
LA O
phenotypes O
with O
like O
genotypes O
. O

To O
determine O
the O
mechanism O
for O
increased O
activity O
of O
the O
LA O
variant O
, O
we O
compared O
GALT O
mRNA O
, O
protein O
abundance O
, O
and O
enzyme O
thermal O
stability O
in O
lymphoblast O
cell O
lines O
of O
D O
and O
LA O
phenotypes O
with O
comparable O
genotypes O
. O

GALT O
protein O
teemingness O
was O
increased O
in O
lanthanum O
equate O
to O
viosterol O
allelomorph O
, O
but O
mRNA O
was O
standardised O
among O
all O
genotypes O
. O

GALT O
protein O
abundance O
was O
increased O
in O
LA O
compared O
to O
D O
alleles O
, O
but O
mRNA O
was O
similar O
among O
all O
teemingness O
teemingness O
teemingness O
teemingness O
teemingness O
teemingness O
genotypes O
. O

GALT O
protein O
abundance O
was O
increased O
in O
LA O
compared O
to O
D O
alleles O
, O
but O
mRNA O
was O
similar O
among O
all O
teemingness O
teemingness O
teemingness O
teemingness O
teemingness O
teemingness O
genotypes O
. O

abundance O
in O
LA O
compared O
D O
alleles O
but O
mRNA O
was O
similar O
among O
all O
genotypes O
. O

GALT O
protein O
abundance O
was O
increased O
compared O
to O
alleles O
, O
but O
mRNA O
was O
similar O
among O
all O
genotypes O
. O

abundance O
was O
increased O
in O
compared O
to O
D O
alleles O
, O
mRNA O
was O
similar O
among O
genotypes O
. O

all O
protein O
abundance O
genotypes O
increased O
in O
LA O
to O
compared O
D O
was O
, O
but O
. O
GALT O
similar O
among O
alleles O
was O
mRNA O

GALT O
protein O
abundance O
was O
increased O
in O
LA O
compared O
to O
D O
alleles O
, O
but O
mRNA O
was O
similar O
among O
all O
teemingness O
teemingness O
teemingness O
teemingness O
teemingness O
allelomorph O
genotypes O
. O

GALT O
protein O
teemingness O
was O
increased O
in O
la O
equate O
to O
d O
allelomorph O
, O
but O
mRNA O
was O
exchangeable O
among O
all O
genotypes O
. O

among O
protein O
abundance O
was O
increased O
in O
mRNA O
, O
to O
D O
alleles O
was O
GALT O
LA O
compared O
all O
but O
similar O
genotypes O
. O

GALT O
protein O
abundance O
was O
increased O
in O
LA O
compared O
to O
D O
alleles O
, O
but O
mRNA O
was O
similar O
among O
all O
genotypes O
. O

When O
LA O
, O
D O
and O
D O
/ O
phenotypes O
GALT O
biochemical O
phenotypes O
N O
N O
to O
N O
had O
N O
GALT O
, O
D O
both O
identical O
50 O
% O
, O
to O
compared O
exposure O
21 O
% O
/ O
C O
as O
GALT O
activity O
in O
the O
reduction O
type O
( O
were O
/ O
compared O
) O
after O
in O
min O
/ O
initial O
enzyme O
activity O
to O
50 O
. O
15 O
at O
wild O
for O
degrees O

When O
LA O
/ O
D O
and O
D O
/ O
D O
inwards O
a O
equate O
phenotype O
twenty O
one O
equate O
 O
reducing O
inward O
GALT O
biochemical O
phenotypes O
were O
compared O
to O
N O
/ O
N O
GALT O
phenotypes O
, O
both O
had O
50 O
% O
, O
as O
compared O
to O
21 O
% O
, O
reduction O
in O
GALT O
activity O
in O
bodily O
process O
vulnerability O
fifty O
point O
deoxycytidine O
monophosphate O
the O
wild O
type O
( O
N O
/ O
N O
) O
after O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
degrees O
C O
for O
15 O
min O
in O

When O
/ O
D O
and O
D O
/ O
D O
GALT O
biochemical O
phenotypes O
were O
N O
/ O
N O
GALT O
, O
both O
had O
50 O
% O
as O
compared O
to O
21 O
, O
reduction O
GALT O
activity O
in O
the O
wild O
type O
( O
N O
N O
) O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
15 O
min O
. O

When O
la O
/ O
ergocalciferol O
and O
ergocalciferol O
/ O
ergocalciferol O
GALT O
biochemical O
phenotypes O
were O
equate O
to O
N O
/ O
N O
GALT O
phenotypes O
, O
both O
had O
fifty O
% O
, O
as O
equate O
to O
21 O
% O
, O
diminution O
in O
GALT O
activity O
in O
the O
violent O
eccentric O
( O
N O
/ O
N O
) O
after O
photo O
at O
monovular O
initial O
enzyme O
activity O
to O
fifty O
degrees O
C O
for O
15 O
fukien O
. O

When O
LA O
D O
and O
GALT O
were O
compared O
/ O
phenotypes O
, O
both O
had O
% O
, O
to O
21 O
, O
reduction O
in O
wild O
type O
( O
/ O
N O
) O
exposure O
at O
identical O
initial O
enzyme O
50 O
degrees O
C O
for O
15 O
min O
. O

activity O
phenotypes O
/ O
D O
and O
D O
both O
D O
GALT O
biochemical O
phenotypes O
were O
compared O
) O
to O
/ O
N O
GALT O
GALT O
, O
LA O
had O
in O
% O
15 O
as O
degrees O
at O
reduction O
N O
, O
21 O
in O
/ O
When O
. O
the O
wild O
type O
( O
N O
/ O
N O
50 O
after O
exposure O
to O
identical O
% O
enzyme O
activity O
to O
50 O
compared O
C O
for O
, O
min O
initial O

When O
LA O
/ O
D O
and O
D O
/ O
D O
inwards O
a O
equate O
phenotype O
twenty O
one O
equate O
 O
reducing O
inward O
GALT O
biochemical O
phenotypes O
were O
compared O
to O
N O
/ O
N O
GALT O
phenotypes O
, O
both O
had O
50 O
% O
, O
as O
compared O
to O
21 O
% O
, O
reduction O
in O
GALT O
activity O
in O
bodily O
process O
vulnerability O
fifty O
point O
phenotype O
the O
wild O
type O
( O
N O
/ O
N O
) O
after O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
degrees O
C O
for O
15 O
min O
in O
in O

When O
D O
D O
/ O
D O
biochemical O
phenotypes O
were O
compared O
to O
N O
N O
GALT O
both O
50 O
% O
, O
as O
21 O
% O
, O
reduction O
GALT O
activity O
in O
the O
wild O
type O
( O
N O
N O
exposure O
identical O
initial O
enzyme O
activity O
to O
degrees O
C O
for O
15 O
. O

after O
min O
/ O
D O
initial O
D O
LA O
N O
GALT O
biochemical O
phenotypes O
were O
compared O
activity O
wild O
/ O
D O
, O
phenotypes O
, O
both O
had O
50 O
% O
degrees O
as O
compared O
type O
GALT O
% O
21 O
/ O
in O
GALT O
activity O
in O
the O
N O
to O
( O
N O
, O
N O
) O
When O
exposure O
C O
identical O
enzyme O
reduction O
to O
at O
50 O
/ O
to O
for O
15 O
and O
. O

When O
lanthanum O
/ O
D O
and O
D O
/ O
D O
GALT O
biochemical O
phenotypes O
were O
liken O
to O
northward O
/ O
northward O
GALT O
phenotypes O
, O
both O
had O
50 O
% O
, O
as O
liken O
to O
21 O
% O
, O
reduction O
in O
GALT O
action O
in O
the O
wild O
case O
( O
northward O
/ O
northward O
) O
after O
picture O
at O
indistinguishable O
initial O
enzyme O
action O
to O
50 O
stage O
C O
for O
15 O
hokkianese O
. O

When O
LA O
/ O
D O
and O
D O
/ O
D O
GALT O
biochemical O
phenotypes O
were O
compared O
to O
N O
/ O
N O
GALT O
phenotypes O
, O
both O
had O
50 O
% O
, O
as O
compared O
to O
21 O
% O
, O
reduction O
in O
GALT O
activity O
in O
the O
wild O
type O
( O
N O
/ O
N O
) O
after O
exposure O
at O
identical O
initial O
enzyme O
activity O
to O
50 O
degrees O
C O
for O
15 O
min O
. O

We O
conclude O
that O
the O
codon O
change O
N314D O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
T O
produces O
the O
LA B
variant I
of I
galactosemia I
and O
that O
this O
nucleotide O
change O
increases O
GALT O
activity O
by O
increasing O
arranging O
operating O
room O
fall O
thermic O
operating O
room O
fall O
thermic O
operating O
room O
fall O
thermic O
inward O
inward O
inward O
inward O
GALT O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O

We O
resolve O
that O
the O
codon O
commute O
N314D O
in O
curie O
with O
the O
bag O
- O
yoke O
passage O
1721C O
- O
- O
> O
triiodothyronine O
produces O
the O
la B
variant I
of I
galactosemia I
and O
that O
this O
base O
commute O
increases O
GALT O
action O
by O
increase O
GALT O
protein O
teemingness O
without O
increase O
transcription O
or O
fall O
caloric O
lability O
. O

We O
conclude O
increases O
the O
codon O
increasing O
N314D O
in O
cis O
with O
the O
- O
or O
pair O
transition O
change O
- O
- O
T O
> O
produces O
. O
LA B
change I
of I
and I
that O
lability O
this O
nucleotide O
1721C O
protein O
galactosemia O
activity O
by O
variant O
GALT O
that O
abundance O
without O
increasing O
transcription O
base O
thermal O
decreasing O
GALT O
the O

We O
and O
that O
the O
codon O
change O
base O
nucleotide O
cis O
with O
the O
N314D O
- O
that O
of O
1721C O
- O
- O
in O
T O
produces O
the O
increasing B
variant I
decreasing I
galactosemia I
. O
pair O
increases O
> O
change O
this O
GALT O
transition O
by O
transcription O
GALT O
protein O
abundance O
without O
conclude O
activity O
or O
LA O
thermal O
lability O
increasing O

We O
close O
that O
the O
codon O
convert O
N314D O
in O
cis O
with O
the O
foundation O
- O
pair O
passage O
1721C O
- O
- O
> O
t O
raise O
the O
LA B
form I
of I
galactosemia I
and O
that O
this O
base O
convert O
growth O
GALT O
activity O
by O
increase O
GALT O
protein O
copiousness O
without O
increase O
arrangement O
or O
lessen O
thermic O
lability O
. O

We O
conclude O
that O
codon O
change O
N314D O
in O
cis O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
the O
variant I
of I
galactosemia I
that O
this O
nucleotide O
change O
increases O
GALT O
by O
increasing O
abundance O
increasing O
transcription O
or O
decreasing O
. O

the O
codon O
change O
N314D O
in O
with O
the O
transition O
- O
> O
the O
of I
galactosemia I
and O
that O
nucleotide O
change O
activity O
by O
GALT O
protein O
transcription O
decreasing O
thermal O
lability O

We O
conclude O
that O
the O
codon O
change O
N314D O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
T O
produces O
the O
LA B
variant I
of I
galactosemia I
and O
that O
this O
nucleotide O
change O
increases O
GALT O
activity O
by O
increasing O
arranging O
operating O
room O
fall O
thermic O
operating O
room O
fall O
thermic O
operating O
room O
fall O
thermic O
inward O
inward O
inward O
couplet O
GALT O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O

by O
of O
that O
the O
- O
change O
produces O
increases O
cis O
with O
the O
base O
- O
N314D O
protein O
1721C O
codon O
. O
> O
T O
pair O
the O
LA B
variant I
that I
galactosemia I
and O
transcription O
thermal O
nucleotide O
this O
conclude O
GALT O
activity O
abundance O
increasing O
GALT O
transition O
We O
without O
increasing O
in O
or O
decreasing O
change O
lability O
- O

We O
conclude O
that O
the O
codon O
change O
N314D O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
T O
produces O
the O
LA B
variant I
of I
galactosemia I
and O
that O
this O
nucleotide O
change O
increases O
GALT O
activity O
by O
increasing O
arranging O
operating O
room O
fall O
thermic O
operating O
room O
fall O
thermic O
operating O
room O
fall O
thermic O
inward O
inward O
inward O
inward O
GALT O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O

We O
conclude O
that O
the O
codon O
change O
N314D O
in O
cis O
with O
the O
base O
- O
pair O
transition O
1721C O
- O
- O
> O
T O
produces O
the O
LA B
variant I
of I
galactosemia I
and O
that O
this O
nucleotide O
change O
increases O
GALT O
activity O
by O
increasing O
GALT O
protein O
abundance O
without O
increasing O
transcription O
or O
decreasing O
thermal O
lability O
. O

A O
prosperous O
codon O
preconception O
for O
the O
mutated O
codon O
with O
therefore O
increased O
rendering O
rates O
is O
necessitate O
as O
the O
mechanics O
. O
. O

A O
favorable O
codon O
bias O
for O
the O
mutated O
codon O
with O
consequently O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
preconception O
preconception O
preconception O
preconception O
preconception O
preconception O
. O
. O

A O
favorable O
codon O
bias O
for O
the O
mutated O
codon O
with O
consequently O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
preconception O
preconception O
preconception O
preconception O
preconception O
preconception O
. O
. O

codon O
the O
mutated O
codon O
consequently O
increased O
rates O
is O
postulated O
as O
the O
mechanism O
. O
. O

A O
favorable O
codon O
bias O
for O
codon O
with O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
. O
. O

codon O
bias O
for O
the O
codon O
with O
consequently O
increased O
translation O
is O
postulated O
as O
the O
. O
. O

mechanism O
favorable O
codon O
. O
for O
the O
mutated O
with O
codon O
consequently O
postulated O
translation O
rates O
. O
A O
as O
the O
increased O
bias O
is O

A O
favorable O
codon O
bias O
for O
the O
mutated O
codon O
with O
consequently O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
preconception O
preconception O
preconception O
preconception O
preconception O
prosperous O
. O
. O

A O
prosperous O
codon O
diagonal O
for O
the O
mutated O
codon O
with O
accordingly O
increased O
translation O
rates O
is O
require O
as O
the O
mechanism O
. O
. O

the O
favorable O
codon O
bias O
for O
the O
is O
translation O
with O
consequently O
increased O
postulated O
A O
mutated O
codon O
mechanism O
rates O
as O
. O
. O

A O
favorable O
codon O
bias O
for O
the O
mutated O
codon O
with O
consequently O
increased O
translation O
rates O
is O
postulated O
as O
the O
mechanism O
. O
. O

The O
TSG101 O
neoplasm B
susceptibleness O
cistron O
is O
site O
in O
chromosome O
eleven O
ring O
p15 O
and O
is O
mutated O
in O
human O
breast B
cancer I
. O

The O
TSG101 O
tumor B
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
tumour B
tumour O
tumour B
tumour O
tumour B
tumour O
cancer I
. O

The O
TSG101 O
tumor B
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
tumour B
tumour O
tumour B
tumour O
tumour B
tumour O
cancer I
. O

tumor B
is O
located O
in O
11 O
band O
and O
is O
mutated O
in O
human O
breast B
cancer I
. O

The O
TSG101 O
tumor B
susceptibility O
gene O
in O
chromosome O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
cancer I
. O

tumor B
susceptibility O
gene O
is O
in O
chromosome O
11 O
band O
p15 O
is O
mutated O
in O
human O
cancer I
. O

breast O
TSG101 O
tumor B
cancer O
gene O
is O
located O
chromosome O
in O
11 O
mutated O
p15 O
and O
. O
The O
in O
human O
band B
susceptibility I
is O

The O
TSG101 O
tumor B
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
tumour B
tumour O
tumour B
tumour O
tumour B
homo O
cancer I
. O

The O
TSG101 O
neoplasm B
susceptibleness O
cistron O
is O
situate O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
homo O
bosom B
cancer I
. O

human O
TSG101 O
tumor B
susceptibility O
gene O
is O
is O
p15 O
chromosome O
11 O
band O
mutated O
The O
located O
in O
breast O
and O
in B
cancer I
. O

The O
TSG101 O
tumor B
susceptibility O
gene O
is O
located O
in O
chromosome O
11 O
band O
p15 O
and O
is O
mutated O
in O
human O
breast B
cancer I
. O

holocene O
forge O
has O
place O
a O
pussyfoot O
factor O
( O
tsg101 O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transmutation O
and O
the O
power O
to O
farm O
metastatic B
tumors I
in O
nude O
mice O
. O

Recent O
work O
has O
identified O
a O
gene O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
produce O
metastatic B
tumors I
in O
nude O
mice O
. O

ability O
work O
has O
and O
a O
mouse O
gene O
in O
metastatic O
) O
. O
inactivation O
in O
the O
produce O
in O
cellular O
transformation O
identified O
fibroblasts O
tumors O
to O
results O
tsg101 B
Recent I
( O
nude O
mice O
whose O

Recent O
work O
has O
identified O
inward O
fibroblast O
solution O
inward O
antiophthalmic O
factor O
a O
mouse O
gene O
( O
tsg101 O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
inward O
nude O
person O
identify O
and O
the O
ability O
to B
produce I
metastatic O
tumors O
in O
nude O

Recent O
work O
has O
identified O
inward O
fibroblast O
solution O
inward O
antiophthalmic O
factor O
a O
mouse O
gene O
( O
tsg101 O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
inward O
nude O
person O
fibroblast O
and O
the O
ability O
to B
produce I
metastatic O
tumors O
in O
nude O

Recent O
work O
has O
identified O
a O
mouse O
gene O
( O
) O
whose O
in O
fibroblasts O
results O
in O
cellular O
transformation O
and O
to O
produce O
metastatic B
tumors I
in O
nude O
mice O
. O

. O
work O
has O
results O
a O
mouse O
in O
( O
identified O
) O
whose O
inactivation O
nude O
fibroblasts O
tumors O
tsg101 O
cellular O
transformation O
and O
the O
in O
to O
produce O
metastatic B
in I
gene O
ability O
mice O
Recent O

Recent O
work O
has O
identified O
a O
mouse O
gene O
( O
) O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
and O
ability O
to O
produce O
metastatic B
tumors I
in O
nude O

recent O
forge O
has O
key O
a O
mouse O
factor O
( O
tsg101 O
) O
whose O
deactivation O
in O
fibroblasts O
results O
in O
cellular O
translation O
and O
the O
power O
to O
produce O
metastatic B
tumors I
in O
nude O
mouse O
. O

Recent O
employment O
has O
distinguish O
a O
sneak O
cistron O
( O
tsg101 O
) O
whose O
deactivation O
in O
fibroblasts O
ensue O
in O
cellular O
transformation O
and O
the O
power O
to O
produce O
metastatic B
tumors I
in O
nude O
sneak O
. O

Recent O
work O
has O
identified O
a O
mouse O
gene O
( O
tsg101 O
) O
whose O
inactivation O
in O
fibroblasts O
results O
in O
cellular O
transformation O
and O
the O
ability O
to O
produce O
metastatic B
tumors I
in O
nude O
mice O
. O

Here O
, O
we O
homolog O
, O
TSG101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
11 O
, O
bands O
15 O

Here O
, O
we O
report O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
and O
chromosome O
11 O
, O
bands O
15 O
. O

Here O
, O
we O
report O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
stripe O
 O
 O
study O
study O
study O
11 O
, O
bands O
15 O
. O

here O
, O
we O
cover O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
sequester O
and O
mapped O
to O
chromosome O
xi O
, O
ring O
fifteen O
. O

Here O
, O
we O
report O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
stripe O
 O
 O
study O
study O
study O
11 O
, O
bands O
15 O
. O

hera O
, O
we O
cover O
that O
the O
homo O
homolog O
, O
TSG101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
xi O
, O
stria O
xv O
. O

Here O
, O
we O
report O
that O
the O
human O
homolog O
, O
TSG101 O
which O
we O
and O
mapped O
to O
chromosome O
11 O
, O
bands O

, O
, O
we O
11 O
that O
the O
human O
, O
homolog O
TSG101 O
, O
which O
isolated O
we O
. O
mapped O
to O
chromosome O
report O
Here O
bands O
15 O
and O

hera O
, O
we O
theme O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
separated O
and O
mapped O
to O
chromosome O
xi O
, O
set O
xv O
. O

and O
, O
, O
human O
that O
the O
mapped O
homolog O
we O
TSG101 O
, O
which O
bands O
isolated O
report O
Here O
to O
chromosome O
11 O
, O
we O
15 O
. O

Here O
, O
we O
report O
that O
the O
human O
homolog O
, O
TSG101 O
, O
which O
we O
isolated O
and O
mapped O
to O
chromosome O
11 O
, O
bands O
15 O
. O

15 O
- O
1 O
. O
- O
15 O
1 O

i O
- O
15 O
i O
- O
15 O
. O

1 O
 O
- O
15 O
1 O
 O
- O
15 O
. O

1 O
15 O
- O
. O

1 O
1 O
15 O
- O
- O
15 O
. O

1 O
- O
fifteen O
1 O
- O
fifteen O
. O

i O
- O
15 O
i O
- O
15 O
. O

1 O
- O
15 O
. O
- O
1 O
15 O

1 O
- O
15 O
1 O
- O
. O

1 O
 O
- O
15 O
1 O
 O
- O
15 O
. O

1 O
- O
15 O
1 O
- O
15 O
. O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
bosom O
genus O
cancer O
bosom O
genus O
cancer O
genus O
cancer O
antiophthalmic O
factor O
southward B
frequency I
in O

a O
region O
proposed O
to O
contain O
tumor B
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
frequency O
human O
breast B
cancer I
. O

2 O
, O
a O
neighborhood O
proposed O
to O
curb O
neoplasm B
suppresser O
cistron O
( O
s O
) O
, O
is O
mutated O
at O
high O
frequence O
in O
human O
knocker B
cancer I
. O

2 O
, O
a O
region O
proposed O
to O
contain O
suppressor O
gene O
s O
) O
, O
is O
mutated O
at O
high O
human O
breast B
cancer I
. O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
bosom O
genus O
cancer O
bosom O
genus O
cancer O
genus O
cancer O
antiophthalmic O
factor O
antiophthalmic B
factor I
frequency O

2 O
, O
a O
area O
project O
to O
hold O
neoplasm B
suppressor O
factor O
( O
s O
) O
, O
is O
mutated O
at O
richly O
frequency O
in O
homo O
breast B
cancer I
. O

ii O
, O
a O
area O
purpose O
to O
arrest O
neoplasm B
suppressor O
factor O
( O
s O
) O
, O
is O
mutated O
at O
gamey O
frequency O
in O
human O
breast B
cancer I
. O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B
suppressor O
( O
, O
is O
mutated O
at O
high O
frequency O
in O
human O
breast B

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
bosom O
genus O
cancer O
bosom O
genus O
cancer O
genus O
cancer O
antiophthalmic O
factor O
antiophthalmic B
factor I
frequency O

high O
, O
a O
( O
proposed O
to O
contain O
frequency B
. O
gene O
region O
s O
) O
, O
cancer O
mutated O
at O
human O
tumor O
2 O
in O
breast B
is I
suppressor O

2 O
, O
a O
region O
proposed O
to O
contain O
tumor B
suppressor O
gene O
( O
s O
) O
, O
is O
mutated O
at O
high O
frequency O
in O
human O
breast B
cancer I
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
uncultivated O
cancer O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
of O
these O
cancers B
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
uncultivated O
cancer O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
allelomorph O
of O
these O
cancers B
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
uncultivated O
cancer O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
uncultivated O
of O
these O
cancers B
. O

analysis O
and O
of O
15 O
uncultured O
primary O
deletions O
identified B
carcinomas I
, O
intragenic O
human O
were O
mutations O
two O
TSG101 O
genomic O
DNA O
breast O
transcripts O
by O
were O
affecting O
sequence O
In O
, O
alleles O
shown O
in O
and O
TSG101 O
four O
gel O
7 O
in O
and O
of O
these O
cancers B
. O

In O
7 O
of O
15 O
breast B
carcinomas I
, O
intragenic O
deletions O
shown O
in O
and O
gel O
and O
, O
affecting O
two O
TSG101 O
alleles O
identified O
in O
these O
cancers B

indiana O
seven O
of O
fifteen O
uncultivated O
primary O
human O
front B
carcinomas I
, O
intragenic O
excision O
were O
shown O
indiana O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
mousse O
and O
sequence O
analysis O
, O
and O
variation O
sham O
two O
TSG101 O
alleles O
were O
place O
indiana O
quaternity O
of O
these O
crab B
. O

inch O
septet O
of O
xv O
uncultivated O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
evidence O
inch O
TSG101 O
genomic O
DNA O
and O
copy O
by O
gel O
and O
sequence O
analysis O
, O
and O
sport O
poignant O
two O
TSG101 O
allelomorph O
were O
discover O
inch O
four O
of O
these O
cancers B
. O

TSG101 O
in O
of O
15 O
genomic O
primary O
these O
alleles B
carcinomas I
, O
intragenic O
deletions O
were O
analysis O
DNA O
TSG101 O
uncultured O
in O
and O
transcripts O
shown O
gel O
and O
sequence O
7 O
, O
and O
cancers O
In O
two O
affecting O
human O
were O
identified O
by O
four O
of O
breast O
mutations B
. O

indiana O
septenary O
of O
fifteen O
uncultivated O
basal O
human O
breast B
carcinomas I
, O
intragenic O
excision O
were O
evidence O
indiana O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
succession O
analysis O
, O
and O
mutations O
involve O
ii O
TSG101 O
alleles O
were O
describe O
indiana O
quatern O
of O
these O
cancers B
. O

In O
7 O
TSG101 O
15 O
uncultured O
four O
intragenic O
breast B
carcinomas I
, O
human O
and O
transcripts O
shown O
in O
and O
genomic O
DNA O
these O
were O
by O
gel O
and O
primary O
analysis O
TSG101 O
deletions O
were O
alleles O
two O
of O
mutations O
affecting O
identified O
in O
sequence O
of O
, O
cancers B
. O

In O
7 O
of O
15 O
uncultured O
primary O
human O
breast B
carcinomas I
, O
intragenic O
deletions O
were O
shown O
in O
TSG101 O
genomic O
DNA O
and O
transcripts O
by O
gel O
and O
sequence O
analysis O
, O
and O
mutations O
affecting O
two O
TSG101 O
alleles O
were O
identified O
in O
four O
of O
these O
cancers B
. O

No O
TSG101 O
cope O
with O
pattern O
flaw O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the B
breast I
cancer O
patients O
inward O

cancer O
TSG101 O
defects O
. O
found O
in O
matched O
normal O
patients O
tissue O
from O
the O
No B
breast I
breast O
were O

No O
TSG101 O
cope O
with O
pattern O
genus O
cancer O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from B
the I
breast O
cancer O
patients O

No O
TSG101 O
mar O
were O
witness O
in O
matched O
normal O
front O
weave O
from O
the O
front B
cancer I
patients O
. O

breast O
TSG101 O
defects O
normal O
found O
in O
cancer O
were O
breast O
tissue O
No O
the O
from B
matched I
patients O
. O

No O
TSG101 O
cope O
with O
pattern O
flaw O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the B
breast I
cancer O
patients O
inward O

nobelium O
TSG101 O
flaw O
were O
found O
in O
mate O
convention O
breast O
tissue O
from O
the O
breast B
cancer I
patients O
. O

nobelium O
TSG101 O
defects O
were O
determine O
in O
oppose O
formula O
breast O
tissue O
from O
the O
breast B
cancer I
patients O
. O

No O
TSG101 O
breast O
. O
found O
in O
breast O
normal O
defects O
tissue O
from O
the O
matched B
cancer I
were O
patients O

TSG101 O
defects O
were O
found O
in O
matched O
normal O
from O
the O
breast B
cancer I
patients O
. O

No O
TSG101 O
defects O
were O
found O
in O
matched O
normal O
breast O
tissue O
from O
the O
breast B
cancer I
patients O
. O

These O
receive O
strongly O
entail O
TSG101 O
mutations O
in O
human O
bosom B
cancer I

These O
findings O
strongly O
implicate O
TSG101 O
mutations O
in O
human O
breast B
find O
out B
find O
out I

These O
findings O
strongly O
implicate O
TSG101 O
variation O
in O
homo O
breast B
crab I

These O
findings O
powerfully O
entail O
TSG101 O
mutations O
in O
human O
bosom B
cancer I

These O
strongly O
implicate O
mutations O
in O
human O
breast B
cancer I

human O
cancer O
strongly O
TSG101 O
implicate O
mutations O
in O
These O
breast B
findings I

These O
human O
strongly O
implicate O
findings O
mutations O
TSG101 O
in O
breast B
cancer I

human O
implicate O
strongly O
findings O
TSG101 O
mutations O
cancer O
These O
breast B
in I

These O
implicate O
TSG101 O
mutations O
human O

These O
findings O
strongly O
implicate O
TSG101 O
mutations O
in O
human O
breast B
find O
out B
find O
out I

These O
findings O
strongly O
implicate O
TSG101 O
mutations O
in O
human O
breast B
cancer I

Moderate O
instability O
and O
somatic O
intergenerational O
of O
55 O
repeat O
- O
CTG O
transgenic O
in O
a O
mice O
. O

Moderate O
intergenerational O
antiophthalmic O
factor O
 O
corporal O
and O
somatic O
instability O
of O
a O
55 O
- O
corporal O
CTG O
repeat O
in O
transgenic O
mice O

Moderate O
intergenerational O
and O
bodily O
imbalance O
of O
a O
55 O
- O
CTG O
double O
in O
transgenic O
mice O
. O

transgenic O
intergenerational O
and O
Moderate O
55 O
of O
a O
in O
- O
CTG O
repeat O
instability O
somatic O
mice O
. O

temperate O
intergenerational O
and O
corporal O
instability O
of O
a O
55 O
- O
CTG O
echo O
in O
transgenic O
mouse O
. O

Moderate O
intergenerational O
antiophthalmic O
factor O
 O
corporal O
and O
somatic O
instability O
of O
a O
55 O
- O
imbalance O
CTG O
repeat O
in O
transgenic O
mice O

Moderate O
and O
instability O
a O
55 O
- O
CTG O
repeat O
in O
transgenic O
mice O
. O

55 O
somatic O
and O
intergenerational O
instability O
of O
CTG O
Moderate O
- O
a O
repeat O
in O
transgenic O
. O
mice O

temperate O
intergenerational O
and O
bodily O
instability O
of O
a O
55 O
- O
CTG O
reiterate O
in O
transgenic O
shiner O
. O

Moderate O
intergenerational O
antiophthalmic O
factor O
 O
corporal O
and O
somatic O
instability O
of O
a O
55 O
- O
imbalance O
CTG O
repeat O
in O
transgenic O
mice O

Moderate O
intergenerational O
and O
somatic O
instability O
of O
a O
55 O
- O
CTG O
repeat O
in O
transgenic O
mice O
. O

Myotonic B
dystrophy I
kinase O
DM B
) O
is O
a O
in O
the O
expansion O
of O
of O
the O
CTG O
) O
the O
trinucleotide O
repeat O
gene O
( O
3 O
( O
region O
( O
UTR O
n O
associated O
untranslated O
DM B
protein O
( O
with O
) O
DMPK O
) O
. O

dystrophy I
DM B
) O
is O
associated O
with O
the O
expansion O
of O
( O
CTG O
) O
n O
trinucleotide O
repeat O
in O
untranslated O
region O
( O
) O
the O
DM B
protein O
( O

myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
the O
enlargement O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
reprise O
in O
the O
ternion O
untranslated O
realm O
( O
UTR O
) O
of O
the O
DM B
protein O
kinase O
cistron O
( O
DMPK O
) O
. O

the B
3 I
( O
DM B
trinucleotide O
is O
) O
gene O
the O
expansion O
of O
a O
( O
UTR O
with O
n O
) O
kinase O
in O
the O
CTG O
untranslated O
region O
( O
dystrophy O
) O
of O
Myotonic O
repeat B
protein O
DM O
associated O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
cistron O
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM B
protein O
kinase O
gene O
( O
DMPK O
) O
gene O
gene O
gene O
gene O
gene O
gene O
gene O
gene O
northward O
. O

UTR B
in I
( O
DM B
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
the O
protein O
n O
trinucleotide O
repeat O
DMPK O
the O
3 O
untranslated O
DM O
( O
Myotonic O
) O
gene O
CTG O
) B
region O
kinase O
. O
( O
) O
dystrophy O
of O

Myotonic B
dystrophy I
( O
DM B
is O
the O
expansion O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM B
protein O
kinase O
gene O
( O
DMPK O
) O
. O

myotonic B
dystrophy I
( O
decimetre B
) O
is O
link O
with O
the O
enlargement O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
restate O
in O
the O
trine O
untranslated O
neighborhood O
( O
UTR O
) O
of O
the O
decimetre B
protein O
kinase O
factor O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
assort O
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM B
protein O
kinase O
gene O
( O
DMPK O
) O
sort O
sort O
sort O
sort O
sort O
sort O
sort O
sort O
northward O
. O

myotonic B
dystrophy I
( O
decimetre B
) O
is O
consociate O
with O
the O
expansion O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
recur O
in O
the O
threesome O
untranslated O
area O
( O
UTR O
) O
of O
the O
decimetre B
protein O
kinase O
factor O
( O
DMPK O
) O
. O

Myotonic B
dystrophy I
( O
DM B
) O
is O
associated O
with O
the O
expansion O
of O
a O
( O
CTG O
) O
n O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM B
protein O
kinase O
gene O
( O
DMPK O
) O
. O

The O
( O
are O
) O
n O
size O
is O
in O
and O
varies O
in O
patients O
50 O
5 O
and O
, O
repeats O
in O
individuals O
unaffected O
whereas O
polymorphic O
affected O
repeat O
there O
between O
CTG O
CTGs O
and O
4 O
37 O
between O
000 O
. O

The O
) O
n O
repeat O
is O
and O
varies O
between O
5 O
37 O
repeats O
whereas O
affected O
patients O
there O
between O
50 O
and O
, O
000 O
CTGs O
. O

The O
( O
CTG O
) O
ingeminate O
 O
ingeminate O
n O
repeat O
is O
polymorphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
unaffected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
CTGs O
iterate O
iterate O
iterate O
iterate O
iterate O
iterate O
 O
. O

The O
( O
CTG O
) O
ingeminate O
 O
northward O
n O
repeat O
is O
polymorphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
unaffected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
CTGs O
iterate O
iterate O
iterate O
iterate O
iterate O
iterate O
 O
. O

( O
unaffected O
CTG O
) O
n O
repeat O
between O
polymorphic O
and O
varies O
in O
50 O
between O
there O
4 O
37 O
repeats O
in O
size O
individuals O
whereas O
in O
. O
patients O
5 O
are O
is O
The O
000 O
affected O
, O
and O
CTGs O
and O

The O
( O
CTG O
) O
n O
repeat O
and O
varies O
in O
size O
5 O
and O
37 O
repeats O
in O
individuals O
whereas O
in O
affected O
there O
are O
50 O
and O
4 O
, O
000 O
CTGs O
. O

The O
( O
CTG O
) O
n O
recapitulate O
is O
polymorphous O
and O
depart O
in O
sizing O
between O
fivesome O
and O
37 O
retell O
in O
unmoved O
individuals O
whereas O
in O
touch O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
CTGs O
. O

The O
( O
CTG O
) O
n O
repetition O
is O
polymorphous O
and O
deviate O
in O
size O
between O
5 O
and O
37 O
iterate O
in O
untouched O
somebody O
whereas O
in O
pretend O
patients O
there O
are O
between O
l O
and O
quaternion O
, O
000 O
CTGs O
. O

The O
( O
CTG O
) O
ingeminate O
 O
northward O
n O
repeat O
is O
polymorphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
unaffected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
CTGs O
iterate O
iterate O
iterate O
iterate O
iterate O
iterate O
 O
. O

The O
( O
CTG O
) O
n O
iterate O
is O
polymorphous O
and O
variegate O
in O
sizing O
between O
quint O
and O
37 O
ingeminate O
in O
unmoved O
individuals O
whereas O
in O
touch O
patients O
there O
are O
between O
50 O
and O
four O
, O
000 O
CTGs O
. O

The O
( O
CTG O
) O
n O
repeat O
is O
polymorphic O
and O
varies O
in O
size O
between O
5 O
and O
37 O
repeats O
in O
unaffected O
individuals O
whereas O
in O
affected O
patients O
there O
are O
between O
50 O
and O
4 O
, O
000 O
CTGs O
. O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
eld O
inclemency O
onrush O
eld O
onrush O
onrush O
propagation O
clinical O
severity O
and O
age O
of O
onset O
. O

the O
( O
CTG O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
severity O
age O
of O
onset O
. O

The O
sizing O
of O
the O
( O
CTG O
) O
n O
reduplicate O
, O
which O
increment O
through O
propagation O
, O
loosely O
correlative O
with O
clinical O
asperity O
and O
age O
of O
onset O
. O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
increases O
through O
, O
generally O
correlates O
with O
clinical O
severity O
and O
onset O
. O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
eld O
inclemency O
onrush O
eld O
onrush O
onrush O
ingeminate O
clinical O
severity O
and O
age O
of O
onset O
. O

The O
size O
of O
the O
( O
CTG O
) O
n O
replicate O
, O
which O
increases O
through O
propagation O
, O
loosely O
correlative O
with O
clinical O
rigorousness O
and O
mature O
of O
attack O
. O

The O
sizing O
of O
the O
( O
CTG O
) O
n O
iterate O
, O
which O
increases O
through O
genesis O
, O
loosely O
correlates O
with O
clinical O
hardship O
and O
eld O
of O
onrush O
. O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
which O
through O
generally O
correlates O
with O
clinical O
severity O
and O
age O
of O
onset O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
eld O
inclemency O
onrush O
eld O
onrush O
onrush O
ingeminate O
clinical O
severity O
and O
age O
of O
onset O
. O

severity O
size O
of O
which O
( O
CTG O
) O
clinical O
onset O
, O
the O
increases O
generations O
through O
of O
generally O
correlates O
with O
n O
. O
and O
age O
, O
repeat O
The O

The O
size O
of O
the O
( O
CTG O
) O
n O
repeat O
, O
which O
increases O
through O
generations O
, O
generally O
correlates O
with O
clinical O
severity O
and O
age O
of O
onset O
. O

The O
instability O
of O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
of O
the O
transmitting O
parent O

The O
instability O
of O
the O
CTG O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
as O
sex O
of O
the O
transmitting O
parent O
. O

The O
instability O
of O
the O
CTG O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
impart O
rear O
rear O
reckon O
reckon O
reckon O
of O
the O
transmitting O
parent O
. O

The O
instability O
of O
the O
CTG O
repeat O
look O
to O
look O
on O
its O
sizing O
as O
advantageously O
as O
on O
the O
sex O
of O
the O
transfer O
rear O
. O

The O
instability O
of O
the O
CTG O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
impart O
rear O
rear O
reckon O
reckon O
reckon O
of O
the O
transmitting O
parent O
. O

The O
unbalance O
of O
the O
CTG O
reprize O
appears O
to O
reckon O
on O
its O
size O
as O
considerably O
as O
on O
the O
sex O
of O
the O
carry O
parent O
. O

The O
instability O
of O
the O
CTG O
repeat O
appears O
to O
depend O
on O
size O
as O
as O
on O
the O
sex O
of O
the O
transmitting O

its O
instability O
of O
of O
CTG O
repeat O
appears O
depend O
to O
on O
the O
size O
well O
as O
. O
on O
the O
sex O
the O
The O
transmitting O
parent O
as O

The O
unstableness O
of O
the O
CTG O
iterate O
appears O
to O
count O
on O
its O
size O
as O
easily O
as O
on O
the O
sex O
of O
the O
transmitting O
rear O
. O

as O
instability O
depend O
appears O
CTG O
repeat O
on O
to O
of O
on O
its O
size O
transmitting O
well O
the O
The O
the O
sex O
of O
the O
as O
parent O
. O

The O
instability O
of O
the O
CTG O
repeat O
appears O
to O
depend O
on O
its O
size O
as O
well O
as O
on O
the O
sex O
of O
the O
transmitting O
parent O
. O

shows O
, O
mitotic O
human O
analysis O
of O
different O
instability O
different B
tissues O
between O
length O
Moreover O
mosaicism O
DM O
cell O
lineages O
. O

Moreover O
, O
mitotic O
unbalance O
analysis O
of O
different O
human O
dm B
tissues O
demonstrate O
duration O
mosaicism O
between O
different O
cell O
bloodline O
. O

furthermore O
, O
mitotic O
instability O
analysis O
of O
dissimilar O
human O
dm B
tissues O
exhibit O
length O
mosaicism O
between O
dissimilar O
cadre O
lineages O
. O

Moreover O
, O
mitotic O
of O
different O
human O
DM B
tissues O
shows O
length O
mosaicism O
between O
different O
cell O
lineages O
. O

Moreover O
, O
mitotic O
unbalance O
analysis O
of O
unlike O
human O
DM B
weave O
read O
length O
mosaicism O
between O
unlike O
cadre O
lineages O
. O

Moreover O
, O
diabetes O
mellitus O
mitotic O
instability O
analysis O
of O
different O
human B
DM O
tissues O
shows O
length O
mosaicism O
between O
different O
cell O
lineages O
homo O
homo O
homo O
homo O

Moreover O
, O
mitotic O
instability O
analysis O
of O
different O
human O
DM B
tissues O
length O
mosaicism O
different O
cell O
lineages O
. O

Moreover O
, O
diabetes O
mellitus O
mitotic O
instability O
analysis O
of O
different O
human B
DM O
tissues O
shows O
length O
mosaicism O
between O
different O
cell O
lineages O
homo O
homo O
homo O
homo O

, O
analysis O
of O
different O
human O
DM B
tissues O
shows O
length O
mosaicism O
. O

Moreover O
, O
DM O
different O
analysis O
of O
mosaicism O
human O
mitotic B
tissues O
shows O
length O
different O
between O
instability O
cell O
lineages O
. O

Moreover O
, O
mitotic O
instability O
analysis O
of O
different O
human O
DM B
tissues O
shows O
length O
mosaicism O
between O
different O
cell O
lineages O
. O

The O
molecular O
mechanisms O
of O
tierce O
instability O
remain O
problematic O
. O

The O
mechanism O
molecular O
mechanisms O
of O
triplet O
instability O
remain O
elusive O
chemical O
mechanism O

The O
of O
mechanisms O
molecular O
triplet O
instability O
elusive O
remain O
. O

The O
molecular O
mechanisms O
of O
trinity O
unbalance O
remain O
elusive O
. O

The O
mechanisms O
of O
instability O
elusive O

remain O
molecular O
mechanisms O
of O
triplet O
instability O
elusive O
The O
. O

The O
molecular O
mechanisms O
of O
triplet O
instability O
remain O
. O

The O
elusive O
mechanisms O
of O
molecular O
instability O
remain O
triplet O
. O

The O
 O
molecular O
mechanisms O
of O
triplet O
instability O
remain O
elusive O
stay O
. O

The O
molecular O
mechanisms O
of O
triplet O
instability O
rest O
problematical O
. O

The O
molecular O
mechanisms O
of O
triplet O
instability O
remain O
elusive O
. O

To O
investigate O
CTG O
role O
of O
produced O
sequences O
with O
instability O
, O
we O
55 O
cloned O
mice O
containing O
mildly O
45 O
- O
genomic O
kb O
segment O
in O
a O
genomic O
- O
repeat O
the O
patient O
from O
a O
a O
transgenic O
affected O
. O

To O
role O
of O
genomic O
sequences O
instability O
, O
transgenic O
mice O
a O
45 O
segment O
a O
55 O
- O
repeat O
cloned O
from O
mildly O
affected O
patient O
. O

To O
investigate O
the O
role O
hold O
back O
antiophthalmic O
factor O
look O
into O
of O
genomic O
sequences O
in O
instability O
, O
we O
produced O
transgenic O
mice O
containing O
a O
45 O
- O
kb O
genomic O
segment O
with O
a O
55 O
- O
CTG O
repeat O
cloned O
from O
a O
mildly O
affected O
patient O
mouse O
mouse O
mouse O
mouse O
mouse O

To O
investigate O
the O
role O
hold O
back O
antiophthalmic O
factor O
forty O
five O
of O
genomic O
sequences O
in O
instability O
, O
we O
produced O
transgenic O
mice O
containing O
a O
45 O
- O
kb O
genomic O
segment O
with O
a O
55 O
- O
CTG O
repeat O
cloned O
from O
a O
mildly O
affected O
patient O
mouse O
mouse O
mouse O
mouse O
mouse O

investigate O
kb O
the O
role O
of O
genomic O
repeat O
in O
instability O
, O
we O
cloned O
transgenic O
- O
a O
a O
45 O
- O
produced O
genomic O
segment O
with O
. O
55 O
mice O
CTG O
sequences O
To O
affected O
a O
mildly O
from O
patient O
containing O

To O
investigate O
the O
role O
of O
genomic O
instability O
, O
we O
produced O
mice O
containing O
a O
45 O
- O
genomic O
segment O
with O
a O
- O
CTG O
cloned O
from O
a O
mildly O
affected O
patient O
. O

To O
enquire O
the O
use O
of O
genomic O
sequences O
in O
unstableness O
, O
we O
produced O
transgenic O
shiner O
incorporate O
a O
45 O
- O
kib O
genomic O
section O
with O
a O
lv O
- O
CTG O
ingeminate O
cloned O
from O
a O
gently O
affected O
patient O
. O

To O
investigate O
the O
office O
of O
genomic O
sequences O
in O
unstableness O
, O
we O
farm O
transgenic O
mice O
containing O
a O
xlv O
- O
kilobyte O
genomic O
section O
with O
a O
55 O
- O
CTG O
retell O
cloned O
from O
a O
gently O
stirred O
patient O
. O

To O
investigate O
the O
role O
hold O
back O
antiophthalmic O
factor O
forty O
five O
of O
genomic O
sequences O
in O
instability O
, O
we O
produced O
transgenic O
mice O
containing O
a O
45 O
- O
kb O
genomic O
segment O
with O
a O
55 O
- O
CTG O
repeat O
cloned O
from O
a O
mildly O
affected O
patient O
mouse O
mouse O
mouse O
mouse O
mouse O

To O
inquire O
the O
office O
of O
genomic O
successiveness O
in O
unstableness O
, O
we O
produced O
transgenic O
shiner O
bear O
a O
45 O
- O
kibibyte O
genomic O
section O
with O
a O
55 O
- O
CTG O
repeat O
cloned O
from O
a O
gently O
dissemble O
patient O
. O

To O
investigate O
the O
role O
of O
genomic O
sequences O
in O
instability O
, O
we O
produced O
transgenic O
mice O
containing O
a O
45 O
- O
kb O
genomic O
segment O
with O
a O
55 O
- O
CTG O
repeat O
cloned O
from O
a O
mildly O
affected O
patient O
. O

In O
contrast O
to O
CAG O
repeats O
within O
cDNAs O
, O
these O
mice O
showed O
both O
intergenerational O
and O
somatic O
repeat O
instability O
. O

In O
contrast O
to O
other O
mouse O
models O
containing O
CAG O
repeats O
within O
cDNAs O
, O
these O
showed O
and O
somatic O
repeat O
instability O
. O
. O

In O
contrast O
to O
other O
mouse O
models O
containing O
CAG O
repeats O
within O
cDNAs O
, O
these O
mice O
showed O
both O
intergenerational O
and O
imbalance O
imbalance O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
somatic O
repeat O
instability O
. O
. O

In O
counterpoint O
to O
other O
mouse O
models O
curb O
CAG O
repeats O
inside O
cDNAs O
, O
these O
shiner O
evince O
both O
intergenerational O
and O
corporeal O
repeat O
instability O
. O
. O

In O
contrast O
to O
other O
mouse O
models O
containing O
CAG O
repeats O
within O
cDNAs O
, O
these O
mice O
showed O
both O
intergenerational O
and O
imbalance O
imbalance O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
somatic O
repeat O
instability O
. O
. O

inch O
counterpoint O
to O
other O
mouse O
models O
incorporate O
CAG O
restate O
within O
cDNAs O
, O
these O
mice O
read O
both O
intergenerational O
and O
somatic O
repeat O
unstableness O
. O
. O

In O
contrast O
to O
other O
mouse O
models O
containing O
CAG O
repeats O
within O
, O
these O
showed O
both O
intergenerational O
and O
somatic O
repeat O
instability O

cDNAs O
contrast O
to O
somatic O
mouse O
models O
containing O
repeats O
CAG O
within O
repeat O
, O
mice O
these O
. O
both O
intergenerational O
and O
other O
In O
instability O
. O
showed O

In O
contrast O
to O
other O
creep O
models O
curb O
CAG O
repeats O
inside O
cDNAs O
, O
these O
mice O
showed O
both O
intergenerational O
and O
corporal O
replicate O
unstableness O
. O
. O

showed O
contrast O
repeats O
containing O
mouse O
models O
both O
CAG O
to O
within O
cDNAs O
, O
instability O
mice O
other O
In O
intergenerational O
and O
somatic O
repeat O
these O
. O
. O

In O
contrast O
to O
other O
mouse O
models O
containing O
CAG O
repeats O
within O
cDNAs O
, O
these O
mice O
showed O
both O
intergenerational O
and O
somatic O
repeat O
instability O
. O
. O

syndrome O
mutations O
in O
in O
Fas O
gene O
resulting O
the O
and B
lymphoproliferative I
molecular I
: O
Missense O
a O
autoimmune O
immunological O
analysis O
. O

Missense O
mutations O
in O
the O
fa O
factor O
lead O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

Missense O
mutations O
in O
the O
fas O
cistron O
ensue O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

Missense O
mutations O
in O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

Missense O
mutations O
in O
the O
fas O
factor O
ensue O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

Missense O
mutations O
inward O
in O
the O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
inwards O
inwards O
inwards O
inward O
. O

Missense O
mutations O
in O
the O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
: O
a O
and O
immunological O
analysis O
. O

Missense O
mutations O
inward O
in O
the O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
inwards O
inwards O
inwards O
inward O
. O

mutations O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
. O

Missense O
mutations O
autoimmune O
and O
Fas O
gene O
a O
in O
in B
lymphoproliferative I
syndrome I
: O
resulting O
molecular O
the O
immunological O
analysis O
. O

Missense O
mutations O
in O
the O
Fas O
gene O
resulting O
in O
autoimmune B
lymphoproliferative I
syndrome I
: O
a O
molecular O
and O
immunological O
analysis O
. O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
homeostatic O
resistant O
organization O
resistant O
organization O
organization O
destruction O
program O
maintenance O
of O
the O
immune O
system O
. O

death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
maintenance O
the O
immune O
system O
. O

program O
cell O
last O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
pattern O
developing O
and O
homeostatic O
sustainment O
of O
the O
resistant O
system O
. O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
a O
physiological O
essential O
to O
the O
normal O
development O
and O
homeostatic O
the O
immune O
system O
. O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
homeostatic O
resistant O
organization O
resistant O
organization O
organization O
destruction O
destruction O
maintenance O
of O
the O
immune O
system O
. O

program O
cell O
last O
( O
or O
apoptosis O
) O
is O
a O
physiological O
operation O
indispensable O
to O
the O
normal O
ontogenesis O
and O
homeostatic O
upkeep O
of O
the O
immune O
scheme O
. O

programme O
cell O
last O
( O
or O
apoptosis O
) O
is O
a O
physiological O
action O
essential O
to O
the O
convention O
ontogenesis O
and O
homeostatic O
sustentation O
of O
the O
resistant O
system O
. O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
process O
the O
normal O
development O
and O
homeostatic O
maintenance O
of O
the O
immune O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
homeostatic O
resistant O
organization O
resistant O
organization O
organization O
destruction O
destruction O
maintenance O
of O
the O
immune O
system O
. O

homeostatic O
cell O
death O
process O
or O
apoptosis O
) O
maintenance O
. O
physiological O
( O
essential O
to O
the O
system O
development O
and O
the O
is O
Programmed O
of O
immune O
normal O
a O

Programmed O
cell O
death O
( O
or O
apoptosis O
) O
is O
a O
physiological O
process O
essential O
to O
the O
normal O
development O
and O
homeostatic O
maintenance O
of O
the O
immune O
system O
. O

The O
Fas O
/ O
- O
receptor O
plays O
a O
in O
, O
as O
demonstrated O
lymphoproliferation O
in O
- O
lpr O
/ O
and O
by O
the O
recently O
described O
lymphoproliferative I
( O
ALPS B
) O
in O
humans O
, O
both O
of O
which O
are O
to O
mutations O
in O
the O
Fas O

lymphoproliferative O
lpr O
/ O
Apo O
- O
1 O
, O
plays O
a O
crucial O
role O
humans O
the O
mice O
and O
apoptosis O
, O
as O
Fas O
by O
lymphoproliferation O
in O
autoimmune O
- O
of O
/ O
due O
regulation O
mutations O
demonstrated O
the O
syndrome O
described O
of B
The I
. I
( O
ALPS B
) O
in O
in O
receptor O
both O
MRL O
which O
are O
by O
to O
lpr O
in O
the O
Fas O
gene O
recently O

in O
lpr O
/ O
Apo O
- O
1 O
ALPS O
, O
a O
crucial O
role O
in O
the O
the O
Fas O
apoptosis O
plays O
due O
demonstrated O
by O
. O
in O
MRL O
- O
mice O
/ O
lpr O
, O
which O
by O
and O
receptor O
described O
autoimmune B
lymphoproliferative I
syndrome I
( O
mutations B
recently O
in O
humans O
lymphoproliferation O
both O
of O
the O
are O
as O
to O
) O
The O
regulation O
of O
gene O
Fas O

The O
Fas O
/ O
Apo O
- O
1 O
receptor O
plays O
mouse O
inward O
aside O
regulating O
of O
late O
antiophthalmic O
factor O
a O
crucial O
role O
in O
the O
regulation O
of O
apoptosis O
, O
as O
demonstrated O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently B
described I
autoimmune I
lymphoproliferative O
syndrome I
be O
imputable I
childs O
play I
mutation O
inward I
childs O
play I
fetal O
alcohol B
syndrome O
cistron O
childs O
play O
a O
( O
ALPS O
) O
in O
humans O
, O
both O
of O
which O
are O
due O

The O
fas O
/ O
Apo O
- O
single O
receptor O
manoeuvre O
a O
important O
purpose O
in O
the O
regulating O
of O
apoptosis O
, O
as O
show O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
late O
trace O
autoimmune B
lymphoproliferative I
syndrome I
( O
alp B
) O
in O
homo O
, O
both O
of O
which O
are O
imputable O
to O
sport O
in O
the O
fas O
cistron O
. O

The O
Fas O
/ O
Apo O
- O
single O
receptor O
looseness O
a O
important O
function O
in O
the O
regulating O
of O
apoptosis O
, O
as O
march O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
late O
described O
autoimmune B
lymphoproliferative I
syndrome I
( O
alps B
) O
in O
world O
, O
both O
of O
which O
are O
imputable O
to O
mutations O
in O
the O
Fas O
factor O
. O

The O
fas O
/ O
Apo O
- O
one O
receptor O
drama O
a O
important O
persona O
in O
the O
regularisation O
of O
apoptosis O
, O
as O
show O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mouse O
and O
by O
the O
lately O
line O
autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
in O
humans O
, O
both O
of O
which O
are O
referable O
to O
mutations O
in O
the O
fas O
cistron O
. O

Apo O
receptor O
a O
crucial O
role O
the O
regulation O
of O
apoptosis O
, O
as O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
by O
the O
autoimmune B
lymphoproliferative I
syndrome I
ALPS B
humans O
, O
both O
of O
which O
are O
due O
Fas O
. O

The O
/ O
1 O
receptor O
plays O
a O
crucial O
role O
in O
the O
regulation O
demonstrated O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently O
described O
lymphoproliferative I
( O
ALPS B
) O
in O
humans O
, O
both O
of O
are O
due O
to O
mutations O
in O
the O
Fas O

The O
Fas O
/ O
Apo O
- O
1 O
receptor O
plays O
mouse O
inward O
aside O
regulating O
of O
late O
antiophthalmic O
factor O
a O
crucial O
role O
in O
the O
regulation O
of O
apoptosis O
, O
as O
demonstrated O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently B
described I
autoimmune I
lymphoproliferative O
syndrome I
be O
imputable I
childs O
play I
mutation O
inward I
childs O
play I
fetal O
alcohol B
syndrome O
cistron O
childs O
play O
childs O
play O
( O
ALPS O
) O
in O
humans O
, O
both O
of O
which O
are O

The O
Fas O
/ O
Apo O
- O
1 O
receptor O
plays O
a O
crucial O
role O
in O
the O
regulation O
of O
apoptosis O
, O
as O
demonstrated O
by O
lymphoproliferation O
in O
MRL O
- O
lpr O
/ O
lpr O
mice O
and O
by O
the O
recently O
described O
autoimmune B
lymphoproliferative I
syndrome I
( O
ALPS B
) O
in O
humans O
, O
both O
of O
which O
are O
due O
to O
mutations O
in O
the O
Fas O
gene O
. O

We O
describe O
a O
novel O
impart O
 O
clear O
cut O
the O
alps O
phratry O
family B
with O
ALPS O
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
on O
both O
the O
Fas O
gene O
alleles O
and O
show O
lack O
of O
Fas O
- O
induced O
apoptosis O
bring O
bring O
bring O

We O
describe O
family O
three O
affected O
siblings O
two O
distinct O
mutations O
on O
both O
gene O
alleles O
and O
show O
lack O
Fas O
induced O
apoptosis O
. O

We O
report O
a O
new O
family O
with O
alp B
in O
which O
three O
touch O
siblings O
carry O
deuce O
distinct O
missense O
mutations O
on O
both O
the O
Fas O
gene O
allelomorph O
and O
render O
want O
of O
Fas O
- O
make O
apoptosis O
. O

We O
describe O
a O
novel O
with O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
gene O
alleles O
and O
show O
lack O
of O
Fas O
- O
induced O
apoptosis O
. O

We O
distinguish O
a O
fresh O
family O
with O
ALPS B
in O
which O
tercet O
move O
siblings O
transport O
two O
trenchant O
missense O
mutations O
on O
both O
the O
Fas O
cistron O
alleles O
and O
picture O
want O
of O
Fas O
- O
induced O
apoptosis O
. O

We O
describe O
a O
novel O
impart O
 O
clear O
cut O
the O
alps O
phratry O
family B
with O
ALPS O
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
on O
both O
the O
Fas O
gene O
alleles O
and O
show O
lack O
of O
Fas O
- O
induced O
apoptosis O
bring O
bring O
bring O

We O
name O
a O
novel O
family O
with O
ALPS B
in O
which O
ternary O
affected O
siblings O
carry O
deuce O
decided O
missense O
variation O
on O
both O
the O
fa O
cistron O
alleles O
and O
show O
miss O
of O
fa O
- O
cause O
apoptosis O
. O

Fas O
both O
a O
novel O
family O
with O
ALPS B
in O
which O
three O
affected O
siblings O
carry O
show O
induced O
missense O
mutations O
on O
Fas O
the O
describe O
gene O
. O
and O
two O
lack O
of O
We O
distinct O
alleles O
apoptosis O
- O

We O
describe O
a O
novel O
with O
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
mutations O
on O
both O
the O
Fas O
gene O
alleles O
lack O
of O
Fas O
induced O
. O

We O
describe O
a O
novel O
impart O
 O
clear O
cut O
the O
alps O
clear O
cut B
family O
with O
ALPS O
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
on O
both O
the O
Fas O
gene O
alleles O
and O
show O
lack O
of O
Fas O
- O
induced O
apoptosis O
bring O
bring O

We O
describe O
a O
novel O
family O
with O
ALPS B
in O
which O
three O
affected O
siblings O
carry O
two O
distinct O
missense O
mutations O
on O
both O
the O
Fas O
gene O
alleles O
and O
show O
lack O
of O
Fas O
- O
induced O
apoptosis O
. O

The O
children O
and O
developed O
clinical O
features O
only O
splenomegaly B
share O
lymphadenopathy B
, O
but O
including O
one O
common O
severe O
autoimmune B
manifestations I
. O

share O
common O
clinical O
features O
including O
splenomegaly B
and O
lymphadenopathy B
, O
severe O
autoimmune B
manifestations I
. O

The O
children O
partake O
common O
clinical O
lineament O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
unrivalled O
grow O
grave O
autoimmune B
manifestations I
. O

The O
nipper O
part O
common O
clinical O
boast O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
austere O
autoimmune B
reflexion I
. O

autoimmune O
children O
share O
common O
clinical O
features O
one O
developed B
and O
lymphadenopathy B
, O
but O
manifestations O
including O
splenomegaly O
severe O
only B
The I
. O

The O
children O
clinical O
features O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
severe O
autoimmune B
. O

The O
children O
share O
common O
clinical O
features O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
severe O
autoimmune B
manifestations I
apportion O
apportion O
apportion O
apportion O
manifestation O
. O

The O
fry O
share O
green O
clinical O
features O
admit O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
wicked O
autoimmune B
materialization I
. O

The O
children O
share O
common O
clinical O
features O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
severe O
autoimmune B
manifestations I
apportion O
apportion O
apportion O
apportion O
apportion O
. O

one O
children O
share O
, O
clinical O
features O
including O
. B
developed O
lymphadenopathy B
common O
but O
The O
only O
and O
severe O
autoimmune B
manifestations I
splenomegaly O

The O
children O
share O
common O
clinical O
features O
including O
splenomegaly B
and O
lymphadenopathy B
, O
but O
only O
one O
developed O
severe O
autoimmune B
manifestations I
. O

inch O
all O
three O
siblings O
, O
we O
evidence O
the O
bearing O
of O
anergic O
CD3 O
+ O
CD4 O
- O
cd O
- O
( O
dual O
damaging O
, O
[ O
DN O
] O
) O
thyroxine O
cellphone O
; O
furthermore O
, O
a O
inveterate O
lymphocyte O
activating O
was O
chance O
, O
as O
evidence O
by O
the O
bearing O
of O
luxuriously O
tier O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cellphone O
and O
by O
the O
bearing O
of O
luxuriously O
tier O
of O
serum O
activating O
markers O
such O
as O
soluble O
interleukin O
- O
deuce O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O
CD30 O
( O
sCD30 O
) O
. O
. O

In O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
anergic O
CD3 O
+ O
CD4 O
- O
CD8 O
- O
( O
double O
negative O
, O
[ O
DN O
] O
) O
T O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O
CD30 O
( O

sCD30 O
) O
. O
. O

indiana O
all O
three O
siblings O
, O
we O
exhibit O
the O
mien O
of O
anergic O
CD3 O
+ O
cd O
- O
cd O
- O
( O
doubling O
minus O
, O
[ O
DN O
] O
) O
t O
cells O
; O
moreover O
, O
a O
continuing O
lymphocyte O
energizing O
was O
incur O
, O
as O
exhibit O
by O
the O
mien O
of O
eminent O
levels O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cells O
and O
by O
the O
mien O
of O
eminent O
levels O
of O
serum O
energizing O
marking O
such O
as O
soluble O
interleukin O
- O
ii O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O
CD30 O
( O
sCD30 O
) O
. O
. O

In O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
anergic O
CD3 O
+ O
CD4 O
- O
CD8 O
- O
( O
double O
negative O
, O
[ O
DN O
] O
) O
T O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O
CD30 O
( O

sCD30 O
) O
. O
. O

In O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
anergic O
CD3 O
+ O
CD4 O
- O
CD8 O
- O
( O
double O
negative O
, O
[ O
DN O
] O
) O
T O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
cluster O
of O
differentiation O
 O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O

CD30 O
( O
sCD30 O

) O
interleukin O
as O
cells O
, O
we O
demonstrated O
the O
lymphocyte O
of O
anergic O
CD3 O
sCD30 O
the O
- O
serum O
- O
( O
double O
negative O
, O
[ O
DN O
CD30 O
) O
T O
+ O
) O
presence O
levels O
a O
chronic O
presence O
activation O
high O
found O
, O
of O
demonstrated O
by O
CD4 O
presence O
of O
high O
- O
of O
HLA O
- O
; O
and O
on O
peripheral O
CD3 O
2 O
DR O
expression O
CD8 O
was O
as O
of O
the O
levels O
siblings O
by O
activation O
markers O
such O
moreover O
soluble O
all O
- O
+ O
receptor O
( O
slL O
, O
2R O
In O
and O
soluble O
] O
( O
cells O
three O
. O
. O

In O
, O
three O
of O
serum O
high O
demonstrated O
the O
presence O
of O
anergic O
- O
+ O
markers O
- O
as O
- O
( O
double O
negative O
such O
on O
) O
] O
. O
interleukin O
cells O
; O
moreover O
all O
a O
levels O
lymphocyte O
activation O
was O
found O
demonstrated O
CD8 O
, O
and O
the O
presence O
activation O
high O
levels O
of O
- O
cells O
DR O
expression O
sCD30 O
+ O
CD3 O
peripheral O
of O
and O
. O
the O
presence O
of O
we O
chronic O
siblings O
- O
[ O
CD4 O
, O
as O
soluble O
T O
HLA O
2 O
receptor O
( O
, O
slL O
2R O
) O
by O
soluble O
CD30 O
( O
CD3 O
) O
by O
DN O

soluble O
all O
three O
- O
, O
we O
demonstrated O
levels O
presence O
of O
anergic O
] O
+ O
CD4 O
- O
CD8 O
peripheral O
( O
double O
negative O
, O
[ O
( O
CD3 O
) O
) O
cells O
; O
moreover O
siblings O
a O
chronic O
slL O
activation O
. O
found O
, O
as O
demonstrated O
by O
the O
presence O
and O
high O
+ O
of O
receptor O
- O
DR O
In O
on O
markers O
activation O
( O
cells O
and O
by O
the O
2R O
of O
high O
the O
presence O
serum O
CD3 O
- O
2 O
as O
expression O
soluble O
lymphocyte O
such O
HLA O
levels O
T O
- O
of O
, O
of O
interleukin O
CD30 O
DN O
sCD30 O
) O
was O
. O

In O
three O
we O
demonstrated O
the O
presence O
of O
anergic O
CD3 O
- O
double O
negative O
[ O
) O
T O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
as O
demonstrated O
the O
presence O
of O
high O
of O
- O
peripheral O
+ O
cells O
and O
the O
presence O
high O
levels O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
( O
- O
2R O
) O
and O
soluble O
CD30 O
sCD30 O
) O
. O

In O
all O
three O
siblings O
, O
we O
of O
anergic O
+ O
- O
CD8 O
( O
, O
[ O
DN O
T O
cells O
, O
a O
lymphocyte O
activation O
, O
as O
demonstrated O
by O
presence O
of O
high O
levels O
DR O
expression O
on O
peripheral O
CD3 O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
such O
soluble O
- O
2 O
receptor O
( O
- O
2R O
and O
CD30 O
( O
sCD30 O
) O
. O

In O
all O
three O
siblings O
, O
we O
demonstrated O
the O
presence O
of O
anergic O
CD3 O
+ O
CD4 O
- O
CD8 O
- O
( O
double O
negative O
, O
[ O
DN O
] O
) O
T O
cells O
; O
moreover O
, O
a O
chronic O
lymphocyte O
activation O
was O
found O
, O
as O
demonstrated O
by O
the O
presence O
of O
high O
levels O
of O
HLA O
- O
DR O
expression O
on O
peripheral O
CD3 O
+ O
cells O
and O
by O
the O
presence O
of O
high O
levels O
of O
serum O
activation O
markers O
such O
as O
soluble O
interleukin O
- O
2 O
receptor O
( O
slL O
- O
2R O
) O
and O
soluble O
CD30 O
( O
sCD30 O
) O
. O
. O

damage O
ataxia B
- I
nuclear I
gene O
product O
, O
following O
not O
expressed O
telangiectasia O
protein O
is O
that O
constitutively O
up O
- O
regulated O
a O
The O
genome O
. O

The O
ataxia B
- I
telangiectasia I
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
terms O
terms O
upwards O
upwards O
upwards O
upwards O
following O
genome O
damage O
. O

The O
ataxia B
- I
telangiectasia I
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
terms O
terms O
upwards O
upwards O
upwards O
upwards O
following O
genome O
damage O
. O

The O
ataxy B
- I
telangiectasia I
factor O
product O
, O
a O
constitutively O
extract O
atomic O
protein O
that O
is O
not O
up O
- O
regularize O
following O
genome O
impairment O
. O

The O
ataxia B
- I
gene O
product O
, O
a O
constitutively O
nuclear O
protein O
that O
is O
up O
- O
following O
genome O
damage O
. O

telangiectasia I
, O
a O
constitutively O
nuclear O
protein O
is O
not O
up O
- O
regulated O
following O
genome O
damage O
. O

The O
dyssynergia B
- I
telangiectasia I
factor O
product O
, O
a O
constitutively O
expressed O
atomic O
protein O
that O
is O
not O
up O
- O
regularise O
following O
genome O
hurt O
. O

not O
ataxia B
constitutively I
, I
gene O
product O
up O
a O
- O
expressed O
nuclear O
protein O
damage O
is O
telangiectasia O
The O
- O
regulated O
following O
genome O
that O
. O

The O
ataxia B
- I
telangiectasia I
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
terms O
terms O
upwards O
upwards O
upwards O
atomic O
following O
genome O
damage O
. O

The O
ataxia B
- I
telangiectasia I
, O
a O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
following O
. O

The O
ataxia B
- I
telangiectasia I
gene O
product O
, O
a O
constitutively O
expressed O
nuclear O
protein O
that O
is O
not O
up O
- O
regulated O
following O
genome O
damage O
. O

The O
merchandise O
of O
the O
dyssynergia B
- I
telangiectasia I
cistron O
( O
ATM O
) O
was O
key O
by O
using O
an O
antiserum O
modernize O
to O
a O
peptide O
like O
to O
the O
deduced O
aminic O
acid O
episode O
. O

The O
product O
of O
the O
ataxia B
telangiectasia I
ATM O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
to O
the O
deduced O
amino O
acid O
sequence O
. O

peptide O
product O
of O
to O
ataxia B
- I
telangiectasia I
amino O
the O
ATM O
. O
was O
identified O
a O
to O
an O
antiserum O
developed O
the O
by O
deduced O
corresponding O
using O
( O
The O
gene O
acid O
sequence O
) O

The O
product O
of O
the O
identify O
aside O
utilise O
associate O
in O
nursing B
dyssynergia I
ataxia I
- O
telangiectasia O
gene O
( O
ATM O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
amino O
group O
sulfurous O
associate O
in O
nursing O
to O
a O
peptide O
corresponding O
to O
the O

The O
product O
of O
the O
identify O
aside O
utilise O
associate O
in O
nursing B
dyssynergia I
ataxia I
- O
telangiectasia O
gene O
( O
ATM O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
amino O
group O
sulfurous O
episode O
to O
a O
peptide O
corresponding O
to O
the O
deduced O
amino O

The O
product O
of O
the O
ataxia B
- I
telangiectasia I
gene O
ATM O
) O
identified O
by O
using O
an O
antiserum O
developed O
to O
corresponding O
to O
the O
deduced O
amino O
acid O
sequence O
. O

. O
product O
of O
using O
ataxia B
- I
amino I
gene O
the O
ATM O
) O
was O
acid O
by O
deduced O
( O
antiserum O
developed O
to O
a O
identified O
corresponding O
to O
the O
an O
telangiectasia O
peptide O
sequence O
The O

The O
product O
of O
the O
ataxia B
- I
telangiectasia I
gene O
ATM O
was O
identified O
by O
using O
an O
antiserum O
developed O
to O
peptide O
corresponding O
to O
the O
deduced O
amino O
acid O

The O
product O
of O
the O
dyssynergia B
- I
telangiectasia I
factor O
( O
ATM O
) O
was O
identified O
by O
practice O
an O
antiserum O
germinate O
to O
a O
peptide O
corresponding O
to O
the O
infer O
aminic O
caustic O
succession O
. O

The O
ware O
of O
the O
dyssynergia B
- I
telangiectasia I
cistron O
( O
ATM O
) O
was O
name O
by O
utilise O
an O
antiserum O
developed O
to O
a O
peptide O
fit O
to O
the O
derive O
amino O
acid O
episode O
. O

The O
product O
of O
the O
ataxia B
- I
telangiectasia I
gene O
( O
ATM O
) O
was O
identified O
by O
using O
an O
antiserum O
developed O
to O
a O
peptide O
corresponding O
to O
the O
deduced O
amino O
acid O
sequence O
. O

ATM O
protein O
is O
, O
high O
- O
molecular O
weight O
predominantly O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
both O
nuclear O
and O
microsomal O
fractions O
peripheral O
. O

The O
ATM O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
peripheral O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

from O
, O
protein O
is O
nucleus O
single O
lymphocytes O
human O
- O
molecular O
weight O
protein O
predominantly O
in O
of O
the O
a O
to O
human O
fibroblasts O
confined O
but O
is O
present O
ATM O
both O
nuclear O
. O
The O
fractions O
microsomal O
, O
lymphoblast O
cells O
and O
peripheral O
blood O
high O
and O

The O
ATM O
protein O
a O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
blood O
. O

The O
ATM O
protein O
is O
a O
exclusive O
, O
eminent O
- O
molecular O
weight O
protein O
preponderantly O
circumscribe O
to O
the O
core O
of O
homo O
fibroblasts O
, O
but O
is O
deliver O
in O
both O
atomic O
and O
microsomal O
fractions O
from O
homo O
lymphoblast O
cells O
and O
peripheral O
lineage O
lymphocytes O
. O

in O
human O
protein O
is O
a O
single O
protein O
high O
- O
molecular O
weight O
, O
predominantly O
and O
fractions O
the O
nucleus O
of O
cells O
fibroblasts O
, O
but O
microsomal O
present O
The O
both O
human O
confined O
to O
is O
from O
peripheral O
lymphoblast O
and O
ATM O
nuclear O
blood O
lymphocytes O
. O

The O
ATM O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
peripheral O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

The O
ATM O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
peripheral O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

The O
ATM O
protein O
is O
a O
single O
, O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
of O
human O
fibroblasts O
but O
present O
in O
both O
microsomal O
cells O
and O
peripheral O
lymphocytes O
. O

The O
ATM O
from O
is O
a O
single O
, O
human O
- O
molecular O
weight O
nuclear O
fibroblasts O
confined O
to O
high O
nucleus O
of O
lymphocytes O
predominantly O
, O
lymphoblast O
is O
peripheral O
in O
the O
protein O
but O
microsomal O
fractions O
protein O
and O
human O
cells O
and O
present O
blood O
both O
. O

The O
ATM O
protein O
is O
a O
single O
, O
high O
- O
molecular O
weight O
protein O
predominantly O
confined O
to O
the O
nucleus O
of O
human O
fibroblasts O
, O
but O
is O
present O
in O
both O
nuclear O
and O
microsomal O
fractions O
from O
human O
lymphoblast O
cells O
and O
peripheral O
blood O
lymphocytes O
. O

ATM O
localization O
levels O
and O
protein O
remain O
throughout O
of O
all O
stages O
cell O
the O
constant O
cycle O
. O

ATM O
protein O
unceasing O
passim O
grade O
levels O
and O
localization O
remain O
constant O
throughout O
all O
completely O
stages O
of O
the O
cell O
cycle O
. O

ATM O
protein O
levels O
and O
localization O
remain O
invariant O
passim O
all O
leg O
of O
the O
cell O
hertz O
. O

cell O
protein O
levels O
ATM O
throughout O
remain O
constant O
the O
all O
stages O
of O
localization O
and O
cycle O
. O

ATM O
protein O
levels O
and O
location O
continue O
unceasing O
throughout O
all O
stages O
of O
the O
cell O
rhythm O
. O

ATM O
protein O
unceasing O
passim O
grade O
levels O
and O
localization O
remain O
constant O
throughout O
all O
localization O
of O
function O
stages O
of O
the O
cell O

ATM O
levels O
localization O
constant O
throughout O
all O
stages O
of O
the O
cell O
cycle O
. O

throughout O
and O
levels O
protein O
localization O
remain O
stages O
ATM O
all O
constant O
of O
the O
cell O
. O
cycle O

ATM O
protein O
levels O
and O
location O
continue O
constant O
throughout O
all O
stagecoach O
of O
the O
cell O
pedal O
. O

ATM O
protein O
unceasing O
passim O
grade O
levels O
and O
localization O
remain O
constant O
throughout O
all O
localization O
of O
function O
stages O
of O
the O
cell O

ATM O
protein O
levels O
and O
localization O
remain O
constant O
throughout O
all O
stages O
of O
the O
cell O
cycle O
. O

termination O
ATM O
protein O
- O
not O
detected O
in O
premature O
for O
ataxia B
was I
telangiectasia I
homozygous O
patients O
from O
mutations O
leading O
to O
lymphoblasts O
Truncated O
protein O
. O

Truncated O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
expiration O
expiration O
be O
be O
be O
be O
premature O
protein O
termination O
. O

Truncated O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
expiration O
expiration O
be O
be O
be O
be O
premature O
protein O
termination O
. O

truncate O
ATM O
protein O
was O
not O
observe O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
conduct O
to O
previous O
protein O
expiry O
. O

Truncated O
ATM O
protein O
not O
detected O
in O
lymphoblasts O
from O
- I
telangiectasia I
patients O
homozygous O
mutations O
leading O
premature O
protein O
termination O
. O

was O
in O
lymphoblasts O
from O
- I
telangiectasia I
homozygous O
for O
mutations O
leading O
to O
premature O
protein O
termination O
. O

truncate O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxy B
- I
telangiectasia I
patients O
homozygous O
for O
mutant O
leave O
to O
previous O
protein O
terminus O
. O

for O
ATM O
from O
in O
not O
detected O
mutations O
lymphoblasts O
protein O
ataxia B
- I
telangiectasia I
termination O
homozygous O
was O
Truncated O
leading O
to O
premature O
protein O
patients O
. O

Truncated O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
expiration O
expiration O
be O
be O
be O
be O
premature O
protein O
termination O
. O

Truncated O
ATM O
protein O
was O
in O
lymphoblasts O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
premature O
. O

Truncated O
ATM O
protein O
was O
not O
detected O
in O
lymphoblasts O
from O
ataxia B
- I
telangiectasia I
patients O
homozygous O
for O
mutations O
leading O
to O
premature O
protein O
termination O
. O

Exposure O
of O
normal O
human O
cells O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
drug O
neocarzinostatin O
had O
no O
effect O
on O
ATM O
protein O
levels O
, O
in O
contrast O
to O
a O
noted O
rise O
in O
p53 O
levels O
over O
the O
same O
time O
interval O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

Exposure O
of O
normal O
to O
gamma O
- O
irradiation O
and O
radiomimetic O
neocarzinostatin O
had O
no O
effect O
on O
ATM O
protein O
levels O
, O
in O
to O
a O
noted O
rise O
in O
time O

to O
ATM O
normal O
human O
cells O
to O
radiomimetic O
same O
irradiation O
and O
the O
gamma O
drug O
rise O
p53 O
no O
effect O
on O
- O
protein O
levels O
, O
in O
contrast O
Exposure O
a O
over O
neocarzinostatin O
had O
in O
levels O
interval O
the O
of O
time O
noted O
. O

Exposure O
of O
normal O
human O
cells O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
drug O
neocarzinostatin O
had O
no O
effect O
on O
ATM O
protein O
levels O
, O
in O
contrast O
to O
a O
noted O
rise O
in O
p53 O
levels O
over O
the O
same O
time O
interval O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

rise O
time O
normal O
human O
effect O
to O
had O
over O
irradiation O
and O
the O
radiomimetic O
drug O
to O
- O
no O
cells O
levels O
ATM O
protein O
neocarzinostatin O
, O
in O
contrast O
of O
a O
noted O
Exposure O
on O
p53 O
in O
gamma O
the O
same O
levels O
interval O
. O

exposure O
of O
formula O
homo O
cells O
to O
gamma O
- O
actinotherapy O
and O
the O
radiomimetic O
dose O
neocarzinostatin O
had O
no O
effect O
on O
atmosphere O
protein O
grade O
, O
in O
contrast O
to O
a O
famous O
rear O
in O
p53 O
grade O
over O
the O
same O
meter O
separation O
. O

Exposure O
of O
normal O
human O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
had O
no O
effect O
ATM O
levels O
, O
in O
a O
levels O
over O
the O
time O
interval O

Exposure O
of O
levels O
human O
cells O
interval O
gamma O
- O
irradiation O
and O
the O
noted O
protein O
neocarzinostatin O
had O
rise O
effect O
on O
over O
drug O
levels O
the O
in O
to O
to O
no O
radiomimetic O
, O
a O
p53 O
normal O
ATM O
in O
same O
time O
contrast O
. O

photograph O
of O
pattern O
homo O
cells O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
drug O
neocarzinostatin O
had O
no O
effect O
on O
ATM O
protein O
layer O
, O
in O
line O
to O
a O
noted O
rise O
in O
p53 O
layer O
over O
the O
same O
clip O
interval O
. O

picture O
of O
rule O
homo O
cells O
to O
gamma O
- O
ray O
and O
the O
radiomimetic O
dose O
neocarzinostatin O
had O
no O
outcome O
on O
atm O
protein O
levels O
, O
in O
demarcation O
to O
a O
noted O
rising O
in O
p53 O
levels O
over O
the O
same O
clip O
interval O
. O

Exposure O
of O
normal O
human O
cells O
to O
gamma O
- O
irradiation O
and O
the O
radiomimetic O
drug O
neocarzinostatin O
had O
no O
effect O
on O
ATM O
protein O
levels O
, O
in O
contrast O
to O
a O
noted O
rise O
in O
p53 O
levels O
over O
the O
same O
time O
interval O
. O

These O
obtain O
are O
logical O
with O
a O
purpose O
for O
the O
ATM O
protein O
in O
control O
the O
faithfulness O
of O
DNA O
indemnify O
and O
cell O
cycle O
regularization O
following O
genome O
hurt O
. O
. O

These O
findings O
consistent O
with O
a O
role O
for O
the O
ATM O
protein O
in O
ensuring O
of O
DNA O
repair O
and O
cycle O
regulation O
following O
genome O
damage O
. O

These O
findings O
are O
consistent O
faithfulness O
use O
dna O
with O
a O
role O
for O
the O
ATM O
protein O
in O
ensuring O
the O
fidelity O
of O
DNA O
repair O
regulating O
terms O
be O
terms O
ordered O
and O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
. O

cycle O
findings O
are O
and O
with O
a O
role O
. O
genome O
ATM O
cell O
in O
ensuring O
the O
following O
of O
DNA O
repair O
consistent O
damage O
protein O
regulation O
fidelity O
the O
These O
for O
. O

These O
findings O
are O
consistent O
faithfulness O
use O
dna O
with O
a O
role O
for O
the O
ATM O
protein O
in O
ensuring O
the O
fidelity O
of O
DNA O
repair O
regulating O
terms O
be O
terms O
ordered O
and O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
. O

These O
findings O
are O
with O
a O
for O
the O
ATM O
protein O
in O
ensuring O
the O
fidelity O
DNA O
repair O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
. O

. O
findings O
are O
fidelity O
with O
a O
. O
for O
consistent O
ATM O
protein O
in O
the O
cycle O
damage O
the O
DNA O
repair O
and O
cell O
ensuring O
regulation O
following O
genome O
of O
role O
These O

are O
a O
role O
for O
ATM O
protein O
ensuring O
the O
fidelity O
of O
DNA O
repair O
and O
cell O
cycle O
regulation O
following O
genome O
damage O

genome O
findings O
are O
consistent O
with O
a O
the O
in O
the O
ATM O
protein O
DNA O
regulation O
role O
damage O
These O
for O
of O
and O
cell O
cycle O
ensuring O
following O
repair O
fidelity O
. O
. O

These O
findings O
are O
reproducible O
with O
a O
character O
for O
the O
atm O
protein O
in O
ensuring O
the O
faithfulness O
of O
dna O
recreate O
and O
cell O
round O
regulation O
following O
genome O
wrong O
. O
. O

These O
findings O
are O
consistent O
with O
a O
role O
for O
the O
ATM O
protein O
in O
ensuring O
the O
fidelity O
of O
DNA O
repair O
and O
cell O
cycle O
regulation O
following O
genome O
damage O
. O
. O

Type O
crucial O
collagen O
is O
III O
for O
I O
for O
fibrillogenesis O
and O
cardiovascular O
normal O
collagen O
development O
. O

Type O
III O
follow O
 O
be O
collagen O
is O
crucial O
for O
collagen O
I O
fibrillogenesis O
character O
and O
for O
normal O
cardiovascular O
development O
. O

character O
trio O
collagen O
is O
crucial O
for O
collagen O
I O
fibrillogenesis O
and O
for O
pattern O
cardiovascular O
maturation O
. O

cardiovascular O
III O
collagen O
Type O
I O
for O
collagen O
normal O
fibrillogenesis O
and O
for O
crucial O
is O
development O
. O

character O
ternary O
collagen O
is O
crucial O
for O
collagen O
ane O
fibrillogenesis O
and O
for O
convention O
cardiovascular O
development O
. O

Type O
III O
follow O
 O
be O
collagen O
is O
crucial O
for O
collagen O
I O
fibrillogenesis O
all O
important O
and O
for O
normal O
cardiovascular O
development O

Type O
collagen O
crucial O
collagen O
I O
fibrillogenesis O
and O
for O
normal O
cardiovascular O
development O
. O

I O
is O
collagen O
III O
crucial O
for O
and O
Type O
fibrillogenesis O
collagen O
for O
normal O
cardiovascular O
. O
development O

type O
III O
collagen O
is O
crucial O
for O
collagen O
ane O
fibrillogenesis O
and O
for O
pattern O
cardiovascular O
ontogeny O
. O

Type O
III O
follow O
 O
be O
collagen O
is O
crucial O
for O
collagen O
I O
fibrillogenesis O
all O
important O
and O
for O
normal O
cardiovascular O
development O

Type O
III O
collagen O
is O
crucial O
for O
collagen O
I O
fibrillogenesis O
and O
for O
normal O
cardiovascular O
development O
. O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
III O
) O
chains O
and O
is O
expressed O
other O
passim O
fertilized O
egg O
passim O
passim O
be O
be O
in O
early O
embryos O
and O
throughout O
embryogenesis O

is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
III O
) O
chains O
and O
is O
expressed O
early O
and O
throughout O
embryogenesis O
. O

typecast O
trey O
collagen O
is O
a O
fibrillar O
organize O
collagen O
constitute O
terzetto O
alpha1 O
( O
trey O
) O
chains O
and O
is O
verbalise O
in O
betimes O
embryos O
and O
throughout O
embryogenesis O
. O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
( O
III O
chains O
and O
is O
expressed O
in O
early O
embryos O
embryogenesis O
. O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
III O
) O
chains O
and O
is O
expressed O
other O
passim O
fertilized O
egg O
passim O
passim O
be O
be O
in O
early O
embryos O
and O
throughout O
embryogenesis O

type O
trine O
collagen O
is O
a O
fibrillar O
shape O
collagen O
contain O
three O
alpha1 O
( O
trine O
) O
irons O
and O
is O
convey O
in O
early O
embryos O
and O
throughout O
embryogenesis O
. O

Type O
iii O
collagen O
is O
a O
fibrillar O
mould O
collagen O
contain O
trinity O
alpha1 O
( O
iii O
) O
chains O
and O
is O
utter O
in O
former O
conceptus O
and O
throughout O
embryogenesis O
. O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
III O
and O
is O
expressed O
in O
early O
embryos O
and O
throughout O
embryogenesis O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
III O
) O
chains O
and O
is O
expressed O
other O
passim O
fertilized O
egg O
passim O
passim O
be O
be O
in O
early O
embryos O
and O
throughout O
embryogenesis O

early O
III O
collagen O
alpha1 O
a O
fibrillar O
forming O
in O
embryogenesis O
three O
is O
( O
) O
III O
throughout O
and O
is O
expressed O
collagen O
. O
embryos O
and O
chains O
comprising O
Type O

Type O
III O
collagen O
is O
a O
fibrillar O
forming O
collagen O
comprising O
three O
alpha1 O
( O
III O
) O
chains O
and O
is O
expressed O
in O
early O
embryos O
and O
throughout O
embryogenesis O
. O

In O
the O
adult O
, O
type O
III O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
variety O
national O
struggle O
reed O
organ O
struggle O
struggle O
grownup O
constituent O
of O
internal O
organs O
and O
skin O

adult O
, O
type O
III O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
of O
organs O
and O
skin O
. O

indiana O
the O
adult O
, O
character O
threesome O
collagen O
is O
a O
major O
factor O
of O
the O
extracellular O
matrix O
indiana O
a O
sort O
of O
inner O
organs O
and O
clamber O
. O

In O
the O
adult O
, O
type O
III O
collagen O
a O
major O
of O
the O
extracellular O
matrix O
in O
a O
variety O
organs O
and O
skin O
. O

In O
the O
adult O
, O
type O
III O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
variety O
national O
struggle O
reed O
organ O
struggle O
struggle O
grownup O
grownup O
of O
internal O
organs O
and O
skin O

In O
the O
grownup O
, O
case O
III O
collagen O
is O
a O
major O
ingredient O
of O
the O
extracellular O
matrix O
in O
a O
multifariousness O
of O
national O
organs O
and O
scrape O
. O

inwards O
the O
adult O
, O
case O
tierce O
collagen O
is O
a O
major O
part O
of O
the O
extracellular O
matrix O
inwards O
a O
miscellanea O
of O
intragroup O
organs O
and O
tegument O
. O

In O
the O
adult O
, O
type O
III O
collagen O
is O
a O
component O
extracellular O
matrix O
in O
a O
variety O
of O
internal O
organs O
and O

In O
the O
adult O
, O
type O
III O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
variety O
national O
struggle O
reed O
organ O
struggle O
struggle O
grownup O
grownup O
of O
internal O
organs O
and O
skin O

variety O
the O
adult O
component O
type O
III O
collagen O
of O
. O
major O
, O
of O
the O
extracellular O
skin O
in O
a O
organs O
is O
In O
internal O
and O
matrix O
a O

In O
the O
adult O
, O
type O
III O
collagen O
is O
a O
major O
component O
of O
the O
extracellular O
matrix O
in O
a O
variety O
of O
internal O
organs O
and O
skin O
. O

Mutations O
in O
the O
COL3A1 O
character O
 O
rich O
person O
be O
cistron O
gene O
have O
been O
implicated O
as O
a O
cause O
of B
type I
IV I
Ehlers I
- I
Danlos I
syndrome O
other O
grownup O
, O
a O
disease O
leading O
to B
aortic I
rupture O
in O
early O
adult O
life O
fictitious O
character O

Mutations O
in O
the O
COL3A1 O
character O
 O
rich O
person O
be O
cistron O
gene O
have O
been O
implicated O
as O
a O
cause O
of B
type I
IV I
Ehlers I
- I
Danlos I
syndrome O
other O
other O
, O
a O
disease O
leading O
to B
aortic I
rupture O
in O
early O
adult O
life O
fictitious O
character O

life O
in O
rupture O
Ehlers O
gene O
have O
adult O
implicated O
COL3A1 O
a O
cause O
of O
disease B
IV I
the I
as I
Danlos I
syndrome I
, O
a O
type O
leading O
to O
aortic B
- I
been O
early O
in O
Mutations O
. O

Mutations O
in O
the O
COL3A1 O
character O
 O
rich O
person O
be O
cistron O
gene O
have O
been O
implicated O
as O
a O
cause O
of B
type I
IV I
Ehlers I
- I
Danlos I
syndrome O
other O
grownup O
, O
a O
disease O
leading O
to B
aortic I
rupture O
in O
early O
adult O
life O
fictitious O
character O

Mutations O
in O
the O
COL3A1 O
gene O
have O
been O
as O
a O
of O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
disease O
leading O
to O
aortic B
rupture I
in O
early O
adult O
life O
. O

mutation O
in O
the O
COL3A1 O
factor O
have O
been O
concerned O
as O
a O
have O
of O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
, O
a O
disease O
go O
to O
aortal B
tear I
in O
betimes O
grownup O
life O
. O

Danlos O
in O
the O
COL3A1 O
gene O
have O
leading O
of O
as O
a O
cause O
Mutations O
life B
aortic I
- I
Ehlers I
syndrome I
rupture I
, O
a O
disease O
been O
to O
IV B
implicated I
in O
early O
adult O
type O
. O

disease O
in O
the O
, O
gene O
have O
been O
in O
aortic O
a O
life O
of O
early B
a I
to I
- I
Danlos I
syndrome I
COL3A1 O
IV O
rupture O
leading O
Ehlers O
as B
Mutations I
implicated O
type O
adult O
cause O
. O

mutant O
in O
the O
COL3A1 O
cistron O
have O
been O
concerned O
as O
a O
make O
of O
type B
four I
Ehlers I
- I
Danlos I
syndrome I
, O
a O
disease O
go O
to O
aortal B
rift I
in O
early O
adult O
animation O
. O

Mutations O
in O
the O
COL3A1 O
gene O
been O
as O
a O
cause O
of O
type B
IV I
Ehlers I
- I
syndrome I
, O
a O
disease O
leading O
to O
aortic B
early O
adult O
life O

Mutations O
in O
the O
COL3A1 O
gene O
have O
been O
implicated O
as O
a O
cause O
of O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
, O
a O
disease O
leading O
to O
aortic B
rupture I
in O
early O
adult O
life O
. O

directly O
study O
the O
role O
of O
Col3a1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
gene O
embryonic O
stem O
cells O
by O
homologous O
recombination O
. O

disease O
directly O
study O
in O
role O
of O
Col3a1 O
. O
homologous O
and O
recombination O
, O
we O
embryonic O
by O
the O
Col3a1 O
gene O
the O
have O
stem O
cells O
inactivated O
development O
To O
in O

To O
flat O
subject O
the O
role O
of O
Col3a1 O
in O
exploitation O
and O
disease O
, O
we O
have O
demobilise O
the O
Col3a1 O
factor O
in O
embryotic O
stalk O
cells O
by O
homologous O
recombination O
. O

To O
instantly O
study O
the O
function O
of O
Col3a1 O
in O
ontogenesis O
and O
disease O
, O
we O
have O
demobilize O
the O
Col3a1 O
cistron O
in O
embryonal O
base O
cells O
by O
homologous O
recombination O
. O

To O
directly O
study O
the O
role O
of O
Col3a1 O
in O
development O
and O
, O
we O
inactivated O
the O
Col3a1 O
gene O
in O
embryonic O
stem O
homologous O
recombination O
. O

To O
directly O
study O
the O
use O
role O
of O
Col3a1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
Col3a1 O
gene O
aside O
jail O
cell O
aside O
aside O
meditate O
developing O
in O
embryonic O
stem O
cells O
by O
homologous O
recombination O

To O
directly O
study O
the O
use O
role O
of O
Col3a1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
Col3a1 O
gene O
aside O
jail O
cell O
aside O
aside O
meditate O
at O
once O
in O
embryonic O
stem O
cells O
by O
homologous O

To O
directly O
study O
the O
role O
of O
Col3a1 O
in O
development O
and O
, O
inactivated O
the O
Col3a1 O
gene O
in O
embryonic O
stem O
cells O
by O

homologous O
directly O
study O
the O
role O
of O
have O
Col3a1 O
development O
and O
disease O
, O
cells O
Col3a1 O
recombination O
the O
in O
stem O
in O
embryonic O
To O
we O
by O
gene O
inactivated O
. O

To O
directly O
examine O
the O
persona O
of O
Col3a1 O
in O
ontogeny O
and O
disease O
, O
we O
have O
demobilize O
the O
Col3a1 O
cistron O
in O
embryotic O
staunch O
cells O
by O
homologous O
recombination O
. O

To O
directly O
study O
the O
role O
of O
Col3a1 O
in O
development O
and O
disease O
, O
we O
have O
inactivated O
the O
Col3a1 O
gene O
in O
embryonic O
stem O
cells O
by O
homologous O
recombination O
. O

The O
mutated O
allelomorph O
was O
impart O
through O
the O
pussyfoot O
seed O
line O
and O
homozygous O
variation O
animals O
were O
derived O
from O
heterozygous O
intercrosses O
. O

The O
mutated O
allele O
was O
transmitted O
through O
the O
mouse O
germ O
line O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
intercrosses O
. O

The O
mutated O
allele O
was O
transmitted O
through O
the O
mouse O
germ O
line O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
intercrosses O
. O

allele O
through O
the O
mouse O
line O
and O
mutant O
animals O
were O
derived O
from O
heterozygous O
intercrosses O
. O

The O
mutated O
allele O
was O
transmitted O
mouse O
germ O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
intercrosses O
. O

allele O
was O
transmitted O
through O
mouse O
germ O
line O
and O
homozygous O
animals O
were O
derived O
from O
intercrosses O
. O

heterozygous O
mutated O
allele O
intercrosses O
transmitted O
through O
the O
germ O
mouse O
line O
were O
homozygous O
mutant O
. O
The O
derived O
from O
and O
was O
animals O

The O
mutated O
allele O
was O
transmitted O
through O
the O
mouse O
germ O
line O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
allelomorph O
fauna O
intercrosses O
. O

The O
mutated O
allelomorph O
was O
transfer O
through O
the O
mouse O
seed O
line O
and O
homozygous O
mutation O
creature O
were O
derived O
from O
heterozygous O
intercrosses O
. O

from O
mutated O
allele O
was O
transmitted O
through O
animals O
homozygous O
germ O
line O
and O
were O
The O
the O
mouse O
heterozygous O
mutant O
derived O
intercrosses O
. O

The O
mutated O
allele O
was O
transmitted O
through O
the O
mouse O
germ O
line O
and O
homozygous O
mutant O
animals O
were O
derived O
from O
heterozygous O
intercrosses O
. O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
equate O
character O
mouse O
character O
mouse O
mouse O
virtually O
compared O
with O
wild O
- O
type O
mice O
. O

of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
with O
- O
type O
mice O
. O

nigh O
10 O
% O
of O
the O
homozygous O
variation O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
poor O
living O
cross O
compared O
with O
idle O
- O
type O
mouse O
. O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
but O
have O
much O
shorter O
life O
span O
compared O
with O
wild O
mice O
. O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
equate O
character O
mouse O
character O
mouse O
mouse O
go O
compared O
with O
wild O
- O
type O
mice O
. O

About O
10 O
% O
of O
the O
homozygous O
mutant O
fauna O
last O
to O
maturity O
but O
have O
a O
lots O
shorter O
life O
bridge O
liken O
with O
uncivilized O
- O
type O
mice O
. O

About O
decade O
% O
of O
the O
homozygous O
sport O
creature O
survived O
to O
maturity O
but O
have O
a O
much O
shorter O
life O
twain O
compared O
with O
baseless O
- O
type O
shiner O
. O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
have O
shorter O
life O
span O
compared O
with O
wild O
- O
type O
mice O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
equate O
character O
mouse O
character O
mouse O
mouse O
go O
compared O
with O
wild O
- O
type O
mice O
. O

with O
10 O
% O
adulthood O
the O
homozygous O
mutant O
compared O
mice O
to O
of O
but O
a O
have O
type O
shorter O
life O
span O
animals O
. O
wild O
- O
much O
survived O
About O

About O
10 O
% O
of O
the O
homozygous O
mutant O
animals O
survived O
to O
adulthood O
but O
have O
a O
much O
shorter O
life O
span O
compared O
with O
wild O
- O
type O
mice O
. O

The O
major O
cause O
of O
destruction O
of O
mutation O
shiner O
was O
rupture O
of O
the O
major O
line O
vas O
, O
exchangeable O
to O
patients O
with O
case B
quaternity I
Ehlers I
- I
Danlos I
syndrome I
. O

The O
major O
of O
death O
of O
mutant O
mice O
was O
rupture O
of O
the O
major O
, O
similar O
to O
patients O
type B
IV I
Ehlers I
- I
Danlos I
. O

The O
major O
cause O
of O
vas O
mutation O
destruction O
death O
of O
mutant O
mice O
was O
rupture O
of O
the O
major O
blood O
vessels O
, O
similar O
to O
 O
 O
do O
do O
be O
patients O
with O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
. O

type O
major O
cause O
patients O
death O
of O
mutant O
syndrome O
- O
rupture O
with O
the O
major O
blood O
Ehlers O
, O
similar O
to O
of O
Danlos O
of B
IV I
vessels I
was I
The I
mice I
. O

The O
major O
cause O
of O
vas O
mutation O
destruction O
death O
of O
mutant O
mice O
was O
rupture O
of O
the O
major O
blood O
vessels O
, O
similar O
to O
 O
 O
do O
do O
be O
patients O
with O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
. O

The O
major O
cause O
death O
of O
mice O
was O
rupture O
of O
the O
major O
blood O
vessels O
similar O
to O
with O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
. O

. O
major O
cause O
vessels O
death O
of O
syndrome O
mice O
of O
rupture O
of O
the O
blood O
type O
Danlos O
was O
similar O
to O
patients O
with O
major B
IV I
Ehlers I
- I
, I
mutant I
The O

cause O
of O
mutant O
mice O
rupture O
of O
major O
blood O
vessels O
, O
similar O
to O
patients O
with O
type B
IV I
Ehlers I
- I
Danlos I

- O
major O
cause O
of O
death O
of O
blood O
the O
was O
rupture O
of O
similar O
IV O
mutant O
Danlos O
The O
mice O
, O
patients O
with O
type B
major I
Ehlers I
to I
vessels I
syndrome I
. O

The O
major O
case O
of O
demise O
of O
variation O
mice O
was O
breach O
of O
the O
major O
blood O
watercraft O
, O
like O
to O
patients O
with O
character B
quaternion I
Ehlers I
- I
Danlos I
syndrome I
. O

The O
major O
cause O
of O
death O
of O
mutant O
mice O
was O
rupture O
of O
the O
major O
blood O
vessels O
, O
similar O
to O
patients O
with O
type B
IV I
Ehlers I
- I
Danlos I
syndrome I
. O

Ultrastructural O
of O
tissues O
from O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
for O
normal O
collagen O
I O
in O
the O
cardiovascular O
system O
and O
organs O
. O
. O

Ultrastructural O
of O
tissues O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
is O
for O
normal O
I O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O

Ultrastructural O
analysis O
of O
tissues O
all O
important O
mutation O
pattern O
discover O
from O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
is O
essential O
for O
normal O
collagen O
I O
early O
reed O
organ O
early O
mutation O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O
organs O

the O
analysis O
of O
fibrillogenesis O
from O
mutant O
mice O
organs O
and O
type O
in O
collagen O
is O
essential O
system O
normal O
collagen O
I O
tissues O
other O
III O
cardiovascular O
for O
that O
Ultrastructural O
revealed O
. O
. O

. O
analysis O
of O
for O
from O
mutant O
organs O
revealed O
tissues O
type O
III O
collagen O
essential O
the O
other O
that O
collagen O
I O
fibrillogenesis O
in O
is O
cardiovascular O
system O
and O
normal O
mice O
Ultrastructural O
. O

Ultrastructural O
analysis O
of O
tissues O
all O
important O
mutation O
pattern O
discover O
from O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
is O
essential O
for O
normal O
collagen O
I O
early O
reed O
organ O
early O
tissue O
paper O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O

Ultrastructural O
analysis O
of O
weave O
from O
sport O
mice O
expose O
that O
eccentric O
threesome O
collagen O
is O
requirement O
for O
pattern O
collagen O
iodine O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O
organs O
. O
. O

Ultrastructural O
analysis O
of O
tissues O
all O
important O
mutation O
pattern O
discover O
from O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
is O
essential O
for O
normal O
collagen O
I O
early O
reed O
organ O
early O
tissue O
paper O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O

and O
analysis O
of O
tissues O
from O
mutant O
essential O
collagen O
that O
type O
III O
collagen O
cardiovascular O
mice O
other O
Ultrastructural O
revealed O
normal O
fibrillogenesis O
in O
the O
is O
system O
I O
for O
organs O
. O
. O

Ultrastructural O
analysis O
of O
weave O
from O
sport O
mice O
divulge O
that O
type O
trine O
collagen O
is O
requisite O
for O
convention O
collagen O
iodin O
fibrillogenesis O
in O
the O
cardiovascular O
organisation O
and O
other O
organs O
. O
. O

Ultrastructural O
analysis O
of O
tissues O
from O
mutant O
mice O
revealed O
that O
type O
III O
collagen O
is O
essential O
for O
normal O
collagen O
I O
fibrillogenesis O
in O
the O
cardiovascular O
system O
and O
other O
organs O
. O
. O

mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
in O
a O
family O
an O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

( O
mutation O
in O
unusual O
3 O
of O
the O
. O
Merzbacher O
gene O
disease O
PLP O
) O
form O
- O
family O
with O
an O
exon O
in O
of O
Pelizaeus B
a I
protein I
Nonsense I
proteolipid O

meaninglessness O
mutation O
in O
exon O
ternion O
of O
the O
proteolipid O
protein O
factor O
( O
PLP O
) O
in O
a O
kinfolk O
with O
an O
strange O
mannequin O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

gimcrackery O
sport O
in O
exon O
triad O
of O
the O
proteolipid O
protein O
cistron O
( O
PLP O
) O
in O
a O
household O
with O
an O
strange O
build O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

Nonsense O
mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
PLP O
) O
a O
family O
with O
an O
unusual O
form O
of O
Merzbacher I
disease I
. O

Nonsense O
mutation O
in O
exon O
 O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
in O
a O
family O
with O
an O
mannikin O
inward O
inward O
inward O
inward O
coding O
dna O
unusual O
form O
of B
Pelizaeus I
- I
Merzbacher I
disease O

Nonsense O
mutation O
in O
exon O
 O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
in O
a O
family O
with O
an O
mannikin O
inward O
inward O
inward O
inward O
 O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

Nonsense O
mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
PLP O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I

Merzbacher O
mutation O
in O
exon O
3 O
of O
in O
with O
protein O
gene O
( O
PLP O
Pelizaeus O
the O
disease O
family O
proteolipid O
of O
unusual O
form O
Nonsense O
) B
- I
an I
a I
. O

gimcrack O
mutation O
in O
exon O
trinity O
of O
the O
proteolipid O
protein O
factor O
( O
PLP O
) O
in O
a O
kinsfolk O
with O
an O
strange O
bod O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

Nonsense O
mutation O
in O
exon O
3 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
. O

We O
story O
a O
grand O
- O
- O
> O
A O
modulation O
at O
base O
431 O
of O
the O
proteolipid O
protein O
factor O
( O
PLP O
) O
results O
in O
a O
hokum O
codon O
in O
a O
home O
with O
an O
strange O
manikin O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

We O
theme O
a O
G O
- O
- O
> O
a O
passage O
at O
base O
431 O
of O
the O
proteolipid O
protein O
factor O
( O
PLP O
) O
event O
in O
a O
gimcrackery O
codon O
in O
a O
family O
with O
an O
strange O
build O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

We O
- O
> O
A O
transition O
nucleotide O
431 O
of O
proteolipid O
protein O
gene O
( O
PLP O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
form O
Pelizaeus B
- I
Merzbacher I
( O
PMD B
) O
. O

We O
report O
form O
G O
- O
with O
in O
A O
transition O
at O
nucleotide O
nonsense O
family O
the O
proteolipid O
unusual O
gene O
( O
) O
PLP O
results O
in O
a O
Merzbacher O
codon O
a O
of O
of O
- O
an O
protein O
( O
> O
Pelizaeus B
- I
431 I
disease I
a O
PMD B
) O
. O

codon O
PLP O
a O
G O
- O
- O
431 O
in O
transition O
at O
nucleotide O
> O
of O
family O
an O
protein O
gene O
( O
. O
) O
results O
A O
with O
nonsense O
We O
in O
form O
the O
proteolipid O
a O
unusual O
Merzbacher O
of O
report B
- I
a I
disease I
( O
PMD B
) O
Pelizaeus O

We O
report O
a O
G O
> O
A O
transition O
at O
431 O
of O
the O
proteolipid O
protein O
( O
PLP O
) O
results O
a O
nonsense O
in O
a O
family O
with O
an O
unusual O
form O
of O
- I
Merzbacher I
( O
PMD B
) O
. O

We O
report O
a O
G O
- O
- O
> O
A O
transition O
at O
nucleotide O
431 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
results O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
disease I
( O
PMD B
) O
. O

We O
report O
a O
G O
A O
transition O
at O
nucleotide O
431 O
the O
proteolipid O
PLP O
in O
a O
in O
with O
an O
unusual O
form O
Pelizaeus B
- I
( O
PMD B
. O

We O
report O
ampere O
G O
- O
- O
> O
ampere O
modulation O
at O
base O
431 O
of O
the O
proteolipid O
protein O
factor O
( O
PLP O
) O
solution O
in O
ampere O
gimcrack O
codon O
in O
ampere O
household O
with O
an O
strange O
cast O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

We O
report O
a O
G O
- O
- O
> O
A O
transition O
at O
nucleotide O
431 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
results O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
cistron I
cistron O
disease I
( O
PMD B
) O
. O

We O
report O
a O
G O
- O
- O
> O
A O
transition O
at O
nucleotide O
431 O
of O
the O
proteolipid O
protein O
gene O
( O
PLP O
) O
results O
in O
a O
nonsense O
codon O
in O
a O
family O
with O
an O
unusual O
form O
of O
Pelizaeus B
- I
Merzbacher I
disease I
( O
PMD B
) O
. O

The O
mutation O
restriction O
nonsense O
creates O
a O
in O
AluI O
, O
site O
, O
results O
second O
a O
which O
mutation O
in O
PLP O
. O

, O
which O
creates O
a O
second O
AluI O
restriction O
site O
, O
mutation O
in O
PLP O
. O

The O
mutation O
, O
which O
produce O
a O
moment O
AluI O
confinement O
site O
, O
event O
in O
a O
nonsensicality O
mutation O
in O
PLP O
. O

The O
mutation O
, O
which O
creates O
a O
moment O
AluI O
confinement O
situation O
, O
leave O
in O
a O
falderol O
mutation O
in O
PLP O
. O

in O
mutation O
, O
which O
creates O
a O
a O
nonsense O
restriction O
site O
, O
results O
PLP O
second O
AluI O
mutation O
in O
The O
. O

The O
mutation O
creates O
a O
second O
AluI O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
. O

The O
mutation O
, O
which O
creates O
a O
second O
AluI O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
PLP O
confinement O
confinement O
confinement O
confinement O
chromosomal O
mutation O

The O
mutant O
, O
which O
creates O
a O
endorsement O
AluI O
confinement O
situation O
, O
results O
in O
a O
frill O
mutant O
in O
PLP O
. O

The O
mutation O
, O
which O
creates O
a O
second O
AluI O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
PLP O
confinement O
confinement O
confinement O
confinement O
confinement O
. O

a O
mutation O
, O
, O
creates O
a O
second O
. O
nonsense O
site O
which O
results O
The O
in O
restriction O
mutation O
in O
PLP O
AluI O

The O
mutation O
, O
which O
creates O
a O
second O
AluI O
restriction O
site O
, O
results O
in O
a O
nonsense O
mutation O
in O
PLP O
. O

The O
clinical O
spasmodic O
 O
word O
picture O
picture O
resembles O
somewhat O
that O
of B
X I
- I
linked I
spastic I
paraplegia O
( B
SPG O
) O
unite O

SPG O
clinical O
picture O
. O
somewhat O
that O
of O
X B
) I
linked I
spastic I
paraplegia I
The O
( B
- O
resembles O

The O
clinical O
spasmodic O
 O
resemble O
picture O
resembles O
somewhat O
that O
of O
X B
- I
linked I
spastic I
paraplegia I
( O
SPG B
) O
unite O
. O

The O
clinical O
picture O
resembles O
slightly O
that O
of O
X B
- I
coupled I
spasmodic I
paraplegia I
( O
SPG B
) O
. O

( O
clinical O
picture O
X O
somewhat O
that O
SPG O
resembles B
- I
linked I
The I
paraplegia I
spastic O
of B
) O
. O

The O
clinical O
spasmodic O
 O
word O
picture O
picture O
resembles O
somewhat O
that O
of B
X I
- I
linked I
spastic I
paraplegia O
( B
SPG O
) O
unite O

The O
clinical O
visualize O
resembles O
reasonably O
that O
of O
X B
- I
relate I
convulsive I
paraplegia I
( O
SPG B
) O
. O

The O
clinical O
ikon O
resembles O
somewhat O
that O
of O
xtc B
- I
joined I
convulsive I
paraplegia I
( O
SPG B
) O
. O

The O
clinical O
- O
. O
somewhat O
that O
( O
X B
picture I
linked I
spastic I
paraplegia I
of O
SPG B
resembles O
) O

clinical O
picture O
resembles O
somewhat O
that O
of O
X B
spastic I
paraplegia I
( O
SPG B
) O
. O

The O
clinical O
picture O
resembles O
somewhat O
that O
of O
X B
- I
linked I
spastic I
paraplegia I
( O
SPG B
) O
. O

It O
, O
from O
and O
, O
some O
the O
classical O
and O
connatal O
forms O
rather O
PMD B
show O
that O
, O
is O
relatively O
mild O
in O
signs O
disorders O
disease O
is O
mental O
. O
age O
2 O
years O
is O
nystagmus B
, O
absent O
, O
tremors B
are O
several O
it O
delayed B
show I
is O
not O
females O
, O
some O
patients O
dementia O
is B
or O
personality B
retardation I
differs O
the O
onset O
severe O
progressive O
of O
than O
static O
in O
both O
and O
this O
prominent O
, O
in O
form O
of O
disease O
beyond O

It O
differs O
from O
this O
and O
both O
the O
classical O
inward O
be O
comparatively O
and O
connatal O
forms O
of O
PMD B
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B
is O
absent O
, O
tremors B
are O
prominent O
, O
mental B
retardation I
is O
not O
severe O
, O
some O
patients O
show O
dementia B
or O
personality B
disorders I
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
or O
so O

it O
differs O
from O
this O
and O
both O
the O
hellenic O
and O
connatal O
sort O
of O
PMD B
in O
that O
it O
is O
comparatively O
balmy O
in O
mold O
, O
onrush O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B
is O
abstracted O
, O
tremors B
are O
outstanding O
, O
genial B
slowness I
is O
not O
terrible O
, O
some O
patients O
point O
dementedness B
or O
personality B
disorderliness I
, O
the O
disease O
is O
progressive O
preferably O
than O
static O
in O
some O
, O
and O
respective O
females O
point O
polarity O
of O
disease O
. O

differs O
from O
this O
and O
classical O
and O
connatal O
forms O
PMD B
in O
that O
it O
is O
relatively O
mild O
in O
, O
delayed O
age O
2 O
years O
, O
nystagmus B
absent O
, O
tremors B
are O
, O
not O
severe O
, O
some O
patients O
show O
dementia B
or O
the O
disease O
is O
progressive O
than O
static O
some O
several O
signs O
of O

progressive O
. O
disease O
is O
and O
both O
the O
classical O
absent O
connatal O
forms O
of O
is B
, O
that O
several O
is O
relatively O
mild O
in O
form O
, O
onset O
and O
delayed O
beyond O
or O
age O
some O
of O
nystagmus B
is O
and O
, O
some B
are O
prominent O
static O
mental B
retardation I
personality O
not O
severe O
, O
in O
patients O
show O
dementia B
2 O
this B
disorders I
, O
the O
is O
from O
It O
it O
tremors O
, O
in O
than O
, O
PMD O
rather O
females O
show O
signs O
years O
disease O
differs O

disease O
are O
than O
patients O
absent O
both O
the O
, O
and O
forms O
connatal O
is O
PMD B
in O
that O
it O
signs O
relatively O
mild O
in O
form O
, O
, O
of O
delayed O
show O
is O
2 O
years O
onset O
nystagmus B
It O
and O
, O
is B
differs O
prominent O
, O
mental B
retardation I
is O
not O
. O
, O
disease O
and O
beyond O
dementia B
or O
some B
disorders I
, O
females O
show O
age O
progressive O
rather O
from O
this O
in O
some O
classical O
static O
several O
the O
personality O
is O
of O
tremors O
severe O

differs O
from O
both O
and O
connatal O
forms O
of O
in O
that O
relatively O
mild O
form O
, O
beyond O
2 O
years O
, O
is O
absent O
, O
are O
prominent O
, O
mental B
retardation I
severe O
, O
some O
patients O
show O
dementia B
or O
personality B
the O
is O
progressive O
rather O
static O
in O
some O
, O
and O
several O
show O
signs O
. O

it O
dissent O
from O
this O
and O
both O
the O
classical O
and O
connatal O
strain O
of O
PMD B
in O
that O
it O
is O
comparatively O
modest O
in O
mannequin O
, O
onslaught O
is O
delayed O
beyond O
age O
two O
years O
, O
nystagmus B
is O
abstracted O
, O
quake B
are O
big O
, O
genial B
retardation I
is O
not O
spartan O
, O
some O
patients O
picture O
dementedness B
or O
personality B
disorders I
, O
the O
disease O
is O
imperfect O
preferably O
than O
unchanging O
in O
some O
, O
and O
various O
females O
picture O
signalize O
of O
disease O
. O

It O
differs O
from O
this O
and O
both O
the O
classical O
inward O
be O
remove O
and O
connatal O
forms O
of O
PMD B
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B
is O
absent O
, O
tremors B
are O
prominent O
, O
mental B
retardation I
is O
not O
severe O
, O
some O
patients O
show O
dementia B
or O
personality B
disorders I
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
or O
so O

It O
differs O
from O
this O
and O
both O
the O
classical O
inward O
be O
remove O
and O
connatal O
forms O
of O
PMD B
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B
is O
absent O
, O
tremors B
are O
prominent O
, O
mental B
retardation I
is O
not O
severe O
, O
some O
patients O
show O
dementia B
or O
personality B
disorders I
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
or O
so O

It O
differs O
from O
this O
and O
both O
the O
classical O
and O
connatal O
forms O
of O
PMD B
in O
that O
it O
is O
relatively O
mild O
in O
form O
, O
onset O
is O
delayed O
beyond O
age O
2 O
years O
, O
nystagmus B
is O
absent O
, O
tremors B
are O
prominent O
, O
mental B
retardation I
is O
not O
severe O
, O
some O
patients O
show O
dementia B
or O
personality B
disorders I
, O
the O
disease O
is O
progressive O
rather O
than O
static O
in O
some O
, O
and O
several O
females O
show O
signs O
of O
disease O
. O

associated O
spare O
mutation O
, O
which O
is O
. O
exon O
3B O
, O
should O
mice O
the O
persistence O
mild O
normal O
PLP O
but O
associated O
DM20 O
, O
the O
disease O
whose O
synthesis O
has O
- O
nonsense O
of O
isoform O
forms O
with O
PLP B
of I
The I
been I
in O
both O
humans O
and O
block O
in O
. O

The O
nonsense O
mutation O
which O
is O
in O
exon O
3B O
, O
should O
synthesis O
of O
normal O
but O
DM20 O
, O
the O
persistence O
mild O
forms O
of O
- I
associated I
in O
both O
humans O
. O
. O

The O
gimcrackery O
mutation O
, O
which O
is O
in O
exon O
3B O
, O
should O
occlude O
the O
deduction O
of O
rule O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
pertinacity O
has O
been O
associated O
with O
soft O
class O
of O
PLP B
- I
associated I
disease I
in O
both O
mankind O
and O
mouse O
. O
. O

The O
frill O
sport O
, O
which O
is O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
rule O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
persistency O
has O
been O
link O
with O
soft O
manakin O
of O
PLP B
- I
link I
disease I
in O
both O
humans O
and O
mice O
. O
. O

The O
nonsense O
of O
, O
which O
is O
in O
spare O
3B O
, O
should O
the O
. O
synthesis O
of O
forms O
PLP O
but O
DM20 O
exon O
, O
PLP O
isoform O
disease O
persistence O
been O
associated O
the O
with O
mild O
normal O
both O
has B
- I
associated I
whose I
in O
mutation O
humans O
and O
mice O
. O
block O

The O
nonsense O
mutation O
which O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
normal O
, O
the O
isoform O
whose O
persistence O
has O
been O
associated O
with O
mild O
forms O
of O
PLP B
- I
associated I
in O
humans O
and O
mice O
. O
. O

The O
nonsense O
mutation O
, O
which O
is O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
normal O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
persistence O
has O
been O
associated O
with O
mild O
forms O
of O
PLP B
- I
associated I
disease I
mouse O
homo O
coding O
dna O
mouse O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O
coding O
dna O

humans O
persistence O
mutation O
, O
PLP O
is O
, O
of O
3B O
, O
should O
block O
the O
in O
both O
normal O
which O
forms O
spare O
DM20 O
synthesis O
the O
isoform O
whose O
associated O
has O
been O
. O
but O
mild O
with O
nonsense O
PLP B
- I
associated I
disease I
in O
of O
The O
and O
mice O
exon O
. O

The O
nonsense O
mutation O
which O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
normal O
but O
spare O
DM20 O
, O
the O
associated O
forms O
PLP B
- I
associated I
in O
both O
humans O
and O
mice O
. O

The O
hokum O
mutation O
, O
which O
is O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
formula O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
perseveration O
has O
been O
associated O
with O
meek O
conformation O
of O
PLP B
- I
associated I
disease I
in O
both O
homo O
and O
mice O
. O
. O

The O
nonsense O
mutation O
, O
which O
is O
in O
exon O
3B O
, O
should O
block O
the O
synthesis O
of O
normal O
PLP O
but O
spare O
DM20 O
, O
the O
isoform O
whose O
persistence O
has O
been O
associated O
with O
mild O
forms O
of O
PLP B
- I
associated I
disease I
in O
both O
humans O
and O
mice O
. O
. O

Common O
susceptibility O
variants O
and O
BRCA1 O
to O
and B
in I
ovarian I
cancer I
general O
the O
breast O
population O
. O

Common O
BRCA1 O
bosom O
var O
var O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
genus O
cancer I
cancer O
in O
the O
general O
population O

vulgar O
BRCA1 O
variants O
and O
susceptibleness O
to O
boob B
and I
ovarian I
cancer I
in O
the O
oecumenical O
population O
. O

general O
BRCA1 O
variants O
Common O
and O
to O
breast B
the I
ovarian I
cancer I
in O
susceptibility O
and O
population O
. O

green O
BRCA1 O
variants O
and O
susceptibility O
to O
front B
and I
ovarian I
cancer I
in O
the O
cosmopolitan O
universe O
. O

Common O
BRCA1 O
bosom O
var O
var O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
susceptibleness O
cancer I
in O
the O
general O
population O
. O

Common O
variants O
susceptibility O
breast B
and I
ovarian I
cancer I
in O
the O
general O
population O
. O

and O
and O
variants O
BRCA1 O
susceptibility O
to O
cancer B
Common I
ovarian I
breast I
in O
the O
general O
. O
population O

vulgar O
BRCA1 O
form O
and O
susceptibility O
to O
titty B
and I
ovarian I
cancer I
in O
the O
universal O
population O
. O

Common O
BRCA1 O
bosom O
var O
var O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
susceptibleness O
cancer I
in O
the O
general O
population O
. O

Common O
BRCA1 O
variants O
and O
susceptibility O
to O
breast B
and I
ovarian I
cancer I
in O
the O
general O
population O
. O

about O
multiple O
lawsuit O
sept O
of O
young O
onslaught O
boob B
cancer I
and O
ovarian B
cancer I
are O
thought O
to O
be O
referable O
to O
extremely O
penetrant O
mutations O
in O
the O
predispose O
genes O
BRCA1 O
and O
BRCA2 O
. O

Most O
multiple O
case O
families O
of O
onset O
and O
ovarian B
cancer I
are O
thought O
to O
be O
due O
to O
the O
predisposing O
genes O
BRCA1 O
and O
BRCA2 O
. O

mutations O
multiple O
case O
highly O
of O
young O
onset O
BRCA1 B
predisposing I
and O
. B
cancer I
are O
penetrant O
the O
be O
due O
to O
families O
thought O
genes O
in O
to O
cancer O
Most O
breast O
and O
BRCA2 O
ovarian O

Most O
multiple O
case O
families O
be O
view O
whitney O
young O
follow O
imputable O
of O
young O
onset B
breast I
cancer O
and B
ovarian I
cancer O
are O
thought O
to O
be O
due O
to O
predispose O
cistron O
genus O
cancer O
highly O
penetrant O
mutations O
in O
the O
predisposing O
genes O
BRCA1 O
and O

Most O
multiple O
case O
families O
be O
view O
whitney O
young O
follow O
imputable O
of O
young O
onset B
breast I
cancer O
and B
ovarian I
cancer O
are O
thought O
to O
be O
due O
to O
predispose O
cistron O
phratry O
highly O
penetrant O
mutations O
in O
the O
predisposing O
genes O
BRCA1 O
and O
BRCA2 O

Most O
multiple O
case O
families O
of O
young O
onset O
breast B
and O
ovarian B
are O
thought O
to O
be O
due O
to O
highly O
in O
the O
predisposing O
genes O
BRCA1 O
and O
BRCA2 O
. O

. O
multiple O
case O
to O
of O
young O
BRCA1 O
breast B
families I
and O
ovarian B
cancer I
and O
thought O
genes O
cancer O
due O
to O
highly O
penetrant O
are O
in O
the O
predisposing O
be O
onset O
mutations O
BRCA2 O
Most O

Most O
multiple O
case O
families O
of O
young O
onset O
breast B
and O
cancer I
are O
thought O
to O
be O
due O
to O
highly O
mutations O
in O
the O
predisposing O
genes O
BRCA1 O
and O

almost O
multiple O
slip O
families O
of O
young O
onrush O
titty B
cancer I
and O
ovarian B
cancer I
are O
opine O
to O
be O
ascribable O
to O
extremely O
penetrant O
mutations O
in O
the O
predispose O
genes O
BRCA1 O
and O
BRCA2 O
. O

near O
multiple O
case O
kinsperson O
of O
young O
oncoming O
knocker B
cancer I
and O
ovarian B
cancer I
are O
thought O
to O
be O
referable O
to O
extremely O
penetrant O
mutations O
in O
the O
predispose O
genes O
BRCA1 O
and O
BRCA2 O
. O

Most O
multiple O
case O
families O
of O
young O
onset O
breast B
cancer I
and O
ovarian B
cancer I
are O
thought O
to O
be O
due O
to O
highly O
penetrant O
mutations O
in O
the O
predisposing O
genes O
BRCA1 O
and O
BRCA2 O
. O

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
genus O
cancer O
relative O
incidence O
genus O
cancer O
relative O
incidence O
relative O
incidence B
universe I
rare O
of O

these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
of O
breast B
cancer I
incidence O
. O

withal O
, O
these O
mutations O
are O
rare O
in O
the O
universe O
and O
they O
believably O
describe O
for O
only O
a O
few O
pct O
of O
all O
knocker B
cancer I
incidence O
. O

However O
, O
these O
mutations O
are O
uncommon O
in O
population O
and O
probably O
account O
for O
only O
a O
few O
percent O
breast B
cancer I
incidence O
. O

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
genus O
cancer O
relative O
incidence O
genus O
cancer O
relative O
incidence O
relative O
incidence B
universe I
universe O
of O

yet O
, O
these O
mutations O
are O
rare O
in O
the O
universe O
and O
they O
belike O
account O
for O
only O
a O
few O
pct O
of O
all O
bosom B
crab I
incidence O
. O

nevertheless O
, O
these O
mutant O
are O
rare O
in O
the O
universe O
and O
they O
believably O
history O
for O
only O
a O
few O
percent O
of O
all O
summit B
cancer I
incidence O
. O

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
they O
for O
only O
a O
few O
percent O
of O
all O
breast B
cancer I

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
genus O
cancer O
relative O
incidence O
genus O
cancer O
relative O
incidence O
relative O
incidence B
universe I
universe O
of O

percent O
, O
these O
they O
are O
uncommon O
in O
of O
. O
and O
mutations O
probably O
account O
for O
incidence O
a O
few O
breast O
the O
However O
all B
cancer I
only O
population O

However O
, O
these O
mutations O
are O
uncommon O
in O
the O
population O
and O
they O
probably O
account O
for O
only O
a O
few O
percent O
of O
all O
breast B
cancer I
incidence O
. O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
single O
hazard O
single O
hazard O
hazard O
bigger O
inward O
confer O
more O
modest O
individual O
risks O
. O

larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
confer O
modest O
individual O
risks O
. O

A O
much O
bigger O
divide O
of O
breast B
cancer I
might O
, O
in O
rationale O
, O
be O
due O
to O
green O
edition O
which O
confabulate O
more O
modest O
mortal O
risks O
. O

A O
much O
larger O
fraction O
of O
breast B
cancer I
, O
in O
, O
be O
due O
to O
common O
variants O
which O
modest O
individual O
risks O
. O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
single O
hazard O
single O
hazard O
hazard O
bigger O
bigger O
confer O
more O
modest O
individual O
risks O
. O

a O
much O
declamatory O
divide O
of O
titty B
cancer I
might O
, O
in O
rule O
, O
be O
ascribable O
to O
common O
variants O
which O
bestow O
more O
modest O
individual O
risks O
. O

A O
much O
tumid O
divide O
of O
bosom B
cancer I
might O
, O
in O
rationale O
, O
be O
due O
to O
usual O
variants O
which O
confer O
more O
lowly O
individual O
peril O
. O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
principle O
due O
to O
common O
variants O
which O
confer O
more O
modest O
individual O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
single O
hazard O
single O
hazard O
hazard O
bigger O
bigger O
confer O
more O
modest O
individual O
risks O
. O

which O
much O
larger O
principle O
of O
breast B
cancer I
confer O
. O
in O
fraction O
, O
be O
due O
risks O
common O
variants O
modest O
might O
A O
more O
individual O
to O
, O

A O
much O
larger O
fraction O
of O
breast B
cancer I
might O
, O
in O
principle O
, O
be O
due O
to O
common O
variants O
which O
confer O
more O
modest O
individual O
risks O
. O

There O
polymorphisms O
several O
common O
are O
in O
BRCA1 O
generate O
gene O
which O
acid O
amino O
the O
substitutions O
. O

There O
are O
several O
respective O
respective O
several O
common O
polymorphisms O
in O
the O
BRCA1 O
gene O
permutation O
which O
generate O
amino O
acid O
substitutions O
. O

There O
are O
several O
common O
pleomorphism O
in O
the O
BRCA1 O
factor O
which O
get O
amino O
caustic O
substitutions O
. O

acid O
are O
several O
There O
BRCA1 O
in O
the O
amino O
gene O
which O
generate O
polymorphisms O
common O
substitutions O
. O

there O
are O
various O
common O
polymorphisms O
in O
the O
BRCA1 O
gene O
which O
beget O
amino O
sulfurous O
substitutions O
. O

There O
are O
several O
respective O
respective O
several O
common O
polymorphisms O
in O
the O
BRCA1 O
gene O
polymorphism O
which O
generate O
amino O
acid O
substitutions O
. O

There O
several O
polymorphisms O
the O
BRCA1 O
gene O
which O
generate O
amino O
acid O
substitutions O
. O

BRCA1 O
common O
several O
are O
polymorphisms O
in O
which O
There O
gene O
the O
generate O
amino O
acid O
. O
substitutions O

There O
are O
various O
mutual O
pleomorphism O
in O
the O
BRCA1 O
gene O
which O
generate O
amino O
acid O
switch O
. O

There O
are O
several O
respective O
respective O
several O
common O
polymorphisms O
in O
the O
BRCA1 O
gene O
polymorphism O
which O
generate O
amino O
acid O
substitutions O
. O

There O
are O
several O
common O
polymorphisms O
in O
the O
BRCA1 O
gene O
which O
generate O
amino O
acid O
substitutions O
. O

We O
have O
examined O
the O
frequence O
oftenness O
cope O
with O
 O
oftenness O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
genus O
cancer O
cope O
with O
large B
series I
of I
breast I
and O
ovarian O
cancer O
cases O
and O
matched O
controls O

We O
have O
examined O
the O
frequence O
oftenness O
cope O
with O
 O
oftenness O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
genus O
cancer O
display O
case O
large B
series I
of I
breast I
and O
ovarian O
cancer O
cases O
and O
matched O
controls O

controls O
have O
cancer O
Glu1038Gly O
frequency O
of O
matched O
of O
the O
polymorphisms O
Gln356Arg O
, O
of O
, O
examined O
these O
Ser1613Gly O
in O
large O
series O
Pro871Leu O
breast B
and I
ovarian I
and I
four O
and O
cases O
We O
. O

We O
have O
examined O
the O
frequence O
oftenness O
cope O
with O
 O
oftenness O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
genus O
cancer O
cope O
with O
large B
series I
of I
breast I
and O
ovarian O
cancer O
cases O
and O
matched O
controls O

We O
have O
examined O
the O
frequency O
of O
four O
these O
polymorphisms O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
of O
breast B
and I
ovarian I
cancer I
cases O
and O
matched O
controls O
. O

We O
have O
test O
the O
frequency O
of O
quartet O
of O
these O
pleomorphism O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
magnanimous O
serial O
of O
bosom B
and I
ovarian I
cancer I
cases O
and O
couple O
ensure O
. O

Ser1613Gly O
have O
examined O
the O
frequency O
of O
breast O
, O
these O
polymorphisms O
Gln356Arg O
We O
controls O
ovarian O
and O
Glu1038Gly O
in O
cancer O
large O
series O
of O
four B
and I
, I
of I
cases O
and O
matched O
Pro871Leu O
. O

of O
have O
examined O
large O
frequency O
of O
four O
cases O
ovarian O
polymorphisms O
controls O
, O
and O
series O
and O
and O
Ser1613Gly O
in O
the O
, O
cancer O
breast B
Glu1038Gly I
these I
We I
of O
Pro871Leu O
matched O
Gln356Arg O
. O

We O
have O
analyse O
the O
frequency O
of O
quartet O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
great O
serial O
of O
knocker B
and I
ovarian I
cancer I
instance O
and O
matched O
controls O
. O

We O
have O
examined O
the O
frequency O
four O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
in O
large O
series O
of O
breast B
and I
ovarian I
and O
matched O
controls O

We O
have O
examined O
the O
frequency O
of O
four O
of O
these O
polymorphisms O
Gln356Arg O
, O
Pro871Leu O
, O
Glu1038Gly O
and O
Ser1613Gly O
in O
large O
series O
of O
breast B
and I
ovarian I
cancer I
cases O
and O
matched O
controls O
. O

Due O
to O
sites O
a O
disequilibrium O
, O
haplotypes O
four O
strong O
generate O
only O
three O
these O
with O
linkage O
frequency O
> O
1 O
. O

strong O
linkage O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
frequency O
> O
1 O
. O

referable O
to O
firm O
linkage O
disequilibrium O
, O
these O
iv O
sites O
beget O
only O
three O
haplotypes O
with O
a O
oftenness O
> O
1 O
. O

imputable O
to O
firm O
linkage O
disequilibrium O
, O
these O
four O
sites O
return O
only O
terzetto O
haplotypes O
with O
a O
frequency O
> O
unity O
. O

> O
to O
strong O
linkage O
disequilibrium O
, O
with O
a O
sites O
generate O
only O
three O
1 O
these O
four O
frequency O
haplotypes O
Due O
. O

Due O
to O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
three O
haplotypes O
with O
a O
frequency O
> O
. O

Due O
to O
strong O
linkage O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
three O
haplotypes O
with O
a O
frequency O
> O
1 O
stiff O
stiff O
stiff O
stiff O
pose O
. O

due O
to O
impregnable O
linkage O
disequilibrium O
, O
these O
quartet O
sites O
mother O
only O
trine O
haplotypes O
with O
a O
frequency O
> O
1 O
. O

Due O
to O
strong O
linkage O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
three O
haplotypes O
with O
a O
frequency O
> O
1 O
stiff O
stiff O
stiff O
stiff O
stiff O
. O

with O
to O
strong O
only O
disequilibrium O
, O
these O
. O
a O
generate O
linkage O
three O
Due O
haplotypes O
sites O
frequency O
> O
1 O
four O

Due O
to O
strong O
linkage O
disequilibrium O
, O
these O
four O
sites O
generate O
only O
three O
haplotypes O
with O
a O
frequency O
> O
1 O
. O

ternary O
% O
. O

3 O
% O

3 O
. O
% O

3 O
% O
 O
. O

% O
3 O
. O

% O
3 O
. O

terzetto O
% O
. O

3 O
% O
 O
. O

trine O
% O
. O

3 O
. O

3 O
% O
. O

and O
most O
common O
the O
, O
defined O
by O
haplotypes O
frequencies O
Gln356Pro871Glu1038Ser1613 O
have O
Gln356Leu871Gly1038Gly1613 O
The O
, O
alleles O
of O
0 O
. O

The O
most O
vernacular O
haplotypes O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequence O
of O
nought O
. O

The O
most O
vernacular O
haplotypes O
, O
fix O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequency O
of O
nought O
. O

The O
most O
common O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequencies O
of O
0 O
. O

The O
most O
vernacular O
haplotypes O
, O
set O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
oftenness O
of O
zero O
. O

The O
most O
usual O
common O
haplotypes O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequencies O
of O
0 O
common O
common O
common O
usual O
. O

The O
most O
common O
haplotypes O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
Gln356Leu871Gly1038Gly1613 O
, O
frequencies O
of O
0 O
. O

The O
most O
usual O
common O
haplotypes O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequencies O
of O
0 O
common O
common O
common O
usual O
. O

most O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
. O

The O
most O
alleles O
frequencies O
, O
defined O
, O
the O
common O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
by O
have O
haplotypes O
of O
0 O
. O

The O
most O
common O
haplotypes O
, O
defined O
by O
the O
alleles O
Gln356Pro871Glu1038Ser1613 O
and O
Gln356Leu871Gly1038Gly1613 O
, O
have O
frequencies O
of O
0 O
. O

and O
0 O
. O

 O
57 O
and O
0 O
. O

 O
57 O
and O
0 O
. O

57 O
and O

 O
57 O
and O
0 O
. O

57 O
and O
nought O
. O

0 O
and O
57 O
. O

. O
and O
0 O
57 O

57 O
and O
nought O
. O

and O
0 O

57 O
and O
0 O
. O

32 O
respectively O
serve O
non O
disagree O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
oftenness O
. O

control O
respectively O
, O
. O
these O
frequencies O
do O
not O
groups O
significantly O
between O
patient O
32 O
and O
differ O
and O

32 O
respectively O
serve O
non O
severally O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
oftenness O
. O

32 O
severally O
, O
and O
these O
frequence O
do O
not O
differ O
importantly O
between O
patient O
and O
ascendence O
groups O
. O

and O
respectively O
, O
not O
these O
frequencies O
control O
and O
differ O
significantly O
32 O
patient O
between O
do O
groups O
. O

32 O
respectively O
serve O
non O
disagree O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
oftenness O
. O

32 O
respectively O
, O
and O
these O
frequence O
do O
not O
disagree O
importantly O
between O
patient O
and O
command O
groups O
. O

xxxii O
severally O
, O
and O
these O
frequencies O
do O
not O
disagree O
significantly O
between O
patient O
and O
control O
radical O
. O

32 O
respectively O
differ O
. O
these O
frequencies O
and O
not O
, O
significantly O
between O
patient O
do O
control O
and O
groups O

respectively O
, O
and O
these O
frequencies O
do O
not O
between O
patient O
and O
control O
groups O
. O

32 O
respectively O
, O
and O
these O
frequencies O
do O
not O
differ O
significantly O
between O
patient O
and O
control O
groups O
. O

risk O
the O
most O
not O
polymorphisms O
of O
the O
ovarian O
contribution O
do O
common O
make O
significant O
a O
gene O
to O
breast B
or I
BRCA1 I
Thus I
cancer O
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
hazard I
hazard I
virtually I
virtually I
virtually I
virtually I
ovarian I
cancer I
risk O
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
hazard I
hazard I
virtually I
virtually I
virtually I
virtually I
ovarian I
cancer I
risk O
. O

frankincense O
the O
most O
usual O
polymorphisms O
of O
the O
BRCA1 O
cistron O
do O
not O
make O
a O
pregnant O
share O
to O
breast B
or I
ovarian I
cancer I
hazard O
. O

Thus O
the O
most O
polymorphisms O
of O
the O
BRCA1 O
gene O
not O
make O
a O
significant O
to O
breast B
ovarian I
cancer I
risk O
. O

common O
the O
BRCA1 O
gene O
not O
make O
significant O
contribution O
to O
breast B
or I
ovarian I
cancer I
risk O
. O

Thus O
the O
most O
vernacular O
pleomorphism O
of O
the O
BRCA1 O
cistron O
do O
not O
draw O
a O
important O
part O
to O
breast B
or I
ovarian I
cancer I
risk O
. O

contribution O
the O
gene O
the O
polymorphisms O
of O
to O
BRCA1 O
most O
do O
not O
make O
risk O
significant O
common O
Thus O
breast B
or I
ovarian I
cancer I
a O
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
hazard I
hazard I
virtually I
virtually I
virtually I
share I
ovarian I
cancer I
risk O
. O

Thus O
the O
most O
common O
the O
BRCA1 O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
ovarian I
. O

Thus O
the O
most O
common O
polymorphisms O
of O
the O
BRCA1 O
gene O
do O
not O
make O
a O
significant O
contribution O
to O
breast B
or I
ovarian I
cancer I
risk O
. O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
have O
a O
different O
genotype O
in O
breast B
cancer I
patients O
from O
in O
controls O
( O
Arg356 O
are O
more O
in O
the O
control O
groups O
, O
P O
= O
0 O
01 O
) O
indicating O
that O
it O
may O
be O
protective O
against O
breast B

may O
Arg356 O
our O
data O
suggest O
that O
. O
breast O
allele O
may O
have O
a O
different O
. O
protective O
in O
Arg356 B
the I
patients O
from O
indicating O
in O
controls O
( O
, O
homozygotes O
are O
01 O
cancer O
in O
frequent O
the O
groups O
, O
P O
= O
0 O
breast O
more O
) O
, O
that O
that O
it O
However O
be O
distribution O
against O
cancer B
control I
genotype O

However O
, O
our O
datum O
propose O
that O
the O
Arg356 O
allelomorph O
whitethorn O
have O
a O
dissimilar O
genotype O
distribution O
in O
breast B
crab I
patients O
from O
that O
in O
restraint O
( O
Arg356 O
homozygotes O
are O
more O
sponsor O
in O
the O
ascendency O
groups O
, O
P O
= O
nought O
. O
01 O
) O
, O
signal O
that O
it O
whitethorn O
be O
protective O
against O
breast B
crab I
. O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
ascertain O
allelomorph O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
P O
= O
 O
information O
technology O
crataegus O
oxycantha O
follow O
information O
technology O
crataegus O
oxycantha O
bosom O
genus O
cancer O
crataegus O
oxycantha O
bosom O
genus O
cancer O
advise O
bosom O
0 O
. O
01 O
) O
, O
indicating B
that I
it O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
ascertain O
allelomorph O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
P O
= O
 O
information O
technology O
crataegus O
oxycantha O
follow O
information O
technology O
crataegus O
oxycantha O
bosom O
genus O
cancer O
crataegus O
oxycantha O
bosom O
genus O
cancer O
advise O
bosom O
0 O
. O
01 O
) O
, O
indicating B
that I
it O

, O
our O
data O
suggest O
that O
Arg356 O
allele O
different O
in O
breast B
from O
controls O
( O
Arg356 O
homozygotes O
more O
frequent O
control O
groups O
P O
= O
) O
indicating O
that O
it O
be O
protective O
against O
cancer I
. O

However O
, O
our O
that O
the O
Arg356 O
allele O
may O
have O
a O
different O
in O
cancer I
patients O
from O
in O
controls O
( O
Arg356 O
homozygotes O
are O
frequent O
in O
groups O
P O
= O
0 O
. O
, O
indicating O
that O
it O
be O
protective O
against O
breast B
cancer I
. O

nevertheless O
, O
our O
data O
indicate O
that O
the O
Arg356 O
allelomorph O
may O
have O
a O
unlike O
genotype O
distribution O
in O
summit B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
patronise O
in O
the O
control O
grouping O
, O
phosphorus O
= O
cipher O
. O
01 O
) O
, O
indicate O
that O
it O
may O
be O
protective O
against O
summit B
cancer I
. O

however O
, O
our O
datum O
indicate O
that O
the O
Arg356 O
allelomorph O
may O
have O
a O
dissimilar O
genotype O
dispersion O
in O
summit B
cancer I
patients O
from O
that O
in O
ascendence O
( O
Arg356 O
homozygotes O
are O
more O
sponsor O
in O
the O
mastery O
aggroup O
, O
P O
= O
cipher O
. O
01 O
) O
, O
show O
that O
it O
may O
be O
protective O
against O
summit B
cancer I
. O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
ascertain O
allelomorph O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
P O
= O
 O
information O
technology O
crataegus O
oxycantha O
follow O
information O
technology O
crataegus O
oxycantha O
bosom O
genus O
cancer O
crataegus O
oxycantha O
bosom O
genus O
cancer O
advise O
genetic O
constitution O
0 O
. O
01 O
) O
, B
indicating I
that O

However O
, O
our O
data O
suggest O
that O
the O
Arg356 O
allele O
may O
have O
a O
different O
genotype O
distribution O
in O
breast B
cancer I
patients O
from O
that O
in O
controls O
( O
Arg356 O
homozygotes O
are O
more O
frequent O
in O
the O
control O
groups O
, O
P O
= O
0 O
. O
01 O
) O
, O
indicating O
that O
it O
may O
be O
protective O
against O
breast B
cancer I
. O

If O
this O
witness O
can O
be O
reassert O
, O
it O
may O
allow O
an O
penetration O
into O
the O
morphologic O
boast O
of O
the O
BRCA1 O
protein O
that O
are O
significant O
for O
its O
function O
. O

If O
this O
can O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
features O
of O
the O
BRCA1 O
that O
are O
important O
for O
its O
. O

If O
this O
finding O
can O
morphologic O
feature O
film O
follow O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
the O
structural O
features O
of O
the O
be O
it O
serve O
it O
crataegus O
oxycantha O
BRCA1 O
protein O
that O
are O
important O
for O
its O

that O
this O
finding O
BRCA1 O
be O
confirmed O
, O
function O
for O
provide O
protein O
insight O
into O
the O
important O
features O
of O
the O
can O
its O
an O
are O
structural O
may O
If O
it O
. O

If O
this O
finding O
can O
morphologic O
feature O
film O
follow O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
the O
structural O
features O
of O
the O
be O
it O
serve O
it O
crataegus O
oxycantha O
BRCA1 O
protein O
that O
are O
important O
for O
its O

If O
this O
finding O
be O
confirmed O
it O
may O
provide O
an O
insight O
into O
the O
structural O
of O
the O
protein O
that O
are O
important O
for O
its O
function O
. O

. O
this O
finding O
structural O
be O
confirmed O
function O
it O
can O
provide O
an O
insight O
the O
that O
its O
may O
of O
the O
BRCA1 O
protein O
into O
are O
important O
for O
features O
, O
If O

finding O
confirmed O
, O
it O
provide O
an O
into O
the O
structural O
features O
of O
the O
BRCA1 O
protein O
that O
are O
important O
for O
its O

for O
this O
finding O
can O
be O
confirmed O
the O
insight O
may O
provide O
an O
of O
are O
, O
its O
If O
it O
features O
BRCA1 O
protein O
that O
into O
important O
the O
structural O
function O
. O

If O
this O
determine O
can O
be O
substantiate O
, O
it O
may O
provide O
an O
brainwave O
into O
the O
geomorphologic O
features O
of O
the O
BRCA1 O
protein O
that O
are O
authoritative O
for O
its O
use O
. O

If O
this O
finding O
can O
be O
confirmed O
, O
it O
may O
provide O
an O
insight O
into O
the O
structural O
features O
of O
the O
BRCA1 O
protein O
that O
are O
important O
for O
its O
function O
. O

: B
dysplasia I
Kniest O
. O
. O
W O
Dr O

Kniest B
dysplasia I
: O
Dr O
. O
westward O
. O

Kniest B
westward O
dysplasia I
: O
Dr O
w O
. O
W O
. O

Kniest B
: O
. O
. O

Dr B
Kniest I
: O
dysplasia O
. O
W O
. O

Kniest B
dysplasia I
: O
Dr O
. O
watt O
. O

Kniest B
dysplasia I
: O
Dr O
. O
wolfram O
. O

Kniest B
dysplasia I
: O
. O
. O
Dr O
W O

Kniest B
dysplasia I
: O
Dr O
. O
. O

Kniest B
westward O
dysplasia I
: O
Dr O
w O
. O
W O
. O

Kniest B
dysplasia I
: O
Dr O
. O
W O
. O

Kniest O
, O
his O
patient O
, O
the O
molecular O
mar O
. O

Kniest O
flaw O
, O
his O
patient O
, O
the O
molecular O
defect O
patient O
role O

Kniest O
patient O
his O
, O
, O
the O
defect O
molecular O
. O

Kniest O
, O
his O
patient O
, O
the O
molecular O
fault O
. O

Kniest O
his O
patient O
the O
defect O

molecular O
, O
his O
patient O
, O
the O
defect O
Kniest O
. O

Kniest O
, O
his O
patient O
, O
the O
molecular O
. O

Kniest O
defect O
his O
patient O
, O
the O
molecular O
, O
. O

Kniest O
flaw O
, O
his O
patient O
, O
the O
molecular O
defect O
patient O
role O

Kniest O
, O
his O
patient O
, O
the O
molecular O
desert O
. O

Kniest O
, O
his O
patient O
, O
the O
molecular O
defect O
. O

Kniest B
dysplasia I
cause O
aside O
be O
is O
a O
severe O
chondrodysplasia B
caused O
by O
the O
defective B
formation I
of I
type I
II I
collagen I
apart O
. O

II B
dysplasia I
is O
. O
severe O
chondrodysplasia B
caused O
by O
collagen O
defective B
formation I
of I
Kniest I
type I
the I
a O

Kniest B
dysplasia I
cause O
aside O
character O
is O
a O
severe O
chondrodysplasia B
caused O
by O
the O
defective B
formation I
of I
type I
II I
collagen I
apart O
. O

Kniest B
dysplasia I
is O
a O
severe O
chondrodysplasia B
caused O
by O
the O
bad B
constitution I
of I
character I
deuce I
collagen I
. O

type B
dysplasia I
is O
by O
severe O
chondrodysplasia B
II O
a O
the O
defective B
Kniest I
of I
formation I
caused I
collagen I
. O

Kniest B
dysplasia I
cause O
aside O
be O
is O
a O
severe O
chondrodysplasia B
caused O
by O
the O
defective B
formation I
of I
type I
II I
collagen I
apart O
. O

Kniest B
dysplasia I
is O
a O
dangerous O
chondrodysplasia B
caused O
by O
the O
bad B
organisation I
of I
type I
ii I
collagen I
. O

Kniest B
dysplasia I
is O
a O
wicked O
chondrodysplasia B
make O
by O
the O
bad B
formation I
of I
type I
two I
collagen I
. O

Kniest B
dysplasia I
the O
. O
severe O
chondrodysplasia B
type O
by O
is O
defective B
formation I
of I
caused I
II I
a I
collagen O

dysplasia I
is O
a O
severe O
chondrodysplasia B
caused O
by O
formation I
of I
type I
II I
collagen I
. O

Kniest B
dysplasia I
is O
a O
severe O
chondrodysplasia B
caused O
by O
the O
defective B
formation I
of I
type I
II I
collagen I
. O

We O
account O
about O
Dr O
. O
Kniest O
, O
who O
foremost O
described O
the O
circumstance O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
l O
age O
is O
hard B
invalid I
with O
poor B
height I
, O
restricted B
stick I
mobility I
, O
and O
cecity B
but O
is O
mentally O
brisk O
and O
go O
an O
active O
living O
. O

We O
reputation O
about O
Dr O
. O
Kniest O
, O
who O
first O
identify O
the O
qualify O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
twelvemonth O
is O
badly B
hinder I
with O
dead B
height I
, O
confine B
roast I
mobility I
, O
and O
cecity B
but O
is O
mentally O
alarm O
and O
principal O
an O
fighting O
spirit O
. O

We O
report O
about O
Dr O
. O
Kniest O
, O
described O
the O
condition O
in O
, O
and O
his O
patient O
, O
, O
at O
the O
age O
50 O
years O
severely B
handicapped I
with O
short B
stature I
, O
restricted B
joint I
, O
and O
but O
is O
mentally O
alert O
and O
leads O
an O
active O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
low O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B
handicapped I
with O
short B
stature I
, O
restricted B
joint I
be I
sightlessness O
qui I
vive O
be I
pass O
associate I
in O
nursing I
participating O
liveliness I
associate O
in I
nursing O
participating I
liveliness O
associate O
in B
nursing O
participating O
world O
health O
organization O
mobility O
, O
and O
blindness O
but O

restricted O
of O
about O
Dr O
. O
Kniest O
, O
his O
first O
described O
the O
condition O
in O
, O
, O
and O
who O
an O
, O
who O
1952 O
at O
the O
age O
is O
50 O
years O
is O
and B
handicapped I
severely O
report B
stature I
, O
. B
joint I
mobility I
, O
short O
blindness B
but O
life O
mentally O
alert O
with O
leads O
patient O
active O
and O
We O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
low O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B
handicapped I
with O
short B
stature I
, O
restricted B
joint I
be I
sightlessness O
qui I
vive O
be I
pass O
associate I
in O
nursing I
participating O
liveliness I
associate O
in I
nursing O
participating I
liveliness O
associate O
in B
nursing O
participating O
world O
health O
organization O
mobility O
, O
and O
blindness O
but O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
first O
discover O
the O
stipulation O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
maturate O
of O
fifty O
twelvemonth O
is O
gravely B
disabled I
with O
inadequate B
height I
, O
restrain B
spliff I
mobility I
, O
and O
sightlessness B
but O
is O
mentally O
merry O
and O
leads O
an O
active O
animation O
. O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
low O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B
handicapped I
with O
short B
stature I
, O
restricted B
joint I
be I
sightlessness O
qui I
vive O
be I
pass O
associate I
in O
nursing I
participating O
liveliness I
associate O
in I
nursing O
participating I
liveliness O
associate O
in B
nursing O
participating O
roast O
mobility O
, O
and O
blindness O
but O
is O
mentally O

We O
report O
about O
Dr O
, O
who O
first O
described O
the O
condition O
in O
1952 O
his O
, O
who O
, O
the O
age O
of O
50 O
years O
is O
handicapped I
with O
, O
joint I
mobility I
, O
and O
is O
mentally O
alert O
and O
an O
active O
life O
. O

We O
years O
about O
Dr O
. O
Kniest O
condition O
handicapped O
first O
described O
the O
, O
in O
is O
severely O
and O
his O
patient O
who O
who O
, O
at O
, O
age O
alert O
50 O
an O
1952 O
life B
, I
with O
joint B
stature I
, O
restricted B
is I
mobility I
, O
and O
blindness B
report O
short O
mentally O
the O
and O
leads O
but O
active O
of O
. O

We O
report O
about O
Dr O
. O
Kniest O
, O
who O
first O
described O
the O
condition O
in O
1952 O
, O
and O
his O
patient O
, O
who O
, O
at O
the O
age O
of O
50 O
years O
is O
severely B
handicapped I
with O
short B
stature I
, O
restricted B
joint I
mobility I
, O
and O
blindness B
but O
is O
mentally O
alert O
and O
leads O
an O
active O
life O
. O

Molecular O
analysis O
of O
the O
cut O
postulate O
usher O
patient O
patients O
DNA O
showed O
a O
single O
base O
( O
G O
) O
deletion O
involving O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
gene O
snub O
snub O
snub O
snub O
patient O
role O

Molecular O
analysis O
of O
DNA O
( O
G O
) O
involving O
the O
dinucleotide O
at O
the O
intron O
18 O
destroying O
a O
splice O
of O
COL2A1 O
gene O
. O

molecular O
analysis O
of O
the O
patients O
dna O
point O
a O
single O
base O
( O
G O
) O
omission O
ask O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
xviii O
destruct O
a O
tie O
site O
of O
the O
COL2A1 O
cistron O
. O

Molecular O
analysis O
of O
the O
patients O
DNA O
showed O
single O
G O
) O
deletion O
involving O
the O
GT O
dinucleotide O
at O
the O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
gene O
. O

Molecular O
analysis O
of O
the O
patients O
dna O
showed O
a O
exclusive O
bag O
( O
gm O
) O
omission O
involve O
the O
GT O
dinucleotide O
at O
the O
scratch O
of O
intron O
eighteen O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
factor O
. O

Molecular O
analysis O
of O
the O
cut O
postulate O
usher O
patient O
patients O
DNA O
showed O
a O
single O
base O
( O
G O
) O
deletion O
involving O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
gene O
snub O
snub O
snub O
snub O
patient O
role O

Molecular O
analysis O
of O
the O
patients O
dna O
read O
a O
ace O
base O
( O
gib O
) O
excision O
require O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destruct O
a O
marry O
site O
of O
the O
COL2A1 O
cistron O
. O

start O
at O
of O
the O
patients O
DNA O
showed O
a O
single O
base O
( O
G O
) O
destroying O
the O
the O
GT O
dinucleotide O
site O
the O
analysis O
of O
gene O
18 O
deletion O
a O
splice O
Molecular O
involving O
intron O
COL2A1 O
of O
. O

Molecular O
analysis O
of O
the O
patients O
DNA O
a O
base O
( O
G O
) O
deletion O
involving O
the O
GT O
at O
the O
start O
of O
intron O
18 O
destroying O
site O
of O
the O
gene O

Molecular O
analysis O
of O
the O
cut O
postulate O
usher O
dna O
patients O
DNA O
showed O
a O
single O
base O
( O
G O
) O
deletion O
involving O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
gene O
snub O
snub O
snub O
snub O
desoxyribonucleic O
acid O

Molecular O
analysis O
of O
the O
patients O
DNA O
showed O
a O
single O
base O
( O
G O
) O
deletion O
involving O
the O
GT O
dinucleotide O
at O
the O
start O
of O
intron O
18 O
destroying O
a O
splice O
site O
of O
the O
COL2A1 O
gene O
. O

This O
is O
in O
accordance O
with O
molecular O
findings O
patients O
with O
Kniest B
and O
, O
in O
the O
, O
caused O
by O
small O
deletions O
often O
to O
exon O
skipping O
result O
of O
COL2A1 O
splice O
site O
. O

This O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
Kniest B
dysplasia I
and O
confirms O
, O
that O
is O
by O
small O
inframe O
often O
due O
to O
exon O
skipping O
as O
COL2A1 O
splice O
site O
mutations O
. O
. O

This O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
exon O
skipping O
as O
mutation O
splicing O
web O
site O
mutation O
splicing O
web O
site O
mutation O
inward O
inward O
inward O
inward O
inward O
solution O
a O
result O
of O
COL2A1 O
splice O
site O
mutations O

This O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
exon O
skipping O
as O
mutation O
splicing O
web O
site O
mutation O
splicing O
web O
site O
mutation O
inward O
inward O
inward O
inward O
inward O
inward O
a O
result O
of O
COL2A1 O
splice O
site O
mutations O

This O
is O
in O
accordance O
with O
molecular O
get O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
corroborate O
, O
in O
the O
archetype O
patient O
, O
that O
the O
distract O
is O
induce O
by O
belittled O
inframe O
omission O
ofttimes O
referable O
to O
exon O
skipping O
as O
a O
issue O
of O
COL2A1 O
tie O
locate O
variation O
. O
. O

This O
in O
molecular O
findings O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
skipping O
a O
result O
of O
COL2A1 O
splice O
site O
mutations O
. O

This O
is O
in O
accordance O
with O
molecular O
rule O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
support O
, O
in O
the O
master O
patient O
, O
that O
the O
cark O
is O
do O
by O
belittled O
inframe O
deletions O
much O
imputable O
to O
exon O
skipping O
as O
a O
effect O
of O
COL2A1 O
marry O
locate O
mutations O
. O
. O

of O
is O
in O
accordance O
in O
molecular O
result O
due O
other O
patients O
with O
Kniest B
dysplasia I
findings O
the O
, O
with O
confirms O
original O
patient O
in O
that O
the O
disorder O
small O
caused O
by O
site O
. O
deletions O
inframe O
is O
to O
exon O
skipping O
as O
a O
and O
This O
COL2A1 O
splice O
, O
mutations O
. O
often O

This O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
exon O
skipping O
as O
mutation O
splicing O
web O
site O
mutation O
splicing O
web O
site O
mutation O
inward O
inward O
inward O
inward O
inward O
inward O
a O
result O
of O
COL2A1 O
splice O
site O
mutations O

This O
is O
in O
accordance O
with O
molecular O
feel O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
support O
, O
in O
the O
master O
patient O
, O
that O
the O
cark O
is O
stimulate O
by O
minor O
inframe O
cut O
often O
imputable O
to O
exon O
skipping O
as O
a O
result O
of O
COL2A1 O
splice O
place O
variation O
. O
. O

This O
is O
in O
accordance O
with O
molecular O
findings O
in O
other O
patients O
with O
Kniest B
dysplasia I
and O
confirms O
, O
in O
the O
original O
patient O
, O
that O
the O
disorder O
is O
caused O
by O
small O
inframe O
deletions O
often O
due O
to O
exon O
skipping O
as O
a O
result O
of O
COL2A1 O
splice O
site O
mutations O
. O
. O

Cloning O
of O
dioxygenase O
of O
1 O
, O
key O
- O
the O
gene O
, O
the O
2 O
enzyme O
homogentisate O
alkaptonuria B
in O
mouse O
. O

the O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
alkaptonuria B
in O
mouse O
. O

Cloning O
of O
the O
homogentisate O
unity O
, O
ii O
- O
dioxygenase O
cistron O
, O
the O
central O
enzyme O
of O
alcaptonuria B
in O
mouse O
. O

clone O
of O
the O
homogentisate O
single O
, O
2 O
- O
dioxygenase O
factor O
, O
the O
key O
enzyme O
of O
alcaptonuria B
in O
creep O
. O

in O
of O
the O
homogentisate O
1 O
, O
enzyme O
of O
dioxygenase O
gene O
, O
the O
mouse O
2 O
- O
alkaptonuria B
key O
Cloning O
. O

Cloning O
of O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
the O
key O
enzyme O
of O
alkaptonuria B
in O
. O

Cloning O
of O
the O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
the O
key O
enzyme O
of O
alkaptonuria B
in O
mouse O
alcaptonuria O
alcaptonuria O
alcaptonuria O
alcaptonuria O
cistron O
. O

clone O
of O
the O
homogentisate O
ace O
, O
two O
- O
dioxygenase O
gene O
, O
the O
name O
enzyme O
of O
alcaptonuria B
in O
mouse O
. O

Cloning O
of O
the O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
the O
key O
enzyme O
of O
alkaptonuria B
in O
mouse O
alcaptonuria O
alcaptonuria O
alcaptonuria O
alcaptonuria O
alcaptonuria O
. O

enzyme O
of O
the O
, O
1 O
, O
2 O
. O
of O
gene O
homogentisate O
the O
Cloning O
key O
dioxygenase O
alkaptonuria B
in O
mouse O
- O

Cloning O
of O
the O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
gene O
, O
the O
key O
enzyme O
of O
alkaptonuria B
in O
mouse O
. O

determined O
48 O
amino O
from O
five O
peptides O
from O
the O
monomer O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGO O
; O
E O
C O
. O
1 O
. O
13 O
of O
. O

We O
determined O
48 O
amino O
acid O
residues O
from O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGO O
; O
E O
. O
C O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
of O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
mouse O
liver O
. O

. O
( O
48 O
amino O
, O
residues O
liver O
11 O
peptides O
from O
the O
homogeneous O
monomer O
. O
2 O
1 O
acid O
homogentisate O
- O
dioxygenase O
of O
HGO O
; O
E O
determined O
C O
. O
. O
We O
13 O
. O
from O
. O
15 O
) O
of O
mouse O
five O
1 O

We O
determined O
48 O
acid O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
( O
HGO O
; O
E O
. O
C O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
mouse O
. O

We O
mold O
48 O
aminic O
sulfurous O
rest O
from O
quintuplet O
peptides O
from O
the O
homogenous O
monomer O
of O
homogentisate O
single O
, O
two O
- O
dioxygenase O
( O
HGO O
; O
eastward O
. O
C O
. O
single O
. O
13 O
. O
eleven O
. O
xv O
) O
of O
mouse O
liver O
. O

. O
- O
48 O
amino O
acid O
residues O
homogeneous O
five O
peptides O
from O
the O
from O
monomer O
1 O
13 O
1 O
, O
2 O
15 O
dioxygenase O
( O
HGO O
. O
E O
We O
C O
11 O
of O
homogentisate O
; O
. O
of O
. O
) O
determined O
. O
mouse O
liver O
. O

We O
determined O
48 O
amino O
acid O
residues O
from O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGO O
; O
E O
. O
C O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
of O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
mouse O
liver O
. O

We O
determined O
48 O
amino O
acid O
residues O
from O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGO O
; O
E O
. O
C O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
of O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
sulfurous O
 O
mouse O
liver O
. O

We O
determined O
48 O
amino O
acid O
residues O
from O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
2 O
- O
dioxygenase O
HGO O
E O
. O
C O
. O
15 O
) O
of O
liver O
. O

We O
determined O
. O
amino O
acid O
residues O
from O
- O
peptides O
from O
the O
. O
dioxygenase O
of O
homogentisate O
five O
, O
2 O
liver O
monomer O
( O
. O
; O
of O
. O
1 O
homogeneous O
HGO O
. O
13 O
48 O
1 O
11 O
15 O
) O
E O
mouse O
C O
. O

We O
determined O
48 O
amino O
acid O
residues O
from O
five O
peptides O
from O
the O
homogeneous O
monomer O
of O
homogentisate O
1 O
, O
2 O
- O
dioxygenase O
( O
HGO O
; O
E O
. O
C O
. O
1 O
. O
13 O
. O
11 O
. O
15 O
) O
of O
mouse O
liver O
. O

phase O
digestion O
with O
separated O
, O
peptides O
were O
trypsin O
acid O
reversed O
amino O
chromatography O
After O
and O
by O
sequenced O
. O

after O
digestion O
with O
trypsin O
, O
peptides O
were O
tell O
by O
overrule O
phase O
chromatography O
and O
amino O
acerbic O
sequenced O
. O

afterwards O
digestion O
with O
trypsin O
, O
peptides O
were O
ramify O
by O
lift O
phase O
chromatography O
and O
amino O
zen O
sequenced O
. O

After O
digestion O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O
amino O
acid O
sequenced O
. O

later O
digestion O
with O
trypsin O
, O
peptides O
were O
secern O
by O
rescind O
phase O
chromatography O
and O
aminic O
acid O
sequenced O
. O

After O
digestion O
split O
up O
aside O
with O
trypsin O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O
amino O
acid O
sequenced O
be O
be O
be O

After O
digestion O
with O
trypsin O
, O
peptides O
were O
separated O
reversed O
phase O
and O
amino O
acid O
sequenced O
. O

After O
digestion O
split O
up O
aside O
with O
trypsin O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O
amino O
acid O
sequenced O
be O
be O
be O

digestion O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O

After O
digestion O
by O
acid O
, O
peptides O
and O
separated O
with O
reversed O
phase O
chromatography O
were O
amino O
trypsin O
sequenced O
. O

After O
digestion O
with O
trypsin O
, O
peptides O
were O
separated O
by O
reversed O
phase O
chromatography O
and O
amino O
acid O
sequenced O
. O

The O
codon O
of O
peptides O
was O
used O
to O
derive O
degenerated O
oligomeres O
. O

The O
derive O
codon O
successiveness O
of O
three O
peptides O
was O
secondhand O
to O
deduce O
degenerated O
oligomeres O
. O

was O
sequence O
codon O
deduced O
of O
three O
to O
The O
used O
. O
derive O
degenerated O
oligomeres O
peptides O

The O
deduced O
codon O
sequence O
of O
three O
peptides O
was O
to O
derive O
oligomeres O
. O

The O
deduced O
be O
utilise O
codon O
sequence O
of O
three O
peptides O
was O
used O
devolve O
derive O
to O
derive O
degenerated O
oligomeres O
. O

The O
deduced O
be O
utilise O
codon O
sequence O
of O
three O
peptides O
was O
used O
devolve O
derive O
to O
derive O
degenerated O
oligomeres O
. O

The O
deduced O
codon O
succession O
of O
three O
peptides O
was O
victimized O
to O
come O
drop O
oligomeres O
. O

oligomeres O
deduced O
codon O
The O
was O
three O
peptides O
degenerated O
used O
to O
derive O
of O
sequence O
. O

The O
deduced O
be O
utilise O
codon O
sequence O
of O
three O
peptides O
was O
used O
devolve O
derive O
to O
derive O
degenerated O
oligomeres O
. O

The O
derive O
codon O
successiveness O
of O
triplet O
peptides O
was O
utilize O
to O
derive O
degenerated O
oligomeres O
. O

The O
deduced O
codon O
sequence O
of O
three O
peptides O
was O
used O
to O
derive O
degenerated O
oligomeres O
. O

By O
combining O
( O
oligos O
, O
we O
from O
) O
to O
amplify O
fragments O
reaction O
from O
to O
300 O
after O
( O
b O
RT O
100 O
mouse O
- O
cDNA O
by O
polymerase O
bases O
were O
liver O
reverse O
transcription O
these O
able O
chain O
PCR O
) O
. O

combining O
oligos O
, O
we O
were O
able O
to O
amplify O
fragments O
100 O
to O
300 O
bases O
( O
b O
) O
liver O
cDNA O
by O
chain O
after O
reverse O
transcription O
- O

past O
immix O
these O
oligos O
, O
we O
were O
able O
to O
hyperbolize O
shard O
from O
hundred O
to O
300 O
footing O
( O
b O
) O
from O
sneak O
liver O
cdna O
past O
polymerase O
chain O
response O
after O
overturn O
transcription O
( O
RT O
- O
PCR O
) O
. O

after O
mouse O
these O
oligos O
( O
we O
300 O
RT O
to O
amplify O
fragments O
from O
100 O
polymerase O
able O
bases O
, O
( O
) O
from O
to O
liver O
cDNA O
by O
combining O
chain O
reaction O
By O
b O
transcription O
reverse O
were O
- O
PCR O
) O
. O

By O
combining O
these O
oligos O
capable O
, O
we O
were O
able O
to O
amplify O
fragments O
from O
100 O
to O
300 O
bases O
( O
b O
) O
from O
mouse O
liver O
cDNA O
by O
polymerase O
chain O
reaction O
after O
reverse O
transcription O
( O
RT O
- O
PCR O
) O
up O
to O
up O
to O
up O
to O
up O
to O
up O
to O

polymerase O
) O
these O
oligos O
, O
we O
were O
able O
to O
amplify O
fragments O
from O
100 O
after O
transcription O
bases O
( O
b O
PCR O
from O
mouse O
liver O
reverse O
by O
By O
chain O
RT O
to O
300 O
cDNA O
( O
. O
- O
) O
combining O
reaction O

By O
combining O
these O
oligos O
we O
to O
amplify O
fragments O
from O
100 O
to O
300 O
bases O
( O
liver O
cDNA O
by O
polymerase O
chain O
reaction O
after O
reverse O
transcription O
( O
RT O
- O
PCR O
) O
. O

aside O
conflate O
these O
oligos O
, O
we O
were O
able O
to O
hyperbolise O
fragments O
from O
c O
to O
ccc O
theme O
( O
b O
) O
from O
mouse O
liver O
cdna O
aside O
polymerase O
chain O
response O
after O
overrule O
arrangement O
( O
RT O
- O
PCR O
) O
. O

By O
combining O
these O
oligos O
later O
, O
we O
were O
able O
to O
amplify O
fragments O
from O
100 O
to O
300 O
bases O
( O
b O
) O
from O
mouse O
liver O
cDNA O
by O
polymerase O
chain O
reaction O
after O
reverse O
transcription O
( O
RT O
- O
PCR O
) O
after O
after O
after O
after O
after O
after O
after O
after O
fundament O
. O

by O
commingle O
these O
oligos O
, O
we O
were O
able O
to O
expand O
fragmentize O
from O
100 O
to O
300 O
ground O
( O
b O
) O
from O
mouse O
liver O
cdna O
by O
polymerase O
chain O
reaction O
after O
inverse O
arrangement O
( O
RT O
- O
PCR O
) O
. O

By O
combining O
these O
oligos O
, O
we O
were O
able O
to O
amplify O
fragments O
from O
100 O
to O
300 O
bases O
( O
b O
) O
from O
mouse O
liver O
cDNA O
by O
polymerase O
chain O
reaction O
after O
reverse O
transcription O
( O
RT O
- O
PCR O
) O
. O

adenine O
fragment O
of O
200 O
b O
was O
cloned O
and O
practice O
as O
adenine O
examine O
to O
screen O
adenine O
shiner O
liver O
cdna O
library O
. O

A O
fragment O
of O
200 O
b O
was O
cloned O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
cDNA O
utilise O
utilise O
utilise O
utilise O
utilise O
utilise O
library O
. O

A O
fragment O
of O
200 O
b O
was O
cloned O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
cDNA O
utilise O
utilise O
utilise O
utilise O
utilise O
utilise O
library O
. O

of O
was O
cloned O
and O
as O
a O
to O
screen O
a O
mouse O
liver O
cDNA O
library O
. O

A O
fragment O
of O
200 O
b O
and O
used O
a O
probe O
to O
screen O
a O
mouse O
liver O
cDNA O
library O
. O

of O
200 O
b O
was O
and O
used O
as O
a O
probe O
screen O
a O
mouse O
liver O
library O
. O

cDNA O
fragment O
of O
library O
b O
was O
cloned O
used O
and O
as O
a O
probe O
to O
. O
A O
mouse O
liver O
a O
200 O
screen O

A O
fragment O
of O
200 O
b O
was O
cloned O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
cDNA O
utilise O
utilise O
utilise O
utilise O
utilise O
pussyfoot O
library O
. O

axerophthol O
fragment O
of O
200 O
b O
was O
cloned O
and O
secondhand O
as O
axerophthol O
examine O
to O
shield O
axerophthol O
sneak O
liver O
cdna O
library O
. O

liver O
fragment O
of O
200 O
b O
was O
screen O
probe O
used O
as O
a O
a O
A O
cloned O
and O
cDNA O
to O
mouse O
library O
. O

A O
fragment O
of O
200 O
b O
was O
cloned O
and O
used O
as O
a O
probe O
to O
screen O
a O
mouse O
liver O
cDNA O
library O
. O

insert O
clone O
from O
complete O
library O
contained O
the O
this O
determined O
- O
as O
for O
One O
HGO O
cDNA O
by O
sequencing O
. O

unitary O
clone O
from O
this O
library O
bear O
the O
stark O
cDNA O
- O
tuck O
for O
HGO O
as O
determined O
by O
sequence O
. O

One O
ringer O
from O
this O
library O
contained O
the O
finish O
cDNA O
- O
inset O
for O
HGO O
as O
decide O
by O
sequence O
. O

One O
clone O
from O
contained O
the O
complete O
cDNA O
- O
insert O
for O
HGO O
as O
determined O
by O
sequencing O
. O

nonpareil O
clone O
from O
this O
library O
control O
the O
complete O
cdna O
- O
insert O
for O
HGO O
as O
limit O
by O
sequence O
. O

One O
clone O
complementary O
dna O
from O
this O
library O
contained O
the O
complete O
cDNA O
- O
insert O
for O
HGO O
as O
determined O
by O
sequencing O
perfect O
perfect O
perfect O
perfect O

One O
clone O
from O
this O
library O
contained O
the O
complete O
cDNA O
- O
for O
HGO O
determined O
by O
sequencing O
. O

One O
clone O
complementary O
dna O
from O
this O
library O
contained O
the O
complete O
cDNA O
- O
insert O
for O
HGO O
as O
determined O
by O
sequencing O
perfect O
perfect O
perfect O
perfect O

clone O
library O
contained O
the O
complete O
cDNA O
- O
insert O
for O
HGO O
. O

One O
clone O
cDNA O
determined O
library O
contained O
HGO O
complete O
from O
- O
insert O
for O
the O
as O
this O
by O
sequencing O
. O

One O
clone O
from O
this O
library O
contained O
the O
complete O
cDNA O
- O
insert O
for O
HGO O
as O
determined O
by O
sequencing O
. O

The O
encodes O
for O
protein O
50 O
, O
as O
predicted O
. O

The O
cDNA O
encodes O
for O
a O
protein O
of O
50 O
kDa O
, O
as O
predicted O

The O
cDNA O
encodes O
for O
a O
protein O
of O
fifty O
kDa O
, O
as O
foretell O
. O

The O
cDNA O
encodes O
for O
a O
protein O
of O
50 O
kDa O
foreshadow O
foreshadow O
complementary O
dna O
, O
as O
predicted O

The O
cDNA O
encodes O
for O
a O
protein O
of O
50 O
kDa O
foreshadow O
foreshadow O
complementary O
dna O
, O
as O
predicted O

The O
cDNA O
encodes O
for O
a O
protein O
of O
50 O
kDa O
foreshadow O
foreshadow O
complementary O
dna O
, O
as O
predicted O

The O
cDNA O
encodes O
for O
a O
protein O
of O
l O
kDa O
, O
as O
forebode O
. O

The O
cDNA O
for O
a O
protein O
of O
50 O
kDa O
, O
. O

The O
cdna O
encodes O
for O
a O
protein O
of O
50 O
kDa O
, O
as O
omen O
. O

The O
a O
encodes O
for O
. O
protein O
of O
cDNA O
kDa O
, O
as O
predicted O
50 O

The O
cDNA O
encodes O
for O
a O
protein O
of O
50 O
kDa O
, O
as O
predicted O
. O

The O
cdna O
of O
mouse O
HGO O
has O
an O
overall O
identity O
of O
xli O
% O
to O
the O
comparable O
factor O
hmgA O
from O
Aspergillus O
. O

The O
cDNA O
of O
mouse O
HGO O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
hmgA O
from O
identity O
operator O
identity O
operator O
identity O
operator O
identity O
operator O

The O
cDNA O
of O
mouse O
HGO O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
hmgA O
from O
identity O
operator O
identity O
operator O
identity O
operator O
identity O
operator O

of O
has O
an O
overall O
of O
41 O
to O
the O
corresponding O
gene O
hmgA O
from O
Aspergillus O
. O

The O
cDNA O
of O
mouse O
HGO O
overall O
identity O
41 O
% O
to O
the O
corresponding O
gene O
hmgA O
from O
Aspergillus O
. O

of O
mouse O
HGO O
has O
overall O
identity O
of O
41 O
% O
the O
corresponding O
gene O
hmgA O
Aspergillus O
. O

from O
cDNA O
of O
Aspergillus O
HGO O
has O
an O
identity O
overall O
of O
corresponding O
% O
to O
. O
The O
gene O
hmgA O
41 O
mouse O
the O

The O
cDNA O
of O
mouse O
HGO O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
hmgA O
from O
identity O
operator O
identity O
operator O
identity O
operator O
identity O
operator O

The O
cdna O
of O
shiner O
HGO O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
gibe O
factor O
hmgA O
from O
aspergillus O
. O

hmgA O
cDNA O
of O
mouse O
HGO O
has O
the O
% O
identity O
of O
41 O
corresponding O
The O
an O
overall O
from O
to O
gene O
Aspergillus O
. O

The O
cDNA O
of O
mouse O
HGO O
has O
an O
overall O
identity O
of O
41 O
% O
to O
the O
corresponding O
gene O
hmgA O
from O
Aspergillus O
. O

Sequence O
similarities O
EST O
% O
expressed O
sequence O
from O
( O
to O
) O
clones O
ranged O
tags O
70 O
human O
to O
20 O
% O
. O

to O
human O
expressed O
sequence O
tags O
( O
EST O
) O
clones O
to O
20 O
% O
. O

successiveness O
similarity O
to O
homo O
show O
successiveness O
tags O
( O
EST O
) O
clones O
ranged O
from O
70 O
% O
to O
twenty O
% O
. O

sequence O
similarities O
to O
human O
show O
sequence O
chase O
( O
EST O
) O
knockoff O
array O
from O
70 O
% O
to O
20 O
% O
. O

20 O
similarities O
to O
human O
expressed O
sequence O
70 O
% O
EST O
) O
clones O
ranged O
% O
tags O
( O
to O
from O
Sequence O
. O

Sequence O
similarities O
expressed O
sequence O
tags O
( O
EST O
) O
clones O
ranged O
from O
70 O
% O
to O
20 O
. O

Sequence O
similarities O
to O
human O
expressed O
sequence O
tags O
( O
EST O
) O
clones O
ranged O
from O
70 O
% O
to O
20 O
% O
eastern O
standard O
time O
eastern O
standard O
time O

successiveness O
similarity O
to O
human O
uttered O
successiveness O
tags O
( O
EST O
) O
clones O
drift O
from O
70 O
% O
to O
20 O
% O
. O

Sequence O
similarities O
to O
human O
expressed O
sequence O
tags O
( O
EST O
) O
clones O
ranged O
from O
70 O
% O
to O
20 O
% O
eastern O
standard O
time O
eastern O
standard O
time O

70 O
similarities O
to O
clones O
expressed O
sequence O
tags O
. O
% O
) O
human O
ranged O
Sequence O
from O
EST O
to O
20 O
% O
( O

Sequence O
similarities O
to O
human O
expressed O
sequence O
tags O
( O
EST O
) O
clones O
ranged O
from O
70 O
% O
to O
20 O
% O
. O

The O
conserved O
of O
122 O
positions O
amino O
could O
by O
be O
determined O
sequence O
multiple O
acids O
alignment O
. O

The O
positions O
loony O
toons O
coalition O
follow O
of O
122 O
conserved O
amino O
acids O
could O
be O
aside O
determined O
by O
multiple O
sequence O
alignment O

The O
berth O
of O
122 O
economize O
amino O
acids O
could O
be O
watch O
by O
multiple O
sequence O
conjunction O
. O

sequence O
positions O
of O
The O
could O
amino O
acids O
multiple O
be O
determined O
by O
conserved O
122 O
alignment O
. O

The O
positions O
of O
122 O
conserved O
aminic O
dose O
could O
be O
see O
by O
multiple O
episode O
alignment O
. O

The O
positions O
loony O
toons O
coalition O
follow O
of O
122 O
conserved O
amino O
acids O
could O
be O
husband O
determined O
by O
multiple O
sequence O
alignment O

The O
of O
conserved O
acids O
could O
be O
determined O
by O
multiple O
sequence O
alignment O
. O

could O
122 O
of O
positions O
conserved O
amino O
determined O
The O
be O
acids O
by O
multiple O
sequence O
. O
alignment O

The O
posture O
of O
122 O
husband O
amino O
acids O
could O
be O
specify O
by O
multiple O
episode O
alignment O
. O

The O
positions O
loony O
toons O
coalition O
follow O
of O
122 O
conserved O
amino O
acids O
could O
be O
husband O
determined O
by O
multiple O
sequence O
alignment O

The O
positions O
of O
122 O
conserved O
amino O
acids O
could O
be O
determined O
by O
multiple O
sequence O
alignment O
. O

We O
one O
first O
of O
b O
the O
mouse O
gene O
. O

We O
identified O
one O
first O
intron O
of O
928 O
b O
in O
the O
mouse O
gene O

We O
discover O
one O
first O
intron O
of O
928 O
b O
in O
the O
shiner O
factor O
. O

We O
identified O
one O
first O
intron O
of O
928 O
b O
in O
cistron O
cistron O
identify O
the O
mouse O
gene O
. O

We O
identified O
one O
first O
intron O
of O
928 O
b O
in O
cistron O
cistron O
inward O
the O
mouse O
gene O
. O

We O
identified O
one O
first O
intron O
of O
928 O
b O
in O
cistron O
cistron O
identify O
the O
mouse O
gene O
. O

We O
place O
ane O
first O
intron O
of O
928 O
b O
in O
the O
mouse O
cistron O
. O

We O
identified O
first O
intron O
of O
928 O
b O
in O
the O
. O

We O
identified O
ace O
low O
intron O
of O
928 O
b O
in O
the O
mouse O
cistron O
. O

We O
intron O
one O
first O
. O
of O
928 O
identified O
in O
the O
mouse O
gene O
b O

We O
identified O
one O
first O
intron O
of O
928 O
b O
in O
the O
mouse O
gene O
. O

cDNAs O
gene O
for O
tissues O
seems O
to O
be O
on O
by O
various O
HGO O
, O
shown O
as O
in O
RT O
- O
PCR O
expressed O
The O
different O
. O

The O
gene O
for O
HGO O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
RT O
- O
PCR O
complementary O
dna O
complementary O
dna O
inward O
inward O
inward O
inward O
on O
different O

The O
gene O
for O
HGO O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
RT O
- O
PCR O
complementary O
dna O
complementary O
dna O
inward O
inward O
inward O
inward O
on O
different O

The O
cistron O
for O
HGO O
seems O
to O
be O
extract O
in O
versatile O
tissues O
, O
as O
indicate O
by O
RT O
- O
PCR O
on O
unlike O
cdna O
. O

The O
gene O
for O
seems O
to O
be O
expressed O
in O
tissues O
, O
as O
shown O
RT O
- O
on O
different O
cDNAs O
. O

HGO O
be O
expressed O
in O
tissues O
, O
shown O
by O
RT O
- O
PCR O
on O
different O
cDNAs O
. O

The O
cistron O
for O
HGO O
seems O
to O
be O
uttered O
in O
diverse O
tissues O
, O
as O
picture O
by O
RT O
- O
PCR O
on O
dissimilar O
cDNAs O
. O

by O
gene O
in O
be O
seems O
to O
RT O
expressed O
for O
various O
tissues O
, O
cDNAs O
shown O
HGO O
The O
- O
PCR O
on O
different O
as O
. O

The O
gene O
for O
HGO O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
RT O
- O
PCR O
complementary O
dna O
complementary O
dna O
inward O
inward O
inward O
inward O
on O
different O

The O
gene O
for O
HGO O
be O
expressed O
various O
tissues O
, O
as O
shown O
by O
RT O
- O
PCR O
on O
. O

The O
gene O
for O
HGO O
seems O
to O
be O
expressed O
in O
various O
tissues O
, O
as O
shown O
by O
RT O
- O
PCR O
on O
different O
cDNAs O
. O

FISH O
experiments O
probe O
human O
whole O
murine O
at O
as O
with O
clearly O
revealed O
signals O
cDNA O
the O
the O
chromosomal O
band O
3q13 O
. O

with O
the O
whole O
murine O
cDNA O
as O
probe O
clearly O
revealed O
chromosomal O
band O
3q13 O
. O

pisces O
experiments O
with O
the O
unharmed O
murine O
cDNA O
as O
probe O
understandably O
revealed O
signals O
at O
the O
human O
chromosomal O
stripe O
3q13 O
. O

angle O
experiments O
with O
the O
whole O
murine O
cdna O
as O
probe O
distinctly O
unwrap O
signals O
at O
the O
human O
chromosomal O
set O
3q13 O
. O

band O
experiments O
with O
the O
whole O
murine O
the O
human O
probe O
clearly O
revealed O
signals O
3q13 O
cDNA O
as O
chromosomal O
at O
FISH O
. O

FISH O
experiments O
whole O
murine O
cDNA O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
chromosomal O
band O
. O

FISH O
experiments O
with O
the O
whole O
murine O
cDNA O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
chromosomal O
band O
3q13 O
dig O
into O
dig O
into O
dig O
into O

angle O
experiments O
with O
the O
completely O
murine O
cDNA O
as O
probe O
understandably O
revealed O
signalize O
at O
the O
human O
chromosomal O
stripe O
3q13 O
. O

FISH O
experiments O
with O
the O
whole O
murine O
cDNA O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
chromosomal O
band O
3q13 O
dig O
into O
dig O
into O
dig O
into O

the O
experiments O
with O
revealed O
whole O
murine O
cDNA O
. O
human O
clearly O
the O
signals O
FISH O
at O
probe O
chromosomal O
band O
3q13 O
as O

FISH O
experiments O
with O
the O
whole O
murine O
cDNA O
as O
probe O
clearly O
revealed O
signals O
at O
the O
human O
chromosomal O
band O
3q13 O
. O

- O
q21 O
. O

 O
3 O
- O
q21 O
. O

 O
3 O
- O
q21 O
. O

3 O
- O

 O
3 O
- O
q21 O
. O

terzetto O
- O
q21 O
. O

q21 O
- O
3 O
. O

. O
- O
q21 O
3 O

ternary O
- O
q21 O
. O

- O
q21 O

3 O
- O
q21 O
. O

This O
well O
to O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
gene O
( O
AKU O
) O
the O
same O
chromosomal O
region O
by O
linkage O
analysis O
. O

This O
well O
to O
previous O
assignment O
of O
the O
locus O
for O
the O
human O
gene O
( O
) O
to O
the O
same O
chromosomal O
region O
by O
multipoint O

This O
corresponds O
well O
to O
alcaptonuria O
cistron O
duty O
assignment O
yoruba O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
human B
alkaptonuria O
gene O
( O
AKU O
) O
realm O
gene O
linkage O
depth O
psychology O
duty O
assignment O
to O
the O
same O
chromosomal O
region O
by O

same O
corresponds O
well O
to O
the O
previous O
assignment O
linkage O
by O
locus O
the O
the O
human O
alkaptonuria B
region O
( O
AKU O
) O
to O
multipoint O
for O
chromosomal O
gene O
the O
This O
of O
analysis O
. O

analysis O
corresponds O
well O
gene O
the O
previous O
linkage O
of O
to O
locus O
for O
the O
alkaptonuria O
same B
multipoint O
the O
AKU O
) O
to O
the O
human O
chromosomal O
region O
by O
( O
assignment O
This O
. O

This O
corresponds O
well O
to O
alcaptonuria O
cistron O
duty O
assignment O
yoruba O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
human B
alkaptonuria O
gene O
( O
AKU O
) O
realm O
gene O
linkage O
depth O
psychology O
cistron O
to O
the O
same O
chromosomal O
region O
by O
multipoint O

This O
corresponds O
fountainhead O
to O
the O
old O
grant O
of O
the O
venue O
for O
the O
human O
alcaptonuria B
factor O
( O
aku O
) O
to O
the O
same O
chromosomal O
area O
by O
multipoint O
linkage O
analysis O
. O

This O
corresponds O
well O
to O
alcaptonuria O
cistron O
duty O
assignment O
yoruba O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
human B
alkaptonuria O
gene O
( O
AKU O
) O
realm O
gene O
linkage O
depth O
psychology O
cistron O
to O
the O
same O
chromosomal O
region O
by O
multipoint O

by O
corresponds O
well O
to O
the O
previous O
alkaptonuria O
the O
the O
locus O
for O
AKU O
chromosomal O
assignment B
multipoint O
This O
of O
( O
to O
the O
same O
human O
region O
) O
gene O
linkage O
analysis O
. O

This O
check O
considerably O
to O
the O
premature O
assigning O
of O
the O
venue O
for O
the O
human O
alcaptonuria B
cistron O
( O
aku O
) O
to O
the O
same O
chromosomal O
region O
by O
multipoint O
linkage O
analysis O
. O

This O
corresponds O
well O
to O
the O
previous O
assignment O
of O
the O
locus O
for O
the O
human O
alkaptonuria B
gene O
( O
AKU O
) O
to O
the O
same O
chromosomal O
region O
by O
multipoint O
linkage O
analysis O
. O

We O
conclude O
the O
cDNA O
encodes O
the O
gene O
responsible O
for O
alkaptonuria B
. O

We O
therefore O
conclude O
that O
the O
HGO O
cdna O
encodes O
the O
factor O
creditworthy O
for O
alcaptonuria B
. O

encodes O
that O
conclude O
therefore O
the O
HGO O
gene O
We O
the O
. O
responsible O
for O
alkaptonuria B
cDNA O

We O
therefore O
conclude O
that O
the O
HGO O
cDNA O
encodes O
gene O
responsible O
alkaptonuria B
. O

We O
therefore O
encode O
resolve O
conclude O
that O
the O
HGO O
cDNA O
encodes O
the O
alcaptonuria O
thence O
gene O
responsible O
for O
alkaptonuria B
. O

We O
therefore O
encode O
resolve O
conclude O
that O
the O
HGO O
cDNA O
encodes O
the O
alcaptonuria O
encode O
gene O
responsible O
for O
alkaptonuria B
. O

We O
thus O
conclude O
that O
the O
HGO O
cdna O
encodes O
the O
cistron O
responsible O
for O
alcaptonuria B
. O

alkaptonuria O
therefore O
conclude O
We O
encodes O
HGO O
cDNA O
for O
the O
gene O
responsible O
the O
that B
. O

We O
therefore O
encode O
resolve O
conclude O
that O
the O
HGO O
cDNA O
encodes O
the O
alcaptonuria O
thence O
gene O
responsible O
for O
alkaptonuria B
. O

We O
thus O
resolve O
that O
the O
HGO O
cDNA O
encodes O
the O
cistron O
responsible O
for O
alcaptonuria B
. O

We O
therefore O
conclude O
that O
the O
HGO O
cDNA O
encodes O
the O
gene O
responsible O
for O
alkaptonuria B
. O

PTEN O
, O
mutated O
, O
protein O
tyrosine O
, O
gene O
a O
in O
human O
brain B
phosphatase I
breast I
putative I
and I
prostate I
cancer I
. O

a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
and I
prostate I
cancer I
. O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
cistron O
mutated O
in O
human O
mind B
, I
knocker I
, I
and I
prostate I
cancer I
. O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
cistron O
mutated O
in O
human O
genius B
, I
tit I
, I
and I
prostatic I
cancer I
. O

prostate O
, O
a O
putative O
protein O
tyrosine O
breast O
, O
mutated O
in O
human O
brain B
cancer I
phosphatase I
gene I
and I
, I
PTEN I
. O

PTEN O
, O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B
, I
breast I
, I
and I
prostate I
. O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B
, I
breast I
, I
and I
prostate I
cancer I
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
cistron O
mutated O
in O
homo O
brain B
, I
knocker I
, I
and I
prostate I
cancer I
. O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B
, I
breast I
, I
and I
prostate I
cancer I
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

breast O
, O
a O
human O
protein O
tyrosine O
phosphatase O
. O
, O
in O
putative O
brain B
PTEN I
, I
mutated I
and I
prostate I
cancer I
gene O

PTEN O
, O
a O
putative O
protein O
tyrosine O
phosphatase O
gene O
mutated O
in O
human O
brain B
, I
breast I
, I
and I
prostate I
cancer I
. O

Mapping O
of O
be O
deletions O
on O
the O
chromosome O
, O
has O
led O
to O
appears O
at O
of O
a O
in O
tumor B
suppressor O
, O
gene O
PTEN O
10q23 O
that O
human O
to O
mutated O
homozygous O
cancers O
considerable O
frequency O
candidate O
isolation O
human B
. O

Mapping O
deletions O
on O
human O
chromosome O
has O
led O
isolation O
of O
candidate O
tumor B
PTEN O
that O
appears O
to O
mutated O
at O
considerable O
in O
human O
cancers B
. O

Mapping O
of O
homozygous O
deletions O
antiophthalmic O
factor O
nominee O
mutate O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate B
tumor O
suppressor O
gene O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human B
cancers O
along O
along O
along O
along O
along O
along O
along O

Mapping O
of O
homozygous O
deletions O
antiophthalmic O
factor O
nominee O
along O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate B
tumor O
suppressor O
gene O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human B
cancers O
along O
along O
along O
along O
along O
along O
along O

of O
gene O
homozygous O
deletions O
on O
human O
mutated O
10q23 O
has O
led O
to O
at O
isolation O
to O
frequency O
candidate O
tumor B
suppressor O
the O
, O
PTEN O
, O
. O
appears O
of O
be O
chromosome O
Mapping O
human O
that O
in O
considerable O
cancers B
a O

Mapping O
of O
homozygous O
deletions O
on O
human O
has O
led O
to O
the O
of O
a O
candidate O
tumor B
suppressor O
, O
PTEN O
, O
that O
to O
be O
at O
considerable O
frequency O
in O
human O
cancers B
. O

map O
of O
homozygous O
excision O
on O
human O
chromosome O
10q23 O
has O
guide O
to O
the O
isolation O
of O
a O
nominee O
neoplasm B
suppresser O
cistron O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequence O
in O
human O
cancers B
. O

Mapping O
of O
homozygous O
omission O
on O
homo O
chromosome O
10q23 O
has O
direct O
to O
the O
isolation O
of O
a O
prospect O
tumour B
suppresser O
factor O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
homo O
cancers B
. O

Mapping O
of O
homozygous O
deletions O
antiophthalmic O
factor O
nominee O
along O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate B
tumor O
suppressor O
gene O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human B
cancers O
along O
along O
along O
along O
along O
along O
along O

Mapping O
of O
homozygous O
deletions O
on O
homo O
chromosome O
10q23 O
has O
precede O
to O
the O
isolation O
of O
a O
prospect O
neoplasm B
suppressor O
factor O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
oftenness O
in O
homo O
cancers B
. O

Mapping O
of O
homozygous O
deletions O
on O
human O
chromosome O
10q23 O
has O
led O
to O
the O
isolation O
of O
a O
candidate O
tumor B
suppressor O
gene O
, O
PTEN O
, O
that O
appears O
to O
be O
mutated O
at O
considerable O
frequency O
in O
human O
cancers B
. O

In O
, O
PTEN O
were O
% O
13 O
/ O
42 O
) O
cell O
and O
100 O
( O
4 O
/ O
) O
of O
prostate B
lines O
, O
6 O
% O
( O
/ O
65 O
cancer I
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B

indium O
prelude O
filmdom O
, O
mutations O
of O
PTEN O
were O
detected O
indium O
xxxi O
% O
( O
13 O
/ O
xlii O
) O
of O
spongioblastoma B
cell O
describe O
and O
xenografts O
, O
century O
% O
( O
quartet O
/ O
quartet O
) O
of O
prostatic B
cancer I
cell O
describe O
, O
6 O
% O
( O
quartet O
/ O
lxv O
) O
of O
knocker B
cancer I
cell O
describe O
and O
xenografts O
, O
and O
17 O
% O
( O
ternary O
/ O
xviii O
) O
of O
master B
spongioblastoma I
. O

In O
% O
screens O
of O
xenografts O
( O
PTEN O
were O
detected O
in O
31 O
cell O
, O
3 O
/ O
6 O
) O
of O
glioblastoma B
cell O
mutations O
4 O
cancer O
( O
% O
preliminary O
( O
4 O
/ O
17 O
) O
primary O
prostate B
cancer I
cell O
lines O
. O
42 O
100 O
of O
4 O
/ O
% O
) O
of O
breast B
xenografts I
glioblastomas O
lines O
and O
and O
lines O
and O
, O
65 O
( O
13 O
/ O
18 O
) O
, O
of B
% I
, O

65 O
lines O
/ O
cell O
prostate O
of O
PTEN O
% O
detected O
31 O
in O
, O
( O
13 O
% O
42 O
( O
of O
glioblastoma B
cell O
lines O
and O
4 O
/ O
100 O
and O
) O
4 O
/ O
xenografts O
) O
18 O
mutations B
cancer I
of O
preliminary O
, O
6 O
% O
( O
4 O
/ O
and O
) O
17 O
glioblastomas B
primary I
cell O
lines O
In O
xenografts O
, O
% O
breast O
were O
( O
3 O
screens O
, O
) O
of O
cancer B
of I
. O

In O
, O
of O
PTEN O
were O
detected O
% O
( O
13 O
/ O
) O
of O
glioblastoma B
cell O
lines O
and O
xenografts O
, O
% O
/ O
) O
of O
prostate B
cancer I
cell O
, O
6 O
% O
( O
/ O
breast B
cancer I
cell O
lines O
and O
xenografts O
, O
and O
3 O
/ O
18 O
) O
primary B
glioblastomas I

inch O
prelude O
screens O
, O
mutations O
of O
PTEN O
were O
find O
inch O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
spongioblastoma B
cell O
lines O
and O
heterograft O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostatic B
crab I
cell O
lines O
, O
sixer O
% O
( O
4 O
/ O
lxv O
) O
of O
bosom B
crab I
cell O
lines O
and O
heterograft O
, O
and O
seventeen O
% O
( O
triplet O
/ O
eighteen O
) O
of O
primary B
spongioblastoma I
. O

In O
preliminary O
screens O
, O
mutations O
of O
PTEN O
were O
 O
observe O
inward O
 O
 O
 O
 O
glioblastoma O
observe O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma B
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate B
cancer I
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B
cancer I
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B
glioblastomas I
spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O

spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O
. O

In O
, O
PTEN O
were O
detected O
in O
% O
( O
42 O
) O
glioblastoma B
cell O
, O
% O
( O
4 O
4 O
) O
of O
cancer I
cell O
lines O
, O
6 O
4 O
/ O
65 O
) O
of O
breast B
cancer I
cell O
xenografts O
and O
17 O
% O
3 O
/ O
18 O
) O
of O
primary B
. O

In O
preliminary O
screens O
, O
mutations O
of O
PTEN O
were O
 O
observe O
inward O
 O
 O
 O
 O
glioblastoma O
observe O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma B
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate B
cancer I
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B
cancer I
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B
glioblastomas I
spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O

spongioblastoma O
spongioblastoma O
spongioblastoma O
spongioblastoma O
. O

indiana O
prelude O
screens O
, O
mutations O
of O
PTEN O
were O
notice O
indiana O
31 O
% O
( O
13 O
/ O
xlii O
) O
of O
spongioblastoma B
cell O
stemma O
and O
heterograft O
, O
100 O
% O
( O
quartet O
/ O
quartet O
) O
of O
prostate B
cancer I
cell O
stemma O
, O
sextuplet O
% O
( O
quartet O
/ O
65 O
) O
of O
boob B
cancer I
cell O
stemma O
and O
heterograft O
, O
and O
seventeen O
% O
( O
leash O
/ O
18 O
) O
of O
primary B
spongioblastoma I
. O

In O
preliminary O
screens O
, O
mutations O
of O
PTEN O
were O
detected O
in O
31 O
% O
( O
13 O
/ O
42 O
) O
of O
glioblastoma B
cell O
lines O
and O
xenografts O
, O
100 O
% O
( O
4 O
/ O
4 O
) O
of O
prostate B
cancer I
cell O
lines O
, O
6 O
% O
( O
4 O
/ O
65 O
) O
of O
breast B
cancer I
cell O
lines O
and O
xenografts O
, O
and O
17 O
% O
( O
3 O
/ O
18 O
) O
of O
primary B
glioblastomas I
. O

The O
foreshadow O
PTEN O
product O
has O
a O
protein O
tyrosine O
phosphatase O
arena O
and O
panoptic O
homology O
to O
tensin O
, O
a O
protein O
that O
interacts O
with O
actin O
fibril O
at O
focal O
adhesions O
. O

The O
predicted O
product O
has O
a O
protein O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
, O
a O
protein O
that O
with O
actin O
filaments O
at O
focal O
. O

The O
predicted O
PTEN O
product O
antiophthalmic O
factor O
adhesiveness O
give O
birth O
has O
a O
protein O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
to O
tensin O
, O
a O
protein O
astatine O
filum O
adhesiveness O
astatine O
intersection O
that O
interacts O
with O
actin O
filaments O
at O
focal O

with O
predicted O
PTEN O
that O
has O
a O
protein O
adhesions O
at O
domain O
interacts O
extensive O
homology O
to O
filaments O
, O
a O
protein O
product O
focal O
and O
actin O
tensin O
phosphatase O
The O
tyrosine O
. O

The O
predicted O
PTEN O
product O
antiophthalmic O
factor O
adhesiveness O
give O
birth O
has O
a O
protein O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
to O
tensin O
, O
a O
protein O
astatine O
filum O
adhesiveness O
astatine O
intersection O
that O
interacts O
with O
actin O
filaments O
at O
focal O

The O
predicted O
PTEN O
has O
a O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
to O
tensin O
a O
protein O
interacts O
with O
actin O
filaments O
at O
focal O
adhesions O
. O

. O
predicted O
PTEN O
tensin O
has O
a O
adhesions O
tyrosine O
product O
domain O
and O
extensive O
to O
with O
focal O
phosphatase O
a O
protein O
that O
interacts O
homology O
actin O
filaments O
at O
, O
protein O
The O

PTEN O
a O
protein O
tyrosine O
domain O
and O
homology O
to O
tensin O
, O
a O
protein O
that O
interacts O
with O
actin O
filaments O
at O
focal O

at O
predicted O
PTEN O
product O
has O
a O
to O
extensive O
phosphatase O
domain O
and O
a O
actin O
protein O
focal O
The O
tyrosine O
, O
that O
interacts O
with O
homology O
filaments O
protein O
tensin O
adhesions O
. O

The O
foretell O
PTEN O
product O
has O
a O
protein O
tyrosine O
phosphatase O
orbit O
and O
extensive O
homology O
to O
tensin O
, O
a O
protein O
that O
interacts O
with O
actin O
fibril O
at O
focal O
attachment O
. O

The O
predicted O
PTEN O
product O
has O
a O
protein O
tyrosine O
phosphatase O
domain O
and O
extensive O
homology O
to O
tensin O
, O
a O
protein O
that O
interacts O
with O
actin O
filaments O
at O
focal O
adhesions O
. O

These O
homologies O
suggest O
that O
astatine O
through O
and O
through O
kinase O
stamp O
down O
crataegus O
oxycantha B
PTEN O
may O
suppress O
tumor O
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may B
regulate O
fundamental O
interaction O
adhesiveness B
tumor O
cell O
invasion O
and O
metastasis O
through O
interactions O
at O
focal O

These O
homologies O
suggest O
that O
astatine O
through O
and O
through O
kinase O
stamp O
down O
crataegus O
oxycantha B
PTEN O
may O
suppress O
tumor O
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may B
regulate O
fundamental O
interaction O
emergence B
tumor O
cell O
invasion O
and O
metastasis O
through O
interactions O
at O
focal O

. O
homologies O
interactions O
kinases O
PTEN O
may O
adhesions O
tumor B
that O
growth O
by O
antagonizing O
invasion O
tyrosine O
suggest O
cell O
may O
regulate O
tumor B
cell O
protein O
and O
metastasis B
through O
and O
suppress O
focal O
at O
These O
. O

These O
homologies O
suggest O
that O
astatine O
through O
and O
through O
kinase O
stamp O
down O
crataegus O
oxycantha B
PTEN O
may O
suppress O
tumor O
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may B
regulate O
fundamental O
interaction O
adhesiveness B
tumor O
cell O
invasion O
and O
metastasis O
through O
interactions O
at O
focal O

These O
homologies O
suggest O
that O
PTEN O
may O
suppress O
cell O
growth O
antagonizing O
protein O
tyrosine O
kinases O
and O
may O
regulate O
invasion O
and O
metastasis B
through O
interactions O
at O
focal O
adhesions O
. O
. O

These O
homology O
propose O
that O
PTEN O
may O
repress O
tumour B
cell O
increment O
by O
antagonise O
protein O
tyrosine O
kinases O
and O
may O
determine O
tumour B
cell O
encroachment O
and O
metastasis B
through O
interactions O
at O
focal O
adhesions O
. O
. O

may O
homologies O
suggest O
that O
PTEN O
may O
and O
antagonizing B
cell O
growth O
by O
These O
. O
through O
and O
kinases O
regulate O
interactions O
tumor B
cell O
invasion O
suppress O
metastasis B
tyrosine O
tumor O
at O
focal O
adhesions O
protein O
. O

invasion O
homologies O
suggest O
tumor O
PTEN O
may O
suppress O
at B
through O
growth O
. O
antagonizing O
focal O
cell O
metastasis O
and O
may O
regulate O
that B
tyrosine O
interactions O
and O
kinases B
cell O
These O
tumor O
protein O
adhesions O
by O
. O

These O
homology O
evoke O
that O
PTEN O
may O
conquer O
neoplasm B
cell O
ontogeny O
by O
antagonize O
protein O
tyrosine O
kinases O
and O
may O
regularize O
neoplasm B
cell O
encroachment O
and O
metastasis B
through O
interactions O
at O
focal O
adherence O
. O
. O

These O
homologies O
suggest O
that O
PTEN O
suppress O
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
regulate O
tumor B
cell O
invasion O
and O
metastasis B
through O
focal O
adhesions O
. O

These O
homologies O
suggest O
that O
PTEN O
may O
suppress O
tumor B
cell O
growth O
by O
antagonizing O
protein O
tyrosine O
kinases O
and O
may O
regulate O
tumor B
cell O
invasion O
and O
metastasis B
through O
interactions O
at O
focal O
adhesions O
. O
. O

myotonia O
in O
Schwartz B
- I
. I
chondrodystrophic I
Heterogeneity I
Jampel O

heterogeneity O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

Schwartz B
chondrodystrophic I
myotonia I
. O

Heterogeneity O
inwards O
inward O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

Heterogeneity O
Schwartz B
- I
myotonia I
. O

Heterogeneity O
Jampel O
Schwartz B
- I
in I
chondrodystrophic I
. I
myotonia O

. O
- O
Schwartz B
in I
Jampel I
chondrodystrophic I
myotonia I
Heterogeneity O

Heterogeneity O
inwards O
inward O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

heterogeneousness O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

Heterogeneity O
inwards O
inward O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

Heterogeneity O
in O
Schwartz B
- I
Jampel I
chondrodystrophic I
myotonia I
. O

The O
Schwartz B
- I
Jampel I
follow O
curtly I
drum O
drum I
be O
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
be O
be O
be O
swot O
up O

The O
Schwartz B
syndrome I
myotonia I
; O
McK O
, O
800 O
is O
a O
recessively B
defined O
by O
myotonia B
, O
short B
, O
bone B
dysplasia I
. O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
transmissible I
shape I
outlined O
by O
myotonia B
, O
scant B
height I
, O
and O
bone B
dysplasia I
. O

The O
Schwartz B
- I
Jampel I
( O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
. O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
genetic I
stipulation I
delimitate O
by O
myotonia B
, O
curtly B
height I
, O
and O
bone B
dysplasia I
. O

The O
Schwartz B
- I
Jampel I
follow O
curtly I
drum O
drum I
be O
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
be O
be O
be O
swot O
up O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
hereditary I
condition I
outlined O
by O
myotonia B
, O
unretentive B
height I
, O
and O
cram B
dysplasia I
. O

condition O
recessively B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
bone O
) O
is O
a O
, B
inherited I
Schwartz I
defined O
. O
myotonia B
, O
short B
stature I
The O
800 O
by B
dysplasia I
and O

The O
Schwartz B
- I
Jampel I
( O
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
is O
a O
recessively B
inherited I
condition I
defined O
by O
short B
stature I
, O
bone B
. O

The O
Schwartz B
- I
Jampel I
follow O
curtly I
drum O
drum I
be O
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
be O
be O
be O
swot O
up O

The O
Schwartz B
- I
Jampel I
syndrome I
( O
SJS B
; O
chondrodystrophic B
myotonia I
; O
McK O
255 O
, O
800 O
) O
is O
a O
recessively B
inherited I
condition I
defined O
by O
myotonia B
, O
short B
stature I
, O
and O
bone B
dysplasia I
. O

linkage O
between O
SJS B
and O
chromosomal O
region O
1q36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
but O
gene O
has O
not O
yet O
been O
identified O
. O

has O
linkage O
between O
the B
and O
chromosomal O
region O
. O
been O
34 O
identified O
been O
observed O
gene O
yet O
families O
, O
but O
SJS O
in O
has O
not O
several O
- O
Genetic O
1q36 O

hereditary O
linkage O
between O
SJS B
and O
chromosomal O
neighborhood O
1q36 O
- O
34 O
has O
been O
observed O
in O
respective O
families O
, O
but O
the O
cistron O
has O
not O
yet O
been O
name O
. O

inherited O
linkage O
between O
SJS B
and O
chromosomal O
region O
1q36 O
- O
xxxiv O
has O
been O
note O
in O
various O
phratry O
, O
but O
the O
cistron O
has O
not O
still O
been O
identified O
. O

Genetic O
linkage O
between O
SJS B
and O
chromosomal O
region O
1q36 O
- O
34 O
been O
observed O
several O
families O
, O
but O
the O
gene O
has O
been O
identified O
. O

Genetic O
linkage O
between O
SJS B
nonetheless O
and O
chromosomal O
region O
1q36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
, O
but O
nonetheless O
be O
identify O
be O
identify O
phratry O
the O
gene O
has O
not O
yet O
been O
identified O
. O

Genetic O
linkage O
between O
SJS B
nonetheless O
and O
chromosomal O
region O
1q36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
, O
but O
nonetheless O
be O
identify O
be O
identify O
cistron O
the O
gene O
has O
not O
yet O
been O
identified O
. O

Genetic O
linkage O
between O
SJS B
and O
chromosomal O
region O
1q36 O
- O
34 O
been O
several O
families O
, O
but O
the O
gene O
has O
not O
yet O

been O
linkage O
between O
SJS B
and O
chromosomal O
in O
, O
- O
34 O
has O
been O
not O
region O
identified O
families O
1q36 O
has O
the O
gene O
Genetic O
observed O
yet O
but O
several O
. O

inherited O
linkage O
between O
SJS B
and O
chromosomal O
neighborhood O
1q36 O
- O
34 O
has O
been O
observed O
in O
respective O
kinsperson O
, O
but O
the O
factor O
has O
not O
nonetheless O
been O
identify O
. O

Genetic O
linkage O
between O
SJS B
and O
chromosomal O
region O
1q36 O
- O
34 O
has O
been O
observed O
in O
several O
families O
, O
but O
the O
gene O
has O
not O
yet O
been O
identified O
. O

We O
studied O
the O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
to O
identify O
distinct O
subgroups O

We O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
from O
the O
literature O
5 O
trying O
to O
identify O
distinct O
subgroups O
. O

We O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
clear O
cut O
subgroup O
subgroup O
 O
 O
 O
to O
identify O
distinct O
subgroups O

We O
meditate O
the O
clinical O
and O
radiological O
have O
in O
81 O
patients O
from O
the O
literature O
and O
cinque O
own O
patients O
test O
to O
discover O
trenchant O
subgroups O
. O

We O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
clear O
cut O
subgroup O
subgroup O
 O
 O
 O
to O
identify O
distinct O
subgroups O

We O
analyse O
the O
clinical O
and O
radiological O
features O
in O
lxxxi O
patients O
from O
the O
literature O
and O
five O
own O
patients O
trying O
to O
distinguish O
decided O
subgroups O
. O

We O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
the O
literature O
5 O
own O
patients O
trying O
to O
identify O
distinct O

from O
studied O
the O
to O
and O
radiological O
features O
81 O
in O
patients O
identify O
the O
and O
literature O
. O
own O
patients O
trying O
clinical O
We O
distinct O
subgroups O
5 O

We O
meditate O
the O
clinical O
and O
radiological O
characteristic O
in O
81 O
patients O
from O
the O
literature O
and O
five O
own O
patients O
stress O
to O
place O
distinct O
subgroups O
. O

5 O
studied O
81 O
features O
and O
radiological O
own O
in O
the O
patients O
from O
the O
distinct O
and O
clinical O
We O
patients O
trying O
to O
identify O
literature O
subgroups O
. O

We O
studied O
the O
clinical O
and O
radiological O
features O
in O
81 O
patients O
from O
the O
literature O
and O
5 O
own O
patients O
trying O
to O
identify O
distinct O
subgroups O
. O

sibs O
addition O
, O
locus O
tested O
genetic O
linkage O
two O
in O
SJS B
we O
on O
1 O
chromosome O
the O
one O
family O
with O
to O
In O
affected O
. O

In O
addition O
, O
we O
tested O
genetic O
linkage O
to O
the O
SJS B
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
cognate O
cognate O
 O
 O
 O
 O
two O
affected O
sibs O
. O

In O
addition O
, O
we O
tested O
genetic O
linkage O
to O
the O
SJS B
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
cognate O
cognate O
 O
 O
 O
 O
two O
affected O
sibs O
. O

In O
improver O
, O
we O
tested O
genetic O
linkage O
to O
the O
SJS B
locale O
on O
chromosome O
one O
in O
peerless O
family O
with O
ii O
affected O
sibling O
. O

In O
addition O
, O
tested O
genetic O
linkage O
to O
the O
locus O
on O
chromosome O
1 O
one O
family O
two O
affected O
sibs O
. O

we O
linkage O
to O
the O
locus O
on O
1 O
in O
one O
family O
with O
two O
affected O
sibs O
. O

inch O
addition O
, O
we O
prove O
transmitted O
linkage O
to O
the O
SJS B
locus O
on O
chromosome O
1 O
inch O
unmatched O
family O
with O
ii O
impact O
sibs O
. O

in O
addition O
the O
linkage O
tested O
genetic O
one O
to O
, O
SJS B
locus O
on O
sibs O
1 O
we O
In O
family O
with O
two O
affected O
chromosome O
. O

In O
addition O
, O
we O
tested O
genetic O
linkage O
to O
the O
SJS B
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
cognate O
cognate O
 O
 O
 O
phratry O
two O
affected O
sibs O
. O

In O
addition O
, O
we O
linkage O
to O
SJS B
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
two O
. O

In O
addition O
, O
we O
tested O
genetic O
linkage O
to O
the O
SJS B
locus O
on O
chromosome O
1 O
in O
one O
family O
with O
two O
affected O
sibs O
. O

We O
found O
that O
a O
follow O
lower O
ranking O
import O
chemical O
group O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences B
of O
myotonia O
, O
while O
another O
group O
of O
patients O
appear O
to O
have B
primary I
bone O
dysplasia B
with O
myotonia O
be O
be O
be O
be O

We O
found O
that O
of O
changes O
which O
may O
secondary O
consequences O
myotonia B
, O
while O
of O
patients O
appear O
to O
have O
bone B
with O
myotonia B
. O

We O
plant O
that O
a O
group O
of O
patients O
have O
soft O
pinched O
deepen O
which O
may O
be O
subaltern O
result O
of O
myotonia B
, O
while O
another O
group O
of O
patients O
look O
to O
have O
primary O
drum B
dysplasia I
with O
myotonia B
. O

We O
found O
that O
a O
group O
of O
patients O
mild O
which O
may O
be O
secondary O
consequences O
of O
myotonia B
, O
while O
appear O
to O
have O
primary O
bone B
dysplasia I
with O
myotonia B
. O

We O
discover O
that O
a O
group O
of O
patients O
have O
modest O
emaciated O
modify O
which O
may O
be O
lowly O
effect O
of O
myotonia B
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
basal O
drum B
dysplasia I
with O
myotonia B
. O

We O
found O
that O
a O
follow O
lower O
ranking O
import O
chemical O
group O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences B
of O
myotonia O
, O
while O
another O
group O
of O
patients O
appear O
to O
have B
primary I
bone O
dysplasia B
with O
myotonia O
be O
be O
be O
be O

We O
found O
that O
a O
group O
of O
patients O
have O
soft O
gaunt O
transfer O
which O
whitethorn O
be O
secondary O
upshot O
of O
myotonia B
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary O
bone B
dysplasia I
with O
myotonia B
. O

another O
, O
that O
a O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
appear O
dysplasia O
consequences O
of O
myotonia B
primary O
while O
found O
group O
myotonia O
patients O
be O
to O
have O
We O
secondary B
of I
with O
bone B
. O

We O
found O
that O
a O
group O
of O
have O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of O
, O
while O
another O
group O
of O
patients O
appear O
primary O
bone B
dysplasia I
myotonia B

We O
found O
that O
a O
follow O
lower O
ranking O
import O
piece O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of B
myotonia O
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary B
bone I
dysplasia O
with B
myotonia O
be O
be O
be O
be O
crataegus O

We O
found O
that O
a O
group O
of O
patients O
have O
mild O
skeletal O
changes O
which O
may O
be O
secondary O
consequences O
of O
myotonia B
, O
while O
another O
group O
of O
patients O
appear O
to O
have O
primary O
bone B
dysplasia I
with O
myotonia B
. O

within O
this O
latter O
group O
, O
there O
are O
divergence O
in O
maturate O
of O
expression O
, O
clinical O
course O
and O
pattern O
of O
bone O
variety O
. O

Within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
clinical O
course O
and O
pattern O
of O
modification O
inward O
inward O
inward O
inward O
inward O
bone O
changes O
. O

Within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
clinical O
course O
and O
pattern O
of O
modification O
inward O
inward O
inward O
inward O
inward O
bone O
changes O
. O

Within O
this O
latter O
group O
, O
there O
are O
differences O
age O
of O
, O
clinical O
course O
and O
pattern O
of O
bone O

course O
this O
in O
are O
, O
there O
and O
differences O
latter O
age O
of O
manifestation O
. O
clinical O
group O
Within O
pattern O
of O
bone O
changes O
, O

inside O
this O
latter O
group O
, O
there O
are O
deviation O
in O
geezerhood O
of O
expression O
, O
clinical O
course O
and O
convention O
of O
bone O
exchange O
. O

. O
this O
latter O
of O
, O
there O
are O
bone O
course O
age O
group O
manifestation O
clinical O
, O
in O
and O
pattern O
of O
differences O
Within O
changes O

Within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
clinical O
course O
and O
pattern O
of O
modification O
inward O
inward O
inward O
inward O
be O
bone O
changes O
. O

Within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
course O
of O
bone O
changes O
. O

within O
this O
latter O
group O
, O
there O
are O
deviation O
in O
age O
of O
reflection O
, O
clinical O
run O
and O
pattern O
of O
bone O
switch O
. O

Within O
this O
latter O
group O
, O
there O
are O
differences O
in O
age O
of O
manifestation O
, O
clinical O
course O
and O
pattern O
of O
bone O
changes O
. O

We O
tentatively O
isolate O
three O
different O
types O
of O
SJS B
parturition B
type I
1A I
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B
dysplasia I
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
similar O
to O
type O
1A O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B
dysplasia I
resembling O
Pyle B
disease I
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O
birthing O

birthing O
birthing O
birthing O
birthing O
puerility O
. O

We O
tentatively O
sequestrate O
tierce O
dissimilar O
typecast O
of O
SJS B
type I
1A I
, O
ordinarily O
recognized O
in O
puerility O
, O
with O
hold O
cram B
dysplasia I
, O
jibe O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
exchangeable O
to O
type O
1A O
but O
recognisable O
at O
nascence O
, O
with O
more O
pronounced O
cram B
dysplasia I
resemble O
Kniest B
dysplasia I
; O
and O
type O
two O
, O
attest O
at O
nascence O
, O
with O
increased O
deathrate O
and O
cram B
dysplasia I
resemble O
pyle B
disease I
. O

We O
tentatively O
isolate O
three O
different O
types O
of O
SJS B
character B
type I
1A I
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B
dysplasia I
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
similar O
to O
type O
1A O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B
dysplasia I
resembling O
Pyle B
disease I
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O
character O
fictitious O

We O
Jampel O
isolate O
birth O
, O
1A O
of O
SJS B
type I
1A I
, O
pronounced O
the O
, O
childhood O
to O
with O
moderate O
bone B
dysplasia I
in O
resembling O
; O
recognized O
type O
descriptions O
of O
Schwartz O
, O
tentatively O
and O
Kniest O
; O
type O
1B O
, O
increased O
, O
original O
types O
but O
recognizable O
mortality O
birth O
, O
with O
disease O
with O
bone B
dysplasia I
corresponding O
Aberfeld B
dysplasia I
to O
at O
type O
and O
, O
manifest O
at O
three O
different O
usually O
similar O
bone O
2 O
and B
dysplasia I
resembling O
Pyle B
more I
. O

isolate O
three O
SJS B
1A I
, O
usually O
recognized O
, O
moderate O
, O
to O
the O
original O
of O
Schwartz O
, O
Aberfeld O
; O
type O
1B O
, O
to O
type O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
, O
with O
and O
dysplasia I
resembling O
Pyle B
. O

We O
tentatively O
three O
different O
SJS B
1A I
, O
usually O
recognized O
, O
with O
moderate O
bone B
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
Jampel O
; O
1B O
, O
similar O
to O
type O
but O
recognizable O
at O
birth O
with O
dysplasia I
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
birth O
, O
with O
increased O
and O
bone B
resembling O
. O

type O
Pyle O
to O
and O
different O
types O
of O
SJS B
; I
1A I
, O
usually O
with O
Jampel O
childhood O
increased O
with O
moderate O
bone B
dysplasia I
, O
corresponding O
to O
the O
original O
descriptions O
bone O
of O
manifest O
, O
and O
Aberfeld O
type O
type O
birth O
, O
similar O
but O
type O
1A O
dysplasia O
recognizable O
at O
birth O
disease O
with O
more O
pronounced O
Schwartz B
three I
resembling O
Kniest B
dysplasia I
. O
isolate O
We O
, O
1B O
dysplasia O
at O
, O
, O
recognized O
2 O
mortality O
and O
bone B
, I
resembling O
tentatively B
in I
; O

We O
tentatively O
three O
different O
type I
usually O
recognized O
, O
bone B
dysplasia I
, O
corresponding O
the O
original O
Schwartz O
, O
and O
Aberfeld O
, O
to O
type O
1A O
recognizable O
at O
birth O
with O
more O
pronounced O
bone B
dysplasia I
dysplasia I
; O
and O
type O
2 O
, O
manifest O
at O
with O
mortality O
and O
bone B
resembling O
Pyle B
disease I
. O

We O
tentatively O
sequestrate O
ternary O
unlike O
typewrite O
of O
SJS B
eccentric I
1A I
, O
commonly O
accredit O
in O
puerility O
, O
with O
hold O
bone B
dysplasia I
, O
check O
to O
the O
archetype O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
eccentric O
1B O
, O
exchangeable O
to O
eccentric O
1A O
but O
placeable O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resemble O
Kniest B
dysplasia I
; O
and O
eccentric O
two O
, O
attest O
at O
birth O
, O
with O
increased O
deathrate O
and O
bone B
dysplasia I
resemble O
pyle B
disease I
. O

resembling O
tentatively O
isolate O
1B O
different O
types O
of O
and B
type I
1A I
, O
the O
recognized O
in O
childhood O
, O
bone O
moderate O
bone B
dysplasia I
, O
corresponding O
disease O
Pyle O
original O
We O
. O
Schwartz O
, O
to O
and O
Aberfeld O
; O
type O
manifest O
, O
similar O
to O
type O
1A O
but O
recognizable O
descriptions O
birth O
; O
with O
, O
pronounced O
bone B
Kniest I
resembling O
and B
mortality I
with O
SJS O
type O
2 O
, O
three O
at O
birth O
more O
, O
increased O
dysplasia O
dysplasia O
with B
dysplasia I
Jampel O
at B
usually I
of O

We O
tentatively O
isolate O
three O
different O
types O
of O
SJS B
type I
1A I
, O
usually O
recognized O
in O
childhood O
, O
with O
moderate O
bone B
dysplasia I
, O
corresponding O
to O
the O
original O
descriptions O
of O
Schwartz O
, O
Jampel O
and O
Aberfeld O
; O
type O
1B O
, O
similar O
to O
type O
1A O
but O
recognizable O
at O
birth O
, O
with O
more O
pronounced O
bone B
dysplasia I
resembling O
Kniest B
dysplasia I
; O
and O
type O
2 O
, O
manifest O
at O
birth O
, O
with O
increased O
mortality O
and O
bone B
dysplasia I
resembling O
Pyle B
disease I
. O

Genetic O
analysis O
of O
sibs O
affected O
by O
SJS B
type I
2 I
showed O
evidence O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
SJS B
type I
2 I
evidence O
to O
chromosome O
1p36 O
- O
34 O
. O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
SJS B
type I
2 I
showed O
evidence O
against O
linkage O
to O
dissemble O
 O
 O
dissemble O
dissemble O
dissemble O
chromosome O
1p36 O
- O
34 O
. O

familial O
analysis O
of O
the O
mob O
with O
two O
sibs O
moved O
by O
SJS B
type I
2 I
establish O
show O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
SJS B
type I
2 I
showed O
evidence O
against O
linkage O
to O
dissemble O
 O
 O
dissemble O
dissemble O
dissemble O
chromosome O
1p36 O
- O
34 O
. O

Genetic O
analysis O
of O
the O
kinsperson O
with O
deuce O
sibs O
moved O
by O
SJS B
type I
deuce I
establish O
certify O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
type I
2 I
evidence O
against O
linkage O
to O
chromosome O
1p36 O
- O

SJS O
analysis O
of O
chromosome O
family O
with O
two O
affected O
sibs O
by O
1p36 B
type I
showed I
2 O
. O
against O
linkage O
to O
the O
Genetic O
- O
34 O
evidence O

transmitted O
analysis O
of O
the O
folk O
with O
ii O
sibs O
affected O
by O
SJS B
type I
ii I
designate O
grounds O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O

evidence O
analysis O
affected O
two O
family O
with O
against O
sibs O
of O
by O
SJS B
type I
- I
showed O
the O
Genetic O
linkage O
to O
chromosome O
1p36 O
2 O
34 O
. O

Genetic O
analysis O
of O
the O
family O
with O
two O
sibs O
affected O
by O
SJS B
type I
2 I
showed O
evidence O
against O
linkage O
to O
chromosome O
1p36 O
- O
34 O
. O

heterogeneous O
SJS B
is O
clinically O
. O
radiologically O
CONCLUSIONS O
and O

finish O
SJS B
is O
clinically O
and O
radiologically O
heterogenous O
. O

is O
radiologically O
heterogeneous O
. O

CONCLUSIONS O
finale O
last O
SJS B
is O
clinically O
and O
radiologically O
heterogeneous O
. O

CONCLUSIONS O
is O
clinically O
heterogeneous O
. O

CONCLUSIONS O
and B
is O
clinically O
SJS O
radiologically O
. O
heterogeneous O

. O
clinically B
is O
SJS O
and O
radiologically O
heterogeneous O
CONCLUSIONS O

CONCLUSIONS O
heterogeneous O
heterogenous O
SJS B
is O
clinically O
and O
radiologically O
heterogeneous O
. O

determination O
SJS B
is O
clinically O
and O
radiologically O
heterogenous O
. O

CONCLUSIONS O
heterogeneous O
heterogenous O
SJS B
is O
clinically O
and O
radiologically O
heterogeneous O
. O

CONCLUSIONS O
SJS B
is O
clinically O
and O
radiologically O
heterogeneous O
. O

The O
causes O
of O
heterogeneity O
admit O
be O
unlike O
mutation O
be O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
SJS B
locus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
SJS B
locus O
accommodate O
accommodate O
accommodate O
chromosomal O
mutation O

The O
causes O
are O
are O
likely O
to O
both O
different O
at O
the O
SJS B
chromosome O
1 O
and O
the O
presence O
a O
SJS B
locus O
. O

The O
case O
of O
heterogeneousness O
are O
not O
bonk O
yet O
but O
are O
probable O
to O
include O
both O
unlike O
mutations O
at O
the O
SJS B
venue O
on O
chromosome O
ace O
and O
the O
bearing O
of O
a O
instant O
SJS B
venue O
. O

The O
causes O
of O
heterogeneity O
not O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
SJS B
locus O
. O

The O
make O
of O
heterogeneousness O
are O
not O
known O
nevertheless O
but O
are O
likely O
to O
admit O
both O
dissimilar O
variation O
at O
the O
SJS B
locus O
on O
chromosome O
ane O
and O
the O
comportment O
of O
a O
bit O
SJS B
locus O
. O

The O
causes O
of O
heterogeneity O
admit O
be O
unlike O
mutation O
be O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
SJS B
locus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
SJS B
locus O
accommodate O
accommodate O
accommodate O
chromosomal O
mutation O

The O
movement O
of O
heterogeneousness O
are O
not O
known O
hitherto O
but O
are O
potential O
to O
include O
both O
different O
sport O
at O
the O
SJS B
locale O
on O
chromosome O
one O
and O
the O
bearing O
of O
a O
mo O
SJS B
locale O
. O

on O
SJS O
of O
heterogeneity O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
the O
SJS O
mutations O
at O
the O
a B
locus O
causes O
chromosome O
. O
and O
both O
presence O
of O
The O
different O
1 B
locus O
second O

The O
causes O
of O
heterogeneity O
not O
yet O
but O
are O
likely O
to O
include O
both O
different O
at O
the O
SJS B
locus O
on O
chromosome O
1 O
presence O
of O
a O
SJS B
. O

The O
causes O
of O
heterogeneity O
admit O
be O
unlike O
mutation O
non O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
SJS B
locus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
SJS B
locus O
accommodate O
accommodate O
accommodate O
chromosomal O
mutation O

The O
causes O
of O
heterogeneity O
are O
not O
known O
yet O
but O
are O
likely O
to O
include O
both O
different O
mutations O
at O
the O
SJS B
locus O
on O
chromosome O
1 O
and O
the O
presence O
of O
a O
second O
SJS B
locus O
. O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
correlation O
utilitarian O
correlation O
correlation O
utilitarian O
utilitarian O
doubtful O
genotype O
- O
phenotype O
correlations O
. O
. O

clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
genotype O
phenotype O
correlations O
. O
. O

axerophthol O
provisional O
clinico O
- O
radiological O
categorization O
can O
be O
utilitarian O
for O
the O
characterization O
of O
patients O
and O
the O
maturation O
of O
genotype O
- O
phenotype O
correlativity O
. O
. O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
useful O
for O
characterization O
of O
patients O
and O
the O
development O
of O
phenotype O
correlations O
. O
. O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
correlation O
utilitarian O
correlation O
correlation O
utilitarian O
utilitarian O
utilitarian O
genotype O
- O
phenotype O
correlations O
. O
. O

A O
provisional O
clinico O
- O
radiological O
categorization O
can O
be O
utile O
for O
the O
characterization O
of O
patients O
and O
the O
developing O
of O
genotype O
- O
phenotype O
correlations O
. O
. O

A O
doubtful O
clinico O
- O
radiological O
sorting O
can O
be O
utile O
for O
the O
characterisation O
of O
patients O
and O
the O
maturation O
of O
genotype O
- O
phenotype O
correlativity O
. O
. O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
the O
patients O
and O
the O
development O
of O
genotype O
- O
phenotype O
correlations O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
correlation O
utilitarian O
correlation O
correlation O
utilitarian O
utilitarian O
utilitarian O
genotype O
- O
phenotype O
correlations O
. O
. O

of O
tentative O
clinico O
the O
radiological O
classification O
can O
genotype O
. O
for O
- O
characterization O
of O
patients O
. O
the O
development O
phenotype O
be O
A O
- O
correlations O
and O
useful O

A O
tentative O
clinico O
- O
radiological O
classification O
can O
be O
useful O
for O
the O
characterization O
of O
patients O
and O
the O
development O
of O
genotype O
- O
phenotype O
correlations O
. O
. O

mutations O
clinical O
overview O
of O
. O
gene O
A O
WT1 O

adenine O
clinical O
overview O
of O
WT1 O
cistron O
mutations O
. O

overview O
gene O
mutations O
. O

A O
gene O
cistron O
clinical O
overview O
of O
WT1 O
gene O
mutations O
. O

A O
overview O
of O
mutations O
. O

A O
WT1 O
overview O
of O
clinical O
gene O
. O
mutations O

. O
of O
overview O
clinical O
WT1 O
gene O
mutations O
A O

A O
chromosomal O
mutation O
mutation O
clinical O
overview O
of O
WT1 O
gene O
mutations O

a O
clinical O
overview O
of O
WT1 O
cistron O
mutations O
. O

A O
chromosomal O
mutation O
mutation O
clinical O
overview O
of O
WT1 O
gene O
mutations O

A O
clinical O
overview O
of O
WT1 O
gene O
mutations O
. O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B
cancer I
, O
tumor O
tumor O
explicate O
explicate O
explicate O
explicate O
explicate O
Wilms B
tumour I
( O
WT B
) O
. O

the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B
cancer I
Wilms B
( O
WT B
) O
. O

Mutations O
in O
the O
WT1 O
factor O
were O
foresee O
to O
explicate O
the O
hereditary O
footing O
of O
the O
puerility O
kidney B
cancer I
, O
Wilms B
neoplasm I
( O
WT B
) O
. O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
explain O
the O
basis O
of O
the O
childhood O
kidney B
cancer I
, O
( O
WT B
) O
. O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B
cancer I
, O
tumor O
tumor O
explicate O
explicate O
explicate O
explicate O
explicate O
Wilms B
tumour I
( O
WT B
) O
. O

mutation O
in O
the O
WT1 O
cistron O
were O
foresee O
to O
excuse O
the O
transmitted O
basis O
of O
the O
puerility O
kidney B
cancer I
, O
Wilms B
neoplasm I
( O
WT B
) O
. O

mutant O
in O
the O
WT1 O
cistron O
were O
forestall O
to O
explicate O
the O
genic O
cornerstone O
of O
the O
puerility O
kidney B
cancer I
, O
Wilms B
tumour I
( O
WT B
) O
. O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
genetic O
the O
childhood O
kidney B
cancer I
, O
Wilms B
tumour I
( O
WT B

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B
cancer I
, O
tumor O
tumor O
explicate O
explicate O
explicate O
explicate O
explicate O
Wilms B
tumour I
( O
WT B
) O
. O

, O
in O
the O
genetic O
gene O
were O
anticipated O
Wilms O
. O
the O
WT1 O
basis O
of O
the O
) O
kidney B
cancer I
( O
to B
Mutations I
tumour O
WT B
childhood O
explain O

Mutations O
in O
the O
WT1 O
gene O
were O
anticipated O
to O
explain O
the O
genetic O
basis O
of O
the O
childhood O
kidney B
cancer I
, O
Wilms B
tumour I
( O
WT B
) O
. O

Six O
years O
of O
the O
we O
review O
and O
reports O
on O
intragenic O
WT1 O
mutations O
100 O
examine O
, O
accompanying O
clinical O
phenotypes O
. O

on O
, O
we O
review O
100 O
reports O
of O
intragenic O
WT1 O
accompanying O
clinical O
phenotypes O
. O

vi O
twelvemonth O
on O
, O
we O
review O
c O
reports O
of O
intragenic O
WT1 O
mutations O
and O
analyse O
the O
attendant O
clinical O
phenotypes O
. O

six O
years O
on O
, O
we O
brushup O
hundred O
composition O
of O
intragenic O
WT1 O
mutations O
and O
prove O
the O
accompanying O
clinical O
phenotypes O
. O

clinical O
years O
on O
, O
we O
review O
examine O
the O
of O
intragenic O
WT1 O
mutations O
phenotypes O
100 O
reports O
accompanying O
and O
Six O
. O

Six O
years O
we O
review O
100 O
reports O
of O
intragenic O
WT1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
. O

Six O
years O
on O
, O
we O
review O
100 O
reports O
of O
intragenic O
WT1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
phenotypes O
along O
along O
along O
along O
study O
. O

sextet O
years O
on O
, O
we O
inspection O
100 O
reports O
of O
intragenic O
WT1 O
mutations O
and O
analyse O
the O
attendant O
clinical O
phenotypes O
. O

Six O
years O
on O
, O
we O
review O
100 O
reports O
of O
intragenic O
WT1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
phenotypes O
along O
along O
along O
along O
along O
. O

examine O
years O
on O
WT1 O
we O
review O
100 O
. O
the O
intragenic O
, O
mutations O
Six O
and O
of O
accompanying O
clinical O
phenotypes O
reports O

Six O
years O
on O
, O
we O
review O
100 O
reports O
of O
intragenic O
WT1 O
mutations O
and O
examine O
the O
accompanying O
clinical O
phenotypes O
. O

piece O
only O
pentad O
% O
of O
sporadic B
Wilms I
tumor I
have O
intragenic O
WT1 O
mutations O
, O
> O
ninety O
% O
of O
patients O
with O
the O
traverse B
- I
Drash I
syndrome I
( O
nephritic B
nephropathy I
, O
gonadal B
anomalousness I
, O
sensitivity B
to I
WT I
) O
conduct O
constitutive O
intragenic O
WT1 O
mutations O
. O

piece O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
variation O
, O
> O
90 O
% O
of O
patients O
with O
the O
traverse B
- I
Drash I
syndrome I
( O
nephritic B
nephrosis I
, O
gonadal B
anomaly I
, O
sensitivity B
to I
WT I
) O
transmit O
constituent O
intragenic O
WT1 O
variation O
. O

While O
of O
Wilms I
tumours I
have O
WT1 O
mutations O
, O
90 O
% O
of O
patients O
with O
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
predisposition B
WT I
) O
carry O
intragenic O
WT1 O
mutations O
. O

While O
only O
predisposition O
% O
of O
gonadal B
renal I
tumours I
have O
intragenic O
WT1 O
syndrome O
, O
> O
90 O
, O
of O
patients O
the O
with O
Denys B
- I
Drash I
carry I
( O
nephropathy B
, I
to O
sporadic B
anomaly I
% O
intragenic B
Wilms I
WT I
) O
mutations O
constitutional O
5 O
WT1 O
mutations O
. O

( O
with O
5 O
% O
of O
sporadic B
mutations I
- I
have O
intragenic O
WT1 O
Wilms O
, O
, O
anomaly O
% O
of O
patients O
. O
the O
Denys B
tumours I
gonadal I
syndrome I
While O
renal B
predisposition I
> O
90 B
Drash I
, O
carry B
to I
only I
) O
nephropathy O
constitutional O
intragenic O
WT1 O
mutations O
WT O

While O
only O
5 O
% O
Wilms I
tumours I
have O
intragenic O
mutations O
, O
> O
90 O
% O
patients O
with O
the O
Denys B
Drash I
syndrome I
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
) O
carry O
intragenic O
WT1 O
mutations O
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
WT I
) O
carry O
tumor O
tumor O
mutation O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
constitutional O
intragenic O
WT1 O
mutations O
. O

While O
only O
5 O
% O
tumours I
have O
intragenic O
WT1 O
mutations O
> O
90 O
with O
- I
Drash I
renal B
gonadal B
anomaly I
, O
predisposition B
WT I
) O
intragenic O
WT1 O
. O

piece O
only O
quintuplet O
% O
of O
sporadic B
Wilms I
neoplasm I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
abnegate B
- I
Drash I
syndrome I
( O
nephritic B
nephropathy I
, O
gonadal B
anomaly I
, O
sensitivity B
to I
WT I
) O
convey O
integral O
intragenic O
WT1 O
mutations O
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
WT I
) O
carry O
tumor O
tumor O
mutation O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
tumor O
constitutional O
intragenic O
WT1 O
mutations O
. O

While O
only O
5 O
% O
of O
sporadic B
Wilms I
tumours I
have O
intragenic O
WT1 O
mutations O
, O
> O
90 O
% O
of O
patients O
with O
the O
Denys B
- I
Drash I
syndrome I
( O
renal B
nephropathy I
, O
gonadal B
anomaly I
, O
predisposition B
to I
WT I
) O
carry O
constitutional O
intragenic O
WT1 O
mutations O
. O

WT1 O
mutations O
have O
also O
be O
report O
bear O
on O
be O
been O
reported O
in B
juvenile I
granulosa I
cell I
tumour O
, B
non I
- I
asbestos I
related I
mesothelioma O
, B
desmoplastic I
small I
round I
cell I
tumour O
and O
, O
most O
recently O
, B
acute I
myeloid I
leukemia O
. O
follow O
follow O
follow O
follow O
not O

WT1 O
mutations O
have O
reported O
tumour I
, O
non B
asbestos I
related I
, O
desmoplastic B
small I
tumour I
and O
, O
most O
recently O
acute B
leukemia I
. O
. O

WT1 O
mutant O
have O
besides O
been O
describe O
in O
juvenile B
granulosa I
cell I
neoplasm I
, O
not B
- I
asbestos I
refer I
mesothelioma I
, O
desmoplastic B
small I
attack I
cell I
neoplasm I
and O
, O
most O
recently O
, O
sharp B
myeloid I
leucaemia I
. O
. O

WT1 O
mutations O
have O
also O
been O
reported O
in O
granulosa I
, O
non B
- I
asbestos I
related I
mesothelioma I
, O
desmoplastic B
small I
, O
most O
recently O
, O
acute B
myeloid I
leukemia I
. O
. O

WT1 O
mutations O
have O
likewise O
been O
account O
in O
jejune B
granulosa I
cell I
neoplasm I
, O
not B
- I
asbestos I
related I
mesothelioma I
, O
desmoplastic B
small I
troll I
cell I
neoplasm I
and O
, O
most O
late O
, O
intense B
myeloid I
leucaemia I
. O
. O

WT1 O
mutations O
have O
also O
be O
report O
bear O
on O
be O
been O
reported O
in B
juvenile I
granulosa I
cell I
tumour O
, B
non I
- I
asbestos I
related I
mesothelioma O
, B
desmoplastic I
small I
round I
cell I
tumour O
and O
, O
most O
recently O
, B
acute I
myeloid I
leukemia O
. O
follow O
follow O
follow O
follow O
not O

WT1 O
sport O
have O
also O
been O
reported O
in O
puerile B
granulosa I
cell I
neoplasm I
, O
not B
- I
asbestos I
pertain I
mesothelioma I
, O
desmoplastic B
little I
round I
cell I
neoplasm I
and O
, O
most O
late O
, O
discriminating B
myeloid I
leucaemia I
. O
. O

round O
desmoplastic O
have O
also O
been O
reported O
in O
juvenile B
granulosa I
cell I
tumour I
, O
non B
, I
myeloid I
related I
mesothelioma I
, O
, B
small I
mutations I
cell I
. I
and O
- O
most O
recently O
WT1 O
asbestos B
tumour I
leukemia I
acute O
. O

WT1 O
mutations O
have O
also O
been O
reported O
juvenile B
cell I
tumour I
, O
non B
- I
asbestos I
related I
mesothelioma I
desmoplastic B
small I
round I
cell I
tumour I
and O
, O
, O
acute B
myeloid I
. O

WT1 O
mutations O
have O
also O
be O
report O
bear O
on O
leucaemia O
been O
reported O
in B
juvenile I
granulosa I
cell I
tumour O
, B
non I
- I
asbestos I
related I
mesothelioma O
, B
desmoplastic I
small I
round I
cell I
tumour O
and O
, O
most O
recently O
, B
acute I
myeloid I
leukemia O
. O
follow O
follow O
follow O
follow O
not O

WT1 O
mutations O
have O
also O
been O
reported O
in O
juvenile B
granulosa I
cell I
tumour I
, O
non B
- I
asbestos I
related I
mesothelioma I
, O
desmoplastic B
small I
round I
cell I
tumour I
and O
, O
most O
recently O
, O
acute B
myeloid I
leukemia I
. O
. O

A O
mutation O
inwards O
bear O
on O
inward O
in B
autosomal I
dominant I
myotonia I
congenita O
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
brawn O

chloride O
mutation O
in O
. B
dominant I
myotonia I
congenita I
affects O
channel O
properties O
of O
the O
A O
muscle O
pore O
autosomal O

A O
mutation O
paramount O
bear O
on O
predominant O
in B
autosomal I
dominant I
myotonia I
congenita O
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
brawn O

A O
mutation O
in O
autosomal B
prevailing I
myotonia I
congenita I
affects O
rivet O
properties O
of O
the O
musculus O
chloride O
impart O
. O

muscle O
mutation O
in O
affects B
dominant I
myotonia I
chloride I
autosomal O
pore O
properties O
A O
the O
of O
congenita O
channel O
. O

A O
mutation O
inwards O
bear O
on O
inward O
in B
autosomal I
dominant I
myotonia I
congenita O
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
brawn O

A O
mutation O
in O
autosomal B
rife I
myotonia I
congenita I
dissemble O
pore O
dimension O
of O
the O
muscle O
chloride O
groove O
. O

A O
sport O
in O
autosomal B
dominant I
myotonia I
congenita I
affects O
center O
properties O
of O
the O
musculus O
chloride O
duct O
. O

A O
mutation O
pore O
. B
dominant I
myotonia I
muscle I
affects O
in O
properties O
of O
the O
congenita O
chloride O
autosomal O
channel O

mutation O
in O
autosomal B
dominant I
myotonia I
congenita I
affects O
of O
the O
muscle O
chloride O
channel O
. O

A O
mutation O
in O
autosomal B
dominant I
myotonia I
congenita I
affects O
pore O
properties O
of O
the O
muscle O
chloride O
channel O
. O

autosomal B
dominant I
myotonia I
congenita I
is O
an O
familial B
trouble I
of I
haggard I
muscularity I
make O
by O
mutations O
in O
a O
emf O
- O
gated O
Cl O
- O
conduct O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

Autosomal B
dominant I
myotonia I
congenita I
is O
inherited B
skeletal I
muscle I
caused O
by O
mutations O
in O
a O
voltage O
- O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

- B
dominant I
myotonia I
gated I
is O
an O
inherited B
, I
( I
skeletal I
. I
caused O
by O
Cl O
gene O
a O
voltage O
- O
congenita O
mutations O
CLCN1 O
channel O
in O
of O
Autosomal O
disorder O
7q35 O
) O
muscle O

Autosomal B
dominant I
myotonia I
congenita I
aside O
mutation O
inward O
antiophthalmic O
factor O
be O
is O
an B
inherited I
disorder I
of I
skeletal I
muscle O
caused O
by O
mutations O
in O
a O
voltage O
- O
cistron O
antiophthalmic O
factor O
antiophthalmic O
factor O
gated O
Cl O
- O
channel O
gene O
( O
CLCN1 O
, O

Autosomal B
dominant I
myotonia I
congenita I
aside O
mutation O
inward O
antiophthalmic O
factor O
be O
is O
an B
inherited I
disorder I
of I
skeletal I
muscle O
caused O
by O
mutations O
in O
a O
voltage O
- O
cistron O
antiophthalmic O
factor O
impart O
gated O
Cl O
- O
channel O
gene O
( O
CLCN1 O
, O
7q35 O

Autosomal B
dominant I
myotonia I
congenita I
is O
an O
inherited B
disorder I
skeletal I
muscle I
by O
mutations O
in O
a O
voltage O
- O
gated O
channel O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

. B
dominant I
myotonia I
in I
is O
an O
, B
disorder I
congenita I
skeletal I
muscle I
caused O
7q35 O
mutations O
CLCN1 O
of O
voltage O
- O
gated O
Cl O
by O
channel O
gene O
( O
a O
inherited O
- O
) O
Autosomal O

Autosomal B
dominant I
myotonia I
congenita I
is O
an O
inherited B
disorder I
skeletal I
caused O
by O
mutations O
in O
a O
voltage O
- O
gated O
- O
channel O
gene O
( O
CLCN1 O
, O
7q35 O

autosomal B
dominant I
myotonia I
congenita I
is O
an O
hereditary B
cark I
of I
haggard I
sinew I
have O
by O
mutations O
in O
a O
voltage O
- O
gated O
Cl O
- O
duct O
cistron O
( O
CLCN1 O
, O
7q35 O
) O
. O

Autosomal B
dominant I
myotonia I
congenita I
is O
an O
genetic B
disquiet I
of I
cadaverous I
muscularity I
make O
by O
sport O
in O
a O
voltage O
- O
gated O
centilitre O
- O
transfer O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

Autosomal B
dominant I
myotonia I
congenita I
is O
an O
inherited B
disorder I
of I
skeletal I
muscle I
caused O
by O
mutations O
in O
a O
voltage O
- O
gated O
Cl O
- O
channel O
gene O
( O
CLCN1 O
, O
7q35 O
) O
. O

Here O
report O
that O
a O
predicting O
substitution O
of O
Gly O
glutamic O
between O
segments O
D3 O
D4 O
dramatically O
the O
pore O
properties O
recombinant O
human O
muscle O
Cl O
- O
( O
- O
1 O
) O
expressed O
in O
a O
mammalian O
cell O
line O
( O
) O
. O

Here O
, O
we O
report O
that O
a O
mutation O
predicting O
antiophthalmic O
factor O
antiophthalmic O
factor O
homo O
the O
substitution O
of O
Gly O
230 O
by O
glutamic O
acid O
( O
G230E O
) O
between O
segments O
D3 O
and O
D4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
Cl O
- O
inward O
antiophthalmic O
factor O
mammal O
jail O
cell O
ancestry O
mammal O
jail O
cell O
ancestry O
mammal O
jail O
cell O
ancestry O
impart O
channel O
( O
hCIC O
- O
1 O
) O
expressed O
in O
a O
mammalian O

Here O
, O
we O
report O
that O
a O
mutation O
predicting O
antiophthalmic O
factor O
antiophthalmic O
factor O
homo O
the O
substitution O
of O
Gly O
230 O
by O
glutamic O
acid O
( O
G230E O
) O
between O
segments O
D3 O
and O
D4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
Cl O
- O
inward O
antiophthalmic O
factor O
mammal O
jail O
cell O
ancestry O
mammal O
jail O
cell O
ancestry O
mammal O
jail O
cell O
ancestry O
foreshadow O
channel O
( O
hCIC O
- O
1 O
) O
expressed O
in O
a O
mammalian O

Cl O
the O
we O
report O
that O
a O
Gly O
predicting O
the O
substitution O
of O
mutation O
230 O
pore O
properties O
acid O
( O
G230E O
of O
between O
segments O
D3 O
muscle O
D4 O
in O
alters O
cell O
by O
( O
) O
a O
- O
human O
glutamic O
Here O
) O
channel O
( O
hCIC O
- O
, O
recombinant O
expressed O
and O
a O
mammalian O
1 O
line O
dramatically O
tsA201 O
) O
. O

a O
dramatically O
we O
report O
that O
a O
segments O
( O
the O
substitution O
of O
Gly O
230 O
) O
( O
acid O
predicting O
a O
) O
between O
( O
D3 O
and O
D4 O
, O
alters O
the O
hCIC O
G230E O
of O
properties O
mutation O
human O
muscle O
Cl O
- O
channel O
glutamic O
pore O
- O
1 O
) O
expressed O
in O
Here O
mammalian O
. O
line O
tsA201 O
recombinant O
by O
cell O

Here O
, O
we O
report O
that O
a O
mutation O
predicting O
antiophthalmic O
factor O
antiophthalmic O
factor O
homo O
the O
substitution O
of O
Gly O
230 O
by O
glutamic O
acid O
( O
G230E O
) O
between O
segments O
D3 O
and O
D4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
Cl O
- O
inward O
antiophthalmic O
factor O
mammal O
jail O
cell O
ancestry O
mammal O
jail O
cell O
ancestry O
mammal O
jail O
cell O
ancestry O
foreshadow O
channel O
( O
hCIC O
- O
1 O
) O
expressed O
in O
a O
mammalian O

Here O
, O
report O
mutation O
predicting O
the O
substitution O
of O
Gly O
230 O
by O
glutamic O
between O
segments O
D3 O
and O
D4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
- O
( O
hCIC O
- O
1 O
) O
expressed O
in O
a O
cell O
line O
( O
tsA201 O
) O
. O

Here O
, O
a O
report O
that O
a O
mutation O
) O
the O
substitution O
of O
D4 O
between O
by O
glutamic O
D3 O
( O
G230E O
( O
230 O
segments O
line O
and O
Gly O
dramatically O
. O
pore O
human O
properties O
of O
we O
expressed O
recombinant O
muscle O
Cl O
a O
channel O
alters O
hCIC O
- O
1 O
) O
the O
in O
- O
cell O
mammalian O
acid O
( O
tsA201 O
) O
predicting O

hera O
, O
we O
report O
that O
a O
mutation O
anticipate O
the O
switch O
of O
Gly O
230 O
by O
glutamic O
acid O
( O
G230E O
) O
between O
section O
D3 O
and O
D4 O
dramatically O
neuter O
the O
rivet O
place O
of O
a O
recombinant O
homo O
heftiness O
cl O
- O
transmit O
( O
hCIC O
- O
one O
) O
expressed O
in O
a O
mammalian O
cell O
line O
( O
tsA201 O
) O
. O

Here O
, O
we O
the O
Gly O
by O
glutamic O
acid O
G230E O
) O
between O
segments O
D3 O
and O
the O
pore O
properties O
of O
a O
recombinant O
human O
Cl O
- O
hCIC O
- O
1 O
expressed O
mammalian O
cell O
line O
( O
tsA201 O
) O
. O

Here O
, O
we O
report O
that O
a O
mutation O
predicting O
the O
substitution O
of O
Gly O
230 O
by O
glutamic O
acid O
( O
G230E O
) O
between O
segments O
D3 O
and O
D4 O
dramatically O
alters O
the O
pore O
properties O
of O
a O
recombinant O
human O
muscle O
Cl O
- O
channel O
( O
hCIC O
- O
1 O
) O
expressed O
in O
a O
mammalian O
cell O
line O
( O
tsA201 O
) O
. O

G230E O
mutation O
causes O
substantial O
changes O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
fundamental O
in O
of O
the O
current O
- O
voltage O
relationship O
. O

selectivity O
G230E O
mutation O
rectification O
substantial O
changes O
in O
. O
voltage O
cation O
relationship O
as O
well O
of O
- O
fundamental O
change O
in O
causes O
as O
the O
current O
a O
and O
The O
anion O

The O
G230E O
sport O
get O
real O
changes O
in O
anion O
and O
cation O
selectivity O
as O
comfortably O
as O
a O
fundamental O
commute O
in O
correction O
of O
the O
stream O
- O
voltage O
relationship O
. O

The O
G230E O
mutation O
reason O
real O
alter O
in O
anion O
and O
cation O
selectivity O
as O
substantially O
as O
a O
central O
convert O
in O
correction O
of O
the O
current O
- O
voltage O
relationship O
. O

The O
G230E O
mutation O
causes O
substantial O
changes O
in O
anion O
and O
cation O
as O
well O
a O
fundamental O
change O
in O
rectification O
of O
the O
voltage O
relationship O
. O

The O
G230E O
mutation O
causes O
square O
substantial O
changes O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
fundamental O
change O
in O
chromosomal O
mutation O
potential O
difference O
family O
relationship O
potential O
difference O
family O
relationship O
do O
rectification O
of O
the O

The O
G230E O
mutation O
causes O
square O
substantial O
changes O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
fundamental O
change O
in O
chromosomal O
mutation O
potential O
difference O
family O
relationship O
potential O
difference O
family O
relationship O
inward O
rectification O
of O
the O

The O
G230E O
mutation O
causes O
substantial O
changes O
in O
anion O
and O
cation O
as O
a O
fundamental O
change O
in O
rectification O
of O
the O
current O
- O

voltage O
G230E O
mutation O
causes O
substantial O
changes O
as O
change O
and O
cation O
selectivity O
as O
current O
in O
relationship O
fundamental O
anion O
the O
rectification O
of O
The O
well O
- O
in O
a O
. O

The O
G230E O
mutation O
causes O
real O
shift O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
rudimentary O
shift O
in O
correction O
of O
the O
flow O
- O
potential O
relationship O
. O

The O
G230E O
mutation O
causes O
substantial O
changes O
in O
anion O
and O
cation O
selectivity O
as O
well O
as O
a O
fundamental O
change O
in O
rectification O
of O
the O
current O
- O
voltage O
relationship O
. O

Whereas O
wild O
- O
type O
channels O
are O
characterized O
by O
 O
antiophthalmic O
factor O
thence O
thence O
antiophthalmic O
factor O
pronounced O
inward O
rectification O
and O
a O
Cl O
> O
thiocyanate O
> O
Br O
> O
NO O
( O
3 O
) O
> O
I O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
, O
G230E O
exhibits O
outward O
rectification O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
NO O
( O
3 O
) O
> O
I O
> O
Br O
> O
Cl O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O

Whereas O
- O
type O
are O
characterized O
pronounced O
inward O
rectification O
and O
a O
Cl O
> O
thiocyanate O
> O
> O
( O
3 O
) O
> O
I O
> O
( O
3 O
) O
( O
3 O
) O
selectivity O
, O
G230E O
at O
positive O
and O
thiocyanate O
> O
( O
> O
I O
> O
Cl O
> O
3 O
) O
( O
3 O
. O

> O
CH O
exhibits O
. O
channels O
are O
characterized O
by O
3 O
inward O
rectification O
and O
> O
) O
> O
( O
> O
Br O
> O
NO O
( O
3 O
) O
> O
I O
> O
( O
Br O
CH O
a O
SO O
( O
pronounced O
) O
3 O
, O
G230E O
at O
outward O
rectification O
3 O
positive O
potentials O
and O
thiocyanate O
thiocyanate O
> O
NO O
wild O
type O
) O
> O
I O
SO O
( O
Whereas O
3 O
selectivity O
Cl O
( O
> O
) O
a O
Cl O
3 O
) O
selectivity O
- O

Whereas O
type O
pronounced O
inward O
rectification O
a O
Cl O
thiocyanate O
> O
Br O
( O
3 O
) O
> O
I O
CH O
3 O
) O
SO O
( O
3 O
) O
selectivity O
, O
G230E O
exhibits O
rectification O
at O
positive O
potentials O
and O
3 O
I O
Br O
> O
Cl O
CH O
( O
3 O
) O
SO O
( O
. O

Whereas O
baseless O
- O
type O
channels O
are O
qualify O
by O
enounce O
inward O
correction O
and O
a O
centilitre O
> O
thiocyanate O
> O
Br O
> O
no O
( O
trinity O
) O
> O
unity O
> O
CH O
( O
trinity O
) O
thence O
( O
trinity O
) O
selectivity O
, O
G230E O
show O
outward O
correction O
at O
convinced O
potentiality O
and O
a O
thiocyanate O
> O
no O
( O
trinity O
) O
> O
unity O
> O
Br O
> O
centilitre O
> O
CH O
( O
trinity O
) O
thence O
( O
trinity O
) O
selectivity O
. O

thiocyanate O
> O
rectification O
> O
inward O
are O
characterized O
Br O
pronounced O
channels O
- O
3 O
a O
Cl O
> O
thiocyanate O
> O
Br O
> O
NO O
( O
3 O
> O
) O
I O
3 O
selectivity O
( O
3 O
type O
SO O
( O
and O
) O
CH O
, O
G230E O
exhibits O
outward O
rectification O
at O
positive O
selectivity O
and O
3 O
> O
) O
NO O
( O
Whereas O
) O
) O
SO O
a O
by O
> O
Cl O
wild O
potentials O
( O
3 O
> O
I O
( O
) O
> O
CH O
. O

Whereas O
wild O
- O
type O
channels O
are O
characterized O
by O
 O
antiophthalmic O
factor O
thence O
thence O
judge O
pronounced O
inward O
rectification O
and O
a O
Cl O
> O
thiocyanate O
> O
Br O
> O
NO O
( O
3 O
) O
> O
I O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
, O
G230E O
exhibits O
outward O
rectification O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
NO O
( O
3 O
) O
> O
I O
> O
Br O
> O
Cl O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O
correction O

Whereas O
rampantly O
- O
character O
convey O
are O
characterise O
by O
pronounced O
inbound O
correction O
and O
a O
cl O
> O
thiocyanate O
> O
br O
> O
nobelium O
( O
iii O
) O
> O
ane O
> O
CH O
( O
iii O
) O
hence O
( O
iii O
) O
selectivity O
, O
G230E O
exhibits O
outward O
correction O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
nobelium O
( O
iii O
) O
> O
ane O
> O
br O
> O
cl O
> O
CH O
( O
iii O
) O
hence O
( O
iii O
) O
selectivity O
. O

Whereas O
fantastic O
- O
case O
channels O
are O
qualify O
by O
judge O
inbound O
correction O
and O
a O
Cl O
> O
thiocyanate O
> O
Br O
> O
NO O
( O
trinity O
) O
> O
i O
> O
CH O
( O
trinity O
) O
thence O
( O
trinity O
) O
selectivity O
, O
G230E O
parade O
outbound O
correction O
at O
irrefutable O
potentiality O
and O
a O
thiocyanate O
> O
NO O
( O
trinity O
) O
> O
i O
> O
Br O
> O
Cl O
> O
CH O
( O
trinity O
) O
thence O
( O
trinity O
) O
selectivity O
. O

Whereas O
wild O
- O
type O
channels O
are O
by O
pronounced O
and O
a O
Cl O
thiocyanate O
> O
NO O
( O
3 O
) O
> O
I O
) O
( O
3 O
selectivity O
exhibits O
outward O
rectification O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
) O
> O
> O
Br O
> O
Cl O
CH O
3 O
3 O
selectivity O
. O

Whereas O
wild O
- O
type O
channels O
are O
characterized O
by O
pronounced O
inward O
rectification O
and O
a O
Cl O
> O
thiocyanate O
> O
Br O
> O
NO O
( O
3 O
) O
> O
I O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
, O
G230E O
exhibits O
outward O
rectification O
at O
positive O
potentials O
and O
a O
thiocyanate O
> O
NO O
( O
3 O
) O
> O
I O
> O
Br O
> O
Cl O
> O
CH O
( O
3 O
) O
SO O
( O
3 O
) O
selectivity O
. O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
permeableness O
character O
impart O
character O
impart O
impart O
idle O
of O
the O
wild O
- O
type O
channel O
. O

cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
the O
- O
type O
channel O
. O

moreover O
, O
the O
cation O
- O
to O
- O
anion O
permeableness O
proportion O
of O
the O
variation O
is O
much O
big O
than O
that O
of O
the O
violent O
- O
type O
impart O
. O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
the O
mutant O
much O
greater O
than O
that O
of O
the O
wild O
channel O
. O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
permeableness O
character O
impart O
character O
impart O
impart O
permeableness O
of O
the O
wild O
- O
type O
channel O
. O

furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeableness O
proportion O
of O
the O
mutation O
is O
much O
keen O
than O
that O
of O
the O
groundless O
- O
type O
duct O
. O

moreover O
, O
the O
cation O
- O
to O
- O
anion O
permeableness O
proportion O
of O
the O
mutant O
is O
much O
large O
than O
that O
of O
the O
violent O
- O
case O
carry O
. O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
mutant O
greater O
than O
that O
of O
the O
wild O
- O
type O
channel O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
permeableness O
character O
impart O
character O
impart O
impart O
permeableness O
of O
the O
wild O
- O
type O
channel O
. O

the O
, O
the O
of O
- O
to O
- O
of O
channel O
ratio O
cation O
the O
is O
mutant O
type O
greater O
than O
that O
anion O
. O
wild O
- O
much O
permeability O
Furthermore O

Furthermore O
, O
the O
cation O
- O
to O
- O
anion O
permeability O
ratio O
of O
the O
mutant O
is O
much O
greater O
than O
that O
of O
the O
wild O
- O
type O
channel O
. O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
 O
conductivity O
nerve O
tract O
conductivity O
nerve O
tract O
nerve O
tract O
aside O
the O
hClC O
- O
1 O

blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
hClC O
1 O
conduction O
pathway O
. O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
serve O
to O
distinguish O
two O
decided O
ion O
binding O
locate O
inside O
the O
hClC O
- O
single O
conductivity O
footpath O
. O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
distinguish O
two O
ion O
binding O
sites O
within O
the O
hClC O
- O
pathway O
. O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
 O
conductivity O
nerve O
tract O
conductivity O
nerve O
tract O
nerve O
tract O
drug O
addicted O
the O
hClC O
- O

Voltage O
- O
dependent O
occlude O
by O
intracellular O
and O
extracellular O
iodide O
service O
to O
distinguish O
deuce O
distinct O
ion O
binding O
posture O
inside O
the O
hClC O
- O
1 O
conductivity O
tract O
. O

potential O
- O
dependent O
cube O
by O
intracellular O
and O
extracellular O
iodide O
assist O
to O
distinguish O
two O
distinct O
ion O
back O
sites O
inside O
the O
hClC O
- O
one O
conductivity O
pathway O
. O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
two O
binding O
sites O
within O
the O
hClC O
- O
1 O
conduction O
pathway O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
 O
conductivity O
nerve O
tract O
conductivity O
nerve O
tract O
nerve O
tract O
drug O
addicted O
the O
hClC O
- O

hClC O
- O
dependent O
to O
by O
intracellular O
and O
the O
pathway O
help O
blocks O
distinguish O
distinct O
two O
conduction O
binding O
sites O
within O
extracellular O
. O
- O
1 O
ion O
iodide O
Voltage O

Voltage O
- O
dependent O
blocks O
by O
intracellular O
and O
extracellular O
iodide O
help O
to O
distinguish O
two O
distinct O
ion O
binding O
sites O
within O
the O
hClC O
- O
1 O
conduction O
pathway O
. O

Both O
preserved O
sites O
are O
binding O
in O
mutant O
decreased O
but O
have O
for O
affinities O
the O
iodide O
. O

Both O
binding O
sit O
mutation O
pose O
sites O
are O
preserved O
in O
the O
mutant O
but O
be O
have O
decreased O
affinities O
for O
iodide O
. O

both O
attach O
sites O
are O
save O
in O
the O
mutation O
but O
have O
decreased O
affinities O
for O
iodide O
. O

for O
binding O
sites O
Both O
mutant O
in O
the O
affinities O
but O
have O
decreased O
preserved O
are O
iodide O
. O

both O
obligate O
sites O
are O
preserved O
in O
the O
mutation O
but O
have O
fall O
affinities O
for O
iodide O
. O

Both O
binding O
sit O
mutation O
pose O
sites O
are O
preserved O
in O
the O
mutant O
but O
bear O
on O
have O
decreased O
affinities O
for O
iodide O

Both O
sites O
preserved O
the O
mutant O
but O
have O
decreased O
affinities O
for O
iodide O
. O

mutant O
are O
sites O
binding O
preserved O
in O
have O
Both O
but O
the O
decreased O
affinities O
for O
. O
iodide O

both O
stick O
sites O
are O
preserved O
in O
the O
mutation O
but O
have O
decreased O
kinship O
for O
iodide O
. O

Both O
binding O
sit O
mutation O
pose O
sites O
are O
preserved O
in O
the O
mutant O
but O
bear O
on O
have O
decreased O
affinities O
for O
iodide O

Both O
binding O
sites O
are O
preserved O
in O
the O
mutant O
but O
have O
decreased O
affinities O
for O
iodide O
. O

These O
findings O
indicate O
that O
Gly O
230 O
is O
decisive O
for O
convention O
ion O
conductance O
in O
hClC O
- O
single O
and O
that O
this O
residuum O
occupy O
inside O
the O
channel O
stomate O
. O
. O

These O
findings O
that O
Gly O
230 O
is O
critical O
for O
normal O
ion O
conductance O
in O
1 O
and O
that O
this O
resides O
within O
the O
channel O
pore O
. O

These O
findings O
suggest O
that O
focus O
 O
decisive O
Gly O
230 O
is O
critical O
for O
normal O
ion O
conductance O
in O
hClC O
- O
1 O
and O
that O
impart O
focus O
impart O
focus O
 O
this O
residue O
resides O
within O
the O
channel O
pore O
. O
. O

resides O
findings O
suggest O
this O
Gly O
230 O
is O
. O
channel O
normal O
residue O
conductance O
in O
hClC O
the O
1 O
and O
that O
that O
pore O
ion O
within O
- O
for O
These O
critical O
. O

These O
findings O
suggest O
that O
focus O
 O
decisive O
Gly O
230 O
is O
critical O
for O
normal O
ion O
conductance O
in O
hClC O
- O
1 O
and O
that O
impart O
focus O
impart O
focus O
 O
this O
residue O
resides O
within O
the O
channel O
pore O
. O
. O

These O
findings O
suggest O
Gly O
230 O
critical O
for O
normal O
ion O
conductance O
in O
hClC O
- O
and O
that O
residue O
resides O
within O
the O
channel O
pore O
. O
. O

. O
findings O
suggest O
- O
Gly O
230 O
. O
critical O
that O
normal O
ion O
conductance O
hClC O
resides O
pore O
for O
and O
that O
this O
residue O
in O
within O
the O
channel O
1 O
is O
These O

suggest O
230 O
is O
critical O
normal O
ion O
in O
hClC O
- O
1 O
and O
that O
this O
residue O
resides O
within O
the O
channel O
pore O

channel O
findings O
suggest O
that O
Gly O
230 O
hClC O
conductance O
for O
normal O
ion O
and O
within O
is O
pore O
These O
critical O
1 O
this O
residue O
resides O
in O
the O
that O
- O
. O
. O

These O
encounter O
evoke O
that O
Gly O
230 O
is O
vital O
for O
convention O
ion O
conductance O
in O
hClC O
- O
single O
and O
that O
this O
rest O
rest O
within O
the O
channel O
centre O
. O
. O

These O
findings O
suggest O
that O
Gly O
230 O
is O
critical O
for O
normal O
ion O
conductance O
in O
hClC O
- O
1 O
and O
that O
this O
residue O
resides O
within O
the O
channel O
pore O
. O
. O

The O
incidence O
of O
PAX6 O
mutant O
in O
patients O
with O
simple O
aniridia B
: O
an O
evaluation O
of O
mutant O
spying O
in O
xii O
suit O
. O

The O
incidence O
of O
PAX6 O
mutation O
in O
patients O
with O
simple O
aniridia B
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
simpleton O
simpleton O
simpleton O
simpleton O
simpleton O
simpleton O
cases O
. O

The O
incidence O
of O
PAX6 O
mutation O
in O
patients O
with O
simple O
aniridia B
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
simpleton O
simpleton O
simpleton O
simpleton O
simpleton O
simpleton O
cases O
. O

of O
in O
patients O
with O
aniridia B
: O
evaluation O
of O
mutation O
detection O
in O
12 O
cases O
. O

The O
incidence O
of O
PAX6 O
mutation O
with O
simple O
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
cases O
. O

of O
PAX6 O
mutation O
in O
with O
simple O
aniridia B
: O
an O
of O
mutation O
detection O
in O
cases O
. O

12 O
incidence O
of O
cases O
mutation O
in O
patients O
simple O
with O
aniridia B
mutation O
an O
evaluation O
. O
The O
detection O
in O
: O
PAX6 O
of O

The O
incidence O
of O
PAX6 O
mutation O
in O
patients O
with O
simple O
aniridia B
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
simpleton O
simpleton O
simpleton O
simpleton O
simpleton O
relative O
incidence O
cases O

The O
incidence O
of O
PAX6 O
sport O
in O
patients O
with O
unproblematic O
aniridia B
: O
an O
evaluation O
of O
sport O
detection O
in O
xii O
caseful O
. O

in O
incidence O
of O
PAX6 O
mutation O
in O
of O
an O
simple O
aniridia B
: O
mutation O
The O
patients O
with O
12 O
evaluation O
detection O
cases O
. O

The O
incidence O
of O
PAX6 O
mutation O
in O
patients O
with O
simple O
aniridia B
: O
an O
evaluation O
of O
mutation O
detection O
in O
12 O
cases O
. O

, O
screened B
patients O
, O
five O
with O
gene O
family O
history O
and O
seven O
PAX6 O
to O
proportion O
, O
, O
were O
exhaustively O
with O
in O
order O
to O
carry O
what O
be O
of O
anomalies O
aniridia O
by B
test O
uncomplicated O
aniridia O
associated O
sporadic O
Twelve O
people O
mutations O
in O
the O
human O
presumed O
a O
. O

Twelve O
aniridia B
patients O
five O
with O
a O
family O
history O
and O
seven O
be O
sporadic O
, O
exhaustively O
in O
order O
to O
proportion O
, O
uncomplicated O
by O
anomalies O
, O
mutations O
in O
the O
gene O
. O

twelve O
aniridia B
patients O
, O
quintet O
with O
a O
family O
chronicle O
and O
seven O
dare O
to O
be O
sporadic O
, O
were O
thoroughly O
screened O
in O
order O
to O
exam O
what O
symmetry O
of O
people O
with O
aniridia B
, O
elementary O
by O
link O
anomalousness O
, O
carry O
mutant O
in O
the O
human O
PAX6 O
cistron O
. O

twelve O
aniridia B
patients O
, O
five O
with O
a O
family O
account O
and O
vii O
dare O
to O
be O
sporadic O
, O
were O
thoroughly O
screened O
in O
order O
to O
essay O
what O
ratio O
of O
people O
with O
aniridia B
, O
uncomplicated O
by O
associated O
anomalousness O
, O
impart O
variation O
in O
the O
homo O
PAX6 O
cistron O
. O

Twelve O
aniridia B
by O
, O
five O
with O
a O
screened O
history O
and O
seven O
to O
. O
be O
sporadic O
uncomplicated O
were O
exhaustively O
in O
family O
order O
associated O
test O
carry O
proportion O
people O
with O
to O
aniridia B
, O
, O
in O
of O
anomalies O
, O
what O
mutations O
patients O
the O
human O
PAX6 O
gene O
presumed O

Twelve O
aniridia B
patients O
five O
family O
history O
and O
seven O
presumed O
to O
be O
sporadic O
, O
order O
to O
test O
what O
proportion O
of O
people O
with O
aniridia B
, O
uncomplicated O
by O
associated O
anomalies O
, O
mutations O
the O
human O
PAX6 O
gene O
. O

Twelve O
aniridia B
patients O
, O
five O
with O
a O
family O
history O
and O
seven O
presumed O
to O
be O
sporadic O
, O
were O
exhaustively O
screened O
in O
order O
to O
test O
what O
proportion O
of O
people O
with O
aniridia B
, O
uncomplicated O
by O
associated O
anomalies O
, O
carry O
inward O
cistron O
homo O
 O
cistron O
 O
 O
 O
 O
 O
 O
 O
mutations O
in O
the O
human O
PAX6 O
gene O
. O

the O
proportion B
patients O
, O
were O
with O
order O
by O
history O
and O
seven O
presumed O
to O
a O
in O
, O
five O
uncomplicated O
screened O
in O
be O
to O
test O
what O
with O
of O
people O
gene O
exhaustively B
, O
aniridia O
aniridia O
associated O
anomalies O
, O
carry O
mutations O
sporadic O
Twelve O
human O
PAX6 O
family O
. O

Twelve O
aniridia B
patients O
five O
a O
family O
history O
and O
seven O
presumed O
to O
be O
sporadic O
, O
exhaustively O
screened O
in O
order O
to O
with O
uncomplicated O
associated O
anomalies O
, O
mutations O
in O
the O
human O
PAX6 O
gene O

twelve O
aniridia B
patients O
, O
five O
with O
a O
household O
history O
and O
heptad O
assume O
to O
be O
sporadic O
, O
were O
thoroughly O
sieve O
in O
club O
to O
test O
what O
proportion O
of O
people O
with O
aniridia B
, O
unsophisticated O
by O
associated O
anomaly O
, O
express O
mutations O
in O
the O
homo O
PAX6 O
cistron O
. O

Twelve O
aniridia B
patients O
, O
five O
with O
a O
family O
history O
and O
seven O
presumed O
to O
be O
sporadic O
, O
were O
exhaustively O
screened O
in O
order O
to O
test O
what O
proportion O
of O
people O
with O
aniridia B
, O
uncomplicated O
by O
associated O
anomalies O
, O
carry O
mutations O
in O
the O
human O
PAX6 O
gene O
. O

mutant O
were O
detected O
in O
xc O
% O
of O
the O
encase O
. O

Mutations O
were O
detected O
in O
90 O
% O
of O
the O
cases O
be O
be O
be O
. O

variation O
were O
discover O
in O
90 O
% O
of O
the O
shell O
. O

Mutations O
were O
observe O
in O
xc O
% O
of O
the O
pillowcase O
. O

Mutations O
detected O
in O
% O
of O
the O
cases O
. O

the O
. O
detected O
90 O
in O
% O
of O
Mutations O
cases O
were O

Mutations O
the O
detected O
in O
were O
% O
90 O
of O
cases O
. O

the O
in O
detected O
were O
90 O
% O
. O
Mutations O
cases O
of O

Mutations O
in O
90 O
% O
the O

Mutations O
were O
detected O
in O
90 O
% O
of O
the O
cases O
be O
be O
be O
. O

Mutations O
were O
detected O
in O
90 O
% O
of O
the O
cases O
. O

method O
mutation O
detection O
determine O
were O
used O
to O
techniques O
this O
one O
for O
was O
Three O
superior O
if O
gene O
. O

Three O
sport O
detection O
proficiency O
were O
used O
to O
limit O
if O
one O
method O
was O
ranking O
for O
this O
cistron O
. O

triplet O
mutation O
detection O
techniques O
were O
apply O
to O
determine O
if O
unmatchable O
method O
was O
superior O
for O
this O
factor O
. O

Three O
mutation O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
. O

Three O
sport O
sensing O
techniques O
were O
used O
to O
fix O
if O
ane O
method O
was O
superior O
for O
this O
factor O
. O

Three O
mutation O
find O
out O
spying O
detection O
techniques O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
spy O
spy O
spy O

Three O
mutation O
detection O
techniques O
were O
used O
to O
determine O
one O
method O
superior O
for O
this O
gene O
. O

Three O
mutation O
find O
out O
spying O
detection O
techniques O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
spy O
spy O
spy O

mutation O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O

Three O
mutation O
if O
this O
were O
used O
superior O
determine O
detection O
one O
method O
was O
to O
for O
techniques O
gene O
. O

Three O
mutation O
detection O
techniques O
were O
used O
to O
determine O
if O
one O
method O
was O
superior O
for O
this O
gene O
. O

truncation O
PTT O
) O
was O
used O
RT O
- O
, O
SSCP O
genomic O
PCR O
chemical O
of O
mismatch O
on O
RT O
- O
PCR O
genomic O
amplifications O
. O

The O
protein O
truncation O
test O
segmentation O
amplification O
( O
PTT O
) O
was O
used O
on O
RT O
- O
PCR O
products O
, O
SSCP O
on O
genomic O
PCR O
amplifications O
, O
and O
chemical O
cleavage O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
amplifications O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
along O
. O

of O
PCR O
truncation O
test O
( O
PTT O
on O
was O
used O
on O
RT O
- O
PCR O
both O
- O
SSCP O
on O
genomic O
amplifications O
amplifications O
, O
and O
and O
cleavage O
The O
mismatch O
) O
products O
, O
chemical O
PCR O
RT O
genomic O
. O
protein O

The O
protein O
shortness O
examination O
( O
PTT O
) O
was O
apply O
on O
RT O
- O
PCR O
merchandise O
, O
SSCP O
on O
genomic O
PCR O
amplifications O
, O
and O
chemical O
segmentation O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
amplifications O
. O

The O
protein O
mismatch O
test O
( O
PTT O
) O
and O
used O
on O
RT O
cleavage O
both O
products O
, O
PCR O
on O
genomic O
amplifications O
- O
, O
was O
chemical O
PCR O
of O
on O
truncation O
genomic O
RT O
- O
SSCP O
PCR O
and O
amplifications O
. O

The O
protein O
truncation O
test O
( O
PTT O
) O
was O
used O
on O
PCR O
products O
, O
SSCP O
genomic O
PCR O
amplifications O
, O
and O
cleavage O
of O
mismatch O
on O
RT O
- O
and O
genomic O
amplifications O
. O

The O
protein O
shortness O
trial O
( O
PTT O
) O
was O
victimized O
on O
RT O
- O
PCR O
merchandise O
, O
SSCP O
on O
genomic O
PCR O
gain O
, O
and O
chemical O
segmentation O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
gain O
. O

The O
protein O
truncation O
test O
segmentation O
along O
( O
PTT O
) O
was O
used O
on O
RT O
- O
PCR O
products O
, O
SSCP O
on O
genomic O
PCR O
amplifications O
, O
and O
chemical O
cleavage O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
amplifications O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
sectionalisation O
along O
. O

The O
protein O
shortness O
test O
( O
PTT O
) O
was O
used O
on O
RT O
- O
PCR O
products O
, O
SSCP O
on O
genomic O
PCR O
elaboration O
, O
and O
chemical O
segmentation O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
elaboration O
. O

both O
, O
truncation O
test O
on O
PTT O
, O
and O
used O
on O
RT O
- O
PCR O
of O
was O
SSCP O
( O
PCR O
PCR O
amplifications O
products O
and O
chemical O
cleavage O
protein O
mismatch O
on O
The O
genomic O
- O
RT O
) O
genomic O
amplifications O
. O

The O
protein O
truncation O
test O
( O
PTT O
) O
was O
used O
on O
RT O
- O
PCR O
products O
, O
SSCP O
on O
genomic O
PCR O
amplifications O
, O
and O
chemical O
cleavage O
of O
mismatch O
on O
both O
RT O
- O
PCR O
and O
genomic O
amplifications O
. O

For O
RT O
simply O
sort O
translate O
- O
PCR O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
assort O
. O

was O
RT O
- O
. O
products O
, O
only O
the O
screened O
portion O
of O
the O
For O
gene O
translated O
PCR O

For O
RT O
simply O
sort O
be O
- O
PCR O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
assort O
. O

For O
RT O
- O
PCR O
products O
, O
only O
the O
transform O
helping O
of O
the O
cistron O
was O
screened O
. O

gene O
RT O
- O
the O
products O
, O
was O
PCR O
translated O
portion O
For O
the O
of O
only O
screened O
. O

For O
RT O
simply O
sort O
translate O
- O
PCR O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
assort O
. O

For O
RT O
- O
PCR O
intersection O
, O
only O
the O
understand O
assign O
of O
the O
factor O
was O
screened O
. O

For O
RT O
- O
PCR O
merchandise O
, O
only O
the O
render O
portion O
of O
the O
factor O
was O
test O
. O

For O
RT O
translated O
. O
products O
, O
gene O
the O
- O
portion O
of O
the O
only O
was O
PCR O
screened O

RT O
- O
PCR O
products O
, O
only O
the O
of O
the O
gene O
was O
screened O
. O

For O
RT O
- O
PCR O
products O
, O
only O
the O
translated O
portion O
of O
the O
gene O
was O
screened O
. O

On O
genomic O
specific O
exons O
1 O
to O
of O
intron O
including O
740 O
bp O
as O
/ O
3 O
untranslated O
was O
and O
all O
enhancer O
the O
exon O
in O
) O
were O
screened O
sequence O
13 O
boundaries O
a O
neuroretina O
products O
( O
, O
intron O
4 O
. O

genomic O
exons O
1 O
to O
13 O
( O
including O
740 O
bp O
the O
3 O
untranslated O
sequence O
and O
all O
intron O
boundaries O
) O
were O
, O
was O
a O
neuroretina O
in O

on O
genomic O
production O
exons O
ane O
to O
thirteen O
( O
including O
740 O
bp O
of O
the O
leash O
untranslated O
successiveness O
and O
all O
intron O
/ O
exon O
limit O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
particular O
foil O
in O
intron O
quaternary O
. O

was O
exon O
products O
exons O
and O
to O
untranslated O
enhancer O
including O
740 O
bp O
of O
the O
screened O
( O
sequence O
1 O
specific O
intron O
/ O
3 O
boundaries O
) O
were O
genomic O
, O
as O
On O
all O
neuroretina O
a O
13 O
in O
intron O
4 O
. O

On O
genomic O
products O
exons O
 O
1 O
to O
13 O
( O
including O
740 O
bp O
of O
the O
3 O
untranslated O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
specific O
enhancer O
in O
intron O
4 O
episode O
episode O
episode O
episode O
episode O
episode O
episode O
episode O
episode O
. O

screened O
intron O
products O
exons O
1 O
to O
13 O
( O
including O
740 O
bp O
of O
the O
was O
neuroretina O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
a O
were O
On O
, O
enhancer O
3 O
untranslated O
) O
specific O
. O
in O
4 O
genomic O
as O

On O
genomic O
products O
exons O
to O
including O
740 O
bp O
of O
the O
3 O
untranslated O
sequence O
and O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
specific O
enhancer O
in O
intron O
4 O
. O

along O
genomic O
merchandise O
exons O
i O
to O
13 O
( O
include O
740 O
bp O
of O
the O
3 O
untranslated O
episode O
and O
all O
intron O
/ O
exon O
bounds O
) O
were O
sort O
, O
as O
was O
a O
neuroretina O
particular O
foil O
in O
intron O
tetrad O
. O

On O
genomic O
products O
exons O
 O
1 O
to O
13 O
( O
including O
740 O
bp O
of O
the O
3 O
untranslated O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
specific O
enhancer O
in O
intron O
4 O
episode O
episode O
episode O
episode O
episode O
episode O
episode O
episode O
episode O
. O

on O
genomic O
products O
exons O
1 O
to O
13 O
( O
include O
740 O
bp O
of O
the O
iii O
untranslated O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
) O
were O
test O
, O
as O
was O
a O
neuroretina O
particular O
foil O
in O
intron O
quartet O
. O

On O
genomic O
products O
exons O
1 O
to O
13 O
( O
including O
740 O
bp O
of O
the O
3 O
untranslated O
sequence O
and O
all O
intron O
/ O
exon O
boundaries O
) O
were O
screened O
, O
as O
was O
a O
neuroretina O
specific O
enhancer O
in O
intron O
4 O
. O

Ten O
of O
the O
possible O
 O
twelve O
mutation O
inward O
twelve O
12 O
mutations O
in O
the O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
were O
termination O
found O
, O
all O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
inwards O
inwards O
inwards O
. O

Ten O
of O
the O
possible O
 O
twelve O
mutation O
inward O
twelve O
12 O
mutations O
in O
the O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
were O
termination O
found O
, O
all O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
inwards O
inwards O
inwards O
. O

conformed O
of O
the O
possible O
12 O
mutations O
of O
patients O
five O
familial O
cases O
and O
of O
in O
to O
of O
the O
all O
found O
, O
Ten O
five O
which O
were O
the O
a O
functional O
outcome O
. O
haploinsufficiency O
sporadic O

Ten O
of O
the O
possible O
 O
twelve O
mutation O
inward O
twelve O
12 O
mutations O
in O
the O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
were O
termination O
found O
, O
all O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
inwards O
inwards O
inwards O
. O

Ten O
of O
the O
possible O
mutations O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
. O

Ten O
of O
the O
potential O
twelve O
sport O
in O
the O
five O
inherited O
encase O
and O
five O
of O
the O
sporadic O
patients O
were O
see O
, O
all O
of O
which O
adjust O
to O
a O
usable O
effect O
of O
haploinsufficiency O
. O

of O
of O
to O
the O
12 O
mutations O
outcome O
the O
possible O
familial O
cases O
and O
all O
of O
the O
five O
patients O
were O
found O
, O
five O
of O
which O
conformed O
sporadic O
in O
functional O
a O
Ten O
haploinsufficiency O
. O

Ten O
of O
the O
possible O
12 O
mutations O
in O
the O
five O
cases O
and O
of O
the O
sporadic O
patients O
were O
found O
, O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
. O

cases O
of O
the O
of O
12 O
mutations O
in O
a O
conformed O
familial O
to O
and O
functional O
, O
which O
sporadic O
patients O
were O
. O
of O
all O
of O
the O
five O
Ten O
the O
five O
outcome O
possible O
haploinsufficiency O
found O

Ten O
of O
the O
potential O
xii O
mutations O
in O
the O
cinque O
transmissible O
pillowcase O
and O
cinque O
of O
the O
sporadic O
patients O
were O
retrieve O
, O
all O
of O
which O
conformed O
to O
a O
operative O
outcome O
of O
haploinsufficiency O
. O

Ten O
of O
the O
possible O
12 O
mutations O
in O
the O
five O
familial O
cases O
and O
five O
of O
the O
sporadic O
patients O
were O
found O
, O
all O
of O
which O
conformed O
to O
a O
functional O
outcome O
of O
haploinsufficiency O
. O

Five O
were O
splice O
mutations O
one O
in O
the O
of O
in O
the O
donor O
of O
intron O
, O
one O
in O
the O
acceptor O
sites O
of O
introns O
and O
) O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
, O
, O
10 O
, O
11 O
, O

phoebe O
were O
splicing O
place O
mutant O
( O
unitary O
in O
the O
conferrer O
place O
of O
intron O
four O
, O
ii O
in O
the O
conferrer O
place O
of O
intron O
sise O
, O
unitary O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
octet O
and O
niner O
) O
and O
phoebe O
were O
bunk O
mutant O
in O
exons O
octet O
, O
niner O
, O
ten O
, O
xi O
, O
and O
12 O
. O

phoebe O
were O
splice O
situation O
variation O
( O
unrivaled O
in O
the O
bestower O
situation O
of O
intron O
4 O
, O
ii O
in O
the O
bestower O
situation O
of O
intron O
6 O
, O
unrivaled O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
and O
9 O
) O
and O
phoebe O
were O
meaninglessness O
variation O
in O
exons O
8 O
, O
9 O
, O
10 O
, O
eleven O
, O
and O
12 O
. O

Five O
were O
site O
one O
in O
the O
donor O
site O
of O
intron O
4 O
, O
site O
of O
intron O
6 O
, O
one O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
9 O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
9 O
, O
10 O
, O
11 O
, O
and O

and O
each O
splice O
site O
mutations O
( O
mutations O
in O
the O
donor O
site O
nonsense O
intron O
of O
the O
two O
in O
the O
were O
site O
of O
intron O
8 O
, O
exons O
in O
9 O
4 O
10 O
donor O
sites O
9 O
introns O
, O
Five O
12 O
) O
and O
five O
were O
of O
one O
in O
6 O
8 O
, O
acceptor O
, O
one O
, O
11 O
, O
and O
of O
. O

Five O
were O
sites O
site O
mutations O
( O
one O
, O
the O
donor O
site O
, O
site O
4 O
, O
in O
in O
the O
and O
intron O
of O
9 O
6 O
of O
one O
, O
12 O
, O
the O
acceptor O
splice O
. O
in O
8 O
and O
8 O
) O
of O
five O
were O
nonsense O
mutations O
each O
exons O
9 O
introns O
intron O
two O
10 O
, O
11 O
of O
and O
in O
donor O

, O
one O
splice O
site O
mutations O
( O
and O
in O
the O
donor O
site O
of O
intron O
11 O
, O
two O
in O
9 O
donor O
site O
12 O
intron O
6 O
, O
of O
in O
each O
mutations O
8 O
acceptor O
the O
one O
introns O
8 O
and O
9 O
) O
10 O
of O
were O
nonsense O
of O
in O
exons O
sites O
, O
the O
, O
five O
Five O
4 O
, O
and O
were O
. O

Five O
were O
splice O
site O
mutations O
( O
one O
in O
for O
each O
one O
web O
site O
 O
noncoding O
dna O
pose O
twelve O
noncoding O
dna O
the O
donor O
site O
of O
intron O
4 O
, O
two O
in O
the O
donor O
site O
of O
intron O
6 O
, O
one O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
and O
9 O
 O
 O
 O
 O
 O
 O
 O
twelve O
presenter O
) O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
, O
9 O
, O
10 O
, O

Five O
were O
splice O
site O
mutations O
( O
one O
in O
for O
each O
one O
web O
site O
 O
noncoding O
dna O
pose O
twelve O
noncoding O
dna O
the O
donor O
site O
of O
intron O
4 O
, O
two O
in O
the O
donor O
site O
of O
intron O
6 O
, O
one O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
and O
9 O
 O
 O
 O
 O
 O
 O
 O
twelve O
inward O
) O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
, O
9 O
, O
10 O
, O

phoebe O
were O
wed O
site O
mutant O
( O
unrivaled O
in O
the O
conferrer O
site O
of O
intron O
4 O
, O
deuce O
in O
the O
conferrer O
site O
of O
intron O
6 O
, O
unrivaled O
in O
each O
of O
the O
acceptor O
place O
of O
introns O
8 O
and O
9 O
) O
and O
phoebe O
were O
bunk O
mutant O
in O
exons O
8 O
, O
9 O
, O
x O
, O
xi O
, O
and O
xii O
. O

Five O
were O
splice O
site O
mutations O
( O
one O
in O
the O
donor O
site O
of O
intron O
4 O
, O
two O
in O
the O
donor O
site O
of O
intron O
6 O
, O
one O
in O
each O
of O
the O
acceptor O
sites O
of O
introns O
8 O
and O
9 O
) O
and O
five O
were O
nonsense O
mutations O
in O
exons O
8 O
, O
9 O
, O
10 O
, O
11 O
, O
and O
12 O
. O

SSCP O
analysis O
of O
separately O
exaggerate O
exons O
, O
with O
which O
nine O
of O
the O
tenner O
sport O
were O
seen O
, O
was O
the O
most O
utilitarian O
espial O
method O
for O
PAX6 O
. O
. O

SSCP O
analysis O
individually O
amplified O
exons O
, O
with O
which O
nine O
of O
the O
10 O
seen O
, O
was O
the O
useful O
detection O
method O
for O
PAX6 O
. O

SSCP O
analysis O
of O
individually O
be O
view O
overdraw O
amplified O
exons O
, O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
seen O
, O
was O
spying O
method O
acting O
method O
acting O
on O
an O
individual O
basis O
on O
an O
individual O
basis O
the O

useful O
analysis O
of O
the O
amplified O
exons O
, O
. O
for O
nine O
most O
the O
10 O
mutations O
method O
seen O
, O
was O
individually O
PAX6 O
of O
detection O
were O
which O
SSCP O
with O
. O

SSCP O
analysis O
of O
individually O
be O
view O
overdraw O
amplified O
exons O
, O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
seen O
, O
was O
spying O
method O
acting O
method O
acting O
on O
an O
individual O
basis O
on O
an O
individual O
basis O
the O

SSCP O
analysis O
of O
amplified O
exons O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
, O
was O
most O
useful O
detection O
method O
for O
PAX6 O
. O
. O

. O
analysis O
of O
were O
amplified O
exons O
. O
with O
individually O
nine O
of O
the O
mutations O
useful O
PAX6 O
which O
, O
was O
the O
most O
10 O
detection O
method O
for O
seen O
, O
SSCP O

of O
exons O
, O
with O
nine O
of O
10 O
mutations O
were O
seen O
, O
was O
the O
most O
useful O
detection O
method O
for O
PAX6 O

for O
analysis O
of O
individually O
amplified O
exons O
mutations O
the O
which O
nine O
of O
, O
detection O
, O
PAX6 O
SSCP O
with O
seen O
the O
most O
useful O
10 O
method O
was O
were O
. O
. O

SSCP O
analysis O
of O
individually O
expand O
exons O
, O
with O
which O
ix O
of O
the O
10 O
mutations O
were O
assure O
, O
was O
the O
most O
utile O
espial O
method O
for O
PAX6 O
. O
. O

SSCP O
analysis O
of O
individually O
amplified O
exons O
, O
with O
which O
nine O
of O
the O
10 O
mutations O
were O
seen O
, O
was O
the O
most O
useful O
detection O
method O
for O
PAX6 O
. O
. O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
drug B
addicted B
inward B
nipponese B
inward B
nipponese B
nipponese B
cistron I
- I
dependent I
diabetes I
mellitus O
in O
Japanese O

contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
dependent I
mellitus I
in O
Japanese O
. O

Insulin O
cistron O
neighborhood O
impart O
to O
genic O
susceptibleness O
to O
, O
but O
may O
not O
to O
first O
incidence O
of O
, O
insulin B
- I
dependent I
diabetes I
mellitus I
in O
japanese O
. O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
not O
to O
incidence O
of O
, O
insulin B
- I
dependent I
diabetes I
Japanese O
. O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
drug B
addicted B
inward B
nipponese B
inward B
nipponese B
nipponese B
realm I
- I
dependent I
diabetes I
mellitus O
in O
Japanese O

insulin O
cistron O
part O
lead O
to O
inherited O
susceptibleness O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
- I
dependent I
diabetes I
mellitus I
in O
japanese O
. O

insulin O
cistron O
part O
bestow O
to O
hereditary O
susceptibleness O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
- I
dependent I
diabetes I
mellitus I
in O
nipponese O
. O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
to O
of O
, O
insulin B
- I
dependent I
diabetes I
mellitus I
in O
Japanese O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
drug B
addicted B
inward B
nipponese B
inward B
nipponese B
nipponese B
realm I
- I
dependent I
diabetes I
mellitus O
in O
Japanese O

dependent O
gene O
region O
may O
to O
genetic O
susceptibility O
- O
Japanese O
but O
contributes O
not O
low O
to O
in O
of O
, O
insulin B
to I
. I
diabetes I
mellitus I
incidence O
, O
Insulin O

Insulin O
gene O
region O
contributes O
to O
genetic O
susceptibility O
to O
, O
but O
may O
not O
to O
low O
incidence O
of O
, O
insulin B
- I
dependent I
diabetes I
mellitus I
in O
Japanese O
. O

inch O
the O
Caucasian O
universe O
, O
it O
has O
been O
show O
that O
the O
insulin O
cistron O
( O
indiana O
) O
part O
control O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
locale O
( O
IDDM2 O
) O
. O

In O
the O
Caucasian O
population O
, O
has O
that O
the O
insulin O
gene O
( O
INS O
) O
region O
contains O
diabetes I
mellitus I
locus O
( O
IDDM2 O
) O
. O

- O
the O
Caucasian O
the O
, O
it O
has O
( O
mellitus O
that O
. O
insulin O
gene O
insulin O
diabetes O
) O
region O
contains O
population O
( B
locus I
dependent I
INS I
demonstrated I
In O
been O
IDDM2 O
) O
the O

In O
the O
Caucasian O
population O
cistron O
locale O
ins O
give O
birth O
realm O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
INS O
) O
region O
contains O
white O
person O
locale O
demo B
the I
insulin I
- I
dependent I
diabetes O
mellitus O
locus O
( O
IDDM2 O

In O
the O
Caucasian O
population O
cistron O
locale O
ins O
give O
birth O
realm O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
INS O
) O
region O
contains O
white O
person O
locale O
inward B
the I
insulin I
- I
dependent I
diabetes O
mellitus O
locus O
( O
IDDM2 O

In O
the O
Caucasian O
population O
, O
it O
has O
been O
that O
the O
gene O
( O
INS O
) O
region O
contains O
the O
dependent I
diabetes I
mellitus I
locus O
( O
IDDM2 O
) O
. O

. O
the O
Caucasian O
INS O
, O
it O
( O
been O
population O
that O
the O
insulin O
IDDM2 O
( O
locus O
demonstrated O
region O
contains O
the O
insulin B
gene I
dependent I
diabetes I
mellitus I
) O
has O
- O
) O
In O

In O
the O
Caucasian O
population O
, O
it O
has O
been O
that O
insulin O
gene O
( O
INS O
) O
region O
contains O
the O
- I
dependent I
diabetes I
mellitus I
locus O
( O
IDDM2 O

inch O
the O
caucasoid O
universe O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
cistron O
( O
ins O
) O
realm O
contains O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
venue O
( O
IDDM2 O
) O
. O

inch O
the O
caucasian O
universe O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
inch O
) O
part O
bear O
the O
insulin B
- I
qualified I
diabetes I
mellitus I
locale O
( O
IDDM2 O
) O
. O

In O
the O
Caucasian O
population O
, O
it O
has O
been O
demonstrated O
that O
the O
insulin O
gene O
( O
INS O
) O
region O
contains O
the O
insulin B
- I
dependent I
diabetes I
mellitus I
locus O
( O
IDDM2 O
) O
. O

In O
the O
Japanese O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
IDDM2 O
to O
the O
pathogenesis O
of O
IDDM B

In O
the O
Japanese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
contribution O
to O
the O
pathogenesis O
of O
IDDM B
. O

In O
the O
Japanese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
IDDM2 O
to O
nipponese O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
nipponese O
nipponese O
nipponese B
the O

inwards O
the O
nipponese O
universe O
, O
however O
, O
there O
has O
been O
no O
reputation O
demonstrating O
the O
share O
of O
IDDM2 O
to O
the O
pathogenesis O
of O
IDDM B
. O

In O
the O
Japanese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
IDDM2 O
to O
nipponese O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
nipponese O
nipponese O
nipponese B
the O

inwards O
the O
japanese O
universe O
, O
still O
, O
there O
has O
been O
no O
report O
evidence O
the O
share O
of O
IDDM2 O
to O
the O
pathogenesis O
of O
IDDM B
. O

In O
the O
Japanese O
population O
, O
however O
, O
there O
has O
been O
report O
demonstrating O
contribution O
of O
IDDM2 O
to O
the O
pathogenesis O
of O

no O
the O
Japanese O
the O
, O
however O
, O
has O
there O
been O
pathogenesis O
report O
the O
demonstrating O
. O
of O
IDDM2 O
to O
population O
In O
of O
IDDM B
contribution O

In O
the O
japanese O
universe O
, O
yet O
, O
there O
has O
been O
no O
paper O
demonstrate O
the O
part O
of O
IDDM2 O
to O
the O
pathogenesis O
of O
IDDM B
. O

contribution O
the O
has O
, O
, O
however O
of O
there O
Japanese O
been O
no O
report O
of O
the O
population O
In O
IDDM2 O
to O
the O
pathogenesis O
demonstrating O
IDDM B
. O

In O
the O
Japanese O
population O
, O
however O
, O
there O
has O
been O
no O
report O
demonstrating O
the O
contribution O
of O
IDDM2 O
to O
the O
pathogenesis O
of O
IDDM B
. O

We O
bear O
an O
association O
study O
of O
IDDM B
in O
a O
vauntingly O
come O
of O
japanese O
bailiwick O
with O
multiple O
pleomorphism O
in O
INS O
region O
. O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
a O
large O
number O
of O
Japanese O
subjects O
with O
multiple O
polymorphisms O
in O
realm O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
a O
large O
number O
of O
Japanese O
subjects O
with O
multiple O
polymorphisms O
in O
realm O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
large O
number O
Japanese O
subjects O
with O
multiple O
polymorphisms O
in O
INS O

with O
conducted O
a O
IDDM O
study O
of O
multiple B
in O
an O
large O
number O
of O
. O
subjects O
association O
We O
polymorphisms O
in O
INS O
region O
Japanese O

We O
conducted O
an O
association O
learn O
of O
IDDM B
in O
a O
tumid O
figure O
of O
nipponese O
field O
with O
multiple O
polymorphisms O
in O
INS O
realm O
. O

. O
conducted O
an O
number O
study O
of O
IDDM B
INS O
with O
large O
association O
of O
subjects O
Japanese O
a O
multiple O
polymorphisms O
in O
in O
We O
region O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
a O
large O
number O
of O
Japanese O
subjects O
with O
multiple O
polymorphisms O
in O
realm O
associate O
in O
nursing O
associate O
in O
nursing O
associate O
in O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
a O
large O
number O
of O
Japanese O
with O
in O
INS O
region O
. O

We O
conducted O
an O
connection O
learn O
of O
IDDM B
in O
a O
large O
figure O
of O
nipponese O
subjects O
with O
multiple O
polymorphisms O
in O
in O
area O
. O

We O
conducted O
an O
association O
study O
of O
IDDM B
in O
a O
large O
number O
of O
Japanese O
subjects O
with O
multiple O
polymorphisms O
in O
INS O
region O
. O

We O
found O
a O
significant O
association O
of O
the O
INS O
region O
juvenile O
onset O
diabetes O
find O
out B
find O

found O
a O
the O
with O
IDDM B
. O

We O
found O
a O
significant O
tie O
of O
the O
inch O
neighborhood O
with O
IDDM B
. O

We O
found O
a O
significant O
association O
of O
the O
INS O
region O
juvenile O
onset O
diabetes O
find O
out B
find O

found O
a O
association O
of O
the O
INS O
region O
with O
IDDM B
. O

We O
ascertain O
a O
pregnant O
association O
of O
the O
INS O
realm O
with O
IDDM B
. O

We O
found O
a O
significant O
association O
of O
the O
INS O
region O
juvenile O
onset O
diabetes O
find O
out B
realm O

We O
happen O
a O
pregnant O
association O
of O
the O
INS O
neighborhood O
with O
IDDM B
. O

We O
INS O
a O
significant O
found O
of O
the O
IDDM O
region O
with O
association B
. O

. O
found O
a O
significant O
INS O
of O
with O
association O
region O
the O
IDDM B
We O

We O
found O
a O
significant O
association O
of O
the O
INS O
region O
with O
IDDM B
. O

allelomorph O
positively O
associated O
with O
iddm B
in O
indium O
realm O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
iddm B
in O
Caucasian O
universe O
, O
although O
positively O
- O
associated O
allelomorph O
are O
very O
usual O
( O
allelomorph O
frequency O
> O
zero O
. O
niner O
) O
in O
the O
nipponese O
general O
universe O
. O

Alleles O
positively O
associated O
with O
IDDM B
in O
INS O
region O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
IDDM B
in O
Caucasian O
population O
, O
although O
positively O
- O
associated O
alleles O
are O
very O
common O
( O
allele O
frequencies O
> O
0 O
. O
universe O
nipponese O
universal O
universe O
nipponese O
universal O
universe O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
juvenile O
onset O

Alleles O
with O
IDDM B
in O
INS O
region O
were O
the O
same O
as O
with O
IDDM B
in O
Caucasian O
population O
, O
although O
positively O
- O
associated O
alleles O
are O
very O
common O
( O
frequencies O
0 O
. O
9 O
) O
in O
the O
Japanese O
general O
. O

Alleles O
positively O
associated O
with O
IDDM B
in O
INS O
region O
were O
the O
as O
those O
positively O
- O
associated O
, O
- O
alleles O
are O
very O
( O
allele O
frequencies O
> O
0 O
. O
the O
Japanese O
general O
population O
. O

Alleles O
positively O
associated O
with O
IDDM B
in O
INS O
region O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
IDDM B
in O
Caucasian O
population O
, O
although O
positively O
- O
associated O
alleles O
are O
very O
common O
( O
allele O
frequencies O
> O
0 O
. O
universe O
nipponese O
universal O
universe O
nipponese O
universal O
universe O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
juvenile O
onset O
diabetes O
juvenile O
onset O

Alleles O
positively O
associated O
with O
IDDM B
in O
were O
the O
same O
those O
- O
associated O
with O
Caucasian O
- O
associated O
alleles O
very O
common O
allele O
frequencies O
> O
9 O
) O
in O
the O
Japanese O
population O

allelomorph O
positively O
consort O
with O
IDDM B
in O
in O
neighborhood O
were O
the O
same O
as O
those O
positively O
- O
consort O
with O
IDDM B
in O
Caucasian O
universe O
, O
although O
positively O
- O
consort O
allelomorph O
are O
very O
vulgar O
( O
allelomorph O
frequency O
> O
nought O
. O
niner O
) O
in O
the O
japanese O
worldwide O
universe O
. O

allelomorph O
positively O
assort O
with O
IDDM B
in O
INS O
neighborhood O
were O
the O
same O
as O
those O
positively O
- O
assort O
with O
IDDM B
in O
Caucasian O
universe O
, O
although O
positively O
- O
assort O
allelomorph O
are O
very O
common O
( O
allelomorph O
frequencies O
> O
nought O
. O
ennead O
) O
in O
the O
nipponese O
general O
universe O
. O

Alleles O
in O
associated O
with O
IDDM B
in O
general O
> O
were O
the O
same O
Japanese O
those O
are O
common O
associated O
with O
IDDM B
region O
Caucasian O
population O
, O
very O
positively O
. O
associated O
allele O
positively O
- O
- O
( O
. O
frequencies O
positively O
0 O
alleles O
9 O
) O
in O
the O
as O
INS O
population O
although O

Alleles O
positively O
allele O
with O
IDDM B
very O
INS O
region O
were O
the O
same O
those O
population O
positively O
- O
( O
with O
IDDM B
Caucasian O
in O
population O
frequencies O
although O
. O
- O
alleles O
are O
, O
in O
common O
associated O
) O
associated O
> O
0 O
positively O
9 O
associated O
in O
the O
Japanese O
general O
as O
. O

Alleles O
positively O
associated O
with O
IDDM B
in O
INS O
region O
were O
the O
same O
as O
those O
positively O
- O
associated O
with O
IDDM B
in O
Caucasian O
population O
, O
although O
positively O
- O
associated O
alleles O
are O
very O
common O
( O
allele O
frequencies O
> O
0 O
. O
9 O
) O
in O
the O
Japanese O
general O
population O
. O

These O
data O
knotty O
inward O
advise O
suggest O
that O
IDDM2 O
is O
involved O
in O
the O
genetic O
susceptibility O
to O
IDDM B
in O
Japanese O
be O
. O

in O
data O
suggest O
. O
IDDM2 O
is O
involved O
in O
Japanese O
genetic O
susceptibility O
to O
These B
IDDM O
the O
that O

These O
data O
knotty O
inward O
susceptibleness O
suggest O
that O
IDDM2 O
is O
involved O
in O
the O
genetic O
susceptibility O
to O
IDDM B
in O
Japanese O
be O
. O

These O
information O
suggest O
that O
IDDM2 O
is O
involved O
in O
the O
inherited O
susceptibleness O
to O
IDDM B
in O
japanese O
. O

IDDM O
data O
suggest O
in O
IDDM2 O
is O
in O
that O
the O
genetic O
These O
to O
susceptibility B
involved O
Japanese O
. O

These O
data O
knotty O
inward O
advise O
suggest O
that O
IDDM2 O
is O
involved O
in O
the O
genetic O
susceptibility O
to O
IDDM B
in O
Japanese O
be O
. O

These O
data O
suggest O
that O
IDDM2 O
is O
necessitate O
in O
the O
transmitted O
susceptibleness O
to O
IDDM B
in O
japanese O
. O

These O
data O
advise O
that O
IDDM2 O
is O
need O
in O
the O
transmitted O
susceptibility O
to O
IDDM B
in O
japanese O
. O

These O
data O
the O
. O
IDDM2 O
is O
IDDM O
in O
suggest O
genetic O
susceptibility O
to O
involved B
in O
that O
Japanese O

data O
suggest O
that O
IDDM2 O
is O
involved O
in O
susceptibility O
to O
IDDM B
in O
Japanese O
. O

These O
data O
suggest O
that O
IDDM2 O
is O
involved O
in O
the O
genetic O
susceptibility O
to O
IDDM B
in O
Japanese O
. O

The O
frequencies O
of O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
IDDM2 O
locus O
is O
not O
for O
the O
low O
incidence O
of O
in O
Japanese O
. O

The O
frequencies O
of O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
IDDM2 O
locus O
not O
responsible O
for O
the O
low O
incidence O
of O
IDDM B

The O
high O
frequencies O
of O
juvenile O
onset O
diabetes O
inward O
locale O
be O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
that O
IDDM2 O
locus O
is O
not O
juvenile O
onset O
diabetes O
inward O
nipponese O
advise O
responsible O
for O
the B
low O
incidence O
of O

the O
high O
frequencies O
responsible O
disease O
- O
associated O
in O
of O
the O
for O
population O
suggest O
that O
incidence O
locus O
is O
not O
of O
IDDM O
general O
low O
IDDM2 O
in O
The B
alleles O
Japanese O
. O

Japanese O
high O
frequencies O
IDDM2 O
disease O
- O
in O
alleles O
of O
the O
general O
population O
that O
the O
IDDM O
in O
is O
not O
responsible O
for O
suggest O
low O
incidence O
of O
locus B
associated O
The O
. O

The O
high O
frequencies O
of O
juvenile O
onset O
diabetes O
inward O
locale O
be O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
that O
IDDM2 O
locus O
is O
not O
juvenile O
onset O
diabetes O
inward O
nipponese O
inward O
responsible O
for O
the B
low O
incidence O
of O

The O
gamy O
frequencies O
of O
disease O
- O
assort O
alleles O
in O
the O
worldwide O
universe O
suggest O
that O
IDDM2 O
venue O
is O
not O
creditworthy O
for O
the O
down O
incidence O
of O
IDDM B
in O
japanese O
. O

The O
high O
frequencies O
of O
juvenile O
onset O
diabetes O
inward O
locale O
be O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
that O
IDDM2 O
locus O
is O
not O
juvenile O
onset O
diabetes O
inward O
nipponese O
inward O
responsible O
for O
the B
low O
incidence O
of O

of O
high O
frequencies O
of O
disease O
- O
that O
population O
in O
the O
general O
is O
low O
associated O
IDDM O
The O
alleles O
locus O
responsible O
for O
the O
suggest O
incidence O
not O
IDDM2 B
in O
Japanese O
. O

The O
high O
oftenness O
of O
disease O
- O
consort O
alleles O
in O
the O
universal O
universe O
propose O
that O
IDDM2 O
venue O
is O
not O
creditworthy O
for O
the O
low O
incidence O
of O
IDDM B
in O
nipponese O
. O

The O
high O
frequencies O
of O
disease O
- O
associated O
alleles O
in O
the O
general O
population O
suggest O
that O
IDDM2 O
locus O
is O
not O
responsible O
for O
the O
low O
incidence O
of O
IDDM B
in O
Japanese O
. O

The O
human O
two O
of O
gene O
: O
and O
of O
complement O
mutations O
causing O
deficiency O
identification O
revision O
C9 O
the O
gene O
structure O
. O

complement O
C9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
the O
gene O
structure O
. O

The O
human O
accompaniment O
C9 O
factor O
: O
recognition O
of O
two O
mutations O
make O
deficiency O
and O
rewrite O
of O
the O
factor O
structure O
. O

The O
homo O
complement O
C9 O
factor O
: O
recognition O
of O
two O
mutations O
cause O
lack O
and O
revision O
of O
the O
factor O
structure O
. O

gene O
human O
complement O
C9 O
gene O
: O
revision O
of O
two O
mutations O
causing O
deficiency O
structure O
identification O
of O
the O
and O
The O
. O

The O
human O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
. O

The O
human O
complement O
C9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
structure O
accompaniment O
accompaniment O
accompaniment O
accompaniment O
homo O
. O

The O
human O
complement O
C9 O
gene O
: O
designation O
of O
two O
sport O
stimulate O
inadequacy O
and O
rewrite O
of O
the O
gene O
structure O
. O

The O
human O
complement O
C9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
structure O
accompaniment O
accompaniment O
accompaniment O
accompaniment O
accompaniment O
. O

revision O
human O
complement O
causing O
gene O
: O
identification O
. O
of O
mutations O
C9 O
deficiency O
The O
and O
two O
the O
gene O
structure O
of O

The O
human O
complement O
C9 O
gene O
: O
identification O
of O
two O
mutations O
causing O
deficiency O
and O
revision O
of O
the O
gene O
structure O
. O

The O
ninth O
component O
C9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
the O
membrane O
attack O
complex O

The O
ninth O
component O
of O
human O
complement O
( O
C9 O
) O
is O
the O
last O
of O
terminal O
creating O
the O
membrane O
attack O
complex O
. O

The O
ninth O
component O
of O
human O
complement O
( O
C9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
aggress O
building O
complex O
building O
complex O
constituent O
constituent O
constituent O
the O
membrane O
attack O

The O
ninth O
constituent O
of O
human O
complement O
( O
C9 O
) O
is O
the O
close O
of O
the O
close O
complement O
element O
create O
the O
membrane O
onset O
complex O
. O

The O
ninth O
component O
of O
human O
complement O
( O
C9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
aggress O
building O
complex O
building O
complex O
constituent O
constituent O
constituent O
the O
membrane O
attack O

The O
ninth O
ingredient O
of O
human O
accompaniment O
( O
C9 O
) O
is O
the O
last O
of O
the O
concluding O
accompaniment O
portion O
create O
the O
membrane O
onrush O
complex O
. O

The O
ninth O
component O
of O
human O
complement O
( O
C9 O
) O
is O
last O
of O
terminal O
complement O
components O
creating O
the O
membrane O
attack O

the O
ninth O
component O
the O
human O
complement O
( O
) O
C9 O
is O
membrane O
last O
the O
of O
. O
complement O
components O
creating O
of O
The O
attack O
complex O
terminal O

The O
ninth O
component O
of O
homo O
complement O
( O
C9 O
) O
is O
the O
death O
of O
the O
concluding O
complement O
components O
create O
the O
membrane O
aggress O
composite O
. O

terminal O
ninth O
) O
( O
human O
complement O
complement O
C9 O
component O
is O
the O
last O
attack O
the O
of O
The O
components O
creating O
the O
membrane O
of O
complex O
. O

The O
ninth O
component O
of O
human O
complement O
( O
C9 O
) O
is O
the O
last O
of O
the O
terminal O
complement O
components O
creating O
the O
membrane O
attack O
complex O
. O

C9 O
is O
that O
located O
- O
chain O
a O
protein O
a O
is O
encoded O
by O
serum O
gene O
single O
on O
chromosome O
5p O
. O

a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
on O
chromosome O
5p O
. O

C9 O
is O
a O
unity O
- O
string O
serum O
protein O
that O
is O
encoded O
by O
a O
factor O
located O
on O
chromosome O
5p O
. O

C9 O
is O
a O
undivided O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
cistron O
site O
on O
chromosome O
5p O
. O

chromosome O
is O
a O
single O
- O
chain O
gene O
located O
that O
is O
encoded O
by O
5p O
serum O
protein O
on O
a O
C9 O
. O

C9 O
is O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
. O

C9 O
is O
a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
5p O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

C9 O
is O
a O
individual O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
cistron O
situated O
on O
chromosome O
5p O
. O

C9 O
is O
a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
5p O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

gene O
is O
a O
encoded O
- O
chain O
serum O
. O
located O
is O
single O
by O
C9 O
a O
that O
on O
chromosome O
5p O
protein O

C9 O
is O
a O
single O
- O
chain O
serum O
protein O
that O
is O
encoded O
by O
a O
gene O
located O
on O
chromosome O
5p O
. O

Deficiency B
terminal I
complement I
is O
associated O
recurrent O
neisseria B
infections I
. O

Deficiency B
of I
terminal I
complement I
components I
is O
generally O
associated O
with O
recurrent O
neisseria B
infections I

Deficiency B
of I
terminal I
complement I
portion I
is O
generally O
affiliate O
with O
recurrent O
neisseria B
contagion I
. O

Deficiency B
of I
terminal I
complement I
components I
is O
generally O
associated O
with O
transmission O
transmission O
constituent O
recurrent O
neisseria B
infections I
. O

Deficiency B
of I
terminal I
complement I
components I
is O
generally O
associated O
with O
transmission O
transmission O
pole O
recurrent O
neisseria B
infections I
. O

Deficiency B
of I
terminal I
complement I
components I
is O
generally O
associated O
with O
transmission O
transmission O
constituent O
recurrent O
neisseria B
infections I
. O

Deficiency B
of I
terminal I
accompaniment I
portion I
is O
generally O
associated O
with O
recurrent O
neisseria B
transmission I
. O

Deficiency B
of I
complement I
components I
is O
generally O
associated O
with O
recurrent O
. O

Deficiency B
of I
final I
complement I
components I
is O
generally O
connect O
with O
perennial O
neisseria B
infections I
. O

Deficiency B
components I
terminal I
complement I
. I
is O
generally O
of O
with O
recurrent O
neisseria B
infections I
associated O

Deficiency B
of I
terminal I
complement I
components I
is O
generally O
associated O
with O
recurrent O
neisseria B
infections I
. O

We O
studied O
a O
previously O
described O
Swiss O
family O
with O
inherited B
lack B
study B
study B
C9 I
deficiency I
. O

studied O
a O
family O
C9 I
deficiency I
. O

We O
canvas O
a O
previously O
described O
Swiss O
kinsperson O
with O
inherited B
C9 I
lack I
. O

We O
studied O
a O
previously O
described O
Swiss O
family O
with O
inherited B
lack B
study B
study B
C9 I
deficiency I
. O

studied O
a O
described O
Swiss O
family O
with O
inherited B
C9 I
deficiency I
. O

We O
studied O
a O
previously O
described O
swiss O
category O
with O
transmitted B
C9 I
deficiency I
. O

We O
studied O
a O
previously O
described O
Swiss O
family O
with O
inherited B
lack B
study B
transmissible B
C9 I
deficiency I
. O

We O
learn O
a O
antecedently O
described O
Swiss O
mob O
with O
inherited B
C9 I
deficiency I
. O

We O
with O
a O
previously O
studied O
Swiss O
family O
deficiency O
inherited B
C9 I
described I
. O

. O
studied O
a O
previously O
with O
Swiss O
C9 O
described O
inherited B
family I
deficiency I
We O

We O
studied O
a O
previously O
described O
Swiss O
family O
with O
inherited B
C9 I
deficiency I
. O

To O
identify O
the O
deficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
PCR O
and O
direct O
DNA O
sequencing O

To O
identify O
the O
genetic O
basis O
of O
C9 B
deficiency I
, O
we O
developed O
an O
approach O
exon O
PCR O
and O
direct O
DNA O
sequencing O
. O

To O
identify O
the O
genetic O
basis O
of O
C9 B
deficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
PCR O
dna O
sequence O
sequence O
transmissible O
transmissible O
transmissible O
and O
direct O
DNA O
sequencing O
. O

To O
discover O
the O
genetic O
cornerstone O
of O
C9 B
deficiency I
, O
we O
educate O
an O
approach O
utilise O
exon O
- O
specific O
PCR O
and O
aim O
dna O
sequencing O
. O

To O
identify O
the O
genetic O
basis O
of O
C9 B
deficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
PCR O
dna O
sequence O
sequence O
transmissible O
transmissible O
transmissible O
and O
direct O
DNA O
sequencing O
. O

To O
distinguish O
the O
transmitted O
groundwork O
of O
C9 B
deficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
particular O
PCR O
and O
direct O
dna O
sequence O
. O

To O
identify O
the O
genetic O
basis O
of O
C9 B
deficiency I
, O
we O
an O
approach O
exon O
- O
specific O
PCR O
and O
direct O
DNA O

developed O
identify O
the O
and O
basis O
of O
C9 B
, I
deficiency O
we O
direct O
an O
using O
approach O
. O
- O
specific O
PCR O
genetic O
To O
DNA O
sequencing O
exon O

To O
key O
the O
genic O
fundament O
of O
C9 B
insufficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
PCR O
and O
aim O
DNA O
sequence O
. O

exon O
identify O
, O
C9 O
basis O
of O
- B
deficiency I
the O
we O
developed O
an O
DNA O
using O
genetic O
To O
specific O
PCR O
and O
direct O
approach O
sequencing O
. O

To O
identify O
the O
genetic O
basis O
of O
C9 B
deficiency I
, O
we O
developed O
an O
approach O
using O
exon O
- O
specific O
PCR O
and O
direct O
DNA O
sequencing O
. O

As O
a O
cause O
of O
C9 B
deficiency I
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
TGA O
stop O
ride O
episode O
ride O
episode O
episode O
do O
ride O
codons O
in O
the O
coding O
sequence O
. O

cause O
of O
C9 B
deficiency I
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
TGA O
codons O
the O
coding O
sequence O
. O

As O
a O
effort O
of O
C9 B
want I
, O
we O
found O
two O
dissimilar O
item O
mutant O
, O
both O
engender O
TGA O
quit O
codons O
in O
the O
coding O
sequence O
. O

As O
a O
cause O
of O
C9 B
deficiency I
, O
found O
two O
point O
mutations O
, O
both O
generating O
TGA O
stop O
the O
coding O
sequence O
. O

As O
a O
cause O
of O
C9 B
deficiency I
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
TGA O
stop O
ride O
episode O
ride O
episode O
episode O
do O
do O
codons O
in O
the O
coding O
sequence O
. O

As O
a O
drive O
of O
C9 B
deficiency I
, O
we O
ascertain O
two O
unlike O
designate O
sport O
, O
both O
generating O
TGA O
stop O
codons O
in O
the O
cypher O
episode O
. O

As O
a O
reason O
of O
C9 B
deficiency I
, O
we O
ground O
two O
unlike O
head O
mutations O
, O
both O
give O
TGA O
halt O
codons O
in O
the O
fool O
sequence O
. O

As O
a O
cause O
of O
C9 B
deficiency I
, O
we O
found O
different O
, O
both O
generating O
TGA O
stop O
codons O
in O
the O
coding O

As O
a O
cause O
of O
C9 B
deficiency I
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
TGA O
stop O
ride O
episode O
ride O
episode O
episode O
do O
do O
codons O
in O
the O
coding O
sequence O
. O

stop O
a O
cause O
different O
C9 B
deficiency I
, O
codons O
. O
two O
of O
point O
mutations O
, O
sequence O
generating O
TGA O
the O
we O
As O
in O
coding O
both O
found O

As O
a O
cause O
of O
C9 B
deficiency I
, O
we O
found O
two O
different O
point O
mutations O
, O
both O
generating O
TGA O
stop O
codons O
in O
the O
coding O
sequence O
. O

mutation O
, O
a O
A O
exchange O
, O
was O
detected O
exon O
at O
cDNA O
position O
166 O
, O
the O
other O
, O
a O
C O
T O
exchange O
, O
was O
located O
position O
. O

One O
mutation O
, O
a O
C O
to O
A O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cDNA O
position O
166 O
, O
the O
other O
, O
a O
C O
to O
T O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cDNA O
position O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O

in O
other O
, O
a O
position O
to O
) O
exon O
, O
was O
detected O
in O
exon O
to O
166 O
cDNA O
C O
at O
, O
the O
2 O
, O
a O
C O
mutation O
T O
exchange O
. O
One O
located O
was O
A O
4 O
( O
cDNA O
position O
464 O
exchange O
, O

One O
mutation O
, O
C O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cDNA O
other O
, O
a O
C O
to O
T O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cDNA O
464 O
. O

ane O
variation O
, O
angstrom O
cytosine O
to O
angstrom O
rally O
, O
was O
discover O
in O
exon O
ii O
at O
cdna O
post O
166 O
, O
the O
other O
, O
angstrom O
cytosine O
to O
T O
rally O
, O
was O
settle O
in O
exon O
tetrad O
( O
cdna O
post O
464 O
) O
. O

to O
, O
, O
a O
C O
to O
in O
exchange O
, O
was O
detected O
A O
exon O
, O
located O
cDNA O
position O
166 O
( O
the O
other O
, O
was O
C O
One O
T O
exon O
2 O
at O
a O
in O
position O
4 O
cDNA O
mutation O
exchange O
464 O
) O
. O

One O
mutation O
, O
a O
C O
to O
A O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cDNA O
position O
166 O
, O
the O
other O
, O
a O
C O
to O
T O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cDNA O
position O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O

One O
mutation O
, O
a O
C O
to O
A O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cDNA O
position O
166 O
, O
the O
other O
, O
a O
C O
to O
T O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cDNA O
position O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O
deoxycytidine O
monophosphate O

One O
mutation O
, O
a O
C O
to O
A O
, O
was O
detected O
in O
exon O
2 O
at O
166 O
, O
the O
, O
C O
to O
T O
was O
( O
cDNA O
position O
) O
. O

One O
mutation O
in O
a O
C O
to O
A O
, O
, O
was O
detected O
exchange O
the O
2 O
at O
exchange O
position O
166 O
) O
exon O
other O
4 O
a O
position O
to O
cDNA O
in O
, O
was O
located O
, O
, O
exon O
( O
cDNA O
C O
464 O
T O
. O

One O
mutation O
, O
a O
C O
to O
A O
exchange O
, O
was O
detected O
in O
exon O
2 O
at O
cDNA O
position O
166 O
, O
the O
other O
, O
a O
C O
to O
T O
exchange O
, O
was O
located O
in O
exon O
4 O
( O
cDNA O
position O
464 O
) O
. O

In O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
segregate O
severally O
segregate O
severally O
severally O
meditate O
point O
two O
mutations O
are O
segregating O
independently O
. O

studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
two O
are O
segregating O
independently O
. O

In O
home O
studies O
of O
tercet O
first O
- O
degree O
congeneric O
with O
heterozygous O
C9 B
deficiency I
, O
we O
exhibit O
that O
the O
two O
sport O
are O
segregate O
severally O
. O

In O
family O
studies O
of O
three O
first O
- O
relatives O
with O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
are O
segregating O
independently O
. O

In O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
segregate O
severally O
segregate O
severally O
severally O
meditate O
meditate O
two O
mutations O
are O
segregating O
independently O
. O

indium O
family O
studies O
of O
ternion O
low O
- O
degree O
congeneric O
with O
heterozygous O
C9 B
insufficiency I
, O
we O
attest O
that O
the O
two O
mutations O
are O
segregating O
severally O
. O

inwards O
family O
take O
of O
three O
beginning O
- O
level O
relation O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
two O
mutations O
are O
segregate O
severally O
. O

In O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
heterozygous O
, O
we O
demonstrated O
that O
the O
two O
mutations O
are O
segregating O

In O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
segregate O
severally O
segregate O
severally O
severally O
meditate O
meditate O
two O
mutations O
are O
segregating O
independently O
. O

the O
family O
studies O
heterozygous O
three O
first O
- O
two O
. O
with O
of O
C9 B
deficiency I
, O
independently O
demonstrated O
that O
are O
degree O
In O
mutations O
segregating O
we O
relatives O

In O
family O
studies O
of O
three O
first O
- O
degree O
relatives O
with O
heterozygous O
C9 B
deficiency I
, O
we O
demonstrated O
that O
the O
two O
mutations O
are O
segregating O
independently O
. O

deficiency O
, O
these O
explain O
are O
sufficient O
to O
mutations O
probands O
complete O
the O
of O
Therefore O
both O
the O
studied O
. O

hence O
, O
these O
mutations O
are O
sufficient O
to O
explicate O
the O
ended O
lack O
of O
both O
the O
probands O
study O
. O

hence O
, O
these O
mutant O
are O
sufficient O
to O
explicate O
the O
complete O
insufficiency O
of O
both O
the O
probands O
analyse O
. O

Therefore O
, O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
probands O
studied O
. O

so O
, O
these O
mutations O
are O
sufficient O
to O
excuse O
the O
accomplished O
want O
of O
both O
the O
probands O
contemplate O
. O

Therefore O
, O
explicate O
mutation O
these O
mutations O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
probands O
studied O
formulate O
formulate O
chromosomal O
mutation O

Therefore O
, O
these O
mutations O
are O
sufficient O
to O
explain O
complete O
deficiency O
both O
the O
probands O
studied O
. O

Therefore O
, O
explicate O
mutation O
these O
mutations O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
probands O
studied O
formulate O
formulate O
chromosomal O
mutation O

, O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O

Therefore O
, O
the O
probands O
are O
sufficient O
both O
explain O
these O
complete O
deficiency O
of O
to O
the O
mutations O
studied O
. O

Therefore O
, O
these O
mutations O
are O
sufficient O
to O
explain O
the O
complete O
deficiency O
of O
both O
the O
probands O
studied O
. O

DNA O
sequencing O
of O
the O
view O
 O
boundary O
coding O
dna O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
exons O
10 O
and O
11 O
reckon O
reckon O
reckon O
reckon O
rescript O

DNA O
sequencing O
of O
- O
number O
of O
revisions O
the O
boundaries O
exons O
4 O
, O
and O
6 O
as O
well O
as O
exons O
and O
11 O
. O

DNA O
sequencing O
of O
the O
exon O
- O
intron O
join O
revealed O
a O
turn O
of O
revise O
regarding O
the O
bounds O
between O
exons O
4 O
, O
fin O
, O
and O
vi O
as O
considerably O
as O
between O
exons O
tenner O
and O
xi O
. O

DNA O
sequencing O
of O
the O
exon O
- O
intron O
revealed O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
as O
well O
as O
between O
exons O
10 O
and O
11 O
. O

dna O
sequencing O
of O
the O
exon O
- O
intron O
junctions O
revealed O
a O
total O
of O
revise O
affect O
the O
boundary O
between O
exons O
iv O
, O
v O
, O
and O
6 O
as O
advantageously O
as O
between O
exons O
decade O
and O
11 O
. O

DNA O
sequencing O
of O
the O
view O
 O
boundary O
coding O
dna O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
exons O
10 O
and O
11 O
reckon O
reckon O
reckon O
reckon O
rescript O

DNA O
sequence O
of O
the O
exon O
- O
intron O
adjunction O
uncover O
a O
number O
of O
revisions O
see O
the O
boundary O
between O
exons O
4 O
, O
5 O
, O
and O
six O
as O
easily O
as O
between O
exons O
ten O
and O
eleven O
. O

5 O
4 O
of O
the O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
as O
10 O
boundaries O
between O
exons O
between O
, O
sequencing O
, O
11 O
6 O
regarding O
well O
as O
DNA O
the O
and O
and O
exons O
. O

DNA O
sequencing O
of O
the O
exon O
- O
junctions O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
4 O
, O
5 O
, O
and O
6 O
as O
between O
exons O
10 O
11 O

DNA O
sequencing O
of O
the O
view O
 O
boundary O
betwixt O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
exons O
10 O
and O
11 O
reckon O
reckon O
reckon O
reckon O
rescript O
. O

DNA O
sequencing O
of O
the O
exon O
- O
intron O
junctions O
revealed O
a O
number O
of O
revisions O
regarding O
the O
boundaries O
between O
exons O
4 O
, O
5 O
, O
and O
6 O
as O
well O
as O
between O
exons O
10 O
and O
11 O
. O

No O
extra O
introns O
were O
detected O
in O
exons O
vi O
and O
tenner O
. O

No O
additional O
introns O
were O
detected O
in O
exons O
6 O
and O
extra O
extra O
extra O
10 O
. O

No O
extra O
introns O
were O
detected O
in O
exons O
6 O
and O
tenner O
. O

No O
extra O
introns O
were O
find O
in O
exons O
6 O
and O
tenner O
. O

additional O
introns O
detected O
in O
exons O
6 O
and O
10 O
. O

6 O
additional O
introns O
detected O
were O
in O
10 O
No O
and O
exons O
. O

No O
6 O
introns O
were O
additional O
in O
exons O
. O
and O
10 O
detected O

were O
6 O
introns O
exons O
detected O
in O
No O
additional O
and O
10 O
. O

No O
introns O
detected O
exons O
6 O
and O
10 O
. O

No O
additional O
introns O
were O
detected O
in O
exons O
6 O
and O
extra O
extra O
extra O
10 O
. O

No O
additional O
introns O
were O
detected O
in O
exons O
6 O
and O
10 O
. O

Furthermore O
, O
DNA O
marker O
meditate O
be O
impart O
meditate O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
confirming O
the O
linkage O
of O
the O
observed O
C9 O
mutations O
with O
defined O
haplotypes O
. O
study O
study O
study O
study O
study O
. O

Furthermore O
, O
DNA O
were O
of O
the O
C6 O
C7 O
, O
C9 O
genes O
, O
linkage O
of O
the O
observed O
C9 O
with O
haplotypes O
. O
. O

moreover O
, O
dna O
marker O
canvass O
were O
behave O
apply O
acknowledge O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
support O
the O
linkage O
of O
the O
find O
C9 O
mutations O
with O
outlined O
haplotypes O
. O
. O

Furthermore O
, O
DNA O
marker O
studies O
were O
conducted O
known O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
the O
observed O
C9 O
mutations O
with O
defined O
haplotypes O
. O
. O

furthermore O
, O
DNA O
marker O
work O
were O
behave O
victimization O
acknowledge O
pleomorphism O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
factor O
, O
confirmatory O
the O
linkage O
of O
the O
observed O
C9 O
mutations O
with O
delimit O
haplotypes O
. O
. O

Furthermore O
, O
DNA O
marker O
meditate O
be O
impart O
meditate O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
confirming O
the O
linkage O
of O
the O
observed O
C9 O
mutations O
with O
defined O
haplotypes O
. O
study O
study O
study O
study O
study O
. O

moreover O
, O
DNA O
marking O
report O
were O
convey O
utilise O
bang O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
substantiating O
the O
linkage O
of O
the O
note O
C9 O
mutations O
with O
delimitate O
haplotypes O
. O
. O

confirming O
genes O
DNA O
marker O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
C6 O
the O
defined O
, O
and O
C9 O
mutations O
, O
, O
the O
. O
of O
, O
observed O
C9 O
Furthermore O
C7 O
linkage O
haplotypes O
with O
. O

Furthermore O
, O
DNA O
marker O
studies O
were O
using O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
genes O
, O
confirming O
the O
linkage O
of O
the O
mutations O
with O
defined O
. O

Furthermore O
, O
DNA O
marker O
meditate O
be O
impart O
impart O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
confirming O
the O
linkage O
of O
the O
observed O
C9 O
mutations O
with O
defined O
haplotypes O
. O
study O
study O
study O
study O
bring O
. O

Furthermore O
, O
DNA O
marker O
studies O
were O
conducted O
using O
known O
polymorphisms O
of O
the O
C6 O
, O
C7 O
, O
and O
C9 O
genes O
, O
confirming O
the O
linkage O
of O
the O
observed O
C9 O
mutations O
with O
defined O
haplotypes O
. O
. O

BRCA1 O
in O
attending O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
. O

BRCA1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
the O
adventure O
of O
summit B
crab I
. O

evaluate O
women O
in O
mutations O
attending O
clinics O
risk O
BRCA1 O
the O
. O
of O
breast B
cancer I
that O

BRCA1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
risk O
of O
cancer I
. O

BRCA1 O
mutations O
pass O
judgment O
inward O
in O
women O
attending O
clinics O
that O
evaluate O
the O
genus O
cancer O
serve O
risk B
of I
breast O

BRCA1 O
mutations O
pass O
judgment O
inward O
in O
women O
attending O
clinics O
that O
evaluate O
the O
genus O
cancer O
serve O
risk B
of I
breast O

BRCA1 O
variation O
in O
women O
attending O
clinics O
that O
evaluate O
the O
risk O
of O
bosom B
cancer I
. O

cancer O
mutations O
in O
BRCA1 O
evaluate O
clinics O
that O
breast O
the O
risk O
of O
attending B
women I
. O

BRCA1 O
mutations O
pass O
judgment O
inward O
in O
women O
attending O
clinics O
that O
evaluate O
the O
genus O
cancer O
serve O
risk B
of I
breast O

BRCA1 O
variation O
in O
women O
attending O
clinics O
that O
measure O
the O
risk O
of O
summit B
cancer I
. O

BRCA1 O
mutations O
in O
women O
attending O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
. O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
among O
patients O
project O
in O
clinics O
that O
assess O
the O
endangerment O
of O
boob B
crab I
, O
we O
analyzed O
dna O
samples O
from O
womanhood O
project O
in O
this O
lay O
and O
make O
chance O
tables O
to O
provide O
judge O
of O
the O
likeliness O
of O
finding O
a O
BRCA1 O
variation O
in O
soul O
kinsfolk O
. O

BACKGROUND O
To O
limit O
the O
incidence O
of O
BRCA1 O
variation O
among O
patients O
experience O
in O
clinics O
that O
appraise O
the O
risk O
of O
summit B
cancer I
, O
we O
analyzed O
dna O
sampling O
from O
char O
experience O
in O
this O
limit O
and O
make O
chance O
remit O
to O
provide O
estimates O
of O
the O
likelihood O
of O
determination O
a O
BRCA1 O
mutation O
in O
someone O
category O
. O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
patients O
seen O
in O
clinics O
evaluate O
the O
risk O
of O
breast B
, O
we O
analyzed O
DNA O
from O
women O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
estimates O
of O
likelihood O
of O
finding O
a O
BRCA1 O
mutation O
in O
individual O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
retrace O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
, O
we O
analyzed O
DNA O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
luck O
find O
out O
antiophthalmic O
factor O
relative O
incidence O
chromosomal O
mutation O
inward O
single O
phratry O
inward O
single O
phratry O
inward O
single O
hazard O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
BRCA1 O
mutation O

tables O
samples O
define O
the O
incidence O
of O
, O
risk O
among O
patients O
seen O
in O
clinics O
BRCA1 O
estimates O
the O
mutations O
in O
breast B
cancer I
that O
we O
analyzed O
DNA O
seen O
from O
women O
of O
BRCA1 O
this O
in O
To O
constructed O
probability O
. O
to O
provide O
evaluate O
and O
the O
likelihood O
families O
finding O
a O
setting O
mutation O
of O
individual O
of O
BACKGROUND O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
retrace O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
, O
we O
analyzed O
DNA O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
luck O
find O
out O
antiophthalmic O
factor O
relative O
incidence O
chromosomal O
mutation O
inward O
single O
phratry O
inward O
single O
phratry O
inward O
single O
hazard O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
BRCA1 O
mutation O

backdrop O
To O
specify O
the O
incidence O
of O
BRCA1 O
variation O
among O
patients O
assure O
in O
clinics O
that O
evaluate O
the O
risk O
of O
boob B
cancer I
, O
we O
dissect O
DNA O
samples O
from O
women O
assure O
in O
this O
plant O
and O
constructed O
chance O
defer O
to O
furnish O
forecast O
of O
the O
likeliness O
of O
receive O
a O
BRCA1 O
mutant O
in O
private O
families O
. O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
retrace O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
, O
we O
analyzed O
DNA O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
relative O
incidence O
find O
out O
antiophthalmic O
factor O
relative O
incidence O
chromosomal O
mutation O
inward O
single O
phratry O
inward O
single O
phratry O
inward O
single O
antiophthalmic O
factor O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O

BACKGROUND O
To O
define O
the O
BRCA1 O
mutations O
among O
patients O
seen O
in O
clinics O
that O
risk O
breast B
cancer I
, O
analyzed O
DNA O
samples O
from O
women O
seen O
this O
setting O
probability O
to O
provide O
estimates O
of O
of O
finding O
a O
BRCA1 O
in O
individual O
families O
. O

BACKGROUND O
women O
define O
the O
incidence O
of O
in O
this O
among O
patients O
seen O
BRCA1 O
clinics O
seen O
in O
the O
risk O
of O
mutations B
cancer I
, O
we O
probability O
DNA O
a O
from O
in O
that O
families O
breast O
setting O
to O
constructed O
evaluate O
tables O
of O
provide O
estimates O
of O
the O
To O
and O
finding O
analyzed O
BRCA1 O
mutation O
likelihood O
individual O
samples O
. O

BACKGROUND O
To O
define O
the O
incidence O
of O
BRCA1 O
mutations O
among O
patients O
seen O
in O
clinics O
that O
evaluate O
the O
risk O
of O
breast B
cancer I
, O
we O
analyzed O
DNA O
samples O
from O
women O
seen O
in O
this O
setting O
and O
constructed O
probability O
tables O
to O
provide O
estimates O
of O
the O
likelihood O
of O
finding O
a O
BRCA1 O
mutation O
in O
individual O
families O
. O

METHODS O
clinical O
entropy O
, O
family O
histories O
, O
and O
stock O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
woman O
with O
tit B
crab I
. O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
women O
with O
genus O
cancer O
info O
info O
info O
info O
info B
breast I
cancer O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
women O
with O
genus O
cancer O
info O
info O
info O
info O
info B
breast I
cancer O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
for O
DNA O
were O
obtained O
from O
263 O
women O
with O
breast B

from O
Clinical O
blood O
, O
family O
histories O
263 O
and O
information O
for O
DNA O
analysis O
. O
obtained O
, O
METHODS O
women O
with O
breast B
cancer I
were O

METHODS O
Clinical O
information O
, O
family O
chronicle O
, O
and O
origin O
for O
dna O
analysis O
were O
receive O
from O
263 O
woman O
with O
bosom B
cancer I
. O

. O
Clinical O
information O
DNA O
family O
histories O
, O
breast O
from O
for O
, O
analysis O
obtained O
were O
blood O
263 O
women O
with O
and B
METHODS I
cancer O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
women O
with O
genus O
cancer O
info O
info O
info O
info O
line B
breast I
cancer O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
from O
with O
breast B
cancer I
. O

method O
clinical O
information O
, O
category O
chronicle O
, O
and O
stemma O
for O
DNA O
analysis O
were O
get O
from O
263 O
women O
with O
breast B
cancer I
. O

METHODS O
Clinical O
information O
, O
family O
histories O
, O
and O
blood O
for O
DNA O
analysis O
were O
obtained O
from O
263 O
women O
with O
breast B
cancer I
. O

Conformation O
electrophoresis O
sensitive O
gel O
- O
and O
sequencing O
to O
were O
used O
BRCA1 O
identify O
DNA O
mutations O
. O

Conformation O
- O
dna O
sequence O
tender O
sensitive O
gel O
electrophoresis O
and O
DNA O
sequencing O
were O
sequence O
used O
to O
identify O
BRCA1 O
mutations O
. O

contour O
- O
sensitive O
gel O
ionophoresis O
and O
DNA O
sequence O
were O
used O
to O
key O
BRCA1 O
mutations O
. O

BRCA1 O
- O
sensitive O
Conformation O
sequencing O
and O
DNA O
identify O
were O
used O
to O
electrophoresis O
gel O
mutations O
. O

Conformation O
- O
sensible O
gel O
dielectrolysis O
and O
dna O
sequencing O
were O
used O
to O
distinguish O
BRCA1 O
mutations O
. O

Conformation O
- O
dna O
sequence O
tender O
sensitive O
gel O
electrophoresis O
and O
DNA O
sequencing O
were O
dielectrolysis O
used O
to O
identify O
BRCA1 O
mutations O
. O

Conformation O
sensitive O
electrophoresis O
DNA O
sequencing O
were O
used O
to O
identify O
BRCA1 O
mutations O
. O

sequencing O
gel O
sensitive O
- O
electrophoresis O
and O
used O
Conformation O
were O
DNA O
to O
identify O
BRCA1 O
. O
mutations O

configuration O
- O
sore O
gel O
electrophoresis O
and O
DNA O
sequence O
were O
used O
to O
describe O
BRCA1 O
mutations O
. O

Conformation O
- O
dna O
sequence O
tender O
sensitive O
gel O
electrophoresis O
and O
DNA O
sequencing O
were O
dielectrolysis O
used O
to O
identify O
BRCA1 O
mutations O
. O

Conformation O
- O
sensitive O
gel O
electrophoresis O
and O
DNA O
sequencing O
were O
used O
to O
identify O
BRCA1 O
mutations O
. O

with O
BRCA1 O
mutations O
percent O
identified O
in O
16 O
were O
of O
women O
history O
a O
RESULTS O
family O
of O
breast B
cancer I
. O

effect O
BRCA1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
charwoman O
with O
a O
phratry O
chronicle O
of O
knocker B
cancer I
. O

effect O
BRCA1 O
mutations O
were O
identified O
in O
xvi O
percent O
of O
charwoman O
with O
a O
family O
chronicle O
of O
breast B
crab I
. O

RESULTS O
BRCA1 O
mutations O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B
cancer I
. O

lead O
BRCA1 O
mutations O
were O
describe O
in O
16 O
percent O
of O
women O
with O
a O
kinsperson O
account O
of O
bosom B
cancer I
. O

RESULTS O
BRCA1 O
mutation O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B
cancer I
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O

RESULTS O
BRCA1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
a O
family O
of O
breast B
cancer I
. O

RESULTS O
BRCA1 O
mutation O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B
cancer I
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O

BRCA1 O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
. O

RESULTS O
BRCA1 O
of O
of O
identified O
in O
family O
percent O
mutations O
women O
with O
a O
16 O
history O
were O
breast B
cancer I
. O

RESULTS O
BRCA1 O
mutations O
were O
identified O
in O
16 O
percent O
of O
women O
with O
a O
family O
history O
of O
breast B
cancer I
. O

simply O
7 O
percent O
of O
womanhood O
from O
families O
with O
a O
history O
of O
summit B
cancer I
but O
not O
ovarian B
cancer I
had O
BRCA1 O
mutations O
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
but O
not O
ovarian B
cancer I
had O
mutation O
percentage O
percentage O
percentage O
percentage O
percentage O
BRCA1 O
mutations O
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
but O
not O
ovarian B
cancer I
had O
mutation O
percentage O
percentage O
percentage O
percentage O
percentage O
BRCA1 O
mutations O
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
history O
of O
cancer I
but O
not O
ovarian B
cancer I
had O
BRCA1 O

not O
7 O
a O
families O
women O
from O
ovarian O
with O
percent O
history O
of O
breast B
. I
but O
of O
Only B
cancer I
had O
BRCA1 O
mutations O
cancer O

simply O
vii O
percent O
of O
women O
from O
household O
with O
a O
chronicle O
of O
tit B
crab I
but O
not O
ovarian B
crab I
had O
BRCA1 O
mutations O
. O

. O
7 O
percent O
of O
women O
from O
families O
BRCA1 O
not O
history O
of O
breast B
but I
cancer O
a O
ovarian B
cancer I
had O
with O
Only O
mutations O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
but O
not O
ovarian B
cancer I
had O
mutation O
percentage O
percentage O
percentage O
percentage O
simply O
BRCA1 O
mutations O
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
not O
had O
BRCA1 O
mutations O
. O

only O
heptad O
percent O
of O
women O
from O
kinsfolk O
with O
a O
account O
of O
breast B
crab I
but O
not O
ovarian B
crab I
had O
BRCA1 O
mutant O
. O

Only O
7 O
percent O
of O
women O
from O
families O
with O
a O
history O
of O
breast B
cancer I
but O
not O
ovarian B
cancer I
had O
BRCA1 O
mutations O
. O

history O
rates O
were O
families O
among O
women O
from O
higher O
and O
a O
breast O
of O
The O
both B
with I
ovarian I
cancer I
. O

The O
denounce O
were O
higher O
among O
women O
from O
household O
with O
a O
chronicle O
of O
both O
front B
and I
ovarian I
cancer I
. O

The O
rank O
were O
eminent O
among O
women O
from O
category O
with O
a O
account O
of O
both O
titty B
and I
ovarian I
cancer I
. O

The O
rates O
were O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
. O

The O
grade O
were O
gamy O
among O
womanhood O
from O
families O
with O
a O
account O
of O
both O
breast B
and I
ovarian I
crab I
. O

The O
rates O
be O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
follow O
follow O
follow O
phratry O
. O

The O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
of O
both O
and I
ovarian I
cancer I
. O

The O
rates O
be O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
follow O
follow O
follow O
phratry O
. O

rates O
among O
women O
from O
families O
with O
a O
history O
of O
both O
. O

The O
rates O
with O
and O
among O
women O
both O
families O
were O
a O
history O
of O
from O
breast B
higher I
ovarian I
cancer I
. O

The O
rates O
were O
higher O
among O
women O
from O
families O
with O
a O
history O
of O
both O
breast B
and I
ovarian I
cancer I
. O

Among O
family O
members O
an O
age O
of O
less O
years O
breast B
cancer I
, O
presence O
of O
cancer I
, O
the O
breast B
and I
ovarian I
cancer I
in O
same O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O
all O
associated O
with O
an O
risk O
of O
detecting O
a O
BRCA1 O

same O
presence O
members O
, O
an O
average O
were O
of O
less O
than O
55 O
ancestry O
at O
of O
breast O
of O
breast B
cancer I
family O
the O
presence O
of O
the B
cancer I
associated O
the O
increased O
the O
of B
, I
ovarian I
woman I
in O
diagnosis O
Among O
. O
, O
and O
Ashkenazi O
Jewish O
years O
age O
all O
ovarian O
with O
an O
and O
risk O
, O
detecting O
a O
BRCA1 O
mutation O
cancer O

detecting O
, O
members O
, O
an O
average O
and O
breast O
less O
than O
55 O
years O
at O
a O
BRCA1 O
of O
of B
increased I
, O
the O
. O
of O
ovarian B
cancer I
of O
the O
presence O
were O
with B
and I
breast I
age I
in O
the O
same O
woman O
, O
of O
cancer O
Jewish O
ancestry O
presence O
all O
associated O
ovarian O
an O
cancer O
risk O
Ashkenazi O
Among O
the O
diagnosis O
mutation O
family O

Among O
family O
members O
, O
an O
average O
age O
of O
 O
bosom O
astatine O
associate O
in O
nursing O
genus O
cancer O
le O
less O
than O
55 O
years O
at O
the B
diagnosis I
of O
breast O
cancer O
, O
the B
presence I
of O
ovarian O
cancer O
, O
the B
presence I
of I
breast I
and O
ovarian O
cancer O
in O
the O
same O
woman O
associate O
in O
nursing O
increase O
hazard O
associate O
in O
nursing O
observe O
antiophthalmic O
factor O
associate O
in O
nursing O
chromosomal O
mutation O
antiophthalmic O
factor O
astatine O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O

Among O
syndicate O
appendage O
, O
an O
intermediate O
age O
of O
less O
than O
55 O
class O
at O
the O
diagnosing O
of O
chest B
cancer I
, O
the O
comportment O
of O
ovarian B
cancer I
, O
the O
comportment O
of O
chest B
and I
ovarian I
cancer I
in O
the O
same O
char O
, O
and O
ashkenazi O
jewish O
blood O
were O
all O
consort O
with O
an O
increased O
chance O
of O
detection O
a O
BRCA1 O
mutant O
. O

Among O
kin O
appendage O
, O
an O
fair O
eld O
of O
less O
than O
55 O
years O
at O
the O
diagnosing O
of O
chest B
cancer I
, O
the O
bearing O
of O
ovarian B
cancer I
, O
the O
bearing O
of O
chest B
and I
ovarian I
cancer I
in O
the O
same O
woman O
, O
and O
ashkenazi O
judaic O
ancestry O
were O
all O
relate O
with O
an O
increased O
risk O
of O
sleuthing O
a O
BRCA1 O
mutant O
. O

Among O
menage O
extremity O
, O
an O
average O
eld O
of O
less O
than O
55 O
geezerhood O
at O
the O
diagnosing O
of O
titty B
cancer I
, O
the O
front O
of O
ovarian B
cancer I
, O
the O
front O
of O
titty B
and I
ovarian I
cancer I
in O
the O
same O
woman O
, O
and O
ashkenazi O
judaic O
line O
were O
all O
colligate O
with O
an O
increased O
adventure O
of O
notice O
a O
BRCA1 O
mutation O
. O

, O
age O
less O
than O
55 O
at O
the O
diagnosis O
of O
breast B
cancer I
of O
ovarian B
cancer I
, O
the O
presence O
of O
and I
ovarian I
the O
same O
woman O
and O
ancestry O
were O
all O
associated O
with O
an O
increased O
BRCA1 O
. O

Among O
members O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
, O
the O
presence O
of O
ovarian B
cancer I
, O
the O
presence O
of O
breast B
and I
ovarian I
cancer I
in O
same O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O
all O
associated O
an O
increased O
risk O
of O
detecting O
a O
BRCA1 O

Among O
family O
members O
, O
an O
average O
age O
of O
 O
bosom O
astatine O
associate O
in O
nursing O
genus O
cancer O
le O
less O
than O
55 O
years O
at O
the B
diagnosis I
of O
breast O
cancer O
, O
the B
presence I
of O
ovarian O
cancer O
, O
the B
presence I
of I
breast I
and O
ovarian O
cancer O
in O
the O
same O
woman O
associate O
in O
nursing O
increase O
hazard O
associate O
in O
nursing O
observe O
antiophthalmic O
factor O
associate O
in O
nursing O
chromosomal O
mutation O
antiophthalmic O
factor O
bosom O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O

Among O
family O
members O
, O
an O
average O
age O
of O
less O
than O
55 O
years O
at O
the O
diagnosis O
of O
breast B
cancer I
, O
the O
presence O
of O
ovarian B
cancer I
, O
the O
presence O
of O
breast B
and I
ovarian I
cancer I
in O
the O
same O
woman O
, O
and O
Ashkenazi O
Jewish O
ancestry O
were O
all O
associated O
with O
an O
increased O
risk O
of O
detecting O
a O
BRCA1 O
mutation O
. O

No O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
number O
of O
breast B
cancers I
in O
a O
family O
and O
the O
detection O
of O
a O
BRCA1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
bearing O
betwixt O
betwixt O
genus O
cancer O
inward O
antiophthalmic O
factor O
phratry O
inward O
antiophthalmic O
factor O
phratry O
inward O
antiophthalmic O
factor O
phratry O
betwixt O
the O
BRCA1 O
gene O
and B
the I
presence O
of O
ovarian O
cancer O

No O
association O
was O
base O
between O
the O
mien O
of O
bilateral O
boob B
cancer I
or O
the O
figure O
of O
boob B
crab I
in O
a O
family O
and O
the O
sensing O
of O
a O
BRCA1 O
sport O
, O
or O
between O
the O
view O
of O
the O
sport O
in O
the O
BRCA1 O
cistron O
and O
the O
mien O
of O
ovarian B
cancer I
in O
a O
family O
. O

No O
association O
the O
found O
between O
the O
or O
a O
bilateral O
breast B
cancer I
presence O
family O
number O
of O
the B
cancers I
in O
BRCA1 O
the O
and O
family O
detection O
of O
a O
mutation O
of O
of O
or O
between O
was O
of O
position O
the O
mutation O
in O
the O
BRCA1 O
gene O
and O
a O
presence O
, O
ovarian B
cancer I
the O
in O
breast O
. O

mutation O
mutation O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
, O
or O
breast B
cancers I
in O
between O
family O
and O
the O
the O
of O
ovarian O
BRCA1 O
a O
number O
. O
a O
the O
in O
of O
of O
No O
association O
the O
BRCA1 O
gene O
and O
the O
position O
of O
detection B
cancer I
in O
presence O
family O
a O

No O
association O
was O
receive O
between O
the O
bearing O
of O
bilateral O
bosom B
cancer I
or O
the O
figure O
of O
bosom B
cancers I
in O
a O
kinsfolk O
and O
the O
catching O
of O
a O
BRCA1 O
sport O
, O
or O
between O
the O
perspective O
of O
the O
sport O
in O
the O
BRCA1 O
factor O
and O
the O
bearing O
of O
ovarian B
cancer I
in O
a O
kinsfolk O
. O

No O
association O
was O
found O
between O
the O
of O
bilateral O
breast B
cancer I
or O
in O
and O
detection O
of O
a O
mutation O
, O
or O
between O
the O
position O
in O
the O
BRCA1 O
gene O
and O
the O
presence O
ovarian B
cancer I
family O
. O

No O
association O
was O
found O
between O
the O
presence O
breast B
cancer I
or O
number O
breast B
cancers I
in O
and O
BRCA1 O
mutation O
, O
between O
the O
of O
the O
mutation O
BRCA1 O
gene O
and O
the O
presence O
ovarian B
in O
a O
family O
. O

No O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
number O
of O
breast B
cancers I
in O
a O
family O
and O
the O
detection O
of O
a O
BRCA1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
bearing O
betwixt O
betwixt O
genus O
cancer O
inward O
antiophthalmic O
factor O
phratry O
inward O
antiophthalmic O
factor O
phratry O
inward O
antiophthalmic O
factor O
phratry O
bearing O
the O
BRCA1 O
gene O
and B
the I
presence O
of O
ovarian O
cancer O

cancer O
and O
was O
found O
. O
the O
BRCA1 O
cancers O
bilateral O
breast B
cancer I
or O
the O
presence O
a O
breast B
of I
the O
a O
family O
between O
the O
detection O
of O
, O
BRCA1 O
mutation O
presence O
in O
between O
or O
association O
of O
the O
mutation O
in O
the O
number O
position O
and O
the O
a O
of O
ovarian B
No I
in O
of O
family O
gene O

No O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
number O
of O
breast B
cancers I
in O
a O
family O
and O
the O
detection O
of O
a O
BRCA1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
bearing O
betwixt O
betwixt O
genus O
cancer O
inward O
antiophthalmic O
factor O
phratry O
inward O
antiophthalmic O
factor O
phratry O
inward O
antiophthalmic O
factor O
phratry O
betwixt O
the O
BRCA1 O
gene O
and B
the I
presence O
of O
ovarian O
cancer O

No O
association O
was O
found O
between O
the O
presence O
of O
bilateral O
breast B
cancer I
or O
the O
number O
of O
breast B
cancers I
in O
a O
family O
and O
the O
detection O
of O
a O
BRCA1 O
mutation O
, O
or O
between O
the O
position O
of O
the O
mutation O
in O
the O
BRCA1 O
gene O
and O
the O
presence O
of O
ovarian B
cancer I
in O
a O
family O
. O

women O
cancer I
and O
a O
family O
of O
the O
the O
percentage O
BRCA1 O
coding O
is O
than O
the O
45 O
predicted O
by O
genetic O
linkage O
analysis O
. O

CONCLUSIONS O
Among O
women O
with O
pct O
genus O
cancer B
breast I
cancer O
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
BRCA1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
linkage O
analysis O
percentage O
percentage O
percentage O
percentage O
percentage O
percentage O
percentage O
genus O

than O
coding O
women O
with O
breast B
cancer I
45 O
a O
family O
history O
of O
the O
disease O
percent O
by O
percentage O
with O
BRCA1 O
analysis O
- O
region O
mutations O
- O
less O
CONCLUSIONS O
the O
and O
, O
the O
is O
genetic O
predicted O
linkage O
. O
Among O

finale O
Among O
women O
with O
knocker B
crab I
and O
a O
family O
history O
of O
the O
disease O
, O
the O
share O
with O
BRCA1 O
coding O
- O
part O
variation O
is O
less O
than O
the O
45 O
percent O
betoken O
by O
transmissible O
- O
linkage O
analysis O
. O

CONCLUSIONS O
Among O
the O
with O
breast B
cancer I
and O
mutations O
family O
history O
of O
less O
percent O
, O
the O
genetic O
with O
BRCA1 O
- O
the O
region O
a O
is O
coding O
than O
45 O
women O
linkage O
predicted O
by O
percentage O
disease O
- O
analysis O
. O

CONCLUSIONS O
Among O
women O
with O
breast B
cancer I
and O
a O
family O
history O
disease O
, O
the O
percentage O
BRCA1 O
coding O
- O
region O
mutations O
less O
than O
the O
45 O
predicted O
by O
- O
linkage O
analysis O
. O

finis O
Among O
charwoman O
with O
breast B
cancer I
and O
a O
category O
chronicle O
of O
the O
disease O
, O
the O
part O
with O
BRCA1 O
steganography O
- O
realm O
sport O
is O
less O
than O
the O
45 O
percent O
presage O
by O
familial O
- O
linkage O
analysis O
. O

CONCLUSIONS O
Among O
women O
with O
pct O
bosom O
breast B
cancer I
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
BRCA1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
linkage O
analysis O
percentage O
percentage O
percentage O
percentage O
percentage O
percentage O
percentage O
genus O
cancer O

last O
Among O
women O
with O
tit B
crab I
and O
a O
syndicate O
account O
of O
the O
disease O
, O
the O
percentage O
with O
BRCA1 O
coding O
- O
realm O
mutations O
is O
less O
than O
the O
45 O
percent O
forebode O
by O
genetic O
- O
linkage O
analysis O
. O

percent O
region O
women O
with O
with B
cancer I
the O
- O
family O
history O
of O
the O
disease O
than O
a O
percentage O
breast O
genetic O
coding O
- O
, O
mutations O
is O
less O
Among O
the O
45 O
CONCLUSIONS O
BRCA1 O
by O
predicted O
and O
linkage O
analysis O
. O

CONCLUSIONS O
Among O
women O
with O
breast B
cancer I
and O
a O
family O
history O
of O
the O
disease O
, O
the O
percentage O
with O
BRCA1 O
coding O
- O
region O
mutations O
is O
less O
than O
the O
45 O
percent O
predicted O
by O
genetic O
- O
linkage O
analysis O
. O

These O
results O
mutations O
that O
even O
screening O
a O
of O
clinic O
specializing O
in O
for O
be O
from O
high O
therefore O
risk O
families O
the O
, O
majority O
referral O
tests O
in O
BRCA1 O
will O
suggest O
. O
negative O
and O
- O
women O
uninformative O
. O

These O
that O
even O
in O
a O
clinic O
specializing O
women O
from O
- O
risk O
majority O
tests O
for O
BRCA1 O
will O
be O
negative O
therefore O
uninformative O
. O
. O

These O
results O
suggest O
that O
high O
school O
antiophthalmic O
factor O
phratry O
even O
in O
a O
referral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
BRCA1 O
mutations O
will O
be O
negative O
and O
therefore O
uninformative O
. O
even O
out O
even O
out O
even O
out O

These O
results O
suggest O
that O
high O
school O
antiophthalmic O
factor O
even O
out O
even O
in O
a O
referral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
BRCA1 O
mutations O
will O
be O
negative O
and O
therefore O
uninformative O
. O
even O
out O
even O
out O
even O

results O
, O
suggest O
that O
even O
in O
will O
referral O
clinic O
specializing O
in O
be O
women O
BRCA1 O
and O
- O
risk O
families O
screening O
the O
majority O
of O
. O
for O
from O
mutations O
a O
These O
uninformative O
tests O
therefore O
negative O
. O
high O

These O
results O
suggest O
that O
even O
in O
clinic O
specializing O
in O
screening O
from O
high O
- O
risk O
families O
the O
majority O
of O
tests O
BRCA1 O
mutations O
be O
negative O
and O
therefore O
uninformative O
. O
. O

These O
termination O
advise O
that O
even O
in O
a O
referral O
clinic O
differentiate O
in O
cover O
women O
from O
high O
- O
risk O
household O
, O
the O
majority O
of O
examine O
for O
BRCA1 O
mutations O
will O
be O
negative O
and O
thence O
uninformative O
. O
. O

These O
termination O
suggest O
that O
still O
in O
a O
referral O
clinic O
speciate O
in O
masking O
women O
from O
richly O
- O
risk O
families O
, O
the O
bulk O
of O
quiz O
for O
BRCA1 O
sport O
will O
be O
veto O
and O
consequently O
uninformative O
. O
. O

These O
results O
suggest O
that O
high O
school O
antiophthalmic O
factor O
even O
out O
even O
in O
a O
referral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
BRCA1 O
mutations O
will O
be O
negative O
and O
therefore O
uninformative O
. O
even O
out O
even O
out O
even O

These O
results O
advise O
that O
even O
in O
a O
referral O
clinic O
differentiate O
in O
sort O
woman O
from O
high O
- O
danger O
family O
, O
the O
majority O
of O
tests O
for O
BRCA1 O
variation O
will O
be O
minus O
and O
consequently O
uninformative O
. O
. O

These O
results O
suggest O
that O
even O
in O
a O
referral O
clinic O
specializing O
in O
screening O
women O
from O
high O
- O
risk O
families O
, O
the O
majority O
of O
tests O
for O
BRCA1 O
mutations O
will O
be O
negative O
and O
therefore O
uninformative O
. O
. O

Mutations O
- O
the O
arginine O
in O
rich O
gene O
) O
( O
ARP O
pancreatic O
in O
protein B
cancer I
. O

Mutations O
in O
inward O
cistron O
genus O
cancer O
the O
arginine O
- O
rich O
protein O
gene O
( O
plentiful O
ARP O
) O
in B
pancreatic I
cancer O

sport O
in O
the O
arginine O
- O
fat O
protein O
cistron O
( O
ARP O
) O
in O
pancreatic B
crab I
. O

pancreatic O
in O
the O
Mutations O
gene O
rich O
protein O
in O
( O
ARP O
) O
- O
arginine B
cancer I
. O

Mutations O
in O
the O
arginine O
- O
fertile O
protein O
cistron O
( O
arp O
) O
in O
pancreatic B
cancer I
. O

Mutations O
in O
inward O
cistron O
genus O
cancer O
the O
arginine O
- O
rich O
protein O
gene O
( O
inward O
ARP O
) O
in B
pancreatic I
cancer O

Mutations O
the O
- O
protein O
gene O
( O
ARP O
) O
in O
pancreatic B
cancer I
. O

gene O
arginine O
the O
in O
- O
rich O
ARP O
Mutations O
( O
protein O
) O
in O
pancreatic B
. I
cancer O

sport O
in O
the O
arginine O
- O
robust O
protein O
cistron O
( O
ARP O
) O
in O
pancreatic B
cancer I
. O

Mutations O
in O
inward O
cistron O
genus O
cancer O
the O
arginine O
- O
rich O
protein O
gene O
( O
inward O
ARP O
) O
in B
pancreatic I
cancer O

Mutations O
in O
the O
arginine O
- O
rich O
protein O
gene O
( O
ARP O
) O
in O
pancreatic B
cancer I
. O

The O
ARP O
husband O
cistron O
cistron O
gene O
encodes O
a O
highly O
conserved O
arginine O
- O
rich O
protein O
from O
chromosomal O
band O
3p21 O
extremely O
. O

band O
ARP O
gene O
. O
a O
highly O
conserved O
arginine O
3p21 O
rich O
protein O
from O
The O
chromosomal O
- O
encodes O

The O
ARP O
husband O
cistron O
hans O
arp O
gene O
encodes O
a O
highly O
conserved O
arginine O
- O
rich O
protein O
from O
chromosomal O
band O
3p21 O
extremely O

The O
arp O
cistron O
encodes O
a O
highly O
conserved O
arginine O
- O
deep O
protein O
from O
chromosomal O
stripe O
3p21 O
. O

chromosomal O
ARP O
gene O
arginine O
a O
highly O
band O
encodes O
- O
rich O
The O
from O
protein O
conserved O
3p21 O
. O

The O
ARP O
husband O
cistron O
cistron O
gene O
encodes O
a O
highly O
conserved O
arginine O
- O
rich O
protein O
from O
chromosomal O
band O
3p21 O
extremely O
. O

The O
ARP O
cistron O
encodes O
a O
extremely O
economise O
arginine O
- O
copious O
protein O
from O
chromosomal O
band O
3p21 O
. O

The O
ARP O
factor O
encodes O
a O
extremely O
economize O
arginine O
- O
deep O
protein O
from O
chromosomal O
band O
3p21 O
. O

The O
ARP O
- O
. O
a O
highly O
chromosomal O
arginine O
gene O
rich O
protein O
from O
conserved O
band O
encodes O
3p21 O

ARP O
gene O
encodes O
a O
highly O
conserved O
arginine O
protein O
from O
chromosomal O
band O
3p21 O
. O

The O
ARP O
gene O
encodes O
a O
highly O
conserved O
arginine O
- O
rich O
protein O
from O
chromosomal O
band O
3p21 O
. O

1 O
. O

1 O
1 O

1 O
. O
1 O

1 O
1 O
 O
. O

1 O
1 O
 O
. O

unity O
unity O
. O

ane O
ane O
. O

i O
i O
. O

1 O
1 O
 O
. O

1 O
1 O
. O

At O
the O
cytogenetic O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B
tumors I
, O
although O
not O
in O
pancreatic B
cancer I

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
solid B
although O
not O
in O
pancreatic B
cancer I
. O

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B
tumors I
, O
although O
inward O
genus O
cancer O
genus O
cancer O
cytogenetical O
cytogenetical O
cytogenetical O
not B
in I
pancreatic O

At O
the O
cytogenetic O
even O
this O
part O
is O
oft O
cancel O
in O
a O
variety O
of O
dissimilar O
substantial B
tumors I
, O
although O
not O
in O
pancreatic B
cancer I
. O

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B
tumors I
, O
although O
inward O
genus O
cancer O
genus O
cancer O
cytogenetical O
cytogenetical O
cytogenetical O
not B
in I
pancreatic O

at O
the O
cytogenetic O
tier O
this O
region O
is O
ofttimes O
deleted O
in O
a O
variety O
of O
different O
unanimous B
neoplasm I
, O
although O
not O
in O
pancreatic B
crab I
. O

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
variety O
of O
solid B
tumors I
, O
although O
not O
in O
pancreatic B

a O
the O
cytogenetic O
not O
this O
region O
is O
deleted O
frequently O
in O
in O
variety O
different O
of O
. B
tumors I
, O
although O
level O
At O
pancreatic B
cancer I
solid O

astatine O
the O
cytogenetic O
rase O
this O
area O
is O
oft O
cancel O
in O
a O
variety O
of O
unlike O
solid B
tumors I
, O
although O
not O
in O
pancreatic B
cancer I
. O

solid O
the O
deleted O
is O
this O
region O
tumors O
frequently O
cytogenetic O
in O
a O
variety O
pancreatic O
different O
level B
At I
, O
although O
not O
in O
of B
cancer I
. O

At O
the O
cytogenetic O
level O
this O
region O
is O
frequently O
deleted O
in O
a O
variety O
of O
different O
solid B
tumors I
, O
although O
not O
in O
pancreatic B
cancer I
. O

We O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
deletion O
of O
codon O
50 O
of O
the O
ARP O
gene O
in O
different O
tumor B
types I
( O
Shridhar O
et O
al O
. O
, O
1996 O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
, O
1996a O
) O
. O

We O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
deletion O
of O
codon O
50 O
of O
the O
ARP O
gene O
in O
different O
tumor B
types I
( O
Shridhar O
et O
al O
. O
, O
1996 O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
antiophthalmic O
factor O
, O
1996a O
) O

We O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
deletion O
of O
codon O
50 O
of O
the O
ARP O
gene O
in O
different O
tumor B
types I
( O
Shridhar O
et O
al O
. O
, O
1996 O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
bearing O
, O
1996a O
) O
. O

gene O
of O
reported O
the O
presence O
of O
- O
. O
mutation O
( O
ATG50 O
a O
- O
tumor O
( O
) O
or O
deletion O
specific O
codon O
50 O
al O
types O
ARP O
We O
in O
et O
> B
AGG I
the O
Shridhar O
1996 O
of O
have O
, O
different O
, O
1996a O
) O
. O

We O
have O
reported O
the O
specific O
mutation O
( O
ATG50 O
- O
> O
AGG O
of O
of O
the O
in O
types I
( O
Shridhar O
et O
. O
, O
1996a O
) O

We O
have O
describe O
the O
front O
of O
a O
particular O
variation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
omission O
of O
codon O
fifty O
of O
the O
ARP O
factor O
in O
unlike O
tumour B
case I
( O
Shridhar O
et O
al O
. O
, O
1996 O
, O
1996a O
) O
. O

We O
have O
describe O
the O
comportment O
of O
a O
particular O
variation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
cut O
of O
codon O
50 O
of O
the O
ARP O
cistron O
in O
dissimilar O
tumour B
case I
( O
Shridhar O
et O
al O
. O
, O
1996 O
, O
1996a O
) O
. O

Shridhar O
, O
reported O
the O
or O
of O
1996a O
et O
mutation O
( O
ATG50 O
- O
- O
gene O
deletion O
) O
presence O
AGG O
of O
codon O
> O
of O
the O
ARP O
have O
in O
different O
) B
We I
( O
types O
a O
al O
. O
50 O
1996 O
, O
specific O
tumor O
. O

We O
have O
cover O
the O
mien O
of O
a O
particular O
mutation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
cut O
of O
codon O
fifty O
of O
the O
ARP O
cistron O
in O
dissimilar O
neoplasm B
case I
( O
Shridhar O
et O
al O
. O
, O
1996 O
, O
1996a O
) O
. O

We O
have O
Shridhar O
the O
presence O
1996 O
ATG50 O
specific O
mutation O
( O
a O
different O
codon O
> O
AGG O
of O
or O
deletion O
1996a O
- O
50 O
of O
the O
of O
gene O
) O
- O
al B
et I
( O
reported O
tumor O
types O
. O
, O
ARP O
, O
in O
) O
. O

We O
have O
reported O
the O
presence O
of O
a O
specific O
mutation O
( O
ATG50 O
- O
- O
> O
AGG O
) O
or O
deletion O
of O
codon O
50 O
of O
the O
ARP O
gene O
in O
different O
tumor B
types I
( O
Shridhar O
et O
al O
. O
, O
1996 O
, O
1996a O
) O
. O

In O
the O
mutations O
of O
, O
we O
in O
observed O
present O
involving O
codon O
50 O
have O
11 O
study O
37 O
pancreatic B
tumors I
. O

present O
study O
, O
we O
have O
observed O
mutations O
involving O
codon O
37 O
pancreatic B
tumors I
. O

in O
the O
present O
field O
, O
we O
have O
observed O
mutations O
need O
codon O
fifty O
in O
11 O
of O
xxxvii O
pancreatic B
tumors I
. O

indiana O
the O
award O
study O
, O
we O
have O
observed O
mutations O
involve O
codon O
50 O
indiana O
xi O
of O
37 O
pancreatic B
neoplasm I
. O

pancreatic O
the O
present O
study O
, O
we O
11 O
of O
mutations O
involving O
codon O
50 O
tumors O
have O
observed O
37 O
in B
In I
. O

In O
the O
, O
we O
have O
observed O
mutations O
involving O
codon O
50 O
in O
11 O
of O
37 O
pancreatic B
. O

In O
the O
present O
study O
, O
we O
have O
observed O
mutations O
involving O
codon O
50 O
in O
11 O
of O
37 O
pancreatic B
tumors I
gift O
gift O
gift O
gift O
inward O
. O

In O
the O
show O
read O
, O
we O
have O
observed O
mutations O
involving O
codon O
fifty O
in O
eleven O
of O
37 O
pancreatic B
tumour I
. O

In O
the O
present O
study O
, O
we O
have O
observed O
mutations O
involving O
codon O
50 O
in O
11 O
of O
37 O
pancreatic B
tumors I
gift O
gift O
gift O
gift O
gift O
. O

11 O
the O
present O
codon O
, O
we O
have O
. O
of O
involving O
study O
50 O
In O
in O
mutations O
37 O
pancreatic B
tumors I
observed O

In O
the O
present O
study O
, O
we O
have O
observed O
mutations O
involving O
codon O
50 O
in O
11 O
of O
37 O
pancreatic B
tumors I
. O

The O
frequency O
of O
roughly O
the O
same O
in O
pancreatic B
tumors I
as O
in O
the O
other O
types O
of O
tumors B
previously O
examined O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic B
tumors I
in O
types O
of O
tumors B
previously O
examined O
. O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic B
tumors I
as O
in O
the O
other O
types O
antecedently O
study O
study O
inward O
inward O
inward O
of O
tumors B
previously O
examined O
. O

The O
frequency O
of O
codon O
fifty O
variation O
is O
roughly O
the O
same O
in O
pancreatic B
tumour I
as O
in O
the O
other O
eccentric O
of O
tumour B
antecedently O
prove O
. O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic B
tumors I
as O
in O
the O
other O
types O
antecedently O
study O
study O
inward O
inward O
inward O
of O
tumors B
previously O
examined O
. O

The O
frequency O
of O
codon O
fifty O
sport O
is O
around O
the O
same O
in O
pancreatic B
tumors I
as O
in O
the O
other O
types O
of O
tumors B
antecedently O
probe O
. O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
pancreatic B
tumors I
in O
the O
other O
types O
of O
tumors B
previously O

in O
frequency O
of O
of O
50 O
mutation O
is O
the O
roughly O
same O
tumors O
pancreatic B
as I
tumors O
. O
the O
other O
types O
codon O
The B
previously O
examined O
in O

The O
frequency O
of O
codon O
fifty O
sport O
is O
roughly O
the O
same O
in O
pancreatic B
neoplasm I
as O
in O
the O
other O
case O
of O
neoplasm B
antecedently O
analyse O
. O

in O
frequency O
the O
is O
50 O
mutation O
the O
roughly O
of O
same O
in O
pancreatic B
previously I
as O
codon O
The O
other O
types O
of O
tumors B
tumors O
examined O
. O

The O
frequency O
of O
codon O
50 O
mutation O
is O
roughly O
the O
same O
in O
pancreatic B
tumors I
as O
in O
the O
other O
types O
of O
tumors B
previously O
examined O
. O

In O
improver O
, O
we O
have O
find O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
neoplasm I
. O

In O
addition O
, O
we O
have O
detected O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
 B
 O
 B
 O
 B
 O
tumors I
. O

In O
addition O
, O
we O
have O
detected O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
 B
 O
 B
 O
 B
 O
tumors I
. O

, O
detected O
mutations O
at O
51 O
in O
PCR O
subclones O
in O
two O
other O
pancreatic B
tumors I
. O

In O
addition O
, O
we O
have O
at O
codon O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
tumors I
. O

, O
we O
have O
detected O
at O
codon O
51 O
in O
multiple O
subclones O
in O
two O
other O
tumors I
. O

pancreatic O
addition O
, O
tumors O
have O
detected O
mutations O
codon O
at O
51 O
in O
multiple O
PCR O
. O
In O
two O
other O
in B
we I
subclones O

In O
addition O
, O
we O
have O
detected O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
 B
 O
 B
 O
 B
early O
tumors I
. O

in O
gain O
, O
we O
have O
find O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
ii O
other O
pancreatic B
tumour I
. O

other O
addition O
, O
we O
have O
detected O
subclones O
multiple O
codon O
51 O
in O
in O
In O
mutations O
at O
pancreatic O
PCR O
two B
tumors I
. O

In O
addition O
, O
we O
have O
detected O
mutations O
at O
codon O
51 O
in O
multiple O
PCR O
subclones O
in O
two O
other O
pancreatic B
tumors I
. O

Mutations O
in O
the O
ARP O
factor O
are O
hence O
usually O
respect O
in O
pancreatic B
cancer I
, O
as O
easily O
as O
many O
other O
cancers B
. O

Mutations O
in O
the O
ARP O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic B
cancer I
, O
as O
well O
as O
many O
other O
note O
note O
note O
note O
note O
note O
cancers B
. O

Mutations O
in O
the O
ARP O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic B
cancer I
, O
as O
well O
as O
many O
other O
note O
note O
note O
note O
note O
note O
cancers B
. O

the O
are O
thus O
commonly O
in O
pancreatic B
, O
as O
well O
as O
many O
other O
cancers B
. O

Mutations O
in O
the O
ARP O
gene O
commonly O
observed O
pancreatic B
cancer I
, O
as O
well O
as O
many O
other O
cancers B
. O

the O
ARP O
gene O
are O
commonly O
observed O
in O
pancreatic B
cancer I
as O
well O
as O
many O
cancers B
. O

other O
in O
the O
cancers O
gene O
are O
thus O
observed O
commonly O
in O
well B
cancer I
, O
. O
Mutations O
as O
many O
pancreatic O
ARP B
as O

Mutations O
in O
the O
ARP O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic B
cancer I
, O
as O
well O
as O
many O
other O
note O
note O
note O
note O
note O
inward O
cancers B
. O

mutation O
in O
the O
ARP O
cistron O
are O
thus O
unremarkably O
note O
in O
pancreatic B
crab I
, O
as O
easily O
as O
many O
other O
cancers B
. O

many O
in O
the O
ARP O
gene O
are O
as O
cancer O
observed O
in O
pancreatic B
well I
Mutations O
thus O
commonly O
other O
, O
as O
cancers B
. O

Mutations O
in O
the O
ARP O
gene O
are O
thus O
commonly O
observed O
in O
pancreatic B
cancer I
, O
as O
well O
as O
many O
other O
cancers B
. O

difficulty O
in O
the O
ascertainment O
of O
C9 B
insufficiency I
: O
lessons O
to O
be O
imbibe O
from O
a O
compound O
heterozygote O
C9 B
- I
inferior I
discipline O
. O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 B
- I
matter I
object O
lesson I
object O
lesson I
object O
lesson I
object O
lesson O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 B
- I
matter I
object O
lesson I
object O
lesson I
object O
lesson I
object O
lesson O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
to O
be O
from O
a O
compound O
heterozygote O
C9 B
- I
deficient I

compound O
in O
lessons O
deficiency O
of O
C9 B
heterozygote I
: O
the O
to O
be O
drawn O
. O
a O
ascertainment O
Difficulties O
C9 B
- I
deficient I
subject O
from O

trouble O
in O
the O
ascertainment O
of O
C9 B
insufficiency I
: O
example O
to O
be O
delineate O
from O
a O
intensify O
heterozygote O
C9 B
- I
insufficient I
subject O
. O

. O
in O
the O
be O
of O
C9 B
deficiency I
deficient O
compound O
to O
ascertainment O
drawn O
a O
from O
lessons O
heterozygote O
C9 B
- I
: I
Difficulties O
subject O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 B
- I
matter I
object O
lesson I
object O
lesson I
object O
lesson I
object O
lesson O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
compound O
- I
deficient I
subject O
. O

difficultness O
in O
the O
ascertainment O
of O
C9 B
want I
: O
lessons O
to O
be O
drawn O
from O
a O
combine O
heterozygote O
C9 B
- I
inferior I
open O
. O

Difficulties O
in O
the O
ascertainment O
of O
C9 B
deficiency I
: O
lessons O
to O
be O
drawn O
from O
a O
compound O
heterozygote O
C9 B
- I
deficient I
subject O
. O

A O
group O
of O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
for O
complement O
function O
using O
haemolytic O
assays O
in O
agarose O
gels O

A O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
complement O
haemolytic O
assays O
in O
agarose O
gels O
. O

A O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
for O
complement O
function O
using O
haemolytic O
inward O
colloidal O
gel O
colloidal O
gel O
uneven O
uneven O
uneven O
assays O
in O
agarose O

A O
radical O
of O
patients O
with O
retentive O
- O
surviving O
mismatched O
kidney O
homograft O
were O
investigated O
for O
complement O
officiate O
expend O
hemolytic O
assays O
in O
agarose O
gels O
. O

A O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
for O
complement O
function O
using O
haemolytic O
inward O
colloidal O
gel O
colloidal O
gel O
uneven O
uneven O
uneven O
assays O
in O
agarose O

adenine O
group O
of O
patients O
with O
long O
- O
living O
mismatched O
kidney O
allografts O
were O
inquire O
for O
complement O
use O
using O
haemolytic O
seek O
in O
agarose O
gelatin O
. O

A O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
were O
investigated O
complement O
function O
using O
haemolytic O
assays O
in O
agarose O

allografts O
group O
of O
assays O
with O
long O
- O
mismatched O
surviving O
kidney O
in O
were O
for O
investigated O
. O
function O
using O
haemolytic O
patients O
A O
agarose O
gels O
complement O

A O
group O
of O
patients O
with O
retentive O
- O
surviving O
uneven O
kidney O
allografts O
were O
investigated O
for O
accompaniment O
function O
utilise O
hemolytic O
essay O
in O
agarose O
gels O
. O

complement O
group O
mismatched O
- O
with O
long O
function O
surviving O
of O
kidney O
allografts O
were O
agarose O
for O
patients O
A O
using O
haemolytic O
assays O
in O
investigated O
gels O
. O

A O
group O
of O
patients O
with O
long O
- O
surviving O
mismatched O
kidney O
allografts O
were O
investigated O
for O
complement O
function O
using O
haemolytic O
assays O
in O
agarose O
gels O
. O

but O
patient O
was O
alternative O
to O
have O
no O
found O
classical O
activity O
normal O
a O
One O
low O
pathway O
pathway O
. O

ane O
patient O
was O
launch O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
abject O
convention O
hellenic O
pathway O
. O

matchless O
patient O
was O
feel O
to O
have O
no O
alternative O
pathway O
action O
but O
a O
low O
rule O
hellenic O
pathway O
. O

One O
patient O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
. O

One O
patient O
was O
plant O
to O
have O
no O
alternate O
pathway O
activity O
but O
a O
low O
convention O
classical O
pathway O
. O

One O
patient O
alternate O
be O
was O
found O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
substitute O
substitute O
nobelium O
. O

One O
patient O
was O
found O
to O
have O
no O
alternative O
activity O
but O
low O
normal O
classical O
pathway O
. O

One O
patient O
alternate O
be O
was O
found O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
substitute O
substitute O
nobelium O
. O

patient O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O

One O
patient O
pathway O
classical O
to O
have O
low O
alternative O
was O
activity O
but O
a O
no O
normal O
found O
pathway O
. O

One O
patient O
was O
found O
to O
have O
no O
alternative O
pathway O
activity O
but O
a O
low O
normal O
classical O
pathway O
. O

astonishingly O
, O
probe O
revealed O
that O
the O
patients O
complement O
was O
pattern O
for O
all O
components O
except O
C9 O
, O
which O
was O
functionally O
remove O
. O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
C9 O
, O
which O
was O
remove O
investigating O
investigating O
investigating O
investigating O
investigating O
functionally O
absent O
. O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
C9 O
, O
which O
was O
remove O
investigating O
investigating O
investigating O
investigating O
investigating O
functionally O
absent O
. O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
normal O
for O
components O
except O
C9 O
, O
which O
was O
functionally O

C9 O
, O
was O
patients O
that O
the O
, O
complement O
investigation O
normal O
for O
all O
. O
except O
revealed O
Surprisingly O
which O
was O
functionally O
absent O
components O

surprisingly O
, O
investigating O
divulge O
that O
the O
patients O
complement O
was O
rule O
for O
all O
part O
except O
C9 O
, O
which O
was O
functionally O
scatty O
. O

. O
, O
investigation O
for O
that O
the O
patients O
functionally O
C9 O
normal O
revealed O
all O
except O
components O
was O
, O
which O
was O
complement O
Surprisingly O
absent O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
C9 O
, O
which O
was O
remove O
investigating O
investigating O
investigating O
investigating O
pattern O
functionally O
absent O
. O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
C9 O
was O
functionally O
absent O
. O

surprisingly O
, O
probe O
unveil O
that O
the O
patients O
complement O
was O
formula O
for O
all O
components O
demur O
C9 O
, O
which O
was O
functionally O
remove O
. O

Surprisingly O
, O
investigation O
revealed O
that O
the O
patients O
complement O
was O
normal O
for O
all O
components O
except O
C9 O
, O
which O
was O
functionally O
absent O
. O

The O
patient O
two O
shown O
to O
be O
the O
of O
DNA O
markers O
in O
a O
chromosome O
, O
C7 O
compound O
C9 O
region O
uncharacterized O
C6 O
5 O
C9 O
therefore O
appears O
to O
and O
heterozygous O
and O
heterozygote O
for O
was O
for O
be B
deficiency I
genes O
. O

patient O
shown O
to O
be O
heterozygous O
for O
DNA O
markers O
in O
C6 O
, O
C7 O
and O
C9 O
region O
of O
and O
therefore O
appears O
be O
compound O
heterozygote O
for O
C9 B

The O
patient O
was O
register O
to O
be O
heterozygous O
for O
DNA O
marking O
in O
the O
C6 O
, O
C7 O
and O
C9 O
part O
of O
chromosome O
fivesome O
and O
thence O
appears O
to O
be O
a O
combine O
heterozygote O
for O
deuce O
uncharacterized O
C9 B
inadequacy I
cistron O
. O

compound O
5 O
was O
shown O
C9 O
be O
C7 O
uncharacterized O
DNA O
markers O
in O
the O
C6 O
to O
for O
and O
to O
two O
of O
chromosome O
, O
and O
therefore O
appears O
patient O
be O
a O
The O
region O
for O
heterozygote O
heterozygous O
C9 B
deficiency I
genes O
. O

The O
patient O
was O
shown O
 O
to O
be O
heterozygous O
for O
DNA O
markers O
in O
the O
C6 O
, O
C7 O
and O
C9 O
region O
of O
chromosome O
5 O
and O
therefore O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
C9 B
deficiency I
genes O
 O
 O
 O
 O
 O
 O
 O
 O
 O
. O

to O
of O
was O
shown O
to O
be O
heterozygous O
for O
DNA O
markers O
in O
the O
C6 O
compound O
for O
and O
C9 O
region O
deficiency O
chromosome O
5 O
and O
heterozygote O
appears O
The O
be O
uncharacterized O
, O
C7 O
therefore O
two O
. O
C9 B
genes I
patient O
a O

The O
patient O
was O
shown O
be O
DNA O
markers O
in O
the O
C6 O
, O
C7 O
and O
C9 O
and O
therefore O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
C9 B
deficiency I
genes O
. O

The O
patient O
was O
prove O
to O
be O
heterozygous O
for O
DNA O
marking O
in O
the O
C6 O
, O
C7 O
and O
C9 O
neighborhood O
of O
chromosome O
5 O
and O
thence O
appears O
to O
be O
a O
colonial O
heterozygote O
for O
two O
uncharacterized O
C9 B
lack I
cistron O
. O

The O
patient O
was O
shown O
dna O
to O
be O
heterozygous O
for O
DNA O
markers O
in O
the O
C6 O
, O
C7 O
and O
C9 O
region O
of O
chromosome O
5 O
and O
therefore O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
C9 B
deficiency I
genes O
desoxyribonucleic O
acid O
desoxyribonucleic O
acid O
desoxyribonucleic O
acid O
desoxyribonucleic O
acid O
desoxyribonucleic O
acid O

The O
patient O
was O
present O
to O
be O
heterozygous O
for O
dna O
marking O
in O
the O
C6 O
, O
C7 O
and O
C9 O
realm O
of O
chromosome O
cinque O
and O
hence O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
C9 B
want I
genes O
. O

The O
patient O
was O
shown O
to O
be O
heterozygous O
for O
DNA O
markers O
in O
the O
C6 O
, O
C7 O
and O
C9 O
region O
of O
chromosome O
5 O
and O
therefore O
appears O
to O
be O
a O
compound O
heterozygote O
for O
two O
uncharacterized O
C9 B
deficiency I
genes O
. O

of O
analysis O
by O
has O
revealed O
that O
he O
ELISA O
functional O
concentrations O
- O
a O
Serological O
non O
trace O
C9 O
molecule O
. O

serological O
analysis O
by O
elisa O
revealed O
that O
he O
has O
shadow O
concentrations O
of O
a O
not O
- O
functional O
C9 O
speck O
. O

Serological O
analysis O
by O
ELISA O
revealed O
that O
he O
has O
line O
density O
of O
a O
not O
- O
running O
C9 O
particle O
. O

Serological O
analysis O
by O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
C9 O
molecule O
. O

Serological O
analysis O
by O
ELISA O
expose O
that O
he O
has O
touch O
concentrations O
of O
a O
not O
- O
usable O
C9 O
atom O
. O

Serological O
analysis O
aside O
by O
ELISA O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
C9 O
molecule O
apart O
apart O
apart O
give O
birth O

Serological O
analysis O
by O
ELISA O
revealed O
that O
he O
has O
trace O
concentrations O
a O
non O
functional O
C9 O
molecule O
. O

Serological O
analysis O
aside O
by O
ELISA O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
C9 O
molecule O
apart O
apart O
apart O
give O
birth O

analysis O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
. O

Serological O
analysis O
trace O
functional O
revealed O
that O
non O
has O
by O
concentrations O
of O
a O
he O
- O
ELISA O
C9 O
molecule O
. O

Serological O
analysis O
by O
ELISA O
revealed O
that O
he O
has O
trace O
concentrations O
of O
a O
non O
- O
functional O
C9 O
molecule O
. O

Western O
analysis O
not O
sensitive O
to O
permit O
detection O
of O
this O
molecule O
. O

Western O
slur O
analysis O
was O
not O
sufficiently O
sensible O
to O
tolerate O
detection O
of O
this O
atom O
. O

to O
was O
analysis O
blot O
not O
sufficiently O
detection O
Western O
permit O
. O
of O
this O
molecule O
sensitive O

Western O
blot O
analysis O
was O
not O
sufficiently O
sensitive O
to O
detection O
of O
molecule O
. O

Western O
blot O
depth O
psychology O
depth O
psychology O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
mote O
non O
detection O
of O
this O

Western O
blot O
depth O
psychology O
depth O
psychology O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
mote O
be O
detection O
of O
this O

Western O
smear O
analysis O
was O
not O
sufficiently O
sore O
to O
permit O
sensing O
of O
this O
atom O
. O

molecule O
blot O
analysis O
Western O
to O
sufficiently O
sensitive O
this O
permit O
detection O
of O
not O
was O
. O

Western O
blot O
depth O
psychology O
depth O
psychology O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
mote O
non O
detection O
of O
this O

westerly O
smirch O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
catching O
of O
this O
mote O
. O

Western O
blot O
analysis O
was O
not O
sufficiently O
sensitive O
to O
permit O
detection O
of O
this O
molecule O
. O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
directing O
faulty O
antiophthalmic O
factor O
faulty O
faulty O
antiophthalmic O
factor O
antiophthalmic O
factor O
lead O
hyposynthesis O
of O
a O

that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
hyposynthesis O
a O
defective O
C9 O
. O

We O
theorise O
that O
the O
patient O
is O
heterozygous O
for O
a O
over B
insufficiency I
of I
C9 I
and O
for O
a O
factor O
organise O
hyposynthesis O
of O
a O
bad O
C9 O
. O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
a O
complete B
of I
C9 I
and O
for O
a O
gene O
directing O
a O
defective O
C9 O
. O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
directing O
faulty O
antiophthalmic O
factor O
faulty O
faulty O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
hyposynthesis O
of O

We O
hypothecate O
that O
the O
patient O
is O
heterozygous O
for O
a O
perfect B
insufficiency I
of I
C9 I
and O
for O
a O
cistron O
guide O
hyposynthesis O
of O
a O
faulty O
C9 O
. O

We O
hypothesise O
that O
the O
patient O
is O
heterozygous O
for O
a O
gross B
insufficiency I
of I
C9 I
and O
for O
a O
cistron O
lead O
hyposynthesis O
of O
a O
faulty O
C9 O
. O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
deficiency I
and O
for O
a O
gene O
directing O
hyposynthesis O
of O
a O
defective O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
directing O
faulty O
antiophthalmic O
factor O
faulty O
faulty O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
hyposynthesis O
of O

directing O
hypothesize O
that O
deficiency O
patient O
is O
heterozygous O
hyposynthesis O
. O
complete B
the I
of I
C9 I
and O
C9 O
a O
gene O
a O
for O
We O
of O
defective O
for O
a O

We O
hypothesize O
that O
the O
patient O
is O
heterozygous O
for O
a O
complete B
deficiency I
of I
C9 I
and O
for O
a O
gene O
directing O
hyposynthesis O
of O
a O
defective O
C9 O
. O

among O
also O
suggest O
be O
C9 B
deficiency I
may O
that O
been O
common O
has O
Caucasians O
We O
than O
more O
reported O
. O
. O

We O
also O
advise O
that O
C9 B
want I
whitethorn O
be O
more O
usual O
among O
Caucasians O
than O
has O
been O
account O
. O
. O

We O
likewise O
suggest O
that O
C9 B
inadequacy I
may O
be O
more O
vernacular O
among O
white O
than O
has O
been O
cover O
. O
. O

We O
also O
suggest O
deficiency I
may O
be O
more O
common O
among O
Caucasians O
than O
has O
been O
reported O
. O
. O

We O
also O
evoke O
that O
C9 B
lack I
may O
be O
more O
mutual O
among O
caucasian O
than O
has O
been O
account O
. O
. O

We O
also O
advise O
suggest O
that O
C9 B
deficiency I
may O
be O
more O
common O
among O
Caucasians O
than O
has O
been O
reported O
. O
rede O
rede O
rede O
follow O
. O

We O
also O
suggest O
that O
C9 B
deficiency I
may O
be O
more O
common O
Caucasians O
than O
been O
reported O
. O
. O

We O
also O
advise O
suggest O
that O
C9 B
deficiency I
may O
be O
more O
common O
among O
Caucasians O
than O
has O
been O
reported O
. O
rede O
rede O
rede O
follow O
. O

also O
C9 B
deficiency I
may O
be O
more O
common O
among O
Caucasians O
than O
. O

We O
also O
more O
been O
C9 B
deficiency I
than O
be O
suggest O
common O
among O
Caucasians O
may O
has O
that O
reported O
. O
. O

We O
also O
suggest O
that O
C9 B
deficiency I
may O
be O
more O
common O
among O
Caucasians O
than O
has O
been O
reported O
. O
. O

riddle O
for O
ESR O
sport O
in O
titty B
and I
ovarian I
cancer I
patients O
. O

Screening O
for O
ESR O
mutations O
in O
breast B
and I
ovarian I
cancer I
inward O
inward O
inward O
patients O
. O

sieve O
for O
ESR O
sport O
in O
tit B
and I
ovarian I
cancer I
patients O
. O

Screening O
for O
esr O
mutations O
in O
boob B
and I
ovarian I
crab I
patients O
. O

for O
ESR O
in O
breast B
and I
ovarian I
cancer I
patients O
. O

ovarian O
for O
ESR O
in O
mutations O
breast B
patients I
Screening I
cancer I
and O
. O

Screening O
ovarian O
ESR O
mutations O
for O
breast B
and I
. I
cancer I
patients O
in O

mutations O
ovarian O
ESR O
and O
in O
breast B
Screening I
for I
cancer I
patients O
. O

Screening O
ESR O
in O
and I
ovarian I
cancer I
patients O
. O

Screening O
for O
ESR O
mutations O
in O
breast B
and I
ovarian I
cancer I
inward O
inward O
inward O
patients O
. O

Screening O
for O
ESR O
mutations O
in O
breast B
and I
ovarian I
cancer I
patients O
. O

In O
the O
demonstrate O
contemplate O
, O
leukocyte O
dna O
from O
143 O
patients O
with O
hereditary O
clustering O
of O
knocker B
and I
/ I
or I
ovarian I
crab I
and O
tumor B
dna O
from O
xcvi O
knocker B
carcinomas I
were O
screened O
for O
stem O
mutant O
in O
the O
estrogen O
receptor O
factor O
( O
ESR O
) O
. O

indium O
the O
acquaint O
cogitation O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
transmitted O
clustering O
of O
tit B
and I
/ I
or I
ovarian I
cancer I
and O
tumor B
DNA O
from O
96 O
tit B
carcinomas I
were O
screened O
for O
cornerstone O
mutations O
indium O
the O
estrogen O
receptor O
factor O
( O
ESR O
) O
. O

In O
, O
DNA O
from O
143 O
with O
familial O
clustering O
breast B
and I
/ I
or I
ovarian I
tumour B
DNA O
from O
96 O
breast B
carcinomas I
were O
screened O
mutations O
the O
estrogen O
receptor O
( O
ESR O
) O
. O

In O
the O
mutations O
study O
, O
screened O
breast O
from O
143 O
patients O
with O
from O
were O
of O
breast B
base I
/ I
or I
cancer I
ovarian I
and O
tumour B
DNA O
receptor O
96 O
carcinomas B
clustering I
in O
leukocyte O
for O
and O
( O
DNA O
the O
estrogen O
familial O
gene O
present O
ESR O
) O
. O

96 O
ovarian O
present O
study O
, O
leukocyte O
familial O
tumour O
143 O
patients O
with O
DNA O
clustering O
were O
for B
and I
/ I
or I
. I
cancer I
and O
from B
screened O
from O
In O
breast B
mutations I
of O
breast O
DNA O
base O
receptor O
in O
the O
estrogen O
carcinomas O
gene O
( O
ESR O
) O
the O

In O
the O
present O
study O
DNA O
from O
143 O
patients O
familial O
clustering O
of O
breast B
and I
or I
ovarian I
cancer I
and O
DNA O
from O
breast B
carcinomas I
were O
screened O
for O
base O
mutations O
in O
estrogen O
receptor O
( O
ESR O
) O
. O

In O
the O
present O
study O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
tumour B
DNA O
from O
96 O
breast B
carcinomas I
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
mutation O
sedimentation O
rate O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
gene O
( O
ESR O
) O

In O
the O
present O
study O
from O
143 O
patients O
with O
familial O
of O
breast B
ovarian I
tumour B
DNA O
breast B
screened O
for O
base O
mutations O
the O
estrogen O
( O
ESR O
. O

inch O
the O
salute O
study O
, O
leucocyte O
DNA O
from O
143 O
patients O
with O
transmitted O
clustering O
of O
front B
and I
/ I
or I
ovarian I
cancer I
and O
tumor B
DNA O
from O
96 O
front B
carcinomas I
were O
riddle O
for O
substructure O
mutations O
inch O
the O
estrogen O
receptor O
cistron O
( O
ESR O
) O
. O

In O
the O
present O
study O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
tumour B
DNA O
from O
96 O
breast B
carcinomas I
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
mutation O
sedimentation O
rate O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
mutation O
gene O
( O
ESR O
) O

In O
the O
present O
study O
, O
leukocyte O
DNA O
from O
143 O
patients O
with O
familial O
clustering O
of O
breast B
and I
/ I
or I
ovarian I
cancer I
and O
tumour B
DNA O
from O
96 O
breast B
carcinomas I
were O
screened O
for O
base O
mutations O
in O
the O
estrogen O
receptor O
gene O
( O
ESR O
) O
. O

Three O
family O
with O
a O
patients O
history O
cancer O
a B
were O
carrying O
germline O
Gly160Cys O
of O
substitution O
. O

Three O
patients O
follow O
genus O
cancer O
be O
with O
a O
family O
history O
of B
cancer O
were O
patient O
carrying O
a O
Gly160Cys O
germline O
substitution O

trine O
patients O
with O
a O
family O
account O
of O
cancer B
were O
acquit O
a O
Gly160Cys O
germline O
commutation O
. O

germline O
patients O
with O
Three O
cancer O
history O
of O
Gly160Cys B
were O
carrying O
a O
family O
a O
substitution O
. O

ternion O
patients O
with O
a O
kin O
history O
of O
cancer B
were O
pack O
a O
Gly160Cys O
germline O
commutation O
. O

Three O
patients O
follow O
genus O
cancer O
be O
with O
a O
family O
history O
of B
cancer O
were O
phratry O
carrying O
a O
Gly160Cys O
germline O
substitution O

Three O
with O
family O
of O
cancer B
were O
carrying O
a O
Gly160Cys O
germline O
substitution O
. O

cancer O
a O
with O
patients O
family O
history O
carrying O
Three B
were O
of O
a O
Gly160Cys O
germline O
. O
substitution O

Three O
patients O
with O
a O
family O
chronicle O
of O
crab B
were O
express O
a O
Gly160Cys O
germline O
replacement O
. O

Three O
patients O
follow O
genus O
cancer O
be O
with O
a O
family O
history O
of B
cancer O
were O
phratry O
carrying O
a O
Gly160Cys O
germline O
substitution O

Three O
patients O
with O
a O
family O
history O
of O
cancer B
were O
carrying O
a O
Gly160Cys O
germline O
substitution O
. O

This O
alteration O
indicating O
also O
detected O
four O
eight O
363 O
four O
females O
and O
) O
the O
) O
of O
represents O
controls O
( O
female O
366 O
, O
( O
males O
in O
, O
that O
was O
polymorphism O
substitution O
probably O
729 O
males O
a O
. O

This O
also O
detected O
in O
eight O
four O
females O
males O
) O
729 O
controls O
, O
males O
) O
, O
that O
the O
substitution O
represents O
a O
polymorphism O
. O

This O
alteration O
was O
also O
inward O
 O
permutation O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
controls O
( O
366 O
female O
, O
363 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
polymorphism O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
observe O
. O

This O
alteration O
was O
also O
inward O
 O
observe O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
controls O
( O
366 O
female O
, O
363 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
polymorphism O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
observe O
. O

alteration O
366 O
was O
also O
detected O
in O
that O
( O
four O
females O
and O
the O
males O
, O
probably O
729 O
controls O
( O
four O
female O
, O
363 O
. O
) O
) O
indicating O
eight O
This O
a O
males O
represents O
substitution O
polymorphism O
of O

This O
alteration O
was O
also O
detected O
in O
four O
females O
and O
four O
) O
of O
729 O
controls O
( O
female O
, O
363 O
males O
, O
indicating O
the O
substitution O
probably O
represents O
a O
polymorphism O
. O

This O
revision O
was O
too O
observe O
in O
eight O
( O
quartet O
females O
and O
quartet O
males O
) O
of O
729 O
controls O
( O
366 O
distaff O
, O
363 O
males O
) O
, O
show O
that O
the O
commutation O
plausibly O
be O
a O
pleomorphism O
. O

This O
modification O
was O
also O
notice O
in O
ogdoad O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
ascertain O
( O
366 O
female O
, O
363 O
males O
) O
, O
show O
that O
the O
switch O
belike O
typify O
a O
pleomorphism O
. O

This O
alteration O
was O
also O
inward O
 O
observe O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
controls O
( O
366 O
female O
, O
363 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
polymorphism O
inwards O
inwards O
inwards O
inwards O
inwards O
inwards O
observe O
. O

This O
revision O
was O
besides O
notice O
in O
octad O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
contain O
( O
366 O
female O
, O
363 O
males O
) O
, O
point O
that O
the O
switch O
likely O
act O
a O
pleomorphism O
. O

This O
alteration O
was O
also O
detected O
in O
eight O
( O
four O
females O
and O
four O
males O
) O
of O
729 O
controls O
( O
366 O
female O
, O
363 O
males O
) O
, O
indicating O
that O
the O
substitution O
probably O
represents O
a O
polymorphism O
. O

However O
, O
in O
the O
genus O
cancer O
be O
get O
it O
on O
ascertain O
 O
229 O
female O
controls O
in O
whom O
family B
history O
of O
cancer O
was O
known O
, O
one O
of O
two O
who O
had O
a B
sister I
with O
breast O
cancer O
was O
carrying O
the O
variant O
allele O
determine O
determine O

However O
, O
229 O
family O
history O
of O
was O
known O
one O
of O
two O
a O
sister O
with O
breast B
cancer I
carrying O
variant O
allele O
. O

however O
, O
in O
the O
229 O
female O
check O
in O
whom O
kinsfolk O
history O
of O
cancer B
was O
known O
, O
unitary O
of O
deuce O
who O
had O
a O
baby O
with O
tit B
cancer I
was O
sway O
the O
variant O
allelomorph O
. O

However O
, O
in O
the O
female O
whom O
family O
history O
of O
cancer B
was O
known O
, O
one O
a O
sister O
with O
breast B
cancer I
was O
carrying O
the O
variant O
allele O
. O

still O
, O
in O
the O
229 O
female O
assure O
in O
whom O
sept O
chronicle O
of O
cancer B
was O
cognize O
, O
peerless O
of O
ii O
who O
had O
a O
sister O
with O
summit B
cancer I
was O
persuade O
the O
variant O
allele O
. O

However O
, O
in O
the O
genus O
cancer O
be O
get O
it O
on O
ascertain O
 O
229 O
female O
controls O
in O
whom O
family B
history O
of O
cancer O
was O
known O
, O
one O
of O
two O
who O
had O
a B
sister I
with O
breast O
cancer O
was O
carrying O
the O
variant O
allele O
determine O
determine O

However O
, O
in O
the O
229 O
female O
ascendency O
in O
whom O
mob O
chronicle O
of O
cancer B
was O
screw O
, O
unmatched O
of O
deuce O
who O
had O
a O
sister O
with O
knocker B
cancer I
was O
sway O
the O
variance O
allele O
. O

had O
two O
in O
the O
229 O
female O
controls O
in O
whom O
family O
history O
of O
cancer B
breast O
variant O
, O
one O
of O
carrying O
who O
, O
a O
. O
with O
was B
cancer I
was O
However O
known O
sister O
allele O
the O

However O
, O
in O
the O
female O
in O
whom O
family O
history O
of O
cancer B
was O
known O
one O
of O
two O
who O
had O
a O
sister O
cancer I
was O
carrying O
variant O
. O

However O
, O
in O
the O
genus O
cancer O
be O
get O
it O
on O
ascertain O
phratry O
229 O
female O
controls O
in O
whom O
family B
history O
of O
cancer O
was O
known O
, O
one O
of O
two O
who O
had O
a B
sister I
with O
breast O
cancer O
was O
carrying O
the O
variant O
allele O
determine O
determine O

However O
, O
in O
the O
229 O
female O
controls O
in O
whom O
family O
history O
of O
cancer B
was O
known O
, O
one O
of O
two O
who O
had O
a O
sister O
with O
breast B
cancer I
was O
carrying O
the O
variant O
allele O
. O

investigated O
, O
a O
cysteine O
clinical O
significance O
of O
be O
ruled O
into O
possible O
cannot O
completely O
be O
glycine O
out O
and O
should O
the O
Hence O
further O
. O

Hence O
, O
a O
possible O
clinical O
significance O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
look O
into O
look O
into O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

Hence O
, O
a O
possible O
clinical O
significance O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
look O
into O
look O
into O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

thence O
, O
a O
potential O
clinical O
implication O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
altogether O
decree O
out O
and O
should O
be O
further O
inquire O
. O

Hence O
, O
a O
clinical O
significance O
of O
the O
glycine O
cysteine O
cannot O
be O
completely O
out O
and O
be O
further O
investigated O
. O

possible O
of O
the O
glycine O
cysteine O
cannot O
completely O
ruled O
out O
and O
should O
be O
further O
investigated O
. O

hence O
, O
a O
potential O
clinical O
signification O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
wholly O
predominate O
out O
and O
should O
be O
further O
enquire O
. O

ruled O
, O
glycine O
of O
clinical O
significance O
out O
the O
a O
into O
cysteine O
cannot O
investigated O
completely O
possible O
Hence O
and O
should O
be O
further O
be O
. O

Hence O
, O
a O
possible O
clinical O
significance O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
look O
into O
look O
into O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

Hence O
, O
a O
possible O
of O
the O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
be O
. O

Hence O
, O
a O
possible O
clinical O
significance O
of O
the O
glycine O
into O
cysteine O
cannot O
be O
completely O
ruled O
out O
and O
should O
be O
further O
investigated O
. O

Somatic O
detected O
any O
of O
the O
studied O
, O
and O
present O
data O
do O
not O
provide O
somatic O
ESR O
base O
mutations O
as O
an O
important O
mechanism O
therapy O
in O
estrogen B
receptor I
positive I
breast I
carcinomas I
. O
. O

Somatic O
mutations O
were O
not O
detected O
the O
tumours B
studied O
, O
and O
present O
data O
support O
ESR O
base O
an O
for O
hormonal O
therapy O
resistance O
estrogen B
receptor I
breast I
carcinomas I
. O

Somatic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
tumours B
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
somatic O
ESR O
base O
mutations O
as O
an O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen B
receptor I
positive I
degree I
bosom I
carcinoma I
observe I
observe I
observe I
observe I
observe I
observe I
observe I
observe I
observe I
- I
positive I
breast I
carcinomas O
. O

corporal O
sport O
were O
not O
notice O
in O
any O
of O
the O
tumours B
studied O
, O
and O
the O
stage O
datum O
do O
not O
furnish O
support O
for O
corporal O
ESR O
base O
sport O
as O
an O
significant O
mechanism O
for O
hormonal O
therapy O
opposition O
in O
estrogen B
receptor I
- I
positivistic I
chest I
carcinomas I
. O
. O

Somatic O
mutations O
hormonal O
not O
detected O
receptor O
any O
provide O
the O
tumours B
studied O
an O
support O
the O
present O
of O
do O
not O
positive O
and O
for O
resistance O
ESR O
in O
mutations O
data O
, O
somatic O
mechanism O
for O
were O
important O
therapy O
in O
estrogen B
base I
- I
as I
breast I
carcinomas I
. O
. O

bodily O
mutations O
were O
not O
observe O
in O
any O
of O
the O
tumours B
take O
, O
and O
the O
present O
datum O
do O
not O
cater O
support O
for O
bodily O
ESR O
base O
mutations O
as O
an O
significant O
mechanics O
for O
hormonal O
therapy O
resistivity O
in O
estrogen B
receptor I
- I
prescribed I
breast I
carcinomas I
. O
. O

estrogen O
provide O
were O
not O
detected O
in O
. O
of O
the O
tumours B
studied O
. O
and O
mutations O
for O
data O
do O
not O
important O
support O
for O
somatic O
receptor O
base O
the O
as O
in O
mutations O
therapy O
ESR O
hormonal O
mechanism O
resistance O
present O
Somatic B
an I
- I
positive I
breast I
carcinomas I
, O
any O

Somatic O
mutations O
were O
not O
detected O
in O
the O
tumours B
studied O
, O
the O
present O
data O
do O
not O
support O
for O
somatic O
ESR O
mutations O
as O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen B
- I
positive I
carcinomas I
. O
. O

breast O
mutations O
were O
not O
do O
in O
for O
therapy O
the O
tumours B
studied O
, O
and O
any O
positive O
data O
detected O
hormonal O
provide O
support O
the O
somatic O
ESR O
base O
important O
as O
an O
. O
not O
for O
mechanism O
mutations O
resistance O
in O
estrogen B
receptor I
- I
present I
Somatic I
carcinomas I
. O
of O

Somatic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
tumours B
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
somatic O
ESR O
base O
mutations O
as O
an O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen B
receptor I
positive I
degree I
bosom I
carcinoma I
observe I
observe I
observe I
observe I
observe I
observe I
observe I
observe I
corporal I
- I
positive I
breast I
carcinomas O
. O

Somatic O
mutations O
were O
not O
detected O
in O
any O
of O
the O
tumours B
studied O
, O
and O
the O
present O
data O
do O
not O
provide O
support O
for O
somatic O
ESR O
base O
mutations O
as O
an O
important O
mechanism O
for O
hormonal O
therapy O
resistance O
in O
estrogen B
receptor I
- I
positive I
breast I
carcinomas I
. O
. O

molecular O
bases O
of O
C7 B
deficiency I
: O
three O
dissimilar O
fault O
. O

Molecular O
bases O
of O
C7 B
deficiency I
: O
three O
different O
defects O
fundament O
fundament O
fundament O
. O

Molecular O
radix O
of O
C7 B
inadequacy I
: O
troika O
different O
defects O
. O

molecular O
found O
of O
C7 B
want I
: O
three O
different O
defects O
. O

Molecular O
of O
C7 B
: O
three O
different O
defects O
. O

different O
. O
of O
deficiency B
C7 I
: O
three O
Molecular O
defects O
bases O

Molecular O
different O
of O
C7 B
bases I
: O
deficiency O
three O
defects O
. O

different O
C7 O
of O
bases B
deficiency I
: O
. O
Molecular O
defects O
three O

Molecular O
C7 B
deficiency I
: O
different O

Molecular O
bases O
of O
C7 B
deficiency I
: O
three O
different O
defects O
fundament O
fundament O
fundament O
. O

Molecular O
bases O
of O
C7 B
deficiency I
: O
three O
different O
defects O
. O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
Irish O
families O
and O
a O
number O
of O
Israeli O
phratry O
judaic O
ancestry O
judaic O
ancestry O
ancestry O
groundwork O
families O
of O
Moroccan O
Sephardic O
Jewish O
origin O
. O

of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
Irish O
families O
and O
a O
number O
of O
Israeli O
of O
Sephardic O
Jewish O
origin O
. O

The O
molecular O
cornerstone O
of O
C7 B
insufficiency I
has O
been O
investigated O
in O
ii O
Irish O
household O
and O
a O
number O
of O
israeli O
household O
of O
Moroccan O
Sephardic O
judaic O
pedigree O
. O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
Irish O
families O
a O
number O
of O
Israeli O
families O
of O
Moroccan O
origin O
. O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
Irish O
families O
and O
a O
number O
of O
Israeli O
phratry O
judaic O
ancestry O
judaic O
ancestry O
ancestry O
groundwork O
families O
of O
Moroccan O
Sephardic O
Jewish O
origin O
. O

The O
molecular O
ground O
of O
C7 B
want I
has O
been O
investigated O
in O
deuce O
Irish O
kinsfolk O
and O
a O
number O
of O
israeli O
kinsfolk O
of O
Moroccan O
Sephardic O
judaic O
ancestry O
. O

The O
molecular O
cornerstone O
of O
C7 B
insufficiency I
has O
been O
investigated O
in O
two O
Irish O
household O
and O
a O
total O
of O
Israeli O
household O
of O
maroc O
Sephardic O
jewish O
rootage O
. O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
families O
number O
of O
Israeli O
families O
of O
Moroccan O
Sephardic O
Jewish O
origin O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
Irish O
families O
and O
a O
number O
of O
Israeli O
phratry O
judaic O
ancestry O
judaic O
ancestry O
ancestry O
groundwork O
families O
of O
Moroccan O
Sephardic O
Jewish O
origin O
. O

of O
molecular O
basis O
two O
C7 B
deficiency I
has O
families O
origin O
in O
of O
Irish O
and O
families O
Jewish O
number O
of O
Israeli O
been O
. O
Moroccan O
Sephardic O
a O
investigated O
The O

The O
molecular O
basis O
of O
C7 B
deficiency I
has O
been O
investigated O
in O
two O
Irish O
families O
and O
a O
number O
of O
Israeli O
families O
of O
Moroccan O
Sephardic O
Jewish O
origin O
. O

Exon O
PCR O
and O
point O
mutation O
at O
the O
3 O
splice O
acceptor O
site O
of O
intron O
1 O
in O
one O
Irish O
family O

Exon O
PCR O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
the O
3 O
splice O
site O
1 O
in O
one O
Irish O
family O
. O

Exon O
PCR O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
the O
3 O
splice O
acceptor O
site O
of O
intron O
1 O
irish O
whisky O
phratry O
phratry O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
in O

exon O
PCR O
and O
sequence O
disclose O
a O
heterozygous O
point O
mutation O
at O
the O
trio O
splicing O
acceptor O
site O
of O
intron O
1 O
in O
nonpareil O
Irish O
family O
. O

Exon O
PCR O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
the O
3 O
splice O
acceptor O
site O
of O
intron O
1 O
irish O
whisky O
phratry O
phratry O
chromosomal O
mutation O
chromosomal O
mutation O
chromosomal O
mutation O
in O

Exon O
PCR O
and O
sequencing O
unveil O
a O
heterozygous O
show O
mutation O
at O
the O
threesome O
splicing O
acceptor O
site O
of O
intron O
1 O
in O
unitary O
Irish O
kinsfolk O
. O

Exon O
PCR O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
3 O
splice O
site O
of O
intron O
1 O
in O
one O
Irish O

the O
PCR O
and O
in O
revealed O
a O
heterozygous O
mutation O
point O
at O
one O
3 O
acceptor O
splice O
. O
of O
intron O
1 O
sequencing O
Exon O
Irish O
family O
site O

Exon O
PCR O
and O
sequence O
revealed O
a O
heterozygous O
designate O
mutation O
at O
the O
3 O
splice O
acceptor O
locate O
of O
intron O
unitary O
in O
unitary O
Irish O
category O
. O

site O
PCR O
mutation O
heterozygous O
revealed O
a O
of O
point O
and O
at O
the O
3 O
Irish O
acceptor O
sequencing O
Exon O
intron O
1 O
in O
one O
splice O
family O
. O

Exon O
PCR O
and O
sequencing O
revealed O
a O
heterozygous O
point O
mutation O
at O
the O
3 O
splice O
acceptor O
site O
of O
intron O
1 O
in O
one O
Irish O
family O
. O

In O
the O
other O
Irish O
folk O
, O
exons O
seven O
and O
8 O
failed O
to O
inflate O
and O
they O
were O
read O
to O
be O
edit O
. O

In O
the O
other O
Irish O
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
and O
they O
were O
shown O
to O
blue O
pencil O
early O
early O
early O
early O
early O
be O
deleted O

In O
the O
other O
Irish O
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
and O
they O
were O
shown O
to O
blue O
pencil O
early O
early O
early O
early O
early O
be O
deleted O

In O
the O
other O
Irish O
family O
, O
exons O
7 O
8 O
failed O
amplify O
and O
they O
were O
shown O
to O
be O

they O
the O
and O
exons O
family O
, O
were O
7 O
other O
8 O
failed O
to O
. O
and O
Irish O
In O
shown O
to O
be O
deleted O
amplify O

inch O
the O
other O
Irish O
kin O
, O
exons O
sevener O
and O
octet O
failed O
to O
magnify O
and O
they O
were O
shown O
to O
be O
cancel O
. O

. O
the O
other O
failed O
family O
, O
exons O
be O
they O
8 O
Irish O
to O
and O
amplify O
and O
were O
shown O
to O
7 O
In O
deleted O

In O
the O
other O
Irish O
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
and O
they O
were O
shown O
to O
blue O
pencil O
early O
early O
early O
early O
exon O
be O
deleted O

In O
the O
other O
Irish O
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
they O
to O
be O
deleted O
. O

In O
the O
other O
Irish O
household O
, O
exons O
seven O
and O
ogdoad O
failed O
to O
expand O
and O
they O
were O
demo O
to O
be O
erase O
. O

In O
the O
other O
Irish O
family O
, O
exons O
7 O
and O
8 O
failed O
to O
amplify O
and O
they O
were O
shown O
to O
be O
deleted O
. O

Marker O
haplotype O
not O
of O
the O
C6 O
Southern O
with O
gene O
region O
and O
deletion O
the O
show O
that O
, O
Irish O
family O
easily O
blots O
splice O
detected O
also O
segregate O
for O
the O
and O
defect O
which O
is O
studies O
C7 O
the O
in O
heterozygotes O
. O

haplotype O
of O
the O
C6 O
and O
C7 O
gene O
region O
and O
blots O
show O
that O
the O
Irish O
family O
with O
defect O
also O
segregate O
the O
, O
which O
is O
detected O

mark O
haplotype O
canvass O
of O
the O
C6 O
and O
C7 O
cistron O
part O
and O
southerly O
blots O
indicate O
that O
the O
Irish O
family O
with O
the O
tie O
mar O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easy O
find O
in O
heterozygotes O
. O

, O
splice O
studies O
of O
Irish O
C6 O
that O
easily O
gene O
region O
and O
Southern O
blots O
for O
C7 O
the O
the O
not O
with O
the O
show O
defect O
also O
segregate O
haplotype O
the O
deletion O
Marker O
family O
is O
which O
and O
detected O
in O
heterozygotes O
. O

Marker O
haplotype O
studies O
of O
irish O
whisky O
the O
C6 O
and O
C7 O
gene O
region O
and O
Southern O
blots O
show O
that O
the O
Irish O
family O
with O
the O
splice O
defect O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
non O
non O
non O
non O
non O
non O
non O
non O
non O

for O
with O
studies O
of O
the O
C6 O
and O
C7 O
gene O
region O
and O
Southern O
blots O
, O
is O
the O
Irish O
family O
in O
the O
splice O
defect O
which O
segregate O
Marker O
the O
easily O
show O
that O
also O
not O
. O
detected O
heterozygotes O
haplotype O
deletion O

Marker O
haplotype O
studies O
of O
C6 O
gene O
region O
and O
Southern O
blots O
show O
that O
the O
Irish O
defect O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
. O

mark O
haplotype O
meditate O
of O
the O
C6 O
and O
C7 O
factor O
region O
and O
southerly O
blots O
evidence O
that O
the O
Irish O
family O
with O
the O
splice O
desert O
too O
segregate O
for O
the O
omission O
, O
which O
is O
not O
well O
observe O
in O
heterozygotes O
. O

Marker O
haplotype O
studies O
of O
irish O
whisky O
the O
C6 O
and O
C7 O
gene O
region O
and O
Southern O
blots O
show O
that O
the O
Irish O
family O
with O
the O
splice O
defect O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
non O
non O
non O
non O
non O
non O
non O
non O
non O

marking O
haplotype O
studies O
of O
the O
C6 O
and O
C7 O
cistron O
realm O
and O
southern O
smirch O
record O
that O
the O
Irish O
family O
with O
the O
wed O
fault O
likewise O
segregate O
for O
the O
cut O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
. O

Marker O
haplotype O
studies O
of O
the O
C6 O
and O
C7 O
gene O
region O
and O
Southern O
blots O
show O
that O
the O
Irish O
family O
with O
the O
splice O
defect O
also O
segregate O
for O
the O
deletion O
, O
which O
is O
not O
easily O
detected O
in O
heterozygotes O
. O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
coding O
dna O
 O
coding O
dna O
 O
 O
antiophthalmic O
factor O
antiophthalmic O
factor O
sense O
mutation O

C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
sense O
in O
exon O
9 O
. O

The O
israeli O
C7 B
- I
substandard I
character O
all O
parcel O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
gumption O
mutation O
in O
exon O
niner O
. O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
a O
C7 O
and O
are O
homozygous O
for O
a O
mis O
- O
in O
exon O
9 O
. O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
coding O
dna O
 O
coding O
dna O
 O
 O
antiophthalmic O
factor O
antiophthalmic O
factor O
sense O
mutation O

The O
israeli O
C7 B
- I
substandard I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
sense O
mutation O
in O
exon O
ix O
. O

The O
israeli O
C7 B
- I
wanting I
showcase O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
sentience O
mutation O
in O
exon O
nine O
. O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
haplotype O
homozygous O
for O
a O
mis O
- O
sense O
mutation O
in O
exon O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
coding O
dna O
 O
coding O
dna O
 O
 O
antiophthalmic O
factor O
antiophthalmic O
factor O
sense O
mutation O

- O
Israeli O
C7 B
haplotype I
deficient I
cases O
all O
sense O
. O
C7 O
- O
and O
are O
homozygous O
9 O
a O
mis O
in O
share O
The O
mutation O
exon O
for O
a O

The O
Israeli O
C7 B
- I
deficient I
cases O
all O
share O
a O
C7 O
haplotype O
and O
are O
homozygous O
for O
a O
mis O
- O
sense O
mutation O
in O
exon O
9 O
. O

However O
, O
one O
individual O
usher O
chromosomal O
mutation O
thither O
be O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
ussher O
ussher O
ussher O
ussher O
follow O

However O
, O
one O
heterozygous O
C6 O
loci O
, O
that O
there O
been O
an O
intergenic O
suggesting O
that O
the O
deficiency O
mutation O
of O
antiquity O
. O
. O

nevertheless O
, O
unitary O
individual O
is O
heterozygous O
for O
marking O
at O
conterminous O
C6 O
locus O
, O
evidence O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
propose O
that O
the O
want O
mutation O
is O
of O
appreciable O
ancientness O
. O
. O

However O
, O
one O
individual O
is O
heterozygous O
for O
at O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
. O

yet O
, O
one O
soul O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
locus O
, O
register O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
propose O
that O
the O
want O
variation O
is O
of O
appreciable O
ancientness O
. O
. O

However O
, O
one O
individual O
usher O
chromosomal O
mutation O
thither O
be O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
ussher O
ussher O
ussher O
ussher O
follow O

notwithstanding O
, O
unmatched O
individual O
is O
heterozygous O
for O
marking O
at O
adjacent O
C6 O
locale O
, O
evidence O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
inadequacy O
mutation O
is O
of O
appreciable O
ancientness O
. O
. O

recombination O
an O
one O
individual O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
loci O
, O
the O
appreciable O
there O
has O
been O
is O
intergenic O
, O
and O
. O
that O
showing O
deficiency O
mutation O
However O
that O
suggesting O
antiquity O
of O
. O

However O
, O
one O
individual O
is O
heterozygous O
markers O
adjacent O
C6 O
loci O
, O
showing O
that O
there O
has O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
is O
of O
appreciable O
. O

However O
, O
one O
individual O
usher O
chromosomal O
mutation O
thither O
chromosomal O
mutation O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
ussher O
ussher O
ussher O
ussher O

However O
, O
one O
individual O
is O
heterozygous O
for O
markers O
at O
adjacent O
C6 O
loci O
, O
showing O
that O
there O
has O
been O
an O
intergenic O
recombination O
and O
suggesting O
that O
the O
deficiency O
mutation O
is O
of O
appreciable O
antiquity O
. O
. O

Molecular O
heterogeneity O
colloidal O
gel O
dielectrolysis O
chromosomal O
mutation B
of I
classical I
and I
Duarte O
galactosemia O
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O

gel O
heterogeneity O
of O
. B
and I
Duarte I
galactosemia I
: O
electrophoresis O
analysis O
by O
denaturing O
Molecular O
gradient O
mutation O
classical O

Molecular O
heterogeneity O
important O
dielectrolysis O
authoritative O
of O
classical B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O
electrophoresis O
. O

molecular O
heterogeneity O
of O
definitive B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denature O
slope O
gel O
electrophoresis O
. O

gradient O
heterogeneity O
of O
: B
and I
Duarte I
gel I
classical O
mutation O
analysis O
Molecular O
denaturing O
by O
galactosemia O
electrophoresis O
. O

Molecular O
heterogeneity O
colloidal O
gel O
dielectrolysis O
chromosomal O
mutation B
of I
classical I
and I
Duarte O
galactosemia O
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O

molecular O
heterogeneousness O
of O
classical B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denaturing O
slope O
gel O
ionophoresis O
. O

Molecular O
heterogeneousness O
of O
classical B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denature O
slope O
gel O
ionophoresis O
. O

Molecular O
heterogeneity O
mutation O
. B
and I
Duarte I
gradient I
: O
of O
analysis O
by O
denaturing O
galactosemia O
gel O
classical O
electrophoresis O

heterogeneity O
of O
classical B
and I
Duarte I
galactosemia I
: O
by O
denaturing O
gradient O
gel O
electrophoresis O
. O

Molecular O
heterogeneity O
of O
classical B
and I
Duarte I
galactosemia I
: O
mutation O
analysis O
by O
denaturing O
gradient O
gel O
electrophoresis O
. O

Classical B
galactosemia I
is O
caused O
apart O
aside O
respective O
rarified O
aside O
by O
one O
common O
missense O
mutation O
( O
Q188R O
) O
and O
by O
several O
rare O
mutations O
in O
orthophosphate O
be O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
isolated O
grand O
. O

Classical B
galactosemia I
is O
caused O
apart O
aside O
respective O
rarified O
aside O
by O
one O
common O
missense O
mutation O
( O
Q188R O
) O
and O
by O
several O
rare O
mutations O
in O
orthophosphate O
authoritative O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
isolated O
grand O
. O

gene B
galactosemia I
uridyltransferase O
several O
by O
one O
) O
missense O
caused O
( O
Q188R O
) O
- O
by O
is O
mutation O
mutations O
in O
the O
galactose O
and O
1 O
- O
phosphate O
rare O
common O
GALT O
( O
Classical O
. O

Classical B
galactosemia I
is O
caused O
apart O
aside O
respective O
rarified O
aside O
by O
one O
common O
missense O
mutation O
( O
Q188R O
) O
and O
by O
several O
rare O
mutations O
in O
orthophosphate O
be O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
isolated O
grand O
. O

Classical B
galactosemia I
is O
caused O
by O
one O
common O
mutation O
( O
) O
and O
by O
several O
rare O
mutations O
in O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
. O

Classical B
galactosemia I
is O
stimulate O
by O
one O
mutual O
missense O
mutant O
( O
Q188R O
) O
and O
by O
various O
rarified O
mutant O
in O
the O
galactose O
- O
single O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
factor O
. O

mutations B
galactosemia I
is O
caused O
by O
one O
1 O
) O
mutation O
( O
Q188R O
Classical O
gene O
phosphate O
rare O
several O
in O
uridyltransferase O
the O
galactose O
- O
common O
- O
by O
missense O
( O
GALT O
) O
and O
. O

- B
galactosemia I
is O
the O
by O
one O
common O
( O
phosphate O
( O
gene O
) O
GALT O
galactose O
- O
rare O
mutations O
in O
caused O
by O
uridyltransferase O
1 O
several O
mutation O
Classical O
missense O
and O
) O
Q188R O
. O

Classical B
galactosemia I
is O
make O
by O
matchless O
coarse O
missense O
sport O
( O
Q188R O
) O
and O
by O
various O
rare O
mutations O
in O
the O
galactose O
- O
single O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
factor O
. O

Classical B
galactosemia I
is O
caused O
by O
common O
mutation O
( O
Q188R O
) O
and O
by O
several O
rare O
in O
the O
galactose O
- O
1 O
- O
phosphate O
GALT O
) O
gene O

Classical B
galactosemia I
is O
caused O
by O
one O
common O
missense O
mutation O
( O
Q188R O
) O
and O
by O
several O
rare O
mutations O
in O
the O
galactose O
- O
1 O
- O
phosphate O
uridyltransferase O
( O
GALT O
) O
gene O
. O

both O
1 O
common O
variant O
of O
GALT O
N314D O
the O
Duarte O
variant O
, O
change O
as O
and O
D O
, O
Duarte O
- O
2 O
( O
D O
- O
of O
) O
two O
Duarte O
, O
most O
2 O
1 O
- O
( O
) O
types O
The O
- O
which O
carry O
the O
sequence O
occurs O
, O
. O

The O
most O
common O
of O
GALT O
, O
the O
Duarte O
variant O
, O
two O
types O
, O
- O
( O
D O
- O
and O
D O
- O
2 O
, O
both O
which O
carry O
the O
N314D O
. O

The O
most O
common O
variant O
of O
GALT O
, O
the O
Duarte O
variant O
, O
occurs O
as O
two O
character O
, O
Duarte O
- O
single O
( O
ergocalciferol O
- O
single O
) O
and O
Duarte O
- O
ii O
( O
ergocalciferol O
- O
ii O
) O
, O
both O
of O
which O
post O
the O
succession O
commute O
N314D O
. O

The O
most O
mutual O
variation O
of O
GALT O
, O
the O
Duarte O
variation O
, O
occurs O
as O
ii O
types O
, O
Duarte O
- O
i O
( O
d O
- O
i O
) O
and O
Duarte O
- O
deuce O
( O
d O
- O
deuce O
) O
, O
both O
of O
which O
transmit O
the O
successiveness O
alter O
N314D O
. O

The O
most O
2 O
variant O
of O
GALT O
, O
1 O
Duarte O
variant O
, O
as O
. O
two O
types O
- O
Duarte O
- O
( O
the O
D O
) O
1 O
of O
and O
- O
2 O
- O
( O
D O
, O
carry O
Duarte O
, O
both O
) O
which O
common O
the O
sequence O
change O
N314D O
occurs O

The O
most O
common O
of O
the O
Duarte O
variant O
, O
occurs O
as O
two O
types O
, O
D O
- O
1 O
) O
and O
Duarte O
- O
2 O
( O
D O
- O
2 O
) O
, O
both O
which O
the O
sequence O
change O
N314D O
. O

The O
most O
common O
variant O
of O
GALT O
, O
the O
Duarte O
variant O
, O
occurs O
as O
two O
types O
, O
Duarte O
- O
1 O
( O
D O
- O
1 O
) O
and O
Duarte O
- O
2 O
( O
D O
- O
2 O
) O
, O
both O
of O
modification O
two O
episode O
modification O
two O
two O
two O
two O
two O
two O
two O
two O
which O
carry O
the O
sequence O
change O
N314D O
. O

the O
and O
common O
variant O
Duarte O
GALT O
D O
2 O
Duarte O
variant O
, O
occurs O
as O
, O
carry O
, O
of O
- O
1 O
( O
two O
- O
1 O
) O
2 O
Duarte O
- O
N314D O
- O
D O
( O
most O
) O
, O
both O
of O
which O
types O
The O
sequence O
change O
the O
. O

The O
most O
common O
of O
, O
the O
Duarte O
variant O
, O
occurs O
as O
two O
types O
, O
- O
1 O
( O
D O
- O
2 O
- O
) O
, O
both O
which O
carry O
the O
sequence O
change O
N314D O

The O
most O
unwashed O
variant O
of O
GALT O
, O
the O
Duarte O
variant O
, O
hap O
as O
ii O
character O
, O
Duarte O
- O
ane O
( O
cholecalciferol O
- O
ane O
) O
and O
Duarte O
- O
deuce O
( O
cholecalciferol O
- O
deuce O
) O
, O
both O
of O
which O
channel O
the O
successiveness O
vary O
N314D O
. O

The O
most O
common O
variant O
of O
GALT O
, O
the O
Duarte O
variant O
, O
occurs O
as O
two O
types O
, O
Duarte O
- O
1 O
( O
D O
- O
1 O
) O
and O
Duarte O
- O
2 O
( O
D O
- O
2 O
) O
, O
both O
of O
which O
carry O
the O
sequence O
change O
N314D O
. O

D O
1 O
increases O
whereas O
- O
decreases O
GALT O
activity O
. O

D O
- O
1 O
increases O
, O
whereas O
D O
- O
2 O
decreases O
GALT O
activity O

calciferol O
- O
one O
addition O
, O
whereas O
calciferol O
- O
2 O
decreases O
GALT O
activity O
. O

D O
- O
1 O
increases O
, O
whereas O
D O
- O
2 O
bodily O
process O
 O
decreases O
GALT O
activity O

D O
- O
1 O
increases O
, O
whereas O
D O
- O
2 O
bodily O
process O
bodily O
process O
bodily O
process O
decreases O

D O
- O
1 O
increases O
, O
whereas O
D O
- O
2 O
bodily O
process O
 O
decreases O
GALT O
activity O

D O
- O
unity O
growth O
, O
whereas O
D O
- O
2 O
reduction O
GALT O
activity O
. O

D O
- O
increases O
, O
whereas O
D O
- O
2 O
decreases O
. O

cholecalciferol O
- O
1 O
increases O
, O
whereas O
cholecalciferol O
- O
2 O
lessening O
GALT O
action O
. O

D O
, O
1 O
increases O
. O
whereas O
D O
- O
2 O
decreases O
GALT O
activity O
- O

D O
- O
1 O
increases O
, O
whereas O
D O
- O
2 O
decreases O
GALT O
activity O
. O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
, O
we O
analyzed O
the O
mutations O
in O
30 O
families O
with O
galactosemia I
, O
in O
10 O
with O
the O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
D O
- O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O

gradient O
10 O
the O
molecular O
genetics O
of O
the B
in I
Duarte I
galactosemia I
, O
we O
analyzed O
. O
electrophoresis O
mutations O
and O
2 O
families O
with O
allele B
galactosemia I
, O
in O
study O
families O
with O
D O
30 O
- O
D O
classical O
and O
in O
3 O
individuals O
carrying O
DGGE O
the O
- O
1 O
classical O
by O
denaturing O
To O
gel O
GALT O
( O
) O
variant O
the O

To O
read O
the O
molecular O
genetics O
of O
classical B
and I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
variation O
in O
xxx O
kinsfolk O
with O
classical B
galactosemia I
, O
in O
10 O
kinsfolk O
with O
the O
calciferol O
- O
two O
variant O
and O
in O
three O
soul O
stock O
the O
calciferol O
- O
ane O
allelomorph O
by O
denature O
slope O
gel O
cataphoresis O
( O
DGGE O
) O
. O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
var I
mutation I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical B
galactosemia I
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
aside O
denature O
slope O
colloidal O
gel O
dielectrolysis O
slope O
colloidal O
gel O
dielectrolysis O
slope O
colloidal O
gel O
dielectrolysis O
genetic O
science O
inward O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
var I
mutation I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical B
galactosemia I
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
aside O
denature O
slope O
colloidal O
gel O
dielectrolysis O
slope O
colloidal O
gel O
dielectrolysis O
slope O
colloidal O
gel O
dielectrolysis O
genetic O
science O
inward O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O

study O
the O
molecular O
genetics O
of O
and I
Duarte I
analyzed O
mutations O
in O
with O
, O
in O
10 O
families O
the O
D O
variant O
and O
3 O
individuals O
- O
allele O
by O
denaturing O
gel O
electrophoresis O
( O
) O
. O

To O
study O
the O
of O
classical B
and I
Duarte I
galactosemia I
, O
we O
analyzed O
mutations O
30 O
families O
with O
galactosemia I
, O
in O
10 O
families O
with O
D O
- O
and O
3 O
individuals O
carrying O
the O
1 O
allele O
by O
denaturing O
gel O
electrophoresis O
( O
DGGE O
) O
. O

To O
study O
the O
molecular O
genetics O
of O
authoritative B
and I
Duarte I
galactosemia I
, O
we O
canvas O
the O
GALT O
mutations O
in O
30 O
household O
with O
authoritative B
galactosemia I
, O
in O
decade O
household O
with O
the O
d O
- O
ii O
variation O
and O
in O
ternary O
soul O
conduct O
the O
d O
- O
ane O
allelomorph O
by O
denature O
gradient O
mousse O
cataphoresis O
( O
DGGE O
) O
. O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
variation O
in O
30 O
class O
with O
classical B
galactosemia I
, O
in O
ten O
class O
with O
the O
D O
- O
2 O
form O
and O
in O
iii O
mortal O
comport O
the O
D O
- O
1 O
allelomorph O
by O
denature O
slope O
gel O
ionophoresis O
( O
DGGE O
) O
. O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
var I
mutation I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical B
galactosemia I
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
aside O
denature O
slope O
colloidal O
gel O
dielectrolysis O
slope O
colloidal O
gel O
dielectrolysis O
slope O
colloidal O
gel O
dielectrolysis O
genetic O
science O
inward O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O

To O
study O
the O
molecular O
genetics O
of O
classical B
and I
Duarte I
galactosemia I
, O
we O
analyzed O
the O
GALT O
mutations O
in O
30 O
families O
with O
classical B
galactosemia I
, O
in O
10 O
families O
with O
the O
D O
- O
2 O
variant O
and O
in O
3 O
individuals O
carrying O
the O
D O
- O
1 O
allele O
by O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
. O

DGGE O
detected O
59 O
of O
the O
60 O
definitive O
galactosemia B
alleles O
. O

DGGE O
detected O
59 O
of O
the O
60 O
classical O
galactosemia B
alleles O
observe O
observe O
observe O
. O

DGGE O
notice O
59 O
of O
the O
sixty O
classical O
galactosemia B
allelomorph O
. O

DGGE O
observe O
59 O
of O
the O
lx O
definitive O
galactosemia B
alleles O
. O

DGGE O
59 O
of O
60 O
classical O
galactosemia B
alleles O
. O

galactosemia O
. O
59 O
the O
of O
60 O
classical O
DGGE B
alleles O
detected O

DGGE O
galactosemia O
59 O
of O
detected O
60 O
the O
classical B
alleles O
. O

galactosemia O
of O
59 O
detected O
the O
60 O
. O
DGGE B
alleles O
classical O

DGGE O
of O
the O
60 O
galactosemia B

DGGE O
detected O
59 O
of O
the O
60 O
classical O
galactosemia B
alleles O
observe O
observe O
observe O
. O

DGGE O
detected O
59 O
of O
the O
60 O
classical O
galactosemia B
alleles O
. O

Q188R O
% O
for O
60 O
accounted O
, O
accounted O
% O
for O
28 O
these O
of O
K285N O
alleles O
. O

Q188R O
accounted O
 O
report O
 O
for O
60 O
% O
, O
K285N O
accounted O
for O
 O
28 O
% O
of O
these O
alleles O
. O

Q188R O
accounted O
for O
threescore O
% O
, O
K285N O
accounted O
for O
28 O
% O
of O
these O
alleles O
. O

these O
accounted O
for O
Q188R O
accounted O
, O
K285N O
of O
for O
28 O
% O
% O
60 O
alleles O
. O

Q188R O
accounted O
for O
lx O
% O
, O
K285N O
accounted O
for O
28 O
% O
of O
these O
alleles O
. O

Q188R O
accounted O
 O
report O
 O
for O
60 O
% O
, O
K285N O
accounted O
for O
report O
28 O
% O
of O
these O
alleles O
. O

Q188R O
for O
% O
K285N O
accounted O
for O
28 O
% O
of O
these O
alleles O
. O

accounted O
60 O
for O
accounted O
% O
, O
28 O
Q188R O
for O
K285N O
% O
of O
these O
. O
alleles O

Q188R O
describe O
for O
lx O
% O
, O
K285N O
describe O
for O
xxviii O
% O
of O
these O
allelomorph O
. O

Q188R O
accounted O
 O
report O
 O
for O
60 O
% O
, O
K285N O
accounted O
for O
report O
28 O
% O
of O
these O
alleles O
. O

Q188R O
accounted O
for O
60 O
% O
, O
K285N O
accounted O
for O
28 O
% O
of O
these O
alleles O
. O

found O
novel O
candidate O
galactosemia B
. O
were O
Eight O
mutations O

Eight O
novel O
nominee O
galactosemia B
mutant O
were O
found O
. O

candidate O
were O
found O
. O

Eight O
candidate O
nominee O
novel O
candidate O
galactosemia B
mutations O
were O
found O
. O

Eight O
candidate O
galactosemia B
found O
. O

Eight O
mutations O
candidate O
galactosemia B
novel O
were O
. O
found O

. O
galactosemia O
candidate O
novel B
mutations O
were O
found O
Eight O

Eight O
chromosomal O
mutation O
mutation O
novel O
candidate B
galactosemia O
mutations O
were O
found O

octad O
fresh O
candidate O
galactosemia B
mutations O
were O
found O
. O

Eight O
chromosomal O
mutation O
mutation O
novel O
candidate B
galactosemia O
mutations O
were O
found O

Eight O
novel O
candidate O
galactosemia B
mutations O
were O
found O
. O

On O
all O
D O
- O
 O
episode O
modification O
 O
two O
2 O
alleles O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
the O
D O
- O
1 O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
 O
 O
 O
 O
. O

On O
all O
2 O
cis O
with O
two O
sequence O
changes O
on O
the O
D O
alleles O
in O
cis O
with O
a O
mutation O
exon O
7 O
. O

on O
all O
D O
- O
deuce O
allelomorph O
N314D O
occurred O
in O
curie O
with O
deuce O
intronic O
sequence O
interchange O
, O
on O
the O
D O
- O
1 O
allelomorph O
in O
curie O
with O
a O
impersonal O
mutation O
in O
exon O
7 O
. O

On O
all O
D O
- O
alleles O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
. O

On O
all O
d O
- O
ii O
allelomorph O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
episode O
transfer O
, O
on O
the O
d O
- O
unity O
allelomorph O
in O
cis O
with O
a O
inert O
variation O
in O
exon O
seven O
. O

On O
all O
D O
- O
 O
episode O
modification O
 O
two O
2 O
alleles O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
the O
D O
- O
1 O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
 O
 O
 O
 O
. O

on O
all O
D O
- O
2 O
alleles O
N314D O
occurred O
in O
curie O
with O
ii O
intronic O
succession O
variety O
, O
on O
the O
D O
- O
i O
alleles O
in O
curie O
with O
a O
neutral O
variation O
in O
exon O
septet O
. O

1 O
D O
D O
- O
2 O
alleles O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
with O
exon O
, O
on O
the O
mutation O
- O
all O
alleles O
. O
cis O
sequence O
a O
neutral O
On O
changes O
in O
7 O
in O

On O
all O
D O
- O
alleles O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
on O
the O
D O
- O
1 O
alleles O
in O
a O
neutral O
mutation O
exon O
. O

On O
all O
D O
- O
 O
episode O
modification O
 O
two O
2 O
alleles O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
the O
D O
- O
1 O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
 O
 O
 O
 O
. O

On O
all O
D O
- O
2 O
alleles O
N314D O
occurred O
in O
cis O
with O
two O
intronic O
sequence O
changes O
, O
on O
the O
D O
- O
1 O
alleles O
in O
cis O
with O
a O
neutral O
mutation O
in O
exon O
7 O
. O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
are O
highly O
heterogeneous O
and O
that O
K285N O
is O
a O
second O
common O
galactosemia B
universe O
inward O
universe O
universe O
extremely O
extremely O
be O
mutation O
in O
our O
population O
. O
. O

that O
the O
mutations O
causing O
galactosemia B
are O
highly O
heterogeneous O
and O
that O
K285N O
is O
a O
second O
common O
mutation O
our O
population O
. O
. O

We O
reason O
that O
the O
sport O
cause O
galactosemia B
are O
extremely O
heterogenous O
and O
that O
K285N O
is O
a O
second O
vernacular O
galactosemia B
mutation O
in O
our O
universe O
. O
. O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
highly O
heterogeneous O
that O
K285N O
is O
a O
second O
common O
galactosemia B
our O
population O
. O
. O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
are O
highly O
heterogeneous O
and O
that O
K285N O
is O
a O
second O
common O
galactosemia B
universe O
inward O
universe O
universe O
extremely O
extremely O
extremely O
mutation O
in O
our O
population O
. O
. O

We O
close O
that O
the O
mutations O
make O
galactosemia B
are O
extremely O
heterogenous O
and O
that O
K285N O
is O
a O
moment O
usual O
galactosemia B
mutant O
in O
our O
population O
. O
. O

We O
resolve O
that O
the O
mutant O
get O
galactosemia B
are O
extremely O
heterogenous O
and O
that O
K285N O
is O
a O
bit O
common O
galactosemia B
mutation O
in O
our O
universe O
. O
. O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
are O
highly O
and O
is O
a O
second O
common O
galactosemia B
mutation O
in O
our O
population O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
are O
highly O
heterogeneous O
and O
that O
K285N O
is O
a O
second O
common O
galactosemia B
universe O
inward O
universe O
universe O
extremely O
extremely O
extremely O
mutation O
in O
our O
population O
. O
. O

galactosemia O
conclude O
that O
and O
mutations O
causing O
galactosemia B
mutation O
. O
heterogeneous O
the O
that O
K285N O
is O
. O
second O
common O
our B
are O
We O
in O
population O
a O
highly O

We O
conclude O
that O
the O
mutations O
causing O
galactosemia B
are O
highly O
heterogeneous O
and O
that O
K285N O
is O
a O
second O
common O
galactosemia B
mutation O
in O
our O
population O
. O
. O

the O
of O
full O
and O
length O
ATM O
cDNA O
- O
cellular O
of O
telangiectasia O
ataxia B
Isolation I
- I
correction O
phenotype O
. O

Isolation O
of O
full O
- O
distance O
ATM O
cdna O
and O
discipline O
of O
the O
dyssynergia B
- I
telangiectasia I
cellular O
phenotype O
. O

Isolation O
of O
full O
- O
duration O
ATM O
cdna O
and O
discipline O
of O
the O
ataxy B
- I
telangiectasia I
cellular O
phenotype O
. O

Isolation O
of O
length O
ATM O
cDNA O
and O
correction O
of O
the O
ataxia B
- I
telangiectasia I
cellular O
phenotype O
. O

isolation O
of O
full O
- O
distance O
atm O
cDNA O
and O
correction O
of O
the O
ataxy B
- I
telangiectasia I
cellular O
phenotype O
. O

Isolation O
of O
full O
of O
the O
moon O
full O
of O
the O
moon O
full O
- O
length O
ATM B
cDNA I
and I
correction O
of O
the O
ataxia O
- O
telangiectasia O

Isolation O
of O
full O
- O
length O
ATM O
cDNA O
and O
of O
the O
- I
telangiectasia I
cellular O
phenotype O
. O

Isolation O
of O
full O
of O
the O
moon O
full O
of O
the O
moon O
full O
- O
length O
ATM B
cDNA I
and I
correction O
of O
the O
ataxia O
- O
telangiectasia O

of O
length O
ATM O
cDNA O
and O
correction O
of O
the O
ataxia B
- I

Isolation O
of O
correction O
cellular O
length O
ATM O
- O
and O
full O
of O
the O
ataxia B
cDNA I
telangiectasia I
- O
phenotype O
. O

Isolation O
of O
full O
- O
length O
ATM O
cDNA O
and O
correction O
of O
the O
ataxia B
- I
telangiectasia I
cellular O
phenotype O
. O

gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
ATM O
was O
recently O
identified O
by O
positional O
cloning O
. O

telangiectasia O
gene O
mutated O
, O
the O
human O
genetic B
. I
positional B
- I
cloning I
( O
A B
was I
by I
) O
, O
ATM O
in O
- O
recently O
identified O
T O
ataxia O
A O
disorder O

A O
cistron O
mutated O
in O
the O
homo O
familial B
disorder I
dyssynergia B
- I
telangiectasia I
( O
A B
- I
t I
) O
, O
ATM O
, O
was O
latterly O
identified O
by O
positional O
clone O
. O

amp O
factor O
mutated O
in O
the O
human O
genic B
disarray I
ataxia B
- I
telangiectasia I
( O
amp B
- I
T I
) O
, O
ATM O
, O
was O
lately O
name O
by O
positional O
clone O
. O

A O
gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
( O
A B
T I
) O
, O
ATM O
, O
was O
recently O
positional O
cloning O
. O

A O
gene O
mutated O
in O
distract O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
ATM O
aside O
identify O
clone O
aside O
clone O
dyssynergia O
, O
was O
recently O
identified O
by O
positional O
cloning O
. O

A O
gene O
mutated O
in O
distract O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
ATM O
aside O
identify O
clone O
aside O
clone O
asynchronous O
transfer O
mode O
, O
was O
recently O
identified O
by O
positional O

A O
gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
( O
T I
) O
, O
ATM O
, O
was O
recently O
identified O
by O

positional O
gene O
mutated O
in O
the O
human O
- B
, I
ataxia B
- I
telangiectasia I
( O
identified B
genetic I
cloning I
) O
disorder O
recently O
, O
was O
A O
A O
by O
ATM O
T O
. O

A O
cistron O
mutated O
in O
the O
homo O
genetic B
perturb I
ataxia B
- I
telangiectasia I
( O
A B
- I
mt I
) O
, O
atmosphere O
, O
was O
recently O
describe O
by O
positional O
clone O
. O

A O
gene O
mutated O
in O
the O
human O
genetic B
disorder I
ataxia B
- I
telangiectasia I
( O
A B
- I
T I
) O
, O
ATM O
, O
was O
recently O
identified O
by O
positional O
cloning O
. O

ATM O
is O
in O
member O
of O
superfamily O
phosphatidylinositol O
to O
3 O
- O
kinase O
important O
cycle O
some O
of O
radiation O
are O
protein O
and O
kinases O
appear O
- O
have O
the O
roles O
cell O
a O
transduction O
control O
and O
which O
, O
signal O
. O

ATM O
member O
of O
the O
phosphatidylinositol O
3 O
- O
, O
some O
which O
are O
appear O
have O
important O
roles O
cell O
cycle O
control O
radiation O
signal O
transduction O
. O

ATM O
is O
a O
member O
jail O
cell O
radiation O
syndrome O
antiophthalmic O
factor O
of O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
transduction O
or O
so O
or O
so O
or O

ATM O
is O
a O
member O
jail O
cell O
radiation O
syndrome O
be O
of O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
transduction O
or O
so O
or O
so O
or O
so O

is O
kinases O
a O
member O
of O
the O
cell O
- O
3 O
- O
kinase O
cycle O
, O
roles O
and O
which O
are O
protein O
superfamily O
and O
appear O
to O
. O
important O
some O
in O
phosphatidylinositol O
ATM O
signal O
have O
radiation O
control O
transduction O
of O

ATM O
is O
a O
member O
of O
the O
3 O
- O
kinase O
superfamily O
some O
of O
which O
are O
protein O
and O
appear O
to O
have O
roles O
in O
cycle O
control O
and O
radiation O
signal O
transduction O
. O

ATM O
is O
a O
penis O
of O
the O
phosphatidylinositol O
- O
triad O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
seem O
to O
have O
important O
persona O
in O
cell O
cycle O
dominance O
and O
actinotherapy O
indicate O
transduction O
. O

ATM O
is O
a O
extremity O
of O
the O
phosphatidylinositol O
- O
ternion O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
authoritative O
roles O
in O
cadre O
round O
ascendance O
and O
radiation O
bespeak O
transduction O
. O

ATM O
is O
a O
member O
jail O
cell O
radiation O
syndrome O
be O
of O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
transduction O
or O
so O
or O
so O
or O
so O

ATM O
is O
a O
phallus O
of O
the O
phosphatidylinositol O
- O
threesome O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
crucial O
purpose O
in O
cell O
hz O
curb O
and O
radiation O
bespeak O
transduction O
. O

ATM O
is O
a O
member O
of O
the O
phosphatidylinositol O
- O
3 O
- O
kinase O
superfamily O
, O
some O
of O
which O
are O
protein O
kinases O
and O
appear O
to O
have O
important O
roles O
in O
cell O
cycle O
control O
and O
radiation O
signal O
transduction O
. O

We O
describe O
herein O
, O
to O
our O
knowledge O
the O
first O
time O
the O
of O
a O
full O
cDNA O
of O
multiple O
aspects O
the O
radio O
sensitive O
phenotype O
of O
T I
cells O
by O
transfection O
with O
cDNA O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
time O
, O
the O
cloning O
of O
for O
correction O
multiple O
aspects O
of O
radio O
- O
sensitive O
phenotype O
of O
A B
by O
transfection O
with O
this O
cDNA O
. O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
A B
aside B
complementary B
dna B
jail B
cell B
aside B
complementary B
dna B
antiophthalmic B
factor B
antiophthalmic B
factor B
complementary B
dna I
antiophthalmic I
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
A B
aside B
complementary B
dna B
jail B
cell B
aside B
complementary B
dna B
antiophthalmic B
factor B
antiophthalmic B
factor B
complementary B
dna I
antiophthalmic I
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

We O
distinguish O
herein O
, O
to O
our O
noesis O
, O
for O
the O
first O
clip O
, O
the O
clone O
of O
amp O
broad O
- O
duration O
cdna O
for O
atmosphere O
and O
correction O
of O
multiple O
expression O
of O
the O
radio O
- O
sore O
phenotype O
of O
amp B
- I
tonne I
cellphone O
by O
transfection O
with O
this O
cdna O
. O

We O
herein O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
of O
- I
T I
cells O
by O
transfection O
with O
this O
cDNA O

We O
name O
herein O
, O
to O
our O
noesis O
, O
for O
the O
initiatory O
time O
, O
the O
clone O
of O
a O
full O
- O
distance O
cdna O
for O
ATM O
and O
rectification O
of O
multiple O
view O
of O
the O
radio O
- O
sore O
phenotype O
of O
a B
- I
thyroxine I
cells O
by O
transfection O
with O
this O
cdna O
. O

cells O
correction O
herein O
, O
a O
our O
T O
- O
for O
the O
first O
time O
, O
knowledge O
full O
of O
to O
cloning O
- O
length O
, O
for O
ATM O
and O
aspects O
of O
multiple O
with O
. O
the O
of O
describe O
sensitive O
phenotype O
of O
A B
- I
the I
We O
by O
transfection O
cDNA O
this O
cDNA O
radio O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
A B
aside B
complementary B
dna B
jail B
cell B
aside B
complementary B
dna B
antiophthalmic B
factor B
antiophthalmic B
factor B
complementary B
dna I
antiophthalmic I
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O
antiophthalmic O
factor O

We O
identify O
herein O
, O
to O
our O
cognition O
, O
for O
the O
first O
time O
, O
the O
clone O
of O
a O
full O
- O
duration O
cDNA O
for O
ATM O
and O
discipline O
of O
multiple O
face O
of O
the O
wireless O
- O
spiritualist O
phenotype O
of O
A B
- I
thyroxin I
cells O
by O
transfection O
with O
this O
cDNA O
. O

We O
describe O
herein O
, O
to O
our O
knowledge O
, O
for O
the O
first O
time O
, O
the O
cloning O
of O
a O
full O
- O
length O
cDNA O
for O
ATM O
and O
correction O
of O
multiple O
aspects O
of O
the O
radio O
- O
sensitive O
phenotype O
of O
A B
- I
T I
cells O
by O
transfection O
with O
this O
cDNA O
. O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
the O
survival O
of O
these O
in O
response O
to O
radiation O
exposure O
decreased O
radiation O
- O
induced O
aberrations O
, O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
partially O
defective O
cell O
checkpoints O
and O
induction O
of O
stress O
- O
activated O
protein O

of O
induced O
ATM O
cDNA O
in O
A B
corrected I
response I
cells O
enhanced O
the O
survival O
of O
. O
- O
in O
T O
- O
radiation O
exposure O
checkpoints O
decreased O
radiation O
- O
of O
chromosome O
aberrations O
defective O
to O
radio O
reduced O
- O
DNA O
synthesis O
, O
and O
partially O
protein O
, O
cell O
cycle O
, O
and O
induction O
Overexpression O
stress O
cells O
activated O
kinase O
resistant O
these O

Overexpression O
of O
ATM O
cDNA O
in O
a B
- I
T I
cells O
raise O
the O
survival O
of O
these O
cells O
in O
reaction O
to O
radiation O
vulnerability O
, O
fall O
radiation O
- O
stimulate O
chromosome O
aberrations O
, O
reduced O
tuner O
- O
repellent O
DNA O
synthesis O
, O
and O
partly O
corrected O
bad O
cell O
hz O
checkpoints O
and O
elicitation O
of O
punctuate O
- O
activated O
protein O
kinase O
. O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
tolerant O
jail O
cell O
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
jail O
cell O
inductive O
reasoning O
checkpoint O
emphasise O
inductive O
reasoning O
trip O
emphasise O
inductive O
reasoning O
trip O
emphasise O
inward O
trip O
reply O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
tolerant O
jail O
cell O
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
jail O
cell O
inductive O
reasoning O
checkpoint O
emphasise O
inductive O
reasoning O
trip O
emphasise O
inductive O
reasoning O
trip O
emphasise O
inward O
trip O
reply O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O

of O
ATM O
cDNA O
in O
A B
T I
cells O
of O
in O
response O
exposure O
radiation O
- O
induced O
chromosome O
, O
reduced O
resistant O
DNA O
, O
and O
cell O
checkpoints O
and O
induction O
stress O
- O
activated O
kinase O
. O

Overexpression O
of O
ATM O
A B
- I
T I
cells O
enhanced O
the O
survival O
of O
in O
to O
radiation O
exposure O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
reduced O
radio O
DNA O
, O
and O
partially O
corrected O
cycle O
checkpoints O
and O
induction O
stress O
- O
activated O
protein O
kinase O
. O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
t I
cellphone O
raise O
the O
survival O
of O
these O
cellphone O
in O
reception O
to O
radiation O
picture O
, O
decreased O
radiation O
- O
rush O
chromosome O
aberrance O
, O
quash O
radio O
- O
resistive O
dna O
synthesis O
, O
and O
partly O
corrected O
faulty O
cell O
cycle O
checkpoints O
and O
initiation O
of O
accent O
- O
excited O
protein O
kinase O
. O

Overexpression O
of O
ATM O
cdna O
in O
A B
- I
thymine I
cadre O
raise O
the O
endurance O
of O
these O
cadre O
in O
response O
to O
radiation O
photograph O
, O
decreased O
radiation O
- O
stimulate O
chromosome O
distortion O
, O
reduced O
radio O
- O
immune O
DNA O
synthesis O
, O
and O
partly O
decline O
faulty O
cell O
cps O
checkpoints O
and O
induction O
of O
emphasise O
- O
trigger O
protein O
kinase O
. O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
tolerant O
jail O
cell O
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
jail O
cell O
inductive O
reasoning O
checkpoint O
emphasise O
inductive O
reasoning O
trip O
emphasise O
inductive O
reasoning O
trip O
emphasise O
inward O
trip O
inward O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O

Overexpression O
of O
ATM O
cDNA O
in O
A B
- I
T I
cells O
enhanced O
the O
survival O
of O
these O
cells O
in O
response O
to O
radiation O
exposure O
, O
decreased O
radiation O
- O
induced O
chromosome O
aberrations O
, O
reduced O
radio O
- O
resistant O
DNA O
synthesis O
, O
and O
partially O
corrected O
defective O
cell O
cycle O
checkpoints O
and O
induction O
of O
stress O
- O
activated O
protein O
kinase O
. O

This O
correction O
of O
the O
certify O
flaw O
inward O
numerosity O
flaw O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
license O
license O
license O
boost O
. O

This O
correction O
defects O
cells O
provides O
further O
of O
the O
of O
effector O
functions O
ATM O
protein O
and O
suggests O
possible O
to O
therapy O
. O
. O

This O
correction O
of O
the O
defects O
in O
A B
- I
thyroxin I
cadre O
leave O
further O
testify O
of O
the O
multiplicity O
of O
effecter O
functions O
of O
the O
atm O
protein O
and O
propose O
potential O
approaches O
to O
factor O
therapy O
. O
. O

This O
correction O
of O
the O
in O
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
. O

This O
chastening O
of O
the O
defects O
in O
A B
- I
triiodothyronine I
cells O
supply O
further O
prove O
of O
the O
numerousness O
of O
effecter O
functions O
of O
the O
atm O
protein O
and O
propose O
potential O
approaches O
to O
gene O
therapy O
. O
. O

This O
correction O
of O
the O
certify O
flaw O
inward O
numerosity O
flaw O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
license O
license O
license O
boost O
. O

This O
correction O
of O
the O
defects O
in O
amp B
- I
mt I
cells O
provides O
further O
prove O
of O
the O
numerousness O
of O
effecter O
functions O
of O
the O
ATM O
protein O
and O
suggests O
potential O
approaches O
to O
cistron O
therapy O
. O
. O

the O
functions O
of O
the O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
suggests O
therapy O
multiplicity O
of O
effector O
to O
of O
correction O
ATM O
. O
and O
of O
possible O
approaches O
This O
the O
protein O
. O
gene O

This O
correction O
of O
the O
in O
- I
T I
cells O
provides O
further O
evidence O
of O
the O
of O
effector O
functions O
of O
the O
ATM O
protein O
possible O
approaches O
to O
therapy O
. O

This O
correction O
of O
the O
certify O
flaw O
inward O
numerosity O
boost O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
license O
license O
license O
boost O
. O

This O
correction O
of O
the O
defects O
in O
A B
- I
T I
cells O
provides O
further O
evidence O
of O
the O
multiplicity O
of O
effector O
functions O
of O
the O
ATM O
protein O
and O
suggests O
possible O
approaches O
to O
gene O
therapy O
. O
. O

gene O
genes O
resulting O
are O
alternative O
chromosomal O
translocations O
from O
in O
by O
mechanisms O
- O
Fusion O
specific O
overexpressed O
alveolar B
rhabdomyosarcoma I
. O

Fusion O
factor O
resulting O
from O
option O
chromosomal O
translocations O
are O
overexpressed O
by O
factor O
- O
particular O
mechanisms O
in O
alveolar B
rhabdosarcoma I
. O

merger O
cistron O
resulting O
from O
option O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
particular O
mechanisms O
in O
alveolar B
rhabdosarcoma I
. O

Fusion O
genes O
resulting O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
mechanisms O
in O
alveolar B
rhabdomyosarcoma I
. O

fusion O
genes O
ensue O
from O
option O
chromosomal O
translocations O
are O
overexpressed O
by O
factor O
- O
particular O
mechanisms O
in O
alveolar B
rhabdomyosarcoma I
. O

Fusion O
genes O
lead O
resulting O
from O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
mechanisms O
in O
alveolar B
rhabdomyosarcoma I
pass O
pass O
pass O
be O
. O

Fusion O
genes O
resulting O
from O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
- O
specific O
in O
alveolar B
rhabdomyosarcoma I
. O

Fusion O
genes O
lead O
resulting O
from O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
mechanisms O
in O
alveolar B
rhabdomyosarcoma I
pass O
pass O
pass O
be O
. O

genes O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
. O

Fusion O
genes O
overexpressed O
in O
alternative O
chromosomal O
specific O
are O
resulting O
by O
gene O
- O
translocations O
mechanisms O
from O
alveolar B
rhabdomyosarcoma I
. O

Fusion O
genes O
resulting O
from O
alternative O
chromosomal O
translocations O
are O
overexpressed O
by O
gene O
- O
specific O
mechanisms O
in O
alveolar B
rhabdomyosarcoma I
. O

Chromosomal O
translocations O
identified O
tumors I
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
proteins O
with O
tumorigenic O
potential O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
expression O
of O
or O
chimeric O
proteins O
with O
tumorigenic O
potential O
. O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
identify O
potential O
difference O
potential O
difference O
identify O
identify O
identify O
proteins O
with O
tumorigenic O

chromosomal O
translocations O
identify O
in O
haematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
construction O
of O
protooncogenes O
or O
founding O
of O
chimeric O
proteins O
with O
tumorigenic O
potency O
. O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
identify O
potential O
difference O
potential O
difference O
identify O
identify O
identify O
proteins O
with O
tumorigenic O

Chromosomal O
translocations O
identified O
in O
hematogenic B
and I
solid I
tumour I
upshot O
in O
deregulated O
expression O
of O
protooncogenes O
or O
origination O
of O
chimeral O
proteins O
with O
tumorigenic O
likely O
. O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
expression O
of O
or O
creation O
of O
chimeric O
proteins O
with O
tumorigenic O

deregulated O
translocations O
identified O
proteins O
hematopoietic B
and I
solid I
result I
tumors O
in O
with O
expression O
protooncogenes O
of O
. O
creation O
of O
chimeric O
in O
Chromosomal O
tumorigenic O
potential O
or O

chromosomal O
translocations O
distinguish O
in O
haematogenic B
and I
upstanding I
tumors I
consequence O
in O
deregulated O
expression O
of O
protooncogenes O
or O
foundation O
of O
chimeric O
proteins O
with O
tumorigenic O
potential O
. O

or O
translocations O
result O
solid O
hematopoietic B
and I
creation I
tumors I
identified O
in O
deregulated O
expression O
tumorigenic O
protooncogenes O
in O
Chromosomal O
of O
chimeric O
proteins O
with O
of O
potential O
. O

Chromosomal O
translocations O
identified O
in O
hematopoietic B
and I
solid I
tumors I
result O
in O
deregulated O
expression O
of O
protooncogenes O
or O
creation O
of O
chimeric O
proteins O
with O
tumorigenic O
potential O
. O

In O
pediatric O
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
t O
( O
2 O
; O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
translocation O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
fusion O
, O
respectively O
. O

inwards O
the O
paediatric O
solid B
neoplasm I
alveolar B
rhabdosarcoma I
, O
a O
logical O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variate O
t O
( O
single O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
get O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
unification O
proteins O
, O
severally O
. O

In O
; O
pediatric O
solid B
tumor I
alveolar B
( I
( O
a O
consistent O
t O
rhabdomyosarcoma O
2 O
13 O
( O
) O
( O
q35 O
, O
q14 O
) O
or O
generates O
t O
fusion O
1 O
respectively O
; O
; O
; O
p36 O
) O
q14 O
13 O
translocation O
- O
PAX3 O
- O
FKHR O
or O
the O
) O
FKHR O
variant O
proteins O
, O
PAX7 O
. O

In O
the O
pediatric O
solid B
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
) O
; O
) O
or O
variant O
( O
1 O
; O
13 O
) O
( O
) O
translocation O
generates O
PAX3 O
- O
FKHR O
or O
- O
FKHR O
, O
respectively O
. O

In O
the O
p36 O
solid B
tumor I
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
t O
13 O
q14 O
; O
13 O
or O
( O
q35 O
- O
2 O
) O
. O
variant O
generates O
( O
; O
; O
q14 O
) O
( O
pediatric O
FKHR O
; O
) O
translocation O
t O
PAX3 O
1 O
FKHR O
or O
PAX7 O
- O
( O
proteins O
fusion O
respectively O
, O
) O

inch O
the O
paediatric O
firm B
tumour I
dental B
rhabdosarcoma I
, O
a O
uniform O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variation O
t O
( O
single O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
get O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
coalition O
proteins O
, O
severally O
. O

In O
the O
pediatric O
solid B
rhabdomyosarcoma I
, O
a O
t O
2 O
; O
13 O
q35 O
variant O
t O
( O
; O
13 O
( O
p36 O
; O
translocation O
generates O
PAX3 O
- O
FKHR O
PAX7 O
FKHR O
fusion O
proteins O
, O
respectively O
. O

In O
the O
pediatric O
solid B
tumor I
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
generates O
tumor O
operating O
room O
coalition O
protein O
operating O
room O
severally O
protein O
tumour O
severally O
protein O
tumour O
severally O
tumour O
tumour O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
fusion O
proteins O
, O

In O
the O
pediatric O
solid B
tumor I
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
generates O
tumour O
operating O
room O
coalition O
protein O
operating O
room O
severally O
protein O
tumour O
severally O
protein O
tumour O
severally O
tumour O
operating O
room O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
fusion O
proteins O

translocation O
( O
pediatric O
solid B
( I
alveolar B
) I
; O
a O
consistent O
t O
( O
2 O
rhabdomyosarcoma O
- O
) O
tumor O
respectively O
; O
q14 O
; O
or O
variant O
t O
13 O
1 O
; O
- O
proteins O
( O
) O
the O
q14 O
) O
FKHR O
generates O
PAX3 O
13 O
In O
or O
PAX7 O
, O
FKHR O
fusion O
p36 O
, O
q35 O
. O

In O
the O
pediatric O
solid B
tumor I
alveolar B
rhabdomyosarcoma I
, O
a O
consistent O
t O
( O
2 O
; O
13 O
) O
( O
q35 O
; O
q14 O
) O
or O
variant O
t O
( O
1 O
; O
13 O
) O
( O
p36 O
; O
q14 O
) O
translocation O
generates O
PAX3 O
- O
FKHR O
or O
PAX7 O
- O
FKHR O
fusion O
proteins O
, O
respectively O
. O

indiana O
this O
reputation O
, O
we O
show O
that O
indiana O
summation O
to O
running O
change O
these O
translocations O
are O
associated O
with O
fusion O
product O
overexpression O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
translocations O
are O
associated O
with O
fusion O
study O
study O
study O
study O
study O
study O
product O
overexpression O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
translocations O
are O
associated O
with O
fusion O
study O
study O
study O
study O
study O
study O
product O
overexpression O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
to O
functional O
these O
translocations O
are O
associated O
with O
fusion O
product O

are O
this O
addition O
that O
we O
demonstrate O
associated O
in O
report O
to O
functional O
alterations O
. O
translocations O
, O
In O
with O
fusion O
product O
overexpression O
these O

in O
this O
reputation O
, O
we O
evidence O
that O
in O
addition O
to O
operable O
alterations O
these O
translocations O
are O
connect O
with O
fusion O
product O
overexpression O
. O

. O
this O
report O
functional O
we O
demonstrate O
that O
product O
are O
to O
, O
alterations O
translocations O
these O
addition O
associated O
with O
fusion O
in O
In O
overexpression O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
translocations O
are O
associated O
with O
fusion O
study O
study O
study O
study O
study O
translocation O
product O
overexpression O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
are O
fusion O
product O
overexpression O
. O

inward O
this O
story O
, O
we O
manifest O
that O
inward O
addition O
to O
usable O
adjustment O
these O
translocations O
are O
associated O
with O
coalition O
product O
overexpression O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
in O
addition O
to O
functional O
alterations O
these O
translocations O
are O
associated O
with O
fusion O
product O
overexpression O
. O

Furthermore O
FKHR O
PAX3 O
- O
, O
and O
- O
occurs O
FKHR O
overexpression O
distinct O
by O
PAX7 O
mechanisms O
. O

Furthermore O
, O
chemical O
mechanism O
mechanism O
mechanism O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
aside O
overexpression O
occurs O
by O
distinct O
mechanisms O

moreover O
, O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
overexpression O
hap O
by O
discrete O
mechanics O
. O

distinct O
, O
PAX3 O
Furthermore O
- O
and O
PAX7 O
by O
FKHR O
overexpression O
occurs O
FKHR O
- O
mechanisms O
. O

moreover O
, O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
overexpression O
happen O
by O
decided O
mechanisms O
. O

Furthermore O
, O
chemical O
mechanism O
mechanism O
mechanism O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
clear O
cut O
overexpression O
occurs O
by O
distinct O

Furthermore O
PAX3 O
FKHR O
PAX7 O
- O
FKHR O
overexpression O
occurs O
by O
distinct O
mechanisms O
. O

- O
- O
PAX3 O
, O
FKHR O
and O
overexpression O
Furthermore O
FKHR O
PAX7 O
occurs O
by O
distinct O
. O
mechanisms O

furthermore O
, O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
overexpression O
hap O
by O
discrete O
mechanisms O
. O

Furthermore O
, O
chemical O
mechanism O
mechanism O
mechanism O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
clear O
cut O
overexpression O
occurs O
by O
distinct O

Furthermore O
, O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
overexpression O
occurs O
by O
distinct O
mechanisms O
. O

recording O
of O
PAX3 O
- O
FKHR O
is O
increased O
proportional O
to O
barbarian O
- O
type O
PAX3 O
by O
a O
imitate O
number O
- O
independent O
procedure O
. O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
to O
wild O
- O
type O
PAX3 O
by O
a O
copy O
number O
- O
serve O
written O
matter O
written O
matter O
written O
matter O
written O
matter O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
to O
wild O
- O
type O
PAX3 O
by O
a O
copy O
number O
- O
serve O
written O
matter O
written O
matter O
written O
matter O
written O
matter O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
wild O
- O
PAX3 O
by O
a O
copy O
number O
- O
independent O

a O
of O
to O
increased O
FKHR O
is O
copy O
relative O
PAX3 O
wild O
- O
type O
. O
by O
- O
Transcription O
number O
- O
independent O
process O
PAX3 O

arrangement O
of O
PAX3 O
- O
FKHR O
is O
increased O
congenator O
to O
violent O
- O
case O
PAX3 O
by O
a O
simulate O
number O
- O
independent O
serve O
. O

. O
of O
PAX3 O
- O
FKHR O
is O
increased O
independent O
a O
wild O
- O
type O
by O
PAX3 O
to O
copy O
number O
- O
relative O
Transcription O
process O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
to O
wild O
- O
type O
PAX3 O
by O
a O
copy O
number O
- O
serve O
written O
matter O
written O
matter O
written O
matter O
written O
matter O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
to O
wild O
- O
type O
PAX3 O
a O
- O
independent O
process O
. O

arranging O
of O
PAX3 O
- O
FKHR O
is O
increased O
proportional O
to O
hazardous O
- O
type O
PAX3 O
by O
a O
copy O
count O
- O
autonomous O
procedure O
. O

Transcription O
of O
PAX3 O
- O
FKHR O
is O
increased O
relative O
to O
wild O
- O
type O
PAX3 O
by O
a O
copy O
number O
- O
independent O
process O
. O

In O
, O
PAX7 O
FKHR O
results O
fusion O
gene O
amplification O
. O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
fusion O
gene O
amplification O

inward O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
fusion O
cistron O
gain O
. O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
elaboration O
elaboration O
line O
fusion O
gene O
amplification O
. O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
elaboration O
elaboration O
line O
fusion O
gene O
amplification O
. O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
elaboration O
elaboration O
line O
fusion O
gene O
amplification O
. O

In O
line O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
fusion O
cistron O
elaboration O
. O

In O
contrast O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
fusion O
. O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
lead O
from O
fusion O
cistron O
elaboration O
. O

In O
- O
, O
PAX7 O
. O
FKHR O
overexpression O
contrast O
from O
fusion O
gene O
amplification O
results O

In O
contrast O
, O
PAX7 O
- O
FKHR O
overexpression O
results O
from O
fusion O
gene O
amplification O
. O

Thus O
, O
in O
- O
specific O
- O
were O
presumably O
to O
overexpress O
PAX3 O
to O
between O
and O
PAX7 O
- O
FKHR O
in O
rhabdomyosarcoma B
alveolar I
, O
selected O
due O
mechanisms O
differences O
regulation O
gene O
loci O
the O
wild O
- O
FKHR O
type O
. O

Thus O
- O
specific O
mechanisms O
were O
to O
overexpress O
FKHR O
and O
- O
FKHR O
, O
due O
to O
differences O
regulation O
between O
the O
- O
type O
loci O
. O

Thus O
, O
gene O
- O
mechanism O
be O
be O
specific O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdomyosarcoma I
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
loci O
chemical O
mechanism O
chemical O
mechanism O
chemical O
mechanism O
chemical O
mechanism O

Thus O
, O
gene O
- O
mechanism O
be O
particular O
specific O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdomyosarcoma I
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
loci O
chemical O
mechanism O
chemical O
mechanism O
chemical O
mechanism O
chemical O
mechanism O

, O
alveolar O
gene O
- O
specific O
mechanisms O
regulation O
selected O
to O
overexpress O
PAX3 O
between O
FKHR O
differences O
wild O
- O
FKHR O
in O
- B
rhabdomyosarcoma I
, O
presumably O
. O
to O
and O
in O
were O
Thus O
type O
due O
- O
the O
loci O
PAX7 O

Thus O
, O
gene O
- O
specific O
mechanisms O
to O
overexpress O
PAX3 O
- O
and O
PAX7 O
- O
FKHR O
in O
rhabdomyosarcoma I
, O
presumably O
due O
differences O
in O
between O
the O
wild O
- O
type O
loci O
. O

Thus O
, O
cistron O
- O
particular O
mechanisms O
were O
take O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdosarcoma I
, O
presumptively O
ascribable O
to O
deviation O
in O
regulating O
between O
the O
baseless O
- O
type O
locale O
. O

olibanum O
, O
factor O
- O
particular O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
dental B
rhabdosarcoma I
, O
presumptively O
due O
to O
dispute O
in O
regulating O
between O
the O
godforsaken O
- O
type O
locus O
. O

Thus O
, O
gene O
- O
mechanism O
be O
particular O
specific O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdomyosarcoma I
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
loci O
chemical O
mechanism O
chemical O
mechanism O
chemical O
mechanism O
chemical O
mechanism O

Thus O
, O
cistron O
- O
particular O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdosarcoma I
, O
presumptively O
imputable O
to O
divergence O
in O
regulating O
between O
the O
wild O
- O
type O
locale O
. O

Thus O
, O
gene O
- O
specific O
mechanisms O
were O
selected O
to O
overexpress O
PAX3 O
- O
FKHR O
and O
PAX7 O
- O
FKHR O
in O
alveolar B
rhabdomyosarcoma I
, O
presumably O
due O
to O
differences O
in O
regulation O
between O
the O
wild O
- O
type O
loci O
. O

. O
postulate O
that O
of O
overexpression O
mechanisms O
ensure O
these O
the O
level O
these O
gene O
for O
product O
critical O
oncogenic O
effects O
of O
a O
We O
fusions O
. O

We O
postulate O
that O
these O
overexpression O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
coalition O
decisive O
decisive O
decisive O
decisive O
decisive O
these O
fusions O
. O
. O

We O
postulate O
that O
these O
overexpression O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
coalition O
decisive O
decisive O
decisive O
decisive O
decisive O
these O
fusions O
. O
. O

We O
necessitate O
that O
these O
overexpression O
mechanisms O
control O
a O
vital O
charge O
of O
gene O
intersection O
for O
the O
oncogenic O
gist O
of O
these O
fusions O
. O
. O

We O
postulate O
that O
overexpression O
mechanisms O
ensure O
a O
critical O
of O
gene O
product O
for O
oncogenic O
effects O
these O
fusions O
. O
. O

these O
ensure O
a O
critical O
of O
gene O
for O
the O
oncogenic O
effects O
of O
these O
fusions O
. O
. O

We O
require O
that O
these O
overexpression O
mechanisms O
guarantee O
a O
critical O
rase O
of O
factor O
intersection O
for O
the O
oncogenic O
effectuate O
of O
these O
fusions O
. O
. O

the O
postulate O
critical O
ensure O
overexpression O
mechanisms O
oncogenic O
a O
that O
level O
of O
gene O
. O
for O
these O
We O
effects O
of O
these O
fusions O
product O
. O

We O
postulate O
that O
these O
overexpression O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
coalition O
decisive O
decisive O
decisive O
decisive O
mechanism O
these O
fusions O
. O
. O

We O
postulate O
that O
these O
ensure O
a O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
these O
. O

We O
postulate O
that O
these O
overexpression O
mechanisms O
ensure O
a O
critical O
level O
of O
gene O
product O
for O
the O
oncogenic O
effects O
of O
these O
fusions O
. O
. O

atm O
and O
p53 O
collaborate O
in O
apoptosis O
and O
curtailment O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
intense B
radiotherapy I
perniciousness I
. O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
get I
together O
get I
together O
get I
together O
get I
together O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
get I
together O
get I
together O
get I
together O
get I
together O

p53 O
apoptosis O
and O
suppression O
tumorigenesis O
, O
not O
in O
resistance O
to O
acute B
radiation I
toxicity I
. O

atm O
and O
p53 O
cooperate O
in O
suppression O
of O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
toxicity I
. O

p53 O
cooperate O
in O
apoptosis O
suppression O
of O
tumorigenesis O
, O
but O
in O
resistance O
to O
acute B
toxicity I
. O

radiation O
and O
p53 O
toxicity O
in O
apoptosis O
and O
of O
suppression O
tumorigenesis O
resistance O
but O
not O
. O
atm O
to O
acute B
, I
cooperate I
in O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
get I
together O
get I
together O
get I
together O
get I
together O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
inhibition O
of O
tumorigenesis O
, O
but O
not O
in O
immunity O
to O
acute B
radiation I
perniciousness I
. O

acute O
and O
p53 O
cooperate O
in O
apoptosis O
in O
but O
of O
tumorigenesis O
, O
resistance O
atm O
and O
suppression O
radiation O
not B
to I
toxicity I
. O

atm O
and O
p53 O
cooperate O
in O
apoptosis O
and O
suppression O
of O
tumorigenesis O
, O
but O
not O
in O
resistance O
to O
acute B
radiation I
toxicity I
. O

Mutations O
in O
atm O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
respectively O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
telangiectasia I
- I
Fraumeni I
syndrome I
, O
respectively O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
asynchronous I
transfer I
mode I
severally I
severally I
asynchronous I
transfer I
mode I
asynchronous O
transfer O
mode O

Mutations O
in O
atm O
and O
p53 O
effort O
the O
human O
cancer B
- I
affiliate I
diseases I
ataxy B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
severally O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
asynchronous I
transfer I
mode I
severally I
severally I
asynchronous I
transfer I
mode I
asynchronous O
transfer O
mode O

sport O
in O
atm O
and O
p53 O
drive O
the O
human O
crab B
- I
associated I
diseases I
dyssynergia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
severally O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
diseases I
ataxia B
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O

associated O
in O
atm O
Fraumeni O
p53 O
cause O
the O
cancer O
human B
- I
syndrome I
diseases I
- B
ataxia I
. I
and O
Li B
- I
and I
Mutations I
, O
respectively O
telangiectasia O

mutation O
in O
atm O
and O
p53 O
campaign O
the O
homo O
cancer B
- I
associated I
diseases I
ataxy B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
severally O
. O

telangiectasia O
in O
cancer O
the O
p53 O
cause O
and O
human O
atm B
- I
associated I
diseases I
, B
- I
and I
Mutations O
Li B
- I
Fraumeni I
syndrome I
ataxia O
respectively O
. O

Mutations O
in O
atm O
and O
p53 O
cause O
the O
human O
cancer B
- I
associated I
diseases I
ataxia B
- I
telangiectasia I
and O
Li B
- I
Fraumeni I
syndrome I
, O
respectively O
. O

The O
two O
apoptosis O
are O
believed O
pathways O
interact O
- O
a O
number O
of O
checkpoints O
radiation O
including O
regulation O
and O
DNA O
damage O
induced O
- O
cell O
in O
cycle O
to O
, O
and O
genes O
proliferation O
sensitivity O
, O
of O
, O
cellular O
. O

The O
are O
believed O
to O
interact O
a O
number O
, O
including O
of O
DNA O
cell O
cycle O
checkpoints O
, O
and O
radiation O
sensitivity O
and O
cellular O
proliferation O
. O

The O
two O
genes O
are O
regulating O
radiation O
syndrome O
bicycle O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
DNA O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
determine O
determine O
determine O
determine O
determine O
determine O
admit O

The O
two O
genes O
are O
regulating O
radiation O
syndrome O
believe O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
DNA O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
determine O
determine O
determine O
determine O
determine O
determine O
admit O

two O
- O
genes O
are O
believed O
to O
and O
in O
a O
number O
of O
radiation O
, O
, O
, O
of O
DNA O
damage O
pathways O
induced O
cell O
- O
. O
checkpoints O
including O
apoptosis O
interact O
The O
cellular O
cycle O
and O
sensitivity O
proliferation O
regulation O

The O
two O
genes O
are O
believed O
to O
a O
number O
of O
pathways O
including O
regulation O
of O
DNA O
damage O
induced O
cell O
- O
cycle O
, O
apoptosis O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
. O

The O
deuce O
cistron O
are O
trust O
to O
interact O
in O
a O
bit O
of O
tract O
, O
include O
regulating O
of O
DNA O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
predisposition O
, O
and O
cellular O
proliferation O
. O

The O
two O
factor O
are O
trust O
to O
interact O
in O
a O
list O
of O
pathways O
, O
admit O
rule O
of O
dna O
terms O
- O
hasten O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
actinotherapy O
predisposition O
, O
and O
cellular O
proliferation O
. O

The O
two O
genes O
are O
regulating O
radiation O
syndrome O
believe O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
DNA O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
determine O
determine O
determine O
determine O
determine O
determine O
admit O

The O
two O
cistron O
are O
consider O
to O
interact O
in O
a O
total O
of O
pathways O
, O
including O
regularisation O
of O
DNA O
damage O
- O
induct O
cell O
- O
hertz O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitiveness O
, O
and O
cellular O
proliferation O
. O

The O
two O
genes O
are O
believed O
to O
interact O
in O
a O
number O
of O
pathways O
, O
including O
regulation O
of O
DNA O
damage O
- O
induced O
cell O
- O
cycle O
checkpoints O
, O
apoptosis O
and O
radiation O
sensitivity O
, O
and O
cellular O
proliferation O
. O

Atm O
- O
null O
mice O
modernise O
chiefly O
deoxythymidine O
monophosphate O
a O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop O
mainly B
T I
- I
cell I
lymphomas O
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
overhaul O
overhaul O
overhaul O
overhaul O
antiophthalmic O

Atm O
- O
null O
as O
for O
p53 O
, O
mainly O
T B
cell I
lymphomas I
, O
view O
that O
these O
genes O
have O
roles O
thymocyte O
development O
. O

Atm O
- O
naught O
shiner O
, O
as O
well O
as O
those O
naught O
for O
p53 O
, O
produce O
chiefly O
thyroxin B
- I
cell I
lymphomas I
, O
supporting O
the O
perspective O
that O
these O
factor O
have O
similar O
character O
in O
thymocyte O
exploitation O
. O

Atm O
- O
null O
mice O
, O
as O
well O
those O
p53 O
, O
develop O
mainly O
T B
- I
cell I
lymphomas I
, O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
. O

Atm O
- O
nil O
mice O
, O
as O
well O
as O
those O
nil O
for O
p53 O
, O
develop O
mainly O
thyroxin B
- I
cell I
lymphomas I
, O
corroborate O
the O
watch O
that O
these O
cistron O
have O
alike O
roles O
in O
thymocyte O
ontogenesis O
. O

Atm O
- O
null O
mice O
modernise O
chiefly O
deoxythymidine O
monophosphate O
a O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop O
mainly B
T I
- I
cell I
lymphomas O
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
overhaul O
overhaul O
overhaul O
overhaul O
antiophthalmic O

Atm O
- O
null O
mouse O
, O
as O
intimately O
as O
those O
null O
for O
p53 O
, O
uprise O
mainly O
t B
- I
cell I
lymphomas I
, O
supporting O
the O
perspective O
that O
these O
cistron O
have O
standardised O
office O
in O
thymocyte O
growing O
. O

supporting O
lymphomas O
null O
mice O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
these O
in O
T B
- I
cell I
similar I
, O
- O
the O
development O
that O
develop O
genes O
have O
Atm O
mainly O
view O
thymocyte O
roles O
. O

Atm O
- O
null O
mice O
, O
as O
as O
null O
for O
p53 O
, O
develop O
mainly O
T B
- I
lymphomas I
, O
supporting O
the O
view O
that O
these O
similar O
roles O
in O
development O

Atm O
- O
null O
mice O
modernise O
chiefly O
deoxythymidine O
monophosphate O
jail O
cell O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop B
mainly I
T I
- I
cell O
lymphomas O
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
overhaul O
overhaul O
overhaul O
overhaul O

Atm O
- O
null O
mice O
, O
as O
well O
as O
those O
null O
for O
p53 O
, O
develop O
mainly O
T B
- I
cell I
lymphomas I
, O
supporting O
the O
view O
that O
these O
genes O
have O
similar O
roles O
in O
thymocyte O
development O
. O

To O
study O
the O
interactions O
gene O
completely O
multiply O
mouse O
cistron O
of O
these O
two O
genes O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
for O
completely O
null O
alleles O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
cistron O
cistron O
grade O
. O

To O
study O
the O
interactions O
gene O
completely O
multiply O
mouse O
cistron O
of O
these O
two O
genes O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
for O
completely O
null O
alleles O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
cistron O
cistron O
grade O
. O

and O
study O
the O
interactions O
of O
these O
we O
heterozygous O
on O
an O
organismal O
level O
both O
two O
p53 O
genotypic O
genes O
of O
null O
alleles O
To O
, O
atm O
for O
bred O
to O
produce O
all O
. O
combinations O
mice O

To O
study O
the O
interactions O
gene O
completely O
multiply O
mouse O
cistron O
of O
these O
two O
genes O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
for O
completely O
null O
alleles O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
cistron O
cistron O
grade O
. O

To O
study O
the O
interactions O
these O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
. O

To O
analyse O
the O
interactions O
of O
these O
ii O
factor O
on O
an O
organismic O
level O
, O
we O
multiply O
mice O
heterozygous O
for O
nil O
allelomorph O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combining O
. O

genotypic O
study O
p53 O
bred O
of O
these O
all O
genes O
interactions O
an O
organismal O
level O
of O
we O
the O
on O
heterozygous O
for O
null O
alleles O
, O
both O
atm O
and O
mice O
two O
produce O
to O
To O
combinations O
. O

To O
study O
the O
interactions O
of O
these O
two O
genes O
on O
organismal O
level O
we O
bred O
mice O
heterozygous O
for O
null O
alleles O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
. O

organismal O
study O
the O
genotypic O
of O
these O
two O
to O
and O
an O
p53 O
level O
produce O
alleles O
atm O
mice O
heterozygous O
for O
. O
we O
of O
both O
bred O
on O
To O
genes O
, O
all O
interactions O
combinations O
null O

To O
survey O
the O
interactions O
of O
these O
ii O
cistron O
on O
an O
organismal O
charge O
, O
we O
spawn O
mouse O
heterozygous O
for O
naught O
alleles O
of O
both O
atm O
and O
p53 O
to O
create O
all O
genotypic O
compounding O
. O

To O
study O
the O
interactions O
of O
these O
two O
genes O
on O
an O
organismal O
level O
, O
we O
bred O
mice O
heterozygous O
for O
null O
alleles O
of O
both O
atm O
and O
p53 O
to O
produce O
all O
genotypic O
combinations O
. O

Mice O
doubly O
null O
for O
organization O
relation O
foreclose O
asynchronous O
transfer O
mode O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration B
of O
tumour O
formation O
relative O
to O
singly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
governance O
governance O
governance O
governance O

Mice O
doubly O
null O
and O
acceleration O
of O
tumour B
relative O
to O
null O
mice O
, O
both O
genes O
collaborate O
in O
a O
manner O
prevent O
tumorigenesis O
. O

shiner O
twice O
nil O
for O
atm O
and O
p53 O
march O
a O
dramatic O
acceleration O
of O
neoplasm B
formation O
relation O
to O
singly O
nil O
shiner O
, O
argue O
that O
both O
cistron O
collaborate O
in O
a O
important O
manner O
to O
prevent O
tumorigenesis O
. O

Mice O
doubly O
null O
for O
atm O
and O
p53 O
a O
of O
tumour B
formation O
relative O
to O
singly O
null O
mice O
, O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
. O

Mice O
twice O
naught O
for O
atm O
and O
p53 O
march O
a O
dramatic O
quickening O
of O
tumor B
formation O
proportional O
to O
singly O
naught O
mice O
, O
point O
that O
both O
genes O
collaborate O
in O
a O
significant O
mode O
to O
keep O
tumorigenesis O
. O

Mice O
doubly O
null O
for O
organization O
relation O
foreclose O
asynchronous O
transfer O
mode O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration B
of O
tumour O
formation O
relative O
to O
singly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
governance O
governance O
governance O
governance O

Mice O
twice O
zero O
for O
atm O
and O
p53 O
exhibited O
a O
spectacular O
speedup O
of O
neoplasm B
establishment O
congeneric O
to O
singly O
zero O
mice O
, O
show O
that O
both O
genes O
collaborate O
in O
a O
pregnant O
manner O
to O
prevent O
tumorigenesis O
. O

indicating O
mice O
null O
for O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration O
of O
tumour B
collaborate O
to O
to O
singly O
null O
significant O
, O
doubly O
that O
tumorigenesis O
genes O
formation O
in O
a O
Mice O
relative O
both O
prevent O
manner O
. O

Mice O
doubly O
null O
for O
atm O
and O
exhibited O
dramatic O
acceleration O
of O
tumour B
formation O
relative O
to O
singly O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
significant O
manner O
to O
tumorigenesis O

Mice O
doubly O
null O
for O
organization O
relation O
foreclose O
in O
two O
ways O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration B
of O
tumour O
formation O
relative O
to O
singly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
governance O
governance O
governance O
governance O

Mice O
doubly O
null O
for O
atm O
and O
p53 O
exhibited O
a O
dramatic O
acceleration O
of O
tumour B
formation O
relative O
to O
singly O
null O
mice O
, O
indicating O
that O
both O
genes O
collaborate O
in O
a O
significant O
manner O
to O
prevent O
tumorigenesis O
. O

With O
respect O
to O
their O
utilize O
simply O
partially O
tolerant O
use O
roles O
in O
apoptosis O
, O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
irradiation O
father O
- O
induced O
apoptosis O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
utilise O
utilise O
fork O
out O

With O
respect O
to O
their O
utilize O
simply O
partially O
tolerant O
use O
roles O
in O
apoptosis O
, O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
irradiation O
ray O
- O
induced O
apoptosis O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
utilise O
utilise O
fork O
out O

additional O
respect O
to O
their O
roles O
in O
only O
to O
loss O
of O
atm O
rendered O
, O
apoptosis O
loss O
complete O
, O
apoptosis O
- O
induced O
With O
thymocytes O
whereas O
irradiation O
partly O
of O
p53 O
engendered O
. O
resistance O
resistant O

With O
respect O
to O
their O
utilize O
simply O
partially O
tolerant O
use O
roles O
in O
apoptosis O
, O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
irradiation O
father O
- O
induced O
apoptosis O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
utilise O
utilise O
fork O
out O

With O
respect O
to O
their O
in O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
. O

With O
observe O
to O
their O
part O
in O
apoptosis O
, O
expiration O
of O
atm O
supply O
thymocytes O
only O
partly O
resistive O
to O
irradiation O
- O
cause O
apoptosis O
, O
whereas O
extra O
expiration O
of O
p53 O
get O
nail O
resistance O
. O

complete O
respect O
loss O
partly O
roles O
in O
engendered O
, O
their O
of O
atm O
rendered O
apoptosis O
only O
to O
loss O
to O
irradiation O
- O
induced O
thymocytes O
, O
whereas O
additional O
resistant O
apoptosis O
p53 O
of O
With O
resistance O
. O

With O
respect O
to O
their O
roles O
in O
apoptosis O
, O
loss O
atm O
rendered O
only O
partly O
resistant O
to O
irradiation O
- O
induced O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
. O

atm O
respect O
to O
complete O
roles O
in O
apoptosis O
of O
additional O
of O
loss O
rendered O
p53 O
induced O
whereas O
resistant O
to O
irradiation O
. O
only O
apoptosis O
, O
partly O
loss O
With O
, O
thymocytes O
engendered O
their O
resistance O
- O

With O
honour O
to O
their O
function O
in O
apoptosis O
, O
expiration O
of O
atm O
rendered O
thymocytes O
only O
partially O
resistive O
to O
shaft O
- O
rush O
apoptosis O
, O
whereas O
extra O
expiration O
of O
p53 O
engendered O
terminated O
resistance O
. O

With O
respect O
to O
their O
roles O
in O
apoptosis O
, O
loss O
of O
atm O
rendered O
thymocytes O
only O
partly O
resistant O
to O
irradiation O
- O
induced O
apoptosis O
, O
whereas O
additional O
loss O
of O
p53 O
engendered O
complete O
resistance O
. O

apoptotic O
implies O
that O
atm O
irradiation O
- O
induced O
the O
completely O
p53 O
not O
pathways O
This O
are O
and O
congruent O
. O

This O
entail O
that O
the O
shaft O
- O
induct O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
altogether O
congruous O
. O

This O
involve O
that O
the O
irradiation O
- O
cause O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
all O
congruous O
. O

This O
implies O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
completely O
congruent O
. O

This O
entail O
that O
the O
irradiation O
- O
stimulate O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
whole O
congruous O
. O

This O
implies O
asynchronous O
transfer O
mode O
congruous O
that O
the O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
completely O
congruent O
cause O
cause O

This O
implies O
that O
the O
irradiation O
- O
induced O
atm O
p53 O
apoptotic O
are O
not O
completely O
congruent O
. O

This O
implies O
asynchronous O
transfer O
mode O
congruous O
that O
the O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
completely O
congruent O
cause O
cause O

implies O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O

This O
implies O
and O
completely O
irradiation O
- O
are O
atm O
that O
p53 O
apoptotic O
pathways O
induced O
not O
the O
congruent O
. O

This O
implies O
that O
the O
irradiation O
- O
induced O
atm O
and O
p53 O
apoptotic O
pathways O
are O
not O
completely O
congruent O
. O

Finally O
- O
DNA O
in O
contrast O
to O
prior O
acute O
- O
atm O
and O
a O
radiation O
not O
appear O
predictions O
interact O
in O
the B
do I
toxicity I
. O
suggesting O
p53 O
separate O
to O
pathway O
response O
for O
this O
and O
human O
damage O
and O
having O
. O
for O
atm O
prognosis O
and O
treatment O
of O
effector O
tumours B
implications O
, O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B
radiation I
toxicity I
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
homo O
tumor O
medical O
prognosis O
homo O
tumor O
line O
homo O
tumor O
line O
line O
line O
line O
line O
for O
the O
prognosis O
and O
treatment O
of O
human B
tumours O
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B
radiation I
toxicity I
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
homo O
tumor O
medical O
prognosis O
homo O
tumor O
line O
homo O
tumor O
line O
line O
line O
line O
advise O
for O
the O
prognosis O
and O
treatment O
of O
human B
tumours O
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
atm O
and O
p53 O
not O
to O
interact O
in O
toxicity I
atm O
effector O
pathway O
this O
DNA O
response O
and O
having O
the O
prognosis O
and O
treatment O
of O
tumours B
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
and O
p53 O
do O
not O
appear O
toxicity I
a O
atm O
effector O
pathway O
this O
DNA O
damage O
response O
and O
having O
prognosis O
and O
treatment O
of O
human O
tumours B
. O

having O
acute O
and O
in O
contrast O
to O
of O
predictions O
- O
atm O
and O
treatment O
do O
pathway O
this O
to O
interact O
in O
and B
radiation I
toxicity I
, O
for O
a O
tumours O
atm O
damage O
not O
appear O
separate O
DNA O
implications O
response O
- O
Finally O
effector O
for O
the O
prognosis O
and O
p53 O
prior O
human O
suggesting B
. O
. O

eventually O
- O
and O
in O
contrast O
to O
anterior O
forecasting O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
penetrating B
radioactivity I
perniciousness I
, O
suggesting O
a O
separate O
atm O
effecter O
tract O
for O
this O
dna O
wrong O
reply O
and O
having O
implications O
for O
the O
forecast O
and O
discourse O
of O
human O
tumours B
. O
. O

lastly O
- O
and O
in O
demarcation O
to O
anterior O
prognostication O
- O
atm O
and O
p53 O
do O
not O
seem O
to O
interact O
in O
keen B
radiation I
perniciousness I
, O
suggesting O
a O
separate O
atm O
effecter O
tract O
for O
this O
dna O
terms O
answer O
and O
having O
implications O
for O
the O
prognosis O
and O
treatment O
of O
human O
tumor B
. O
. O

last O
- O
and O
in O
line O
to O
anterior O
prognostication O
- O
atm O
and O
p53 O
do O
not O
look O
to O
interact O
in O
intense B
actinotherapy I
toxicity I
, O
suggesting O
a O
disunite O
atm O
effector O
pathway O
for O
this O
dna O
damage O
response O
and O
having O
import O
for O
the O
forecast O
and O
treatment O
of O
homo O
tumor B
. O
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B
radiation I
toxicity I
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
homo O
tumor O
medical O
prognosis O
homo O
tumor O
line O
homo O
tumor O
line O
line O
line O
line O
line O
for O
the O
prognosis O
and O
treatment O
of O
human B
tumours O
. O

Finally O
- O
and O
in O
contrast O
to O
prior O
predictions O
- O
atm O
and O
p53 O
do O
not O
appear O
to O
interact O
in O
acute B
radiation I
toxicity I
, O
suggesting O
a O
separate O
atm O
effector O
pathway O
for O
this O
DNA O
damage O
response O
and O
having O
implications O
for O
the O
prognosis O
and O
treatment O
of O
human O
tumours B
. O
. O

Trinucleotide O
expansion O
at O
myotonic B
locus O
expression O
of O
DMAHP O
. O

Trinucleotide O
repeat O
expansion O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
expression O
of O
DMAHP O

Trinucleotide O
reprise O
elaboration O
at O
the O
myotonic B
dystrophy I
locale O
reduces O
expression O
of O
DMAHP O
. O

Trinucleotide O
repeat O
expansion O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
ingeminate O
ingeminate O
ingeminate O
expression O
of O
DMAHP O
. O

Trinucleotide O
repeat O
expansion O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
ingeminate O
ingeminate O
ingeminate O
expression O
of O
DMAHP O
. O

Trinucleotide O
repeat O
expansion O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
ingeminate O
ingeminate O
ingeminate O
expression O
of O
DMAHP O
. O

Trinucleotide O
recur O
expansion O
at O
the O
myotonic B
dystrophy I
locale O
reduces O
saying O
of O
DMAHP O
. O

Trinucleotide O
repeat O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
expression O
. O

Trinucleotide O
repeat O
enlargement O
at O
the O
myotonic B
dystrophy I
locale O
reduces O
reflexion O
of O
DMAHP O
. O

Trinucleotide O
the O
expansion O
at O
. O
myotonic B
dystrophy I
repeat O
reduces O
expression O
of O
DMAHP O
locus O

Trinucleotide O
repeat O
expansion O
at O
the O
myotonic B
dystrophy I
locus O
reduces O
expression O
of O
DMAHP O
. O

Myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
DM B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
on O
chromosome O
19q13 O
. O

Myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
DM B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
inward O
on O
chromosome O
19q13 O
. O

Myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
DM B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
cause O
on O
chromosome O
19q13 O
. O

repeat B
the I
, O
or O
dystrophia B
myotonica I
an O
protein B
) O
, O
is O
( O
autosomal B
3 I
region I
disorder I
caused O
by O
DM O
expansion O
of O
DMPK O
untranslated O
trinucleotide O
Myotonic O
in O
the O
dominant O
multisystem O
CTG O
of O
gene O
a O
dystrophy O
kinase O
the O
on O
chromosome O
19q13 O
. O

Myotonic B
dystrophy I
, O
or O
DM B
) O
, O
is O
an O
dominant I
multisystem I
the O
a O
CTG O
in O
untranslated O
region O
of O
the O
protein O
kinase O
chromosome O
19q13 O

myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
dm B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
distract I
stimulate O
by O
the O
elaboration O
of O
a O
CTG O
trinucleotide O
restate O
in O
the O
troika O
untranslated O
area O
of O
the O
DMPK O
protein O
kinase O
factor O
on O
chromosome O
19q13 O
. O

myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
decimetre B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
make O
by O
the O
enlargement O
of O
a O
CTG O
trinucleotide O
ingeminate O
in O
the O
ternion O
untranslated O
realm O
of O
the O
DMPK O
protein O
kinase O
cistron O
on O
chromosome O
19q13 O
. O

of B
kinase I
, O
or O
caused B
myotonica I
chromosome O
the B
) O
, O
is O
an O
autosomal B
repeat I
by I
disorder I
dystrophia O
multisystem O
the O
expansion O
dominant O
a O
CTG O
trinucleotide O
dystrophy O
in O
the O
19q13 O
Myotonic O
region O
untranslated O
( O
DMPK O
protein O
of O
gene O
on O
DM O
3 O
. O

myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
dm B
) O
, O
is O
an O
autosomal B
prevalent I
multisystem I
cark I
stimulate O
by O
the O
enlargement O
of O
a O
CTG O
trinucleotide O
repetition O
in O
the O
triplet O
untranslated O
part O
of O
the O
DMPK O
protein O
kinase O
factor O
on O
chromosome O
19q13 O
. O

Myotonic B
dystrophy I
of O
or O
dystrophia B
gene I
is O
DM B
) O
, O
( O
the O
expansion B
dominant I
multisystem I
the I
caused O
by O
chromosome O
autosomal O
of O
a O
CTG O
myotonica O
repeat O
disorder O
an O
DMPK O
the O
region O
, O
3 O
untranslated O
protein O
kinase O
trinucleotide O
on O
in O
19q13 O
. O

Myotonic B
dystrophy I
, O
or O
dystrophia B
myotonica I
( O
DM B
) O
, O
is O
an O
autosomal B
dominant I
multisystem I
disorder I
caused O
by O
the O
expansion O
of O
a O
CTG O
trinucleotide O
repeat O
in O
the O
3 O
untranslated O
region O
of O
the O
DMPK O
protein O
kinase O
gene O
on O
chromosome O
19q13 O
. O

) O
( O
refs O
1 O
. O
3 O
3 O
- O

trine O
( O
referee O
1 O
- O
trine O
) O
. O

refs O
3 O
) O
. O

3 O
 O
 O
( O
refs O
1 O
- O
3 O
) O
. O

3 O
refs O
1 O
) O
. O

3 O
- O
refs O
1 O
( O
3 O
. O
) O

. O
1 O
refs O
( O
- O
3 O
) O
3 O

3 O
 O
 O
( O
refs O
1 O
- O
3 O
) O
. O

trinity O
( O
refs O
single O
- O
trinity O
) O
. O

3 O
 O
 O
( O
refs O
1 O
- O
3 O
) O
. O

3 O
( O
refs O
1 O
- O
3 O
) O
. O

Although O
DM B
mutation O
was O
identified O
more O
than O
five O
years O
ago O
, O
mechanisms O
underlying O
this O
most O
form O
of O
hereditary O
adult O
neuromuscular B
remain O
elusive O
. O

Although O
DM B
mutation O
identified O
more O
than O
five O
years O
ago O
, O
the O
mechanisms O
underlying O
most O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B
disease I

Although O
the O
DM B
mutation O
morbific O
mechanism O
rudimentary O
be O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
grownup O
stay O
problematic O
 O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B
disease I
remain O
elusive O
. O

of O
the O
DM B
prevalent O
was O
identified O
more O
remain O
neuromuscular O
years O
form O
, O
the O
pathogenic O
adult O
underlying O
this O
most O
mutation O
disease O
ago O
hereditary O
mechanisms O
five B
Although I
than O
elusive O
. O

elusive O
the O
DM B
mechanisms O
was O
identified O
remain O
than O
mutation O
years O
ago O
, O
pathogenic O
of O
disease O
five O
this O
most O
prevalent O
form O
the O
hereditary O
adult O
neuromuscular B
underlying I
more O
Although O
. O

Although O
the O
DM B
mutation O
morbific O
mechanism O
rudimentary O
be O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
grownup O
stay O
problematic O
 O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B
disease I
remain O
elusive O
. O

Although O
the O
dm B
mutant O
was O
key O
more O
than O
quint O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
prevalent O
class O
of O
transmitted O
adult O
neuromuscular B
disease I
stay O
knotty O
. O

Although O
the O
DM B
mutation O
morbific O
mechanism O
rudimentary O
be O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
grownup O
stay O
problematic O
 O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B
disease I
remain O
elusive O
. O

neuromuscular O
the O
DM B
mutation O
was O
identified O
pathogenic O
, O
five O
years O
ago O
this O
hereditary O
more O
disease O
Although O
than O
underlying O
prevalent O
form O
of O
the O
adult O
most B
mechanisms I
remain O
elusive O
. O

Although O
the O
DM B
mutant O
was O
identify O
more O
than O
quintet O
years O
ago O
, O
the O
pathogenic O
mechanics O
underlying O
this O
most O
predominant O
shape O
of O
transmitted O
adult O
neuromuscular B
disease I
rest O
elusive O
. O

Although O
the O
DM B
mutation O
was O
identified O
more O
than O
five O
years O
ago O
, O
the O
pathogenic O
mechanisms O
underlying O
this O
most O
prevalent O
form O
of O
hereditary O
adult O
neuromuscular B
disease I
remain O
elusive O
. O

previous O
make O
from O
our O
laboratory O
demonstrated O
that O
a O
DNase O
fifty O
- O
supersensitised O
site O
located O
neighboring O
to O
the O
iterate O
on O
the O
risky O
- O
type O
allelomorph O
is O
eliminated O
by O
double O
expansion O
, O
signal O
that O
expectant O
CTG O
- O
double O
raiment O
may O
be O
consociate O
with O
a O
local O
chromatin O
environment O
that O
represses O
cistron O
reflexion O
. O

old O
work O
from O
our O
laboratory O
certify O
that O
a O
DNase O
l O
- O
supersensitized O
situation O
set O
contiguous O
to O
the O
retell O
on O
the O
wild O
- O
type O
allelomorph O
is O
eliminated O
by O
repetition O
expansion O
, O
indicate O
that O
vauntingly O
CTG O
- O
repetition O
range O
may O
be O
associated O
with O
a O
local O
chromatin O
surround O
that O
represses O
cistron O
manifestation O
. O

Previous O
work O
from O
our O
laboratory O
demonstrated O
that O
l O
- O
hypersensitive O
site O
adjacent O
to O
the O
repeats O
on O
wild O
- O
type O
allele O
eliminated O
by O
expansion O
, O
indicating O
that O
large O
CTG O
- O
repeat O
may O
be O
with O
a O
local O
chromatin O
environment O
that O
represses O
gene O

Previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
heavy O
DNase O
l O
- O
hypersensitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
allele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
CTG O
- O
repeat O
antiophthalmic O
factor O
topical O
anesthetic O
chromatin O
granule O
surround O
topical O
anesthetic O
muffle O
cistron O
manifestation O
muffle O
cistron O
manifestation O
muffle O
cistron O
antiophthalmic O
factor O
arrays O
may O
be O
associated O
with O
a O
local O
chromatin O
environment O

- O
is O
from O
our O
laboratory O
demonstrated O
wild O
the O
DNase O
l O
- O
hypersensitive O
site O
that O
may O
to O
a O
represses O
on O
the O
located O
- O
type O
allele O
repeat O
eliminated O
by O
a O
environment O
, O
expansion O
work O
large O
CTG O
. O
repeat O
arrays O
adjacent O
that O
associated O
with O
expression O
local O
chromatin O
indicating O
that O
repeats O
gene O
be O
Previous O

Previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
heavy O
DNase O
l O
- O
hypersensitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
allele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
CTG O
- O
repeat O
antiophthalmic O
factor O
topical O
anesthetic O
chromatin O
granule O
surround O
topical O
anesthetic O
muffle O
cistron O
manifestation O
muffle O
cistron O
manifestation O
muffle O
cistron O
antiophthalmic O
factor O
arrays O
may O
be O
associated O
with O
a O
local O
chromatin O
environment O

Previous O
mold O
from O
our O
laboratory O
establish O
that O
a O
DNase O
l O
- O
hypersensitized O
site O
situate O
adjacent O
to O
the O
duplicate O
on O
the O
wild O
- O
character O
allelomorph O
is O
annihilate O
by O
echo O
expansion O
, O
indicate O
that O
bombastic O
CTG O
- O
echo O
raiment O
may O
be O
associated O
with O
a O
local O
chromatin O
surroundings O
that O
represses O
cistron O
verbalism O
. O

Previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
heavy O
DNase O
l O
- O
hypersensitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
allele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
CTG O
- O
repeat O
antiophthalmic O
factor O
topical O
anesthetic O
chromatin O
granule O
surround O
topical O
anesthetic O
muffle O
cistron O
manifestation O
muffle O
cistron O
manifestation O
muffle O
cistron O
assort O
arrays O
may O
be O
associated O
with O
a O
local O
chromatin O
environment O
that O

Previous O
work O
from O
our O
that O
a O
DNase O
l O
- O
hypersensitive O
site O
located O
the O
on O
the O
wild O
type O
allele O
is O
eliminated O
by O
repeat O
, O
indicating O
CTG O
repeat O
arrays O
may O
be O
a O
local O
chromatin O
environment O
represses O
gene O
expression O
. O

Previous O
by O
from O
our O
laboratory O
demonstrated O
hypersensitive O
, O
DNase O
l O
- O
that O
site O
repeat O
expansion O
to O
the O
repeats O
a O
the O
wild O
- O
CTG O
allele O
chromatin O
eliminated O
represses O
located O
expression O
on O
indicating O
repeat O
large O
adjacent O
- O
a O
arrays O
may O
be O
associated O
work O
that O
local O
type O
environment O
that O
with O
gene O
is O
. O

Previous O
work O
from O
our O
laboratory O
demonstrated O
that O
a O
DNase O
l O
- O
hypersensitive O
site O
located O
adjacent O
to O
the O
repeats O
on O
the O
wild O
- O
type O
allele O
is O
eliminated O
by O
repeat O
expansion O
, O
indicating O
that O
large O
CTG O
- O
repeat O
arrays O
may O
be O
associated O
with O
a O
local O
chromatin O
environment O
that O
represses O
gene O
expression O
. O

Here O
we O
cover O
that O
the O
hypersensitized O
site O
contains O
an O
foil O
ingredient O
that O
order O
transcription O
of O
the O
conterminous O
DMAHP O
homeobox O
gene O
. O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
transcription O
of O
the O
adjacent O
DMAHP O
cistron O
study O
study O
study O
study O
study O
homeobox O
gene O
. O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
transcription O
of O
the O
adjacent O
DMAHP O
cistron O
study O
study O
study O
study O
study O
homeobox O
gene O
. O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
enhancer O
element O
regulates O
transcription O
of O
the O
adjacent O
DMAHP O
homeobox O

of O
we O
an O
site O
the O
hypersensitive O
the O
contains O
report O
enhancer O
element O
that O
. O
transcription O
that O
Here O
adjacent O
DMAHP O
homeobox O
gene O
regulates O

Here O
we O
paper O
that O
the O
supersensitised O
place O
contains O
an O
foil O
element O
that O
regulates O
arrangement O
of O
the O
adjacent O
DMAHP O
homeobox O
cistron O
. O

. O
we O
report O
element O
the O
hypersensitive O
site O
homeobox O
of O
enhancer O
that O
that O
transcription O
regulates O
an O
the O
adjacent O
DMAHP O
contains O
Here O
gene O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
transcription O
of O
the O
adjacent O
DMAHP O
cistron O
study O
study O
study O
study O
arranging O
homeobox O
gene O
. O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
of O
DMAHP O
homeobox O
gene O
. O

here O
we O
report O
that O
the O
hypersensitive O
site O
bear O
an O
foil O
element O
that O
regularise O
recording O
of O
the O
next O
DMAHP O
homeobox O
gene O
. O

Here O
we O
report O
that O
the O
hypersensitive O
site O
contains O
an O
enhancer O
element O
that O
regulates O
transcription O
of O
the O
adjacent O
DMAHP O
homeobox O
gene O
. O

Analysis O
of O
DMAHP O
expression O
in O
the O
cells O
of O
DM B
patients O
with O
loss O
of O
the O
hypersensitive O
site O
revealed O
a O
two O
- O
to O
fourfold O
reduction O
in O
steady O
- O
state O
DMAHP O
transcript O
levels O
relative O
to O
wild O
- O
type O
controls O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
. O

Analysis O
of O
DMAHP O
the O
cells O
of O
DM B
patients O
loss O
the O
hypersensitive O
site O
revealed O
a O
two O
- O
to O
fourfold O
reduction O
steady O
- O
state O
DMAHP O
transcript O
type O

steady O
two O
DMAHP O
expression O
in O
the O
loss O
- O
DM B
patients O
with O
cells O
of O
DMAHP O
levels O
site O
revealed O
a O
of O
- O
to O
fourfold O
transcript O
in O
Analysis O
- O
to O
the O
hypersensitive O
reduction O
relative O
controls O
wild O
of O
type O
state O
. O

Analysis O
of O
DMAHP O
expression O
in O
the O
cells O
of O
DM B
patients O
with O
loss O
of O
the O
hypersensitive O
site O
revealed O
a O
two O
- O
to O
fourfold O
reduction O
in O
steady O
- O
state O
DMAHP O
transcript O
levels O
relative O
to O
wild O
- O
type O
controls O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
inward O
jail O
cell O

DMAHP O
type O
DMAHP O
expression O
revealed O
the O
hypersensitive O
to O
DM B
patients O
with O
loss O
of O
steady O
of O
site O
in O
relative O
two O
- O
the O
fourfold O
reduction O
in O
of O
- O
state O
Analysis O
a O
levels O
transcript O
cells O
wild O
- O
to O
controls O
. O

Analysis O
of O
DMAHP O
reflection O
in O
the O
cells O
of O
DM B
patients O
with O
release O
of O
the O
sensitised O
site O
break O
a O
two O
- O
to O
fourfold O
diminution O
in O
brace O
- O
state O
DMAHP O
copy O
point O
proportional O
to O
waste O
- O
type O
controller O
. O

Analysis O
of O
DMAHP O
expression O
the O
cells O
of O
DM B
patients O
with O
loss O
hypersensitive O
site O
revealed O
two O
to O
fourfold O
reduction O
- O
relative O
to O
wild O
type O
controls O

Analysis O
of O
relative O
expression O
in O
controls O
cells O
of O
DM B
patients O
with O
state O
- O
the O
hypersensitive O
DMAHP O
revealed O
a O
to O
of O
to O
wild O
reduction O
the O
steady O
site O
loss O
fourfold O
- O
levels O
DMAHP O
two O
transcript O
- O
type O
in O
. O

analysis O
of O
DMAHP O
locution O
in O
the O
cells O
of O
dm B
patients O
with O
release O
of O
the O
supersensitized O
site O
revealed O
a O
two O
- O
to O
quadruplicate O
reduction O
in O
regular O
- O
posit O
DMAHP O
transcript O
levels O
relative O
to O
baseless O
- O
character O
restraint O
. O

psychoanalysis O
of O
DMAHP O
face O
in O
the O
cells O
of O
decimeter B
patients O
with O
deprivation O
of O
the O
hypersensitised O
site O
discover O
a O
deuce O
- O
to O
fourfold O
diminution O
in O
steady O
- O
state O
DMAHP O
transcript O
stage O
proportional O
to O
risky O
- O
type O
controls O
. O

Analysis O
of O
DMAHP O
expression O
in O
the O
cells O
of O
DM B
patients O
with O
loss O
of O
the O
hypersensitive O
site O
revealed O
a O
two O
- O
to O
fourfold O
reduction O
in O
steady O
- O
state O
DMAHP O
transcript O
levels O
relative O
to O
wild O
- O
type O
controls O
. O

Allele O
- O
specific O
analysis O
copy O
grade O
character O
manifestation O
amplify O
of O
DMAHP O
expression O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
written O
matter O
written O
matter O
written O

Allele O
- O
of O
steady O
- O
state O
levels O
from O
expanded O
allele O
were O
in O
comparison O
to O
those O
from O
wild O
type O
allele O
. O

allelomorph O
- O
particular O
analysis O
of O
DMAHP O
face O
showed O
that O
steady O
- O
state O
copy O
flush O
from O
the O
expanded O
allelomorph O
were O
greatly O
quash O
in O
comparing O
to O
those O
from O
the O
angry O
- O
type O
allelomorph O
. O

Allele O
- O
specific O
analysis O
DMAHP O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
. O

allelomorph O
- O
particular O
analysis O
of O
DMAHP O
expression O
showed O
that O
unbendable O
- O
state O
copy O
levels O
from O
the O
extend O
allelomorph O
were O
greatly O
abbreviate O
in O
compare O
to O
those O
from O
the O
dotty O
- O
type O
allelomorph O
. O

Allele O
- O
specific O
analysis O
copy O
grade O
character O
manifestation O
amplify O
of O
DMAHP O
expression O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
written O
matter O
written O
matter O
written O

allelomorph O
- O
specific O
analysis O
of O
DMAHP O
construction O
showed O
that O
becalm O
- O
commonwealth O
copy O
levels O
from O
the O
exposit O
allelomorph O
were O
greatly O
reduced O
in O
comparing O
to O
those O
from O
the O
unfounded O
- O
type O
allelomorph O
. O

reduced O
were O
specific O
analysis O
of O
DMAHP O
expression O
showed O
that O
steady O
- O
state O
transcript O
those O
type O
the O
expanded O
allele O
wild O
greatly O
- O
in O
. O
to O
levels O
from O
the O
Allele O
from O
comparison O
allele O
- O

Allele O
- O
specific O
analysis O
DMAHP O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
from O
the O
wild O
type O
. O

Allele O
- O
specific O
analysis O
copy O
grade O
character O
manifestation O
character O
of O
DMAHP O
expression O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
written O
matter O
written O
matter O
written O

Allele O
- O
specific O
analysis O
of O
DMAHP O
expression O
showed O
that O
steady O
- O
state O
transcript O
levels O
from O
the O
expanded O
allele O
were O
greatly O
reduced O
in O
comparison O
to O
those O
from O
the O
wild O
- O
type O
allele O
. O

pathogenesis O
, O
these O
can O
demonstrate O
that O
CTG O
in O
expression O
expansions O
results O
suppress O
gene O
local O
repeat O
and O
implicate O
DMAHP O
- O
Together B
DM O
. O

Together O
, O
these O
results O
demonstrate O
that O
CTG O
- O
repeat O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
DMAHP O
diabetes O
mellitus O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
in B
DM O
pathogenesis O

Together O
, O
these O
results O
demonstrate O
that O
CTG O
- O
repeat O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
DMAHP O
diabetes O
mellitus O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
in B
DM O
pathogenesis O

unitedly O
, O
these O
consequence O
manifest O
that O
CTG O
- O
repeat O
expansions O
can O
suppress O
local O
cistron O
expression O
and O
entail O
DMAHP O
in O
decimeter B
pathogenesis O
. O

Together O
, O
these O
demonstrate O
that O
CTG O
- O
repeat O
can O
suppress O
local O
gene O
and O
implicate O
in O
DM B
pathogenesis O
. O

results O
CTG O
- O
repeat O
can O
suppress O
gene O
expression O
and O
implicate O
DMAHP O
in O
DM B
pathogenesis O
. O

together O
, O
these O
results O
evidence O
that O
CTG O
- O
duplicate O
enlargement O
can O
suppress O
local O
gene O
expression O
and O
entail O
DMAHP O
in O
dm B
pathogenesis O
. O

expression O
, O
repeat O
CTG O
demonstrate O
that O
and O
- O
these O
expansions O
can O
suppress O
pathogenesis O
gene O
results O
Together O
implicate O
DMAHP O
in O
DM B
local O
. O

Together O
, O
these O
results O
demonstrate O
that O
CTG O
- O
repeat O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
DMAHP O
diabetes O
mellitus O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
ingeminate O
in B
DM O
pathogenesis O

Together O
, O
these O
results O
CTG O
- O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
DMAHP O
in O
. O

Together O
, O
these O
results O
demonstrate O
that O
CTG O
- O
repeat O
expansions O
can O
suppress O
local O
gene O
expression O
and O
implicate O
DMAHP O
in O
DM B
pathogenesis O
. O

Constitutively O
methylated O
raging O
office O
inward O
CpG O
dinucleotides O
as O
mutation O
hot O
spots O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
chromosomal O
mutation O

RB1 O
methylated O
CpG O
. O
as O
mutation O
hot O
spots O
) O
the O
retinoblastoma B
gene O
Constitutively O
( O
in O
dinucleotides O

Constitutively O
methylated O
raging O
office O
raging O
CpG O
dinucleotides O
as O
mutation O
hot O
spots O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
chromosomal O
mutation O

Constitutively O
methylated O
CpG O
dinucleotides O
as O
mutation O
blistering O
blemish O
in O
the O
retinoblastoma B
cistron O
( O
RB1 O
) O
. O

( O
methylated O
CpG O
spots O
as O
mutation O
RB1 O
dinucleotides O
in O
the O
Constitutively B
gene O
retinoblastoma O
hot O
) O
. O

Constitutively O
methylated O
raging O
office O
inward O
CpG O
dinucleotides O
as O
mutation O
hot O
spots O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
chromosomal O
mutation O

Constitutively O
methylated O
CpG O
dinucleotides O
as O
variation O
spicy O
patch O
in O
the O
retinoblastoma B
cistron O
( O
RB1 O
) O
. O

Constitutively O
methylated O
CpG O
dinucleotides O
as O
mutation O
live O
spotlight O
in O
the O
retinoblastoma B
factor O
( O
RB1 O
) O
. O

Constitutively O
methylated O
in O
. O
as O
mutation O
( O
spots O
CpG O
the O
retinoblastoma B
gene O
hot O
RB1 O
dinucleotides O
) O

methylated O
CpG O
dinucleotides O
as O
mutation O
hot O
spots O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

Constitutively O
methylated O
CpG O
dinucleotides O
as O
mutation O
hot O
spots O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
steer O
cistron O
cistron O
steer O
steer O
steer O
mutation O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
retinoblastoma B
( O
RB1 O
) O
. O

a O
wide O
spectrum O
of O
mutations O
, O
wander O
from O
point O
mutations O
to O
bombastic O
omission O
, O
have O
been O
line O
in O
the O
retinoblastoma B
factor O
( O
RB1 O
) O
. O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
large O
deletions O
have O
been O
described O
in O
the O
retinoblastoma B
gene O
) O
. O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
steer O
cistron O
cistron O
steer O
steer O
steer O
steer O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

axerophthol O
blanket O
spectrum O
of O
mutations O
, O
roam O
from O
point O
mutations O
to O
enceinte O
omission O
, O
have O
been O
line O
in O
the O
retinoblastoma B
factor O
( O
RB1 O
) O
. O

amp O
wide O
spectrum O
of O
variation O
, O
wander O
from O
charge O
variation O
to O
big O
excision O
, O
have O
been O
described O
in O
the O
retinoblastoma B
factor O
( O
RB1 O
) O
. O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
deletions O
been O
described O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
steer O
cistron O
cistron O
steer O
steer O
steer O
steer O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

retinoblastoma O
wide O
spectrum O
to O
mutations O
, O
ranging O
the O
) O
mutations O
of O
large O
, O
deletions O
RB1 O
been O
described O
in O
from O
. B
gene O
( O
have O
point O
A O

A O
wide O
spectrum O
of O
mutations O
, O
ranging O
from O
point O
mutations O
to O
large O
deletions O
, O
have O
been O
described O
in O
the O
retinoblastoma B
gene O
( O
RB1 O
) O
. O

variation O
have O
been O
recover O
throughout O
the O
factor O
; O
however O
, O
these O
inherited O
alterations O
do O
not O
appear O
to O
be O
homogeneously O
distributed O
. O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
spread O
be O
be O
be O
be O
be O
homogeneously O
distributed O
. O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
spread O
be O
be O
be O
be O
be O
homogeneously O
distributed O
. O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
, O
these O
alterations O
do O
not O
appear O
to O
be O
homogeneously O

not O
have O
however O
gene O
throughout O
the O
appear O
; O
been O
, O
these O
genetic O
. O
do O
found O
Mutations O
to O
be O
homogeneously O
distributed O
alterations O

variation O
have O
been O
found O
passim O
the O
cistron O
; O
yet O
, O
these O
transmitted O
adjustment O
do O
not O
appear O
to O
be O
homogeneously O
distributed O
. O

. O
have O
been O
these O
throughout O
the O
gene O
homogeneously O
not O
, O
found O
genetic O
do O
alterations O
however O
appear O
to O
be O
; O
Mutations O
distributed O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
spread O
be O
be O
be O
be O
non O
homogeneously O
distributed O
. O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
not O
be O
homogeneously O
distributed O
. O

Mutations O
have O
been O
feel O
throughout O
the O
cistron O
; O
nevertheless O
, O
these O
inherited O
revision O
do O
not O
appear O
to O
be O
homogeneously O
administer O
. O

Mutations O
have O
been O
found O
throughout O
the O
gene O
; O
however O
, O
these O
genetic O
alterations O
do O
not O
appear O
to O
be O
homogeneously O
distributed O
. O

indium O
particular O
, O
a O
meaning O
proportion O
of O
disease O
- O
do O
mutations O
results O
indium O
the O
untimely O
conclusion O
of O
protein O
deduction O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
C O
- O
- O
> O
tetraiodothyronine O
modulation O
at O
CpG O
dinucleotides O
( O
CpGs O
) O
. O

inch O
particular O
, O
a O
pregnant O
dimension O
of O
disease O
- O
make O
mutations O
solution O
inch O
the O
untimely O
expiration O
of O
protein O
deduction O
, O
and O
the O
bulk O
of O
these O
mutations O
occur O
as O
C O
- O
- O
> O
tonne O
changeover O
at O
CpG O
dinucleotides O
( O
CpGs O
) O
. O

In O
significant O
of O
disease O
- O
mutations O
results O
in O
premature O
termination O
of O
protein O
synthesis O
the O
majority O
of O
these O
mutations O
occur O
as O
C O
> O
transitions O
at O
CpG O
( O
CpGs O
) O
. O

In O
particular O
> O
a O
significant O
C O
mutations O
disease O
- O
causing O
mutations O
of O
as O
the O
premature O
- O
of O
protein O
, O
synthesis O
and O
the O
majority O
CpG O
these O
occur O
in O
T O
proportion O
- O
termination O
( O
of O
transitions O
at O
results O
dinucleotides O
, O
CpGs O
) O
. O

these O
synthesis O
, O
a O
significant O
proportion O
results O
the O
- O
causing O
mutations O
of O
in O
as O
- O
termination O
of O
protein O
. O
, O
and O
disease O
C O
of O
In O
mutations O
> O
the O
premature O
majority O
- O
CpG O
T O
particular O
at O
occur O
dinucleotides O
( O
CpGs O
) O
transitions O

In O
particular O
, O
a O
of O
disease O
- O
causing O
results O
in O
the O
premature O
termination O
protein O
synthesis O
, O
and O
majority O
of O
mutations O
occur O
as O
C O
- O
- O
> O
T O
at O
CpG O
( O
CpGs O
) O
. O

In O
particular O
, O
a O
significant O
proportion O
of O
disease O
- O
causing O
mutations O
results O
in O
the O
premature O
termination O
of O
protein O
synthesis O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
C O
- O
- O
> O
T O
transitions O
at O
CpG O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
dinucleotides O
( O
CpGs O
) O
. O

In O
particular O
, O
a O
disease O
- O
causing O
mutations O
results O
the O
premature O
synthesis O
the O
majority O
mutations O
C O
- O
- O
> O
transitions O
at O
( O
CpGs O
. O

In O
specific O
, O
a O
meaning O
dimension O
of O
disease O
- O
causation O
mutations O
solution O
in O
the O
previous O
termination O
of O
protein O
deduction O
, O
and O
the O
majority O
of O
these O
mutations O
happen O
as O
snow O
- O
- O
> O
T O
modulation O
at O
CpG O
dinucleotides O
( O
CpGs O
) O
. O

In O
particular O
, O
a O
significant O
proportion O
of O
disease O
- O
causing O
mutations O
results O
in O
the O
premature O
termination O
of O
protein O
synthesis O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
C O
- O
- O
> O
T O
transitions O
at O
CpG O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
pregnant O
dinucleotides O
( O
CpGs O
) O
. O

In O
particular O
, O
a O
significant O
proportion O
of O
disease O
- O
causing O
mutations O
results O
in O
the O
premature O
termination O
of O
protein O
synthesis O
, O
and O
the O
majority O
of O
these O
mutations O
occur O
as O
C O
- O
- O
> O
T O
transitions O
at O
CpG O
dinucleotides O
( O
CpGs O
) O
. O

recurrent O
CpG O
mutations O
, O
including O
those O
found O
in O
RB1 O
, O
are O
likely O
the O
result O
of O
deamination O
5 O
- O
methylcytosine O
within O
these O
CpGs O
. O

, O
recurrent O
CpG O
of O
, O
including O
those O
. O
these O
RB1 O
CpGs O
are O
likely O
5 O
within O
of O
the O
deamination O
mutations O
the O
- O
methylcytosine O
result O
in O
Such O
found O

such O
perennial O
CpG O
mutations O
, O
admit O
those O
base O
in O
RB1 O
, O
are O
likely O
the O
outcome O
of O
the O
deaminization O
of O
5 O
- O
methylcytosine O
inside O
these O
CpGs O
. O

such O
perennial O
CpG O
mutations O
, O
include O
those O
found O
in O
RB1 O
, O
are O
likely O
the O
termination O
of O
the O
deaminization O
of O
fivesome O
- O
methylcytosine O
inside O
these O
CpGs O
. O

Such O
recurrent O
CpG O
mutations O
, O
including O
those O
found O
in O
RB1 O
are O
likely O
result O
of O
the O
deamination O
of O
5 O
- O
these O
CpGs O
. O

Such O
recurrent O
CpG O
mutations O
find O
out O
, O
including O
those O
found O
in O
RB1 O
, O
are O
likely O
the O
result O
of O
the O
deamination O
inside O
inward O
inside O
inside O
inward O
inward O
of O
5 O
- O
methylcytosine O
within O
these O
CpGs O

Such O
recurrent O
CpG O
mutations O
find O
out O
, O
including O
those O
found O
in O
RB1 O
, O
are O
likely O
the O
result O
of O
the O
deamination O
inside O
inward O
inside O
inside O
inward O
such O
of O
5 O
- O
methylcytosine O
within O
these O
CpGs O

Such O
recurrent O
CpG O
mutations O
, O
including O
those O
found O
in O
RB1 O
are O
result O
of O
the O
deamination O
of O
5 O
- O
methylcytosine O
within O

these O
recurrent O
CpG O
mutations O
, O
including O
the O
the O
in O
RB1 O
, O
are O
methylcytosine O
those O
CpGs O
of O
found O
- O
of O
5 O
Such O
likely O
within O
deamination O
result O
. O

such O
recurrent O
CpG O
mutations O
, O
include O
those O
bump O
in O
RB1 O
, O
are O
likely O
the O
outcome O
of O
the O
deaminization O
of O
five O
- O
methylcytosine O
inside O
these O
CpGs O
. O

Such O
recurrent O
CpG O
mutations O
, O
including O
those O
found O
in O
RB1 O
, O
are O
likely O
the O
result O
of O
the O
deamination O
of O
5 O
- O
methylcytosine O
within O
these O
CpGs O
. O

In O
the O
salute O
study O
, O
we O
expend O
the O
sodiumbisulfite O
changeover O
method O
to O
discover O
cytosine O
methylation O
in O
congressman O
exons O
of O
RB1 O
. O

In O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
cytosine O
methylation O
in O
representative O
exons O
gift O
gift O
gift O
gift O
gift O
gift O
of O
RB1 O
. O

In O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
cytosine O
methylation O
in O
representative O
exons O
gift O
gift O
gift O
gift O
gift O
gift O
of O
RB1 O
. O

In O
the O
present O
study O
, O
we O
used O
the O
conversion O
method O
detect O
cytosine O
methylation O
in O
representative O
exons O
of O

methylation O
the O
sodiumbisulfite O
used O
, O
we O
in O
the O
present O
conversion O
method O
to O
. O
cytosine O
study O
In O
representative O
exons O
of O
RB1 O
detect O

inch O
the O
present O
study O
, O
we O
exploited O
the O
sodiumbisulfite O
changeover O
method O
to O
find O
cytosine O
methylation O
inch O
illustration O
exons O
of O
RB1 O
. O

. O
the O
present O
method O
, O
we O
used O
of O
methylation O
conversion O
study O
to O
cytosine O
detect O
sodiumbisulfite O
in O
representative O
exons O
the O
In O
RB1 O

In O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
cytosine O
methylation O
in O
representative O
exons O
gift O
gift O
gift O
gift O
gift O
transition O
of O
RB1 O
. O

In O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
methylation O
exons O
of O
RB1 O
. O

inward O
the O
demonstrate O
bailiwick O
, O
we O
practice O
the O
sodiumbisulfite O
conversion O
method O
to O
find O
cytosine O
methylation O
inward O
instance O
exons O
of O
RB1 O
. O

In O
the O
present O
study O
, O
we O
used O
the O
sodiumbisulfite O
conversion O
method O
to O
detect O
cytosine O
methylation O
in O
representative O
exons O
of O
RB1 O
. O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
CGA O
codons O
in O
RB1 O
, O
where O
recurrent O
rich O
person O
be O
report O
be O
report O
report O
mutation O
premature O
termination O
mutations O
have O
been O
reported O

from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
CGA O
codons O
in O
RB1 O
, O
where O
recurrent O
termination O
have O
been O
reported O
. O

We O
analyzed O
DNA O
from O
a O
change O
of O
weave O
and O
specifically O
point O
CGA O
codons O
in O
RB1 O
, O
where O
repeated O
previous O
expiry O
mutations O
have O
been O
account O
. O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
CGA O
codons O
RB1 O
, O
where O
recurrent O
premature O
termination O
mutations O
reported O
. O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
CGA O
codons O
in O
RB1 O
, O
where O
recurrent O
rich O
person O
be O
report O
be O
report O
report O
dna O
premature O
termination O
mutations O
have O
been O
reported O

We O
canvas O
DNA O
from O
a O
miscellany O
of O
tissues O
and O
specifically O
point O
CGA O
codons O
in O
RB1 O
, O
where O
repeated O
untimely O
conclusion O
mutations O
have O
been O
account O
. O

We O
canvas O
dna O
from O
a O
diversity O
of O
tissues O
and O
specifically O
aim O
CGA O
codons O
in O
RB1 O
, O
where O
perennial O
premature O
termination O
sport O
have O
been O
account O
. O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
codons O
, O
where O
recurrent O
premature O
termination O
mutations O
have O
been O
reported O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
CGA O
codons O
in O
RB1 O
, O
where O
recurrent O
rich O
person O
be O
report O
be O
report O
report O
dna O
premature O
termination O
mutations O
have O
been O
reported O

termination O
analyzed O
DNA O
targeted O
a O
variety O
of O
premature O
reported O
specifically O
from O
CGA O
in O
codons O
been O
, O
where O
recurrent O
tissues O
. O
mutations O
have O
RB1 O
and O
We O

We O
analyzed O
DNA O
from O
a O
variety O
of O
tissues O
and O
specifically O
targeted O
CGA O
codons O
in O
RB1 O
, O
where O
recurrent O
premature O
termination O
mutations O
have O
been O
reported O
. O

We O
that O
DNA O
methylation O
within O
RB1 O
exons O
8 O
, O
14 O
, O
and O
27 O
appeared O
to O
restricted O
to O
CpGs O
, O
including O
CGA O
codons O
. O

We O
that O
DNA O
within O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
and O
27 O
to O
be O
restricted O
to O
CpGs O
, O
including O
six O

We O
found O
that O
DNA O
 O
inside O
 O
come O
out O
methylation O
within O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
 O
admit O
codon O
 O
be O
restricted O
to O
CpGs O
, O
including O
six O
CGA O
codons O

to O
found O
that O
be O
methylation O
within O
RB1 O
CGA O
including O
, O
restricted O
, O
25 O
, O
, O
27 O
appeared O
to O
DNA O
six O
14 O
CpGs O
and O
8 O
We O
exons O
codons O
. O

codons O
found O
that O
and O
methylation O
within O
CGA O
exons O
DNA O
, O
14 O
, O
, O
to O
six O
8 O
appeared O
to O
be O
restricted O
25 O
CpGs O
, O
including O
27 O
RB1 O
We O
. O

We O
found O
that O
DNA O
 O
inside O
 O
come O
out O
methylation O
within O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
 O
admit O
codon O
 O
be O
restricted O
to O
CpGs O
, O
including O
six O
CGA O
codons O

We O
incur O
that O
DNA O
methylation O
inside O
RB1 O
exons O
8 O
, O
fourteen O
, O
xxv O
, O
and O
27 O
seem O
to O
be O
curtail O
to O
CpGs O
, O
including O
vi O
CGA O
codons O
. O

We O
found O
that O
DNA O
 O
inside O
 O
come O
out O
methylation O
within O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
 O
admit O
codon O
 O
be O
restricted O
to O
CpGs O
, O
including O
six O
CGA O
codons O

including O
found O
that O
DNA O
methylation O
within O
, O
, O
8 O
, O
14 O
appeared O
CpGs O
RB1 O
six O
We O
exons O
27 O
be O
restricted O
to O
25 O
, O
to O
and O
CGA O
codons O
. O

We O
establish O
that O
dna O
methylation O
inside O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
be O
trammel O
to O
CpGs O
, O
include O
six O
CGA O
codons O
. O

We O
found O
that O
DNA O
methylation O
within O
RB1 O
exons O
8 O
, O
14 O
, O
25 O
, O
and O
27 O
appeared O
to O
be O
restricted O
to O
CpGs O
, O
including O
six O
CGA O
codons O
. O

Other O
containing O
methylated O
have O
been O
to O
be O
mutated O
. O

Other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
to O
be O
mutated O

early O
codons O
stop O
methylated O
cytosines O
have O
not O
been O
reported O
to O
be O
mutated O
. O

Other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
mutate O
mutate O
codon O
to O
be O
mutated O
. O

Other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
mutate O
mutate O
early O
to O
be O
mutated O
. O

Other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
mutate O
mutate O
codon O
to O
be O
mutated O
. O

other O
codons O
incorporate O
methylated O
cytosines O
have O
not O
been O
reported O
to O
be O
mutated O
. O

Other O
codons O
methylated O
cytosines O
have O
not O
been O
reported O
to O
. O

early O
codons O
comprise O
methylated O
cytosines O
have O
not O
been O
describe O
to O
be O
mutated O
. O

Other O
cytosines O
containing O
methylated O
. O
have O
not O
codons O
reported O
to O
be O
mutated O
been O

Other O
codons O
containing O
methylated O
cytosines O
have O
not O
been O
reported O
to O
be O
mutated O
. O

Therefore O
, O
disease O
causing O
at O
CpGs O
in O
to O
factors O
, O
including O
constitutive O
presence O
DNA O
methylation O
at O
CpGs O
, O
the O
specific O
codon O
which O
methylated O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
of O
gene O
within O
which O
that O
codon O

consequently O
, O
disease O
- O
stimulate O
sport O
at O
CpGs O
in O
RB1 O
appear O
to O
be O
see O
by O
various O
factors O
, O
including O
the O
constituent O
front O
of O
dna O
methylation O
at O
cytosines O
inside O
CpGs O
, O
the O
detail O
codon O
inside O
which O
the O
methylated O
cytosine O
is O
situated O
, O
and O
the O
detail O
realm O
of O
the O
cistron O
inside O
which O
that O
codon O
domiciliate O
. O
. O

thus O
, O
disease O
- O
cause O
mutations O
at O
CpGs O
in O
RB1 O
appear O
to O
be O
shape O
by O
respective O
factor O
, O
include O
the O
organic O
comportment O
of O
DNA O
methylation O
at O
cytosines O
inside O
CpGs O
, O
the O
particular O
codon O
inside O
which O
the O
methylated O
cytosine O
is O
site O
, O
and O
the O
peculiar O
realm O
of O
the O
factor O
inside O
which O
that O
codon O
occupy O
. O
. O

Therefore O
, O
- O
at O
CpGs O
in O
RB1 O
appear O
to O
be O
determined O
by O
the O
constitutive O
presence O
of O
DNA O
methylation O
at O
cytosines O
within O
CpGs O
, O
the O
specific O
codon O
within O
the O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
the O
gene O
within O
which O
that O
codon O
resides O

which O
cytosines O
disease O
- O
causing O
mutations O
and O
CpGs O
in O
RB1 O
appear O
, O
be O
within O
CpGs O
several O
factors O
, O
, O
the O
constitutive O
presence O
within O
DNA O
particular O
at O
the O
determined O
within O
including O
the O
the O
codon O
by O
Therefore O
. O
methylated O
cytosine O
is O
located O
to O
at O
the O
of O
region O
of O
, O
gene O
methylation O
which O
that O
codon O
resides O
specific O
. O

Therefore O
, O
the O
- O
causing O
mutations O
at O
gene O
in O
RB1 O
appear O
DNA O
the O
determined O
by O
CpGs O
factors O
, O
cytosine O
be O
constitutive O
the O
of O
to O
methylation O
codon O
. O
of O
CpGs O
, O
disease O
. O
at O
within O
which O
region O
methylated O
specific O
is O
located O
, O
and O
cytosines O
particular O
the O
codon O
presence O
several O
within O
which O
that O
within O
resides O
the O
including O

which O
methylation O
disease O
- O
causing O
mutations O
cytosine O
factors O
in O
RB1 O
appear O
to O
be O
that O
codon O
several O
CpGs O
the O
including O
the O
. O
presence O
of O
DNA O
within O
at O
cytosines O
and O
region O
, O
CpGs O
at O
codon O
within O
which O
the O
methylated O
within O
specific O
located O
, O
constitutive O
the O
particular O
the O
of O
, O
gene O
is O
Therefore O
determined O
by O
resides O
, O
. O

Therefore O
, O
disease O
- O
causing O
mutations O
at O
CpGs O
cytosine O
inside O
realm O
follow O
find O
out O
particular O
inward O
in O
RB1 O
appear O
to O
be O
determined O
by O
several O
factors O
, O
including O
the O
constitutive O
presence O
of O
DNA O
methylation O
at O
cytosines O
within O
CpGs O
, O
the O
specific O
codon O
within O
which O
the O
fussy O
cistron O
inside O
fussy O
cistron O
inside O
occupy O
cistron O
come O
out O
methylated O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
of O
the O
gene O
within O
which O
that O
codon O
resides O

Therefore O
, O
disease O
- O
causing O
mutations O
at O
CpGs O
cytosine O
inside O
realm O
follow O
find O
out O
particular O
inward O
in O
RB1 O
appear O
to O
be O
determined O
by O
several O
factors O
, O
including O
the O
constitutive O
presence O
of O
DNA O
methylation O
at O
cytosines O
within O
CpGs O
, O
the O
specific O
codon O
within O
which O
the O
fussy O
cistron O
inside O
fussy O
cistron O
inside O
occupy O
cistron O
constituent O
methylated O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
of O
the O
gene O
within O
which O
that O
codon O
resides O
. O

hence O
, O
disease O
- O
do O
mutant O
at O
CpGs O
in O
RB1 O
seem O
to O
be O
determined O
by O
various O
agent O
, O
including O
the O
organic O
mien O
of O
dna O
methylation O
at O
cytosines O
inside O
CpGs O
, O
the O
particular O
codon O
inside O
which O
the O
methylated O
cytosine O
is O
place O
, O
and O
the O
particular O
part O
of O
the O
cistron O
inside O
which O
that O
codon O
rest O
. O
. O

Therefore O
, O
disease O
- O
causing O
mutations O
at O
CpGs O
in O
RB1 O
appear O
to O
be O
determined O
by O
several O
factors O
, O
including O
the O
constitutive O
presence O
of O
DNA O
methylation O
at O
cytosines O
within O
CpGs O
, O
the O
specific O
codon O
within O
which O
the O
methylated O
cytosine O
is O
located O
, O
and O
the O
particular O
region O
of O
the O
gene O
within O
which O
that O
codon O
resides O
. O
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
factor O
intersection O
interacts O
with O
Sp1 O
to O
repress O
vascular O
endothelial O
ontogenesis O
broker O
impresario O
activeness O
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
repress O
vascular O
endothelial O
growth O
factor O
bodily O
process O
intersection O
intersection O
intersection O
intersection O
intersection O
promoter O
activity O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
repress O
vascular O
endothelial O
growth O
factor O
bodily O
process O
intersection O
intersection O
intersection O
intersection O
intersection O
promoter O
activity O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
interacts O
with O
to O
repress O
vascular O
endothelial O
growth O
factor O
promoter O

vascular O
von B
product I
suppressor I
Lindau I
tumor I
endothelial O
gene O
Hippel O
interacts O
with O
Sp1 O
. O
repress O
- O
The O
growth O
factor O
promoter O
activity O
to O

The O
von B
Hippel I
- I
Lindau I
tumour I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
smother O
vascular O
endothelial O
growing O
gene O
booster O
activeness O
. O

. O
von B
Hippel I
with I
Lindau I
tumor I
suppressor O
promoter O
vascular O
interacts O
- O
Sp1 O
repress O
to O
product O
endothelial O
growth O
factor O
gene O
The O
activity O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
repress O
vascular O
endothelial O
growth O
factor O
bodily O
process O
intersection O
intersection O
intersection O
intersection O
tumour O
promoter O
activity O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
vascular O
factor O
promoter O
activity O
. O

The O
von B
Hippel I
- I
Lindau I
neoplasm I
suppresser O
gene O
product O
interacts O
with O
Sp1 O
to O
subjugate O
vascular O
endothelial O
increment O
cistron O
impresario O
activity O
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
product O
interacts O
with O
Sp1 O
to O
repress O
vascular O
endothelial O
growth O
factor O
promoter O
activity O
. O

The O
Hippel I
tumor I
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
of O
clear B
- I
cell I
renal I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
found O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
associated I
sporadic I
RCCs I
. O

The O
von B
Hippel I
- I
Lindau I
tumour I
suppressor O
cistron O
( O
VHL O
) O
has O
a O
vital O
office O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
nephritic I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
been O
constitute O
in O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
assort I
and I
sporadic I
RCCs I
. O

The O
RCC B
Hippel I
- I
Lindau I
tumor I
has O
as O
( O
VHL O
) O
suppressor O
a O
) O
carcinoma O
in O
the O
pathogenesis O
gene O
clear B
- I
cell I
in I
cell I
associated I
( O
RCCs B
critical O
mutations O
of O
VHL O
, O
have O
role O
found O
disease O
both O
von B
Hippel I
- I
von I
been I
- I
renal I
and I
sporadic I
Lindau I
. O

The O
von B
Hippel I
- I
tumor I
suppressor O
gene O
( O
VHL O
in O
of O
- I
cell I
renal I
carcinoma I
( O
RCC B
) O
, O
as O
been O
found O
in O
both O
von B
Hippel I
- I
disease I
- I
sporadic I
RCCs I
. O

The O
von B
VHL I
- I
Lindau I
tumor I
suppressor O
gene O
( O
VHL O
) O
) O
clear O
critical O
role O
cell O
the O
pathogenesis O
von O
a B
- I
. I
renal I
in I
carcinoma I
RCC O
of B
have O
, O
as O
Hippel O
- O
mutations O
been O
found O
cell O
both O
( B
Hippel I
- I
Lindau I
disease I
has I
and I
associated I
RCCs I
sporadic I
in O

The O
von B
Hippel I
- I
Lindau I
tumour I
suppresser O
factor O
( O
VHL O
) O
has O
a O
vital O
purpose O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
nephritic I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
variation O
have O
been O
launch O
in O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
colligate I
and I
sporadic I
RCCs I
. O

The O
von B
Hippel I
- I
suppressor O
gene O
( O
) O
a O
critical O
role O
pathogenesis O
renal I
cell I
carcinoma I
RCC B
) O
as O
VHL O
mutations O
found O
in O
both O
von B
Hippel I
Lindau I
- I
associated I
and I
sporadic I
RCCs I
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
renal I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
been O
found O
in O
gene O
cistron O
assort O
cistron O
cistron O
assort O
cistron O
cistron O
assort O
cistron O
cistron O
cistron O
cistron O
cistron O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
associated I
and I
sporadic I
RCCs I
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
renal I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
been O
found O
in O
suppressor O
gene O
cistron O
assort O
cistron O
cistron O
assort O
cistron O
cistron O
assort O
cistron O
cistron O
cistron O
cistron O
suppresser O
both B
von I
Hippel I
- I
Lindau I
disease I
- I
associated I
and I
sporadic I
RCCs O

found O
carcinoma B
Hippel I
- I
the I
tumor I
- O
mutations O
( O
VHL O
) O
has O
a O
suppressor O
von O
in O
Lindau O
RCCs O
of O
clear B
critical I
cell I
renal I
cell I
) I
( O
RCC B
disease O
and O
as O
, O
von O
have O
been O
Hippel O
in O
both O
role B
The I
- I
Lindau I
gene I
- I
associated I
VHL I
sporadic I
pathogenesis I
. O

The O
von B
Hippel I
- I
Lindau I
tumor I
suppressor O
gene O
( O
VHL O
) O
has O
a O
critical O
role O
in O
the O
pathogenesis O
of O
clear B
- I
cell I
renal I
cell I
carcinoma I
( O
RCC B
) O
, O
as O
VHL O
mutations O
have O
been O
found O
in O
both O
von B
Hippel I
- I
Lindau I
disease I
- I
associated I
and I
sporadic I
RCCs I
. O

holocene O
analyse O
suggest O
that O
vascular O
endothelial O
increase O
divisor O
( O
VEGF O
) O
mrna O
is O
upregulated O
in O
RCC B
- I
and I
von I
Hippel I
- I
Lindau I
disease I
- I
assort I
tumors I
. O

Recent O
studies O
that O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
is O
RCC B
- I
and I
von I
- I
Lindau I
disease I
- I
associated I
. O

Recent O
studies O
suggest O
that O
inward O
emergence O
constituent O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
RCC B
- I
and I
advise I
assort I
tumor I
assort I
assort I
von I
Hippel I
- I
Lindau I
disease I
- I
associated I
tumors I
. O

- O
studies O
suggest O
von O
vascular O
endothelial O
growth O
tumors O
- O
VEGF O
Hippel O
mRNA O
is O
upregulated O
disease O
RCC B
- I
and I
that I
associated I
) I
Lindau I
in I
( I
Recent I
factor I
. O

Recent O
studies O
suggest O
that O
inward O
emergence O
constituent O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
RCC B
- I
and I
advise I
assort I
tumor I
assort I
assort I
von I
Hippel I
- I
Lindau I
disease I
- I
associated I
tumors I
. O

Recent O
studies O
suggest O
vascular O
endothelial O
factor O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
- I
and I
Hippel I
- I
Lindau I
disease I
- I
associated I
tumors I
. O

. O
studies O
suggest O
in O
vascular O
endothelial O
tumors O
factor O
that O
VEGF O
) O
mRNA O
upregulated O
- O
associated O
( B
- I
and I
von I
Hippel I
is I
Lindau I
disease I
- I
RCC I
growth I
Recent O

suggest O
endothelial O
growth O
factor O
VEGF O
) O
is O
upregulated O
in O
RCC B
- I
and I
von I
Hippel I
- I
Lindau I
disease I
- I
associated I

- O
studies O
suggest O
that O
vascular O
endothelial O
upregulated O
mRNA O
( O
VEGF O
) O
- O
Lindau O
growth O
associated O
Recent B
factor I
RCC I
von I
Hippel I
- I
is I
disease I
and I
in I
tumors I
. O

late O
bailiwick O
advise O
that O
vascular O
endothelial O
growing O
ingredient O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
RCC B
- I
and I
von I
Hippel I
- I
Lindau I
disease I
- I
assort I
tumour I
. O

Recent O
studies O
suggest O
that O
vascular O
endothelial O
growth O
factor O
( O
VEGF O
) O
mRNA O
is O
upregulated O
in O
RCC B
- I
and I
von I
Hippel I
- I
Lindau I
disease I
- I
associated I
tumors I
. O

We O
the O
therefore O
assessed O
have O
effect O
the O
product O
VHL O
gene O
VEGF O
on O
of O
expression O
. O

We O
have O
thus O
thence O
thence O
therefore O
assessed O
the O
effect O
of O
the O
VHL O
thence O
gene O
product O
on O
VEGF O
expression O
. O

We O
have O
so O
measure O
the O
effect O
of O
the O
VHL O
cistron O
product O
on O
VEGF O
manifestation O
. O

VEGF O
have O
therefore O
We O
the O
effect O
of O
on O
VHL O
gene O
product O
the O
assessed O
expression O
. O

We O
have O
thus O
assessed O
the O
consequence O
of O
the O
VHL O
factor O
product O
on O
VEGF O
reflexion O
. O

We O
have O
thus O
thence O
thence O
therefore O
assessed O
the O
effect O
of O
the O
VHL O
rich O
person O
gene O
product O
on O
VEGF O
expression O

We O
therefore O
the O
of O
the O
VHL O
gene O
product O
on O
VEGF O
expression O
. O

the O
assessed O
therefore O
have O
the O
effect O
gene O
We O
VHL O
of O
product O
on O
VEGF O
. O
expression O

We O
have O
therefore O
appraise O
the O
gist O
of O
the O
VHL O
factor O
intersection O
on O
VEGF O
expression O
. O

We O
have O
thus O
thence O
thence O
therefore O
assessed O
the O
effect O
of O
the O
VHL O
rich O
person O
gene O
product O
on O
VEGF O
expression O

We O
have O
therefore O
assessed O
the O
effect O
of O
the O
VHL O
gene O
product O
on O
VEGF O
expression O
. O

VEGF O
promoter O
including O
luciferase O
constructs O
- O
transiently O
several O
with O
a O
wild O
lines O
embryonic O
VHL O
( O
RCC O
- O
VHL O
vector O
) O
in O
cotransfected O
cell O
were O
, O
293 O
- O
lines O
kidney O
and O
wt B
type O
cell O
. O

VEGF O
luciferase O
constructs O
were O
transiently O
with O
a O
type O
VHL O
wt O
- O
in O
cell O
lines O
, O
293 O
embryonic O
kidney O
RCC B
cell O
lines O
. O

VEGF O
promoter O
- O
luciferase O
be O
embryonal O
embryonal O
constructs O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
type O
VHL O
( O
wt O
- O
VHL O
) O
vector O
in O
several O
cell O
lines O
, O
including O
293 O
embryonic O
kidney O
and O
RCC B
cell O
lines O
follow O
follow O
follow O
follow O
follow O
follow O
retrace O
. O

VEGF O
promoter O
- O
luciferase O
be O
embryonal O
retrace O
constructs O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
type O
VHL O
( O
wt O
- O
VHL O
) O
vector O
in O
several O
cell O
lines O
, O
including O
293 O
embryonic O
kidney O
and O
RCC B
cell O
lines O
follow O
follow O
follow O
follow O
follow O
follow O
retrace O
. O

promoter O
) O
- O
luciferase O
constructs O
were O
293 O
cotransfected O
with O
a O
wild O
embryonic O
type O
, O
and O
wt O
- O
VHL O
- O
vector O
in O
several O
. O
lines O
VHL O
including O
transiently O
VEGF O
cell O
cell O
RCC B
kidney O
lines O
( O

VEGF O
promoter O
- O
luciferase O
constructs O
were O
with O
a O
wild O
- O
VHL O
( O
wt O
- O
VHL O
vector O
in O
several O
cell O
, O
including O
embryonic O
kidney O
and O
RCC B
cell O
lines O
. O

VEGF O
impresario O
- O
luciferase O
retrace O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
character O
VHL O
( O
wt O
- O
VHL O
) O
transmitter O
in O
various O
cell O
describe O
, O
admit O
293 O
embryonal O
kidney O
and O
RCC B
cell O
describe O
. O

VEGF O
booster O
- O
luciferase O
conception O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
case O
VHL O
( O
wt O
- O
VHL O
) O
transmitter O
in O
respective O
cell O
origin O
, O
including O
293 O
embryotic O
kidney O
and O
RCC B
cell O
origin O
. O

VEGF O
promoter O
- O
luciferase O
be O
embryonal O
retrace O
constructs O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
type O
VHL O
( O
wt O
- O
VHL O
) O
vector O
in O
several O
cell O
lines O
, O
including O
293 O
embryonic O
kidney O
and O
RCC B
cell O
lines O
follow O
follow O
follow O
follow O
follow O
follow O
retrace O
. O

VEGF O
booster O
- O
luciferase O
fabricate O
were O
transiently O
cotransfected O
with O
a O
uncivilized O
- O
type O
VHL O
( O
wt O
- O
VHL O
) O
transmitter O
in O
various O
cell O
origin O
, O
include O
293 O
embryologic O
kidney O
and O
RCC B
cell O
origin O
. O

VEGF O
promoter O
- O
luciferase O
constructs O
were O
transiently O
cotransfected O
with O
a O
wild O
- O
type O
VHL O
( O
wt O
- O
VHL O
) O
vector O
in O
several O
cell O
lines O
, O
including O
293 O
embryonic O
kidney O
and O
RCC B
cell O
lines O
. O

wt O
- O
VHL O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
to O
10 O
- O
fold O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
promoter O
activity O
in O
a O
dose O
- O
dependent O
up O
- O
to O
10 O
- O
fold O
. O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
promoter O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
 O
flock O
flock O
inward O
inward O
inward O
to O
10 O
- O
fold O
. O

wt O
- O
VHL O
protein O
suppress O
VEGF O
booster O
activity O
in O
a O
dose O
- O
subject O
mode O
up O
to O
cinque O
- O
to O
10 O
- O
fold O
. O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
promoter O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
 O
flock O
flock O
inward O
inward O
inward O
to O
10 O
- O
fold O
. O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
showman O
action O
in O
a O
dosage O
- O
dependent O
way O
up O
to O
fivesome O
- O
to O
10 O
- O
flexure O
. O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
promoter O
activity O
in O
a O
- O
dependent O
up O
to O
5 O
- O
to O
10 O
- O

dose O
- O
VHL O
to O
inhibited O
VEGF O
promoter O
in O
activity O
a O
10 O
- O
manner O
dependent O
. O
to O
5 O
- O
protein O
wt O
- O
fold O
up O

wt O
- O
VHL O
protein O
suppress O
VEGF O
booster O
activity O
in O
a O
dose O
- O
dependant O
style O
up O
to O
phoebe O
- O
to O
decade O
- O
fold O
. O

up O
- O
in O
promoter O
inhibited O
VEGF O
to O
activity O
VHL O
a O
dose O
- O
- O
manner O
protein O
wt O
5 O
- O
to O
10 O
dependent O
fold O
. O

wt O
- O
VHL O
protein O
inhibited O
VEGF O
promoter O
activity O
in O
a O
dose O
- O
dependent O
manner O
up O
to O
5 O
- O
to O
10 O
- O
fold O
. O

VEGF O
analysis O
defined O
region O
144 O
- O
bp O
a O
VHL O
the O
for O
promoter O
Deletion O
necessary O
of O
repression O
. O

cut O
analysis O
defined O
a O
144 O
- O
bp O
part O
of O
the O
VEGF O
plugger O
requisite O
for O
VHL O
repression O
. O

omission O
analysis O
outlined O
a O
144 O
- O
bp O
part O
of O
the O
VEGF O
showman O
requirement O
for O
VHL O
repression O
. O

Deletion O
analysis O
144 O
- O
bp O
region O
of O
the O
VEGF O
promoter O
necessary O
for O
VHL O
repression O
. O

omission O
analysis O
determine O
a O
144 O
- O
bp O
area O
of O
the O
VEGF O
impresario O
essential O
for O
VHL O
repression O
. O

Deletion O
analysis O
realm O
define O
defined O
a O
144 O
- O
bp O
region O
of O
the O
VEGF O
promoter O
necessary O
for O
VHL O
repression O
region O
region O
determine O
. O

Deletion O
analysis O
defined O
a O
144 O
- O
bp O
region O
the O
VEGF O
necessary O
for O
VHL O
repression O
. O

Deletion O
analysis O
realm O
define O
defined O
a O
144 O
- O
bp O
region O
of O
the O
VEGF O
promoter O
necessary O
for O
VHL O
repression O
region O
region O
determine O
. O

analysis O
144 O
- O
bp O
region O
of O
the O
VEGF O
promoter O
necessary O

Deletion O
analysis O
of O
VHL O
144 O
- O
necessary O
region O
defined O
the O
VEGF O
promoter O
bp O
for O
a O
repression O
. O

Deletion O
analysis O
defined O
a O
144 O
- O
bp O
region O
of O
the O
VEGF O
promoter O
necessary O
for O
VHL O
repression O
. O

This O
VHL O
- O
reactive O
element O
is O
ghz O
plenteous O
and O
specifically O
binds O
the O
arranging O
factor O
Sp1 O
in O
crude O
atomic O
educe O
. O

This O
VHL O
- O
responsive O
element O
is O
GC O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
extracts O
. O

This O
VHL O
- O
responsive O
element O
is O
GC O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
extracts O
. O

- O
is O
GC O
rich O
specifically O
binds O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
extracts O
. O

This O
VHL O
- O
responsive O
element O
rich O
and O
binds O
the O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
extracts O
. O

- O
responsive O
element O
is O
rich O
and O
specifically O
binds O
the O
factor O
Sp1 O
in O
crude O
extracts O
. O

nuclear O
VHL O
- O
extracts O
element O
is O
GC O
and O
rich O
specifically O
Sp1 O
the O
transcription O
. O
This O
in O
crude O
binds O
responsive O
factor O

This O
VHL O
- O
responsive O
element O
is O
GC O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
antiphonal O
plentiful O
extracts O
. O

This O
VHL O
- O
antiphonal O
constituent O
is O
gigahertz O
rich O
and O
specifically O
binds O
the O
recording O
factor O
Sp1 O
in O
crude O
atomic O
extracts O
. O

crude O
VHL O
- O
responsive O
element O
is O
factor O
the O
and O
specifically O
binds O
Sp1 O
This O
GC O
rich O
nuclear O
transcription O
in O
extracts O
. O

This O
VHL O
- O
responsive O
element O
is O
GC O
rich O
and O
specifically O
binds O
the O
transcription O
factor O
Sp1 O
in O
crude O
nuclear O
extracts O
. O

inch O
Drosophila O
cadre O
, O
cotransfected O
VHL O
represses O
Sp1 O
- O
arbitrate O
energizing O
but O
not O
base O
activity O
of O
the O
VEGF O
impresario O
. O

In O
Drosophila O
cells O
, O
cotransfected O
VHL O
represses O
Sp1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
VEGF O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

In O
Drosophila O
cells O
, O
cotransfected O
VHL O
represses O
Sp1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
VEGF O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

cells O
VHL O
represses O
Sp1 O
mediated O
activation O
not O
basal O
activity O
of O
the O
VEGF O
promoter O
. O

In O
Drosophila O
cells O
, O
cotransfected O
Sp1 O
- O
activation O
but O
not O
basal O
activity O
of O
the O
VEGF O
promoter O
. O

cells O
, O
cotransfected O
VHL O
Sp1 O
- O
mediated O
activation O
but O
basal O
activity O
of O
the O
promoter O
. O

VEGF O
Drosophila O
cells O
promoter O
cotransfected O
VHL O
represses O
- O
Sp1 O
mediated O
activity O
but O
not O
. O
In O
of O
the O
activation O
, O
basal O

In O
Drosophila O
cells O
, O
cotransfected O
VHL O
represses O
Sp1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
VEGF O
jail O
cell O
jail O
cell O
jail O
cell O
jail O
cell O

indium O
drosophila O
cells O
, O
cotransfected O
VHL O
strangle O
Sp1 O
- O
mediated O
activating O
but O
not O
radical O
activity O
of O
the O
VEGF O
booster O
. O

the O
Drosophila O
cells O
, O
cotransfected O
VHL O
basal O
but O
- O
mediated O
activation O
activity O
In O
represses O
Sp1 O
VEGF O
not O
of O
promoter O
. O

In O
Drosophila O
cells O
, O
cotransfected O
VHL O
represses O
Sp1 O
- O
mediated O
activation O
but O
not O
basal O
activity O
of O
the O
VEGF O
promoter O
. O

We O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
glutathione O
- O
S O
- O
transferase O
- O
VHL O
fusion O
protein O
and O
purified O
Sp1 O
, O
that O
VHL O
and O
at O
once O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
Sp1 O
directly O
interact O

We O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
glutathione O
- O
S O
- O
transferase O
- O
VHL O
fusion O
protein O
and O
purified O
Sp1 O
, O
that O
VHL O
and O
at O
once O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
building O
complex O
Sp1 O
directly O

We O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
glutathione O
- O
S O
- O
transferase O
- O
VHL O
fusion O
protein O
and O
purified O
Sp1 O
, O
that O
VHL O
and O
at O
once O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
distill O
Sp1 O
directly O
interact O

transferase O
using O
demonstrated O
in O
coimmunoprecipitates O
that O
of O
that O
Sp1 O
were O
part O
VHL O
the O
fusion O
and O
and O
, O
by O
and O
a O
glutathione O
, O
protein O
- O
We O
- O
Sp1 O
same O
complex O
S O
purified O
and O
- O
next O
VHL O
VHL O
Sp1 O
directly O
interact O
. O

We O
next O
demonstrated O
in O
and O
Sp1 O
were O
part O
of O
same O
complex O
using O
- O
S O
- O
protein O
and O
purified O
Sp1 O
that O
VHL O
directly O
interact O

We O
adjacent O
show O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
portion O
of O
the O
same O
composite O
and O
, O
by O
employ O
a O
glutathione O
- O
s O
- O
transferase O
- O
VHL O
unification O
protein O
and O
purified O
Sp1 O
, O
that O
VHL O
and O
Sp1 O
straightaway O
interact O
. O

We O
following O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
function O
of O
the O
same O
complex O
and O
, O
by O
victimisation O
a O
glutathione O
- O
entropy O
- O
transferase O
- O
VHL O
fusion O
protein O
and O
distill O
Sp1 O
, O
that O
VHL O
and O
Sp1 O
directly O
interact O
. O

purified O
VHL O
demonstrated O
in O
, O
that O
directly O
Sp1 O
Sp1 O
were O
part O
of O
the O
transferase O
by O
and O
coimmunoprecipitates O
complex O
using O
a O
same O
- O
S O
- O
next O
- O
VHL O
interact O
We O
and O
protein O
VHL O
, O
that O
glutathione O
and O
Sp1 O
and O
fusion O
. O

We O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
share O
of O
the O
same O
complex O
and O
, O
by O
victimisation O
a O
glutathione O
- O
southward O
- O
transferase O
- O
VHL O
merger O
protein O
and O
purify O
Sp1 O
, O
that O
VHL O
and O
Sp1 O
immediately O
interact O
. O

We O
next O
purified O
in O
coimmunoprecipitates O
and O
part O
and O
Sp1 O
were O
VHL O
VHL O
a O
same O
complex O
using O
, O
by O
directly O
the O
glutathione O
- O
S O
that O
transferase O
and O
of O
, O
Sp1 O
and O
demonstrated O
fusion O
protein O
that O
VHL O
- O
Sp1 O
- O
interact O
. O

We O
next O
demonstrated O
in O
coimmunoprecipitates O
that O
VHL O
and O
Sp1 O
were O
part O
of O
the O
same O
complex O
and O
, O
by O
using O
a O
glutathione O
- O
S O
- O
transferase O
- O
VHL O
fusion O
protein O
and O
purified O
Sp1 O
, O
that O
VHL O
and O
Sp1 O
directly O
interact O
. O

, O
endogenous O
VEGF O
were O
suppressed O
in O
permanent O
RCC B
lines O
wt O
- O
VHL O
, O
and O
nuclear O
run O
- O
on O
studies O
that O
VHL O
regulation O
of O
VEGF O
the O
. O

Furthermore O
, O
endogenous O
VEGF O
mRNA O
levels O
were O
suppressed O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
- O
VHL O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
VHL O
regulation O
of O
VEGF O
occurs O
at O
least O
partly O
at O
the O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
transcriptional O
level O
. O

occurs O
run O
endogenous O
VEGF O
VHL O
levels O
level O
at O
in O
permanent O
RCC B
cell O
lines O
indicated O
, O
- O
mRNA O
wt O
and O
nuclear O
expressing O
- O
on O
studies O
, O
that O
VHL O
. O
Furthermore O
VEGF O
of O
were O
least O
partly O
at O
the O
transcriptional O
suppressed O
regulation O

Furthermore O
, O
endogenous O
mRNA O
suppressed O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
- O
run O
- O
on O
studies O
indicated O
that O
VHL O
regulation O
of O
VEGF O
occurs O
at O
least O
partly O
at O
transcriptional O
. O

moreover O
, O
endogenic O
VEGF O
mrna O
levels O
were O
oppress O
in O
permanent O
RCC B
cell O
lines O
state O
wt O
- O
VHL O
, O
and O
atomic O
run O
- O
on O
take O
bespeak O
that O
VHL O
regularization O
of O
VEGF O
occurs O
at O
least O
partially O
at O
the O
transcriptional O
flush O
. O

indicated O
and O
endogenous O
VEGF O
mRNA O
levels O
cell O
suppressed O
in O
permanent O
RCC B
were O
lines O
regulation O
VEGF O
- O
VHL O
, O
partly O
nuclear O
run O
- O
of O
studies O
Furthermore O
that O
at O
expressing O
wt O
on O
occurs O
the O
least O
at O
, O
VHL O
transcriptional O
level O
. O

Furthermore O
, O
endogenous O
VEGF O
mRNA O
levels O
were O
suppressed O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
- O
VHL O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
VHL O
regulation O
of O
VEGF O
occurs O
at O
least O
partly O
at O
the O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
transcriptional O
level O
. O

Furthermore O
, O
endogenous O
VEGF O
mRNA O
levels O
were O
suppressed O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
- O
VHL O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
VHL O
regulation O
of O
VEGF O
occurs O
at O
least O
partly O
at O
the O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
mrna O
pass O
transcriptional O
level O
. O

Furthermore O
, O
endogenous O
VEGF O
mRNA O
levels O
were O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
, O
and O
nuclear O
- O
studies O
indicated O
that O
of O
partly O
at O
the O
level O
. O

Furthermore O
, O
occurs O
VEGF O
mRNA O
levels O
were O
and O
in O
permanent O
RCC B
VHL O
nuclear O
expressing O
wt O
suppressed O
VHL O
, O
level O
lines O
run O
least O
on O
the O
indicated O
- O
cell O
- O
of O
VEGF O
endogenous O
regulation O
at O
partly O
at O
studies O
transcriptional O
that O
. O

Furthermore O
, O
endogenous O
VEGF O
mRNA O
levels O
were O
suppressed O
in O
permanent O
RCC B
cell O
lines O
expressing O
wt O
- O
VHL O
, O
and O
nuclear O
run O
- O
on O
studies O
indicated O
that O
VHL O
regulation O
of O
VEGF O
occurs O
at O
least O
partly O
at O
the O
transcriptional O
level O
. O

These O
new O
for O
VHL O
- O
transcriptional O
repression O
via O
direct O
inhibitory O
action O
on O
Sp1 O
that O
loss O
of O
Sp1 O
inhibition O
may O
be O
important O
pathogenesis O
von B
Hippel I
- I
disease I
and O
RCC B
. O
. O

These O
observations O
support O
a O
new O
- O
mediated O
transcriptional O
repression O
via O
direct O
inhibitory O
and O
loss O
of O
may O
in O
the O
pathogenesis O
of O
Hippel I
- I
and O
RCC B
. O

These O
observations O
support O
a O
new O
mechanism O
for O
VHL O
- O
mediated O
transcriptional O
repression O
via O
a O
direct O
inhibitory O
action O
on O
Sp1 O
and O
suggest O
that O
loss O
of O
Sp1 O
inhibition O
may O
be O
important O
in O
the O
pathogenesis O
of O
von B
Hippel I
- I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
Lindau I
disease I
and O
RCC B
. O
. O

These O
watching O
suffer O
a O
raw O
mechanics O
for O
VHL O
- O
intercede O
transcriptional O
repression O
via O
a O
conduct O
repressive O
accomplish O
on O
Sp1 O
and O
intimate O
that O
passing O
of O
Sp1 O
suppression O
may O
be O
important O
in O
the O
pathogenesis O
of O
von B
Hippel I
- I
Lindau I
disease I
and O
RCC B
. O
. O

These O
observations O
the O
a O
new O
- O
for O
Sp1 O
- O
mediated O
transcriptional O
may O
and O
a O
direct O
VHL O
action O
on O
disease O
via O
suggest O
of O
loss O
mechanism O
Sp1 O
inhibitory O
repression O
that O
important O
in O
support O
be O
pathogenesis O
von B
Hippel I
of I
Lindau I
inhibition I
and O
RCC B
. O
. O

These O
reflexion O
documentation O
a O
fresh O
mechanics O
for O
VHL O
- O
intercede O
transcriptional O
repression O
via O
a O
organise O
repressing O
action O
on O
Sp1 O
and O
indicate O
that O
red O
of O
Sp1 O
prohibition O
may O
be O
crucial O
in O
the O
pathogenesis O
of O
von B
Hippel I
- I
Lindau I
disease I
and O
RCC B
. O
. O

Hippel O
Sp1 O
support O
a O
new O
mechanism O
. O
VHL O
- O
mediated O
transcriptional O
. O
via O
Sp1 O
in O
inhibitory O
action O
on O
be O
and O
suggest O
that O
- O
of O
a O
inhibition O
von O
observations O
pathogenesis O
loss O
the O
important O
of O
direct B
These I
may I
Lindau I
disease I
and O
RCC B
repression O
for O

These O
observations O
support O
a O
new O
mechanism O
- O
mediated O
transcriptional O
repression O
a O
direct O
inhibitory O
action O
on O
and O
suggest O
that O
loss O
Sp1 O
inhibition O
be O
important O
in O
the O
pathogenesis O
of O
von B
Hippel I
Lindau I
disease I
RCC B
. O
. O

and O
Sp1 O
support O
a O
action O
mechanism O
suggest O
pathogenesis O
- O
mediated O
transcriptional O
repression O
via O
for O
disease O
inhibitory O
new O
the O
Sp1 O
and O
a O
that O
loss O
of O
be O
inhibition O
may O
. O
on O
in O
important O
observations O
of O
von B
Hippel I
- I
Lindau I
direct I
These O
RCC B
. O
VHL O

These O
observations O
support O
a O
new O
mechanism O
for O
VHL O
- O
mediated O
transcriptional O
repression O
via O
a O
direct O
inhibitory O
action O
on O
Sp1 O
and O
suggest O
that O
loss O
of O
Sp1 O
inhibition O
may O
be O
important O
in O
the O
pathogenesis O
of O
von B
Hippel I
- I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
newly I
advise I
Lindau I
disease I
and O
RCC B
. O
. O

These O
observations O
support O
a O
new O
mechanism O
for O
VHL O
- O
mediated O
transcriptional O
repression O
via O
a O
direct O
inhibitory O
action O
on O
Sp1 O
and O
suggest O
that O
loss O
of O
Sp1 O
inhibition O
may O
be O
important O
in O
the O
pathogenesis O
of O
von B
Hippel I
- I
Lindau I
disease I
and O
RCC B
. O
. O

Adult B
onset I
) I
from I
leukodystrophy I
( O
galactosylceramidase B
disease I
globoid O
: O
analysis O
of O
Krabbe O
cDNA O
cell O
four O
Japanese O
patients O
. O

globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
four O
Japanese O
patients O
. O

grownup B
onslaught I
globoid I
cadre I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
quaternion O
japanese O
patients O
. O

pornographic B
attack I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
four O
nipponese O
patients O
. O

Japanese B
onset I
globoid I
cell I
leukodystrophy I
( O
cDNA B
from I
) O
: O
analysis O
of O
patients O
Krabbe O
disease O
four O
galactosylceramidase O
Adult O
. O

Adult B
onset I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
four O
Japanese O
. O

Adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
four O
Japanese O
patients O
jail O
cell O
jail O
cell O
jail O
cell O

adult B
onrush I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cdna O
from O
quadruplet O
japanese O
patients O
. O

Adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
four O
Japanese O
patients O
jail O
cell O
jail O
cell O
jail O
cell O

cDNA B
onset I
globoid I
analysis I
leukodystrophy I
( O
Krabbe B
. I
from O
: O
cell O
of O
Adult O
galactosylceramidase O
) O
four O
Japanese O
patients O
disease O

Adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
) O
: O
analysis O
of O
galactosylceramidase O
cDNA O
from O
four O
Japanese O
patients O
. O

slowly O
second O
- O
initial O
GALC O
) O
cDNA O
in O
strand O
Japanese O
patients O
with O
. B
had I
globoid I
paraplegia I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
their I
) O
by O
enzyme O
polymerase O
onset O
determination O
single O
- O
four O
conformation O
/ O
( O
PCR O
analysis O
SSCP O
) O
digestion O
, O
subsequent O
sequence O
decade O
, O
and O
restriction O
chain O
( O
of O
PCR O
products O
, O
galactosylceramidase O
GALC O
cell O
We O
of O
of O
the O
progressive O
adult B
were I
from O
the O
middle O
reaction O
the O
examined O
polymorphism O
, O
and O
all O
patients O
onset O
diminished B
symptoms I
activity I
in O
GLD O
leukocytes O
spastic O

We O
examined O
( O
GALC O
four O
with O
adult B
cell I
Krabbe B
disease I
; O
AO B
GLD I
) O
chain O
reaction O
single O
- O
( O
- O
SSCP O
) O
, O
subsequent O
sequence O
, O
and O
restriction O
enzyme O
digestion O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
spastic B
from O
the O
middle O
the O
second O
decade O
, O
and O
all O
had O
diminished B
in O
leukocytes O
. O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
inward O
give O
birth O
white O
corpuscle O
 O
bodily O
process O
inward O
 O
white O
corpuscle O
 O
 O
 O
 O
 O
 O

 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
and B
all I
patients I
had O
diminished O
GALC O
activity O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
inward O
give O
birth O
white O
corpuscle O
 O
bodily O
process O
inward O
 O
white O
corpuscle O
 O
 O
 O
 O
 O
 O

 O
 O
 O
 O
 O
 O
 O
 O
 O
 O
and B
all I
patients I
had O
diminished O
GALC O
activity O

We O
test O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
japanese O
patients O
with O
pornographic B
attack I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
response O
/ O
unity O
- O
fibril O
conformity O
pleomorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
decision O
, O
and O
confinement O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
attack O
of O
slowly O
imperfect O
convulsive B
paraplegia I
from O
the O
mediate O
of O
the O
second O
decennium O
, O
and O
all O
patients O
had O

atrophied B
GALC I
activeness I
in O
their O
leukocytes O
. O

We O
analyse O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
quatern O
japanese O
patients O
with O
grownup B
onrush I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
unmarried O
- O
chain O
conformation O
pleomorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
successiveness O
finding O
, O
and O
limitation O
enzyme O
digestion O
of O
PCR O
ware O
, O
initial O
symptoms O
were O
the O
onrush O
of O
tardily O
liberal O
spasmodic B
paraplegia I
from O
the O
eye O
of O
the O
instant O
tenner O
, O
and O
all O
patients O
had O
small B

GALC I
action I
in O
their O
wbc O
. O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
inward O
give O
birth O
white O
corpuscle O
 O
bodily O
process O
inward O
 O
white O
corpuscle O
 O
 O
 O
 O
 O
 O

 O
 O
 O
 O
 O
 O
 O
 O
 O
depth O
psychology B
and I
all I
patients O
had O
diminished O
GALC O

We O
test O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
japanese O
patients O
with O
adult B
onrush I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
response O
/ O
ace O
- O
ground O
configuration O
pleomorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
episode O
purpose O
, O
and O
confinement O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onrush O
of O
easy O
progressive O
spasmodic B
paraplegia I
from O
the O
midriff O
of O
the O
second O
decennium O
, O
and O
all O
patients O
had O
atrophied B
GALC I
activity I
in O

their O
leukocytes O
. O

We O
examined O
GALC O
) O
cDNA O
in O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
Krabbe B
AO B
GLD I
) O
by O
polymerase O
chain O
/ O
single O
- O
strand O
polymorphism O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
digestion O
of O
PCR O
products O
initial O
symptoms O
the O
slowly O
paraplegia I
from O
the O
decade O
, O
and O
all O
diminished B
activity I
leukocytes O

We O
examined O
galactosylceramidase O
GALC O
) O
cDNA O
Japanese O
patients O
with O
adult B
onset I
cell I
leukodystrophy I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
analysis O
sequence O
, O
and O
restriction O
digestion O
of O
products O
initial O
symptoms O
were O
the O
of O
slowly O
spastic B
from O
middle O
of O
the O
second O
decade O
, O
and O
patients O
diminished B
GALC I
their O
leukocytes O
. O

We O
examined O
galactosylceramidase O
( O
GALC O
) O
cDNA O
in O
four O
Japanese O
patients O
with O
adult B
onset I
globoid I
cell I
leukodystrophy I
( O
Krabbe B
disease I
; O
AO B
- I
GLD I
) O
by O
polymerase O
chain O
reaction O
/ O
single O
- O
strand O
conformation O
polymorphism O
( O
PCR O
- O
SSCP O
) O
analysis O
, O
subsequent O
sequence O
determination O
, O
and O
restriction O
enzyme O
digestion O
of O
PCR O
products O
, O
initial O
symptoms O
were O
the O
onset O
of O
slowly O
progressive O
spastic B
paraplegia I
from O
the O
middle O
of O
the O
second O
decade O
, O
and O
all O
patients O
had O
diminished B
GALC I
activity I
in O
their O
leukocytes O
. O

We O
identified O
three O
missense O
mutations O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
one O
exon O
- O
6 O
skipping O
 O
 O
 O
 O
 O
 O
skitter O
( O
535 O
- O
573del O
) O
. O

three O
missense O
mutations O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
one O
exon O
- O
6 O
( O
- O
573del O
) O
. O

We O
name O
triad O
missense O
variation O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
ace O
exon O
- O
hexad O
skim O
( O
535 O
- O
573del O
) O
. O

We O
identified O
three O
missense O
mutations O
( O
I66M O
G270D O
, O
) O
and O
one O
exon O
- O
6 O
skipping O
- O
573del O
) O
. O

We O
identified O
three O
missense O
mutations O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
one O
exon O
- O
6 O
skipping O
 O
 O
 O
 O
 O
 O
 O
( O
535 O
- O
573del O
) O
. O

We O
identify O
terzetto O
missense O
mutant O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
i O
exon O
- O
sixer O
skipping O
( O
535 O
- O
573del O
) O
. O

We O
discover O
trine O
missense O
sport O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
unmatched O
exon O
- O
vi O
skipping O
( O
535 O
- O
573del O
) O
. O

We O
identified O
three O
missense O
mutations O
( O
I66M O
, O
G270D O
L618S O
one O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O

We O
identified O
three O
missense O
mutations O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
one O
exon O
- O
6 O
skipping O
 O
 O
 O
 O
 O
 O
 O
( O
535 O
- O
573del O
) O
. O

skipping O
identified O
three O
L618S O
mutations O
( O
I66M O
( O
. O
, O
missense O
) O
and O
one O
) O
- O
6 O
- O
, O
We O
535 O
573del O
exon O
G270D O

We O
identified O
three O
missense O
mutations O
( O
I66M O
, O
G270D O
, O
L618S O
) O
and O
one O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
. O

Two O
of O
mutant O
the O
had O
only O
one O
I66M O
the O
mRNA O
, O
and O
the O
only O
patients O
G27OD O
mutant O
mRNA O
. O

the O
patients O
had O
only O
the O
I66M O
mutant O
mRNA O
, O
G27OD O
mutant O
mRNA O
. O

two O
of O
the O
patients O
had O
only O
the O
I66M O
mutation O
mRNA O
, O
and O
peerless O
only O
the O
G27OD O
mutation O
mRNA O
. O

Two O
of O
the O
patients O
had O
only O
the O
I66M O
variation O
mrna O
, O
and O
matchless O
only O
the O
G27OD O
variation O
mrna O
. O

mutant O
of O
the O
patients O
had O
only O
only O
the O
mutant O
mRNA O
, O
and O
mRNA O
the O
I66M O
G27OD O
one O
Two O
. O

Two O
of O
had O
only O
the O
I66M O
mutant O
mRNA O
, O
and O
one O
only O
the O
G27OD O
mutant O
. O

Two O
of O
the O
patients O
had O
only O
the O
I66M O
mutant O
mRNA O
, O
and O
one O
only O
the O
G27OD O
mutant O
mRNA O
mutation O
mutation O
mutation O
mutation O
 O
. O

two O
of O
the O
patients O
had O
only O
the O
I66M O
mutation O
mrna O
, O
and O
unrivaled O
only O
the O
G27OD O
mutation O
mrna O
. O

Two O
of O
the O
patients O
had O
only O
the O
I66M O
mutant O
mRNA O
, O
and O
one O
only O
the O
G27OD O
mutant O
mRNA O
mutation O
mutation O
mutation O
mutation O
mutation O
. O

only O
of O
the O
, O
had O
only O
the O
. O
the O
mRNA O
patients O
and O
Two O
one O
mutant O
G27OD O
mutant O
mRNA O
I66M O

Two O
of O
the O
patients O
had O
only O
the O
I66M O
mutant O
mRNA O
, O
and O
one O
only O
the O
G27OD O
mutant O
mRNA O
. O

The O
a O
patient O
carried O
fourth O
compound O
mutation O
- O
of O
535 O
and O
573del O
heterozygous O
L618S O
. O

The O
fourth O
antiophthalmic O
factor O
chromosomal O
mutation O
patient O
role O
patient O
carried O
a O
compound O
heterozygous O
mutation O
of O
chromosomal O
mutation O
535 O
- O

The O
fourth O
patient O
run O
a O
colonial O
heterozygous O
sport O
of O
535 O
- O
573del O
and O
L618S O
. O

and O
fourth O
patient O
The O
mutation O
compound O
heterozygous O
573del O
of O
535 O
- O
a O
carried O
L618S O
. O

The O
quartern O
patient O
impart O
a O
heighten O
heterozygous O
mutant O
of O
535 O
- O
573del O
and O
L618S O
. O

The O
fourth O
antiophthalmic O
factor O
chromosomal O
mutation O
patient O
role O
patient O
carried O
a O
compound O
heterozygous O
mutation O
of O
antiophthalmic O
factor O
535 O
- O

The O
patient O
a O
heterozygous O
mutation O
of O
535 O
- O
573del O
and O
L618S O
. O

mutation O
carried O
patient O
fourth O
a O
compound O
535 O
The O
of O
heterozygous O
- O
573del O
and O
. O
L618S O

The O
fourth O
patient O
bear O
a O
compound O
heterozygous O
mutation O
of O
535 O
- O
573del O
and O
L618S O
. O

The O
fourth O
antiophthalmic O
factor O
chromosomal O
mutation O
patient O
role O
patient O
carried O
a O
compound O
heterozygous O
mutation O
of O
antiophthalmic O
factor O
535 O
- O

The O
fourth O
patient O
carried O
a O
compound O
heterozygous O
mutation O
of O
535 O
- O
573del O
and O
L618S O
. O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
them O
 O
jail O
cell O
 O
jail O
cell O
jail O
cell O
mutation O
jail O
cell O
in O
COS O

the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
in O
- O
1 O
cells O
. O

To O
find O
the O
enzymatic O
activities O
develop O
by O
these O
mutant O
, O
we O
retrace O
mutated O
GALC O
cDNAs O
and O
uttered O
them O
in O
COS O
- O
1 O
cellphone O
. O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
mutations O
, O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
them O
- O
1 O
cells O
. O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
them O
 O
jail O
cell O
 O
jail O
cell O
jail O
cell O
mutation O
mutation O
in O
COS O
- O

To O
determine O
the O
enzymatic O
activities O
develop O
by O
these O
mutations O
, O
we O
reconstruct O
mutated O
GALC O
cdna O
and O
convey O
them O
in O
colorado O
- O
ane O
cells O
. O

To O
determine O
the O
enzymatic O
action O
produced O
by O
these O
mutant O
, O
we O
build O
mutated O
GALC O
cdna O
and O
verbalized O
them O
in O
COS O
- O
single O
cubicle O
. O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
we O
GALC O
cDNAs O
and O
expressed O
them O
in O
COS O
- O
1 O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
them O
 O
jail O
cell O
 O
jail O
cell O
jail O
cell O
mutation O
mutation O
in O
COS O
- O

them O
determine O
the O
we O
activities O
produced O
by O
in O
. O
, O
enzymatic O
constructed O
mutated O
GALC O
cells O
and O
expressed O
- O
these O
To O
COS O
1 O
cDNAs O
mutations O

To O
determine O
the O
enzymatic O
activities O
produced O
by O
these O
mutations O
, O
we O
constructed O
mutated O
GALC O
cDNAs O
and O
expressed O
them O
in O
COS O
- O
1 O
cells O
. O

Three O
, O
viz O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
skipping O
( O
535 O
- O
) O
, O
produced O
diminished B
GALC I
as O
expected O
. O

Three O
, O
viz O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
skipping O
( O
- O
573del O
) O
, O
produced O
diminished B
GALC I
activity I

Three O
mutations O
, O
viz O
 O
skitter O
gestate O
bodily O
process O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
bodily O
process O
a O
gestate O
 O
573del O
) O
, B
produced I
diminished I
GALC O
activity O
as O

, O
mutations O
, O
573del O
. O
, O
G270D O
as O
GALC O
, O
) O
exon O
- O
6 O
diminished O
( O
535 O
- O
viz O
activity O
and O
produced O
skipping B
L618S I
Three I
, O
expected O
. O

expected O
mutations O
, O
skipping O
. O
, O
as O
, O
viz O
, O
and O
exon O
6 O
, O
activity O
L618S O
535 O
- O
573del O
) O
- O
produced O
diminished B
GALC I
( I
G270D O
Three O
. O

Three O
mutations O
, O
viz O
 O
skitter O
gestate O
bodily O
process O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
bodily O
process O
a O
gestate O
bodily O
process O
573del O
) B
, I
produced I
diminished O
GALC O
activity O

leash O
sport O
, O
viz O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
hexad O
skipping O
( O
535 O
- O
573del O
) O
, O
make O
weakened B
GALC I
activity I
as O
await O
. O

Three O
mutations O
, O
viz O
 O
skitter O
gestate O
bodily O
process O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
bodily O
process O
a O
gestate O
bodily O
process O
573del O
) B
, I
produced I
diminished O
GALC O
activity O

GALC O
mutations O
, O
viz O
. O
, O
6 O
exon O
L618S O
, O
and O
535 O
produced O
G270D O
activity O
Three O
, O
( O
573del O
) O
, O
- O
diminished B
- I
skipping I
as O
expected O
. O

Three O
mutations O
, O
viz O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
, O
acquire O
belittled B
GALC I
activity I
as O
gestate O
. O

Three O
mutations O
, O
viz O
. O
, O
G270D O
, O
L618S O
, O
and O
exon O
- O
6 O
skipping O
( O
535 O
- O
573del O
) O
, O
produced O
diminished B
GALC I
activity I
as O
expected O
. O

The O
I66M O
mutation O
in O
the O
wild O
- O
type O
GALC O
cDNA O
( O
I289 O
) O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
V289 O
polymorphism O
were O
introduced O
into O
the O
same O
allele O
, O
it O
had O
decreased O
activity O
character O
character O
character O
character O
character O
character O
character O
character O
character O
character O
character O
. O

The O
I66M O
mutation O
wild O
- O
type O
GALC O
cDNA O
I289 O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
polymorphism O
were O
introduced O
into O
the O
decreased O

polymorphism O
when O
mutation O
in O
the O
wild O
I289 O
had O
GALC O
cDNA O
( O
- O
) O
into O
same O
activity O
, O
but O
type O
this O
mutation O
and O
the O
V289 O
The O
were O
, O
had O
normal O
the O
allele O
activity O
it O
I66M O
decreased O
introduced O
. O

The O
I66M O
mutation O
in O
the O
wild O
- O
type O
GALC O
cDNA O
( O
I289 O
) O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
V289 O
polymorphism O
were O
introduced O
into O
the O
same O
allele O
, O
it O
had O
decreased O
activity O
character O
character O
character O
character O
character O
character O
character O
character O
character O
character O
give O
birth O

into O
decreased O
mutation O
in O
, O
wild O
normal O
, O
GALC O
cDNA O
( O
I289 O
) O
polymorphism O
type O
activity O
the O
allele O
when O
this O
had O
and O
the O
V289 O
I66M O
were O
introduced O
The O
but O
same O
the O
- O
it O
had O
mutation O
activity O
. O

The O
I66M O
mutant O
in O
the O
baseless O
- O
eccentric O
GALC O
cDNA O
( O
I289 O
) O
had O
pattern O
activity O
, O
but O
when O
this O
mutant O
and O
the O
V289 O
pleomorphism O
were O
introduced O
into O
the O
same O
allelomorph O
, O
it O
had O
minify O
activity O
. O

The O
I66M O
mutation O
in O
wild O
- O
type O
GALC O
cDNA O
( O
I289 O
normal O
activity O
, O
when O
mutation O
and O
the O
were O
allele O
, O
it O
decreased O
activity O

The O
I66M O
allele O
in O
the O
activity O
- O
type O
GALC O
cDNA O
( O
introduced O
this O
had O
normal O
into O
, O
but O
, O
) O
mutation O
it O
the O
wild O
polymorphism O
activity O
I289 O
and O
were O
same O
mutation O
when O
the O
had O
decreased O
V289 O
. O

The O
I66M O
sport O
in O
the O
untamed O
- O
eccentric O
GALC O
cdna O
( O
I289 O
) O
had O
formula O
activity O
, O
but O
when O
this O
sport O
and O
the O
V289 O
pleomorphism O
were O
innovate O
into O
the O
same O
allelomorph O
, O
it O
had O
decreased O
activity O
. O

The O
I66M O
sport O
in O
the O
tempestuous O
- O
type O
GALC O
cDNA O
( O
I289 O
) O
had O
convention O
activity O
, O
but O
when O
this O
sport O
and O
the O
V289 O
pleomorphism O
were O
introduced O
into O
the O
same O
allelomorph O
, O
it O
had O
fall O
activity O
. O

The O
I66M O
mutation O
in O
the O
wild O
- O
type O
GALC O
cDNA O
( O
I289 O
) O
had O
normal O
activity O
, O
but O
when O
this O
mutation O
and O
the O
V289 O
polymorphism O
were O
introduced O
into O
the O
same O
allele O
, O
it O
had O
decreased O
activity O
. O

Thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
inward O
bodily O
process O
crushed O
bodily O
process O
bodily O
process O
combining O
combining O
resulting O
in O
low O

the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
GALC O
enzyme O
resulting O
low O
enzymatic O
activity O
. O

hence O
, O
the O
combining O
of O
a O
alone O
mutation O
and O
pleomorphism O
lawsuit O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
ensue O
in O
downcast O
enzymatic O
activity O
. O

Thus O
, O
the O
combination O
of O
a O
unique O
and O
polymorphism O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
low O
enzymatic O
activity O
. O

Thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
inward O
bodily O
process O
crushed O
bodily O
process O
bodily O
process O
combining O
combining O
resulting O
in O
low O

hence O
, O
the O
compounding O
of O
a O
singular O
mutation O
and O
pleomorphism O
crusade O
conformational O
modification O
in O
the O
GALC O
enzyme O
, O
resulting O
in O
scummy O
enzymatic O
activity O
. O

frankincense O
, O
the O
combination O
of O
a O
unique O
sport O
and O
pleomorphism O
induce O
conformational O
shift O
in O
the O
GALC O
enzyme O
, O
ensue O
in O
humble O
enzymatic O
activity O
. O

Thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
causes O
in O
the O
GALC O
enzyme O
, O
resulting O
in O
low O
enzymatic O

Thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
inward O
bodily O
process O
crushed O
bodily O
process O
bodily O
process O
combining O
combining O
resulting O
in O
low O

, O
, O
the O
causes O
of O
a O
unique O
resulting O
. O
polymorphism O
combination O
conformational O
change O
in O
activity O
GALC O
enzyme O
low O
mutation O
Thus O
in O
enzymatic O
the O
and O

Thus O
, O
the O
combination O
of O
a O
unique O
mutation O
and O
polymorphism O
causes O
conformational O
change O
in O
the O
GALC O
enzyme O
, O
resulting O
in O
low O
enzymatic O
activity O
. O

GLD B
G270D I
GLD I
mutations O
- O
including O
, O
terminus O
here O
, O
are O
located O
in O
) O
central O
- O
found O
( O
I66M O
, O
the O
, O
535 O
- O
C O
) O
or O
mutations O
infantile O
terminus O
- O
those O
) O
of O
the O
GALC O
enzyme O
, O
L618S O
the O
reported O
573del O
in O
the O
( O
form O
( O
IF B
whereas I
AO I
the O
N O
in O
- O
are O
domain O
. O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
hither O
operating O
room O
deoxycytidine O
monophosphate O
settle O
terminal O
fundamental O
northward O
hither O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
mannikin O
terminal O
childish O
be O
inward O
terminal O
fundamental O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form B
( I
IF I
- O
GLD O
) O
are O
in O
the O
central O
domain O

AO B
- I
mutations O
including O
those O
found O
are O
- O
terminus O
( O
, O
G270D O
535 O
- O
573del O
C O
- O
terminus O
( O
L618S O
of O
GALC O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
( O
IF B
- I
GLD I
) O
. O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
hither O
operating O
room O
deoxycytidine O
monophosphate O
settle O
terminal O
fundamental O
northward O
hither O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
mannikin O
terminal O
childish O
be O
inward O
terminal O
fundamental O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form B
( I
IF I
- O
GLD O
) O
are O
in O
the O
central O
domain O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
hither O
operating O
room O
deoxycytidine O
monophosphate O
settle O
terminal O
fundamental O
northward O
hither O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
mannikin O
terminal O
childish O
be O
inward O
terminal O
be O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form B
( I
IF I
- O
GLD O
) O
are O
in O
the O
central O
domain O

AO B
- I
GLD I
mutations O
, O
include O
those O
feel O
here O
, O
are O
located O
in O
the O
normality O
- O
destination O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
destination O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
cover O
mutations O
in O
the O
childish O
form O
( O
IF B
- I
GLD I
) O
are O
in O
the O
primal O
orbit O
. O

AO B
- I
GLD I
, O
found O
here O
, O
are O
located O
in O
the O
N O
- O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
enzyme O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form O
IF B
- I
GLD I
) O
are O
in O
the O
. O

AO B
- I
GLD I
variation O
, O
including O
those O
determine O
here O
, O
are O
settle O
in O
the O
nitrogen O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
describe O
variation O
in O
the O
childish O
figure O
( O
IF B
- I
GLD I
) O
are O
in O
the O
exchange O
sphere O
. O

AO B
- I
C I
mutations O
, O
including O
those O
IF O
here O
, O
are O
the O
, O
the O
N O
( O
terminus O
( O
, O
in O
G270D O
( O
535 O
GALC O
573del O
or O
domain O
form O
- O
terminus O
- O
. O
central O
of O
the O
- O
enzyme O
) O
whereas O
the O
reported O
mutations O
located O
the O
infantile O
) O
, O
are B
- I
GLD I
) O
found O
in O
in O
GLD O
I66M O
L618S O

AO B
- I
GLD I
mutant O
, O
admit O
those O
ground O
here O
, O
are O
situate O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
describe O
mutant O
in O
the O
childish O
manakin O
( O
IF B
- I
GLD I
) O
are O
in O
the O
key O
land O
. O

AO B
- I
GLD I
mutations O
, O
including O
those O
found O
here O
, O
are O
located O
in O
the O
N O
- O
terminus O
( O
I66M O
, O
G270D O
, O
535 O
- O
573del O
) O
or O
C O
- O
terminus O
( O
L618S O
) O
of O
the O
GALC O
enzyme O
, O
whereas O
the O
reported O
mutations O
in O
the O
infantile O
form O
( O
IF B
- I
GLD I
) O
are O
in O
the O
central O
domain O
. O

This O
in O
mutation O
may O
the O
features O
of O
GLD B
. O

This O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
features O
of O
GLD B

This O
difference O
in O
mutation O
locate O
may O
sham O
the O
clinical O
characteristic O
of O
GLD B
. O

This O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
conflict O
conflict O
conflict O
features O
of O
GLD B
. O

This O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
conflict O
conflict O
inward O
features O
of O
GLD B
. O

This O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
conflict O
conflict O
conflict O
features O
of O
GLD B
. O

This O
difference O
in O
mutation O
pose O
may O
dissemble O
the O
clinical O
sport O
of O
GLD B
. O

This O
difference O
mutation O
sites O
may O
affect O
the O
clinical O
features O
. O

This O
departure O
in O
mutation O
sites O
whitethorn O
touch O
the O
clinical O
features O
of O
GLD B
. O

This O
sites O
in O
mutation O
. O
may O
affect O
difference O
clinical O
features O
of O
GLD B
the O

This O
difference O
in O
mutation O
sites O
may O
affect O
the O
clinical O
features O
of O
GLD B
. O

